BackgroundUsing O +
antibodies O +
to O +
specific O +
protein O +
antigens O +
is O +
the O +
method O +
of O +
choice O +
to O +
assign O +
and O +
identify O +
cell O +
lineage O +
through O +
simultaneous O +
analysis O +
of O +
surface O +
molecules O +
and O +
intracellular O +
markers O -
. O -

Embryonic O +
stem O +
cell O +
research O +
can O +
be O +
benefited O +
from O +
using O +
antibodies O +
specific O +
to O +
transcriptional O +
factors O -
/ O -
markers O +
that O +
contribute O +
to O +
the O +
" O -
stemness O -
" O +
phenotype O +
or O +
critical O +
for O +
cell O +
lineage O -
. O -

ResultsIn O +
this O +
report O -
, O +
we O +
have O +
developed O +
and O +
validated O +
antibodies O +
( O -
either O +
monoclonal O +
or O +
polyclonal O -
) O +
specific O +
to O +
human U-Species +
embryonic O +
stem O +
cell O +
antigens O +
and O +
early O +
differentiation O +
transcriptional O +
factors O -
/ O -
markers O +
that O +
are O +
critical O +
for O +
cell O +
differentiation O +
into O +
definite O +
lineage O -
. O -

ConclusionThese O +
antibodies O +
enable O +
stem O +
cell O +
biologists O +
to O +
conveniently O +
identify O +
stem O +
cell O +
characteristics O +
and O +
to O +
quantitatively O +
assess O +
differentiation O -
. O -

Although O +
the O +
stem O +
cell O +
concept O +
was O +
introduced O +
decades O +
ago O -
, O +
to O +
date O -
, O +
stem O +
cells O +
can O +
only O +
be O +
defined O +
functionally O -
, O +
not O +
morphologically O +
or O +
phenotypically O -
. O -

Two O +
functions O +
define O +
stem O +
cells O -
. O -

Firstly O -
, O +
they O +
are O +
self O -
- O -
renewing O -
, O +
thus O +
able O +
to O +
propagate O +
to O +
generate O +
additional O +
stem O +
cells O -
. O -

Secondly O +
they O +
can O +
differentiate O +
into O +
various O +
progenitor O +
cells O -
, O +
which O +
commit O +
to O +
further O +
maturation O +
along O +
a O +
specific O +
lineage O -
. O -

While O +
stem O +
cells O +
can O +
be O +
best O +
defined O +
functionally O -
, O +
a O +
good O +
number O +
of O +
molecular O +
markers O +
have O +
been O +
used O +
to O +
prospectively O +
identify O +
various O +
stem O +
cell O +
populations O -
. O -

Although O +
the O +
functional O +
importance O +
of O +
many O +
of O +
these O +
antigens O +
remains O +
unknown O -
, O +
their O +
unique O +
expression O +
pattern O +
and O +
timing O +
of O +
expression O +
provide O +
a O +
useful O +
tool O +
for O +
scientists O +
to O +
identify O +
as O +
well O +
as O +
isolate O +
stem O +
cells O -
. O -

Embryonic O +
stem O +
cells O +
( O -
ESC O -
) O -
, O +
derived O +
from O +
the O +
inner O +
cell O +
mass O +
of O +
pre O -
- O -
implantation O +
embryos O -
, O +
have O +
been O +
recognized O +
as O +
the O +
earliest O +
stem O +
cell O +
population O +
[ O -
1,2 O -
] O -
. O -

This O +
pluripotent O +
population O +
can O +
differentiate O +
into O +
all O +
somatic O +
tissue O +
including O +
germ O +
cells O -
. O -

In O +
the O +
case O +
of O +
human U-Species +
ESC O -
, O +
they O +
can O +
differentiate O +
into O +
some O +
extra O -
- O -
embryonic O +
derivatives O +
as O +
well O -
. O -

Like O +
mouse U-Species +
ESC O -
, O +
human U-Species +
ES O +
cells O +
can O +
be O +
maintained O +
and O +
propagated O +
on O +
mouse U-Species +
fibroblast O +
feeders O +
for O +
extended O +
periods O +
in O +
media O +
containing O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
[ O -
3 O -
] O -
. O -

Gene O +
expression O +
of O +
undifferentiated O +
human U-Species +
ES O +
cells O +
has O +
been O +
investigated O +
among O +
several O +
ES O +
cell O +
lines O +
by O +
a O +
variety O +
of O +
techniques O -
. O -

They O +
include O +
comparison O +
with O +
databases O -
, O +
reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O -
, O +
focused O +
cDNA O +
microarrays O -
, O +
and O +
immunocytochemistry O -
. O -

A O +
list O +
of O +
molecules O +
comprised O +
of O +
known O +
ES O -
- O -
specific O +
or O +
-highly O +
expressed O +
genes O +
and O +
candidates O +
that O +
can O +
serve O +
as O +
markers O +
for O +
human U-Species +
ESCs O +
and O +
may O +
also O +
contribute O +
to O +
the O +
" O -
stemness O -
" O +
phenotype O +
has O +
been O +
established O +
[ O -
3 O -
- O -
11 O -
] O -
. O -

For O +
example O -
, O +
pluripotent O +
ESC O +
can O +
be O +
characterized O +
by O +
high O +
level O +
expression O +
of O +
Oct3 O -
/ O -
4 O +
( O -
POU O +
domain O -
, O +
class O +
5 O -
, O +
transcription O +
factor O +
1 O -
, O +
Pou5f1 O -
) O +
and O +
Nanog O -
, O +
which O +
are O +
a O +
member O +
of O +
POU O +
domain O +
and O +
homeobox O +
transcription O +
factors O +
respectively O -
. O -

A O +
critical O +
amount O +
of O +
Oct3 O -
/ O -
4 O +
and O +
Nanog O +
expression O +
is O +
required O +
to O +
sustain O +
stem O -
- O -
cell O +
pluripotency O +
and O +
both O +
of O +
these O +
markers O +
are O +
downregulated O +
as O +
cells O +
differentiate O +
in O +
vitro O +
and O +
in O +
vivo O +
[ O -
4 O -
- O -
9 O -
] O -
. O -

Antibodies O +
to O +
Oct3 O -
/ O -
4 O +
which O +
cross O +
react O +
with O +
human U-Species +
Oct O +
3 O -
/ O -
4 O +
have O +
been O +
widely O +
used O +
to O +
monitor O +
the O +
presence O +
of O +
undifferentiated O +
ESC O -
. O -

No O +
single O +
marker O +
however O +
is O +
sufficient O +
or O +
unique O +
for O +
identifying O +
ESCs O -
. O -

Oct3 O -
/ O -
4 O +
for O +
example O +
is O +
expressed O +
by O +
germ O +
cells O +
and O +
may O +
be O +
expressed O +
by O +
specific O +
populations O +
later O +
in O +
development O -
. O -

Likewise O -
, O +
Nanog O +
has O +
been O +
shown O +
to O +
express O +
in O +
other O +
tissues O -
. O -

We O +
and O +
other O +
have O +
noted O +
however O -
, O +
that O +
while O +
no O +
single O +
marker O +
is O +
sufficient O +
a O +
constellation O +
of O +
positive O +
and O +
negative O +
markers O +
can O +
in O +
concert O +
unambiguously O +
allow O +
one O +
to O +
define O +
the O +
state O +
of O +
ESC O +
cultures O +
and O +
that O +
surface O +
markers O +
in O +
combination O +
can O +
be O +
used O +
to O +
prospectively O +
sort O +
for O +
ESC O -
. O -

Based O +
on O +
published O +
data O +
at O +
the O +
level O +
of O +
gene O +
expression O -
, O +
we O +
have O +
cloned O +
a O +
number O +
of O +
candidate O +
marker O +
genes O -
. O -

We O +
have O +
also O +
expressed O +
the O +
recombinant O +
protein O +
and O +
generated O +
a O +
panel O +
of O +
monoclonal O +
or O +
polyclonal O +
antibodies O +
to O +
these O +
proteins O -
. O -

Using O +
these O +
antibodies O +
we O +
have O +
confirmed O +
the O +
specificity O +
and O +
selectivity O +
of O +
these O +
antibodies O +
on O +
several O +
ESC O +
lines O +
and O +
established O +
their O +
utility O +
as O +
stem O +
cells O +
markers O -
. O -

Our O +
results O +
confirm O +
the O +
expression O +
pattern O +
and O +
timing O +
of O +
these O +
cell O +
markers O +
at O +
the O +
protein O +
level O -
, O +
whereas O +
previous O +
data O +
reported O +
at O +
the O +
level O +
of O +
gene O +
expression O -
. O -

Characterization O +
of O +
undifferentiated O +
human U-Species +
ES O +
cells O +
and O +
differentiated O +
EBs O +
by O +
antibodiesAll O +
monoclonal O +
antibodies O +
were O +
initially O +
selected O +
for O +
their O +
abilities O +
to O +
recognize O +
recombinant O +
proteins O +
in O +
direct O +
ELISAs O -
. O -

A O +
subset O +
were O +
also O +
tested O +
by O +
Western O +
Blot O +
analysis O +
using O +
recombinant O +
proteins O +
and O +
cell O +
lysate O +
to O +
confirm O +
binding O +
to O +
a O +
single O +
epitope O -
. O -

The O +
best O +
clone O +
was O +
later O +
screened O +
for O +
its O +
applications O +
for O +
immunocytochemistry O +
and O +
flow O +
cytometry O +
using O +
various O +
cell O +
lines O -
. O -

Human U-Species +
peripheral O +
blood O +
platelets O +
were O +
used O +
for O +
screening O +
mouse U-Species +
anti O -
- O -
human U-Species +
CD9 O +
antibody O -
. O -

MCF-7 O +
cells O +
were O +
used O +
for O +
screening O +
mouse U-Species +
anti O -
- O -
human U-Species +
E O -
- O -
Cadherin O +
and O +
PODXL O +
( O -
podocalyxin O -
- O -
like O -
) O +
antibodies O -
. O -

MG-63 O +
cells O +
were O +
used O +
for O +
screening O +
mouse U-Species +
anti O -
- O -
human U-Species +
GATA1 O +
( O -
GATA O +
binding O +
protein O +
1 O -
) O +
antibody O -
. O -

Beta O -
- O -
TC6 O +
cells O +
were O +
used O +
for O +
screening O +
for O +
mouse U-Species +
anti O -
- O -
human U-Species -
/ O -
mouse U-Species +
PDX-1 O +
( O -
pancreatic O +
duodenal O +
homeobox-1 O -
) O +
antibody O -
. O -

NTERA-2 O +
cells O +
were O +
used O +
for O +
screening O +
mouse U-Species +
anti O -
- O -
human U-Species +
Oct3 O -
/ O -
4 O +
and O +
SOX2 O +
( O -
sex O -
- O -
determining O +
region O +
Y O -
- O -
box O +
2 O -
) O +
antibodies O -
. O -

All O +
polyclonal O +
antibodies O +
were O +
affinity O -
- O -
purified O +
using O +
recombinant O +
proteins O +
and O +
validated O +
by O +
direct O +
ELISAs O +
and O +
Western O -
. O -

Caco-2 O +
cells O +
were O +
used O +
for O +
validation O +
of O +
goat O +
anti O -
- O -
human U-Species +
GATA6 O +
antibody O +
and O +
NTERA-2 O +
cells O +
were O +
used O +
for O +
validation O +
of O +
goat O +
anti O -
- O -
human U-Species +
Nanog O +
and O +
anti O -
- O -
human U-Species +
Oct3 O -
/ O -
4 O +
antibodies O +
( O -
Summarized O +
in O +
Table O +
1 O -
) O -
.Table O +
1Summary O +
list O +
of O +
antibody O +
verification O +
by O +
western O +
blot O -
. O -

AntibodySample O +
used O +
for O +
analysisMol O -
. O -

Wt O -
. O -

( O -
KD O -
) O -
Gt O +
× O +
hBrachyurymouse O +
ES O -
- O -
derived O +
EB O +
lysate48Ms O +
× O +
hDPPA5N O -
/ O -
AN O -
/ O -
AGt O +
× O +
hGATA6Caco2 O +
cell O +
lysate65Gt O +
× O +
hNanogNTERA-2 O +
cell O +
lysate33Gt O +
× O +
hOct O +
3 O -
/ O -
4NTERA-2 O +
cell O +
lysate39Gt O +
× O +
hPDX1beta O -
- O -
TC O +
6 O +
cell O +
lysate32Gt O +
× O +
hSOX17mouse O +
ES O -
- O -
derived O +
EB O +
lysate45Ms O +
× O +
hCD9PBMC25Rt O +
× O +
hGATA-1N O -
/ O -
AN O -
/ O -
AMs O +
× O +
hE O -
- O -
CadherinMCF-7 O +
cell O +
lysate97Ms O +
× O +
hPODXLMCF-7 O +
cell O +
lysate57Ms O +
× O +
hSOX2NTERA-2 O +
cell O +
lysate36N O -
/ O -
A O -
: O +
1 O -
. O -

DPPA5 O +
is O +
still O +
being O +
subcloned O -
. O -

Only O +
Elisa O +
verification O +
is O +
available.2 O -
. O -

The O +
clone O +
for O +
GATA-1 O +
( O -
MAB1779 O -
) O +
does O +
not O +
work O +
for O +
Western O +
blot O +
application O +
but O +
is O +
useful O +
for O +
IHC O -
, O +
The O +
clone O +
picked O +
for O +
Western O +
blot O +
analysis O +
does O +
not O +
work O +
for O +
IHC O +
( O -
MAB17791 O -
, O +
see O +
data O +
in O +
) O -
.After O -

antibodies O +
were O +
validated O +
in O +
direct O +
ELISAs O -
, O +
Western O +
blot O +
or O +
cell O +
lines O +
( O -
Fig. O +
1 O +
and O +
data O +
not O +
shown O -
) O -
, O +
they O +
were O +
used O +
to O +
examine O +
the O +
expression O +
of O +
individual O +
molecules O +
in O +
undifferentiated O +
human U-Species +
ES O +
cells O +
and O +
differentiated O +
EBs O -
. O -

When O +
examined O +
by O +
immunohistochemistry O -
, O +
high O +
level O +
of O +
expressions O +
of O +
Oct3 O -
/ O -
4 O -
, O +
SOX2 O -
, O +
E O -
- O -
Cadherin O -
, O +
PODXL O +
and O +
Nanog O +
were O +
observed O +
in O +
undifferentiated O +
human U-Species +
ES O +
cells O +
( O -
Fig. O +
2A O -
, O +
2B O +
and O +
2C O -
) O -
. O -

DPPA5 O +
( O -
developmental O +
pluripotency O +
associated O +
5 O -
) O +
expression O +
was O +
also O +
observed O +
in O +
undifferentiated O +
human U-Species +
ES O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O -

We O +
noted O +
that O +
a O +
subset O +
of O +
the O +
proteins O +
used O +
were O +
membrane O +
bound O +
proteins O -
. O -

To O +
test O +
if O +
any O +
of O +
the O +
antibodies O +
generated O +
could O +
recognize O +
an O +
extracellular O +
epitope O +
and O +
thus O +
be O +
used O +
for O +
live O +
cell O +
sorting O -
, O +
we O +
repeated O +
staining O +
of O +
live O +
cells O +
as O +
previously O +
described O -
. O -

The O +
CD9 O -
, O +
E O -
- O -
Cadherin O +
and O +
PODXL O +
antibodies O +
recognized O +
an O +
extracellular O +
epitope O +
and O +
their O +
ability O +
to O +
select O +
cells O +
by O +
FACS O +
was O +
confirmed O +
( O -
Fig. O +
3 O -
) O -
. O -

Minimal O +
or O +
no O +
expressions O +
of O +
Oct3 O -
/ O -
4 O -
, O +
E O -
- O -
Cadherin O -
, O +
PODXL O +
and O +
Nanog O +
were O +
detected O +
in O +
the O +
differentiated O +
EBs O +
( O -
Fig. O +
2D O -
, O +
2E O +
and O +
2F O -
) O -
. O -

However O -
, O +
SOX2 O +
expression O -
, O +
which O +
is O +
observed O +
in O +
neural O +
progenitor O +
cells O -
, O +
is O +
persistent O +
in O +
subsets O +
of O +
EBs O -
. O -

Figure O +
1Western O +
blot O +
analysis O +
for O +
Gt O +
× O +
hOct3 O -
/ O -
4 O +
( O -
A O -
) O -
, O +
Gt O +
× O +
hNanog O +
( O -
B O -
) O +
and O +
Ms O +
× O +
hSOX2 O +
( O -
C O -
) O +
in O +
NTERA-2 O +
cell O +
lysate O -
, O +
Ms O +
× O +
hE O -
- O -
Cadherin O +
( O -
D O -
) O +
in O +
MCF-7 O +
cell O +
lysate O -
, O +
Ms O +
× O +
hCD9 O +
( O -
E O -
) O +
in O +
PBMC O +
lysate O +
and O +
Ms O +
× O +
hPDX-1 O -
( O -
F O -
) O +
in O +
β O -
- O -
TC-6 O +
cell O +
lysate O -
. O -

Numbers O +
indicate O +
the O +
positions O +
of O +
molecular O +
weight O +
markers O -
. O -

Figure O +
2Undifferentiated O +
human U-Species +
ES O +
cells O +
( O -
A O -
, O +
B O -
, O +
and O +
C O -
) O +
and O +
differentiated O +
EBs O +
( O -
D O -
, O +
E O +
and O +
F O -
) O +
were O +
analyzed O +
using O +
antibodies O +
to O +
indicated O +
molecular O +
markers O -
. O -

Immunostaining O +
with O +
goat O +
anti O -
- O -
human U-Species +
Oct3 O -
/ O -
4 O +
( O -
Red O +
in O +
A O +
and O +
D O -
) O -
, O +
mouse U-Species +
anti O -
- O -
human U-Species +
SOX2 O +
( O -
Green O +
in O +
A O +
and O +
D O -
) O -
, O +
goat O +
anti O -
- O -
human U-Species +
E O -
- O -
Cadherin O +
( O -
Red O +
in O +
B O +
and O +
E O -
) O -
, O +
mouse U-Species +
anti O -
- O -
human U-Species +
PODXL O +
( O -
Green O +
in O +
B O +
and O +
E O -
) O -
, O +
and O +
goat O +
anti O -
- O -
human U-Species +
Nanog O +
( O -
Red O +
in O +
C O +
and O +
F O -
) O -
, O +
are O +
contrasted O +
with O +
DAPI O +
nuclear O +
staining O +
( O -
Blue O +
in O +
C O -
- O -
F O -
) O -
. O -

Note O +
the O +
dramatic O +
downregulation O +
of O +
ESC O +
specific O +
markers O +
( O -
Oct3 O -
/ O -
4 O -
, O +
E O -
- O -
Cadherin O -
, O +
PODXL O -
, O +
and O +
Nanog O -
) O +
in O +
EBs O -
. O -

However O -
, O +
SOX2 O +
expression O +
is O +
persistent O +
in O +
subsets O +
of O +
EB O +
cells O -
. O -

Scale O +
bars O +
= O +
100 O +
μm O -
. O -

Figure O +
3Human O +
embryonic O +
stem O +
cells O +
stained O +
with O +
anti O -
- O -
CD9 O +
( O -
A O -
) O -
, O +
anti O -
- O -
E O -
- O -
Cadherin O +
( O -
B O -
) O -
, O +
and O +
anti O -
- O -
PODXL O +
( O -
C O -
) O +
and O +
antigen O +
expression O +
detected O +
by O +
a O +
flow O +
cytometer O -
. O -

The O +
specific O +
staining O +
is O +
indicated O +
by O +
green O +
histogram O +
and O +
corresponding O +
isotype O +
control O +
is O +
indicated O +
by O +
black O +
histogram O -
. O -

Suspension O +
culture O +
with O +
FGF O +
withdrawal O +
is O +
known O +
to O +
induce O +
differentiation O +
of O +
ES O +
cells O +
to O +
all O +
three O +
germ O +
layer O +
precursors O +
[ O -
12 O -
] O -
. O -

The O +
differentiation O +
status O +
of O +
the O +
EB O +
used O +
here O +
was O +
detected O +
to O +
contain O +
all O +
germ O +
cell O +
markers O +
by O +
RT O -
- O -
PCR O +
( O -
Fig. O +
4 O -
) O -
. O -

In O +
order O +
to O +
examine O +
how O +
more O +
antibodies O +
can O +
be O +
used O +
for O +
characterization O +
of O +
early O +
differentiation O +
events O +
from O +
human U-Species +
ES O +
cells O -
, O +
we O +
examined O +
the O +
expressions O +
of O +
endodermal O +
markers O -
, O +
SOX17 O -
, O +
GATA6 O +
and O +
PDX-1 O -
, O +
and O +
mesodermal O +
markers O -
, O +
Brachyury O +
and O +
GATA1 O -
, O +
in O +
the O +
undifferentiated O +
human U-Species +
ES O +
cells O +
and O +
differentiated O +
EBs O -
. O -

Expressions O +
of O +
SOX17 O -
, O +
GATA6 O -
, O +
PDX-1 O -
, O +
Brachyury O +
and O +
GATA1 O +
were O +
not O +
detected O +
in O +
undifferentiated O +
human U-Species +
ES O +
cells O +
( O -
data O +
not O +
shown O -
) O -
. O -

In O +
contrast O +
to O +
the O +
undifferentiated O +
ES O +
cells O -
, O +
subpopulations O +
of O +
SOX17- O -
, O +
GATA6- O -
, O +
Brachyury- O +
and O +
GATA1-positive O +
cells O +
were O +
observed O +
( O -
Fig O +
4 O -
) O -
. O -

These O +
results O +
suggest O +
that O +
both O +
endodermal O +
and O +
mesodermal O +
precursors O +
exist O +
in O +
EBs O +
with O +
FGF O +
withdrawal O +
for O +
8 O +
days O -
. O -

However O -
, O +
no O +
PDX-1-positive O +
cells O +
were O +
seen O +
in O +
EBs O +
differentiated O +
with O +
the O +
same O +
treatment O +
( O -
data O +
not O +
shown O -
) O -
.Figure O +
4Differentiated O +
EBs O +
were O +
analyzed O +
by O +
either O +
immunocytochemistry O +
or O +
RT O -
- O -
PCR O +
to O +
the O +
indicated O +
molecular O +
markers O -
. O -

( O -
A O -
) O +
Immunostaining O +
with O +
goat O +
anti O -
- O -
human U-Species +
SOX17 O +
( O -
Red O -
) O -
, O +
is O +
contrasted O +
with O +
Fluoro O +
Nissl O +
nuclear O +
staining O +
( O -
Green O -
) O -
. O -

( O -
B O -
) O +
Immunostaining O +
with O +
goat O +
anti O -
- O -
human U-Species +
GATA6 O +
( O -
Red O -
) O -
, O +
is O +
contrasted O +
with O +
DAPI O +
nuclear O +
staining O +
( O -
Blue O -
) O -
. O -

( O -
C O -
) O +
Immunostaining O +
with O +
goat O +
anti O -
- O -
human U-Species +
brachyury O +
( O -
Red O -
) O -
, O +
is O +
contrasted O +
with O +
DAPI O +
nuclear O +
staining O +
( O -
Blue O -
) O -
. O -

( O -
D O -
) O +
Immunostaining O +
with O +
mouse U-Species +
anti O -
- O -
human U-Species +
GATA1 O +
( O -
Red O -
) O -
. O -

Note O +
that O +
each O +
antibody O +
recognizes O +
subsets O +
of O +
EB O +
cells O -
. O -

Scale O +
bars O +
= O +
100 O +
μm O -
. O -

( O -
E O -
) O +
The O +
differentiation O +
status O +
of O +
EB O +
is O +
detected O +
by O +
RT O -
- O -
PCR O +
using O +
different O +
germ O +
layer O +
cell O +
markers O -
. O -

Selected O +
endoderm O +
markers O +
AFP O -
, O +
FoxA2 O -
; O +
mesoderm O +
markers O +
Hand1 O -
, O +
MSX1 O +
and O +
ectoderm O +
marker O +
Msl1 O +
were O +
all O +
highly O +
expressed O +
in O +
the O +
EB O +
samples O +
while O +
their O +
expression O +
was O +
either O +
undetectable O +
or O +
at O +
low O +
level O +
in O +
the O +
ES O +
samples O -
. O -

G3PDH O +
was O +
a O +
positive O +
control O +
showing O +
similar O +
amount O +
of O +
RNA O +
samples O +
were O +
used O +
for O +
analysis O -
. O -

Examination O +
of O +
cross O -
- O -
reactivity O +
of O +
antibodies O +
on O +
mouse U-Species +
ES O +
and O +
differentiated O +
cellsWe O +
have O +
also O +
examined O +
the O +
cross O -
- O -
reactivities O +
of O +
these O +
antibodies O +
to O +
mouse U-Species +
ES O +
cells O +
using O +
mouse U-Species +
D3 O +
ES O +
cell O +
line O +
and O +
mouse U-Species +
fetal O +
endodermal O +
tissue O -
. O -

Cross O -
- O -
reactivity O +
to O +
mouse U-Species +
of O +
goat O +
anti O -
- O -
Oct3 O -
/ O -
4 O -
, O +
goat O +
anti O -
- O -
PDX-1 O -
, O +
goat O +
anti O -
- O -
SOX17 O +
and O +
mouse U-Species +
anti O -
- O -
SOX2 O +
was O +
detected O -
. O -

Minimal O +
cross O -
- O -
reactivity O +
to O +
mouse U-Species -
, O +
measured O +
by O +
10 O -
% O +
intensity O +
to O +
human U-Species +
by O +
higher O +
than O +
control O +
cells O -
, O +
was O +
observed O +
in O +
mouse U-Species +
anti O -
- O -
CD9 O +
and O +
mouse U-Species +
anti O -
- O -
E O -
- O -
cadherin O +
antibodies O -
. O -

Goat U-Species +
anti O -
- O -
Nanog O +
and O +
mouse U-Species +
anti O -
- O -
PODXL O +
antibodies O +
appear O +
to O +
be O +
human U-Species -
- O -
specific O +
as O +
well O +
( O -
data O +
not O +
shown O -
) O -
. O -

The O +
subtypes O +
of O +
monoclonal O +
antibodies O +
were O +
also O +
identified O +
in O +
the O +
best O +
clones O -
. O -

These O +
results O +
are O +
summarized O +
in O +
Table O +
2.Table O +
2Summary O +
of O +
antibodies O +
detection O +
in O +
ES O +
and O +
EB O +
samples O -
. O -

AntibodyESEBReactivity O +
to O +
mouseIsotype U-Species +
of O +
monoclonal O +
antibody O +
( O -
Clone O +
No. O -
) O -
Gt O +
× O +
hBrachyuryNoYesNT*Ms O +
× O +
hDPPA5YesNT*NT*ND*Gt O +
× O +
hGATA6NoYesNT*Gt O +
× O +
hNanogYesDownNoGt O +
× O +
hOct O +
3 O -
/ O -
4YesDownYesGt O +
× O +
hPDX-1NoNoYesGt O +
× O +
hSOX17NoYesYesMs O +
× O +
hCD9YesNoMinimalMouse O +
IgG2B O +
( O -
clone O +
209306 O -
) O -
Ms O +
× O +
hE O -
- O -
cadherinYesNoMinimalMouse O +
IgG2B O +
( O -
clone O +
180224 O -
) O -
Ms O +
× O +
hGATA1NoYesNT*Rat O +
IgG2B O +
( O -
clone O +
234732 O -
) O -
Ms O +
× O +
hPODXLYesNoNoMouse O +
IgG2A O +
( O -
clone O +
222328 O -
) O -
Ms O +
× O +
hSOX2YesYesYesMouse O +
IgG2A O +
( O -
clone O +
245610 O -
) O -
*NT O -
, O +
Not O +
tested O -
; O +
ND O -
, O +
Not O +
determined O -
. O -

The O +
expression O +
patterns O +
detected O +
using O +
antibodies O +
developed O +
in O +
our O +
facility O +
are O +
consistent O +
with O +
data O +
reported O +
using O +
reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O +
or O +
cDNA O +
microarrays O -
. O -

Moreover O +
several O +
of O +
the O +
monoclonal O +
antibodies O +
have O +
differing O +
heavy O +
chain O +
subunits O +
allowing O +
double O +
labeling O +
using O +
subtype O +
specific O +
markers O +
to O +
be O +
performed O -
. O -

In O +
summary O -
, O +
we O +
have O +
developed O +
a O +
useful O +
collection O +
of O +
antibodies O +
that O +
would O +
be O +
useful O +
for O +
identification O +
of O +
stem O +
cell O +
characteristics O +
and O +
assessment O +
of O +
differentiation O -
. O -

Several O +
additional O +
antibodies O +
to O +
the O +
molecules O +
that O +
have O +
been O +
identified O +
as O +
potential O +
cell O +
lineage O +
markers O +
[ O -
13 O -
] O +
are O +
currently O +
under O +
development O +
using O +
the O +
same O +
approach O -
. O -

Cloning O +
and O +
expression O +
of O +
Brachyury O -
, O +
DPPA5 O -
, O +
CD9 O -
, O +
E O -
- O -
Cadherin O -
, O +
GATA1 O -
, O +
GATA6 O -
, O +
Nanog O -
, O +
Oct3 O -
/ O -
4 O -
, O +
PDX-1 O -
, O +
PODXL O -
, O +
SOX2 O +
and O +
SOX17Brachyury O +
( O -
aa O -
. O -

1–202 O -
) O -
, O +
DPPA5 O +
( O -
a.a O -
. O -

1–116 O -
) O -
, O +
GATA1 O +
( O -
a.a O -
. O +
1–413 O -
) O -
, O +
GATA6 O +
( O -
aa O -
. O -

1–449 O -
) O -
, O +
Nanog O +
( O -
aa O -
. O -

153–305 O -
) O -
, O +
Oct3 O -
/ O -
4 O +
( O -
aa O -
. O +
1–265 O -
) O -
, O +
PDX-1 O +
( O -
aa O -
. O -

1–283 O -
) O -
, O +
SOX2 O +
( O -
aa O -
. O +
135–317 O -
) O +
and O +
SOX17 O +
( O -
aa O -
. O +
177–414 O -
) O +
were O +
expressed O +
in O +
E. O +
Coli O +
and O +
extracellular O +
domains O +
of O +
CD9 O -
, O +
E O -
- O -
Cadherin O -
, O +
PODXL O +
were O +
expressed O +
in O +
mouse U-Species +
NSO O +
cells O -
. O -

All O +
proteins O +
were O +
purified O +
and O +
sequenced O +
before O +
they O +
were O +
used O +
as O +
antigens O +
for O +
immunizations O +
and O +
as O +
substrate O +
for O +
antibody O +
screening O +
and O +
subcloning O -
. O -

Production O +
and O +
purification O +
of O +
antibodiesAll O +
monoclonal O +
antibodies O +
were O +
derived O +
from O +
fusions O +
of O +
mouse U-Species +
myeloma O +
with O +
B O +
cells O +
obtained O +
from O +
BALB B-Species -
/ I-Species -
c I-Species +
mice L-Species +
which O +
had O +
been O +
immunized O +
with O +
purified O +
antigen O -
. O -

The O +
IgG O +
fraction O +
of O +
the O +
culture O +
supernatant O +
was O +
purified O +
by O +
Protein O +
G O +
affinity O +
chromatography O +
( O -
Sigma O -
) O -
. O -

Each O +
panel O +
of O +
antibodies O +
was O +
screened O +
and O +
selected O +
for O +
their O +
abilities O +
to O +
detect O +
purified O +
recombinant O +
antigen O +
in O +
direct O +
ELISA O +
and O +
Western O +
blot O -
. O -

All O +
polyclonal O +
antibodies O +
were O +
derived O +
from O +
sera O +
of O +
goats U-Species +
which O +
had O +
been O +
immunized O +
and O +
boost O +
it O +
with O +
purified O +
antigen O -
. O -

Antibody O +
was O +
purified O +
from O +
the O +
sera O +
by O +
an O +
antigen O -
- O -
affinity O +
chromatography O -
. O -

Cells O +
and O +
cell O +
cultureHuman O +
Caco-2 O -
, O +
MG-63 O -
, O +
MCF-7 O -
, O +
NTERA-2 O +
and O +
mouse U-Species +
D3 O +
cells O +
were O +
purchased O +
from O +
American O +
Type O +
Culture O +
Collection O +
( O -
ATCC O -
) O -
. O -

Cells O +
were O +
cultured O +
according O +
to O +
the O +
ATCC O +
instructions O -
. O -

Information O +
regarding O +
human U-Species +
ES O +
cell O +
line O +
HSF-6 O +
( O -
NIH O +
code O +
UC06 O -
) O +
can O +
be O +
obtained O +
at O +
the O +
website O +
[ O -
14 O -
] O -
. O -

Undifferentiated O +
human U-Species +
ES O +
cells O +
were O +
cultured O +
according O +
to O +
the O +
protocol O +
provided O +
by O +
the O +
University O +
of O +
California O -
, O +
San O +
Francisco O +
in O +
human U-Species +
ES O +
culture O +
medium O +
[ O -
DMEM O +
supplemented O +
with O +
20 O -
% O +
KnockOut O +
Serum O +
Replacement O +
( O -
Invitrogen O -
) O +
and O +
5 O +
ng O -
/ O -
mL O +
of O +
bFGF O +
( O -
R&D O +
Systems O -
) O -
] O -
. O -

To O +
induce O +
formation O +
of O +
embryoid O +
bodies O +
( O -
EBs O -
) O -
, O +
ES O +
colonies O +
were O +
harvested O -
, O +
separated O +
from O +
the O +
MEF O +
feeder O +
cells O +
by O +
gravity O -
, O +
gently O +
resuspended O +
in O +
ES O +
culture O +
medium O +
and O +
transferred O +
to O +
non O -
- O -
adherent O +
suspension O +
culture O +
dishes O +
( O -
Corning O -
) O -
. O -

Unless O +
otherwise O +
noted O -
, O +
EBs O +
derived O +
from O +
human U-Species +
ES O +
cell O +
aggregates O +
were O +
cultured O +
for O +
8 O +
days O +
in O +
ES O +
culture O +
medium O +
deprived O +
of O +
bFGF O +
and O +
used O +
for O +
analysis O +
by O +
immunohistochemistry O +
as O +
described O -
. O -

Western O +
blotCells O +
are O +
solubilized O +
in O +
hot O +
2 O -
× O +
SDS O +
gel O +
sample O +
buffer O +
( O -
20 O +
mM O +
dithiothreitol O -
, O +
6 O -
% O +
SDS O -
, O +
0.25 O +
M O +
Tris O -
, O +
pH O +
6.8 O -
, O +
10 O -
% O +
glycerol O -
, O +
10 O +
mM O +
NaF O +
and O +
bromophenyl O +
blue O -
) O +
at O +
2 O +
× O +
106 O +
per O +
mL. O +
The O +
extracts O +
are O +
heated O +
in O +
a O +
boiling O +
water O +
bath O +
for O +
5 O +
minutes O +
and O +
sonicated O +
with O +
a O +
probe O +
sonicator O +
with O +
3–4 O +
bursts O +
of O +
5–10 O +
seconds O +
each O -
. O -

Samples O +
are O +
diluted O +
with O +
1 O -
× O +
SDS O +
sample O +
buffer O +
to O +
the O +
desired O +
loading O +
of O +
1–5 O +
× O +
103 O +
per O +
lane O -
. O -

Lysates O +
were O +
resolved O +
by O +
SDS O -
- O -
PAGE O -
, O +
transferred O +
to O +
Immobilon O -
- O -
P O +
membrane O -
, O +
and O +
immunoblotted O +
with O +
0.5 O +
μg O -
/ O -
mL O +
primary O +
Abs O +
as O +
described O +
in O +
R&D O +
Systems O +
Website O +
[ O -
15 O -
] O -
. O -

ImmunohistochemistryAntibodies O +
were O +
used O +
with O +
the O +
appropriate O +
secondary O +
reagents O +
at O +
a O +
concentration O +
of O +
5 O +
to O +
10 O +
μg O -
/ O -
ml O -
. O -

Cells O +
or O +
sections O +
of O +
EBs O +
were O +
fixed O +
with O +
4 O -
% O +
paraformaldehyde O +
in O +
PBS O +
at O +
room O +
temperature O +
for O +
20 O +
min O -
, O +
then O +
blocked O +
and O +
permeabilized O +
with O +
0.1 O -
% O +
Triton O +
X-100 O -
, O +
1 O -
% O +
BSA O -
, O +
10 O -
% O +
normal O +
donkey U-Species +
serum O +
in O +
PBS O +
at O +
room O +
temperature O +
for O +
45 O +
min O -
. O -

After O +
blocking O -
, O +
cells O +
were O +
incubated O +
with O +
diluted O +
primary O +
antibody O +
overnight O +
at O +
4 O -
° O -
C O +
followed O +
by O +
coupled O +
anti O -
- O -
mouse U-Species +
or O +
anti O -
- O -
goat O +
IgG O +
( O -
Molecular O +
Probes O -
) O +
at O +
room O +
temperature O +
in O +
the O +
dark O +
for O +
an O +
hour O -
. O -

Between O +
each O +
step O +
cells O +
were O +
washed O +
with O +
PBS O +
with O +
0.1 O -
% O +
BSA O -
. O -

RT O -
- O -
PCRTotal O +
RNA O +
was O +
extracted O +
from O +
EBs O +
using O +
Trizol O +
LS O +
( O -
Invitrogen O -
) O -
. O -

cDNA O +
was O +
synthesized O +
by O +
using O +
Superscript O +
II O +
reverse O +
transcriptase O +
( O -
Invitrogen O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
recommendations O -
. O -

The O +
PCR O +
primers O +
are O +
available O +
upon O +
request O -
. O -

Flow O +
cytometryAntibodies O +
were O +
prepared O +
at O +
the O +
concentration O +
of O +
0.1 O +
mg O -
/ O -
mL. O +
10 O +
μL O +
of O +
the O +
stock O +
solution O +
was O +
added O +
to O +
1 O +
– O +
2.5 O +
× O +
105 O +
cells O +
in O +
a O +
total O +
reaction O +
volume O +
not O +
exceeding O +
200 O +
μL. O +
The O +
sample O +
was O +
then O +
incubated O +
for O +
20 O +
min O +
at O +
2–8 O +
° O -
C O -
. O -

Following O +
incubation O -
, O +
excess O +
antibody O +
was O +
removed O +
by O +
washing O +
cells O +
twice O +
with O +
FACS O +
buffer O +
( O -
2 O -
% O +
FCS O +
and O +
0.1 O -
% O +
sodium O +
azide O +
in O +
Hank O -
's O +
buffer O -
) O -
. O -

After O +
wash O -
, O +
cells O +
were O +
resuspend O +
in O +
200 O +
μL O +
of O +
FACS O +
buffer O +
and O +
the O +
binding O +
of O +
unlabeled O +
monoclonal O +
antibodies O +
was O +
visualized O +
by O +
adding O +
10 O +
μL O +
of O +
a O +
25 O +
μg O -
/ O -
mL O +
stock O +
solution O +
of O +
a O +
secondary O +
developing O +
reagent O +
such O +
as O +
goat O +
anti O -
- O -
mouse U-Species +
IgG O +
conjugated O +
to O +
a O +
fluorochrome O +
for O +
20 O +
min O +
at O +
2–8 O -
° O -
C O -
. O -

Following O +
incubation O -
, O +
cells O +
were O +
washed O +
once O +
with O +
FACS O +
buffer O -
, O +
once O +
with O +
PBS O -
. O -

After O +
wash O -
, O +
cells O +
were O +
resuspend O +
in O +
400 O +
μL O +
of O +
PBS O +
and O +
analyzed O +
on O +
a O +
FACScant O +
flow O +
cytometer O +
( O -
Becton O -
- O -
Dickinson O -
, O +
Mountain O +
View O -
, O +
CA O -
) O -
. O -

Five O +
thousand O +
events O +
were O +
collected O +
and O +
analyzed O +
using O +
CELL O +
Quest O +
software O -
. O -

BackgroundIn O +
order O +
to O +
compare O +
the O +
gene O +
expression O +
profiles O +
of O +
human U-Species +
embryonic O +
stem O +
cell O +
( O -
hESC O -
) O +
lines O +
and O +
their O +
differentiated O +
progeny O +
and O +
to O +
monitor O +
feeder O +
contaminations O -
, O +
we O +
have O +
examined O +
gene O +
expression O +
in O +
seven O +
hESC O +
lines O +
and O +
human U-Species +
fibroblast O +
feeder O +
cells O +
using O +
Illumina O -
® O +
bead O +
arrays O +
that O +
contain O +
probes O +
for O +
24,131 O +
transcript O +
probes O -
. O -

ResultsA O +
total O +
of O +
48 O +
different O +
samples O +
( O -
including O +
duplicates O -
) O +
grown O +
in O +
multiple O +
laboratories O +
under O +
different O +
conditions O +
were O +
analyzed O +
and O +
pairwise O +
comparisons O +
were O +
performed O +
in O +
all O +
groups O -
. O -

Hierarchical O +
clustering O +
showed O +
that O +
blinded O +
duplicates O +
were O +
correctly O +
identified O +
as O +
the O +
closest O +
related O +
samples O -
. O -

hESC O +
lines O +
clustered O +
together O +
irrespective O +
of O +
the O +
laboratory O +
in O +
which O +
they O +
were O +
maintained O -
. O -

hESCs O +
could O +
be O +
readily O +
distinguished O +
from O +
embryoid O +
bodies O +
( O -
EB O -
) O +
differentiated O +
from O +
them O +
and O +
the O +
karyotypically O +
abnormal O +
hESC O +
line O +
BG01V O -
. O -

The O +
embryonal O +
carcinoma O +
( O -
EC O -
) O +
line O +
NTera2 O +
is O +
a O +
useful O +
model O +
for O +
evaluating O +
characteristics O +
of O +
hESCs O -
. O -

Expression O +
of O +
subsets O +
of O +
individual O +
genes O +
was O +
validated O +
by O +
comparing O +
with O +
published O +
databases O -
, O +
MPSS O +
( O -
Massively O +
Parallel O +
Signature O +
Sequencing O -
) O +
libraries O -
, O +
and O +
parallel O +
analysis O +
by O +
microarray O +
and O +
RT O -
- O -
PCR.Conclusionwe O +
show O +
that O +
Illumina O -
's O +
bead O +
array O +
platform O +
is O +
a O +
reliable O -
, O +
reproducible O +
and O +
robust O +
method O +
for O +
developing O +
base O +
global O +
profiles O +
of O +
cells O +
and O +
identifying O +
similarities O +
and O +
differences O +
in O +
large O +
number O +
of O +
samples O -
. O -

Embryonic O +
stem O +
cells O +
( O -
ESCs O -
) O -
, O +
derived O +
from O +
the O +
inner O +
cell O +
mass O +
of O +
pre O -
- O -
implantation O +
embryos O -
, O +
have O +
been O +
recognized O +
as O +
the O +
most O +
pluripotent O +
stem O +
cell O +
population O -
. O -

Human U-Species +
ES O +
cells O +
( O -
hESCs O -
) O +
can O +
be O +
maintained O +
and O +
propagated O +
on O +
mouse U-Species +
or O +
human U-Species +
fibroblast O +
feeders O +
for O +
extended O +
periods O +
in O +
media O +
containing O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
[ O -
1 O -
- O -
4 O -
] O +
while O +
retaining O +
the O +
ability O +
to O +
differentiate O +
into O +
ectoderm O -
, O +
endoderm O +
and O +
mesoderm O +
as O +
well O +
as O +
trophoectoderm O +
and O +
germ O +
cells O -
. O -

Gene O +
expression O +
in O +
hESC O +
has O +
been O +
investigated O +
by O +
a O +
variety O +
of O +
techniques O +
including O +
massively O +
parallel O +
signature O +
sequencing O +
( O -
MPSS O -
) O -
, O +
serial O +
analysis O +
of O +
gene O +
expression O +
( O -
SAGE O -
) O -
, O +
expressed O +
sequence O +
tag O +
( O -
EST O -
) O +
scan O -
, O +
large O +
scale O +
microarrays O -
, O +
focused O +
cDNA O +
microarrays O -
, O +
and O +
immunocytochemistry O +
[ O -
5 O -
- O -
7 O -
] O -
. O -

Markers O +
for O +
hESCs O +
that O +
may O +
also O +
contribute O +
to O +
the O +
" O -
stemness O -
" O +
phenotype O +
have O +
been O +
established O +
and O +
markers O +
that O +
distinguish O +
ESCs O +
from O +
embryoid O +
bodies O +
( O -
EB O -
) O +
have O +
been O +
developed O -
. O -

Novel O +
stage O -
- O -
specific O +
genes O +
that O +
distinguish O +
between O +
hESCs O +
and O +
EBs O +
have O +
been O +
identified O +
and O +
allelic O +
differences O +
between O +
ESC O +
have O +
begun O +
to O +
be O +
recognized O +
[ O -
8 O -
- O -
10 O -
] O -
. O -

As O +
the O +
potential O +
of O +
hESCs O +
and O +
their O +
derivatives O +
for O +
regenerative O +
medicine O +
is O +
being O +
evaluated O -
, O +
it O +
has O +
become O +
clear O +
that O +
the O +
overall O +
state O +
of O +
the O +
cells O -
, O +
degree O +
of O +
contamination O +
and O +
comparisons O +
of O +
the O +
more O +
than O +
a O +
hundred O +
different O +
newly O +
derived O +
lines O +
will O +
need O +
to O +
be O +
performed O -
. O -

It O +
will O +
be O +
necessary O +
to O +
develop O +
methods O +
to O +
monitor O +
and O +
assess O +
hESC O +
and O +
their O +
derivatives O +
on O +
a O +
routine O +
basis O -
. O -

Since O +
differentiated O +
cells O +
are O +
often O +
scattered O +
within O +
or O +
at O +
the O +
edge O +
of O +
colonies O +
[ O -
11 O -
] O +
and O +
the O +
differentiation O +
is O +
so O +
subtle O +
that O +
morphological O +
characteristics O +
and O +
even O +
immunohistochemistry O +
are O +
insufficient O +
to O +
detect O +
it O -
, O +
larger O +
scale O +
methods O +
of O +
analysis O +
need O +
to O +
be O +
developed O -
. O -

Our O +
strategy O +
was O +
to O +
compare O +
a O +
variety O +
of O +
different O +
hESC O +
lines O +
that O +
were O +
derived O +
and O +
expanded O +
by O +
three O +
different O +
institutions O +
( O -
WiCell O +
Research O +
Institute O -
, O +
BresaGen O -
, O +
Inc. O -
, O +
and O +
Technion O -
- O -
Israel O +
Institute O +
of O +
Technology O -
) O -
, O +
and O +
cultured O +
in O +
two O +
separate O +
laboratories O +
( O -
Burnham O +
Institute O +
and O +
NIA O -
) O +
to O +
a O +
baseline O +
set O +
of O +
data O +
against O +
which O +
cell O +
samples O +
can O +
be O +
compared O -
. O -

By O +
using O +
cells O +
grown O +
in O +
different O +
conditions O +
we O +
expected O +
to O +
be O +
able O +
to O +
identify O +
core O +
commonalities O +
and O +
by O +
comparing O +
feeders O +
and O +
embryoid O +
bodies O +
( O -
EB O -
) O +
with O +
hESC O +
identify O +
measures O +
of O +
contamination O +
and O +
early O +
markers O +
of O +
differentiation O -
. O -

Further O -
, O +
by O +
comparing O +
embryonal O +
carcinoma O +
cell O +
( O -
EC O -
) O +
and O +
karyotypically O +
variant O +
lines O +
with O +
hESC O -
, O +
we O +
would O +
be O +
able O +
to O +
directly O +
assess O +
their O +
utility O +
as O +
surrogates O +
( O -
for O +
quality O +
control O +
purposes O -
) O +
for O +
hESC O -
. O -

We O +
employed O +
a O +
pre O -
- O -
commercial O +
prototype O +
of O +
the O +
Illumina O +
HumanRef-8 U-Species +
BeadChip O +
[ O -
12 O -
] O -
, O +
a O +
genome O -
- O -
scale O +
bead O +
based O +
array O +
technology O +
that O +
combines O +
the O +
sensitivity O +
and O +
low O +
cost O +
of O +
a O +
focused O +
array O +
with O +
the O +
coverage O +
of O +
a O +
large O +
scale O +
array O -
, O +
while O +
requiring O +
much O +
smaller O +
sample O +
sizes O +
than O +
MPSS O -
, O +
EST O +
scan O +
or O +
SAGE O -
. O -

We O +
show O +
that O +
the O +
Illumina O +
bead O +
based O +
array O +
correctly O +
identified O +
blinded O +
duplicates O +
as O +
the O +
closest O +
related O +
samples O +
and O +
readily O +
distinguished O +
between O +
hESC O +
lines O -
, O +
as O +
well O +
as O +
between O +
ESCs O +
and O +
EBs O +
derived O +
from O +
them O -
. O -

This O +
array O +
allowed O +
us O +
to O +
estimate O +
the O +
degree O +
of O +
feeder O +
contamination O +
present O +
in O +
the O +
cultures O -
. O -

Similarities O +
and O +
differences O +
between O +
EC O +
line O +
NTera2 O +
and O +
hESC O +
lines O +
could O +
be O +
determined O +
and O +
verified O -
, O +
and O +
the O +
database O +
comparisons O +
allowed O +
us O +
to O +
identify O +
core O +
self O -
- O -
renewal O +
pathways O +
that O +
regulate O +
hESC O +
propagation O -
. O -

Multiple O +
hESC O +
lines O +
can O +
be O +
assessed O +
by O +
Illumina O +
bead O +
arrayForty O -
- O -
eight O +
samples O +
were O +
selected O +
from O +
multiple O +
laboratories O +
and O +
gene O +
expression O +
profiles O +
were O +
examined O +
using O +
a O +
bead O +
array O +
containing O +
24,131 O +
transcripts O +
derived O +
from O +
the O +
Human U-Species +
RefSeq O +
database O +
that O +
included O +
full O +
length O +
and O +
splice O +
variants O -
. O -

Each O +
gene O +
was O +
represented O +
by O +
sequences O +
containing O +
an O +
average O +
of O +
thirty O +
beads O +
to O +
provide O +
an O +
internal O +
measure O +
of O +
reliability O -
. O -

Samples O +
included O +
7 O +
hESC O +
lines O +
BG01 O -
, O +
BG02 O -
, O +
BG03 O -
, O +
I6 O -
, O +
H1 O -
, O +
H7 O +
and O +
H9 O -
, O +
EBs O +
that O +
were O +
differentiated O +
from O +
hESCs O +
of O +
the O +
three O +
BG O +
lines O -
, O +
human U-Species +
fibroblast O +
feeder O +
HS27 O +
( O -
ATCC O -
) O -
, O +
hESC O -
- O -
derived O +
fibroblasts O -
, O +
karyotypically O +
abnormal O +
hESC O +
line O +
BG01 O +
Variant O +
( O -
BG01V O -
) O +
[ O -
13 O -
] O +
and O +
EC O +
line O +
NTera2 O +
[ O -
14 O -
] O -
. O -

Samples O +
were O +
blinded O +
and O +
biological O +
and O +
technical O +
repeats O +
were O +
examined O +
at O +
the O +
same O +
time O -
. O -

A O +
single O +
slide O +
contained O +
eight O +
replicates O +
and O +
six O +
such O +
slides O +
were O +
used O +
for O +
the O +
present O +
set O +
of O +
samples O -
. O -

Results O +
were O +
normalized O +
to O +
average O +
following O +
Illumina O +
Beadstudio O +
manual O +
and O +
the O +
quality O +
of O +
each O +
sample O +
was O +
assessed O +
by O +
immunocytochemitsry O +
and O +
RT O -
- O -
PCR O +
prior O +
to O +
subjecting O +
them O +
for O +
analysis O +
( O -
data O +
not O +
shown O -
) O -
. O -

Results O +
from O +
the O +
entire O +
sample O +
set O +
are O +
available O +
for O +
download O +
as O +
an O +
excel O +
spreadsheet O +
( O -
Additional O +
file O +
1 O -
) O +
and O +
a O +
CD O +
of O +
the O +
results O +
is O +
available O +
upon O +
request O -
. O -

The O +
total O +
number O +
of O +
genes O +
identified O +
as O +
expressed O +
at O +
> O -
0.99 O +
confidence O +
is O +
summarized O +
in O +
Table O +
1 O -
. O -

Intensity O +
results O +
are O +
reported O +
in O +
arbitrary O +
units O +
and O +
ranged O +
from O +
10 O +
to O +
20,000 O +
( O -
a O +
two O +
thousand O +
fold O +
range O -
) O -
. O -

Although O +
the O +
sensitivity O +
of O +
the O +
array O +
has O +
been O +
reported O +
to O +
be O +
high O -
, O +
in O +
the O +
present O +
report O +
we O +
have O +
restricted O +
our O +
analysis O +
to O +
expression O +
of O +
at O +
least O +
100 O +
units O +
in O +
any O +
one O +
sample O -
. O -

Using O +
this O +
cutoff O -
, O +
on O +
average O +
cells O +
expressed O +
approximately O +
8,000 O +
transcripts O +
( O -
Table O +
1 O -
, O +
2 O -
) O -
, O +
a O +
number O +
similar O +
to O +
the O +
number O +
detected O +
by O +
SAGE O -
, O +
MPSS O +
and O +
EST O +
analysis O +
[ O -
5 O -
- O -
7,10,15,16 O -
] O -
. O -

As O +
with O +
other O +
analysis O -
, O +
genes O +
with O +
the O +
highest O +
abundance O +
were O +
housekeeping O +
genes O -
, O +
ribosomal O +
genes O +
and O +
structural O +
genes O +
( O -
Table O +
2 O +
and O +
Additional O +
file O +
1 O -
) O -
. O -

These O +
genes O +
were O +
similar O +
in O +
most O +
samples O +
though O +
relative O +
levels O +
varied O -
. O -

Table O +
1Correlation O +
coefficients O +
of O +
paired O +
samples O +
in O +
this O +
bead O +
array O +
In O +
order O +
to O +
test O +
the O +
reproducibility O +
and O +
reliability O +
of O +
the O +
bead O +
array O -
, O +
duplicate O +
samples O +
of O +
hESC O +
lines O +
H9 O -
, O +
I6 O -
, O +
and O +
EC O +
line O +
NTera2 O +
and O +
human U-Species +
fibroblast O +
feeders O +
( O -
HS27 O -
) O +
were O +
run O +
at O +
the O +
same O +
time O +
and O +
correlation O +
coefficients O +
( O -
R2 O -
) O +
of O +
duplicates O +
were O +
generated O +
using O +
the O +
entire O +
data O +
of O +
all O +
genes O +
with O +
expression O +
level O +
> O -
0 O +
( O -
§ O -
) O -
, O +
or O +
genes O +
with O +
detection O +
confidence O +
> O -
0.99 O +
( O -
* O -
) O -
, O +
or O +
genes O +
with O +
detection O +
confidence O +
> O -
0.99 O +
and O +
expression O +
level O +
> O +
100 O +
arbitrary O +
units O +
( O -
# O -
) O -
. O -

Note O +
that O +
the O +
correlation O +
coefficients O +
are O +
in O +
the O +
range O +
of O +
0.9382–0.9761 O +
and O +
the O +
number O +
of O +
genes O +
was O +
in O +
the O +
range O +
of O +
10,000–14,000.Duplicate O +
SamplesNo O -
. O +
of O +
all O +
genes O +
( O -
expr.>0 O -
) O -
§R2of O +
all O +
genes O +
( O -
expr O -
. O -

> O -
0 O -
) O -
No O -
. O +
of O +
genes O +
( O -
> O -
0.99 O -
) O -
*R2 O +
of O +
genes O +
( O -
> O -
0.99 O -
) O -
*No O -
. O +
( O -
> O -
0.99 O -
, O +
level>100 O -
) O -
#H918,8990.868113,6720.97087,408I619,1390.866312,5700.97616,826NTera219,1620.874114,0360.93827,147Feeder18,1570.872410,6060.97517,021Table O +
2Distribution O +
of O +
genes O +
with O +
expression O +
levels O +
< O -
50 O +
and O +
> O -
50–10,000 O +
as O +
detected O +
by O +
Illumina O +
bead O +
array O +
in O +
8 O +
hESC O +
populations O +
All O +
human U-Species +
ESC O +
samples O +
were O +
hybridized O +
in O +
one O +
experiment O +
and O +
the O +
relative O +
detection O +
levels O +
of O +
genes O +
were O +
binned O +
to O +
obtain O +
a O +
global O +
overview O +
of O +
transcription O -
, O +
approximately O +
8 O -
, O +
000 O +
genes O +
( O -
~50 O -
% O -
) O +
were O +
greater O +
than O +
100 O +
arbitrary O +
units O -
. O -

The O +
numbers O +
are O +
similar O +
to O +
results O +
obtained O +
by O +
other O +
large O +
scale O +
analysis O +
such O +
as O +
MPSS.Abundance O +
( O -
relative O +
detection O +
levels O -
) O -
H9H9 O +
on O +
human U-Species +
feedersI6BG01BG02BG03BG01VPooled O +
( O -
H1 O -
, O +
H7 O -
, O +
H9 O -
) O -
No.%No.%No.%No.%No.%No.%No.%No.%<502,90921.26,06738.43,55925.34,52830.74,25630.54,70632.24194.35,80334.4>5010,81778.89,74761.610,48474.710,23269.39,69469.59,91567.89,43895.711,08565.6>1008,12659.27,53947.77,40952.87,70352.27,49653.77,43050.87,23073.38,21748.7>5003,07722.42,94718.62,62618.73,06520.82,95021.12,85219.52,85128.92,94117.4>10001,62911.91,62510.31,49010.61,63811.11,58911.41,51710.41,56615.91,5549.2>50002481.82571.62561.82561.72631.92621.82752.82511.5>10000900.7940.61120.8920.61000.71070.71011.0940.6Total O +
No. O +
of O +
genes O +
detected O +
at O +
> O -
0.99 O +
confidence13,72615,81414,04314,76013,95014,6219,85716,888One O +
of O +
the O +
advantages O +
of O +
the O +
Illumina O +
arrays O +
is O +
the O +
ability O +
of O +
running O +
multiple O +
samples O +
simultaneously O +
thus O +
allowing O +
multiple O +
pairwise O +
comparisons O +
to O +
be O +
performed O +
readily O -
. O -

To O +
show O +
the O +
similarity O +
of O +
relative O +
gene O +
expression O +
between O +
samples O -
, O +
we O +
have O +
used O +
Illumina O +
Beadstudio O +
and O +
clustering O +
software O +
packages O +
Pcluster O +
[ O -
17 O -
] O +
and O +
TreeView O +
[ O -
18 O -
] O +
to O +
generate O +
a O +
heat O -
- O -
map O +
( O -
Figure O +
1 O -
) O +
and O +
a O +
dendrogram O +
( O -
Figure O +
2 O -
) O -
. O -

Based O +
on O +
their O +
properties O -
, O +
we O +
classified O +
some O +
of O +
our O +
samples O +
into O +
four O +
groups O -
, O +
( O -
A O -
) O +
undifferentiated O +
hESCs O +
( O -
including O +
a O +
sample O +
from O +
karyotypically O +
abnormal O +
variant O -
, O +
designated O +
as O +
" O -
ES O -
" O -
, O +
n O +
= O +
11 O -
) O -
; O +
( O -
B O -
) O +
differentiated O +
ES O +
cells O +
and O +
EBs O +
( O -
designated O +
as O +
" O -
EB O -
" O -
, O +
n O +
= O +
6 O -
) O -
; O +
( O -
C O -
) O +
hESC O +
derived O +
neural O +
cells O +
( O -
designated O +
as O +
" O -
NS O -
" O -
, O +
n O +
= O +
3 O -
) O -
; O +
and O +
( O -
D O -
) O +
hESC O +
derived O +
mesenchyme O +
and O +
human U-Species +
fibroblast O +
feeder O +
cells O +
( O -
designated O +
as O +
" O -
FB O -
" O -
, O +
n O +
= O +
5 O -
) O +
and O +
these O +
groups O +
were O +
shown O +
in O +
the O +
heat O -
- O -
map O -
. O -

Comparing O +
the O +
overall O +
pattern O +
of O +
expression O -
, O +
we O +
made O +
several O +
important O +
observations O -
: O +
1 O -
) O +
Duplicates O +
clustered O +
close O +
to O +
each O +
other O +
and O +
were O +
more O +
related O +
to O +
each O +
other O +
than O +
to O +
any O +
other O +
sample O -
; O +
2 O -
) O +
ESCs O +
appeared O +
more O +
similar O +
to O +
each O +
other O +
than O +
to O +
EBs O -
; O +
3 O -
) O +
NTera2 O +
cells O +
appeared O +
more O +
similar O +
to O +
ESCs O +
while O +
differentiated O +
NTera2 O +
and O +
EBs O +
can O +
be O +
readily O +
distinguished O +
from O +
their O +
parent O +
populations O +
( O -
Figure O +
2 O -
) O -
; O +
4 O -
) O +
BG01V O +
appeared O +
similar O +
to O +
undifferentiated O +
BG01 O +
cells O -
; O +
5 O -
) O +
In O +
general O +
ESC O +
lines O +
grown O +
in O +
one O +
laboratory O +
appeared O +
more O +
similar O +
than O +
samples O +
grown O +
in O +
other O +
laboratories O -
, O +
suggesting O +
that O +
culture O +
conditions O +
affected O +
gene O +
expression O +
but O +
that O +
this O +
effect O +
was O +
much O +
smaller O +
than O +
the O +
effect O +
of O +
differentiation O -
. O -

Figure O +
1Unsupervised O +
two O -
- O -
way O +
hierarchical O +
cluster O +
analysis O +
of O +
differentially O +
expressed O +
genes O +
illustrated O +
in O +
a O +
heat O -
- O -
map O -
. O -

Each O +
row O +
represents O +
the O +
relative O +
levels O +
of O +
expression O +
of O +
a O +
single O +
gene O -
. O -

Each O +
column O +
represents O +
a O +
sample O -
. O -

The O +
samples O +
include O +
four O +
groups O +
of O +
cells O -
, O +
ES O +
designates O +
11 O +
samples O +
of O +
hESCs O -
, O +
EB O +
contains O +
6 O +
samples O +
of O +
differentiated O +
ESCs O +
and O +
EBs O -
, O +
NS O +
consists O +
of O +
3 O +
hESC O +
derived O +
neural O +
cells O +
and O +
FB O +
is O +
a O +
collection O +
of O +
hESC O +
derived O +
mesenchyme O +
and O +
fibroblasts O -
. O -

High O +
expressions O +
relative O +
to O +
mean O +
are O +
colored O +
red O -
. O -

Low O +
expressions O +
are O +
colored O +
green O -
. O -

Black O +
represents O +
no O +
significant O +
change O +
in O +
expression O +
level O +
between O +
mean O +
and O +
sample O -
. O -

Samples O +
cluster O +
closer O +
within O +
their O +
own O +
group O +
than O +
samples O +
from O +
other O +
groups O -
. O -

Figure O +
2Dendrogram O +
of O +
unsupervised O +
one O -
- O -
way O +
hierarchical O +
clustering O +
analysis O +
of O +
relative O +
expression O +
of O +
genes O +
in O +
selected O +
samples O -
. O -

The O +
clustering O +
analysis O +
was O +
based O +
on O +
the O +
average O +
linkage O +
and O +
Euclidean O +
distances O +
as O +
the O +
similarity O +
metric O +
using O +
differentially O +
expressed O +
genes O +
identified O +
by O +
ANOVA O +
( O -
p O +
< O +
0.05 O -
) O -
. O -

hESCs O +
clustered O +
together O +
and O +
BG O +
lines O +
cultured O +
in O +
the O +
same O +
laboratory O +
shared O +
the O +
largest O +
similarities O -
. O -

EBs O +
were O +
separated O +
from O +
hESCs O +
from O +
which O +
they O +
were O +
derived O -
. O -

EC O +
line O +
NTera2 O +
and O +
feeder O +
cells O +
can O +
be O +
distinguished O +
from O +
hESCs O +
respectively O -
. O -

The O +
global O +
analysis O +
suggested O +
that O +
the O +
bead O +
arrays O +
used O +
were O +
sufficiently O +
sensitive O +
such O +
that O +
individual O +
subsets O +
of O +
genes O +
could O +
be O +
analyzed O -
, O +
different O +
populations O +
of O +
cells O +
could O +
be O +
readily O +
distinguished O +
and O +
that O +
a O +
subset O +
of O +
candidate O +
genes O +
could O +
be O +
sufficient O +
to O +
distinguish O +
between O +
groups O +
of O +
cells O -
. O -

The O +
comparison O +
across O +
multiple O +
samples O +
will O +
allow O +
a O +
set O +
of O +
core O +
stem O +
cell O +
markers O +
to O +
be O +
identified O -
. O -

In O +
subsequent O +
sections O +
we O +
have O +
performed O +
such O +
analysis O -
. O -

Readers O +
are O +
urged O +
to O +
analyze O +
the O +
expression O +
of O +
desired O +
genes O +
directly O +
as O +
it O +
is O +
impossible O +
to O +
test O +
every O +
gene O +
given O +
the O +
large O +
body O +
of O +
data O +
generated O -
. O -

Comparison O +
between O +
MPSS O +
and O +
Illumina O +
bead O +
array O +
resultsWe O +
have O +
previously O +
used O +
EST O +
scan O +
and O +
MPSS O +
to O +
analyze O +
pooled O +
samples O +
of O +
ESCs O +
and O +
EBs O +
from O +
three O +
different O +
WiCell O +
lines O +
( O -
H1 O -
, O +
H7 O +
and O +
H9 O -
) O +
[ O -
5 O -
] O -
. O -

Comparison O +
between O +
the O +
two O +
methodologies O +
indicated O +
that O +
while O +
there O +
is O +
good O +
concordance O +
for O +
genes O +
expressed O +
at O +
high O +
levels O -
, O +
this O +
does O +
not O +
hold O +
for O +
genes O +
expressed O +
at O +
lower O +
levels O -
. O -

As O +
a O +
test O +
of O +
the O +
quality O +
of O +
the O +
data O +
generated O +
in O +
these O +
experiments O +
and O +
to O +
evaluate O +
whether O +
comparisons O +
can O +
be O +
made O +
across O +
different O +
methodologies O -
, O +
we O +
re O -
- O -
ran O +
the O +
identical O +
samples O +
on O +
the O +
bead O +
array O +
platform O -
. O -

The O +
complete O +
comparison O +
of O +
gene O +
expression O +
is O +
shown O +
in O +
Additional O +
file O +
2 O +
and O +
is O +
summarized O +
in O +
Tables O +
3 O +
and O +
Table O +
4 O -
. O -

Overall O -
, O +
concordance O +
in O +
Illumina O +
array O +
was O +
better O +
than O +
that O +
evident O +
between O +
EST O +
scan O +
and O +
MPSS O +
datasets O +
[ O -
9 O -
] O -
, O +
but O +
clearly O +
showed O +
much O +
wider O +
differences O +
than O +
that O +
seen O +
with O +
running O +
duplicates O +
in O +
the O +
same O +
assay O +
format O -
. O -

Nevertheless O -
, O +
this O +
comparison O +
provides O +
an O +
independent O +
verification O +
of O +
the O +
data O +
and O +
suggests O +
that O +
if O +
a O +
sample O +
is O +
detected O +
in O +
more O +
than O +
one O +
large O -
- O -
scale O +
analysis O -
, O +
the O +
reliability O +
of O +
the O +
gene O +
expression O +
detection O +
is O +
high O -
, O +
which O +
also O +
reduces O +
the O +
number O +
of O +
individual O +
genes O +
needed O +
to O +
be O +
verified O -
. O -

Caution O +
should O +
be O +
observed O +
in O +
comparing O +
different O +
samples O +
run O +
on O +
different O +
platforms O -
, O +
especially O +
when O +
there O +
has O +
not O +
been O +
rigorous O +
bioinformatic O +
matching O +
of O +
the O +
source O +
sequences O +
used O +
to O +
identify O +
genes O +
in O +
the O +
platforms O -
. O -

Often O +
genes O +
called O +
by O +
the O +
same O +
symbol O +
originate O +
from O +
different O +
database O +
records O -
, O +
which O +
may O +
originate O +
from O +
different O +
splice O +
variants O +
or O +
contain O +
sequence O +
differences O +
due O +
to O +
polymorphisms O +
or O +
outright O +
error O +
[ O -
19 O -
] O -
.Table O +
3Expression O +
of O +
hESC O +
specific O +
markers O +
in O +
pooled O +
hESC O +
sample O +
as O +
detected O +
by O +
Illumina O +
bead O +
array O +
The O +
expression O +
of O +
previously O +
identified O +
hESC O +
markers O +
was O +
examined O +
in O +
all O +
hESC O +
samples O +
( O -
the O +
values O +
displayed O +
represent O +
the O +
expression O +
level O +
of O +
pooled O +
H1 O -
, O +
H7 O +
and O +
H9 O -
) O -
. O -

Most O +
of O +
the O +
genes O +
were O +
also O +
identified O +
using O +
Illumina O +
bead O +
array O +
in O +
all O +
8 O +
hESC O +
populations O +
in O +
this O +
study O +
( O -
1 O -
* O -
) O -
, O +
the O +
gene O +
CER1 O +
was O +
detected O +
in O +
all O +
except O +
one O +
duplicate O +
of O +
H9 O +
( O -
2 O -
* O -
) O -
, O +
Nanog O +
was O +
not O +
detected O +
in O +
all O +
populations O +
( O -
3 O -
* O -
) O +
and O +
Sox2 O -
, O +
Lin41 O -
, O +
NR6A1 O +
and O +
FoxD3 O +
were O +
not O +
detected O +
in O +
the O +
array O +
although O +
they O +
were O +
present O +
in O +
the O +
chips O +
for O +
hybridization O +
( O -
4* O -
) O -
.AccessionSymbolPooled O +
ES O +
( O -
H1 O -
, O +
7 O -
, O +
9 O -
) O -
CommentsNM_003641.1IFITM188441*NM_020997.2LEFTB6579.61*NM_024674.3LIN283944.11*NM_175849.1DNMT3B33911*NM_003212.1TDGF131691*NM_001769.2CD92930.81*NM_000165.2GJA12404.41*NM_021195.2CLDN62247.21*NM_004360.2CDH11972.91*NM_021127.1PMAIP11601.51*NM_032805.1ZNF2061504.51*NM_003577.1UTF11444.11*XM_050625.2SFRP21353.91*NM_006548.3IMP-212061*NM_152312.2GYLTL1B1066.61*NM_015973.2GAL1043.31*NM_003240.2EBAF944.11*NM_054023.2SCGB3A2890.51*NM_020990.2CKMT1742.41*NM_033668.1ITGB1694.71*NM_003744.3NUMB618.31*NM_007015.1LECT1597.41*NM_021912.2GABRB3482.71*NM_006729.2DIAPH2467.11*NM_000222.1KIT188.91*NM_005454.1CER1151.52*NM_024865.1NANOG56.93*NM_002701.1POU5F1694.41*NM_003106SOX2ND4*NM_006458.2LIN41ND4*NM_001489.3NR6A1ND4*NM_012183FOXD3ND4*Table O +
4Comparison O +
of O +
MPSS O +
and O +
Illumina O +
bead O +
array O +
results O +
The O +
samples O +
were O +
analyzed O +
by O +
MPSS O +
and O +
bead O +
array O -
. O -

The O +
number O +
of O +
genes O +
detected O +
by O +
each O +
method O +
and O +
the O +
degree O +
of O +
overlap O +
is O +
summarized O -
. O -

Note O +
much O +
higher O +
degree O +
of O +
overlap O +
when O +
the O +
top O +
2000 O +
hits O +
were O +
compared O -
. O -

* O -
: O +
Most O +
of O +
the O +
genes O +
detected O +
by O +
MPSS O +
were O +
novel O +
genes O +
not O +
included O +
in O +
the O +
bead O +
array O -
. O -

ESNo.%Common O +
in O +
both O +
( O -
Top O +
2000 O +
hits O -
) O -
1,62281.1Common O +
in O +
both O +
( O -
All O +
hits O -
) O -
5,07146.0By O +
bead O +
array O +
only3,46231.4By O +
MPSS O +
only O +
* O -
2,50422.7Total11,037100EBNo.%Common O +
in O +
both O +
( O -
All O +
hits O -
) O -
5,16843.1By O +
bead O +
array O +
only4,13134.4By O +
MPSS O +
only O +
* O -
2,69422.5Total11,993100 O +
Human U-Species +
feeders O +
and O +
hESCs O +
can O +
be O +
readily O +
distinguished O +
and O +
contamination O +
can O +
be O +
readily O +
assessedFor O +
all O +
samples O -
, O +
we O +
conducted O +
an O +
unsupervised O +
one O -
- O -
way O +
hierarchical O +
clustering O +
analysis O -
. O -

The O +
clustering O +
analysis O +
was O +
based O +
on O +
the O +
average O +
linkage O +
and O +
Euclidean O +
distances O +
as O +
the O +
similarity O +
metric O +
using O +
differentially O +
expressed O +
genes O +
identified O +
by O +
ANOVA O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

The O +
analysis O +
revealed O +
the O +
underlying O +
features O +
and O +
variation O +
patterns O +
of O +
gene O +
expression O +
in O +
each O +
cell O +
types O -
. O -

Figure O +
2 O +
shows O +
results O +
of O +
the O +
cluster O +
analysis O +
of O +
relative O +
gene O +
expression O +
in O +
selected O +
samples O -
. O -

As O +
one O +
of O +
our O +
purposes O +
of O +
this O +
study O +
was O +
to O +
distinguish O +
between O +
human U-Species +
fibroblast O +
feeders O +
cells O +
and O +
hESCs O +
and O +
hEBs O -
, O +
wishing O +
to O +
readily O +
detect O +
feeder O +
contamination O +
in O +
hESCs O -
, O +
we O +
included O +
one O +
of O +
the O +
human U-Species +
feeder O +
cells O +
HS27 O +
( O -
ATCC O -
) O +
in O +
this O +
study O -
. O -

We O +
have O +
been O +
using O +
HS27 O +
as O +
feeder O +
cells O +
for O +
H9 O +
hESCs O +
for O +
more O +
than O +
two O +
years O +
and O +
all O +
hESCs O +
grown O +
on O +
HS27 O +
had O +
normal O +
karyotype O -
, O +
expressed O +
all O +
undifferentiated O +
markers O -
, O +
and O +
made O +
teratomas O +
with O +
all O +
germ O +
layers O +
( O -
data O +
not O +
show O -
) O -
. O -

The O +
global O +
pairwise O +
comparison O +
clearly O +
showed O +
that O +
human U-Species +
feeders O +
were O +
far O +
more O +
dissimilar O +
to O +
hESCs O +
than O +
hESCs O +
grown O +
in O +
different O +
laboratories O -
, O +
hESCs O +
compared O +
to O +
their O +
differentiated O +
EBs O +
that O +
contained O +
mesodermal O +
tissue O -
, O +
and O +
hESCs O +
compared O +
to O +
the O +
karyotypically O +
variant O +
hESC O +
line O +
BG01V O -
. O -

Pairwise O +
comparisons O +
of O +
human U-Species +
feeders O +
with O +
hESCs O +
resulted O +
in O +
a O +
correlation O +
coefficient O +
of O +
0.66 O -
, O +
which O +
was O +
less O +
than O +
the O +
correlation O +
coefficient O +
of O +
0.71–0.74 O +
observed O +
between O +
hESCs O +
and O +
their O +
corresponding O +
EBs O -
. O -

The O +
large O +
difference O +
between O +
human U-Species +
feeders O +
and O +
hESCs O +
suggested O +
that O +
it O +
would O +
be O +
possible O +
to O +
identify O +
markers O +
that O +
were O +
robust O +
and O +
reliable O +
in O +
distinguishing O +
the O +
two O +
populations O -
, O +
and O +
these O +
markers O +
would O +
be O +
sufficiently O +
sensitive O +
in O +
detecting O +
contamination O +
of O +
feeders O -
. O -

We O +
examined O +
the O +
data O +
to O +
develop O +
a O +
list O +
of O +
genes O +
that O +
had O +
high O +
levels O +
of O +
expression O +
in O +
human U-Species +
feeder O +
cells O +
maintained O +
in O +
hESC O +
medium O +
but O +
whose O +
expression O +
was O +
low O +
or O +
absent O +
in O +
either O +
ESCs O +
or O +
EBs O -
. O -

The O +
absence O +
of O +
expression O +
in O +
EBs O +
was O +
used O +
as O +
a O +
control O +
for O +
spontaneous O +
differentiation O +
of O +
ESC O +
colonies O +
( O -
including O +
mesodermal O +
differentiation O -
) O +
which O +
may O +
occur O +
and O +
the O +
markers O +
selected O +
should O +
be O +
able O +
to O +
distinguish O +
between O +
these O +
two O +
events O -
. O -

A O +
complete O +
list O +
of O +
genes O +
expressed O +
at O +
least O +
ten O -
- O -
fold O +
higher O +
in O +
human U-Species +
feeders O +
is O +
provided O +
in O +
Figure O +
3 O -
. O -

Quantitative O +
RT O -
- O -
PCR O +
( O -
qPCR O -
) O +
was O +
used O +
to O +
verify O +
the O +
fold O +
change O +
of O +
the O +
expression O +
of O +
4 O +
genes O -
, O +
including O +
THBS1 O -
, O +
MMP3 O -
, O +
TNFRSF11B O +
and O +
KRTHA4 O +
( O -
Figure O +
3C O -
) O -
. O -

Further O +
confirmation O +
can O +
also O +
be O +
done O +
using O +
immunocytochemistry O -
, O +
as O +
antibodies O +
against O +
these O +
genes O +
are O +
commercially O +
available O -
. O -

Figure O +
3Human O +
fibroblast O +
feeder O +
cells O +
can O +
be O +
distinguished O +
from O +
hESCs O +
and O +
EBs O -
. O -

Bead O +
array O +
identified O +
lists O +
of O +
genes O +
that O +
were O +
uniquely O +
expressed O +
in O +
human U-Species +
fibroblast O +
feeders O +
as O +
compared O +
to O +
hESCs O +
( O -
A O -
) O +
and O +
hEBs O +
( O -
B O -
) O -
. O -

The O +
four O +
genes O +
whose O +
expression O +
was O +
confirmed O +
by O +
qPCR O +
( O -
C O -
) O +
were O +
in O +
bold O -
. O -

In O +
the O +
graph O +
( O -
C O -
) O -
, O +
gene O +
expression O +
of O +
each O +
gene O +
in O +
feeder O +
cells O +
was O +
designated O +
as O +
1 O +
fold O +
and O +
the O +
bars O +
represented O +
fold O +
decrease O +
for O +
each O +
gene O -
. O -

Thus O +
this O +
comparison O +
allowed O +
us O +
to O +
distinguish O +
between O +
hESCs O +
and O +
human U-Species +
feeders O +
and O +
identify O +
candidate O +
markers O +
that O +
could O +
detect O +
feeder O +
cell O +
contamination O +
should O +
human U-Species +
feeders O +
be O +
used O +
in O +
the O +
propagation O +
of O +
hESCs O -
. O -

hESCs O +
and O +
EBs O +
can O +
be O +
distinguished O +
from O +
each O +
otherIllumina O +
bead O +
array O +
analysis O +
confirmed O +
that O +
hESCs O +
could O +
be O +
readily O +
distinguished O +
from O +
EBs O +
by O +
global O +
analysis O -
. O -

This O +
raised O +
the O +
possibility O +
that O +
specific O +
subsets O +
of O +
markers O +
could O +
be O +
identified O -
. O -

We O +
and O +
others O +
have O +
used O +
MPSS O +
and O +
EST O +
scan O +
and O +
generated O +
array O +
data O +
to O +
make O +
lists O +
of O +
hESC O -
- O -
specific O +
genes O +
[ O -
5,9,10,20 O -
] O -
. O -

As O +
discussed O +
above O -
, O +
most O +
hESC O +
markers O +
identified O +
by O +
MPSS O +
have O +
been O +
detected O +
in O +
the O +
present O +
bead O +
array O +
analysis O +
( O -
Table O +
3 O -
) O -
, O +
confirming O +
the O +
utility O +
of O +
these O +
previously O +
identified O +
markers O +
for O +
use O +
in O +
assessing O +
undifferentiated O +
status O +
of O +
hESCs O -
. O -

In O +
addition O -
, O +
we O +
have O +
generated O +
a O +
list O +
of O +
genes O +
differentially O +
expressed O +
at O +
higher O +
level O +
in O +
EBs O +
than O +
in O +
hESCs O -
, O +
a O +
subset O +
of O +
which O +
is O +
shown O +
in O +
Table O +
5 O -
. O -

These O +
markers O +
were O +
common O +
to O +
all O +
EB O +
samples O +
tested O +
and O +
included O +
genes O +
known O +
to O +
be O +
expressed O +
in O +
ectoderm O -
, O +
endoderm O +
and O +
mesoderm O -
. O -

The O +
entire O +
set O +
of O +
differentially O +
expressed O +
genes O +
is O +
provided O +
in O +
Additional O +
file O +
3 O -
. O -

Thus O -
, O +
the O +
bead O +
array O +
format O -
, O +
which O +
allows O +
multiple O +
pairwise O +
comparisons O -
, O +
can O +
be O +
used O +
to O +
identify O +
genes O +
that O +
are O +
expressed O +
by O +
all O +
differentiating O +
EB O +
samples O +
in O +
the O +
present O +
study O -
. O -

Our O +
data O +
suggested O +
that O +
a O +
core O +
set O +
of O +
limited O +
markers O +
might O +
be O +
sufficient O +
to O +
monitor O +
the O +
process O +
of O +
differentiation O -
. O -

By O +
suitable O +
selection O +
of O +
different O +
germ O +
cell O +
layer O +
specific O +
markers O +
one O +
may O +
also O +
assess O +
the O +
overall O +
quality O +
of O +
differentiation O +
toward O +
germ O +
cells O -
. O -

Table O +
5Genes O +
which O +
are O +
differentially O +
expressed O +
at O +
higher O +
levels O +
in O +
EBs O +
than O +
in O +
hESCsSymbolAll O +
EBAll O +
ESEB O -
/ O -
ESRELN11120.52224.0SST1394.25.5253.5SLC40A11210.19.1133.0IGF24896.938.4127.5SLN2017.817118.7DCN7588.176.299.6ANXA84048.941.996.6AQP11665.420.581.2APOB1256.415.879.5AHSG1414.320.868.0NID21476.731.447.0FGB221052.442.2LUM8439.4205.441.1MGP2772.469.839.7THBD1206.434.435.1SERPINA11255.643.728.7HAND112294437.428.1HBE11106.542.626.0TTR7661.2347.122.1HBG21601.185.618.7COL2A11636.291.817.8KIAA09771370.87817.6AFP8941552.316.2COL3A11355796714.0IGFBP38446.3603.414.0PAX61577.8118.213.3APOA19398.1709.813.2FRZB3523.7315.711.2SPON21548.7159.49.7CEBPD1100.2122.79.0DLK13355.8374.89.0RDC11589.7192.18.3BMP41851.5227.38.1PITX21057.9131.28.1ACTA25045629.88.0GAS11215.61547.9AGTRL11053.8135.17.8COL5A15876.4765.47.7CDKN1C3134.1412.97.6CXCL142220.5312.67.1DOK41011.1145.27.0ARHGDIB1635.3246.56.6FLRT21879.5314.36.0MSX12771.8499.75.5 O +
Smaller O +
but O +
distinct O +
differences O +
among O +
undifferentiated O +
hESC O +
linesOur O +
cluster O +
analysis O +
indicated O +
that O +
BG01 O -
, O +
BG02 O +
and O +
BG03 O +
cell O +
lines O +
were O +
overall O +
more O +
similar O +
to O +
each O +
other O +
than O +
to O +
other O +
lines O +
( O -
Figure O +
1 O +
and O +
2 O -
) O -
, O +
but O +
nevertheless O +
showed O +
additional O +
differences O +
than O +
technical O +
or O +
biological O +
repeats O +
of O +
the O +
same O +
sample O -
. O -

This O +
raised O +
the O +
possibility O +
that O +
this O +
microarray O +
strategy O +
may O +
be O +
sufficiently O +
sensitive O +
to O +
identify O +
relatively O +
cell O +
type O +
specific O +
candidate O +
genes O +
that O +
could O +
be O +
used O +
to O +
distinguish O +
one O +
hESC O +
population O +
from O +
another O +
or O +
to O +
identify O +
differences O +
that O +
were O +
due O +
to O +
varied O +
isolation O +
and O +
growth O +
conditions O -
. O -

As O +
a O +
test O +
we O +
looked O +
for O +
differences O +
between O +
BG01 O -
, O +
BG02 O +
and O +
BG03 O -
, O +
which O +
were O +
grown O +
in O +
the O +
same O +
laboratory O +
under O +
the O +
same O +
conditions O -
. O -

Lists O +
of O +
candidate O +
genes O +
are O +
shown O +
in O +
Figure O +
4A O -
, O +
C O +
and O +
4E O +
and O +
the O +
comparison O +
of O +
these O +
three O +
lines O +
are O +
shown O +
in O +
scatter O +
plots O +
in O +
Figure O +
4B O -
, O +
D O +
and O +
4F.Figure O +
4BG O +
lines O +
show O +
small O +
but O +
distinct O +
differences O +
as O +
assessed O +
by O +
bead O +
array O -
. O -

These O +
three O +
hESC O +
lines O +
share O +
high O +
similarities O +
as O +
shown O +
by O +
the O +
scatterplots O +
of O +
BG01 O +
vs O +
BG02 O +
( O -
B O -
) O -
, O +
BG01 O +
vs O +
BG03 O +
( O -
D O -
) O +
and O +
BG02 O +
vs O +
BG03 O +
( O -
F O -
) O -
. O -

Comparisons O +
of O +
all O +
three O +
lines O +
were O +
made O +
and O +
lists O +
of O +
selected O +
genes O +
that O +
were O +
specifically O +
expressed O +
in O +
BG01 O +
( O -
A O -
) O -
, O +
BG02 O +
( O -
C O -
) O +
and O +
BG03 O +
( O -
F O -
) O +
are O +
shown O -
. O -

Correlation O +
coefficients O +
( O -
R2 O -
) O +
were O +
generated O +
using O +
all O +
genes O +
with O +
expression O +
level O +
> O -
0 O +
( O -
black O +
and O +
blue O +
dots O -
) O -
, O +
or O +
all O +
genes O +
with O +
detection O +
confidence O +
> O -
0.99 O +
( O -
blue O +
dots O -
) O -
. O -

Genes O +
outside O +
the O +
two O +
thin O +
red O +
lines O +
were O +
detected O +
at O +
> O -
2.5- O +
fold O +
difference O -
. O -

We O +
reasoned O +
as O +
well O +
that O +
such O +
a O +
global O +
comparison O +
should O +
allow O +
us O +
to O +
distinguish O +
between O +
male O +
and O +
female O +
lines O +
if O +
genes O +
present O +
on O +
the O +
Y O +
chromosome O +
were O +
expressed O +
at O +
high O +
levels O +
in O +
the O +
undifferentiated O +
state O +
and O +
were O +
detected O +
by O +
the O +
bead O +
array O -
. O -

Several O +
such O +
candidate O +
genes O +
were O +
identified O -
. O -

The O +
most O +
robust O +
were O +
RPS4Y O -
, O +
RPS4Y2 O -
, O +
and O +
EIF1AY O +
( O -
Figure O +
5 O -
) O -
. O -

To O +
confirm O +
that O +
these O +
were O +
useful O +
markers O -
, O +
we O +
designed O +
RT O -
- O -
PCR O +
primers O +
and O +
tested O +
their O +
expression O +
in O +
a O +
male O +
( O -
BG01 O -
) O +
and O +
a O +
female O +
( O -
BG03 O -
) O +
line O +
( O -
Figure O +
5B O -
) O -
. O -

We O +
noted O +
that O +
several O +
of O +
these O +
continued O +
to O +
be O +
expressed O +
at O +
high O +
levels O +
as O +
ESCs O +
differentiated O +
to O +
form O +
EBs O +
and O +
upon O +
further O +
differentiation O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
these O +
markers O +
might O +
be O +
used O +
in O +
adult O +
stem O +
cell O +
and O +
germ O +
cell O +
populations O +
as O +
well O -
. O -

Figure O +
5Male O +
and O +
female O +
hESC O +
lines O +
can O +
be O +
distinguished O +
by O +
genes O +
identified O +
by O +
bead O +
array O -
. O -

Five O +
potential O +
genes O +
RPS4Y O -
, O +
RPS4Y2 O -
, O +
EIF1AY O -
, O +
VCY O -
, O +
and O +
AMELY O +
are O +
located O +
in O +
the O +
Y O +
chromosome O -
. O -

By O +
comparing O +
the O +
expression O +
level O +
of O +
these O +
genes O +
in O +
all O +
hESC O +
lines O -
, O +
we O +
have O +
found O +
that O +
3 O +
out O +
of O +
5 O +
were O +
specifically O +
expressed O +
in O +
male O +
hESC O +
lines O +
I6 O -
, O +
BG01 O +
and O +
BG02 O +
( O -
A O -
) O +
and O +
this O +
was O +
verified O +
by O +
RT O -
- O -
PCR O +
in O +
male O +
line O +
BG01 O +
and O +
female O +
line O +
BG03 O +
( O -
B O -
) O -
. O -

G3PDH O +
was O +
used O +
as O +
an O +
internal O +
control O -
. O -

* O -
: O +
represents O +
the O +
gene O +
expression O +
level O +
is O +
detected O +
at O +
< O -
0.99 O +
confidence O -
. O -

In O +
summary O -
, O +
our O +
data O +
suggest O +
that O +
the O +
bead O +
array O +
format O +
is O +
sufficiently O +
sensitive O +
and O +
global O +
that O +
it O +
can O +
distinguish O +
one O +
cell O +
line O +
from O +
another O +
even O +
if O +
those O +
two O +
cell O +
lines O +
are O +
grown O +
in O +
the O +
same O +
laboratory O +
under O +
virtually O +
identical O +
conditions O -
. O -

Bead O +
array O +
can O +
also O +
be O +
used O +
to O +
distinguish O +
between O +
male O +
and O +
female O +
lines O -
. O -

Comparison O +
of O +
diploid O +
pluripotent O +
cells O +
with O +
NTera2 O +
and O +
BG01 O +
variantOur O +
previous O +
results O +
have O +
suggested O +
that O +
EC O +
lines O +
share O +
many O +
of O +
the O +
properties O +
of O +
hESCs O +
and O +
can O +
be O +
used O +
as O +
a O +
useful O +
model O +
for O +
initial O +
testing O +
of O +
biological O +
questions O +
[ O -
21 O -
] O -
. O -

More O +
recently O +
we O +
have O +
identified O +
BG01V O +
as O +
a O +
karyotypically O +
abnormal O +
variant O +
that O +
behaves O +
much O +
like O +
its O +
normal O +
counterpart O +
BG01 O -
, O +
but O +
is O +
not O +
subject O +
to O +
the O +
same O +
constraints O +
of O +
use O +
as O +
karyotypically O +
normal O +
hESCs O +
[ O -
13 O -
] O -
. O -

Given O +
the O +
sensitivity O +
of O +
the O +
bead O +
array O +
analysis O -
, O +
we O +
tested O +
its O +
ability O +
to O +
detect O +
the O +
overall O +
similarities O +
and O +
differences O +
between O +
NTera2 O +
and O +
a O +
pooled O +
ESC O +
sample O +
or O +
between O +
the O +
karyotypically O +
abnormal O +
BG01V O +
and O +
its O +
normal O +
parent O +
line O +
( O -
Figure O +
6 O -
) O -
.Figure O +
6Diploid O +
pluripotent O +
EC O +
cell O +
line O +
NTera2 O +
and O +
karyotypically O +
abnormal O +
hESC O +
line O +
BG01V O +
can O +
be O +
distinguished O +
from O +
normal O +
hESCs O +
using O +
Illumina O +
array O -
. O -

Comparison O +
of O +
NTera2 O +
and O +
pooled O +
hESC O +
sample O +
resulted O +
a O +
correlation O +
coefficient O +
of O +
0.8997 O -
. O -

Two O +
lists O +
of O +
genes O -
, O +
which O +
were O +
specifically O +
expressed O +
in O +
NTera2 O +
( O -
C O -
) O +
or O +
in O +
hESCs O +
( O -
E O -
) O +
were O +
identified O -
. O -

Likewise O -
, O +
while O +
sharing O +
similarities O +
with O +
BG01 O +
( O -
B O -
, O +
correlation O +
coefficient= O +
0.9043 O -
) O -
, O +
BG01V O +
was O +
different O +
from O +
BG01 O +
in O +
expression O +
for O +
many O +
genes O -
, O +
particularly O +
genes O +
from O +
the O +
TGFβ O +
pathway O +
( O -
D O -
, O +
F O -
) O -
. O -

Black O +
dots O +
represent O +
genes O +
that O +
were O +
detected O +
at O +
> O -
0 O +
expression O +
level O -
, O +
blue O +
dots O +
represent O +
genes O +
that O +
were O +
detected O +
both O +
at O +
> O +
0 O +
expression O +
level O +
and O +
at O +
> O -
0.99 O +
confidence O -
. O -

Genes O +
plotted O +
outside O +
the O +
two O +
thin O +
red O +
lines O +
were O +
detected O +
at O +
> O -
2.5- O +
fold O +
difference O -
. O -

Our O +
results O +
showed O +
that O -
, O +
while O +
NTera2 O +
shared O +
a O +
high O +
similarity O +
with O +
hESCs O +
[ O -
21 O -
] O -
, O +
it O +
did O +
have O +
important O +
differences O +
with O +
hESC O +
lines O -
. O -

Examining O +
these O +
differences O +
( O -
summarized O +
in O +
Figure O +
6C O +
and O +
6E O -
) O -
, O +
we O +
noted O +
that O +
some O +
reflected O +
the O +
origin O +
of O +
the O +
tumor O +
cells O +
from O +
which O +
this O +
line O +
was O +
derived O +
[ O -
14 O -
] O -
. O -

Several O +
germ O +
cell O +
markers O +
such O +
as O +
GAGE2 O -
, O +
GAGE7 O +
and O +
GAGE8 O +
were O +
highly O +
expressed O +
in O +
NTera2 O +
but O +
were O +
absent O +
( O -
or O +
present O +
at O +
low O +
levels O -
) O +
in O +
any O +
of O +
the O +
hESC O +
lines O +
examined O +
( O -
See O +
Figure O +
6C O +
and O +
Additional O +
file O +
1 O -
. O -

Note O +
that O +
the O +
GAGE O +
genes O +
are O +
highly O +
similar O +
in O +
sequence O -
, O +
making O +
it O +
difficult O +
to O +
distinguish O +
one O +
family O +
member O +
from O +
another O +
through O +
hybridization O -
; O +
thus O -
, O +
while O +
all O +
of O +
these O +
GAGE O +
gene O +
probes O +
gave O +
positive O +
signal O -
, O +
it O +
is O +
difficult O +
to O +
say O +
if O +
the O +
signal O +
came O +
from O +
the O +
specific O +
gene O +
itself O +
or O +
from O +
cross O -
- O -
hybridization O +
from O +
one O +
of O +
the O +
other O +
family O +
members O -
) O -
. O -

None O +
of O +
these O +
were O +
present O +
in O +
BG01V O -
, O +
indicating O +
that O +
the O +
karyotypically O +
abnormal O +
variant O +
is O +
not O +
the O +
equivalent O +
of O +
a O +
teratocarcinoma O +
line O +
such O +
as O +
NTera2 O -
. O -

In O +
addition O +
to O +
the O +
expression O +
of O +
germ O +
cell O +
markers O -
, O +
we O +
noticed O +
a O +
significant O +
difference O +
in O +
the O +
expression O +
of O +
genes O +
in O +
the O +
TGFβ O +
pathway O -
, O +
such O +
as O +
GDF3 O +
( O -
Figure O +
6C O -
) O -
, O +
TGFBI O -
, O +
CDKN1A O -
, O +
IGFBP7 O -
, O +
IGFBP3 O -
, O +
NODAL O -
, O +
CER1 O +
and O +
BMP2 O +
( O -
Figure O +
6E O -
) O -
. O -

This O +
is O +
consistent O +
with O +
the O +
postulated O +
role O +
of O +
this O +
pathway O +
in O +
germ O +
cell O +
differentiation O +
[ O -
22,23 O -
] O +
and O +
suggests O +
that O +
TGFβ O +
pathway O +
can O -
not O +
be O +
reliably O +
tested O +
using O +
NTera2 O +
as O +
a O +
model O +
for O +
hESC.The O +
BG01V O +
showed O +
clear O +
differences O +
from O +
its O +
normal O +
counterpart O +
and O +
some O +
major O +
changes O +
are O +
summarized O +
in O +
Figure O +
6D O +
and O +
6F O -
. O -

Early O +
markers O +
of O +
differentiation O +
appeared O +
to O +
be O +
present O +
at O +
higher O +
levels O +
in O +
BG01V O +
as O +
compared O +
to O +
any O +
of O +
the O +
hESC O +
lines O +
examined O -
, O +
although O +
hESC O +
specific O +
genes O +
continued O +
to O +
be O +
expressed O +
at O +
high O +
levels O +
( O -
see O +
Additional O +
file O +
4 O -
) O -
. O -

In O +
particular O -
, O +
the O +
Wnt O +
pathway O +
and O +
the O +
TGFβ O +
signaling O +
pathway O +
( O -
Figure O +
6D O -
) O -
, O +
both O +
of O +
which O +
involved O +
in O +
the O +
early O +
process O +
of O +
differentiation O +
[ O -
24,25 O -
] O -
, O +
appeared O +
to O +
be O +
activated O +
( O -
Additional O +
file O +
4 O -
) O -
, O +
suggesting O +
that O +
the O +
role O +
of O +
growth O +
factors O +
and O +
signaling O +
in O +
these O +
early O +
events O +
can O -
not O +
be O +
readily O +
studied O +
in O +
this O +
cell O +
line O -
. O -

In O +
summary O -
, O +
the O +
analysis O +
highlighted O +
the O +
utility O +
of O +
the O +
potential O +
reference O +
standards O +
NTera2 O +
and O +
BG01V O -
, O +
demonstrated O +
their O +
general O +
similarity O +
and O +
provided O +
detail O +
on O +
potential O +
caveats O +
to O +
their O +
application O -
. O -

Global O +
arrays O +
provide O +
a O +
snapshot O +
of O +
the O +
state O +
of O +
the O +
cells O +
and O +
identify O +
core O +
self O -
- O -
renewal O +
pathwaysWe O +
have O +
utilized O +
a O +
small O +
fraction O +
of O +
the O +
data O +
to O +
demonstrate O +
the O +
overall O +
utility O +
of O +
this O +
approach O +
and O +
its O +
sensitivity O +
in O +
identifying O +
small O +
differences O +
in O +
cell O +
populations O -
. O -

An O +
additional O +
potential O +
application O +
of O +
such O +
an O +
analysis O +
is O +
the O +
ability O +
to O +
examine O +
the O +
general O +
state O +
of O +
a O +
particular O +
signaling O +
pathway O +
and O +
determine O +
whether O +
it O +
is O +
active O -
. O -

By O +
comparing O +
across O +
many O +
samples O -
, O +
a O +
procedure O +
previously O +
expensive O +
and O +
difficult O +
in O +
terms O +
of O +
the O +
RNA O +
and O +
replicate O +
requirement O -
, O +
one O +
can O +
rapidly O +
identify O +
key O +
regulatory O +
pathways O -
. O -

To O +
test O +
whether O +
we O +
could O +
use O +
such O +
multiple O +
pairwise O +
comparisons O +
to O +
elucidate O +
the O +
major O +
regulatory O +
pathways O +
that O +
may O +
be O +
required O +
for O +
hESC O +
self O -
- O -
renewal O -
, O +
we O +
examined O +
several O +
metabolic O +
pathways O -
. O -

The O +
results O +
of O +
the O +
analysis O +
of O +
the O +
insulin O -
/ O -
insulin O -
- O -
like O +
growth O +
factor O +
( O -
IGF O -
) O +
signaling O +
pathway O +
are O +
shown O +
in O +
Figure O +
7 O -
. O -

Using O +
the O +
same O +
4 O +
groups O +
of O +
samples O +
as O +
in O +
Figure O +
1 O -
, O +
we O +
conducted O +
PAM O +
( O -
Prediction O +
Analysis O +
of O +
Microarray O -
) O +
[ O -
26 O -
] O -
, O +
in O +
search O +
for O +
biomarkers O +
used O +
in O +
diagnostic O +
identification O +
of O +
these O +
four O +
groups O -
, O +
ES O -
, O +
EB O -
, O +
NS O -
, O +
and O +
FB O -
. O -

In O +
PAM O -
, O +
a O +
list O +
of O +
significant O +
IGF O +
pathway O +
genes O +
whose O +
expression O +
characterizes O +
each O +
diagnostic O +
class O +
was O +
obtained O -
. O -

The O +
average O +
gene O +
expression O +
level O +
in O +
each O +
class O +
was O +
divided O +
by O +
the O +
within O -
- O -
class O +
standard O +
deviation O -
. O -

The O +
nearest O +
centroid O +
classification O +
computed O +
took O +
the O +
gene O +
expression O +
profile O +
from O +
a O +
new O +
sample O +
and O +
compared O +
it O +
to O +
each O +
of O +
these O +
class O +
centroids O -
. O -

For O +
cross O -
- O -
validation O +
of O +
prediction O +
results O -
, O +
multiple O +
classification O +
processes O +
were O +
performed O +
on O +
two O +
data O +
sets O +
randomly O +
constructed O +
each O +
time O +
from O +
the O +
entire O +
gene O +
expression O +
dataset O -
. O -

The O +
first O +
dataset O -
, O +
consisting O +
of O +
70 O -
% O +
of O +
the O +
total O +
data O -
, O +
was O +
used O +
as O +
the O +
training O +
dataset O -
, O +
and O +
the O +
other O +
dataset O -
, O +
containing O +
the O +
remaining O +
30 O -
% O +
of O +
data O -
, O +
was O +
used O +
for O +
the O +
data O +
prediction O +
and O +
verification O +
process O -
. O -

The O +
final O +
biomarkers O +
were O +
determined O +
in O +
such O +
a O +
way O +
that O +
the O +
misclassification O +
error O +
rate O +
was O +
minimal O -
. O -

The O +
resulting O +
graph O +
( O -
Figure O +
7 O -
) O +
showed O +
the O +
shrunken O +
class O +
centroids O +
for O +
genes O +
that O +
had O +
at O +
least O +
one O +
nonzero O +
difference O +
in O +
each O +
diagnostic O +
class O -
. O -

The O +
genes O +
with O +
nonzero O +
components O +
in O +
each O +
class O +
were O +
almost O +
mutually O +
exclusive O +
and O +
represented O +
candidate O +
biomarkers O +
for O +
the O +
diagnosis O +
of O +
each O +
class O -
. O -

All O +
data O +
analyses O +
were O +
performed O +
using O +
the O +
bioconductor O +
package O +
[ O -
17 O -
] O -
.Figure O +
7Identification O +
of O +
diagnostic O +
markers O +
by O +
PAM O -
. O -

The O +
shrunken O +
class O +
centroids O +
for O +
genes O +
which O +
have O +
at O +
least O +
one O +
nonzero O +
difference O +
are O +
shown O -
. O -

The O +
genes O +
with O +
nonzero O +
components O +
in O +
each O +
class O +
were O +
almost O +
mutually O +
exclusive O +
and O +
were O +
the O +
candidate O +
molecular O +
markers O +
for O +
the O +
diagnosis O +
of O +
the O +
four O +
groups O +
of O +
cell O +
populations O -
, O +
including O -
, O +
( O -
from O +
left O +
to O +
right O -
) O +
hESC O +
derived O +
mesenchyme O +
and O +
human U-Species +
fibroblast O +
feeder O +
cells O +
( O -
" O -
FB O -
" O -
, O +
n O +
= O +
5 O -
) O -
, O +
undifferentiated O +
hESCs O +
( O -
" O -
ES O -
" O -
, O +
n O +
= O +
11 O -
) O -
, O +
hESC O +
derived O +
neural O +
cells O +
( O -
" O -
NS O -
" O -
, O +
n O +
= O +
3 O -
) O -
, O +
and O +
differentiated O +
ES O +
cells O +
and O +
EB O -
, O +
( O -
" O -
EB O -
" O -
, O +
n O +
= O +
6 O -
) O -
. O -

The O +
identified O +
biomarkers O +
can O +
be O +
used O +
to O +
distinguish O +
the O +
four O +
groups O +
of O +
cell O +
populations O -
. O -

Undifferentiated O +
hESCs O +
have O +
been O +
analyzed O +
by O +
EST O +
scan O -
, O +
MPSS O -
, O +
SAGE O +
and O +
microarray O +
[ O -
5,10,16 O -
] O -
. O -

The O +
goal O +
of O +
these O +
experiments O +
including O +
our O +
own O +
is O +
to O +
develop O +
a O +
low O +
cost O +
reliable O +
method O +
to O +
assess O +
multiple O +
samples O +
to O +
generate O +
a O +
global O +
database O +
of O +
markers O +
and O +
to O +
provide O +
a O +
method O +
of O +
identifying O +
core O +
measures O +
of O +
similarities O +
and O +
differences O +
across O +
multiple O +
laboratories O -
. O -

We O +
and O +
others O +
have O +
proposed O +
three O +
alternative O +
methods O +
of O +
assessment O -
: O +
Quantitative O +
RT O -
- O -
PCR O +
[ O -
9,20 O -
] O -
, O +
focused O +
arrays O +
[ O -
27 O -
] O +
or O +
a O +
large O +
scale O +
array O +
with O +
bioinformatics O +
tools O +
being O +
utilized O +
to O +
focus O +
on O +
appropriate O +
subsets O +
of O +
genes O +
[ O -
5,7,15,16,28 O -
] O -
. O -

Each O +
of O +
these O +
methods O +
has O +
its O +
advantages O +
and O +
disadvantages O -
. O -

The O +
present O +
results O +
suggest O +
that O +
the O +
global O +
Illumina O +
bead O +
array O +
retains O +
the O +
advantages O +
of O +
low O +
cost O +
per O +
sample O +
associated O +
with O +
focused O +
arrays O +
yet O +
still O +
has O +
the O +
strength O +
of O +
the O +
global O +
attributes O +
of O +
MPSS O +
or O +
EST O +
scan O +
while O +
requiring O +
much O +
less O +
RNA O +
and O +
turnaround O +
time O -
. O -

To O +
test O +
this O +
array O +
format O +
we O +
examined O +
samples O +
from O +
a O +
variety O +
of O +
laboratories O +
in O +
a O +
blinded O +
fashion O +
to O +
determine O +
whether O +
the O +
array O +
was O +
sufficiently O +
sensitive O +
and O +
rapid O +
for O +
routine O +
assessment O -
. O -

Duplicates O +
using O +
100 O +
ng O +
of O +
RNA O +
were O +
run O +
and O +
results O +
obtained O +
forty O -
- O -
eight O +
hours O +
later O -
. O -

The O +
resolution O +
was O +
sufficient O +
that O +
ESC O +
samples O +
could O +
be O +
distinguished O +
from O +
one O +
another O +
and O +
a O +
variant O +
karyotypically O +
abnormal O +
subclone O +
could O +
be O +
distinguished O +
from O +
the O +
parent O +
population O +
( O -
correlation O +
coefficient O +
= O +
0.9043 O -
) O -
. O -

Aliquots O +
of O +
the O +
pooled O +
ES O +
and O +
pooled O +
EB O +
samples O -
, O +
which O +
we O +
had O +
prepared O +
for O +
MPSS O -
, O +
were O +
included O +
in O +
this O +
run O +
to O +
compare O +
these O +
two O +
methods O +
directly O -
. O -

The O +
current O +
analysis O +
confirms O +
that O +
comparison O +
across O +
platforms O +
is O +
difficult O +
and O +
that O +
only O +
positive O +
results O +
can O +
be O +
treated O +
with O +
any O +
reliability O -
. O -

The O +
absence O +
of O +
expression O +
can O -
not O +
be O +
readily O +
interpreted O -
. O -

In O +
particular O -
, O +
genes O +
expressed O +
at O +
low O +
levels O +
( O -
greater O +
than O +
70 O -
% O +
of O +
all O +
genes O +
detected O -
) O +
should O +
not O +
be O +
assessed O +
in O +
cross O +
platform O +
comparisons O -
. O -

The O +
limited O +
concordance O +
at O +
low O +
levels O +
raises O +
a O +
question O +
as O +
to O +
how O +
many O +
genes O +
are O +
actually O +
expressed O +
by O +
any O +
one O +
cell O +
line O +
and O +
whether O +
the O +
cutoff O +
of O +
3 O +
tpm O +
used O +
for O +
MPSS O +
or O +
100 O +
intensity O +
units O +
for O +
bead O +
arrays O +
is O +
a O +
reasonable O +
cutoff O -
. O -

We O +
used O +
100 O +
units O +
for O +
our O +
analysis O +
and O +
we O +
would O +
suggest O +
that O +
readers O +
exercise O +
similar O +
caution O -
. O -

Nevertheless O +
even O +
at O +
this O +
higher O +
cutoff O +
the O +
arrays O +
were O +
remarkably O +
sensitive O +
and O +
allowed O +
us O +
to O +
readily O +
distinguish O +
between O +
samples O +
including O +
cells O +
grown O +
in O +
the O +
same O +
laboratory O -
. O -

The O +
basis O +
of O +
the O +
sensitivity O +
could O +
be O +
attributed O +
to O +
a O +
limited O +
set O +
of O +
genes O +
and O +
those O +
genes O +
could O +
be O +
identified O +
for O +
future O +
use O -
. O -

For O +
example O +
BG01V O -
, O +
while O +
much O +
more O +
similar O +
to O +
BG01 O +
than O +
to O +
any O +
other O +
cell O +
type O -
, O +
could O +
still O +
be O +
distinguished O +
from O +
a O +
biological O +
replicate O +
of O +
BG01 O +
by O +
the O +
expression O +
of O +
a O +
particular O +
subset O +
of O +
differentiation O +
markers O +
( O -
Figure O +
6 O -
) O -
. O -

EC O +
cells O +
such O +
as O +
NTera2 O +
could O +
be O +
distinguished O +
from O +
hESCs O +
by O +
the O +
expression O +
of O +
germ O +
cell O +
markers O +
and O +
the O +
presence O +
of O +
a O +
partially O +
inactivated O +
TGFβ O +
( O -
BMP O -
) O +
signaling O +
pathway O +
( O -
Figure O +
6 O -
) O -
. O -

Distinguishing O +
ESCs O +
from O +
EBs O +
was O +
relatively O +
straightforward O -
. O -

We O +
have O +
confirmed O +
the O +
utility O +
of O +
previously O +
identified O +
markers O +
for O +
use O +
in O +
this O +
platform O +
as O +
well O +
as O +
identified O +
an O +
additional O +
set O +
of O +
markers O +
that O +
can O +
serve O +
as O +
biomarkers O +
to O +
distinguish O +
between O +
the O +
hESC O +
and O +
EB O +
states O -
. O -

A O +
subset O +
of O +
these O +
markers O +
have O +
been O +
used O +
to O +
develop O +
a O +
qPCR O +
assay O +
that O +
shows O +
such O +
a O +
high O +
sensitivity O +
that O +
changes O +
in O +
cell O +
behavior O +
can O +
be O +
detected O +
after O +
as O +
little O +
as O +
twenty O -
- O -
four O +
hours O +
and O +
the O +
development O +
of O +
EBs O +
can O +
be O +
reliably O +
staged O +
[ O -
10,20 O -
] O -
. O -

During O +
the O +
identification O +
of O +
ES O +
and O +
EB O +
specific O +
markers O -
, O +
we O +
have O +
noticed O +
that O +
some O +
known O +
hESC O +
markers O -
, O +
such O +
as O +
Nanog O -
, O +
was O +
not O +
detected O +
in O +
all O +
populations O +
of O +
hESCs O +
that O +
were O +
included O +
in O +
this O +
analysis O -
. O -

Several O +
ESC O -
- O -
specific O +
gene O -
, O +
including O +
Lin41 O -
, O +
Sox2 O +
and O +
FoxD3 O -
, O +
were O +
not O +
detected O +
in O +
the O +
array O +
either O +
( O -
Table O +
3 O -
) O -
. O -

We O +
believe O +
that O +
the O +
problem O +
with O +
Lin O +
41 O -
, O +
Sox2 O +
and O +
FoxD3 O +
is O +
a O +
technical O +
one O +
as O +
we O +
were O +
able O +
to O +
confirm O +
expression O +
using O +
alternate O +
methods O -
. O -

We O +
are O +
in O +
progress O +
of O +
redesigning O +
appropriate O +
probes O +
for O +
these O +
genes O -
. O -

In O +
the O +
case O +
of O +
the O +
gene O +
Nanog O -
, O +
there O +
are O +
several O +
pseudo O +
genes O +
in O +
the O +
genome O +
for O +
Nanog O +
and O +
it O +
has O +
been O +
a O +
major O +
technical O +
challenge O +
designing O +
primers O +
or O +
probes O +
that O +
are O +
specific O +
and O +
sensitive O -
. O -

We O +
believe O +
that O +
a O +
partial O +
explanation O +
for O +
the O +
variability O +
in O +
Nanog O +
expression O +
is O +
due O +
to O +
the O +
lack O +
of O +
sensitivity O +
to O +
this O +
gene O -
. O -

However O -
, O +
immunocytochemistry O +
while O +
not O +
strictly O +
quantitative O +
shows O +
similar O +
variability O +
when O +
used O +
to O +
assess O +
Nanog O +
expression O +
in O +
different O +
cell O +
lines O +
[ O -
9,27,28 O -
] O -
. O -

This O +
large O +
comparison O +
between O +
samples O +
allowed O +
us O +
to O +
identify O +
markers O +
that O +
distinguish O +
human U-Species +
feeder O +
cells O +
from O +
hESC O -
. O -

While O +
we O +
have O +
listed O +
19 O +
potential O +
markers O +
( O -
Figure O +
3 O -
) O +
and O +
identified O +
several O +
hundred O +
potential O +
markers O +
as O +
shown O +
in O +
Additional O +
file O +
5 O -
, O +
we O +
suggest O +
that O +
as O +
few O +
as O +
3–4 O +
genes O +
may O +
be O +
sufficient O -
. O -

Previously O +
we O +
found O +
that O +
as O +
few O +
as O +
four O +
were O +
satisfactory O +
to O +
distinguish O +
between O +
hESCs O +
and O +
hEBs O -
, O +
which O +
are O +
two O +
much O +
more O +
closely O +
related O +
samples O +
[ O -
9 O -
] O -
. O -

In O +
this O +
study O +
we O +
have O +
confirmed O +
by O +
qPCR O +
the O +
differential O +
expression O +
of O +
four O +
genes O -
, O +
THBS1 O -
, O +
MMP3 O -
, O +
TNFRSF11B O +
and O +
KRTH4 O -
, O +
to O +
separate O +
human U-Species +
fibroblast O +
feeders O +
and O +
hESCs O +
( O -
Figure O +
3 O -
) O -
. O -

Several O +
markers O +
such O +
as O +
MMP3 O +
and O +
TNFRSF11B O +
have O +
commercially O +
available O +
antibodies O +
( O -
R&D O +
systems O -
) O +
that O +
may O +
be O +
used O +
to O +
further O +
confirm O +
contamination O +
of O +
feeder O +
cells O +
by O +
immunocytochemistry O -
. O -

Efforts O +
to O +
identify O +
other O +
useful O +
antibodies O +
based O +
on O +
these O +
results O +
continue O +
[ O -
29 O -
] O -
. O -

While O +
we O +
have O +
focused O +
on O +
the O +
immediate O +
utility O +
of O +
the O +
Illumina O +
array O +
platform O -
, O +
it O +
is O +
important O +
to O +
remember O +
that O +
this O +
array O +
provides O +
a O +
global O +
snapshot O +
of O +
cell O +
state O +
and O +
the O +
data O +
obtained O +
can O +
be O +
readily O +
compared O +
in O +
order O +
to O +
determine O +
key O +
signaling O +
pathways O -
. O -

The O +
ability O +
to O +
compare O +
multiple O +
samples O +
in O +
one O +
run O +
enhances O +
data O +
selectivity O +
and O +
reliability O -
. O -

To O +
make O +
such O +
analysis O +
more O +
readily O +
available O -
, O +
we O +
utilized O +
several O +
software O +
tools O +
including O +
the O +
software O +
package O +
available O +
through O +
Illumina O -
. O -

The O +
BeadStudio O +
software O +
provided O +
with O +
the O +
BeadLab O +
and O +
BeadStudio O +
genetic O +
analysis O +
systems O +
for O +
use O +
with O +
the O +
bead O +
array O +
datasets O +
provides O +
a O +
useful O +
set O +
of O +
analytical O +
and O +
presentation O +
tools O +
that O +
allow O +
straightforward O +
comparisons O -
, O +
which O +
are O +
sufficient O +
for O +
average O +
users O -
. O -

For O +
detailed O +
analysis O +
we O +
recommend O +
using O +
more O +
specific O +
commercial O +
tools O +
or O +
software O +
packages O +
developed O +
by O +
NCBI O -
. O -

In O +
summary O -
, O +
the O +
Illumina O +
bead O +
array O +
has O +
several O +
key O +
strengths O +
including O +
high O +
throughput O -
, O +
low O +
cost O +
and O +
high O +
sensitivity O -
. O -

By O +
using O +
this O +
array O -
, O +
we O +
can O +
readily O +
detect O +
contaminating O +
feeders O +
and O +
spontaneous O +
differentiation O -
, O +
differentiate O +
male O +
and O +
female O +
lines O +
and O +
distinguish O +
between O +
one O +
undifferentiated O +
population O +
and O +
another O -
. O -

Such O +
a O +
global O +
analysis O +
allows O +
us O +
to O +
assess O +
context O +
dependent O +
signaling O +
and O +
identify O +
biomarkers O +
of O +
particular O +
states O +
of O +
cells O -
. O -

Our O +
future O +
efforts O +
will O +
focus O +
on O +
data O +
mining O +
and O +
developing O +
better O +
cross O +
platform O +
comparison O +
tools O +
and O +
generating O +
focused O +
high O +
throughput O +
arrays O +
for O +
quality O +
control O +
in O +
clinical O +
and O +
research O +
settings O -
. O -

hESC O +
cultureThe O +
hESC O +
lines O +
H1 O -
, O +
H7 O +
and O +
H9 O +
( O -
WiCell O -
, O +
Madison O -
, O +
WI O -
) O +
were O +
cultured O +
on O +
feeder O +
layers O +
derived O +
from O +
mitotically O +
inactivated O +
HS27 O +
human U-Species +
fibroblast O +
cells O +
( O -
HS27 O -
, O +
ATCC O -
) O -
, O +
or O +
mouse U-Species +
embryonic O +
fibroblsts O +
or O +
under O +
feeder O -
- O -
free O +
conditions O +
on O +
Matrigel O +
( O -
BD O -
, O +
Franklin O +
Lakes O -
, O +
NJ O -
) O +
coated O +
plates O +
for O +
at O +
least O +
10 O +
passages O -
. O -

Culture O +
medium O +
for O +
all O +
cultures O +
was O +
composed O +
of O +
DMEM O -
/ O -
F12-Glutamax O +
1:1 O -
, O +
20 O -
% O +
Knockout O +
Serum O +
Replacement O -
, O +
2 O +
mM O +
nonessential O +
amino O +
acids O -
, O +
100 O +
μM O +
beta O -
- O -
mercaptoethanol O -
, O +
50 O +
μg O -
/ O -
ml O +
Pen O -
- O -
Strep O +
( O -
all O +
from O +
Invitrogen O -
, O +
Carlsbad O -
, O +
CA O -
) O -
, O +
and O +
4 O +
ng O -
/ O -
ml O +
human U-Species +
recombinant O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
/ O -
FGF2 O -
; O +
PeproTech O +
Inc. O -
, O +
Rocky O +
Hill O -
, O +
NJ O -
. O -
) O -

Feeder O -
- O -
free O +
cultures O +
were O +
prepared O +
for O +
gene O +
expression O +
analysis O +
by O +
manually O +
harvesting O +
individual O +
colonies O +
with O +
uniform O +
typical O +
undifferentiated O +
ESC O +
morphology O -
. O -

BG01 O +
( O -
46 O -
, O +
XY O -
) O -
, O +
BG02 O +
( O -
46 O -
, O +
XY O -
) O -
, O +
BG03 O +
( O -
46 O -
, O +
XX O -
) O -
, O +
I6 O +
( O -
46 O -
, O +
XY O -
) O +
and O +
BG01V O +
( O -
BG01 O +
karyotypic O +
variant O -
: O +
49 O -
, O +
XXY O -
, O +
+ O -
12 O -
, O +
+ O -
17 O -
) O -
: O +
Cells O +
were O +
maintained O +
for O +
3 O +
( O -
BG01V O -
) O -
, O +
7 O +
( O -
BG02 O -
) O -
, O +
8 O +
( O -
BG01 O -
) O -
, O +
or O +
21 O +
( O -
BG03 O -
) O +
passages O +
under O +
feeder O -
- O -
free O +
condition O +
on O +
fibronectin O -
- O -
coated O +
plates O +
in O +
medium O +
that O +
had O +
been O +
conditioned O +
by O +
mouse U-Species +
embryonic O +
fibroblasts O +
for O +
24 O +
hours O -
. O -

Culture O +
medium O +
was O +
DMEM O -
/ O -
F12 O -
, O +
1:1 O +
supplemented O +
with O +
20 O -
% O +
Knockout O +
Serum O +
Replacement O -
, O +
2 O +
mM O +
non O -
- O -
essential O +
amino O +
acids O -
, O +
2 O +
mM O +
L O -
- O -
glutamine O -
, O +
50 O +
μg O -
/ O -
ml O +
Pen O -
- O -
Strep O -
, O +
100 O +
μM O +
beta O -
- O -
mercaptoethanol O -
, O +
and O +
4 O +
ng O -
/ O -
ml O +
of O +
bFGF.Different O +
hESC O +
lines O +
were O +
grown O +
in O +
slightly O +
different O +
culture O +
conditions O +
as O +
described O +
above O -
. O -

H O +
lines O +
were O +
grown O +
on O +
Matrigel O +
coated O +
dishes O -
, O +
while O +
BG O +
lines O +
on O +
fibronectin O +
treated O +
dishes O -
. O -

These O +
coating O +
substrata O +
supported O +
the O +
growth O +
of O +
hESCs O +
similarly O -
, O +
as O +
evaluated O +
by O +
colony O +
morphology O -
, O +
immunocytochemistry O +
and O +
proliferation O +
rate O +
( O -
data O +
not O +
shown O -
) O -
.Embryoid O +
bodies O +
( O -
EBs O -
) O +
were O +
prepared O +
from O +
BG O +
lines O +
as O +
described O +
in O +
[ O -
5 O -
] O -
. O -

Cells O +
were O +
aggregated O +
and O +
cultured O +
on O +
non O -
- O -
adherent O +
substrata O +
for O +
fourteen O +
days O -
. O -

Other O +
cellsNTera2 O +
cells O +
were O +
purchased O +
from O +
ATCC O +
and O +
cultured O +
in O +
parallel O +
with O +
hESCssamples O +
using O +
protocols O +
described O +
previously O +
[ O -
21 O -
] O -
. O -

HS27 O +
embryonic O +
human U-Species +
newborn O +
foreskin O +
cells O +
( O -
ATCC O +
CRL-1634 O -
) O +
were O +
grown O +
in O +
DMEM O +
with O +
10%FBS.All O +
samples O +
included O +
in O +
this O +
study O +
can O +
be O +
found O +
in O +
Additional O +
file O +
6.Bead O +
array O +
gene O +
expression O +
analysisRNA O +
was O +
isolated O +
from O +
cultured O +
cells O +
using O +
the O +
Qiagen O +
RNEasy O +
kit O +
( O -
Qiagen O -
, O +
Inc O -
, O +
Valencia O -
, O +
CA O -
) O -
. O -

Sample O +
amplification O +
was O +
performed O +
using O +
100 O +
ng O +
of O +
total O +
RNA O +
as O +
input O +
material O +
by O +
the O +
method O +
of O +
Van O +
Gelder O +
et O +
al O +
[ O -
30 O -
] O -
. O -

Amplified O +
RNA O +
synthesized O +
from O +
limited O +
quantities O +
of O +
heterogenous O +
cDNA O +
[ O -
30 O -
] O +
was O +
performed O +
using O +
the O +
Illumina O +
RNA O +
Amplification O +
kit O +
( O -
Ambion O -
, O +
Inc. O -
, O +
Austin O -
, O +
TX O -
) O +
following O +
the O +
Manufacturer O +
instructions O -
. O -

Labeling O +
was O +
achieved O +
by O +
use O +
of O +
the O +
incorporation O +
of O +
biotin-16-UTP O +
( O -
Perkin O +
Elmer O +
Life O +
and O +
Analytical O +
Sciences O -
, O +
Boston O -
, O +
MA O -
) O +
present O +
at O +
a O +
ratio O +
of O +
1:1 O +
with O +
unlabeled O +
UTP O -
. O -

Labeled O -
, O +
amplified O +
material O +
( O -
700 O +
ng O +
per O +
array O -
) O +
was O +
hybridized O +
to O +
a O +
pilot O +
version O +
of O +
the O +
Illumina O +
HumanRef-8 U-Species +
BeadChip O +
according O +
to O +
the O +
Manufacturer O -
's O +
instructions O +
( O -
Illumina O -
, O +
Inc. O -
, O +
San O +
Diego O -
, O +
CA O -
) O -
. O -

Amersham O +
fluorolink O +
streptavidin O -
- O -
Cy3 O +
( O -
GE O +
Healthcare O +
Bio O -
- O -
Sciences O -
, O +
Little O +
Chalfont O -
, O +
UK O -
) O +
following O +
the O +
BeadChip O +
manual O -
. O -

Arrays O +
were O +
scanned O +
with O +
an O +
Illumina O +
Bead O +
array O +
Reader O +
confocal O +
scanner O +
according O +
to O +
the O +
Manufacturer O -
's O +
instructions O -
. O -

Array O +
data O +
processing O +
and O +
analysis O +
was O +
performed O +
using O +
Illumina O +
BeadStudio O +
software O -
. O -

Identification O +
of O +
differentially O +
expressed O +
genes O +
and O +
clustering O +
analysisDifferentially O +
expressed O +
genes O +
between O +
ES O +
and O +
EB O +
were O +
identified O +
by O +
ANOVA O +
at O +
p O +
value O +
0.05 O +
using O +
bioconductor O +
[ O -
17 O -
] O -
. O -

Unsupervised O +
hierarchical O +
clustering O +
analysis O +
and O +
principal O +
component O +
analysis O +
( O -
PCA O -
) O +
were O +
conducted O +
using O +
software O +
Pcluster O +
[ O -
31 O -
] O +
and O +
TreeView O +
[ O -
18 O -
] O -
.Identification O +
of O +
diagnostic O +
markersPAM O +
( O -
prediction O +
analysis O +
of O +
microarray O -
) O +
was O +
employed O +
for O +
the O +
identification O +
of O +
diagnostic O +
markers O +
from O +
insulin O +
pathway O +
genes O +
by O +
using O +
the O +
software O +
package O +
bioconductor O +
[ O -
17 O -
] O -
. O -

PAM O +
is O +
a O +
class O +
prediction O +
method O +
for O +
expression O +
data O +
mining O -
. O -

It O +
can O +
provide O +
a O +
list O +
of O +
significant O +
genes O +
whose O +
expression O +
characterizes O +
each O +
diagnostic O +
class O -
. O -

The O +
average O +
gene O +
expression O +
level O +
in O +
multiple O +
classes O -
, O +
such O +
as O +
ES O -
, O +
EB O -
, O +
NS O -
, O +
and O +
FB O -
, O +
was O +
divided O +
by O +
the O +
within O -
- O -
class O +
standard O +
deviation O +
for O +
that O +
gene O -
. O -

The O +
nearest O +
centroid O +
classification O +
computed O +
by O +
PAM O +
takes O +
the O +
protein O +
expression O +
profile O +
from O +
a O +
new O +
sample O -
, O +
and O +
compares O +
it O +
to O +
each O +
of O +
these O +
class O +
centroids O +
[ O -
26 O -
] O -
.RT O -
- O -
PCR O +
and O +
quantitative O +
real O -
- O -
time O +
PCR O +
analysisTotal O +
RNA O +
was O +
isolated O +
with O +
TRIzol O +
( O -
Invitrogen O -
. O -

cDNA O +
was O +
synthesized O +
using O +
2.5 O +
μg O +
total O +
RNA O +
in O +
a O +
20-μl O +
reaction O +
with O +
Superscript O +
II O +
( O -
Invitrogen O -
) O +
and O +
oligo O +
( O -
dT O -
) O -
12–18 O +
( O -
Promega O -
; O +
Madison O -
, O +
WI O -
) O -
. O -

One O +
microliter O +
RNase O +
H O +
( O -
Invitrogen O -
) O +
was O +
added O +
to O +
each O +
tube O +
and O +
incubated O +
for O +
20 O +
minutes O +
at O +
37 O -
° O -
C O +
before O +
proceeding O +
to O +
the O +
RT O -
- O -
PCR O +
analysis O -
. O -

The O +
PCR O +
primers O +
are O -
: O +
RPS4Y O -
- O -
forward O -
: O +
5 O -
' O +
AGATTCTCTTCCGTCGCAG O +
3 O -
' O -
, O +
RPS4Y O -
- O -
reverse O -
, O +
5 O -
' O +
CTCCACCAATCACCATACAC O +
3 O -
' O -
; O +
EIFAY O -
- O -
forward O -
, O +
5 O -
' O +
CTGCTGCATCTTAGTTCAGTC O +
3 O -
' O -
; O +
EIFAY O -
- O -
reverse O +
5 O -
' O +
CTTCCAATCGTCCATTTCCC O +
3 O -
' O -
. O -

Quantitative O +
real O +
time O +
PCR O +
gene O +
specific O +
primer O +
pairs O +
and O +
probes O +
were O +
purchased O +
from O +
Applied O +
Biosystems O +
( O -
Foster O +
City O -
, O +
CA O -
) O +
for O +
the O +
following O +
genes O -
: O +
MMP3 O +
( O -
Hs00233962_m1 O -
) O -
, O +
TFRSF11B O +
( O -
Hs00171068_m1 O -
) O -
, O +
THBS1 O +
( O -
Hs00170236_m1 O -
) O -
, O +
KRTHA4 O +
( O -
Hs00606019_gH O -
) O -
, O +
and O +
for O +
internal O +
control O +
β O -
- O -
actin O +
( O -
ACTB O -
, O +
Hs99999903_m1 O -
) O -
. O -

BackgroundHuman O +
stem O +
cells O +
are O +
viewed O +
as O +
a O +
possible O +
source O +
of O +
neurons O +
for O +
a O +
cell O -
- O -
based O +
therapy O +
of O +
neurodegenerative O +
disorders O -
, O +
such O +
as O +
Parkinson O -
's O +
disease O -
. O -

Several O +
protocols O +
that O +
generate O +
different O +
types O +
of O +
neurons O +
from O +
human U-Species +
stem O +
cells O +
( O -
hSCs O -
) O +
have O +
been O +
developed O -
. O -

Nevertheless O -
, O +
the O +
cellular O +
mechanisms O +
that O +
underlie O +
the O +
development O +
of O +
neurons O +
in O +
vitro O +
as O +
they O +
are O +
subjected O +
to O +
the O +
specific O +
differentiation O +
protocols O +
are O +
often O +
poorly O +
understood O -
. O -

ResultsWe O +
have O +
designed O +
a O +
focused O +
DNA O +
( O -
oligonucleotide O -
- O -
based O -
) O +
large O -
- O -
scale O +
microarray O +
platform O +
( O -
named O +
" O -
NeuroStem O +
Chip O -
" O -
) O +
and O +
used O +
it O +
to O +
study O +
gene O +
expression O +
patterns O +
in O +
hSCs O +
as O +
they O +
differentiate O +
into O +
neurons O -
. O -

We O +
have O +
selected O +
genes O +
that O +
are O +
relevant O +
to O +
cells O +
( O -
i O -
) O +
being O +
stem O +
cells O -
, O +
( O -
ii O -
) O +
becoming O +
neurons O -
, O +
and O +
( O -
iii O -
) O +
being O +
neurons O -
. O -

The O +
NeuroStem O +
Chip O +
has O +
over O +
1,300 O +
pre O -
- O -
selected O +
gene O +
targets O +
and O +
multiple O +
controls O +
spotted O +
in O +
quadruplicates O +
( O -
~46,000 O +
spots O +
total O -
) O -
. O -

In O +
this O +
study O -
, O +
we O +
present O +
the O +
NeuroStem O +
Chip O +
in O +
detail O +
and O +
describe O +
the O +
special O +
advantages O +
it O +
offers O +
to O +
the O +
fields O +
of O +
experimental O +
neurology O +
and O +
stem O +
cell O +
biology O -
. O -

To O +
illustrate O +
the O +
utility O +
of O +
NeuroStem O +
Chip O +
platform O -
, O +
we O +
have O +
characterized O +
an O +
undifferentiated O +
population O +
of O +
pluripotent O +
human U-Species +
embryonic O +
stem O +
cells O +
( O -
hESCs O -
, O +
cell O +
line O +
SA02 O -
) O -
. O -

In O +
addition O -
, O +
we O +
have O +
performed O +
a O +
comparative O +
gene O +
expression O +
analysis O +
of O +
those O +
cells O +
versus O +
a O +
heterogeneous O +
population O +
of O +
hESC O -
- O -
derived O +
cells O +
committed O +
towards O +
neuronal O -
/ O -
dopaminergic O +
differentiation O +
pathway O +
by O +
co O -
- O -
culturing O +
with O +
PA6 O +
stromal O +
cells O +
for O +
16 O +
days O +
and O +
containing O +
a O +
few O +
tyrosine O +
hydroxylase O -
- O -
positive O +
dopaminergic O +
neurons O -
. O -

ConclusionWe O +
characterized O +
the O +
gene O +
expression O +
profiles O +
of O +
undifferentiated O +
and O +
dopaminergic O +
lineage O -
- O -
committed O +
hESC O -
- O -
derived O +
cells O +
using O +
a O +
highly O +
focused O +
custom O +
microarray O +
platform O +
( O -
NeuroStem O +
Chip O -
) O +
that O +
can O +
become O +
an O +
important O +
research O +
tool O +
in O +
human U-Species +
stem O +
cell O +
biology O -
. O -

We O +
propose O +
that O +
the O +
areas O +
of O +
application O +
for O +
NeuroStem O +
microarray O +
platform O +
could O +
be O +
the O +
following O -
: O +
( O -
i O -
) O +
characterization O +
of O +
the O +
expression O +
of O +
established O -
, O +
pre O -
- O -
selected O +
gene O +
targets O +
in O +
hSC O +
lines O -
, O +
including O +
newly O +
derived O +
ones O -
, O +
( O -
ii O -
) O +
longitudinal O +
quality O +
control O +
for O +
maintained O +
hSC O +
populations O -
, O +
( O -
iii O -
) O +
following O +
gene O +
expression O +
changes O +
during O +
differentiation O +
under O +
defined O +
cell O +
culture O +
conditions O -
, O +
and O +
( O -
iv O -
) O +
confirming O +
the O +
success O +
of O +
differentiation O +
into O +
specific O +
neuronal O +
subtypes O -
. O -

Modern O +
DNA O +
microarrays O +
permit O +
a O +
comprehensive O +
analysis O +
of O +
quantitative O +
and O +
qualitative O +
changes O +
in O +
RNA O +
transcript O +
abundance O -
, O +
outlining O +
the O +
cross O -
- O -
sections O +
of O +
gene O +
expression O +
and O +
alterations O +
of O +
these O +
in O +
response O +
to O +
genetic O +
or O +
environmental O +
stimuli O -
. O -

Genome O -
- O -
scale O +
microarrays O +
( O -
cDNA- O +
or O +
oligonucleotide O -
- O -
based O -
) O +
are O +
most O +
valuable O +
when O +
screening O +
populations O +
of O +
cells O +
for O +
the O +
novel O +
genes O +
reflecting O +
potential O +
diagnostic O +
and O +
prognostic O +
markers O +
or O +
for O +
an O +
identification O +
of O +
novel O +
therapeutic O +
targets O -
. O -

On O +
the O +
other O +
hand O -
, O +
custom O +
microarray O +
platforms O +
that O +
focus O +
on O +
specific O +
pre O -
- O -
selected O +
subset O +
of O +
genes O +
relevant O +
to O +
a O +
particular O +
field O +
of O +
investigation O +
can O +
be O +
less O +
costly O +
and O +
more O +
suitable O +
for O +
detection O +
of O +
smaller O +
gene O +
expression O +
changes O -
. O -

Microarray O +
technology O +
has O +
added O +
important O +
information O +
on O +
both O +
normal O +
development O +
and O +
pathological O +
changes O +
in O +
neurons O -
. O -

This O +
is O +
well O +
illustrated O +
by O +
multiple O +
studies O +
on O +
substantia O +
nigra O +
dopaminergic O +
neurons O -
, O +
which O +
degenerate O +
in O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O +
[ O -
1 O -
- O -
5 O -
] O -
. O -

The O +
shortcomings O +
of O +
pharmacological O +
therapies O +
in O +
PD O +
have O +
stimulated O +
a O +
search O +
for O +
alternative O +
treatment O +
strategies O -
. O -

In O +
successful O +
cases O -
, O +
transplants O +
of O +
human U-Species +
embryonic O +
mesencephalic O +
dopaminergic O +
neurons O +
can O +
both O +
restore O +
dopaminergic O +
neurotransmission O +
and O +
provide O +
some O +
symptomatic O +
relief O +
[ O -
6 O -
- O -
8 O -
] O -
. O -

A O +
wider O +
application O +
of O +
neural O +
transplantation O +
in O +
PD O +
is O -
, O +
however O -
, O +
currently O +
not O +
feasible O +
due O +
to O +
the O +
unpredictable O +
and O +
variable O +
outcome O -
, O +
the O +
risks O +
of O +
unwanted O +
side O -
- O -
effects O +
( O -
dyskinesias O -
) O +
[ O -
9,10 O -
] O +
and O +
ethical O +
and O +
practical O +
problems O +
associated O +
with O +
using O +
donor O +
cells O +
obtained O +
from O +
aborted O +
embryos O +
and O +
fetuses O +
[ O -
11,12 O -
] O -
. O -

Human U-Species +
embryonic O +
stem O +
cells O +
( O -
hESCs O -
) O +
are O +
considered O +
a O +
promising O +
future O +
source O +
of O +
cells O +
for O +
cell O +
replacement O +
therapy O +
in O +
PD O +
and O +
other O +
neurological O +
conditions O +
[ O -
13 O -
] O -
. O -

They O +
could O +
constitute O +
a O +
virtually O +
infinite O +
source O +
of O +
self O -
- O -
renewing O +
cells O +
that O +
can O +
be O +
persuaded O +
to O +
differentiate O +
into O +
specific O +
types O +
of O +
neural O +
cells O -
, O +
including O +
dopaminergic O +
neurons O +
[ O -
14 O -
- O -
16 O -
] O -
. O -

The O +
molecular O +
mechanisms O +
that O +
govern O +
development O +
of O +
cultured O +
hESCs O +
into O +
specific O +
types O +
of O +
neural O +
cells O +
are O +
not O +
fully O +
understood O -
. O -

To O +
promote O +
our O +
understanding O +
of O +
such O +
mechanisms O -
, O +
it O +
would O +
be O +
valuable O +
to O +
have O +
tools O +
that O +
readily O +
and O +
reproducibly O +
can O +
help O +
to O +
characterize O +
the O +
cells O +
as O +
they O +
differentiate O +
from O +
pluripotent O +
stem O +
cells O +
into O +
post O -
- O -
mitotic O +
neurons O -
. O -

This O +
important O +
issue O +
was O +
addressed O +
in O +
earlier O +
studies O +
by O +
Luo O +
et O +
al. O +
and O +
Yang O +
et O +
al. O -
, O +
who O +
designed O +
small O -
- O -
to O -
- O -
moderate O +
scale O +
custom O +
microarray O +
platforms O +
( O -
281 O +
and O +
755 O +
gene O +
targets O -
, O +
respectively O -
) O +
[ O -
17,18 O -
] O -
. O -

In O +
addition O +
SuperArray O +
Bioscience O +
Corporation O +
( O -
Frederick O -
, O +
MD O -
, O +
USA O -
) O +
have O +
manufactured O +
a O +
range O +
of O +
small O -
- O -
scale O +
arrays O +
( O -
263 O +
gene O +
targets O +
for O +
human O +
array O -
; O +
[ O -
19 O -
] O -
) O -
. O -

We O +
sought O +
to O +
create O +
an O +
improved O +
and O +
updated O +
microarray O +
platform O +
for O +
hESC O -
/ O -
neuronal O +
differentiation O -
- O -
oriented O +
gene O +
expression O +
studies O -
. O -

Therefore O -
, O +
we O +
generated O +
a O +
specialized O +
large O -
- O -
scale O +
DNA O +
microarray O +
platform O +
( O -
the O +
" O -
NeuroStem O +
Chip O -
" O -
) O +
that O +
has O +
over O +
1,300 O +
pre O -
- O -
selected O +
gene O +
targets O +
and O +
multiple O +
controls O +
spotted O +
in O +
quadruplicates O +
( O -
~46,000 O +
spots O +
total O -
) O -
. O -

Here O +
we O +
introduce O +
the O +
platform O +
and O +
the O +
advantages O +
it O +
can O +
offers O +
to O +
neuroscientists O +
and O +
stem O +
cell O +
biologists O -
: O +
particularly O -
, O +
in O +
the O +
niche O +
of O +
gene O +
expression O -
- O -
oriented O +
characterization O +
of O +
the O +
samples O +
using O +
an O +
assay O +
of O +
pre O -
- O -
selected O -
, O +
already O +
established O +
gene O +
targets O -
. O -

In O +
the O +
current O +
study O -
, O +
we O +
use O +
the O +
NeuroStem O +
Chip O +
to O +
characterize O +
an O +
undifferentiated O +
population O +
of O +
pluripotent O +
hESCs O +
( O -
cell O +
line O +
SA02 O -
, O +
Cellartis O +
AB O -
, O +
Göteborg O -
, O +
Sweden O -
) O +
and O +
compare O +
the O +
gene O +
expression O +
in O +
those O +
cells O +
with O +
that O +
of O +
a O +
hESC O -
- O -
derived O +
cell O +
population O +
rich O +
in O +
neurons O -
, O +
including O +
tyrosine O +
hydroxylase O -
- O -
positive O +
dopaminergic O +
neurons O -
. O -

Stem O +
cells O +
have O +
unique O +
biological O +
characteristics O -
, O +
but O +
only O +
a O +
limited O +
number O +
of O +
genes O +
are O +
currently O +
recognized O +
as O +
established O +
stem O +
cell O +
markers O -
. O -

Examples O +
include O +
POU O +
domain O -
, O +
class O +
5 O -
, O +
transcription O +
factor O +
1 O +
( O -
Oct3 O -
/ O -
4 O -
) O -
, O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O -
Stat3 O -
) O -
, O +
teratocarcinoma O -
- O -
derived O +
growth O +
factor O +
( O -
Tdgf1 O -
) O -
, O +
Enk O -
- O -
pending O +
( O -
Nanog O -
) O -
, O +
undifferentiated O +
embryonic O +
cell O +
transcription O +
factor O +
1 O +
( O -
Utf1 O -
) O +
and O +
DNA O +
methyltransferase O +
3B O +
( O -
Dnmt3b O -
) O +
[ O -
20 O -
] O -
. O -

At O +
the O +
same O +
time O -
, O +
hundreds O +
of O +
genes O +
are O +
suggested O +
as O +
candidate O +
markers O +
for O +
" O -
stemness O -
" O -
, O +
but O +
their O +
coupling O +
to O +
the O +
undifferentiated O +
stem O +
cell O +
state O +
is O +
not O +
yet O +
fully O +
verified O +
[ O -
21 O -
] O -
. O -

The O +
concept O +
of O +
" O -
stemness O -
" O +
( O -
term O +
introduced O +
in O +
1986 O +
by O +
Grossman O +
& O +
Levine O -
) O +
is O +
defined O +
as O +
" O -
core O +
stem O +
cell O +
properties O +
that O +
underlie O +
self O -
- O -
renewal O +
and O +
the O +
ability O +
to O +
generate O +
differentiated O +
progeny O -
" O +
[ O -
22 O -
] O -
. O -

Considering O +
the O +
complexity O +
of O +
the O +
processes O +
involved O -
, O +
stemness O +
can O +
hardly O +
be O +
ensured O +
by O +
co O -
- O -
operation O +
of O +
just O +
a O +
few O +
genes O -
. O -

Nevertheless O -
, O +
three O +
stemness O +
genes O +
( O -
namely O -
, O +
Oct3 O -
/ O -
4 O -
, O +
Stat3 O +
and O +
Nanog O -
) O +
are O +
considered O +
" O -
master O -
"- O -
genes O +
that O +
control O +
the O +
self O -
- O -
renewing O +
process O +
[ O -
23,24 O -
] O -
. O -

Various O +
types O +
of O +
stem O +
cells O -
, O +
such O +
as O +
hematopoietic O -
, O +
mesenchymal O +
and O +
neural O +
( O -
HSCs O -
, O +
MSCs O +
and O +
NSCs O -
, O +
respectively O -
) O -
, O +
embryonic O +
germ O +
and O +
embryonic O +
carcinoma O +
cells O +
( O -
EGCs O +
and O +
ECCs O -
, O +
respectively O -
) O +
are O +
all O +
characterized O +
by O +
variations O +
in O +
gene O +
expression O +
profiles O -
, O +
and O +
only O +
a O +
few O +
gene O +
markers O +
are O +
associated O +
with O +
all O +
these O +
cell O +
types O +
[ O -
25,26 O -
] O -
. O -

We O +
have O +
aimed O +
to O +
embrace O +
the O +
most O +
comprehensive O +
set O +
of O +
those O +
genes O +
into O +
a O +
solitary O +
array O -
, O +
the O +
NeuroStem O +
Chip O -
. O -

Thereby O -
, O +
it O +
is O +
possible O +
to O +
employ O +
it O +
to O +
monitor O +
the O +
relative O +
expression O +
levels O +
of O +
numerous O +
known O +
and O +
candidate O +
stemness O +
genes O +
in O +
a O +
single O +
experiment O -
. O -

Similar O +
to O +
the O +
genetic O +
bases O +
underlying O +
stemness O -
, O +
cell O +
differentiation O +
is O +
associated O +
with O +
altered O +
expression O +
levels O +
of O +
certain O +
recognized O +
or O +
candidate O +
genes O +
[ O -
25 O -
] O -
. O -

We O +
therefore O +
incorporated O +
gene O +
markers O +
of O +
development O +
and O +
differentiation O +
in O +
general O -
, O +
and O +
that O +
of O +
neuronal O +
and O +
dopaminergic O +
differentiation O +
in O +
particular O -
, O +
into O +
the O +
NeuroStem O +
Chip O -
. O -

Examples O +
include O +
markers O +
for O +
the O +
processes O +
of O +
neuronal O +
maturation O -
, O +
axonal O +
branching O -
, O +
neural O -
/ O -
neuronal O +
survival O -
, O +
etc O -
. O -

Finally O -
, O +
we O +
ensured O +
that O +
known O +
markers O +
for O +
specific O +
types O +
of O +
neurons O -
, O +
allowing O +
identification O +
of O +
individual O +
cell O +
types O -
, O +
were O +
present O +
on O +
the O +
chip O -
. O -

We O +
paid O +
special O +
attention O +
to O +
genes O +
associated O +
with O +
the O +
differentiation O +
and O +
maturation O +
of O +
dopaminergic O +
neurons O -
. O -

In O +
many O +
published O +
studies O -
, O +
the O +
expression O +
of O +
only O +
a O +
single O +
( O -
tyrosine O +
hydroxylase O -
, O +
TH O -
) O +
or O +
2–3 O +
markers O +
for O +
dopaminergic O +
neurons O +
( O -
e.g. O +
amino O +
acid O +
decarboxylase O +
( O -
AADC O -
) O -
, O +
dopamine O +
transporter O +
( O -
DAT O -
) O -
, O +
vesicular O +
monoamine O +
transporter O +
2 O +
( O -
VMAT2 O -
) O -
) O +
have O +
been O +
used O +
to O +
indicate O +
dopaminergic O +
identity O +
of O +
neurons O -
. O -

In O +
contrast O -
, O +
the O +
NeuroStem O +
Chip O +
includes O +
oligonucleotide O +
probes O +
for O +
88 O +
genes O +
related O +
to O +
dopaminergic O +
neurons O -
, O +
thus O +
being O +
more O +
comprehensive O +
in O +
this O +
sense O -
, O +
compared O +
to O +
other O +
existing O +
microarray O +
platforms O -
, O +
including O +
focused O +
ones O +
[ O -
17,18 O -
] O -
. O -

Those O +
entries O +
encompass O +
recognized O +
and O +
candidate O +
markers O +
for O +
dopaminergic O +
neurons O +
( O -
mature O +
and O +
early O -
) O +
and O +
progenitors O -
, O +
as O +
well O +
as O +
markers O +
for O +
the O +
maturation O +
and O +
differentiation O +
of O +
the O +
latter O +
( O -
Table O +
1 O -
) O -
. O -

Table O +
2 O +
represents O +
conditional O +
functional O +
breakdown O +
of O +
genes O +
targeted O +
by O +
the O +
NeuroStem O +
microarray O +
platform O -
. O -

A O +
number O +
of O +
important O +
gene O +
groups O +
that O +
are O +
included O +
in O +
the O +
chip O +
are O +
not O +
mentioned O +
in O +
Table O +
2 O -
. O -

Among O +
these O -
, O +
entries O +
related O +
to O +
Dickkopf O +
gene O +
family O -
, O +
galanin- O -
, O +
melatonin- O -
, O +
vasoactive O +
intestinal O +
peptide O +
( O -
VIP O -
) O -
- O -
, O +
cAMP O +
response O +
element O -
- O -
binding O +
protein O +
( O -
CREB O -
) O -
- O +
and O +
B O +
cell O +
leukemia O +
2 O +
( O -
Bcl2 O -
) O +
oncogene O -
- O -
related O +
are O +
present O -
. O -

Many O +
of O +
them O +
play O +
potentially O +
important O -
, O +
yet O +
undefined O -
, O +
roles O +
in O +
the O +
biology O +
of O +
stem O +
cells O -
. O -

Additionally O -
, O +
we O +
included O +
some O +
genes O +
implicated O +
in O +
disease O +
mechanisms O +
of O +
neurodegenerative O +
disorders O +
( O -
most O +
importantly O -
, O +
Parkinson O -
's O +
disease O +
and O +
Alzheimer O -
's O +
disease O -
) O +
in O +
the O +
chip O -
. O -

Furthermore O -
, O +
we O +
incorporated O +
a O +
number O +
of O +
markers O +
for O +
distinct O +
differentiation O +
pathways O +
( O -
e.g. O +
hematopoietic O +
and O +
pancreatic O -
) O +
and O +
cell O +
types O +
( O -
e.g. O +
cancer O +
subtypes O +
and O +
a O +
range O +
of O +
normal O +
cell O +
types O -
) O +
to O +
serve O +
as O +
essential O +
controls O -
. O -

Taken O +
together O -
, O +
we O +
believe O +
that O +
in O +
its O +
present O +
form O +
NeuroStem O +
Chip O +
represents O +
currently O +
most O +
comprehensive O +
gene O +
expression O +
platform O +
for O +
studies O +
on O +
stem O +
cells O -
, O +
neural O -
/ O -
neuronal O +
differentiation O -
, O +
human U-Species +
neurodegeneration O +
and O +
neuronal O +
survival O -
, O +
both O +
in O +
vivo O +
and O +
in O +
vitro O -
. O -

The O +
complete O +
layout O +
of O +
NeuroStem O +
Chip O +
will O +
be O +
disclosed O +
to O +
the O +
academic O +
community O -
, O +
upon O +
request O -
. O -

The O +
microarray O +
format O +
we O +
selected O +
relies O +
on O +
long O +
oligonucleotide O +
molecules O +
( O -
69–71 O +
nucleotides O -
) O +
printed O +
over O +
a O +
solid O +
surface O -
. O -

We O +
spotted O +
the O +
synthesized O +
oligonucleotides O +
( O -
Operon O +
Biotechnologies O -
) O +
with O +
a O +
constant O +
concentration O +
across O +
the O +
slides O -
, O +
and O +
evaluated O +
the O +
quality O +
and O +
consistency O +
of O +
spotting O +
in O +
a O +
series O +
of O +
control O +
experiments O -
. O -

We O +
then O +
illustrated O +
the O +
utility O +
and O +
technical O +
reliability O +
of O +
the O +
NeuroStem O +
Chip O +
by O +
characterizing O +
the O +
gene O +
expression O +
profile O +
of O +
commonly O +
utilized O +
hESC O +
line O +
SA02 O +
( O -
Sahlgrenska O +
2 O -
; O +
[ O -
27 O -
] O -
) O -
, O +
including O +
( O -
i O -
) O +
undifferentiated O +
cells O +
and O +
( O -
ii O -
) O +
cells O +
committed O +
towards O +
neuronal O -
/ O -
dopaminergic O +
differentiation O +
pathway O -
. O -

For O +
the O +
first O +
of O +
these O -
, O +
we O +
used O +
total O +
RNA O +
sample O +
purified O +
from O +
hESC O +
colonies O +
that O +
exhibited O +
morphology O +
consistent O +
with O +
cell O +
proliferation O +
and O +
the O +
absence O +
of O +
spontaneous O +
differentiation O +
( O -
Figure O +
1A O -
) O -
. O -

We O +
also O +
evaluated O +
the O +
expression O +
of O +
the O +
cell O +
cycle O +
marker O +
Ki67 O +
and O +
the O +
pluripotency O +
marker O +
OCT3 O -
/ O -
4 O +
in O +
the O +
sample O +
by O +
immunocytochemistry O +
( O -
Figure O +
1B O -
– O -
E O -
) O -
. O -

Co O -
- O -
culturing O +
of O +
ESCs O +
with O +
murine U-Species +
stromal O +
cells O +
( O -
including O +
PA6 O +
cell O +
line O -
) O +
rapidly O +
generates O +
dopaminergic O +
neurons O +
from O +
ESCs O +
by O +
an O +
unexplained O +
mechanism O +
termed O +
stromal O +
cell O -
- O -
derived O +
inducing O +
activity O +
( O -
SDIA O -
; O +
[ O -
28,29 O -
] O -
) O -
. O -

We O +
therefore O +
committed O +
hESCs O +
toward O +
the O +
neuronal O -
/ O -
dopaminergic O +
differentiation O +
pathway O +
by O +
co O -
- O -
culturing O +
with O +
PA6 O +
cells O +
for O +
16 O +
days O -
, O +
resulting O +
in O +
appearance O +
of O +
cells O +
positive O +
for O +
early O +
and O +
late O +
neuronal O +
markers O -
, O +
including O +
nestin O -
, O +
β O -
- O -
III O -
- O -
tubulin O -
, O +
and O +
TH O -
, O +
the O +
established O +
marker O +
of O +
dopaminergic O +
neurons O +
( O -
Figure O +
2 O -
) O -
. O -

To O +
verify O +
the O +
expression O +
of O +
some O +
key O +
stem O +
cell- O +
and O +
neural O +
phenotype O -
- O -
associated O +
genes O +
we O +
performed O +
RT O -
- O -
PCR O +
comparing O +
RNA O +
samples O +
from O +
the O +
undifferentiated O +
hESCs O +
with O +
hESCs O +
of O +
the O +
same O +
line O +
differentiated O +
toward O +
neuronal O -
/ O -
dopaminergic O +
pathway O -
, O +
as O +
described O +
above O -
. O -

The O +
expression O +
profile O +
outlined O +
by O +
RT O -
- O -
PCR O +
confirmed O +
the O +
identity O +
of O +
the O +
sample O +
used O +
( O -
Figure O +
3 O -
) O -
. O -

After O +
performing O +
RNA O +
integrity O +
tests O -
, O +
we O +
incorporated O +
fluorescent O +
labels O +
to O +
the O +
amplified O +
RNA O +
samples O +
from O +
hESCs O +
( O -
Cyanine O +
3-CTP O +
( O -
Cy3 O -
) O +
and O +
Cyanine O +
5-CTP O +
( O -
Cy5 O -
) O -
) O -
, O +
hESC O -
- O -
derived O +
cells O +
containing O +
TH O -
- O -
positive O +
neurons O +
( O -
Cy3 O +
and O +
Cy5 O -
) O +
and O +
human O +
universal O +
reference O +
RNA O +
( O -
Cy5 O -
) O -
, O +
and O +
hybridized O +
aliquots O +
with O +
NeuroStem O +
microarray O +
slides O +
using O +
the O +
following O +
conditions O -
: O +
hESC O +
vs. O +
reference O -
, O +
Cy3 O +
: O +
Cy5 O +
= O +
( O -
i O -
) O +
20:10 O +
pmol O -
, O +
and O +
( O -
ii O -
) O +
10:5 O +
pmol O -
; O +
and O +
hESC O +
vs. O +
hESC O -
- O -
derived O +
cells O -
, O +
Cy3 O +
: O +
Cy5 O +
= O +
( O -
iii O -
) O +
30:20 O +
pmol O -
, O +
respectively O -
. O -

Universal O +
reference O +
RNA O +
has O +
been O +
previously O +
established O +
as O +
a O +
standard O +
reference O +
material O +
for O +
microarray O +
experiments O -
, O +
proving O +
an O +
ability O +
to O +
effectively O +
hybridize O +
to O +
a O +
large O +
fraction O +
of O +
microarray O +
spots O +
[ O -
30 O -
] O -
. O -

We O +
performed O +
two O -
- O -
color O +
hybridizations O +
( O -
e.g. O +
for O +
the O +
experiment O +
vs. O +
reference O -
) O +
following O +
an O +
established O +
protocol O +
[ O -
31 O -
] O -
, O +
and O +
included O +
dye O -
- O -
flip O +
technical O +
replicates O +
in O +
the O +
analysis O +
( O -
Figure O +
4 O -
) O -
. O -

Using O +
the O +
online O +
software O +
program O +
BASE O +
[ O -
32 O -
] O +
we O +
sequentially O +
filtered O +
the O +
data O +
by O +
background O +
subtraction O -
, O +
negative O +
flagging O -
, O +
negative O +
intensities O +
and O +
for O +
inconsistent O +
data O +
amongst O +
replicates O +
[ O -
33 O -
] O -
. O -

Figure O +
5A O +
shows O +
a O +
comparison O +
of O +
the O +
spot O +
intensities O +
prior O +
to O +
normalization O +
( O -
M O +
versus O +
A O +
plot O -
) O -
, O +
with O +
the O +
Log2 O +
of O +
the O +
expression O +
ratio O +
between O +
Cy3 O -
/ O -
Cy5 O +
being O +
plotted O +
as O +
a O +
function O +
of O +
the O +
log10 O +
of O +
the O +
mean O +
of O +
the O +
total O +
expression O +
intensities O +
for O +
Cy3 O +
and O +
Cy5 O +
channels O -
. O -

The O +
deviation O +
of O +
the O +
line O +
from O +
zero O +
revealed O +
a O +
need O +
for O +
normalization O -
, O +
so O +
prior O +
to O +
data O +
analyses O +
we O +
normalized O +
signals O +
using O +
a O +
locally O +
weighted O +
scatterplot O -
- O -
smoothing O +
regression O +
( O -
LOWESS O -
) O +
algorithm O +
( O -
Figure O +
5A O -
– O -
B O -
; O +
fitted O +
line O -
) O +
implemented O +
in O +
BASE O -
. O -

Since O +
the O +
reproducibility O +
of O +
two O -
- O -
color O +
microarray O +
gene O +
expression O +
data O +
is O +
critically O +
important O -
, O +
we O +
calculated O +
Pearson O +
correlation O +
coefficients O +
of O +
the O +
reporters O +
present O +
in O +
the O +
filtered O +
database O +
comparing O +
the O +
average O +
expression O +
ratios O +
( O -
7005 O +
for O +
hESCs O +
vs. O +
universal O +
reference O -
; O +
6947 O +
for O +
undifferentiated O +
vs. O +
neuronal O -
/ O -
dopaminergic O +
lineage O -
- O -
committed O +
hESCs O -
) O -
. O -

Results O +
obtained O +
revealed O +
that O +
data O +
were O +
consistent O +
across O +
technical O +
replicates O +
( O -
dye O -
- O -
swap O +
and O +
amount O +
of O +
loaded O +
material O -
) O -
, O +
showing O +
general O +
high O +
reproducibility O -
: O +
e.g. O -
, O +
correlation O +
coefficients O +
were O +
greater O +
than O +
0.96 O +
for O +
technical O +
replicates O +
and O +
0.78 O +
for O +
dye O -
- O -
swapping O +
samples O +
in O +
hESCs O +
vs. O +
universal O +
reference O +
hybridizations O +
( O -
Table O +
3 O -
) O -
. O -

To O +
detect O +
genes O +
with O +
high O +
expression O +
levels O +
in O +
hESC O +
samples O -
, O +
we O +
filtered O +
data O +
for O +
intensity O +
values O +
> O -
100 O +
in O +
the O +
hESC O +
sample O +
and O +
performed O +
clustering O +
analysis O +
using O +
the O +
TIGR O +
MultiExperiment O +
Viewer O +
( O -
MEV O -
; O +
[ O -
34 O -
] O -
) O -
. O -

To O +
visualize O +
variations O +
of O +
spot O -
/ O -
reporter O +
per O +
technical O +
replicate O -
, O +
hierarchical O +
clustering O +
was O +
performed O +
by O +
K O -
- O -
means O +
classifier O +
based O +
on O +
the O +
linear O -
- O -
correlation O -
- O -
based O +
distance O +
( O -
Pearson O -
, O +
centred O -
) O +
method O -
. O -

The O +
optimal O +
number O +
of O +
clusters O +
was O +
determined O +
empirically O +
to O +
produce O +
the O +
most O +
balanced O +
ratio O +
of O +
entries O +
to O +
cluster O +
of O +
highly O +
expressed O +
genes O -
. O -

A O +
cluster O +
of O +
101 O +
genes O +
up O -
- O -
regulated O +
in O +
the O +
hESC O +
sample O +
[ O -
see O +
Additional O +
file O +
1 O -
] O -
, O +
was O +
plotted O +
in O +
a O +
centroid O +
graph O +
( O -
Figure O +
5C O -
) O -
; O +
the O +
variation O +
across O +
technical O +
replicates O +
was O +
low O -
. O -

We O +
merged O +
technical O +
replicates O +
to O +
generate O +
a O +
list O +
of O +
the O +
most O +
up O -
- O -
regulated O +
genes O +
expressed O +
in O +
the O +
hESC O +
sample O +
compared O +
to O +
the O +
universal O +
reference O +
RNA O +
( O -
Table O +
4 O -
) O -
. O -

Standard O +
error O +
of O +
the O +
mean O +
expressed O +
as O +
percentage O +
was O +
calculated O +
for O +
the O +
4 O +
technical O +
replicates O -
, O +
and O +
was O +
6.7 O -
% O +
for O +
the O +
top O +
25 O +
genes O +
up O -
- O -
regulated O +
in O +
hESC O +
samples O -
, O +
compared O +
to O +
universal O +
reference O +
RNA O -
. O -

We O +
performed O +
the O +
analysis O +
of O +
microarray O +
data O -
, O +
as O +
described O +
in O +
the O +
Methods O -
, O +
and O +
spot O +
error O +
values O +
were O +
generally O +
in O +
the O +
lower O +
range O -
, O +
indicating O +
high O +
stringency O +
of O +
the O +
signals O +
and O +
low O +
variance O -
. O -

As O +
seen O +
in O +
Table O +
4 O +
and O +
Table O +
5 O -
, O +
the O +
NeuroStem O +
Chip O +
identified O +
numerous O +
genes O +
associated O +
with O +
stem O +
cells O -
. O -

In O +
particular O -
, O +
homeo O +
box O +
expressed O +
in O +
ES O +
cells O +
1 O +
( O -
Hesx1 O -
) O +
gene O +
was O +
identified O +
as O +
the O +
most O +
up O -
- O -
regulated O +
in O +
the O +
ES O +
cell O +
preparation O -
, O +
compared O +
to O +
universal O +
reference O +
RNA O -
. O -

Highly O +
expressed O +
in O +
pluripotent O +
ESCs O -
, O +
Hesx1 O +
expression O +
is O +
down O -
- O -
regulated O +
upon O +
embryonic O +
stem O +
cell O +
differentiation O +
[ O -
35,36 O -
] O -
, O +
as O +
also O +
clearly O +
seen O +
in O +
differentiation O +
experiment O +
of O +
our O +
own O +
( O -
Table O +
4 O -
) O -
. O -

Similarly O -
, O +
Gremlin O +
1 O +
homolog O -
, O +
cysteine O +
knot O +
superfamily O +
gene O +
( O -
Grem1 O -
, O +
also O +
known O +
as O +
Cktsf1b1 O +
and O +
Dand2 O -
) O +
is O +
a O +
recognized O +
factor O +
of O +
cell O -
- O -
fate O +
determination O +
of O +
ESCs O +
[ O -
37 O -
] O -
. O -

Many O +
more O +
genes O +
highly O +
up O -
- O -
regulated O +
in O +
the O +
hESC O +
sample O +
in O +
comparison O +
with O +
universal O +
reference O +
RNA O +
are O +
associated O +
with O +
stem O +
cells O -
: O +
further O +
examples O +
include O +
Gap O +
junction O +
protein O +
α1 O +
( O -
Gja1 O -
) O +
and O +
Zic O +
family O +
member O +
3 O +
heterotaxy O +
1 O +
( O -
Zic3 O -
) O +
( O -
Table O +
4 O -
) O +
[ O -
20 O -
] O -
. O -

The O +
expression O +
of O +
fibroblast O +
growth O +
factor O +
receptor O +
2 O +
( O -
Fgfr2 O -
) O +
is O +
of O +
particular O +
interest O -
. O -

Basic O +
fibroblast O +
growth O +
factor O +
( O -
FGF2 O -
, O +
bFGF O -
) O +
supports O +
hESC O +
proliferation O +
and O +
their O +
ability O +
to O +
maintain O +
undifferentiated O +
phenotype O +
when O +
cultured O +
in O +
vitro O +
[ O -
38,39 O -
] O -
. O -

Moreover O -
, O +
in O +
some O +
hESC O +
lines O +
a O +
very O +
high O +
concentration O +
of O +
FGF2 O +
could O +
substitute O +
for O +
the O +
need O +
of O +
feeder O +
cells O +
[ O -
40 O -
] O -
. O -

At O +
the O +
same O +
time O -
, O +
genes O +
listed O +
in O +
Table O +
4 O +
represent O +
the O +
most O +
highly O +
up O -
- O -
regulated O +
entries O +
in O +
a O +
relatively O +
limited O +
group O +
of O +
genes O +
( O -
Figure O +
5C O -
) O -
. O -

Many O +
other O +
genes O +
involved O +
in O +
maintenance O +
of O +
ESC O +
phenotype O +
( O -
i.e. O +
established O +
or O +
candidate O +
markers O +
of O +
stem O +
cells O -
) O +
have O +
lower O +
levels O +
of O +
expression O +
( O -
Table O +
5 O -
) O -
. O -

Examples O +
include O +
undifferentiated O +
embryonic O +
cell O +
transcription O +
factor O +
1 O +
( O -
Utf1 O -
) O -
, O +
DNA O +
methyltransferase O +
3B O +
( O -
Dnmt3b O -
) O -
, O +
developmental O +
pluripotency O +
associated O +
4 O +
( O -
Dppa4 O -
, O +
a O +
newly O +
established O +
pluripotency O +
marker O +
[ O -
41 O -
] O -
) O +
and O +
numerous O +
candidate O +
markers O +
of O +
" O -
stemness O -
" O -
: O +
e.g. O +
genes O +
for O +
KIAA1573 O +
protein O -
, O +
forkhead O +
box O +
O1A O +
( O -
Foxo1a O -
) O -
, O +
high O -
- O -
mobility O +
group O +
box O +
1 O +
( O -
Hmgb1 O -
) O -
, O +
C O -
- O -
terminal O +
binding O +
protein O +
2 O +
( O -
Ctbp2 O -
) O +
and O +
left O -
- O -
right O +
determination O +
factor O +
1 O +
( O -
Lefty1 O -
) O -
, O +
as O +
well O +
as O +
others O -
. O -

For O +
numerous O +
established O +
or O +
candidate O +
markers O +
of O +
stem O +
cells O +
the O +
expression O +
levels O +
were O +
not O +
considerably O +
higher O +
( O -
Log2 O +
ratio O +
< O +
1 O -
) O +
in O +
the O +
hESC O +
sample O +
compared O +
to O +
the O +
universal O +
reference O +
RNA O -
. O -

For O +
example O -
, O +
the O +
expression O +
of O +
Nanog O -
, O +
DNA O +
( O -
cytosine-5- O -
) O -
-methyltransferase O +
3α O +
( O -
Dnmt3a O -
) O -
, O +
MutS O +
homolog O +
2 O -
, O +
colon O +
cancer O -
, O +
nonpolyposis O +
type O +
1 O +
( O -
E. O +
coli O -
) O +
( O -
Msh2 O -
) O -
, O +
Thy-1 O +
cell O +
surface O +
antigen O +
( O -
Thy1 O -
) O -
, O +
high O -
- O -
mobility O +
group O +
box O +
2 O +
( O -
Hmgb2 O -
) O -
, O +
transcription O +
factor O +
3 O +
( O -
Tcf3 O -
) O -
, O +
Nanos O +
homolog O +
1 O +
( O -
Nanos1 O -
) O -
, O +
MyoD O +
family O +
inhibitor O +
( O -
Mdfi O -
) O -
, O +
Calumenin O +
( O -
Calu O -
) O +
and O +
soluble O +
thymidine O +
kinase O +
1 O +
( O -
Tk1 O -
) O +
was O +
detected O +
in O +
hES O +
SA02 O +
cells O +
with O +
Log2 O +
ratio O +
value O +
< O +
1 O -
. O -

Expression O +
levels O +
of O +
those O +
genes O +
range O +
from O +
being O +
inconsiderably O +
higher O +
to O +
nearly O +
equal O +
to O +
that O +
in O +
universal O +
reference O +
RNA O +
sample O -
. O -

We O +
believe O +
that O +
those O +
findings O +
could O +
be O +
explained O +
by O +
cellular O +
composition O +
of O +
human O +
universal O +
reference O +
RNA O +
sample O +
[ O -
42 O -
] O -
, O +
which O +
includes O +
pooled O +
RNA O +
samples O +
from O +
proliferating O +
cells O +
( O -
e.g. O -
, O +
skin O +
and O +
testis O +
cell O +
lines O -
) O -
. O -

Thus O -
, O +
the O +
relative O +
difference O +
between O +
gene O +
expression O +
of O +
certain O +
markers O +
of O +
stem O +
cells O +
in O +
undifferentiated O +
hESCs O +
and O +
universal O +
reference O +
RNA O +
is O +
naturally O +
decreased O -
. O -

Taken O +
together O -
, O +
the O +
gene O +
expression O +
signature O +
of O +
hES O +
SA02 O +
cell O +
line O +
profiled O +
by O +
NeuroStem O +
Chip O +
is O +
indeed O +
characteristic O +
for O +
pluripotent O +
stem O +
cells O -
, O +
providing O +
proof O -
- O -
of O -
- O -
concept O -
. O -

Notably O -
, O +
comparison O +
of O +
expression O +
profiles O +
of O +
undifferentiated O +
hESCs O +
and O +
hESC O -
- O -
derived O +
cells O +
committed O +
toward O +
dopaminergic O +
differentiation O +
pathway O +
by O +
co O -
- O -
culturing O +
with O +
SDIA O +
for O +
16 O +
days O +
have O +
revealed O +
that O +
many O +
of O +
the O +
stem O +
cell O +
marker O +
genes O +
mentioned O +
above O +
were O +
down O -
- O -
regulated O +
in O +
differentiation O +
( O -
Table O +
5 O -
) O -
. O -

Expectedly O -
, O +
Hesx1 O -
, O +
Grem1 O -
, O +
Dnmt3b O -
, O +
Utf1 O +
and O +
Nanog O +
could O +
be O +
listed O +
among O +
these O -
. O -

At O +
the O +
same O +
time O -
, O +
numerous O +
other O +
genes O -
, O +
including O +
Pitx2 O -
, O +
Dlk1 O +
and O +
Msx1 O +
were O +
up O -
- O -
regulated O +
in O +
the O +
latter O +
sample O +
( O -
[ O -
see O +
Additional O +
file O +
2 O -
] O -
, O +
Figure O +
3 O -
) O -
. O -

Table O +
1 O +
lists O +
24 O +
dopaminergic O +
system O -
- O -
related O +
entries O +
( O -
e.g. O -
, O +
Ptx3 O -
, O +
Th O -
, O +
Lhx1 O -
) O +
with O +
gene O +
expression O +
up O -
- O -
regulated O +
by O +
Day O +
16 O +
of O +
hESC O +
differentiation O +
protocol O -
; O +
few O +
more O +
genes O +
have O +
demonstrated O +
less O +
prominent O +
up O -
- O -
regulation O +
( O -
Log2 O +
ratio O +
values O +
in O +
the O +
range O +
of O +
0.7 O -
/ O -
0.97–1.0 O -
) O -
. O -

The O +
gene O +
expression O +
profiles O +
generated O +
are O +
therefore O +
consistent O +
with O +
the O +
results O +
of O +
earlier O +
studies O +
utilizing O +
hSC O -
- O -
derived O +
samples O +
with O +
similar O +
characteristics O +
[ O -
43,44 O -
] O -
. O -

Diversity O +
of O +
NeuroStem O +
Chip O +
entries O +
responsive O +
to O +
hESC O +
commitment O +
toward O +
neuronal O -
/ O -
dopaminergic O +
differentiation O +
pathway O +
clearly O +
illustrates O +
the O +
complexity O +
of O +
that O +
pathway O -
. O -

The O +
cell O +
population O +
obtained O +
after O +
16 O +
day O +
exposure O +
to O +
SDIA O +
is O +
highly O +
heterogeneous O -
. O -

Only O +
around O +
0.2 O -
% O +
of O +
the O +
cells O +
are O +
TH O -
- O -
positive O +
cells O +
( O -
Figure O +
2 O -
) O -
. O -

This O +
heterogeneity O -
, O +
with O +
an O +
apparent O +
presence O +
of O +
residual O +
pluripotent O +
cells O +
explains O +
the O +
presence O +
of O +
stem O +
cell O +
marker O +
genes O -
, O +
including O +
homeobox O +
transcription O +
factor O +
Nanog O -
, O +
as O +
revealed O +
by O +
RT O -
- O -
PCR O +
data O +
( O -
Figure O +
3 O -
) O -
. O -

It O +
would O +
be O +
therefore O +
impossible O +
to O +
apply O +
the O +
platform O +
to O +
identify O +
novel O +
genes O +
associated O +
with O +
the O +
process O +
of O +
differentiation O -
; O +
for O +
that O +
application O -
, O +
the O +
genome O -
- O -
scale O +
microarray O +
platforms O +
( O -
e.g. O -
, O +
Affymetrix O -
) O +
are O +
clearly O +
superior O -
. O -

Nevertheless O -
, O +
being O +
based O +
upon O +
a O +
moderate O +
assay O +
of O +
pre O -
- O -
selected O +
specific O +
gene O +
targets O -
, O +
the O +
comparative O +
analysis O +
of O +
microarray O +
data O +
derived O +
from O +
undifferentiated O +
and O +
dopaminergic O +
differentiate O +
pathway O -
- O -
committed O +
hESCs O +
provides O +
a O +
valuable O +
cross O -
- O -
cut O +
of O +
complex O +
relationship O +
between O +
factors O +
driving O +
or O +
indicative O +
to O +
neuronal O -
/ O -
dopaminergic O +
differentiation O +
[ O -
see O +
Additional O +
file O +
2 O -
] O -
. O -

RT O -
- O -
PCR O +
analyses O +
have O +
validated O +
the O +
overall O +
reliability O +
of O +
NeuroStem O +
microarray O +
platform O -
: O +
all O +
of O +
the O +
entries O +
detected O +
in O +
the O +
hybridization O +
experiments O +
have O +
demonstrated O +
similar O +
trends O +
when O +
analyzed O +
by O +
RT O -
- O -
PCR O +
means O +
( O -
Figure O +
3 O -
) O -
. O -

Those O +
entries O +
include O +
Sox2 O -
, O +
En1 O +
and O +
Nanog O +
( O -
ratio O +
of O +
differentiated O -
/ O -
undifferentiated O +
hESC O +
sample O +
normalized O +
spot O +
intensity O +
< O +
0.75 O -
, O +
down O -
- O -
regulated O -
) O -
, O +
Gadph O -
, O +
Aldh1a1 O -
, O +
Sdha O -
, O +
Tubb O +
and O +
Nestin O +
( O -
ratio O +
.1.0 O -
, O +
unchanged O -
) O -
, O +
Actb O -
, O +
Th O -
, O +
Msx1 O +
and O +
Pitx2 O +
( O -
ratio O +
> O -
1.25 O -
, O +
up O -
- O -
regulated O -
) O -
. O -

Some O +
of O +
the O +
housekeeping O +
genes O +
( O -
Gapdh O -
, O +
Sdha O -
, O +
Tubb O -
, O +
Actb O -
) O +
have O +
somewhat O +
different O +
expression O +
in O +
undifferentiated O +
vs. O +
differentiated O +
cells O -
, O +
consistent O +
with O +
previous O +
reports O +
on O +
certain O +
established O +
housekeeping O +
genes O +
( O -
including O +
Gapdh O -
) O +
being O +
variable O +
in O +
human U-Species +
samples O +
[ O -
45 O -
] O -
. O -

Importantly O -
, O +
all O +
the O +
observed O +
gene O +
expression O +
trends O +
were O +
similar O +
in O +
both O +
microarray O +
and O +
RT O -
- O -
PCR O -
. O -

Our O +
experiment O +
therefore O +
confirms O +
that O +
the O +
NeuroStem O +
Chip O +
microarray O +
platform O +
can O +
still O +
identify O +
gene O +
expression O +
changes O +
related O +
to O +
early O +
stages O +
of O +
differentiation O +
of O +
hESC O +
into O +
dopaminergic O +
neurons O -
. O -

Recent O +
technological O +
advances O +
have O +
led O +
to O +
DNA O +
microarrays O +
which O +
contain O +
over O +
hundred O +
thousand O +
of O +
spots O +
of O +
DNA O +
material O -
, O +
reaching O +
a O +
truly O +
genomic O +
scale O -
. O -

Highly O +
specialized O +
DNA O +
microarrays O +
of O +
smaller O +
scale O +
( O -
e.g. O +
the O +
NeuroStem O +
Chip O -
) O +
still O +
have O +
an O +
important O +
role O +
in O +
the O +
directed O +
studies O +
in O +
particular O +
fields O -
. O -

Since O +
they O +
are O +
significantly O +
less O +
expensive O -
, O +
compared O +
to O +
many O +
recognized O +
large O -
- O -
scale O +
platforms O +
( O -
e.g. O +
Affymetrix O +
Human U-Species +
Genome O +
platforms O -
) O -
, O +
they O +
have O +
a O +
clear O +
advantage O +
in O +
routine O +
work O +
involving O +
samples O +
from O -
, O +
e.g. O -
, O +
multiple O +
cell O +
culture O +
conditions O -
. O -

While O +
there O +
is O +
a O +
risk O +
that O +
one O +
will O +
miss O +
out O +
on O +
changes O +
in O +
genes O +
previously O +
not O +
believed O +
to O +
be O +
relevant O +
to O +
neural O +
differentiation O -
, O +
the O +
restricted O +
number O +
of O +
genes O +
in O +
the O +
NeuroStem O +
Chip O +
also O +
simplifies O +
analysis O +
and O +
adds O +
power O -
. O -

NeuroStem O +
Chip O +
is O +
comparable O +
to O +
other O +
stem O +
cell O -
- O -
related O +
focused O +
microarray O +
platforms O +
in O +
regards O +
to O +
manufacturing O +
costs O +
and O +
technical O +
simplicity O +
of O +
the O +
recommended O +
hybridization O +
protocols O -
. O -

At O +
the O +
same O +
time O -
, O +
it O +
currently O +
implies O +
an O +
advantage O +
in O +
both O +
the O +
scale O +
and O +
the O +
spectrum O +
of O +
pre O -
- O -
selected O -
, O +
specific O +
gene O +
targets O +
assayed O -
. O -

Some O +
suggested O +
areas O +
of O +
application O +
for O +
NeuroStem O +
microarray O +
platform O +
could O +
be O +
the O +
following O -
: O +
( O -
i O -
) O +
characterization O +
of O +
the O +
expression O +
of O +
established O -
, O +
pre O -
- O -
selected O +
gene O +
targets O +
in O +
human U-Species +
stem O +
cell O +
( O -
hSC O -
) O +
lines O -
, O +
including O +
newly O +
derived O +
ones O -
, O +
( O -
ii O -
) O +
longitudinal O +
quality O +
control O +
for O +
maintained O +
hSC O +
populations O -
, O +
( O -
iii O -
) O +
following O +
gene O +
expression O +
changes O +
during O +
differentiation O +
under O +
defined O +
cell O +
culture O +
conditions O -
, O +
and O +
( O -
iv O -
) O +
confirming O +
the O +
success O +
of O +
differentiation O +
into O +
specific O +
neuronal O +
subtypes O -
. O -

In O +
addition O -
, O +
the O +
NeuroStem O +
Chip O +
can O +
be O +
used O +
to O +
characterize O +
gene O +
changes O +
in O +
intracerebral O +
grafts O +
of O +
human U-Species +
cells O -
, O +
even O +
when O +
they O +
are O +
transplanted O +
into O +
experimental O +
animals O -
. O -

We O +
specifically O +
wish O +
to O +
stress O +
that O +
we O +
are O +
about O +
to O +
make O +
the O +
NeuroStem O +
Chip O +
available O +
at O +
a O +
non O -
- O -
profit O +
cost O +
to O +
the O +
research O +
community O -
. O -

We O +
believe O +
it O +
has O +
the O +
potential O +
to O +
become O +
an O +
important O +
screening O +
tool O +
in O +
the O +
expanding O +
field O +
of O +
hSC O +
studies O +
in O +
application O +
to O +
neurological O -
/ O -
neurodegenerative O +
disorders O -
. O -

Human U-Species +
embryonic O +
stem O +
cell O +
( O -
hESC O -
) O +
culturesUndifferentiated O +
hESCs O +
of O +
SA02 O +
( O -
Sahlgrenska O +
2 O -
) O +
line O +
( O -
Cellartis O +
AB O -
, O +
Göteborg O -
, O +
Sweden O -
; O +
see O +
NIH O +
Human O +
Embryonic O +
Stem O +
Cell O +
Registry O +
at O +
[ O -
46 O -
] O -
) O +
were O +
maintained O +
over O +
a O +
monolayer O +
of O +
human U-Species +
" O -
feeder O +
cells O -
" O +
( O -
hFCs U-Species -
; O +
human U-Species +
foreskin O +
fibroblasts O -
, O +
ATCC O -
; O +
cell O +
line O +
CCD-1112Sk O -
) O -
. O -

Feeder O +
cells O +
were O +
grown O +
in O +
hFC O +
medium O +
( O -
Iscove O -
's O +
modified O +
Dulbecco O -
's O +
medium O +
( O -
IMDM O -
) O +
supplemented O +
with O +
10 O -
% O +
heat O -
- O -
inactivated O +
FCS O +
( O -
Stem O +
Cell O +
Technologies O -
, O +
USA O -
) O +
and O +
0.5 O -
% O +
Penicillin O -
/ O -
Streptomycin O +
mix O -
) O +
for O +
11 O +
passages O -
. O -

One O +
day O +
prior O +
to O +
hESC O +
plating O -
, O +
hFC O +
medium O +
was O +
washed O +
away O +
from O +
the O +
hFCs O -
, O +
the O +
latter O +
were O +
resuspended O +
in O +
a O +
hESC O +
proliferation O +
medium O +
( O -
VitroHES O +
media O +
( O -
Vitrolife O +
AB O -
, O +
Sweden O -
) O +
supplemented O +
with O +
4 O +
ng O -
/ O -
ml O +
human U-Species +
recombinant O +
basic O +
FGF O +
( O -
hrbFGF O -
, O +
Biosource O +
International O -
, O +
USA O -
) O +
and O +
plated O +
in O +
a O +
central O +
ring O +
of O +
gelatinized O +
in O +
vitro O +
fertilization O +
( O -
IVF O -
) O +
dishes O +
with O +
a O +
cell O +
density O +
of O +
120,000 O +
cells O -
/ O -
dish O -
. O -

The O +
outer O +
rings O +
of O +
the O +
IVF O +
dishes O +
were O +
filled O +
with O +
Dulbecco O -
's O +
modified O +
Eagle O +
medium O +
( O -
DMEM O -
) O +
supplemented O +
with O +
0.5 O -
% O +
Penicillin O -
/ O -
Streptomycin O +
mix O -
. O -

One O +
half O +
of O +
the O +
culture O +
medium O +
was O +
replaced O +
every O +
other O +
day O -
. O -

The O +
cells O +
were O +
maintained O +
at O +
37 O -
° O -
C O -
, O +
5 O -
% O +
CO2 O -
, O +
95 O -
% O +
humidity O +
settings O -
. O -

Every O +
6 O +
days O -
, O +
fragments O +
of O +
the O +
hESC O +
colonies O +
( O -
around O +
10–14 O +
colonies O +
per O +
dish O -
, O +
measuring O +
around O +
0.015 O +
× O +
0.015 O +
mm O -
) O +
that O +
had O +
an O +
unaltered O +
morphology O +
( O -
indicating O +
lack O +
of O +
spontaneous O +
differentiation O -
) O +
were O +
mechanically O +
cut O +
from O +
dishes O +
using O +
stem O +
cell O +
knives O -
/ O -
transfer O +
pipettes O +
( O -
SweMed O +
Lab O +
International O +
AB O -
, O +
Sweden O -
) O +
and O +
then O +
plated O +
on O +
fresh O +
hFCs O -
. O -

Commitment O +
of O +
hESCs O +
towards O +
neuronal O -
/ O -
dopaminergic O +
differentiation O +
pathwayCo O -
- O -
culturing O +
with O +
the O +
PA6 O +
stromal O +
cell O +
line O +
( O -
MC3T3-G2 O -
/ O -
Pa6 O -
, O +
from O +
RIKEN O +
Cell O +
Bank O +
Japan O +
( O -
RCB O +
1127 O -
) O -
, O +
derived O +
from O +
newborn O +
mouse U-Species +
calvaria O +
rapidly O +
generates O +
high O +
numbers O +
of O +
DA O +
neurons O +
from O +
mouse U-Species +
and O +
monkey U-Species +
ESCs O +
by O +
an O +
unknown O +
mechanism O +
named O +
stromal O -
- O -
derived O +
inducing O +
activity O +
( O -
SDIA O -
; O +
[ O -
28,29 O -
] O -
) O -
. O -

For O +
differentiation O +
experiments O -
, O +
PA6 O +
cells O +
were O +
plated O +
on O +
gelatine O -
- O -
coated O +
T25 O +
flasks O +
at O +
16 O +
× O +
103 O +
cells O -
/ O -
cm2 O +
( O -
400,000 O +
cells O -
/ O -
flask O -
) O +
density O +
2 O +
days O +
prior O +
to O +
introducing O +
hESCs O +
into O +
the O +
co O -
- O -
culture O +
and O +
cultured O +
at O +
PA6 O +
culturing O +
media O +
( O -
containing O +
minimum O +
essential O +
medium O +
alpha O +
( O -
α O -
- O -
MEM O -
) O +
supplemented O +
with O +
10 O -
% O +
FCS O +
and O +
0.5 O -
% O +
Penicillin O -
/ O -
Streptomycin O -
) O -
. O -

Alternatively O -
, O +
PA6 O +
cells O +
were O +
plated O +
over O +
Type O +
I O +
collagen O -
- O -
coated O +
glass O +
cover O -
- O -
slips O +
placed O +
in O +
wells O +
of O +
4-well O -
- O -
plates O +
( O -
50,000 O +
cells O -
/ O -
well O -
, O +
for O +
immunocytochemical O +
( O -
ICC O -
) O +
analysis O -
) O -
. O -

Three O +
hours O +
prior O +
to O +
initiation O +
of O +
co O -
- O -
culture O -
, O +
PA6 O +
cells O +
were O +
rinsed O +
3 O +
times O +
with O +
PBS O +
and O +
media O +
was O +
replaced O +
with O +
co O -
- O -
culture O +
media O +
( O -
Glasgow O -
's O +
modified O +
Eagle O -
's O +
media O +
( O -
G O -
- O -
MEM O -
) O +
supplemented O +
with O +
8 O -
% O +
knock O -
- O -
out O +
serum O +
replacement O +
( O -
KSR O -
) O -
, O +
2 O +
mM O +
glutamine O -
, O +
0.1 O +
mM O +
non O -
- O -
essential O +
amino O -
- O -
acids O +
( O -
NEAA O -
) O -
, O +
1 O +
mM O +
pyruvate O -
, O +
0.1 O +
mM O +
β O -
- O -
mercaptoethanol O +
( O -
βME O -
) O +
and O +
4 O +
ng O -
/ O -
μl O +
bFGF O -
) O -
. O -

Fragments O +
of O +
hESC O +
colonies O +
( O -
80–90 O +
per O +
flask O -
; O +
4–5 O +
per O +
well O +
of O +
4-well O -
- O -
plate O -
) O +
presenting O +
undifferentiated O +
morphology O +
were O +
manually O +
passaged O +
onto O +
the O +
confluent O +
PA6 O +
monolayer O +
and O +
cell O +
co O -
- O -
cultures O +
were O +
maintained O +
at O +
37 O -
° O -
C O -
, O +
5 O -
% O +
CO2 O -
, O +
95 O -
% O +
humidity O +
settings O -
. O -

One O +
half O +
of O +
the O +
co O -
- O -
culture O +
medium O +
was O +
replaced O +
every O +
other O +
day O +
for O +
first O +
10 O +
days O -
, O +
and O +
daily O +
onwards O -
. O -

Characterization O +
of O +
hESCs O +
and O +
hESC O -
- O -
derived O +
cells O +
by O +
immunocytochemistry O +
( O -
ICC O -
) O +
and O +
RT O -
- O -
PCRIVF O +
dishes O +
with O +
hESCs O +
grown O +
atop O +
hFCs O +
and O +
4-well O +
plate O +
dishes O +
with O +
hESCs O +
growing O +
atop O +
PA6 O +
cells O +
were O +
fixed O +
with O +
4 O -
% O +
paraformaldehyde O +
( O -
PFA O -
) O +
for O +
15 O +
minutes O +
at O +
the O +
day O +
of O +
passage O -
/ O -
harvest O +
( O -
Day O +
6 O +
of O +
hESC O -
/ O -
hFC O +
co O -
- O -
culturing O -
) O +
and O +
Day O +
16 O +
of O +
co O -
- O -
culturing O +
with O +
PA6 O +
cells O -
, O +
respectively O -
. O -

Cells O +
were O +
pre O -
- O -
incubated O +
with O +
blocking O +
solution O +
containing O +
PBS O -
, O +
0.5 O -
% O +
Triton O +
X-100 O +
and O +
5 O -
% O +
of O +
donkey U-Species +
serum O -
. O -

They O +
were O +
then O +
incubated O +
with O +
primary O +
antibodies O +
in O +
blocking O +
solution O +
overnight O +
at O +
room O +
temperature O -
. O -

After O +
three O +
washes O +
with O +
PBS O -
, O +
cells O +
were O +
incubated O +
with O +
the O +
donkey U-Species +
anti O -
- O -
rabbit U-Species +
IgG O +
conjugated O +
with O +
FITC O +
or O +
anti O -
- O -
mouse U-Species +
Cy3 O +
( O -
1:200 O -
, O +
Jackson O +
ImmunoResearch O +
Laboratories O -
) O -
. O -

Cells O +
were O +
then O +
washed O +
once O +
with O +
PBS O -
, O +
incubated O +
with O +
1:1000 O +
DAPI O +
in O +
PBS O +
for O +
10 O +
minutes O -
, O +
followed O +
by O +
another O +
wash O +
with O +
PBS O -
. O -

Coverslips O +
were O +
mounted O +
onto O +
glass O +
slides O +
with O +
PVA O +
mounting O +
medium O +
containing O +
anti O -
- O -
fading O +
reagent O +
DABCO O -
. O -

The O +
following O +
primary O +
antibodies O +
were O +
used O -
: O +
mouse U-Species +
anti O -
- O -
Oct3 O -
/ O -
4 O +
( O -
1:500 O -
, O +
Santa O +
Cruz O +
Biotechnology O +
Inc. O -
) O -
; O +
rabbit U-Species +
anti O -
- O -
Ki67 O +
( O -
1:200 O -
, O +
Novocastra O +
Ltd. O -
) O -
; O +
rabbit U-Species +
anti O -
- O -
TH O +
( O -
1:500 O -
, O +
Chemicon O -
) O -
. O -

Immunostained O +
cell O +
cultures O +
were O +
visualized O +
using O +
a O +
Zeiss O +
fluorescent O +
microscope O +
attached O +
to O +
a O +
Nikon O +
digital O +
camera O -
. O -

Using O +
RT O -
- O -
PCR O -
, O +
all O +
RNA O +
samples O +
used O +
in O +
this O +
study O +
were O +
tested O +
negative O +
for O +
the O +
presence O +
of O +
gDNA O +
( O -
data O +
not O +
shown O -
) O -
. O -

The O +
intron O -
- O -
spanning O +
primers O +
for O +
RT O -
- O -
PCR O +
were O +
selected O +
from O +
published O +
works O +
or O +
designed O +
using O +
Oligo O +
4.0 O +
software O +
( O -
Molecular O +
Biology O +
Insight O -
) O +
or O +
Clone O +
Manager O +
Suite O +
7.1 O +
( O -
Sci O +
Ed O +
Software O -
, O +
NC O -
, O +
USA O -
) O +
and O +
ordered O +
from O +
TAG O +
Copenhagen O +
A O -
/ O -
S O -
, O +
Denmark O -
, O +
as O +
the O +
following O -
: O +
Sox2 O -
, O +
SRY O -
- O -
box O +
2 O -
: O +
5'-TAC O +
CTC O +
TTC O +
CTC O +
CC O +
CTC O +
CA-3 O -
' O -
, O +
5'-ACT O +
CTC O +
CTC O +
TTT O +
TGC O +
ACC O +
CC-3 O -
' O -
; O +
En1 O -
, O +
Engrailed O +
1 O -
: O +
5'-AAG O +
GGA O +
CGA O +
AAC O +
TGC O +
GAA O +
CTC O +
C-3 O -
' O -
, O +
5'-GAC O +
ACG O +
AAA O +
GGA O +
AAC O +
ACA O +
CAC O +
TCT O +
CG-3 O -
' O +
[ O -
47 O -
] O -
; O +
Nanog O -
: O +
5'-TGC O +
TTA O +
TTC O +
AGG O +
ACA O +
GCC O +
T-3 O -
' O -
, O +
5'-TCT O +
GGT O +
CTT O +
CTG O +
TTT O +
CTT O +
GAC O +
T-3 O -
' O +
[ O -
48 O -
] O -
; O +
Gapdh O -
, O +
glyceraldehydes-3-phosphate O +
dehydrogenase O -
: O +
5'-GGA O +
AGG O +
TGA O +
AGG O +
TCG O +
GAG O +
TCA O +
A-3 O -
' O -
, O +
5'-GAT O +
CTC O +
GCT O +
CCT O +
GGA O +
AGA O +
TGG O +
T-3 O -
' O -
; O +
Aldh1A1 O -
, O +
aldehyde O +
dehydrogenase O +
1 O +
family O -
, O +
member O +
A1 O -
: O +
5'-GGG O +
CAG O +
CCA O +
TTT O +
CTT O +
CTC O +
AC-3 O -
' O -
, O +
5'-CTT O +
CTT O +
AGC O +
CCG O +
CTC O +
AAC O +
AC-3 O -
' O +
[ O -
49 O -
] O -
; O +
Sdha O -
, O +
succinate O +
dehydrogenase O -
: O +
5'-TGG O +
GAA O +
CAA O +
GAG O +
GGC O +
ATC O +
TG-3 O -
' O -
, O +
5'-CCA O +
CCA O +
CTG O +
CAT O +
CAA O +
ATT O +
CAT O +
G-3 O -
' O +
[ O -
50 O -
] O -
; O +
Tubb O -
, O +
β O -
- O -
tubulin O -
: O +
5'-CTC O +
ACA O +
AGT O +
ACG O +
TGC O +
CTC O +
GAG-3 O -
' O -
, O +
5'-GCA O +
CGA O +
CGC O +
TGA O +
AGG O +
TGT O +
TCA-3 O -
' O -
; O +
Nestin O -
: O +
5'-AGA O +
GGG O +
GAA O +
TTC O +
CTG O +
CT O +
GAG-3 O -
' O -
, O +
5'-CTG O +
AGG O +
ACC O +
AGG O +
ACT O +
CTC O +
TA-3 O -
' O +
[ O -
47 O -
] O -
; O +
Actb O -
, O +
β O -
- O -
actin O -
: O +
5'-CAT O +
CGA O +
GCA O +
CGG O +
CAT O +
CGT O +
CA-3 O -
' O -
, O +
5'-TAG O +
CAC O +
AGC O +
CTG O +
GAT O +
AGC O +
AAC-3 O -
' O +
[ O -
51 O -
] O -
; O +
Th O -
, O +
Tyrosine O +
hydroxylase O -
: O +
5'-CGA O +
GCT O +
GTG O +
AAG O +
GTG O +
TTT O +
G-3 O -
' O -
, O +
5'-TTG O +
GTG O +
ACC O +
AGG O +
TGA O +
TGA O +
C-3 O -
' O -
; O +
Msx1 O -
, O +
homolog O +
of O +
Drosophila O +
muscle O +
segment O +
homolog O +
1 O -
: O +
5'-CTC O +
AAG O +
CTG O +
CCA O +
GAA O +
GAT O +
GC-3 O -
' O -
, O +
5'-TCC O +
AGC O +
TCT O +
GCC O +
TCT O +
TGT O +
AG-3 O -
' O -
; O +
Pitx2 O -
, O +
paired O -
- O -
like O +
homeodomain O +
transcription O +
factor O +
2 O -
: O +
5'-ACC O +
TTA O +
CGG O +
AAG O +
CCC O +
GAG O +
TC-3 O -
' O -
, O +
5'-TGG O +
ATA O +
GGG O +
AGG O +
CGG O +
ATG O +
TA-3 O -
' O +
[ O -
49 O -
] O -
. O -

cDNA O +
was O +
synthesized O +
from O +
1 O +
mg O +
of O +
total O +
RNA O +
using O +
SuperScript O +
II O +
( O -
Invitrogen O -
) O -
, O +
and O +
RT O -
- O -
PCR O +
amplifications O +
were O +
performed O +
using O +
the O +
MiniOpticon O +
system O +
( O -
Bio O -
- O -
Rad O -
) O +
with O +
REDTaq O +
Polymerase O +
( O -
Sigma O -
- O -
Aldrich O -
) O +
essentially O +
as O +
described O +
by O +
the O +
manufacturer O -
. O -

Following O +
initial O +
denaturation O +
for O +
5 O +
min O +
at O +
95 O -
° O -
C O -
, O +
DNA O +
amplifications O +
were O +
performed O +
for O +
35 O +
( O -
En1 O -
, O +
Nanog O -
, O +
Aldh1a1 O -
) O -
, O +
33 O +
( O -
Sox2 O -
, O +
Nestin O -
, O +
Th O -
, O +
Msx1 O -
) O -
, O +
32 O +
( O -
Tubb O -
, O +
Pitx2 O -
) O -
, O +
27 O +
( O -
Sdha O -
) O -
, O +
25 O +
( O -
Actb O -
) O +
or O +
22 O +
( O -
Gapdh O -
) O +
cycles O +
of O +
1 O +
min O +
at O +
95 O -
° O -
C O -
, O +
1 O +
min O +
at O +
55 O -
° O -
C O +
( O -
En1 O -
, O +
Pitx2 O -
) O -
, O +
57 O -
° O -
C O +
( O -
Sox2 O -
, O +
Nanog O -
, O +
Sdha O -
, O +
Nestin O -
) O -
, O +
58 O -
° O -
C O +
( O -
Tubb O -
) O -
, O +
58.5 O -
° O -
C O +
( O -
Aldh1a1 O -
, O +
Th O -
) O +
or O +
59 O -
° O -
C O +
( O -
Gapdh O -
, O +
Actb O -
, O +
Msx1 O -
) O -
, O +
and O +
1 O +
min O +
at O +
72 O -
° O -
C O -
. O -

The O +
final O +
extension O +
was O +
5 O +
min O +
at O +
72 O -
° O -
C O -
. O -

Twenty O +
μl O +
volumes O +
of O +
RT O -
- O -
PCR O +
products O +
were O +
analyzed O +
by O +
electrophoresis O +
at O +
1 O -
% O +
agarose O +
gels O +
and O +
visualized O +
by O +
ethidium O +
bromide O +
staining O -
. O -

RNA O +
purification O +
and O +
fluorescent O +
dye O +
incorporationFor O +
RNA O +
purification O +
of O +
undifferentiated O +
hESCs O -
, O +
the O +
latter O +
were O +
mechanically O +
separated O +
from O +
hFCs O -
, O +
collected O +
in O +
a O +
500 O +
μl O +
volume O +
of O +
VitroHES O +
media O -
, O +
rinsed O +
in O +
PBS O +
buffer O +
and O +
spun O +
down O +
at O +
300 O +
rcf O +
for O +
5 O +
min O -
. O -

hESC O -
- O -
derived O +
cells O +
grown O +
atop O +
PA6 O +
cells O +
were O +
harvested O +
using O +
a O +
papain O +
dissociation O +
kit O +
( O -
Worthington O +
Biochemical O +
Corporation O -
) O -
, O +
rinsed O +
in O +
PBS O +
buffer O +
and O +
spun O +
down O +
as O +
described O +
above O -
. O -

The O +
resulting O +
cell O +
pellets O +
were O +
resuspended O +
in O +
RLT O +
buffer O +
( O -
Qiagen O -
, O +
USA O -
) O -
, O +
passed O +
through O +
the O +
shredder O +
column O +
( O -
Qiagen O -
) O +
and O +
stored O +
at O +
-80 O -
° O -
C O +
until O +
the O +
RNA O +
sample O +
was O +
purified O +
following O +
the O +
RNeasy O +
Micro O +
Kit O +
( O -
Qiagen O -
) O +
protocol O +
( O -
without O +
carrier O +
RNA O -
) O -
; O +
with O +
DNase O +
I O +
( O -
Quiagen O -
) O +
treatment O +
incorporated O +
to O +
the O +
latter O -
. O -

RNA O +
integrity O +
was O +
tested O +
using O +
both O +
ND-1000 O +
specrophotometer O +
( O -
NanoDrop O -
, O +
USA O -
) O +
and O +
RNA O +
Nano O +
LabChip O -
/ O -
2100 O +
Bioanalyzer O +
system O +
( O -
Agilent O +
Technologies O -
, O +
USA O -
) O -
.Fluorescent O +
label O +
( O -
24 O +
nmol O +
of O +
the O +
Cyanine O +
3-CTP O +
( O -
Cy3 O -
) O -
; O +
PerkinElmer O -
, O +
USA O -
) O +
was O +
incorporated O +
to O +
350–500 O +
ng O +
of O +
total O +
RNA O +
amplified O +
using O +
Low O +
RNA O +
Input O +
Fluorescent O +
Linear O +
Amplification O +
Kit O +
( O -
Agilent O +
Technologies O -
) O -
, O +
generally O +
following O +
the O +
kit O +
manufacturer O -
's O +
protocol O -
. O -

Similarly O -
, O +
24 O +
nmols O +
of O +
the O +
Cyanine O +
5-CTP O +
( O -
Cy5 O -
; O +
PerkinElmer O -
) O +
fluorescent O +
label O +
were O +
incorporated O +
to O +
400 O +
ng O +
sample O +
of O +
Human U-Species +
Universal O +
Reference O +
RNA O +
( O -
Stratagene O -
, O +
USA O -
) O -
; O +
in O +
addition O -
, O +
dye O -
- O -
swap O +
replicate O +
amplification O +
were O +
performed O -
. O -

Amplified O +
fluorescent O +
cRNA O +
samples O +
were O +
purified O +
using O +
RNeasy O +
mini O -
- O -
columns O +
( O -
Quiagen O -
) O -
, O +
and O +
fluorescence O +
of O +
the O +
eluted O +
products O +
was O +
measured O +
using O +
ND-1000 O +
specrophotometer O +
( O -
NanoDrop O -
) O -
. O -

Microarray O +
technologyLong O +
oligonucleotide O +
probes O +
( O -
69–71 O +
nucleotides O -
) O +
matching O +
gene O +
targets O +
of O +
interest O +
were O +
selected O +
from O +
Operon O +
V2 O +
and O +
V3 O +
human O +
AROS O +
sets O +
( O -
Operon O +
Biotechnologies O +
Inc. O -
, O +
USA O -
) O -
. O -

Arrays O +
were O +
produced O +
by O +
the O +
SweGene O +
DNA O +
Microarray O +
Resource O +
Centre O -
, O +
Department O +
of O +
Oncology O +
at O +
Lund O +
University O +
( O -
Sweden O -
) O +
using O +
a O +
MicroGrid O +
II O +
600R O +
arrayer O +
fitted O +
with O +
MicroSpot O +
10 O +
K O +
pins O +
( O -
Harvard O +
BioRobotics O -
, O +
USA O -
) O -
. O -

Printing O +
was O +
performed O +
in O +
a O +
temperature- O +
( O -
18–20 O -
° O -
C O -
) O +
and O +
humidity- O +
( O -
44–49 O -
% O +
RH O -
) O +
controlled O +
area O +
on O +
Corning O +
UltraGAPS O +
aminosilane O +
slides O +
( O -
Corning O +
Inc. O -
, O +
USA O -
) O +
with O +
140 O +
μm O +
spot O -
- O -
to O -
- O -
spot O +
centerdistance O +
and O +
90–110 O +
μm O +
average O +
spot O +
size O -
. O -

Following O +
printing O -
, O +
arrays O +
were O +
dried O +
for O +
48 O +
hours O +
andstored O +
in O +
a O +
dessicator O +
until O +
used O -
. O -

Microarray O +
slides O +
were O +
UV O -
- O -
cross O -
- O -
linked O +
( O -
800 O +
mJ O -
/ O -
cm2 O -
) O -
, O +
pre O -
- O -
hybridizedwith O +
fluorescently O +
labeled O +
samples O +
using O +
the O +
Pronto O -
! O -

Universal O +
Microarray O +
Hybridization O +
Kit O +
( O -
Corning O -
) O +
and O +
subsequently O +
hybridized O +
with O +
test O +
( O -
Cy3-labeled O -
) O -
/ O -
reference O +
( O -
Cy5-labeled O -
) O +
RNA O +
samples O +
( O -
or O +
in O +
reverse O +
dye O -
- O -
labeling O +
order O -
) O +
at O +
42 O -
° O -
C O +
for O +
17 O +
h O +
using O +
a O +
MAUI O +
hybridization O +
station O +
( O -
BioMicro O +
Systems O +
Inc. O -
, O +
USA O -
) O +
and O +
the O +
Pronto O -
! O -

Universal O +
Microarray O +
Hybridization O +
Kit O -
, O +
generally O +
following O +
manufacturer O -
's O +
instructions O -
, O +
with O +
several O +
minor O +
adaptations O +
[ O -
31 O -
] O -
. O -

Data O +
acquisition O +
and O +
statistical O +
analysisImmediately O +
following O +
the O +
washing O +
steps O -
, O +
the O +
fluorescence O +
intensities O +
were O +
measured O +
using O +
a O +
confocal O +
laser O +
scanner O +
( O -
G2505B O -
, O +
Agilent O +
Technologies O -
) O -
. O -

After O +
image O +
formatting O +
by O +
Tiff O +
Image O +
Channel O +
Splitter O +
Utility O +
( O -
Agilent O +
Technologies O -
) O +
and O +
grid O +
annotation O -
, O +
a O +
complete O +
set O +
of O +
spots O +
was O +
visually O +
inspected O +
for O +
each O +
slide O -
. O -

Using O +
GenePix O +
Pro O +
( O -
Molecular O +
Devices O +
Corp. O +
USA O -
) O +
flags O +
for O +
artifactual O +
spots O +
were O +
annotated O +
for O +
each O +
spot O -
. O -

Median O +
pixel O +
intensity O +
minus O +
the O +
median O +
local O +
background O +
for O +
both O +
dyes O +
was O +
used O +
to O +
obtain O +
a O +
test O +
over O +
reference O +
intensity O +
ratio O -
. O -

Data O +
normalization O +
was O +
performed O +
per O +
array O +
subgrid O +
using O +
LOWESS O +
curve O +
fitting O +
with O +
a O +
smoothing O +
factor O +
of O +
0.33 O +
[ O -
52,53 O -
] O -
. O -

All O +
normalizations O -
, O +
filtering O -
, O +
merging O +
of O +
technical O +
replicates O +
and O +
analyses O +
were O +
performed O +
in O +
the O +
BioArray O +
Software O +
Environment O +
database O +
[ O -
32 O -
] O -
. O -

To O +
visualize O +
sample O -
- O -
dependent O +
variation O +
of O +
spot O +
intensities O -
, O +
data O +
was O +
uploaded O +
to O +
the O +
TIGR O +
MultiExperiment O +
Viewer O +
( O -
MEV O -
; O +
[ O -
34 O -
] O -
) O -
. O -

Recently O -
, O +
it O +
was O +
shown O +
that O +
diclofenac O +
was O +
metabolized O +
in O +
rats U-Species +
to O +
reactive O +
benzoquinone O +
imines O +
via O +
cytochrome O +
P450-catalyzed O +
oxidation O -
. O -

These O +
metabolites O +
also O +
were O +
detected O +
in O +
human U-Species +
hepatocyte O +
cultures O +
in O +
the O +
form O +
of O +
glutathione O +
( O -
GSH O -
) O -
adducts O -
. O -

This O +
report O +
describes O +
the O +
results O +
of O +
further O +
studies O +
aimed O +
at O +
characterizing O +
the O +
human U-Species +
hepatic O +
P450-mediated O +
bioactivation O +
of O +
diclofenac O -
. O -

The O +
reactive O +
metabolites O +
formed O +
in O +
vitro O +
were O +
trapped O +
by O +
GSH O +
and O +
analyzed O +
by O +
LC O -
/ O -
MS O -
/ O -
MS O -
. O -

Thus O -
, O +
three O +
GSH O +
adducts O -
, O +
namely O -
, O +
5-hydroxy-4- O -
( O -
glutathion O -
- O -
S O -
- O -
yl O -
) O -
diclofenac O +
( O -
M1 O -
) O -
, O +
4'-hydroxy-3'- O -
( O -
glutathion O -
- O -
S O -
- O -
yl O -
) O -
diclofenac O +
( O -
M2 O -
) O -
, O +
and O +
5-hydroxy-6- O -
( O -
glutathion O -
- O -
S O -
- O -
yl O -
) O -
diclofenac O +
( O -
M3 O -
) O -
, O +
were O +
identified O +
in O +
incubations O +
of O +
diclofenac O +
with O +
human U-Species +
liver O +
microsomes O +
in O +
the O +
presence O +
of O +
NADPH O +
and O +
GSH O -
. O -

The O +
formation O +
of O +
the O +
adducts O +
was O +
taken O +
to O +
reflect O +
the O +
intermediacy O +
of O +
the O +
corresponding O +
putative O +
benzoquinone O +
imines O -
. O -

While O +
M2 O +
was O +
the O +
dominant O +
metabolite O -
over O +
a O +
substrate O +
concentration O +
range O +
of O +
10 O -
- O -
50 O +
microM O -
, O +
M1 O +
and O +
M3 O +
became O +
equally O +
important O +
products O +
at O +
> O -
/=100 O +
microM O +
diclofenac O -
. O -

The O +
formation O +
of O +
M2 O +
was O +
inhibited O +
by O +
sulfaphenazole O +
or O +
an O +
anti O -
- O -
P450 O +
2C9 O +
antibody O +
( O -
5 O -
- O -
10 O -
% O +
of O +
control O +
values O -
) O -
. O -

The O +
formation O +
of O +
M1 O +
and O +
M3 O +
was O +
inhibited O +
by O +
troleandomycin O -
, O +
ketoconazole O -
, O +
or O +
an O +
anti O -
- O -
P450 O +
3A4 O +
antibody O +
( O -
30 O -
- O -
50 O -
% O +
of O +
control O +
values O -
) O -
. O -

In O +
studies O +
in O +
which O +
recombinant O +
P450 O +
isoforms O +
were O +
used O -
, O +
M2 O +
was O +
generated O +
only O +
by O +
P450 O +
2C9-catalyzed O -
reaction O -
, O +
while O +
M1 O +
and O +
M3 O +
were O +
produced O +
by O +
P450 O +
3A4-catalyzed O +
reaction O -
. O -

Good O +
correlations O +
were O +
established O +
between O +
the O +
extent O +
of O +
formation O +
of O +
M2 O +
and O +
P450 O +
2C9 O -
activities O +
( O -
r O +
= O +
0.93 O -
, O +
n O +
= O +
10 O -
) O +
and O +
between O +
the O +
extent O +
of O +
formation O +
of O +
M1 O +
and O +
M3 O +
and O +
P450 O +
3A4 O +
activities O +
( O -
r O +
= O +
0.98 O -
, O +
n O +
= O +
10 O -
) O +
in O +
human U-Species +
liver O +
microsomal O +
incubations O -
. O -

Taken O +
together O -
, O +
the O +
data O +
suggest O +
that O +
the O +
biotransformation O +
of O +
diclofenac O +
to O +
M2 O +
is O +
P450 O +
2C9-dependent O -
, O +
whereas O +
metabolism O +
of O +
the O +
drug O +
to O +
M1 O +
and O +
M3 O +
involves O +
mainly O +
P450 O +
3A4 O -
. O -

Although O +
P450s O +
2C9 O +
and O +
3A4 O +
both O +
catalyze O +
the O +
bioactivation O +
of O +
diclofenac O -
, O +
P450 O +
2C9 O +
is O +
capable O +
of O +
producing O +
the O +
benzoquinone O +
imine O +
intermediate O -
at O +
lower O +
drug O +
concentrations O +
which O +
may O +
be O +
more O +
clinically O +
relevant O -
. O +

Cytochrome O +
P450 O +
2C11 O +
in O +
rats U-Species +
was O +
recently O +
found O +
to O +
metabolize O +
diclofenac O +
into O +
a O +
highly O +
reactive O +
product O +
that O +
covalently O +
bound O +
to O +
this O +
enzyme O +
before O +
it O +
could O +
diffuse O +
away O +
and O +
react O +
with O +
other O +
proteins O -
. O -

To O +
determine O +
whether O +
cytochromes O +
P450 O +
in O +
human U-Species +
liver O +
could O +
catalyze O +
a O +
similar O +
reaction O -
, O +
we O +
have O +
studied O +
the O +
covalent O +
binding O +
of O +
diclofenac O +
in O +
vitro O +
to O +
liver O +
microsomes O +
of O +
16 O +
individuals U-Species -
. O -

Only O +
three O -
of O +
16 O +
samples O +
were O +
found O +
by O +
immunoblot O +
analysis O +
to O +
activate O +
diclofenac O +
appreciably O +
to O +
form O +
protein O +
adducts O +
in O +
a O +
NADPH O -
- O -
dependent O +
pathway O -
. O -

Cytochrome O +
P450 O +
2C9 O -
, O +
which O +
catalyzes O +
the O +
major O +
route O +
of O +
oxidative O +
metabolism O +
of O +
diclofenac O +
to O +
produce O +
4'-hydroxydiclofenac O -
, O +
did O +
not O +
appear O +
to O +
be O +
responsible O +
for O +
the O +
formation O -
of O +
the O +
protein O +
adducts O -
, O +
because O +
sulfaphenazole O -
, O +
an O +
inhibitor O +
of O +
this O +
enzyme O -
, O +
did O -
not O +
affect O +
protein O +
adduct O +
formation O -
. O -

In O +
contrast O -
, O +
troleandomycin O -
, O +
an O +
inhibitor O +
of O +
P450 O +
3A4 O -
, O +
inhibited O +
both O +
protein O +
adduct O +
formation O +
and O +
5-hydroxylation O +
of O +
diclofenac O -
. O -

These O +
findings O +
were O +
confirmed O +
with O +
the O +
use O +
of O +
baculovirus O -
- O -
expressed O +
human U-Species +
P450 O +
2C9 O +
and O +
P450 O +
3A4 O -
. O -

One O +
possible O +
reactive O +
intermediate O +
that O +
would O +
be O +
expected O +
to O +
bind O +
covalently O +
to O +
liver O +
proteins O +
was O +
the O +
p O -
- O -
benzoquinone O +
imine O +
derivative O +
of O +
5-hydroxydiclofenac O -
. O -

This O +
product O +
was O +
formed O +
by O +
an O +
apparent O +
metal O -
- O -
catalyzed O +
oxidation O +
of O +
5-hydroxydiclofenac O +
that O +
was O +
inhibited O +
by O +
EDTA O -
, O +
glutathione O -
, O +
and O +
NADPH O -
. O -

The O +
p O -
- O -
benzoquinone O +
imine O +
decomposition O +
product O +
bound O +
covalently O +
to O +
human U-Species +
liver O +
microsomes O +
in O +
vitro O +
in O +
a O +
reaction O +
that O +
was O +
inhibited O +
by O +
GSH O -
. O -

In O +
contrast O -
, O +
GSH O +
did O +
not O +
prevent O +
the O +
covalent O +
binding O +
of O +
diclofenac O +
to O +
human U-Species +
liver O +
microsomes O -
. O -

These O +
results O +
suggest O +
that O +
for O +
appreciable O +
P450-mediated O +
bioactivation O +
of O +
diclofenac O +
to O +
occur O +
in O +
vivo O -
, O +
an O +
individual O +
may O +
have O +
to O +
have O +
both O +
high O +
activities O +
of O +
P450 O +
3A4 O +
and O +
perhaps O +
low O +
activities O +
of O +
other O +
enzymes O +
that O +
catalyze O +
competing O +
pathways O +
of O +
metabolism O +
of O +
diclofenac O -
. O -

Moreover O -
, O +
the O +
p O -
- O -
benzoquinone O +
imine O +
derivative O +
of O +
5-hydroxydiclofenac O +
probably O +
has O +
a O +
role O +
in O +
covalent O +
binding O +
in O +
the O +
liver O +
only O +
under O +
the O +
conditions O +
where O +
levels O +
of O +
NADPH O -
, O +
GSH O -
, O +
and O +
other O +
reducing O +
agents O +
would O +
be O +
expected O +
to O +
be O +
low O -
. O +

The O +
marked O +
analgesic O +
efficacy O +
of O +
ketorolac O +
in O +
humans U-Species -
, O +
relative O +
to O +
other O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
, O +
has O +
lead O +
to O +
speculation O +
as O +
to O +
whether O +
additional O +
non O -
- O -
NSAID O +
mechanism O -
( O -
s O -
) O +
contribute O +
to O +
its O +
analgesic O +
actions O -
. O -

To O +
evaluate O +
this O +
possibility O -
, O +
we O +
characterized O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O -
's O +
pharmacological O +
properties O +
in O +
vivo O +
and O +
in O +
vitro O +
using O +
the O +
nonselective O +
cyclooxygenase O +
( O -
COX O -
) O +
inhibitors O +
[ O -
indomethacin O +
( O -
INDO O -
) O +
and O +
diclofenac O +
sodium O +
( O -
DS O -
) O -
] O +
as O +
well O +
as O +
the O +
selective O +
COX-2 O +
inhibitor O -
, O +
celecoxib O -
, O +
as O +
references O -
. O -

The O +
potency O +
of O +
racemic O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
was O +
similar O +
in O +
tests O +
of O +
acetic O +
acid O -
- O -
induced O +
writhing O -
, O +
carrageenan O -
- O -
induced O +
paw O +
hyperalgesia O -
, O +
and O +
carrageenan O -
- O -
induced O +
edema O +
formation O +
in O -
rats U-Species -
; O +
ID50 O +
values O +
= O +
0.24 O -
, O +
0 O -
. O +
29 O -
, O +
and O +
0.08 O +
mg O -
/ O -
kg O -
, O +
respectively O -
. O -

( O -
R O -
, O -
S O -
) O -
-ketorolac O -
's O -
actions O +
were O +
stereospecific O -
, O +
with O +
( O -
S O -
) O -
-ketorolac O +
possessing O +
the O +
biological O +
activity O +
of O +
the O +
racemate O +
in O +
the O +
above O +
tests O -
. O -

The O +
analgesic O +
potencies O +
for O +
( O -
R O -
, O -
S O -
) O -
- O -
, O -
( O -
S O -
) O -
- O -
, O +
and O +
( O -
R O -
) O -
-ketorolac O -
, O +
INDO O -
, O +
and O +
DS O +
were O +
highly O +
correlated O +
with O +
their O +
anti O -
- O -
inflammatory O +
potencies O -
, O +
suggesting O +
a O +
common O +
mechanism O -
. O -

( O -
R O -
, O -
S O -
) O -
-ketorolac O +
was O +
significantly O +
more O +
potent O +
than O +
INDO O +
or O +
DS O +
in O +
vivo O -
. O -

Neither O +
difference O +
in O +
relative O +
potency O +
of O +
COX O +
inhibition O +
for O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
over O +
INDO O +
and O +
DS O +
nor O +
activity O +
of O +
( O -
S O -
) O -
-ketorolac O +
at O +
a O +
number O +
of O +
other O +
enzymes O -
, O +
channels O -
, O +
or O +
receptors O +
could O +
account O -
for O +
the O +
differences O +
in O +
observed O +
potency O -
. O -

The O +
distribution O +
coefficient O +
for O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
was O +
approximately O +
30-fold O +
less O +
than O +
for O +
DS O +
or O +
INDO O -
, O +
indicating O +
that O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
is O +
much O +
less O +
lipophilic O +
than O +
these O +
NSAIDs O -
. O -

Therefore O -
, O +
the O +
physicochemical O +
and O +
pharmacokinetics O +
properties O +
of O +
( O -
R O -
, O -
S O -
) O -
-ketorolac O +
may O +
optimize O +
the O +
concentrations O +
of O +
( O -
S O -
) O -
-ketorolac O +
at O +
its O +
biological O +
target O -
( O -
s O -
) O -
, O +
resulting O +
in O +
greater O +
efficacy O +
and O +
potency O +
in O +
vivo O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
distribution O -
, O +
excretion O +
and O +
metabolism O +
of O +
1,2-dimethylnaphthalene- O -
[ O -
ring O -
- O -
U-3H O -
] O +
in O +
rats U-Species -
. O -

The O +
experiments O +
were O +
performed O +
on O +
54 O +
male O +
outbred O +
IMP O -
: O -

Wist O +
rats U-Species +
with O +
body O +
weight O +
of O +
200 O +
g O +
+ O -
/- O -

20 O -
% O -
. O -

The O +
compound O +
was O +
given O +
i.p O -
. O -

in O +
olive O +
oil O +
in O +
a O +
single O +
dose O +
of O +
28 O +
mg O -
/ O -
kg O +
( O -
about O +
6.2 O +
MBq O -
per O +
animal O -
) O -
. O -

3H O +
radioactivity O +
was O +
traced O +
in O +
selected O +
organs O +
and O +
tissues O -
, O +
blood O -
, O +
urine O +
and O +
faeces O -
, O +
1 O -
- O -
72 O +
h O +
following O +
the O +
administration O -
. O -

The O +
main O +
metabolites O +
were O -
isolated O +
from O +
urine O +
and O +
identified O +
by O +
the O +
GC O -
- O -
MS O +
method O -
. O -

Faeces O +
and O +
urine O +
proved O +
to O +
be O +
the O +
main O +
route O +
of O +
tritium O +
elimination O -
. O -

Over O +
93 O -
% O +
of O +
the O +
given O +
compound O +
was O +
excreted O +
during O +
the O +
first O +
72 O +
h. O +
Maximum O +
level O +
of O +
tritium O +
in O +
plasma O +
was O +
observed O +
during O +
the O +
4th O +
h O +
after O +
the O +
compound O +
administration O -
. O -

The O +
accretion O +
of O +
3H O +
proceeded O +
with O +
kinetic O +
constant O +
of O +
0.7 O +
h O -
, O +
followed O +
by O +
monophasic O +
decline O +
with O +
the O +
half O -
- O -
life O +
of O +
about O +
19h O -
. O -

In O +
organs O +
and O +
tissue O -
, O +
the O +
highest O +
concentration O +
during O +
the O +
first O +
hours O +
after O +
administration O +
were O +
detected O +
in O +
the O +
fat O -
, O +
adrenals O -
, O +
liver O -
, O +
spleen O +
and O -
kidneys O -
. O -

Then O +
gradual O +
decline O +
of O +
tritium O +
was O +
noticed O +
in O +
all O +
examined O +
tissues O -
. O -

The O +
following O +
urinary O +
metabolites O +
were O +
identified O -
: O +
1 O -
. O -

1,2-dimethylthionaphthalene O -
, O +
2 O -
. O -

1,2-dimethylnaphthol O -
, O +
3 O -
. O +
1-methylnaphthalene-2-methanol O -
, O +
4 O -
. O +
1-methyl-2-naphthoic O -
acid O +
and O +
5 O -
. O -

1,2-dimethylmethylthionaphthalene O -
. O -

In O +
conclusion O -
, O +
1,2-dimethylnaphthalene O +
has O +
a O +
relatively O +
rapid O +
turnover O +
rate O +
in O +
the O +
rat U-Species +
organism O -
and O +
does O +
not O +
form O +
deposits O +
in O +
the O +
tissue O -
. O -

The O +
metabolism O +
encompasses O +
ring O +
hydroxylation O +
and O +
glutathione O +
conjugation O +
leading O +
to O +
thionaphthol O +
and O +
oxygenation O -
, O +
and O +
then O +
to O +
naphthoic O +
acid O -
. O +

Trimethylbenzene O +
isomers O +
( O -
TMBs O -
) O -
: O +
1,2,4-TMB O +
( O -
pseudocumene O -
-- O -
PS O -
) O -
, O +
1,2,3-TMB O +
( O -
hemimellitene O -
-- O -
HM O -
) O +
and O +
1,3,5-TMB O +
( O -
mesitylene O -
-- O -
MES O -
) O +
are O +
important O +
constituents O +
of O +
solvent O +
mixtures O -
. O -

In O +
the O +
US O -
, O +
the O +
adopted O +
TLV O -
- O -
TWA O +
value O +
for O +
TMBs O +
is O +
125 O +
mg O -
/ O -
m3 O +
or O +
25 O +
ppm O +
( O -
ACGIH O +
1996 O -
) O -
. O -

Recent O +
experiments O +
at O +
our O +
laboratory O +
have O +
revealed O +
an O +
impaired O +
learning O +
of O +
passive O +
and O +
active O +
avoidance O +
responses O +
and O +
a O +
longer O +
persistence O +
of O +
an O +
effect O +
of O +
footshock O +
( O -
increase O +
in O +
latency O +
of O +
the O +
paw O -
- O -
lick O +
response O +
to O +
heat O -
) O +
in O +
rats U-Species +
tested O +
several O +
weeks O +
after O +
a O +
four O -
- O -
week O +
inhalation O +
exposure O +
( O -
6h O -
/ O -
day O -
, O +
five O +
days O -
/ O -
week O -
) O +
to O +
PS O +
at O +
a O +
concentration O +
of O +
100 O +
or O +
250 O +
ppm O +
( O -
15 O -
) O -
. O -

The O +
concentration O -
- O -
effect O +
relationship O +
appeared O +
to O +
be O +
nonlinear O -
; O +
the O +
effect O -
of O +
100 O +
ppm O +
HM O +
was O +
more O +
pronounced O +
than O +
that O +
of O +
250 O +
ppm O -
. O -

In O +
the O +
present O +
experiment O +
we O +
investigated O +
the O +
effects O +
of O +
a O +
repeated O +
four O -
- O -
week O +
( O -
6h O -
/ O -
day O -
, O +
5 O +
days O -
/ O -
week O -
) O +
inhalation O +
exposure O +
to O +
HM O +
at O +
concentrations O +
of O +
0 O -
, O +
25 O -
, O +
100 O +
or O +
250 O +
ppm O +
on O +
radial O -
- O -
maze O +
performance O -
, O +
open O -
- O -
field O +
activity O -
, O +
passive O +
and O +
active O +
avoidance O +
learning O -
, O +
and O +
on O +
the O +
shock O -
- O -
induced O +
changes O +
in O +
latency O +
of O +
the O +
paw O -
- O -
lick O +
response O +
to O +
heat O +
( O -
hot O -
- O -
plate O +
test O -
) O -
. O -

The O +
tests O +
were O +
performed O +
between O +
days O +
14 O +
and O +
61 O +
after O +
the O -
last O +
exposure O -
. O -

No O +
significant O +
effects O +
on O +
radial O -
- O -
maze O +
performance O +
and O +
open O -
- O -
field O +
activity O +
were O +
noted O +
in O +
any O +
of O +
the O +
dose O +
groups O -
. O -

In O +
the O +
remaining O +
tests O +
effects O +
of O -
exposure O +
were O +
noted O +
but O -
, O +
similarly O +
as O +
in O +
the O +
case O +
of O +
PS O +
exposure O -
, O +
the O +
concentration O -
- O -
effect O +
relationship O +
was O +
not O +
linear O -
. O -

In O +
rats U-Species +
exposed O +
to O +
HM O +
at O +
25 O +
or O -
100 O +
ppm O -
, O +
but O +
not O +
250 O +
ppm O -
, O +
learning O +
of O +
the O +
passive O +
avoidance O -
, O +
i.e. O +
refraining O +
from O +
performance O +
of O +
a O +
punished O +
response O +
( O -
stepping O +
off O +
an O +
elevated O +
platform O -
) O +
was O +
significantly O +
impaired O -
. O -

Moreover O -
, O +
in O +
rats U-Species +
exposed O +
to O +
100 O -
, O +
but O +
not O +
250 O +
ppm O +
of O +
HM O -
, O -
acquisition O +
of O +
the O +
two O -
- O -
way O +
active O +
avoidance O +
in O +
the O +
shuttle O -
- O -
box O +
was O +
slower O +
and O +
the O +
footshock O -
- O -
induced O +
increase O +
in O +
latency O +
of O +
the O +
paw O -
- O -
lick O +
response O +
to O +
heat O +
persisted O -
longer O +
than O +
in O +
the O +
unexposed O +
animals O -
. O -

The O +
results O +
suggest O +
that O +
a O +
low O -
- O -
level O +
inhalation O +
exposure O +
to O +
HM O -
, O +
just O +
like O +
low O -
- O -
level O +
exposure O +
to O +
PS O -
, O +
may O +
lead O +
to O +
long O -
- O -
lasting O +
disturbances O +
in O +
the O +
CNS O +
functions O -
. O -

The O +
nonlinear O +
concentration O -
- O -
effect O +
relationship O +
observed O +
in O +
the O +
case O +
of O +
both O +
TMB O -
- O -
s O +
requires O +
clarification O +
in O +
further O +
studies O -
. O +

All O +
the O +
benzodiazepines O +
( O -
BZDs O -
) O +
in O +
clinical O +
use O +
have O +
the O +
capacity O +
to O +
promote O +
the O +
binding O +
of O +
the O +
major O +
inhibitory O +
neurotransmitter O -
, O +
gamma O -
- O -
amino O -
- O -
butyric O +
acid O +
( O -
GABA O -
) O -
, O +
to O +
sub O -
- O -
types O +
of O +
GABA O +
receptors O +
which O +
exist O +
as O +
multi O -
- O -
subunit O +
ligand O -
- O -
gated O -
chloride O +
channels O -
. O -

Thus O -
, O +
the O +
BZDs O +
facilitate O +
the O +
actions O +
of O +
GABA O +
in O +
the O +
brain O -
. O -

The O +
BZDs O +
in O +
use O +
as O +
antiepileptic O +
drugs O +
are O +
diazepam O -
, O +
clonazepam O -
, O +
clobazam O -
, O +
nitrazepam O -
, O +
and O +
lately O -
, O +
also O +
lorazepam O +
and O +
midazolam O +
as O +
emergency O +
therapy O -
. O -

The O +
BZDs O +
have O +
a O +
wide O -
- O -
spectrum O +
of O +
proven O +
clinical O +
efficacy O +
in O +
the O +
prevention O +
of O +
different O +
kind O +
of O +
seizures O -
. O -

Clonazepam O +
and O +
clobazam O -
, O +
as O +
well O +
as O +
nitrazepam O +
in O +
some O +
cases O -
, O +
can O +
be O +
useful O +
as O +
an O +
adjunct O +
treatment O +
in O +
refractory O +
epilepsies O -
. O -

However O -
, O +
the O +
clinical O +
use O +
of O +
BZDs O +
for O +
the O +
prophylactic O +
treatment O +
of O +
epilepsy O +
is O +
associated O +
with O +
two O +
major O +
problems O +
which O +
have O +
limited O +
the O +
long O -
- O -
term O +
use O +
of O +
these O -
drugs O -
: O +
the O +
potential O +
for O +
side O -
- O -
effects O -
, O +
especially O +
sedative O +
effects O -
, O +
and O +
the O +
high O -
risk O +
of O +
development O +
of O +
tolerance O -
. O -

Despite O +
the O +
limitations O +
of O +
BZDs O +
in O +
the O +
prophylactic O +
treatment O +
of O +
epilepsies O -
, O +
these O +
drugs O +
play O +
a O +
prominent O +
role O +
in O +
clinical O +
practice O +
in O +
the O +
emergency O +
management O +
of O +
acute O +
seizures O +
and O +
status O +
epilepticus O -
. O -

Diazepam O -
, O +
clonazepam O +
and O +
lorazepam O +
are O +
all O +
considered O +
first O -
- O -
line O +
agents O +
in O +
the O +
emergency O +
management O +
of O +
acute O +
seizures O +
and O +
status O +
epilepticus O -
. O -

Furthermore O -
, O +
the O +
value O +
of O +
midazolam O +
as O +
an O +
emergency O +
therapy O +
in O +
epilepsy O +
has O +
been O -
increasingly O +
recognized O +
in O +
recent O +
years O -
. O +

Anti O -
- O -
ulcer O +
effects O +
of O +
cetraxate O -
, O +
a O +
new O +
compound O +
possessing O +
anti O -
- O -
plasmin O -
, O +
anti O -
- O -
casein O +
and O +
anti O -
- O -
trypsin O +
actions O +
were O +
investigated O +
by O +
using O +
experimental O +
gastric O +
ulcer O +
models O +
in O +
rats U-Species -
. O -

Cetraxate O -
, O +
300 O +
mg O -
/ O -
kg O +
p.o O -
. O +
showed O +
significant O +
inhibitory O +
effects O +
of O +
65.3 O -
% O -
, O +
70.0 O -
% O -
, O +
30.2 O -
% O -
, O +
and O +
67.1 O -
% O +
against O +
aucte O +
types O +
of O +
ulcers O +
producing O +
by O +
aspirin O -
, O +
phenylbutazone O -
, O +
indomethacin O -
, O +
and O +
pyloric O +
ligature O +
( O -
Shay O -
's O +
ulcer O -
) O -
, O +
respectively O -
. O -

These O +
effects O +
were O +
greater O +
than O +
those O +
obtained O +
by O +
gefarnate O +
and O +
aluminum O +
sucrose O +
sulfate O +
may O +
be O +
mainly O +
attributed O +
to O +
the O +
protecting O +
action O +
of O +
this O +
drug O +
on O +
gastric O +
mucosa O -
. O -

Ctraxate O +
further O +
revealed O +
remarkable O +
inhibitory O +
effects O +
on O +
chronic O +
types O +
of O +
ulcers O +
produced O +
by O +
acetic O +
acid O -
, O +
clamping O -
, O -
and O +
clamping O -
- O -
cortisone O -
. O -

In O +
acetic O +
acid O +
ulcer O +
in O +
particular O -
, O +
cetraxate O +
was O +
found O +
to O +
have O +
a O +
dose O -
- O -
dependent O +
inhibitory O +
effect O +
at O +
doses O +
over O +
50 O +
mg O -
/ O -
kg O -
. O -

Of O +
test O +
drugs O -
including O +
L O -
- O -
glutamine O +
and O +
methylmethionine O +
sulfonium O +
chloride O -
, O +
cetraxate O +
showed O +
the O +
most O +
remarkable O +
inhibitory O +
effect O +
on O +
beta O -
- O -
glucuronidase O +
activity O +
in O +
ulcer O +
tissue O +
of O +
these O +
three O +
types O +
of O +
ulcers O -
. O -

These O +
findings O +
suggest O +
that O +
cetraxate O +
may O -
prevent O +
the O +
connective O +
tissue O +
in O +
the O +
ulcer O +
location O +
from O +
decomposition O +
due O +
to O +
lysosomal O +
enzymes O +
such O +
as O +
beta O -
- O -
glucuronidase O -
, O +
thereby O +
accelerating O +
the O +
recovery O +
from O +
ulcer O -
. O +

Sequence O +
analysis O +
reveals O +
that O +
the O +
Bacillus B-Species +
subtilis L-Species +
168 O +
tuaABCDEFGH O +
operon O +
encodes O +
enzymes O +
required O +
for O +
the O +
polymerization O +
of O +
teichuronic O +
acid O +
as O +
well O +
as O +
for O +
the O +
synthesis O +
of O +
one O +
of O +
its O +
precursors O -
, O +
the O +
UDP O -
- O -
glucuronate O -
. O -

Mutants O +
deficient O +
in O +
any O +
of O +
the O +
tua O +
genes O -
, O +
grown O +
in O +
batch O +
cultures O +
under O +
conditions O +
of O +
phosphate O +
limitation O -
, O +
were O +
characterized O +
by O +
reduced O +
amounts O +
of O +
uronate O +
in O +
their O +
cell O +
walls O -
. O -

The O +
teichuronic O +
acid O +
operon O +
belongs O +
to O +
the O +
Pho O +
regulon O -
, O +
as O +
phosphate O -
limitation O +
induces O +
its O +
transcription O -
. O -

Placing O +
the O +
tuaABCDEFGH O +
operon O +
under O +
the O +
control O +
of O +
the O +
inducible O +
Pspac O +
promoter O +
allowed O +
its O +
constitutive O +
expression O +
independently O +
of O +
the O +
phosphate O +
concentration O +
in O +
the O +
medium O -
; O +
the O +
level O +
of O +
uronic O +
acid O +
in O +
cell O +
walls O +
was O +
dependent O +
on O +
the O +
concentration O +
of O +
the O +
inducer O -
. O -

Apparently O -
, O +
owing O +
to O +
an O +
interdependence O +
between O +
teichoic O +
and O +
teichuronic O +
acid O +
incorporation O +
into O +
the O +
cell O +
wall O -
, O +
in O +
examined O +
growth O +
conditions O -
, O +
the O +
balance O +
between O +
the O +
two O +
polymers O +
is O +
maintained O +
in O +
order O +
to O +
insure O +
a O +
constant O +
level O +
of O +
the O +
wall O +
negative O +
charge O -
. O +

Evidence O +
has O +
accumulated O +
supporting O +
the O +
concept O +
that O +
reactive O +
oxygen O +
metabolites O -
, O +
including O +
free O +
radical O +
spe­cies O +
( O -
such O +
as O +
superoxide O +
and O +
hydroxyl O -
) O -
, O +
and O +
other O +
oxygen O +
metabolites O +
( O -
such O +
as O +
hydrogen O +
peroxide O +
and O +
hypochlo­rous O +
acid O -
) O +
play O +
an O +
important O +
role O +
in O +
tissue O +
injury O +
( O -
BAUD O +
and O +
ARDALILLOU O +
1986 O -
) O -
. O -

Recent O +
in O +
vitro O +
and O +
in O +
vivo O +
studies O +
have O +
implicated O +
reactive O +
oxygen O +
metabolites O +
in O +
various O +
forms O +
of O +
toxic O +
nephropathy O +
( O -
PALLER O +
et O +
al. O +
1984 O -
; O +
WALKER O +
and O +
SHAH O +
1987 O -
, O +
1988 O -
; O +
PALLER O +
1988 O -
; O +
SHAH O +
1989 O -
) O -
. O -

The O +
putative O +
site O +
of O +
injury O +
in O +
most O +
forms O +
of O +
toxic O +
nephropathy O +
is O +
the O +
epithelial O +
cells O +
lining O +
the O +
tubules O +
( O -
BREZIS O +
et O +
al. O +
1991 O -
) O -
. O -

From O +
this O +
viewpoint O -
, O +
therefore O -
, O +
protecting O +
these O +
cells O +
from O +
toxic O +
oxygen O +
metabolites O +
may O +
reduce O +
the O +
risk O +
of O +
renal O +
disorders O -
. O -

Although O +
a O +
native O +
scavenger O +
system O +
is O +
capable O +
ofdoing O +
this O -
, O +
it O +
may O +
lose O +
its O +
activity O +
under O +
pathogenic O +
conditions O +
due O +
to O +
organ O +
dysfunction O +
and O +
an O +
excess O +
of O +
free O +
radicals O -
. O -

Therefore O -
, O +
supplementation O +
with O +
chemical O +
scavengers O +
would O +
be O +
necessary O +
in O +
order O +
to O +
decompose O +
these O +
excess O +
pathogenic O +
metabolites O -
. O -

In O +
this O +
study O -
, O +
we O +
evaluated O +
the O +
membrane O +
protective O +
effects O +
of O +
some O +
flavonoids O +
on O +
the O +
LLC B-Species -
- I-Species -
PKj L-Species +
cell O +
line O -
, O +
which O +
maintains O +
the O +
differentiated O +
characteristics O +
of O +
renal O +
proximal O +
tubular O +
cells O +
( O -
CANTIELLO O +
et O +
al. O +
1987 O -
) O -
. O -

This O +
cell O +
line O +
has O +
been O +
used O +
extensively O +
in O +
in O +
vitro O +
studies O +
to O +
examine O +
both O +
physiologic O +
and O +
pathophysiologic O +
mecha­nisms O +
in O +
renal O +
tubules O +
( O -
CANTIELLO O +
et O +
al. O +
1987 O -
; O +
MULLIN O +
and O +
McGINN O +
1988 O -
; O +
ANDREOLI O +
and O +
McATEER O +
1990 O -
; O +
ER­COLANI O +
et O +
al. O +
1990 O -
; O +
YOKOZAWA O +
et O +
al. O +
1997a O -
, O +
1997b O -
) O -
. O -

The O +
purposes O +
of O +
this O +
study O +
were O +
to O +
screen O +
out O +
a O +
potentially O +
useful O +
agent O +
for O +
cell O +
membrane O +
protection O -
, O +
and O +
to O +
shed O +
light O +
on O +
the O +
possible O +
mechanism O +
of O +
this O +
process O -
. O -

Material O +
and O +
methods O -
Compounds O -
: O +
Flavones O +
( O -
acacetin O -
, O +
apigenin O -
, O +
apiin O -
, O +
bai­calein O -
, O +
baicalin O -
, O +
chrysoeriol O -
, O +
cirsilineol O -
, O +
cirsiliol O -
, O +
cirsimarin O -
, O +
cirsimaritin O -
, O +
cosmosiin O -
, O +
genkwanin O -
, O +
6-hydroxyluteolin O -
, O +
linarin O -
, O +
luteolin O -
, O +
luteolin O +
7 O +
-glucoside O -
, O +
pectolinarigenin O -
, O +
pec­tolinarin O -
, O +
plantaginin O -
, O +
rhoifolin O -
, O +
scutellarein O -
, O +
sorbarin O -
, O +
tecto­chrysin O +
and O +
toringin O -
) O +
and O +
flavonols O +
( O -
afzelin O -
, O +
chrysosplenol O +
B O -
, O +
chrysosplenol O +
C O -
, O +
chrysosplenol O +
D O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaempferol O -
, O +
kaempferol-7­glucoside O -
, O +
oxyayanin O +
A O -
, O +
quercetin O -
, O +
quercimeritrin O -
, O +
quer­citrin O -
, O +
rhamnetin O -
, O +
rutin O +
and O +
tetramethylquercitin O -
) O +
used O +
in O +
this O +
experiment O +
were O +
isolated O +
from O +
natural O +
sources O -
. O -

Medium O +
and O +
reagents O -
: O +
Dulbecco O -
's O +
modified O +
Eagle O +
medium O -
/ O -
nutrient O +
mixture O +
F-12 O +
( O -
D O -
- O -
MEMIF-12 O -
) O +
and O +
fetal U-Species +
calf O +
serum O +
( O -
FCS O -
) O +
were O +
purchased O +
from O +
Life O +
Technologies O -
, O -
Exp O +
Toxic O +
Patho151 O +
( O -
1999 O -
) O +
1 O -
ries O +
( O -
Cleveland O -
, O +
OH O -
, O +
USA O -
) O -
, O +
respectively O -
. O -

A O +
commercial O +
kit O +
( O -
lactate O +
dehydrogenase O +
ClI O -
- O -
Test O +
Wako O -
) O +
for O +
assaying O +
lactate O +
dehydrogenase O +
( O -
LDH O -
) O +
was O +
obtained O +
from O +
Wako O +
Pure O +
Chemical O +
Industries O -
, O +
Ltd. O -
, O +
Osaka O -
, O +
Japan O -
. O -

Cultured O +
cell O +
experiments O -
: O +
Commercially O +
available O +
LLC B-Species -
- I-Species -
PK1 L-Species +
cells O +
were O +
maintained O +
at O +
37 O -
° O -
C O +
in O +
a O +
humidified O +
at­mosphere O +
of O +
5 O +
% O +
CO2 O +
in O +
air O +
( O -
routine O +
conditions O -
) O +
on O +
culture O +
plates O +
with O +
5 O +
% O -
FCS O -
- O -
supplemented O +
D O -
- O -
MEM O -
/ O -
F-12 O +
medium O -
. O -

After O +
confluence O +
had O +
been O +
reached O -
, O +
the O +
cells O +
were O +
seeded O +
on O +
fresh O +
96-well O +
culture O +
plates O +
at O +
104 O +
per O +
well O -
. O -

Each O +
flavonoid O +
compound O +
was O +
added O +
to O +
the O +
culture O +
2 O +
h O +
later O -
, O +
and O +
the O +
plates O +
were O +
incubated O +
under O +
routine O +
conditions O +
for O +
48 O +
h. O +
Leakage O +
of O +
LDH O +
into O +
the O +
culture O +
medium O +
was O +
assayed O +
using O +
a O +
com­mercial O +
kit O -
. O -

The O +
level O +
of O +
lipid O +
peroxidant O +
released O +
from O +
the O +
cultured O +
cells O +
was O +
estimated O +
by O +
measuring O +
the O +
amount O +
of O +
malondialdehyde O +
( O -
MDA O -
) O +
as O +
described O +
by O +
YAGI O +
( O -
1976 O -
) O -
. O -

All O +
assays O +
were O +
performed O +
5 O +
times O -
. O -

Statistics O -
: O +
Data O +
are O +
presented O +
as O +
mean O +
± O +
S.E. O +
Differences O +
among O +
groups O +
were O +
analyzed O +
by O +
Dunnett O -
's O +
test O -
. O -

Signifi­cance O +
was O +
accepted O +
at O +
p O +
< O +
0.05 O -
. O -

Results O -
Flavone O -
- O -
type O +
compounds O -
: O +
Eighteen O +
of O +
24 O +
flavones O +
( O -
75 O +
% O -
) O +
demonstrated O +
different O +
degrees O +
of O +
membrane O +
pro­tective O +
activity O -
. O -

Baicalin O -
, O +
cirsimaritin O -
, O +
6-hydroxyluteolin O -
, O +
luteolin O -
, O +
plantaginin O -
, O +
rhoifolin O +
and O +
sorbarin O +
appeared O +
to O +
be O +
the O +
most O +
effective O +
compounds O +
for O +
preventing O +
LDH O +
leakage O -
, O +
since O +
only O +
a O +
very O +
low O +
concentration O +
of O +
0.25 O +
Ilg O -
/ O -
ml O +
was O +
needed O +
for O +
coculture O +
with O +
the O +
cells O -
, O +
as O +
shown O +
in O +
table O -
1 O -
. O -

Cirsimarin O -
, O +
luteolin O +
7 O +
-glucoside O -
, O +
pectolinarigenin O -
, O +
tec­tochrysin O +
and O +
toringin O +
showed O +
significant O +
inhibition O +
at O +
a O +
concentration O +
of O +
0.5 O +
Ilg O -
/ O -
ml O -
. O -

Five O +
compounds O -
, O +
baicalein O -
, O +
chrysoeriol O -
, O +
cirsiliol O -
, O +
linarin O +
and O +
scutellarein O -
, O +
suppressed O +
the O +
leakage O +
significantly O +
at O +
a O +
minimum O +
concentration O +
of O -
2.5 O -
Ilg O -
/ O -
ml O -
. O -

However O -
, O +
the O +
other O +
flavone O +
compounds O +
acted O +
only O +
weakly O +
in O +
comparison O +
with O +
those O +
described O +
above O -
. O -

In O +
addition O -
, O +
LDH O +
efflux O +
was O +
apparently O +
associated O +
with O +
the O +
MDA O +
level O -
. O -

The O +
amount O +
ofthis O +
lipid O +
peroxidant O +
form­ed O +
declined O +
markedly O +
when O +
the O +
cells O +
were O +
cultured O +
in O +
the O +
presence O +
of O +
baicalin O -
, O +
cirsimarin O -
, O +
cirsimaritin O -
, O +
6-hydroxy­luteolin O -
, O +
luteolin O -
, O +
luteolin O +
7-glucoside O -
, O +
pectolinarigenin O -
, O +
plantaginin O -
, O +
rhoifolin O -
, O +
sorbarin O +
and O +
tectochrysin O -
. O -

The O +
in­hibition O +
ofMDA O +
formation O +
by O +
these O +
compounds O +
was O +
con­centration O -
- O -
dependent O -
. O -

Flavonol O -
- O -
type O +
compounds O -
: O +
As O +
shown O +
in O +
table O +
2 O -
, O +
most O +
flavonol O +
compounds O +
tested O +
( O -
14 O +
out O +
of O +
17 O -
) O +
revealed O +
much O +
higher O +
activity O +
in O +
preventing O +
enzyme O +
efflux O -
. O -

Afzelin O -
, O +
hy­perin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaemp­ferol-7 O +
-glucoside O -
, O +
oxyayanin O +
A O -
, O +
quercetin O -
, O +
quercitrin O -
, O +
rhamnetin O +
and O +
rutin O +
were O +
markedly O +
effective O +
because O +
the O +
released O +
LDH O +
was O +
significantly O +
decreased O +
when O +
they O +
were O +
cocultured O +
with O +
the O +
cells O +
even O +
at O +
a O +
concentration O +
of O -
0.25 O +
Ilg O -
/ O -
ml O -
, O +
isoquercitrin O +
and O +
isorhamnetin O +
exerting O +
the O +
strongest O +
effect O -
. O -

Higher O +
concentrations O +
of O +
chrysosplenol O +
B O +
and O +
chrysosplenol O +
C O +
( O -
20 O +
times O +
those O +
of O +
the O +
above O +
com­pounds O -
) O +
were O +
required O +
to O +
inhibit O +
LDH O +
release O +
to O +
the O +
same O +
extent O -
, O +
but O +
tetramethylquercitin O +
did O +
not O +
affect O +
LDH O +
re- O -
Exp O +
Toxic O +
Pathol O +
51 O +
( O -
1999 O -
) O +
1 O -
MDA O +
leakage O +
from O +
LLC B-Species -
- I-Species -
PK1 L-Species -
Compound O -
Con­ O -
centration O -
( O -
Ilg O -
/ O -
ml O -
) O -
Acacetin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Apigenin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Apiin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Baicalein O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Baicalin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Chrysoeriol O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Cirsilineol O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Cirsiliol O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Cirsimarin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Cirsimaritin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
Cosmosiin O -
0.25 O -
0.5 O -
2.5 O -
5 O -
cells O -
. O -

LDH O +
leakage O +
rate O +
( O -
% O -
) O -
92.8 O +
± O +
6.2 O -
90.2 O +
± O +
6.3 O -
89.8 O +
± O +
5.9 O -
89.2 O +
± O +
9.5 O -
96.7 O +
±6.7 O -
94.9 O -
± O +
5.6 O -
95.5 O -
± O +
7.5 O -
91.8 O +
± O +
5.2 O -
98.3 O +
± O +
6.3 O +
89.2 O +
± O +
7.0 O +
88.9 O +
± O +
6.2 O +
87.9±7.1 O -
96.5 O +
± O +
2.8 O -
91.3 O +
± O +
4.2 O -
82.9 O +
± O +
9.4b O -
81.4 O +
± O +
6.lb O -
80.0 O +
± O +
6.5 O -
" O -
80.3 O +
± O +
5.ge O -
80.7 O +
± O +
5.8e O -
76.2 O +
± O +
3.4 O -
< O -
101.1 O +
± O +
5.7 O -
89.3 O +
± O +
4.3 O -
84.6 O -
± O +
8.9b O -
85.2 O -
± O +
8.0 O -
" O -
99.9 O +
± O +
5.9 O -
96.5 O +
± O +
8.9 O -
93.9 O +
± O +
9.5 O -
88.1 O +
± O +
7.6 O -
94.0 O +
±7.9 O -
88.4 O +
± O +
7.0 O -
82.9 O +
± O +
6.4 O -
" O -
71.6 O +
± O +
6.3c O -
89.3 O +
± O +
6.4 O -
82.9 O +
± O +
6.1b O -
77.3 O +
± O +
5.7e O -
67.6 O +
± O +
6.7e O -
80.5 O +
± O +
5.1e O -
71.1 O +
±5.9c O -
59.9 O +
± O +
6.7c O -
52.8 O +
± O +
7.4c O -
97.5 O +
± O +
6.1 O -
88.6 O +
± O +
6.5 O -
85.5 O +
± O +
6.7 O -
79.1 O +
±7.5 O -
" O -
MDA O +
leakage O +
rate O +
( O -
% O -
) O -
89.5 O +
± O +
8.4 O -
85.7 O -
± O +
8.5 O -
86.4 O -
± O +
8.2 O -
79.9 O +
± O +
6.8b O -
97.3 O +
± O +
9.7 O -
95.6 O +
± O +
8.3 O -
88.5 O +
± O +
5.4 O -
85.7 O +
± O +
6.6 O -
93.2 O -
± O +
5.1 O -
94.2 O -
± O +
5.7 O -
94.2 O +
± O +
5.7 O -
92.4 O +
± O +
4.4 O -
95.5 O +
± O +
4.7 O -
93.2 O +
± O +
6.1 O -
91.7 O +
± O +
4.2 O -
89.1 O +
±4.4 O -
" O -
81.9 O +
± O +
7.8b O -
79.0 O +
± O +
5.2b O -
75.4 O +
± O +
6.3e O -
72.1 O +
± O +
6.1c O -
97.9 O +
± O +
8.7 O -
95.8 O +
± O +
8.7 O -
93.7 O +
± O +
7.6 O -
89.4 O +
± O +
7.8 O -
95.6 O +
± O +
5.7 O -
94.2 O +
± O +
8.7 O -
90.5 O +
± O +
7.8 O -
92.6 O +
± O +
6.4 O -
97.8±7.1 O -
91.6 O +
± O +
5.8 O -
80.0 O +
± O +
7.8b O -
76.1 O +
± O +
5.9c O -
85.7 O +
± O +
6.7 O -
" O -
83.2 O +
± O +
7.2b O -
76.6 O +
± O +
5.7e O -
69.5 O +
± O +
5.8c O -
85.2 O +
± O +
6.7 O -
" O -
75.7 O +
± O +
5.7c O -
63.7 O +
± O +
6.1e O -
57.3 O +
± O +
6.0e O -
93.1 O +
± O +
7.1 O -
89.6 O +
± O +
7.1 O -
82.6 O +
± O +
6.8 O -
" O -
77.2 O +
± O +
6.3b O -
Compound O -
Con- O +
LDH O +
leakage O -
MDA O +
leakage O -

Compound O -
Con- O +
LDH O +
leakage O -
MDAleakage O -
centration O -
rate O -
rate O -
centration O -
rate O -
rate O -
( O -
Ilg O -
/ O -
ml O -
) O -
( O -
% O -
) O -
( O -
% O -
) O -
( O -
Ilg O -
/ O -
ml O -
) O -
( O -
% O -
) O -
( O -
% O -
) O -
Genkwanin O -
0.25 O +
0.5 O -
116.4 O +
± O +
18.1 O +
108.1 O +
± O +
11.9 O -
110.5 O +
± O +
13.6 O +
106.8 O +
± O +
7.1 O -
Tectochrysin O -
0.25 O +
0.5 O -
93.6 O +
± O -

6.0 O +
84.5 O +
± O +
6.7a O -
95.0 O +
± O +
7.5 O +
85.2 O +
± O +
7.7b O -
2.5 O -
101.9 O +
± O +
10.9 O -
103.7 O +
± O +
6.5 O -
2.5 O -
82.2 O +
± O +
7.5b O -
85.8 O +
± O +
6.9a O -
5 O -
100.2 O +
± O +
9.2 O -
103.4 O +
± O +
6.2 O -
5 O -
71.2 O +
± O +
5.ge O -
68.4 O +
± O +
7.6e O -
6-Hydro­ O -
xyluteolin O -
0.25 O -
n.3 O +
± O +
7.2e O -
78.6 O +
± O +
5.2e O -
Toringin O -
0.25 O -
88.9 O +
± O +
6.5 O -
91.0 O +
± O +
6.9 O -
0.5 O -
69.1 O +
±5.7e O -
n.6 O +
± O +
6.8c O -
0.5 O -
86.9 O +
± O +
7.8a O -
89.3 O +
± O +
6.3 O -
2.5 O -
53.8 O +
± O +
5.8c O -
59.4±6.1c O -
2.5 O -
83.4 O +
± O +
6.1b O -
78.4 O +
± O +
5.7e O -
5 O -
50.9 O +
± O +
5.6e O -
54.7 O +
± O +
7.2e O -
5 O -
76.5 O +
± O +
5.4e O -
73.9 O +
± O +
4.ge O -
Linarin O -
0.25 O -
97.4 O +
± O +
5.6 O -
95.3 O +
± O +
7.6 O -
Control O -
100.0 O +
± O +
6.1 O -
100.0 O +
± O +
6.9 O -
0.5 O -
94.5 O +
± O +
5.1 O -
' O -
91.4 O +
± O +
7.1 O -
2.5 O -
79.3 O +
± O +
7.3e O -
82.1 O +
± O +
6.2b O -
Significantly O +
different O +
from O +
the O +
control O +
value O -
: O +
ap O +
< O +
0.05 O -
, O -
5 O -
68.2 O +
± O +
8.2e O -
69.5 O +
± O +
7.6e O -
bp O +
< O +
0.01 O -
, O +
ep O +
< O +
0.001 O -
. O -

Luteolin O -
0.25 O -
78.9±4.1e O -
83.5 O +
± O +
6.2b O -
Table O +
2 O -
. O -

Effect O +
of O +
flavonol O -
- O -
type O +
compounds O +
on O +
LDH O +
and O -
0.5 O -
76.6 O +
± O +
5.7e O -
81.7±6.1b O -
MDA O +
leakage O +
from O +
LLC B-Species -
- I-Species -
PK1 L-Species +
cells O -
. O -

2.5 O -
74.6 O +
± O +
5.8e O -
78.0 O +
± O +
5.4e O -
5 O -
67.8 O +
± O +
5.2e O -
66.8 O +
± O +
6.ge O -
Compound O -
Con- O +
LDH O +
leakage O -
MDA O +
leakage O -
Luteolin O -
centration O -
rate O -
rate O -
7 O +
-glucoside O -
0.25 O -
97.5 O +
± O +
5.6 O -
96.3 O +
± O +
4.9 O -
( O -
Ilg O -
/ O -
ml O -
) O -
( O -
% O -
) O -
( O -
% O -
) O -
0.5 O -
83.2±7.1b O -
86.3 O +
± O +
6.2a O -
2.5 O +
5 O -
70.3 O +
± O +
7.ge O +
63.2 O +
± O +
7.4e O -
75.2 O +
± O +
6.2e O +
65.7 O +
± O +
5.8e O -
Afzelin O -
0.25 O +
0.5 O -
67.8 O +
± O +
3.5b O +
63.2±3.1b O -
73.9 O +
± O +
5.9b O +
70.8 O +
± O +
6.4b O -
Pecto­ O +
2.5 O -
59.7 O +
± O +
6.9b O -
65.3 O +
± O +
6.7b O -
linarigenin O -
0.25 O -
93.2 O +
± O +
7.7 O -
96.8 O +
±4.7 O -
5 O -
56.1 O +
± O +
4.5b O -
53.7 O +
± O +
4.6b O -
0.5 O -
69.2 O +
± O +
5.2e O -
n.6±7.1e O -
Chryso­ O -
2.5 O -
57.4 O +
± O +
6.1c O -
62.6 O +
± O +
6.4e O -
splenol O +
B O -
0.25 O -
107.7 O +
± O +
7.0 O -
100.2 O +
± O +
9.1 O -
5 O -
48.0 O +
± O +
6.5 O -
< O -
54.1 O +
± O +
5.3e O -
0.5 O -
100.3 O +
± O +
6.7 O -
95.8 O +
± O +
7.6 O -
2.5 O -
89.8 O +
± O +
6.4 O -
92.7 O +
± O +
6.7 O -
Pectolinarin O -
0.25 O -
103.8 O +
± O +
5.7 O -
103.1 O +
± O +
5.1 O -
5 O -
70.4 O +
± O +
5.3b O -
76.2 O +
± O +
6.8b O -
0.5 O -
100.5 O +
± O +
7.1 O -
100.3 O +
± O +
6.2 O -
Chryso­ O -
2.5 O -
99.2 O +
± O +
5.1 O -
96.3 O +
± O +
4.8 O -
splenol O +
C O -
0.25 O -
100.7 O +
± O +
6.9 O -
94.8 O +
± O +
5.8 O -
5 O -
89.3 O +
± O +
6.2 O -
92.0 O +
± O +
5.7 O -
0.5 O -
98.2 O +
± O +
6.6 O -
94.2 O +
±4.5 O -

2.5 O -
94.6 O +
± O +
6.5 O -
90.5 O +
± O +
7.7 O -
Plantaginin O -
0.25 O -
80.0 O +
± O +
4.2c O -
83.2 O +
± O +
4.4b O -
5 O -
84.2 O +
± O +
4.7a O -
81.1 O +
±6.4b O -
0.5 O -
71.3 O +
± O +
5.2e O -
76.8 O +
± O +
4.7e O -
Chryso­ O -
2.5 O -
67.5 O +
± O +
5.7e O -
67.8 O +
± O +
6.2e O -
splenol O +
D O -
0.25 O -
91.6 O +
± O +
6.8 O -
95.2 O +
± O +
4.2 O -
5 O -
63.0 O +
± O +
6.3e O -
59.5 O +
± O +
5.0e O -
0.5 O -
84.7 O +
± O +
5.3a O -
90.5 O +
± O +
7.4 O -
2.5 O -
80.8 O +
± O +
4.4b O -
81.1 O +
± O +
5.8b O -
Rhoifolin O -
0.25 O -
82.4 O +
± O +
5.7e O -
85.3±6.1b O -
5 O -
75.6 O +
± O +
5.4b O -
73.7±5.1b O -
0.5 O +
2.5 O +
5 O -
79.5 O +
± O +
5.1e O +
71.9±6.1e O +
71.3 O +
± O +
4.4e O -
81.5 O +
± O +
5.ge O +
73.9 O +
± O +
6.3e O +
n.l O +
± O +
6.ge O -
Hyperin O -
0.25 O +
0.5 O +
2.5 O -
86.9 O +
± O +
6.8a O +
63.7 O +
± O +
5.6b O +
50.2 O +
± O +
3.9b O -
94.6 O +
± O +
6.1 O +
71.7 O +
± O +
6.9b O +
59.5 O +
± O +
4.4b O -
Scutellarein O -
0.25 O -
95.9 O +
± O +
7.4 O -
93.7 O +
± O +
4.2 O -
5 O -
41.9 O +
± O +
4.0b O -
48.2 O +
± O +
4.3b O -
0.5 O +
2.5 O +
5 O -
90.6 O +
± O +
6.9 O +
80.6 O +
± O +
7.7b O +
63.5 O +
± O +
6.4e O -
91.4 O +
± O +
5.9 O +
84.3 O +
± O +
7.4b O +
60.0 O +
± O +
5.3e O -
Isoquercitrin O -
0.25 O +
0.5 O +
2.5 O -
47.6 O +
± O +
4.9b O +
46.5 O +
± O +
3.5b O +
42.2 O +
± O +
4.7b O -
57.1 O +
±4.9b O +
52.0 O +
± O +
4.9b O +
50.5 O +
± O +
5.8b O -
Sorbarin O -
0.25 O -
60.0 O +
± O +
4.4e O -
63.3 O +
± O +
6.7e O -
5 O -
39.1 O +
± O +
3.5b O -
45.6 O +
± O +
4.0b O -
0.5 O +
2.5 O +
5 O -
54.9 O +
± O +
5.5 O -
< O +
50.1 O +
± O +
7.8e O +
47.0 O +
± O +
5.2e O -
59.2 O +
± O +
5.5 O -
< O +
53.3 O +
± O +
5.8e O +
42.6 O +
± O +
4.8e O -
Isorhamnetin O -
0.25 O +
0.5 O +
2.5 O -
63.0 O +
± O +
5.4b O +
51.4 O +
± O +
4.8b O +
32.2 O +
± O +
3.7b O -
74.2 O +
± O +
6.8b O +
62.8 O +
± O +
6.2b O +
40.1 O +
± O +
3.6b O -
5 O -
21.6 O +
± O +
3.7b O -
32.3 O +
± O +
3.0b O -
Exp O +
Toxic O +
Pathol51 O +
( O -
1999 O -
) O -

I O -
Discussion O -
Compound O -
Con O -
- O -
LDH O +
leakage O +
MDAleakage O +
centration O +
rate O +
rate O +
( O -
Ilg O -
/ O -
ml O -
) O +
( O -
% O -
) O +
( O -
% O -
) O -
Kaempferitrin O -
0.25 O +
78.5 O +
± O +
5.4b O +
82.2 O +
± O +
6.1b O -
0.5 O -
75.9 O +
± O +
3.2b O +
78.9 O +
± O +
6.8b O -
2.5 O -
74.3 O +
± O +
5.6b O +
71.6 O +
± O +
4.3b O -
5 O -
72.3 O +
± O +
6.1b O +
68.4 O +
± O +
4.9b O -
Kaempferol O -
0.25 O +
99.3 O +
± O +
5.4 O +
92.6 O +
± O +
7.1 O -
0.5 O -
79.4 O +
± O +
6.5b O +
84.1 O +
± O +
4.7a O -
2.5 O -
73.3 O +
± O +
5.7b O +
78.9 O +
± O +
4.9b O -
5 O -
66.9 O +
±4.4b O +
62.1 O +
±4.6b O -
Kaempferol- O +
0.25 O +
77.2 O +
± O +
5.7b O +
81.5 O +
± O +
6.9b O -
7-glucoside O -
0.5 O +
72.2 O +
±4.1b O +
77.9±5.1b O -
2.5 O -
61.4 O +
± O +
5.7b O +
66.3 O +
± O +
6.2b O -
5 O -
53.7 O +
± O +
4.8b O +
60.2 O +
± O +
4.2b O -
Oxyayanin O +
A O -
0.25 O +
86.0 O +
± O +
5.78 O +
83.7 O +
± O +
4.3a O -
0.5 O -
83.3 O +
± O +
4.8b O +
77.3±7.1b O -
2.5 O -
73.5 O +
± O +
4.7b O +
68.9 O +
± O +
6.9b O -
5 O -
67.6 O +
± O +
4.8b O +
60.2 O +
± O +
5.2b O -
Quercetin O -
0.25 O +
77.2 O +
± O +
5.8b O +
81.5 O +
± O +
5.6b O -
0.5 O -
76.5 O +
±4.8b O +
79.7 O +
± O +
6.2b O -
2.5 O -
75.6 O +
± O +
3.3b O +
72.1 O +
± O +
5.0b O -
5 O -
73.5 O +
± O +
4.3b O +
69.5 O +
±4.6b O -
Quercimeritrin O +
0.25 O +
107.0 O +
± O +
7.1 O +
99.9 O +
±4.0 O -
0.5 O -
98.7 O +
±4.7 O +
94.7 O +
± O +
6.9 O -
2.5 O -
86.3 O +
± O +
5.7a O +
89.4 O +
± O +
6.1 O -
5 O -
74.6 O +
± O +
4.4b O +
77.4 O +
±4.9b O -
Quercitrin O -
0.25 O +
79.1 O +
± O +
3.1b O +
81.4 O +
± O +
5.5b O -
0.5 O -
75.5 O +
± O +
4.2b O +
82.1 O +
± O +
4.8b O -
2.5 O -
70.5 O +
±4.9b O +
74.2 O +
± O +
4.2b O -
5 O -
63.5 O +
± O +
4.5b O +
58.1 O +
± O +
5.3b O -
Rhamnetin O -
0.25 O +
70.4 O +
± O +
4.1 O +
b O +
80.2 O +
± O +
5.2b O -
0.5 O -
66.3 O +
± O +
4.2b O +
71.0 O +
± O +
5.6b O -
2.5 O -
51.3±3.1b O +
56.5 O +
± O +
4.8b O -
5 O -
32.3 O +
± O +
3.2b O +
38.4 O +
± O +
2.5b O -
Rutin O -
0.25 O +
73.2 O +
± O +
5.1b O +
79.5 O +
± O +
5.5b O -
0.5 O -
68.4 O +
± O +
4.4b O +
73.4 O +
± O +
6.2b O -
2.5 O -
62.5 O +
± O +
4.2b O +
69.7 O +
± O +
5.5b O -
5 O -
57.2 O +
± O +
4.6b O +
62.6 O +
± O +
6.8b O -
Tetramethyl-0.25 O +
99.6 O +
± O +
7.4 O +
97.1 O +
± O +
4.9 O +
quercitin O +
0.5 O +
94.1 O +
± O +
7.7 O +
96.3 O +
± O +
5.3 O -
2.5 O -
94.3±7.1 O +
91.5 O +
± O +
7.7 O -
5 O -
93.4 O +
± O +
6.8 O +
90.5 O +
± O +
8.0 O -
Control O -
100.0± O +
5.8 O +
100.0 O +
± O +
7.1 O -
Significantly O +
different O +
from O +
the O +
control O +
value O -
: O +
ap O +
< O -
0.01 O -
, O +
bp O +
< O -
0.001 O -
. O -

lease O -
. O -

The O +
generation O +
of O +
MDA O +
was O +
found O +
to O +
be O +
markedly O +
decreased O +
in O +
the O +
groups O +
with O +
decreased O +
LDH O +
efflux O -
, O +
which O +
indicated O +
a O +
possible O +
cause O +
and O +
effect O +
relationship O +
between O +
them O -
. O -

Exp O +
Toxic O +
Patho151 O +
( O -
1999 O -
) O +
1 O -
One O +
ofremarkable O +
features O +
ofcellular O +
injury O +
is O +
leakage O +
ofLDH O -
, O +
a O +
soluble O +
cytosolic O +
enzyme O -
, O +
from O +
inside O +
the O +
cells O -
. O -

This O +
leakage O +
is O +
due O +
largely O +
to O +
increased O +
membrane O +
per­meability O -
, O +
which O +
is O +
probably O +
modified O +
by O +
certain O +
factors O +
such O +
as O +
antineoplastic O +
drugs O -
, O +
radiation O -
, O +
and O +
attack O +
by O +
oxy­gen O +
free O +
radical O +
species O -
. O -

It O +
is O +
therefore O +
a O +
useful O +
indicator O +
of O +
membrane O +
integrity O +
and O +
provides O +
a O +
convenient O +
ap­proach O +
for O +
cytotoxicity O +
evaluation O -
. O -

On O +
the O +
other O +
hand O -
, O +
ANDREOLI O +
and O +
McATEER O +
( O -
1990 O -
) O -
, O +
RaVIN O +
et O +
al. O +
( O -
1990 O -
) O +
and O +
WALKER O +
and O +
SHAH O +
( O -
1991 O -
) O +
have O +
reported O +
that O +
renal O +
tubule O +
cells O +
have O +
the O +
potential O +
to O +
produce O +
reactive O +
oxygen O +
meta­bolites O +
in O +
response O +
to O +
various O +
stimuli O -
, O +
and O +
are O +
the O +
major O +
site O +
affected O +
in O +
renal O +
failure O -
. O -

In O +
this O +
study O -
, O +
therefore O -
, O +
we O +
used O +
LDH O +
leakage O +
from O +
LLC B-Species -
- I-Species -
PK1 L-Species +
cells O +
as O +
an O +
indicator O +
to O +
evaluate O +
cellular O +
membrane O +
permeability O +
upon O +
incubation O +
with O +
41 O +
flavonoids O +
under O +
normal O +
culture O +
conditions O -
. O -

Flavonoids O +
are O +
phenolic O +
compounds O +
widely O +
distributed O +
in O +
plants U-Species -
, O +
with O +
thousands O +
of O +
individual O +
substances O +
known O -
, O +
and O +
the O +
list O +
is O +
constantly O +
expanding O -
. O -

These O +
important O +
bio­active O +
compounds O +
have O +
been O +
shown O +
to O +
have O +
many O +
medi­cal O +
uses O -
, O +
such O +
as O +
diuresis O -
, O +
laxation O -
, O +
and O +
antispasmodic O -
, O +
antihypertensive O +
and O +
anti O -
- O -
inflammatory O +
actions O +
( O -
MITsv­HASHI O +
et O +
al. O +
1989 O -
) O -
. O -

Most O +
of O +
the O +
compounds O +
we O +
tested O +
in O +
this O +
study O +
also O +
showed O +
significant O +
effectiveness O +
in O +
in­hibiting O +
the O +
efflux O +
of O +
LDH O +
from O +
LLC B-Species -
- I-Species -
PK1 L-Species +
cells O -
, O +
and O +
thus O +
appeared O +
to O +
change O +
the O +
permeability O +
of O +
the O +
cellular O +
mem­brane O -
. O -

To O +
determine O +
the O +
nature O +
of O +
their O +
effect O -
, O +
we O +
measur­ed O +
the O +
MDA O +
content O +
in O +
the O +
culture O +
medium O -
, O +
and O +
found O +
that O +
under O +
routine O +
culture O +
conditions O +
such O +
as O +
5 O +
% O +
CO2 O -
, O +
95 O +
% O +
air O +
and O +
37 O +
DC O +
for O +
48 O +
h O -
, O +
a O +
certain O +
amount O +
of O +
MDA O +
was O +
generated O -
. O -

This O +
suggests O +
that O +
LDH O +
efflux O +
from O +
the O +
cells O +
may O +
be O +
due O +
largely O +
to O +
lipid O +
peroxidation O +
of O +
the O +
mem­brane O -
, O +
although O +
this O +
may O +
occur O +
slowly O +
under O +
normal O +
con­ditions O -
. O -

Interestingly O -
, O +
when O +
the O +
cells O +
were O +
cocultured O +
with O +
different O +
types O +
of O +
flavones O +
and O +
flavonols O -
, O +
the O +
levels O +
of O +
both O +
LDH O +
and O +
MDA O +
in O +
the O +
medium O +
showed O +
an O +
obvious O +
de­crease O -
, O +
indicating O +
a O +
possible O +
link O +
between O +
them O -
. O -

Itis O +
there­fore O +
reasonable O +
to O +
infer O +
that O +
an O +
antiperoxidation O +
or O +
free O +
ra­dical O +
scavenging O +
mechanism O +
is O +
involved O +
in O +
this O +
process O +
because O +
of O +
the O +
reducing O +
property O +
of O +
these O +
compounds O -
. O -

Much O +
attention O +
has O +
been O +
drawn O +
to O +
the O +
antioxidative O +
ac­tivity O +
of O +
flavonoids O +
due O +
to O +
their O +
structure O -
, O +
especially O +
since O +
a O +
superoxidation O +
injury O +
hypothesis O +
has O +
been O +
put O +
forward O +
to O +
explain O +
the O +
etiology O +
and O +
pathology O +
of O +
some O +
diseases O -
, O +
and O +
this O +
has O +
prompted O +
extensive O +
studies O +
on O +
their O +
antioxi­dative O +
and O +
lipid O +
peroxidation O -
- O -
inhibiting O +
potential O -
. O -

Our O +
data O +
revealed O +
that O +
the O +
action O +
of O +
flavonoids O +
was O +
closely O +
re­lated O +
to O +
their O +
chemical O +
structures O -
. O -

First O -
, O +
as O +
shown O +
in O +
table O +
3 O -
, O +
those O +
that O +
demonstrated O +
marked O +
inhibition O +
of O +
LDH O +
efflux O +
activity O +
possess O +
more O +
phenolic O +
hydroxyl O +
groups O +
linked O +
to O +
the O +
backbone O -
. O -

For O +
example O -
, O +
having O +
an O +
extra O +
OH O +
at O +
the O +
3-position O +
made O +
10 O +
of O +
the O +
17 O +
flavonols O +
tested O +
here O +
exhibit O +
a O +
significant O +
effect O +
at O +
a O +
concentration O +
as O +
low O +
as O -
0.25 O +
Ilg O +
in O +
the O +
medium O -
; O +
in O +
contrast O -
, O +
among O +
flavone O +
types O -
, O +
only O +
7 O +
out O +
of O +
24 O +
( O -
about O +
29 O +
% O -
) O +
showed O +
such O +
activity O +
at O +
the O +
same O +
concentration O -
, O +
suggesting O +
that O +
hydroxyl O +
groups O +
are O +
of O +
prime O +
importance O +
for O +
their O +
effects O -
. O -

Compound O -
5 O -
6 O -
7 O -
8 O -
3 O -
2 O -
' O -
3 O -
' O -
4 O -
' O -
5 O -
' O -
6 O -
' O -
* O -
Aeaeetin O -
OH O -

OH O -
OMe O -
Apigenin O -
OH O -
OH O -
OH O -
Apiin O -
OH O -

OH O -
* O -
OH O -
apioglue O -
Baicalein O -
OH O -
OH O -
OH O -
Baiealin O -
OH O -
OH O -

OH O -

* O -
glueur O -
Chrysoeriol O -
OH O -
OH O -
OMe O -
OH O -
Cirsilineol O -
OH O -
OMe O -
OMe O -
OMe O -
OH O -
Cirsiliol O -
OH O -
OMe O -
OMe O -
OH O -

OH O -
Cirsimarin O -
OH O -
OMe O -
OMe O -
OH O -

* O -
glue O -
Cirsimaritin O -
OH O -
OMe O -
OMe O -
OH O -
Cosmosiin O -
OH O -

OH O -

* O -
OH O -
glue O -
Genkwanin O -
OH O -
OMe O -
OH O -
6-Hydroxyluteolin O -
OH O -
OH O -
OH O -
OH O -
OH O -
Linarin O -
OH O -

OH O -
* O -
OMe O -
rham O -
, O +
glue O -
Luteolin O -
OH O -
OH O -
OH O -
OH O -
Luteolin O +
7-glueoside O -
OH O -

OH O -

* O -
OH O -
OH O -
glue O -
Peetolinarigenin O -
OH O -
OMe O -
OMe O -
OMe O -
rham O -
, O +
glue O -
Peetolinarin O -
OH O -
OMe O -
OH O -
* O -
OMe O -
rham O -
, O +
glue O -
Plantaginin O -

OH O -
OH O -

OH O -

* O -
OH O -
glue O -
Rhoifolin O -
OH O -

OH O -
* O -
OH O -
rham O -
, O +
glue O -
Scutellarein O -
OR O -
OH O -
OH O -
OH O -
Sorbarin O -

OH O -
OH O -

OH O -
* O -
OH O -
rham O -
Tectochrysin O -
OH O -
OMe O -

Toringin O -
OH O -

* O -
OH O -
gluc O -
Afzelin O -
OH O -
OH O -

OH O -
* O -
OH O -
rham O -
Chrysosplenol O +
B O -
OH O -
OMe O -
OMe O -
OMe O -
OH O -
OH O -
Chrysosplenol O +
C O -
OH O -
OH O -
OMe O -
OMe O -
OMe O -
OH O -
Chrysosplenol O +
D O -
OH O -
OMe O -
OMe O -
OMe O -
OH O -
OH O -
Hyperin O -

OH O -
OH O -

OH O -

* O -
OH O -
OH O -
galac O -
Isoquercitrin O -
OH O -
OR O -
OH O -

* O -
OH O -
OH O -
gluc O -
Isorhamnetin O -
OR O -
OH O -
OH O -
OMe O -
OH O -
Kaempferitrin O -
OH O -

OH O -

* O -
OH O -
* O -
OH O -
rham O -
Kaempferol O -
OH O -
OH O -
OH O -
OH O -
Kaempferol-7 O +
-glucoside O -
OH O -

OR O -
* O -
OH O -
OH O -
gluc O -
Oxyayanin O +
A O -
OH O -
OMe O -
OMe O -
OH O -
OMe O -
OH O -
Quercetin O -
OH O -
OH O -
OH O -
OH O -
OH O -
Quercimeritrin O -
OH O -
OR O -
* O -
OH O -
OH O -
OH O -
gluc O -
Quercitrin O -
OH O -
OH O -

OH O -
* O -
OH O -
OH O -
rham O -
Rhamnetin O -
OH O -
OMe O -
OH O -
OH O -
OH O -
Rutin O -

OH O -
OH O -

OH O -
* O -
OH O -
OH O -
rham O -
, O +
gluc O -
Tetramethylquercitin O -
OMe O -
OMe O -
OH O -
OMe O -
OMe O -
Exp O +
Toxic O +
Pathol51 O +
( O -
1999 O -
) O +
1 O -
On O +
the O +
other O +
hand O -
, O +
different O +
capabilities O +
of O +
cell O +
mem­brane O +
protection O +
were O +
observed O +
in O +
compounds O +
ofthe O +
same O +
type O -
, O +
due O +
mainly O +
to O +
the O +
hydroxyl O +
group O +
position O +
on O +
the O +
fla­vonoid O +
backbone O -
. O -

Most O +
flavone O -
- O -
type O +
compounds O +
gener­ally O +
possessing O +
6-or O +
3'-OH O +
in O +
their O +
structure O +
demonstrat­ed O +
marked O +
LDH O +
leakage O +
inhibition O +
and O +
antioxidation O +
activity O -
. O -

For O +
example O -
, O +
baicalin O -
, O +
plantaginin O +
and O +
sorbarin O +
belonged O +
to O +
the O +
former O -
, O +
while O +
luteolin O +
and O +
luteolin O +
7-glu­coside O +
were O +
ofthe O +
latter O +
type O -
; O +
6-hydroxyluteolin O +
had O +
both O -
. O -

However O -
, O +
there O +
were O +
some O +
exceptions O -
. O -

Although O +
lacking O +
6-and O +
3'-OH O -
, O +
cirsimaritin O +
and O +
rhoifolin O +
still O +
showed O +
membrane O +
protection O +
and O +
banding O +
MDA O +
production O -
; O +
in O +
contrast O -
, O +
baicalein O -
, O +
cirsiliol O +
and O +
scutellarein O +
showed O +
a O +
weak O +
effect O -
, O +
even O +
though O +
they O +
possess O +
either O +
6 O -
- O -
0H O +
or O +
3'­OH O -
. O -

The O +
reason O +
for O +
this O +
remains O +
unclear O -
. O -

In O +
addition O -
, O +
it O +
has O +
been O +
observed O +
that O +
linked O +
sugar O +
might O +
contribute O +
to O +
membrane O +
protection O -
. O -

Among O +
the O +
most O +
effective O +
com­pounds O +
in O +
this O +
study O +
-baicalin O -
, O +
cirsimaritin O -
, O +
6-hydroxy­luteolin O -
, O +
luteolin O -
, O +
plantaginin O -
, O +
rhoifolin O +
and O +
sorbarin O +
­four O +
possess O +
glucuronic O +
acid O -
, O +
glucose O +
or O +
rhamnose O -
. O -

This O +
implies O +
that O +
sugar O +
may O +
account O +
for O +
the O +
varying O +
radical O +
scavenger O +
activity O +
through O +
changing O +
the O +
electron O +
distri­bution O +
and O +
participating O +
in O +
electron O +
delocalization O +
on O +
the O +
structural O +
backbone O -
, O +
or O +
through O +
some O +
other O +
unknown O +
mechanisms O -
. O -

Similarly O -
, O +
flavonol O -
- O -
type O +
compounds O -
, O +
having O +
an O +
addi­tional O +
-OH O +
at O +
C-3 O -
, O +
performed O +
more O +
effectively O +
than O +
the O +
previous O +
type O -
. O -

Chemically O -
, O +
their O +
actions O +
were O +
probably O +
dependent O +
on O +
C-7 O -
, O +
3 O -
' O +
or O +
4 O -
' O -
, O +
as O +
well O +
as O +
3 O -
- O -
0H O -
, O +
such O +
as O +
af­zelin O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
isorhamnetin O -
, O +
kaempferitrin O -
, O +
kaempferol-7-glucoside O -
, O +
quercetin O -
, O +
quercitrin O -
, O +
rhamnetin O +
and O +
rutin O -
. O -

Sugar O +
linked O +
at O +
C-3 O +
would O +
also O +
affect O +
antioxi­dation O +
capability O -
. O -

For O +
example O -
, O +
a O +
lack O +
of O +
3'-OH O -
, O +
but O +
pos­session O +
of O +
rhamnoses O +
at O +
C-3 O +
and O +
7 O -
, O +
made O +
kaempferitrin O +
act O +
powerfully O +
in O +
both O +
membrane O +
protection O +
and O +
anti­peroxidation O -
, O +
similarly O +
to O +
afzelin O -
, O +
hyperin O -
, O +
isoquercitrin O -
, O +
kaempferol-7 O +
-glucoside O -
, O +
quercitrin O +
and O +
rutin O -
. O -

In O +
terms O +
of O +
results O -
, O +
we O +
attempted O +
to O +
draw O +
a O +
general O +
con­cept O +
about O +
the O +
structural O +
principles O +
necessary O +
for O +
optimal O +
cellular O +
membrane O +
protection O +
and O +
antioxidative O +
capacity O -
. O -

It O +
is O +
assumed O +
that O +
the O +
bioactivity O +
of O +
both O +
types O +
of O +
com­pounds O +
is O +
decided O +
mainly O +
by O +
the O +
following O +
three O +
impor­tant O +
structural O +
groups O -
: O +
( O -
a O -
) O +
the O +
o O -
- O -
dihydroxy O +
( O -
catechol O -
) O +
structure O +
in O +
the O +
B O +
ring O -
, O +
which O +
is O +
the O +
obvious O +
radical O +
target O +
site O +
for O +
all O +
flavonoids O +
with O +
a O +
saturated O +
2,3-bond O +
( O -
flavan­3-ols O -
, O +
flavanones O -
) O -
; O +
( O -
b O -
) O +
the O +
2,3-double O +
bond O +
in O +
conjugation O +
with O +
a O +
4-oxo O +
function O -
, O +
which O +
are O +
responsible O +
for O +
electron O +
delocalization O +
from O +
the O +
B O +
ring O -
; O +
and O +
( O -
c O -
) O +
the O +
additional O +
pre­sence O +
of O +
both O +
3-and O +
5-hydroxyl O +
groups O +
for O +
maximal O +
radical O -
- O -
scavenging O +
potential O +
and O +
strongest O +
radical O +
absorp­tion O -
; O +
in O +
fact O -
, O +
the O +
3-and O +
5-hydroxyl O +
groups O +
are O +
equivalent O +
owing O +
to O +
their O +
hydrogen O +
bonds O +
with O +
the O +
keto O +
group O -
, O +
from O +
a O +
kinetic O +
standpoint O +
( O -
SLABBERT O +
1977 O -
) O -
. O -

These O +
sites O +
can O +
be O +
considered O +
as O +
the O +
active O +
centers O +
on O +
the O +
compounds O -
, O +
or O +
as O +
a O +
prerequisite O +
factor O +
for O +
the O +
scavenging O +
of O +
oxygen O +
free O +
radicals O -
. O -

Here O -
, O +
we O +
should O +
note O +
that O +
from O +
tables O +
1 O +
and O +
2 O -
, O +
the O +
po­tentials O +
of O +
the O +
two O +
types O +
of O +
compounds O +
are O +
not O +
absolutely O -
Exp O +
Toxic O +
Pathol51 O +
( O -
1999 O -
) O +
1 O -
affected O +
by O +
whether O +
they O +
are O +
flavonoids O +
or O +
aglycones O -
. O -

It O +
is O +
thought O +
that O +
the O +
configuration O +
of O +
functional O +
groups O +
may O +
also O +
playa O +
crucial O +
role O +
in O +
determining O +
their O +
bioactivity O -
. O +

The O +
FM4 O -
- O -
64 O -
, O +
a O +
member O +
of O +
the O +
family O +
of O +
fluorescent O +
dyes O -
, O +
has O +
been O +
applied O +
to O +
the O +
cerebellar O +
cortex O +
to O +
evaluate O +
its O +
properties O +
as O +
an O +
intracellular O +
stain O +
and O +
intracortical O +
tracer O -
. O -

Slabs O +
of O +
hamster U-Species +
cerebellum O -
, O +
1 O -
- O -
2 O +
mm O +
thick O -
, O +
were O +
incubated O +
in O +
10 O -
, O +
30 O -
, O +
and O +
100 O +
microns O +
solutions O +
of O +
FM4 O -
- O -
64 O +
in O +
sodium O +
phosphate O +
buffer O +
and O +
observed O +
in O +
a O +
slow O +
scan O +
confocal O +
laser O +
scanning O +
microscope O -
. O -

Mossy O +
and O +
climbing O +
fibers O +
were O +
traced O +
in O +
the O +
cerebellar O +
white O +
and O +
gray O +
substances O -
. O -

They O +
exhibited O +
a O -
high O +
fluorescence O +
signal O +
at O +
the O +
level O +
of O +
the O +
myelin O +
sheath O -
. O -

Mossy O +
fibers O +
were O +
identified O +
in O +
the O +
granular O +
layer O +
by O +
their O +
typical O +
rosette O +
formation O +
and O +
dichotomous O +
bifurcation O +
pattern O -
. O -

Climbing O +
fiber O +
bundles O +
were O +
observed O +
crossing O +
the O +
granular O +
layer O +
and O +
giving O +
collateral O +
branches O +
around O +
Golgi O +
cell O +
bodies O -
. O -

They O -
ascend O +
to O +
the O +
Purkinje O +
cell O +
layer O +
on O +
their O +
way O +
to O +
the O +
molecular O +
layer O -
. O -

Cerebellar O +
macroneurons O +
( O -
Golgi O +
and O +
Purkinje O +
cells O -
) O +
and O +
microneurons O +
( O -
granule O -
, O +
basket O -
, O +
and O +
stellate O +
cells O -
) O +
showed O +
optimal O +
intracellular O +
staining O +
of O +
cell O +
soma O -
, O +
axonal O -
, O +
and O +
dendritic O +
processes O -
. O -

The O +
z O -
- O -
series O +
of O +
stacks O +
of O +
optodigital O +
sections O +
allowed O +
us O +
to O +
explore O +
in O +
depth O +
the O +
cytoarchitectonic O +
arrangement O -
, O +
nerve O +
and O +
glial O +
cell O +
morphology O -
, O +
and O +
the O +
topographic O +
relationship O +
with O +
the O +
afferent O +
fibers O -
. O +

AIMS O -
: O +
Cysteamine O -
, O +
the O +
only O +
drug O +
available O +
for O +
the O +
treatment O +
of O +
cystinosis O +
in O +
paediatric O +
patients U-Species -
, O +
is O +
available O +
as O +
the O +
hydrochloride O -
, O +
the O +
bitartrate O +
and O +
as O +
sodium O +
phosphocysteamine O +
salts O -
. O -

It O +
has O +
been O +
suggested O +
that O +
cysteamine O +
bitartrate O -
and O +
phosphocysteamine O +
are O +
better O +
tolerated O +
and O +
may O +
have O +
a O +
better O +
bioavailability O -
than O +
cysteamine O +
hydrochloride O -
. O -

This O +
has O -
, O +
however O -
, O +
never O +
been O +
demonstrated O -
. O -

METHODS O -
: O +
We O +
compared O +
the O +
pharmacokinetics O +
and O +
tolerance O +
of O +
these O +
three O +
formulations O +
of O +
cysteamine O +
in O +
18 O +
healthy O +
adult B-Species +
male I-Species +
volunteers L-Species +
in O +
a O +
double O -
- O -
blind O -
, O +
latin O -
- O -
square O -
, O +
three O -
- O -
period O -
, O +
single O +
oral O +
dose O +
cross O -
- O -
over O +
relative O +
bioavailability O -
study O -
. O -

RESULTS O -
: O +
No O +
statistical O +
difference O +
was O +
found O +
between O +
relative O +
bioavailabilities O -
, O +
AUC O +
( O -
0 O -
, O +
infinity O -
) O +
( O -
geometric O +
mean O +
and O +
s.d O -
. O -

in O +
micromol O +
l O -
( O -
-1 O -
) O +
h O -
: O +
169+ O -
/ O -
-51 O -
, O +
158+ O -
/ O -
-46 O -
, O +
173+ O -
/ O -
-49 O +
with O +
cysteamine O +
hydrochloride O -
, O +
phosphocysteamine O -
and O +
cysteamine O +
bitartrate O +
respectively O -
) O -
, O +
Cmax O +
( O -
geometric O +
mean O +
and O +
s.d O -
. O -

in O +
micromol O +
l O -
( O -
-1 O -
) O -
; O +
66+ O -
/ O -
-25.5 O -
, O +
59+ O -
/ O -
-12 O -
, O +
63+ O -
/ O -
-20 O -
) O +
and O +
tmax O +
( O -
median O +
and O +
range O +
in O +
h O -
: O +
0.88 O +
( O -
0.25 O -
- O -
2 O -
) O -
, O +
1.25 O +
( O -
0.25 O -
- O -
2 O -
) O -
, O +
0.88 O +
( O -
0.25 O -
- O -
2 O -
) O -
) O +
with O +
each O +
of O +
the O +
three O +
forms O +
of O +
cysteamine O +
tested O -
. O -

Bioequivalence O +
statistics O +
( O -
90 O -
% O +
confidence O +
intervals O -
) O +
showed O +
non O +
equivalence O +
of O +
Cmax O +
of O +
cysteamine O +
base O +
as O +
the O +
only O +
non O +
equivalence O +
of O +
pharmacokinetics O +
between O +
the O +
three O +
formulations O -
: O +
90 O -
% O +
CI O +
for O +
Cmax O +
relative O +
ratios O -
to O +
cysteamine O +
hydrochloride O +
were O +
[ O -
75.6 O -
- O -
105.81 O +
for O +
phosphocysteamine O +
and O +
[ O -
74.2 O -
- O -
124.2 O -
] O +
for O +
cysteamine O +
bitartrate O -
. O -

The O +
only O +
significant O +
adverse O +
event O +
was O +
vomiting O +
whose O +
frequency O +
was O +
inversely O +
correlated O +
with O +
body O +
weight O +
( O -
Spearman O -
's O +
r=-0.76 O -
, O +
P<0.001 O -
) O -
. O -

The O +
nature O +
of O +
the O +
salt O +
tested O +
did O +
not O +
influence O +
vomiting O -
. O -

CONCLUSIONS O -
: O +
While O +
none O +
of O +
the O +
three O +
forms O +
of O +
cysteamine O +
tested O +
has O +
a O +
clear O +
advantage O +
over O +
the O +
others O +
in O +
terms O +
of O +
pharmacokinetics O +
and O +
tolerance O +
profile O -
, O +
this O +
should O +
now O +
however O +
be O +
addressed O +
in O +
patients U-Species +
treated O +
for O +
cystinosis O +
during O +
repeat O +
administrations O -
. O +

Both O +
alpha- O +
and O +
beta O -
- O -
D O -
- O -
glucose O +
pentaacetate O +
( O -
1.7 O +
mM O +
each O -
) O +
augmented O -
, O +
to O +
almost O +
the O +
same O +
extent O -
, O +
insulin O +
release O +
caused O +
by O +
succinic O +
acid O +
dimethyl O +
ester O +
( O -
10.0 O +
mM O -
) O +
in O +
rat U-Species +
pancreatic O +
islets O -
. O -

The O +
secretory O +
response O +
to O +
these O +
hexose O +
esters O +
largely O +
exceeded O +
that O +
evoked O +
by O +
unesterified O +
D O -
- O -
glucose O +
tested O +
at O +
the O +
same O +
concentration O +
( O -
1.7 O +
mM O -
) O -
. O -

The O +
release O +
of O +
insulin O +
provoked O +
by O +
succinic O +
acid O +
dimethyl O +
ester O +
was O +
inhibited O -
, O +
however O -
, O +
by O +
alpha O -
- O -
D O -
- O -
galactose O +
pentaacetate O -
, O +
whilst O +
being O +
unaffected O +
by O +
beta O -
- O -
D O -
- O -
galactose O +
pentaacetate O +
( O -
each O +
also O +
1.7 O +
mM O -
) O -
. O -

It O +
appears O -
, O +
therefore O -
, O +
that O +
the O +
insulinotropic O +
action O +
of O +
hexose O +
esters O +
is O +
not O +
attributable O +
solely O +
to O +
the O +
catabolism O +
of O +
their O +
carbohydrate O +
moiety O -
, O +
but O +
may O +
also O +
involve O +
a O +
receptor O +
system O +
that O +
displays O +
anomeric O +
specificity O +
and O +
can O +
be O +
directly O +
activated O +
or O +
inhibited O +
by O -
the O +
esters O +
themselves O -
. O -

Hence O -
, O +
it O +
is O +
proposed O +
that O +
selected O +
esters O +
of O +
non O -
- O -
nutrient O +
monosaccharides O +
may O +
represent O +
new O +
tools O +
to O +
either O +
stimulate O +
insulin O +
release O +
in O +
diabetes O +
or O +
prevent O +
excessive O +
hormonal O +
secretion O +
in O +
situations O +
of O +
hyperinsulinemia O -
. O +

Bioassay O -
- O -
directed O +
fractionation O +
of O +
the O +
methanolic O +
extract O +
of O +
seeds O +
of O +
Casimiroa B-Species +
edulis L-Species +
led O +
to O +
the O +
isolation O +
of O +
seven O +
constituents O +
with O +
cardiovascular O +
activity O -
, O +
namely O +
the O +
new O +
compound O +
synephrine O +
acetonide O +
and O +
the O +
known O +
compounds O +
N O -
- O -
monomethylhistamine O -
, O +
N O -
, O -
N O -
- O -
dimethylhistamine O -
, O +
proline O -
, O +
N O -
- O -
methylproline O -
, O +
gamma O -
- O -
aminobutyric O +
acid O +
and O +
casimiroedine O -
. O -

In O +
anesthetized O +
rats U-Species -
, O +
both O +
histamine O +
derivatives O +
produced O +
transient O +
hypotension O +
mediated O +
via O +
H1-histaminergic O +
receptors O +
and O +
in O +
the O +
case O +
of O +
N O -
, O -
N O -
- O -
dimethylhistamine O -
, O +
via O +
nitric O +
oxide O +
release O -
. O -

Synephrine O +
acetonide O +
produced O +
transient O +
hypertension O +
and O +
tachycardia O -
, O +
mediated O +
via O +
alpha- O +
and O +
alpha- O +
and O +
beta O -
- O -
adrenergic O +
receptores O -
, O +
respectively O -
. O -

The O +
chromatographic O +
zone O +
containing O +
N O -
- O -
methyproline O -
, O +
proline O +
and O +
gamma O -
- O -
aminobutyric O +
acid O +
elicited O +
marked O +
and O +
prolonged O +
hypotension O -
. O -

Finally O -
, O +
casimiroedine O +
did O +
not O +
modify O +
the O +
blood O +
pressure O +
of O +
anesthetized O +
rats U-Species -
, O +
but O +
lowered O +
it O +
persistently O +
in O +
anesthetized O +
guinea B-Species +
pigs L-Species -
. O -

It O +
was O +
concluded O +
that O +
hypotension O +
produced O +
by O +
C. B-Species +
edulis L-Species +
is O +
due O +
to O +
several O +
active O +
components O -
. O -

The O +
immediate O +
effect O +
can O +
be O +
attributed O +
to O +
the O +
histamine O +
derivatives O +
acting O +
on O +
H1-receptors O -
. O -

More O +
prolonged O +
hypotension O +
would O +
be O +
produced O +
by O +
the O +
mixture O +
of O +
amino O +
acids O +
through O +
an O +
unknown O +
mechanism O -
, O +
as O -
well O +
as O +
by O +
casimiroedine O -
, O +
possibly O +
by O +
activation O +
of O +
H3-receptors O -
. O -

Hypotension O +
is O -
partially O +
offset O +
by O +
synephrine O +
acetonide O +
through O +
adrenergic O +
mechanisms O -
. O +

Fractionation O +
of O +
cube O +
resin O +
from O +
Lonchocarpus B-Species +
utilus L-Species +
and O +
L. B-Species +
urucu L-Species +
roots O +
led O +
to O +
the O +
isolation O +
and O +
identification O +
of O +
11 O +
minor O +
flavonoids O +
and O +
stilbenes O +
containing O -
the O +
gem O -
- O -
dimethylpyran O +
moiety O +
or O +
a O +
dihydrodiol O +
derivative O +
thereof O -
. O -

The O +
eight O +
new O +
compounds O +
were O +
as O +
follows O -
: O +
the O +
isoflavonoid O +
cis-4'',5''-dihydro-4'',5 O -
' O +
' O -
-dihydroxylonchocarpusone O +
( O -
2 O -
) O -
; O +
four O +
( O -
2S O -
) O -
-6- O -
( O -
gamma O -
, O +
gamma O -
- O -
dimethylallyl O -
) O -
-6'',6''-dimethylpyran O -
[ O -
2'',3'':7 O -
, O +
8 O -
] O -
flavanones O +
with O +
substituents O +
of O +
5-hydroxy-3',4'-dimethoxy O +
( O -
3 O -
) O -
, O +
5 O -
, O +
3'-dihydroxy-4'-methoxy O +
( O -
4 O -
) O -
, O +
5,4'-dihydroxy-3'-methoxy O +
( O -
5 O -
) O -
, O +
and O +
3 O -
' O -
, O +
4'-dimethoxy O +
( O -
6 O -
) O -
; O +
and O +
three O +
6'',6''-dimethylpyran O -
[ O -
2'',3'':3 O -
' O -
, O +
4' O -
] O -
stilbenes O +
with O +
4-hydroxy-5'-methoxy O +
( O -
9 O -
) O -
, O +
3,5'-dimethoxy-4-hydroxy O +
( O -
10 O -
) O +
and O +
3,4,5-trimethoxy O +
( O -
11 O -
) O +
substitution O +
patterns O -
. O -

Structure O -
- O -
activity O +
relationships O +
for O +
inhibition O +
of O +
NADH O -
: O -
ubiquinone O +
oxidoreductase O +
activity O +
( O -
bovine U-Species +
heart O +
electron O +
transport O +
particles O -
) O +
and O +
phorbol O +
ester O -
- O -
induced O +
ornithine O +
decarboxylase O +
activity O +
( O -
cultured O +
MCF-7 O +
cells O -
) O +
generally O +
parallel O +
those O -
for O +
cytotoxicity O +
( O -
MCF-7 O +
and O +
Hepa O +
1clc7 O +
cells O -
) O -
. O +

Reinvestigation O +
of O +
fractions O +
derived O +
from O +
large O -
- O -
scale O +
fractionation O +
of O +
Maytenus B-Species +
buchananii L-Species +
led O +
to O +
the O +
isolation O +
of O +
two O +
new O +
maytansinoids O -
. O -

The O +
structures O +
of O +
these O +
principles O +
were O +
determined O +
using O +
electrospray O +
MS O -
, O +
1H O +
NMR O -
, O +
13C O +
NMR O -
, O +
and O +
2D O +
NMR O +
techniques O -
. O -

One O +
principle O +
was O +
found O +
to O +
be O +
2'-N O -
- O -
demethylmaytanbutine O +
( O -
2 O -
) O -
, O +
while O +
the O +
other O +
was O +
found O +
to O +
be O +
maytanbicyclinol O +
( O -
3 O -
) O -
, O +
the O +
first O +
maytansinoid O +
with O +
two O +
macrocyclic O +
rings O +
to O +
be O +
isolated O +
from O +
a O +
Maytenus U-Species +
species O -
. O +

Previous O +
studies O +
have O +
indicated O +
that O +
part O +
of O +
the O +
binding O +
of O +
[ O -
3H O -
] O +
[ O -
1- O -
[ O -
2- O -
( O -
diphenylmethoxy O -
) O -
ethyl O -
] O -
-4- O -
( O -
3-phenylpropyl O -
) O +
piperazine O +
dihydrochloride O -
] O +
( O -
[ O -
3H O -
] O -
GBR O +
12935 O -
) O +
to O +
human U-Species +
platelets O +
is O +
to O +
a O +
piperazine O +
acceptor O +
site O -
, O +
which O +
might O -
be O +
associated O +
with O +
cytochrome O +
P-450IID6 O +
( O -
CYP4502D6 O -
, O +
debrisoquine-4-hydroxylase O -
) O -
. O -

Due O +
to O +
mutant O +
CYP4502D6 O +
alleles O -
, O +
5 O -
- O -
10 O -
% O +
of O +
Caucasians U-Species +
are O +
poor O +
metabolizers O +
of O +
CYP4502D6 O +
substrates O +
such O +
as O +
debrisoquine O +
and O +
dextromethorphan O -
. O -

In O +
the O +
present O +
study O -
, O +
possible O +
differences O +
in O +
binding O +
characteristics O +
of O +
[ O -
3H O -
] O -
GBR O +
12935 O +
in O +
platelets O +
from O +
CYP4502D6 O +
poor O +
and O +
extensive O +
metabolizers O +
were O +
investigated O -
. O -

The O +
most O +
prominent O +
finding O +
was O +
a O +
gender O +
difference O -
, O +
with O +
males U-Species +
having O +
significantly O +
higher O +
Kd O +
values O +
than O +
females U-Species -
. O -

There O +
were O +
no O +
differences O +
in O +
Bmax O -
. O -

After O +
correction O +
for O +
gender O -
, O +
there O +
was O +
a O +
tendency O +
towards O +
higher O +
Kd O +
values O +
in O +
poor O +
metabolizers O +
than O +
in O +
extensive O +
metabolizers O -
, O +
although O +
the O +
difference O +
was O +
not O +
statistically O +
significant O -
. O -

Whether O +
this O +
finding O +
corresponds O +
to O +
reduced O +
CYP4502D6 O -
activity O +
is O +
a O +
matter O +
of O +
further O +
investigation O -
. O +

Rhus B-Species +
javanica L-Species -
, O +
a O +
medicinal O +
herb O -
, O +
has O +
been O +
shown O +
to O +
exhibit O +
oral O +
therapeutic O +
anti O -
- O -
herpes O +
simplex O +
virus O +
( O -
HSV O -
) O +
activity O +
in O +
mice U-Species -
. O -

We O +
purified O +
two O +
major O +
anti O -
- O -
HSV O -
compounds O -
, O +
moronic O +
acid O +
and O +
betulonic O +
acid O -
, O +
from O +
the O +
herbal O +
extract O +
by O +
extraction O +
with O +
ethyl O +
acetate O +
at O +
pH O +
10 O +
followed O +
by O +
chromatographic O +
separations O +
and O +
examined O -
their O +
anti O -
- O -
HSV O +
activity O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

Moronic O +
acid O +
was O +
quantitatively O +
a O +
major O +
anti O -
- O -
HSV O +
compound O +
in O +
the O +
ethyl O +
acetate O -
- O -
soluble O +
fraction O -
. O -

The O +
effective O +
concentrations O +
for O +
50 O -
% O +
plaque O +
reduction O +
of O +
moronic O +
acid O +
and O +
betulonic O +
acid O +
for O +
wild O -
- O -
type O +
HSV O +
type O +
1 O +
( O -
HSV-1 O -
) O +
were O +
3.9 O +
and O +
2.6 O +
microgram O -
/ O -
ml O -
, O +
respectively O -
. O -

The O +
therapeutic O +
index O +
of O +
moronic O +
acid O +
( O -
10.3 O -
- O -
16.3 O -
) O +
was O +
larger O +
than O +
that O +
of O +
betulonic O +
acid O +
( O -
6.2 O -
) O -
. O -

Susceptibility O +
of O +
acyclovir O -
- O -
phosphonoacetic O +
acid O -
- O -
resistant O +
HSV-1 O -
, O +
thymidine O +
kinase O -
- O -
deficient O +
HSV-1 O -
, O +
and O +
wild O -
- O -
type O +
HSV O +
type O +
2 O +
to O +
moronic O +
acid O +
was O +
similar O +
to O +
that O +
of O +
the O +
wild O -
- O -
type O +
HSV-1 O -
. O -

When O +
this O +
compound O +
was O +
administered O +
orally O +
to O +
mice U-Species +
infected O +
cutaneously O +
with O +
HSV-1 O +
three O +
times O +
daily O -
, O +
it O +
significantly O +
retarded O +
the O +
development O +
of O +
skin O +
lesions O +
and/or O +
prolonged O +
the O +
mean O -
survival O +
times O +
of O +
infected O +
mice U-Species +
without O +
toxicity O +
compared O +
with O +
the O +
control O -
. O -

Moronic O +
acid O +
suppressed O +
virus O +
yields O +
in O +
the O +
brain O +
more O +
efficiently O +
than O +
those O +
in O -
the O +
skin O -
. O -

This O +
was O +
consistent O +
with O +
the O +
prolongation O +
of O +
mean O +
survival O +
times O -
. O -

Thus O -
, O +
moronic O +
acid O +
was O +
purified O +
as O +
a O +
major O +
anti O -
- O -
HSV O +
compound O +
from O +
the O +
herbal O +
extract O +
of O +
Rhus B-Species +
javanica L-Species -
. O -

Mode O +
of O +
the O +
anti O -
- O -
HSV O +
activity O +
was O +
different O +
from O +
that O +
of O +
ACV O -
. O -

Moronic O +
acid O +
showed O +
oral O +
therapeutic O +
efficacy O +
in O +
HSV O -
- O -
infected O +
mice U-Species +
and O +
possessed O -
novel O +
anti O -
- O -
HSV O +
activity O +
that O +
was O +
consistent O +
with O +
that O +
of O +
the O +
extract O -
. O +

IC202A O +
( O -
1 O -
) O +
was O +
isolated O +
from O +
the O +
culture O +
filtrate O +
of O +
Streptoalloteichus B-Species +
sp. I-Species +
1454 I-Species -
- I-Species -
19 L-Species -
. O -

The O +
structure O +
of O +
1 O +
was O +
determined O +
by O +
spectral O +
analysis O +
including O +
a O +
variety O +
of O +
two O -
- O -
dimentional O +
NMR O +
and O +
FAB O -
- O -
MS O +
experiments O -
. O -

IC202A O +
is O +
a O +
ferrioxamine O -
- O -
related O +
compound O +
containing O +
a O +
butylidene O +
N O -
- O -
oxide O +
function O -
. O +

It O +
is O +
suspected O +
that O +
not O +
only O +
fibrinogen O +
concentration O +
but O +
also O +
the O +
quality O +
of O +
fibrin O +
networks O +
may O +
contribute O +
to O +
cardiovascular O +
risk O -
. O -

Evidence O +
is O +
accumulating O +
that O +
a O +
" O -
prudent O -
" O +
diet O +
may O +
protect O +
against O +
diseases O +
associated O +
with O +
raised O +
clotting O +
factors O -
. O -

The O +
effect O +
of O +
diet O +
on O +
fibrinogen O +
is O -
, O +
however O -
, O +
still O +
controversial O -
. O -

In O +
a O +
previous O +
study O +
performed O +
in O +
our O +
laboratory O -
, O +
it O +
was O +
shown O +
that O +
dietary O +
pectin O +
influences O +
fibrin O +
network O +
architecture O +
in O +
hypercholesterolaemic O +
men U-Species +
without O +
causing O +
any O +
changes O +
in O +
fibrinogen O +
concentration O -
. O -

To O +
elucidate O +
the O +
possible O +
mechanisms O -
, O +
it O +
was O +
necessary O +
to O +
study O +
the O +
possibility O +
that O +
pectin O +
may O +
itself O +
have O +
indirect O +
effects O +
on O +
fibrin O +
network O +
architecture O -
. O -

Pectin O +
is O +
fermented O -
in O +
the O +
gastrointestinal O +
tract O +
to O +
acetate O -
, O +
propionate O -
, O +
and O +
butyrate O -
. O -

In O +
humans U-Species -
, O +
only O +
acetate O +
reaches O +
the O +
circulation O +
beyond O +
the O +
liver O -
. O -

This O +
investigation O +
primarily O +
examined O +
the O +
possibility O +
that O +
pectin O +
may O -
, O +
through O +
acetate O -
, O +
influence O +
fibrin O +
network O +
architecture O +
in O +
vivo O -
. O -

The O +
effects O +
of O +
pectin O +
and O +
acetate O +
supplementation O +
in O +
hypercholesterolaemic O +
subjects O +
were O +
compared O -
. O -

Furthermore O -
, O +
this O +
study O +
also O +
aimed O +
at O +
describing O +
the O +
possible O +
in O +
vitro O +
effects O +
of O +
acetate O +
on O +
fibrin O +
network O +
architecture O -
. O -

Two O +
groups O +
of O +
10 O +
male O +
hyperlipidaemic O +
volunteers O +
each O +
received O +
a O +
pectin O +
( O -
15 O +
g O -
/ O -
day O -
) O +
or O +
acetate O +
( O -
6.8 O +
g O -
/ O -
day O -
) O +
supplement O +
for O +
4 O +
weeks O -
. O -

Acetate O +
supplementation O +
did O +
not O +
cause O +
a O +
significant O +
change O +
in O +
plasma O +
fibrinogen O +
levels O -
. O -

As O +
in O +
the O +
pectin O +
group O -
, O +
significant O +
differences O +
were O +
found O +
in O +
the O +
characteristics O +
of O +
fibrin O +
networks O +
developed O +
in O +
plasma O +
after O +
4 O +
weeks O +
of O +
acetate O +
supplementation O -
. O -

Fibrin O +
networks O +
were O +
more O +
permeable O +
( O -
from O +
213+ O -
/ O -
-76 O +
to O +
307+ O -
/ O -
-81 O +
x O +
10 O -
( O -
11 O -
) O +
cm2 O -
) O -
, O +
had O +
lower O +
tensile O +
strength O +
( O -
from O +
23+ O -
/ O -
-3 O +
to O +
32+ O -
/ O -
-9 O -
% O +
compaction O -
) O -
, O +
and O -
were O +
more O +
lyseable O +
( O -
from O +
252+ O -
/ O -
-11 O +
to O +
130+ O -
/ O -
-15 O +
minutes O -
) O -
. O -

These O +
results O +
strongly O +
suggest O +
that O +
the O +
effect O +
of O +
pectin O +
on O +
network O +
architecture O +
could O +
partially O +
be O +
mediated O +
by O +
acetate O -
. O -

Progressive O +
amounts O +
of O +
acetate O +
were O +
used O +
in O +
vitro O +
to O +
investigate O +
the O +
possibility O +
that O +
acetate O +
may O +
be O +
directly O +
responsible O +
for O +
changes O -
that O +
occurred O +
in O +
fibrin O +
network O +
architecture O +
in O +
the O +
plasma O +
medium O -
. O -

Results O +
indicated O +
that O +
acetate O +
influenced O +
fibrin O +
network O +
architecture O +
directly O -
. O -

From O +
the O -
results O -
, O +
it O +
seems O +
highly O +
possible O +
that O +
acetate O +
may O +
be O +
responsible O +
in O +
part O +
for O +
the O +
beneficial O +
effects O +
of O +
pectin O +
supplementation O +
in O +
vivo O -
. O -

It O +
is O +
evident O +
that O +
pectin O +
or O +
acetate O +
supplementation O +
can O +
be O +
useful O +
during O +
the O +
treatment O +
or O +
prevention O +
of O +
some O +
clinical O +
manifestations O -
, O +
especially O +
those O +
associated O +
with O +
raised O +
total O +
cholesterol O +
and O +
possibly O +
also O +
plasma O +
fibrinogen O -
. O +

INTRODUCTION O -
Chemical O +
substitution O +
of O +
ribosomal O +
proteins O +
by O +
dansyl O +
chloride O +
[ O -
I O -
] O +
and O -
iodoacetamide O +
[ O -
2 O -
] O +
has O +
yielded O +
first O +
results O +
concerning O +
the O +
localisation O +
of O -
proteins O +
in O +
rat U-Species +
liver O +
ribosomes O -
. O -

The O +
accessibility O +
of O +
proteins O +
can O +
be O +
further O -
Abbreviations O -
: O +
MAI O -
, O +
methyl O +
acetimidate O -
; O +
NPA O -
, O +
p O -
- O -
nitrophenyl O +
acetate O -
; O +
TEA O -
, O +
triethanol- O -
amine O -
. O -

310 O -
studied O +
by O +
substitution O +
of O +
their O +
amino O +
groups O +
by O +
NPA O +
or O +
by O +
MAI O +
as O +
will O +
be O -
demonstrated O +
in O +
this O +
paper O -
. O -

These O +
new O +
results O +
agree O +
in O +
general O +
with O +
those O +
ob- O -
tained O +
earlier O -
, O +
but O +
give O +
more O +
precise O +
data O +
as O +
to O +
the O +
localisation O +
of O +
proteins O +
in O -
the O +
ribosomal O +
subunit O -
. O -

MATERIAL O +
AND O +
METHODS O -
[ O -
~4C O -
] O -
MAI O +
was O +
prepared O +
immediately O +
before O +
use O +
according O +
to O +
Hunter O +
and O -
Ludwig O +
[ O -
3 O -
] O +
using O +
[ O -
~4C O -
] O +
acetonitrile O +
( O -
1.85 O +
mCi O -
/ O -
mmole O -
; O +
Institute O +
for O +
Isotopes O -
, O -
Budapest O -
) O -
. O -

[ O -
3H O -
] O -
NPA O -
, O +
synthesized O +
as O +
described O +
elsewhere O +
[ O -
4 O -
] O +
was O +
a O +
gift O +
from O -
Dr. O +
B. O +
Mehlis O -
. O -

Preparation O +
of O +
ribosomal O +
subunits O -
Polysomes O +
isolated O +
from O +
rat U-Species +
livers O +
according O +
to O +
Noll O +
et O +
al. O +
[ O -
5 O -
] O +
were O +
in- O -
cubated O +
in O +
500 O +
mM O +
KCI O -
, O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
1.5 O +
mM O +
MgC12 O -
, O +
5 O +
mM O -
fi O -
- O -
mercaptoethanol O +
and O +
0.1 O +
mM O +
puromycin O +
for O +
30 O +
min O +
at O +
0 O +
and O +
then O +
for O -
10 O +
min O +
at O +
37 O +
[ O -
6 O -
] O -
. O -

The O +
ribosomal O +
subunits O +
were O +
separated O +
according O +
to O -
Eikenberry O +
et O +
al. O +
[ O -
7 O -
] O +
and O +
pelleted O +
after O +
dilution O +
of O +
the O +
gradient O +
fractions O -
with O +
2 O +
vol O -
. O +
of O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
30 O +
mM O +
MgC12 O -
. O -

Thereafter O +
the O +
sub- O -
units O +
were O +
dialysed O +
against O +
a O +
buffer O +
of O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O +
50 O +
mM O -
KC1 O +
and O +
5 O +
mM O +
MgC12 O +
( O -
buffer O +
A O -
) O +
and O +
clarified O +
by O +
centrifugation O +
for O +
10 O +
min O +
at O -
10 O +
000 O +
g. O -
Isolation O +
of O +
proteins O +
of O +
ribosomal O +
subunits O -
To O +
the O +
solution O +
of O +
ribosomal O +
subunits O +
( O -
5 O +
mg O -
/ O -
ml O -
) O +
1 O -
/ O -
3 O +
vol O -
. O +
of O +
1 O +
N O +
HC1 O +
was O -
added O +
[ O -
8 O -
] O -
, O +
the O +
RNA O +
was O +
pelleted O +
by O +
centrifugation O +
for O +
10 O +
min O +
at O +
10 O +
000 O +
g O -
and O +
the O +
supernatant O +
dialysed O +
against O +
50 O +
mM O +
KC1 O -
, O +
50 O +
mM O +
TEA O +
HC1 O -
, O +
pH O +
7.8 O -
, O -
1 O +
mM O +
MgC12 O -
, O +
4 O +
M O +
urea O +
( O -
buffer O +
B O -
) O -
. O -

Substitution O +
of O +
proteins O +
or O +
ribosomal O +
subunits O +
by O +
[ O -
~4C O -
] O -
methyl O +
acetimidate O -
To O +
3 O +
mg O +
of O +
total O +
ribosomal B-Species +
protein L-Species +
mixture O +
in O +
1 O +
ml O +
buffer O +
B O +
or O +
to O +
5 O +
mg O -
ribosomal O +
subunits O +
in O +
1 O +
ml O +
buffer O +
A O -
, O +
3 O +
pmoles O +
MAI O +
were O +
added O +
and O +
incu- O -
bated O +
for O +
30 O +
min O +
at O +
37 O -
. O -

Thereafter O +
4 O +
M O +
NH4C1 O +
was O +
added O +
to O +
give O +
a O +
final O -
concentration O +
of O +
50 O +
mM. O +
The O +
proteins O +
were O +
isolated O +
as O +
described O +
and O +
dial- O -
ysed O +
against O +
6 O +
M O +
urea O -
, O +
5 O +
mM O +
methylamine O +
acetate O -
, O +
pH O +
5.0 O -
, O +
5 O +
mM O +
fi O -
- O -
mercap- O -
toethanol O -
. O -

A O +
label O +
of O +
4.9 O +
10s O +
dpm O +
with O +
an O +
average O +
error O +
of O +
+ O +
10 O -
% O +
was O +
counted O +
per O -
mg O +
protein O +
of O +
the O +
small O +
ribosomal O +
subunit O +
after O +
dialysis O +
against O +
0.1 O +
M O +
sodium O -
acetate O +
( O -
pH O +
5.5 O -
) O +
and O +
solubilization O +
in O +
a O +
hyamine O +
hydroxide O +
containing O +
scin- O -
tillation O +
mixture O +
as O +
described O +
below O -
. O -

Protein O +
was O +
estimated O +
by O +
the O +
Lowry O -
method O +
using O +
ribosomal O +
protein O +
as O +
a O +
standard O -
. O -

The O +
labelling O +
value O +
corre- O -
sponds O +
to O +
2.4 O +
acetimidoyl O +
groups O +
per O +
20 O +
000 O +
daltons O +
which O +
is O +
the O +
mean O -
molecular O +
weight O +
of O +
the O +
proteins O +
of O +
the O +
small O +
ribosomal O +
subunit O +
( O -
see O +
also O +
ref O -
. O -

5 O -
) O -
. O -

For O +
the O +
proteins O +
of O +
the O +
large O +
ribosomal O +
subunit O +
3.9 O +
acetimidoyl O +
groups O -
per O +
20 O +
000 O +
daltons O +
were O +
calculated O -
. O -

Substitution O +
of O +
proteins O +
or O +
ribosomal O +
subunits O +
by O +
[ O -
3 O +
H O -
] O -
p O -
- O -
nitrophenyl O +
acetate O -
The O +
substitution O +
was O +
performed O +
using O +
1.5 O +
pmoles O +
NPA O +
( O -
10 O +
mCi O -
/ O -
mmole O -
) O -
311 O -
per O +
1.0 O +
ml O +
by O +
incubation O +
for O +
60 O +
min O +
at O +
37 O +
in O +
analogy O +
to O +
the O +
reaction O +
de- O -
scribed O +
before O -
. O -

The O +
excess O +
of O +
reagent O +
was O +
destroyed O +
by O +
incubation O +
with O +
0.25 O -
N O +
HC1 O +
for O +
1 O +
h O +
at O +
0 O -
. O -

TABLE O +
I O -
SUBSTITUTION O +
OF O +
PROTEINS O +
ISOLATED O +
FROM O +
SMALL O +
RIBOSOME O +
SUBUNITS O -
OF O +
RAT U-Species +
LIVER O +
AND O +
OF O +
SMALL O +
RIBOSOMAL O +
SUBUNITS O +
BY O +
[ O -
14C O -
] O -
METHYL O -
ACETIMIDATE O +
OR O +
BY O +
[ O +
3H O +
] O -
ao O -
- O -
NITROPHENYL O +
ACETATE O -
Average O +
values O +
of O +
5 O -
- O -
-10 O +
independent O +
experiments O +
are O +
given O -
; O +
the O +
average O +
errors O +
of O +
the O -
mean O +
values O +
not O +
specified O +
for O +
the O +
individual O +
proteins O +
did O +
not O +
exceed O +
10 O -
% O -
. O -

Small O -
subunit O -
protein O -
Label O +
of O +
proteins O +
obtained O +
by O -
[ O +
14C O -
] O -
methyl O +
acetimidate O -
Label O +
of O +
proteins O +
obtained O -

by O -
[ O -
3H O +
] O -
p O -
- O -
nitrophenyl O +
acetate O -
1 O -
2 O -
3 O -
4 O -
1 O -
2 O -
3 O -
Protein O -
Par- O -
Ratio O -
Classifi- O -
Protein O -
Par- O -

Ratio O -
mixture O -
ticle O -
of O +
2 O +
: O +
1 O -
cation O -
mixture O -
ticle O -
of O +
6 O +
: O +
5 O -
dpm O -
/ O -
AsT8"10 O -
- O -
3 O +
% O -
dpm O -
/ O -
AsTs O -
" O +
10 O -
- O -
3 O +
% O -
4 O -
Classifi- O -
cation O -
$ O -
1 O -
3.4 O -
4.3 O -
126 O -
23.2 O -
5.4 O -
23 O -
2 O -
4.4 O -

5.4 O -
123 O -
32.5 O -
15.4 O -
47 O -
+ O -
3 O -
n.d O -
. O -

3.8 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

4 O -
7.5 O -
4.2 O -
56 O -
-- O -
19.8 O -
8.3 O -
42 O -
+ O -
5 O -
2.2 O -
6.1 O -
277 O -
+ O -
29.8 O -
7.4 O -
25 O -
6 O -
n.d O -
. O -

5.2 O -
n.d O -
. O -

36.1 O -
23.7 O -
66 O -
+ O -
7 O -
3.2 O -
5.8 O -
181 O -
+ O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

8 O -
4.1 O -
4.2 O -
102 O -
37.1 O -
13.9 O -
37 O -
+ O -
9 O -
6.1 O -
4.8 O -
79 O -
26.2 O -
4.1 O -
16 O -
-- O -
10 O -
5.0 O -
7.1 O -
142 O -
+ O -
33.6 O -
10.7 O -
32 O -
+ O -
11 O -
5.6 O -
3.8 O -
68 O -
-- O -
21.3 O -
6.9 O -
32 O -
+ O -
12 O -
5.4 O -
3.2 O -
59 O -
-- O -
27.4 O -
16.2 O -
59 O -
+ O -
13 O -
3.7 O -
2.9 O -
78 O -
15.6 O -
4.4 O -
28 O -
14 O -
6.1 O -
4.3 O -
70 O -
-- O -
34.1 O -
7.5 O -
22 O -
-- O -
15 O -
6.8 O -
6.8 O -
100 O -

26.7 O -
11.4 O -
43 O -
+ O -
16 O -
3.3 O -
4.4 O -
133 O -
+ O -
30.2 O -
7.1 O -
24 O -
17 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

31.0 O -
7.2 O -
23 O -
18 O -
3.4 O -
4.3 O -
126 O -
22.5 O -
6.8 O -
30 O -
-+ O -
19 O -
3.8 O -
3.4 O -
89 O -
27.3 O -
5.5 O -
20 O -
-- O -
20 O -
5.2 O -
4.2 O -
81 O -
-+ O -
21.1 O -
3.9 O -
18 O -
-- O -
21 O -
3.9 O -
2.7 O -
69 O -
-- O -
17.3 O -
4.2 O -
24 O -
22 O -
4.4 O -
4.2 O -
95 O -
27.3 O -
9.1 O -
33 O -
+ O -
23 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

25.4 O -
5.1 O -
20 O -
-- O -
24 O -
7.9 O -
5.2 O -
66 O -
-- O -
35.3 O -
7.3 O -
21 O -
-- O -
25 O -
7.9 O -
5.2 O -
66 O -
-- O -
33.3 O -
7.3 O -
22 O -
-- O -
26 O -
8.3 O -
9.0 O -
108 O -
24.7 O -
6.9 O -
28 O -
27 O -
4.4 O -
2.0 O -
45 O -
-- O -
15.1 O -
5.9 O -
39 O -
+ O -
28 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

26.3 O -
3.0 O -
11 O -
-- O -
29 O -
4.3 O -
2.0 O -
46 O -
-- O -
10.6 O -
2.9 O -
27 O -
30 O -
n.d O -
. O -

4.7 O -
n.d O -
. O -

12.5 O -
2.7 O -
22 O -
-- O -
31 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

TABLE O +
II O -
SUBSTITUTION O +
OF O +
PROTEINS O +
ISOLATED O +
FROM O +
LARGE O +
RIBOSOMAL O +
SUBUNITS O +
OF O +
RAT U-Species +
LIVER O +
AND O +
OF O +
LARGE O +
RIBO- O -
SOMAL O +
SUBUNITS O +
BY O +
[ O +
14C O -
] O -
METHYL O +
ACETIMIDATE O -
Average O +
values O +
of O +
5 O -
- O -
-10 O +
independent O +
experiments O +
are O +
given O -
; O +
the O +
average O +
errors O +
of O +
the O +
mean O +
values O +
not O +
specified O +
for O +
the O +
individual O +
proteins O -
did O +
not O +
exceed O +
10 O -
% O -
. O -

b.a O -
b~ O -
Large O -
Labelling O +
coefficients O -
Large O -
subunit O -
subunit O -
protein O -
1 O -
2 O -
3 O -
4 O -
protein O -
Protein O -
Particle O -
Ratio O -
Classifi- O -
mixture O -
of O +
2 O +
: O +
1 O -
cation O -
dpm O -
/ O -
AsT8 O +
10 O -
- O -
3 O -
% O -
Labelling O +
coefficients O -
1 O -
2 O -
3 O -
4 O -
Protein O -
Particle O -
Ratio O -
Classifi- O -
mixture O -
of O +
2 O +
: O +
1 O -
cation O -
dpm O -
/ O -
AsTs O +
10 O -
- O -
3 O -
% O -
L O +
1 O -
n.d O -
. O -

5.8 O -
n.d O -
. O -

L O +
21 O -
2 O -
9.3 O -
. O -

1.1 O -
12 O -
-- O -
22 O -
3 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

23 O -
4 O -
11.0 O -
3.0 O -
27 O -
+ O -
24 O -
5 O -
13.0 O -
4.6 O -
35 O -
+ O -
25 O -
6 O -
14.2 O -
5.1 O -
36 O -
+ O -
26 O -
7 O -
13.9 O -
3.0 O -
22 O -
+ O -
27 O -
8 O -
12.4 O -
2.2 O -
18 O -
-- O -
28 O -
9 O -
9.6 O -
1.9 O -
20 O -
-- O -
29 O -
10 O -
9.0 O -
1.8 O -
20 O -
-- O -
30 O -
11 O -
9.0 O -
1.8 O -
20 O -
-- O -
31 O -
12 O -
9.7 O -
n.d O -
. O -

n.d O -
. O -

32 O -
13 O -
6.9 O -
2.5 O -
36 O -
+ O -
33 O -
14 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

34 O -
15 O -
8.1 O -
2.4 O -
30 O -
+ O -
35 O -
16 O -
n.d O -
. O -

3.5 O -
n.d O -
. O -

36 O -
17 O -
6.6 O -
3.0 O -
45 O -
+ O -
37 O -
18 O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

38 O -
19 O -
6.1 O -
1.0 O -
16 O -
-- O -
39 O -
20 O -
5.9 O -
1.4 O -
24 O -
-+ O -
10.1 O -
2.3 O -
23 O -
+ O -
12.3 O -
1.9 O -
15 O -
-- O -
5.9 O -
3.6 O -
61 O -
+ O -
4.8 O -
2.1 O -
44 O -
+ O -
8.3 O -
2.4 O -
29 O -
+ O -
6.2 O -
1.8 O -
29 O -
+ O -
8.2 O -
2.3 O -
28 O -
+ O -
6.6 O -
1.6 O -
24 O -
-+ O -
7.5 O -
2.3 O -
31 O -
+ O -
6.1 O -
1.9 O -
31 O -
+ O -
9.3 O -
1.3 O -
14 O -
-- O -
7.9 O -
1.3 O -
16 O -
-- O -
4.8 O -
1.5 O -
31 O -
+ O -
6.0 O -
2.4 O -
40 O -
+ O -
7.0 O -
2.0 O -
28 O -
+ O -
- O -
7.3 O -
1.7 O -
23 O -
+ O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

5.5 O -
3.1 O -
56 O -
+ O -
n.d O -
. O -

n.d O -
. O -

n.d O -
. O -

313 O -
For O +
the O +
proteins O +
of O +
the O +
small O +
ribosomal O +
subunit O +
1.9 O +
106 O +
dpm O +
per O +
mg O -
protein O +
were O +
measured O +
by O +
the O +
method O +
described O +
above O -
, O +
corresponding O +
to O +
1.7 O -
acetyl O +
groups O +
per O +
20 O +
000 O +
daltons O +
protein O -
. O -

TABLE O +
III O -
TENTATIVE O -
LOCALIZATION O -
OF O -
PROTEINS O -
IN O +
RIBOSOMAL O +
SUBUNITS O +
OF O +
RAT U-Species -
LIVER O +
ESTIMATED O +
BY O +
USING O +
CHEMICAL O +
SUBSTITUTIONS O -
Small O -
Substitution O +
" O -
by O -
Preponderant O -
subunit O -
localization O -
protein O -
Methyl O -
p O -
- O -
Nitrophenyl O -
Iodo- O -
acetimidate O -
acetate O -
acetamide O -
S O +
2 O -
+ O -
+ O -
+ O -
exposed O -
5 O -
+ O -
-+ O -
+ O -
exposed O -
7 O -
+ O -
n.d O -
. O -

+ O -
exposed O -
8 O -
-+ O -
+ O -
+ O -
exposed O -
9 O -
+ O -
-- O -
-- O -
buried O -
10 O -
+ O -
+ O -

-+ O -
exposed O -
13 O -
+ O -
+ O -
+ O -
exposed O -
14 O -
-- O -
-- O -
-- O -
buried O -
19 O -
+ O -
-- O -
-- O -
buried O -
20 O -
+ O -
-- O -
-- O -

buried O -
24 O -
-- O -
-- O -
+ O -
buried O -
25 O -
-- O -
-- O -
-- O -
buried O -
27 O -
-- O -
+ O -
-- O -

buried O -
29 O -
-- O -
+ O -
-- O -
buried O -
30 O -
n.d O -
. O -

-- O -
-- O -
buried O -
Large O -
subunit O -
protein O -
L O +
1 O -
n.d O -
. O -

-- O -
buried O -
7 O -
+ O -
-- O -
buried O -
-- O -
buried O -
8 O -
-- O -
buried O -
10 O -
+ O -
11 O -
15 O -
+ O -
+ O -
exposed O -
17 O -
+ O -
+ O -
exposed O -
-- O -
buried O -
19 O -
20 O -
+ O -
- O -
+ O -
exposed O -
24 O -
+ O -
+ O -
exposed O -
25 O -
+ O -
+ O -
exposed O -
27 O -
+ O -
+ O -
exposed O -
28 O -
+ O -
-- O -
buried O -
29 O -
+ O -
+ O -
exposed O -
-- O -

buried O -
31 O -
-- O -
buried O -
32 O -
33 O -
+ O -
+ O -
exposed O -
34 O -
+ O -
+ O -
exposed O -
35 O -
-+ O -
+ O -
exposed O -
38 O -
+ O -
+ O -
exposed O -
314 O -
Two O -
- O -
dimensional O +
polyacrylamide O +
gel O +
electrophoresis O +
and O +
estimation O +
of O +
the O -
labelling O +
of O +
the O +
proteins O -
Electrophoresis O +
and O +
numbering O +
of O +
the O +
protein O +
spots O +
were O +
performed O +
as O +
de- O -
scribed O +
by O +
Welfle O +
et O +
al. O +
[ O -
9 O -
] O -
. O -

The O +
gel O +
slabs O +
were O +
stained O +
with O +
0.0005 O -
% O +
Coo- O -
massie O +
Brillant O +
Blue O +
G O +
250 O +
in O +
3 O -
% O +
trichloroacetic O +
acid O +
for O +
24 O +
h. O +
Thereafter O +
the O -
gel O +
pieces O +
containing O +
the O +
stained O +
proteins O +
were O +
cut O +
and O +
their O +
staining O +
intensi- O -
ties O +
measured O +
in O +
10 O +
mm O +
glass O +
cuvettes O +
at O +
578 O +
nm O -
. O -

For O +
the O +
estimation O +
of O +
the O -
labelling O +
the O +
gel O +
pieces O +
were O +
squashed O +
using O +
a O +
1 O +
ml O +
syringe O +
with O +
a O +
I O +
mm O -
aperture O +
and O +
incubated O +
for O +
16 O +
h O +
with O +
1 O +
ml O +
of O +
0.5 O +
N O +
hyamine O +
hydroxide O -
( O -
Packard O +
Instruments O -
, O +
Ill. O -
) O +
in O +
toluene O -
. O -

The O +
counting O +
efficiency O +
against O +
an O +
ex- O -
ternal O +
standard O +
was O +
about O +
80 O -
% O +
using O +
a O +
scintillation O +
mixture O +
with O +
0.4 O -
% O +
2,5- O -
diphenyloxazole O -
, O +
0.01 O -
% O +
1,4-bis- O -
( O -
5-phenyloxazol-2-yl O -
) O -
benzene O -
, O +
10 O -
% O +
Triton O +
X- O -
100 O -
, O +
0.3 O -
% O +
acetic O +
acid O +
in O +
toluene O -
. O -

After O +
measuring O +
the O +
label O +
for O +
10 O +
min O +
the O +
disin- O -
tegrations O +
per O +
min O +
( O -
dpm O -
) O +
were O +
correlated O +
for O +
each O +
spot O +
to O +
1.0 O +
A O +
s78 O -
. O -

The O +
average O -
values O +
of O +
5 O -
- O -
-10 O +
independent O +
experiments O +
are O +
given O +
in O +
Tables O +
I O +
and O +
II O -
. O -

The O -
average O +
errors O +
of O +
the O +
mean O +
values O +
not O +
specified O +
for O +
the O +
individual O +
proteins O +
did O -
not O +
exceed O +
10 O -
% O -
. O -

RESULTS O -
MAI O +
reacts O +
exclusively O +
with O +
the O +
amino O +
groups O +
of O +
proteins O +
[ O -
3 O -
] O -
, O +
whereas O -
NPA O +
also O +
substitutes O +
tyrosine O +
and O +
cysteine O +
residues O +
[ O -
10 O -
] O -
. O -

Because O +
of O +
the O -
relatively O +
high O +
lysine O +
content O -
, O +
the O +
low O +
portion O +
of O +
tyrosine O +
and O +
cysteine O +
in O -
ribosomal O +
proteins O +
of O +
rat U-Species +
liver O +
[ O -
11 O -
] O +
and O +
the O +
lower O +
reactivity O +
of O +
tyrosine O +
OH- O -
groups O +
[ O -
12 O -
] O -
, O +
it O +
can O +
be O +
expected O +
that O +
both O +
reagents O +
predominantly O +
react O +
with O -
amino O +
groups O -
. O -

The O +
substitution O +
of O +
ribosomal O +
protein O +
mixtures O +
by O +
both O +
reagents O +
is O +
com- O -
pleted O +
after O +
30 O +
min O +
at O +
37 O +
to O +
more O +
than O +
90 O -
% O -
. O -

The O +
proteins O +
isolated O +
from O -
the O +
small O +
ribosomal O +
subunit O +
incorporate O +
on O +
the O +
average O +
1,7-acetyl O +
and O +
2,4- O -
acetimidoyl O +
groups O -
, O +
respectively O -
, O +
per O +
20 O +
000 O +
dalton O -
, O +
and O +
the O +
proteins O +
of O +
the O -
large O +
subunit O +
bind O +
3,9-acetimidoyl O +
groups O +
per O +
20 O +
000 O +
dalton O -
. O -

The O +
labelling O +
values O +
for O +
the O +
proteins O +
of O +
the O +
small O +
subunit O +
are O +
presented O +
in O -
Table O +
I. O +
The O +
values O +
for O +
labelling O +
of O +
the O +
protein O +
mixture O +
with O +
NPA O +
vary O +
from O -
10 O +
600 O +
to O +
37 O +
100 O +
dpm O +
per O +
1.0 O +
As78 O -
. O -

When O +
using O +
the O +
subunits O -
, O +
values O +
between O -
2700 O +
and O +
23 O +
700 O +
dpm O +
per O +
1.0 O +
AsTa O +
are O +
measured O -
. O -

It O +
is O +
obvious O +
from O +
these O -
results O +
that O +
the O +
reactive O +
groups O +
of O +
the O +
proteins O +
in O +
the O +
subunit O +
structure O +
are O -
only O +
available O +
to O +
about O +
10 O +
to O +
65 O -
% O -
. O -

28 O +
proteins O +
can O +
be O +
classified O +
into O +
3 O +
groups O -
with O +
10 O -
- O -
-22 O -
% O -
, O +
23 O -
- O -
-30 O -
% O +
and O +
31 O -
- O -
-66 O -
% O +
remaining O +
reactivity O -
: O +
Proteins O +
$ O -
9 O -
, O +
14 O -
, O -
19 O -
, O +
20 O -
, O +
23 O -
, O +
24 O -
, O +
25 O -
, O +
28 O +
and O +
30 O +
{ O -
marked O +
by-- O -
) O +
are O +
strongly O +
protected O -
, O +
the O -
reactivity O +
of O +
9 O +
other O +
proteins O +
is O +
diminished O +
moderately O +
( O -
$ O -
1 O -
, O +
5 O -
, O +
13 O -
, O +
16 O -
, O +
17 O -
, O -
18 O -
, O +
21 O -
, O +
26 O +
and O +
29 O +
( O -
marked O +
by O +
+ O -
) O -
, O +
and O +
the O +
proteins O +
$ O -
2 O -
, O +
4 O -
, O +
6 O -
, O +
8 O -
, O +
10 O -
, O +
11 O -
, O +
12 O -
, O -
15 O -
, O +
22 O +
and O +
27 O +
( O -
marked O +
by O +
+ O -
) O +
are O +
exposed O +
to O +
a O +
relatively O +
high O +
extent O -
. O -

The O +
reaction O +
of O +
proteins O +
with O +
MAI O +
in O +
the O +
small O +
ribosomal O +
subunit O +
is O +
on O +
the O -
average O +
only O +
little O +
decreased O +
in O +
comparison O +
to O +
the O +
free O +
proteins O -
. O -

As O +
demon- O -
strated O +
in O +
Table O +
I O -
, O +
the O +
reactivity O +
of O +
proteins O +
$ O -
4 O -
, O +
11 O -
, O +
12 O -
, O +
14 O -
, O +
21 O -
, O +
24 O -
, O +
25 O -
, O +
27 O -
and O +
29 O +
( O -
marked O +
by O +
-- O -
} O +
is O +
inhibited O +
by O +
30 O -
% O +
or O +
more O +
if O +
the O +
subunit O +
is O +
com- O -
315 O -
pared O +
with O +
the O +
protein O +
mixture O -
. O -

The O +
proteins O +
$ O -
5 O -
, O +
7 O -
, O +
10 O +
and O +
16 O +
( O -
marked O -
by O +
+ O +
} O +
are O +
labelled O +
more O +
strongly O +
in O +
the O +
subunit O +
than O +
in O +
the O +
isolated O +
protein O -
mixture O -
, O +
showing O +
values O +
of O +
more O +
than O +
130 O -
% O -
. O -

For O +
11 O +
proteins O +
( O -
S1 O -
, O +
2 O -
, O +
8 O -
, O +
9 O -
, O +
13 O -
, O -
15 O -
, O +
18 O -
, O +
19 O -
, O +
20 O -
, O +
22 O +
and O +
26 O -
; O +
marked O +
by O +
-+ O -
) O -
, O +
the O +
labelling O +
is O +
about O +
the O +
same O +
both O -
in O +
the O +
subunit O +
and O +
in O +
the O +
protein O +
mixture O +
{ O -
70 O -
- O -
-130% O -
} O -
. O -
A O +
stronger O +
inhibition O +
of O +
the O +
reaction O +
of O +
MAI O +
with O +
proteins O +
is O +
observed O +
in O -
the O +
large O +
ribosomal O +
subunit O +
( O -
Table O +
II O -
) O -
. O -

On O +
the O +
average O +
a O +
value O +
of O +
30 O -
% O +
is O +
es- O -
timated O +
in O +
comparison O +
ta O +
the O +
protein O +
mixture O -
. O -

Proteins O +
L2 O -
, O +
8 O -
, O +
9 O -
, O +
10 O -
, O +
11 O -
, O +
19 O -
, O -
22 O -
, O +
31 O +
and O +
32 O +
( O -
marked O +
by O +
-- O -
) O +
in O +
the O +
subunit O +
structure O +
take O +
up O +
only O +
20 O -
% O +
or O -
even O +
less O +
of O +
the O +
label O +
taken O +
up O +
by O +
the O +
isolated O +
protein O +
mixture O -
. O -

When O +
la- O -
belled O +
in O +
the O +
subunit O +
a O +
second O +
group O +
of O +
proteins O +
( O -
L4 O -
, O +
7 O -
, O +
20 O -
, O +
21 O -
, O +
27 O -
, O +
28 O -
, O +
35 O -
and O +
36 O -
; O +
marked O +
by O +
+ O -
) O +
show O +
21 O -
- O -
-28 O -
% O +
and O +
a O +
third O +
group O +
{ O -
L5 O -
, O +
6 O -
, O +
13 O -
, O +
15 O -
, O +
17 O -
; O -
23 O -
, O +
24 O -
, O +
25 O -
, O +
26 O -
, O +
29 O -
, O +
30 O -
, O +
33 O -
, O +
34 O +
and O +
38 O -
; O +
marked O +
by O +
+ O -
) O -
more O +
than O +
29 O -
% O +
of O +
the O -
label O +
of O +
the O +
protein O +
mixture O -
. O -

DISCUSSION O -
Chemical O +
substitutions O +
of O +
ribosomal O +
proteins O +
by O +
iodoacetate O +
and O +
2- O -
methoxy-5-nitrotropone O +
[ O -
13 O -
] O -
, O +
fluorescein O +
isothiocyanate O +
[ O -
14 O -
] O -
, O +
acetanhy- O -
dride O +
[ O -
15 O -
] O -
, O +
iodine O +
[ O -
16,17 O -
] O -
, O +
5,5-dithiobis- O -
( O -
2-nitro O -
- O -
benzoic O +
acid O -
) O +
[ O -
18 O -
] O -
, O +
N- O -
ethyl O -
- O -
maleimide O +
and O +
iodoacetamide O +
[ O -
19 O -
] O -
, O +
aldehydes O +
[ O -
20 O -
] O +
and O +
kethoxal O +
[ O -
21 O -
] O -
have O +
been O +
successfully O +
used O +
to O +
elucidate O +
the O +
topography O +
of O +
proteins O +
in O +
ribo- O -
somal O +
subunits O +
of O +
E. B-Species +
coli L-Species -
. O -

As O +
was O +
demonstrated O +
before O -
, O +
all O +
proteins O +
organized O +
in O +
the O +
ribosomal O +
sub- O -
units O +
of O +
rat U-Species +
liver O +
are O +
accessible O +
to O +
the O +
reaction O +
with O +
MAI O +
and O +
with O +
NPA O -
. O -

The O -
extent O +
of O +
reaction O -
, O +
however O -
, O +
is O +
less O +
than O +
with O +
the O +
isolated O +
protein O +
mixture O -
. O -

Both O +
findings O +
are O +
in O +
good O +
agreement O +
with O +
results O +
obtained O +
with O +
iodoacet- O -
amide O +
[ O -
2 O -
] O -
, O +
2-methoxy-5-nitrotropone O +
[ O -
22 O -
] O +
and O +
also O +
with O +
conclusions O +
drawn O -
from O +
iodination O +
experiments O +
[ O -
23 O -
] O -
. O -

When O +
comparing O +
experiments O +
with O +
MAI O +
and O +
NPA O +
it O +
is O +
remarkable O +
that O +
the O -
reactivity O +
to O +
NPA O +
of O +
the O +
proteins O +
organized O +
in O +
the O +
small O +
ribosomal O +
subunit O +
is O -
inhibited O +
more O +
strongly O +
than O +
the O +
reactivity O +
to O +
MAI O +
in O +
comparison O +
to O +
the O +
free O -
protein O +
mixture O -
. O -

This O +
may O +
be O +
due O +
to O +
the O +
less O +
hydrophilic O +
properties O +
of O +
NPA O -
which O +
prevent O +
this O +
reagent O +
from O +
penetrating O +
the O +
ribosomal O +
subunit O +
structure O -
as O +
readily O +
as O +
the O +
more O +
hydrophilic O +
MAI O +
obviously O +
can O -
. O -

The O +
reaction O +
of O +
the O +
proteins O +
in O +
the O +
small O +
ribosomal O +
subunit O +
to O +
MAI O -
, O +
on O +
the O -
whole O -
, O +
occurs O +
more O +
readily O +
than O +
those O +
in O +
the O +
large O +
ribosomal O +
subunit O +
in O +
com- O -
parison O +
to O +
the O +
corresponding O +
free O +
protein O +
mixtures O -
. O -

This O +
finding O +
favours O +
a O -
more O +
dense O +
structure O +
of O +
the O +
large O +
ribosomal O +
subunit O -
. O -

The O +
explanation O +
that O -
more O +
reactive O +
protein O +
groups O +
are O +
localized O +
on O +
the O +
surface O +
of O +
the O +
small O +
ribo- O -
somal O +
subunit O +
in O +
comparison O +
to O +
their O +
total O +
number O +
than O +
in O +
the O +
large O +
ribo- O -
somal O +
subunit O +
is O +
unlikely O -
, O +
because O +
the O +
reaction O +
of O +
small O +
and O +
large O +
subunit O -
proteins O +
with O +
NPA O +
is O +
inhibited O +
to O +
the O +
same O +
extent O +
in O +
the O +
subunit O +
structures O -
. O -

Different O +
proportions O +
of O +
reactive O +
amino O +
groups O +
in O +
small O +
and O +
large O +
ribosomal O -
subunits O +
from O +
E. B-Species +
coli L-Species +
have O +
also O +
been O +
reported O +
by O +
Slobin O +
[ O -
24 O -
] O +
using O +
methyl O -
picolinimidate O -
. O -

316 O -
If O +
the O +
proteins O +
are O +
classified O +
as O +
weakly O +
exposed O +
( O -
-- O -
) O -
, O +
moderately O +
exposed O -
( O -
-+ O -
) O +
and O +
strongly O +
exposed O +
( O -
+ O -
) O +
proteins O -
, O +
it O +
can O +
be O +
demonstrated O +
that O +
the O +
re- O -
sults O +
obtained O +
with O +
different O +
reagents O +
agree O +
for O +
the O +
preponderantly O +
buried O -
proteins O +
$ O -
14 O -
, O +
25 O -
, O +
L8 O -
, O +
10 O -
, O +
11 O -
, O +
19 O -
, O +
31 O +
and O +
32 O +
and O +
for O +
the O +
mainly O +
exposed O +
pro- O -
teins O +
L15 O -
, O +
17 O -
, O +
25 O -
, O +
29 O -
, O +
33 O -
, O +
34 O +
and O +
38 O +
( O -
see O +
Table O +
III O -
) O -
. O -

For O +
the O +
other O +
proteins O -
also O +
listed O +
in O +
Table O +
III O -
, O +
the O +
results O +
obtained O +
with O +
different O +
reagents O +
are O +
not O +
in O -
full O +
agreement O -
. O -

However O -
, O +
the O +
accessibility O +
of O +
proteins O +
in O +
the O +
subunit O +
struc- O -
ture O +
to O +
trypsin O +
[ O -
25 O -
] O +
and O +
their O +
tendency O +
to O +
be O +
split O +
from O +
the O +
subunits O +
by O +
dif- O -
ferent O +
LiC1 O +
concentrations O +
[ O -
26 O -
] O +
argue O +
in O +
favour O +
of O +
a O +
relatively O +
buried O +
locali- O -
zation O +
of O +
the O +
proteins O +
$ O -
9 O -
, O +
19 O -
, O +
20 O -
, O +
24 O -
, O +
27 O -
, O +
29 O -
, O +
30 O -
, O +
L1 O -
, O +
7 O +
and O +
28 O +
and O +
an O +
ex- O -
posed O +
arrangement O +
of O +
the O +
proteins O +
$ O -
2,5 O -
, O +
7 O -
, O +
8 O -
, O +
10 O -
, O +
13 O -
, O +
L20 O -
, O +
24 O -
, O +
27 O +
and O +
35 O -
. O -

Exposed O +
positions O +
were O +
also O +
reported O +
for O +
proteins O +
moving O +
electrophoreti- O -
cally O +
like O +
L17 O -
, O +
24 O +
and O +
29 O +
by O +
Reboud O -
, O +
studying O +
the O +
reaction O +
of O +
large O +
subunits O -
of O +
rat U-Species +
liver O +
ribosomes O +
with O +
2-methoxy-5-nitrotropone O +
and O +
glutaraldehyde O -
[ O +
22 O +
] O -
, O +
respectively O -
. O +

Glutamate O +
contributes O +
to O +
secondary O +
brain O +
damage O -
, O +
resulting O +
in O +
cell O +
swelling O +
and O +
brain O +
edema O -
. O -

Under O +
in O +
vitro O +
conditions O -
, O +
increased O +
extracellular O +
levels O +
of O +
the O +
amino O +
acid O +
taurine O +
reflect O +
glutamate O -
- O -
induced O +
osmotic O +
cell O +
swelling O -
. O -

In O +
vivo O -
, O +
increases O +
in O +
cerebrospinal O +
fluid O +
( O -
CSF O -
) O +
taurine O +
could O -
, O +
therefore O -
, O +
unmask O +
glutamate O -
- O -
mediated O +
cytotoxic O +
edema O +
formation O +
and O +
possibly O +
differentiate O +
it O +
from O +
vasogenic O +
edema O -
. O -

To O +
test O +
this O +
hypothesis O -
, O +
ventricular O +
CSF O +
glutamate O +
and O +
taurine O +
levels O +
were O +
measured O +
in O +
28 O +
severely O +
brain O -
- O -
injured O +
patients U-Species +
on O +
days O +
1 O -
, O +
5 O -
, O +
and O +
14 O +
after O +
trauma O -
. O -

Posttraumatic O +
changes O +
in O +
CSF O +
amino O +
acids O +
were O +
investigated O +
in O +
regard O +
to O +
extent O +
of O +
tissue O +
damage O +
and O +
alterations O +
in O +
brain O +
edema O +
as O +
estimated O +
by O -
computerized O +
tomography O -
. O -

On O +
day O +
1 O -
, O +
CSF O +
glutamate O +
and O +
taurine O +
levels O +
were O +
significantly O +
increased O +
in O +
patients O +
with O +
subdural O +
or O +
epidural O +
hematomas O +
( O -
8+ O -
/ O -
-0.8 O -
/ O -
71+ O -
/ O -
-12 O +
microM O -
) O -
, O +
contusions O +
( O -
21+ O -
/ O -
-4.1 O -
/ O -
122+ O -
/ O -
-18 O +
microM O -
) O -
, O +
and O +
generalized O -
brain O +
edema O +
( O -
13+ O -
/ O -
-3.2 O -
/ O -
80+ O -
/ O -
-15 O +
microM O -
) O +
compared O +
to O +
lumbar O +
control O +
CSF O +
( O -
1.3+ O -
/ O -
-0.1 O -
/ O -
12+ O -
/ O -
-1 O +
microM O -
; O +
p O +
< O +
0.001 O -
) O -
. O -

CSF O +
amino O +
acids O -
, O +
however O -
, O +
did O +
not O +
reflect O +
edema O +
formation O +
and O +
resolution O +
as O +
estimated O +
by O +
computerized O +
tomography O -
. O -

CSF O +
taurine O +
correlated O +
positively O +
with O +
glutamate O -
, O +
eventually O +
depicting O +
glutamate O -
- O -
induced O +
cell O +
swelling O -
. O -

However O -
, O +
parallel O +
neuronal O +
release O +
of O +
taurine O +
with O +
its O +
inhibitory O +
function O +
can O -
not O +
be O +
excluded O -
. O -

Thus O -
, O +
the O +
sensitivity O +
of O +
taurine O +
in O +
unmasking O +
cytotoxic O +
edema O +
formation O +
is O +
weakened O +
by O +
the O +
inability O +
in O +
defining O +
its O +
origin O +
and O +
function O +
under O +
the O +
conditions O +
chosen O +
in O +
the O +
present O +
study O -
. O -

Overall O -
, O +
persisting O +
pathologic O +
ventricular O +
CSF O +
glutamate O +
and O +
taurine O +
levels O +
are O +
highly O +
suggestive O +
of O +
ongoing O +
glial O +
and O +
neuronal O +
impairment O +
in O +
humans U-Species +
following O +
severe O +
traumatic O +
brain O +
injury O -
. O +

Dopamine O +
is O +
a O +
biogenic O +
amine O +
synthesized O +
in O +
the O +
hypothalamus O -
, O +
in O +
the O +
arcuate O +
nucleus O -
, O +
the O +
caudad O -
, O +
and O +
various O +
areas O +
of O +
the O +
central O +
and O +
peripheral O +
nervous O +
system O -
. O -

It O +
has O +
been O +
widely O +
established O +
that O +
dopamine O +
and O +
its O +
agonists O +
play O +
an O +
important O +
role O +
in O +
cardiovascular O -
, O +
renal O -
, O +
hormonal O -
, O +
and O +
central O +
nervous O +
system O +
regulation O +
through O +
stimulation O +
of O +
alpha O +
and O +
beta O +
adrenergic O +
and O +
dopaminergic O +
receptors O -
. O -

There O +
are O +
several O +
agonists O +
of O +
dopamine-2 O +
( O -
DA O +
2 O +
) O +
dopaminergic O +
receptors O -
, O +
such O +
as O +
bromocriptine O -
, O +
pergolide O -
, O +
lisuride O -
, O +
quinpirole O -
, O +
and O +
carmoxirole O -
, O +
which O +
inhibit O +
norepinephrine O +
release O +
and O +
produce O +
a O +
decrease O +
in O +
arterial O +
blood O +
pressure O -
; O +
in O +
some O +
cases O -
, O +
bromocriptine O +
and O +
pergolide O +
also O +
reduce O +
heart O +
rate O -
. O -

From O +
a O +
therapeutic O +
point O +
of O +
view O -
, O +
the O +
above O -
- O -
mentioned O +
agonists O +
are O +
used O +
for O +
treating O +
Parkinson O -
's O +
disease O -
, O +
acting O +
over O +
DA O +
2 O +
dopaminergic O +
receptors O +
of O +
the O +
nigrostriatal O +
system O -
. O -

Bromocriptine O +
and O +
the O +
other O +
dopaminergic O +
agonists O +
mentioned O +
act O +
over O +
DA O +
2 O +
receptors O +
of O +
the O +
tuberoinfundibular O +
system O -
, O +
inhibiting O +
prolactin O +
release O +
and O +
decreasing O +
hyperprolactinemia O +
and O +
tumor O +
size O -
. O -

Among O +
DA O +
1 O +
receptor O +
agonists O -
, O +
we O +
can O +
mention O +
fenoldopam O -
, O +
piribedil O -
, O +
ibopamine O -
, O +
SKF O +
3893 O -
, O +
and O +
apomorphine O +
( O -
nonspecific O -
) O -
. O -

Activation O +
of O +
these O +
receptors O +
decreases O +
peripheral O +
resistance O -
, O +
inducing O +
lowering O +
of O +
arterial O +
blood O +
pressure O +
and O +
increases O +
in O +
heart O +
rate O -
, O +
sympathetic O +
tone O -
, O +
and O +
activity O +
of O +
the O +
renin O +
aldosterone O +
system O -
. O -

Among O +
DA O +
2 O -
receptor O +
antagonists O -
, O +
we O +
can O +
mention O +
metoclopramide O -
, O +
domperidone O -
, O +
sulpiride O -
, O +
and O -
haloperidol O -
. O -

From O +
a O +
therapeutic O +
point O +
of O +
view O -
, O +
metoclopramide O +
and O +
domperidone O +
are O +
used O +
in O +
gastric O +
motility O +
disorders O -
, O +
and O +
haloperidol O +
is O +
used O +
in O +
psychotic O +
alterations O -
. O -

Antagonists O +
of O +
DA O +
1 O +
receptors O +
are O +
SCH23390 O +
and O +
clozapine O -
. O -

Clozapine O -
is O +
used O +
for O +
treating O +
schizophrenia O -
. O +

Administered O +
to O +
rats U-Species +
by O +
stomach O +
tubing O +
oxythioquinox O +
( O -
Morestan O -
) O +
toxicity O +
is O +
very O -
strongly O +
increased O +
after O +
solubilisation O +
in O +
olive O +
oil O -
. O -

The O +
oxythioquinox O +
DL50 O -
, O +
in O -
this O +
case O -
, O +
is O +
500 O +
mg O -
/ O -
kg O +
although O +
we O +
can O +
reach O +
2.8 O +
g O -
/ O -
kg O +
in O +
aqueous O +
suspensions O -
. O -

When O +
it O +
is O +
administered O +
( O -
1 O +
g O -
/ O -
kg O -
) O +
in O +
aqueous O +
suspension O -
, O +
the O +
decrease O +
in O +
body O +
weight O +
is O +
the O +
same O +
as O +
these O +
observed O +
with O +
a O +
5 O +
fold O +
lower O +
dose O +
in O +
oil O -
. O -

Conversion O -
rate O +
feed O +
and O +
weight O +
of O +
differents O +
organs O +
decrease O +
when O +
animals O +
are O +
daily O +
submitted O +
to O +
oxythioquinox O +
in O +
oil O -
, O +
during O +
16 O +
days O -
, O +
compared O +
with O +
animals O +
treated O -
with O +
an O +
equivalent O +
dose O +
in O +
aqueous O +
suspension O -
. O -

Potentiation O -
, O +
in O +
oil O +
solutions O -
, O +
of O +
the O +
decrease O +
of O +
oxythioquinox O +
intestinal O +
transit O -
, O +
promoting O +
its O +
absorption O -
, O +
could O +
explain O +
the O +
increase O +
of O +
oxythioquinox O +
toxicity O +
in O +
oil O +
solution O -
. O +

We O +
have O +
previously O +
shown O +
that O +
the O +
methyl O +
ester O +
of O +
hepoxilin O +
A3 O +
causes O +
a O +
receptor O -
- O -
induced O +
rise O +
in O +
intracellular O +
calcium O +
through O +
the O +
release O +
from O +
intracellular O +
stores O +
in O +
suspended O +
human U-Species +
neutrophils O -
. O -

The O +
corresponding O +
free O +
acid O -
was O +
devoid O +
of O +
activity O -
. O -

We O +
now O +
report O +
that O +
the O +
action O +
of O +
the O +
free O +
acid O +
form O +
of O +
hepoxilin O +
A3 O +
is O +
dependent O +
on O +
the O +
type O +
of O +
vehicle O +
used O -
, O +
i.e. O +
it O +
is O +
active O +
in O +
releasing O +
calcium O +
when O +
used O +
in O +
an O +
ethanol O +
vehicle O +
but O +
not O +
in O +
DMSO O -
. O -

The O +
methyl O +
ester O +
is O +
equally O +
active O +
in O +
either O +
vehicle O -
. O -

The O +
pattern O +
of O +
calcium O +
release O +
between O +
the O +
free O +
acid O +
and O +
the O +
methyl O +
ester O +
is O +
qualitatively O +
different O -
. O -

Both O +
compounds O +
show O +
a O +
biphasic O +
pattern O -
, O +
i.e. O +
an O +
initial O +
rapid O +
phase O +
followed O +
by O +
a O +
slow O +
decline O +
in O +
calcium O +
levels O +
but O +
never O +
reaching O +
pre O -
- O -
hepoxilin O +
A3 O +
baseline O +
levels O -
. O -

The O +
methyl O +
ester O +
appears O +
slightly O +
more O +
potent O +
in O +
the O +
initial O +
phase O +
of O +
calcium O +
release O +
than O +
the O +
free O +
acid O +
( O -
methyl O +
= O +
188+ O -
/ O -
-14 O +
S.D. O -
, O +
free O +
acid O +
= O +
135+ O -
/ O -
-11 O +
S.D. O +
nM O -
, O +
P O +
< O +
0.0005 O -
) O -
. O -

Both O +
compounds O +
appear O +
to O +
reach O +
the O +
same O +
calcium O +
levels O +
at O +
the O +
plateau O +
of O +
the O +
second O +
prolonged O +
phase O +
( O -
methyl O +
= O +
88+ O -
/ O -
-8 O +
S.D. O -
, O +
free O +
acid O +
= O +
107+ O -
/ O -
-15 O +
S.D. O +
nM O -
, O +
not O +
significant O -
) O -
. O -

Lanthanum O +
chloride O +
( O -
an O +
inhibitor O +
of O +
calcium O +
influx O -
) O +
interfered O +
with O +
the O +
second O +
phase O +
of O +
the O +
curve O +
causing O +
calcium O +
levels O +
to O +
return O +
to O +
normal O +
pre O -
- O -
hepoxilin O +
levels O +
for O +
both O +
compounds O -
. O -

Addition O +
of O +
lanthanum O +
chloride O +
prior O +
to O -
the O +
hepoxilin O +
addition O +
or O +
carrying O +
out O +
the O +
experiments O +
in O +
calcium O -
- O -
free O +
medium O -
, O +
eliminated O +
the O +
second O +
phase O +
completely O -
, O +
with O +
the O +
calcium O +
peak O +
returning O +
rapidly O +
to O +
normal O +
baseline O +
levels O -
, O +
suggesting O +
that O +
the O +
second O +
phase O +
is O +
due O +
to O +
calcium O +
influx O -
. O -

Again O +
the O +
methyl O +
ester O +
is O +
more O +
active O +
than O +
the O +
free O +
acid O +
( O -
methyl O -
, O +
189+ O -
/ O -
-12 O -
; O +
free O +
acid O -
, O +
145+ O -
/ O -
-6 O +
S.D. O +
nM O -
, O +
P<0.005 O -
) O -
. O -

Additional O +
experiments O +
with O +
tritium O -
- O -
labelled O +
methyl O +
ester O +
of O +
hepoxilin O +
A3 O +
demonstrated O +
that O +
the O +
compound O +
is O +
hydrolyzed O +
into O +
the O +
free O +
acid O +
intracellularly O -
. O -

These O +
experiments O +
demonstrate O +
that O +
DMSO O +
interacts O +
with O +
hepoxilin O +
free O +
acid O -
, O +
interfering O +
with O +
its O +
entry O +
into O +
the O +
cell O +
while O +
ethanol O +
does O +
not O -
. O -

Once O +
inside O +
the O +
cell O -
, O +
hepoxilin O +
interacts O +
with O +
its O +
own O +
receptor O +
to O +
release O +
calcium O +
rapidly O +
from O +
stores O -
, O +
but O +
it O +
also O +
causes O +
a O +
more O +
prolonged O +
influx O +
of O +
calcium O +
from O +
the O +
extracellular O +
milieu O -
. O +

We O +
have O +
recently O +
shown O +
that O +
hepoxilin O +
( O -
Hx O -
) O +
A3 O -
interacts O +
with O +
a O +
specific O +
binding O +
protein O +
in O +
the O +
intact O +
human U-Species +
neutrophil O +
resulting O +
in O +
the O +
release O +
of O +
intracellular O +
calcium O +
[ O -
1 O -
] O +
. O -

In O +
those O +
studies O +
we O +
used O +
the O +
methyl O +
( O -
Me O -
) O +
ester O +
form O +
in O +
DMSO O +
because O +
we O +
found O +
that O +
the O +
free O +
acid O +
( O -
FA O -
) O +
was O +
without O +
effect O +
in O +
intact O +
cells O +
both O +
in O +
terms O +
of O +
binding O +
and O +
calcium O +
release O +
[ O -
2 O -
] O +
. O -

We O +
also O +
found O +
that O +
both O +
the O +
FA O +
and O +
Me O +
ester O +
( O -
in O +
DMSO O -
) O +
were O +
active O +
in O +
specific O +
binding O +
to O +
disrupted O +
neutrophil O +
membranes O +
[ O -
3 O -
] O +
. O -

This O +
suggested O +
that O +
the O +
FA O +
did O +
not O +
penetrate O +
into O +
the O +
intact O +
cell O +
and O +
that O +
the O +
binding O +
protein O +
was O +
intracellular O +
and O +
not O +
at O +
the O +
outside O +
surface O +
of O +
the O +
plasma O +
membrane O -
. O -

We O +
now O +
describe O +
new O +
findings O +
which O +
support O +
a O +
binding O -
/ O -
calcium O +
release O +
coupling O +
where O +
both O +
the O +
FA O +
and O +
the O +
Me O +
ester O +
are O +
found O +
active O +
( O -
in O +
ethanol O +
vehicle O -
) O +
in O +
the O +
intact O +
neutrophil O +
and O +
demonstrate O +
a O +
biphasic O +
action O +
of O +
HxA3 O +
, O +
one O +
in O +
releasing O +
calcium O +
from O +
intracellular O +
stores O -
, O +
a O +
second O +
in O +
increasing O +
calcium O +
influx O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Pure O +
8 O -
( O -
R O -
) O -
-HxA3 O -
Me O +
ester O +
was O +
prepared O +
in O +
our O +
laboratory O +
as O +
previously O +
reported O +
[ O -
4 O -
] O +
. O -

The O +
FA O +
was O +
prepared O +
by O +
hydrolysis O +
of O +
the O +
Me O +
ester O +
with O +
1 O +
N O +
KOH O -
/ O -
ethanol O +
followed O +
by O +
mild O +
acidification O -
, O +
extraction O +
and O +
further O +
purification O +
by O +
chromatography O +
[ O -
5 O -
] O +
. O -

[ O -
3 O +
H6 O +
] O -
( O -
8R O -
) O -
-HxA3 O -
Me O +
ester O +
was O +
prepared O +
as O +
previously O +
reported O +
[ O -
5 O -
] O +
. O -

Lanthanum O +
chloride O +
was O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O -

2.2 O +
Preparation O +
of O +
human U-Species +
neutrophils O +
Human U-Species +
neutrophils O +
were O +
prepared O +
essentially O +
as O +
described O +
previously O +
[ O -
3 O -
] O +
. O -

Typically O -
, O +
neutrophils O +
were O +
obtained O +
from O +
40 O +
ml O +
venous O +
blood O +
from O +
volunteers U-Species +
that O +
had O +
not O +
taken O +
any O +
medication O -
. O -

The O +
blood O +
was O +
anti O -
- O -
coagulated O +
with O +
heparin O +
sodium O +
( O -
Organon O +
Tecknica O -
, O +
Durham O -
, O +
NC O -
, O +
USA O -
) O -
. O -

Erythrocytes O +
were O +
removed O +
by O +
4.5 O -
% O +
dextran O +
sedimentation O -
. O -

Neutrophils O +
were O +
collected O +
and O +
pelleted O +
after O +
Ficoll O -
- O -
Paque O +
gradient O +
centrifugation O -
. O -

Further O +
removal O +
of O +
contaminating O +
erythrocytes O +
was O +
carried O +
out O +
by O +
ammonium O +
chloride O +
lysis O -
. O -

After O +
washing O +
twice O +
with O +
centrifugation O -
, O +
neutrophils O +
were O +
resuspended O +
in O +
RPMI O +
1640 O +
medium O +
and O +
were O +
counted O +
in O +
a O +
Coulter O +
counter O +
( O -
Model O +
901 O -
) O -
. O -

The O +
cells O +
were O +
adjusted O +
to O +
a O +
concentration O +
of O +
107 O -
cells O -
/ O -
ml O +
in O +
RPMI O +
1640 O +
medium O -
. O -

2.3 O +
Intracellular O +
calcium O +
release O +
Freshly O +
prepared O +
neutrophil O +
suspensions O +
( O -
1 O +
ml O -
: O +
1 O -
× O -
107 O -
cells O -
) O +
were O +
loaded O +
with O +
3 O +
mM O +
( O -
final O +
concentration O +
3 O +
μM O -
) O +
of O +
the O +
acetoxymethyl O +
ester O +
precursor O +
of O +
the O +
calcium O +
indicator O +
( O -
Indo-1-AM O -
, O +
Calbiochem O -
, O +
La O +
Jolla O -
, O +
CA O -
, O +
USA O -
) O +
during O +
30 O +
min O +
at O +
37 O -
° O -
C O -
. O -

Excess O +
dye O +
was O +
removed O +
by O +
centrifugation O +
and O +
the O +
cells O +
were O +
suspended O +
in O +
fresh O +
RPMI O +
1640 O +
medium O -
. O -

Dye O -
- O -
loaded O +
cells O +
were O +
kept O +
at O +
room O +
temperature O +
on O +
a O +
rotator O -
. O -

Each O +
measurement O +
consisted O +
of O +
the O +
following O -
: O +
2 O -
× O -
106 O -
cells O +
were O +
suspended O +
in O +
1 O +
ml O +
of O +
assay O +
medium O +
of O +
the O +
following O +
composition O +
in O +
mM O -
: O +
NaCl O +
140 O -
, O +
KCl O +
5 O -
, O +
MgCl2 O -
1 O -
, O +
CaCl2 O -
1 O -
, O +
HEPES O +
sodium O -
- O -
free O +
10 O +
and O +
glucose O +
10 O -
, O +
pH O +
7.3 O +
and O +
placed O +
in O +
a O +
plastic O +
cuvette O +
( O -
Diamed O +
Lab O -
. O -
, O +
Toronto O -
, O +
Canada O -
) O +
whose O +
temperature O +
was O +
controlled O +
at O +
37 O -
° O -
C O -
. O -

Calcium O -
- O -
free O +
media O +
contained O +
no O +
calcium O +
and O +
1 O +
mM O +
EGTA O +
was O +
added O -
. O -

The O +
cell O +
suspension O +
was O +
continuously O +
stirred O +
magnetically O -
. O -

Fluorescence O +
was O +
continuously O +
monitored O +
with O +
a O +
Perkin O -
- O -
Elmer O +
fluorescence O +
spectrophotometer O +
( O -
model O +
650 O -
- O -
40 O -
) O +
and O +
recorded O +
on O +
a O +
chart O +
recorder O +
( O -
LKB O +
model O +
2210 O -
) O +
set O +
at O +
1 O +
cm O -
/ O -
min O -
. O -

The O +
excitation O +
wavelength O +
was O +
set O +
at O +
331 O +
nm O -
, O +
the O +
emission O +
wavelength O +
at O +
410 O +
nm O -
, O +
with O +
slits O +
of O +
excitation O +
and O +
emission O +
set O +
at O +
3 O +
and O +
15 O +
nm O +
respectively O -
. O -

At O +
the O +
end O +
of O +
each O +
test O -
, O +
a O +
calibration O +
was O +
carried O +
out O +
to O +
determine O +
the O +
maximal O +
fluorescence O +
by O +
adding O +
ionomycin O +
( O -
Sigma O -
) O +
at O +
1 O +
mM O +
( O -
final O +
concentration O +
1 O +
μM O -
) O +
and O +
minimal O +
fluorescence O +
by O +
adding O +
MnCl2 O -
( O -
final O +
concentration O +
3 O +
mM O -
) O +
as O +
previously O +
described O +
[ O -
6 O -
] O +
. O -

Test O +
compounds O +
were O +
prepared O +
in O +
DMSO O +
( O -
Caledon O -
, O +
Georgetown O -
, O +
OR O -
, O +
USA O -
) O +
or O +
glass O -
- O -
distilled O +
ethanol O +
( O -
100 O -
% O -
) O +
at O +
a O +
stock O +
solution O +
of O +
1 O +
μg O -
/ O -
μl O +
or O +
5 O +
μg O -
/ O -
μl O +
and O +
1 O +
μl O +
of O +
this O +
solution O +
was O +
added O +
to O +
2 O -
× O -
106 O -
cells O +
in O +
1 O +
ml O -
. O -

2.4 O +
Metabolism O +
of O +
[ O -
3 O +
H6 O +
] O -
HxA3 O -
Me O +
ester O +
Freshly O +
prepared O +
human U-Species +
neutrophils O +
were O +
incubated O +
in O +
the O +
above O +
assay O +
medium O +
in O +
a O +
siliconized O +
glass O +
tube O +
to O +
which O +
had O +
been O +
added O +
[ O -
3 O +
H O -
] O -
( O -
8R O -
) O -
-HxA3 O -
Me O +
ester O +
( O -
5 O -
× O -
106 O -
cpm O -
) O +
diluted O +
with O +
3 O +
μg O +
of O +
the O +
unlabelled O +
compound O -
. O -

The O +
mixture O +
was O +
incubated O +
for O +
1 O +
or O +
5 O +
minutes O +
and O +
the O +
incubation O +
mixture O +
was O +
extracted O +
with O +
ethyl O +
acetate O +
without O +
prior O +
acidification O +
to O +
extract O +
the O +
intact O +
Hx O +
structure O +
and O +
its O +
products O +
( O -
which O +
are O +
acid O +
sensitive O -
) O -
. O -

The O +
solvent O +
was O +
evaporated O +
to O +
dryness O +
with O +
N2 O -
gas O +
and O +
the O +
residue O +
was O +
dissolved O +
in O +
a O +
small O +
amount O +
of O +
ethyl O +
acetate O +
and O +
spotted O +
on O +
TLC O +
( O -
silica O +
gel O +
G O -
, O +
ethyl O +
acetate O -
/ O -
acetic O +
acid O +
99.5 O -
/ O -
0.5 O +
( O -
v O -
/ O -
v O -
) O -
) O -
. O -

The O +
plate O +
was O +
developed O +
for O +
60 O +
min O -
, O +
then O +
the O +
solvent O +
was O +
dried O +
with O +
cold O +
air O +
and O +
scanned O +
for O +
radioactivity O +
on O +
a O +
TLC O +
radiochromatogram O +
scanner O +
( O -
Berthold O -
) O -
. O -

Authentic O +
standards O +
of O +
HxA3 O -
Me O +
ester O +
and O +
FA O +
as O +
well O +
as O +
the O +
ω O -
- O -
hydroxy O +
( O -
ωH O -
) O +
metabolite O +
FA O +
( O -
product O +
of O +
ω O -
- O -
oxidation O +
[ O -
7 O -
] O +
) O +
and O +
the O +
trihydroxy O +
metabolite O +
FA O +
( O -
product O +
of O +
epoxide O +
hydrolase O -
) O +
were O +
spotted O +
as O +
reference O +
compounds O -
. O -

3 O +
Results O +
and O +
discussion O +
We O +
show O +
herein O +
that O +
HxA3 O -
FA O +
but O +
not O +
the O +
Me O +
ester O +
is O +
vehicle O +
sensitive O +
in O +
evoking O +
a O +
rise O +
in O +
intracellular O +
calcium O +
in O +
suspensions O +
of O +
human U-Species +
neutrophils O -
. O -

Fig. O +
1 O -
A O +
shows O +
a O +
typical O +
pattern O +
of O +
intracellular O +
calcium O +
resulting O +
from O +
the O +
addition O +
of O +
HxA3 O -
Me O +
ester O +
( O -
upper O +
trace O -
) O +
and O +
FA O +
( O -
lower O +
trace O -
) O +
in O +
DMSO O +
as O +
vehicle O -
. O -

This O +
is O +
compared O +
with O +
the O +
same O +
two O +
compounds O +
added O +
in O +
ethanol O +
as O +
vehicle O +
( O -
Fig. O +
1 O +
B O -
) O -
. O -

The O +
following O +
three O +
points O +
are O +
apparent O -
. O -

First O -
, O +
the O +
pattern O +
for O +
the O +
Me O +
ester O +
is O +
similar O +
and O +
independent O +
of O +
the O +
vehicle O +
used O +
( O -
compare O +
upper O +
traces O +
in O +
Fig. O +
1 O +
A O +
and O +
B O -
) O -
. O -

Second O -
, O +
the O +
FA O +
is O +
inactive O +
when O +
made O +
up O +
in O +
DMSO O +
but O +
is O +
active O +
when O +
added O +
in O +
ethanol O +
vehicle O +
( O -
compare O +
lower O +
traces O +
in O +
Fig. O +
1 O +
A O +
and O +
B O -
) O -
. O -

Third O -
, O +
both O +
compounds O +
added O +
in O +
ethanol O +
show O +
a O +
rapid O +
action O +
( O -
rise O +
in O +
intracellular O +
calcium O -
) O +
and O +
a O +
slower O +
more O +
prolonged O +
decrease O +
in O +
calcium O +
levels O +
but O +
never O +
decreasing O +
to O +
pre O -
- O -
HxA3 O -
levels O +
( O -
see O +
Fig. O +
1 O +
B O -
) O -
. O -

The O +
Me O +
ester O +
appears O +
more O +
potent O +
in O +
the O +
rapid O +
initial O +
phase O +
of O +
calcium O +
release O +
than O +
the O +
FA O +
( O -
Me O -
, O +
188±14 O +
S.D. O -
; O +
FA O -
, O +
135±11 O +
S.D. O +
nM O -
, O +
P O +
< O -
0.0005 O -
, O +
n O +
=3 O -
) O +
and O +
decreases O +
to O +
a O +
similar O +
plateau O +
level O +
as O +
with O +
the O +
FA O +
( O -
Me O -
, O +
88±8 O +
S.D. O -
; O +
FA O -
, O +
107±15 O +
S.D. O +
nM O -
, O +
not O +
significant O -
, O +
n O +
= O -
3 O -
) O -
. O -

Hence O -
, O +
the O +
decrease O +
to O +
the O +
second O +
phase O +
( O -
prolonged O +
calcium O +
rise O -
) O +
is O +
greater O +
with O +
the O +
Me O +
ester O +
( O -
from O +
188 O +
to O +
88 O +
nM=53 O -
% O -
) O +
than O +
with O +
the O +
FA O +
( O -
from O +
135 O +
to O +
107 O +
nM=20 O -
% O -
) O -
. O -

In O +
order O +
to O +
address O +
this O +
second O +
phase O +
of O +
calcium O +
` O -
retention O -
' O -
, O +
we O +
administered O +
lanthanum O +
chloride O +
( O -
1 O +
μM O +
final O +
concentration O -
) O +
at O +
the O +
plateau O +
of O +
the O +
profile O +
( O -
about O +
5 O +
min O +
after O +
the O +
addition O +
of O +
HxA3 O +
) O -
. O -

Lanthanum O +
chloride O +
blocks O +
the O +
entry O +
of O +
calcium O +
by O +
inhibiting O +
calcium O +
channels O +
[ O -
8 O -
, O +
9 O -
] O +
. O -

Lanthanum O +
caused O +
an O +
immediate O +
decrease O +
in O +
intracellular O +
calcium O +
levels O +
towards O +
the O +
baseline O +
for O +
both O +
the O +
Me O +
ester O +
as O +
well O +
as O +
the O +
FA O +
( O -
Fig. O +
1 O +
B O -
, O +
upper O +
and O +
lower O +
traces O -
) O -
. O -

In O +
separate O +
experiments O +
( O -
Fig. O +
1 O +
C O -
) O +
carried O +
out O +
in O +
medium O +
devoid O +
of O +
extracellular O +
calcium O +
( O -
containing O +
EGTA O -
) O -
, O +
the O +
Me O +
ester O +
( O -
tested O +
in O +
DMSO O +
or O +
ethanol O -
) O +
effected O +
the O +
same O +
rapid O +
initial O +
phase O +
of O +
intracellular O +
calcium O +
rise O +
but O +
the O +
peak O +
response O +
quickly O +
returned O +
to O +
baseline O +
( O -
Fig. O +
1 O +
C O -
, O +
upper O +
trace O -
) O -
, O +
suggesting O +
that O +
the O +
second O +
( O -
longer O -
) O +
phase O +
of O +
the O +
normal O +
HxA3 O -
response O +
was O +
due O +
to O +
the O +
entry O +
of O +
extracellular O +
calcium O -
. O -

Similar O +
results O +
were O +
observed O +
with O +
the O +
FA O +
of O +
HxA3 O -
( O -
Fig. O +
1 O +
C O -
, O +
lower O +
trace O -
) O -
. O -

Again O +
the O +
Me O +
ester O +
is O +
slightly O +
more O +
potent O +
than O +
the O +
FA O +
( O -
Me O -
, O +
189±12 O +
S.D. O -
; O +
FA O -
, O +
145±6 O +
S.D. O +
nM O -
, O +
P O +
< O -
0.005 O -
, O +
n O +
= O -
3 O -
) O -
. O -

Similar O +
results O +
to O +
the O +
extracellular O +
calcium O -
- O -
free O +
experiments O +
were O +
observed O +
when O +
lanthanum O +
chloride O +
was O +
added O +
to O +
the O +
cells O +
prior O +
to O +
HxA3 O -
( O -
data O +
not O +
shown O -
) O -
. O -

In O +
order O +
to O +
investigate O +
further O +
whether O +
the O +
calcium O +
releasing O +
action O +
of O +
HxA3 O -
on O +
neutrophils O +
was O +
mediated O +
via O +
its O +
conversion O +
into O +
other O +
compounds O -
, O +
we O +
incubated O +
tritiated O +
HxA3 O -
Me O +
ester O +
with O +
human U-Species +
neutrophils O +
and O +
analyzed O +
the O +
products O +
after O +
1 O +
and O +
5 O +
min O +
incubation O -
, O +
the O +
periods O +
of O +
maximal O +
change O +
in O +
intracellular O +
calcium O -
. O -

The O +
ethyl O +
acetate O +
extract O +
of O +
the O +
incubation O +
was O +
analyzed O +
by O +
TLC O -
. O -

Fig. O +
2 O -
shows O +
that O +
within O +
a O +
1 O +
min O +
incubation O +
( O -
the O +
period O +
of O +
sharp O +
initial O +
calcium O +
rise O -
) O +
the O +
Me O +
ester O +
is O +
only O +
partially O +
hydrolyzed O +
( O -
about O +
10 O -
% O -
) O +
into O +
the O +
FA O +
by O +
intracellular O +
esterases O -
, O +
demonstrating O +
that O +
the O +
Me O +
ester O +
penetrates O +
into O +
the O +
cell O +
where O +
it O +
acts O +
to O +
release O +
calcium O +
from O +
calcium O +
stores O +
( O -
rapid O +
initial O +
phase O -
) O -
. O -

About O +
50 O -
% O +
of O +
the O +
Me O +
ester O +
is O +
converted O +
into O +
the O +
FA O +
as O +
the O +
sole O +
metabolite O +
within O +
5 O +
min O +
of O +
incubation O -
. O -

Hence O -
, O +
the O +
rapid O +
initial O +
phase O +
of O +
the O +
calcium O +
profile O +
of O +
the O +
Me O +
ester O +
of O +
HxA3 O -
is O +
due O +
to O +
a O +
large O +
part O +
to O +
the O +
Me O +
ester O +
form O +
itself O +
while O +
the O +
prolonged O +
phase O +
occurs O +
during O +
and O +
subsequent O +
to O +
the O +
formation O +
of O +
the O +
FA O -
. O -

The O +
important O +
experiment O +
in O +
Fig. O +
1 O +
C O +
( O -
bottom O +
trace O -
) O +
demonstrates O +
that O +
the O +
FA O +
is O +
also O +
active O +
on O +
intracellular O +
stores O +
to O +
cause O +
the O +
release O +
of O +
intracellular O +
calcium O -
, O +
i.e. O +
it O +
has O +
dual O +
actions O -
. O -

These O +
experiments O +
demonstrate O +
that O +
HxA3 O +
, O +
both O +
as O +
the O +
FA O +
as O +
well O +
as O +
the O +
Me O +
ester O -
, O +
are O +
taken O +
up O +
into O +
the O +
cell O +
and O +
act O +
to O +
release O +
calcium O +
from O +
intracellular O +
stores O -
. O -

Within O +
the O +
time O +
frame O +
of O +
initial O +
action O +
( O -
rapid O +
phase O -
, O +
1 O +
min O -
) O -
, O +
studies O +
with O +
tritiated O +
HxA3 O -
show O +
that O +
the O +
Me O +
ester O +
is O +
not O +
substantially O +
hydrolyzed O +
into O +
the O +
FA O -
, O +
although O +
this O +
takes O +
place O +
subsequently O +
and O +
is O +
likely O +
involved O +
in O +
calcium O +
influx O -
. O -

Supporting O +
this O +
is O +
the O +
finding O +
that O +
the O +
second O +
phase O +
of O +
calcium O +
response O +
is O +
equally O +
pronounced O +
when O +
the O +
FA O +
is O +
used O +
( O -
Fig. O +
1 O +
B O -
) O +
and O +
is O +
absent O +
in O +
calcium O -
- O -
free O +
medium O +
( O -
Fig. O +
1 O +
C O -
) O -
. O -

Finally O -
, O +
caution O +
should O +
be O +
exerted O +
in O +
the O +
choice O +
of O +
vehicle O +
as O +
we O +
show O +
that O +
DMSO O +
interacts O +
with O +
the O +
FA O +
form O +
of O +
HxA3 O -
( O -
likely O +
through O +
formation O +
of O +
a O +
polar O +
hydrogen O -
- O -
bonded O +
DMSO O -
- O -
HxA3 O -
adduct O +
[ O -
10 O -
] O +
) O +
making O +
the O +
adduct O +
incapable O +
of O +
entering O +
the O +
cell O +
and O +
rendering O +
HxA3 O -
inactive O -
. O -

In O +
ethanol O +
as O +
vehicle O -
, O +
the O +
FA O +
enters O +
the O +
cell O +
where O +
it O +
is O +
capable O +
both O +
of O +
releasing O +
calcium O +
from O +
intracellular O +
stores O +
( O -
see O +
Fig. O +
1 O +
C O -
) O +
and O +
causing O +
influx O +
of O +
extracellular O +
calcium O +
( O -
compare O +
Fig. O +
1 O +
B O +
and O +
C O -
) O -
. O -

Similar O +
findings O +
were O +
observed O +
with O +
Hx O +
binding O +
studies O -
. O -

The O +
FA O +
dissolved O +
in O +
DMSO O +
did O +
not O +
bind O +
to O +
intact O +
neutrophils O +
but O +
did O +
bind O +
to O +
membranes O +
from O +
disrupted O +
cells O -
, O +
while O +
the O +
Me O +
ester O +
was O +
equally O +
well O +
bound O +
to O +
the O +
intact O +
cell O +
as O +
well O +
as O +
disrupted O +
cells O +
[ O -
3 O -
] O +
. O -

Acknowledgements O +
This O +
study O +
was O +
supported O +
by O +
a O +
Grant O +
( O -
MT-4181 O -
) O +
to O +
CRP O -
- O -
A O +
from O +
the O +
Medical O +
Research O +
Council O +
of O +
Canada O +
and O +
from O +
FO O -
/ O -
FUB O +
to O +
SN O -
. O +

Manoalide O +
is O +
a O +
potent O +
analgesic O +
and O +
antiinflammatory O +
sesterterpene O +
isolated O +
in O +
1980 O +
from O +
a O +
marine B-Species +
sponge L-Species -
. O -

The O +
antiinflammatory O +
activity O +
of O +
manoalide O +
is O +
due O +
to O +
inhibition O +
of O +
PLA2 O -
, O +
through O +
irreversible O +
binding O +
to O +
several O +
lysine O +
residues O -
. O -

The O -
binding O +
is O +
realized O +
by O +
means O +
of O +
the O +
two O +
masked O +
aldehyde O +
functions O +
present O +
in O +
the O -
polar O +
part O +
of O +
manoalide O -
. O -

Of O +
the O +
two O +
aldehyde O +
groups O -
, O +
only O +
that O +
present O +
in O +
the O +
g O -
- O -
hydroxybutenolide O +
ring O +
seems O +
to O +
be O +
essential O -
, O +
since O +
cacospongionolides O -
, O +
naturally O +
occurring O +
analogues O +
lacking O +
the O +
second O +
masked O +
aldehyde O +
group O -
, O +
were O +
also O +
shown O +
to O +
be O +
irreversible O +
PLA2 O +
inhibitors O -
. O -

It O +
appears O +
that O +
the O +
minimum O +
structural O -
requirement O +
for O +
exhibiting O +
manoalide O -
- O -
like O +
PLA2 O +
inhibition O +
would O +
be O +
the O +
presence O +
in O +
the O +
inhibitor O +
of O +
functional O +
groups O +
able O +
to O +
seize O +
the O +
amino O +
groups O +
of O +
PLA2 O +
lysine O +
residues O +
with O +
formation O +
of O +
stable O +
covalent O +
bonds O -
. O -

Many O +
manoalide O +
analogues O +
have O +
been O +
isolated O +
from O +
marine B-Species +
sponges I-Species -
, L-Species +
most O +
of O +
them O +
sharing O +
PLA2 O +
inhibitory O +
properties O -
. O -

Other O +
interesting O +
bioactivities O +
have O +
also O +
been O +
reported O +
for O +
some O +
of O +
these O +
compounds O -
. O +

Bis O -
( O -
monoacylglycerol O -
) O -
phosphate O +
( O -
BMP O -
) O +
was O +
first O +
described O +
in O +
1967 O +
by O +
Body O +
and O +
Gray O +
[ O -
1 O -
] O +
, O +
and O +
was O +
shown O +
by O +
Waite O +
et O +
al. O +
[ O -
2 O -
] O -
to O +
be O +
synthesized O +
in O +
alveolar O +
macrophages O +
from O +
exogenous O +
phosphatidylglycerol O +
( O -
PG O -
) O -
. O -

BMP O +
is O +
a O +
unique O +
phospholipid O +
having O +
a O +
sn O +
-1 O +
rather O +
than O +
sn O +
-3 O +
glycerol O +
phosphate O +
ester O +
[ O -
3 O -
] O -
and O +
one O +
acyl O +
group O +
attached O +
to O +
each O +
of O +
the O +
glycerol O +
moieties O -
. O -

While O +
it O +
is O +
unclear O +
whether O +
the O +
acyl O +
esters O +
are O +
at O +
the O +
primary O +
or O +
secondary O +
hydroxyl O +
[ O -
4,5 O -
] O +
, O +
the O +
acyl O +
groups O +
of O +
BMP O +
are O +
unusually O +
rich O +
in O +
polyunsaturated O +
species O +
[ O -
5–7 O -
] O -
which O +
implies O +
acyl O +
linkage O +
at O +
the O +
sn O +
-2 O +
and O +
sn O +
-2′ O +
positions O -
. O -

We O +
proposed O +
a O +
biochemical O +
pathway O +
by O +
which O +
BMP O +
is O +
synthesized O +
but O +
this O +
remains O +
to O +
be O +
proven O +
( O -
Scheme O +
1 O -
) O +
[ O -
8 O -
] O +
. O -

Recent O +
work O +
within O +
our O +
laboratory O +
has O +
focused O +
on O +
characterizing O +
the O +
enzymes O +
that O +
are O +
involved O +
in O +
the O +
biosynthesis O +
of O +
BMP O +
from O +
PG O -
. O -

In O +
this O +
proposed O +
pathway O -
, O +
PG O -
, O +
presumably O +
from O +
lung O +
surfactant O -
, O +
is O +
taken O +
into O +
the O +
cell O +
and O +
metabolized O +
to O +
BMP O -
. O -

There O +
is O +
reason O +
to O +
suggest O +
that O +
BMP O +
synthesis O +
occurs O +
in O +
the O +
endosomal O +
system O +
since O +
a O +
role O +
for O +
BMP O +
in O +
the O +
endosomal O +
function O +
has O +
recently O +
been O +
proposed O +
[ O -
9 O -
] O +
. O -

The O +
first O +
proposed O +
step O +
in O +
conversion O +
to O +
BMP O +
is O +
the O +
hydrolysis O +
of O +
PG O +
catalyzed O +
by O +
a O +
lysosomal O +
PLA2 O -
to O +
form O +
1-acyl O -
- O -
sn O +
-glycero-3-phospho O -
- O -
rac O +
-glycerol O +
( O -
LPG O -
) O -
. O -

In O +
the O +
second O +
step O -
, O +
sn O +
-3 O -
: O -
sn O +
-1′ O +
LPG O +
is O +
acylated O +
on O +
the O +
head O +
group O +
( O -
prime O +
designation O -
) O +
glycerol O +
with O +
an O +
acyl O +
group O +
from O +
a O +
donor O +
phospholipid O -
. O -

The O +
next O +
step O +
proposed O +
is O +
the O +
reorientation O +
of O +
the O +
phosphoryl O +
ester O +
from O +
the O +
sn O +
-3 O +
to O +
the O +
sn O +
-1 O +
position O -
, O +
with O +
liberation O +
of O +
the O +
sn O +
-1 O +
linked O +
acyl O +
chain O +
concomitant O +
to O +
the O +
phosphoryl O +
migration O +
[ O -
10 O -
] O +
. O -

While O +
this O +
proposal O +
provides O +
the O +
energy O +
and O +
specificity O +
for O +
the O +
transfer O +
of O +
the O +
phosphate O +
to O +
the O +
sn O +
-1 O +
position O -
, O +
it O +
has O +
yet O +
to O +
be O +
demonstrated O +
in O +
a O +
cell O +
homogenate O -
. O -

The O +
final O +
proposed O +
step O +
is O +
a O +
second O +
transacylation O +
to O +
incorporate O +
an O +
acyl O +
chain O +
into O +
the O +
original O +
backbone O +
glycerol O +
( O -
non O -
- O -
prime O +
designation O -
) O +
of O +
sn O +
-1 O -
: O -
sn O +
-1′ O +
LPG O -
. O -

If O +
the O +
sn O +
-2 O +
chain O +
of O +
a O +
phospholipid O +
were O +
the O +
substrate O +
for O +
the O +
transacylation O +
steps O -
, O +
the O +
final O +
BMP O +
structure O +
would O +
contain O +
the O +
expected O +
polyunsaturated O +
fatty O +
acid O -
. O -

Various O +
groups O +
have O +
shown O +
that O +
diacyl O +
phospholipid O +
stimulates O +
the O +
conversion O +
of O +
sn O +
-3 O -
: O -
sn O +
-1′ O +
LPG O +
to O +
sn O +
-3 O -
: O -
sn O +
-1′ O +
BMP O +
( O -
Scheme O +
1 O -
step O +
2 O -
) O -
. O -

Our O +
studies O +
[ O -
8 O -
] O -
showed O +
that O +
the O +
lipid O +
product O +
of O +
the O +
reaction O +
catalyzed O +
by O +
the O +
partially O +
purified O +
transacylase O +
was O +
BMP O -
, O +
as O +
predicted O +
in O +
Scheme O +
1 O +
. O -

Matsuzawa O +
et O +
al. O +
[ O -
11 O -
] O -
earlier O +
reported O +
that O +
PI O +
was O +
preferentially O +
used O +
by O +
a O +
rat U-Species +
liver O +
lysosomal O +
transacylase O +
to O +
form O +
BMP O -
, O +
whereas O +
the O +
work O +
of O +
Huterer O +
and O +
Wherett O +
[ O -
12 O -
] O -
indicated O +
that O +
the O +
acyl O +
moiety O +
from O +
either O +
the O +
sn O +
-1 O +
or O +
sn O +
-2 O +
position O +
of O +
PC O +
was O +
incorporated O +
into O +
BMP O -
. O -

Huterer O +
et O +
al. O +
[ O -
13 O -
] O -
proposed O +
that O +
the O +
lysosomal O +
PLA1 O -
is O +
also O +
a O +
transacylase O +
and O +
could O +
be O +
responsible O +
for O +
the O +
formation O +
of O +
BMP O +
and O +
acylphosphatidylglycerol O +
( O -
APG O -
) O -
. O -

The O +
stereoconfiguration O +
of O +
the O +
BMP O +
formed O +
was O +
not O +
determined O +
in O +
the O +
later O +
reports O -
. O -

Considering O +
the O +
differences O +
in O +
these O +
reports O -
, O +
we O +
felt O +
it O +
necessary O +
to O +
more O +
clearly O +
define O +
the O +
transacylation O +
step O +
( O -
Scheme O +
1 O -
step O +
2 O -
) O -
. O -

In O +
particular O -
, O +
we O +
set O +
out O +
to O +
establish O +
what O +
the O +
substrate O -
( O -
s O -
) O +
for O +
the O +
reaction O +
are O +
and O +
if O +
indeed O +
the O +
presence O +
of O +
polyunsaturated O +
fatty O +
acids O +
in O +
BMP O +
was O +
accounted O +
for O +
by O +
this O +
transacylation O -
. O -

To O +
our O +
surprise O +
LPG O +
served O +
as O +
both O +
the O +
acyl O +
donor O +
and O +
acyl O +
acceptor O -
, O +
even O +
though O +
diradyl O +
phospholipid O +
enhanced O +
activity O +
several O -
- O -
fold O -
. O -

The O +
data O +
supporting O +
this O +
conclusion O +
are O +
reported O +
herein O -
. O -

2 O +
Methods O +
and O +
materials O +
2.1 O -

Materials O +
RAW B-Species +
264.7 L-Species +
( O -
murine B-Species +
monocytic I-Species -
, I-Species +
macrophage I-Species +
like I-Species -
, I-Species +
Abelson I-Species +
leukemia I-Species +
virus I-Species +
transformed I-Species +
BALB I-Species -
/ I-Species -
c L-Species -
) O +
cells O +
were O +
purchased O +
from O +
American O +
Type O +
Tissue O +
Culture O -
. O -

Tissue O +
culture O +
medium O +
was O +
from O +
Gibco O -
. O -

Phospholipids O +
( O -
except O +
for O +
RAW B-Species +
264.7 L-Species +
lipid O -
) O +
were O +
from O +
Avanti O +
Polar O +
Lipids O -
. O -

Salts O -
, O +
buffers O -
, O +
and O +
organic O +
solvents O +
were O +
from O +
Fisher O -
. O -

Protein O +
assay O +
reagents O +
were O +
from O +
Pierce O +
and O +
microconcentrators O +
were O +
from O +
Amicon O -
. O -

S-300 O +
column O +
matrix O +
was O +
from O +
Pharmacia O -
. O -

Silica O +
gel O +
G O +
plates O +
were O +
from O +
Analtech O -
. O -

Preparative O +
enzymes O +
were O +
from O +
Sigma O -
. O -

The O +
1-acyl O -
[ O -
1,2,3 O -
- O -
3 O +
H O -
] O -
-sn O +
-glycero-3-phospho O -
- O -
rac O +
-glycerol O +
( O -
[ O -
3 O +
H O -
] O -
LPG O -
) O +
was O +
synthesized O +
as O +
described O +
earlier O +
[ O -
14 O -
] O +
. O -

2.2 O +
Cell O +
culture O +
RAW B-Species +
264.7 L-Species +
cells O +
were O +
grown O +
in O +
Dulbecco O -
's O +
minimum O +
essential O +
medium O +
with O +
10 O +
mM O +
HEPES O -
, O +
pH O +
7.4 O -
, O +
4.5 O +
g O -
/ O -
l O +
of O +
d O +
-glucose O -
, O +
584 O +
mg O -
/ O -
l O +
of O +
l O +
-glutamine O -
, O +
110 O +
mg O -
/ O -
l O +
of O +
sodium O +
pyruvate O -
, O +
4 O +
mg O -
/ O -
l O +
of O +
pyridoxal O +
HCl O -
, O +
10 O -
% O +
heat O +
inactivated O +
FBS O +
( O -
by O +
volume O -
) O +
in O +
an O +
atmosphere O +
supplemented O +
with O +
5 O -
% O +
CO2 O +
. O -

These O +
cells O +
were O +
grown O +
to O +
confluence O +
in O +
15 O +
ml O +
of O +
medium O +
in O +
a O +
75 O +
cm2 O -
flask O -
, O +
then O +
passaged O +
into O +
150 O +
ml O +
of O +
medium O +
in O +
225 O +
cm2 O -
plates O -
. O -

Once O +
the O +
population O +
reached O +
1 O -
× O -
108 O -
total O +
cells O -
, O +
the O +
cells O +
were O +
passed O +
into O +
200 O +
ml O +
of O +
medium O +
and O +
transferred O +
to O +
a O +
500 O +
ml O +
cell O +
culture O +
stir O +
bottle O +
and O +
placed O +
in O +
a O +
second O +
incubator O -
. O -

Since O +
this O +
incubator O +
did O +
not O +
have O +
a O +
CO2 O -
atmosphere O +
supplementation O +
system O -
, O +
the O +
medium O +
buffering O +
capacity O +
was O +
increased O +
with O +
additional O +
HEPES O +
( O -
pH O +
7.4 O -
, O +
20 O +
mM O -
) O -
. O -

Suspension O +
cultures O +
were O +
initiated O +
with O +
5 O -
× O -
105 O -
cells O -
/ O -
ml O +
and O +
allowed O +
to O +
proliferate O +
until O +
reaching O +
approx O -
. O -

2 O -
× O -
106 O +
/ml O -
. O -

They O +
were O +
then O +
passed O +
into O +
600 O +
ml O +
of O +
medium O +
in O +
a O +
1 O +
l O +
culture O +
bottle O +
and O +
allowed O +
to O +
grow O +
until O +
the O +
population O +
reached O +
6 O -
× O -
108 O -
cells O +
at O +
which O +
time O +
the O +
cells O +
were O +
taken O +
for O +
LPG O +
transacylase O +
( O -
TA O -
) O +
isolation O -
. O -

2.3 O +
Transacylase O +
isolation O +
RAW B-Species +
264.7 L-Species +
( O -
6 O -
× O -
108 O +
) O +
cells O +
were O +
pelleted O +
from O +
medium O +
by O +
centrifugation O +
at O +
1000 O -
× O -
g O +
, O +
resuspended O -
, O +
then O +
washed O +
twice O +
by O +
centrifugation O +
in O +
ice O +
cold O +
0.9 O -
% O +
saline O -
. O -

Cells O +
were O +
resuspended O +
in O +
5 O +
ml O +
of O +
1 O +
mM O +
NaHCO3 O -
and O +
lipids O +
were O +
removed O +
by O +
adding O +
an O +
equal O +
volume O +
of O +
water O -
- O -
saturated O +
1-butanol O -
. O -

The O +
mixture O +
was O +
vortexed O +
for O +
15 O +
s O -
, O +
placed O +
on O +
ice O +
for O +
2 O +
min O -
, O +
then O +
the O +
phases O +
were O +
separated O +
by O +
centrifugation O +
at O +
20 O +
000 O -
× O -
g O -
for O +
15 O +
min O +
at O +
4 O -
° O -
C O -
. O -

The O +
aqueous O +
( O -
lower O -
) O +
layer O +
was O +
applied O +
to O +
an O +
S-300 O +
column O +
( O -
1.5 O +
cm O -
× O -
84 O +
cm O -
) O +
which O +
had O +
been O +
previously O +
equilibrated O +
in O +
10 O +
mM O +
Tris O -
, O +
pH O +
7.4 O -
, O +
and O +
eluted O +
with O +
the O +
same O +
buffer O +
at O +
a O +
flow O +
rate O +
of O +
0.55 O +
ml O -
/ O -
min O -
. O -

Fifty O +
fractions O +
of O +
2.2 O +
ml O +
were O +
collected O +
from O +
the O +
S-300 O +
column O -
, O +
assayed O +
for O +
TA O +
activity O -
, O +
and O +
those O +
fractions O +
exhibiting O +
TA O +
activity O +
were O +
pooled O -
. O -

Pooled O +
TA O +
intended O +
for O +
experiments O +
utilizing O +
gas O +
chromatography O +
( O -
GC O -
) O +
or O +
mass O +
spectrometry O +
( O -
MS O -
) O +
analysis O +
were O +
concentrated O +
using O +
an O +
Amicon O +
filtration O +
system O -
. O -

Pooled O +
fractions O +
were O +
then O +
assayed O +
for O +
total O +
protein O +
concentration O -
. O -

2.4 O +
Transacylase O +
assay O +
For O +
each O +
assay O -
, O +
10 O +
nmol O +
of O +
diradyl O +
lipid O -
, O +
[ O -
3 O +
H O -
] O -
LPG O +
( O -
5 O -
× O -
104 O -
DPM O -
, O +
200 O +
pmol O -
) O +
and O +
10 O +
nmol O +
of O +
1-myristoyl O +
LPG O +
were O +
dried O +
under O +
a O +
stream O +
of O +
N2 O -
and O +
0.1 O +
ml O +
of O +
1 O +
M O +
Na O +
acetate O -
, O +
pH O +
4.5 O +
was O +
added O -
. O -

The O +
lipids O +
were O +
sonically O +
dispersed O +
and O +
0.1 O +
ml O +
of O +
the O +
solution O +
was O +
aliquoted O +
to O +
the O +
various O +
tubes O -
. O -

Seventy O -
- O -
five O +
μg O +
of O +
the O +
TA O +
were O +
added O +
to O +
each O +
tube O -
, O +
the O +
reaction O +
volume O +
was O +
adjusted O +
to O +
1 O +
ml O +
with O +
water O -
, O +
and O +
samples O +
were O +
incubated O +
for O +
1 O +
h O +
at O +
37 O -
° O -
C O -
. O -

The O +
reactions O +
were O +
stopped O +
and O +
the O +
lipids O +
extracted O +
by O +
the O +
method O +
of O +
Bligh O +
and O +
Dyer O +
[ O -
15 O -
] O +
. O -

The O +
organic O +
phase O +
was O +
evaporated O +
under O +
N2 O +
, O +
and O +
lipids O +
were O +
spotted O +
on O +
a O +
silica O +
G O +
plate O +
in O +
methanol O +
and O +
separated O +
by O +
a O +
thin O +
layer O +
chromatography O +
( O -
TLC O -
) O +
system O +
containing O +
chloroform O -
/ O -
methanol O -
/ O -
ammonium O +
hydroxide O +
( O -
130:70:10 O +
v O -
/ O -
v O -
/ O -
v O -
) O +
( O -
R O +
f O -
values O -
: O +
LPG O +
0.27 O -
, O +
PG O +
0.40 O -
, O +
BMP O +
0.53 O -
) O -
. O -

Radioactive O +
lipids O +
were O +
visualized O +
by O +
scanning O +
the O +
TLC O +
plate O +
using O +
a O +
Bioscanner O +
detector O +
and O +
compared O +
to O +
authentic O +
standards O -
. O -

Silica O -
, O +
containing O +
the O +
radioactive O +
products O -
, O +
was O +
scraped O +
from O +
the O +
plate O +
into O +
a O +
scintillation O +
vial O +
and O +
then O +
counted O +
in O +
a O +
liquid O +
scintillation O +
counter O +
and O +
TA O +
activity O +
was O +
determined O +
as O +
the O +
percentage O +
of O +
the O +
radiolabeled O +
BMP O +
formed O +
compared O +
to O +
the O +
sum O +
of O +
radioactivity O +
from O +
the O +
silica O +
plate O +
plus O +
the O +
methanol O -
/ O -
water O +
phase O +
of O +
the O +
extract O -
. O -

This O +
percentage O +
was O +
converted O +
to O +
mass O +
based O +
on O +
the O +
specific O +
radioactivity O +
of O +
the O +
substrate O -
. O -

Due O +
to O +
enzyme O +
instability O -
, O +
experiments O +
were O +
completed O +
within O +
1–2 O +
days O +
of O +
preparation O -
. O -

Even O +
so O -
, O +
considerable O +
variability O +
in O +
specific O +
enzymatic O +
activity O +
existed O +
between O +
preparations O -
. O -

2.5 O +
Gas O +
chromatographic O +
analysis O +
Fatty O +
acid O +
methyl O +
esters O +
were O +
prepared O +
and O +
examined O +
by O +
the O +
method O +
of O +
Wang O +
and O +
Peter O +
[ O -
16 O -
] O +
. O -

The O +
lipids O +
were O +
separated O +
by O +
TLC O +
and O +
5 O +
μg O +
of O +
pentadecanoic O +
acid O +
( O -
C15:0 O -
) O +
in O +
hexane O +
was O +
pipetted O +
onto O +
each O +
zone O +
of O +
the O +
silica O +
plate O +
to O +
be O +
scraped O -
. O -

In O +
these O +
and O +
experiments O +
employing O +
MS O -
, O +
a O +
trace O +
amount O +
of O +
[ O -
3 O +
H O -
] O -
LPG O +
was O +
included O +
to O +
localize O +
BMP O +
on O +
the O +
TLC O +
plate O -
. O -

One O +
ml O +
of O +
7 O -
% O +
HCl O +
in O +
MeOH O +
was O +
added O +
to O +
the O +
scraped O +
silica O -
, O +
vortexed O -
, O +
and O +
heated O +
to O +
100 O -
° O -
C O +
for O +
15 O +
min O -
. O -

After O +
cooling O +
to O +
0 O -
° O -
C O -
, O +
2 O +
ml O +
of O +
hexane O +
were O +
added O +
followed O +
by O +
the O +
addition O +
of O +
1 O +
ml O +
of O +
2.5 O +
N O +
NaOH O -
. O -

The O +
hexane O +
was O +
collected O -
, O +
the O +
samples O +
were O +
extracted O +
again O +
with O +
2 O +
ml O +
of O +
hexane O +
and O +
the O +
hexane O +
was O +
dried O +
under O +
N2 O +
. O -

The O +
fatty O +
acid O +
methyl O +
esters O +
were O +
dissolved O +
in O +
100 O +
μl O +
of O +
undecane O +
and O +
analyzed O +
by O +
gas O +
chromatography O -
/ O -
flame O +
ionization O +
detection O +
( O -
GC O -
/ O -
FID O -
) O -
. O -

2.6 O +
MS O +
analysis O +
MS O +
analysis O +
was O +
conducted O +
by O +
the O +
method O +
of O +
Lehmann O +
[ O -
17 O -
] O +
. O -

BMP O +
was O +
isolated O +
by O +
TLC O -
, O +
dissolved O +
in O +
250 O +
μl O +
of O +
MeOH O -
: O -
MeCl2 O -
1:1 O -
, O +
injected O +
into O +
a O +
VG O +
Quattro O +
II O +
triple O +
quadrupole O +
mass O +
spectrometer O -
, O +
and O +
resultant O +
data O +
analyzed O +
using O +
Masslynx O +
software O -
. O -

Both O +
parent O +
and O +
daughter O +
ions O +
were O +
detected O +
over O +
a O +
range O +
from O +
200 O +
to O +
900 O +
m O -
/ O -
z O -
. O -

Ion O +
spectra O +
were O +
assigned O +
acyl O +
compositions O +
based O +
on O +
detected O +
ion O +
molecular O +
weight O +
and O +
previously O +
determined O +
standards O -
. O -

Parent O +
ions O +
were O +
detected O +
in O +
the O +
first O +
quadrupole O -
, O +
ionized O +
in O +
the O +
second O +
quadrupole O +
and O +
daughter O +
ions O +
corresponding O +
to O +
acyl O +
chains O +
esterified O +
on O +
BMP O +
detected O +
in O +
the O +
third O +
quadrupole O -
. O -

3 O +
Results O +
Studies O +
reported O +
thus O +
far O +
have O +
not O +
established O +
systematically O +
the O +
optimal O +
conditions O +
for O +
the O +
TA O -
. O -

For O +
these O +
studies O -
, O +
it O +
is O +
important O +
to O +
remove O +
contaminating O +
phospholipases O +
that O +
may O +
hydrolyze O +
substrates O +
and/or O +
products O -
. O -

Previous O +
work O +
from O +
our O +
lab O +
demonstrates O +
that O +
lysosomal O +
PLA O +
activity O +
was O +
minimal O +
in O +
our O +
transacylase O +
preparation O +
and O +
that O +
no O +
ATP O +
and O +
CoA O +
dependent O +
transacylases O +
were O +
present O +
[ O -
8 O -
] O +
. O -

We O +
first O +
demonstrated O +
that O +
the O +
reaction O +
was O +
linear O +
for O +
30 O +
min O +
using O +
our O +
standard O +
assay O +
conditions O -
, O +
and O +
although O +
at O +
a O +
somewhat O +
decreased O +
rate O -
, O +
the O +
enzyme O +
was O +
active O +
up O +
to O +
90 O +
min O +
( O -
data O +
not O +
shown O -
) O -
. O -

Optimal O +
activity O +
was O +
observed O +
between O +
pH O +
4.0 O +
and O +
5.5 O -
, O +
as O +
previously O +
reported O +
with O +
lower O +
concentrations O +
of O +
substrate O +
[ O -
8 O -
] O +
. O -

We O +
also O +
showed O +
using O +
10 O +
or O +
30 O +
μM O +
LPG O +
that O +
lipids O +
extracted O +
from O +
the O +
RAW B-Species +
264.7 L-Species +
cells O +
stimulated O +
the O +
TA O +
in O +
concentrations O +
up O +
to O +
50 O +
μM. O +
Since O +
it O +
would O +
be O +
difficult O +
to O +
define O +
the O +
substrates O +
involved O +
in O +
transacylation O +
using O +
total O +
lipid O +
extracts O -
, O +
we O +
used O +
synthetic O +
substrates O +
with O +
defined O +
acyl O +
groups O -
, O +
with O +
the O +
exception O +
of O +
the O +
[ O -
3 O +
H O -
] O -
LPG O +
which O +
contained O +
mainly O +
palmitate O -
. O -

The O +
[ O -
3 O +
H O -
] O -
LPG O +
used O +
was O +
present O +
in O +
trace O +
amounts O -
, O +
being O +
diluted O +
approx O -
. O -

100-fold O +
with O +
synthetic O +
1-myristoyl O +
LPG O -
. O -

Using O +
LPG O +
and O +
either O +
1-palmitoyl-2-oleoyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
POPC O -
) O +
or O +
1-palmitoyl-2-oleoyl O -
- O -
sn O +
-glycero-3-phosphoethanolamine O +
( O -
POPE O -
) O -
, O +
we O +
find O +
a O +
concentration O +
dependence O +
of O +
both O +
the O +
LPG O +
and O +
the O +
POPC O +
( O -
Fig. O +
1A O -
, O -
B O -
) O -
. O -

On O +
the O +
other O +
hand O -
, O +
POPE O +
did O +
not O +
stimulate O +
the O +
transacylase O +
( O -
Fig. O +
1B O +
) O -
. O -

The O +
concentration O +
dependence O +
of O +
LPG O +
and O +
POPC O +
showed O +
that O +
both O +
were O +
required O +
in O +
concentrations O +
above O +
1–3 O +
μM O +
before O +
stimulation O +
was O +
seen O -
. O -

The O +
complexity O +
of O +
substrate O +
dependence O +
suggests O +
that O +
the O +
physical O +
state O +
of O +
the O +
substrate O +
may O +
regulate O +
the O +
TA O -
. O -

In O +
order O +
to O +
better O +
define O +
the O +
properties O +
of O +
the O +
reaction O +
we O +
investigated O +
the O +
effects O +
of O +
detergents O +
on O +
transacylation O +
( O -
Fig. O +
2A O -
) O -
. O -

Only O +
the O +
bile O +
acids O +
deoxycholic O +
acid O +
( O -
DOC O -
) O +
or O +
cholic O +
acid O +
( O -
CHO O -
) O +
were O +
seen O +
to O +
stimulate O +
activity O +
and O +
both O +
Tween O +
20 O +
and O +
cetyltrimethylammonium O +
bromide O +
markedly O +
inhibited O +
at O +
20 O +
μM. O +
The O +
stimulation O +
by O +
DOC O +
was O +
optimal O +
between O +
10 O +
and O +
500 O +
μM O +
while O +
it O +
became O +
inhibitory O +
above O +
that O +
concentration O +
( O -
Fig. O +
2B O +
) O -
. O -

At O +
pH O +
4.5 O +
DOC O +
and O +
CHO O +
are O +
protonated O -
. O -

This O +
reduces O +
their O +
critical O +
micellar O +
concentration O +
and O +
may O +
account O +
for O +
their O +
stimulatory O +
properties O -
. O -

We O +
next O +
sought O +
to O +
determine O +
the O +
effects O +
on O +
transacylation O +
of O +
various O +
phospholipids O +
in O +
the O +
presence O +
of O +
20 O +
μM O +
DOC O +
( O -
Fig. O +
3 O -
) O -
. O -

The O +
purpose O +
of O +
these O +
experiments O +
was O +
to O +
determine O +
whether O +
phospholipid O +
had O +
an O +
additional O +
stimulatory O +
effect O +
beyond O +
that O +
of O +
DOC O +
and O +
to O +
determine O +
whether O +
phospholipid O +
that O +
lacked O +
an O +
acyl O +
group O +
in O +
sn O +
-1 O +
and O +
sn O +
-2 O +
positions O +
would O +
stimulate O +
the O +
TA O -
. O -

In O +
this O +
case O +
a O +
plasmalogen O +
rich O +
PE O +
from O +
brain O +
was O +
stimulatory O -
. O -

Perhaps O +
the O +
most O +
striking O +
feature O +
of O +
Fig. O +
3 O -
is O +
the O +
stimulation O +
by O +
1,2-dihexadecyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
dialkyl O +
PC O -
) O -
, O +
a O +
phospholipid O +
with O +
ether O +
rather O +
than O +
ester O +
bonds O +
that O +
can O -
not O +
undergo O +
transacylation O -
. O -

This O +
indicates O +
that O +
the O +
stimulatory O +
effect O +
of O +
diradyl O +
phospholipids O +
on O +
transacylation O +
may O +
not O +
be O +
as O +
a O +
substrate O +
but O +
provides O +
a O +
favorable O +
lipid O +
milieu O -
. O -

Since O +
the O +
lipids O +
used O +
in O +
these O +
studies O +
have O +
defined O +
acyl O +
groups O -
, O +
we O +
determined O +
whether O +
an O +
acyl O +
group O +
is O +
transferred O +
from O +
PC O +
by O +
fatty O +
acid O +
analysis O +
of O +
the O +
product O +
BMP O -
. O -

Fig. O +
4 O -
shows O +
the O +
acyl O +
composition O +
of O +
the O +
BMP O +
in O +
which O +
1-myristoyl O +
LPG O +
and O +
POPC O +
were O +
used O +
as O +
substrates O +
( O -
from O +
Fig. O +
1 O +
) O -
. O -

As O +
determined O +
by O +
the O +
GC O -
, O +
myristate O +
was O +
the O +
predominant O +
fatty O +
acid O +
present O +
in O +
BMP O +
with O +
only O +
a O +
trace O +
of O +
the O +
acyl O +
groups O -
, O +
palmitate O +
and O +
oleate O -
, O +
from O +
the O +
POPC O +
being O +
used O +
in O +
the O +
biosynthesis O +
of O +
BMP O -
. O -

These O +
data O +
show O +
that O +
PC O +
does O +
not O +
participate O +
significantly O +
as O +
substrate O +
in O +
transacylation O -
. O -

This O +
observation O +
is O +
consistent O +
with O +
the O +
finding O +
that O +
dialkyl O +
PC O +
can O +
stimulate O +
transacylation O +
( O -
Fig. O +
3 O +
) O -
. O -

The O +
results O +
of O +
Fig. O +
4 O -
were O +
verified O +
using O +
lipids O +
with O +
different O +
acyl O +
chains O +
to O +
rule O +
out O +
the O +
possibility O +
that O +
the O +
TA O +
was O +
selecting O +
only O +
myristate O -
. O -

When O +
1-palmitoyl O +
LPG O +
and O +
1-myristoyl-2-stearoyl O -
- O -
sn O +
-glycero-3-phosphocholine O +
( O -
MSPC O -
) O +
were O +
used O +
in O +
combination O +
and O +
the O +
product O +
BMP O +
analyzed O +
by O +
electrospray O +
tandem O +
MS O -
, O +
the O +
mass O +
was O +
721 O -
, O +
showing O +
that O +
BMP O +
contained O +
two O +
palmitate O +
chains O +
( O -
Fig. O +
5 O -
) O -
. O -

In O +
this O +
experiment O +
MSPC O +
increased O +
transacylation O +
3-fold O +
which O +
indicates O +
that O +
MSPC O +
was O +
capable O +
of O +
stimulation O -
, O +
but O +
not O +
acyl O +
donation O -
. O -

Using O +
MS O +
we O +
could O +
also O +
determine O +
whether O +
the O +
TA O +
has O +
substrate O +
specificity O +
for O +
the O +
acyl O +
chains O -
. O -

We O +
analyzed O +
BMP O +
synthesized O +
from O +
reactions O +
that O +
contained O +
dialkyl O +
PC O +
and O +
mixed O +
LPGs O -
, O +
in O +
which O +
the O +
LPG O +
contained O +
either O +
myristate O -
, O +
palmitate O -
, O +
stearate O -
, O +
or O +
oleate O +
on O +
the O +
sn O +
-1 O +
position O -
. O -

Fig. O +
6A O -
shows O +
that O +
all O +
of O +
the O +
saturated O +
fatty O +
acyl O +
moieties O +
on O +
LPG O +
were O +
present O +
in O +
BMP O +
synthesized O +
whereas O +
monounsaturated O +
oleate O +
was O +
not O -
. O -

( O -
In O +
other O +
experiments O -
, O +
not O +
shown O -
, O +
where O +
a O +
single O +
species O +
of O +
LPG O +
was O +
used O -
, O +
1-oleoyl O +
LPG O +
was O +
transacylated O +
to O +
a O +
low O +
extent O +
only O -
. O -
) O -

The O +
major O +
BMP O +
ion O +
at O +
721 O +
m O -
/ O -
z O +
could O +
be O +
a O +
mixture O +
of O +
myristoyl O -
/ O -
stearoyl O +
BMP O +
and O +
dipalmitoyl O +
BMP O +
so O +
the O +
daughter O +
ions O +
were O +
determined O +
( O -
Fig. O +
6B O +
) O -
. O -

Although O +
the O +
daughter O +
ion O +
analysis O +
is O +
not O +
strictly O +
qualitative O -
, O +
it O +
appears O +
that O +
the O +
721 O +
m O -
/ O -
z O +
peak O +
contains O +
approximately O +
equimolar O +
amounts O +
of O +
myristate O -
, O +
palmitate O -
, O +
and O +
stearate O -
. O -

Table O +
1 O -
has O +
the O +
quantitative O +
analysis O +
of O +
the O +
data O +
in O +
Fig. O +
6A O -
and O +
indicates O +
that O -
, O +
assuming O +
equal O +
amounts O +
of O +
dipalmitoyl O +
and O +
myristoyl O -
/ O -
stearoyl O +
BMP O +
are O +
present O +
in O +
the O +
721 O +
m O -
/ O -
z O +
peak O -
, O +
the O +
TA O +
has O +
a O +
slight O +
preference O +
for O +
the O +
longer O +
chain O +
species O +
of O +
LPG O -
. O -

We O +
then O +
examined O +
the O +
relative O +
activity O +
of O +
1-palmitoyl O +
LPG O +
vs. O +
2-oleoyl O +
LPG O +
( O -
Fig. O +
7 O -
) O -
. O -

We O +
had O +
studied O +
their O +
metabolism O +
earlier O +
with O +
low O +
concentrations O +
of O +
LPGs O +
but O +
without O +
stimulatory O +
diradyl O +
phospholipid O -
. O -

In O +
that O +
case O +
we O +
found O +
that O +
the O +
TA O +
had O +
approximately O +
equal O +
activity O +
on O +
the O +
two O +
LPG O +
species O +
[ O -
8 O -
] O +
. O -

For O +
the O +
study O +
reported O +
here O -
, O +
1-palmitoyl-2-oleoyl O -
- O -
sn O +
-glycero-3-phospho O -
- O -
rac O +
-glycerol O +
( O -
POPG O -
) O +
was O +
hydrolyzed O +
by O +
either O +
a O +
lipase O +
from O +
Rhizopus B-Species +
arrhizus I-Species -
var I-Species -
. L-Species -

delemer U-Species -
, O -
which O +
yields O +
2-oleoyl O +
LPG O +
[ O -
18 O -
] O -
or O +
porcine U-Species +
pancreatic O +
PLA2 O +
, O +
which O +
yields O +
1-palmitoyl O +
LPG O +
[ O -
19 O -
] O +
. O -

When O +
used O +
as O +
substrates O +
singly O +
or O +
in O +
combination O -
, O +
the O +
1-palmitoyl O +
LPG O +
was O +
the O +
better O +
substrate O +
( O -
Fig. O +
6 O +
) O -
. O -

Ideally O -
, O +
the O +
experiment O +
should O +
be O +
conducted O +
with O +
the O +
same O +
acyl O +
chain O +
present O +
in O +
either O +
the O +
sn O +
-1 O +
or O +
sn O +
-2 O +
position O -
. O -

Technically O +
this O +
was O +
not O +
possible O -
. O -

We O +
can O -
not O +
conclude O -
, O +
therefore O -
, O +
that O +
the O +
difference O +
in O +
transacylation O +
using O +
these O +
two O +
substrates O +
is O +
the O +
sole O +
result O +
of O +
the O +
position O +
of O +
the O +
acyl O +
group O -
. O -

Since O +
some O +
1-oleoyl O +
LPG O +
was O +
transacylated O +
in O +
samples O +
containing O +
1-oleoyl O +
LPG O +
and O +
dialkyl O +
PC O +
( O -
data O +
not O +
shown O -
) O +
it O +
appears O +
that O +
the O +
TA O +
does O +
not O +
exclude O +
naturally O +
occurring O +
2-acyl O +
LPG O +
that O +
has O +
an O +
unsaturated O +
acyl O +
chain O +
as O +
substrate O -
. O -

The O +
question O +
then O +
arose O -
, O +
is O +
the O +
TA O +
specific O +
for O +
LPG O +
or O +
can O +
other O +
lysolipids O +
serve O +
as O +
substrates O -
. O -

Fig. O +
8 O -
shows O +
that O +
none O +
of O +
the O +
1-acyl O +
lysolipids O +
examined O +
were O +
substrates O +
at O +
10 O +
or O +
100 O +
μM O +
concentrations O -
. O -

Further O -
, O +
when O +
these O +
lysolipids O +
were O +
mixed O +
at O +
a O +
concentration O +
equal O +
to O +
LPG O -
, O +
inhibition O +
was O +
seen O -
. O -

While O +
not O +
studied O +
further O -
, O +
this O +
could O +
be O +
a O +
competitive O +
type O +
inhibition O +
or O +
the O +
result O +
of O +
surface O +
dilution O +
of O +
LPG O +
in O +
the O +
lipid O +
aggregate O -
. O -

4 O +
Discussion O +
The O +
results O +
presented O +
here O +
show O +
that O +
the O +
TA O +
that O +
converts O +
LPG O +
to O +
BMP O +
is O +
intramolecular O +
involving O +
the O +
transfer O +
of O +
the O +
acyl O +
group O +
from O +
one O +
LPG O +
to O +
another O -
. O -

The O +
enzyme O -
, O +
previously O +
shown O +
to O +
be O +
independent O +
of O +
ATP O +
and O +
CoA O +
[ O -
8 O -
] O +
, O +
most O +
likely O +
involves O +
an O +
acyl U-Species +
enzyme O +
intermediate O -
, O +
although O +
this O +
point O +
can O -
not O +
be O +
proven O +
since O +
both O +
acceptor O +
and O +
donor O +
are O +
always O +
present O -
. O -

The O +
physical O +
state O +
of O +
the O +
substrate O +
appears O +
to O +
play O +
a O +
significant O +
role O +
in O +
the O +
reaction O -
. O -

The O +
1-myristoyl O +
LPG O +
is O +
reported O +
to O +
have O +
a O +
high O +
critical O +
micellar O +
concentration O +
( O -
CMC O -
) O +
ranging O +
from O +
160 O +
to O +
3000 O +
μM O -
, O +
depending O +
on O +
the O +
presence O +
of O +
salt O +
[ O -
20 O -
] O +
. O -

Under O +
the O +
conditions O +
used O +
in O +
our O +
standard O +
assay O -
, O +
10 O +
μM O +
LPG O -
, O +
most O +
substrate O -
, O +
if O +
not O +
all O -
, O +
is O +
monomeric O -
. O -

The O +
presence O +
of O +
diradyl O +
lipid O +
or O +
bile O +
acid O +
would O +
lead O +
to O +
partitioning O +
of O +
the O +
LPG O +
into O +
a O +
lipid O +
aggregate O +
such O +
as O +
a O +
bilayer O +
vesicle O +
or O +
a O +
mixed O +
micelle O -
. O -

If O +
so O -
, O +
the O +
enzyme O +
appears O +
to O +
prefer O +
a O +
lipid O -
/ O -
H2 O +
O O +
interface O +
over O +
monomolecular O +
dispersions O +
of O +
LPG O -
. O -

The O +
unusual O +
dependence O +
of O +
transacylation O +
on O +
both O +
the O +
LPG O +
and O +
PC O +
concentration O +
is O +
consistent O +
with O +
this O +
interpretation O +
( O -
Fig. O +
1 O +
) O -
. O -

Where O +
increasing O +
amounts O +
of O +
POPC O +
( O -
1–100 O +
μM O -
) O +
are O +
added O +
to O +
a O +
fixed O +
amount O +
of O +
LPG O +
( O -
30 O +
μM O -
; O +
Fig. O +
1B O +
) O -
, O +
two O +
considerations O +
must O +
be O +
made O -
, O +
first O +
the O +
intermicellar O +
concentration O +
( O -
IMC O -
) O +
of O +
LPG O +
partitioning O +
into O +
POPC O -
, O +
and O +
second O +
the O +
surface O +
dilution O +
of O +
1-myristoyl O +
LPG O +
in O +
POPC O -
. O -

The O +
fact O +
that O +
POPC O +
does O +
not O +
increase O +
transacylation O +
until O +
the O +
threshold O +
of O +
10 O +
μM O +
is O +
reached O -
, O +
but O +
continues O +
to O +
stimulate O +
to O +
100 O +
μM O -
, O +
suggests O +
that O +
the O +
partitioning O +
of O +
LPG O +
into O +
the O +
lipid O +
interface O -
, O +
the O +
IMC O -
, O +
has O +
more O +
influence O +
on O +
transacylation O +
than O +
does O +
substrate O +
dilution O -
. O -

Comparison O +
of O +
POPC O +
and O +
POPE O +
( O -
Fig. O +
1B O +
) O +
also O +
suggests O +
that O +
not O +
all O +
lipid O -
/ O -
H2 O +
O O +
interfaces O +
support O +
transacylation O -
. O -

POPE O -
, O +
a O +
lipid O +
known O +
to O +
form O +
a O +
Hex O +
II O +
phase O +
[ O -
21 O -
] O +
, O +
was O +
without O +
effect O -
, O +
either O +
the O +
result O +
of O +
little O +
LPG O +
partitioning O +
into O +
the O +
POPE O +
or O +
a O +
lipid O +
polymorphic O +
structure O -
, O +
presumably O +
Hex O +
II O -
, O +
that O +
the O +
TA O +
is O +
unable O +
to O +
productively O +
bind O -
. O -

When O +
a O +
different O +
matrix O +
is O +
present O +
and O +
PE O +
is O +
added O +
with O +
DOC O -
, O +
stimulation O +
is O +
observed O +
( O -
Fig. O +
3 O +
) O -
. O -

We O +
recognize O +
that O +
these O +
interpretations O +
are O +
speculative O +
without O +
data O +
on O +
the O +
lipid O +
structures O +
involved O -
. O -

They O +
do O +
provide O -
, O +
however O -
, O +
a O +
reasonable O +
approach O +
to O +
the O +
understanding O +
of O +
the O +
nature O +
of O +
the O +
lipid O +
mixtures O +
used O -
. O -

Previous O +
work O +
by O +
us O +
and O +
others O +
suggested O +
that O +
the O +
conversion O +
of O +
LPG O +
to O +
BMP O +
involves O +
transferring O +
an O +
acyl O +
chain O +
from O +
a O +
diacyl O +
phospholipid O +
[ O -
8,11–13 O -
] O +
. O -

Those O +
results O +
were O +
obtained O +
with O +
sub O -
- O -
μM O +
concentrations O +
of O +
LPG O +
and O +
transacylation O +
was O +
dependent O +
on O +
added O +
phospholipid O -
. O -

No O +
attempt O +
was O +
made O +
in O +
those O +
experiments O -
, O +
however O -
, O +
to O +
demonstrate O +
the O +
transfer O +
of O +
a O +
radiolabeled O +
fatty O +
acid O +
to O +
BMP O -
. O -

In O +
unpublished O +
experiments O +
we O +
found O +
that O +
a O +
few O +
percent O +
of O +
radiolabeled O +
fatty O +
acid O +
are O +
transferred O +
to O +
BMP O +
from O +
diradyl O +
phospholipids O -
, O +
relative O +
to O +
the O +
total O +
amount O +
of O +
BMP O +
synthesized O -
. O -

How O +
do O +
the O +
results O +
presented O +
here O +
reconcile O +
with O +
those O +
of O +
others O -
? O -

One O +
possible O +
explanation O +
is O +
that O +
multiple O +
transacylases O +
were O +
present O +
in O +
the O +
lysosomal O +
preparation O +
used O +
by O +
others O -
, O +
but O +
not O +
in O +
our O +
partially O +
purified O +
TA O -
. O -

For O +
example O -
, O +
Huterer O +
and O +
Wherett O +
showed O +
that O +
a O +
preparation O +
of O +
rat U-Species +
liver O +
lysosomes O +
transferred O +
[ O -
3 O +
H O -
] O -
oleate O +
from O +
PC O +
to O +
form O +
BMP O +
[ O -
22 O -
] O +
. O -

However O -
, O +
the O +
vast O +
majority O +
of O +
the O +
oleate O +
was O +
released O +
as O +
a O +
free O +
oleate O +
and O +
less O +
than O +
1 O -
% O +
was O +
recovered O +
in O +
BMP O -
. O -

Further O -
, O +
the O +
amount O +
of O +
BMP O +
formed O +
from O +
LPG O +
was O +
far O +
in O +
excess O +
of O +
the O +
amount O +
of O +
oleate O +
incorporated O -
. O -

These O +
data O +
are O +
consistent O +
with O +
our O +
results O +
here O +
that O +
show O +
little O -
, O +
if O +
any O -
, O +
BMP O +
is O +
formed O +
by O +
the O +
transfer O +
of O +
an O +
acyl O +
group O +
from O +
diradyl O +
lipids O -
. O -

The O +
different O +
transacylases O +
described O +
can O +
be O +
classified O +
as O +
follows:1 O -
. O -

acyl O -
- O -
CoA O +
acyltransferases O -
; O -
2 O -
. O -

CoA O +
independent O +
transacylases O -
; O -
3 O -
. O +
lysophospholipases O -
; O -
4 O -
. O -

LPG O +
transacylases O +
( O -
TA O -
) O -
. O -

The O +
acyl O -
- O -
CoA O +
acyltransferase O +
employs O +
an O +
acyl O -
- O -
CoA O +
formed O +
by O +
acyl O -
- O -
CoA O +
synthetase O +
in O +
microsomes O +
and O +
is O +
optimal O +
at O +
pH O +
7.5 O +
[ O -
23 O -
] O +
. O -

These O +
characteristics O +
make O +
it O +
clearly O +
different O +
from O +
the O +
activity O +
described O +
here O -
. O -

The O +
CoA O +
independent O +
transacylase O +
is O +
an O +
enzyme O +
that O +
transfers O +
an O +
acyl O +
group O +
from O +
the O +
sn O +
-2 O +
position O +
of O +
a O +
diradyl O +
phospholipid O +
to O +
a O +
lysolipid O +
[ O -
24 O -
] O +
. O -

If O +
that O +
were O +
the O +
enzyme O +
involved O +
we O +
would O +
expect O +
that O +
PG O +
would O +
be O +
formed O +
from O +
LPG O +
yet O +
none O +
was O +
detected O +
( O -
data O +
not O +
shown O -
) O -
. O -

The O +
transfer O +
of O +
the O +
acyl O +
group O +
only O +
to O +
the O +
head O +
group O +
( O -
prime O -
) O +
glycerol O +
is O +
different O +
from O +
other O +
CoA O +
independent O +
transacylases O -
. O -

The O +
third O -
, O +
lysophospholipase O -
, O +
has O +
one O +
similarity O +
to O +
the O +
activity O +
reported O +
here O -
; O +
two O +
molecules O +
of O +
the O +
same O +
lysolipid O +
are O +
used O +
to O +
form O +
one O +
diradyl O +
phospholipid O +
[ O -
25 O -
] O +
. O -

This O +
enzyme O +
is O +
different O +
from O +
the O +
TA O +
in O +
two O +
important O +
respects O -
, O +
however O -
. O -

First O -
, O +
we O +
find O +
no O +
evidence O +
for O +
lysophospholipase O +
activity O +
in O +
the O +
TA O -
, O +
based O +
on O +
the O +
lack O +
of O +
fatty O +
acid O +
released O +
( O -
data O +
not O +
shown O -
) O -
. O -

Second O -
, O +
the O +
LPC O -
: O -
LPC O +
transacylase O +
has O +
a O +
broad O +
substrate O +
specificity O +
and O +
can O +
use O +
LPG O -
, O +
but O +
in O +
that O +
case O +
PG O -
, O +
not O +
BMP O -
, O +
is O +
formed O +
[ O -
26 O -
] O +
. O -

The O +
TA O +
described O +
here O -
, O +
therefore O -
, O +
appears O +
to O +
be O +
unique O -
. O -

How O +
do O +
the O +
findings O +
reported O +
here O +
fit O +
with O +
the O +
proposed O +
role O +
of O +
the O +
LPG O +
transacylase O +
in O +
Scheme O +
1 O +
? O -

Scheme O +
2 O -
provides O +
a O +
modification O +
of O +
the O +
TA O +
reaction O +
proposed O +
in O +
step O +
2 O +
of O +
Scheme O +
1 O +
. O -

Rather O +
than O +
utilizing O +
a O +
diacyl O +
phospholipid O +
in O +
transacylation O -
, O +
a O +
second O +
molecule O +
of O +
LPG O +
is O +
the O +
acyl O +
donor O +
with O +
the O +
production O +
of O +
glycerophosphoglycerol O +
( O -
GPG O -
) O +
in O +
addition O +
to O +
BMP O -
. O -

The O +
major O +
factor O +
that O +
can O -
not O +
be O +
accommodated O +
is O +
the O +
failure O +
of O +
the O +
TA O +
to O +
use O +
unsaturated O +
fatty O +
acids O +
significantly O -
. O -

We O +
must O +
conclude O +
that O +
polyunsaturated O +
fatty O +
acids O +
such O +
as O +
arachidonate O +
[ O -
7 O -
] O -
or O -
, O +
in O +
particular O -
, O +
docosahexanoate O +
[ O -
27 O -
] O -
are O +
incorporated O +
by O +
some O +
other O +
mechanism O -
. O -

Until O +
the O +
mechanism O +
of O +
stereochemical O +
rearrangement O +
is O +
defined O -
, O +
this O +
question O +
of O +
polyunsaturated O +
fatty O +
acid O +
incorporation O +
remains O +
open O -
. O -

Acknowledgements O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
National O +
Institutes O +
of O +
Health O +
HL-50395 O +
and O +
National O +
Cancer O +
Institute O +
Comprehensive O +
Cancer O +
Center O +
of O +
Wake O +
Forest O +
Grant O +
CA-12197 O -
. O -

Use O +
of O +
the O +
Tissue O +
Culture O +
Core O +
Laboratory O +
is O +
gratefully O +
acknowledged O -
. O -

We O +
especially O +
thank O +
Dr. O +
Mike O +
Thomas O +
and O +
Mike O +
Samuel O +
from O +
Wake O +
Forest O +
University O +
for O +
their O +
technical O +
support O +
in O +
examining O +
the O +
MS O +
samples O -
, O +
and O +
Dr. O +
Nick O +
Ralston O +
and O +
Dr. O +
Koji O +
Shinozaki O +
for O +
their O +
advice O +
and O +
assistance O +
in O +
the O +
laboratory O -
. O +

The O +
authors O +
attempted O +
to O +
evaluate O +
different O +
reagents O +
in O +
order O +
to O +
quantify O +
the O +
amino O +
groups O +
of O +
the O +
platelet O +
membrane O -
. O -

The O +
study O +
was O +
carried O +
out O +
by O +
the O +
action O +
of O +
different O +
aldehydes O +
and O +
acid O +
anhydrides O -
. O -

The O +
use O +
of O +
2,4,6-trinitrobenzenesulfonic O +
acid O +
made O +
possible O +
an O +
approach O +
by O +
electrophoresis O +
and O +
chemical O +
assay O -
. O -

The O +
results O +
showed O +
an O +
increase O +
in O +
the O +
surface O +
charge O +
corresponding O +
to O +
a O +
mean O +
number O +
of O +
amino O -
groups O +
varying O +
from O +
1.86.10 O -
( O -
5 O -
) O +
groups O +
with O +
citraconic O +
acid O +
to O +
3.94.10 O -
( O -
5 O -
) O +
groups O +
with O +
acetaldehyde O -
. O +

The O +
study O +
on O +
the O +
metabolism O +
after O +
oral O +
administration O +
of O +
chenodeoxycholic O +
acid-24 O -
- O -
14C O +
was O +
performed O +
by O +
analysis O +
of O +
radioactivity O +
that O +
had O +
appeared O +
in O +
bile O -
and O +
feces O +
of O +
male O +
hamsters U-Species -
. O -

The O +
radioactive O +
bile O +
acids O +
were O +
analyzed O +
by O +
thin O +
layer O +
chromatography O +
and O +
identified O +
by O +
the O +
isotope O +
dilution O +
method O -
. O -

In O +
the O +
bile O +
of O +
the O +
hamsters U-Species +
with O +
bile O +
fistula O -
, O +
radioactivity O +
was O +
originated O +
from O +
unchanged O +
chenodeoxycholic O +
acid O +
for O +
the O +
most O +
part O -
, O +
and O +
7-ketolithocholic O +
acid O -
, O +
lithocholic O -
acid O -
, O +
and O +
beta O -
- O -
muricholic O +
acid O +
for O +
the O +
remainder O -
. O -

In O +
the O +
feces O +
lithocholic O +
acid O -
, O -
dehydrolithocholic O +
acid O -
, O +
isolithocholic O +
acid O -
, O +
and O +
unchanged O +
form O +
were O +
identified O -
. O -

After O +
the O +
multiple O +
dosing O +
of O +
chenodeoxycholic O +
acid-24 O -
- O -
14C O +
for O +
6 O +
days O -
, O +
beta O -
- O -
muricholic O +
acid O +
was O +
also O +
identified O +
in O +
the O +
feces O -
. O +

1 O -
. O -

Normal O +
human U-Species +
urine O +
contains O +
small O +
amounts O +
( O -
less O +
than O +
4 O +
mg O -
/ O -
g O +
of O +
creatinine O -
) O +
of O -
2-ethylhydracrylic O +
acid O -
, O +
formed O -
, O +
we O +
believe O -
, O +
by O +
a O +
previously O +
undisclosed O +
endogenous O +
catabolic O +
pathway O +
for O +
the O +
oxidation O +
of O +
a O +
newly O +
described O +
series O +
of O +
R O +
metabolites O +
of O +
isoleucine O -
. O -

2 O -
. O -

Urinary O +
excretion O +
of O +
2-ethylhydracrylic O +
acid O +
is O +
variably O +
increased O +
in O +
defects O +
of O +
isoleucine O +
oxidation O +
at O +
distal O +
steps O +
in O +
the O +
catabolic O +
pathway O +
( O -
3-oxoacyl O -
- O -
CoA O +
thiolase O +
deficiency O +
and O +
methylmalonyl O -
- O -
CoA O +
mutase O +
deficiency O -
) O +
and O +
is O +
diminished O +
when O +
proximal O +
steps O +
of O +
the O +
oxidative O +
pathway O +
are O +
blocked O +
as O +
in O +
branched O -
- O -
chain O +
oxo O +
acid O +
decarboxylase O +
deficiency O +
( O -
' O -
maple O -
- O -
syrup O -
- O -
urine O -
' O +
disease O -
) O -
. O -

3 O -
. O +
Precursors O +
of O +
R O -
- O -
pathway O +
metabolites O +
[ O -
R O -
( O -
- O -
) O -
-2-methylbutyrate O +
and O +
2-ethylacrylate O +
] O +
lead O +
to O +
increased O +
2-ethylhydracrylate O +
excretion O +
in O +
the O +
mammal U-Species -
( O -
rat U-Species -
, O +
rabbit U-Species +
and O +
dog U-Species -
) O -
; O +
the O +
corresponding O +
S O +
metabolites O +
[ O -
S O -
( O -
+ O -
) O -
-2-methylbutyric O +
acid O +
and O +
tiglic O +
acid O +
] O -
, O +
when O +
given O +
in O +
equimolar O +
amounts O -
, O +
have O +
little O +
effect O +
on O +
its O +
excretion O -
, O +
suggesting O +
that O -
little O +
or O +
no O +
interconversion O +
between O +
S O +
and O +
R O +
metabolites O +
occurs O +
in O +
vivo O -
. O -

4 O -
. O +
Studies O +
with O +
2H O -
- O -
labelled O +
precursors O +
indicate O +
that O +
conversion O +
of O +
R O +
2-methylbutyrate O +
into O +
2-ethylhydracrylic O +
acid O +
occurs O +
by O +
a O +
direct O +
pathway O +
( O -
apparently O +
via O +
2-ethylacrylic O +
acid O -
) O -
. O -

5 O -
. O -

The O +
further O +
oxidation O +
of O +
2-ethylhydracrylic O +
acid O +
to O +
ethylmalonic O +
acid O +
was O +
demonstrated O -
, O +
and O +
may O +
be O +
analogous O +
to O +
S O -
- O -
metabolite O +
oxidation O +
via O +
methyl O +
malonate O -
. O -

6 O -
. O -

Valine O +
metabolites O +
do O +
not O +
interact O +
with O +
the O +
R O -
= O -
isoleucine O +
pathway O +
under O +
the O +
conditions O +
of O +
these O +
experiments O +
in O +
vivo O -
. O +

In O +
six O +
persons U-Species +
with O +
contact O +
allergy O +
to O +
chrysanthemum U-Species +
of O +
florists U-Species -
, O +
patch O +
tests O +
were O +
performed O +
with O +
25 O +
sequiterpene O +
lactones O -
. O -

Positive O +
responses O +
were O +
observed O +
to O +
15 O +
lactones O -
. O -

The O +
most O +
frequently O +
encountered O +
positive O +
responses O +
were O +
to O +
alantolactone O +
( O -
positive O +
in O +
all O +
cases O -
) O +
and O +
to O +
arbusculin O +
A O -
, O +
8-deoxycumambrin O -
, O +
ambrosin O -
, O +
damsin O +
and O +
psilostachynin O -
. O -

The O +
findings O +
corroborate O +
the O +
assumption O +
that O +
an O +
alpha O -
- O -
methylene O +
group O +
attached O +
to O +
the O +
gamma O -
- O -
lactone O +
ring O +
is O +
an O +
essential O +
prerequisite O +
for O +
allergenic O +
activity O +
of O +
sesquiterpene O +
lactones O -
. O -

Pyrethrum U-Species +
produced O +
a O +
positive O +
reaction O +
in O +
one O +
of O +
the O +
patients U-Species -
, O +
pyrethrins O +
gave O +
negative O +
reactions O +
in O +
all O -
. O -

Some O +
of O +
the O +
chrysanthemum U-Species +
patients U-Species +
were O +
also O +
hypersensitive O +
to O -
turpentine O +
and O +
colophony O +
and O +
to O +
garlic U-Species -
, O +
primin O +
and O +
tars O -
. O +

Depression O +
is O +
a O +
common O +
condition O +
that O +
is O +
often O +
unrecognised O -
, O +
misdiagnosed O +
and/or O -
undertreated O -
. O -

It O +
is O +
associated O +
with O +
substantial O +
direct O -
, O +
indirect O +
and O +
intangible O +
costs O -
. O -

The O +
indirect O +
costs O +
of O +
lost O +
earnings O -
/ O -
productivity O +
and O +
premature O +
death O +
account O +
for O +
the O +
majority O +
of O +
these O +
costs O -
; O +
drug O +
costs O +
account O +
for O +
only O +
about O +
1 O +
to O +
2 O -
% O +
of O +
total O +
costs O +
and O +
about O +
10 O +
to O +
12 O -
% O +
of O +
direct O +
costs O -
. O -

Thus O -
, O +
better O +
recognition O +
and O +
appropriate O +
treatment O +
of O +
depression O +
would O +
increase O +
the O +
direct O +
costs O +
associated O +
with O +
this O +
illness O -
, O +
but O +
would O +
also O +
have O +
the O +
potential O +
to O +
greatly O +
reduce O +
indirect O +
costs O +
and O +
consequently O +
the O +
overall O +
cost O +
of O +
depression O -
. O -

Because O +
of O +
their O -
higher O +
acquisition O +
costs O +
relative O +
to O +
tricyclic O +
antidepressants O +
( O -
TCAs O -
) O -
, O +
there O +
has O -
been O +
much O +
debate O +
about O +
whether O +
the O +
use O +
of O +
sertraline O +
or O +
other O +
selective O +
serotonin O +
reuptake O +
inhibitors O +
( O -
SSRIs O -
) O +
for O +
first O -
- O -
line O +
treatment O +
of O +
depression O +
can O +
be O +
justified O -
. O -

While O +
these O +
agents O +
have O +
similar O +
efficacy O +
to O +
TCAs O -
, O +
they O +
are O +
better O +
tolerated O +
and O +
have O +
a O +
lower O +
risk O +
of O +
death O +
on O +
overdosage O -
. O -

Despite O +
the O +
large O +
economic O +
burden O +
of O +
depression O +
on O +
society O -
, O +
pharmacoeconomic O +
data O +
on O +
sertraline O +
and O +
antidepressant O +
drugs O +
in O +
general O +
are O +
scarce O -
. O -

Most O +
of O +
the O +
available O +
studies O +
on O +
sertraline O +
are O +
limited O +
to O +
considerations O +
of O +
direct O +
costs O +
and O +
do O +
not O +
assess O +
costs O -
from O +
a O +
societal O +
perspective O -
. O -

In O +
addition O -
, O +
a O +
number O +
of O +
studies O +
have O +
significant O +
methodological O +
problems O +
which O +
limit O +
determination O +
of O +
meaningful O +
conclusions O -
. O -

Nonetheless O -
, O +
data O +
from O +
2 O +
more O +
recent O +
studies O +
with O +
fewer O +
methodological O +
problems O +
than O +
earlier O +
studies O +
indicated O +
that O +
sertraline O +
was O +
more O +
cost O -
- O -
effective O +
than O +
TCAs O -
because O +
of O +
fewer O +
psychiatrist O +
consultations O -
, O +
and O +
less O +
costly O +
than O +
fluoxetine O +
because O +
of O +
fewer O +
absences O +
from O +
work O +
and O +
fewer O +
medical O +
consultations O -
. O -

The O +
cost O -
- O -
utility O +
ratio O +
of O +
maintenance O +
therapy O +
of O +
depression O +
with O +
sertraline O +
appears O +
to O +
fall O +
within O +
the O +
range O +
of O +
accepted O +
cost O -
- O -
utility O +
ratios O +
of O +
common O +
healthcare O +
interventions O -
. O -

Thus O -
, O +
studies O +
to O +
date O +
have O +
generally O +
shown O +
that O +
overall O +
treatment O -
costs O +
with O +
sertraline O +
and O +
other O +
SSRIs O +
are O +
no O +
greater O +
than O +
those O +
for O +
TCAs O -
; O +
this O +
is O +
despite O +
the O +
lower O +
acquisition O +
costs O +
of O +
the O +
latter O +
agents O -
. O -

Therefore O -
, O +
it O +
is O +
clear O -
from O +
these O +
data O +
that O +
it O +
is O +
misleading O +
to O +
classify O +
antidepressant O +
agents O +
as O +
expensive O +
or O +
inexpensive O +
based O +
solely O +
on O +
their O +
acquisition O +
costs O -
. O -

Sertraline O -
, O +
therefore O -
, O +
can O +
be O +
considered O +
as O +
a O +
first O -
- O -
line O +
alternative O +
to O +
TCAs O +
and O +
other O +
SSRIs O -
for O +
the O +
treatment O +
of O +
depression O +
on O +
both O +
clinical O +
and O +
pharmacoeconomic O +
grounds O -
. O +

The O +
55-kDa O +
receptor O +
for O +
tumor O +
necrosis O +
factor O +
( O -
TR55 O -
) O +
triggers O +
multiple O +
signaling O -
cascades O +
initiated O +
by O +
adapter O +
proteins O +
like O +
TRADD O +
and O +
FAN O -
. O -

By O +
use O +
of O +
the O +
primary O -
amine O +
monodansylcadaverine O +
( O -
MDC O -
) O -
, O +
we O +
addressed O +
the O +
functional O +
role O +
of O +
tumor O +
necrosis O +
factor O +
( O -
TNF O -
) O +
receptor O +
internalization O +
for O +
intracellular O +
signal O +
distribution O -
. O -

We O +
show O +
that O +
MDC O +
does O +
not O +
prevent O +
the O +
interaction O +
of O +
the O +
p55 O +
TNF O +
receptor O +
( O -
TR55 O -
) O +
with O +
FAN O +
and O +
TRADD O -
. O -

Furthermore O -
, O +
the O +
activation O +
of O +
plasmamembrane O -
- O -
associated O +
neutral O +
sphingomyelinase O +
activation O +
as O +
well O +
as O +
the O +
stimulation O +
of O +
proline O -
- O -
directed O +
protein O +
kinases O +
were O +
not O +
affected O +
in O +
MDC O -
- O -
treated O -
cells O -
. O -

In O +
contrast O -
, O +
activation O +
of O +
signaling O +
enzymes O +
that O +
are O +
linked O +
to O +
the O +
" O -
death O +
domain O -
" O +
of O +
TR55 O -
, O +
like O +
acid O +
sphingomyelinase O +
and O +
c O -
- O -
Jun O -
- O -
N O -
- O -
terminal O +
protein O +
kinase O +
as O +
well O +
as O +
TNF O +
signaling O +
of O +
apoptosis O +
in O +
U937 O +
and O +
L929 O +
cells O -
, O +
are O +
blocked O +
in O +
the O -
presence O +
of O +
MDC O -
. O -

The O +
results O +
of O +
our O +
study O +
suggest O +
a O +
role O +
of O +
TR55 O +
internalization O -
for O +
the O +
activation O +
of O +
select O +
TR55 O +
death O +
domain O +
signaling O +
pathways O +
including O +
those O +
leading O +
to O +
apoptosis O -
. O +

Amiodarone O +
( O -
AD O -
) O +
is O +
an O +
effective O +
antidysrythmic O +
drug O -
, O +
however O -
, O +
there O +
can O +
be O +
serious O +
side O +
effects O -
, O +
such O +
as O +
hepatic O +
and O +
neurological O +
alterations O -
, O +
as O +
well O +
as O +
skin O +
photosensitization O -
, O +
as O +
seen O +
in O +
porphyrias O -
. O -

Clinical O +
signs O +
in O +
porphyrias O +
might O +
be O +
triggered O +
by O +
the O +
so O -
- O -
called O +
porphyrinogenic O +
drugs O -
. O -

Without O +
sound O +
basis O -
, O +
Amiodarone O +
has O +
been O +
classified O +
as O +
an O +
unsafe O +
drug O +
for O +
porphyric O +
patients U-Species -
. O -

The O +
aim O -
of O +
this O +
work O +
has O +
been O +
to O +
study O +
the O +
effect O +
of O +
AD O -
, O +
both O +
in O +
vivo O +
and O +
in O +
vitro O -
, O +
on O +
heme O +
metabolism O -
. O -

In O +
the O +
in O +
vivo O +
assays O -
, O +
the O +
activities O +
of O +
5-aminolevulinate O +
synthetase O +
( O -
ALA O -
- O -
S O -
) O -
, O +
ALA O +
dehydratase O +
( O -
ALA O -
- O -
D O -
) O -
, O +
porphobilinogenase O +
( O -
PBGase O -
) O +
and O +
PBG O -
- O -
deaminase O +
( O -
PBG O -
- O -
D O -
) O +
in O +
blood O -
, O +
liver O -
, O +
and O +
kidney O -
; O +
hepatic O +
and O +
fecal O +
porphyrins O -
, O -
urinary O +
ALA O -
, O +
PBG O +
and O +
porphyrins O +
in O +
male O +
mice B-Species +
strain I-Species +
CF1 L-Species +
treated O +
with O +
AD O +
( O -
100 O +
mg O +
i.p O -
. O -

daily O -
) O +
for O +
1 O +
week O +
and O +
1 O +
month O -
, O +
were O +
measured O -
. O -

No O +
significanat O +
differences O +
were O +
found O +
for O +
any O +
of O +
these O +
parameters O +
in O +
the O +
AD O +
treated O +
animals U-Species +
as O +
compared O +
to O +
controls O -
. O -

In O +
the O +
in O +
vitro O +
experiments O +
human U-Species +
blood O -
, O +
and O +
mice U-Species +
blood O -
, O +
liver O -
, O +
and O +
kidney O -
, O +
were O +
used O +
to O +
measure O +
the O +
activities O +
of O +
ALA O -
- O -
S O -
, O +
ALA O -
- O -
D O -
, O +
PBGase O -
, O +
PBG O -
- O -
D O +
and O +
uroporphyrinogen O +
decarboxylase O -
, O +
in O +
the O +
presence O +
of O +
varying O +
concentrations O +
of O +
AD O +
( O -
0.0172 O -
- O -
4.304 O +
mM O -
) O -
. O -

AD O +
did O +
not O +
modify O +
any O +
of O +
the O +
enzyme O +
activities O -
. O -

All O +
of O +
the O +
above O +
biochemical O +
parameters O +
were O +
studied O +
in O +
17 O +
cardiac O +
patients U-Species +
under O +
AD O +
treatment O +
for O +
3 O +
to O +
20 O +
years O -
. O -

Neither O +
the O +
activities O +
of O +
the O +
heme O +
enzymes O -
, O +
nor O +
the O -
levels O +
of O +
precursors O +
and O +
porphyrins O +
in O +
urine O +
and O +
plasma O +
were O +
altered O -
. O -

These O +
findings O +
clearly O +
demonstrate O +
that O +
AD O +
is O +
a O +
pharmacologically O +
safe O +
drug O +
and O +
can O +
be O -
used O +
for O +
the O +
treatment O +
of O +
associated O +
pathologies O +
in O +
porphyrias O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
antimutagenicity O +
of O +
WR-1065 O +
added O -
after O +
irradiation O +
of O +
cells O +
of O +
cell O +
lines O +
differing O +
in O +
their O +
ability O +
to O +
rejoin O +
radiation O -
- O -
induced O +
DNA O +
double O -
- O -
strand O +
breaks O +
( O -
DSBs O -
) O -
. O -

The O +
postirradiation O +
antimutagenicity O +
of O +
WR-1065 O +
at O +
the O +
thymidine O +
kinase O +
locus O +
was O +
demonstrated O +
for O +
L5178Y O +
( O -
LY O -
) O -
-S1 O +
cells O +
that O +
are O +
deficient O +
in O +
repair O +
of O +
DNA O +
DSBs O -
. O -

Less O +
postirradiation O +
antimutagenicity O +
of O +
WR-1065 O +
was O +
observed O +
in O +
LY O -
- O -
R16 O +
and O +
LY O -
- O -
SR1 O +
cells O -
, O +
which O +
are O +
relatively O +
efficient O +
in O +
DSB O +
repair O -
. O -

Postirradiation O +
treatment O +
with O +
WR-1065 O +
had O +
only O +
a O +
small O +
stimulatory O +
effect O +
on O +
DSB O +
rejoining O -
. O -

A O +
3-h O +
incubation O +
of O +
irradiated O +
LY O +
cells O +
with O +
WR-1065 O +
caused O +
slight O +
changes O +
in O +
the O +
distribution O +
of O +
cells O +
in O +
the O +
phases O +
of O +
the O +
cell O +
cycle O +
that O +
differed O +
between O +
LY O -
- O -
S1 O +
and O +
LY O -
- O -
SR1 O +
cells O -
. O -

Both O +
LY O -
- O -
S1 O +
and O +
LY O -
- O -
SR1 O +
cells O +
were O +
protected O +
against O +
the O +
cytotoxic O +
and O +
mutagenic O +
effects O +
of O +
radiation O +
when O +
WR-1065 O +
was O +
present O +
30 O +
min O +
before O +
and O +
during O +
the O +
irradiation O -
. O -

We O +
conclude O +
that O +
the O +
differential O +
postirradiation O +
effects O +
of O +
WR-1065 O +
in O +
the O +
LY O -
- O -
S1 O +
and O +
LY O -
- O -
SR1 O +
cells O +
are O +
not O +
caused O +
by O +
differences O +
in O +
cellular O +
uptake O +
of O +
the O +
radioprotector O +
or O +
in O +
its O +
radical O +
scavenging O +
activity O -
. O -

Possible O +
mechanisms O +
for O +
the O +
postirradiation O +
antimutagenicity O +
of O +
WR-1065 O +
are O +
discussed O -
. O +

Nitric O +
oxide O +
( O -
NO O -
) O +
and O +
tumor O +
necrosis O +
factor O +
alpha O +
( O -
TNF O -
- O -
alpha O -
) O +
are O +
the O +
major O +
mediators O +
produced O +
in O +
activated O +
macrophages O +
which O +
contribute O +
to O +
the O +
circulatory O +
failure O +
associated O +
with O +
septic O +
shock O -
. O -

A O +
sesquiterpene O +
lactone O +
compound O +
( O -
dehydrocostus O +
lactone O -
) O +
isolated O +
from O +
the O +
medicinal O +
plant O -
, O +
Saussurea B-Species +
lappa L-Species -
, O +
inhibited O +
the O +
production O +
of O +
NO O +
in O +
lipopolysaccharide O +
( O -
LPS O -
) O -
-activated O +
RAW B-Species +
264.7 L-Species +
cells O +
by O +
suppressing O +
inducible O +
nitric O +
oxide O +
synthase O +
enzyme O +
expression O -
. O -

This O +
compound O +
also O +
decreased O +
the O +
TNF O -
- O -
alpha O +
level O +
in O +
LPS O -
- O -
activated O +
systems O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

Thus O -
, O +
dehydrocostus O +
lactone O +
may O +
be O +
a O +
possible O +
candidate O +
for O +
the O +
development O +
of O +
new O +
drugs O +
to O +
treat O +
endotoxemia O +
accompanied O +
by O +
the O +
overproduction O +
of O +
NO O +
and O +
TNF O -
- O -
alpha O -
. O +

The O +
putative O +
biosynthetic O +
gene O +
cluster O +
for O +
the O +
alpha O -
- O -
glucosidase O +
inhibitor O +
acarbose O +
was O +
identified O +
in O +
the O +
producer O +
Actinoplanes B-Species +
sp. I-Species +
50 I-Species -
/ I-Species -
110 L-Species +
by O +
cloning O +
a O +
DNA O -
segment O +
containing O +
the O +
conserved O +
gene O +
for O +
dTDP O -
- O -
D O -
- O -
glucose O +
4,6-dehydratase O -
, O +
acbB. O +
The O +
two O +
flanking O +
genes O +
were O +
acbA O +
( O -
dTDP O -
- O -
D O -
- O -
glucose O +
synthase O -
) O +
and O +
acbC O -
, O +
encoding O +
a O +
protein O +
with O +
significant O +
similarity O +
to O +
3-dehydroquinate O +
synthases O +
( O -
AroB O +
proteins O -
) O -
. O -

The O +
acbC O +
gene O +
was O +
overexpressed O +
heterologously O +
in O +
Streptomyces B-Species +
lividans I-Species +
66 L-Species -
, O +
and O +
the O +
product O +
was O +
shown O +
to O +
be O +
a O +
C7-cyclitol O +
synthase O +
using O +
sedo O -
- O -
heptulose O +
7-phosphate O -
, O +
but O +
not O +
ido O -
- O -
heptulose O +
7-phosphate O -
, O +
as O +
its O +
substrate O -
. O -

The O +
cyclization O +
product O -
, O +
2-epi-5-epi O -
- O -
valiolone O +
( O -
( O -
2S,3S,4S,5R O -
) O -
-5- O -
( O -
hydroxymethyl O -
) O -
cyclohexanon-2,3,4,5-tetrol O -
) O -
, O +
is O +
a O +
precursor O +
of O +
the O +
valienamine O +
moiety O +
of O +
acarbose O -
. O -

A O +
possible O +
five O -
- O -
step O +
reaction O +
mechanism O +
is O +
proposed O +
for O +
the O +
cyclization O +
reaction O +
catalyzed O +
by O +
AcbC O +
based O +
on O +
the O +
recent O +
analysis O +
of O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
a O +
eukaryotic O +
3-dehydroquinate O +
synthase O +
domain O +
( O -
Carpenter O -
, O +
E. O +
P. O -
, O +
Hawkins O -
, O +
A. O +
R. O -
, O +
Frost O -
, O +
J. O +
W. O -
, O +
and O +
Brown O -
, O +
K. O +
A. O +
( O -
1998 O -
) O +
Nature O +
394 O -
, O +
299 O -
- O -
302 O -
) O -
. O +

The O +
mechanism O +
of O +
DNA O +
damage O +
induced O +
by O +
metabolites O +
of O +
nitrobenzene O +
was O +
investigated O +
in O +
relation O +
to O +
the O +
carcinogenicity O +
and O +
reproductive O +
toxicity O +
of O +
nitrobenzene O -
. O -

Nitrosobenzene O -
, O +
a O +
nitrobenzene O +
metabolite O -
, O +
induced O +
NADH O +
plus O +
Cu O -
( O -
II O -
) O -
-mediated O +
DNA O +
cleavage O +
frequently O +
at O +
thymine O +
and O +
cytosine O +
residues O -
. O -

Catalase O +
and O +
bathocuproine O +
inhibited O +
the O +
DNA O +
damage O -
, O +
suggesting O +
the O +
involvement O +
of O +
H2O2 O +
and O +
Cu O -
( O -
I O -
) O -
. O -

Typical O +
free O +
hydroxyl O +
radical O +
scavengers O +
showed O +
no O +
inhibitory O -
effects O +
on O +
DNA O +
damage O -
. O -

Nitrosobenzene O +
caused O +
the O +
formation O +
of O +
8-oxo-7 O -
, O +
8-dihydro-2'-deoxyguanosine O +
in O +
calf U-Species +
thymus O +
DNA O +
in O +
the O +
presence O +
of O +
NADH O +
and O +
Cu O -
( O -
II O -
) O -
. O -

ESR O +
spectroscopic O +
study O +
has O +
confirmed O +
that O +
nitrosobenzene O +
is O +
reduced O +
by O +
NADH O +
to O +
the O +
phenylhydronitroxide O +
radical O +
even O +
in O +
the O +
absence O +
of O +
Cu O -
( O -
II O -
) O -
. O -

These O +
results O +
suggest O +
that O +
nitrosobenzene O +
can O +
be O +
reduced O +
non O -
- O -
enzymatically O +
by O +
NADH O -
, O +
and O +
the O +
redox O +
cycle O +
reaction O +
resulted O +
in O +
oxidative O +
DNA O +
damage O +
due O +
to O +
the O +
copper O -
- O -
oxygen O +
complex O -
, O +
derived O +
from O +
the O +
reaction O +
of O +
Cu O -
( O -
I O -
) O +
with O +
H2O2 O -
. O +

1 O -
. O -

The O +
urinary O +
metabolic O +
fate O +
of O +
4-fluoroaniline O +
( O -
4-FA O -
) O +
and O +
1- O -
[ O -
13C O -
] O -
-4-fluoroacetanilide O +
( O -
4-FAA O -
) O +
has O +
been O +
studied O +
using O +
NMR O -
- O -
based O +
methods O +
after O +
50 O +
and O +
100 O +
mg O +
kg O -
( O -
-1 O -
) O +
i.p O -
. O -

doses O +
respectively O +
to O +
the O +
male O +
Sprague B-Species -
- I-Species -
Dawley I-Species +
rat L-Species -
. O -

2 O -
. O +
4-FA O +
was O +
both O +
ortho- O +
and O +
para O -
- O -
hydroxylated O -
. O -

The O +
major O +
metabolite O +
produced O +
by O +
ortho O -
- O -
hydroxylation O +
was O +
2-amino-5-fluorophenylsulphate O +
accounting O +
for O +
approximately O +
30 O -
% O +
of O +
the O +
dose O -
. O -

Of O +
the O +
dose O -
, O +
approximately O +
10 O -
% O +
was O +
excreted O +
via O +
para O -
- O -
hydroxylation O +
and O +
the O +
resulting O +
defluorinated O +
metabolites O +
were O +
N O -
- O -
acetylated O -
and O +
excreted O +
as O +
sulphate O +
( O -
major O -
) O -
, O +
glucuronide O +
( O -
minor O -
) O +
and O +
N O -
- O -
acetyl O -
- O -
cysteinyl O +
( O -
minor O -
) O +
conjugates O +
of O +
4-acetamidophenol O +
( O -
paracetamol O -
) O -
. O -

3 O -
. O -

The O +
major O +
route O +
of O +
metabolism O +
of O +
1- O -
[ O -
13C O -
] O -
-4-FAA O +
was O +
N O -
- O -
deacetylation O +
and O +
the O +
metabolites O +
excreted O +
in O +
the O +
urine O +
were O +
qualitatively O +
identical O +
to O +
4-FA O -
. O -

The O +
paracetamol O +
metabolites O +
produced O +
via O +
para O -
- O -
hydroxylation O +
were O +
also O +
a O +
product O +
of O +
N O -
- O -
deacetylation O +
and O +
reacetylation O -
, O +
as O +
the O +
[ O -
13C O -
] O -
-label O +
was O +
not O +
retained O -
. O -

4 O -
. O -

These O +
studies O +
demonstrate O -
the O +
value O +
of O +
[ O -
13C O -
] O -
-labelling O +
in O +
understanding O +
the O +
contribution O +
of O +
N O -
- O -
acetylation O -
, O -
and O +
futile O +
deacetylation O -
- O -
reacetylation O +
reactions O -
, O +
in O +
aniline O +
metabolism O -
. O -

In O +
addition O -
, O +
this O +
work O +
sheds O +
new O +
light O +
on O +
the O +
metabolic O +
lability O +
of O +
certain O +
aromatic O +
fluorine O +
substituents O -
. O +

Masoprocol O +
( O -
nordihydroguaiaretic O +
acid O -
) O +
is O +
a O +
lipoxygenase O +
inhibitor O +
isolated O +
from O -
the O +
creosote B-Species +
bush L-Species +
and O +
used O +
by O +
native O +
healers O +
to O +
treat O +
type O +
2 O +
diabetes O -
. O -

It O +
has O +
been O +
recently O +
shown O +
to O +
decrease O +
serum O +
glucose O -
, O +
free O +
fatty O +
acid O +
( O -
FFA O -
) O -
, O +
and O +
triglyceride O +
( O -
TG O -
) O +
concentrations O +
in O +
rodent U-Species +
models O +
of O +
type O +
2 O +
diabetes O -
. O -

The O +
current O +
study O +
was O +
initiated O +
to O +
quantify O +
the O +
effects O +
of O +
masoprocol O +
incubation O +
of O +
adipocytes O +
isolated O +
from O +
normal O +
rats U-Species -
. O -

The O +
results O +
indicate O +
that O +
masoprocol O +
significantly O +
increased O +
glucose O +
uptake O +
by O +
adipocytes O +
in O +
both O +
the O +
absence O +
and O +
presence O +
of O +
insulin O -
. O -

In O +
addition O -
, O +
the O +
maximal O +
rate O +
of O +
insulin O -
- O -
stimulated O +
glucose O -
transport O +
was O +
increased O +
in O +
adipocytes O +
incubated O +
with O +
masoprocol O +
and O +
the O +
insulin O +
concentration O +
resulting O +
in O +
a O +
half O -
- O -
maximal O +
glucose O +
transport O +
rate O +
( O -
ED50 O -
) O +
decreased O -
. O -

Finally O -
, O +
isoproterenol O -
- O -
stimulated O +
increases O +
in O +
FFA O +
and O +
glycerol O +
release O +
were O +
significantly O +
decreased O +
in O +
the O +
presence O +
of O +
masoprocol O -
. O -

These O +
results O +
provide O +
an O +
explanation O +
at O +
the O +
cellular O +
level O +
for O +
the O +
observation O +
that O +
masoprocol O -
decreases O +
serum O +
glucose O -
, O +
insulin O -
, O +
and O +
FFA O +
concentrations O +
in O +
rodent U-Species +
models O +
of O +
type O +
2 O +
diabetes O -
. O +

Free O +
d O +
-amino O +
acids O +
have O +
been O +
shown O +
to O +
be O +
present O +
in O +
a O +
large O +
variety O +
of O +
species O -
, O +
including O +
mammals U-Species +
and O -
, O +
more O +
specifically O -
, O +
humans U-Species +
[ O -
1,2 O -
] O +
. O -

In O +
particular O -
, O +
d O +
-aspartate O +
has O +
drawn O +
special O +
interest O +
since O +
( O -
a O -
) O +
its O +
levels O +
are O +
often O +
found O +
to O +
be O +
the O +
highest O +
amongst O +
d O +
-amino O +
acids O +
[ O -
3 O -
] O +
, O +
( O -
b O -
) O +
recent O +
reports O +
propose O +
some O +
yet O +
unknown O +
neuronal O +
and O +
neuroendocrine O +
roles O +
of O +
d O +
-aspartate O +
[ O -
4,5 O -
] O +
, O +
( O -
c O -
) O +
high O +
levels O +
of O +
d O +
-aspartate O +
in O +
the O +
brain O +
and O +
other O +
tissues O +
of O +
mammals U-Species +
were O +
discovered O +
by O +
several O +
authors O +
[ O -
6–8 O -
] O +
, O +
( O -
d O -
) O +
abnormal O +
levels O +
of O +
d O +
-aspartate O +
have O +
been O +
reported O +
in O +
relation O +
to O +
Alzheimer O -
, O +
senescence O +
and O +
renal O +
diseases O +
[ O -
9,10 O -
] O +
, O +
( O -
e O -
) O +
various O +
levels O +
of O +
d O +
-amino O +
acids O +
are O +
produced O +
during O +
food O +
processing O +
[ O -
11 O -
] O +
, O +
( O -
f O -
) O +
d O +
-aspartate O +
and O +
other O +
chemically O +
related O +
molecules O +
( O -
such O +
as O +
N O +
-methyl O -
- O -
d O +
-aspartate O -
) O +
are O +
widely O +
used O +
as O +
agonists O +
or O +
antagonists O +
of O +
neurochemical O +
transmitters O +
both O +
in O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
and O +
( O -
h O -
) O +
some O +
of O +
them O +
might O +
play O +
such O +
a O +
role O +
also O +
in O +
vivo O +
[ O -
4,12,13 O -
] O +
. O -

Despite O +
the O +
growing O +
interest O +
in O +
the O +
biological O +
functions O +
of O +
d O +
-aspartate O -
, O +
little O +
is O +
known O +
about O +
its O +
origin O +
and O +
metabolism O +
in O +
mammals U-Species -
. O -

In O +
this O +
regard O -
, O +
a O +
flavoprotein O +
with O +
d O +
-aspartate O +
oxidase O +
activity O +
has O +
been O +
purified O -
, O +
characterized O +
and O +
cloned O +
from O +
beef U-Species +
kidney O +
cortex O +
[ O -
14–17 O -
] O -
and O -
, O +
more O +
recently O -
, O +
from O +
human U-Species +
brain O +
[ O -
18 O -
] O +
. O -

The O +
enzyme O +
from O +
beef U-Species +
kidney O +
cortex O +
( O -
bDASPO O -
) O +
has O +
been O +
thoroughly O +
investigated O +
as O +
far O +
as O +
primary O +
structure O -
, O +
kinetic O +
mechanism O -
, O +
FAD O +
binding O +
and O +
spectroscopic O +
properties O +
of O +
the O +
free O +
and O +
ligand O -
- O -
bound O +
enzyme O +
are O +
concerned O +
[ O -
14–16 O -
] O +
. O -

It O +
is O +
a O +
monomer O +
with O +
a O +
molecular O +
weight O +
of O +
37 O +
659 O +
( O -
apo O -
- O -
protein O -
) O +
containing O +
one O +
molecule O +
of O +
flavin O -
. O -

It O +
is O +
isolated O +
as O +
a O +
mixture O +
of O +
an O +
active O +
form O +
containing O +
FAD O +
( O -
FAD O -
- O -
bDASPO O -
) O +
and O +
an O +
inactive O +
form O +
( O -
9–20 O -
% O +
depending O +
on O +
the O +
purification O -
) O +
containing O +
6-OH O -
- O -
FAD O +
( O -
6-OH O -
- O -
FAD O -
- O -
bDASPO O -
) O -
. O -

The O +
enzyme O +
catalyzes O +
the O +
oxidative O +
deamination O +
of O +
dicarboxylic O +
d O +
-amino O +
acids O +
by O +
O2 O -
with O +
the O +
production O +
of O +
H2 O +
O2 O +
, O +
NH3 O -
and O +
the O +
corresponding O +
α O -
- O -
keto O +
acids O -
. O -

The O +
relatively O +
low O +
abundance O +
of O +
the O +
enzyme O -
, O +
and O +
the O +
consequently O +
long O +
purification O +
procedure O -
, O +
hampered O +
so O +
far O +
the O +
use O +
of O +
this O +
protein O +
as O +
a O +
tool O +
to O +
study O +
the O +
presence O +
and O +
biological O +
significance O +
of O +
dicarboxylic O +
d O +
-amino O +
acids O +
in O +
organisms O -
. O -

In O +
order O +
to O +
overcome O +
this O +
problem O -
, O +
a O +
procedure O +
to O +
overexpress O +
recombinant O +
d O +
-aspartate O +
oxidase O +
( O -
rDASPO O -
) O +
in O +
Escherichia B-Species +
coli L-Species -
has O +
been O +
set O +
up O +
[ O -
17 O -
] O +
. O -

Starting O +
from O +
the O +
latter O +
study O -
, O +
the O +
present O +
paper O +
reports O +
overexpression O +
and O +
purification O +
protocols O +
leading O +
to O +
large O +
amounts O +
of O +
homogeneous O +
and O +
catalytically O +
active O +
rDASPO O -
. O -

The O +
biochemical O +
characterization O +
of O +
the O +
recombinant O +
enzyme O +
shows O +
that O +
rDASPO O +
possesses O +
the O +
same O +
catalytic O +
properties O +
of O +
bDASPO O +
and O -
, O +
therefore O -
, O +
can O +
be O +
used O +
to O +
extend O +
the O +
study O +
of O +
the O +
properties O +
of O +
DASPO O -
. O -

In O +
particular O -
, O +
in O +
this O +
paper O +
we O +
focused O +
our O +
attention O +
on O +
the O +
determination O +
of O +
the O +
redox O +
potential O +
of O +
DASPO O +
and O +
to O +
possible O +
interactions O +
between O +
the O +
enzyme O +
and O +
a O +
variety O +
of O +
molecules O +
used O +
as O +
agonists O +
or O +
antagonists O +
of O +
neurotransmitters O +
[ O -
12 O -
] O +
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Overexpression O +
and O +
purification O +
of O +
rDASPO O +
E. B-Species +
coli I-Species -
GI724 L-Species +
cells O -
, O +
carrying O +
the O +
cI O -
repressor O +
gene O +
engineered O +
into O +
bacterial O +
chromosome O +
under O +
the O +
control O +
of O +
the O +
Trp O -
promoter O -
, O +
were O +
freshly O +
transformed O +
with O +
the O +
recombinant O +
plasmid O +
pED O +
carrying O +
the O +
gene O +
for O +
bovine U-Species +
kidney O +
d O +
-aspartate O +
oxidase O +
under O +
the O +
control O +
of O +
the O +
λ O +
PL O -
promoter O +
[ O -
17 O -
] O +
. O -

200 O +
ml O +
RM O +
medium O +
( O -
6 O +
g O +
Na2 O +
HPO4 O +
, O +
3 O +
g O +
KH2 O +
PO4 O +
, O +
0.5 O +
g O +
NaCl O -
, O +
1 O +
g O +
NH4 O +
Cl O -
, O +
95.21 O +
mg O +
MgCl2 O +
, O +
20 O +
g O +
casamino O +
acids O -
, O +
10 O +
ml O +
glycerol O +
in O +
1 O +
l O -
) O +
containing O +
100 O +
μg O +
ampicillin O +
ml−1 O -
were O +
inoculated O +
with O +
20 O +
ml O +
overnight O +
precultures O +
of O +
GI724 U-Species +
( O -
pED O -
) O +
and O +
the O +
cells O +
grown O +
at O +
30 O -
° O -
C O +
up O +
to O +
A O +
550 O -
0.5 O -
. O -

The O +
material O +
was O +
used O +
to O +
inoculate O +
6 O +
l O +
of O +
induction O +
medium O +
( O -
6 O +
g O +
Na2 O +
HPO4 O +
, O +
3 O +
g O +
KH2 O +
PO4 O +
, O +
0.5 O +
g O +
NaCl O -
, O +
1 O +
g O +
NH4 O +
Cl O -
, O +
95.21 O +
mg O +
MgCl2 O +
, O +
2 O +
g O +
casamino O +
acids O -
, O +
5 O +
g O +
glucose O +
for O +
1 O +
l O -
) O +
containing O +
100 O +
μg O +
ampicillin O +
ml−1 O -
in O +
a O +
fermenter O +
( O -
BioIndustrie O +
Mantovane O -
, O +
Italy O -
) O +
and O +
the O +
cells O +
grown O +
at O +
30 O -
° O -
C O +
until O +
A O +
550 O -
reached O +
0.5 O -
. O -

Expression O +
was O +
induced O +
by O +
adding O +
tryptophan O +
to O +
a O +
final O +
concentration O +
of O +
100 O +
μg O +
ml−1 O -
and O +
raising O +
the O +
temperature O +
to O +
37 O -
° O -
C O -
. O -

The O +
cells O +
were O +
harvested O +
after O +
16 O +
h O -
, O +
centrifuged O +
at O +
14 O +
000 O -
× O -
g O -
for O +
25 O +
min O -
, O +
resuspended O +
in O +
cold O +
0.9 O -
% O +
NaCl O -
, O +
centrifuged O +
at O +
27 O +
000 O -
× O -
g O -
and O +
the O +
pellet O +
stored O +
at O +
−80 O -
° O -
C O -
. O -

All O +
purification O +
steps O +
were O +
performed O +
at O +
4 O -
° O -
C O +
and O +
all O +
buffers O +
contained O +
0.3 O +
mM O +
EDTA O +
and O +
5 O +
mM O +
sodium O +
potassium O +
tartrate O -
, O +
unless O +
otherwise O +
indicated O -
. O -

Cells O +
were O +
resuspended O +
in O +
2 O +
vols O -
. O -

of O +
50 O +
mM O +
NaPi O -
, O +
pH O +
8.0 O -
, O +
1 O +
mM O +
phenylmethylsulfonyl O +
fluoride O -
, O +
20 O +
μM O +
FAD O -
, O +
sonicated O +
and O +
centrifuged O +
at O +
27 O +
000 O -
× O -
g O -
for O +
30 O +
min O -
. O -

Protamine O +
sulfate O +
was O +
slowly O +
added O +
to O +
a O +
final O +
concentration O +
of O +
0.2 O -
% O +
at O +
0 O -
° O -
C O -
, O +
the O +
material O +
was O +
left O +
at O +
the O +
same O +
temperature O +
for O +
an O +
additional O +
15 O +
min O +
and O +
then O +
centrifuged O +
at O +
27 O +
000 O -
× O -
g O -
for O +
1 O +
h. O +
The O +
supernatant O +
was O +
adjusted O +
to O +
0 O -
. O +
15 O +
M O +
NaPi O -
, O +
pH O +
6.75 O +
and O +
loaded O +
on O +
a O +
Phenyl B-Species -
- I-Species -
Sepharose I-Species +
CL-4B L-Species +
column O +
( O -
13 O -
× O -
2.6 O +
cm O -
) O +
equilibrated O +
in O +
the O +
same O +
buffer O -
. O -

The O +
column O +
was O +
washed O +
with O +
2 O +
vols O -
. O -

of O +
starting O +
buffer O +
and O +
the O +
enzyme O +
eluted O +
with O +
10 O +
mM O +
NaPi O -
, O +
pH O +
8.0 O -
. O -

The O +
active O +
fractions O +
( O -
total O +
volume O +
about O +
2.5 O +
l O -
) O +
were O +
brought O +
to O +
20 O +
μM O +
FAD O -
, O +
50 O +
mM O +
MES O +
pH O +
5.5 O +
using O +
a O +
concentrated O +
solution O +
of O +
this O +
buffer O -
, O +
divided O +
in O +
300 O +
ml O +
aliquots O +
and O +
directly O +
loaded O +
on O +
a O +
S15 O +
strong O +
cationic O +
exchanger O +
membrane O +
adsorber O +
( O -
Sartorius O +
AG O -
, O +
Germany O -
) O +
equilibrated O +
in O +
50 O +
mM O +
MES O -
, O +
pH O +
5.5 O -
. O -

The O +
membrane O +
was O +
washed O +
with O +
10 O +
ml O +
of O +
the O +
starting O +
buffer O +
and O +
eluted O +
with O +
the O +
same O +
buffer O +
containing O +
1 O +
M O +
NaCl O +
in O +
2 O +
ml O +
fractions O -
. O -

The O +
active O +
fractions O +
were O +
pooled O +
and O +
equilibrated O +
in O +
50 O +
mM O +
HEPES O -
, O +
pH O +
8.0 O -
, O +
5 O +
mM O +
sodium O +
potassium O +
tartrate O -
, O +
0.3 O +
mM O +
EDTA O -
, O +
20 O +
μM O +
FAD O +
using O +
an O +
Amicon O -
- O -
PM O +
10 O +
membrane O -
. O -

The O +
pure O +
enzyme O +
was O +
stored O +
under O +
these O +
conditions O +
at O +
−80 O -
° O -
C O -
. O -

If O +
necessary O -
, O +
excess O +
FAD O +
and O +
tartrate O +
were O +
removed O +
prior O +
to O +
experiments O +
by O +
gel O +
filtration O +
on O +
a O +
PD-10 O +
column O +
( O -
Pharmacia O -
) O +
equilibrated O +
either O +
in O +
50 O +
mM O +
HEPES O -
, O +
pH O +
8.0 O +
or O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
. O -

In O +
conclusion O -
, O +
the O +
recombinant O +
protein O +
was O +
purified O +
following O +
a O +
new O +
procedure O +
greatly O +
simplified O +
as O +
compared O +
to O +
the O +
one O +
used O +
for O +
the O +
enzyme O +
from O +
beef U-Species +
kidney O +
cortex O +
[ O -
14 O -
] O +
, O +
omitting O +
the O +
heat O -
, O +
gel O +
filtration O +
and O +
Mono O +
Q O +
ion O -
- O -
exchange O +
steps O +
and O +
performing O +
the O +
final O +
ion O -
- O -
exchange O +
step O +
on O +
a O +
S15 O +
strong O +
cationic O +
exchanger O +
membrane O +
adsorber O +
instead O +
of O +
the O +
original O +
Mono O +
S O +
column O -
. O -

The O +
latter O +
modification O +
has O +
the O +
main O +
advantages O +
of O +
avoiding O +
time O +
consuming O +
concentration O +
and O +
equilibration O +
steps O +
and O +
exposure O +
of O +
the O +
enzyme O +
to O +
room O +
temperature O +
during O +
FPLC O +
chromatography O -
. O -

2.2 O +
Activity O +
assay O +
The O +
oxidase O +
activity O +
was O +
determined O +
by O +
the O +
spectrophotometric O +
method O +
set O +
up O +
in O +
[ O -
14 O -
] O -
which O +
couples O +
the O +
production O +
of O +
hydrogen O +
peroxide O +
in O +
the O +
DASPO O -
- O -
catalyzed O +
reaction O +
with O +
the O +
oxidation O +
of O +
o O +
-dianisidine O +
by O +
horseradish O +
peroxidase O +
( O -
ϵ436 O +
= O -
11 O +
610 O +
M−1 O -
cm−1 O +
) O -
. O -

The O +
reaction O +
mixture O +
contained O +
90 O +
μg O +
o O +
-dianisidine-2 O +
HCl O -
, O +
20 O +
nmol O +
FAD O -
, O +
64 O +
μg O +
horseradish O +
peroxidase O +
and O +
variable O +
amounts O +
of O +
substrate O +
( O -
routinely O +
10 O +
mM O +
d O +
-aspartate O -
) O +
in O +
1 O +
ml O +
of O +
50 O +
mM O +
KPi O -
, O +
pH O +
7.4 O -
, O +
at O +
25 O -
° O -
C O -
. O -

The O +
reaction O +
was O +
started O +
by O +
addition O +
of O +
variable O +
amounts O +
of O +
rDASPO O +
( O -
20 O +
ng–4 O +
μg O -
) O +
depending O +
on O +
the O +
substrate O +
tested O -
. O -

1 O +
U O +
of O +
enzyme O +
is O +
defined O +
as O +
the O +
amount O +
which O +
oxidizes O +
1 O +
μmol O +
substrate O +
min−1 O +
. O -

When O +
a O +
compound O +
was O +
not O +
used O +
as O +
substrate O +
by O +
rDASPO O +
it O +
was O +
tested O +
as O +
an O +
inhibitor O +
by O +
determining O +
its O +
effect O +
on O +
the O +
rate O +
of O +
oxidation O +
of O +
d O +
-aspartate O +
( O -
using O +
10 O +
mM O +
of O +
both O +
substrate O +
and O +
inhibitor O -
) O -
. O -

2.3 O +
Protein O +
content O +
Protein O +
content O +
during O +
the O +
purification O +
steps O +
was O +
estimated O +
using O +
an O +
extinction O +
coefficient O +
of O +
1 O +
for O +
a O +
1 O +
mg O +
ml O +
−1 O -
protein O +
solution O -
. O -

The O +
purified O +
enzyme O +
was O +
quantitated O +
using O +
the O +
extinction O +
coefficients O +
previously O +
determined O +
for O +
the O +
various O +
enzyme O +
forms O -
: O +
ϵ454 O +
= O -
11 O +
810 O +
M−1 O -
cm−1 O -
for O +
holo O -
- O -
FAD O -
- O -
bDASPO O +
and O +
ϵ458 O +
= O -
12 O +
300 O +
M−1 O -
cm−1 O -
for O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
bDASPO O +
complex O +
[ O -
14 O -
] O +
. O -

2.4 O +
Apo O -
- O -
enzyme O +
preparation O +
Apo O -
- O -
rDASPO O +
was O +
prepared O +
according O +
to O +
the O +
procedure O +
for O +
the O +
selective O +
removal O +
of O +
FAD O +
from O +
bDASPO O +
described O +
in O +
[ O -
14 O -
] O +
. O -

Briefly O -
, O +
2 O +
mg O +
holo O -
- O -
enzyme O +
were O +
dialyzed O +
at O +
4 O -
° O -
C O +
for O +
3 O +
days O +
against O +
500 O +
ml O +
of O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
0.3 O +
mM O +
EDTA O +
containing O +
3 O +
M O +
KBr O +
and O +
0.5 O -
% O +
charcoal O -
, O +
followed O +
by O +
24 O +
h O +
dialysis O +
against O +
2 O +
l O +
of O +
the O +
same O +
buffer O +
without O +
KBr O +
and O +
charcoal O -
. O -

2.5 O +
Anaerobic O +
reduction O +
of O +
d O +
-aspartate O +
oxidase O +
Anaerobic O +
reduction O +
of O +
rDASPO O +
was O +
conducted O +
at O +
25 O -
° O -
C O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O +
either O +
in O +
the O +
absence O +
or O +
presence O +
of O +
4 O +
mM O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
. O -

Anaerobiosis O +
was O +
achieved O +
by O +
alternate O +
evacuation O +
and O +
flushing O +
with O +
argon O +
freed O +
from O +
any O +
residual O +
oxygen O +
using O +
High O +
Capacity O +
Gas O +
Purifier O +
and O +
OMI O +
Indicating O +
Purifier O +
devices O +
( O -
Supelco O -
, O +
USA O -
) O -
. O -

Photoreduction O +
was O +
achieved O +
by O +
irradiating O +
the O +
protein O +
with O +
a O +
slide O +
projector O +
at O +
0 O -
° O -
C O +
in O +
the O +
presence O +
of O +
10 O +
mM O +
EDTA O -
, O +
0.5 O +
μM O +
5-deazaflavin-3-sulfonate O +
as O +
catalyst O +
and O +
5 O +
μM O +
benzylviologen O +
[ O -
19 O -
] O +
. O -

Following O +
each O +
irradiation O -
, O +
measurements O +
were O +
started O +
when O +
spectral O +
changes O +
in O +
the O +
dark O +
were O +
complete O +
( O -
5–15 O +
min O +
at O +
25 O -
° O -
C O -
) O -
. O -

Alternatively O -
, O +
rDASPO O +
was O +
reduced O +
by O +
mixing O +
the O +
enzyme O +
( O -
2 O +
ml O -
) O +
in O +
the O +
main O +
compartment O +
of O +
an O +
anaerobic O +
cuvette O +
with O +
10 O +
mU O +
of O +
xanthine O +
oxidase O +
[ O -
20 O -
] O +
. O -

After O +
anaerobiosis O -
, O +
xanthine O +
and O +
benzylviologen O +
were O +
added O +
from O +
a O +
side O +
arm O +
to O +
a O +
final O +
concentration O +
of O +
250 O +
μM O +
and O +
5 O +
μM O -
, O +
respectively O -
, O +
to O +
start O +
the O +
reaction O -
. O -

The O +
concentrations O +
of O +
oxidized O -
, O +
semiquinone O +
and O +
reduced O +
enzyme O +
at O +
each O +
point O +
of O +
the O +
reduction O +
were O +
calculated O +
from O +
the O +
total O +
enzyme O +
present O +
and O +
from O +
the O +
absorbance O +
at O +
suitable O +
wavelengths O +
( O -
454 O +
and O +
374 O +
nm O +
for O +
the O +
free O +
enzyme O +
and O +
458 O +
and O +
374 O +
nm O +
for O +
the O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
complex O -
) O +
using O +
the O +
following O +
equation: O -
( O -
1 O -
) O +
ΔA O -
( O -
ox O +
−x O -
) O -
= O -
[ O -
red O -
] O -
( O -
ϵox O +
−ϵred O +
) O -
+ O -
[ O -
sq O -
] O -
( O -
ϵox O +
−ϵsq O +
) O -
were O +
ΔA O -
( O -
ox−x O +
) O +
is O +
the O +
decrease O +
in O +
absorbance O +
in O +
comparison O +
to O +
the O +
spectrum O +
of O +
the O +
oxidized O +
enzyme O -
, O +
ϵox O +
, O +
ϵsq O -
and O +
ϵred O -
are O +
the O +
extinction O +
coefficients O +
for O +
oxidized O -
, O +
semiquinone O +
and O +
reduced O +
form O +
of O +
the O +
enzyme O +
and O +
[ O -
red O -
] O +
and O +
[ O -
sq O -
] O +
are O +
the O +
molar O +
concentrations O +
of O +
reduced O +
and O +
semiquinone O +
rDASPO O -
, O +
respectively O -
. O -

In O +
order O +
to O +
determine O +
the O +
amount O +
of O +
semiquinone O +
thermodynamically O +
stabilized O -
, O +
7.7 O +
μM O +
rDASPO O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
0.5 O +
μM O +
5-deazaflavin-3-sulfonate O -
, O +
10 O +
mM O +
EDTA O +
and O +
5 O +
μM O +
benzylviologen O +
was O +
completely O +
photoreduced O +
anaerobically O +
as O +
described O +
above O +
and O +
mixed O +
with O +
an O +
equimolar O +
amount O +
of O +
concentrated O +
oxidized O +
enzyme O +
previously O +
stored O +
in O +
the O +
side O +
arm O +
of O +
the O +
cell O -
. O -

The O +
reaction O +
was O +
followed O +
at O +
25 O -
° O -
C O +
in O +
the O +
dark O +
until O +
no O +
further O +
absorbance O +
changes O +
could O +
be O +
detected O +
( O -
24 O +
h O -
) O +
and O +
the O +
amount O +
of O +
oxidized O -
, O +
semiquinone O +
and O +
reduced O +
enzyme O +
at O +
equilibrium O +
was O +
calculated O +
as O +
described O +
above O -
. O -

2.6 O +
Determination O +
of O +
redox O +
potentials O +
The O +
redox O +
potential O +
of O +
rDASPO O +
was O +
determined O +
by O +
a O +
spectrophotometric O +
method O +
employing O +
a O +
reducing O +
system O +
of O +
xanthine O -
, O +
xanthine O +
oxidase O +
and O +
a O +
suitable O +
mediator O +
such O +
as O +
benzylviologen O +
[ O -
20 O -
] O +
. O -

Data O +
were O +
plotted O +
according O +
to O +
[ O -
21 O -
] O +
. O -

The O +
amount O +
of O +
oxidized O +
and O +
reduced O +
indicator O +
dye O +
and O +
enzyme O +
was O +
calculated O +
from O +
the O +
experimentally O +
determined O +
extinction O +
coefficients O +
and O +
isosbestic O +
points O +
at O +
the O +
following O +
wavelengths O -
, O +
depending O +
on O +
the O +
experiment O -
: O +
( O -
a O -
) O +
ITS O +
( O -
600 O +
nm O -
) O -
+rDASPO O +
( O -
486 O +
nm O -
, O +
isosbestic O +
for O +
ITS O -
) O -
; O +
( O -
b O -
) O +
IDS O +
( O -
610 O +
nm O -
) O -
+rDASPO O +
( O -
374 O +
and O +
458 O +
nm O -
, O +
the O +
latter O +
being O +
an O +
isosbestic O +
for O +
IDS O -
) O -
; O +
( O -
c O -
) O +
IDS O +
( O -
610 O +
nm O -
) O -
+l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO O +
( O -
458 O +
nm O -
) O -
; O +
( O -
d O -
) O +
HNQ O +
( O -
458 O +
nm O -
) O -
+l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO O +
( O -
364 O +
nm O -
) O -
. O -

2.7 O +
Miscellaneous O +
methods O +
Absorption O +
spectra O +
were O +
measured O +
with O +
a O +
Hewlett O +
Packard O +
HP8452 O +
diode O -
- O -
array O +
spectrophotometer O -
. O -

Fluorescence O +
spectra O +
were O +
recorded O +
on O +
a O +
Jasco O +
( O -
Japan O +
Spectroscopy O -
, O +
Japan O -
) O +
FP O +
750 O +
spectrofluorimeter O -
. O -

SDS O -
- O -
PAGE O +
was O +
performed O +
according O +
to O +
[ O -
22 O -
] O +
. O -

N O -
- O -
Terminal O +
amino O +
acid O +
sequence O +
was O +
determined O +
using O +
an O +
Applied O +
BioSystems O +
( O -
Foster O +
City O -
, O +
USA O -
) O +
model O +
477 O -
/ O -
A O +
automatic O +
protein O +
sequencer O -
. O -

Commercial O +
FAD O +
was O +
purified O +
by O +
HPLC O +
as O +
reported O +
in O +
[ O -
14 O -
] O +
. O -

2.8 O +
Materials O +
Xanthine O +
oxidase O +
was O +
purchased O +
from O +
Sigma O -
. O -

bDASPO O +
was O +
purified O +
from O +
beef U-Species +
kidney O +
cortex O +
as O +
described O +
in O +
[ O -
14 O -
] O +
. O -

5-Deazaflavin-3-sulfonate O +
was O +
a O +
generous O +
gift O +
of O +
V. O +
Massey O +
( O -
University O +
of O +
Michigan O -
, O +
Ann O +
Arbor O -
, O +
MI O -
, O +
USA O -
) O -
. O -

All O +
the O +
other O +
chemicals O +
were O +
of O +
the O +
highest O +
purity O +
commercially O +
available O -
. O -

3 O +
Results O +
3.1 O +
Comparison O +
between O +
the O +
properties O +
of O +
rDASPO O +
and O +
bDASPO O +
Table O +
1 O -
summarizes O +
the O +
purification O +
protocol O +
of O +
rDASPO O +
starting O +
from O +
38 O +
g O +
of O +
wet O +
E. B-Species +
coli L-Species -
paste O -
. O -

Since O +
rDASPO O +
is O +
homogeneous O +
as O +
far O +
as O +
the O +
coenzyme O +
content O +
is O +
concerned O +
( O -
FAD O -
, O +
see O +
below O -
) O -
, O +
while O +
bDASPO O +
is O +
purified O +
as O +
a O +
mixture O +
of O +
an O +
active O +
FAD O -
- O -
containing O +
and O +
an O +
inactive O +
6-OH O -
- O -
FAD O -
- O -
containing O +
form O -
, O +
the O +
specific O +
activity O +
of O +
rDASPO O +
( O -
29.1 O +
U O +
mg−1 O +
) O +
is O +
slightly O +
higher O +
than O +
that O +
of O +
bDASPO O +
( O -
25.3 O +
U O +
mg−1 O +
[ O -
14 O -
] O +
) O -
. O -

As O +
shown O +
in O +
Fig. O +
1 O -
, O +
the O +
molecular O +
mass O +
of O +
rDASPO O +
is O +
38 O +
kDa O -
, O +
in O +
agreement O +
with O +
that O +
of O +
bDASPO O -
. O -

The O +
amino O +
acid O +
sequence O +
of O +
the O +
20 O +
N O -
- O -
terminal O +
residues O +
of O +
purified O +
rDASPO O +
is O +
identical O +
to O +
the O +
one O +
expected O +
from O +
the O +
sequence O +
of O +
bDASPO O -
. O -

It O +
should O +
be O +
pointed O +
out O +
that O +
the O +
N O -
- O -
terminal O +
Met O +
residue O +
in O +
rDASPO O +
is O +
free O +
and O +
not O +
blocked O +
as O +
it O +
is O +
in O +
bDASPO O +
[ O -
16 O -
] O +
. O -

The O +
visible O +
absorption O +
spectra O +
of O +
rDASPO O +
and O +
bDASPO O +
at O +
the O +
end O +
of O +
the O +
respective O +
purification O +
procedures O +
are O +
clearly O +
different O -
, O +
since O +
the O +
former O +
lacks O +
both O +
the O +
long O +
wavelength O +
absorption O +
( O -
centered O +
around O +
610 O +
nm O -
) O +
and O +
the O +
pronounced O +
shoulders O +
around O +
440 O -
, O +
360 O +
and O +
340 O +
nm O +
typically O +
observed O +
with O +
bDASPO O +
( O -
Fig. O +
2 O -
in O +
this O +
paper O +
and O +
Fig. O +
1 O +
of O +
[ O -
14 O -
] O +
) O -
. O -

As O +
reported O +
in O +
[ O -
14 O -
] O +
, O +
such O +
absorption O +
features O +
are O +
due O +
to O +
the O +
presence O +
of O +
variable O +
amounts O +
of O +
6-OH O -
- O -
FAD O +
in O +
bDASPO O -
. O -

In O +
accordance O -
, O +
the O +
visible O +
absorption O +
spectrum O +
of O +
rDASPO O +
resembles O +
that O +
of O +
apo O -
- O -
bDASPO O +
reconstituted O +
with O +
FAD O +
( O -
see O +
Fig. O +
6 O +
of O +
[ O -
14 O -
] O +
) O -
, O +
although O +
the O +
latter O +
showed O +
higher O +
absorbance O +
below O +
400 O +
nm O -
, O +
probably O +
a O +
consequence O +
of O +
the O +
harsh O +
conditions O +
used O +
to O +
obtain O +
the O +
complete O +
apo O -
- O -
protein O +
[ O -
14 O -
] O +
. O -

In O +
order O +
to O +
confirm O +
the O +
absence O +
of O +
6-OH O -
- O -
FAD O +
from O +
preparations O +
of O +
rDASPO O -
, O +
the O +
coenzyme O +
was O +
removed O +
under O +
conditions O +
which O +
allowed O +
the O +
selective O +
removal O +
of O +
FAD O +
( O -
but O +
not O +
of O +
6-OH O -
- O -
FAD O -
) O +
from O +
bDASPO O +
[ O -
14 O -
] O +
. O -

As O +
expected O -
, O +
no O +
visible O +
absorption O +
was O +
present O +
after O +
removal O +
of O +
FAD O +
( O -
not O +
shown O -
) O -
. O -

The O +
absence O +
of O +
the O +
6-OH O -
- O -
FAD O +
form O +
in O +
rDASPO O +
strengthens O +
the O +
hypothesis O +
that O +
such O +
a O +
form O +
has O +
no O +
biological O +
significance O +
and O +
is O +
an O +
artifact O +
of O +
the O +
long O +
lasting O +
purification O +
procedure O +
of O +
the O +
enzyme O +
from O +
the O +
natural O +
source O -
. O -

As O +
it O +
was O +
the O +
case O +
for O +
FAD O -
- O -
bDASPO O -
, O +
rDASPO O +
shows O +
flavin O +
fluorescence O -
. O -

Binding O +
of O +
apo O -
- O -
rDASPO O +
to O +
FAD O +
quenches O +
its O +
fluorescence O +
to O +
a O +
final O +
86 O -
% O +
intensity O -
, O +
a O +
value O +
only O +
slightly O +
higher O +
than O +
the O +
one O +
observed O +
for O +
FAD O -
- O -
bDASPO O +
( O -
70 O -
% O +
[ O -
14 O -
] O +
) O -
. O -

Titration O +
of O +
rDASPO O +
with O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
( O -
Fig. O +
2 O +
) O +
and O +
sulfite O +
[ O -
23 O -
] O -
( O -
data O +
not O +
shown O -
) O -
, O +
two O +
ligands O +
whose O +
complexes O +
with O +
FAD O -
- O -
bDASPO O +
have O +
been O +
thoroughly O +
characterized O -
, O +
further O +
confirmed O +
that O +
the O +
recombinant O +
protein O +
shares O +
the O +
same O +
properties O +
as O +
the O +
FAD O -
- O -
containing O +
form O +
of O +
the O +
enzyme O +
from O +
the O +
natural O +
source O -
. O -

In O +
fact O -
, O +
the O +
dissociation O +
constants O +
determined O +
for O +
the O +
complexes O +
between O +
rDASPO O +
and O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
or O +
sulfite O +
( O -
4.10 O -
× O -
10−5 O -
M O +
and O +
7.5 O -
× O -
10−6 O -
M O -
, O +
respectively O -
) O +
are O +
very O +
similar O +
to O +
those O +
determined O +
in O +
the O +
case O +
of O +
FAD O -
- O -
bDASPO O +
( O -
2.65 O -
× O -
10−5 O -
M O +
and O +
7.4 O -
× O -
10 O +
−6 O -
M O -
, O +
respectively O +
[ O -
14 O -
] O +
) O -
. O -

3.2 O +
Apo O -
- O -
protein O +
preparation O +
and O +
holo O -
- O -
enzyme O +
reconstitution O +
As O +
reported O +
above O -
, O +
the O +
mild O +
conditions O +
used O +
to O +
remove O +
FAD O +
from O +
rDASPO O +
produced O +
a O +
complete O +
apo O -
- O -
protein O +
with O +
no O +
residual O +
visible O +
absorption O +
and O +
activity O -
. O -

Reconstitution O +
of O +
holo O -
- O -
enzyme O +
by O +
addition O +
of O +
FAD O +
resulted O +
in O +
a O +
species O +
with O +
a O +
specific O +
activity O +
of O +
90 O -
% O +
as O +
compared O +
to O +
rDASPO O -
, O +
with O +
a O +
yield O +
of O +
53 O -
% O -
. O -

Such O +
a O +
value O +
is O +
significantly O +
higher O +
than O +
the O +
one O +
obtained O +
in O +
the O +
case O +
of O +
bDASPO O +
( O -
24 O -
% O -
) O -
, O +
due O +
to O +
the O +
harsher O +
conditions O +
necessary O +
to O +
remove O +
6-OH O -
- O -
FAD O +
from O +
bDASPO O +
[ O -
14 O -
] O +
. O -

3.3 O +
Redox O +
potential O +
of O +
rDASPO O +
In O +
order O +
to O +
determine O +
the O +
redox O +
potential O +
of O +
the O +
enzyme O +
by O +
the O +
spectrophotometric O +
method O +
described O +
by O +
Massey O +
[ O -
20 O -
] O -
it O +
was O +
first O +
necessary O +
to O +
determine O +
the O +
extinction O +
coefficients O +
of O +
the O +
oxidized O +
( O -
EFAD O -
) O -
, O +
one O -
- O -
electron O +
reduced O +
( O -
semiquinone O -
, O +
EFAD−⋅ O +
) O +
and O +
two O -
- O -
electron O +
reduced O +
rDASPO O +
( O -
EFADH− O +
) O +
both O +
free O +
and O +
in O +
complex O +
with O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
. O -

Fig. O +
3 O -
shows O +
the O +
reduction O +
of O +
free O +
rDASPO O +
using O +
the O +
xanthine O -
/ O -
xanthine O +
oxidase O +
reducing O +
system O -
. O -

Almost O +
quantitative O +
formation O +
of O +
red O +
anionic O +
semiquinone O +
( O -
91 O -
% O -
) O +
was O +
observed O +
in O +
the O +
first O +
part O +
of O +
the O +
experiment O -
, O +
followed O +
by O +
complete O +
reduction O +
of O +
the O +
enzyme O -
. O -

Extinction O +
coefficients O +
at O +
any O +
wavelength O +
could O +
be O +
obtained O +
for O +
the O +
oxidized O +
and O +
fully O +
reduced O +
form O +
from O +
the O +
initial O +
and O +
the O +
final O +
spectrum O -
, O +
respectively O -
, O +
and O +
for O +
the O +
semiquinone O +
by O +
means O +
of O +
plots O +
such O +
as O +
that O +
shown O +
in O +
the O +
inset O +
of O +
Fig. O +
3 O +
. O -

It O +
should O +
be O +
pointed O +
out O +
that O +
when O +
the O +
enzyme O +
was O +
photoreduced O -
, O +
under O +
the O +
same O +
experimental O +
conditions O -
, O +
a O +
much O +
lower O +
amount O +
of O +
semiquinone O +
was O +
detected O +
( O -
about O +
26 O -
% O +
at O +
maximum O +
formation O -
, O +
data O +
not O +
shown O -
) O -
. O -

The O +
significant O +
difference O +
in O +
the O +
percentage O +
of O +
semiquinone O +
observed O +
during O +
the O +
experiments O +
using O +
different O +
reduction O +
systems O +
suggests O +
that O +
the O +
stabilization O +
of O +
the O +
radical O +
was O +
at O +
least O +
in O +
part O +
kinetic O +
rather O +
than O +
thermodynamic O -
. O -

This O +
was O +
experimentally O +
proved O +
( O -
for O +
the O +
free O +
enzyme O -
) O +
by O +
mixing O +
equimolar O +
amounts O +
of O +
EFADH− O -
and O +
EFAD O +
in O +
the O +
presence O +
of O +
benzylviologen O +
as O +
mediator O +
and O +
allowing O +
the O +
system O +
to O +
reach O +
complete O +
equilibrium O -
; O +
32 O -
% O +
of O +
red O +
semiquinone O +
was O +
observed O +
after O +
24 O +
h. O +
This O +
value O +
corresponds O +
to O +
a O +
semiquinone O +
formation O +
constant O +
K O -
of O +
0.89 O -
, O +
where O +
[ O -
24,25 O -
] O +
( O -
2 O -
) O +
K= O -
{ O -
2 O -
[ O -
semiquinonemax O -
] O -
/ O -
( O -
1− O -
[ O -
semiquinonemax O -
] O -
) O -

} O -
2 O -
From O +
the O +
relation O +
[ O -
24 O -
] O +
( O -
3 O -
) O +
( O -
E2 O +
° O -
′−E1 O +
° O -
′ O -
) O -
=− O -
( O -
RT O -
/ O -
F O -
) O +
ln O -
K O -

it O +
can O +
be O +
predicted O +
that O +
for O +
the O +
free O +
enzyme O +
E O +
2 O +
° O -
′ O +
( O -
EFAD−⋅ O +
/EFADH− O +
) O +
is O +
3 O +
mV O +
more O +
positive O +
than O +
E O +
1 O +
° O -
′ O +
( O -
EFAD O -
/ O -
EFAD−⋅ O +
) O -
. O -

When O +
the O +
reduction O +
was O +
performed O +
in O +
the O +
presence O +
of O +
4 O +
mM O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
a O +
maximum O +
amount O +
of O +
83 O -
% O +
and O +
46 O -
% O +
was O +
observed O +
using O +
the O +
xanthine O -
/ O -
xanthine O +
oxidase O +
or O +
the O +
EDTA O -
/ O -
light O +
reduction O +
method O -
, O +
respectively O -
. O -

Again O -
, O +
extinction O +
coefficients O +
for O +
oxidized O -
, O +
one O -
- O -
electron O +
and O +
two O -
- O -
electron O +
reduced O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO O +
were O +
calculated O +
from O +
the O +
experiment O +
using O +
xanthine O -
/ O -
xanthine O +
oxidase O +
( O -
data O +
not O +
shown O -
) O -
. O -

Table O +
2 O -
shows O +
the O +
experimentally O +
determined O +
redox O +
potential O +
of O +
rDASPO O +
and O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO O +
complex O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
25 O -
° O -
C O -
. O -

The O +
redox O +
potential O +
of O +
the O +
free O +
enzyme O +
was O +
determined O +
using O +
ITS O +
and O +
IDS O +
as O +
indicator O +
dyes O -
. O -

In O +
the O +
case O +
of O +
ITS O +
( O -
Fig. O +
4 O -
) O +
no O +
semiquinone O +
formation O +
was O +
detected O +
and O +
a O +
midpoint O +
potential O +
of O +
−97 O +
mV O +
( O -
slope=1.1 O -
) O +
was O +
calculated O +
from O +
the O +
Minnaert O +
plot O +
shown O +
in O +
inset O +
of O +
Fig. O +
4 O +
. O -

On O +
the O +
contrary O -
, O +
using O +
IDS O +
a O +
significant O +
amount O +
of O +
semiquinone O +
( O -
up O +
to O +
58 O -
% O -
) O +
was O +
detected O -
. O -

This O +
allowed O +
to O +
calculate O +
the O +
redox O +
potentials O +
for O +
each O +
electron O +
using O +
data O +
from O +
the O +
first O +
part O +
of O +
the O +
experiment O +
for O +
E O +
1 O +
° O -
′ O +
( O -
−96 O +
mV O -
, O +
slope=1.9 O -
) O +
and O +
from O +
the O +
second O +
part O +
of O +
the O +
reaction O +
for O +
E O +
2 O +
° O -
′ O +
( O -
−95 O +
mV O -
, O +
slope=2.0 O -
) O +
( O -
Fig. O +
5 O +
and O +
Table O +
2 O -
) O -
. O -

The O +
calculated O +
E O +
m O +
° O -
′ O +
( O -
−95.5 O +
mV O -
) O +
agrees O +
well O +
with O +
the O +
midpoint O +
potential O +
determined O +
with O +
ITS O -
, O +
as O +
does O +
the O +
difference O +
between O +
E O +
2 O +
° O -
′ O +
and O +
E O +
1 O +
° O -
′ O +
( O -
determined O +
+ O -
1 O +
mV O -
, O +
predicted O +
from O +
the O +
semiquinone O +
formation O +
constant O +
+ O -
3 O +
mV O -
) O -
. O -

From O +
the O +
shift O +
in O +
the O +
midpoint O +
potential O +
of O +
FAD O +
( O -
−207 O +
mV O -
, O +
Massey O -
) O +
upon O +
binding O +
to O +
rDASPO O +
( O -
−97 O +
mV O -
) O +
and O +
the O +
known O +
dissociation O +
constant O +
of O +
FAD O +
for O +
the O +
oxidized O +
protein O +
( O -
5 O -
× O -
10−8 O -
M O +
[ O -
14 O -
] O +
) O +
a O +
value O +
of O +
1.0 O -
× O -
10−11 O -
M O +
for O +
K O +
red O -
( O -
the O +
dissociation O +
constant O +
of O +
the O +
reduced O +
coenzyme O -
) O +
can O +
be O +
calculated O +
using O +
the O +
following O +
equation O +
[ O -
24 O -
] O +
: O -
( O -
4 O -
) O +
ΔE O -
° O -
′=RT O -
/ O -
nF O -
× O -
ln O -
( O -
Kox O -
/Kred O -
) O -
In O +
the O +
presence O +
of O +
4 O +
mM O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
, O +
a O +
concentration O +
100-fold O +
higher O +
than O +
the O +
dissociation O +
constant O +
of O +
the O +
ligand O +
for O +
the O +
oxidized O +
enzyme O -
, O +
a O +
midpoint O +
potential O +
of O +
−157 O +
( O -
slope=1.1 O -
) O +
and O +
−156 O +
mV O +
( O -
slope=1.1 O -
) O +
was O +
determined O +
for O +
the O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
- O -
rDASPO O +
complex O +
using O +
IDS O +
and O +
HNQ O +
( O -
Table O +
2 O +
and O +
Fig. O +
6 O -
) O +
as O +
indicator O +
dyes O -
, O +
respectively O -
. O -

No O +
detectable O +
formation O +
of O +
semiquinone O +
was O +
observed O -
. O -

Eq. O +
5 O +
[ O -
26 O -
] O -
allows O +
to O +
calculate O +
the O +
dissociation O +
constant O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
for O +
reduced O +
rDASPO O +
( O -
K O +
red O +
′=3.6 O -
× O -
10−2 O -
M O -
) O -
: O -
( O -
5 O -
) O +
ΔE O -
° O -
′=RT O -
/ O -
nF O -
× O -
ln O -
{ O -
( O -
1+ O -
[ O -
L O +
] O -
/Kred O -
′ O -
) O -
/ O -
( O -
1+ O -
[ O -
L O +
] O -
/Kox O -
′ O -
) O -
} O -
where O +
ΔE O +
° O -
′ O +
is O +
the O +
difference O +
between O +
the O +
redox O +
potential O +
in O +
the O +
presence O +
and O +
in O +
the O +
absence O +
of O +
the O +
ligand O -
, O +
K O +
red O +
′ O +
is O +
the O +
dissociation O +
constant O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
from O +
reduced O +
rDASPO O +
and O +
K O +
ox O +
′ O +
is O +
the O +
known O +
dissociation O +
constant O +
for O +
the O +
same O +
ligand O +
from O +
the O +
oxidized O +
enzyme O +
( O -
K O +
ox O +
′ O -
, O +
4.1 O -
× O -
10−5 O -
M O -
, O +
see O +
above O -
) O -
, O +
and O +
[ O -
L O -
] O +
the O +
concentration O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
used O -
. O -

It O +
can O +
be O +
concluded O +
that O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O +
binds O +
also O +
to O +
EFADH− O +
, O +
although O +
with O +
a O +
much O +
lower O +
affinity O +
as O +
compared O +
to O +
EFAD O -
. O -

This O +
result O +
confirms O +
those O +
obtained O +
for O +
another O +
ligand O +
( O -
oxaloacetate O -
) O +
and O +
for O +
the O +
substrate O +
( O -
d O +
-aspartate O -
) O -
, O +
based O +
on O +
kinetic O +
data O +
[ O -
15 O -
] O +
. O -

3.4 O +
Oxidase O +
activity O +
towards O +
neurotransmitter O +
agonists O +
DASPO O +
is O +
strictly O +
specific O +
for O +
d O +
-amino O +
acids O +
since O +
l O +
-amino O +
acids O +
do O +
not O +
act O +
as O +
substrates O +
or O +
inhibitors O -
. O -

However O -
, O +
it O +
is O +
not O +
strictly O +
specific O +
for O +
d O +
-aspartate O -
, O +
being O +
active O +
also O +
against O +
a O +
variety O +
of O +
other O +
d O +
-amino O +
acids O -
, O +
with O +
a O +
strong O +
preference O +
for O +
dicarboxylic O +
ones O +
[ O -
27,28 O -
] O +
. O -

The O +
availability O +
of O +
large O +
amounts O +
of O +
pure O +
active O +
enzyme O +
allows O +
to O +
extend O +
the O +
characterization O +
of O +
the O +
substrate O +
specificity O +
of O +
DASPO O +
to O +
a O +
series O +
of O +
other O +
d O +
-amino O +
acids O +
which O +
are O +
known O +
to O +
possess O +
pharmacological O +
activity O +
as O +
neurotransmitter O +
agonists O +
[ O -
12 O -
] O +
. O -

The O +
apparent O +
kinetic O +
parameters O +
have O +
been O +
obtained O +
under O +
conditions O +
in O +
which O +
DASPO O +
was O +
shown O +
to O +
follow O +
Michaelis O -
- O -
Menten O +
kinetics O +
with O +
d O +
-aspartate O +
( O -
from O +
2 O +
mM O +
to O +
30 O +
mM O +
[ O -
15 O -
] O +
) O -
. O -

Linear O +
double O +
reciprocal O +
plots O +
were O +
obtained O +
for O +
all O +
substrates O +
in O +
this O +
range O -
. O -

The O +
results O +
obtained O +
are O +
listed O +
in O +
Table O +
3 O -
. O -

It O +
should O +
be O +
pointed O +
out O +
that O +
many O +
of O +
the O +
compounds O +
listed O +
are O +
indeed O +
oxidized O +
at O +
a O +
significant O +
rate O +
by O +
DASPO O -
. O -

Analysis O +
of O +
the O +
data O +
of O +
Table O +
3 O -
suggests O +
that O +
the O +
compounds O +
can O +
be O +
divided O +
into O +
three O +
groups O -
: O +
the O +
first O +
comprises O +
those O +
which O +
do O +
not O +
seem O +
to O +
interact O +
with O +
DASPO O -
, O +
since O +
they O +
are O +
neither O +
substrates O +
nor O +
inhibitors O -
; O +
the O +
second O +
contains O +
d O +
-aspartate O +
and O +
N O +
-methyl O -
- O -
d O +
-aspartate O -
, O +
which O +
are O +
by O +
far O +
the O +
best O +
substrates O -
; O +
the O +
third O +
comprises O +
the O +
remaining O +
substrates O -
, O +
which O +
are O +
oxidized O +
at O +
similar O +
rates O +
( O -
apparent O +
turnover O +
number O +
ranging O +
between O +
0.22 O +
and O +
2.2 O +
s−1 O +
) O -
. O -

As O +
regards O +
the O +
latter O +
group O -
, O +
the O +
results O +
suggest O +
that O +
substitution O +
of O +
a O +
sulfonic O +
( O -
d O -
, O -
l O +
-cysteic O +
acid O -
) O +
or O +
phosphonic O +
( O -
d O -
, O -
l O +
-2-amino-3-phosphonopropanoic O +
acid O -
) O +
group O +
for O +
the O +
β O -
- O -
carboxylic O +
group O +
of O +
d O +
-aspartate O +
causes O +
a O +
dramatic O +
decrease O +
in O +
the O +
turnover O +
number O -
. O -

The O +
presence O +
of O +
a O +
second O +
acidic O +
group O -
, O +
however O -
, O +
is O +
not O +
an O +
absolute O +
requirement O -
, O +
since O +
d O +
-aspartate O -
- O -
β O -
- O -
hydroxamate O +
is O +
a O +
substrate O -
. O -

In O +
accordance O -
, O +
d O +
-proline O +
was O +
shown O +
to O +
be O +
a O +
substrate O +
for O +
bDASPO O +
( O -
apparent O +
turnover O +
number O +
0.4 O +
s−1 O +
, O +
K O +
m O -
9 O -
× O -
10−4 O -
M O +
[ O -
28 O -
] O +
) O +
and O +
d O +
-asparagine O +
and O +
d O +
-glutamine O +
for O +
DASPO O +
from O +
Octopus U-Species -
but O +
not O +
for O +
bDASPO O +
[ O -
28 O -
] O +
. O -

An O +
increase O +
in O +
the O +
length O +
of O +
the O +
carbon O +
chain O +
also O +
causes O +
a O +
drop O +
in O +
the O +
oxidation O +
rate O -
, O +
as O +
observed O +
with O +
d O +
-glutamate O -
, O +
d O +
-homocysteic O +
acid O +
and O -
, O +
more O +
dramatically O -
, O +
with O +
d O -
, O -
l O +
-2-amino-4-phosphonobutanoic O +
acid O -
, O +
which O +
is O +
neither O +
a O +
substrate O +
nor O +
an O +
inhibitor O -
. O -

A O +
further O +
decrease O +
in O +
the O +
rate O +
of O +
oxidation O +
is O +
observed O +
with O +
the O +
C6-dicarboxylic O +
compound O +
d O +
-α O -
- O -
aminoadipic O +
acid O -
. O -

As O +
expected O +
from O +
previous O +
studies O +
on O +
a O +
related O +
compound O +
( O -
2,3-diaminosuccinic O +
acid O +
[ O -
29 O -
] O +
) O -
, O +
threo O +
-β O -
- O -
hydroxy O -
- O -
d O +
-aspartate O +
does O +
not O +
interact O +
with O +
DASPO O +
either O +
as O +
a O +
substrate O +
or O +
an O +
inhibitor O -
. O -

The O +
oxidative O +
activity O +
of O +
DASPO O +
towards O +
glycyl O -
- O -
d O +
-aspartate O +
is O +
of O +
particular O +
relevance O +
since O +
this O +
compound O +
has O +
been O +
proposed O +
to O +
be O +
involved O +
in O +
synaptic O +
transmission O +
in O +
prefrontal O +
cortex O +
in O +
vivo O +
[ O -
13 O -
] O +
. O -

4 O +
Discussion O +
4.1 O +
Purification O +
and O +
properties O +
of O +
rDASPO O +
This O +
paper O +
reports O +
overexpression O +
and O +
purification O +
conditions O +
leading O +
to O +
about O +
2 O +
mg O +
pure O +
rDASPO O +
each O +
g O +
of O +
wet O +
E. B-Species +
coli L-Species -
paste O -
. O -

rDASPO O +
has O +
been O +
shown O +
to O +
possess O +
the O +
same O +
general O +
biochemical O +
properties O +
of O +
bDASPO O -
, O +
except O +
that O +
the O +
former O +
contains O +
only O +
FAD O -
, O +
while O +
the O +
latter O +
is O +
a O +
mixture O +
of O +
two O +
forms O -
, O +
an O +
active O +
one O +
containing O +
FAD O +
and O +
an O +
inactive O +
one O +
containing O +
6-OH O -
- O -
FAD O +
( O -
9–20 O -
% O +
depending O +
on O +
the O +
preparation O -
) O +
[ O -
14 O -
] O +
. O -

For O +
such O +
reason O -
, O +
apart O +
from O +
the O +
amount O +
of O +
enzyme O +
obtained O +
and O +
the O +
ease O +
and O +
quickness O +
of O +
the O +
purification O +
protocol O -
, O +
the O +
procedure O +
reported O +
has O +
the O +
following O +
advantages O +
over O +
the O +
one O +
previously O +
used O +
to O +
obtain O +
bDASPO O +
from O +
the O +
natural O +
source O +
( O -
beef U-Species +
kidney O +
cortex O -
) O -
: O +
rDASPO O +
possesses O +
a O +
specific O +
activity O +
higher O +
than O +
bDASPO O -
, O +
apo O -
- O -
protein O +
preparation O +
requires O +
milder O +
conditions O -
, O +
resulting O +
in O +
a O +
higher O +
yield O +
of O +
reconstitutable O +
holo O -
- O -
enzyme O -
, O +
and O +
spectroscopic O +
studies O +
are O +
facilitated O +
by O +
the O +
absence O +
of O +
a O +
second O +
compound O +
with O +
visible O +
absorption O +
properties O +
which O +
partially O +
overlap O +
those O +
of O +
FAD O -
. O -

The O +
latter O +
feature O +
has O +
been O +
used O +
to O +
determine O +
the O +
redox O +
potential O +
of O +
the O +
enzyme O +
by O +
the O +
spectrophotometric O +
method O +
set O +
up O +
by O +
Massey O +
[ O -
20 O -
] O +
. O -

4.2 O +
Redox O +
potentials O +
of O +
DASPO O +
The O +
midpoint O +
potential O +
of O +
DASPO O +
in O +
0.1 O +
M O +
KPi O -
, O +
pH O +
7.0 O -
, O +
25 O -
° O -
C O +
is O +
−97 O +
mV. O +
Thus O -
, O +
the O +
binding O +
to O +
the O +
apo O -
- O -
enzyme O +
increases O +
the O +
redox O +
potential O +
of O +
the O +
flavin O +
by O +
110 O +
mV O +
as O +
compared O +
to O +
free O +
FAD O -
, O +
a O +
shift O +
which O +
is O +
consistent O +
with O +
the O +
role O +
of O +
the O +
enzyme O +
as O +
a O +
dehydrogenase O -
/ O -
oxidase O -
. O -

Useful O +
comparisons O +
can O +
be O +
made O +
with O +
the O +
redox O +
properties O +
of O +
the O +
closely O +
related O +
well O +
known O +
enzyme O +
d O +
-amino O +
acid O +
oxidase O -
, O +
which O +
catalyzes O +
the O +
same O +
reaction O +
catalyzed O +
by O +
DASPO O +
but O +
with O +
different O +
substrate O +
specificity O -
, O +
being O +
active O +
only O +
towards O +
neutral O +
and O +
basic O +
d O +
-amino O +
acids O +
[ O -
30 O -
] O +
. O -

The O +
general O +
properties O +
of O +
the O +
two O +
enzymes O +
have O +
been O +
shown O +
to O +
be O +
similar O -
, O +
although O +
their O +
kinetic O +
mechanism O +
is O +
slightly O +
different O +
[ O -
15,30 O -
] O +
. O -

Van O +
den O +
Berghe O +
and O +
Stankovich O +
determined O +
E O +
1 O +
° O -
′ O +
of O +
–98 O +
mV O +
and O +
E O +
2 O +
° O -
′ O +
of O +
117 O +
mV O +
in O +
50 O +
mM O +
KPi O -
, O +
pH O +
7.0 O -
, O +
18 O -
° O -
C O +
for O +
d O +
-amino O +
acid O +
oxidase O +
[ O -
31 O -
] O +
. O -

Thus O -
, O +
the O +
calculated O +
midpoint O +
potential O +
and O +
the O +
amount O +
of O +
semiquinone O +
stabilized O +
( O -
–108 O +
mV O +
and O +
40 O -
% O -
, O +
respectively O -
) O +
are O +
only O +
slightly O +
different O +
from O +
the O +
ones O +
determined O +
for O +
DASPO O +
( O -
–97 O +
mV O +
and O +
32 O -
% O -
) O -
. O -

In O +
accordance O -
, O +
the O +
presence O +
of O +
a O +
specific O +
inhibitor O +
causes O +
similar O +
negative O +
shifts O +
in O +
the O +
redox O +
potential O +
of O +
the O +
two O +
enzymes O +
( O -
39 O +
mV O +
in O +
the O +
case O +
of O +
d O +
-amino O +
acid O +
oxidase O +
with O +
benzoate O -
, O +
58 O +
mV O +
for O +
DASPO O +
in O +
the O +
presence O +
of O +
l O +
- O -
( O -
+ O -
) O -
-tartrate O -
) O -
. O -

In O +
conclusion O -
, O +
the O +
redox O +
properties O +
of O +
DASPO O +
conform O +
to O +
those O +
expected O +
for O +
a O +
typical O +
flavoprotein O +
oxidase O +
[ O -
32 O -
] O +
. O -

This O +
is O +
in O +
marked O +
contrast O +
with O +
what O +
has O +
been O +
observed O +
for O +
E. B-Species +
coli L-Species +
l O +
-aspartate O +
oxidase O -
, O +
a O +
flavoenzyme O +
which O +
catalyzes O +
the O +
oxidation O +
of O +
l O +
-aspartate O +
by O +
O2 O -
and O +
can O -
not O +
use O +
d O +
-aspartate O +
as O +
a O +
substrate O -
, O +
whose O +
redox O +
potential O +
( O -
–216 O +
mV O -
) O +
is O +
actually O +
lower O +
than O +
that O +
of O +
free O +
FAD O +
[ O -
33 O -
] O +
. O -

Thus O -
, O +
the O +
redox O +
potential O +
data O +
confirm O +
other O +
experimental O +
evidence O +
which O +
suggests O +
that O -
, O +
although O +
DASPO O +
and O +
l O +
-aspartate O +
oxidase O +
catalyze O +
the O +
same O +
reaction O +
but O +
with O +
different O +
enantio O -
- O -
specificity O -
, O +
their O +
properties O +
are O +
largely O +
different O +
[ O -
33–35 O -
] O +
. O -

This O +
fact O +
can O +
be O +
ascribed O +
both O +
to O +
the O +
need O +
to O +
assure O +
absolute O +
stereospecificity O +
and O +
to O +
respond O +
to O +
totally O +
different O +
metabolic O +
demands O +
and O +
controls O -
. O -

In O +
fact O -
, O +
the O +
biological O +
role O +
of O +
DASPO O +
is O +
likely O +
to O +
be O +
mainly O +
catabolic O +
[ O -
36 O -
] O +
, O +
while O +
that O +
of O +
l O +
-aspartate O +
oxidase O +
is O +
exclusively O +
anabolic O -
, O +
since O +
it O +
catalyzes O +
the O +
first O +
step O +
in O +
the O +
de O +
novo O +
biosynthesis O +
of O +
pyridinic O +
nucleotides O +
in O +
several O +
microorganisms U-Species +
and O +
plants U-Species +
[ O -
37 O -
] O +
. O -

4.3 O +
Substrate O +
specificity O +
of O +
DASPO O +
The O +
investigation O +
of O +
the O +
interaction O +
between O +
DASPO O +
and O +
dicarboxylic O +
compounds O +
which O +
are O +
known O +
to O +
possess O +
pharmacological O +
activities O +
as O +
agonists O -
/ O -
antagonists O +
for O +
excitatory O +
amino O +
acid O +
receptors O +
has O +
allowed O +
to O +
identify O +
two O +
new O +
substrates O +
for O +
the O +
enzyme O -
, O +
i.e. O +
d O +
-aspartate O -
- O -
β O -
- O -
hydroxamate O +
and O +
glycyl O -
- O -
d O +
-aspartate O -
, O +
and O +
to O +
determine O +
the O +
kinetic O +
parameters O +
for O +
these O +
and O +
a O +
number O +
of O +
other O +
substrates O -
. O -

The O +
results O +
are O +
of O +
particular O +
interest O +
for O +
two O +
reasons O -
: O +
first O +
of O +
all O -
, O +
the O +
presence O +
of O +
d O +
-aspartate O -
, O +
d O +
-glutamate O -
, O +
N O +
-methyl O -
- O -
d O +
-aspartate O +
and O +
glycyl O -
- O -
d O +
-aspartate O +
have O +
been O +
reported O +
in O +
several O +
organisms O +
[ O -
4–10,13,38 O -
] O +
; O +
secondly O -
, O +
all O +
of O +
the O +
compounds O +
listed O +
in O +
Table O +
3 O -
are O +
used O +
for O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
as O +
agonists O -
/ O -
antagonists O +
for O +
excitatory O +
amino O +
acid O +
receptors O +
but O +
the O +
metabolic O +
fate O +
of O +
most O -
, O +
if O +
not O +
all O -
, O +
of O +
them O +
is O +
still O +
unknown O -
. O -

Since O +
DASPO O +
has O +
been O +
shown O +
to O +
be O +
present O +
in O +
a O +
number O +
of O +
tissues O -
, O +
the O +
possibility O +
exists O +
that O +
the O +
effect O +
of O +
such O +
compounds O +
can O +
be O +
influenced O +
both O +
in O +
vivo O +
and O +
in O +
vitro O +
by O +
the O +
amount O +
of O +
DASPO O +
present O -
. O -

Acknowledgements O +
We O +
wish O +
to O +
thank O +
Prof. O +
Tatjana O +
Simonic O +
for O +
providing O +
E. O +
coli O -
GI724 O +
( O -
pED O -
) O +
cells O -
. O -

This O +
paper O +
was O +
supported O +
by O +
grants O +
from O +
the O +
Ministero O +
della O +
Università O +
e O +
della O +
Ricerca O +
Scientifica O +
and O +
from O +
the O +
Consiglio O +
Nazionale O +
delle O +
Ricerche O +
( O -
Italy O -
) O -
. O +

The O +
cardiotoxic O +
effect O +
of O +
karminomycin O +
and O +
adriamycin O +
administered O +
intravenously O -
for O +
5 O +
times O +
in O +
equitoxic O +
doses O +
constituting O +
equal O +
portions O +
of O +
LD50 O +
of O +
the O +
respective O +
antibiotic O +
on O +
its O +
single O +
intravenous O +
administration O +
was O +
studied O +
on O +
albino B-Species +
mice L-Species -
. O -

Histological O +
examination O +
of O +
the O +
heart O +
showed O +
that O +
almost O +
identical O +
damages O +
of O +
the O +
myocardium O +
occured O +
after O +
administration O +
of O +
karminomycin O +
and O +
adriamycin O +
in O +
doses O +
of O +
0.45 O +
of O +
LD50 O +
( O -
1.5 O +
mg O -
/ O -
kg O -
) O +
and O +
0.3 O +
of O +
LD50 O +
( O -
6.3 O +
mg O -
/ O -
kg O -
) O +
respectively O -
. O -

The O +
character O +
of O +
the O +
damages O +
due O +
to O +
the O +
antibiotics O +
was O +
close O -
, O +
the O -
most O +
significant O +
changes O +
were O +
observed O +
when O +
the O +
animals O +
were O +
sacrificed O +
1 O +
month O +
after O +
the O +
last O +
administration O +
of O +
the O +
drug O -
. O -

The O +
histological O +
method O +
is O +
of O +
value O +
in O +
estimation O +
of O +
the O +
cardiotoxic O +
effect O +
of O +
the O +
drugs O -
, O +
using O +
mice U-Species +
as O +
the O +
model O +
suitable O +
for O +
the O +
investigation O -
. O -

Adriamycin O +
had O +
more O +
pronounced O +
cumulative O +
properties O +
as O +
compared O +
to O +
karminomycin O -
: O +
suppression O +
of O +
the O +
weight O +
gain O +
in O +
the O +
mice U-Species +
and O +
their O +
death O +
rate O +
were O +
higher O +
with O +
the O +
use O +
of O +
adriamycin O -
. O +

Three O +
sialosylated O +
and O +
three O +
neutral O +
glycosphingolipids O +
sharing O +
a O +
common O +
iso O -
- O -
neolacto O +
core O +
were O +
isolated O +
from O +
porcine U-Species +
kidney O +
cortex O -
. O -

They O +
were O +
purified O +
by O +
preparative O +
HPTLC O -
, O +
and O +
were O +
characterized O +
by O +
partial O +
exoglycosidase O +
hydrolysis O +
followed O +
by O +
thin O +
layer O +
chromatography O +
and O +
immunostaining O +
with O +
anti O -
- O -
Galalpha1 O -
- O -
->3Gal O -
, O +
anti O -
- O -
type O +
2 O +
lactosamine O +
and O +
anti O -
- O -
Lewis O -
( O -
x O -
) O +
antibodies O -
, O +
methylation O +
analysis O -
, O +
MALDI O -
- O -
TOF O +
mass O +
spectrometry O +
and O +
1H O -
- O -
NMR O +
spectroscopy O -
. O -

Among O -
neutral O +
glycolipids O -
, O +
one O +
was O +
a O +
known O +
structure O -
, O +
VI3VI'3 O -
( O -
alphaGal O -
) O -
2-iso O -
- O -
nLc8Cer O -
, O +
and O +
two O +
were O +
novel O +
structures O +
differing O +
by O +
the O +
number O +
of O +
Galalpha3Lewis O -
( O -
x O -
) O +
determinants O -
: O +
VI3VI'3 O -
( O -
alphaGal O -
) O -
2V'3alphaFuc O -
- O -
iso O -
- O -
nLc8 O -
, O +
and O +
VI3VI'3 O -
( O -
alphaGal O -
) O -
2 O +
V3V'3 O -
( O -
alphaFuc O -
) O -
2-iso O -
- O -
nLc8 O -
. O -

The O +
single O +
Galalpha3Lewis O -
( O -
x O -
) O +
determinant O +
was O +
found O +
on O -
the O +
6-linked O +
antenna O -
. O -

Among O +
sialosylated O +
glycolipids O -
, O +
two O +
had O +
been O +
previously O +
found O +
in O +
other O +
species O +
and O +
tissues O -
, O +
VI3VI'3 O -
( O -
NeuAc O -
) O -
2-iso O -
- O -
nLc8 O -
, O +
and O +
VI3NeuAcVI'3alphaGal O -
- O -
iso O -
- O -
nLc8 O -
. O -

A O +
novel O +
structure O +
was O +
discovered O +
presenting O +
a O +
Galalpha3Lewis O -
( O -
x O -
) O +
determinant O +
on O +
the O +
6-linked O +
antenna O +
and O +
a O +
N O -
- O -
acetylneuraminic O +
acid O +
on O +
the O +
3-linked O +
antenna O -
, O +
VI3NeuAcVI'3alphaGalV'3alphaFuc O -
- O -
iso O -
- O -
nLc8 O -
. O -

These O +
results O +
indicate O +
that O -
, O +
in O +
vivo O -
, O +
the O +
porcine U-Species +
kidney O +
alpha3fucosyltransferase O +
synthesizes O +
the O +
Gala3Lewis O -
( O -
x O -
) O +
determinant O -
, O +
acting O +
on O +
the O +
6-linked O +
before O +
the O +
3-linked O +
Galalpha3neolactosamine O -
, O +
and O +
appears O +
unable O +
to O +
synthesize O +
the O +
sialosylated O +
Lewis O -
( O -
x O -
) O +
determinant O +
on O +
neolactoseries O +
glycolipids O -
. O +

A O +
monoclonal O +
antibody O +
( O -
MAb O -
) O +
was O +
produced O +
against O +
the O +
p O -
- O -
nitrophenylphosphate O +
derivative O +
of O +
3 O +
alpha O -
, O +
5 O +
beta O -
- O -
lithocholic O +
acid O -
, O +
a O +
transition O -
- O -
state O +
analog O +
for O +
hydrolysis O +
of O +
a O +
steroidal O +
p O -
- O -
nitrophenylcarbonate O -
. O -

The O +
indicated O +
reaction O +
was O +
catalyzed O +
by O +
this O +
Ab O +
with O +
kinetic O +
constants O +
kcat O +
= O +
4.0 O +
x O +
10 O -
( O -
-2 O -
) O -
/ O -
min O +
and O +
K O -
( O -
m O -
) O +
= O +
3.3 O +
microM O +
at O +
pH O +
9.0 O +
and O +
35 O +
degrees O +
C. O +
The O +
Ab O +
also O +
hydrolyzed O +
the O +
isomeric O +
p O -
- O -
nitrophenylcarbonate O +
of O +
3 O +
beta O -
, O +
5 O +
beta O -
- O -
lithocholic O +
acid O +
with O +
kcat O +
= O +
8.4 O +
x O +
10 O -
( O -
-2 O -
) O -
/ O -
min O +
and O +
K O -
( O -
m O -
) O +
= O +
1.0 O +
microM. O +
Bovine U-Species +
serum O +
albumin O +
( O -
BSA O -
) O +
was O +
found O +
to O +
catalyze O +
the O +
same O +
reactions O +
with O +
similar O +
turnover O +
rates O +
and O +
Michaelis O +
constants O +
of O +
15 O +
and O +
14 O +
microM O -
, O +
respectively O -
. O -

Although O +
the O +
BSA O -
- O -
catalyzed O +
reaction O +
was O +
only O +
weakly O +
inhibited O +
by O +
the O +
phosphate O +
ester O +
TSA O +
( O -
IC50 O +
ca O -
. O -

40 O +
microM O -
) O -
, O +
the O +
Ab O -
- O -
catalyzed O +
reaction O +
was O +
completely O +
inhibited O +
at O +
less O +
than O +
1 O +
microM O +
of O +
the O +
TSA O -
. O -

The O +
relative O +
rates O +
and O +
efficiencies O +
of O +
the O +
MAb O -
- O -
catalyzed O +
and O +
BSA O -
- O -
catalyzed O +
reactions O +
are O +
discussed O +
in O +
the O +
context O +
of O +
the O +
hydrophobic O +
sites O +
and O +
intrinsic O +
reactivity O +
of O +
the O +
protein O +
surfaces O -
, O +
and O +
the O +
induction O +
of O +
groups O +
on O +
the O +
Ab O +
to O +
enhance O +
the O +
enzymatic O +
function O -
. O +

To O +
clarify O +
the O +
relationship O +
between O +
the O +
occurrence O +
of O +
unusual O +
trihydroxy O +
bile O +
acids O -
, O +
namely O +
hyocholic O +
acid O -
, O +
ursocholic O +
acid O +
( O -
UCA O -
) O -
, O +
and O +
omega O -
- O -
muricholic O +
acid O +
( O -
omega O -
- O -
MCA O -
) O +
in O +
urine O +
and O +
liver O +
disease O +
severity O -
, O +
urinary O +
bile O +
acids O +
were O +
analyzed O +
by O +
gas O -
- O -
liquid O +
chromatography O +
in O +
acute O +
and O +
late O +
phases O +
of O +
acute O +
hepatitis O +
and O +
before O +
and O +
after O +
ursodeoxycholic O +
acid O +
( O -
UDCA O -
) O +
loading O +
in O +
healthy O +
adults U-Species +
and O +
liver O -
cirrhosis O +
patients U-Species -
. O -

In O +
11 O +
patients U-Species +
with O +
acute O +
hepatitis O -
, O +
the O +
occurrence O +
rates O +
and O +
amounts O +
of O +
unusual O +
trihydroxy O +
bile O +
acids O +
were O +
increased O +
in O +
the O +
late O +
( O -
recovery O -
) O +
phase O -
, O +
as O +
compared O +
with O +
those O +
in O +
the O +
early O +
phase O -
. O -

In O +
10 O +
patients U-Species +
with O +
severe O +
acute O +
hepatitis O +
who O +
had O +
prothrombin O +
times O +
exceeding O +
16 O +
seconds O -
, O +
these O +
bile O +
acids O -
had O +
completely O +
disappeared O +
from O +
the O +
urine O +
in O +
the O +
early O +
phase O +
but O +
reappeared O +
in O +
the O +
late O +
phase O +
in O +
those O +
who O +
had O +
a O +
good O +
outcome O -
, O +
though O +
never O +
in O +
a O +
patient U-Species +
who O +
died O -
. O -

After O +
UDCA O +
administration O +
for O +
a O +
week O -
, O +
the O +
amounts O +
of O +
unusual O +
bile O +
acids O -
, O +
especially O +
UCA O +
and O +
omega O -
- O -
MCA O -
, O +
which O +
are O +
thought O +
to O +
be O +
synthesized O +
through O +
12 O +
alpha- O +
and O +
6 O +
alpha O -
- O -
hydroxylations O -
, O +
respectively O -
, O +
from O +
UDCA O -
, O +
were O +
clearly O +
increased O +
in O +
10 O +
healthy O +
adults U-Species +
but O +
only O +
slightly O +
changed O +
in O +
10 O +
patients U-Species +
with O +
liver O +
cirrhosis O -
. O -

In O +
conclusion O -
, O +
hepatic O +
hydroxylations O +
of O +
dihydroxy O +
bile O +
acids O +
as O +
a O +
detoxification O +
reaction O +
were O +
impaired O +
in O +
severe O +
liver O +
diseases O -
, O +
which O +
may O +
play O -
a O +
role O +
in O +
the O +
intensification O +
and O +
perpetuation O +
of O +
hepatocellular O +
injuries O -
. O +

1 O -
. O -

Bioactivation O +
of O +
sulphamethoxazole O +
( O -
SMX O -
) O +
to O +
chemically O -
- O -
reactive O +
metabolites O +
and O +
subsequent O +
protein O +
conjugation O +
is O +
thought O +
to O +
be O +
involved O +
in O +
SMX O +
hypersensitivity O -
. O -

We O +
have O +
therefore O +
examined O +
the O +
cellular O +
metabolism O -
, O +
disposition O +
and O +
conjugation O +
of O +
SMX O +
and O +
its O +
metabolites O +
in O +
vitro O -
. O -

2 O -
. O -

Flow O +
cytometry O +
revealed O +
binding O +
of O +
N O -
- O -
hydroxy O +
( O -
SMX O -
- O -
NHOH O -
) O +
and O +
nitroso O +
( O -
SMX O -
- O -
NO O -
) O +
metabolites O +
of O +
SMX O -
, O +
but O +
not O -
of O +
SMX O +
itself O -
, O +
to O +
the O +
surface O +
of O +
viable O +
white O +
blood O +
cells O -
. O -

Cellular O +
haptenation O +
by O +
SMX O -
- O -
NO O +
was O +
reduced O +
by O +
exogenous O +
glutathione O +
( O -
GSH O -
) O -
. O -

3 O -
. O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
were O +
rapidly O +
reduced O +
back O +
to O +
the O +
parent O +
compound O +
by O +
cysteine O +
( O -
CYS O -
) O -
, O +
GSH O -
, O +
human O +
peripheral O +
blood O +
cells O +
and O +
plasma O -
, O +
suggesting O +
that O +
this O +
is O +
an O +
important O +
and O +
ubiquitous O +
bioinactivation O +
mechanism O -
. O -

4 O -
. O +
Fluorescence O +
HPLC O +
showed O +
that O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
depleted O +
CYS O +
and O +
GSH O +
in O +
buffer O -
, O +
and O +
to O +
a O +
lesser O +
extent O -
, O +
in O +
cells O +
and O +
plasma O -
. O -

5 O -
. O -

Neutrophil O +
apoptosis O +
and O +
inhibition O +
of O +
neutrophil O +
function O +
were O +
induced O +
at O +
lower O +
concentrations O +
of O +
SMX O -
- O -
NHOH O +
and O +
SMX O -
- O -
NO O +
than O +
those O +
inducing O +
loss O +
of O +
membrane O +
viability O -
, O +
with O +
SMX O +
having O +
no O +
effect O -
. O -

Lymphocytes O +
were O +
significantly O -
( O -
P<0.05 O -
) O +
more O +
sensitive O +
to O +
the O +
direct O +
cytotoxic O +
effects O +
of O +
SMX O -
- O -
NO O +
than O +
neutrophils O -
. O -

6 O -
. O -

Partitioning O +
of O +
SMX O -
- O -
NHOH O +
into O +
red O +
blood O +
cells O +
was O +
significantly O +
( O -
P<0.05 O -
) O +
lower O +
than O +
with O +
the O +
hydroxylamine O +
of O +
dapsone O -
. O -

7 O -
. O -

Our O +
results O +
suggest O +
that O +
the O +
balance O +
between O +
oxidation O +
of O +
SMX O +
to O +
its O +
toxic O +
metabolites O +
and O +
their O +
reduction O +
is O +
an O +
important O +
protective O +
cellular O +
mechanism O -
. O -

If O +
an O +
imbalance O +
exists O -
, O -
haptenation O +
of O +
the O +
toxic O +
metabolites O +
to O +
bodily O +
proteins O +
including O +
the O +
surface O +
of O -
viable O +
cells O +
can O +
occur O -
, O +
and O +
may O +
result O +
in O +
drug O +
hypersensitivity O -
. O +

Proline O +
( O -
Pro O -
) O +
and O +
hydroxyproline O +
( O -
Hyp O -
) O +
formed O +
by O +
hydroxylation O +
of O +
Pro O +
during O +
collagen O +
biosynthesis O +
are O +
commonly O +
found O +
in O +
connective O +
tissue O +
proteins O +
such O +
as O +
collagen O +
at O +
high O +
concentrations O -
. O -

These O +
amino O +
acids O +
are O +
released O +
after O +
degradation O +
of O +
collagen O +
and O +
excreted O +
into O +
urine O +
as O +
amino O +
acids O -
, O +
small O +
peptides O +
and O +
large O +
peptides O -
. O -

According O +
to O +
previous O +
reports O +
[ O -
1–4 O -
] O +
, O +
total O +
Hyp O +
excreted O +
in O +
urine O +
is O +
comprised O +
of O +
∼85 O -
% O +
small O +
peptides O +
and O +
1–5 O -
% O +
free O +
Hyp O -
. O -

The O +
main O +
peptide O +
containing O +
Hyp O +
was O +
prolylhydroxyproline O +
( O -
Pro O -
– O -
Hyp O -
) O +
which O +
accounted O +
for O +
about O +
60 O -
% O +
of O +
peptide O +
Hyp O +
or O +
44 O -
% O +
of O +
total O +
urinary O +
Hyp O +
[ O -
2,4 O -
] O +
. O -

The O +
concentration O +
of O +
total O +
urinary O +
Pro O +
and O +
Hyp O +
varied O +
in O +
association O +
with O +
various O +
diseases O +
including O +
bone O +
diseases O +
[ O -
1,5–7 O -
] O -
and O +
tumor O +
[ O -
8–10 O -
] O -
and O +
excretion O +
of O +
dipeptides O +
containing O +
Pro O +
or O +
Hyp O +
increases O +
in O +
patients U-Species +
with O +
disorders O +
involving O +
collagen O +
metabolism O +
[ O -
11–13 O -
] O +
. O -

Therefore O -
, O +
sensitive O +
and O +
reliable O +
determinations O +
of O +
these O +
metabolites O +
in O +
human U-Species +
urine O +
are O +
useful O +
for O +
understanding O +
of O +
various O +
disorders O -
. O -

Currently O -
, O +
a O +
few O +
methods O +
for O +
the O +
determination O +
of O +
dipeptides O +
that O +
contain O +
Pro O +
or O +
Hyp O +
in O +
urine O +
by O +
gas O +
chromatograpgy O -
– O -
mass O +
spectrometry O +
( O -
GC O -
– O -
MS O -
) O +
[ O -
11–14 O -
] O +
, O +
liquid O +
chromatography O +
( O -
LC O -
) O -
–MS O +
[ O -
15–17 O -
] O -
and O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
[ O -
18 O -
] O -
have O +
been O +
reported O -
. O -

However O -
, O +
the O +
GC O -
– O -
MS O +
and O +
LC O -
– O -
MS O +
methods O +
require O +
tedious O +
procedures O +
including O +
a O +
two O -
- O -
step O +
column O +
separation O +
for O +
pre O -
- O -
treatment O +
of O +
urine O +
and O +
further O -
, O +
the O +
GC O -
– O -
MS O +
methods O +
require O +
a O +
two O -
- O -
step O +
derivatization O +
procedure O +
to O +
convert O +
dipeptides O +
into O +
volatile O +
derivatives O +
after O +
pre O -
- O -
treatment O -
. O -

In O +
the O +
HPLC O +
method O +
employing O +
a O +
pre O -
- O -
column O +
derivatization O +
technique O +
with O +
4-chloro-7-nitrobenzofurazan O +
as O +
a O +
fluorescent O +
labelling O +
reagent O -
, O +
a O +
relatively O +
large O +
sample O +
volume O +
( O -
5 O +
ml O -
) O +
is O +
required O +
because O +
of O +
low O +
sensitivity O +
to O +
prolyl B-Species +
dipeptides L-Species -
. O -

Recently O -
, O +
we O +
developed O +
an O +
extremely O +
sensitive O +
fluorescent O +
labelling O +
reagent O -
, O +
4- O -
( O -
5,6-dimethoxy-2-phthalimidinyl O -
) O -
-2-methoxyphenylsulfonyl O +
chloride O +
( O -
DMS O -
- O -
Cl O -
) O -
, O +
which O +
reacts O +
quantitatively O +
with O +
amino O +
acids O +
to O +
form O +
fluorescent O +
sulfonamides O +
( O -
maximum O +
wavelength O -
: O +
318 O +
nm O +
for O +
excitation O +
and O +
392 O +
nm O +
for O +
emission O -
) O -
, O +
and O +
applied O +
the O +
reagent O +
for O +
determination O +
of O +
urinary O +
free O +
Hyp O +
by O +
a O +
pre O -
- O -
column O +
HPLC O +
method O +
[ O -
19 O -
] O +
. O -

In O +
the O +
present O +
study O -
, O +
we O +
found O +
DMS O -
- O -
Cl O +
reacted O +
with O +
prolyl O +
dipeptides O +
to O +
give O +
fluorescent O +
derivatives O -
. O -

In O +
addition O -
, O +
a O +
highly O +
sensitive O +
HPLC O +
method O +
for O +
simultaneous O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
by O +
fluorescence O +
detection O +
after O +
pre O -
- O -
column O +
derivatization O +
with O +
DMS O -
- O -
Cl O +
was O +
established O -
. O -

2 O +
Experimental O +
2.1 O +
Chemicals O +
and O +
solvents O +
All O +
chemicals O +
were O +
of O +
analytical O +
reagent O +
grade O -
, O +
unless O +
stated O +
otherwise O -
. O -

DMS O -
- O -
Cl O +
was O +
prepared O +
as O +
described O +
previously O +
[ O -
19 O -
] O +
. O -

o O +
-Phthalaldehyde O +
( O -
OPA O -
) O -
, O +
acetonitrile O +
( O -
HPLC O -
- O -
grade O -
) O +
and O +
Creatinine O +
Test O +
Wako O +
were O +
obtained O +
from O +
Wako O +
Pure O +
Chemicals O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O -

Pro O -
– O -
Asp O -
, O +
Pro O -
– O -
Gln O -
, O +
Pro O -
– O -
Glu O -
, O +
Pro O -
– O -
Leu O -
, O +
Pro O -
– O -
Pro O +
and O +
Pro O -
– O -
Ser O +
were O +
purchased O +
from O +
Kokusan O +
Chemical O +
Works O +
( O -
Tokyo O -
, O +
Japan O -
) O +
and O +
Pro O -
– O -
Ala O -
, O +
Pro O -
– O -
Asn O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Hyp O -
, O -

Pro O -
– O -
Ile O -
, O +
Pro O -
– O -
Met O -
, O +
Pro O -
– O -
Phe O -
, O +
Pro O -
– O -
Trp O -
, O +
Pro O -
– O -
Tyr O -
, O +
Pro O -
– O -
Val O +
and O +
3,4-dehydro O -
- O -
dl O +
-proline O +
( O -
internal O +
standard O -
, O +
I.S. O -
) O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O -

l O +
-Amino O +
acids O +
except O +
Asn O -
, O +
Hyp O +
and O +
Ser O +
( O -
Nacalai O +
Tesque O -
, O +
Kyoto O -
, O +
Japan O -
) O +
were O +
purchased O +
from O +
Kyowa O +
Hakko O +
( O -
Tokyo O -
, O +
Japan O -
) O -
. O -

Organic O +
solvents O +
except O +
acetonitrile O +
were O +
of O +
highest O +
purity O +
available O +
and O +
used O +
as O +
received O -
. O -

Bond O +
Elut O +
C18 O -
( O -
100 O +
mg O -
/ O -
1 O +
ml O -
, O +
Varian O -
, O +
CA O -
, O +
USA O -
) O +
was O +
conditioned O +
with O +
2 O +
ml O +
of O +
methanol O +
followed O +
by O +
2 O +
ml O +
of O +
water O +
and O +
1 O +
ml O +
of O +
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
) O +
prior O +
to O +
use O -
. O -

2.2 O +
Instrumental O +
conditions O +
The O +
HPLC O +
system O +
consisted O +
of O +
two O +
LC-10AD O +
HPLC O +
pumps O +
( O -
Shimadzu O -
, O +
Kyoto O -
, O +
Japan O -
) O -
, O +
a O +
CTO-10AC O +
column O +
oven O +
( O -
Shimadzu O -
) O -
, O +
a O +
DGU-14A O +
on O -
- O -
line O +
degasser O +
( O -
Shimadzu O -
) O -
, O +
an O +
SIL-10Axl O -
auto O +
injector O +
( O -
Shimadzu O -
) O -
, O +
an O +
L-7480 O +
fluorescence O +
detector O +
( O -
Hitachi O -
, O +
Tokyo O -
, O +
Japan O -
) O +
and O +
a O +
CLASS O -
- O -
LC10 O +
LC O +
work O -
- O -
station O +
( O -
Shimadzu O -
) O +
with O +
a O +
CBM-10A O +
communications O +
bus O +
module O +
( O -
Shimadzu O -
) O -
. O -

A O +
TSK O -
- O -
guard O +
gel O +
ODS-80Ts O -
( O -
15 O -
× O -
3.2 O +
mm O +
I.D. O -
, O +
Tosoh O -
, O +
Tokyo O -
, O +
Japan O -
) O +
and O +
tandem O +
Nova O +
Pak O +
C18 O -
columns O +
( O -
150 O -
× O -
3.9 O +
mm O +
I.D. O -
, O +
4 O +
μm O -
, O +
Waters O -
, O +
Milford O -
, O +
MA O -
, O +
USA O -
) O +
were O +
used O +
at O +
55 O -
° O -
C O +
with O +
a O +
gradient O +
system O +
of O +
( O -
A O -
) O +
aqueous O +
acetic O +
acid O +
( O -
10 O +
mM O +
) O -
– O -
( O -
B O -
) O +
acetonitrile O -
– O -
aqueous O +
acetic O +
acid O +
( O -
50 O +
mM O +
) O +
( O -
8:2 O -
, O +
v O -
/ O -
v O -
) O -
. O -

The O +
elution O +
program O +
consisted O +
of O +
an O +
isocratic O +
elution O +
of O +
25 O -
% O +
B O +
for O +
20 O +
min O -
, O +
followed O +
by O +
a O +
linear O +
gradient O +
elution O +
from O +
25 O +
to O +
55 O -
% O +
of O +
B O +
for O +
30 O +
min O -
, O +
and O +
finally O +
a O +
stepwise O +
decrease O +
to O +
25 O -
% O +
of O +
B O +
to O +
re O -
- O -
equilibrate O +
the O +
column O +
for O +
10 O +
min O -
. O -

The O +
flow O -
- O -
rate O +
was O +
1 O +
ml O -
/ O -
min O -
. O -

The O +
fluorescence O +
intensities O +
were O +
monitored O +
at O +
excitation O +
and O +
emission O +
wavelengths O +
of O +
318 O +
nm O +
and O +
392 O +
nm O -
, O +
respectively O -
. O -

2.3 O +
Derivatization O +
procedure O +
To O +
a O +
test O +
solution O +
( O -
20 O +
μl O -
) O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
the O +
I.S. O +
were O +
placed O +
in O +
a O +
screw O -
- O -
capped O +
glass O +
vial O -
, O +
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
, O +
280 O +
μl O -
) O +
and O +
DMS O -
- O -
Cl O +
( O -
2 O +
mM O -
in O +
acetone O -
, O +
500 O +
μl O -
) O +
were O +
successively O +
added O +
and O +
mixed O -
. O -

The O +
mixture O +
was O +
allowed O +
to O +
stand O +
for O +
20 O +
min O +
at O +
70 O -
° O -
C O -
. O -

After O +
cooling O -
, O +
the O +
reaction O +
mixture O +
was O +
mixed O +
with O +
dichloromethane O +
( O -
0.8 O +
ml O -
) O +
and O +
Na2 O +
CO3 O -
( O -
0.1 O +
M O +
, O +
30 O +
μl O -
) O +
and O +
then O +
centrifuged O +
( O -
500 O +
g O +
) O +
for O +
10 O +
min O -
. O -

An O +
aliquot O +
( O -
10 O +
μl O -
) O +
of O +
the O +
aqueous O +
layer O +
was O +
subjected O +
to O +
HPLC O -
. O -

2.4 O +
Procedure O +
for O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
2.4.1 O +
Method O +
A O +
( O -
recommended O +
method O -
) O -
: O +
solid O -
- O -
phase O +
extraction O +
method O +
To O +
human U-Species +
urine O +
( O -
25 O +
μl O -
) O +
were O +
added O +
I.S. O +
( O -
10 O +
μM O +
, O +
25 O +
μl O -
) O -
, O +
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
, O +
150 O +
μl O -
) O +
and O +
OPA O +
[ O -
4 O -
% O -
, O +
w O -
/ O -
v O -
, O +
in O +
acetonitrile O -
– O -
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
) O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O -
, O +
50 O +
μl O -
] O -
. O -

After O +
standing O +
for O +
3 O +
min O -
, O +
the O +
OPA O -
- O -
treated O +
mixture O +
( O -
200 O +
μl O -
) O +
was O +
passed O +
through O +
a O +
Bond O +
Elut O +
C18 O -
column O +
and O +
then O +
the O +
column O +
was O +
washed O +
with O +
acetonitrile O -
– O -
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
) O +
( O -
1:9 O -
, O +
v O -
/ O -
v O -
, O +
800 O +
μl O -
) O -
. O -

The O +
effluent O +
with O +
the O +
OPA O -
- O -
treated O +
mixture O +
and O +
the O +
washings O +
were O +
mixed O -
. O -

The O +
mixture O +
( O -
300 O +
μl O -
) O +
was O +
reacted O +
with O +
DMS O -
- O -
Cl O +
( O -
2 O +
mM O -
in O +
acetone O -
, O +
500 O +
μl O -
) O +
at O +
70 O -
° O -
C O +
for O +
20 O +
min O -
. O -

The O +
reaction O +
mixture O +
was O +
mixed O +
with O +
dichloromethane O +
( O -
0.8 O +
ml O -
) O +
and O +
Na2 O +
CO3 O -
( O -
0.1 O +
M O +
, O +
30 O +
μl O -
) O +
and O +
then O +
centrifuged O +
( O -
500 O +
g O +
) O +
for O +
10 O +
min O -
. O -

The O +
aqueous O +
layer O +
( O -
10 O +
μl O -
) O +
was O +
subjected O +
to O +
HPLC O -
. O -

The O +
Bond O +
Elut O +
C18 O -
column O +
was O +
used O +
at O +
least O +
20 O +
times O +
by O +
washing O +
twice O +
sequentially O +
with O +
methanol O +
and O +
water O +
( O -
2 O +
ml O +
each O -
) O +
after O +
each O +
use O -
. O -

2.4.2 O +
Method O +
B O -
: O +
solvent O +
extraction O -
- O -
stripping O +
method O +
To O +
human U-Species +
urine O +
( O -
20 O +
μl O -
) O +
were O +
added O +
I.S. O +
( O -
10 O +
μM O +
, O +
20 O +
μl O -
) O -
, O +
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
, O +
260 O +
μl O -
) O +
and O +
OPA O +
( O -
4 O -
% O -
, O +
w O -
/ O -
v O -
, O +
in O +
acetone O -
, O +
50 O +
μl O -
) O -
. O -

After O +
standing O +
for O +
3 O +
min O -
, O +
DMS O -
- O -
Cl O +
( O -
2 O +
mM O -
in O +
acetone O -
, O +
450 O +
μl O -
) O +
was O +
successively O +
added O +
and O +
mixed O -
. O -

The O +
mixture O +
was O +
allowed O +
to O +
stand O +
for O +
20 O +
min O +
at O +
70 O -
° O -
C O -
. O -

After O +
cooling O -
, O +
the O +
reaction O +
mixture O +
was O +
acidified O +
with O +
HCl O +
( O -
5 O +
M O +
, O +
50 O +
μl O -
) O -
, O +
saturated O +
with O +
NaCl O +
( O -
ca O -
. O +
150 O +
mg O -
) O +
and O +
then O +
extracted O +
with O +
dichloromethane O +
( O -
1 O +
ml O -
) O -
. O -

The O +
organic O +
layer O +
( O -
1 O +
ml O -
) O +
was O +
mixed O +
with O +
Na2 O +
CO3 O -
( O -
10 O +
mM O +
, O +
300 O +
μl O -
) O +
and O +
then O +
centrifuged O +
( O -
500 O +
g O +
) O +
for O +
10 O +
min O -
. O -

The O +
aqueous O +
layer O +
( O -
10 O +
μl O -
) O +
was O +
subjected O +
to O +
HPLC O -
. O -

3 O +
Results O +
and O +
discussion O +
3.1 O +
Chromatographic O +
separation O +
DMS O -
- O -
Cl O +
reacted O +
with O +
prolyl O +
dipeptides O +
in O +
a O +
basic O +
medium O +
to O +
give O +
the O +
corresponding O +
fluorescent O +
derivatives O +
( O -
Fig. O +
1 O -
) O -
. O -

The O +
separation O +
of O +
the O +
derivatives O +
of O +
prolyl O +
dipeptides O +
( O -
16 O +
species O -
) O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
labelled O +
with O +
DMS O -
- O -
Cl O +
were O +
examined O +
by O +
use O +
of O +
tandem O +
reversed O -
- O -
phase O +
columns O +
and O +
gradient O +
elution O -
. O -

A O +
typical O +
chromatogram O +
of O +
the O +
reaction O +
mixture O +
of O +
a O +
standard O +
solution O +
is O +
shown O +
in O +
Fig. O +
2 O -
. O -

The O +
peaks O +
due O +
to O +
12 O +
species O +
of O +
prolyl O +
dipeptides O +
( O -
retention O +
time O -
: O +
Pro O -
– O -
Asn O -
, O +
14.8 O -
; O +
–Gln O -
, O +
16.2 O -
; O +
–Hyp O -
, O +
17.1 O -
; O +
–Glu O -
, O +
23.9 O -
; O +
–Gly O -
, O +
27.0 O -
; O +
–Ala O -
, O +
33.8 O -
; O +
–Pro O -
, O +
35.0 O -
; O +
–Tyr O -
, O +
37.7 O -
; O +
–Met O -
, O +
42.1 O -
; O +
–Val O -
, O +
43.7 O -
; O +
–Trp O -
, O +
47.3 O -
; O +
–Phe O -
, O +
49.1 O +
min O -
) O -
, O +
Pro O +
( O -
34.4 O +
min O -
) O -
, O +
Hyp O +
( O -
12.2 O +
min O -
) O +
and O +
I.S. O +
( O -
31.0 O +
min O -
) O +
were O +
separate O +
from O +
each O +
other O +
and O +
the O +
reagent O +
blank O +
components O -
, O +
although O +
the O +
peaks O +
due O +
to O +
Pro O -
– O -
Asp O +
( O -
18.6 O +
min O -
) O +
and O +
Pro O -
– O -
Ser O +
( O -
18.7 O +
min O -
) O +
and O +
those O +
due O +
to O +
Pro O -
– O -
Ile O +
( O -
47.9 O +
min O -
) O +
and O +
Pro O -
– O -
Leu O +
( O -
48.0 O +
min O -
) O +
overlapped O -
. O -

As O +
the O +
chromatographic O +
separation O +
of O +
DMS O +
derivatives O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
was O +
affected O +
by O +
the O +
pH O +
in O +
the O +
mobile O +
phase O -
, O +
the O +
effect O +
of O +
the O +
pH O +
was O +
examined O +
using O +
acetate O +
buffer O +
[ O -
10 O +
mM O -
for O +
mobile O +
phase O +
( O -
A O -
) O +
and O +
50 O +
mM O -
for O +
mobile O +
phase O +
( O -
B O -
) O -
, O +
pH O +
4.0–6.0 O -
] O +
instead O +
of O +
acetic O +
acid O -
. O -

As O +
shown O +
in O +
Fig. O +
3 O -
, O +
the O +
retention O +
times O +
of O +
all O +
peaks O +
became O +
shorter O +
with O +
increased O +
pH O +
and O +
the O +
prolyl O +
dipeptide O +
peaks O +
overlapped O +
at O +
pH O +
greater O +
than O +
pH O +
4.5 O -
. O -

The O +
pH O +
of O +
acetic O +
acid O +
( O -
10 O +
mM O +
) O +
in O +
mobile O +
phase O +
was O +
about O +
3.4 O -
. O -

3.2 O +
Labelling O +
reaction O +
conditions O +
A O +
standard O +
solution O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
( O -
10 O +
μM O -
each O -
) O +
was O +
used O +
to O +
determine O +
the O +
optimum O +
labelling O +
conditions O -
. O -

The O +
reaction O +
of O +
Hyp O +
with O +
DMS O -
- O -
Cl O +
was O +
complete O +
within O +
5 O +
min O +
regardless O +
of O +
the O +
temperature O +
( O -
labelling O +
yield O -
: O +
99.7 O -
% O -
) O +
[ O -
19 O -
] O +
. O -

However O -
, O +
the O +
labelling O +
reactions O +
of O +
prolyl O +
dipeptides O +
with O +
DMS O -
- O -
Cl O +
were O +
incomplete O +
under O +
the O +
above O +
conditions O -
, O +
while O +
the O +
reactions O +
of O +
Pro O +
and O +
I.S. O +
with O +
DMS O -
- O -
Cl O +
were O +
similar O +
to O +
that O +
of O +
Hyp O -
. O -

Therefore O -
, O +
the O +
effect O +
of O +
the O +
reaction O +
time O +
on O +
the O +
labelling O +
reaction O +
was O +
examined O +
at O +
various O +
temperatures O -
. O -

The O +
results O +
obtained O +
for O +
Pro O -
– O -
Hyp O +
are O +
shown O +
in O +
Fig. O +
4 O -
. O -

The O +
maximum O +
peak O +
area O +
was O +
obtained O +
from O +
the O +
reactions O +
performed O +
at O +
above O +
70 O -
° O -
C O -
, O +
for O +
10 O +
min O -
. O -

Similar O +
results O +
were O +
obtained O +
from O +
other O +
prolyl O +
dipeptides O -
. O -

Consequently O -
, O +
subsequent O +
labelling O +
reactions O +
for O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
with O +
DMS O -
- O -
Cl O +
were O +
carried O +
out O +
at O +
70 O -
° O -
C O +
for O +
20 O +
min O -
. O -

The O +
reaction O +
mixture O +
was O +
stable O +
for O +
at O +
least O +
48 O +
h O +
at O +
room O +
temperature O -
. O -

As O +
the O +
labelling O +
reaction O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
with O +
DMS O -
- O -
Cl O +
proceeded O +
in O +
a O +
basic O +
medium O -
, O +
the O +
effect O +
of O +
the O +
pH O +
of O +
phosphate O +
buffer O +
( O -
50 O +
mM O +
) O +
on O +
the O +
labelling O +
reaction O +
was O +
examined O -
. O -

The O +
results O +
for O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O +
and O +
I.S. O +
are O +
shown O +
in O +
Fig. O +
5 O -
. O -

Each O +
peak O +
exhibited O +
a O +
maximum O +
and O +
constant O +
area O +
in O +
the O +
range O +
of O +
pH O +
8–10 O -
. O -

Similar O +
results O +
were O +
obtained O +
from O +
other O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O -
. O -

The O +
effect O +
of O +
the O +
anionic O +
component O +
of O +
the O +
buffer O +
solution O +
was O +
also O +
examined O +
using O +
acetate O -
, O +
borate O +
and O +
phosphate O +
buffer O +
( O -
50 O +
mM O +
, O +
pH O +
8) O -
. O -

The O +
maximum O +
peak O +
areas O +
of O +
prolyl O +
dipeptides O +
were O +
obtained O +
in O +
phosphate O +
buffer O +
( O -
peak O +
area O +
relative O +
to O +
phosphate O +
buffer O -
: O +
acetate O +
buffer O -
, O +
75–98 O -
% O -
; O +
borate O +
buffer O -
, O +
91–100 O -
% O +
except O +
61 O -
% O +
for O +
Pro O -
– O -
Tyr O -
) O -
. O -

Therefore O -
, O +
Na2 O +
HPO4 O -
( O -
50 O +
mM O +
, O +
pH O +
ca O -
. O -

9.3 O -
) O +
was O +
adopted O -
. O -

When O +
the O +
effect O +
of O +
the O +
concentration O +
of O +
Na2 O +
HPO4 O -
( O -
10–100 O +
mM O +
) O +
was O +
examined O -
, O +
the O +
maximum O +
and O +
constant O +
peak O +
areas O +
were O +
obtained O +
at O +
a O +
concentration O +
of O +
more O +
than O +
25 O +
mM O +
. O -

The O +
concentration O +
of O +
DMS O -
- O -
Cl O +
was O +
determined O +
by O +
the O +
peak O +
areas O +
due O +
to O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
( O -
100 O +
μM O -
each O -
) O -
. O -

The O +
maximum O +
peak O +
areas O +
were O +
obtained O +
at O +
more O +
than O +
1.5 O +
mM O -
DMS O -
- O -
Cl O -
. O -

Dichloromethane O +
extraction O +
was O +
carried O +
out O +
to O +
remove O +
excess O +
DMS O -
- O -
Cl O -
, O +
which O +
was O +
suspected O +
of O +
causing O +
the O +
guard O +
column O +
to O +
degrade O -
. O -

The O +
extraction O +
was O +
achieved O +
after O +
addition O +
of O +
Na2 O +
CO3 O -
( O -
0.1 O +
M O +
, O +
30 O +
μl O -
) O +
because O +
parts O +
of O +
the O +
derivatives O +
of O +
prolyl O +
dipeptides O +
that O +
eluted O +
after O +
the O +
derivatives O +
of O +
Pro O -
– O -
Ala O +
on O +
the O +
HPLC O +
column O +
were O +
lost O +
with O +
dichloromethane O +
extraction O +
without O +
Na2 O +
CO3 O +
. O -

3.3 O +
Linearity O +
and O +
detection O +
limit O +
Linearity O +
was O +
studied O +
over O +
wide O +
ranges O +
of O +
concentration O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
( O -
between O +
0.1 O +
and O +
100 O +
μM O -
each O -
) O -
. O -

The O +
peak O -
- O -
area O +
ratios O +
of O +
analytes O +
to O +
I.S. O +
were O +
linear O +
in O +
the O +
concentration O +
ranges O +
investigated O +
( O -
r O +
> O -
0.999 O +
each O -
) O -
. O -

When O +
the O +
precision O +
was O +
tested O +
using O +
standard O +
solutions O +
( O -
1 O -
, O +
10 O +
and O +
100 O +
μM O -
each O -
) O -
, O +
the O +
relative O +
standard O +
deviations O +
( O -
RSDs O -
, O +
n O +
= O -
10 O -
) O +
were O +
less O +
than O +
4.1 O -
% O -
. O -

The O +
detection O +
limits O +
( O -
S O -
/ O -
N=3 O -
) O +
for O +
prolyl O +
dipeptides O +
were O +
1–5 O +
fmol O -
/ O -
injection O -
. O -

3.4 O +
Pretreatment O +
of O +
urine O +
and O +
HPLC O +
chromatograms O +
For O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
by O +
pre O -
- O -
column O +
HPLC O -
, O +
OPA O +
treatment O +
[ O -
20 O -
] O -
was O +
employed O +
to O +
eliminate O +
primary O +
amino O +
compounds O +
coexisting O +
with O +
analytes O +
in O +
urine O -
. O -

However O -
, O +
the O +
reaction O +
mixture O +
of O +
urine O +
with O +
OPA O +
was O +
colored O +
darkly O -
. O -

Therefore O -
, O +
two O +
methods O -
, O +
method O +
A O +
( O -
solid O -
- O -
phase O +
extraction O -
) O +
and O +
method O +
B O +
( O -
solvent O +
extraction O -
- O -
stripping O -
) O +
described O +
in O +
Section O +
2.4 O -
were O +
tested O +
to O +
remove O +
the O +
colored O +
products O -
. O -

The O +
colored O +
products O +
were O +
retained O +
on O +
the O +
Bond O +
Elut O +
C18 O -
column O +
in O +
method O +
A O +
and O +
were O +
not O +
extracted O +
with O +
dichloromethane O +
at O +
acidic O +
pH O +
in O +
method O +
B. O +
The O +
typical O +
chromatograms O +
of O +
a O +
standard O +
solution O +
and O +
urine O +
obtained O +
according O +
to O +
the O +
procedures O +
of O +
methods O +
A O +
and O +
B O +
are O +
shown O +
in O +
Fig. O +
6A O +
and O +
B O -
and O +
Fig. O +
7A O +
and O +
B O -
, O +
respectively O -
. O -

As O +
shown O +
in O +
Fig. O +
6A O +
, O +
some O +
prolyldipeptides O +
( O -
Pro O -
– O -
Tyr O -
, O +
–Val O -
, O +
–Met O -
, O +
–Trp O -
, O +
–Ile O -
, O +
–Leu O +
and O +
–Phe O -
) O +
were O +
unable O +
to O +
be O +
measured O +
by O +
method O +
A O -
, O +
because O +
these O +
peptides O +
were O +
retained O +
on O +
the O +
Bond O +
Elut O +
C18 O -
column O +
under O +
the O +
conditions O +
used O -
. O -

When O +
urine O +
was O +
analyzed O +
by O +
method O +
A O -
, O +
peaks O +
due O +
to O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O +
and O +
Hyp O +
at O +
retention O +
times O +
of O +
17.1 O -
, O +
27.0 O -
, O +
35.0 O -
, O +
34.3 O +
and O +
12.2 O +
min O -
, O +
respectively O -
, O +
were O +
observed O +
( O -
Fig. O +
6B O +
) O -
. O -

In O +
contrast O -
, O +
for O +
method O +
B O -
, O +
all O +
prolyl O +
dipeptides O +
in O +
a O +
standard O +
solution O +
were O +
detected O +
( O -
Fig. O +
7A O +
) O -
. O -

However O -
, O +
the O +
seven O +
prolyl O +
dipeptides O +
that O +
could O +
not O +
be O +
measured O +
by O +
method O +
A O +
were O +
not O +
recognized O +
in O +
urine O +
( O -
Fig. O +
7B O +
) O -
, O +
although O +
the O +
three O +
prolyl O +
dipeptides O +
mentioned O +
above O +
were O +
recognized O +
in O +
urine O -
. O -

Despite O +
these O +
issues O -
, O +
urinary O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O -
, O +
Hyp O +
and O +
I.S. O +
were O +
separated O +
from O +
the O +
reagent O +
blank O +
and O +
other O +
urinary O +
components O +
( O -
Figs. O +
6B O +
and O +
7B O +
) O -
. O -

These O +
urinary O +
analytes O +
were O +
identified O +
by O +
comparing O +
the O +
retention O +
times O +
with O +
those O +
of O +
standard O +
solutions O +
and O +
also O +
by O +
co O -
- O -
chromatography O +
of O +
a O +
standard O +
solution O +
and O +
urine O -
. O -

3.5 O +
Recovery O +
and O +
precision O +
Recovery O +
tests O +
were O +
examined O +
by O +
means O +
of O +
both O +
methods O +
using O +
three O +
urine O +
samples O +
spiked O +
with O +
various O +
amounts O +
of O +
standard O +
Pro O -
– O -
Hyp O +
( O -
urinary O +
concentration O -
: O +
25 O -
, O +
50 O -
, O +
100 O -
, O +
250 O +
and O +
500 O +
μM O +
) O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Hyp O +
( O -
0.5 O -
, O +
1 O -
, O +
2 O -
, O +
5 O +
and O +
10 O +
μM O -
each O -
) O +
and O +
Pro O +
( O -
1 O -
, O +
2 O -
, O +
4 O -
, O +
10 O +
and O +
20 O +
μM O +
) O -
. O -

The O +
relationships O +
between O +
the O +
peak O -
- O -
area O +
ratios O +
of O +
analytes O +
to O +
I.S. O +
and O +
the O +
concentrations O +
of O +
analytes O +
were O +
linear O -
. O -

According O +
to O +
method O +
A O -
, O +
the O +
regression O +
equations O +
for O +
standard O +
solutions O +
without O +
urine O +
were O +
y O +
= O -
0.1300x O +
+ O -
0.1183 O +
( O -
r O +
= O -
0.9999 O -
) O +
for O +
Pro O -
– O -
Hyp O -
, O +
y O +
= O -
0.1384x O +
−0.0001 O +
( O -
r O +
= O -
0.9999 O -
) O +
for O +
Pro O -
– O -
Gly O -
, O +
y O +
= O -
0.1069x O +
+ O -
0.0020 O +
( O -
r O +
= O -
0.9998 O -
) O +
for O +
Pro O -
– O -
Pro O -
, O +
y O +
= O -
0.1135x O +
+ O -
0.0735 O +
( O -
r O +
= O -
0.9994 O -
) O +
for O +
Pro O +
and O +
y O +
= O -
0.1140x O +
+ O -
0.0066 O +
( O -
r O +
= O -
0.9996 O -
) O +
for O +
Hyp O -
, O +
where O +
y O -
is O +
the O +
peak O -
- O -
area O +
ratio O +
of O +
analyte O +
to O +
I.S. O +
and O +
x O -
is O +
the O +
concentration O +
of O +
analyte O +
( O -
μM O +
) O -
. O -

The O +
recoveries O +
were O +
obtained O +
from O +
the O +
slope O +
ratios O +
of O +
regression O +
equations O +
of O +
analytes O +
with O -
/ O -
without O +
urine O -
. O -

The O +
slopes O +
of O +
regression O +
equations O +
and O +
the O +
recoveries O +
by O +
methods O +
A O +
and O +
B O +
are O +
shown O +
in O +
Table O +
1 O -
. O -

The O +
recoveries O +
of O +
the O +
analytes O +
except O +
Pro O -
– O -
Gly O +
by O +
method O +
A O +
were O +
almost O +
100 O -
% O -
, O +
while O +
those O +
by O +
method O +
B O +
were O +
very O +
low O -
. O -

In O +
method O +
B O -
, O +
some O +
organic O +
solvents O +
such O +
as O +
chloroform O -
, O +
benzene O -
, O +
ethyl O +
acetate O +
and O +
diethyl O +
ether O +
instead O +
of O +
dichloromethane O +
were O +
also O +
used O -
. O -

However O -
, O +
the O +
maximum O +
peak O +
areas O +
of O +
DMS O -
- O -
derivatives O +
were O +
obtained O +
with O +
use O +
of O +
dichloromethane O -
. O -

In O +
addition O -
, O +
when O +
the O +
concentration O +
of O +
Na2 O +
CO3 O -
( O -
1 O -
, O +
5 O -
, O +
10 O +
and O +
20 O +
mM O +
) O +
for O +
stripping O +
of O +
the O +
derivatives O +
of O +
prolyl O +
dipeptides O +
was O +
examined O -
, O +
maximum O +
peak O +
areas O +
were O +
obtained O +
by O +
use O +
of O +
more O +
than O +
5 O +
mM O -
Na2 O +
CO3 O +
. O -

These O +
results O +
suggest O +
that O +
method O +
A O +
is O +
appropriate O +
for O +
the O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
. O -

Incidentally O -
, O +
when O +
the O +
recoveries O +
of O +
standard O +
prolyl O +
dipeptides O -
, O +
Pro O -
, O +
Hyp O +
( O -
0.02 O -
, O +
0.2 O -
, O +
2 O +
and O +
10 O +
nmol O +
each O -
) O +
and O +
I.S. O +
from O +
Bond O +
Elut O +
C18 O -
were O +
examined O -
, O +
the O +
recoveries O +
were O +
96.1–101.1 O -
% O +
( O -
except O +
the O +
seven O +
species O +
prolyl O +
dipeptides O +
mentioned O +
above O -
) O -
. O -

Therefore O -
, O +
for O +
determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O -
, O +
method O +
A O +
was O +
employed O +
and O +
the O +
regression O +
equations O +
in O +
water O +
described O +
above O +
were O +
used O -
. O -

However O -
, O +
the O +
estimated O +
values O +
of O +
urinary O +
Pro O -
– O -
Gly O +
were O +
corrected O +
using O +
the O +
mean O +
value O +
( O -
0.866 O -
, O +
n O +
= O -
6 O -
) O +
of O +
recovery O +
derived O +
from O +
additional O +
experiments O +
using O +
another O +
three O +
urine O +
samples O +
( O -
the O +
recoveries O -
: O +
85.8 O -
, O +
85.9 O +
and O +
86.8 O -
% O -
) O -
. O -

The O +
within O -
- O -
day O +
and O +
between O -
- O -
day O +
precisions O +
of O +
method O +
A O +
were O +
evaluated O +
using O +
three O +
urine O +
samples O -
. O -

The O +
within O -
- O -
day O +
precision O +
was O +
examined O +
with O +
ten O +
replicate O +
assays O +
in O +
each O +
one O +
day O +
and O +
the O +
between O -
- O -
day O +
precision O +
by O +
assays O +
on O +
five O +
different O +
days O -
. O -

As O +
shown O +
in O +
Table O +
2 O -
, O +
RSDs O +
of O +
the O +
within O -
- O -
day O +
and O +
between O -
- O -
day O +
precisions O +
were O +
1.5–4.8 O +
and O +
1.7–5.8 O -
% O -
, O +
respectively O -
. O -

3.6 O +
Selection O +
of O +
I.S. O +
Some O +
secondary O +
amino O +
acids O +
( O -
10 O +
μM O -
each O -
) O +
were O +
examined O +
to O +
select O +
I.S. O +
Although O +
the O +
peaks O +
due O +
to O +
l O +
-azetidine-2-calboxylic O +
acid O -
, O +
l O +
-thioproline O -
, O +
isonipecotic O +
acid O -
, O +
nipecotic O +
acid O +
and O +
dl O +
-pipecolic O +
acid O +
were O +
eluted O +
at O +
23.0 O -
, O +
34.7 O -
, O +
36.9 O -
, O +
39.9 O +
and O +
42.0 O +
min O -
, O +
respectively O -
, O +
those O +
peaks O +
overlapped O +
with O +
peaks O +
due O +
to O +
urinary O +
components O -
. O -

The O +
peak O +
due O +
to O +
3,4-dehydro O -
- O -
dl O +
-proline O +
( O -
31.0 O +
min O -
) O +
was O +
successfully O +
separated O +
from O +
those O +
of O +
urinary O +
components O -
. O -

3.7 O +
Influence O +
of O +
amino O +
acids O +
The O +
influence O +
of O +
amino O +
acids O +
on O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
by O +
method O +
A O +
was O +
examined O +
with O +
urine O +
spiked O +
with O +
25 O +
species O +
of O +
primary O +
amino O +
acids O +
( O -
Ala O -
, O +
Arg O -
, O +
Asp O -
, O +
Asn O -
, O +
Cit O -
, O +
Cys O -
, O +
Cys O -
– O -
Cys O -
, O +
Glu O -
, O +
Gln O -
, O +
Gly O -
, O +
His O -
, O +
Hse O -
, O +
Ile O -
, O +
Leu O -
, O +
Lys O -
, O +
Met O -
, O +
Orn O -
, O +
Phe O -
, O +
Ser O -
, O +
Thr O -
, O +
Trp O -
, O +
Tyr O -
, O +
Val O -
, O +
γ O -
- O -
aminobutyric O +
acid O +
and O +
ϵ-aminocaproic O +
acid O -
, O +
5 O +
nmol O +
each O -
) O -
. O -

These O +
amino O +
acids O +
did O +
not O +
interfere O +
with O +
the O +
determination O +
of O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O +
and O +
Hyp O -
. O -

3.8 O +
Determination O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
The O +
concentrations O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
from O +
ten O +
healthy O +
volunteers U-Species +
( O -
Japanese O +
staff U-Species +
and O +
students U-Species +
in O +
our O +
laboratory O -
) O +
who O +
were O +
eating O +
self O -
- O -
selected O +
diets O +
were O +
measured O +
by O +
method O +
A. O +
Overnight O +
urine O +
was O +
collected O +
in O +
the O +
early O +
morning O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
until O +
use O -
. O -

The O +
concentrations O +
of O +
urinary O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
are O +
given O +
in O +
Table O +
3 O -
. O -

The O +
mean O +
values O +
( O -
mean±SD O -
) O +
of O +
urinary O +
Pro O -
– O -
Hyp O -
, O +
Pro O -
– O -
Gly O -
, O +
Pro O -
– O -
Pro O -
, O +
Pro O +
and O +
Hyp O +
were O +
97.6±28.2 O -
, O +
2.74±1.48 O -
, O +
2.08±1.13 O -
, O +
6.71±3.34 O +
and O +
2.30±1.59 O +
nmol O -
/ O -
mg O +
creatinine O -
, O +
respectively O -
. O -

When O +
the O +
concentration O +
of O +
Hyp O +
in O +
hydrolysed O +
urine O +
( O -
total O +
Hyp O -
) O +
was O +
measured O +
according O +
to O +
the O +
method O +
reported O +
previously O +
[ O -
20 O -
] O +
, O +
the O +
concentration O +
ratios O +
( O -
% O -
, O +
mean±SD O -
) O +
of O +
Pro O -
– O -
Hyp O +
and O +
free O +
Hyp O +
to O +
total O +
Hyp O +
were O +
45.7–64.5 O -
% O +
( O -
53.1±6.7 O -
% O -
) O +
and O +
0.4–2.2 O -
% O +
( O -
1.3±0.7 O -
% O -
) O -
, O +
respectively O -
. O -

These O +
values O +
were O +
similar O +
to O +
the O +
values O +
reported O +
previously O +
[ O -
2,3,19 O -
] O +
. O -

The O +
proposed O +
method O +
for O +
the O +
determination O +
of O +
prolyl O +
dipeptides O -
, O +
Pro O +
and O +
Hyp O +
in O +
urine O +
is O +
highly O +
sensitive O +
and O +
reliable O -
. O -

As O +
the O +
sensitive O +
and O +
reliable O +
determination O +
of O +
these O +
components O +
can O +
provide O +
useful O +
information O +
for O +
diagnosis O +
and O +
prognosis O +
of O +
diseases O -
, O +
the O +
proposed O +
method O +
may O +
be O +
useful O +
for O +
biochemical O +
and O +
clinical O +
research O -
. O -

Further O +
clinical O +
research O +
including O +
a O +
determination O +
of O +
bone O +
metastasis O +
stages O +
in O +
cancer O +
patients U-Species +
is O +
now O +
progressing O +
in O +
our O +
laboratories O -
. O +

The O +
eight O +
enzymes O +
of O +
the O +
tricarboxylic O +
acid O +
( O -
TCA O -
) O +
cycle O +
are O +
encoded O +
by O +
at O +
least O +
15 O +
different O +
nuclear O +
genes O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species -
. O -

We O +
have O +
constructed O +
a O +
set O +
of O +
yeast U-Species +
strains O +
defective O +
in O +
these O +
genes O +
as O +
part O +
of O +
a O +
comprehensive O +
analysis O +
of O -
the O +
interactions O +
among O +
the O +
TCA O +
cycle O +
proteins O -
. O -

The O +
15 O +
major O +
TCA O +
cycle O +
genes O +
can O +
be O +
sorted O +
into O +
five O +
phenotypic O +
categories O +
on O +
the O +
basis O +
of O +
their O +
growth O +
on O +
nonfermentable O +
carbon O +
sources O -
. O -

We O +
have O +
previously O +
reported O +
a O +
novel O +
phenotype O +
associated O +
with O +
mutants O +
defective O +
in O +
the O +
IDH2 O +
gene O +
encoding O +
the O +
Idh2p O +
subunit O +
of O -
the O +
NAD+-dependent O +
isocitrate O +
dehydrogenase O +
( O -
NAD O -
- O -
IDH O -
) O -
. O -

Null O +
and O +
nonsense O +
idh2 O +
mutants O +
grow O +
poorly O +
on O +
glycerol O -
, O +
but O +
growth O +
can O +
be O +
enhanced O +
by O +
extragenic O +
mutations O -
, O +
termed O +
glycerol O +
suppressors O -
, O +
in O +
the O +
CIT1 O +
gene O +
encoding O +
the O +
TCA O +
cycle O +
citrate O +
synthase O +
and O +
in O +
other O +
genes O +
of O +
oxidative O +
metabolism O -
. O -

The O +
TCA O +
cycle O +
mutant O +
collection O +
was O +
utilized O +
to O +
search O +
for O +
other O +
genes O +
that O +
can O +
suppress O +
idh2 O +
mutants O -
and O +
to O +
identify O +
TCA O +
cycle O +
genes O +
that O +
display O +
a O +
similar O +
suppressible O +
growth O +
phenotype O +
on O +
glycerol O -
. O -

Mutations O +
in O +
7 O +
TCA O +
cycle O +
genes O +
were O +
capable O +
of O +
functioning O +
as O +
suppressors O +
for O +
growth O +
of O +
idh2 O +
mutants O +
on O +
glycerol O -
. O -

The O +
only O +
other O +
TCA O +
cycle O +
gene O +
to O +
display O +
the O +
glycerol O -
- O -
suppressor O -
- O -
accumulation O +
phenotype O +
was O +
IDH1 O -
, O +
which O +
encodes O +
the O +
companion O +
Idh1p O +
subunit O +
of O +
NAD O -
- O -
IDH O -
. O -

These O +
results O +
provide O +
genetic O +
evidence O +
that O +
NAD O -
- O -
IDH O +
plays O +
a O +
unique O +
role O +
in O +
TCA O +
cycle O +
function O -
. O +

A O +
mixture O +
of O +
oligosaccharides O +
produced O +
by O +
beta O -
- O -
galactosidase O +
using O +
lactose O +
as O +
a O +
substrate O +
was O +
fractionated O +
according O +
to O +
degree O +
of O +
polymerization O +
using O +
gel O +
filtration O -
, O +
followed O +
by O +
high O -
- O -
pH O +
anion O -
- O -
exchange O +
chromatography O -
. O -

The O +
fractions O +
obtained O +
were O +
analyzed O +
using O +
monosaccharide O +
analysis O -
, O +
methylation O +
analysis O -
, O +
mass O -
spectrometry O -
, O +
and O +
NMR O +
spectroscopy O -
. O -

Twelve O +
novel O +
non O -
- O -
reducing O +
oligosaccharides O +
were O +
characterized O -
, O +
namely O -
, O +
[ O -
beta O -
- O -
D O -
- O -
Galp- O -
( O -
1 O -
- O -
->4 O -
) O -
] O -
n O -
- O -
alpha O -
- O -
D O -
- O -
Glcp- O +
( O -
1<-->1 O -
) O -
-beta O -
- O -
D O -
- O -
Galp O -
[ O -
- O -
( O -
4<--1 O -
) O -
-beta O -
- O -
D O -
- O -
Galp O -
] O -
m O -
, O +
with O +
n O -
, O +
m O +
= O +
( O -
1 O -
, O +
2 O -
, O +
3 O -
, O +
or O +
4 O -
) O +
and O +
beta O -
- O -
D O -
- O -
Galp- O -
( O -
1 O -
- O -
->2 O -
) O -
-alpha O -
- O -
D O -
- O -
Glcp- O +
( O -
1<-->1 O -
) O -
-beta O -
- O -
D O -
- O -
Galp O -
. O +

Concentration O +
of O +
L O -
- O -
cystathionine O +
was O +
distinctly O +
increased O +
in O +
rabbit U-Species +
brain O +
within O -
the O +
period O +
of O +
maximal O +
action O +
of O +
drugs O -
, O +
stimulating O +
the O +
central O +
nervous O +
system O +
( O -
phenamine O -
, O +
strychnine O +
corasole O -
) O -
. O -

A O +
distinct O +
decrease O +
in O +
content O +
of O +
L O -
- O -
cystathionine O +
was O +
observed O +
within O +
one O +
hour O +
after O +
the O +
administration O +
of O +
strychnine O +
and O +
corasole O -
. O +

Lactosylceramide O +
synthase O +
is O +
an O +
enzyme O +
that O +
catalyzes O +
the O +
transfer O +
of O +
galactose O +
from O +
UDP O -
- O -
Gal O +
to O +
glucosylceramide O -
, O +
and O +
thus O +
participates O +
in O +
the O +
biosynthesis O +
of O +
most O +
glycolipids O +
in O +
mammals U-Species -
. O -

We O +
have O +
isolated O +
and O +
sequenced O +
the O +
cDNA O +
clone O +
encoding O +
human U-Species +
lactosylceramide O +
synthase O -
. O -

The O +
deduced O +
amino O +
acid O +
sequence O +
of O +
the O -
human U-Species +
lactosylceramide O +
synthase O +
showed O +
94.2 O -
% O +
identity O +
with O +
rat U-Species +
lactosylceramide O +
synthase O -
. O -

Northern O +
blotting O +
analysis O +
revealed O +
that O +
lactosylceramide O +
synthase O +
mRNA O +
was O +
expressed O +
in O +
various O +
tissues O -
, O +
with O +
the O +
highest O +
level O +
in O +
brain O +
and O +
adrenal O +
gland O -
. O +

Microsomal O +
cytochrome O +
P450-dependent O +
lauric O +
acid O +
hydroxylase O +
activities O +
were O +
characterized O +
in O +
liver O -
, O +
kidney O -
, O +
and O +
intestinal O +
mucosa O +
of O +
the O +
sea B-Species +
bass L-Species +
( O -
Dicentrarchus B-Species +
labrax L-Species -
) O -
. O -

Microsomes O +
from O +
these O +
organs O +
generated O +
( O -
omega-1 O -
) O -
-hydroxylauric O +
acid O +
and O +
a O +
mixture O +
of O +
positional O +
isomers O +
including O +
( O -
omega O -
) O -
- O -
, O +
( O -
omega-2 O -
) O -
- O -
, O +
( O -
omega-3 O -
) O -
- O +
and O +
( O -
omega-4 O -
) O -
-hydroxylauric O +
acids O -
, O +
which O +
were O +
identified O +
by O +
RP O -
- O -
HPLC O +
and O +
GC O -
- O -
MS O +
analysis O -
. O -

Peroxisome O +
proliferators O -
, O +
such O +
as O +
clofibrate O +
and O +
especially O +
di O -
( O -
2-ethylhexyl O -
) O +
phthalate O -
, O +
increased O +
kidney O +
microsomal O +
lauric O +
acid O +
hydroxylase O +
activities O -
. O -

The O +
synthesis O +
of O +
11-hydroxylauric O +
acid O +
was O +
enhanced O +
5.3-fold O +
in O +
kidney O +
microsomes O -
. O -

Liver O +
microsomal O +
lauric O +
acid O +
hydroxylase O -
activities O +
were O +
weakly O +
affected O +
and O +
no O +
significant O +
induction O +
was O +
found O +
in O +
small O +
intestine O +
microsomes O +
from O +
clofibrate O +
or O +
di O -
( O -
2-ethylhexyl O -
) O +
phthalate O -
- O -
treated O +
fish U-Species -
. O -

The O +
differences O +
in O +
lauric O +
acid O +
metabolisation O +
and O +
the O +
tissue O -
- O -
specific O +
induction O +
by O +
peroxisome O +
proliferators O +
suggest O +
the O +
involvement O +
of O +
several O +
P450s O +
in O +
this O +
reaction O -
. O -

Incubations O +
of O +
liver O +
and O +
kidney O +
microsomes O +
with O +
lauric O +
acid O +
analogues O +
( O -
11- O +
or O +
10-dodecynoic O +
acids O -
) O +
resulted O +
in O +
a O +
time- O +
and O +
concentration O -
- O -
dependent O +
loss O +
of O +
lauric O +
acid O +
hydroxylase O +
activities O -
. O -

The O +
induction O +
of O +
these O +
activities O +
in O +
fish U-Species -
by O +
phthalates O -
, O +
which O +
are O +
widely O -
- O -
distributed O +
environmental O +
pollutants O -
, O +
may O +
be O +
taken O +
into O +
consideration O +
for O +
the O +
development O +
of O +
new O +
biomarkers O -
. O +

6-Chloro-7-arylamino-5,8-isoquinolinediones O +
were O +
newly O +
synthesized O +
and O +
evaluated O -
for O +
in O +
vitro O +
cytotoxic O +
activities O +
against O +
five O +
human U-Species +
solid O +
tumor O +
cell O +
lines O -
. O -

Among O +
them O -
, O +
5b O -
, O +
5c O +
and O +
5d O +
exhibited O +
potent O +
activities O +
against O +
the O +
cell O +
lines O +
HCT-15 O +
and O +
SK O -
- O -
MEL-2 O -
. O +

We O +
developed O +
a O +
novel O +
fluorometric O +
assay O +
method O +
for O +
the O +
measurement O +
of O +
glycosyltransferase O +
activities O +
using O +
mono- O +
and O +
di O -
- O -
saccharides O +
aminated O +
and O +
tagged O +
with O +
7-hydroxycoumarin-3-carboxylic O +
acid O +
( O -
coumarin O -
) O +
as O +
substrates O -
, O +
N O -
- O -
acetylglucosamine O +
( O -
GlcNAc O -
) O -
-coumarin O +
for O +
beta1,4-galactosyltransferase O +
from O +
bovine U-Species +
milk O +
and O +
Gal O +
beta1 O -
- O -
4GlcNAc O -
- O -
coumarin O +
for O +
alpha2,3- O +
and O +
alpha2,6-sialyltransferases O +
from O +
rat U-Species +
liver O -
. O -

Using O +
Gal O +
beta1 O -
- O -
3GlcNAc O +
and O +
Gal O +
beta1 O -
- O -
4Glc O -
- O -
NAc O -
- O -
coumarin O -
, O +
alpha1,3 O -
/ O -
4- O +
and O +
alpha1,3-fucosyltransferase O +
activities O +
were O +
also O +
determined O -
, O +
respectively O -
. O -

These O +
enzymatic O +
products O +
liberated O +
by O +
the O +
reactions O +
of O +
glycosyltransferases O +
in O +
the O +
presence O +
of O +
sugar O +
nucleotides O -
, O +
were O +
separated O +
by O +
a O +
normal O +
phase O +
or O +
an O +
ion O -
- O -
pair O +
reversed O +
phase O +
HPLC O +
with O +
an O +
isocratic O -
elution O +
and O +
fluorescence O +
detection O -
. O -

We O +
applied O +
this O +
assay O +
method O +
to O +
determine O +
the O +
glycosyltransferase O +
activities O +
in O +
8 O +
kinds O +
of O +
human U-Species +
tumor O +
cell O +
lines O -
, O +
including O +
the O +
cell O +
lines O +
derived O +
from O +
hepatocytes O +
( O -
HuH-7 O -
, O +
HepG2 O -
) O -
, O +
colonic O +
cells O +
( O -
Colo205 O -
, O +
HT-29 O -
) O -
, O +
myelocytes O +
( O -
HL-60 O -
, O +
U-937 O -
) O -
, O +
B O -
- O -
lymphocytes O +
( O -
Daudi O -
) O +
and O +
T O -
- O -
lymphocytes O +
( O -
Jurkat O -
) O -
. O -

This O +
assay O +
method O +
is O +
accurate O +
and O +
easy O +
compared O +
with O +
other O +
isotopic O +
and O +
non O -
- O -
isotopic O +
assay O +
methods O -
, O +
and O +
is O +
sensitive O +
enough O +
to O +
measure O +
glycosyltransferase O +
activities O +
in O +
cell O +
homogenates O -
. O +

Anandamide O +
( O -
N O -
- O -
arachidonoylethanolamine O -
) O +
and O +
six O +
fatty O +
acid O +
ethanolamides O +
were O +
synthesized O +
and O +
their O +
pharmacological O +
effects O +
in O +
mice U-Species +
were O +
assessed O +
using O +
catalepsy O -
, O +
hypothermia O +
and O +
pentobarbital O -
- O -
induced O +
sleep O +
prolongation O +
as O +
indices O -
. O -

The O +
effects O +
of O +
phenylmethylsulfonyl O +
fluoride O +
( O -
PMSF O -
) O +
pretreatment O +
on O +
anandamide O +
effects O +
were O +
also O +
evaluated O +
and O +
discussed O +
in O +
relation O +
to O +
inhibition O +
of O +
anandamide O +
amidohydrolase O +
in O +
mouse U-Species +
brain O +
and O +
liver O -
. O -

The O +
cataleptogenic O +
effect O +
of O +
anandamide O -
( O -
ED50=6.0 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
was O +
4 O +
to O +
6 O +
times O +
more O +
active O +
than O +
those O +
of O +
N O -
- O -
oleoyl- O +
( O -
ED50=26.5 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
and O +
N O -
- O -
linoleoylethanolamine O +
( O -
ED50=37.5 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O -
, O +
although O +
the O +
peak O +
time O +
in O +
the O +
effect O +
was O +
observed O +
within O +
1 O +
min O +
after O +
i.v O -
. O -

administration O -
. O -

None O +
of O +
the O +
saturated O +
fatty O +
acid O +
ethanolamides O +
( O -
N O -
- O -
myristoyl- O -
, O +
N O -
- O -
palmitoyl- O -
, O +
N O -
- O -
stearoyl- O +
and O +
N O -
- O -
arachidoylethanolamine O -
) O +
showed O +
a O +
positive O +
response O +
in O +
the O +
cataleptogenic O +
effect O +
even O +
at O +
a O +
dose O +
up O +
to O +
40 O +
mg O -
/ O -
kg O +
i.v O -
. O -

Anandamide O -
, O +
N O -
- O -
linoleoyl- O -
, O +
N O -
- O -
oleoyl- O +
and O +
N O -
- O -
myristoylethanolamine O +
( O -
10 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O -
produced O +
a O +
significant O +
hypothermia O +
( O -
0.19 O +
to O +
0.59 O +
degrees O +
C O -
) O +
at O +
5 O +
to O +
15 O +
min O +
after O -
administration O -
. O -

The O +
duration O +
of O +
the O +
effects O +
of O +
these O +
ethanolamides O +
was O +
also O +
relatively O +
short O -
. O -

Anandamide O -
, O +
N O -
- O -
linoleoyl- O -
, O +
N O -
- O -
oleoyl- O +
and O +
N O -
- O -
palmitoylethanolamine O +
( O -
5 O +
or O +
10 O +
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
significantly O +
prolonged O +
pentobarbital O -
- O -
induced O +
sleeping O +
time O +
by O +
148 O -
- O -
207 O -
% O +
of O +
control O +
sleeping O +
time O -
. O -

The O +
cataleptogenic O +
effect O +
of O +
anandamide O +
was O +
markedly O +
potentiated O +
by O +
pretreatment O +
of O +
mice U-Species +
with O +
PMSF O +
( O -
100 O +
mg O -
/ O -
kg O -
, O +
i.p O -
. O -
) O -
. O -

The O +
ED50 O +
( O -
mg O -
/ O -
kg O -
, O +
i.v O -
. O -
) O +
of O +
anandamide O +
was O +
0.48 O +
( O -
0.24 O -
- O -
0.96 O -
) O +
in O +
PMSF O -
- O -
pretreated O +
mice U-Species -
. O -

The O +
pretreatment O +
of O +
mice U-Species +
with O +
PMSF O +
significantly O +
decreased O +
the O +
metabolic O +
clearance O +
rate O +
of O +
anandamide O +
in O +
microsomal O +
fractions O +
of O +
liver O +
and O +
brain O -
. O -

Thus O -
, O +
the O +
Vmax O -
/ O -
Km O +
values O +
of O +
brain O +
and O +
hepatic O +
microsomes O +
were O +
26 O +
and O +
10 O -
% O -
, O +
respectively O -
, O +
as O +
compared O +
with O +
those O +
of O +
control O +
mice U-Species -
. O -

The O +
present O +
study O +
demonstrated O +
that O +
anandamide O +
and O +
N O -
- O -
acylethanolamines O +
of O +
unsaturated O +
fatty O +
acids O +
exhibited O +
cannabinoid O -
- O -
like O +
effects O +
in O +
mice O -
, O +
and O +
that O +
anandamide O +
amidohydrolase O +
has O +
an O +
important O +
role O +
in O +
the O +
pharmacological O +
effects O +
of O +
anandamide O +
in O +
vivo O -
. O +

Localized O +
1H O +
NMR O +
homonuclear O +
J O +
editing O +
spectroscopy O +
was O +
used O +
to O +
measure O +
the O +
concentration O +
of O +
2-pyrrolidinone O +
( O -
PRDN O -
) O +
in O +
the O +
human U-Species +
occipital O +
lobe O +
of O +
five O +
normal O +
and O +
six O +
epileptic O +
subjects U-Species +
taking O +
vigabatrin O -
. O -

PRDN O +
is O +
a O +
lactam O +
cyclization O +
product O +
of O +
gamma O -
- O -
aminobutyric O +
acid O +
( O -
GABA O -
) O -
. O -

From O +
a O +
localized O +
volume O +
of O +
13.5 O +
cm3 O +
in O +
the O +
occipital O +
cortex O -
, O +
the O +
concentration O +
of O +
PRDN O +
ranged O +
from O +
0.2 O +
to O +
0.3 O +
micromol O -
/ O -
g O +
in O +
normal O +
subjects U-Species -
, O +
whereas O +
in O +
epileptic O +
subjects U-Species +
on O +
vigabatrin O +
PRDN O +
was O +
elevated O +
to O +
0.6 O +
+ O -
/- O -

0.1 O +
micromol O -
/ O -
g O -
. O -

The O +
elevated O +
PRDN O +
in O +
patients U-Species +
on O +
vigabatrin O +
was O +
in O +
accord O +
with O +
raised O +
GABA O +
levels O +
compared O +
with O +
normals O -
. O -

1H O +
NMR O +
measurements O +
of O +
PRDN O +
will O +
be O +
important O +
in O +
assessment O +
of O +
the O +
role O +
of O +
this O +
metabolite O +
for O +
improved O +
seizure O +
control O -
. O +

Phosphatoquinones O +
A O +
and O +
B O +
were O +
isolated O +
from O +
the O +
cultured O +
broth O +
of O +
Streptomyces B-Species +
sp. I-Species +
TA-0363 L-Species +
and O +
their O +
structures O +
were O +
elucidated O +
by O +
spectroscopic O +
analyses O -
. O -

Phosphatoquinones O +
A O +
and O +
B O +
inhibited O +
the O +
protein O +
tyrosine O +
phosphatase O +
activity O +
prepared O +
from O +
human U-Species +
Ball-1 O +
cells O +
with O +
IC50 O +
of O +
28 O +
microM O +
and O +
2.9 O +
microM O -
, O +
respectively O -
. O +

The O +
biosynthesis O +
of O +
polyketomycin O +
was O +
investigated O +
by O +
feeding O +
13C O -
- O -
labeled O +
acetate O +
and O +
propionate O +
to O +
the O +
growing O +
cultures O +
of O +
Streptomyces B-Species +
diastatochromogenes I-Species +
Tu I-Species +
6028 L-Species -
. O -

13C O +
NMR O +
spectral O +
analysis O +
demonstrated O +
the O +
polyketide O +
origin O +
of O +
the O +
aglycone O +
and O +
the O +
dimethylsalicyloyl O +
moieties O -
. O -

The O +
O O -
- O -
methyl O +
group O +
and O +
6-CH3 O +
of O +
the O +
aglycone O +
as O +
well O +
as O +
3B O -
- O -
CH3 O +
of O +
L O -
- O -
axenose O +
and O +
3C O -
- O -
CH3 O +
of O +
the O +
salicyloyl O +
residue O +
were O +
labeled O +
by O +
feeding O +
L- O -
[ O -
methyl-13C O -
] O -
methionine O -
. O -

Both O +
deoxysugars O +
emerged O +
from O +
D O -
- O -
glucose O -
. O -

The O +
biosynthesis O +
of O +
the O +
aglycone O +
and O +
the O +
assembly O +
of O +
the O +
glycoside O +
are O +
discussed O -
. O -

The O +
polyketomycin O +
producing O +
strain O +
may O +
be O +
a O +
candidate O +
for O +
further O +
exploration O +
in O +
combinatorial O +
biosynthesis O -
. O +

The O +
effect O +
of O +
thirteen O +
different O +
fungal U-Species +
azaphilones O -
, O +
which O +
have O +
a O +
common O +
6-iso O -
- O -
chromane O -
- O -
like O +
ring O -
, O +
was O +
tested O +
on O +
cholesteryl O +
ester O +
transfer O +
protein O +
( O -
CETP O -
) O +
activity O +
in O +
vitro O -
. O -

Chaetoviridin O +
B O +
showed O +
the O +
most O +
potent O +
inhibitory O +
activity O +
with O +
an O +
IC50 O +
value O +
of O +
< O +
6.2 O +
microM O -
, O +
followed O +
by O +
sclerotiorin O +
with O +
an O +
IC50 O +
value O +
of O +
19.4 O +
microM. O +
Rotiorin O -
, O +
chaetoviridin O +
A O +
and O +
rubrorotiorin O +
had O +
moderate O +
inhibitory O +
activity O +
( O -
IC50 O +
; O +
30 O +
approximately O +
40 O +
microM O -
) O -
, O +
but O +
others O +
showed O +
very O +
weak O +
or O +
no O +
inhibitory O +
activity O -
. O -

The O +
relationship O +
between O +
the O +
structures O +
and O +
their O +
inhibitory O +
activity O +
indicated O +
that O +
the O +
presence O +
of O +
an O +
electrophilic O +
ketone O -
( O -
s O -
) O +
and/or O +
enone O -
( O -
s O -
) O +
at O +
both O +
C-6 O +
and O +
C-8 O +
positions O +
in O +
the O +
isochromane O -
- O -
like O +
ring O +
is O +
essential O +
for O +
eliciting O +
CETP O +
inhibitory O +
activity O -
. O -

The O +
transfer O +
activity O +
of O +
both O +
CE O +
and O +
TG O +
was O +
inhibited O +
by O +
sclerotiorin O +
to O +
approximately O +
the O +
same O +
extent O +
( O -
IC50 O -
: O +
14.4 O +
and O +
10.3 O +
microM O -
, O +
respectively O -
) O -
. O -

A O +
model O +
of O +
the O +
reaction O +
suggested O +
that O +
sclerotiorin O +
reacts O +
with O +
a O +
primary O +
amine O +
of O +
amino O +
acids O +
such O +
as O +
lysine O +
in O +
the O +
protein O +
to O +
form O +
a O +
covalent O +
bond O -
. O +

Six O +
new O +
( O -
1 O -
- O -
6 O -
) O +
and O +
three O +
known O +
( O -
7 O -
- O -
9 O -
) O +
sesquiterpene O +
esters O +
were O +
isolated O +
from O +
the O +
roots O +
of O +
Celastrus B-Species +
orbiculatus L-Species -
. O -

The O +
structures O +
of O +
the O +
new O +
compounds O +
were O +
elucidated O +
as O +
1beta O -
- O -
acetoxy-6alpha O -
- O -
furoyloxy-9alpha O -
- O -
benzoyl O +
oxydihydro O -
- O -
beta O -
- O -
agarofur O +
an O +
( O -
1 O -
) O -
, O +
1beta O -
- O -
acetoxy-6alpha O -
- O -
benzoyloxy-9alpha O -
- O -
furoyloxydih O +
ydro O -
- O -
beta O -
- O -
agarofur O +
an O +
( O -
2 O -
) O -
, O +
1beta O -
- O -
acetoxy-6alpha O -
, O +
9alpha O -
- O -
difuroyloxydihydro O -
- O -
beta O -
- O -
agarofuran O +
( O -
3 O -
) O -
, O +
1beta O -
, O +
2beta O -
- O -
diacetoxy-6alpha O -
- O -
furoyloxy-9alpha O -
- O -
benzo O +
yloxydihydro O -
- O -
beta O -
- O -
agarof O +
uran O +
( O -
4 O -
) O -
, O -
1beta O -
- O -
acetoxy-2beta O -
, O +
6alpha O -
- O -
difuroyloxy-9alpha O -
- O -
benzoyloxydihydro O -
- O -
beta O +
-agarofuran O +
( O -
5 O -
) O -
, O +
and O +
1beta O -
- O -
acetoxy-2beta,6alpha O -
, O +
9alpha O -
- O -
tribenzoyloxydihydro O -
- O -
beta O -
- O -
agarofuran O -
( O -
6 O -
) O -
. O -

Compounds O +
4 O -
, O +
5 O -
, O +
and O +
7 O -
- O -
9 O +
were O +
shown O +
to O +
be O +
more O +
active O +
than O +
verapamil O +
in O +
reversing O +
vinblastine O +
resistance O +
in O +
multidrug O -
- O -
resistant O +
KB O -
- O -
V1 O +
cells O -
. O +

Late O -
- O -
onset O +
drinking O +
is O +
a O +
common O +
problem O +
in O +
elderly O +
people U-Species +
related O +
to O +
stress O +
induced O +
by O +
social O +
isolation O -
. O -

Experiments O +
were O +
performed O +
in O +
order O +
to O +
evaluate O +
the O -
effects O +
of O +
alprazolam O -
, O +
a O +
benzodiazepine O +
agonist O +
anxiolytic O -
, O +
on O +
the O +
free O -
- O -
choice O +
ethanol O +
consumption O +
in O +
aged O +
rats U-Species +
subjected O +
to O +
isolation O +
stress O -
. O -

The O +
animals O +
we O +
offered O +
a O +
two O -
- O -
bottle O +
choice O +
consumption O +
( O -
one O +
of O +
0.2 O -
% O +
saccharin O +
and O +
the O +
other O +
with O +
10 O -
% O +
ethanol O -
/ O -
0.2 O -
% O +
saccharin O -
) O +
and O +
then O +
exposed O +
to O +
4 O +
days O +
of O +
isolation O +
stress O +
on O +
an O -
irregular O -
, O +
unpredictable O +
schedule O -
. O -

Stress O +
resulted O +
in O +
significant O +
increase O +
in O +
ethanol O +
consumption O -
. O -

Treatment O +
with O +
alprazolam O +
( O -
1 O +
mg O -
/ O -
Kg O -
) O +
partially O +
reversed O +
this O -
adverse O +
effect O +
of O +
stress O -
. O +

The O +
elucidation O +
of O +
N O +
-glycans O +
in O +
plants U-Species +
has O +
raised O +
increasing O +
interest O +
in O +
the O +
past O +
years O +
due O +
to O +
several O +
physiological O +
roles O +
which O +
could O +
be O +
attributed O +
to O +
these O +
structures O -
: O +
correct O +
folding O -
, O +
biological O +
activity O +
and O +
stability O +
of O +
proteins O +
can O +
be O +
affected O +
by O +
the O +
presence O +
of O +
N O +
-glycans O +
( O -
Driouich O -
, O +
Gonnet O -
, O +
Makkie O -
, O +
Laine O -
, O +
& O +
Faye O -
, O +
1989 O -
; O +
Sheldon O -
, O +
& O +
Bowles O -
, O +
1992 O -
; O +
Nagai O -
, O +
& O +
Yamaguchi O -
, O +
1993 O -
) O +
. O -

Moreover O -
, O +
the O +
involvement O +
of O +
N O +
-linked O +
oligosaccharides O +
in O +
plant U-Species +
development O +
was O +
demonstrated O +
( O -
Ettlinger O -
, O +
Schindler O -
, O +
& O +
Lehle O -
, O +
1986 O -
) O +
. O -

Besides O +
these O +
physiological O +
roles O -
, O +
N O +
-glycans O +
can O +
influence O +
the O +
immunogenicity O +
of O +
glycoproteins O -
, O +
representing O +
antigenic O +
epitopes O +
by O +
themselves: O -
( O -
i O -
) O +
The O +
injection O +
of O +
horseradish O +
peroxidase O +
( O -
HRP O -
) O +
into O +
rabbits U-Species +
resulted O +
in O +
polyclonal O +
anti O -
- O -
HRP O +
antiserum O +
which O +
also O +
reacted O +
with O +
many O +
other O +
plant U-Species +
glycoproteins O +
carrying O +
glycans O +
similar O +
to O +
those O +
from O +
horseradish O +
peroxidase O -
. O -

β1,2-xylose O -
, O +
present O +
in O +
all O +
the O +
glycoprotein O -
– O -
glycans O +
of O +
the O +
study O -
, O +
but O +
absent O +
in O +
mammalian U-Species +
organisms O -
, O +
was O +
supposed O +
to O +
be O +
responsible O +
for O +
the O +
observed O +
cross O -
- O -
reactivity O +
( O -
Faye O -
, O +
Johnson O -
, O +
Sturm O -
, O +
& O +
Chrispeels O -
, O +
1993 O -
) O +
. O -

( O -
ii O -
) O +
The O +
crossreactivity O +
of O +
a O +
polyclonal O +
antiserum O +
against O +
HRP O +
with O +
other O +
plant U-Species +
glycoproteins O +
and O +
with O +
bee U-Species -
- O -
venom O +
phospholipase O +
A2 O +
, O +
due O +
to O +
a O +
common O +
carbohydrate O +
epitope O +
could O +
be O +
demonstrated O -
. O -

( O -
Prenner O -
, O +
Mach O -
, O +
Glössl O -
, O +
& O +
März O -
, O +
1992 O +
; O +
Wilson O -
, O +
Harthill O -
, O +
Mullin O -
, O +
Ashford O -
, O +
& O +
Altmann O -
, O +
1998 O -
) O -
. O -

Chemical O +
defucosylation O +
as O +
well O +
as O +
ELISA O +
inhibition O +
experiments O +
indicated O +
that O +
α1,3-fucose O +
is O +
sufficient O +
to O +
create O +
an O +
immunogenic O +
epitope O -
. O -

The O +
assumption O +
that O +
N O +
-glycans O +
or O +
parts O +
of O +
these O +
structures O +
can O +
not O +
only O +
represent O +
antigenic O -
, O +
but O +
also O +
allergenic O +
epitopes O +
was O +
confirmed O +
by O +
Tretter O -
, O +
Altmann O -
, O +
Kubelka O -
, O +
März O -
, O +
and O +
Becker O +
( O -
1993 O -
) O +
; O +
in O +
the O +
case O +
of O +
bee U-Species -
- O -
venom O +
allergic O +
patients O -
, O +
the O +
reactivity O +
of O +
IgE O +
antibodies O +
to O +
glycopeptides O +
of O +
phospholipase O +
A2 O -
was O +
demonstrated O -
; O +
the O +
proximal O +
α1,3-fucose O +
residue O +
was O +
identified O +
as O +
the O +
IgE O -
- O -
reactive O +
determinant O -
. O -

The O +
involvement O +
of O +
carbohydrate O +
structures O +
in O +
food O +
allergies O +
is O +
presently O +
discussed O +
quite O +
controversial O -
. O -

However O -
, O +
there O +
is O +
increasing O +
evidence O +
that O +
certain O +
carbohydrates O -
, O +
especially O +
N O +
-glycans O -
, O +
might O +
play O +
a O +
role O +
in O +
these O +
adverse O +
food O +
reactions O +
( O -
Aalberse O -
, O +
Koshte O -
, O +
& O +
Clemens O -
, O +
1981 O -
) O +
, O +
deduced O +
from O +
the O +
following O +
observations O -
: O +
many O +
proteins O +
which O +
are O +
of O +
allergological O +
importance O +
are O +
glycosylated O -
; O +
many O +
allergic O +
individuals O +
show O +
hypersensitivity O +
to O +
various O +
types O +
of O +
allergens O +
which O +
are O +
not O +
taxonomically O +
related O -
, O +
thus O +
suggesting O +
common O -
, O +
ubiquitous O +
structures O +
as O +
glycans O -
; O +
and O +
finally O -
, O +
many O +
pollen O +
allergic O +
patients O +
are O +
also O +
sensitive O +
to O +
certain O +
food O +
stuffs O -
, O +
which O +
also O +
implies O +
common O +
structural O +
epitopes O +
( O -
Möller O +
et O +
al. O -
, O +
1997 O -
) O +
. O -

In O +
immunological O +
investigations O -
, O +
mostly O +
indirect O +
methods O +
are O +
applied O +
which O +
shall O +
prove O +
the O +
involvement O +
of O +
glycans O +
in O +
allergic O +
reactions O -
, O +
such O +
as O +
deglycosylation O -
, O +
lectin O +
binding O +
and O +
compositional O +
analysis O +
( O -
Petersen O -
, O +
Becker O -
, O +
Moll O -
, O +
Blümke O -
, O +
& O +
Schlaak O -
, O +
1995 O -
; O +
Batanero O -
, O +
Villalba O -
, O +
Monsalve O -
, O +
& O +
Rodriguez O -
, O +
1996 O -
; O +
Tsuji O +
et O +
al. O -
, O +
1997 O -
) O +
; O +
however O -
, O +
structural O +
information O +
is O +
a O +
prerequisite O +
for O +
making O +
correct O +
conclusions O +
about O +
the O +
allergenicity O +
of O +
N O +
-glycans O +
or O +
epitopes O -
, O +
respectively O -
. O -

We O +
report O +
here O +
on O +
the O +
structural O +
elucidation O +
of O +
the O +
N O +
-linked O +
oligosaccharides O +
in O +
tomato U-Species +
fruit O -
, O +
which O +
shall O +
help O +
to O +
understand O +
some O +
observed O +
cross O -
- O -
reactivities O +
reported O +
recently O +
by O +
Petersen O -
, O +
Vieths O -
, O +
Aulepp O -
, O +
Schlaak O -
, O +
and O +
Becker O +
( O -
1996 O -
) O +
. O -

2 O +
Results O +
2.1 O +
Preparation O +
of O +
N O +
-glycans O +
from O +
tomato U-Species +
fruit O +
To O +
isolate O +
the O +
protein O +
fraction O +
from O +
tomato U-Species +
fruit O -
, O +
two O +
procedures O +
were O +
carried O +
out O +
alternatively O -
: O +
on O +
the O +
one O +
hand O -
, O +
the O +
tomatoes U-Species +
were O +
homogenized O +
in O +
an O +
appropriate O +
extraction O +
buffer O +
and O +
the O +
proteins O +
were O +
precipitated O +
by O +
addition O +
of O +
ammonium O +
sulfate O -
. O -

On O +
the O +
other O +
hand O -
, O +
a O +
low O -
- O -
temperature O +
acetone O +
powder O +
method O -
, O +
first O +
described O +
by O +
Clements O +
( O -
1965 O -
) O +
, O +
was O +
employed O -
; O +
the O +
proteins O +
precipitated O +
in O +
acetone O -
, O +
whereas O +
small O +
hydrophobic O +
compounds O +
( O -
flavonoids O -
, O +
carotinoids O -
) O +
as O +
well O +
as O +
most O +
of O +
the O +
salts O +
were O +
effectively O +
removed O -
; O +
the O +
proteins O +
were O +
extracted O +
from O +
the O +
resulting O +
powder O -
, O +
yielding O +
concentrations O +
of O +
180–310 O +
μg O -
/ O -
ml O +
as O +
determined O +
according O +
to O +
Bradford O +
( O -
1976 O -
) O +
; O +
these O +
values O +
are O +
in O +
the O +
same O +
order O +
of O +
magnitude O +
with O +
those O +
reported O +
by O +
Vieths O -
, O +
Schöning O -
, O +
Brockmann O -
, O +
and O +
Aulepp O +
( O -
1992 O -
) O +
, O +
who O +
used O +
this O +
procedure O +
for O +
the O +
preparation O +
of O +
several O +
fruit U-Species +
and O +
vegetable U-Species +
extracts O -
. O -

A O +
cation O -
- O -
exchange O +
chromatography O +
eliminated O +
most O +
of O +
the O +
by O -
- O -
products O +
in O +
the O +
sample O -
. O -

The O +
binding O +
fraction O +
was O +
assayed O +
for O +
the O +
amount O +
of O +
N O +
-acetylglucosamine O +
by O +
OPA O -
- O -
aminosugar O +
analysis O -
, O +
yielding O +
170–260 O +
nmol O +
GlcNAc O -
, O +
dependent O +
on O +
the O +
sample O -
. O -

From O +
these O +
values O +
it O +
could O +
be O +
deduced O +
that O +
about O +
85–130 O +
nmol O +
of O +
N O +
-glycans O +
are O +
present O +
in O +
the O +
glycopeptide O +
fractions O +
( O -
assuming O +
2 O +
moles O +
of O +
GlcNAc O -
/ O -
mol O +
of O +
oligosaccharide O -
) O -
. O -

The O +
oligosaccharides O +
were O +
released O +
from O +
the O +
glycopeptides O +
using O +
N O +
-glycosidase O +
A O -
, O +
separated O +
from O +
peptides O +
and O +
residual O +
glycopeptides O +
by O +
reverse O -
- O -
phase O +
chromatography O +
and O +
derivatized O +
with O +
the O +
fluorescent O +
tag O +
2-aminopyridine O -
. O -

2.2 O +
Separation O +
and O +
structural O +
elucidation O +
of O +
the O +
N O +
-linked O +
oligosaccharides O +
The O +
pyridylaminated O +
oligosaccharides O +
were O +
first O +
size O -
- O -
fractionated O +
on O +
MicroPak O +
AX-5 O +
( O -
Fig. O +
1 O -
Fig. O +
1 O +
A O -
) O -
; O +
11 O +
fractions O +
were O +
manually O +
collected O +
and O +
rechromatographed O +
if O +
necessary O -
. O -

Individual O +
fractions O +
were O +
subjected O +
to O +
reverse O -
- O -
phase O +
HPLC O -
, O +
yielding O +
a O +
total O +
of O +
sixteen O +
subfractions O +
( O -
additionally O -
, O +
an O +
aliquot O +
of O +
the O +
total O +
glycan O +
pool O +
was O +
applied O +
to O +
the O +
reverse O -
- O -
phase O +
system O -
, O +
see O +
Fig. O +
1 O +
B O -
) O -
. O -

The O +
elution O +
position O +
of O +
each O +
isolated O +
oligosaccharides O +
was O +
determined O +
on O +
both O +
columns O +
and O +
compared O +
to O +
those O +
from O +
reference O +
oligosaccharides O -
. O -

The O +
individual O +
peaks O +
were O +
then O +
subjected O +
to O +
exoglycosidase O +
treatment O +
using O +
α O -
- O -
mannosidase O -
, O +
β O -
- O -
N O +
-acetylhexosaminidase O +
and O +
endoglycosidase O +
H. O +
The O +
digests O +
were O +
again O +
chromatographed O +
on O +
reverse O -
- O -
phase O +
and O +
MicroPak O +
to O +
monitor O +
the O +
change O +
in O +
the O +
elution O +
behavior O +
( O +
Tables O +
1 O +
and O +
2 O -
) O -
. O -

Whenever O +
possible O -
, O +
a O +
tentatively O +
identified O +
peak O +
was O +
coinjected O +
with O +
the O +
corresponding O +
reference O +
oligosaccharide O +
to O +
verify O +
the O +
identical O +
elution O +
behavior O -
. O -

In O +
the O +
following O -
, O +
the O +
structural O +
assignment O +
of O +
each O +
peak O +
is O +
described O -
; O +
the O +
proposed O +
structures O +
are O +
depicted O +
in O +
Table O +
3 O -
. O -

2.3 O +
Complex O +
and O +
truncated O +
complex O +
glycans O +
The O +
retention O +
data O +
of O +
oligosaccharide O +
1-A O -
, O +
a O +
minor O +
component O +
present O +
in O +
all O +
the O +
tomato U-Species +
samples O -
, O +
did O +
not O +
fit O +
with O +
any O +
of O +
the O +
available O +
reference O +
compounds O -
. O -

However O -
, O +
the O +
glycan O +
exhibited O +
resistance O +
to O +
α O -
- O -
mannosidase O +
treatment O -
. O -

The O +
identity O +
could O +
be O +
presumed O +
from O +
complete O +
digestion O +
of O +
MMF3 O -
from O +
phospholipase O +
A2 O -
with O +
α O -
- O -
mannosidase O -
, O +
resulting O +
in O +
a O +
peak O +
with O +
the O +
same O +
retention O +
behavior O +
as O +
oligosaccharide O +
1-A O +
on O +
both O +
columns O -
. O -

1-A O +
is O +
therefore O +
presumed O +
to O +
be O +
00F3 O -
. O -

Oligosaccharide O +
1-B O -
also O +
was O +
resistant O +
to O +
α O -
- O -
mannosidase O -
. O -

Together O +
with O +
its O +
size O +
and O +
having O +
the O +
same O +
retention O +
time O +
on O +
reverse O -
- O -
phase O +
HPLC O +
as O +
the O +
product O +
of O +
α O -
- O -
mannosidase O +
digestion O +
of O +
the O +
major O +
structure O +
of O +
horseradish O +
peroxidase O +
( O -
MMXF3 O +
) O -
, O +
1-B O +
was O +
deduced O +
to O +
be O +
00XF3 O -
. O -

The O +
third O +
peak O +
present O +
in O +
the O +
first O +
MicroPak O +
fraction O -
, O +
1-C O +
, O +
showed O +
a O +
remarkably O +
high O +
retention O +
time O +
on O +
reverse O -
- O -
phase O +
( O -
11.0 O +
glucose O +
units O -
) O +
and O +
sensitivity O +
to O +
α O -
- O -
mannosidase O -
, O +
resulting O +
in O +
a O +
reduction O +
of O +
the O +
retention O +
time O +
to O +
8.5 O +
glucose O +
units O -
. O -

This O +
corresponds O +
to O +
the O +
retention O +
time O +
of O +
completely O +
digested O +
MMX O +
from O +
zucchini U-Species +
ascorbate O -
– O -
oxidase O +
( O -
Altmann O -
, O +
1998 O -
) O +
. O -

Coelution O +
of O +
the O +
limited O +
digestion O +
product O +
from O +
the O +
reference O +
oligosaccharide O +
with O +
1-C O +
yields O +
a O +
single O -
, O +
homogenous O +
peak O +
as O +
calculated O +
from O +
addition O +
of O +
the O +
peak O +
areas O -
; O +
1-C O +
was O +
therefore O +
found O +
to O +
be O +
M0X O +
. O -

Peak O +
2 O +
from O +
MicroPak O +
gave O +
a O +
single O +
peak O +
on O +
reverse O -
- O -
phase O -
, O +
which O +
was O +
sensitive O +
to O +
α O -
- O -
mannosidase O -
; O +
two O +
peaks O -
, O +
lacking O +
one O +
and O +
two O +
mannose O +
residues O +
as O +
deduced O +
from O +
the O +
retention O +
behavior O +
on O +
MicroPak O +
HPLC O -
, O +
were O +
obtained O -
. O -

The O +
second O +
peak O +
on O +
the O +
size O +
fractionation O +
column O +
exhibited O +
the O +
same O +
retention O +
time O +
as O +
fraction O +
1 O +
of O +
phospholipase O +
A2 O +
. O -

Therefore O -
, O +
the O +
structure O +
of O +
peak O +
2 O +
was O +
assumed O +
to O +
be O +
MM O +
. O -

This O +
was O +
confirmed O +
by O +
coinjection O +
of O +
MM O +
( O -
prepared O +
from O +
bovine O +
fibrin O -
) O -
, O +
resulting O +
in O +
a O +
single O +
peak O -
. O -

Furthermore O -
, O +
the O +
α O -
- O -
mannosidase O +
digest O +
of O +
fibrin O +
MM O +
behaved O +
exactly O +
the O +
same O +
way O +
as O +
the O +
digest O +
of O +
peak O +
2 O +
on O +
both O +
HPLC O +
columns O -
. O -

Oligosaccharide O +
3-A O -
exhibited O +
the O +
same O +
elution O +
behavior O +
in O +
both O +
HPLC O +
systems O +
as O +
the O +
reference O +
oligosaccharide O +
from O +
pineapple U-Species +
stem O +
bromelain O -
, O +
M0XF3 O -
. O -

α O -
- O -
mannosidase O +
digestion O +
of O +
3-A O +
resulted O +
in O +
a O +
single O +
peak O -
, O +
which O +
coeluted O +
with O +
compound O +
1-B O +
( O -
5.2 O +
glucose O +
units O +
on O +
reverse O -
- O -
phase O +
HPLC O -
) O -
. O -

Peak O +
3-B O -
was O +
identified O +
based O +
on O +
its O +
size O +
and O +
retention O +
times O +
before O +
and O +
after O +
α O -
- O -
mannosidase O +
digestions O +
in O +
comparison O +
with O +
the O +
standard O +
MMX O +
from O +
fraction O +
1 O +
of O +
ascorbate O +
oxidase O -
. O -

Partial O +
digestion O +
with O +
α O -
- O -
mannosidase O +
resulted O +
in O +
a O +
peak O +
which O +
coeluted O +
with O +
compound O +
1-C. O +
The O +
final O +
proof O +
of O +
peak O +
identity O +
was O +
again O +
provided O +
by O +
coinjection O +
of O +
the O +
MMX O -
reference O +
compound O -
. O -

Peak O +
4 O -
, O +
which O +
appeared O +
to O +
be O +
non O -
- O -
homogenous O +
on O +
MicroPak O +
eluted O +
as O +
one O +
major O +
peak O +
( O -
> O -
85 O -
% O -
) O +
on O +
the O +
reverse O -
- O -
phase O +
column O -
. O -

The O +
minor O +
components O +
( O -
at O +
least O +
five O +
peaks O -
) O +
were O +
present O +
in O +
minute O +
quantities O +
and O +
could O +
not O +
be O +
analyzed O +
further O -
. O -

The O +
major O +
peak O +
was O +
subjected O +
to O +
α O -
- O -
mannosidase O +
digestion O -
, O +
yielding O +
two O +
signals O +
on O +
reverse O -
- O -
phase O +
HPLC O +
with O +
retention O +
times O +
of O +
5.1 O +
and O +
4.4 O +
glucose O +
units O -
, O +
thus O +
indicating O +
the O +
presence O +
of O +
two O +
mannose O +
residues O +
in O +
the O +
structure O -
. O -

The O +
first O +
peak O +
on O +
reverse O -
- O -
phase O +
coeluted O +
with O +
compound O +
1-A O -
, O +
thus O +
indicating O +
peak O +
4 O +
to O +
represent O +
MMF3 O -
. O -

This O +
assumption O +
could O +
be O +
proved O +
by O +
( O -
i O -
) O +
coinjection O +
of O +
phospholipase O +
A2 O +
-compound O +
5A O +
( O -
MMF3 O +
) O -
, O +
resulting O +
in O +
a O +
single O +
peak O +
and O +
( O -
ii O -
) O +
by O +
digesting O +
the O +
reference O +
compound O +
with O +
α O -
- O -
mannosidase O -
, O +
yielding O +
the O +
same O +
two O +
degradation O +
products O +
as O +
for O +
peak O +
4 O -
. O -

The O +
major O +
oligosaccharide O +
( O -
5 O -
) O +
in O +
all O +
the O +
samples O -
, O +
representing O +
47–59 O -
% O +
of O +
the O +
total O +
N O +
-glycan O +
amount O -
, O +
was O +
shown O +
to O +
be O +
susceptible O +
to O +
α O -
- O -
mannosidase O +
digestion O -
, O +
resulting O +
in O +
two O +
peaks O -
: O +
the O +
first O +
eluted O +
at O +
retention O +
times O +
identical O +
to O +
those O +
from O +
oligosaccharide O +
3-A O +
and O +
the O +
M0XF3 O -
reference O +
compound O -
, O +
the O +
second O +
coeluted O +
with O +
oligosaccharide O +
1-B O -
, O +
already O +
being O +
elucidated O +
as O +
00XF3 O +
. O -

Furthermore O -
, O +
additional O +
evidence O +
for O +
the O +
peak O +
being O +
MMXF3 O -
was O +
obtained O +
from O +
coinjection O +
of O +
the O +
reference O +
oligosaccharide O +
from O +
horseradish O +
peroxidase O -
, O +
yielding O +
a O +
single O +
peak O -
. O -

Fraction O +
6 O +
from O +
MicroPak O +
gave O +
two O +
peaks O +
on O +
the O +
reverse O -
- O -
phase O +
column O +
with O +
relative O +
retention O +
times O +
of O +
4.7 O +
and O +
5.8 O +
glucose O +
units O -
, O +
respectively O -
. O -

These O +
peaks O +
were O +
digestible O +
by O +
β O -
- O -
N O +
-acetyl O -
- O -
hexosaminidase O +
to O +
a O +
common O +
new O +
compound O -
, O +
exhibiting O +
the O +
same O +
elution O +
behavior O +
as O +
compound O +
5 O -
. O -

Furthermore O -
, O +
hornbeam U-Species +
GnGnXF3 O -
digestion O +
with O +
the O +
same O +
enzyme O +
resulted O +
in O +
formation O +
of O +
the O +
two O +
peaks O +
mentioned O +
above O -
. O -

Again O -
, O +
the O +
final O +
proof O -
, O +
that O +
the O +
two O +
peaks O +
represent O +
MGnXF3 O -
and O +
GnMXF3 O -
was O +
accomplished O +
by O +
coinjection O +
of O +
the O +
corresponding O +
oligosaccharides O +
obtained O +
from O +
limited O +
β O -
- O -
N O +
-acetylglucosaminidase O +
digestion O +
of O +
hornbeam U-Species +
pollen O +
GnGnXF3 O +
. O -

Oligosaccharide O +
8 O +
also O +
gave O +
one O +
major O +
peak O +
on O +
reverse O -
- O -
phase O +
HPLC O -
. O -

An O +
initial O +
hexosaminidase O +
digestion O +
resulted O +
in O +
the O +
presence O +
of O +
the O +
peaks O +
with O +
4.8 O +
and O +
5.8 O +
glucose O +
units O +
on O +
reverse O -
- O -
phase O -
, O +
thus O +
presumably O +
representing O +
the O +
above O +
mentioned O +
components O +
MGnXF3 O -
and O +
GnMXF3 O +
. O -

Complete O +
digestion O +
with O +
β O -
- O -
N O +
-acetyl O -
- O -
hexosaminidase O +
yielded O +
a O +
single O +
peak O -
, O +
coeluting O +
with O +
compound O +
5 O +
and O +
the O +
reference O +
compound O +
MMXF3 O +
. O -

Hence O -
, O +
oligosaccharide O +
8 O +
can O +
be O +
designated O +
to O +
be O +
GnGnXF3 O -
. O -

2.4 O +
Oligomannosidic O +
glycans O +
From O +
the O +
relative O +
retention O +
times O +
on O +
MicroPak O +
of O +
7.7 O -
, O +
8.7 O -
, O +
9.7 O +
and O +
10.6 O +
glucose O +
units O -
, O +
oligomannosidic O +
glycans O +
were O +
predicted O -
. O -

This O +
surmise O +
was O +
verified O +
by O +
performing O +
α O -
- O -
mannosidase O +
digestions O +
of O +
these O +
compounds O -
: O +
each O +
fraction O +
was O +
accessible O +
to O +
α O -
- O -
mannosidase O -
, O +
resulting O +
in O +
the O +
same O +
two O +
peaks O +
( O -
exhibiting O +
relative O +
retention O +
times O +
of O +
3.7 O -
/ O -
8.7 O +
and O +
2.9 O -
/ O -
7.2 O +
glucose O +
units O +
on O +
MicroPak O +
and O +
Hypersil O +
ODS O -
, O +
respectively O -
; O +
Table O +
1 O +
) O +
for O +
all O +
four O +
fractions O -
. O -

The O +
assumption O +
of O +
these O +
peaks O +
being O +
Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc O -
– O -
pyridylamine O +
and O +
Manβ1–4GlcNAcβ1–4GlcNAc O -
– O -
pyridylamine O +
was O +
confirmed O +
by O +
a O +
limited O +
α O -
- O -
mannosidase O +
digest O +
of O +
MM O -
, O +
which O +
yielded O +
the O +
same O +
two O +
peaks O -
. O -

Furthermore O -
, O +
endoglycosidase O +
H O -
- O -
digests O +
of O +
the O +
peaks O +
7 O +
and O +
9–11 O +
resulted O +
in O +
the O +
formation O +
of O +
pyridylamino O -
– O -
GlcNAc O +
( O -
3.5 O +
glucose O +
units O +
on O +
reverse O -
- O -
phase O +
column O -
) O -
, O +
also O +
proving O +
the O +
presence O +
of O +
oligomannosidic O +
structures O -
. O -

Additionally O -
, O +
the O +
authentic O +
oligosaccharides O +
from O +
soybean B-Species +
7S L-Species +
-glycoprotein O +
were O +
used O +
to O +
confirm O +
the O +
identities O +
of O +
the O +
four O +
above O -
- O -
mentioned O +
peaks O -
. O -

Coelution O +
of O +
peaks O +
7 O -
, O +
9 O +
and O +
10 O +
was O +
observed O +
with O +
the O +
corresponding O +
reference O +
compounds O +
Man6 O +
GlcNAc2 O +
–Man8 O +
GlcNAc2 O +
. O -

Peak O +
9 O +
consisted O +
of O +
two O +
structural O +
isomers O +
( O -
M7.1 O -
and O +
M7.2 O +
) O -
, O +
occurring O +
in O +
relative O +
amounts O +
of O +
45 O +
and O +
55 O -
% O +
( O -
for O +
sample O +
NotAP2 O +
( O +
Table O +
4 O +
) O -
) O -
, O +
respectively O -
. O -

Man8 O +
GlcNAc2 O -
is O +
a O +
homogenous O +
peak O +
on O +
reverse O -
- O -
phase O +
( O -
4.7 O +
GcU O -
) O -
, O +
which O +
can O +
be O +
therefore O +
assigned O +
to O +
be O +
the O +
M8.1 O +
-isomer O -
. O -

The O +
elution O +
behavior O +
of O +
peak O +
11 O +
corresponds O +
to O +
published O +
data O +
( O -
Tomiya O +
et O +
al. O -
, O +
1991 O +
; O +
Kubelka O -
, O +
Altmann O -
, O +
Kornfeld O -
, O +
& O +
März O -
, O +
1994 O -
) O +
and O +
can O +
therefore O +
assigned O +
to O +
be O +
the O +
Man9 O +
-isomer O +
M9.1 O +
. O -

Additional O +
confirmation O +
of O +
the O +
results O +
was O +
obtained O +
by O +
MALDI O -
– O -
TOF O +
analysis O +
of O +
individual O +
HPLC O +
fractions O -
. O -

Fig. O +
2 O -
Fig. O +
2 O -
shows O +
the O +
mass O +
spectrum O +
of O +
fraction O +
5 O -
, O +
identified O +
as O +
MMXF3 O +
; O -
Table O +
5 O -
summarizes O +
the O +
results O -
, O +
which O +
corroborate O +
the O +
assignments O +
based O +
upon O +
two O -
- O -
dimensional O +
mapping O -
. O -

2.5 O +
Analysis O +
of O +
tomatoes U-Species +
from O +
two O +
varieties O -
. O -

Analysis O +
of O +
red U-Species +
and O +
green B-Species +
tomatoes L-Species +
Red B-Species +
Notoro I-Species -
- I-Species -
type I-Species +
tomatoes L-Species +
were O +
subjected O +
to O +
the O +
two O +
different O +
isolation O +
procedures O +
in O +
order O +
to O +
monitor O +
the O +
impact O +
of O +
sample O +
preparation O +
on O +
the O +
glycan O +
pattern O +
in O +
terms O +
of O +
quality O +
and O +
quantity O -
. O -

Furthermore O -
, O +
red U-Species +
and O +
green B-Species +
San I-Species +
Marzano I-Species -
- I-Species -
type I-Species +
fruits L-Species +
were O +
analyzed O +
to O +
distinguish O +
differences O +
in O +
the O +
glycan O +
pattern O +
due O +
to O +
the O +
variety O +
and O +
the O +
stage O +
of O +
ripening O -
, O +
respectively O -
. O -

Table O +
4 O -
shows O +
the O +
condensed O +
results O +
in O +
terms O +
of O +
relative O +
abundances O +
of O +
individual O +
fractions O +
on O +
the O +
total O +
N O +
-glycan O +
amounts O -
. O -

It O +
could O +
be O +
demonstrated O +
that O +
irrespective O +
of O +
the O +
preparation O +
method O +
very O +
similar O +
results O +
were O +
obtained O -
; O +
San B-Species +
Marzano I-Species -
- I-Species -
type I-Species +
tomatoes L-Species +
contain O +
the O +
same O +
sixteen O +
structures O +
and O +
also O +
the O +
relative O +
quantities O +
were O +
rather O +
similar O +
in O +
the O +
examined O +
varieties O -
. O -

Interestingly O -
, O +
also O +
the O +
state O +
of O +
ripening O +
does O +
not O +
seem O +
to O +
have O +
a O +
significant O +
impact O +
on O +
the O +
appearance O +
of O +
the O +
glycan O +
pattern O +
in O +
terms O +
of O +
quality O +
and O +
quantity O +
although O +
it O +
has O +
to O +
be O +
stated O +
that O +
more O +
samples O +
have O +
to O +
be O +
analyzed O +
for O +
a O +
statistical O +
interpretation O -
. O -

3 O +
Discussion O +
The O +
N O +
-glycans O +
of O +
tomato U-Species +
fruit O +
were O +
structurally O +
elucidated O -
, O +
thereby O +
comparing O +
two O +
varieties O +
as O +
well O +
as O +
two O +
stages O +
of O +
ripening O -
. O -

The O +
low O +
protein O +
content O +
of O +
tomatoes U-Species +
and O +
the O +
high O +
amount O +
of O +
free O +
sugars O +
and O +
polysaccharides O +
( O -
Seymour O -
, O +
Colquhoun O -
, O +
DuPont O -
, O +
Parsely O -
, O +
& O +
Selvendran O -
, O +
1990 O -
; O +
York O -
, O +
Kumar O +
Kolli O -
, O +
Orlando O -
, O +
Albersheim O -
, O +
& O +
Darvill O -
, O +
1997 O -
) O -
complicated O +
the O +
effective O +
isolation O +
of O +
the O +
protein O +
fraction O -
. O -

However O -
, O +
the O +
employed O +
low O -
- O -
temperature O +
acetone O +
powder O +
method O +
proved O +
to O +
be O +
very O +
efficient O +
for O +
this O +
application O -
: O +
several O +
by O -
- O -
products O +
are O +
effectively O +
removed O -
, O +
the O +
resulting O +
powder O +
can O +
be O +
stored O +
for O +
several O +
months O +
at O +
−20 O -
° O -
C O +
and O -
, O +
although O +
not O +
of O +
relevance O +
in O +
the O +
present O +
study O -
, O +
protein O +
denaturation O +
is O +
minimized O +
due O +
to O +
the O +
extremely O +
low O +
temperature O +
during O +
isolation O -
, O +
yielding O +
extracts O +
of O +
high O +
immunochemical O +
activity O +
( O -
Vieths O -
, O +
Schöning O -
, O +
& O +
Baltes O -
, O +
1992 O -
) O +
. O -

In O +
the O +
further O +
sample O +
preparation O -
, O +
two O +
steps O +
shall O +
be O +
briefly O +
addressed O -
: O +
borohydride O +
reduction O -
, O +
which O +
was O +
employed O +
in O +
order O +
to O +
prevent O +
residual O +
free O +
sugars O +
from O +
subsequent O +
derivatization O +
which O +
proved O +
its O +
necessity O +
in O +
the O +
case O +
of O +
grass U-Species +
pollen O +
extracts O +
where O +
several O +
artefactic O +
peaks O +
appeared O +
on O +
the O +
chromatogramms O +
without O +
this O +
step O +
( O -
F. O +
Altmann O -
, O +
personal O +
communication O -
) O -
. O -

Second O -
, O +
N O +
-glycosidase O +
A O +
from O +
almonds U-Species +
was O +
used O +
for O +
the O +
deglycosylation O +
of O +
the O +
glycopeptides O -
, O +
which O +
is O +
important O -
, O +
since O +
the O +
( O -
more O -
) O +
frequently O +
used O +
N O +
-glycosidase O +
F O +
from O +
Flavobacterium B-Species +
meningosepticum L-Species -
can O -
not O +
cleave O +
glycans O +
containing O +
fucose O +
linked O +
α1–3 O +
to O +
Asn O -
– O -
GlcNAc O +
( O -
Tretter O -
, O +
Altmann O -
, O +
& O +
März O -
, O +
1991 O -
; O +
Altmann O -
, O +
Schweiszer O -
, O +
& O +
Weber O -
, O +
1995 O -
) O +
. O -

The O +
methodology O +
for O +
the O +
structural O +
characterization O -
, O +
using O +
two O -
- O -
dimensional O +
HPLC O +
in O +
combination O +
with O +
exoglycosidase O +
digestions O -
, O +
was O +
first O +
introduced O +
by O +
Tomiya O +
et O +
al. O +
( O -
1988 O -
) O -
and O +
has O +
been O +
employed O +
for O +
glycoprotein O -
– O -
glycans O +
from O +
various O +
sources O +
( O -
Takahashi O +
et O +
al. O -
, O +
1986 O -
; O +
Kubelka O +
et O +
al. O -
, O +
1994 O -
; O +
Ohsuga O +
et O +
al. O -
, O +
1996 O -
) O +
. O -

Complex O -
- O -
type O +
structures O -
, O +
most O +
of O +
them O +
truncated O +
and O +
exhibiting O +
α1–3 O +
linked O +
fucose O +
and/or O +
β1–2 O +
linked O +
xylose O -
, O +
as O +
well O +
as O +
oligomannosidic O +
glycans O +
were O +
detected O -
. O -

Most O +
of O +
these O +
structures O +
have O +
been O +
reported O +
to O +
occur O +
in O +
other O +
plant U-Species +
glycoproteins O -
; O +
MMXF3 O +
, O +
addressed O +
to O +
be O +
the O +
typical O +
vacuole O -
- O -
type O +
plant U-Species +
N O +
-glycan O +
( O -
Sturm O -
, O +
1995 O -
) O -
and O +
the O +
most O +
abundant O +
oligosaccharide O +
in O +
tomato U-Species +
fruit O -
, O +
has O +
also O +
been O +
found O +
in O +
horseradish O +
peroxidase O +
( O -
Kurosaka O +
et O +
al. O -
, O +
1991 O -
) O +
, O +
a O +
protease O +
inhibitor O +
from O +
barbados B-Species +
pride L-Species +
( O -
Caesalpinia B-Species +
Pulcherrima L-Species -
Sw O -
. O -
) O +
seeds O +
( O -
Hase O +
et O +
al. O -
, O +
1986 O -
) O +
, O +
Sophora B-Species +
japonica L-Species -
lectin O +
( O -
Fournet O +
et O +
al. O -
, O +
1987 O -
) O -
and O +
ricin O +
D O +
from O +
the O +
seeds O +
of O +
castor B-Species +
plants L-Species +
( O -
Ricinus B-Species +
communis L-Species +
) O +
( O -
Kimura O +
et O +
al. O -
, O +
1988 O -
) O +
. O -

M0XF3 O +
, O +
another O +
structure O +
which O +
occurs O +
in O +
relatively O +
high O +
amounts O +
in O +
tomato U-Species +
( O -
17–22 O -
% O -
) O -
, O +
has O +
been O +
reported O +
for O +
both O +
pineapple U-Species +
stem O +
bromelain O +
( O -
Van O +
Kuik O +
et O +
al. O -
, O +
1986 O -
) O -
and O +
barley U-Species +
peroxidase O +
( O -
Johannson O -
, O +
Rasmussen O -
, O +
Harthill O -
, O +
& O +
Welinder O -
, O +
1992 O -
) O +
. O -

Small O +
α1,3-fucosylated O +
and/or O +
β1,2-xylosylated O +
glycans O +
that O +
are O +
minor O +
fractions O +
in O +
tomato U-Species -
, O +
have O +
recently O +
also O +
been O +
found O +
in O +
other O +
plants U-Species -
; O +
MMX O +
was O +
found O +
to O +
be O +
the O +
most O +
abundant O +
N O +
-glycan O +
in O +
rice U-Species +
α O -
- O -
amylase O +
from O +
germinated O +
seedlings O +
( O -
Hayashi O +
et O +
al. O -
, O +
1990 O -
) O -
and O +
also O +
represents O +
the O +
complex O +
oligosaccharide O +
side O +
chain O +
of O +
the O +
bean U-Species +
storage O +
protein O +
phaseolin O +
( O -
Sturm O -
, O +
van O +
Kuik O -
, O +
Vliegenthart O -
, O +
& O +
Chrispeels O -
, O +
1987 O -
) O -
. O -

M0X O +
accounts O +
for O +
15 O -
% O +
of O +
the O +
N O +
-glycans O +
of O +
barley U-Species -
( O -
1–3,1–4 O -
) O -
-β O -
- O -
d O +
-glucan O +
4-glucanohydrolase O +
isoenzyme O +
EII O +
( O -
Harthill O -
, O +
& O +
Thomsen O -
, O +
1995 O -
) O +
, O +
whereas O +
MMF3 O -
was O +
found O +
to O +
be O +
a O +
minor O +
fraction O +
of O +
soybean U-Species +
peroxidase O +
( O -
Gray O -
, O +
Yun O +
Yang O -
, O +
Hull O -
, O +
Venzke O -
, O +
& O +
Montgomery O -
, O +
1996 O -
) O +
. O -

Three O +
structures O +
that O +
exhibit O +
outer O -
- O -
arm O +
GlcNAc O +
residues O +
and O +
represent O +
6–14 O -
% O +
of O +
the O +
N O +
-glycans O +
in O +
tomato U-Species +
fruit O -
, O +
have O +
been O +
previously O +
reported O +
for O +
lactase O +
from O +
sycamore U-Species +
cells O +
( O -
Harthill O -
, O +
& O +
Thomsen O -
, O +
1995 O -
) O +
. O -

GnMXF3 O -
and O +
MGnXF3 O -
were O +
also O +
found O +
to O +
be O +
present O +
in O +
red B-Species +
kidney I-Species +
bean L-Species +
Fe O -
( O -
III O -
) O -
–Zn O -
( O -
II O -
) O +
purple O +
acid O +
phosphatase O +
( O -
Stahl O +
et O +
al. O -
, O +
1994 O -
) O +
. O -

Oligomannosidic O +
structures O -
, O +
accounting O +
for O +
only O +
3–9 O -
% O +
of O +
the O +
N O +
-glycans O +
in O +
tomato U-Species +
fruit O -
, O +
are O +
wide O -
- O -
spread O +
among O +
plants U-Species +
( O -
e.g. O +
soybean U-Species +
agglutinin O +
( O -
Dorland O -
, O +
van O +
Halbeek O -
, O +
Vliegenthart O -
, O +
Lis O -
, O +
& O +
Sharon O -
, O +
1981 O -
) O +
, O +
phaseolin O +
of O +
the O +
common O +
bean U-Species +
( O -
Sturm O +
et O +
al. O -
, O +
1987 O -
) O +
, O +
rice U-Species +
α O -
- O -
amylase O +
( O -
Hayashi O +
et O +
al. O -
, O +
1990 O -
) O +
, O +
α O -
- O -
amylase O +
inhibitor O +
from O +
white B-Species +
kidney I-Species +
bean L-Species +
( O -
Phasolus B-Species +
vulgaris L-Species -
) O +
( O -
Yamaguchi O -
, O +
Funaoka O -
, O +
& O +
Iwamoto O -
, O +
1992 O -
) O +
, O +
but O +
are O +
also O +
found O +
in O +
insect U-Species -
, O +
yeast U-Species +
and O +
mammalian U-Species +
glycoproteins O -
. O -

α-1,3-Fucosylation O +
of O +
the O +
innermost O +
N O +
-acetylglucosamine O +
residue O -
, O +
a O +
typical O +
feature O +
of O +
N O +
-glycans O +
from O +
plants U-Species +
but O +
also O +
from O +
insects U-Species -
, O +
was O +
found O +
in O +
8 O +
of O +
the O +
16 O +
tomato U-Species +
N O +
-linked O +
oligosaccharides O -
, O +
accounting O +
for O +
86–90 O -
% O +
of O +
the O +
N O +
-glycan O +
pool O +
in O +
tomato U-Species +
fruits O -
. O -

Such O +
fucosyl O +
residues O +
as O +
well O +
as O +
β1,2-linked O +
xylosyl O +
residues O +
are O +
not O +
present O +
in O +
mammalian U-Species +
glycoproteins O +
and O +
therefore O +
render O +
plant U-Species +
glycoproteins O +
immunogenic O +
( O -
Wilson O +
et O +
al. O -
, O +
1998 O -
) O +
. O -

In O +
fact O -
, O +
even O +
IgE O +
antibodies O +
may O +
be O +
directed O +
against O +
this O +
epitope O -
. O -

Owing O +
to O +
their O +
widespread O +
occurrence O -
, O +
α1,3-fucosylated O +
N O +
-glycans O +
( O -
with O +
or O +
without O +
xylose O -
) O +
constitute O +
a O +
highly O +
cross O -
- O -
reactive O +
carbohydrate O +
determinant O +
detected O +
in O +
a O +
wide O +
variety O +
of O +
plant U-Species +
as O +
well O +
as O +
insect U-Species +
allergens O +
( O -
Tretter O +
et O +
al. O -
, O +
1993 O -
; O +
Garcia O -
- O -
Casado O +
et O +
al. O -
, O +
1996 O -
; O +
Jankiewicz O -
, O +
Aulepp O -
, O +
Altmann O -
, O +
Foetisch O -
, O +
& O +
Vieths O -
, O +
1998 O -
) O +
. O -

As O +
far O +
as O +
tomatoes U-Species +
are O +
concerned O -
, O +
Petersen O +
et O +
al. O +
( O -
1996 O -
) O -
reported O +
the O +
reactivity O +
of O +
IgE O +
antibodies O +
of O +
grass U-Species +
pollen O +
allergic O +
individuals O +
to O +
tomato U-Species +
extracts O -
. O -

Lectin O +
blotting O +
of O +
proteins O +
and O +
ELISA O +
inhibition O +
experiments O +
using O +
glycopeptides O +
of O +
known O +
glycan O +
structures O +
suggested O +
the O +
presence O +
of O +
carbohydrate O +
IgE O +
epitopes O +
with O +
an O +
α1,3-fucose O +
residue O -
. O -

The O +
characterization O +
of O +
the O +
tomato U-Species +
N O +
-glycans O +
presented O +
in O +
this O +
work O -
, O +
revealing O +
a O +
high O +
degree O +
of O +
α1,3-fucosylated O +
structures O +
in O +
the O +
fruit U-Species -
, O +
offers O +
the O +
structural O +
explanation O +
for O +
these O +
findings O -
. O -

4 O +
Experimental O +
4.1 O +
Materials O +
Red B-Species +
tomatoes L-Species +
( O -
variety O +
Notoro U-Species -
) O +
were O +
bought O +
in O +
a O +
retail O +
shop O -
; O +
red U-Species +
and O +
green O +
tomatoes U-Species +
( O -
variety O +
San B-Species +
Marzano L-Species -
) O +
were O +
obtained O +
from O +
RIKILT O -
- O -
DLO O -
, O +
Netherlands O -
. O -

N O +
-glycosidase O +
A O +
from O +
almonds U-Species +
and O +
endoglycosidase O +
H O +
from O +
Streptomyces B-Species +
plicatus L-Species -
were O +
purchased O +
from O +
Boehringer O +
Mannheim O -
. O -

β O -
- O -
N O +
-acetylglucosaminidase O +
( O -
jack B-Species +
bean L-Species -
) O -
, O +
α O -
- O -
mannosidase O +
( O -
jack B-Species +
bean L-Species -
) O +
and O +
pepsin O +
( O -
from O +
porcine U-Species +
stomach O +
mucosa O -
) O +
were O +
obtained O +
from O +
Sigma O -
. O -

2-aminopyridine O -
, O +
sodium O +
cyanoborohydride O -
, O +
dithioerythritol O -
, O +
benzamidine O +
and O +
PMSF O +
were O +
obtained O +
from O +
Sigma O -
. O -

4.2 O +
Precipitation O +
of O +
proteins O +
using O +
a O +
low O -
- O -
temperature O +
acetone O +
powder O +
method O +
The O +
extracts O +
were O +
prepared O +
in O +
a O +
similar O +
manner O +
to O +
that O +
described O +
by O +
Vieths O -
, O +
Schöning O -
, O +
and O +
Petersen O +
( O -
1994 O -
) O +
: O +
200 O +
g O +
of O +
tomato U-Species +
fruit O +
were O +
homogenized O +
in O +
400 O +
ml O +
of O +
ice O -
- O -
cold O +
acetone O +
on O +
dry O +
ice O -
. O -

Another O +
400 O +
ml O +
of O +
ice O -
- O -
cold O +
acetone O +
were O +
added O +
and O +
the O +
sample O +
was O +
kept O +
on O +
dry O +
ice O +
overnight O +
with O +
occasional O +
stirring O +
during O +
the O +
first O +
few O +
hours O -
. O -

The O +
resulting O +
precipitate O +
was O +
filtered O +
through O +
sintered O +
glass O +
and O +
washed O +
twice O +
with O +
acetone O +
and O +
once O +
with O +
acetone O -
/ O -
diethylether O +
( O -
1:1 O -
, O +
v O -
/ O -
v O -
) O +
at O +
−20 O -
° O -
C O -
. O -

The O +
sediment O +
was O +
lyophilized O -
. O -

4 O +
g O +
of O +
acetone O +
powder O +
were O +
taken O +
up O +
in O +
150 O +
ml O +
phosphate O +
buffered O +
saline O +
( O -
10 O +
mM O +
phosphate O +
pH O +
7.4 O -
; O +
0.15 O +
M O +
NaCl O -
) O +
and O +
stirred O +
at O +
4 O -
° O -
C O +
for O +
60 O +
min O -
. O -

After O +
centrifugation O +
( O -
20000 O +
rpm O -
, O +
20 O +
min O -
, O +
0 O -
° O -
C O -
) O -
, O +
the O +
supernatant O +
was O +
filtered O +
( O -
0.45 O +
μm O -
) O -
, O +
extensively O +
dialyzed O +
against O +
double O -
- O -
distilled O +
water O +
( O -
membrane O +
3.5 O +
kD O +
cut O -
- O -
off O -
) O +
overnight O +
and O +
lyophilized O -
. O -

4.3 O +
Ammonium O +
sulfate O +
precipitation O +
As O +
an O +
alternative O +
to O +
the O +
above O -
- O -
mentioned O +
procedure O -
, O +
ammonium O +
sulfate O +
precipitation O +
was O +
per O -
- O -
formed O -
: O +
to O +
200 O +
g O +
of O +
tomato U-Species +
fruit O +
400 O +
ml O +
of O +
extraction O +
buffer O +
( O -
10 O +
mM O +
phosphate O +
pH O +
7.4 O -
, O +
150 O +
mM O +
NaCl O -
, O +
1 O +
mM O +
EDTA O -
, O +
1 O +
mM O +
benzamidine O -
, O +
1 O +
mM O +
DTE O -
, O +
0.1 O +
mM O +
PMSF O -
) O +
was O +
added O +
and O +
the O +
sample O +
was O +
homogenized O -
. O -

Centrifugation O +
was O +
carried O +
out O +
at O +
20000 O +
rpm O +
( O -
20 O +
min O -
, O +
4 O -
° O -
C O -
) O -
. O -

Solid O +
ammonium O +
sulfate O +
was O +
added O +
to O +
the O +
supernatant O +
to O +
a O +
final O +
concentration O +
of O +
80 O -
% O +
saturation O -
. O -

The O +
mixture O +
was O +
stirred O +
at O +
4 O -
° O -
C O +
for O +
3 O +
h O -
, O +
centrifuged O +
( O -
20000 O +
rpm O -
, O +
20 O +
min O -
, O +
4 O -
° O -
C O -
) O +
and O +
the O +
pellet O +
was O +
dialyzed O +
against O +
double O -
- O -
distilled O +
water O +
and O +
lyophilized O -
. O -

4.4 O +
Purification O +
of O +
N O +
-glycans O +
The O +
lyophilisate O +
was O +
dissolved O +
in O +
5 O -
% O +
v O -
/ O -
v O +
formic O +
acid O +
and O +
digested O +
with O +
pepsin O +
( O -
2 O -
% O -
, O +
w O -
/ O -
w O -
) O +
for O +
48 O +
h O +
at O +
37 O -
° O -
C O -
. O -

( O -
Another O +
1 O -
% O +
w O -
/ O -
w O +
pepsin O +
was O +
added O +
after O +
24 O +
h O -
) O -
. O -

After O +
centrifugation O +
( O -
10000 O +
rpm O -
, O +
10 O +
min O -
) O -
, O +
the O +
supernatant O +
was O +
adjusted O +
to O +
pH O +
2.5 O +
and O +
chromatographed O +
on O +
an O +
ion O -
- O -
exchange O +
SP650-M O +
column O -
, O +
1 O -
× O -
5 O +
cm O +
( O -
Toso O +
Haas O -
) O -
, O +
equilibrated O +
with O +
5 O -
% O +
acetic O +
acid O -
. O -

After O +
application O +
of O +
the O +
sample O -
, O +
the O +
column O +
was O +
rinsed O +
with O +
40 O +
ml O +
5 O -
% O +
acetic O +
acid O -
. O -

The O +
glycopeptide O +
fraction O +
was O +
eluted O +
with O +
1 O +
M O +
ammonia O +
( O -
collection O +
of O +
2 O +
ml O +
fractions O -
) O -
. O -

Carbohydrate O -
- O -
positive O +
fractions O -
, O +
detected O +
using O +
the O +
orcinol O -
– O -
sulfuric O +
acid O +
reagent O +
according O +
to O +
Winzler O +
( O -
1955 O -
) O +
, O +
were O +
pooled O +
and O +
lyophilized O -
. O -

The O +
sample O +
was O +
taken O +
up O +
in O +
1 O +
ml O +
water O -
; O +
the O +
pH O +
was O +
adjusted O +
to O +
9 O +
with O +
ammonia O -
. O -

100 O +
μl O +
of O +
a O +
2 O -
% O +
w O -
/ O -
v O +
sodium O +
borohydride O +
solution O +
was O +
added O +
and O +
the O +
sample O +
was O +
incubated O +
at O +
room O +
temperature O +
overnight O -
. O -

After O +
addition O +
of O +
acetic O +
acid O +
and O +
evaporation O -
, O +
this O +
step O +
was O +
repeated O +
twice O +
with O +
1 O -
% O +
v O -
/ O -
v O +
acetic O +
acid O +
in O +
methanol O +
and O +
twice O +
with O +
MeOH O -
. O -

The O +
sample O +
was O +
dissolved O +
in O +
100 O +
μl O +
citrate O -
/ O -
phosphate O +
pH O +
5.0 O +
and O +
digested O +
with O +
0.5 O +
mU O +
of O +
N O +
-glycosidase O +
A O +
for O +
37 O -
° O -
C O +
for O +
48 O +
h. O +
Oligosaccharides O +
were O +
separated O +
from O +
residual O +
glycopeptides O +
and O +
peptides O +
using O +
a O +
reverse O -
- O -
phase O +
cartridge O +
as O +
described O +
by O +
Dell O +
et O +
al. O +
( O -
Dell O +
et O +
al. O -
, O +
1993 O -
) O +
. O -

The O +
glycans O +
were O +
labelled O +
with O +
2-aminopyridine O +
according O +
to O +
Hase O -
, O +
Ibuki O -
, O +
and O +
Ikenaka O +
( O -
1984 O -
) O +
. O -

To O +
remove O +
the O +
excess O +
of O +
reagent O -
, O +
a O +
gelfiltration O +
step O +
was O +
performed O +
using O +
a O +
1 O -
× O -
40 O +
cm O +
Sephadex O +
G15 O +
column O -
, O +
equilibrated O +
with O +
1 O -
% O +
w O -
/ O -
v O +
acetic O +
acid O -
. O -

4.5 O +
Fractionation O +
of O +
pyridylaminated O +
oligosaccharides O +
by O +
two O -
- O -
dimensional O +
HPLC O +
A O +
Shimadzu O +
module O +
system O -
, O +
consisting O +
of O +
a O +
system O +
controller O -
, O +
a O +
pump O +
and O +
a O +
fluorescence O +
detector O +
was O +
used O -
. O -

Separations O +
of O +
the O +
pyridylamino O -
- O -
oligosaccharides O +
using O +
two O +
different O +
HPLC O +
columns O +
were O +
performed O +
at O +
room O +
temperature O -
. O -

Glucose O +
oligomers O +
were O +
used O +
in O +
both O +
systems O +
for O +
calibration O +
and O +
as O +
internal O +
standards O -
. O -

Elution O +
volumes O +
of O +
the O +
samples O +
were O +
expressed O +
in O +
glucose O +
units O +
according O +
to O +
Lee O -
, O +
Lee O -
, O +
Tomiya O -
, O +
and O +
Takahashi O +
( O -
1990 O -
) O +
. O -

Fractionation O +
according O +
to O +
size O +
was O +
accomplished O +
on O +
a O +
MicroPak O +
AX-5 O +
column O +
( O -
4 O -
× O -
300 O +
mm O -
, O +
VARIAN O -
) O -
; O +
the O +
eluents O +
were O +
as O +
follows O -
: O +
( O -
A O -
) O +
3 O -
% O +
w O -
/ O -
v O +
acetic O +
acid O -
, O +
triethylamine O +
pH O +
7.3 O -
: O +
acetonitrile O +
35:65 O -
, O +
v O -
/ O -
v O +
and O +
( O -
B O -
) O +
3 O -
% O +
w O -
/ O -
v O +
acetic O +
acid O -
, O +
triethylamine O +
pH O +
7.3 O -
: O +
acetonitrile O +
50:50 O -
, O +
v O -
/ O -
v O -
. O -

A O +
linear O +
gradient O +
of O +
0–60%B O +
in O +
30 O +
min O +
at O +
a O +
flow O +
rate O +
of O +
1 O +
ml O -
/ O -
min O +
was O +
applied O -
. O -

Further O +
separation O +
was O +
achieved O +
by O +
reverse O -
- O -
phase O +
HPLC O +
on O +
a O +
5 O +
μm O +
hypersil O +
ODS O +
column O +
( O -
Shandon O -
) O -
. O -

The O +
column O +
was O +
equilibrated O +
with O +
0.1 O +
M O +
ammonium O +
acetate O +
pH O +
4.0 O +
and O +
eluted O +
with O +
a O +
linear O +
gradient O +
of O +
0–7.5 O -
% O +
( O -
by O +
vol O -
. O -
) O +
methanol O +
in O +
25 O +
min O +
at O +
a O +
flow O +
rate O +
of O +
1.5 O +
ml O -
/ O -
min O -
. O -

In O +
both O +
systems O -
, O +
pyridylaminated O +
oligosaccharides O +
were O +
detected O +
by O +
fluorescence O +
using O +
excitation O +
and O +
emission O +
wavelengths O +
of O +
320 O +
and O +
400 O +
nm O -
, O +
respectively O -
. O -

4.6 O +
Exoglycosidase O +
digestions O +
Generally O -
, O +
about O +
50–100 O +
pmol O +
of O +
oligosaccharide O +
were O +
incubated O +
for O +
20 O +
h O +
at O +
37 O -
° O -
C O -
. O -

The O +
following O +
buffers O +
and O +
enzyme O +
quantities O +
were O +
used O -
: O +
50 O +
mU O +
α O -
- O -
mannosidase O +
in O +
50 O +
mM O +
sodium O +
acetate O -
, O +
pH O +
4.2 O +
containing O +
0.1 O +
mM O +
ZnCl2 O -
to O +
achieve O +
complete O +
removal O +
of O +
α O -
- O -
linked O +
mannose O +
residues O -
; O +
5 O +
mU O +
of O +
α O -
- O -
mannosidase O +
to O +
selectively O +
remove O +
α1,3-linked O +
mannose O +
residues O -
; O +
2 O +
mU O +
β O -
- O -
N O +
-acetylhexosaminidase O +
( O -
for O +
partial O +
hydrolysis O -
) O +
or O +
10 O +
mU O +
of O +
the O +
enzyme O +
for O +
complete O +
hydrolysis O -
, O +
using O +
0.1 O +
M O +
sodium O +
citrate O -
, O +
pH O +
5.0 O -
; O +
1 O +
mU O +
endoglycosidase O +
H O +
in O +
0.1 O +
M O +
sodium O +
citrate O -
/ O -
phosphate O -
, O +
pH O +
5.0 O -
. O -

4.7 O +
Preparation O +
of O +
reference O +
oligosaccharides O +
Pyridylaminated O +
oligosaccharides O +
used O +
as O +
reference O +
substances O +
were O +
prepared O +
from O +
the O +
following O +
sources O -
: O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
Manβ1–4GlcNAcβ1–4GlcNAc O +
( O -
MM O -
) O +
from O +
bovine U-Species +
fibrin O +
( O -
Staudacher O -
, O +
Kubelka O -
, O +
& O +
März O -
, O +
1992 O -
) O +
; O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4GlcNAc O +
( O -
MMX O -
) O +
from O +
zucchini U-Species +
ascorbate O +
oxidase O +
( O -
Altmann O -
, O +
1998 O -
) O +
; O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
MMF3 O +
) O +
from O +
honeybee U-Species +
venom O +
phospholipase O +
A2 O +
( O -
Kubelka O +
et O +
al. O -
, O +
1993 O -
) O +
; O +
Manα1–6 O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
M0XF3 O +
) O +
from O +
pineapple U-Species +
stem O +
bromelain O +
( O -
Van O +
Kuik O +
et O +
al. O -
, O +
1986 O -
) O +
; O +
Manα1–6 O -
( O -
Manα1–3 O -
) O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
MMXF3 O +
) O +
from O +
horseradish U-Species +
peroxidase O +
( O -
Kurosaka O +
et O +
al. O -
, O +
1991 O -
) O +
; O +
GlcNAcβ1–2Manα1–6 O -
( O -
GlcNAcβ1–2Manα1–3 O -
) O -
( O -
Xylβ1–2 O -
) O -
Manβ1–4GlcNAcβ1–4 O -
( O -
Fucα1–3 O -
) O -
GlcNAc O +
( O -
GnGnXF3 O +
) O +
from O +
hornbeam U-Species +
pollen O +
( O -
Wilson O -
, O +
& O +
Altmann O -
, O +
1998 O -
) O +
; O +
Man6 O +
GlcNAc2 O -
[ O -
M6.1 O -
] O -
1 O +
Codes O +
for O +
oligomannose O +
structures O +
according O +
to O +
Tomiya O +
et O +
al. O +
( O -
1991 O -
) O +
. O -

1 O -
, O +
Man7 O +
GlcNAc2 O -
[ O -
M7.1 O -
] O -
1 O -
, O +
[ O -
M7.2 O -
] O -
1 O -
, O +
and O +
Man8 O +
GlcNAc2 O -
[ O -
M8.1 O -
] O -
1 O -
from O +
soybean U-Species +
7S O +
-glycoprotein O +
( O -
Neeser O -
, O +
Vedovo O -
, O +
Mutsaers O -
, O +
& O +
Vliegenthart O -
, O +
1985 O -
) O +
. O -

The O +
structures O +
of O +
the O +
reference O +
oligosaccharides O +
were O +
confirmed O +
by O +
methylation O +
analysis O +
( O -
data O +
not O +
shown O -
) O -
. O -

For O +
column O +
calibration O -
, O +
pyridylaminated O +
isomaltooligosaccharides O +
were O +
prepared O +
from O +
partially O +
hydrolyzed O +
dextran O -
. O -

4.8 O +
Matrix O -
- O -
assisted O +
laser O +
desorption O -
/ O -
ionization O +
– O +
time O +
of O +
flight O +
– O +
mass O +
spectrometry O +
MALDI O -
– O -
TOF O -
– O -
MS O +
data O +
was O +
obtained O +
using O +
a O +
Dynamo O +
instrument O +
( O -
Thermo O +
Bioanalysis O -
, O +
UK O -
) O -
, O +
operating O +
in O +
the O +
positiv O -
- O -
ion O +
linear O +
mode O -
. O -

About O +
5–10 O +
pmol O +
of O +
pyridylaminated O +
tomato U-Species +
N O +
-glycans O +
( O -
individual O +
reverse O -
- O -
phase O +
HPLC O +
fractions O -
) O +
were O +
repeatedly O +
dried O +
under O +
nitrogen O +
to O +
remove O +
buffer O +
components O -
; O +
the O +
samples O +
were O +
finally O +
dissolved O +
in O +
6 O +
μl O +
water O +
and O +
3 O +
μl O +
matrix O +
solution O +
( O -
2 O -
% O +
2,5-dihydroxybenzoic O +
acid O +
in O +
water O +
containing O +
30 O -
% O +
acetonitrile O +
and O +
0,5 O +
mM O +
NaCl O -
) O -
. O -

Aliquots O +
of O +
1 O +
μl O +
were O +
applied O +
on O +
the O +
target O +
and O +
allowed O +
to O +
dry O -
. O -

Mass O +
spectra O +
were O +
obtained O +
by O +
averaging O +
20 O +
single O +
spectra O -
. O -

External O +
mass O +
calibration O +
was O +
performed O +
with O +
pyridylaminated O +
GlcNAc2 O +
Man3 O +
GlcNAc2 O -
( O -
MNa+ O +
= O -
1418,2 O +
Da O -
) O +
which O +
was O +
prepared O +
from O +
bovine U-Species +
fibrin O +
as O +
described O +
( O -
Altmann O -
, O +
Schwihla O -
, O +
Staudacher O -
, O +
Glössl O -
, O +
& O +
März O -
, O +
1995 O -
) O +
. O -

4.9 O +
HPLC O -
- O -
analysis O +
of O +
OPA O -
- O -
aminosugars O +
An O +
aliquot O +
of O +
the O +
glycopeptide O +
fraction O +
was O +
hydrolyzed O +
with O +
4 O +
M O +
TFA O +
and O +
aminosugar O +
analysis O +
by O +
reverse O -
- O -
phase O +
chromatography O +
was O +
performed O +
as O +
described O +
by O +
Altmann O +
( O -
1992 O -
) O +
. O -

Acknowledgements O -

We O +
thank O +
Hubert O +
Noteborn O -
, O +
RILILT O -
- O -
DLO O +
for O +
supplying O +
us O +
with O +
the O +
tomato U-Species +
samples O +
and O +
Thomas O +
Dalik O +
for O +
performing O +
the O +
aminosugar O +
analyses O -
. O -

This O +
work O +
was O +
financed O +
by O +
the O +
EU O -
- O -
project O +
AIR3-CT94 O -
- O -
2311 O -
. O +

2-Nitrofluorene O +
( O -
NF O -
) O +
is O +
an O +
air O +
pollutant O +
which O +
has O +
been O +
used O +
as O +
a O +
model O +
substance O +
of O +
nitrated O +
polycyclic O +
aromatic O +
hydrocarbons O +
( O -
nitro O -
- O -
PAHs O -
) O +
[ O -
1 O -
, O +
2 O -
] O +
. O -

NF O +
enters O +
in O +
vivo O +
into O +
an O +
oxidative O +
or O +
a O +
reductive O +
metabolic O +
pathway O -
, O +
depending O +
on O +
the O +
route O +
of O +
administration O +
[ O -
3–5 O -
] O +
. O -

Oral O +
administration O +
results O +
mainly O +
in O +
reduced O +
metabolites O +
[ O -
5 O -
] O +
, O +
e.g. O -
, O +
2-aminofluorene O +
( O -
AF O -
) O +
and O +
2-acetylaminofluorene O +
( O -
AAF O -
) O -
, O +
both O +
are O +
carcinogens O -
. O -

It O +
is O +
reported O +
that O +
NF O +
induces O +
DNA O +
adduct O +
formation O +
in O +
vivo O +
with O +
dG O -
- O -
C8-AF O +
as O +
one O +
of O +
the O +
characterized O +
DNA O +
adducts O +
[ O -
6 O -
, O +
7 O -
] O +
. O -

dG O -
- O -
C8-AF O -
, O +
together O +
with O +
other O +
known O +
AF- O +
and O +
AAF O -
- O -
related O +
DNA O +
adducts O +
( O -
i.e. O -
, O +
dG O -
- O -
C8-AAF O -
, O +
dG O -
- O -
N O +
2 O +
-AAF O -
, O +
etc O -
. O -
) O +
have O +
been O +
suspected O +
to O +
be O +
pre O -
- O -
mutagenic O +
or O +
toxic O +
[ O -
8 O -
] O +
. O -

Carcinogens O +
have O +
been O +
shown O +
to O +
induce O +
DNA O +
adducts O +
[ O -
6 O -
, O +
7 O -
, O +
9 O -
, O +
10 O -
] O +
. O -

Exposures O +
of O +
human U-Species +
populations O +
to O +
complex O +
mixtures O +
with O +
known O +
or O +
suspected O +
risk O +
of O +
inducing O +
cancer O +
is O +
also O +
associated O +
with O +
formation O +
of O +
DNA O +
adducts O +
[ O -
11–13 O -
] O +
. O -

High O +
levels O +
of O +
DNA O +
adducts O +
in O +
normal O +
human U-Species +
colonic O +
mucosa O +
is O +
significantly O +
associated O +
with O +
colorectal O +
cancer O +
[ O -
14 O -
] O +
. O -

In O +
polluted O +
areas O -
, O +
the O +
seasonal O +
change O +
of O +
DNA O +
adducts O +
in O +
human U-Species +
lymphocytes O +
varies O +
with O +
the O +
seasonal O +
changes O +
of O +
air O +
pollutants O +
[ O -
15 O -
] O +
. O -

Thus O -
, O +
DNA O +
adducts O +
may O +
be O +
used O +
as O +
biomarkers O +
for O +
genotoxic O +
risk O -
. O -

DNA O +
adducts O +
have O +
different O +
stabilities O +
owing O +
to O +
factors O +
such O +
as O +
DNA O +
repair O +
and O +
chemical O +
instability O -
. O -

No O +
uniform O +
correlation O +
is O +
found O +
between O +
adduct O +
persistence O +
and O +
tumor O +
induction O -
. O -

However O -
, O +
it O +
is O +
postulated O +
that O +
the O +
persistent O +
DNA O +
adducts O +
represent O +
dormant O +
lesions O +
that O +
may O +
become O +
fixed O +
as O +
mutations O +
long O +
after O +
exposure O +
to O +
the O +
carcinogen O +
and O +
contribute O +
to O +
the O +
malignant O +
transformation O +
as O +
a O +
result O +
of O +
cell O +
division O +
[ O -
16 O -
] O +
. O -

Measurement O +
of O +
DNA O +
adducts O +
from O +
carcinogenic O +
alkenylbenzenes O +
in O +
preweanling O +
male O +
B6C3F1 B-Species +
mice L-Species +
suggests O +
the O +
virtual O +
absence O +
of O +
DNA O +
repair O +
for O +
these O +
adducts O +
[ O -
17 O -
] O +
. O -

This O +
has O +
been O +
postulated O +
to O +
play O +
a O +
role O +
in O +
the O +
carcinogenicity O +
of O +
safrole O +
and O +
related O +
alkenylbenzenes O +
in O +
newborn O +
mice U-Species +
[ O -
17–20 O -
] O +
. O -

Further O +
experiments O +
show O +
that O +
rapid O +
repair O +
of O +
O O +
6 O +
-methylguanine O -
- O -
DNA O +
adducts O +
protects O +
transgenic O +
mice U-Species +
from O +
N O +
-methylnitrosourea O -
- O -
induced O +
thymic O +
lymphomas O +
[ O -
21 O -
] O +
. O -

It O +
has O +
also O +
been O +
reported O +
that O +
increased O +
platinum O +
removal O +
from O +
total O +
genomic O +
DNA O +
was O +
associated O +
with O +
increased O +
cisplatin O +
resistance O +
in O +
human U-Species +
ovarian O +
cancer O +
cell O +
lines O +
[ O -
22 O -
] O +
. O -

A O +
recently O +
published O +
long O -
- O -
term O +
tumor O +
study O +
on O +
Wistar B-Species +
rats L-Species +
showed O +
that O +
NF O +
induces O +
tumors O +
in O +
the O +
liver O -
, O +
kidney O +
and O +
forestomach O -
. O -

DNA O +
adducts O +
are O +
formed O +
at O +
higher O +
levels O +
during O +
the O +
early O +
stage O +
of O +
NF O +
administration O +
in O +
these O +
tumor O -
- O -
target O +
organs O +
compared O +
with O +
some O +
non O -
- O -
tumor O +
target O +
organs O +
( O -
heart O -
, O +
spleen O +
and O +
glandular O +
stomach O -
) O +
[ O -
23 O -
] O +
. O -

However O -
, O +
NF O +
and O +
also O +
a O +
lot O +
of O +
other O +
carcinogens O +
induce O +
DNA O +
adducts O +
in O +
both O +
tumor O -
- O -
target O +
and O +
non O -
- O -
tumor O +
target O +
tissues O -
. O -

It O +
is O +
thus O +
of O +
significance O +
to O +
know O +
the O +
biochemical O +
characteristics O +
and O +
mutagenic O +
effects O +
of O +
the O +
individual O +
DNA O +
adduct O +
induced O +
by O +
carcinogens O -
. O -

Better O +
correlation O +
may O +
be O +
achieved O +
when O +
an O +
individual O +
DNA O +
adduct O +
is O +
compared O +
with O +
tumor O +
formation O -
. O -

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
formation O +
and O +
persistence O +
and O +
the O +
characterization O +
of O +
DNA O +
adducts O +
during O +
and O +
after O +
a O +
long O -
- O -
term O +
administration O +
of O +
NF O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Animal U-Species +
experiment O +
Male O +
Wistar B-Species +
rats L-Species +
from O +
Möllegaard O +
Breeding O +
Center O +
( O -
Skensved O -
, O +
Denmark O -
) O +
with O +
a O +
body O +
weight O +
of O +
approximately O +
90 O +
g O -
, O +
were O +
used O +
for O +
the O +
experiment O -
. O -

The O +
rats U-Species +
were O +
housed O +
in O +
wire O -
- O -
bottomed O +
cages O +
under O +
standardized O +
conditions O +
of O +
light O +
( O -
12 O +
h O +
light O +
and O +
dark O +
cycle O -
) O -
, O +
humidity O +
( O -
55–60 O -
% O -
) O +
and O +
temperature O +
( O -
21±1 O -
° O -
C O -
) O -
. O -

The O +
rats U-Species +
were O +
acclimatized O +
for O +
1 O +
week O +
before O +
the O +
start O +
of O +
the O +
experiment O -
. O -

During O +
the O +
entire O +
experiment O -
, O +
the O +
rats U-Species +
had O +
access O +
to O +
food O +
and O +
water O +
ad O +
libitum O -
. O -

The O +
rats U-Species +
were O +
randomly O +
divided O +
into O +
four O +
groups O -
. O -

Three O +
groups O +
were O +
fed O +
diets O +
supplemented O +
with O +
different O +
concentrations O +
of O +
NF O +
which O +
were O +
0.24 O +
mmol O +
( O -
LD O -
= O -
low O +
dose O -
) O -
, O +
0.95 O +
mmol O +
( O -
MD O -
= O -
medium O +
dose O -
) O +
and O +
2.37 O +
mmol O +
( O -
HD O -
= O -
high O +
dose O -
) O +
per O +
kg O +
diet O -
, O +
respectively O -
. O -

One O +
group O +
was O +
fed O +
basal O +
diet O +
( O -
R3 O -
, O +
Ewos O -
, O +
Södertälje O -
, O +
Sweden O -
) O +
as O +
a O +
control O +
group O -
. O -

The O +
rats U-Species +
were O +
fed O +
NF O -
- O -
supplemented O +
diets O +
continuously O +
for O +
11 O +
months O -
, O +
thereafter O -
, O +
all O +
groups O +
were O +
fed O +
basal O +
diet O +
for O +
a O +
further O +
13 O +
months O -
. O -

The O +
tumor O +
results O +
of O +
this O +
study O +
were O +
previously O +
reported O +
[ O -
23 O -
] O +
. O -

In O +
the O +
present O +
study O -
, O +
DNA O +
adducts O +
were O +
not O +
detected O +
in O +
the O +
LD O +
group O -
. O -

Different O +
tissues O -
, O +
i.e. O -
, O +
liver O -
, O +
kidney O -
, O +
forestomach O -
, O +
glandular O +
stomach O +
and O +
spleen O -
, O +
were O +
collected O +
for O +
DNA O +
adduct O +
analysis O -
. O -

The O +
early O +
stage O +
DNA O +
adduct O +
levels O +
were O +
obtained O +
from O +
three O +
rats U-Species +
after O +
10 O +
days O +
of O +
HD O +
NF O +
administration O -
. O -

The O +
later O +
stage O +
DNA O +
adduct O +
analysis O +
was O +
focused O +
on O +
the O +
samples O +
which O +
were O +
obtained O +
from O +
three O +
rats U-Species +
that O +
were O +
killed O +
shortly O +
before O +
the O +
cessation O +
of O +
the O +
HD O +
NF O +
diet O +
( O -
11 O +
months O -
) O -
. O -

The O +
persistence O +
of O +
DNA O +
adduct O +
levels O +
in O +
the O +
liver O +
after O +
the O +
termination O +
of O +
NF O +
administration O +
was O +
monitored O +
in O +
the O +
MD O +
group O -
. O -

2.2 O +
DNA O +
adduct O +
analyses O +
Tissues O +
from O +
the O +
rat U-Species +
were O +
homogenized O +
in O +
a O +
buffer O +
of O +
1 O -
% O +
SDS O -
, O +
1 O +
mM O +
EDTA O +
and O +
10 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
7.4 O -
) O +
while O +
kept O +
cold O +
on O +
an O +
ice O +
bed O -
. O -

After O +
RNAse O +
and O +
proteinase O +
K O +
digestion O -
, O +
DNA O +
was O +
extracted O +
by O +
the O +
phenol O +
and O +
chloroform O +
and O +
then O +
hydrolyzed O +
by O +
micrococcal O +
nuclease O +
and O +
spleen O +
phosphodiesterase O -
. O -

DNA O +
adducts O +
were O +
enriched O +
by O +
butanol O +
extraction O +
in O +
the O +
presence O +
of O +
tetrabutylammonium O +
chloride O -
. O -

DNA O +
adducts O +
were O +
then O +
labeled O +
with O +
[ O -
γ-32 O +
P O -
] O -
ATP O +
by O +
polynucleotide O +
kinase O -
. O -

The O +
method O +
used O +
was O +
originally O +
from O +
Beach O +
and O +
Gupta O +
[ O -
24 O -
] O +
with O +
small O +
modifications O +
in O +
different O +
steps O +
[ O -
25 O -
, O +
26 O -
] O +
. O -

32 O +
P O -
-HPLC O -
- O -
analyses O +
of O +
postlabeled O +
DNA O +
adducts O +
were O +
performed O +
by O +
injecting O +
the O +
total O +
unrefined O +
32 O +
P O -
-labeling O +
mixture O +
into O +
the O +
32 O +
P O -
-HPLC O -
. O -

In O +
each O +
analysis O -
, O +
2.8 O +
μg O +
of O +
DNA O +
( O -
5 O +
μCi O -
) O +
was O +
injected O -
. O -

A O +
DeltaPak O -
™ O +
5 O +
μm O +
C18–100 O +
Å O +
column O -
, O +
with O +
a O +
0.5 O +
ml O -
/ O -
min O +
flow O +
rate O +
of O +
2 O +
M O +
ammonium O +
formate O -
, O +
0.4 O +
M O +
formic O +
acid O +
( O -
pH O +
4.5 O -
) O +
with O +
a O +
linear O +
gradient O +
of O +
0–35 O -
% O +
acetonitrile O +
( O -
0–70 O +
min O -
) O +
was O +
used O +
for O +
the O +
separation O +
of O +
phosphorylated O +
nucleotides O +
and O +
adducts O -
. O -

The O +
32 O +
P O -
-HPLC O +
method O +
for O +
analyses O +
of O +
postlabeled O +
DNA O +
adducts O +
is O +
described O +
in O +
detail O +
elsewhere O +
[ O -
25 O -
, O +
26 O -
] O +
. O -

2.3 O +
Detection O +
of O +
NF O -
- O -
DNA O +
adducts O +
after O +
different O +
enrichment O +
procedures O +
Butanol O +
extraction O +
and O +
nuclease O +
P1 O +
( O -
Sigma O -
, O +
St. O +
Louis O -
, O +
MO O -
) O +
treatment O +
were O +
run O +
in O +
parallel O +
for O +
the O +
comparison O +
of O +
enrichment O +
efficiency O +
of O +
the O +
NF O -
- O -
DNA O +
adducts O -
. O -

Liver O +
samples O +
were O +
collected O +
from O +
rats U-Species +
receiving O +
11 O +
months O +
of O +
HD O +
NF O +
feeding O -
. O -

In O +
the O +
nuclease O +
P1 O +
enrichment O +
procedure O -
, O +
normal O +
nucleotides O +
were O +
dephosphorylated O +
by O +
40 O +
min O +
37 O -
° O -
C O +
incubation O +
with O +
nuclease O +
P1 O +
( O -
in O +
1 O +
mM O +
ZnCI2 O +
) O +
in O +
1 O +
μg O -
/ O -
μg O +
DNA O +
level O -
. O -

The O +
hydrolysates O +
were O +
thereafter O +
evaporated O +
to O +
dryness O +
and O +
redissolved O +
in O +
water O +
for O +
32 O +
P O -
-labeling O +
as O +
described O +
above O -
. O -

2.4 O +
Identification O +
of O +
NF O -
- O -
DNA O +
adducts O +
DNA O +
adducts O +
formed O +
in O +
the O +
liver O +
after O +
11-month O +
HD O +
NF O +
administration O +
were O +
co O -
- O -
chromatographed O +
with O +
DNA O +
adduct O +
standards O -
: O +
dGp O -
- O -
C8-AF O -
, O +
dGp O -
- O -
C8-AAF O +
and O +
dGp O -
- O -
N O +
2 O +
-AAF O +
( O -
Fig. O +
1 O -
) O -
. O -

The O +
DNA O +
adduct O +
standards O +
were O +
kindly O +
supplied O +
by O +
Dr. O +
F.A. O +
Beland O -
, O +
National O +
Center O +
for O +
Toxicological O +
Research O -
, O +
Jefferson O -
, O +
AR O -
, O +
USA O -
. O -

3 O +
Results O +
Four O +
DNA O +
adducts O +
( O -
DNA O +
adduct O +
A O -
, O +
B O -
, O +
C O +
and O +
D O -
) O +
were O +
found O +
in O +
rat U-Species +
tissues O +
after O +
10 O +
days O +
as O +
well O +
as O +
11 O +
months O +
of O +
HD O +
NF O +
feeding O -
. O -

Fig. O +
2 O -
shows O +
representative O +
32 O +
P O -
-HPLC O +
chromatograms O +
of O +
DNA O +
adducts O +
formed O +
in O +
the O +
liver O -
, O +
kidney O +
and O +
spleen O +
after O +
10 O +
days O +
( O -
Fig. O +
2 O +
a O -
– O -
c O -
) O +
and O +
11 O +
months O +
( O -
Fig. O +
2 O +
d O -
– O -
f O -
) O +
of O +
HD O +
NF O +
feeding O -
. O -

DNA O +
adducts O +
A O +
and O +
B O +
increased O +
dramatically O +
in O +
the O +
liver O +
and O +
kidney O +
during O +
the O +
period O +
of O +
NF O +
administration O -
. O -

Adducts O +
C O +
and O +
D O +
showed O +
less O +
marked O +
changes O +
over O +
time O -
. O -

Fig. O +
3 O -
shows O +
representative O +
chromatograms O +
of O +
DNA O +
adducts O +
formed O +
in O +
forestomach O +
and O +
glandular O +
stomach O +
after O +
10 O +
days O +
of O +
HD O +
NF O +
administration O -
. O -

A O +
dramatic O +
difference O +
was O +
seen O +
between O +
these O +
two O +
tissues O +
regarding O +
DNA O +
adduct O +
levels O +
which O +
was O +
mainly O +
caused O +
by O +
high O +
DNA O +
adduct O +
D O +
level O +
in O +
the O +
forestomach O -
. O -

DNA O +
adducts O +
A O +
and O +
C O +
were O +
not O +
detectable O +
either O +
in O +
the O +
forestomach O +
or O +
the O +
glandular O +
stomach O -
. O -

Fig. O +
4 O -
displays O +
the O +
DNA O +
adduct O +
levels O +
in O +
different O +
tissues O +
after O +
10 O +
days O +
( O -
upper O -
) O +
and O +
11 O +
months O +
( O -
lower O -
) O +
of O +
HD O +
NF O +
feeding O -
, O +
respectively O -
. O -

After O +
10 O +
days O +
of O +
NF O +
feeding O -
, O +
the O +
levels O +
of O +
DNA O +
adducts O +
A O -
, O +
B O +
and O +
C O +
were O +
much O +
lower O +
compared O +
to O +
11 O +
months O +
of O +
NF O +
feeding O -
. O -

Adduct O +
D O -
, O +
which O +
was O +
a O +
major O +
DNA O +
adduct O +
especially O +
in O +
the O +
liver O +
at O +
early O +
stage O +
( O -
10 O +
days O -
) O +
of O +
NF O +
feeding O -
, O +
did O +
not O +
increase O +
significantly O +
over O +
time O +
( O -
10 O +
days O +
to O +
11 O +
months O -
) O -
. O -

Adducts O +
A O +
and O +
B O -
, O +
on O +
the O +
other O +
hand O -
, O +
increased O +
dramatically O +
during O +
the O +
NF O +
feeding O +
and O +
consequently O -
, O +
became O +
dominant O +
adducts O +
in O +
the O +
liver O +
and O +
kidney O +
after O +
11 O +
months O +
of O +
NF O +
feeding O -
. O -

Compared O +
to O +
the O +
liver O +
and O +
kidney O -
, O +
spleen O +
showed O +
a O +
different O +
adduct O +
pattern O +
in O +
which O +
adduct O +
A O +
was O +
not O +
detectable O -
. O -

Fig. O +
5 O -
shows O +
the O +
DNA O +
adduct O +
levels O +
formed O +
in O +
the O +
forestomach O +
and O +
glandular O +
stomach O +
after O +
10 O +
days O +
of O +
HD O +
NF O +
feeding O -
. O -

A O +
significant O +
difference O +
was O +
seen O +
with O +
respect O +
to O +
the O +
level O +
of O +
adduct O +
D O +
in O +
these O +
two O +
tissues O -
. O -

DNA O +
adducts O +
A O +
and O +
C O +
were O +
not O +
found O +
in O +
these O +
tissues O -
. O -

To O +
characterize O +
the O +
four O +
major O +
DNA O +
adducts O +
induced O +
by O +
NF O -
, O +
32 O +
P O -
-HPLC O +
co O -
- O -
chromatography O +
was O +
performed O -
. O -

DNA O +
adduct O +
D O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
C8-AF O +
and O +
DNA O +
adduct O +
C O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
N O +
2 O +
-AAF O -
. O -

Neither O +
DNA O +
adduct O +
A O +
nor O +
B O +
co O -
- O -
migrated O +
with O +
any O +
of O +
the O +
three O +
adduct O +
standards O +
( O -
Fig. O +
6 O -
) O -
. O -

Higher O +
levels O +
of O +
DNA O +
adduct O +
A O +
and O +
C O +
were O +
detected O +
after O +
nuclease O +
P1 O +
treatment O +
compared O +
to O +
the O +
butanol O +
extraction O -
. O -

On O +
the O +
other O +
hand O -
, O +
DNA O +
adducts O +
B O +
and O +
D O +
were O +
not O +
detectable O +
after O +
nuclease O +
P1 O +
treatment O +
( O -
Fig. O +
7 O -
) O -
. O -

The O +
decline O +
of O +
total O +
NF O -
- O -
DNA O +
adducts O +
in O +
the O +
rat U-Species +
liver O +
after O +
the O +
withdrawal O +
of O +
MD O +
NF O +
administration O +
showed O +
a O +
biphasic O +
manner O +
( O -
Fig. O +
8 O -
) O -
. O -

The O +
pattern O +
of O +
DNA O +
adduct O +
removal O +
for O +
different O +
DNA O +
adducts O +
varied O -
. O -

Adducts O +
B O +
and O +
D O +
showed O +
a O +
sharp O +
drop O +
1 O +
month O +
after O +
the O +
withdrawal O +
of O +
NF O +
feeding O -
. O -

DNA O +
adduct O +
D O -
, O +
in O +
the O +
later O +
stage O +
of O +
the O +
period O -
, O +
reached O +
an O +
undetectable O +
level O -
. O -

On O +
the O +
other O +
hand O -
, O +
DNA O +
adducts O +
A O +
and O +
C O +
showed O +
a O +
slow O +
decline O -
. O -

DNA O +
adduct O +
A O +
maintained O +
a O +
high O +
level O +
after O +
11 O +
months O +
on O +
the O +
basal O +
diet O +
( O -
Fig. O +
8 O +
) O -
. O -

4 O +
Discussion O +
A O +
long O -
- O -
term O +
NF O +
feeding O +
to O +
rats U-Species +
induces O +
tumors O +
in O +
the O +
liver O -
, O +
kidney O +
and O +
forestomach O +
[ O -
23 O -
] O +
. O -

Both O +
DNA O +
adduct O +
levels O +
and O +
tumor O +
formation O +
showed O +
a O +
dose O -
- O -
dependent O +
manner O +
[ O -
23 O -
] O +
. O -

DNA O +
adduct O +
levels O +
after O +
short O -
- O -
term O +
( O -
days O -
) O +
NF O +
administration O +
were O +
associated O +
with O +
the O +
locations O +
of O +
tumors O +
up O +
to O +
2 O +
years O +
later O +
[ O -
23 O -
] O +
. O -

In O +
the O +
present O +
experiment O -
, O +
four O +
major O +
DNA O +
adducts O -
, O +
named O +
as O +
DNA O +
adduct O +
A O -
, O +
B O -
, O +
C O +
and O +
D O -
, O +
were O +
found O +
in O +
the O +
liver O +
and O +
kidney O +
after O +
10 O +
days O +
and O +
11 O +
months O +
of O +
NF O +
feeding O -
. O -

The O +
levels O +
of O +
different O +
NF O -
- O -
DNA O +
adducts O +
increased O +
with O +
varied O +
rates O +
during O +
the O +
period O +
of O +
NF O +
feeding O -
. O -

In O +
one O +
of O +
the O +
non O -
- O -
tumor O +
target O +
tissues O -
, O +
spleen O -
, O +
adducts O +
B O -
, O +
C O -
, O +
and O +
D O +
were O +
detected O +
at O +
low O +
levels O +
after O +
short- O +
or O +
long O -
- O -
term O +
of O +
NF O +
feeding O -
. O -

Glandular O +
stomach O -
, O +
as O +
another O +
non O -
- O -
tumor O +
target O +
tissue O -
, O +
showed O +
only O +
low O +
levels O +
of O +
DNA O +
adducts O +
B O +
and O +
D O +
after O +
10 O +
days O +
of O +
NF O +
feeding O -
. O -

DNA O +
adduct O +
formation O +
in O +
forestomach O +
after O +
11-month O +
NF O +
administration O +
could O +
not O +
be O +
analysed O +
since O +
multiple O +
tumors O +
which O +
generally O +
covered O +
the O +
forestomach O +
membrane O +
were O +
formed O +
in O +
this O +
tissue O +
in O +
almost O +
all O +
the O +
NF O -
- O -
dosed O +
rats U-Species +
( O -
HD O -
, O +
MD O +
and O +
LD O +
group O -
) O -
. O -

At O +
the O +
early O +
stage O -
, O +
DNA O +
adduct O +
D O -
, O +
which O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
C8-AF O -
, O +
constituted O +
a O +
large O +
part O +
of O +
total O +
NF O -
- O -
DNA O +
adducts O -
, O +
especially O +
in O +
the O +
liver O -
. O -

At O +
the O +
later O +
stage O +
of O +
NF O +
feeding O -
, O +
DNA O +
adducts O +
A O +
and O +
B O +
increased O -
, O +
becoming O +
the O +
major O +
part O +
of O +
total O +
DNA O +
adducts O -
, O +
while O +
DNA O +
adduct O +
D O +
( O -
dG O -
- O -
C8-AF O -
) O +
did O +
not O +
increase O +
significantly O +
compared O +
to O +
the O +
level O +
at O +
the O +
early O +
stage O -
. O -

Expressed O +
as O +
a O +
percentage O +
of O +
total O +
DNA O +
adducts O -
, O +
DNA O +
adduct O +
D O +
( O -
dG O -
- O -
C8-AF O -
) O +
decreased O +
from O +
42 O +
( O -
10-day O +
NF O +
administration O -
) O +
to O +
10 O -
% O +
of O +
total O +
DNA O +
adducts O +
( O -
11-month O +
NF O +
administration O -
) O +
in O +
the O +
liver O +
during O +
the O +
feeding O +
period O -
. O -

The O +
rat U-Species +
stomach O +
consists O +
of O +
two O +
parts O -
, O +
i.e. O -
, O +
the O +
forestomach O +
and O +
the O +
glandular O +
stomach O -
. O -

A O +
dramatically O +
higher O +
DNA O +
adduct O +
level O +
was O +
detected O +
in O +
the O +
forestomach O -
, O +
corresponding O +
to O +
the O +
high O +
tumor O +
incidence O +
in O +
this O +
tissue O -
, O +
compared O +
to O +
the O +
level O +
of O +
DNA O +
adducts O +
in O +
the O +
glandular O +
stomach O -
, O +
a O +
non O -
- O -
tumor O +
target O +
tissue O +
of O +
NF O +
[ O -
23 O -
] O +
. O -

In O +
the O +
high O +
dose O +
group O -
, O +
most O +
of O +
the O +
rats U-Species +
grew O +
liver O +
tumors O +
while O +
they O +
were O +
still O +
on O +
NF O +
diet O +
or O +
not O +
long O +
after O +
the O +
termination O +
of O +
NF O +
diet O -
. O -

Samples O +
were O +
unable O +
to O +
be O +
collected O +
for O +
certain O +
period O +
after O +
the O +
termination O +
of O +
NF O +
diet O -
. O -

MD O +
group O +
of O +
rats U-Species +
grew O +
tumors O +
in O +
a O +
scattered O +
time O +
points O +
generally O +
after O +
the O +
termination O +
of O +
NF O +
diet O -
. O -

Liver O +
samples O +
from O +
the O +
MD O +
group O +
were O +
therefore O +
chosen O +
for O +
the O +
study O +
of O +
DNA O +
adduct O +
persistence O -
. O -

The O +
use O +
of O +
mature O +
rats U-Species +
minimizes O +
the O +
significance O +
of O +
DNA O +
adduct O +
dilution O +
through O +
cell O +
proliferation O +
in O +
the O +
liver O -
. O -

The O +
early O +
rapid O +
diminution O +
of O +
DNA O +
adducts O +
followed O +
by O +
a O +
slower O +
rate O +
of O +
elimination O +
was O +
seen O +
for O +
adducts O +
B O +
and O +
D O +
( O -
but O +
not O +
for O +
adducts O +
A O +
and O +
C O -
) O -
. O -

The O +
biphasic O +
removal O +
is O +
consistent O +
with O +
what O +
observed O +
in O +
rat U-Species +
tissues O +
after O +
in O +
vivo O +
administration O +
of O +
substances O +
that O +
form O +
bulky O +
adducts O +
[ O -
16 O -
, O +
27–30 O -
] O +
. O -

The O +
two O -
- O -
step O +
removal O +
process O +
may O +
be O +
attributed O +
to O +
the O +
heterogeneity O +
in O +
efficiency O +
of O +
DNA O +
repair O -
, O +
with O +
adducts O +
in O +
some O +
genomic O +
regions O +
being O +
more O +
accessible O +
to O +
DNA O +
repair O +
than O +
these O +
in O +
others O +
[ O -
31 O -
, O +
32 O -
] O +
. O -

Among O +
the O +
four O +
major O +
DNA O +
adducts O +
induced O +
by O +
NF O -
, O +
adduct O +
D O +
and O +
C O +
co O -
- O -
migrated O +
with O +
dG O -
- O -
C8-AF O +
and O +
dG O -
- O -
N O +
2 O +
-AAF O -
, O +
respectively O -
. O -

DNA O +
adducts O +
A O +
and O +
B O +
did O +
not O +
co O -
- O -
migrate O +
with O +
any O +
of O +
the O +
adduct O +
standards O +
used O -
. O -

Some O +
characteristics O +
of O +
the O +
four O +
NF O -
- O -
DNA O +
adducts O +
are O +
summarized O +
in O +
Table O +
1 O -
. O -

For O +
DNA O +
adduct O +
enrichment O -
, O +
generally O -
, O +
butanol O +
extraction O +
is O +
used O +
for O +
aromatic O +
amines O -
- O -
DNA O +
adducts O +
and O +
nuclease O +
P1 O +
is O +
used O +
for O +
PAHs O -
- O -
DNA O +
adducts O -
. O -

The O +
values O +
of O +
DNA O +
adduct O +
A O +
and O +
C O +
were O +
much O +
higher O +
after O +
nuclease O +
P1 O +
treatment O +
compared O +
to O +
that O +
of O +
butanol O +
extraction O -
. O -

On O +
the O +
other O +
hand O -
, O +
DNA O +
adducts O +
B O +
and O +
D O +
were O +
undetectable O +
when O +
the O +
nuclease O +
P1 O +
enrichment O +
procedure O +
was O +
used O -
. O -

DNA O +
adduct O +
A O +
as O +
an O +
unknown O +
major O +
NF O +
adduct O +
may O +
be O +
the O +
same O +
DNA O +
adduct O +
as O +
that O +
described O +
by O +
Wierckx O +
et O +
al. O +
[ O -
7 O -
] O +
. O -

This O +
DNA O +
adduct O +
could O +
possibly O +
represent O +
an O +
oxidative O +
NF O +
metabolite O +
reacted O +
with O +
DNA O -
, O +
either O +
via O +
a O +
ring O +
epoxide O +
or O +
via O +
a O +
reaction O +
with O +
the O +
hydroxyl O +
group O -
. O -

It O +
was O +
reported O +
that O +
OH O -
- O -
NFs O +
are O +
potent O +
genotoxins O +
with O +
a O +
hydroxy O +
function O +
at O +
position O +
7 O +
or O +
9 O +
of O +
NF O -
, O +
while O +
hydroxylization O +
at O +
position O +
5 O +
makes O +
a O +
detoxification O +
product O +
[ O -
33 O -
] O +
. O -

DNA O +
adduct O +
B O -
, O +
which O +
was O +
sensitive O +
to O +
nuclease O +
P1 O +
hydrolyzation O -
, O +
could O +
possibly O +
be O +
an O +
arylamine O +
DNA O +
adduct O +
[ O -
34 O -
, O +
35 O -
] O +
. O -

Another O +
possibility O +
is O +
that O +
DNA O +
adduct O +
B O +
is O +
the O +
bis O -
- O -
phosphate O +
of O +
DNA O +
adduct O +
A. O +
Upon O +
nuclease O +
P1 O +
treatment O -
, O +
DNA O +
adduct O +
B O +
is O +
converted O +
to O +
DNA O +
adduct O +
A. O +
Since O +
DNA O +
adduct O +
levels O +
varied O +
after O +
different O +
enrichment O +
procedures O +
( O -
Fig. O +
7 O +
) O -
, O +
it O +
is O +
therefore O +
of O +
importance O +
to O +
relate O +
DNA O +
adduct O +
levels O +
to O +
specific O +
enrichment O +
procedures O -
. O -

Culp O +
et O +
al. O +
[ O -
36 O -
] O +
demonstrates O +
a O +
biphasic O +
removal O +
of O +
DNA O +
adducts O +
in O +
the O +
rat U-Species +
liver O +
after O +
administration O +
of O +
AAF O -
. O -

The O +
present O +
study O +
dealt O +
with O +
NF O -
, O +
which O +
is O +
mainly O +
but O +
not O +
completely O +
metabolized O +
to O +
AF O +
and O +
AAF O +
in O +
rats U-Species +
[ O -
2 O -
, O +
3 O -
, O +
5 O -
] O +
. O -

Two O +
DNA O +
adducts O -
, O +
i.e. O -
, O +
dG O -
- O -
C8-AF O +
and O +
dG O -
- O -
N O +
2 O +
-AAF O -
, O +
were O +
induced O +
in O +
the O +
rat U-Species +
liver O +
both O +
by O +
NF O +
( O -
present O +
study O -
) O +
and O +
AAF O +
[ O -
36 O -
] O +
. O -

Although O +
the O +
strain O +
of O +
the O +
rats U-Species +
and O +
length O +
of O +
administration O +
are O +
different O +
between O +
the O +
present O +
study O +
and O +
the O +
AAF O +
study O +
[ O -
36 O -
] O +
, O +
the O +
persistence O +
of O +
the O +
two O +
common O +
DNA O +
adducts O +
is O +
rather O +
consistent O -
. O -

Three O +
out O +
of O +
the O +
four O +
NF O -
- O -
DNA O +
adducts O +
were O +
still O +
detectable O +
in O +
rat U-Species +
liver O +
after O +
the O +
rats O +
were O +
on O +
basal O +
diet O +
for O +
11 O +
months O -
. O -

The O +
long O +
persistence O +
of O +
NF O -
- O -
DNA O +
adducts O +
may O +
increase O +
their O +
chances O +
to O +
be O +
fixed O +
as O +
mutations O -
. O -

In O +
conclusion O -
, O +
the O +
air O +
pollutant O +
NF O +
induces O +
mainly O +
four O +
DNA O +
adducts O -
. O -

Two O +
DNA O +
adducts O -
, O +
i.e. O -
, O +
adducts O +
C O +
and O +
D O -
, O +
are O +
characterized O +
as O +
dG O -
- O -
N O +
2 O +
-AAF O +
and O +
dG O -
- O -
C8-AF O -
, O +
respectively O -
. O -

DNA O +
adducts O +
A O +
and O +
B O -
, O +
with O +
structures O +
unknown O -
, O +
are O +
the O +
major O +
NF O -
- O -
DNA O +
adducts O +
after O +
11 O +
months O +
of O +
NF O +
feeding O -
. O -

NF O -
- O -
DNA O +
adducts O +
persist O +
long O +
after O +
the O +
withdrawal O +
of O +
NF O -
, O +
especially O +
DNA O +
adducts O +
A O +
and O +
C O +
which O +
are O +
repaired O +
only O +
to O +
a O +
minor O +
extent O +
over O +
a O +
period O +
that O +
corresponds O +
to O +
approximately O +
half O +
the O +
life O +
time O +
of O +
the O +
rats U-Species -
. O -

Three O +
out O +
of O +
the O +
four O +
NF O -
- O -
DNA O +
adducts O +
are O +
still O +
detectable O +
in O +
the O +
rat U-Species +
liver O +
11 O +
months O +
after O +
the O +
withdrawal O +
of O +
NF O +
feeding O -
. O -

Further O +
characterization O +
of O +
individual O +
NF O -
- O -
DNA O +
adducts O +
may O +
help O +
to O +
elucidate O +
the O +
mechanism O +
of O +
NF O -
- O -
induced O +
carcinogenesis O -
. O -

Acknowledgements O +
The O +
authors O +
wish O +
to O +
express O +
their O +
gratitude O +
to O +
Mary O -
- O -
Ann O +
Zetterqvist O +
for O +
skillful O +
technical O +
assistance O -
. O -

This O +
study O +
was O +
supported O +
by O +
grants O +
from O +
Swedish O +
Environmental O +
Protection O +
Agency O +
and O +
Swedish O +
Cancer O +
Society O -
. O +

Nausea O +
and O +
vomiting O +
are O +
frequent O +
side O +
effects O +
caused O +
by O +
cancer O +
chemotherapeutic O +
agents O -
. O -

Traditional O +
Chinese O +
herbal O +
drugs O +
with O -
anti O -
- O -
emetic O +
potential O +
can O +
be O +
used O +
to O +
prevent O +
them O -
. O -

However O -
, O +
the O +
effects O +
of O +
anti O -
- O -
emetic O +
active O +
principles O +
of O +
these O +
crude O +
drugs O -
need O +
to O +
be O +
studied O +
using O +
modern O +
pharmacological O +
methods O -
. O -

One O +
of O +
the O +
difficul­ties O +
in O +
testing O +
for O +
anti O -
- O -
emetic O +
activity O +
of O -
natural O +
prod­ucts O +
is O +
the O +
selection O +
of O +
adequate O +
animal U-Species +
models O -
. O -

We O +
previously O +
reported O +
anti O -
- O -
emetic O +
principles O +
from O +
Magnolia B-Species +
obovata L-Species +
bark O -
, O +
Zingiber B-Species +
officinale L-Species +
rhizome O +
( O -
Kawai O +
et O +
al. O -
, O +
1994 O -
) O -
, O -
Inula B-Species +
linariaefolia L-Species +
flowers O +
and O +
Forsythia B-Species +
suspensa L-Species +
fruits O +
( O -
Kinoshita O +
et O +
al. O -
, O +
1996 O -
) O -
, O +
and O +
Poria B-Species +
cocos L-Species +
( O -
Tai O +
et O +
al. O -
, O +
1995 O -
) O +
using O -
frogs U-Species +
as O +
test O +
sub­jects O -
. O -

The O +
long O +
emetic O +
latency O +
of O +
frogs U-Species +
induced O +
by O +
the O +
emetic O +
agent O +
was O +
not O +
suitable O +
for O +
testing O +
many O -
samples O +
within O +
a O +
short O +
period O +
of O +
time O -
. O -

Therefore O -
, O +
we O +
studied O +
a O +
new O +
screening O +
method O +
using O +
chicks U-Species +
for O +
anti O -
- O -
emetic O +
ac­tivity O -
( O -
Akita O +
et O +
al. O -
, O +
1998 O -
) O +
to O +
overcome O +
these O +
difficulties O -
. O -

The O +
present O +
paper O +
describes O +
the O +
screening O +
of O +
31 O +
ex­tracts O +
from O +
8 O +
traditional O +
Chinese O +
herbal O +
drugs O +
for O +
anti­emetic O +
activities O -
, O -
using O +
young O +
chicks U-Species -
, O +
and O +
the O +
identifica­tion O +
of O +
some O +
of O +
the O +
active O +
principles O +
contained O +
in O +
Po­gostemon B-Species +
cablin I-Species +
( I-Species -
Blanco I-Species -
) I-Species +
Benth L-Species -
. O -

Materials O +
and O +
Methods O -
Materials O -

The O +
dry O +
plant U-Species +
materials O +
used O +
here O +
were O +
commercial O +
products O -
. O -

Alpinia B-Species +
katsumadai L-Species +
seeds O -
, O +
Alpinia B-Species +
officina­rum L-Species +
rhizome O -
, O +
Amomum B-Species -
kravanh L-Species +
fruits O -
, O +
Amomum B-Species +
tsao I-Species -
- I-Species -
ko L-Species +
fruits O -
, O +
Amomum B-Species +
xanthioides L-Species +
fruits O -
, O +
Eupato­rium B-Species +
fortunei L-Species +
leaves O +
and O +
stem O -
, O +
and O +
Nelumbo B-Species +
nucifera L-Species -
seeds O +
were O +
purchased O +
from O +
Kotaro O +
Pharmaceutical O +
Co. O -
, O +
Ltd. O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O -

Pogostemon B-Species +
cab I-Species -
/ I-Species -
in L-Species +
leaves O +
were O +
purchased O +
from O -
Kinokuniya O +
Kanyakkyoku O +
( O -
To­kyo O -
, O +
Japan O -
) O -
. O -

Spectrometry O +
and O +
chromatography O -
lH_and13C O -
- O -
NMRspectrawererecorded O +
usingaJEOL O +
GSX-400 O +
spectrometer O +
in O +
CDCl3 O +
or O +
DMSO O -
- O -
d6 O +
with O +
tet­ramethylsilane O +
as O +
an O +
internal O -
standard O -
. O -

Kieselgel O +
60 O +
F254-precoated O +
plates O +
were O +
employed O +
for O +
thin O -
- O -
layer O +
chromatography O +
( O -
TLC O -
) O -
. O -

Column O +
chromatography O +
was O -
carried O +
out O +
on O +
70 O -
- O -
230 O +
mesh O +
silica O +
gel O -
. O -

HPLC O +
was O +
per­formed O +
using O +
an O +
SSC-3100-J O +
pump O +
with O +
an O +
Oyo O -
- O -
Bunko O +
Uvilog O +
7 O +
UV O +
detector O -
. O -

HR O -
- O -
MS O +
and O +
EI O -
- O -
MS O +
were O +
ob­tained O +
using O +
a O +
JEOL O +
JMX O -
- O -
DX O +
302 O -
. O -

0944 O -
- O -
7113 O -
/ O -
99106 O -
/ O -
02 O -
- O -
089 O +
$ O +
12.0010 O -
Y. O +
Yang O +
et O +
al. O -

Animals U-Species -
nally O +
at O +
a O +
volume O +
of O +
10 O +
rnl O -
/ O -
kg O -
. O -

After O +
10 O +
min O -
, O +
copper O +
sul­ O -
Young O +
male O +
chicks U-Species +
( O -
4 O +
days O +
of O +
age O -
) O +
weighing O +
25 O -
- O -
35 O +
g O +
fate O +
anhydride O +
was O +
administered O +
orally O +
at O +
50 O +
mg O -
/ O -
kg O -
, O -
each O +
were O +
purchased O +
from O +
Goto O +
Furanjo O +
Co. O -
, O +
Ltd. O +
( O -
Sai­then O +
the O +
number O +
of O +
retching O +
( O -
an O +
emetic O +
action O +
without O -
tama O -
, O +
Japan O -
) O -
. O -

vomiting O +
gastric O +
materials O -
) O +
was O +
recorded O +
during O +
the O +
next O +
10 O +
min O -
. O -

The O +
results O +
were O +
judged O +
by O +
the O +
decrease O +
in O -
Bioassay O +
of O +
anti O -
- O -
emetic O +
activity O +
number O +
of O +
retching O +
in O +
contrast O +
with O +
those O +
of O +
control O -
. O -

The O +
young O +
chicks U-Species +
were O +
divided O +
into O +
1 O -
- O -
3 O -
groups O +
con O +
­The O +
inhibition O +
( O -
% O -
) O +
was O +
calculated O +
as O +
follows O -
: O +
sisting O +
of O +
six O +
each O -
, O +
and O +
each O +
young O +
chick U-Species +
was O +
set O +
asi­de O +
for O +
10 O +
min O -
to O +
stabilize O +
in O +
large O +
beakers O +
at O +
25 O -
° O -
C O -
. O -

The O +
Inhibition O +
( O -
% O -
) O +
= O +
[ O -
( O -
A O -
- O -
B O -
) O -
A O -
] O +
X O +
100 O +
sample O +
was O +
dissolved O +
in O +
0.9 O +
% O +
saline O +
containing O +
5 O +
% O -
A O -
: O +
control O +
frequency O +
of O +
retching O +
DMSO O +
and O +
1 O +
% O +
Tween O +
80 O +
and O +
administered O +
abdomi O -
- O -
B O -
: O +
frequency O +
retching O +
after O +
sample O +
treatment O -
Table1 O -
. O -

Screeningtestofmedicinalplantsforanti O -
- O -
emeticeffectagainstcoppersulfate O -
- O -
inducedemesisinyoungchicks O -
. O -

Crude O +
drugs O +
Extracts O +
No. O +
of O +
young O +
chicks U-Species -
No. O +
of O +
retches O +
Inhibition O +
( O -
mean O +
± O +
S.E.M. O -
) O +
( O -
% O +
) O -
control O -

6 O -
69.8 O +
± O +
3.19 O -
Pogostemon B-Species +
cab I-Species -
/ I-Species -
in L-Species -
n O -
- O -
hexane O +
6 O +
28.9 O +
± O +
4.31 O -

* O -
* O -
* O +
58.6 O +
CHCl3 O +
6 O +
45.8 O +
± O +
6.75 O -
" O -
' O +
34.4 O +
MeOH O +
6 O +
47.8 O +
± O +
6.39 O -
" O +
31.5 O -
control O +
6 O -
70.6 O +
± O +
1.25 O -
Alpinia B-Species +
katsumadai L-Species -
n O -
- O -
hexane O +
6 O +
52.4 O +
±3.39 O -
* O -
* O +
25.8 O +
CHCl3 O +
6 O +
28.0 O +
± O +
5.09 O -

* O -

* O -

* O +
60.3 O +
MeOH O +
6 O +
18.4 O +
± O +
0.93 O -

* O -
* O -
* O +
73.9 O +
H2O O +
6 O +
46.2 O +
± O +
8.12 O -
34.6 O -
control O +
6 O -
48.8 O +
± O +
4.34 O -
Amomum B-Species +
tsao I-Species -
- I-Species -
ko L-Species -
n O -
- O -
hexane O +
6 O +
46.6 O +
± O +
3.29 O +
4.5 O +
CHCl3 O +
6 O +
36.6 O +
± O +
5.39 O +
25.6 O +
MeOH O +
6 O +
22.2 O +
± O +
3.28 O -

* O -

* O -
* O +
54.5 O +
H2O O +
6 O +
39.3 O +
± O +
7.23 O +
19.5 O -
control O +
6 O -
75.9 O +
± O +
1.38 O -
Amomum B-Species +
kravanh L-Species -
n O -
- O -
hexane O +
6 O +
78.6 O +
± O +
3.14 O +
-3.6 O +
CHCl3 O +
6 O +
36.0 O +
± O +
5.96 O -
* O -
* O +
52.6 O +
MeOH O +
6 O +
70.0 O +
± O +
11.0 O +
7.8 O +
H2O O +
6 O +
52.0 O +
±2.98 O -
" O +
31.5 O -
control O +
6 O -
64.5 O +
± O +
4.46 O -
Amomum B-Species +
xanthioides L-Species -
n O -
- O -
hexane O +
6 O +
41.8 O +
± O +
9.05 O -
* O +
35.2 O +
CHCI3 O +
6 O +
29.8 O +
± O +
3.94 O -

* O -

* O +
* O -

53.8 O +
MeOH O +
6 O +
34.8 O +
± O +
8.47 O -
* O +
46.0 O +
H2O O +
6 O +
43.5 O +
± O +
7.70 O -
' O -
: O -
' O -
32.6 O -
control O +
6 O -
68.2±2.31 O -
Eupatorium B-Species +
[ I-Species -
ortunei L-Species -
n O -
- O -
hexane O +
6 O +
61.3 O +
± O +
6.68 O +
10.1 O +
CHCI3 O +
6 O +
46.3 O +
± O +
7.32 O +
32.1 O +
MeOH O +
6 O +
50.8 O +
± O +
2.42 O -

* O -
* O +
* O +
25.5 O +
H2O O +
6 O +
54.2 O +
± O +
3.16 O -
* O +
20.5 O -
control O +
6 O +
86.8 O +
± O +
3.69 O +
Nelumbo B-Species +
nucifera L-Species +
n O -
- O -
hexane O +
6 O +
75.3 O +
± O +
9.81 O +
13.2 O +
CHCl3 O +
6 O +
63.2 O +
±3.06 O -
* O -
" O +
27.2 O +
MeOH O +
6 O +
77.6 O +
± O +
2.98 O +
10.6 O +
H2O O +
6 O -
71.6 O +
± O +
5.83 O +
17.6 O -
control O +
6 O -
44.5 O +
± O +
2.33 O -
Alpinia B-Species +
officinarum L-Species -
n O -
- O -
hexane O +
6 O +
37.5 O +
± O +
4.19 O +
15.7 O +
CHel3 O +
6 O +
24.2 O +
± O +
3.23 O -

* O -

* O -
* O +
45.6 O +
MeOH O +
6 O +
32.7 O +
± O +
3.74 O -
* O +
26.5 O +
H2O O +
6 O +
31.2 O +
± O +
4.26 O -
* O +
29.9 O -
Significantly O +
different O +
from O +
the O +
control O +
value O -
, O +
" O -
p O +
< O +
0.05 O -
, O +
" O -
" O -
p O +
< O +
0.01 O -
, O +
* O -
, O -
' O +
" O -
p O +
< O +
0.001 O -
. O -

fate O -
- O -
induced O +
emesis O +
in O +
young O +
chicks U-Species -
. O -

Drugs O -
Dose O -
No. O +
of O +
young O +
chicks U-Species -
No O +
. O -

of O +
retches O -
Inhibition O -
( O -
mg O -
/ O -
kg O -
) O -
( O -
rnean O +
e O +
SEM O -
) O -
( O -
% O -
) O -
control O -
6 O -
47 O +
.8 O +
: O -
! O -
: O +
6.14 O -
Fr O -
. O -

1 O -
150 O -
6 O -
37.4:!:5.17 O -
21.8 O -
Fr O -
. O -

2 O -
150 O -
6 O -
11.6 O -
: O -
! O -

: O -

7.08 O -
· O -
· O -
· O -
· O -
75 O -
. O +
7 O -
Fr O -
. O -

3 O -
150 O -
6 O -
7.6 O +
: O -
! O -

: O +
1.25 O -

* O -
* O -
" O -
84.1 O -
control O -
6 O -
45 O +
.0 O +
: O -
! O -
: O +
8.45 O -
Fr O -
. O -

4 O -
150 O -
6 O -
31.2:!:3.36 O -
30.7 O -
Fr O -
. O -

5 O -
150 O -
6 O -
25 O -
. O +
7 O -
: O -
! O -

: O +
6.92 O -
42.9 O -
Fr O -
. O -

6 O -
150 O -
6 O -
28.4 O +
: O -
! O -

: O +
6.95 O -
36.9 O -
control O -
6 O -
47.8 O +
: O -
! O -
: O +
6.14 O -
Fr O -
. O -

7 O -
150 O -
6 O -
21 O -
. O +
6 O +
: O -
! O -

: O +
4.25 O +
" O -
* O -
54.8 O -
Fr O -
. O -

8 O -
150 O -
6 O -
38.2 O +
: O -
! O -

: O -

7.87 O -
20.1 O -
Significantly O +
different O +
from O +
the O +
control O +
value O -
, O +
* O -
p O +
< O +
0.05 O -
, O -

* O -
* O -
p O +
< O +
0.01 O -
, O +
" O -

* O -
* O +
p O +
< O +
0.001 O -
. O -

Table O +
3 O -
. O -

Anti O -
- O -
emetic O +
effects O +
of O +
compounds O +
1 O -
- O -
5 O +
against O +
sulfate O -
- O -
induced O +
emesis O +
in O +
young O +
chicks U-Species -
. O -

Drugs O -
Dose O +
No. O +
of O +
young O +
chicks U-Species +
No. O +
of O +
retches O +
Inhibition O +
( O -
mg O -
/ O -
kg O -
) O +
( O -
mean O +
a O +
SEM O -
) O +
( O -
% O +
) O -
control O -
6 O +
60.0 O +
: O -
! O -

: O +
4.73 O -
patchouli O +
alcohol O +
( O -
1 O -
) O -
10 O +
6 O +
54.5 O +
: O -
! O -
: O +
7.58 O +
9.2 O +
20 O +
6 O +
50.3 O +
: O -
! O -

: O +
6.90 O +
16.2 O +
50 O +
6 O +
36.0 O -
: O -
! O -

: O +
3.69 O -

* O -
" O +
40.0 O +
70 O +
6 O +
25.4 O -
: O -
! O -

: O -

2.80 O -

* O -

* O -
" O +
57.7 O -
control O -
5 O +
67.2 O +
: O -
! O -
: O +
2.81 O -
pogostol O +
( O -
2 O -
) O -
10 O +
5 O +
40.8 O +
: O -
! O -

: O +
4.79 O -

* O -

* O +
39.3 O +
20 O +
5 O +
38.8 O +
: O -
! O -

: O +
8.73 O -
* O +
42.3 O +
50 O +
5 O +
38.2 O -
: O -
! O -

: O +
6.13 O -
" O -
* O +
43.2 O -
control O +
6 O +
55.7 O -
: O -
! O -
: O +
4.6 O +
stigmast-4-en-10 O +
6 O +
54.9 O -
: O -
! O -
: O +
8.80 O +
1.4 O +
3-one O +
( O -
3 O -
) O +
20 O +
6 O +
39.6 O +
: O -
! O -
: O -

7.48 O +
28.9 O +
50 O +
6 O +
24.7 O +
: O -
! O -

: O +
1.21 O +
" O -
> O -
' O -
* O +
55.7 O -
control O -
6 O +
67.5 O +
: O -
! O -
: O +
6.63 O -
retusin O +
( O -
4 O -
) O -
10 O +
6 O +
49.0 O -
: O -
! O -
: O +
6.97 O +
27.4 O +
20 O +
6 O +
48.0 O -
: O -
! O -
: O -

4.97 O -
* O +
28.9 O +
50 O +
6 O +
36.7:!:3.21 O -
* O -
* O +
45.6 O -
control O -
5 O +
56.6 O +
: O -
! O -
: O +
3.93 O -
pachypodol O +
( O -
5 O -
) O -
10 O +
5 O +
53.4 O -
: O -
! O -
: O +
3.93 O +
5.7 O +
20 O +
5 O +
44.6 O -
: O -
! O -

: O +
7.27 O +
21.2 O +
50 O +
5 O +
28.0 O +
: O -
! O -

: O +
3.09 O -
' O -
' O -
' O -
' O -
* O +
50.5 O -
Significantly O +
different O +
from O +
the O +
control O +
value O -
, O +
" O -
p O +
< O +
0.05 O -
, O +
* O -
" O -
p O +
< O +
0.01 O -
, O +
* O -

* O -
" O -
p O +
< O +
0.001 O -
. O -

Statistical O +
analysis O +
was O +
concentrated O +
to O +
yield O +
n O -
- O -
hexane O -
, O +
CHCI3 O -
, O +
MeOH O -
, O +
All O +
numerical O +
data O +
were O +
expressed O +
as O +
the O +
mean O +
: O -
t O +
and O -
water O +
extracts O -
, O +
respectively O -
. O -

S.E.M. O +
The O +
statistical O +
significance O +
of O +
the O +
difference O +
was O +
determined O +
by O +
an O +
unpaired O +
student O -
's O +
z O -
- O -
test O -
, O -
Isolation O +
and O +
purification O +
of O +
the O +
anti O -
- O -
emetic O +
principles O +
from O +
Pogostemon B-Species +
cablin L-Species +
Preparation O +
of O +
extract O +
The O +
crushed O +
dry O +
leaves O -
of O +
Pogostemon B-Species +
cablin L-Species +
( O -
1 O +
kg O -
) O -
Crusheddryplantmaterials O -
( O -
1kg O -
) O -
wereextractedthree O +
wereextractedsuccessivelywithn O -
- O -
hexane O -
, O -
CHCI3,and O +
timessuccessively O -
with4In O -
- O -
hexane O -
, O -
CHCI3,MeOH O +
MeOH O -
, O +
andeach O +
extractwasexaminedforanti O -
- O -
emetic O +
and O +
water O +
at O +
room O +
temperature O +
for O +
24 O +
h. O -

Each O +
extract O -
activity O +
using O +
young O +
chicks U-Species -
. O -

The O +
n O -
- O -
hexane O +
extract O -
Y. O +
Yang O +
et O +
al. O -
patchouli O +
alcohol O -
( O -
1 O -
) O +
pogostol O +
( O -
2 O -
) O -
sigmast-4-en-3-one O +
( O -
3 O -
) O -
OCHa O +
OH O +
HaCO O +
HaCO O -
OCHa O +
OCH3 O -
OH0 O +
OH0 O -
pachypodol O +
( O -
5 O -
) O -
retusin O -
( O -
4 O -
) O +
Fig. O +
1 O -
. O -

The O +
structures O +
of O +
active O +
compounds O +
isolated O +
from O +
Pogostemon B-Species +
cab I-Species -
/ I-Species -
in I-Species +
Benth L-Species -
which O +
showed O +
the O +
highest O +
anti O -
- O -
emetic O +
activity O +
( O -
58.6 O +
% O -
) O +
was O +
chromatographed O +
on O +
a O +
silica O +
gel O +
column O +
( O -
n O -
- O -
hex­ane O -
: O +
EtOAc O -
) O -
, O +
and O +
8 O -
fractions O +
( O -
fr O -
, O +
1 O -
- O -
8 O -
) O +
obtained O -
. O -

Each O +
fraction O +
was O +
tested O +
for O +
anti O -
- O -
emetic O +
activity O -
, O +
and O +
fro O +
2 O -
, O +
fro O +
3 O -
, O +
fro O +
7 O +
showed O +
positive O +
activity O +
( O -
Table O +
2 O -
) O -
. O -

Fraction O +
2 O +
was O -
subjected O +
to O +
HPLC O +
using O +
a O +
silica O +
gel O +
co­lumn O +
[ O -
Silica-4251-N O +
10 O +
0 O +
X O +
250 O +
mm O -
, O +
n O -
- O -
Hexane­EtOAc O +
( O -
11:1 O -
) O -
] O -
, O +
and O +
compound O +
1 O +
( O -
l.72 O -
g O -
) O +
was O -
obtained O +
and O +
identified O +
as O +
patchouli O +
alcohol O +
by O +
comparison O +
with O +
published O +
spectral O +
data O +
( O -
Barton O +
et O +
al. O -
, O +
1987 O -
) O -
. O -

An O +
active O +
fraction O -
, O +
fro O +
3 O -
, O +
was O +
chromatographed O +
on O +
a O +
silica O +
gel O +
column O +
( O -
n O -
- O -
hexane O -
: O +
acetone O -
) O +
and O +
HPLC O +
using O +
a O +
silica O +
gel O +
column O -
[ O -
Silica-4251-N O +
100 O +
X O +
250 O -
mm O -
, O +
n­Hexane O -
- O -
EtOAc O +
( O -
5:1 O -
) O -
] O -
. O -

Compounds O +
2 O +
( O -
79.7 O +
mg O -
) O +
and O +
3 O -
( O -
41.3 O +
mg O -
) O +
were O +
identified O +
as O +
pogostol O +
and O +
stigmast-4­en O -
- O -
S O -
- O -
one O +
by O +
comparison O +
with O +
published O +
spectral O +
data O +
( O -
Hikino O +
et O +
al. O -
, O +
1968 O -
; O -
Greca O +
et O +
al. O -
, O +
1990 O -
) O -
. O -

Fraction O +
7 O +
was O +
subjected O +
to O +
on O +
HPLC O +
using O +
a O +
silica O +
gel O +
column O +
[ O -
Silica-4251-N O +
100 O +
X O +
250 O -
mm O -
, O +
n O -
- O -
Hexane­acetone O +
( O -
75:25 O -
) O -
] O -
, O +
and O -
compounds O +
4 O +
( O -
62.6 O +
mg O -
) O +
and O +
5 O -
( O -
48.0 O +
mg O -
) O +
were O +
obtained O +
and O +
examined O +
by O +
MS O -
, O +
lH O -
_ O +
and O +
13C O -
- O -
NMR O -
, O +
DEPT O +
experiment O -
, O +
IH_13C O +
COSY O -
, O +
IH_13C O +
long O +
range O +
COSY O +
( O -
COLOq O +
and O -
the O +
difference O +
of O +
Overhauser O +
enhancement O +
( O -
nOe O -
) O +
spectra O -
. O -

These O +
obser­ O -
vations O +
suggested O +
that O +
compounds O +
4 O +
and O +
5 O +
were O +
retusin O +
and O +
pachypodol O -
, O +
respectively O -
. O -

Results O +
and O +
Discussion O -
As O +
shown O +
in O +
Table O +
1,20 O +
extracts O +
significantly O +
inhibited O +
emetic O +
action O +
induced O +
by O +
CUS04 O +
in O +
young O +
chicks U-Species -
. O -

The O +
n O -
- O -
hexane O -
, O +
CHCl3 O -
and O +
MeOH O +
extracts O +
of O +
Pogostemon B-Species +
cablin L-Species +
showed O +
significant O +
inhibition O +
at O +
a O +
dose O +
of O +
300 O +
mg O -
/ O -
kg O -
. O -

Patchouli O +
alcohol O +
( O -
1 O -
) O -
, O +
pogostol O -
( O -
2 O -
) O -
, O +
stigmast-4­en-3-one O +
( O -
3 O -
) O -
, O +
retusin O +
( O -
4 O -
) O +
and O +
pachypodol O +
( O -
5 O -
) O +
previously O +
isolated O +
from O +
the O +
n O -
- O -
hexane O +
extract O +
( O -
Barton O +
et O +
al. O -
, O -
1987 O -
; O +
Hinoki O +
et O +
al. O -
, O +
1968 O -
; O +
Greca O +
et O +
al. O -
, O +
1990 O -
; O +
Dominquez O +
et O +
al. O -
, O +
1968 O -
; O +
Valesi O +
et O +
al. O -
, O +
1972 O -
) O +
also O +
showed O +
anti O -
- O -
emetic O +
activity O -
Patchouli O +
alcohol O +
( O -
1 O -
) O +
was O +
active O +
at O +
two O +
doses O +
of O +
50 O +
mg O -
/ O -
kg O +
and O +
70 O +
mg O -
/ O -
kg O -
. O -

Pogostol O +
( O -
2 O -
) O +
significantly O +
inhibit­ed O +
emetic O +
action O +
at O -
three O +
doses O +
of O +
10 O +
mg O -
/ O -
kg-50 O +
mg O -
/ O -
kg O -
. O -

Stigmast-4-en-3-one O +
( O -
3 O -
) O +
and O +
pachypodol O +
( O -
5 O -
) O +
showed O +
anti O -
- O -
emetic O +
activity O +
at O +
doses O +
of O +
50 O +
mg O -
/ O -
kg O -
. O -

Retusin O +
( O -
4 O -
) O +
inhibited O +
emetic O +
action O +
at O +
two O +
doses O +
of O +
20 O +
mg O -
/ O -
kg O +
and O +
50 O +
mg O -
/ O -
kg O -
. O -

Pogostemon B-Species +
cablin L-Species +
is O +
one O +
of O +
the O +
traditional O +
Chinese O +
medicines O +
used O +
mainly O +
for O +
the O +
treatment O +
of O +
dyspepsia O -
, O +
vomiting O -
, O +
diarrhea O -
and O +
poor O +
appetite O -
. O -

It O +
is O +
also O +
known O +
that O +
inward O +
Ca2 O -
+ O +
influx O +
through O +
the O +
cell O +
membranes O +
may O +
induce O +
excessive O +
excitation O +
of O -
smooth O +
muscles O -
, O +
and O +
excessive O +
contraction O +
of O +
digestive O +
organ O +
muscles O +
may O +
cause O +
vomiting O +
and O +
diarrhea O -
. O -

Therefore O -
, O +
the O +
Ca2 O +
+ O -
antagonist O +
is O +
expected O +
to O +
alleviate O +
those O +
symptoms O +
by O +
depressing O +
excessive O +
contraction O +
of O +
digestive O +
organ O +
muscles O -
. O -

It O +
has O +
been O -
reported O +
that O +
patchouli O +
alcohol O +
showed O +
Ca2 O -
+ O +
antagonist O +
activity O +
in O +
vitro O +
( O -
Ichikawa O +
et O +
al. O -
, O +
1989 O -
) O -
. O -

These O +
results O +
indicate O +
that O -
the O +
anti O -
- O -
emetic O +
activity O +
of O +
patchouli O +
alcohol O +
may O +
be O +
due O +
to O +
depressing O +
excessive O +
contraction O +
of O +
digestive O +
organ O +
muscles O +
by O -
in­hibition O +
of O +
inward O +
Ca2 O -
+ O +
influx O +
through O +
the O +
cell O +
embra­nes O -
. O -

Patchouli O +
alcohol O +
contained O +
abundantly O +
in O +
Po­gostemon B-Species +
cablin L-Species +
( O -
> O -
0.1 O +
% O -
) O +
may O +
playa O +
main O +
role O +
in O +
anti O -
- O -
emetic O +
effect O +
clinically O +
in O +
view O +
of O +
its O +
traditional O +
use O +
in O +
Chinese O +
medicine O -
. O -

Acknowledgements O -
The O +
authors O +
would O +
like O +
to O +
thank O +
Professor O +
emeritus O +
Shoji O +
Shibata O -
, O +
University O +
of O +
Tokyo O -
, O +
for O +
his O +
encouragement O -
. O -

This O +
study O +
was O -
partly O +
supported O +
by O +
a O +
Sasakawa O +
Scientific O +
Research O +
Grant O +
from O +
the O +
Japan O +
Science O +
Society O +
( O -
1996 O -
- O -
7 O -
) O -
. O -

Anti O -
- O -
emetic O +
principles O +
of O +
Pogostemon B-Species +
cablin L-Species +

SCH66336 O -
, O +
( O -
+ O -
) O +
4- O -
{ O -
2- O -
[ O -
4- O -
( O -
8-chloro-3 O -
, O +
10-dibromo-6 O -
, O +
11-dihydro-5H O -
- O -
benzo O +
[ O -
5,6 O -
] O -
cyclohepta O +
[ O -
1,2-b O -
] O +
pyridin-11-yl O -
) O -
-1-piperidinyl O -
] O -
-2-oxoethyl O -
} O -
-1-piperidinecarboxamide O +
( O -
Fig. O +
1 O -
) O -
, O +
is O +
a O +
potent O +
inhibitor O +
of O +
farnesyl O +
protein O +
transferase O +
( O -
FPT O -
) O -
. O -

FPT O +
catalyzes O +
the O +
initial O +
step O +
in O +
the O +
post O -
- O -
translational O +
processing O +
of O +
the O +
ras O -
gene O -
, O +
that O +
is O -
, O +
the O +
transfer O +
of O +
the O +
15-carbon O +
farnesyl O +
group O +
onto O +
a O +
cysteine O +
residue O +
in O +
the O +
carboxy O +
terminal O +
of O +
all O +
Ras O +
proteins O +
[ O -
1–6 O -
] O +
. O -

The O +
farnesylation O +
step O +
appears O +
to O +
be O +
essential O +
for O +
Ras O +
proteins O +
to O +
become O +
membrane O -
- O -
associated O +
and O +
induces O +
cell O +
transformation O +
[ O -
4 O -
] O +
. O -

In O +
normal O +
cells O -
, O +
Ras O +
protein O +
in O +
its O +
active O +
GTP O -
- O -
bound O +
state O +
initiates O +
several O +
intracellular O +
signaling O +
pathways O +
that O +
lead O +
to O +
cell O +
proliferation O +
and O +
differentiation O -
. O -

The O +
signal O +
is O +
terminated O +
by O +
the O +
hydrolysis O +
of O +
GTP O +
to O +
the O +
inactive O +
GDP O -
- O -
bound O +
form O +
of O +
the O +
Ras O +
protein O +
[ O -
7 O -
] O +
. O -

The O +
capacity O +
of O +
certain O +
oncogenic O +
forms O +
of O +
Ras O +
to O +
hydrolyze O +
GTP O +
to O +
GDP O +
is O +
greatly O +
reduced O -
, O +
leading O +
to O +
continuous O +
intracellular O +
signaling O +
which O +
results O +
in O +
alteration O +
of O +
cellular O +
proliferation O +
and O +
differentiation O +
[ O -
4,8 O -
] O +
. O -

Oncogenic O +
forms O +
of O +
Ras O +
proteins O +
have O +
been O +
reported O +
to O +
be O +
associated O +
with O +
nearly O +
one O -
- O -
third O +
of O +
all O +
human U-Species +
cancers O -
, O +
including O +
50 O -
% O +
of O +
colon O +
cancers O +
and O +
90 O -
% O +
of O +
pancreatic O +
cancers O +
[ O -
4 O -
] O +
. O -

Blocking O +
the O +
farnesylation O +
step O +
by O +
inhibiting O +
FPT O +
is O +
an O +
attractive O +
target O +
for O +
the O +
discovery O +
of O +
compounds O +
with O +
anti O -
- O -
tumor O +
activity O +
[ O -
9 O -
] O +
. O -

This O +
form O +
of O +
therapy O +
has O +
enormous O +
potential O +
because O +
of O +
the O +
prevalance O +
of O +
mutated O +
ras O -
gene O +
in O +
human U-Species +
cancers O +
[ O -
4,10 O -
] O +
. O -

In O +
vivo O +
studies O +
in O +
nude O +
mice U-Species +
demonstrated O +
that O +
SCH O +
66336 O +
has O +
a O +
potent O +
oral O +
activity O +
profile O +
in O +
a O +
wide O +
array O +
of O +
human U-Species +
tumor O +
xenograft O +
models O +
including O +
tumors O +
of O +
colon O -
, O +
lung O -
, O +
pancreas O -
, O +
prostate O -
, O +
and O +
urinary O +
bladder O +
origin O +
[ O -
11 O -
] O +
. O -

When O +
used O +
to O +
treat O +
Ha O -
- O -
Ras O +
transgenic O +
mice U-Species +
with O +
spontaneously O +
occurring O +
tumors O +
prior O +
to O +
tumor O +
onset O -
, O +
SCH O +
66336 O +
delayed O +
tumor O +
onset O -
, O +
reduced O +
the O +
average O +
number O +
of O +
tumors O +
per O +
mouse U-Species +
and O +
reduced O +
the O +
average O +
tumor O +
weight O +
per O +
animal U-Species +
[ O -
11 O -
] O +
. O -

In O +
a O +
therapeutic O +
mode O -
, O +
where O +
gavage O +
treatment O +
was O +
initiated O +
after O +
the O +
transgenic O +
mice U-Species +
had O +
developed O +
palpable O +
tumors O -
, O +
significant O +
tumor O +
regression O +
was O +
induced O +
by O +
SCH O +
66336 O +
in O +
a O +
dose O -
- O -
dependent O +
fashion O +
[ O -
11 O -
] O +
. O -

The O +
issue O +
of O +
chirality O +
has O +
emerged O +
as O +
a O +
major O +
theme O +
in O +
drug O +
design O +
and O +
discovery O +
[ O -
12,13 O -
] O +
. O -

Since O +
enantiomers O +
often O +
differ O +
in O +
pharmacological O +
activity O -
, O +
toxicity O +
and O +
pharmacokinetics O +
characteristics O -
, O +
it O +
is O +
important O +
that O +
enantiomeric O +
drug O +
candidates O +
be O +
evaluated O +
in O +
an O +
optically O +
pure O +
form O -
. O -

SCH O +
66336 O +
is O +
a O +
single O +
enantiomer O +
which O +
contains O +
one O +
chiral O +
center O -
. O -

During O +
the O +
discovery O +
stage O +
of O +
this O +
compound O -
, O +
it O +
was O +
of O +
interest O +
to O +
determine O +
its O +
pharmacokinetics O +
and O +
possible O +
chiral O +
inversion O +
in O +
animals U-Species +
prior O +
to O +
administration O +
in O +
humans U-Species -
. O -

Therefore O -
, O +
these O +
studies O +
were O +
initiated O +
to O +
develop O +
HPLC O +
methods O +
for O +
its O +
determination O +
in O +
cynomolgus B-Species +
monkey L-Species +
plasma O +
and O +
for O +
the O +
evaluation O +
of O +
its O +
chiral O +
inversion O +
in O +
rat U-Species +
and O +
cynomolgus B-Species +
monkey L-Species +
plasma O +
that O +
had O +
been O +
dosed O +
with O +
SCH O +
66336 O -
. O -

2 O +
Experimental O +
2.1 O +
Reagents O +
Hexane O -
, O +
methanol O -
, O +
acetonitrile O -
, O +
methylene O +
chloride O -
, O +
ethanol O -
, O +
diethyl O +
amine O +
and O +
sodium O +
bicarbonate O +
were O +
purchased O +
from O +
Fisher O +
Scientific O +
( O -
Fair O +
Lawn O -
, O +
NJ O -
, O +
USA O -
) O -
. O -

SCH O +
66336 O -
, O +
SCH O +
66337 O +
( O -
enantiomer O +
of O +
SCH O +
66336 O -
) O +
and O +
SCH O +
66347 O +
( O -
internal O +
standard O +
for O +
the O +
chiral O +
assay O -
) O +
were O +
provided O +
by O +
Schering O -
- O -
Plough O +
Research O +
Institute O +
( O -
Kenilworth O -
, O +
NJ O -
, O +
USA O -
) O -
. O -

Azatadine O +
maleate O +
( O -
internal O +
standard O +
for O +
the O +
achiral O +
assay O -
) O +
was O +
obtained O +
from O +
U.S. O +
Pharmacopeial O +
Convention O -
, O +
Inc. O +
( O -
Rockville O -
, O +
MD O -
, O +
USA O -
) O -
. O -

2.2 O +
Calibration O +
standards O +
For O +
the O +
achiral O +
HPLC O +
analysis O -
, O +
stock O +
solution O +
of O +
SCH O +
66336 O +
was O +
prepared O +
in O +
methanol O +
at O +
200 O +
μg O -
/ O -
ml O -
; O +
the O +
internal O +
standard O +
was O +
prepared O +
in O +
water O +
at O +
100 O +
μg O -
/ O -
ml O -
. O -

The O +
stock O +
solutions O +
were O +
stored O +
at O +
−20 O -
° O -
C O -
. O -

Eight O +
calibration O +
standards O +
( O -
at O +
0.1 O -
, O +
0.2 O -
, O +
0.5 O -
, O +
1 O -
, O +
2 O -
, O +
5 O -
, O +
10 O -
, O +
and O +
20 O +
μg O -
/ O -
ml O -
) O +
were O +
prepared O +
in O +
triplicate O +
on O +
each O +
of O +
three O +
validation O +
days O -
. O -

Three O +
sets O +
of O +
quality O +
control O +
samples O +
( O -
QC O +
samples O -
) O +
at O +
concentration O +
of O +
0.2 O +
( O -
low O -
) O -
, O +
1.5 O +
( O -
medium O -
) O +
and O +
15 O +
μg O -
/ O -
ml O +
( O -
high O -
) O +
were O +
prepared O +
in O +
bulk O +
from O +
separate O +
weighing O -
, O +
aliquotted O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
for O +
use O +
during O +
the O +
entire O +
validation O +
and O +
sample O +
analysis O -
. O -

For O +
the O +
chiral O +
HPLC O +
assay O -
, O +
stock O +
solutions O +
of O +
SCH O +
66336 O -
, O +
SCH O +
66337 O +
and O +
SCH O +
66347 O +
were O +
prepared O +
in O +
methanol O +
at O +
100 O +
μg O -
/ O -
ml O +
and O +
stored O +
at O +
−20 O -
° O -
C O -
. O -

Three O +
sets O +
of O +
quality O +
control O +
samples O +
at O +
concentration O +
of O +
0.4 O +
( O -
low O -
) O -
, O +
2.5 O +
( O -
medium O -
) O +
and O +
8.0 O +
μg O -
/ O -
ml O +
( O -
high O -
) O +
were O +
prepared O +
in O +
bulk O +
from O +
separate O +
weighings O -
, O +
aliquotted O +
and O +
stored O +
at O +
−20 O -
° O -
C O +
for O +
use O +
during O +
the O +
entire O +
validation O +
and O +
sample O +
analysis O -
. O -

2.3 O +
Sample O +
preparation O +
For O +
the O +
achiral O +
assay O -
, O +
a O +
0.2-ml O +
volume O +
of O +
monkey U-Species +
plasma O +
standard O -
, O +
QC O +
sample O +
or O +
unknown O +
was O +
placed O +
into O +
a O +
15-ml O +
screw O -
- O -
capped O +
test O +
tube O +
containing O +
0.2 O +
ml O +
of O +
internal O +
standard O +
solution O +
( O -
2 O +
μg O -
/ O -
ml O -
) O -
. O -

Saturated O +
sodium O +
bicarbonate O +
solution O +
( O -
0.3 O +
ml O -
) O +
was O +
added O +
followed O +
by O +
4.0 O +
ml O +
of O +
30 O -
% O +
( O -
v O -
/ O -
v O -
) O +
methylene O +
chloride O +
in O +
hexane O -
, O +
mixed O +
on O +
a O +
mechanical O +
vortexer O +
for O +
10 O +
min O +
and O +
centrifuged O -
. O -

The O +
organic O +
layer O +
was O +
transferred O +
into O +
15-ml O +
conical O +
test O +
tubes O +
and O +
20 O +
μl O +
of O +
0.8 O +
M O -
HCl O +
in O +
methanol O +
was O +
added O -
. O -

The O +
samples O +
were O +
evaporated O +
to O +
dryness O +
at O +
40 O -
° O -
C O +
under O +
a O +
gentle O +
stream O +
of O +
nitrogen O -
, O +
the O +
residue O +
was O +
reconstituted O +
in O +
0.2 O +
ml O +
of O +
mobile O +
phase O +
and O +
50 O +
μl O +
was O +
injected O +
onto O +
the O +
HPLC O +
column O +
for O +
analysis O -
. O -

For O +
the O +
chiral O +
analysis O -
, O +
a O +
0.2-ml O +
volume O +
of O +
rat U-Species +
or O +
monkey U-Species +
plasma O +
standard O -
, O +
QC O +
sample O -
, O +
or O +
unknown O +
was O +
applied O +
onto100 O +
mg O +
of O +
the O +
solid O -
- O -
phase O +
extraction O +
( O -
SPE O -
) O +
cartridge O +
ethyl O +
Bond O +
Elute O +
cartridge O +
which O +
has O +
been O +
pre O -
- O -
washed O +
with O +
3 O +
ml O +
of O +
methanol O +
and O +
3 O +
ml O +
of O +
water O -
. O -

The O +
SPE O +
cartridge O +
was O +
washed O +
with O +
2 O +
ml O +
of O +
water O +
and O +
2 O +
ml O +
of O +
10 O -
% O +
( O -
v O -
/ O -
v O -
) O +
acetonitrile O +
in O +
water U-Species -
. O -

The O +
compounds O +
were O +
eluted O +
with O +
3 O +
ml O +
of O +
acetonitrile O -
. O -

The O +
eluate O +
was O +
evaporated O +
to O +
dryness O +
under O +
nitrogen O +
and O +
the O +
residue O +
was O +
reconstituted O +
with O +
0.5 O +
ml O +
of O +
mobile O +
phase O -
; O +
a O +
0.1 O +
ml O +
aliquot O +
was O +
injected O +
onto O +
the O +
HPLC O +
column O +
for O +
analysis O -
. O -

2.4 O +
Chromatographic O +
conditions O +
The O +
HPLC O +
system O +
consisted O +
of O +
a O +
Shimadzu O +
LC-10 O +
AD O +
pump O +
and O +
a O +
Waters O +
486 O +
absorbance O +
detector O +
set O +
at O +
280 O +
nm O -
. O -

The O +
achiral O +
separation O +
was O +
accomplished O +
on O +
a O +
Spherisorb O +
CN O -
, O +
5 O +
μm O -
, O +
150 O -
× O -
4.6 O +
mm O +
column O +
which O +
was O +
preceded O +
by O +
an O +
on O -
- O -
line O +
filter O -
. O -

The O +
Millennium O +
2020 O +
Chromatography O +
Manager O +
Soft O +
System O +
was O +
used O +
for O +
data O +
handling O -
. O -

The O +
mobile O +
phase O +
consisted O +
of O +
0.02 O +
M O -
potassium O +
phosphate O +
( O -
pH O +
4 O -
) O -
–acetonitrile O +
( O -
65:35 O -
, O +
v O -
/ O -
v O -
) O -
, O +
and O +
was O +
delivered O +
at O +
0.9 O +
ml O -
/ O -
min O -
. O -

The O +
chiral O +
HPLC O +
method O +
involved O +
the O +
use O +
of O +
a O +
Chiral O +
Pak O +
AD O +
column O +
( O -
Chiral O +
Technologies O -
, O +
Eaton O -
, O +
PA O -
) O +
set O +
at O +
39 O -
° O -
C O +
and O +
a O +
mobile O +
phase O +
of O +
hexane O -
– O -
ethanol O -
– O -
diethylamine O +
( O -
30:70:0.2 O -
, O +
v O -
/ O -
v O -
/ O -
v O -
) O +
at O +
a O +
flow O +
of O +
0.8 O +
ml O -
/ O -
min O -
. O -

2.5 O +
Administration O +
of O +
SCH O +
66336 O +
Six O +
male O +
cynomolgus B-Species +
monkeys L-Species +
were O +
dosed O +
orally O +
with O +
a O +
100-mg O +
experimental O +
tablet O +
of O +
SCH O +
66336 O +
( O -
approximately O +
15 O +
mg O -
/ O -
kg O -
) O +
for O +
pharmacokinetic O +
evaluation O -
. O -

Also O -
, O +
rats U-Species +
and O +
cynomolgus B-Species +
monkeys L-Species +
were O +
given O +
SCH O +
66336 O +
at O +
a O +
single O +
oral O +
dose O +
of O +
300 O +
and O +
120 O +
mg O -
/ O -
kg O -
, O +
respectively O -
, O +
as O +
a O +
suspension O +
in O +
0.4 O -
% O +
methylcellulose O +
for O +
the O +
evaluation O +
of O +
chiral O +
inversion O +
of O +
SCH O +
66336 O -
. O -

Blood O +
samples O +
were O +
collected O +
at O +
intervals O +
after O +
dosing O -
, O +
centrifuged O +
and O +
plasma O +
stored O +
at O +
−20 O -
° O -
C O +
pending O +
analysis O -
. O -

Plasma O +
concentrations O +
equal O +
to O +
or O +
above O +
the O +
limit O +
of O +
quantitation O +
( O -
LOQ O -
, O +
0.1 O +
μg O -
/ O -
ml O -
) O +
were O +
used O +
for O +
pharmacokinetic O +
analysis O +
using O +
model O -
- O -
independent O +
methods O +
[ O -
14 O -
] O +
. O -

The O +
maximum O +
plasma O +
concentration O +
( O -
C O +
max O +
) O +
and O +
time O +
of O +
maximum O +
plasma O +
concentration O +
( O -
T O +
max O +
) O +
were O +
the O +
observed O +
values O -
. O -

The O +
area O +
under O +
the O +
plasma O +
concentration O -
– O -
time O +
curve O +
from O +
time O +
zero O +
to O +
the O +
time O +
of O +
the O +
final O +
measurable O +
sample O +
[ O -
AUC O -
( O -
tf O -
) O -
] O +
was O +
calculated O +
using O +
the O +
linear O +
trapezoidal O +
method O -
, O +
and O +
was O +
extrapolated O +
to O +
infinity O +
( O -
I O +
) O +
according O +
to O +
the O +
following O +
equation O -
: O -
AUC O -
( O -
I O +
) O -
= O -
AUC O -
( O -
tf O -
) O -
+C O +
( O -
tf O -
) O -
/ O -
k O -
where O +
C O +
( O -
tf O -
) O +
is O +
the O +
estimated O +
concentration O +
at O +
tf O +
using O +
the O +
above O +
regression O -
. O -

3 O +
Results O +
3.1 O +
Achiral O +
HPLC O +
Typical O +
chromatograms O +
of O +
drug O -
- O -
free O +
monkey U-Species +
plasma O +
and O +
plasma O +
spiked O +
with O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
azatadine O +
maleate O +
are O +
illustrated O +
in O +
Fig. O +
2 O -
. O -

The O +
retention O +
times O +
of O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
were O +
approximately O +
7.2 O +
and O +
10.5 O +
min O -
, O +
respectively O -
. O -

There O +
were O +
no O +
endogenous O +
peaks O +
in O +
plasma O +
of O +
six O +
undosed O +
monkeys U-Species +
that O +
coeluted O +
with O +
SCH O +
66336 O +
or O +
the O +
internal O +
standard O -
, O +
indicating O +
that O +
the O +
method O +
was O +
selective O -
. O -

The O +
linearity O +
of O +
the O +
assay O +
was O +
evaluated O +
over O +
a O +
concentration O +
range O +
of O +
0.1–20 O +
μg O -
/ O -
ml O -
. O -

Linear O +
regression O +
parameters O +
of O +
the O +
peak O +
height O +
ratios O +
versus O +
concentrations O +
along O +
with O +
back O -
- O -
calculated O +
concentrations O +
of O +
nine O +
calibration O +
curves O +
are O +
presented O +
in O +
Table O +
1 O -
. O -

The O +
results O +
showed O +
highly O +
reproducible O +
calibration O +
curves O +
with O +
correlation O +
coefficients O +
of O +
> O -
0.99 O -
, O +
indicating O +
that O +
the O +
response O +
was O +
linear O +
over O +
the O +
concentration O +
range O +
studied O -
. O -

Intra O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
evaluated O +
at O +
SCH O +
66336 O +
concentrations O +
of O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
. O -

Six O +
samples O +
were O +
analyzed O +
at O +
each O +
concentration O +
on O +
the O +
same O +
day O -
. O -

The O +
results O +
showed O +
satisfactory O +
intra O -
- O -
day O +
precision O +
and O +
accuracy O +
as O +
indicated O +
by O +
a O +
coefficient O +
of O +
variation O +
( O -
CV O -
) O +
of O +
< O -
2.5 O -
% O +
and O +
a O +
bias O +
of O +
< O -
5.1 O -
% O +
( O -
Table O +
2 O -
) O -
. O -

Inter O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
evaluated O +
at O +
the O +
same O +
concentrations O +
as O +
above O +
and O +
the O +
samples O +
were O +
analyzed O +
on O +
three O +
separate O +
days O -
. O -

The O +
results O +
demonstrated O +
satisfactory O +
inter O -
- O -
day O +
precision O +
and O +
accuracy O +
as O +
shown O +
by O +
CV O +
and O +
bias O +
values O +
of O +
< O -
3.4 O -
% O +
and O +
< O -
6.1 O -
% O -
, O +
respectively O +
( O -
Table O +
3 O -
) O -
. O -

The O +
LOQ O -
, O +
defined O +
as O +
the O +
lowest O +
concentration O +
in O +
the O +
calibration O +
curve O +
that O +
could O +
be O +
determined O +
with O +
acceptable O +
precision O +
and O +
accuracy O -
, O +
was O +
0.1 O +
μg O -
/ O -
ml O -
. O -

At O +
this O +
concentration O -
, O +
the O +
precision O +
and O +
accuracy O +
from O +
the O +
back O -
- O -
calculated O +
concentrations O +
were O +
satisfactory O +
( O -
CV=5 O -
% O -
, O +
bias O +
0 O -
% O -
; O +
Table O +
1 O +
) O -
. O -

The O +
recovery O +
was O +
consistent O +
over O +
a O +
concentration O +
range O +
of O +
0.2–15 O +
μg O -
/ O -
ml O +
( O -
> O -
83 O -
% O -
) O -
. O -

The O +
recovery O +
of O +
the O +
internal O +
standard O +
at O +
the O +
concentration O +
used O +
( O -
2.0 O +
μg O -
/ O -
ml O -
) O +
was O +
88.7 O -
% O -
. O -

The O +
stability O +
of O +
SCH O +
66336 O +
in O +
plasma O +
was O +
evaluated O +
through O +
three O +
freeze O -
– O -
thaw O +
cycles O +
at O +
concentrations O +
of O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
. O -

The O +
samples O +
were O +
thawed O +
in O +
a O +
water O +
bath O +
at O +
room O +
temperature O +
and O +
frozen O +
within O +
5 O +
min O +
of O +
thawing O +
in O +
each O +
cycle O -
. O -

After O +
three O +
cycles O -
, O +
the O +
changes O +
from O +
nominal O +
concentrations O +
were O +
−5.0 O -
, O +
+ O -
13.3 O +
and O +
+ O -
12.7 O -
% O +
for O +
the O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
, O +
respectively O -
, O +
demonstrating O +
that O +
SCH O +
66336 O +
was O +
stable O +
in O +
plasma O +
through O +
three O +
freeze O -
– O -
thaw O +
cycles O -
. O -

Long O -
- O -
term O +
stability O +
was O +
determined O +
following O +
316 O +
days O +
of O +
storage O +
at O +
−20 O -
° O -
C O +
at O +
the O +
concentrations O +
above O -
. O -

The O +
changes O +
from O +
the O +
nominal O +
concentrations O +
ranged O +
from O +
0.7–5.0 O -
% O +
indicating O +
that O +
SCH O +
66336 O +
was O +
stable O +
in O +
plasma O +
for O +
at O +
least O +
316 O +
days O -
. O -

In O -
- O -
process O +
stability O +
was O +
performed O +
for O +
up O +
to O +
72 O +
h O +
after O +
sample O +
processing O -
. O -

Three O +
sets O +
of O +
processed O +
plasma O +
samples O +
at O +
the O +
above O +
SCH O +
66336 O +
concentrations O +
were O +
analyzed O +
after O +
storage O +
at O +
room O +
temperature O +
for O +
72 O +
h. O +
The O +
changes O +
from O +
nominal O +
concentrations O +
were O +
−5.0 O -
, O +
2.0 O +
and O +
3.3 O -
% O +
for O +
the O +
0.2 O -
, O +
1.5 O +
and O +
15 O +
μg O -
/ O -
ml O -
, O +
respectively O -
, O +
demonstrating O +
that O +
SCH O +
66336 O +
was O +
stable O +
under O +
the O +
conditions O +
evaluated O -
. O -

3.2 O +
Chiral O +
HPLC O +
Typical O +
chromatograms O +
of O +
drug O -
- O -
free O +
rat U-Species +
and O +
cynomolgus B-Species +
monkey L-Species +
plasma O +
and O +
plasma O +
spiked O +
with O +
the O +
internal O +
standard O -
, O +
SCH O +
66336 O +
and O +
its O +
enantiomer O +
SCH O +
66337 O +
are O +
illustrated O +
in O +
Figs. O +
3 O +
and O +
4 O -
, O +
respectively O -
. O -

The O +
retention O +
times O +
of O +
SCH O +
66337 O -
, O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
were O +
approximately O +
5.7 O -
, O +
8.3 O +
and O +
13.4 O +
min O -
, O +
respectively O -
. O -

There O +
were O +
no O +
endogenous O +
peaks O +
in O +
plasma O +
of O +
undosed O +
rats U-Species +
or O +
monkeys U-Species +
that O +
coeluted O +
with O +
SCH O +
66337 O -
, O +
SCH O +
66336 O +
or O +
the O +
internal O +
standard O -
, O +
indicating O +
that O +
the O +
method O +
was O +
selective O -
. O -

The O +
linearity O +
was O +
evaluated O +
over O +
a O +
concentration O +
range O +
of O +
0.25–10 O +
μg O -
/ O -
ml O -
, O +
the O +
correlation O +
coefficients O +
were O +
> O -
0.99 O +
indicating O +
that O +
the O +
response O +
was O +
linear O +
over O +
the O +
concentration O +
range O +
studied O +
( O -
Tables O +
4 O +
and O +
5 O -
) O -
. O -

Intra O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
evaluated O +
at O +
plasma O +
SCH O +
66337 O +
and O +
SCH O +
66336 O +
concentrations O +
of O +
0.4 O -
, O +
2.5 O +
and O +
8.0 O +
μg O -
/ O -
ml O -
. O -

Three O +
samples O +
were O +
analyzed O +
at O +
each O +
concentration O +
on O +
the O +
same O +
day O -
; O +
the O +
results O +
are O +
shown O +
in O +
Table O +
6 O -
. O -

Intra O -
- O -
day O +
precision O +
and O +
accuracy O +
were O +
satisfactory O +
as O +
indicated O +
by O +
a O +
CV O +
of O +
< O -
13 O -
% O +
and O +
a O +
bias O +
of O +
< O -
12 O -
% O +
for O +
both O +
enantiomers O -
. O -

The O +
LOQ O +
was O +
0.25 O +
μg O -
/ O -
ml O -
; O +
at O +
this O +
concentration O -
, O +
the O +
precision O +
and O +
accuracy O +
from O +
the O +
back O -
- O -
calculated O +
concentrations O +
were O +
satisfactory O +
( O -
CV O +
< O -
14 O -
% O -
, O +
bias=6 O -
% O -
) O -
. O -

The O +
recovery O +
values O +
at O +
10 O +
μg O -
/ O -
ml O +
for O +
SCH O +
66337 O -
, O +
SCH O +
66336 O +
and O +
the O +
internal O +
standard O +
were O +
83 O -
, O +
80 O +
and O +
79 O -
% O -
, O +
respectively O -
. O -

4 O +
Discussion O +
SCH B-Species +
66336 L-Species +
belongs O +
to O +
the O +
tricyclic O +
class O +
of O +
FPT O +
inhibitors O +
which O +
are O +
structurally O +
distinct O +
from O +
other O +
reported O +
FPT O +
inhibitors O -
, O +
many O +
of O +
which O +
were O +
derived O +
from O +
peptidomimetic O +
approaches O +
[ O -
15,16 O -
] O +
. O -

These O +
differences O -
, O +
including O +
the O +
absence O +
of O +
a O +
sulfhydryl O +
function O -
, O +
are O +
likely O +
to O +
contribute O +
to O +
the O +
favorable O +
oral O +
pharmacokinetic O +
properties O +
of O +
the O +
tricyclic O +
class O -
. O -

Initial O +
compounds O +
in O +
this O +
series O -
, O +
such O +
as O +
SCH O +
44342 O +
( O -
IC50 O +
= O -
250 O +
nM O +
) O -
, O +
displayed O +
less O +
than O +
optimal O +
pharmacokinetic O +
properties O +
in O +
the O +
mouse U-Species -
, O +
including O +
a O +
very O +
rapid O +
oxidative O +
metabolism O +
[ O -
15 O -
] O +
. O -

Blocking O +
the O +
susceptible O +
metabolic O +
sites O +
on O +
SCH O +
44342 O +
greatly O +
improved O +
the O +
pharmacokinetic O +
properties O +
of O +
compounds O +
in O +
this O +
series O -
. O -

SCH O +
66336 O +
was O +
the O +
lead O +
compound O +
that O +
emerged O +
from O +
these O +
efforts O -
. O -

In O +
addition O +
to O +
improved O +
metabolic O +
stability O -
, O +
its O +
intrinsic O +
potency O +
was O +
also O +
improved O +
as O +
indicated O +
by O +
an O +
FPT O +
IC50 O -
of O +
1.9 O +
nM O +
. O -

Due O +
to O +
these O +
improvements O -
, O +
SCH O +
66336 O +
persisted O +
in O +
mouse U-Species +
serum O +
at O +
concentrations O +
greater O +
than O +
its O +
IC50 O -
for O +
Ha O -
- O -
Ras O +
processing O +
in O +
Cos O +
cells O +
for O +
over O +
16 O +
h O +
following O +
a O +
single O +
oral O +
dose O +
of O +
25 O +
mg O -
/ O -
kg O +
[ O -
11 O -
] O +
. O -

We O +
have O +
attempted O +
to O +
improve O +
the O +
sensitivity O +
of O +
the O +
achiral O +
HPLC O +
method O +
by O +
solid O -
- O -
phase O +
extraction O +
on O +
ethyl O +
column O -
. O -

However O -
, O +
because O +
of O +
the O +
high O +
plasma O +
background O -
, O +
the O +
sensitivity O +
was O +
reduced O +
( O -
LOQ O +
was O +
0.25 O +
μg O -
/ O -
ml O -
) O -
. O -

Gas O +
chromatography O +
( O -
GC O -
) O +
with O +
electron O +
capture O +
detection O +
( O -
ECD O -
) O +
appeared O +
to O +
be O +
a O +
suitable O +
mean O +
for O +
developing O +
a O +
sensitive O +
assay O -
, O +
since O +
the O +
compound O +
contains O +
three O +
halogens O +
( O -
Fig. O +
1 O +
) O -
. O -

Because O +
SCH O +
66336 O +
was O +
non O -
- O -
volatile O -
, O +
the O +
GC O +
column O +
temperature O +
needed O +
to O +
be O +
kept O +
above O +
320 O -
° O -
C O +
to O +
observe O +
a O +
signal O -
. O -

However O -
, O +
the O +
compound O +
was O +
thermally O +
unstable O +
at O +
this O +
high O +
temperature O -
. O -

The O +
achiral O +
analytical O +
method O +
was O +
used O +
to O +
characterize O +
the O +
pharmacokinetic O +
profile O +
of O +
SCH O +
66336 O +
in O +
the O +
cynomolgus B-Species +
monkey L-Species +
treated O +
orally O +
with O +
a O +
100-mg O +
experimental O +
capsule O +
of O +
SCH O +
66336 O -
. O -

SCH O +
66336 O +
was O +
quantifiable O +
in O +
plasma O +
between O +
2 O +
and O +
24 O +
h O +
after O +
oral O +
administration O +
( O -
Fig. O +
5 O -
) O -
. O -

The O +
mean O +
C O +
max O -
of O +
SCH O +
66336 O +
was O +
6.82 O +
μg O -
/ O -
ml O +
which O +
was O +
attained O +
at O +
a O +
mean O +
T O +
max O -
of O +
7.67 O +
h. O -

The O +
area O +
under O +
the O +
plasma O +
concentration O -
– O -
time O +
curve O +
( O -
AUC0–24 O +
h O +
) O +
was O +
84.5 O +
μg O +
h O -
/ O -
ml O +
( O -
Table O +
7 O -
) O -
. O -

Enantiomers O +
of O +
biologically O +
active O +
molecules O +
may O +
differ O +
in O +
potency O -
, O +
pharmacological O +
action O -
, O +
metabolism O -
, O +
toxicity O +
and O +
pharmacokinetics O +
[ O -
12 O -
] O +
. O -

Therefore O -
, O +
it O +
is O +
highly O +
desirable O +
that O +
only O +
the O +
active O +
enantiomer O +
be O +
the O +
drug O +
candidate O -
. O -

The O +
tools O +
for O +
chiral O +
resolution O +
have O +
been O +
progressively O +
improving O +
by O +
the O +
development O +
of O +
a O +
great O +
variety O +
of O +
chiral O +
HPLC O -
- O -
stationary O +
phases O -
. O -

Chiral O +
phases O +
containing O +
cavities O +
such O +
as O +
cyclodextrins O +
or O +
cellulose O +
derivatives O +
have O +
played O +
a O +
significant O +
role O +
in O +
the O +
area O +
of O +
chiral O +
resolution O +
[ O -
13 O -
] O +
. O -

The O +
chiral O +
recognition O +
of O +
cavity O -
- O -
containing O +
stationary O +
phases O +
is O +
believed O +
to O +
be O +
a O +
result O +
of O +
the O +
insertion O +
of O +
the O +
aromatic O +
portion O +
of O +
the O +
solute O +
into O +
the O +
chiral O +
cavity O -
, O +
in O +
addition O +
to O +
hydrogen O +
bonding O +
interactions O -
. O -

A O +
great O +
number O +
of O +
chiral O +
drugs O +
have O +
been O +
resolved O +
on O +
cyclodextrin O +
( O -
cyclobond O -
) O -
, O +
cellulose O +
( O -
chiralcel O -
) O +
or O +
amylose O +
( O -
chiralpak O -
) O +
based O +
columns O -
. O -

Several O +
chiral O +
HPLC O +
columns O +
were O +
evaluated O +
for O +
the O +
separation O +
of O +
SCH O +
66336 O +
and O +
SCH O +
66336 O +
including O +
Cyclobond O +
1 O -
, O +
Chiralcel O +
OD O +
( O -
cellulose O +
carbamate O +
derivative O -
) O +
and O +
Chiralpak O +
AD O +
( O -
amylose O +
carbamate O +
derivative O -
) O -
. O -

The O +
Cyclobond O +
1 O +
and O +
Chiralcel O +
OD O +
columns O +
gave O +
broad O +
peaks O +
with O +
asymmetric O +
peak O +
shape O +
( O -
tailing O -
) O +
without O +
baseline O +
separations O -
. O -

The O +
Chiralpak O +
AD O +
column O +
was O +
selected O +
because O +
of O +
symmetrical O +
peaks O +
and O +
baseline O +
separation O +
resulting O +
in O +
a O +
better O +
sensitivity O -
. O -

The O +
chiral O +
HPLC O +
method O +
was O +
used O +
to O +
evaluate O +
the O +
possible O +
chiral O +
inversion O +
of O +
SCH O +
66336 O +
in O +
animals U-Species -
. O -

It O +
should O +
be O +
pointed O +
out O +
that O +
SCH O +
66336 O +
administered O +
to O +
animals U-Species +
contained O +
approximately O +
1.5–2.0 O -
% O +
SCH O +
66337 O +
as O +
an O +
impurity O -
. O -

In O +
rat U-Species +
plasma O -
, O +
SCH O +
66337 O +
concentrations O +
were O +
below O +
the O +
LOQ O -
, O +
while O +
the O +
concentrations O +
of O +
SCH O +
66336 O +
ranged O +
from O +
5.5–25.0 O +
μg O -
/ O -
ml O -
. O -

In O +
cynomolgus B-Species +
monkey L-Species +
plasma O -
, O +
the O +
concentrations O +
of O +
SCH O +
66336 O +
were O +
within O +
the O +
range O +
of O +
0.32– O +
28.9 O +
μg O -
/ O -
ml O -
, O +
while O +
those O +
for O +
SCH O +
66337 O +
were O +
within O +
the O +
range O +
of O +
below O +
the O +
LOQ O +
to O +
0.9 O +
μg O -
/ O -
ml O -
. O -

The O +
ratios O +
of O +
the O +
concentrations O +
of O +
SCH O +
66337 O +
to O +
SCH O +
66337 O +
in O +
the O +
samples O +
that O +
contained O +
quantifiable O +
levels O +
of O +
both O +
analytes O +
were O +
within O +
the O +
range O +
of O +
2.5–3 O -
% O -
, O +
which O +
is O +
similar O +
to O +
the O +
ratio O +
seen O +
as O +
an O +
impurity O +
in O +
SCH O +
66336 O -
. O -

Therefore O -
, O +
it O +
is O +
concluded O +
that O +
SCH O +
66336 O +
is O +
not O +
subjected O +
to O +
chiral O +
inversion O +
in O +
rats U-Species +
and O +
cynomolgus B-Species +
monkeys L-Species -
. O -

In O +
conclusion O -
, O +
the O +
HPLC O +
assay O +
for O +
the O +
determination O +
of O +
SCH O +
66336 O +
in O +
cynomolgus B-Species +
monkey L-Species +
plasma O +
was O +
shown O +
to O +
be O +
accurate O +
and O +
reliable O +
over O +
a O +
concentration O +
range O +
of O +
0.1 O +
to O +
20 O +
μg O -
/ O -
ml O +
with O +
an O +
average O +
CV O +
of O +
6 O -
% O +
and O +
an O +
average O +
bias O +
of O +
7 O -
% O -
. O -

The O +
assay O +
was O +
used O +
successfully O +
to O +
monitor O +
plasma O +
concentrations O +
of O +
SCH O +
66336 O +
in O +
cynomolgus B-Species +
monkey L-Species -
. O -

A O +
reliable O +
chiral O +
HPLC O +
method O +
was O +
also O +
developed O +
to O +
separate O +
SCH O +
66336 O +
from O +
its O +
enantiomer O +
SCH O +
66337 O +
in O +
monkey U-Species +
and O +
rat U-Species +
plasma O -
. O -

Chiral O +
HPLC O +
analysis O +
indicated O +
that O +
SCH O +
66336 O +
was O +
not O +
subjected O +
to O +
chiral O +
inversion O +
in O +
rats U-Species +
and O +
cynomolgus B-Species +
monkeys I-Species -
. L-Species +

The O +
growing O +
demand O +
for O +
peptides O +
with O +
biological O -
, O +
pharmaceutical O +
and O +
food O +
ingredients O +
applications O +
requires O +
the O +
development O +
of O +
efficient O +
synthetic O +
methods O +
[ O -
1 O -
] O +
. O -

Recently O -
, O +
the O +
successful O +
performance O +
of O +
enzymatic O +
peptide O +
synthesis O +
in O +
heterogenous O +
substrate O +
mixtures O +
[ O -
2–5 O -
] O +
has O +
provided O +
a O +
new O +
and O +
efficient O +
route O +
to O +
peptide O +
syntheses O -
. O -

It O +
was O +
found O +
that O +
some O +
amino O +
acid O +
amides O +
can O +
form O +
supercooled O +
liquid O +
mixtures O +
with O +
N O +
-carbobenzyloxy O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
CBZ O -
- O -
Tyroet O -
) O +
and O +
acetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
Ac O -
- O -
Tyroet O -
) O -
, O +
in O +
which O +
enzymic O +
catalysis O +
of O +
transesterfication O +
reactions O +
can O +
take O +
place O -
. O -

For O +
example O -
, O +
the O +
dipeptide O +
( O -
N O +
-CBZ O -
- O -
Tyr O -
- O -
leuNH O -
) O +
was O +
obtained O +
in O +
the O +
supercooled O +
liquid O +
mixtures O +
of O +
l O +
-leucinamide O +
with O +
CBZ O -
- O -
Tyroet O +
when O +
subtilisin O +
or O +
α O -
- O -
chymotrypsin O +
were O +
used O -
. O -

However O -
, O +
the O +
enzymatic O +
peptide O +
synthesis O +
in O +
the O +
absence O +
of O +
solvent O +
depends O +
on O +
the O +
ability O +
of O +
the O +
mixtures O +
to O +
form O +
supercooled O +
liquid O +
mixtures O +
[ O -
2–5 O -
] O +
. O -

For O +
instance O -
, O +
supercooled O -
- O -
liquid O +
mixtures O +
can O -
not O +
be O +
formed O +
on O +
mixing O +
l O +
-leucinamide O +
and O +
N O +
-trifluoroacetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
TFAc O -
- O -
Tyroet O -
) O +
and O +
no O +
dipeptide O +
can O +
be O +
obtained O -
. O -

It O +
is O +
therefore O +
important O +
to O +
understand O +
the O +
mechanism O +
of O +
the O +
formation O +
of O +
supercooled O +
liquid O +
in O +
the O +
mixtures O +
of O +
amino O +
acid O +
amides O +
and O +
tyrosine O +
derivatives O -
. O -

As O +
part O +
of O +
the O +
systematic O +
study O +
of O +
amino O +
acid O +
derivatives O -
, O +
the O +
proton O +
relaxation O +
behaviour O +
and O +
crystal O +
structure O +
of O +
l O +
-leucinamide O +
[ O -
6 O -
, O +
7 O -
] O +
and O +
the O +
proton O +
relaxation O +
of O +
l O +
-alaninamide O +
[ O -
8 O -
] O +
has O +
been O +
studied O -
. O -

It O +
was O +
found O +
that O +
methyl O +
group O +
and O +
amino O +
group O +
rotations O +
are O +
the O +
main O +
spin O -
- O -
lattice O +
relaxation O +
mechanisms O -
. O -

In O +
this O +
paper O -
, O +
we O +
examine O +
the O +
NMR O +
proton O +
relaxation O +
behaviours O +
of O +
three O +
tyrosine O +
derivatives O -
, O +
namely O -
, O +
Ac O -
- O -
Tyroet O -
, O +
CBZ O -
- O -
Tyroet O -
, O +
TFAc O -
- O -
Tyroet O +
( O -
Fig. O +
1 O -
) O -
, O +
and O +
their O +
mixtures O +
with O +
l O +
-leucinamide O +
in O +
order O +
to O +
understand O +
the O +
molecular O +
dynamics O +
of O +
these O +
compounds O +
and O +
the O +
contributions O +
of O +
molecular O +
motions O +
in O +
the O +
formation O +
of O +
supercooled O +
liquids O -
. O -

2 O +
Experimental O +
2.1 O +
Sample O +
preparation O +
2.1.1 O +
N O -
- O -
carbobenzyloxy O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
CBZ O -
- O -
Tyroet O -
) O +
CBZ O -
- O -
Tyroet O +
was O +
prepared O +
from O +
the O +
corresponding O +
free O +
acid O +
using O +
the O +
thionyl O +
chloride O +
method O +
[ O -
9 O -
] O +
. O -

A O +
10 O +
g O +
N O +
-carbobenzyloxy O -
- O -
l O +
-tyrosine O +
( O -
Sigma O -
) O +
was O +
dissolved O +
in O +
absolute O +
ethanol O +
( O -
BDH O -
) O +
and O +
2.8 O +
ml O +
of O +
thionyl O +
chloride O +
( O -
Sigma O -
) O +
was O +
slowly O +
added O +
in O -
. O -

The O +
reaction O +
was O +
carried O +
out O +
at O +
40 O -
° O -
C O +
for O +
2 O +
h O +
in O +
a O +
water O +
bath O +
located O +
in O +
a O +
fume O +
cupboard O -
, O +
followed O +
by O +
rotary O +
evaporation O -
. O -

The O +
products O +
were O +
then O +
dissolved O +
in O +
ethyl O +
acetate O +
( O -
BDH O -
) O +
and O +
washed O +
by O +
0.1 O +
M O +
aqueous O +
sodium O +
hydrogen O +
carbonate O +
( O -
Sigma O -
) O +
solution O +
3 O +
or O +
4 O +
times O +
to O +
remove O +
non O -
- O -
reacted O +
N O +
-carbobenzyloxy O -
- O -
l O +
-tyrosine O -
. O -

To O +
dry O +
the O +
ethyl O +
acetate O +
solution O -
, O +
an O +
excess O +
of O +
magnesium O +
sulphate O +
( O -
BDH O -
) O +
was O +
added O -
, O +
followed O +
by O +
filtration O +
and O +
rotary O +
evaporation O -
. O -

The O +
CBZ O -
- O -
Tyroet O +
was O +
then O +
crystallised O +
from O +
hot O +
ethyl O +
acetate O +
and O +
petroleum O +
ether O +
( O -
BDH O -
) O -
. O -

A O +
deuterated O +
sample O +
( O -
D2-CBZ O -
- O -
Tyroet O -
) O +
was O +
prepared O +
by O +
stirring O +
the O +
CBZ O -
- O -
Tyroet O +
in O +
D2 O +
O O +
( O -
Fluorochem O -
) O +
for O +
ca O -
. O -

2 O +
h O -
, O +
followed O +
by O +
freeze O -
- O -
drying O -
. O -

This O +
process O +
was O +
repeated O +
3 O +
times O +
to O +
ensure O +
that O +
all O +
the O +
exchangeable O +
protons O +
are O +
replaced O +
by O +
deuterium O -
. O -

The O +
samples O +
were O +
stored O +
in O +
a O +
desiccator O +
over O +
di O -
- O -
phosphorus O +
pentoxide O +
at O +
room O +
temperature O -
. O -

The O +
moisture O +
content O +
was O +
0.1 O +
wt.% O +
as O +
measured O +
by O +
Karl O -
– O -
Fischer O +
titration O -
. O -

2.1.2 O +
N O -
- O -
trifluoroacetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
TFAc O -
- O -
Tyroet O -
) O +
TFAc O -
- O -
Tyroet O +
was O +
prepared O +
by O +
trifluoroacetylation O +
of O +
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
Sigma O -
) O +
with O +
ethyl O +
trifluoroacetate O +
( O -
Sigma O -
) O -
, O +
in O +
the O +
presence O +
of O +
tetramethyl O +
guanidine O +
( O -
Sigma O -
) O +
[ O -
10 O -
] O +
. O -

A O +
20 O +
g O +
l O +
-tyrosine O +
ethyl O +
ester O +
was O +
dissolved O +
in O +
120 O +
ml O +
of O +
absolute O +
ethanol O -
, O +
1.2 O +
ml O +
of O +
tetramethyl O +
guanidine O +
followed O +
by O +
12.5 O +
ml O +
of O +
ethyl O +
trifluoroacetate O +
was O +
added O -
. O -

The O +
mixture O +
was O +
stirred O +
at O +
room O +
temperature O +
for O +
5 O +
h O +
in O +
a O +
fume O +
cupboard O -
. O -

When O +
the O +
synthesis O +
had O +
been O +
completed O -
, O +
15 O +
g O +
Dowex O +
50X2 O -
- O -
400 O +
( O -
Sigma O -
) O +
followed O +
by O +
2 O +
g O +
Norit O -
- O -
A O +
activated O +
carbon O +
( O -
Sigma O -
) O +
was O +
added O -
. O -

The O +
mixture O +
was O +
stirred O +
for O +
a O +
further O +
15 O +
min O -
. O -

The O +
mixture O +
was O +
filtered O +
through O +
diatomaceous O +
earth O +
( O -
Sigma O -
) O +
and O +
followed O +
by O +
rotary O +
evaporation O -
. O -

The O +
TFAc O -
- O -
Tyroet O +
was O +
recrystallised O +
from O +
hot O +
dichloromethane O +
( O -
BDH O -
) O +
and O +
ethanol O -
. O -

The O +
moisture O +
content O +
was O +
0.18 O +
wt.% O +
as O +
measured O +
by O +
Karl O -
– O -
Fischer O +
titration O -
. O -

The O +
deuterated O +
TFAc O -
- O -
Tyroet O +
( O -
D2-TFAc O -
- O -
Tyroet O -
) O +
was O +
prepared O +
in O +
the O +
same O +
way O +
as O +
the O +
D2-CBZ O -
- O -
Tyroet O -
. O -

2.1.3 O +
Acetyl O -
- O -
l O +
-tyrosine O +
ethyl O +
ester O +
( O -
Ac O -
- O -
Tyroet O -
) O +
Ac O -
- O -
Tyroet O +
was O +
purchased O +
from O +
Sigma O +
and O +
used O +
without O +
any O +
further O +
treatment O -
. O -

The O +
moisture O +
content O +
was O +
6.5 O +
wt.% O +
as O +
measured O +
by O +
Karl O -
– O -
Fischer O +
titration O -
. O -

The O +
deuterated O +
Ac O -
- O -
Tyroet O +
( O -
D2-Ac O -
- O -
Tyroet O -
) O +
was O +
prepared O +
in O +
the O +
same O +
way O +
as O +
the O +
D2-CBZ O -
- O -
Tyroet O -
. O -

2.2 O +
Solid O +
state O +
NMR O +
measurements O +
All O +
the O +
proton O +
NMR O +
relaxation O +
measurements O +
were O +
carried O +
out O +
on O +
a O +
Bruker O +
MSL-100 O +
spectrometer O +
operating O +
at O +
a O +
proton O +
frequency O +
of O +
100.13 O +
MHz O +
over O +
the O +
temperature O +
range O +
between O +
110 O +
and O +
350 O +
K. O +
Experiments O +
were O +
always O +
started O +
from O +
the O +
lowest O +
temperature O -
. O -

T O +
2 O -
was O +
measured O +
directly O +
from O +
the O +
free O +
induction O +
decay O +
( O -
FID O -
) O +
following O +
a O +
90 O -
° O +
pulse O -
. O -

A O +
90 O -
° O +
pulse O +
length O +
of O +
1 O +
μs O +
was O +
used O +
and O +
the O +
receiver O +
deadtime O +
following O +
the O +
pulse O +
was O +
5 O +
μs O -
. O -

The O +
proton O +
second O +
moment O +
was O +
calculated O +
from O +
the O +
FID O +
assuming O +
Gaussian O +
line O +
shapes O +
[ O -
11 O -
] O +
. O -

The O +
spin O -
- O -
lattice O +
relaxation O +
time O +
( O -
T O +
1 O +
) O +
was O +
measured O +
via O +
the O +
inversion O +
recovery O +
( O -
180x O -
° O -
-τ O +
-90x O -
° O -
-detect O -
) O +
method O +
[ O -
12 O -
] O +
. O -

The O +
signal O +
intensity O +
at O +
the O +
beginning O +
of O +
each O +
FID O +
was O +
recorded O -
, O +
a O +
total O +
of O +
48 O +
data O +
points O +
were O +
collected O -
. O -

In O +
order O +
to O +
ensure O +
that O +
the O +
spread O +
of O +
τ O -
values O +
was O +
sufficient O +
to O +
test O +
for O +
the O +
existence O +
of O +
multi O -
- O -
exponential O +
relaxation O -
, O +
the O +
values O +
of O +
τ O -
were O +
chosen O +
according O +
to O +
τ O +
= O -
A O +
×10 O -
( O -
n O +
−1 O -
) O -
/ O -
12 O +
, O +
where O +
A O -
is O +
a O +
constant O +
varying O +
between O +
1–4 O +
ms O -
, O +
depending O +
on O +
the O +
estimate O +
of O +
T O +
1 O +
, O +
and O +
n O -
is O +
the O +
number O +
of O +
data O +
points O -
. O -

The O +
spin O -
- O -
lattice O +
relaxation O +
times O +
in O +
the O +
rotating O +
frame O -
, O +
T O +
1ρ O +
, O +
were O +
determined O +
by O +
spin O -
- O -
locking O +
the O +
magnetization O +
in O +
the O +
rotating O +
frame O +
for O +
a O +
suitable O +
period O +
and O +
monitoring O +
the O +
intensity O +
of O +
the O +
resulting O +
FID O +
( O -
90 O -
° O -
-spin O -
- O -
lock O -
- O -
acquire O -
) O +
[ O -
13 O -
] O +
. O -

The O +
spin O -
- O -
locking O +
field O +
strength O +
were O +
40 O +
kHz O +
equivalent O +
to O +
a O +
90 O -
° O +
pulse O +
length O +
of O +
6.25 O +
μs O -
. O -

The O +
spin O -
- O -
locking O +
time O +
varied O +
from O +
400 O +
μs O +
to O +
51.2 O +
ms O -
. O -

Single O +
point O +
sampling O +
was O +
used O -
, O +
10 O +
μs O +
after O +
spin O -
- O -
locking O +
pulse O -
. O -

Dependent O +
on O +
the O +
length O +
of O +
the O +
T O +
1ρ O +
, O +
48–128 O +
data O +
points O +
were O +
collected O +
for O +
each O +
experiment O -
. O -

Co O -
- O -
added O +
were O +
2–4 O +
scans O +
to O +
improve O +
the O +
signal O +
to O +
noise O +
ratio O +
in O +
both O +
T O +
1 O -
and O +
T O +
1ρ O -
measurements O -
. O -

All O +
data O +
were O +
analyzed O +
using O +
TableCurve O +
( O -
Jandel O +
Scientific O -
) O +
which O +
is O +
a O +
simultaneous O +
multiple O +
non O -
- O -
linear O +
curve O -
- O -
fitting O +
program O +
and O +
uses O +
the O +
Levenburg O -
– O -
Marquardt O +
algorithm O +
to O +
minimize O +
the O +
sum O +
of O +
squares O +
of O +
the O +
deviations O +
between O +
a O +
calculated O +
summation O +
curve O +
and O +
the O +
observed O +
data O +
points O +
[ O -
14 O -
] O +
. O -

3 O +
Results O +
and O +
discussion O +
3.1 O +
Pure O +
tyrosine O +
derivatives O +
3.1.1 O +
Second O +
moment O +
The O +
transverse O +
relaxation O +
processes O +
of O +
the O +
three O +
tyrosine O +
derivatives O +
can O +
be O +
fitted O +
by O +
a O +
single O +
Gaussian O +
process O -
. O -

Fig. O +
2 O -
shows O +
the O +
temperature O +
dependence O +
of O +
the O +
second O +
moments O +
for O +
the O +
three O +
tyrosine O +
derivatives O -
. O -

Generally O -
, O +
the O +
second O +
moments O +
( O -
M O +
2 O +
) O +
reflect O +
the O +
strength O +
of O +
static O +
dipolar O +
interactions O +
in O +
the O +
system O -
. O -

The O +
general O +
decrease O +
in O +
second O +
moment O +
with O +
increasing O +
temperature O +
is O +
probably O +
due O +
to O +
lattice O +
expansion O +
rather O +
than O +
motional O +
averaging O +
since O +
no O +
clear O +
transition O +
is O +
observed O -
. O -

The O +
lower O +
average O +
value O +
of O +
second O +
moment O +
observed O +
for O +
TFAc O -
- O -
Tyroet O +
compared O +
to O +
Ac O -
- O -
Tyroet O +
is O +
due O +
to O +
the O +
lower O +
density O +
of O +
protons O +
in O +
the O +
sample O -
. O -

The O +
lowest O +
second O +
moments O +
are O +
shown O +
by O +
CBZ O -
- O -
Tyroet O -
, O +
these O +
may O +
be O +
due O +
to O +
the O +
bulky O +
benzene O +
ring O +
substituent O +
causing O +
poor O +
crystal O +
packing O +
and O +
reducing O +
the O +
intermolecular O +
contribution O +
to O +
the O +
second O +
moment O -
. O -

3.1.2 O +
Spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
laboratory O +
frame O +
The O +
T O +
1 O +
s O +
of O +
tyrosine O +
derivatives O +
were O +
measured O +
over O +
the O +
temperature O +
range O +
130–360 O +
K. O +
The O +
relaxation O +
time O +
can O +
be O +
fitted O +
to O +
a O +
single O +
exponential O +
in O +
all O +
cases O -
. O -

The O +
variation O +
of O +
R O +
1 O -
with O +
temperature O +
is O +
shown O +
in O +
Fig. O +
3 O -
. O -

R O +
1 O -
of O +
Ac O -
- O -
Tyroet O +
shows O +
two O +
well O -
- O -
resolved O +
R O +
1 O -
maxima O +
at O +
170 O +
and O +
320 O +
K. O +
This O +
indicates O +
that O +
the O +
spin O -
- O -
lattice O +
relaxation O +
is O +
mainly O +
driven O +
by O +
two O +
independent O +
motions O -
, O +
one O +
of O +
which O +
is O +
effective O +
below O +
250 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
above O +
that O +
temperature O -
. O -

Previous O +
studies O +
on O +
the O +
proton O +
relaxation O +
of O +
amino O +
acid O +
amides O +
suggest O +
that O +
methyl O +
groups O +
and O +
their O +
reorientations O +
are O +
expected O +
to O +
be O +
important O +
in O +
relaxing O +
the O +
system O +
[ O -
6 O -
, O +
8 O -
] O +
. O -

The O +
low O -
- O -
temperature O +
relaxation O +
rate O +
maximum O +
of O +
Ac O -
- O -
Tyroet O +
occurs O +
at O +
within O +
about O +
30 O -
° O -
C O +
of O +
temperature O +
as O +
in O +
l O +
-leucinamide O +
( O -
200 O +
K O -
) O +
[ O -
6 O -
] O +
. O -

Therefore O -
, O +
the O +
effective O +
motion O +
that O +
occurs O +
below O +
250 O +
K O +
is O +
likely O +
to O +
be O +
the O +
methyl O +
group O +
rotation O -
. O -

To O +
identify O +
the O +
relaxation O +
process O +
at O +
high O +
temperature O -
, O +
the O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
deuterated O +
Ac O -
- O -
Tyroet O +
were O +
measured O -
. O -

The O +
temperature O +
dependence O +
of O +
relaxation O +
is O +
similar O +
for O +
both O +
protonated O +
and O +
deuterated O +
Ac O -
- O -
Tyroet O +
and O +
shown O +
in O +
Fig. O +
4 O -
. O -

This O +
phenomenon O +
is O +
also O +
observed O +
in O +
the O +
T O +
1 O -
of O +
deuterated O +
CBZ O -
- O -
Tyroet O +
and O +
TFAc O -
- O -
Tyroet O -
. O -

This O +
implies O +
that O +
motions O +
closely O +
related O +
to O +
NH O +
or O +
OH O +
or O +
residual O +
H2 O +
O O +
can O +
be O +
eliminated O +
( O -
see O +
Section O +
2.1 O +
) O -
. O -

The O +
most O +
likely O +
motion O +
left O +
for O +
relaxing O +
the O +
system O +
is O +
a O +
benzene O +
ring O +
flip O +
motion O -
. O -

Therefore O +
the O +
methyl O +
group O +
reorientation O +
and O +
benzene O +
ring O +
flip O +
are O +
assumed O +
to O +
be O +
the O +
major O +
relaxation O +
mechanisms O +
for O +
Ac O -
- O -
Tyroet O -
. O -

The O +
data O +
were O +
fitted O +
to O +
an O +
expression O +
which O +
was O +
found O +
to O +
be O +
very O +
useful O +
in O +
the O +
previous O +
studies O +
[ O -
6 O -
, O +
8 O -
] O +
: O -
( O -
1 O -
) O +
R1obs O -
= O -
1 O +
T1 O -
= O -
2 O +
3 O -
Pa O -
M2a O -
τa O -
1+ω2 O +
τ2 O +
a O -
+ O -
4τa O -
1 O -
+ O -
4ω2 O +
τ2 O +
a O -
+ O -
2 O +
3 O -
Pb O -
M2b O -
τb O -
1+ω2 O +
τ2 O +
b O -
+ O -
4τb O -
1 O -
+ O -
4ω2 O +
τ2 O +
b O -
. O -

This O +
is O +
an O +
extension O +
of O +
the O +
well O -
- O -
known O +
relaxation O +
expression O +
of O +
Kubo O +
and O +
Tomita O +
[ O -
15 O -
] O +
to O +
two O +
independent O +
relaxation O +
processes O -
. O -

ω O +
/2π O -
is O +
the O +
frequency O +
of O +
measurement O +
in O +
Hertz O -
; O +
τ O -
is O +
the O +
correlation O +
time O +
of O +
the O +
molecular O +
motion O +
responsible O +
for O +
spin O -
- O -
lattice O +
relaxation O +
and O +
M O +
2 O -
is O +
the O +
second O +
moment O +
modulated O +
by O +
the O +
corresponding O +
motion O -
. O -

P O +
a O -
and O +
P O +
b O -
are O +
the O +
relative O +
populations O +
of O +
methyl O +
protons O +
and O +
protons O +
on O +
the O +
aromatic O +
ring O -
. O -

They O +
are O +
6 O -
/ O -
17 O +
and O +
4 O -
/ O -
17 O +
for O +
Ac O -
- O -
Tyroet O -
. O -

It O +
is O +
also O +
assumed O +
that O +
the O +
temperature O +
dependence O +
of O +
the O +
correlation O +
time O +
is O +
exponential O -
, O +
hence: O -
( O -
2 O -
) O +
τ O -
= O -
τ0 O +
exp O -
Ea O -
RT O -
. O -

Fig. O +
3 O -
shows O +
the O +
good O +
agreement O +
between O +
the O +
calculated O +
curve O +
and O +
experimental O +
data O +
for O +
Ac O -
- O -
Tyroet O -
. O -

The O +
optimized O +
motional O +
parameters O +
of O +
M O +
2 O +
, O +
τ O +
0 O -
and O +
E O +
a O -
are O +
summarised O +
in O +
Table O +
1 O -
. O -

The O +
activation O +
energy O +
E O +
a O +
, O +
corresponding O +
to O +
the O +
low O +
temperature O +
motion O -
, O +
is O +
11.8 O +
kJ O -
/ O -
mol O +
which O +
is O +
in O +
good O +
agreement O +
with O +
that O +
found O +
for O +
methyl O +
groups O +
in O +
l O +
-leucinamide O +
( O -
10.9 O +
kJ O -
/ O -
mol O -
) O +
[ O -
6 O -
] O +
. O -

However O -
, O +
the O +
second O +
moment O +
obtained O +
is O +
about O +
1.0 O -
× O -
108 O -
s−2 O -
which O +
is O +
smaller O +
than O +
that O +
from O +
l O +
-leucinamide O +
( O -
2.7 O -
× O -
108 O -
s−2 O +
) O -
. O -

Examination O +
of O +
the O +
chemical O +
formula O +
of O +
Ac O -
- O -
Tyroet O +
shows O +
two O +
methyl O +
groups O -
; O +
one O +
of O +
which O +
is O +
bonded O +
to O +
a O +
carbonyl O +
carbon O +
and O +
the O +
other O +
one O +
is O +
next O +
to O +
a O +
CH2 O -
group O -
. O -

The O +
rotations O +
of O +
the O +
two O +
methyl O +
groups O +
are O +
expected O +
to O +
behave O +
differently O -
; O +
the O +
one O +
bonded O +
to O +
a O +
carbonyl O +
carbon O +
has O +
a O +
larger O +
distance O +
between O +
methyl O +
group O +
and O +
other O +
protons O -
. O -

The O +
behaviour O +
of O +
this O +
methyl O +
group O +
is O +
expected O +
to O +
be O +
similar O +
to O +
those O +
in O +
methionine O +
methyl O +
d O +
-α O -
- O -
galacturonic O +
acid O +
methyl O +
ester O +
[ O -
16 O -
] O +
or O +
methylpyranisides O +
[ O -
17 O -
, O +
18 O -
] O +
. O -

This O +
type O +
of O +
methyl O +
group O +
is O +
less O +
hindered O -
, O +
with O +
a O +
estimated O +
activation O +
energy O +
of O +
6 O +
kJ O -
/ O -
mol O +
and O +
pre O -
- O -
exponential O +
term O +
of O +
2 O -
× O -
10−13 O -
s O +
[ O -
16 O -
] O +
. O -

At O +
100 O +
MHz O -
, O +
this O +
type O +
of O +
methyl O +
group O +
has O +
a O +
relaxation O +
maximum O +
at O +
about O +
80 O +
K. O +
The O +
maximum O +
observed O +
at O +
170 O +
K O +
is O +
therefore O +
likely O +
to O +
be O +
due O +
to O +
the O +
motion O +
of O +
the O +
more O +
hindered O +
group O -
, O +
CH2 O +
–CH3 O +
. O -

In O +
this O +
case O -
, O +
the O +
value O +
of O +
P O +
a O -
in O +
Eq. O +
( O -
1 O -
) O +
should O +
be O +
3 O -
/ O -
17 O +
instead O +
of O +
6 O -
/ O -
17 O -
, O +
and O +
M O +
2a O -
should O +
be O +
2.0 O -
× O -
108 O -
s−2 O -
which O +
is O +
much O +
more O +
consistent O +
with O +
other O +
data O -
. O -

The O +
second O +
motion O +
controlling O +
the O +
relaxation O +
at O +
high O +
temperature O +
( O -
maximum O +
at O +
320 O +
K O -
) O +
was O +
assumed O +
to O +
be O +
a O +
benzene O +
ring O +
flip O -
. O -

The O +
second O +
moment O +
obtained O +
from O +
the O +
curve O +
fitting O +
( O -
2.7 O -
× O -
107 O -
s−2 O +
) O +
is O +
an O +
order O +
of O +
magnitude O +
smaller O +
than O +
that O +
from O +
the O +
methyl O +
group O +
rotation O -
, O +
but O +
is O +
in O +
broad O +
agreement O +
with O +
that O +
found O +
in O +
phenylalanine O +
( O -
M O +
2 O +
: O -
1.3 O -
× O -
107 O -
s−2 O +
) O +
[ O -
19 O -
] O +
. O -

The O +
maximum O +
of O +
relaxation O +
rate O +
occurs O +
at O +
255 O +
K O +
for O +
benzene O +
ring O +
flipping O +
motion O +
in O +
phenylalanine O +
[ O -
19 O -
] O +
. O -

In O +
Ac O -
- O -
Tyroet O -
, O +
there O +
is O +
a O +
hydroxyl O +
group O +
on O +
the O +
end O +
of O +
benzene O +
ring O -
, O +
which O +
is O +
hydrogen O -
- O -
bonded O +
to O +
a O +
amide O +
group O +
in O +
a O +
neighbouring O +
molecule O +
[ O -
20 O -
] O +
and O +
thus O -
, O +
restricting O +
the O +
motion O +
of O +
the O +
ring O -
. O -

Since O +
the O +
rotation O +
is O +
more O +
restricted O -
, O +
the O +
rate O +
maximum O +
is O +
likely O +
to O +
occur O +
at O +
a O +
higher O +
temperature O -
. O -

Fig. O +
3 O -
also O +
shows O +
the O +
temperature O +
dependence O +
of O +
spin O -
- O -
lattice O +
relaxation O +
rate O +
of O +
CBZ O -
- O -
Tyroet O -
. O -

Following O +
the O +
results O +
obtained O +
in O +
Ac O -
- O -
Tyroet O -
, O +
the O +
rotational O +
motion O +
of O +
the O +
methyl O +
group O +
as O +
the O +
origin O +
of O +
spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
laboratory O +
frame O +
at O +
low O +
temperature O +
is O +
also O +
assumed O -
. O -

The O +
data O +
suggest O +
that O +
the O +
relaxation O +
at O +
high O +
temperature O +
is O +
relatively O +
efficient O +
( O -
Fig. O +
3 O -
insert O -
) O -
, O +
indicating O +
a O +
second O +
effective O +
motion O +
occurring O +
above O +
220 O +
K O -
, O +
although O +
no O +
obvious O +
relaxation O +
rate O +
maximum O +
was O +
seen O -
. O -

The O +
second O +
motion O +
is O +
also O +
assumed O +
to O +
be O +
the O +
benzene O +
ring O +
flipping O -
. O -

The O +
observed O +
temperature O +
dependence O +
of O +
R O +
1 O -
was O +
therefore O +
fitted O +
to O +
Eqs. O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
with O +
a O +
P O +
a O -
value O +
of O +
3 O -
/ O -
21 O +
and O +
a O +
P O +
b O -
value O +
of O +
9 O -
/ O -
21 O -
. O -

Good O +
agreement O +
between O +
the O +
fitted O +
curve O +
and O +
experimental O +
data O +
was O +
obtained O -
. O -

Examination O +
of O +
the O +
activation O +
energy O +
and O +
pre O -
- O -
exponential O +
term O +
of O +
methyl O +
group O +
rotation O +
shows O +
good O +
agreement O +
between O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O +
( O -
Table O +
1 O +
) O -
. O -

However O -
, O +
the O +
second O +
moment O +
obtained O +
from O +
assuming O +
both O +
methyl O +
groups O +
were O +
active O +
in O +
Ac O -
- O -
Tyroet O +
is O +
about O +
half O +
of O +
that O +
from O +
CBZ O -
- O -
Tyroet O -
. O -

This O +
further O +
suggests O +
that O +
the O +
methyl O +
group O +
bonded O +
to O +
the O +
carbonyl O +
carbon O +
in O +
Ac O -
- O -
Tyroet O +
is O +
less O +
hindered O +
and O +
does O +
not O +
have O +
contribution O +
to O +
the O +
relaxation O +
at O +
170 O +
K. O +
Effectively O -
, O +
the O +
system O +
is O +
relaxed O +
by O +
only O +
one O +
methyl O +
group O -
. O -

In O +
contrast O +
to O +
Ac O -
- O -
Tyroet O +
where O +
there O +
is O +
an O +
R O +
1 O -
maximum O +
at O +
320 O +
K O -
, O +
there O +
are O +
no O +
obvious O +
high O +
temperature O +
R O +
1 O -
maxima O +
in O +
CBZ O -
- O -
Tyroet O -
. O -

Inspection O +
of O +
the O +
chemical O +
structure O +
of O +
the O +
two O +
molecules O +
shows O +
the O +
presence O +
of O +
two O +
benzene O +
rings O +
in O +
CBZ O -
- O -
Tyroet O -
, O +
one O +
of O +
which O +
is O +
restricted O +
by O +
a O +
hydroxyl O +
group O +
and O +
the O +
other O +
one O +
is O +
not O -
. O -

The O +
relatively O +
free O +
benzene O +
ring O +
motion O +
is O +
expected O +
to O +
relax O +
the O +
system O +
efficiently O +
at O +
the O +
temperature O +
below O +
320 O +
K. O +
It O +
is O +
very O +
likely O +
that O +
the O +
relaxation O +
mechanism O +
occurring O +
at O +
higher O +
temperature O +
comprises O +
two O +
ring O +
flip O +
motions O +
having O +
different O +
activation O +
energies O -
, O +
the O +
non O -
- O -
hydrogen O -
- O -
bonded O +
benzene O +
ring O +
flipping O +
at O +
lower O +
temperature O -
. O -

The O +
presence O +
of O +
unrestricted O +
benzene O +
ring O +
motion O +
is O +
manifest O +
in O +
the O +
differences O +
in O +
proton O +
T O +
1 O -
value O +
of O +
CBZ O -
- O -
Tyroet O +
( O -
1.75 O +
s O -
) O +
and O +
Ac O -
- O -
Tyroet O +
( O -
3.56 O +
s O -
) O +
at O +
250 O +
K. O +
However O -
, O +
the O +
fitting O +
procedure O +
was O +
unable O +
to O +
discriminate O +
two O +
motions O +
and O +
only O +
one O +
motion O +
was O +
assumed O +
in O +
the O +
fit O -
. O -

T O +
1 O +
s O +
of O +
TFAc O -
- O -
Tyroet O +
were O +
measured O +
over O +
the O +
temperature O +
range O +
of O +
150–360 O +
K. O +
The O +
variation O +
of O +
the O +
spin O -
- O -
lattice O +
relaxation O +
rate O +
with O +
temperature O +
is O +
shown O +
in O +
Fig. O +
3 O +
. O -

In O +
contrast O +
to O +
the O +
Ac O -
- O -
Tyroet O +
and O +
CBZ O -
- O -
Tyroet O -
, O +
it O +
shows O +
only O +
one O +
maximum O +
at O +
around O +
170 O +
K. O +
This O +
indicates O +
the O +
presence O +
of O +
a O +
motion O +
whose O +
correlation O +
time O +
is O +
about O +
10−9 O -
s O +
at O +
170 O +
K. O +
Following O +
the O +
previous O +
study O -
, O +
the O +
motion O +
occurring O +
at O +
170 O +
K O +
is O +
likely O +
to O +
be O +
the O +
methyl O +
group O +
rotation O -
. O -

The O +
observed O +
R O +
1 O -
is O +
therefore O +
fitted O +
to O +
the O +
Eqs. O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
assuming O +
that O +
only O +
methyl O +
rotation O +
is O +
present O -
. O -

In O +
this O +
case O -
, O +
P O +
a O -
in O +
the O +
Eq. O +
( O -
1 O -
) O +
is O +
3 O -
/ O -
14 O +
for O +
the O +
TFAc O -
- O -
Tyroet O -
. O -

Good O +
agreement O +
was O +
found O +
between O +
the O +
experimental O +
data O +
and O +
the O +
fitted O +
curve O -
. O -

The O +
calculated O +
relaxation O +
parameters O +
for O +
methyl O +
group O +
reorientation O +
are O +
summarised O +
in O +
Table O +
1 O +
. O -

The O +
calculated O +
relaxation O +
parameters O +
for O +
methyl O +
group O +
rotation O +
in O +
TFAc O -
- O -
Tyroet O +
are O +
in O +
good O +
agreement O +
with O +
those O +
of O +
CBZ O -
- O -
Tyroet O +
and O +
Ac B-Species -
- I-Species -
Tyroet L-Species -
, O +
confirming O +
the O +
assumption O +
made O +
as O +
to O +
the O +
origin O +
of O +
the O +
relaxation O -
. O -

However O -
, O +
the O +
flipping O +
motion O +
of O +
benzene O +
ring O +
in O +
the O +
TFAc O -
- O -
Tyroet O +
is O +
not O +
observed O +
in O +
the O +
temperature O +
range O +
studied O -
, O +
indicating O +
that O +
the O +
motion O +
is O +
significantly O +
hindered O -
. O -

The O +
hindered O +
motion O +
is O +
presumably O +
due O +
to O +
the O +
presence O +
of O +
the O +
perfluorinated O +
group O -
. O -

This O +
lack O +
of O +
motion O +
may O +
have O +
a O +
role O +
in O +
the O +
failure O +
of O +
this O +
compound O +
to O +
form O +
mixtures O +
with O +
amino O +
acid O +
amides O -
. O -

3.1.3 O +
Spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
rotating O +
frame O +
T O +
1ρ O -
of O +
protonated O +
and O +
deuterated O +
Ac O -
- O -
Tyroet O +
were O +
measured O +
at O +
spin O -
- O -
locking O +
field O +
of O +
40 O +
kHz O +
in O +
the O +
temperature O +
range O +
130–290 O +
K O -
, O +
single O -
- O -
exponential O +
T O +
1ρ O -
relaxation O +
was O +
observed O -
. O -

The O +
dependence O +
of O +
R O +
1ρ O -
on O +
temperature O +
shown O +
in O +
Fig. O +
5 O -
clearly O +
illustrates O +
that O +
the O +
system O +
is O +
mainly O +
relaxed O +
by O +
two O +
motions O -
, O +
one O +
motion O +
is O +
effective O +
below O +
240 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
above O +
it O -
. O -

Furthermore O -
, O +
the O +
curves O +
for O +
Ac O -
- O -
Tyroet O +
and O +
D2-Ac O -
- O -
Tyroet O +
are O +
similar O +
at O +
temperatures O +
below O +
240 O +
K O -
, O +
however O -
, O +
the O +
higher O +
temperature O +
motion O +
is O +
affected O +
by O +
replacing O +
exchangeable O +
protons O +
with O +
deuterium O -
. O -

The O +
data O +
can O +
be O +
fitted O +
to O +
equations O +
similar O +
to O +
those O +
used O +
in O +
the O +
T O +
1 O -
analysis O +
[ O -
21 O -
] O +
: O -
( O -
3 O -
) O +
R1ρ O -
= O -
1 O +
T1ρ O -
= O -
Pa O -
M2a O -
τa O -
1 O -
+ O -
4ω2 O +
τ2 O +
a O -
+ O -
Pb O -
M2b O -
τb O -
1 O -
+ O -
4ω2 O +
τ2 O +
b O -
. O -

This O +
equation O +
is O +
generally O +
valid O +
when O +
τ O +
a O -
, O -
b O +
< O -
T O +
2 O -
and O +
B O +
1 O +
≫B O +
L O +
[ O -
22 O -
] O +
; O +
B O +
1 O -
is O +
the O +
spin O -
- O -
locking O +
field O +
and O +
B O +
L O +
, O +
the O +
local O +
dipolar O +
field O -
. O -

In O +
the O +
experiments O -
, O +
B O +
1 O -
of O +
40 O +
kHz O +
was O +
used O +
and O +
the O +
averaged O +
local O +
dipolar O +
field O +
for O +
Ac O -
- O -
Tyroet O +
was O +
52 O +
kHz O -
, O +
thus O -
, O +
B O +
1 O +
< O -
B O +
L O -
which O +
does O +
not O +
meet O +
the O +
requirement O -
. O -

Therefore O -
, O +
account O +
must O +
be O +
taken O +
for O +
the O +
effects O +
of O +
the O +
local O +
dipolar O +
field O -
. O -

McCall O +
and O +
Douglass O +
[ O -
23 O -
] O +
have O +
suggested O +
using O +
an O +
equation O +
of O +
the O +
form O +
ω O +
2 O +
= O -
ω O +
1 O +
2 O +
+ O -
ω O +
L O +
2 O +
, O +
where O +
ω O +
L O +
/2π O -
is O +
the O +
local O +
dipolar O +
field O +
which O +
equals O +
to O +
square O +
root O +
of O +
one O +
third O +
of O +
second O +
moment O -
. O -

From O +
the O +
T O +
1 O -
of O +
Ac O -
- O -
Tyroet O -
, O +
the O +
effect O +
of O +
benzene O +
ring O +
motion O +
was O +
detected O +
at O +
320 O +
K O -
, O +
it O +
is O +
reasonable O +
to O +
assume O +
that O +
the O +
motion O +
below O +
240 O +
K O +
is O +
benzene O +
ring O +
motion O +
since O +
the O +
measurement O +
of O +
spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
rotating O +
frame O +
has O +
the O +
effect O +
of O +
shifting O +
the O +
relaxation O +
maxima O +
into O +
a O +
lower O +
temperature O +
range O -
. O -

Therefore O -
, O +
P O +
a O -
in O +
Eq. O +
( O -
3 O -
) O +
is O +
4 O -
/ O -
17 O +
for O +
Ac O -
- O -
Tyroet O +
and O +
4 O -
/ O -
15 O +
for O +
D2-Ac O -
- O -
Tyroet O -
. O -

Since O +
the O +
second O +
motion O +
is O +
difficult O +
to O +
identify O +
positively O -
, O +
a O +
P O +
b O -
value O +
of O +
13 O -
/ O -
17 O +
for O +
Ac O -
- O -
Tyroet O +
and O +
11 O -
/ O -
15 O +
for O +
D2-Ac O -
- O -
Tyroet O +
is O +
assumed O +
for O +
the O +
curve O +
fitting O -
. O -

Fig. O +
5 O -
shows O +
the O +
quality O +
of O +
the O +
fitting O -
. O -

The O +
results O +
of O +
the O +
fitting O +
are O +
summarised O +
in O +
Table O +
1 O +
. O -

The O +
values O +
of O +
M O +
2 O +
, O +
E O +
a O -
and O +
τ O +
0 O -
are O +
the O +
same O +
within O +
experimental O +
error O +
for O +
both O +
protonated O +
and O +
deuterated O +
samples O +
in O +
the O +
temperature O +
range O +
below O +
240 O +
K O -
, O +
indicating O +
that O +
deuteration O +
has O +
little O +
effect O +
on O +
this O +
motion O -
. O -

Supposing O +
that O +
the O +
benzene O +
ring O +
flip O +
is O +
responsible O +
for O +
the O +
T O +
1ρ O -
relaxation O +
in O +
this O +
temperature O +
range O -
, O +
therefore O -
, O +
the O +
temperature O +
dependence O +
of O +
R O +
1ρ O -
curve O +
can O +
be O +
predicted O +
from O +
the O +
relaxation O +
parameters O +
( O -
within O +
the O +
error O +
range O -
) O +
of O +
benzene O +
flipping O +
motion O +
obtained O +
from O +
T O +
1 O +
. O -

Fig. O +
5 O -
shows O +
the O +
predicted O +
curve O -
. O -

Clearly O -
, O +
the O +
fitted O +
curve O +
does O +
not O +
agree O +
very O +
well O +
with O +
the O +
predicted O +
one O -
; O +
the O +
fitted O +
curve O +
is O +
wider O +
than O +
the O +
predicted O +
one O -
. O -

This O +
may O +
arise O +
because O +
the O +
fitting O +
of O +
the O +
T O +
1 O -
data O +
is O +
rather O +
poor O -
, O +
the O +
peak O +
is O +
rather O +
weak O +
and O +
is O +
at O +
the O +
end O +
of O +
the O +
temperature O +
range O -
. O -

The O +
pre O -
- O -
exponential O +
factor O +
found O +
for O +
the O +
T O +
1 O -
data O +
is O +
also O +
very O +
small O -
. O -

This O +
suggests O +
that O +
the O +
T O +
1ρ O -
data O +
are O +
more O +
reliable O -
. O -

In O +
contrast O +
to O +
the O +
motion O +
at O +
lower O +
temperature O -
, O +
the O +
higher O +
temperature O +
motion O +
is O +
affected O +
by O +
replacing O +
exchangeable O +
protons O +
with O +
deuterium O -
. O -

Fig. O +
5 O -
shows O +
that O +
deuterated O +
sample O +
is O +
relaxed O +
more O +
efficiently O +
in O +
this O +
temperature O +
region O -
. O -

This O +
must O +
be O +
due O +
to O +
the O +
decrease O +
in O +
the O +
number O +
of O +
protons O +
to O +
be O +
relaxed O +
by O +
the O +
motion O +
[ O -
6 O -
, O +
15 O -
] O +
. O -

The O +
motion O +
that O +
becomes O +
apparent O +
may O +
be O +
a O +
motion O +
involving O +
a O +
large O +
part O +
of O +
the O +
molecule O -
. O -

However O -
, O +
its O +
origin O +
is O +
not O +
certain O +
so O +
the O +
motion O +
will O +
be O +
referred O +
to O +
simply O +
as O +
the O +
third O +
motion O -
. O -

T O +
1ρ O -
of O +
solid O +
CBZ O -
- O -
Tyroet O +
was O +
measured O +
over O +
the O +
temperature O +
range O +
150–340 O +
K O +
and O +
the O +
dependence O +
of O +
R O +
1ρ O -
on O +
temperature O +
is O +
shown O +
in O +
Fig. O +
6 O -
. O -

Relaxation O +
of O +
CBZ O -
- O -
Tyroet O +
( O -
Fig. O +
6 O +
) O +
is O +
similar O +
to O +
that O +
of O +
Ac O -
- O -
Tyroet O +
( O -
Fig. O +
5 O +
) O -
. O -

One O +
motion O +
occurs O +
below O +
270 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
at O +
higher O +
temperature O -
. O -

As O +
with O +
Ac O -
- O -
Tyroet O -
, O +
benzene O +
ring O +
flipping O +
and O +
the O +
third O +
mode O +
of O +
motion O +
are O +
assumed O +
to O +
account O +
for O +
the O +
R O +
1ρ O -
of O +
CBZ O -
- O -
Tyroet O -
. O -

The O +
data O +
are O +
therefore O +
fitted O +
to O +
Eq. O +
( O -
3 O -
) O +
with O +
a O +
P O +
a O -
value O +
of O +
9 O -
/ O -
21 O +
and O +
a O +
P O +
b O -
of O +
12 O -
/ O -
21 O +
for O +
CBZ O -
- O -
Tyroet O -
. O -

The O +
local O +
dipolar O +
field O -
, O +
ω O +
L O +
, O +
( O -
44 O +
kHz O -
) O +
has O +
also O +
been O +
taken O +
into O +
account O -
. O -

A O +
fit O +
of O +
Eq. O +
( O -
3 O -
) O +
to O +
the O +
temperature O +
dependence O +
of O +
R O +
1ρ O -
of O +
CBZ O -
- O -
Tyroet O +
gives O +
a O +
pre O -
- O -
exponential O +
factor O +
of O +
7.0 O -
× O -
10−10 O -
for O +
the O +
motion O +
effective O +
below O +
270 O +
K. O +
This O +
value O +
is O +
too O +
high O +
for O +
the O +
motion O +
at O +
low O +
temperature O -
. O -

Usually O -
, O +
this O +
is O +
indicative O +
of O +
a O +
distribution O +
of O +
correlation O +
time O +
[ O -
24 O -
, O +
25 O -
] O +
. O -

From O +
the O +
discussion O +
of O +
T O +
1 O -
of O +
CBZ O -
- O -
Tyroet O -
, O +
two O +
benzene O +
rings O +
are O +
present O +
in O +
the O +
CBZ O -
- O -
Tyroet O -
. O -

Therefore O -
, O +
the O +
relaxation O +
below O +
270 O +
K O +
can O +
be O +
treated O +
simply O +
as O +
the O +
sum O +
of O +
two O +
individual O +
motions O +
corresponding O +
to O +
restricted O +
and O +
unrestricted O +
benzene O +
ring O +
flipping O +
motions O +
and O +
thus O -
, O +
the O +
R O +
1ρ O -
below O +
290 O +
K O +
may O +
be O +
written O +
as: O -
( O -
4 O -
) O +
R1ρ O -
= O -
1 O +
T1ρ O -
= O -
Pa O -
M2a O -
τa O -
1 O -
+ O -
4ω2 O +
τ2 O +
a O -
+ O +
τb O -
1 O -
+ O -
4ω2 O +
τ2 O +
b O -
where O +
τ O +
a O -
and O +
τ O +
b O -
correspond O +
to O +
correlation O +
times O +
of O +
the O +
unrestricted O +
and O +
restricted O +
benzene O +
ring O +
flipping O +
motions O -
. O -

The O +
fitted O +
results O +
are O +
listed O +
in O +
Table O +
1 O +
. O -

Fig. O +
6 O -
shows O +
the O +
good O +
agreement O +
between O +
the O +
fitted O +
curve O +
and O +
the O +
experimental O +
data O -
. O -

The O +
calculated O +
activation O +
energy O +
and O +
the O +
pre O -
- O -
exponential O +
term O +
for O +
the O +
restricted O +
benzene O +
ring O +
motion O +
in O +
CBZ O -
- O -
Tyroet O +
is O +
in O +
good O +
agreement O +
with O +
those O +
in O +
Ac O -
- O -
Tyroet O +
although O +
large O +
uncertainties O +
occurred O +
in O +
the O +
curve O +
fitting O +
( O -
Table O +
1 O +
) O -
. O -

The O +
activation O +
energy O +
obtained O +
for O +
the O +
unrestricted O +
motion O +
is O +
lower O +
than O +
that O +
of O +
restricted O +
one O -
, O +
which O +
is O +
expected O -
. O -

The O +
third O +
motion O +
appearing O +
at O +
higher O +
temperatures O +
is O +
affected O +
by O +
deuterium O +
replacement O +
of O +
exchangeable O +
proton O -
, O +
which O +
is O +
similar O +
to O +
the O +
observation O +
made O +
for O +
Ac O -
- O -
Tyroet O -
. O -

However O -
, O +
since O +
such O +
a O +
small O +
part O +
of O +
the O +
curve O +
was O +
observable O +
no O +
reliable O +
fitted O +
data O +
could O +
be O +
obtained O -
. O -

The O +
variation O +
of O +
R O +
1ρ O -
of O +
TFAc O -
- O -
Tyroet O +
and O +
D2-TFAc O -
- O -
Tyroet O +
with O +
temperature O +
is O +
shown O +
in O +
Fig. O +
7 O -
. O -

The O +
proton O +
spin O -
- O -
lattice O +
relaxation O +
in O +
the O +
rotating O +
frame O +
of O +
both O +
protonated O +
and O +
deuterated O +
samples O +
is O +
increasingly O +
efficient O +
below O +
240 O +
K O +
and O +
no O +
relaxation O +
rate O +
maximum O +
was O +
seen O -
. O -

This O +
is O +
in O +
contrast O +
to O +
the O +
results O +
from O +
Ac O -
- O -
Tyroet O +
and O +
CBZ O -
- O -
Tyroet O +
where O +
benzene O +
ring O +
motion O +
was O +
observed O +
at O +
200 O +
K. O +
In O +
the O +
T O +
1 O -
of O +
TFAc O -
- O -
Tyroet O +
analysis O -
, O +
methyl O +
group O +
reorientation O +
was O +
found O +
to O +
be O +
the O +
only O +
relaxation O +
mechanism O -
. O -

It O +
is O +
expected O +
that O +
it O +
is O +
also O +
responsible O +
for O +
T O +
1ρ O -
relaxation O +
at O +
very O +
low O +
temperature O -
. O -

The O +
temperature O +
at O +
which O +
the O +
maximum O +
occurs O +
is O +
predicted O +
to O +
be O +
around O +
92 O +
K O +
using O +
the O +
relaxation O +
parameters O +
for O +
methyl O +
group O +
rotation O +
found O +
in O +
the O +
T O +
1 O -
analysis O -
. O -

To O +
confirm O +
this O -
, O +
T O +
1ρ O -
of O +
TFAc O -
- O -
Tyroet O +
was O +
measured O +
between O +
110 O +
to O +
140 O +
K O +
and O +
it O +
was O +
found O +
that O +
the O +
relaxation O +
becomes O +
more O +
efficient O +
as O +
the O +
temperature O +
is O +
decreased O +
( O -
see O +
the O +
insert O +
Fig. O +
7 O +
) O -
. O -

Therefore O -
, O +
the O +
only O +
relaxation O +
mechanism O +
for O +
the O +
T O +
1ρ O -
of O +
TFAc O -
- O -
Tyroet O +
can O +
be O +
reasonably O +
assigned O +
to O +
methyl O +
group O +
rotation O -
. O -

This O +
is O +
consistent O +
with O +
the O +
observation O +
made O +
in O +
the O +
T O +
1 O -
analysis O +
and O +
suggests O +
that O +
the O +
crystal O +
structure O +
results O +
in O +
a O +
more O +
rigid O +
molecule O +
than O +
in O +
the O +
other O +
compounds O -
. O -

This O +
may O +
be O +
the O +
cause O +
of O +
the O +
failure O +
to O +
form O +
a O +
supercooled O +
liquid O +
mixture O +
with O +
l O +
-leucinamide O -
. O -

3.2 O +
Mixtures O +
of O +
l O +
-leucinamide O -
/ O -
tyrosine O +
derivatives O +
l O +
-leucinamide O +
can O +
spontaneously O +
form O +
supercooled O +
liquid O +
mixtures O +
with O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O -
. O -

However O -
, O +
the O +
melts O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
do O +
not O +
supercool O +
but O +
rather O +
crystallise O +
into O +
separated O +
phases O -
. O -

The O +
mixtures O +
containing O +
1:1 O +
l O +
-leucinamide O -
/ O -
tyrosine O +
derivatives O +
were O +
studied O +
by O +
the O +
temperature O +
dependence O +
of O +
proton O +
spin O -
- O -
lattice O +
relaxation O +
time O +
in O +
the O +
laboratory O +
frame O -
. O -

For O +
the O +
supercooled O +
liquid O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O -
, O +
a O +
single O +
exponential O +
T O +
1 O -
relaxation O +
was O +
found O +
in O +
the O +
temperature O +
range O +
below O +
330 O +
K O -
, O +
above O +
that O +
temperature O -
, O +
a O +
slightly O +
double O +
exponential O +
recovery O +
of O +
magnetization O +
was O +
detected O -
. O -

For O +
the O +
supercooled O +
liquid O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
, O +
a O +
slightly O +
double O +
exponential O +
recovery O +
of O +
magnetization O +
was O +
detected O +
above O +
345 O +
K. O +
The O +
behaviour O +
of O +
spin O -
- O -
lattice O +
relaxation O +
of O +
a O +
two O -
- O -
component O +
system O +
depends O +
on O +
the O +
spin O +
diffusion O +
rate O +
between O +
the O +
components O -
. O -

When O +
the O +
spin O +
diffusion O +
rate O +
is O +
faster O +
than O +
the O +
rate O +
at O +
which O +
spin O +
energy O +
flows O +
from O +
the O +
spin O +
to O +
lattice O -
, O +
averaging O +
of O +
the O +
spatial O +
inhomogeneities O +
of O +
the O +
spin O -
- O -
lattice O +
relaxation O +
occurs O +
and O +
results O +
in O +
an O +
observed O +
single O +
relaxation O +
time O -
. O -

The O +
spin O +
diffusion O +
rate O +
is O +
dependent O +
on O +
the O +
strength O +
of O +
homonuclear O +
dipolar O +
interactions O +
which O -
, O +
in O +
turn O -
, O +
depends O +
on O +
both O +
the O +
distance O +
between O +
nuclei O +
and O +
molecular O +
mobilities O -
. O -

At O +
below O +
300 O +
K O -
, O +
the O +
transverse O +
relaxation O +
of O +
the O +
mixture O +
comprises O +
a O +
Gaussian O +
and O +
an O +
exponential O +
process O -
, O +
above O +
300 O +
K O +
it O +
is O +
exponential O -
. O -

A O +
single O +
exponential O +
spin O -
- O -
lattice O +
relaxation O +
is O +
observed O +
below O +
300 O +
K. O +
This O +
is O +
due O +
to O +
the O +
strong O +
static O +
dipolar O +
interactions O -
, O +
which O +
exist O +
in O +
this O +
temperature O +
regime O -
. O -

When O +
the O +
temperature O +
is O +
above O +
330 O +
K O -
, O +
the O +
dipolar O +
interactions O +
are O +
weakened O +
as O +
the O +
result O +
of O +
molecular O +
motion O -
, O +
consequently O -
, O +
the O +
spin O +
diffusion O +
rate O +
is O +
slow O -
, O +
resulting O +
in O +
non O -
- O -
exponential O +
recovery O +
of O +
T O +
1 O +
. O -

However O -
, O +
in O +
the O +
temperature O +
range O +
between O +
300 O +
to O +
330 O +
K O -
, O +
the O +
single O +
exponential O +
T O +
1 O -
relaxation O +
observed O +
in O +
the O +
mixture O +
of O +
LeuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
is O +
not O +
the O +
result O +
of O +
strong O +
static O +
interactions O +
since O +
the O +
transverse O +
relaxation O +
of O +
the O +
mixture O +
LeuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
is O +
an O +
exponential O +
process O -
. O -

The O +
single O +
exponential O +
T O +
1 O -
observed O +
in O +
this O +
case O +
may O +
be O +
due O +
to O +
the O +
strong O +
intra- O +
and O +
intermolecular O +
interactions O +
resulting O +
from O +
the O +
fact O +
that O +
molecules O +
in O +
the O +
mixtures O +
are O +
in O +
close O +
contact O +
to O +
each O +
other O -
. O -

The O +
spin O -
- O -
lattice O +
relaxation O +
behaviour O +
of O +
both O +
the O +
mixtures O +
was O +
treated O +
as O +
a O +
single O +
exponential O +
process O +
in O +
the O +
temperature O +
range O +
150–360 O +
K O +
since O +
only O +
a O +
few O +
data O +
show O +
the O +
double O -
- O -
exponential O +
behaviour O -
, O +
and O +
fitting O +
our O +
data O +
to O +
a O +
single O +
exponential O +
function O +
does O +
not O +
affect O +
the O +
analysis O +
drastically O -
. O -

Fig. O +
8 O -
Fig. O +
9 O -
show O +
the O +
spin O -
- O -
lattice O +
relaxation O +
rates O +
of O +
the O +
mixtures O +
LeuNH O -
/ O -
Ac O -
- O -
Tyroet O +
and O +
LeuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
plotted O +
against O +
temperature O -
. O -

Clearly O -
, O +
two O +
independent O +
dominant O +
relaxation O +
mechanisms O +
were O +
detected O -
, O +
one O +
of O +
which O +
is O +
effective O +
below O +
250 O +
K O +
and O +
the O +
other O +
one O +
is O +
effective O +
above O +
that O +
temperature O -
. O -

The O +
methyl O +
group O +
rotation O +
is O +
expected O +
to O +
be O +
responsible O +
for O +
the O +
relaxation O +
at O +
low O +
temperature O +
[ O -
6 O -
] O +
. O -

To O +
clarify O +
the O +
high O +
temperature O +
relaxation O +
mechanism O -
, O +
the O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
a O +
deuterated O +
supercooled O +
liquid O +
mixture O +
of O +
l O +
-leuND O -
/ O -
D2-CBZ O -
- O -
Tyroet O +
( O -
Fig. O +
9 O +
) O +
were O +
measured O +
in O +
the O +
temperature O +
range O +
140–360 O +
K O +
and O +
plotted O +
against O +
temperature O -
. O -

Relatively O +
efficient O +
relaxation O +
was O +
still O +
found O +
at O +
high O +
temperature O -
. O -

This O +
suggests O +
that O +
the O +
spin O -
- O -
lattice O +
relaxation O +
at O +
high O +
temperature O +
is O +
not O +
only O +
due O +
to O +
the O +
motions O +
of O +
NH2 O -
or O +
OH O -
, O +
but O +
also O +
some O +
other O +
contributions O -
. O -

Inspection O +
of O +
the O +
spin O -
- O -
lattice O +
relaxation O +
times O +
of O +
the O +
pure O +
CBZ O -
- O -
Tyroet O +
and O +
Ac O -
- O -
Tyroet O +
shows O +
that O +
the O +
benzene O +
ring O +
flipping O +
motion O +
is O +
expected O +
in O +
this O +
temperature O +
range O -
. O -

However O -
, O +
the O +
strength O +
of O +
the O +
relaxation O +
in O +
the O +
mixtures O +
is O +
much O +
larger O +
than O +
that O +
could O +
be O +
generated O +
by O +
the O +
benzene O +
ring O +
flipping O -
, O +
since O +
this O +
is O +
a O +
weaker O +
relaxation O +
source O +
than O +
the O +
methyl O +
group O +
rotation O +
( O -
Fig. O +
4 O +
) O -
. O -

The O +
system O +
is O +
likely O -
, O +
in O +
this O +
case O -
, O +
to O +
be O +
relaxed O +
by O +
the O +
molecular O +
tumbling O +
motion O +
since O +
considerable O +
line O +
narrowing O +
was O +
observed O +
in O +
the O +
FID O +
in O +
this O +
temperature O +
range O -
. O -

Therefore O -
, O +
it O +
is O +
reasonable O +
to O +
assume O +
that O +
rapid O +
molecule O +
tumbling O +
is O +
the O +
major O +
relaxation O +
mechanism O +
for O +
the O +
spin O -
- O -
lattice O +
relaxation O +
of O +
the O +
system O +
at O +
high O +
temperature O -
. O -

The O +
experimental O +
data O +
were O +
then O +
fitted O +
in O +
Eq. O +
( O -
1 O -
) O +
. O -

P O +
a O -
is O +
the O +
methyl O +
group O +
proton O +
population O -
, O +
the O +
value O +
is O +
9 O -
/ O -
35 O +
for O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
and O +
9 O -
/ O -
31 O +
for O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
. O -

P O +
b O -
is O +
set O +
to O +
unity O +
since O +
all O +
the O +
protons O +
in O +
the O +
mixture O +
contribute O +
to O +
the O +
relaxation O -
. O -

Figs. O +
8 O +
and O +
9 O -
show O +
the O +
good O +
agreement O +
between O +
the O +
fitted O +
curves O +
and O +
experimental O +
data O -
. O -

The O +
results O +
are O +
given O +
in O +
Table O +
2 O -
. O -

The O +
second O +
moment O +
calculated O +
for O +
methyl O +
group O +
rotation O +
is O +
in O +
the O +
same O +
order O +
of O +
magnitude O +
as O +
those O +
in O +
pure O +
solids O -
. O -

However O -
, O +
the O +
activation O +
energy O +
of O +
the O +
methyl O +
group O +
rotation O +
in O +
the O +
mixture O +
is O +
smaller O +
than O +
those O +
found O +
for O +
the O +
pure O +
solids O -
. O -

The O +
molecules O +
in O +
supercooled O +
liquid O +
mixtures O +
are O +
loosely O +
packed O -
. O -

As O +
a O +
consequence O -
, O +
rotation O +
of O +
methyl O +
group O +
might O +
be O +
less O +
hindered O +
compared O +
to O +
the O +
corresponding O +
crystal O +
state O -
. O -

This O +
might O +
be O +
the O +
reason O +
for O +
the O +
low O +
activation O +
energy O +
observed O -
. O -

The O +
relaxation O +
rates O +
of O +
these O +
mixtures O +
at O +
low O +
temperature O +
can O +
be O +
predicted O +
from O +
the O +
corresponding O +
crystals O +
assuming O +
that O +
methyl O +
group O +
rotation O +
is O +
the O +
relaxation O +
mechanism O -
. O -

The O +
predictions O +
shown O +
in O +
Figs. O +
8 O +
and O +
9 O -
differ O +
from O +
the O +
experimental O +
values O -
. O -

This O +
indicates O +
the O +
effects O +
of O +
molecular O +
arrangement O +
on O +
the O +
methyl O +
group O +
rotation O -
. O -

In O +
contrast O +
to O +
the O +
mixtures O +
of O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
and O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
, O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
does O +
not O +
form O +
a O +
supercooled O +
liquid O -
. O -

The O +
T O +
1 O -
of O +
a O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
( O -
1:1 O -
) O +
were O +
measured O +
over O +
the O +
temperature O +
range O +
150–360 O +
K. O +
Unlike O +
the O +
liquid O +
mixtures O -
, O +
double O +
exponential O +
relaxation O +
times O +
were O +
found O +
for O +
the O +
temperature O +
range O +
studied O -
. O -

The O +
short O +
T O +
1 O -
component O +
varied O +
between O +
0.08 O +
to O +
0.69 O +
s O +
and O +
the O +
long O +
T O +
1 O -
component O +
varied O +
between O +
0.3 O +
to O +
10 O +
s. O +
The O +
double O +
exponential O +
behaviour O +
of O +
spin O -
- O -
lattice O +
relaxation O +
indicates O +
that O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
is O +
a O +
two O +
phase O +
system O +
and O +
that O +
the O +
spin O +
diffusion O +
between O +
the O +
two O +
components O +
is O +
slow O +
on O +
the O +
time O +
scale O +
of O +
T O +
1 O +
. O -

The O +
temperature O +
dependence O +
of O +
relaxation O +
rate O +
of O +
both O +
components O +
is O +
shown O +
in O +
Fig. O +
10 O -
. O -

A O +
comparison O +
of O +
both O +
the O +
relaxation O +
times O +
with O +
the O +
pure O +
components O +
of O +
l O +
-leuNH O +
and O +
TFAc O -
- O -
Tyroet O +
shows O +
that O +
the O +
long O +
relaxation O +
component O +
coincides O +
well O +
with O +
the O +
R O +
1 O -
of O +
TFAc O -
- O -
Tyroet O +
and O +
that O +
the O +
short O +
component O +
is O +
close O +
to O +
the O +
R O +
1 O -
of O +
l O +
-leuNH O -
. O -

From O +
this O +
observation O -
, O +
it O +
can O +
be O +
inferred O +
that O +
the O +
mixture O +
of O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O +
behaves O +
as O +
if O +
both O +
components O +
were O +
in O +
their O +
pure O +
states O -
. O -

This O +
suggestion O +
is O +
confirmed O +
by O +
the O +
proportion O +
of O +
the O +
two O +
components O -
. O -

At O +
temperatures O +
above O +
260 O +
K O -
, O +
the O +
proportion O +
of O +
short O +
T O +
1 O -
component O +
comprises O +
about O +
50 O -
% O -
. O -

This O +
agrees O +
very O +
well O +
with O +
the O +
proton O +
population O +
of O +
l O +
-leuNH O -
. O -

The O +
short O +
T O +
1 O -
represents O +
the O +
population O +
of O +
l O +
-leuNH O +
protons O -
, O +
and O +
the O +
long O +
T O +
1 O -
represents O +
that O +
of O +
the O +
TFAc O -
- O -
Tyroet O +
protons O -
. O -

This O +
is O +
in O +
contrast O +
to O +
the O +
liquid O +
mixtures O +
where O +
the O +
mixtures O +
act O +
differently O +
from O +
their O +
pure O +
states O -
. O -

At O +
low O +
temperature O +
( O -
below O +
210 O +
K O -
) O +
there O +
is O +
significant O +
deviation O +
of O +
the O +
LeuNH O +
data O +
in O +
the O +
mixture O +
from O +
the O +
pure O +
state O -
, O +
both O +
apparent O +
population O +
and O +
relaxation O +
rate O +
deviate O -
. O -

This O +
may O +
be O +
due O +
to O +
long O +
range O +
spin O +
diffusion O +
effects O +
at O +
this O +
temperature O -
. O -

The O +
ability O +
to O +
form O +
supercooled O +
liquid O +
mixture O +
can O +
be O +
related O +
to O +
the O +
molecular O +
dynamics O +
of O +
the O +
pure O +
substrates O -
. O -

A O +
comparison O +
of O +
the O +
dynamics O +
of O +
these O +
tyrosine O +
derivatives O +
shows O +
that O +
the O +
benzene O +
ring O +
flipping O +
motion O +
and O +
the O +
third O +
motion O +
are O +
absent O +
in O +
the O +
fluorine O +
substituted O +
compound O -
. O -

The O +
reason O +
remains O +
unclear O -
. O -

The O +
preliminary O +
X O -
- O -
ray O +
data O +
did O +
not O +
show O +
strong O +
interactions O +
between O +
the O +
fluorine O +
atoms O +
and O +
the O +
benzene O +
ring O -
, O +
which O +
agrees O +
with O +
the O +
conclusions O +
from O +
UV O +
and O +
Raman O +
spectra O -
. O -

The O +
absence O +
of O +
benzene O +
ring O +
flipping O +
and O +
the O +
third O +
motion O +
in O +
the O +
fluorinated O +
compound O +
implies O +
that O +
the O +
level O +
of O +
order O +
in O +
this O +
crystal O +
is O +
higher O +
than O +
those O +
in O +
the O +
other O +
compounds O +
studied O -
. O -

On O +
crystallisation O +
there O +
will O +
be O +
only O +
one O +
molecular O +
conformation O +
( O -
with O +
respect O +
to O +
the O +
benzene O +
ring O -
) O +
that O +
is O +
possible O -
. O -

Formation O +
of O +
a O +
crystal O +
is O +
therefore O +
only O +
a O +
matter O +
of O +
the O +
whole O +
molecule O +
assuming O +
the O +
correct O +
orientation O +
with O +
respect O +
to O +
its O +
neighbours O +
and O +
packing O +
closely O -
. O -

In O +
the O +
case O +
of O +
Ac O -
- O -
Tyroet O +
there O +
is O +
variability O +
in O +
the O +
conformation O +
with O +
respect O +
to O +
the O +
benzene O +
ring O +
in O +
molecules O +
in O +
the O +
crystal O -
. O -

This O +
will O +
mean O +
that O -
, O +
in O +
effect O -
, O +
the O +
benzene O +
rings O +
will O +
occupy O +
a O +
greater O +
volume O +
than O +
if O +
they O +
were O +
static O +
( O -
in O +
the O +
case O +
of O +
TFAc O -
- O -
Tyroet O -
) O +
and O +
therefore O -
, O +
the O +
intermolecular O +
distances O +
will O +
be O +
greater O +
than O +
in O +
the O +
fluorinated O +
analogue O -
. O -

This O +
in O +
turn O +
implies O +
a O +
weaker O +
intermolecular O +
interactions O -
. O -

This O +
suggestion O +
is O +
supported O +
by O +
the O +
fact O +
that O +
fluorine O +
substitution O +
increases O +
the O +
melting O +
point O +
of O +
the O +
crystal O +
from O +
about O +
78 O -
° O -
C O +
to O +
175 O -
° O -
C O -
. O -

The O +
presence O +
of O +
highly O +
mobile O -
, O +
non O -
- O -
rigid O +
molecules O +
are O +
also O +
likely O +
to O +
inhibit O +
crystal O +
formation O -
. O -

In O +
the O +
presence O +
of O +
another O +
solute O -
, O +
this O +
is O +
likely O +
to O +
lead O +
to O +
the O +
formation O +
of O +
supercooling O +
systems O +
since O +
only O +
weak O +
interactions O +
in O +
solute O +
will O +
be O +
enough O +
to O +
prevent O +
crystallisation O -
. O -

Similar O +
observations O +
of O +
the O +
effects O +
of O +
fluorination O +
have O +
been O +
made O +
by O +
Dow O +
et O +
al. O +
[ O -
26 O -
] O +
. O -

It O +
was O +
found O +
that O +
fluorine O -
- O -
substituted O +
lipids O +
form O +
solids O +
on O +
cooling O +
in O +
30–60 O +
min O -
, O +
whereas O +
unsubstituted O +
lipids O +
require O +
a O +
cooling O +
period O +
of O +
hours O +
or O +
days O -
. O -

It O +
was O +
also O +
shown O +
that O +
less O +
mobility O +
was O +
associated O +
with O +
fluorine O -
- O -
substituted O +
lipids O +
[ O -
26 O -
] O +
. O -

4 O +
Conclusions O +
The O +
proton O +
relaxation O +
behaviour O +
of O +
three O +
tyrosine O +
derivatives O -
: O +
Ac O -
- O -
Tyroet O -
, O +
CBZ O -
- O -
Tyroet O -
, O +
TFAc O -
- O -
Tyroet O +
and O +
their O +
mixtures O +
with O +
l O +
-leucinamide O +
was O +
studied O -
. O -

The O +
extension O +
of O +
the O +
well O -
- O -
known O +
relaxation O +
expression O +
of O +
Kubo O +
and O +
Tomita O +
to O +
several O +
independent O +
relaxation O +
processes O +
was O +
used O +
to O +
identify O +
the O +
relaxation O +
mechanisms O +
and O +
estimate O +
the O +
relaxation O +
parameters O -
. O -

It O +
was O +
found O +
that O +
methyl O +
group O +
rotation O +
is O +
important O +
for O +
relaxing O +
the O +
system O +
at O +
low O +
temperature O +
in O +
both O +
the O +
pure O +
state O +
and O +
mixtures O -
. O -

In O +
addition O -
, O +
both O +
benzene O +
ring O +
flipping O +
and O +
a O +
third O +
motion O +
were O +
found O +
to O +
be O +
the O +
relaxation O +
mechanisms O +
for O +
Ac O -
- O -
Tyroet O +
and O +
CBZ O -
- O -
Tyroet O -
, O +
however O -
, O +
these O +
motions O +
are O +
absent O +
in O +
TFAc O -
- O -
Tyroet O -
. O -

In O +
the O +
mixtures O -
, O +
molecular O +
tumbling O +
motion O +
is O +
responsible O +
for O +
relaxing O +
the O +
supercooled O +
liquids O +
l O +
-leuNH O -
/ O -
CBZ O -
- O -
Tyroet O +
and O +
l O +
-leuNH O -
/ O -
Ac O -
- O -
Tyroet O -
. O -

However O -
, O +
this O +
motion O +
is O +
absent O +
in O +
the O +
mixture O +
l O +
-leuNH O -
/ O -
TFAc O -
- O -
Tyroet O -
. O -

The O +
absence O +
of O +
benzene O +
ring O +
flipping O +
motion O +
and O +
the O +
third O +
motion O +
in O +
the O +
pure O +
tyrosine O +
derivatives O +
may O +
affect O +
its O +
ability O +
to O +
form O +
a O +
supercooled O +
liquid O +
with O +
l O +
-leucinamide O -
. O -

Acknowledgements O +
The O +
authors O +
wish O +
to O +
acknowledge O +
funding O +
from O +
the O +
BBSRC O +
competitive O +
strategic O +
grant O -
. O -

Y.L. O +
Wang O +
wishes O +
to O +
thank O +
the O +
BBSRC O +
for O +
provision O +
of O +
a O +
studentship O -
. O +

d O +
-Penicillamine O +
( O -
d O +
-pen O -
) O +
is O +
a O +
drug O +
used O +
in O +
the O +
treatment O +
of O +
patients U-Species +
with O +
rheumatoid O +
arthritis O +
( O -
RA O -
) O -
, O +
cystinuria O +
and O +
Wilson O -
's O +
disease O -
. O -

A O +
small O +
molecule O -
, O +
similar O +
in O +
structure O +
to O +
cysteine O +
( O -
see O +
Fig. O +
2 O +
) O -
, O +
it O +
has O +
a O +
sulfhydryl O +
group O +
that O +
allows O +
it O +
to O +
couple O +
covalently O +
to O +
proteins O +
( O -
Coleman O +
et O +
al. O -
, O +
1988 O +
) O -
, O +
resulting O +
in O +
slow O +
elimination O +
from O +
the O +
body O -
. O -

Its O +
mechanism O +
of O +
action O +
in O +
RA O +
remains O +
unclear O -
, O +
but O +
its O +
variable O +
and O +
unpredictable O +
efficacy O -
, O +
coupled O +
with O +
a O +
relatively O +
high O +
incidence O +
of O +
side O -
- O -
effects O -
, O +
has O +
led O +
to O +
a O +
decline O +
in O +
its O +
use O +
in O +
recent O +
years O -
. O -

Such O +
side O -
- O -
effects O +
include O +
the O +
development O +
of O +
a O +
number O +
of O +
autoimmune O +
disorders O +
including O +
lupus O +
erythematosus O -
, O +
pemphigus O -
, O +
Goodpasture O -
's O +
syndrome O -
, O +
neuromyotonia O +
and O +
myasthenia O +
gravis O +
( O -
MG O -
; O +
Fernandes O +
et O +
al. O -
, O +
1980 O +
) O -
. O -

d O +
-Pen O +
is O +
not O +
the O +
only O +
drug O +
capable O +
of O +
inducing O +
autoimmune O +
disease O -
, O +
but O +
it O +
is O +
almost O +
alone O +
in O +
its O +
ability O +
to O +
cause O +
autoimmune O +
MG O -
. O -

As O +
with O +
other O +
drug O -
- O -
induced O +
disorders O -
, O +
d O +
-pen O -
- O -
induced O +
MG O +
is O +
associated O +
with O +
the O +
development O +
of O +
autoantibodies O -
, O +
in O +
this O +
case O +
to O +
the O +
acetylcholine O +
receptor O +
( O -
AChR O -
) O +
( O -
Russell O +
and O +
Lindstrom O -
, O +
1978 O +
) O -
. O -

The O +
avidity O +
and O +
specificities O +
of O +
these O +
autoantibodies O +
in O +
d O +
-pen O -
- O -
induced O +
MG O +
are O +
similar O +
to O +
those O +
found O +
in O +
early O -
- O -
onset O +
patients U-Species +
( O -
EOMG O -
) O -
, O +
particularly O +
early O +
in O +
the O +
course O +
of O +
the O +
disease O +
( O -
Vincent O +
and O +
Newsom O -
- O -
Davis O -
, O +
1982 O +
; O +
Heidenreich O +
et O +
al. O -
, O +
1988 O +
) O -
; O +
however O -
, O +
the O +
MG O +
normally O +
remits O +
within O +
6 O +
months O +
of O +
stopping O +
the O +
drug O -
, O +
with O +
a O +
concomitant O +
fall O +
in O +
the O +
anti O -
- O -
AChR O +
antibody O +
titer O +
( O -
Vincent O +
et O +
al. O -
, O +
1978 O +
; O +
Kuncl O +
et O +
al. O -
, O +
1986 O +
) O -
, O +
whereas O +
idiopathic O +
MG O +
is O +
usually O +
long O -
- O -
lasting O -
. O -

Delamere O +
et O +
al. O +
( O -
1983 O -
) O +
and O +
Garlepp O +
et O +
al. O +
( O -
1983 O -
) O +
reported O +
that O -
, O +
in O +
contrast O +
with O +
other O +
MG O +
subgroups O -
, O +
the O +
condition O +
is O +
associated O +
with O +
HLA O -
- O -
DR1 O -
, O +
though O +
its O +
rarity O +
means O +
that O +
the O +
numbers O +
of O +
patients U-Species +
studied O +
are O +
small O -
. O -

How O +
d O +
-pen O +
induces O +
MG O +
is O +
unclear O -
. O -

Administration O +
of O +
the O +
drug O +
to O +
experimental O +
animals U-Species +
did O +
not O +
result O +
in O +
the O +
production O +
of O +
anti O -
- O -
AChR O +
antibodies O -
, O +
although O +
they O +
showed O +
an O +
augmented O +
antibody O +
response O +
to O +
immunization O +
with O +
AChR O +
and O +
the O +
resulting O +
MG O +
signs O +
were O +
sometimes O +
more O +
severe O +
( O -
Bever O +
et O +
al. O -
, O +
1984 O +
) O -
. O -

The O +
size O +
of O +
the O +
molecule O +
and O +
its O +
reactive O +
sulfhydryl O +
group O +
suggest O +
that O +
the O +
drug O +
is O +
acting O +
as O +
a O +
hapten O +
and/or O +
modifying O +
self O +
protein O -
( O -
s O -
) O -
/ O -
peptide O -
( O -
s O -
) O -
, O +
thereby O +
creating O +
neo O -
- O -
epitope O -
( O -
s O -
) O -
. O -

Indeed O -
, O +
coupling O +
of O +
d O +
-pen O +
to O +
an O +
unidentified O +
serum O +
protein O +
has O +
been O +
demonstrated O +
in O +
patients U-Species +
on O +
d O +
-pen O +
therapy O +
( O -
Laycock O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
though O +
its O +
significance O +
for O +
autoimmunity O +
is O +
not O +
clear O -
. O -

To O +
examine O +
the O +
role O +
of O +
d O +
-pen O +
in O +
MG O -
, O +
we O +
have O +
isolated O +
a O +
number O +
of O +
CD3 O -
+ O +
, O +
CD4 O -
+ O -
T O +
cell O +
clones O +
from O +
the O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMC O -
) O +
of O +
a O +
patient U-Species +
with O +
d O +
-pen O -
- O -
induced O +
MG O +
that O +
respond O +
to O +
the O +
drug O +
in O +
vitro O +
together O +
with O +
HLA O -
- O -
DR1 O -
+ O -
PBMC O -
. O -

We O +
provide O +
evidence O +
that O +
the O +
drug O +
is O +
acting O +
by O +
coupling O +
directly O +
to O +
the O +
MHC O +
class O +
II O -
/ O -
peptide O +
complex O -
, O +
and O +
discuss O +
how O +
this O +
might O +
result O +
in O +
the O +
development O +
of O +
MG O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Patient U-Species +
details O +
We O +
studied O +
a O +
68-year O +
old O +
woman U-Species +
( O -
D B-Species -
- I-Species -
P1 L-Species -
) O +
with O +
erosive O +
seropositive O +
RA O +
( O -
HLA O +
A1,32 O -
; O +
B8,35 O -
; O +
C4,701 O -
; O +
DR1,3,DR52a O -
; O +
DQ2,5 O -
) O +
who O +
had O +
been O +
on O +
d O +
-pen O +
treatment O +
for O +
9 O +
months O +
before O +
she O +
developed O +
right O -
- O -
sided O +
ptosis O -
. O -

Six O +
months O +
later O -
, O +
single O +
fiber O +
electromyography O +
in O +
the O +
affected O +
orbicularis O +
oculi O +
muscle O +
showed O +
markedly O +
increased O +
jitter O -
, O +
consistent O +
with O +
a O +
defect O +
in O +
neuromuscular O +
transmission O -
. O -

Her O +
anti O -
- O -
AChR O +
antibody O +
titer O +
was O +
3.2 O +
nM O -
, O +
confirming O +
the O +
diagnosis O +
of O +
MG O -
: O +
the O +
d O +
-pen O +
treatment O +
was O +
therefore O +
stopped O -
. O -

At O +
this O +
time O -
, O +
we O +
took O +
a O +
blood O +
sample O +
from O +
which O +
d O +
-pen O -
- O -
specific O +
lines O +
and O +
clones O +
were O +
obtained O -
. O -

The O +
recovery O +
of O +
her O +
mainly O +
ocular O +
symptoms O +
was O +
slow O -
; O +
about O +
two O +
years O +
after O +
d O +
-pen O +
treatment O +
started O -
, O +
she O +
was O +
given O +
a O +
short O +
course O +
of O +
oral O +
corticosteroids O +
before O +
they O +
resolved O +
completely O +
within O +
9 O +
further O +
months O -
. O -

2.2 O +
Generation O +
of O +
primary O +
T O +
cell O +
lines O +
d O +
-Pen O +
HCl O +
( O -
Sigma O -
, O +
Poole O -
, O +
UK O -
) O +
was O +
dissolved O +
in O +
sterile O +
water O +
and O +
aliquots O +
stored O +
at O +
−70 O -
° O -
C O -
. O -

The O +
cellular O +
toxicity O +
of O +
the O +
drug O +
was O +
determined O +
by O +
inhibition O +
of O +
PHA O +
( O -
Difco O +
Laboratories O -
, O +
Detroit O -
, O +
USA O -
) O -
-induced O +
proliferation O +
of O +
PBMCs O +
from O +
healthy O +
controls O +
by O +
increasing O +
concentrations O +
of O +
d O +
-pen O -
; O +
doses O +
of O +
100–500 O +
μg O -
/ O -
ml O +
were O +
found O +
to O +
be O +
optimal O -
, O +
and O +
toxicity O +
was O +
seen O +
at O +
doses O +
of O +
1 O +
mg O -
/ O -
ml O +
and O +
above O -
. O -

PBMCs O +
were O +
separated O +
from O +
heparinized O +
blood O +
on O +
Lymphoprep O +
( O -
Nycomed O -
, O +
Oslo O -
, O +
Norway O -
) O -
, O +
washed O +
and O +
cultured O +
at O +
2 O -
× O -
106 O +
/1 O +
ml O +
well O +
( O -
Nunc O -
, O +
Roskilde O -
, O +
Denmark O -
) O +
with O +
100–500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
in O +
RPMI O +
( O -
Hyclone O -
, O +
Cramlington O -
, O +
UK O -
) O +
supplemented O +
with O +
5 O -
% O +
heat O -
- O -
inactivated O +
human O +
serum O +
( O -
Blood O +
Transfusion O +
Service O -
, O +
Oxford O -
, O +
UK O -
) O -
, O +
l O +
-glutamine O +
( O -
Gibco O +
Life O +
Technologies O -
, O +
Paisley O -
, O +
Scotland O -
) O +
and O +
50 O +
μg O -
/ O -
ml O +
gentamycin O +
( O -
Gibco O -
) O -
, O +
i.e. O -
, O +
without O +
penicillin O -
. O -

After O +
7 O +
days O -
, O +
stimulation O +
was O +
assessed O +
by O +
culturing O +
triplicate O +
samples O +
( O -
5 O -
% O -
) O +
from O +
each O +
well O +
with O +
1 O +
μCi O +
of O +
3 O +
H O -
thymidine O +
( O -
Amersham O +
International O -
, O +
Amersham O -
, O +
UK O -
) O +
for O +
18 O +
h O -
, O +
followed O +
by O +
harvesting O +
onto O +
filter O +
mats O +
( O -
Wallac O -
, O +
Turku O -
, O +
Finland O -
) O +
and O +
counting O +
on O +
a O +
Betaplate O +
flatbed O +
liquid O +
scintillation O +
counter O +
( O -
Wallac O -
) O -
. O -

A O +
response O +
was O +
considered O +
positive O +
when O +
the O +
activity O +
was O +
greater O +
than O +
twice O +
the O +
control O +
value O -
, O +
i.e. O -
, O +
the O +
stimulation O +
index O +
( O -
SI O -
) O +
was O +
> O -
2 O -
. O -

We O +
expanded O +
positive O +
wells O +
into O +
lines O +
using O +
a O +
cycle O +
of O +
fortnightly O +
restimulation O +
with O +
autologous O +
30 O +
Gy O -
- O -
irradiated O +
PBMC O +
( O -
PBMCx O -
) O +
and O +
d O +
-pen O -
, O +
and O +
supplementing O +
with O +
20U O +
IL-2 O +
( O -
Biotest O +
( O -
UK O -
) O -
, O +
Solihull O -
, O +
UK O -
) O +
approximately O +
every O +
72 O +
h O +
thereafter O -
. O -

Specificity O +
of O +
the O +
lines O +
for O +
the O +
drug O +
was O +
confirmed O +
by O +
culturing O +
3 O -
× O -
104 O -
T O +
cells O +
with O +
1 O -
× O -
105 O -
PBMCx O +
pretreated O +
with O +
500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
for O +
4 O +
h O +
at O +
37 O -
° O -
C O +
in O +
RPMI O -
/ O -
5 O -
% O +
human O +
serum O +
and O +
then O +
washed O +
twice O +
before O +
being O +
used O +
in O +
the O +
assay O -
. O -

2.3 O +
Isolation O +
of O +
d O +
-pen O -
- O -
specific O +
T O +
cell O +
clones O +
One O +
of O +
the O +
d O +
-pen O -
- O -
specific O +
lines O +
derived O +
from O +
patient B-Species +
D I-Species -
- I-Species -
P1 L-Species +
was O +
cloned O +
by O +
limiting O +
dilution O +
in O +
Terasaki O +
wells O +
( O -
Nunc O -
) O +
using O +
PBMCx O +
prepulsed O +
with O +
500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
as O +
the O +
stimulus O -
. O -

Proliferating O +
clones O +
were O +
expanded O +
with O +
IL-2 O +
and O +
fortnightly O +
restimulation O +
with O +
PHA O +
and O +
allogeneic O +
PBMCx O -
, O +
and O +
then O +
assayed O +
for O +
a O +
response O +
to O +
d O +
-pen O -
, O +
as O +
described O +
above O -
. O -

Specificity O +
was O +
confirmed O +
by O +
comparing O +
the O +
response O +
to O +
d O +
-pen O +
with O +
that O +
to O +
the O +
isomer O -
, O +
l O +
-penicillamine O -
, O +
and O +
the O +
analogue O -
, O +
d O +
-cysteine O +
( O -
both O +
at O +
500 O +
μg O -
/ O -
ml O -
; O +
Sigma O -
) O -
. O -

Surface O +
phenotype O +
was O +
determined O +
by O +
FACS O +
analysis O +
( O -
Becton O +
Dickinson O -
, O +
Oxford O -
, O +
UK O -
) O +
using O +
conventional O +
two O +
color O +
staining O +
with O +
anti O -
- O -
CD3 O +
( O -
OKT3 O -
) O +
directly O +
conjugated O +
to O +
fluorescein O +
isothiocyanate O +
( O -
FITC O -
; O +
gift O +
of O +
S.J. O +
Curnow O -
) O +
and O +
anti O -
- O -
CD4 O +
and O +
-CD8 O +
conjugated O +
to O +
phycoerythrin O +
( O -
Dako O -
, O +
High O +
Wycombe O -
, O +
UK O -
) O -
. O -

2.4 O +
Class O +
II O +
restriction O +
The O +
restricting O +
class O +
II O +
isotype O +
was O +
determined O +
by O +
adding O +
the O +
following O +
class O +
II O -
- O -
blocking O +
mAbs O +
to O +
the O +
presenting O +
cells O +
in O +
the O +
standard O +
assay O -
: O +
mouse U-Species +
anti O -
- O -
human U-Species +
DR O +
( O -
L243 O -
; O +
gift O +
of O +
H. O +
McDevitt O -
) O -
, O +
anti O -
- O -
human U-Species +
DP O +
( O -
gift O +
of O +
F. O +
Brodsky O -
) O +
or O +
anti O -
- O -
human U-Species +
DQ O +
( O -
L2 O -
; O +
gift O +
of O +
D. O +
Altmann O -
) O -
. O -

Comparing O +
the O +
ability O +
of O +
HLA O -
- O -
sharing O +
PBMCx O +
to O +
present O +
d O +
-pen O +
to O +
the O +
clones O +
then O +
identified O +
the O +
allele O -
. O -

2.5 O +
Cytokine O +
profile O +
The O +
supernatant O +
from O +
T O +
cell O +
clones O +
cultured O +
with O +
PBMCx's±d O +
-pen O +
was O +
analyzed O +
for O +
interferon O -
- O -
γ O +
( O -
IFN O -
- O -
γ O -
) O +
and O +
interleukin-4 O +
( O -
IL-4 O -
) O +
by O +
ELISA O +
( O -
Pharmingen O -
, O +
San O +
Diego O -
, O +
CA O -
) O +
according O +
to O +
the O +
manufacturer O -
's O +
instructions O -
. O -

2.6 O +
TCR O +
gene O +
usage O +
T O +
cell O +
receptors O +
were O +
cloned O +
using O +
the O +
anchored O +
polymerase O +
chain O +
reaction O +
( O -
Moss O +
et O +
al. O -
, O +
1993 O +
) O -
. O -

Briefly O -
, O +
cDNA O +
was O +
synthesized O +
from O +
5 O +
μg O +
of O +
RNA O +
using O +
AMV O -
- O -
RT O +
and O +
an O +
oligo O +
dT O +
primer O -
. O -

cDNA O +
was O +
precipitated O +
three O +
times O +
using O +
4 O +
M O +
ammonium O +
acetate O +
and O +
an O +
oligo O +
dG O +
homopolymer O +
tail O +
added O +
using O +
TdT. O +
cDNA O +
was O +
then O +
amplified O +
using O +
an O +
anchor O +
primer O +
and O +
primers O +
complementary O +
to O +
TCRA O +
and O +
TCRB O +
constant O +
regions O -
. O -

PCR O +
products O +
were O +
then O +
cloned O +
into O +
M13mp18 O +
and O +
sequenced O -
. O -

2.7 O +
Requirement O +
for O +
human O +
serum O +
and O +
antigen O +
processing O +
for O +
antigenicity O +
Fresh O +
PBMCs O +
were O +
washed O +
and O +
kept O +
in O +
serum O -
- O -
free O +
medium O +
before O +
irradiation O +
and O +
pulsing O +
in O +
plain O +
RPMI O -
, O +
in O +
5 O -
% O +
human U-Species +
or O +
fetal O +
calf U-Species +
serum O +
( O -
Tissue O +
Culture O +
Services O -
, O +
Buckingham O -
, O +
UK O -
) O +
or O +
in O +
serum O -
- O -
free O +
AIM O +
V O -
® O +
medium O +
( O -
Gibco O -
) O +
which O +
contains O +
human U-Species +
albumin O -
, O +
transferrin O +
and O +
insulin O -
. O -

The O +
PBMCx O +
were O +
then O +
counted O +
so O +
that O +
any O +
cell O +
losses O +
could O +
be O +
corrected O -
. O -

We O +
also O +
tested O +
B O +
cell O +
lines O -
, O +
including O +
the O +
homozygous O +
DR1 O +
line O +
EHM O +
and O +
one O +
raised O +
from O +
the O +
patient U-Species +
herself O -
; O +
they O +
were O +
pretreated O +
with O +
50 O +
μg O -
/ O -
ml O +
of O +
mitomycin O +
C O +
( O -
Sigma O -
) O +
and O +
washed O +
before O +
co O -
- O -
culture O +
with O +
the O +
T O +
cells O -
. O -

The O +
requirement O +
for O +
antigen O +
processing O +
was O +
determined O +
by O +
preincubating O +
the O +
presenting O +
cells O +
with O +
chloroquine O +
( O -
Sigma O -
) O +
for O +
30 O +
min O +
before O +
pulsing O +
with O +
500 O +
μg O -
/ O -
ml O +
d O +
-pen O +
for O +
4 O +
h O -
, O +
after O +
which O +
the O +
cells O +
were O +
washed O +
and O +
plated O +
routinely O -
. O -

To O +
confirm O +
their O +
subsequent O +
viability O -
, O +
we O +
checked O +
their O +
capacity O +
to O +
present O +
peptide O +
antigen O +
to O +
a O +
well O +
characterized O +
T O +
cell O +
clone O -
, O +
TB-2 O -
, O +
that O +
recognizes O +
a O +
fragment O +
of O +
the O +
α O +
subunit O +
of O +
the O +
AChR O -
, O +
α:144–163 O -
, O +
presented O +
by O +
DR52a O +
( O -
Nagvekar O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

3 O +
Results O +
3.1 O +
Initial O +
T O +
cell O +
responses O +
to O +
d O +
-pen O +
In O +
a O +
preliminary O +
screen O +
using O +
d O +
-pen O +
at O +
500 O +
μg O -
/ O -
ml O -
, O +
we O +
found O +
positive O +
responses O +
by O +
PBL O +
T O +
cells O +
( O -
SI>2 O -
) O +
in O +
four O +
of O +
five O +
RA O +
patients U-Species +
with O +
recent O +
onset O +
d O +
-pen O +
MG O +
( O -
SIs O +
3–12 O -
) O -
; O +
in O +
one O +
of O +
four O +
RA O +
patients U-Species +
without O +
MG O +
or O +
anti O -
- O -
AChR O +
antibodies O +
despite O +
d O +
-pen O +
treatment O +
( O -
SI O +
4.1 O -
) O -
; O +
in O +
zero O +
of O +
three O +
patients U-Species +
with O +
idiopathic O +
EOMG O +
and O +
in O +
4 O +
of O +
11 O +
healthy O +
controls O +
( O -
SI O +
2.3 O -
, O +
4.5 O -
, O +
4.8 O +
and O +
15.0 O -
) O -
. O -

All O +
of O +
the O +
d O +
-pen O +
MG O +
patients U-Species +
had O +
HLA O -
- O -
DR1 O -
, O +
as O +
did O +
the O +
one O +
other O +
responder O +
with O +
RA O -
. O -

However O -
, O +
none O +
of O +
the O +
healthy O +
responders O +
was O +
DR1 O -
+ O +
; O +
some O +
of O +
their O +
responses O +
might O +
conceivably O +
be O +
related O +
to O +
prior O +
exposure O +
to O +
penicillin O -
. O -

Only O +
one O +
of O +
the O +
responder O +
d O +
-pen O +
MG O +
patients U-Species +
( O -
D B-Species -
- I-Species -
P1 L-Species -
; O +
SI O +
4.3 O -
) O +
was O +
tested O +
before O +
taking O +
corticosteroids O -
; O +
as O +
she O +
was O +
readily O +
available O +
for O +
further O +
sampling O -
, O +
T O +
cell O +
lines O +
were O +
initiated O +
from O +
her O +
for O +
detailed O +
characterization O +
of O +
this O +
response O -
. O -

3.2 O +
Selecting O +
d O +
-pen O -
- O -
responsive O +
T O +
cell O +
lines O +
and O +
clones O +
from O +
patient B-Species +
D I-Species -
- I-Species -
P1 L-Species +
Several O +
T O +
cell O +
lines O +
were O +
successfully O +
raised O +
and O +
maintained O +
by O +
culturing O +
with O +
d O +
-pen O +
at O +
500 O +
μg O -
/ O -
ml O -
. O -

Three O +
findings O +
established O +
that O +
this O +
drug O +
was O +
not O +
merely O +
acting O +
as O +
a O +
non O -
- O -
specific O +
mitogen O -
. O -

Firstly O -
, O +
two O +
well O -
- O -
characterized O +
AChR O -
- O -
specific O +
T O +
cell O +
clones O -
, O +
TB-2 O +
and O +
PM O -
- O -
A1 O -
, O +
failed O +
to O +
show O +
any O +
proliferative O +
response O +
to O +
d O +
-pen O +
at O +
50–500 O +
μg O -
/ O -
ml O +
( O -
not O +
shown O -
) O -
. O -

Secondly O -
, O +
the O +
drug O -
- O -
specific O +
lines O +
also O +
responded O +
optimally O +
to O +
autologous O +
APC O +
preincubated O +
with O +
the O +
drug O +
for O +
4 O +
h O +
and O +
then O +
washed O +
thoroughly O -
, O +
while O +
unpulsed O +
autologous O +
APC O +
failed O +
to O +
stimulate O -
. O -

Thirdly O -
, O +
there O +
was O +
no O +
response O +
when O +
the O +
APC O +
were O +
HLA O -
- O -
mismatched O +
( O -
see O +
below O -
) O -
. O -

3.3 O +
Characteristics O +
of O +
d O +
-pen O -
- O -
specific O +
T O +
cell O +
clones O +
The O +
d O +
-pen O -
- O -
specific O +
line O +
that O +
showed O +
the O +
greatest O +
response O +
to O +
the O +
drug O +
was O +
cloned O +
by O +
limiting O +
dilution O +
in O +
the O +
presence O +
of O +
d O +
-pen O -
- O -
prepulsed O +
autologous O +
PBMCx O -
. O -

Among O +
the O +
175 O +
clones O +
grown O -
, O +
40 O -
% O +
( O -
70 O -
) O +
responded O +
to O +
d O +
-pen O +
( O -
SI>5 O -
) O -
, O +
showing O +
that O +
there O +
was O +
a O +
high O +
precursor O +
frequency O +
of O +
d O +
-pen O -
- O -
specific O +
T O +
cells O +
in O +
the O +
line O -
. O -

Some O +
10 O +
clones O +
were O +
chosen O +
for O +
further O +
study O -
; O +
they O +
were O +
all O +
CD3 O -
+ O +
CD4 O -
+ O -
and O +
behaved O +
identically O +
in O +
all O +
experiments O -
, O +
responding O +
to O +
autologous O +
PBMCx O +
preincubated O +
with O +
d O +
-pen O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Fig. O +
1 O -
) O -
. O -

Moreover O -
, O +
the O +
clones O +
were O +
highly O +
specific O +
for O +
l O +
-pen O -
, O +
as O +
shown O +
by O +
their O +
failure O +
to O +
respond O +
to O +
the O +
analogues O +
d O +
-pen O +
and O +
d O +
-cysteine O +
( O -
Fig. O +
2 O -
) O -
. O -

The O +
10 O +
clones O +
tested O +
all O +
proved O +
to O +
be O +
restricted O +
to O +
HLA O -
- O -
DR1 O -
. O -

An O +
isotype O -
- O -
specific O +
anti O -
- O -
HLA O -
- O -
DR O +
mAb O +
almost O +
completely O +
blocked O +
the O +
responses O +
of O +
these O +
clones O +
( O -
Fig. O +
3 O -
a O -
) O -
; O +
furthermore O -
, O +
they O +
all O +
recognized O +
d O +
-pen O -
- O -
pulsed O +
PBMCx O +
from O +
a O +
number O +
of O +
healthy O +
DR1 O -
+ O -
individuals O +
( O -
Fig. O +
3 O +
b O -
) O -
. O -

The O +
two O +
clones O +
tested O +
were O +
both O +
phenotypically O +
Th1 O -
, O +
producing O +
large O +
amounts O +
of O +
IFN O -
- O -
γ O +
( O -
2 O -
× O -
104 O -
pg O -
/ O -
ml O -
) O -
, O +
but O +
no O +
detectable O +
IL-4 O +
( O -
not O +
shown O -
) O -
. O -

They O +
proved O +
to O +
have O +
identical O +
TCR O +
gene O +
usage O -
, O +
namely O +
Vα4.1 O -
, O +
Jα1.3 O -
, O +
Vβ6.1 O -
, O +
Jβ2.3 O -
, O +
suggesting O +
that O +
they O +
are O +
sister O +
clones O -
. O -

Intriguingly O -
, O +
this O +
β O +
chain O +
sequence O +
shares O +
a O +
PG O +
motif O +
in O +
the O +
CDR3 O +
region O +
( O -
Fig. O +
4 O -
) O +
with O +
a O +
previously O +
characterized O +
AChR O +
ε O -
- O -
specific O +
T O +
cell O +
clone O +
isolated O +
from O +
a O +
patient U-Species +
with O +
EOMG O +
( O -
Hill O +
et O +
al. O -
, O +
1999 O +
) O -
. O -

3.4 O +
Potential O +
` O -
carrier O -
' O +
molecules O +
for O +
d O +
-pen O +
To O +
determine O +
whether O +
the O +
d O +
-pen O +
was O +
coupling O +
to O +
a O +
serum O +
protein O -
, O +
PBMCx O +
were O +
pulsed O +
with O +
d O +
-pen O +
in O +
the O +
presence O +
or O +
absence O +
of O +
serum O -
. O -

Regardless O +
of O +
whether O +
we O +
used O +
5 O -
% O +
human U-Species +
or O +
fetal O +
calf U-Species +
serum O -
, O +
serum O -
- O -
free O +
AIM O +
V O -
® O +
medium O +
( O -
containing O +
human U-Species +
albumin O -
, O +
transferrin O +
and O +
insulin O -
) O +
or O +
even O +
plain O +
RPMI O -
, O +
the O +
PBMCx O +
all O +
stimulated O +
the O +
two O +
T O +
cell O +
clones O +
tested O +
very O +
efficiently O +
( O -
Fig. O +
5 O -
) O -
. O -

This O +
result O +
suggested O +
that O +
the O +
drug O +
was O +
coupling O +
to O +
pre O -
- O -
existing O +
cellular O +
proteins O -
, O +
whether O +
internal O +
or O +
on O +
the O +
surface O -
. O -

To O +
determine O +
whether O +
these O +
require O +
further O +
processing O -
, O +
we O +
tested O +
the O +
effects O +
of O +
chloroquine O -
, O +
a O +
potent O +
lysosomotropic O +
inhibitor O +
of O +
antigen O +
processing O +
( O -
Ziegler O +
and O +
Unanue O -
, O +
1982 O +
) O -
. O -

As O +
a O +
standard O -
, O +
we O +
used O +
the O +
response O +
of O +
clone O +
TB-2 O +
to O +
both O +
the O +
full O -
- O -
length O +
AChR O +
α O +
subunit O +
( O -
α:1–437 O -
) O -
, O +
which O +
requires O +
processing O -
, O +
and O +
its O +
peptide O -
, O +
α:144–163 O -
, O +
which O +
does O +
not O +
( O -
Fig. O +
6 O -
) O -
. O -

Pretreatment O +
of O +
PBMCx O +
with O +
chloroquine O +
had O +
no O +
detectable O +
effect O +
on O +
the O +
responses O +
to O +
d O +
-pen O +
or O +
α:144–163 O +
at O +
doses O +
that O +
almost O +
completely O +
abolished O +
those O +
to O +
the O +
full O -
- O -
length O +
α:1–437 O +
( O -
Fig. O +
6 O +
b O -
) O -
, O +
clearly O +
showing O +
that O +
the O +
key O +
molecules O +
modified O +
by O +
d O +
-pen O +
do O +
not O +
require O +
subsequent O +
processing O -
. O -

Thus O -
, O +
these O +
data O +
strongly O +
suggest O +
that O +
d O +
-pen O +
is O +
acting O +
by O +
directly O +
coupling O +
to O +
a O +
component O +
of O +
the O +
MHC O -
/ O -
peptide O +
complex O -
. O -

It O +
was O +
therefore O +
intriguing O +
that O +
two O +
different O +
DR1 O -
+ O -
EBV O -
- O -
B O +
cell O +
lines O +
( O -
one O +
of O +
them O +
autologous O -
) O +
consistently O +
failed O +
to O +
` O -
present O -
' O +
d O +
-pen O +
to O +
the O +
clones O -
; O +
this O +
deficiency O +
was O +
not O +
corrected O +
by O +
pre O -
- O -
culturing O +
the O +
EBV O -
- O -
B O +
cells O +
in O +
human U-Species +
serum O +
rather O +
than O +
the O +
FCS O +
in O +
which O +
these O +
cells O +
were O +
normally O +
maintained O +
( O -
Fig. O +
7 O -
) O -
. O -

The O +
autologous O +
B O +
cell O +
line O -
, O +
which O +
also O +
has O +
HLA O -
- O -
DR52a O -
, O +
presented O +
specific O +
peptides O +
very O +
well O +
to O +
the O +
DR52a O -
- O -
restricted O +
clone O +
TB-2 O +
when O +
tested O +
in O +
parallel O -
, O +
confirming O +
its O +
efficient O +
antigen O -
- O -
presenting O +
ability O -
. O -

Thus O -
, O +
these O +
results O +
suggest O +
that O +
these O +
T O +
cells O +
are O +
recognizing O +
a O +
modification O +
of O +
some O +
resident O +
peptide O -
, O +
rather O +
than O +
of O +
the O +
DR1 O +
itself O -
, O +
and O +
that O +
this O +
peptide O +
differs O +
in O +
the O +
PBMC O +
and O +
the O +
B O +
cell O +
lines O -
. O -

4 O +
Discussion O +
In O +
this O +
study O +
on O +
d O +
-pen O -
- O -
induced O +
MG O -
, O +
we O +
report O +
the O +
isolation O +
and O +
characterization O +
of O +
CD4 O -
+ O -
Th1 O +
cell O +
clones O +
specific O +
for O +
d O +
-pen O -
, O +
which O +
recognized O +
DR1 O -
+ O -
APC O +
preincubated O +
with O +
the O +
drug O -
. O -

Our O +
evidence O +
suggests O +
that O +
it O +
is O +
acting O +
by O +
directly O +
modifying O +
pre O -
- O -
existing O +
MHC O +
molecules O +
and/or O +
resident O +
peptides O +
on O +
the O +
APC O +
surface O -
, O +
though O +
the O +
nature O +
of O +
this O +
modification O +
still O +
requires O +
elucidation O -
. O -

Responses O +
of O +
these O +
T O +
cells O +
became O +
significant O +
at O +
approximately O +
50 O +
μg O -
/ O -
ml O +
of O +
d O +
-pen O -
, O +
and O +
optimal O +
at O +
500 O +
μg O -
/ O -
ml O -
; O +
the O +
latter O +
is O +
very O +
similar O +
to O +
that O +
previously O +
used O +
in O +
vitro O +
for O +
d O +
-pen O -
- O -
specific O +
T O +
cells O +
isolated O +
from O +
experimental O +
animals U-Species +
immunized O +
with O +
the O +
drug O +
( O -
O'Donnell O +
and O +
Coleman O -
, O +
1992 O +
) O -
. O -

It O +
apparently O +
contrasts O +
with O +
the O +
peak O +
levels O +
of O +
about O +
5 O +
μg O -
/ O -
ml O +
measured O +
in O +
the O +
peripheral O +
blood O +
of O +
patients U-Species +
taking O +
750 O +
mg O -
/ O -
day O +
( O -
Brooks O +
et O +
al. O -
, O +
1984 O +
) O -
. O -

However O -
, O +
much O +
higher O +
doses O +
are O +
usually O +
required O +
in O +
culture O +
than O +
in O +
vivo O -
, O +
as O +
has O +
been O +
observed O +
previously O +
with O +
other O +
drugs O +
such O +
as O +
sulfonamides O -
, O +
carbamazepine O +
and O +
phenytoin O +
( O -
Mauri O -
- O -
Hellweg O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
as O +
well O +
as O +
with O +
d O +
-pen O +
itself O +
( O -
O'Donnell O +
and O +
Coleman O -
, O +
1992 O +
) O -
. O -

It O +
therefore O +
seems O +
likely O +
that O -
, O +
in O +
vivo O -
, O +
the O +
drug O +
becomes O +
concentrated O +
in O +
specialized O +
microenvironments O +
or O +
reactive O +
under O +
conditions O +
that O +
are O +
not O +
reproduced O +
in O +
culture O -
, O +
and/or O +
that O +
prolonged O +
exposure O +
is O +
required O -
. O -

It O +
is O +
well O +
recognized O +
that O +
d O +
-pen O +
can O +
couple O +
directly O +
to O +
proteins O -
, O +
forming O +
disulfide O +
bonds O +
with O +
free O +
cysteine O +
residues O +
( O -
Coleman O +
et O +
al. O -
, O +
1988 O +
): O +
it O +
can O +
also O +
break O +
pre O -
- O -
existing O +
disulfide O +
bonds O -
, O +
and O +
so O +
unfold O +
proteins O +
or O +
disaggregate O +
complexes O -
. O -

Several O +
published O +
reports O +
demonstrate O +
that O +
it O +
couples O +
directly O +
to O +
the O +
surface O +
of O +
presenting O +
cells O +
of O +
experimental O +
animals U-Species +
in O +
vivo O -
, O +
though O +
the O +
identity O +
of O +
the O +
target O +
protein O -
( O -
s O -
) O +
has O +
not O +
been O +
determined O -
. O -

At O +
doses O +
of O +
125–1000 O +
μg O -
/ O -
ml O -
, O +
d O +
-pen O +
rapidly O +
couples O +
directly O +
to O +
the O +
surface O +
of O +
rat U-Species +
macrophages O -
, O +
a O +
process O +
that O +
is O +
not O +
affected O +
by O +
cell O +
fixation O +
or O +
chloroquine O -
, O +
but O +
is O +
enhanced O +
by O +
oxidizing O +
agents O +
( O -
O'Donnell O +
et O +
al. O -
, O +
1991 O +
) O -
. O -

These O +
cells O +
take O +
up O +
the O +
labeled O +
drug O +
in O +
a O +
dose- O +
and O +
time O -
- O -
dependent O +
manner O +
and O +
retain O +
it O +
for O +
over O +
24 O +
h. O +
In O +
contrast O -
, O +
although O +
lymphocytes O +
rapidly O +
acquire O +
labeled O +
d O +
-pen O -
, O +
they O +
also O +
lose O +
it O +
completely O +
within O +
2 O +
h O +
( O -
Binderup O +
and O +
Arrigoni O -
- O -
Martelli O -
, O +
1979 O +
) O -
. O -

Our O +
present O +
results O +
also O +
suggest O +
that O +
d O +
-pen O +
is O +
acting O +
by O +
coupling O +
directly O +
to O +
the O +
APC O -
, O +
and O +
it O +
seems O +
logical O +
to O +
suppose O +
that O +
its O +
target O +
is O +
the O +
class O +
II O -
/ O -
peptide O +
complex O -
. O -

Since O +
there O +
is O +
a O +
well O -
- O -
known O +
association O +
with O +
HLA O -
- O -
DR1 O +
in O +
d O +
-pen O -
- O -
induced O +
MG O +
( O -
Garlepp O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
the O +
uniform O +
restriction O +
of O +
our O +
clones O +
to O +
this O +
allele O +
argues O +
strongly O +
for O +
their O +
disease O -
- O -
relevance O -
. O -

This O +
would O +
be O +
further O +
supported O +
if O +
the O +
same O +
modification O +
were O +
already O +
present O +
in O +
vivo O +
on O +
the O +
APC O +
of O +
DR1 O -
+ O -
MG O +
patients U-Species +
taking O +
d O +
-pen O -
, O +
and O +
recognizable O +
by O +
the O +
D O -
- O -
P1 O +
T O +
cells O -
. O -

We O +
were O +
unable O +
to O +
test O +
this O +
possibility O +
because O +
our O +
patient U-Species +
had O +
stopped O +
the O +
treatment O +
before O +
enrolment O +
in O +
the O +
study O -
. O -

Several O +
other O +
drugs O -
/ O -
haptens O +
are O +
known O +
to O +
couple O +
either O +
to O +
peptides O +
resident O +
in O +
the O +
MHC O +
groove O +
or O +
directly O +
to O +
MHC O +
molecules O -
. O -

Examples O +
of O +
the O +
former O +
include O +
trinitrophenyl O +
( O -
TNP O -
) O +
and O +
penicillin O +
which O +
both O +
couple O +
to O +
lysine O +
residues O +
( O -
Martin O +
et O +
al. O -
, O +
1992 O +
; O +
Padovan O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
and O +
nickel O +
which O +
couples O +
to O +
histidines O +
( O -
Romagnoli O +
et O +
al. O -
, O +
1992 O +
) O -
, O +
while O +
gold O +
salts O +
are O +
thought O +
to O +
directly O +
modify O +
the O +
class O +
II O +
molecule O +
( O -
Sinigaglia O -
, O +
1994 O +
) O -
. O -

Although O +
further O +
work O +
is O +
required O +
to O +
determine O +
which O +
of O +
these O +
two O +
possibilities O +
applies O +
to O +
d O +
-pen O -
, O +
it O +
is O +
worthy O +
of O +
note O +
that O +
HLA O -
- O -
DR1 O +
is O +
the O +
only O +
human U-Species +
DR O +
molecule O +
that O +
has O +
an O +
unpaired O +
cysteine O +
residue O -
. O -

It O +
is O +
at O +
position O +
30 O +
in O +
the O +
floor O +
of O +
the O +
peptide O -
- O -
binding O +
groove O +
( O -
Stern O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
where O +
modification O +
of O +
analogous O +
amino O +
acids O +
in O +
other O +
HLA O +
alleles O +
can O +
dramatically O +
alter O +
T O +
cell O +
recognition O +
of O +
the O +
epitope O +
peptides O +
( O -
Krieger O +
et O +
al. O -
, O +
1991 O +
; O +
Boehncke O +
et O +
al. O -
, O +
1993 O +
) O -
. O -

Work O +
on O +
the O +
class O +
I O +
allele O +
HLA O -
- O -
B27 O +
also O +
suggests O +
that O +
oxidative O +
modification O +
of O +
the O +
unusual O +
free O +
sulfhydryl O +
group O +
( O -
67 O +
Cys O -
) O +
on O +
this O +
HLA O +
molecule O +
can O +
directly O +
influence O +
its O +
immunogenicity O +
( O -
Archer O +
et O +
al. O -
, O +
1990 O +
) O -
. O -

The O +
failure O +
of O +
the O +
d O +
-pen O -
- O -
treated O +
B O +
cell O +
lines O +
to O +
stimulate O +
our O +
clones O +
is O +
intriguing O +
and O +
argues O +
that O +
the O +
drug O +
was O +
modifying O +
distinctive O +
resident O +
peptides O +
in O +
the O +
autologous O +
PBMC O +
that O +
are O +
not O +
identical O +
in O +
the O +
B O +
cell O +
lines O -
. O -

It O +
would O +
therefore O +
be O +
interesting O +
to O +
identify O +
the O +
key O +
cell O +
type O +
in O +
the O +
PBMC O +
( O -
e.g. O -
, O +
macrophage O +
or O +
dendritic O +
cell O -
) O -
. O -

One O +
might O +
then O -
, O +
in O +
principle O -
, O +
take O +
advantage O +
of O +
this O +
failure O +
by O +
comparing O +
the O +
peptides O +
that O +
react O +
with O +
labeled O +
d O +
-pen O +
in O +
these O +
cells O +
and O +
in O +
the O +
B O +
cell O +
lines O -
, O +
though O +
they O +
may O +
be O +
too O +
heterogeneous O +
to O +
allow O +
precise O +
identification O +
of O +
the O +
key O +
epitope O -
( O -
s O -
) O -
. O -

Remarkably O -
, O +
however O -
, O +
one O +
resident O +
AChR O +
peptide O +
has O +
already O +
been O +
identified O +
in O +
a O +
DR3 O -
+ O -
B O +
cell O +
line O +
( O -
Chicz O +
et O +
al. O -
, O +
1993 O +
) O -
. O -

The O +
d O +
-pen O -
- O -
specific O +
clones O +
characterized O +
here O +
could O +
provide O +
important O +
clues O +
to O +
the O +
pathogenesis O +
of O +
both O +
drug O -
- O -
induced O +
and O +
idiopathic O +
MG O -
. O -

The O +
first O +
obvious O +
mechanism O +
is O +
that O +
d O +
-pen O -
- O -
modified O +
peptides O +
activate O +
T O +
cells O +
that O +
can O +
cross O -
- O -
react O +
with O +
epitopes O +
derived O +
from O +
the O +
AChR O -
, O +
though O +
it O +
is O +
hard O +
to O +
envisage O +
the O +
exact O +
nature O +
of O +
such O +
cross O -
- O -
reactions O -
, O +
and O -
, O +
as O +
yet O -
, O +
there O +
is O +
no O +
direct O +
evidence O +
for O +
them O -
. O -

In O +
fact O -
, O +
the O +
clone O +
we O +
tested O +
showed O +
no O +
detectable O +
recognition O +
of O +
either O +
AChR O +
or O +
its O +
α O -
, O +
γ O +
or O +
ε O +
subunits O +
after O +
these O +
were O +
pre O -
- O -
incubated O +
with O +
d O +
-pen O +
( O -
not O +
shown O -
) O -
, O +
though O +
some O +
of O +
the O +
69 O +
other O +
clones O +
may O +
be O +
sufficiently O +
sensitive O +
to O +
do O +
so O -
. O -

We O +
also O +
tested O +
five O +
patients U-Species +
with O +
d O +
-pen O -
- O -
induced O +
MG O +
for O +
recognition O +
of O +
the O +
untreated O +
AChR O +
α O -
- O -
subunit O +
( O -
present O +
in O +
all O +
isoforms O -
) O -
, O +
the O +
fetal O -
- O -
specific O +
γ O +
and O +
the O +
adult O -
- O -
specific O +
ε O -
. O -

Interestingly O -
, O +
in O +
four O +
of O +
these O +
five O +
cases O -
, O +
we O +
saw O +
responses O +
to O +
the O +
ε O +
rather O +
than O +
the O +
other O +
subunits O +
( O -
not O +
shown O -
) O -
. O -

Since O +
the O +
present O +
case O +
( O -
D B-Species -
- I-Species -
P1 L-Species -
) O +
again O +
appeared O +
to O +
be O +
representative O -
, O +
we O +
went O +
on O +
to O +
isolate O +
clones O +
that O +
proved O +
to O +
be O +
specific O +
for O +
the O +
ε:201–219 O +
sequence O +
( O -
Hill O +
et O +
al. O -
, O +
1999 O +
) O -
. O -

This O +
also O +
appears O +
to O +
be O +
a O +
dominant O +
epitope O +
for O +
EOMG O +
patients U-Species +
and O +
is O +
presented O +
by O +
the O +
candidate O +
susceptibility O +
allele O -
, O +
DR52a O +
( O -
Hill O +
et O +
al. O -
, O +
1999 O +
) O -
. O -

Thus O -
, O +
one O +
might O +
hypothesize O +
that O +
AChR O -
- O -
cross O -
- O -
reactive O +
T O +
cells O +
initially O +
activated O +
by O +
d O +
-pen O +
lead O -
, O +
by O +
a O +
process O +
of O +
determinant O +
spreading O -
, O +
to O +
responsiveness O +
to O +
the O +
ε O +
subunit O +
that O +
then O +
induces O +
a O +
pathogenic O +
autoantibody O +
response O -
, O +
as O +
in O +
idiopathic O +
MG O -
. O -

These O +
T O +
cells O +
would O +
be O +
well O +
equipped O +
to O +
help O +
in O +
the O +
generation O +
of O +
complement O -
- O -
fixing O +
antibodies O +
by O +
virtue O +
of O +
their O +
Th1 O +
cytokine O +
profile O -
. O -

However O -
, O +
whereas O +
this O +
response O +
appears O +
to O +
be O +
self O -
- O -
perpetuating O +
in O +
EOMG O -
, O +
the O +
antibody O +
titers O +
usually O +
fall O +
upon O +
withdrawal O +
of O +
d O +
-pen O -
, O +
with O +
concomitant O +
remission O +
of O +
symptoms O -
. O -

A O +
second O +
possibility O +
is O +
that O +
d O +
-pen O +
directly O +
` O -
haptenates O -
' O +
AChR O +
and/or O +
AChR O +
fragments O +
that O +
then O +
activate O +
pathogenic O +
T O +
cells O -
. O -

Hence O -
, O +
it O +
is O +
interesting O +
that O +
the O +
above O +
ε:201–219 O +
sequence O +
includes O +
an O +
unpaired O +
210 O +
Cys O -
at O +
p6 O +
in O +
the O +
epitope O +
core O +
( O -
Beeson O +
et O +
al. O -
, O +
1993 O +
) O -
. O -

This O +
residue O +
appears O +
to O +
be O +
important O +
for O +
T O +
cell O +
recognition O -
, O +
since O +
pre O -
- O -
exposure O +
to O +
d O +
-pen O +
prevented O +
this O +
peptide O +
from O +
stimulating O +
another O +
ε201–219-specific O +
clone O +
from O +
an O +
EOMG O +
patient U-Species +
( O -
unpublished O +
observations O -
) O -
. O -

Hence O -
, O +
this O +
sequence O +
itself O +
may O +
be O +
an O +
alternative O +
target O +
for O +
d O +
-pen O +
modification O -
. O -

In O +
either O +
case O -
, O +
it O +
is O +
a O +
particularly O +
intriguing O +
possibility O +
that O +
d O +
-pen O +
is O +
mimicking O +
the O +
action O +
of O +
an O +
as O +
yet O +
unidentified O +
natural O +
` O -
counterpart O -
' O +
that O +
is O +
responsible O +
for O +
initiating O +
the O +
idiopathic O +
disease O -
. O -

An O +
analogous O +
process O +
has O +
been O +
implicated O +
in O +
other O +
conditions O +
presenting O +
with O +
autoimmune O +
features O +
such O +
as O +
the O +
plant U-Species +
amino O +
acid O -
, O +
canavanine O -
, O +
in O +
SLE O -
, O +
and O +
an O +
analogue O +
of O +
l O +
-tryptophan O -
, O +
1,1′-ethylidenebis O -
[ O -
l O +
-tryptophan O -
] O +
that O +
is O +
thought O +
to O +
induce O +
Eosinophilia O -
– O -
Myalgia O +
syndrome O +
( O -
Yoshida O +
and O +
Gershwin O -
, O +
1993 O +
) O -
. O -

Although O +
definitive O +
proof O +
that O +
these O +
agents O +
are O +
responsible O +
for O +
causing O +
disease O +
is O +
awaited O -
, O +
the O +
latter O +
compound O +
has O +
been O +
shown O +
to O +
be O +
incorporated O +
into O +
self O -
- O -
proteins O -
, O +
apparently O +
creating O +
novel O +
epitopes O +
( O -
Buss O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

Anti O -
- O -
hapten O +
responses O +
have O +
also O +
been O +
implicated O +
in O +
active O +
ankylosing O +
spondylitis O +
by O +
the O +
isolation O +
of O +
HLA O -
- O -
B27-restricted O +
cytotoxic O +
T O +
cells O +
that O +
recognize O +
both O +
APC O +
treated O +
with O +
the O +
compound O +
homocysteine O +
and O +
B O +
cells O +
infected O +
with O +
Salmonella B-Species +
typhimurium L-Species -
( O -
Gao O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

In O +
summary O -
, O +
the O +
isolation O +
and O +
characterization O +
of O +
these O +
d O +
-pen O -
- O -
specific O +
T O +
cell O +
clones O +
should O +
provide O +
a O +
useful O +
experimental O +
system O +
with O +
which O +
to O +
elucidate O +
the O +
basis O +
of O +
hapten O +
recognition O +
by O +
human U-Species +
T O +
cells O -
, O +
and O +
perhaps O +
also O +
the O +
mechanisms O +
of O +
drug O -
- O -
induced O +
autoimmune O +
disease O -
. O -

Ultimately O +
it O +
may O +
also O +
provide O +
insights O +
into O +
the O +
factors O +
involved O +
in O +
the O +
initiation O +
of O +
idiopathic O +
MG O -
. O -

Acknowledgements O -

We O +
are O +
very O +
grateful O +
to O +
several O +
colleagues O +
for O +
referring O +
patients U-Species +
or O +
providing O +
mAbs O -
, O +
to O +
donor O +
D B-Species -
- I-Species -
P1 L-Species +
and O +
to O +
Drs O -
. O -

E. O +
Sim O -
, O +
J. O +
Coleman O +
and O +
A. O +
Vincent O +
for O +
invaluable O +
suggestions O +
and O +
advice O -
. O -

MEH O +
was O +
supported O +
by O +
the O +
Medical O +
Research O +
Council O +
of O +
Great O +
Britain O -
. O +

Human U-Species +
fascioliasis O -
, O +
caused O +
by O +
Fasciola B-Species +
hepatica I-Species -
, L-Species +
is O +
a O -
great O +
worldwide O +
health O +
problem O +
( O -
CHEN O +
& O +
MOTT O -
, O +
1990 O -
; O -
ESTEBAN O +
et O +
al. O -
, O +
1998e O -
) O -
. O -

Several O +
areas O +
have O +
been O +
de- O -
scribed O +
as O +
presenting O +
true O +
human U-Species +
endemics O -
, O +
ranging O -
from O +
low O +
to O +
very O +
high O +
prevalences O +
and O +
intensities O -
( O -
MAS O -
- O -
COMA O +
al. O -
, O +
1999a O -
) O -
. O -

Studies O +
carried O +
out O +
in O +
recent O -
years O +
have O +
demonstrated O +
that O +
the O +
most O +
important O +
human U-Species -
fascioliasis O +
endemic O +
regions O +
are O +
located O +
in O +
South O +
America O -
( O -
MAS O -
- O -
COMAetfl O -
/ O -
. O -
, O +
1995 O -
, O +
1999a O -
; O +
WHO O -
, O +
1995;HlLLYER O -
& O +
APT O -
, O +
1997 O -
; O +
ESTEBAN O +
et O +
al. O -
, O +
1998e O -
) O -
. O -

Coprological O +
( O -
MAS O -
- O -
COMA O +
al. O -
, O +
1995 O -
; O +
ESTEBAN O +
al. O -
, O -
1997a O -
, O +
1997b O -
) O +
and O +
immunological O +
surveys O +
( O -
HILLYER O +
et O -
al. O -
, O +
1992 O -
; O +
BJORLAND O +
et O +
al. O -
, O +
1995 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O -
1995 O -
; O +
O'NEILL O +
et O +
al. O -
, O +
1998 O -
) O -
, O +
concerning O +
either O +
a O +
given O -
locality O +
or O +
only O +
a O +
very O +
few O -
, O +
have O +
shown O +
that O +
the O +
Northern O -
Bolivian O +
Altiplano O -
, O +
between O +
Lake O +
Titicaca O +
and O +
the O +
valley O -
of O +
the O +
city O +
of O +
La O +
Paz O -
, O +
presents O +
high O +
human U-Species +
prevalences O -
and O +
intensities O -
. O -

Concerning O +
the O +
intermediate O +
snail O +
host O +
involved O -
, O -
despite O +
initial O +
reports O +
of O +
2 O +
different O +
lymnaeid O +
transmit- O -
ting O +
species O +
( O -
Lymnaea B-Species +
matrix L-Species +
and O +
L. B-Species +
cubensis L-Species -
) O +
in O +
the O -
Bolivian O +
Altiplano O +
( O -
UENO O +
et O +
al. O -
, O +
1975 O -
) O -
, O +
it O +
has O +
been O -
recently O +
demonstrated O +
that O +
only O +
1 O +
transmitting O +
species O -
is O +
there O -
. O -

Shell O +
morphology O +
and O +
visceral O +
mass O +
anatomy O -
( O -
OVIEDO O +
et O +
al. O -
, O +
1995 O -
) O -
, O +
and O +
molecular O +
( O -
BARGUES O +
& O +
MAS- O -
COMA O -
, O +
1997 O -
; O +
BARGUES O +
et O +
al. O -
, O +
1997 O -
) O +
and O +
isoenzyme O -
( O -
JABBOUR O -
- O -
ZAHAB O +
et O +
al. O -
, O +
1997 O -
) O +
studies O +
have O +
proved O +
that O -
this O +
species O +
is O +
the O +
European O +
L. B-Species +
truncatula L-Species -
, O +
most O +
probably O -
introduced O +
by O +
Spanish B-Species +
colonizers L-Species +
long O +
ago O -
. O -

Investigations O +
carried O +
out O +
in O +
the O +
Northern O +
Bolivian O -
Altiplano O +
have O +
shown O +
that O +
there O +
are O +
different O +
animal U-Species -
species O +
which O +
play O +
the O +
role O +
of O +
reservoirs O +
and O +
others O +
that O -
are O +
potential O +
definitive O +
hosts O +
( O -
UENO O +
& O +
MORALES O -
, O +
1973 O -
; O -
UENO O +
et O +
al. O -
, O +
1975 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O +
1995 O -
, O +
1997 O -
; O -
HILLYER O +
et O +
al. O -
, O +
1996 O -
; O +
BUCHON O +
et O +
al. O -
, O +
1997 O -
; O +
FUENTES O -
et O +
al. O -
, O +
1997 O -
; O +
GROCK O +
et O +
al. O -
, O +
1998 O -
) O -
. O -

Sheep U-Species +
may O +
be O +
consid- O -
ered O +
the O +
most O +
important O +
reservoir O +
( O -
GROCK O +
et O +
al. O -
, O +
1998 O -
) O -
, O -
followed O +
by O +
cattle U-Species +
( O -
BUCHON O +
et O +
al. O -
, O +
1997 O -
) O -
. O -

Pigs U-Species +
and O -
donkeys U-Species +
represent O +
effective O +
secondary O +
reservoir O +
hosts O +
of O -
the O +
parasite U-Species +
in O +
this O +
area O +
and O +
must O +
also O +
be O +
taken O +
into O -
account O +
within O +
preventive O +
and O +
control O +
measures O +
( O -
MAS- O -
Address O +
for O +
correspondence O -
: O +
Professor O +
Dr O +
Jose O -
- O -
Guillermo O -
Esteban O -
, O +
Department O +
of O +
Parasitology O -
, O +
Faculty O +
of O +
Pharmacy O -
, O -
University O +
of O +
Valencia O -
, O +
Av O -
. O -

Vicente O +
Andres O +
Estelies O +
s O -
/ O -
n O -
, O +
46100 O -
Burjassot O -
- O -
Valencia O -
, O +
Spain O -
; O +
phone O +
+ O -
34 O +
96 O +
3864298 O -
, O +
fax O +
+ O -
34 O +
96 O -
3864769 O -
, O +
e O -
- O -
mail O +
jguillermo O -
. O -

esteban@uv.es O -
COMA O +
al. O -
, O +
1997 O -
) O -
. O -

Horses U-Species -
, O +
goats U-Species -
, O +
llamas U-Species +
and O +
alpacas U-Species -
, O +
as O -
well O +
as O +
rabbits U-Species -
, O +
hares U-Species +
and O +
rodents U-Species -
, O +
do O +
not O +
participate O +
in O -
the O +
transmission O +
( O -
FUENTES O +
et O +
al. O -
, O +
1997 O -
; O +
MAS O -
- O -
COMA O +
et O -
al. O -
, O +
1997 O -
) O -
. O -

The O +
aim O +
of O +
this O +
paper O +
is O +
to O +
present O +
and O +
analyse O +
the O -
results O +
obtained O +
in O +
31 O +
coprological O +
surveys O +
including O -
different O +
Altiplanic O +
localities O -
. O -

The O +
purpose O +
is O +
to O +
obtain O +
a O -
general O +
overview O +
of O +
human U-Species +
infection O +
prevalences O +
and O -
intensities O +
throughout O +
the O +
endemic O +
zone O -
. O -

This O +
is O +
the O +
first O -
time O +
that O +
such O +
a O +
large O +
epidemiological O +
study O +
of O +
a O +
human U-Species -
fascioliasis O +
area O +
has O +
been O +
carried O +
out O -
. O -

Materials O +
and O +
Methods O -
This O +
study O +
was O +
conducted O +
in O +
the O +
Department O +
of O +
La O -
Paz O -
, O +
Bolivia O -
, O +
and O +
more O +
specifically O +
in O +
a O +
region O +
of O +
the O -
Northern O +
Bolivian O +
Altiplano O -
, O +
between O +
Lake O +
Titicaca O +
and O -
the O +
valley O +
of O +
the O +
city O +
of O +
La O +
Paz O -
, O +
at O +
a O +
very O +
high O +
altitude O -
( O -
3800 O -
- O -
4200 O +
m O -
) O +
( O -
Figure O -
) O -
. O -

The O +
surface O +
area O +
and O +
human U-Species -
population O +
characteristics O +
of O +
this O +
zone O +
have O +
already O +
been O -
summarized O +
m O +
a O +
balantidiasis O +
study O +
concerning O +
the O +
same O -
area O +
( O -
ESTEBAN O +
etal O -
. O -
, O +
1998b O -
) O -
. O -

A O +
total O +
of O +
31 O +
coprological O +
surveys O +
were O +
carried O +
out O +
in O -
24 O +
localities O +
over O +
the O +
6-year O +
period O +
1992 O -
- O -
97 O +
( O -
Table O +
1 O -
) O -
. O -

These O +
surveys O +
involved O +
2723 O +
Aymara O +
subjects U-Species +
( O -
1483 O -
males U-Species -
, O +
1240 O +
females U-Species -
) O +
aged O +
1 O -
- O -
100 O +
years O +
( O -
mean O +
SD O -
, O -
10 O -
- O -
9 O +
7 O -
- O -
5 O +
years O -
) O -
, O +
among O +
whom O +
were O +
2521 O +
students O -
( O -
1350 O +
boys U-Species -
, O +
1171 O +
girls U-Species -
) O +
aged O +
5 O +
to O +
19 O +
years O +
( O -
9 O -
- O -
6 O +
-7 O -
years O -
) O +
from O +
the O +
schools O +
of O +
these O +
24 O +
localities O -
. O -

These O -
surveys O +
were O +
carried O +
out O +
so O +
that O +
the O +
sample O +
size O +
in O +
each O -
school O +
was O +
representative O +
of O +
both O +
the O +
student O +
enrolment O -
in O +
the O +
school O +
( O -
at O +
least O +
50 O -
% O -
) O +
and O +
the O +
number O +
of O +
children U-Species -
present O +
on O +
the O +
day O +
of O +
the O +
survey O +
( O -
at O +
least O +
75 O -
% O -
) O -
. O -

In O -
Chijipata O +
Alto O +
and O +
Huacullani O -
, O +
where O +
high O +
prevalences O -
in O +
the O +
schools O +
were O +
detected O -
, O +
surveys O +
were O +
extended O +
to O -
total O +
inhabitants O +
and O +
involved O +
202 O +
subjects O +
( O -
133 O +
males U-Species -
, O -
69 O +
females U-Species -
) O +
aged O +
1 O +
to O +
100 O +
years O +
( O -
26 O -
- O -
7 O +
0 O -
- O -
1 O +
years O -
) O -
. O -

Surveys O +
were O +
performed O +
so O +
that O +
the O +
sample O +
size O +
was O -
always O +
at O +
least O +
20 O -
% O +
of O +
the O +
subject O +
number O +
of O +
each O -
locality O -
. O -

None O +
of O +
the O +
children U-Species +
that O +
participated O +
in O +
these O -
community O +
surveys O +
was O +
included O +
in O +
the O +
school O +
surveys O +
of O -
the O +
same O +
localities O -
. O -

All O +
the O +
surveys O +
were O +
made O +
on O -
randomly O +
selected O +
persons O +
on O +
a O +
given O +
day O +
among O +
all O -
participating O +
subjects O -
. O -

One O +
stool O +
sample O +
per O +
subject O +
was O +
collected O +
from O +
all O -
participating B-Species +
individuals L-Species +
and O +
personal O +
data O +
( O -
name O -
, O +
sex O -
, O -
and O +
age O -
) O +
were O +
noted O -
. O -

The O +
relatively O +
low O +
receptivity O +
of O -
Aymara O +
adults U-Species -
, O +
related O +
to O +
their O +
ethnic O +
and O +
religious O -
characteristics O +
( O -
ESTEBAN O +
et O +
al. O -
, O +
1998b O -
) O -
, O +
made O +
it O +
impos- O -
sible O +
to O +
obtain O +
multiple O +
stool O +
specimens O +
collected O +
at O +
2- O +
or O -
132 O -
JOSE O -
- O -
GUILLERMO O +
ESTEBAN O +
ETAL O -
. O -

Figure O -
. O -

Map O +
showing O +
the O +
location O +
of O +
the O +
24 O +
localities O +
surveyed O +
m O +
the O +
Northern O +
Bolivian O +
Altiplano O -
. O -

Closed O +
circles O -
, O +
localities O +
with O -
fascioliasis O -
; O +
open O +
circles O -
, O +
localities O +
in O +
which O +
fascioliasis O +
was O +
not O +
detected O -
. O -

3-day O +
intervals O -
. O -

Each O +
stool O +
sample O +
was O +
examined O +
using O -
the O +
Kato O -
- O -
Katz O +
technique O +
( O -
KATZ O +
et O +
al. O -
, O +
1972 O -
) O +
for O +
hel- O -
minth O +
eggs O +
and O -
, O +
if O +
possible O -
, O +
direct O +
and O +
concentration O -
MIF O +
( O -
SAPERO O +
& O +
LAWLESS O -
, O +
1953 O -
; O +
BLAGG O +
et O +
al. O -
, O +
1955 O -
) O -
, O -
formol O -
- O -
ether O +
concentration O +
( O -
KNIGHT O +
et O +
al. O -
, O +
1976 O -
) O -
, O +
and O -
modified O +
Ziehl O -
- O -
Neelsen O +
( O -
HENRIKSEN O +
& O +
POHLENZ O -
, O -
1981 O -
) O +
techniques O +
were O +
applied O +
in O +
order O +
to O +
cover O +
all O +
the O -
protozoan O +
spectrum O -
. O -

Statistical O +
analyses O +
were O +
done O +
using O +
SPSS O +
6.1 O +
( O -
SPSS O -
Institute O -
, O +
Chicago O -
, O +
IL O -
, O +
USA O -
) O +
for O +
Windows O -
. O -

Statistical O -
comparison O +
of O +
categorical O +
variables O +
was O +
carried O +
out O +
with O -
X2 O +
or O +
Fisher O -
's O +
exact O +
tests O -
. O -

Normally O +
distributed O +
data O +
were O -
analysed O +
using O +
Student O -
's O +
t O -
- O -
test O +
and O +
analysis O +
of O +
variance O -
( O -
ANOVA O -
) O -
. O -

Mann O -
- O -
Whitney O +
utest O +
and O +
Kruskal O -
- O -
Wallis O -
test O +
( O -
Jf O -
) O +
were O +
used O +
for O +
non O -
- O -
normally O +
distributed O +
data O -
. O -

Prevalences O +
and O +
intensities O +
m O +
the O +
same O +
schoolchildren U-Species -
studied O +
in O +
different O +
years O +
were O +
compared O +
with O +
McNemar O -
and O +
Wilcoxon O +
signed O -
- O -
rank O +
tests O -
, O +
respectively O -
. O -

Values O +
of O -
P O +
< O +
0 O -
- O -
05 O +
were O +
taken O +
as O +
significant O -
. O -

This O +
study O +
was O +
conducted O +
with O +
the O +
agreement O +
of O +
the O -
Secretaria O +
Nacional O +
de O +
Salud O +
del O +
Ministerio O +
de O +
Desar- O -
rollo O +
Humano O +
( O -
La O +
Paz O -
, O +
Bolivia O -
) O +
and O +
was O +
performed O +
in O -
collaboration O +
with O +
the O +
INLASA O +
Institute O +
in O +
La O +
Paz O -
. O -

All O -
investigations O +
were O +
made O +
with O +
the O +
consent O +
of O +
the O +
subjects O -
or O -
, O +
in O +
the O +
case O +
of O +
young O +
children U-Species -
, O +
their O +
guardians O -
. O -

Results O -
Prevalences O -

The O +
total O +
prevalence O +
of O +
fascioliasis O +
in O +
the O +
2723 O +
subjects U-Species -
studied O +
was O +
15 O -
- O -
4 O -
% O -
. O -

The O +
maximum O +
prevalences O +
in O +
the O -
school O +
and O +
community O +
surveys O +
were O +
obtained O +
in O +
Chiji- O -
pata O +
Alto O +
( O -
68 O -
- O -
2 O -
% O +
and O +
65 O -
- O -
4 O -
% O -
, O +
respectively O +
in O +
1996 O -
) O -
, O -
whereas O +
in O +
some O +
other O +
school O +
surveys O +
F. O +
hepatica O +
infec- O -
tion O +
was O +
not O +
even O +
detected O +
( O -
Table O +
1 O -
) O -
. O -

Significant O +
differ- O -
ences O +
between O +
prevalence O +
rates O +
both O +
among O +
combined O -
school O +
surveys O +
and O +
among O +
combined O +
community O +
surveys O -
( O -
P O +
= O +
0 O -
- O -
0001 O +
by O +
Fisher O -
's O +
exact O +
test O -
, O +
and O +
x2=312 O -
, O -
P O +
= O +
0 O -
- O -
0001 O -
, O +
respectively O -
) O +
were O +
detected O -
. O -

Comparison O +
analysis O +
of O +
prevalence O +
rates O +
detected O +
in O -
the O +
surveys O +
carried O +
out O +
in O +
the O +
same O +
school O +
( O -
i.e. O -
, O +
Acha- O -
cachi O -
, O +
Chijipata O +
Alto O +
and O +
Huacullani O -
) O +
or O +
in O +
the O +
same O -
community O +
( O -
i.e. O -
, O +
Huacullani O -
) O +
in O +
different O +
years O +
showed O -
no O +
statistical O +
differences O -
. O -

Moreover O -
, O +
no O +
statistical O +
differ- O -
ences O +
were O +
detected O +
between O +
prevalences O +
among O +
the O -
same O +
schoolchildren U-Species +
analysed O +
in O +
different O +
years O -
. O -

Discrepancies O +
in O +
the O +
results O +
were O -
, O +
however O -
, O +
observed O -
when O +
comparing O +
the O +
total O +
prevalences O +
( O -
including O +
the O -
different O +
years O -
) O +
obtained O +
in O +
the O +
school O +
and O +
community O -
surveys O +
in O +
the O +
same O +
locality O -
: O +
in O +
Chijipata O +
Alto O -

no O +
signifi- O -
ca O -
nt O +
difference O +
was O +
observed O +
( O -
60 O -
- O -
5 O -
% O +
in O +
the O +
2 O +
combined O -
school O +
surveys O +
vs. O +
65 O -
- O -
4 O -
% O +
in O +
the O +
community O -
) O -
, O +
whereas O +
in O -
Huacullani O +
( O -
33 O -
- O -
8 O -
% O +
for O +
the O +
3 O +
combined O +
school O +
surveys O +
vs. O -
16 O -
- O -
5 O -
% O +
for O +
the O +
2 O +
combined O +
community O +
surveys O -
) O +
a O +
signifi- O -
ca O -
nt O +
difference O +
was O +
detected O +
( O -
% O -
2 O +
= O +
19 O -
- O -
06 O -
, O +
P O +
= O +
0 O -
- O -
0001 O -
) O -
. O -

Similar O +
results O +
were O +
obtained O +
when O +
comparing O +
the O +
pre- O -
valences O +
obtained O +
in O +
the O +
school O +
survey O +
and O +
the O +
commu- O -
nity O +
survey O +
in O +
the O +
same O +
locality O +
carried O +
out O +
in O +
the O +
same O -
year O +
1996 O -
: O +
in O +
Chijipata O +
Alto O +
there O +
was O +
no O +
significant O -
difference O +
( O -
68 O -
- O -
2 O -
% O +
in O +
the O +
school O +
vs. O +
65 O -
- O -
4 O -
% O +
in O +
the O +
com- O -
munity O -
) O -
, O +
whereas O +
in O +
Huacullani O +
( O -
34 O -
- O -
8 O -
% O +
in O +
the O +
school O +
vs. O -
18 O -
- O -
4 O -
% O +
in O +
the O +
community O -
) O +
a O +
significant O +
difference O +
was O -
detected O +
( O -
/2 O +
= O +
8 O -
- O -
89 O -
, O +
P O +
= O +
0 O -
- O -
0029 O -
) O -
. O -

The O +
distribution O +
of O +
prevalences O +
according O +
to O +
sex O +
and O -
age O -
- O -
groups O +
in O +
the O +
school O +
surveys O +
and O +
also O +
in O +
the O +
com- O -
munity O +
surveys O +
is O +
shown O +
in O +
Table O +
2 O -
. O -

In O +
relation O +
to O +
sex O -
, O +
a O -
significant O +
difference O +
was O +
detected O +
neither O +
among O -
schools O -
, O +
nor O +
among O +
communities O -
, O +
and O +
a O +
similar O +
result O -
was O +
obtained O +
when O +
considering O +
the O +
total O +
of O +
the O +
subjects U-Species -
studied O +
in O +
all O +
the O +
surveys O -
. O -

In O +
the O +
school O +
surveys O -
, O +
the O +
distribution O +
of O +
prevalences O -
according O +
to O +
age O -
- O -
groups O +
did O +
show O +
significant O +
differences O -
Cy2 O +
= O +
19 O -
- O -
00 O -
, O +
P O +
= O +
0 O -
- O -
0001 O -
) O +
when O +
comparing O +
age O -
- O -
groups O -
established O +
according O +
to O +
school O +
criteria O -
: O +
age O +
5 O -
- O -
8 O +
years O -
, O -
basic O +
level O -
, O +
9 O -
- O -
12 O +
years O -
, O +
intermediate O -
; O +
13 O -
- O -
19 O +
years O -
, O -
medium O +
level O +
and O +
students O +
still O +
in O +
school O +
but O +
eligible O -
for O +
military O +
service O -
. O -

The O +
highest O +
prevalences O +
were O +
de- O -
Table O +
1 O -
. O -

The O +
study O +
populations O +
of O +
the O +
schools O +
and O +
communities O +
surveyed O +
in O +
Bolivia O +
and O +
the O +
prevalences O +
and O +
intensities O +
from O +
faecal O +
egg O +
counts O +
off O -
. O -

hepatica O -
Locality O +
Survey O +
year O +
; O +
Male U-Species +
mple O +
studie O -
< O +
Female U-Species +
i O +
Total O +
Age O +
Range O +
( O -
years O -
) O +
Meai O +
tt O -
( O -
SD O -
) O +
Prevalence% O +
( O -
CI O -
) O -
1 O -
' O +
Inl O +
Range O +
: O -
ensity O +
( O -
epg O -
) O -
' O +
AM O +
GM O -
Schools O -
Achacachi O -
( O -
I O -
) O -
3 O +
1996 O +
48 O +
44 O +
92 O +
5 O -
- O -
13 O +
8 O -
- O -
7 O +
( O -
2 O -
- O -
1 O -
) O +
6 O -
- O -
5 O +
( O -
5 O -
- O -
0 O -
) O +
48 O -
- O -
336 O +
139 O +
106 O -
Achacachi O -
( O -
1 O -
) O +
1997 O +
42 O +
45 O +
87 O +
6 O -
- O -
13 O +
9 O -
- O -
1 O +
( O -
1 O -
- O -
7 O -
) O +
1 O -
- O -
1 O +
( O -
2 O -
- O -
2 O -
) O +
240 O +
- O +
- O -
Acbocalla O -
( O -
ll O -
) O +
1996 O +
92 O +
96 O +
188 O +
5 O -
- O -
16 O +
8 O -
- O -
8 O +
( O -
2 O -
- O -
6 O -
) O +
5 O -
- O -
3 O +
( O -
3 O -
- O -
2 O -
) O +
48 O -
- O -
744 O +
304 O +
226 O -
Ancocagua O +
( O -
9 O -
) O +
1997 O +
85 O +
83 O +
168 O +
5 O -
- O -
19 O +
10 O -
- O -
6 O +
( O -
3 O -
- O -
4 O -
) O +
5 O -
- O -
9 O +
( O -
3 O -
- O -
6 O -
) O +
24 O -
- O -
4512 O +
1229 O +
332 O -
Aygachi O -
( O -
16 O -
) O +
1994 O +
68 O +
37 O +
105 O +
5 O -
- O -
17 O +
11 O -
- O -
1 O +
( O -
2 O -
- O -
8 O -
) O +
17 O -
- O -
1 O +
( O -
7 O -
- O -
2 O -
) O +
24 O -
- O -
1200 O +
320 O +
179 O -
BelYayes O -
( O -
17 O -
) O +
1994 O +
26 O +
17 O +
43 O +
5 O -
- O -
12 O +
8 O -
- O -
5 O +
( O -
1 O -
- O -
9 O -
) O +
7 O -
- O -
0 O +
( O -
7 O -
- O -
6 O -
) O +
72 O -
- O -
144 O +
112 O +
108 O -
Caleria O -
( O -
15 O -
) O +
1993 O +
29 O +
22 O +
51 O +
6 O -
- O -
14 O +
9 O -
- O -
1 O +
( O -
2 O -
- O -
3 O -
) O +
5 O -
- O -
9 O +
( O -
6 O -
- O -
5 O -
) O +
24 O -
- O -
48 O +
40 O +
38 O -
Causaya O +
( O -
24 O -
) O +
1995 O +
22 O +
37 O +
59 O +
5 O -
- O -
18 O +
10 O -
- O -
6 O +
( O -
2 O -
- O -
8 O -
) O +
ND'1 O +
- O +
- O +
- O -
Chambi O +
Grande O +
( O -
23 O -
) O +
1995 O +
9 O +
16 O +
25 O +
5 O -
- O -
12 O +
7.4 O +
( O -
1 O -
- O -
6 O -
) O +
12 O -
- O -
0 O +
( O -
12 O -
- O -
7 O -
) O +
240 O -
- O -
840 O +
496 O +
435 O -
Chijipata O +
Alto O +
( O -
4 O -
) O +
1996 O +
11 O +
11 O +
22 O +
5 O -
- O -
10 O +
7 O -
- O -
5 O +
( O -
1 O -
- O -
3 O -
) O +
68 O -
- O -
2 O +
( O -
19 O -
- O -
5 O -
) O +
24 O -
- O -
3000 O +
613 O +
211 O -
Chijipata O +
Alto O +
( O -
4 O -
) O +
1997 O +
29 O +
25 O +
54 O +
5 O -
- O -
15 O +
8 O -
- O -
7 O +
( O -
2 O -
- O -
4 O -
) O +
57 O -
- O -
4 O +
( O -
13 O -
- O -
2 O -
) O +
24 O -
- O -
2424 O +
477 O +
240 O -
Cohana O +
( O -
18 O -
) O +
1994 O +
97 O +
70 O +
167 O +
5 O -
- O -
16 O +
10 O -
- O -
4 O +
( O -
2 O -
- O -
6 O -
) O +
3 O -
- O -
6 O +
( O -
2 O -
- O -
8 O -
) O +
24 O -
- O -
120 O +
72 O +
60 O -
Corapata O +
( O -
10 O -
) O +
1993 O +
43 O +
42 O +
85 O +
5 O -
- O -
16 O +
10 O -
- O -
2 O +
( O -
2 O -
- O -
7 O -
) O +
17 O -
- O -
6 O +
( O -
8 O -
- O -
1 O -
) O +
48 O -
- O -
480 O +
198 O +
157 O -
Cuyahuani O -
( O -
3 O -
) O +
1996 O +
57 O +
54 O +
111 O +
5 O -
- O -
16 O +
10 O -
- O -
7 O +
( O -
2 O -
- O -
8 O -
) O +
6 O -
- O -
3 O +
( O -
4 O -
- O -
5 O -
) O +
72 O -
- O -
600 O +
300 O +
206 O -
Huacullani O +
( O -
21 O -
) O +
1992 O +
70 O +
53 O +
123 O +
5 O -
- O -
15 O +
10 O -
- O -
0 O +
( O -
1 O -
- O -
9 O -
) O +
38 O -
- O -
2 O +
( O -
8 O -
- O -
6 O -
) O +
24 O -
- O -
2160 O +
283 O +
134 O -
Huacullani O +
( O -
21 O -
) O +
1993 O +
141 O +
115 O +
256 O +
5 O -
- O -
19 O +
10 O -
- O -
8 O +
( O -
3 O -
- O -
4 O -
) O +
31 O -
- O -
2 O +
( O -
5 O -
- O -
7 O -
) O +
24 O -
- O -
5064 O +
705 O +
323 O -
Huacullani O +
( O -
21 O -
) O +
1996 O +
65 O +
70 O +
135 O +
8 O -
- O -
15 O +
11 O -
- O -
5 O +
( O -
1 O -
- O -
5 O -
) O +
34 O -
- O -
8 O +
( O -
8 O -
- O -
0 O -
) O +
24 O -
- O -
4368 O +
347 O +
168 O -
Huatajata O +
( O -
2 O -
) O +
1996 O +
102 O +
91 O +
193 O +
5 O -
- O -
12 O +
7 O -
- O -
8 O +
( O -
1 O -
- O -
7 O -
) O +
ND'1 O +
- O +
- O +
- O -
Iquiaca O +
( O -
8) O +
1995 O +
71 O +
62 O +
133 O +
5 O -
- O -
14 O +
9.4 O +
( O -
2 O -
- O -
3 O -
) O +
9 O -
- O -
0 O +
( O -
4 O -
- O -
9 O -
) O +
48 O -
- O -
2448 O +
415 O +
147 O -
Kajchiri O +
( O -
13 O -
) O +
1994 O +
10 O +
11 O +
21 O +
5 O -
- O -
10 O +
8 O -
- O -
0 O +
( O -
1 O -
- O -
7 O -
) O +
9 O -
- O -
5 O +
( O -
12 O -
- O -
6 O -
) O +
168 O +
168 O +
168 O -
Kharapata O +
( O -
5 O -
) O +
1996 O +
48 O +
49 O +
97 O +
5 O -
- O -
15 O +
9 O -
- O -
5 O +
( O -
2 O -
- O -
2 O -
) O +
11 O -
- O -
3 O -
( O -
6 O -
- O -
3 O -
) O +
24 O -
- O -
216 O +
85 O +
59 O -
Lacaya O +
Baja O +
( O -
20 O -
) O +
1997 O +
39 O +
32 O +
71 O +
5 O -
- O -
12 O +
8 O -
- O -
1 O +
( O -
2 O -
- O -
0 O -
) O +
28 O -
- O -
2 O +
( O -
10 O -
- O -
5 O -
) O +
24 O -
- O -
1224 O +
302 O +
208 O -
Oketiti O -
( O -
7 O -
) O +
1995 O +
9 O +
11 O +
20 O +
5 O -
- O -
9 O +
6 O -
- O -
6 O +
( O -
1 O -
- O -
1 O -
) O +
10 O -
- O -
0 O -
( O -
13 O -
- O -
1 O -
) O +
288 O +
- O +
- O -
Pantini O +
( O -
6 O -
) O +
1995 O +
19 O +
14 O +
33 O +
5 O -
- O -
13 O +
8 O -
- O -
9 O +
( O -
1 O -
- O -
6 O -
) O +
30 O -
- O -
3 O +
( O -
15 O -
- O -
7 O -
) O +
24 O -
- O -
648 O +
230 O +
139 O -
Quiripujo O +
( O -
19 O -
) O +
1993 O +
25 O +
18 O +
43 O +
5 O -
- O -
12 O +
7 O -
- O -
7 O +
( O -
2 O -
- O -
0 O -
) O +
20 O -
- O -
9 O +
( O -
12 O -
- O -
1 O -
) O +
24 O -
- O -
240 O +
102 O +
78 O -
Ticuyo O +
( O -
14 O -
) O +
1995 O +
29 O +
3 O +
32 O +
6 O -
- O -
12 O +
9 O -
- O -
4 O +
( O -
1 O -
- O -
8 O -
) O +
Niy1 O +
- O +
- O +
- O -
Tuni O +
( O -
12 O -
) O +
1994 O +
13 O +
12 O +
25 O +
5 O -
- O -
10 O +
7 O -
- O -
5 O +
( O -
1 O -
- O -
5 O -
) O +
ND'1 O +
- O +
- O +
- O -
Yanarico O +
( O -
22 O -
) O +
1995 O +
51 O +
31 O +
82 O +
5 O -
- O -
16 O +
9 O -
- O -
7 O +
( O -
2 O -
- O -
5 O -
) O +
7 O -
- O -
3 O +
( O -
5 O -
- O -
6 O -
) O +
72 O -
- O -
120 O +
96 O +
93 O -
Total O +
1992 O -
- O -
97 O +
1350 O +
1171 O +
2521 O +
5 O -
- O -
19 O +
9 O -
- O -
6 O +
( O -
2 O -
- O -
7 O -
) O +
14 O -
- O -
8 O -
( O -
1 O -
- O -
4 O -
) O +
24 O -
- O -
5064 O +
419 O +
185 O -
Communities O -
Chijipata O +
Alto O +
( O -
4 O -
) O +
1996 O +
17 O +
9 O +
26 O +
6 O -
- O -
75 O +
25 O -
- O -
8 O +
( O -
20 O -
- O -
8 O -
) O +
65 O -
- O -
4 O -
( O -
18 O -
- O -
3 O -
) O +
48 O -
- O -
4440 O +
1345 O +
678 O -
Huacullani O +
( O -
21 O -
) O +
1996 O +
80 O +
45 O +
125 O +
1 O -
- O -
70 O +
22 O -
- O -
9 O +
( O -
17 O -
- O -
9 O -
) O +
18 O -
- O -
4 O +
( O -
6 O -
- O -
8 O -
) O +
24 O -
- O -
1608 O +
253 O +
140 O -
Huacullani O +
( O -
21 O -
) O +
1997 O +
36 O +
15 O +
51 O +
2 O -
- O -
100 O +
35 O -
- O -
4 O +
( O -
22 O -
- O -
6 O -
) O +
11 O -
- O -
8 O -
( O -
8 O -
- O -
8 O -
) O +
24 O -
- O -
264 O +
144 O +
113 O -
Total O +
1996 O -
- O -
97 O +
133 O +
69 O +
202 O +
1 O -
- O -
100 O +
26 O -
- O -
7 O +
( O -
20 O -
- O -
1 O -
) O +
22 O -
- O -
8 O +
( O -
5 O -
- O -
8 O -
) O +
24 O -
- O -
4440 O +
660 O +
250 O -
Total O +
surveys O +
1992 O -
- O -
97 O +
1483 O +
1240 O +
2723 O +
1 O -
- O -
100 O +
10 O -
- O -
9 O +
( O -
7 O -
- O -
5 O -
) O +
15 O -
- O -
4 O -
( O -
1 O -
- O -
4 O -
) O +
24 O -
- O -
5064 O -

446 O +
191 O -
' O -
Number O +
m O +
map O +
( O -
see O +
Figure O -
) O -
. O -

' O -
' O -
Confidence O +
interval O +
( O -
95 O -
% O -
) O -
. O -

' O -
Eggs O +
per O +
gram O +
of O +
faeces O +
( O -
AM O -
, O +
arithmetic O +
mean O -
; O +
GM O -
, O +
geometric O +
mean O -
) O -
. O -

' O -
' O -
Not O +
detected O -
. O -

154 O -
JOSE O -
- O -
GUILLERMO O +
ESTEBAN O +
ETAL O -
. O -

Table O +
2 O -
. O -

Prevalences O +
and O +
intensities O +
of O +
fasciolia- O -
sis O -
, O +
by O +
sex O +
and O +
age O -
- O -
group O -
, O +
in O +
the O +
school O +
and O +
com- O -
munity O +
surveys O +
in O +
Bolivia O -
Prevalence O +
Intensity O +
( O -
epg O -
) O +
b O -
) O -
% O +
( O -
CI O -
) O -
3 O +
Range O +
AM O +
GM O -
Schools O -
Sex O -
Boys U-Species +
14 O -
- O -
5 O +
( O -
1 O -
- O -
9 O -
) O +
24 O -
- O -
3408 O +
323 O +
159 O -
Girls U-Species +
15 O -
- O -
2 O +
( O -
2 O -
- O -
1 O -
) O +
24 O -
- O -
5064 O +
528 O +
219 O -
Age O -
- O -
group O +
( O -
years O -
) O -
5 O -
- O -
8 O +
10 O -
- O -
8 O +
( O -
2 O -
- O -
0 O -
) O +
24 O -
- O -
4512 O +
377 O +
202 O -
9 O -
- O -
12 O +
17 O -
- O -
0 O +
( O -
2 O -
- O -
1 O -
) O +
24 O -
- O -
5064 O +
446 O +
191 O -
13 O -
- O -
19 O +
17 O -
- O -
9 O -
( O -
3 O -
- O -
8 O -
) O +
24 O -
- O -
4488 O +
401 O +
147 O -
Communities O -
Sex O -
Males U-Species +
20 O -
- O -
3 O +
( O -
6 O -
- O -
8 O -
) O +
24 O -
- O -
4440 O +
753 O +
280 O -
Females U-Species +
27 O -
- O -
5 O +
( O -
10 O -
- O -
5 O -
) O +
48 O -
- O -
3758 O +
525 O +
212 O -
Age O -
- O -
group O +
( O -
years O -
) O -
1 O -
- O -
10 O +
29 O -
- O -
3 O -
( O -
11 O -
- O -
7 O -
) O +
24 O -
- O -
4440 O +
796 O +
198 O -
11 O -
- O -
20 O +
43 O -
- O -
8 O -
( O -
17 O -
- O -
2 O -
) O +
48 O -
- O -
3768 O +
825 O +
410 O -
21 O -
- O -
40 O +
13 O -
- O -
8 O +
( O -
8 O -
- O -
4 O -
) O +
72 O -
- O -
864 O +
373 O +
263 O -
> O -
40 O +
13 O -
- O -
3 O +
( O -
9 O -
- O -
9 O -
) O +
24 O -
- O -
1608 O +
368 O +
147 O -
" O -
Confidence O +
interval O +
( O -
95 O -
% O -
) O -
. O -

' O -
' O -
Eggs O +
per O +
gram O +
of O +
faeces O +
( O -
AM O -
, O +
arithmetic O +
mean O -
; O +
GM O -
, O +
geometric O -
mean O -
) O -
. O -

tected O +
in O +
the O +
age O -
- O -
groups O +
9 O -
- O -
12 O +
years O +
( O -
17 O -
- O -
0 O -
% O -
) O +
and O +
13 O -
- O -
19 O -
years O +
( O -
17 O -
- O -
9 O -
% O -
) O +
( O -
Table O +
2 O -
) O -
. O -

In O +
the O +
community O +
surveys O -
, O -
significant O +
differences O +
( O -
/2 O +
= O +
14 O -
- O -
5 O -
, O +
P O +
= O +
0 O -
- O -
0023 O -
) O +
were O +
also O -
detected O -
, O +
with O +
highest O +
prevalences O +
in O +
the O +
age O -
- O -
groups O +
1 O +
- O -
10 O +
years O +
( O -
29 O -
- O -
3 O -
% O -
) O +
and O +
11 O -
- O -
20 O +
years O +
( O -
43 O -
- O -
8 O -
% O -
) O +
( O -
Table O +
2 O -
) O -
. O -

Intensities O -
Intensity O +
of O +
infection O -
, O +
measured O +
as O +
epg O +
by O +
the O +
Kato- O -
Katz O +
technique O -
, O +
in O +
school O +
and O +
community O +
surveys O +
is O -
shown O +
in O +
Table O +
1 O -
. O -

Absolute O +
egg O +
counts O +
in O +
the O +
total O -
individuals O +
surveyed O +
with O +
detectable O +
infection O +
ranged O -
from O +
24 O +
to O +
5064 O +
epg O -
, O +
with O +
arithmetic O +
and O +
geometric O -
means O +
of O +
446 O +
and O +
191 O +
epg O -
, O +
respectively O -
. O -

Significant O -
differences O +
were O +
detected O +
among O +
the O +
different O +
school O -
surveys O +
( O -
.H O +
= O +
51 O -
- O -
82 O -
, O +
P O +
= O +
0 O -
- O -
0005 O -
) O +
as O +
well O +
as O +
among O +
the O -
different O +
community O +
surveys O -
= O +
12 O -
- O -
66 O -
, O +
P O +
= O +
0 O -
- O -
0018 O -
) O -
. O -

Comparison O +
analysis O +
of O +
intensities O +
detected O +
in O +
school O -
surveys O +
carried O +
out O +
in O +
different O +
years O +
in O +
the O +
same O +
locality O -
did O +
not O +
show O +
statistical O +
differences O +
in O +
the O +
case O +
of O +
Chiji- O -
pata O +
Alto O -
, O +
but O +
it O +
did O +
in O +
that O +
of O +
Huacullani O +
( O -
F O +
= O +
4 O -
- O -
80 O -
, O -
P O +
= O +
0 O -
- O -
009 O -
) O -
. O -

In O +
the O +
latter O -
, O +
however O -
, O +
no O +
significant O +
differ- O -
ence O +
was O +
detected O +
between O +
the O +
results O +
obtained O +
in O +
the O +
2 O -
community O +
surveys O -
. O -

No O +
significant O +
differences O +
were O -
detected O +
between O +
intensities O +
among O +
the O +
same O +
school- B-Species -
children L-Species +
analysed O +
in O +
different O +
years O -
. O -

When O +
comparing O +
the O +
intensity O +
values O +
obtained O +
in O +
the O -
school O +
and O +
community O +
surveys O +
in O +
the O +
same O +
locality O -
, O +
the O -
combined O +
results O +
showed O +
significant O +
differences O +
between O -
the O +
school O +
and O +
the O +
community O +
in O +
Chijipata O +
Alto O -
(= O +
229 O -
- O -
5 O -
, O +
P O +
= O +
0 O -
- O -
0123 O -
) O +
but O +
not O +
between O +
the O +
school O -
and O +
the O +
community O +
in O +
Huacullani O -
. O -

Similar O +
results O +
were O -
obtained O +
when O +
comparing O +
the O +
intensity O +
values O +
obtained O -
in O +
the O +
school O +
survey O +
and O +
community O +
survey O +
carried O +
out O +
in O -
a O +
given O +
locality O +
in O +
the O +
same O +
year O -
: O +
significant O +
differences O +
in O -
Chijipata O +
Alto O +
( O -
( O -
7=75 O -
- O -
0 O -
, O +
P O +
= O +
0 O -
- O -
0472 O -
) O -
, O +
but O +
not O +
in O -
Huacullani O -
. O -

Intensities O +
according O +
to O +
sex O +
and O +
age O -
- O -
groups O +
in O +
the O -
school O +
and O +
community O +
surveys O +
are O +
shown O +
in O +
Table O +
2 O -
. O -

No O -
significant O +
differences O +
according O +
to O +
sex O +
were O +
detected O +
in O -
the O +
total O +
study O +
and O +
in O +
the O +
community O +
surveys O -
, O +
but O +
the O -
significantly O +
higher O +
F. O +
hepatica O +
egg O +
counts O +
for O +
the O +
girls O +
in O -
the O +
school O +
surveys O +
( O -
t O +
= O +
2 O -
- O -
59 O -
, O +
P O +
= O +
0 O -
- O -
010 O -
) O +
is O +
worth O +
men- O -
tioning O -
. O -

The O +
analyses O +
according O +
to O +
age O -
- O -
groups O +
did O +
not O -
show O +
any O +
significant O +
difference O -
. O -

Discussion O -
The O +
prevalences O +
and O +
intensities O +
obtained O +
by O +
coprolo- O -
gical O +
methods O +
in O +
this O +
study O +
are O +
the O +
highest O +
known O +
up O +
to O -
the O +
present O -
. O -

These O +
results O +
are O +
even O +
more O +
noteworthy O -
when O +
taking O +
into O +
consideration O +
the O +
fact O +
that O +
the O +
localities O -
surveyed O +
in O +
the O +
Northern O +
Bolivian O +
Altiplano O +
were O +
se- O -
lected O +
only O +
because O +
of O +
their O +
geographical O +
situation O -
, O +
in O -
order O +
to O +
cover O +
a O +
wide O +
geographical O +
area O -
. O -

The O +
probability O -
of O +
detecting O +
high O +
infection O +
rates O +
of O +
fascioliasis O +
was O +
not O -
taken O +
into O +
account O +
and O +
thus O +
survey O +
efforts O +
were O +
not O -
concentrated O +
on O +
the O +
subzones O +
presenting O +
the O +
highest O -
human U-Species +
fascioliasis O +
rates O -
. O -

Owing O +
to O +
the O +
important O +
clinical O -
and O +
pathogenic O +
effects O +
of O +
fascioliasis O +
( O -
CHEN O +
& O +
MOTT O -
, O -
1990 O -
; O +
MAS O -
- O -
COMA O +
et O +
al. O -
, O +
1999a O -
, O +
m O +
press O -
) O -
, O +
the O +
analyses O +
of O -
prevalences O +
and O +
intensities O +
obtained O +
allow O +
us O +
to O +
conclude O -
that O +
the O +
Northern O +
Bolivian O +
Altiplano O +
must O +
be O +
catalogued O -
as O +
a O +
true O +
human U-Species +
fascioliasis O +
endemic O +
area O -
. O -

The O +
term O -
outbreak O +
sometimes O +
used O +
for O +
this O +
area O +
( O -
BJORLAND O +
et O +
al. O -
, O -
1995 O -
) O +
may O +
consequently O +
be O +
used O +
only O +
when O +
a O +
temporary O -
prevalence O +
increase O +
in O +
a O +
given O +
Altiplanic O +
locality O +
is O -
detected O -
. O -

Differences O +
detected O +
between O +
the O +
results O +
of O +
the O +
pre- O -
valences O +
obtained O +
in O +
different O +
localities O +
are O +
not O +
related O +
to O -
different O +
seasons O +
and O +
may O +
be O +
linked O +
to O +
the O +
patchy O -
distribution O +
of O +
the O +
transmission O +
foci O -
, O +
marked O +
by O +
the O -
presence O +
of O +
the O +
necessary O +
freshwater O +
lymnaeids U-Species -
, O +
as O +
well O -
as O +
to O +
the O +
Aymara O +
children O -
's O +
tendency O +
not O +
to O +
travel O +
far O -
. O -

The O +
lack O +
of O +
seasonality O +
in O +
the O +
prevalences O +
detected O -
contrasts O +
with O +
the O +
well O -
- O -
known O +
seasonal O +
transmission O -
characteristics O +
of O +
fascioliasis O +
in O +
other O +
parts O +
of O +
the O +
world O -
. O -

This O +
may O +
be O +
explained O +
by O +
the O +
absence O +
of O +
marked O +
climatic O -
differences O +
between O +
the O +
different O +
seasons O +
in O +
the O +
Northern O -
Altiplano O -
. O -

The O +
non O -
- O -
significant O +
differences O +
in O +
prevalences O +
by O +
sex O -
and O +
the O +
fact O +
that O +
all O +
ages O +
are O +
susceptible O +
to O +
infection O -
( O -
positive O +
cases O +
from O +
2 O +
to O +
70 O +
years O -
) O -
, O +
despite O +
the O +
fact O +
that O -
the O +
subjects U-Species +
aged O +
< O -
20 O +
years O +
are O +
those O +
with O +
a O +
higher O -
infection O +
risk O -
, O +
could O +
be O +
explained O +
by O +
the O +
lack O +
of O +
gender O -
role O +
differences O +
and O +
by O +
the O +
ingestion O +
of O +
several O +
aquatic O -
vegetables U-Species +
( O -
MAS O -
- O -
COMAeta O -
/ O -
. O -
, O +
1995 O -
) O +
as O +
a O +
risk O +
factor O +
for O +
F. B-Species -
hepatica L-Species +
infection O -
. O -

These O +
results O +
agree O +
with O +
a O +
few O +
studies O -
performed O +
in O +
areas O +
of O +
Egypt O +
( O -
FARAG O +
et O +
al. O -
, O +
1979 O -
) O -
, O +
Peru O -
( O -
KNOBLOCH O +
et O +
al. O -
, O +
1985 O -
; O +
SCHEZ O +
et O +
al. O -
, O +
1993 O -
) O +
and O -
Chile O +
( O -
APT O +
et O +
al. O -
, O +
1993 O -
) O -
. O -

The O +
very O +
high O +
egg O +
counts O +
are O +
worth O +
noting O +
when O -
compared O +
with O +
the O +
epg O +
normally O +
found O +
to O +
date O +
in O +
human U-Species -
fascioliasis O +
diagnosis O -
: O +
1 O -
- O -
4 O +
epg O +
( O -
BENDEZet O +
al. O -
, O +
1982 O -
; O -
KNOBLOCH O +
et O +
al. O -
, O +
1985 O -
) O +
is O +
the O +
most O +
common O -
; O +
a O +
case O +
with O -
440 O +
epg O +
( O -
AKAHANE O +
et O +
al. O -
, O +
1975 O -
) O +
may O +
be O +
considered O +
as O -
rare O -
. O -

However O -
, O +
the O +
prospective O +
study O +
by O +
SAMPAIO O +
SILVA O -
( O -
1990 O -
) O +
provided O +
a O +
geometric O +
mean O +
( O -
range O -
) O +
of O +
233 O +
( O -
25- O -
2100 O -
) O +
epg O -
, O +
which O +
was O +
the O +
highest O +
epg O +
count O +
known O +
up O +
to O -
our O +
study O -
. O -

With O +
the O +
exception O +
of O +
a O +
few O +
localities O -
, O +
the O +
distribution O -
of O +
intensities O +
corresponds O +
to O +
the O +
distribution O +
of O +
preva- O -
lences O -
, O +
and O +
the O +
scarce O +
disagreements O +
in O +
some O +
localities O -
may O +
be O +
explained O +
by O +
the O +
few O +
children U-Species +
coming O +
from O +
the O -
very O +
few O +
surrounding O +
zones O +
including O +
transmission O +
foci O -
. O -

Intensity O +
results O +
obtained O +
in O +
schools O +
and O +
communities O -
surveyed O +
more O +
than O +
once O -
, O +
in O +
different O +
seasons O +
and O -
throughout O +
different O +
years O -
, O +
as O +
well O +
as O +
those O +
obtained O +
in O -
the O +
school O +
and O +
community O +
surveys O +
in O +
the O +
same O +
locality O -
are O +
difficult O +
to O +
interpret O -
. O -

Similarly O -
, O +
the O +
significantly O +
higher O +
F. B-Species +
hepatica L-Species +
egg O -
counts O +
for O +
the O +
girls U-Species +
in O +
the O +
school O +
surveys O +
are O +
surprising O -
. O -

Concerning O +
intensity O +
in O +
humans U-Species -
, O +
a O +
relationship O +
between O -
the O +
number O +
of O +
fluke O +
adults U-Species +
and O +
eggs O +
in O +
faeces O +
has O +
never O -
been O +
studied O -
. O -

Data O +
from O +
animals U-Species +
suggest O +
that O +
a O +
direct O -
relation O +
does O +
not O +
necessarily O +
exist O +
( O -
CHEN O +
& O +
MOTT O -
, O -
1990 O -
) O -
. O -

It O +
is O +
evident O +
that O +
further O +
studies O +
on O +
this O +
aspect O -
are O +
needed O -
. O -

Intensity O +
data O +
according O +
to O +
age O -
- O -
groups O +
show O +
that O +
egg O -
output O +
counts O +
decrease O +
with O +
an O +
increase O +
of O +
age O -
. O -

In O +
3 O -
persons U-Species +
aged O +
> O -
60 O +
years O -
, O +
egg O +
counts O +
of O +
24 O -
- O -
168 O +
epg O +
were O -
found O -
. O -

Consequently O -
, O +
adult U-Species +
subjects O +
either O +
maintain O +
the O -
parasites U-Species +
acquired O +
when O +
young O +
or O +
can O +
be O +
newly O +
infected O -
HUMAN O +
FASCIOLIASIS O +
IN O +
BOLIVIA O -
155 O -
as O +
the O +
consequence O +
of O +
inhabiting O +
a O +
zone O +
of O +
high O +
infection O -
risk O -
. O -

A O +
case O +
of O +
a O +
2-year O -
- O -
old O +
child U-Species +
shedding O +
48 O +
epg O +
is O +
worth O -
mentioning O -
, O +
as O +
it O +
is O +
the O +
youngest O +
human U-Species +
fascioliasis O +
case O -
reported O +
so O +
far O -
. O -

The O +
human U-Species +
health O +
problem O +
of O +
this O +
distomatosis O +
in O +
the O -
Northern O +
Bolivian O +
Altiplano O +
is O +
related O +
to O +
the O +
hygienic- O -
sanitation O +
status O +
of O +
the O +
human U-Species +
population O -
. O -

The O +
numer- O -
ous O +
different O +
protozoan O +
and O +
helminth O +
species O +
detected O +
in O -
the O +
area O +
surveyed O +
and O +
the O +
multiple O +
parasite U-Species +
infections O -
detected O -
, O +
including O +
F. B-Species +
hepatica L-Species +
infection O -
, O +
in O +
the O +
same O -
subjects O +
( O -
ESTEBAN O +
et O +
al. O -
, O +
1996 O -
, O +
1997a O -
; O +
1998a O -
, O +
1998b O -
) O -
are O +
illustrative O +
of O +
this O +
situation O -
. O -

Acknowledgements O -
Collaboration O +
by O +
Dr O +
J. O +
A. O +
Oviedo O +
( O -
Valencia O -
, O +
Spain O -
) O +
and O +
Miss O -
W. O +
Strauss O -
, O +
N. O +
lihoshi O -
, O +
M. O +
Magarinos O +
and O +
Dr O +
C. O +
Aguirre O +
( O -
La O -
Paz O -
, O +
Bolivia O -
) O +
is O +
acknowledged O -
. O -

Thanks O +
are O +
also O +
given O +
to O +
the O -
following O +
Bolivian O +
institutions O +
in O +
La O +
Paz O -
: O +
Direccion O +
Nacional O +
de O -
Epidemiologia O +
of O +
the O +
Ministerio O +
de O +
Prevision O +
Social O +
y O +
Salud O -
Plica O -
; O +
ComitRegional O +
de O +
Zoonosis O +
and O +
Centro O +
Piloto O +
of O +
the O -
Unidad O +
Sanitaria O +
La O +
Paz O -
; O +
and O +
Office O +
of O +
the O +
Pan O +
American O +
Health O -
Organization O -
. O -

This O +
work O +
was O +
supported O +
by O +
funding O +
from O +
the O +
STD O +
Program O -
of O +
the O +
Commission O +
of O +
the O +
European O +
Communities O +
( O -
DG O +
XII O -
: O -
Science O -
, O +
Research O +
and O +
Development O -
) O +
( O -
Contract O +
no. O +
TS3- O -
CT94 O -
- O -
0294 O -
) O -
, O +
Brussels O -
, O +
EU O -
, O +
by O +
the O +
Program O +
of O +
Scientific O +
Co- O -
operation O +
with O +
Latin O +
America O -
, O +
Institute O +
de O +
Cooperaci O +
Ibero- O -
americana O -
, O +
Agencia O +
Espanola O +
de O +
Cooperaci O +
Intemacional O -
( O -
ICI O -
- O -
AECI O -
) O +
and O +
by O +
Projects O +
no. O +
UE96 O -
- O -
0001 O +
and O +
no. O +
PM97- O -
0099 O +
of O +
the O +
Direccion O +
General O +
de O +
Investigacion O +
Cientifica O +
y O -
Tnica O +
( O -
DGICYT O -
) O -
, O +
Spanish O +
Ministry O +
of O +
Education O +
and O -
Science O -
, O +
Madrid O -
. O +

Modular O +
polyketide O +
synthases O +
( O -
PKSs O -
) O +
are O +
responsible O +
for O -
producing O +
a O +
large O +
number O +
of O +
12 O -
, O +
14- O +
and O +
16-membered O -
macrolide O +
antibiotics O +
including O +
methymycin O -
, O +
erythromycin O -
and O +
tylosin O -
. O -

These O +
large O -
, O +
multifunctional O +
enzymes O -
( O -
> O -
300,000 O +
kDa O -
) O +
catalyze O +
the O +
biosynthesis O +
of O +
polyketide O -
macrolactones O +
through O +
multistep O +
pathways O +
involving O -
decarboxylative O +
condensations O +
between O +
acyl O +
thioesters O +
fol- O -
lowed O +
by O +
cycles O +
of O +
varying O +
B O -
- O -
carbon O +
processing O +
[ O -
l O -
] O -
. O -

The O -
ability O +
to O +
control O +
aspects O +
of O +
polyketide O +
biosynthesis O -
, O +
such O -
as O +
monomer O +
selection O -
, O +
degree O +
of O +
B O -
- O -
carbon O +
processing O +
and O -
stereoselectivity O -
, O +
by O +
genetic O +
manipulation O +
of O +
PKSs O +
has O -
stimulated O +
great O +
interest O +
in O +
the O +
combinatorial O +
engineering O -
of O +
novel O +
antibiotics O +
[ O -
2,3 O -
] O -
. O -

Picromycin O +
( O -
1 O -
; O +
Figure O +
1 O -
) O +
is O +
of O +
par- O -
ticular O +
interest O +
for O +
such O +
use O +
because O +
of O +
its O +
close O +
structural O -
relationship O +
to O +
ketolide O +
compounds O +
( O -
e.g. O +
HMR O +
3004 O -
) O -
, O +
a O -
new O +
class O +
of O +
semisynthetic O +
macrolides O +
with O +
activity O +
against O -
pathogens U-Species +
resistant O +
to O +
erythromycin O +
[ O -
4 O -
] O -
. O -

Genetic O +
systems O -
that O +
allow O +
rapid O +
engineering O +
of O +
the O +
picromycin O +
PKS O +
would O -
therefore O +
be O +
valuable O +
for O +
creating O +
novel O +
ketolide O +
analogs O -
for O +
pharmaceutical O +
applications O -
. O -

A O +
pivotal O +
development O +
for O +
modular O +
PKS O +
engineering O +
was O -
the O +
heterologous O +
expression O +
of O +
the O +
erythromycin O +
PKS O -
( O -
6-deoxyerythronolide O +
B O +
synthase O -
, O +
DEBS O -
) O +
in O +
Streptomyces B-Species -
coelicolor L-Species +
[ O -
5,6 O -
] O -
. O -

The O +
advantages O +
to O +
this O +
plasmid O -
- O -
based O -
genetic O +
system O +
for O +
DEBS O +
were O +
that O +
it O +
overcame O +
the O -
tedious O +
and O +
limited O +
techniques O +
for O +
manipulating O +
the O -
natural O +
DEBS O +
host O +
organism O -
, O +
Saccharopolyspora B-Species +
etythaea L-Species -
, O +
it O -
allowed O +
more O +
facile O +
construction O +
of O +
mutant O +
PKSs O -
, O +
and O +
it O -
reduced O +
the O +
complexity O +
of O +
PKS O +
property O +
analysis O +
by O +
pro- O -
viding O +
a O +
leanhost O +
background O -
. O -

This O +
system O +
also O +
expe- O -
dited O +
the O +
construction O +
of O +
the O +
first O +
combinatorial O +
modular O -
polyketide O +
library O +
in O +
Streptomyces U-Species +
[ O -
7 O -
] O -
. O -

Despite O +
the O +
success O -
of O +
this O +
system O -
, O +
as O +
well O +
as O +
the O +
increased O +
number O +
of O +
modular O -
PKS O +
gene O +
clusters O +
currently O +
available O -
, O +
DEBS O +
remained O -
the O +
only O +
modular O +
PKS O +
reported O +
to O +
be O +
expressed O +
in O +
a O +
het- O -
erologous O +
organism O -
. O -

The O +
picromycin O +
gene O +
cluster O +
from O +
Streptomyces B-Species +
venezuelae L-Species -
was O +
recently O +
cloned O +
and O +
sequenced O +
by O +
Sherman O +
and O -
coworkers O +
[ O -
8 O -
] O +
and O +
in O +
our O +
own O +
laboratories O +
( O -
[ O -
9 O -
] O -
; O +
M.C.B. O -
, O -
unpublished O +
observations O -
) O -
. O -

S. B-Species +
venezuelae L-Species +
is O +
unique O +
among O -
macrolide O -
- O -
producing O +
organisms O +
because O +
it O +
produces O -
primary O +
polyketides O +
with O +
two O +
different O +
ring O +
sizes O -
. O -

In O +
addi- O -
tion O +
to O +
the O +
14-membered O +
macrolide O +
picromycin O +
( O -
l O -
) O -
, O +
the O -
12-membered O +
macrolide O +
methymycin O +
( O -
2 O -
; O +
Figure O +
1 O -
) O +
is O +
also O -
produced O -
. O -

Based O +
on O +
the O +
structural O +
similarities O +
between O -
CHBIOL O +
80087 O +
S1074 O -
- O -
5521 O -
( O -
99 O -
) O -
80087 O -
- O -
8 O +
10.1016 O -
/ O -
S1074 O -
- O -
5521 O -
( O -
99 O -
) O -
80087 O -
- O -
8 O -
Elucidating O +
the O +
mechanism O +
of O +
chain O +
termination O +
switching O +
in O +
the O +
picromycin O -
/ O -
methymycin O +
polyketide O +
synthase O +
Li O +
Tang O -
Hong O +
Fu O -

Melanie O +
C O +
Betlach O -

Robert O +
McDaniel O -

* O -
mcdaniel@kosan.com O -

KOSAN O +
Biosciences O -
, O +
Inc. O -
, O +
3832 O +
Bay O +
Center O +
Place O -
, O +
Hayward O -
, O +
CA O +
94545 O -
, O +
USA O -

* O +
Correspondence O -
: O +
Robert O +
McDaniel O -
. O -

Background O +
A O +
single O +
modular O +
polyketide O +
synthase O +
( O -
PKS O -
) O +
gene O +
cluster O +
is O +
responsible O +
for O +
production O +
of O +
both O +
the O +
14-membered O +
macrolide O +
antibiotic O +
picromycin O +
and O +
the O +
12-membered O +
macrolide O +
antibiotic O +
methymycin O +
in O +
Streptomyces B-Species +
Venezuelas I-Species +
. L-Species -

Building O +
on O +
the O +
success O +
of O +
the O +
heterologous O +
expression O +
system O +
engineered O +
using O +
the O +
erythromycin O +
PKS O -
, O +
we O +
have O +
constructed O +
an O +
analogous O +
system O +
for O +
the O +
picromycin O -
/ O -
methymycin O +
PKS O -
. O -

Through O +
heterologous O +
expression O +
and O +
construction O +
of O +
a O +
hybrid O +
PKS O -
, O +
we O +
have O +
examined O +
the O +
contributions O +
that O +
the O +
PKS O -
, O +
its O +
internal O +
thioesterase O +
domain O +
( O -
pikTE O -
) O +
and O +
the O +
Pik O +
TEII O +
thioesterase O +
domain O +
make O +
in O +
termination O +
and O +
cyclization O +
of O +
the O +
two O +
polyketide O +
intermediates O -
. O -

Results O +
The O +
picromycin O -
/ O -
methymycin O +
PKS O +
genes O +
were O +
functionally O +
expressed O +
in O +
the O +
heterologous O +
host O +
Streptomyces B-Species +
lividans L-Species +
, O +
resulting O +
in O +
production O +
of O +
both O +
narbonolide O +
and O +
10-deoxymethynolide O +
( O -
the O +
precursors O +
of O +
picromycin O +
and O +
methymycin O -
, O +
respectively O -
) O -
. O -

Co O -
- O -
expression O +
with O +
the O +
Pik O +
TEII O +
thioesterase O +
led O +
to O +
increased O +
production O +
levels O -
, O +
but O +
did O +
not O +
change O +
the O +
ratio O +
of O +
the O +
two O +
compounds O +
produced O -
, O +
leaving O +
the O +
function O +
of O +
this O +
protein O +
largely O +
unknown O -
. O -

Fusion O +
of O +
the O +
PKS O +
thioesterase O +
domain O +
( O -
pikTE O -
) O +
to O +
6-deoxyerythronolide O +
B O +
synthase O +
( O -
DEBS O -
) O +
resulted O +
in O +
formation O +
of O +
only O +
14-membered O +
macrolactones O -
. O -

Conclusions O +
These O +
experiments O +
demonstrate O +
that O +
the O +
PKS O +
alone O +
is O +
capable O +
of O +
catalyzing O +
the O +
synthesis O +
of O +
both O +
14- O +
and O +
12-membered O +
macrolactones O +
and O +
favor O +
a O +
model O +
by O +
which O +
different O +
macrolactone O +
rings O +
result O +
from O +
a O +
combination O +
of O +
the O +
arrangement O +
between O +
the O +
module O +
5 O +
and O +
module O +
6 O +
subunits O +
in O +
the O +
picromycin O +
PKS O +
complex O +
and O +
the O +
selectivity O +
of O +
the O +
pikTE O +
domain O -
. O -

Key O +
words O +
erythromycin O -
methymycin O -
picromycin O -
polyketide O -
thioesterase O +

Diltiazem O +
( O -
d O +
-cis O +
-diltiazem O -
) O -
, O +
a O +
benzothiazepine O +
Ca2 O -
+ O -
channel O +
blocker O -
, O +
has O +
been O +
used O +
for O +
the O +
treatment O +
of O +
ischemic O +
heart O +
disease O -
. O -

The O +
primary O +
mechanism O +
of O +
the O +
anti O -
- O -
ischemic O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
is O +
considered O +
to O +
be O +
its O +
Ca2 O -
+ O -
channel O +
blocking O +
action O -
, O +
which O +
produces O +
improvement O +
of O +
the O +
myocardial O +
oxygen O +
balance O +
between O +
supply O +
and O +
demand O +
by O +
either O +
increasing O +
coronary O +
flow O +
or O +
decreasing O +
cardiac O +
mechanical O +
function O -
, O +
or O +
both O -
. O -

However O -
, O +
l O +
-cis O +
-diltiazem O -
, O +
which O +
is O +
an O +
optical O +
isomer O +
of O +
d O +
-cis O +
-diltiazem O +
with O +
about O +
1 O -
/ O -
20–1 O -
/ O -
100 O +
the O +
Ca2 O -
+ O -
channel O +
blocking O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
Nasa O +
et O +
al. O -
, O +
1992 O +
; O +
Itogawa O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
and O +
d O +
-cis O +
-diltiazem O +
attenuate O +
the O +
myocardial O +
derangements O +
induced O +
by O +
ischemia O -
– O -
reperfusion O +
to O +
a O +
similar O +
degree O +
( O -
Nasa O +
et O +
al. O -
, O +
1990 O +
) O -
. O -

This O +
fact O +
suggests O +
that O +
the O +
anti O -
- O -
ischemic O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
does O +
not O +
entirely O +
depend O +
on O +
its O +
Ca2 O -
+ O -
channel O +
blocking O +
action O -
, O +
but O +
depends O +
on O +
other O +
unknown O +
actions O -
. O -

Recently O -
, O +
we O +
( O -
Xiao O +
et O +
al. O -
, O +
1997 O +
) O +
have O +
demonstrated O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
myocardial O +
derangements O +
induced O +
by O +
palmitoyl O -
- O -
l O +
-carnitine O -
, O +
which O +
accumulates O +
in O +
the O +
heart O +
during O +
ischemia O +
and O +
reperfusion O -
, O +
supporting O +
the O +
above O +
suggestion O -
. O -

During O +
ischemia O +
and O +
reperfusion O -
, O +
reactive O +
oxygen O +
species O -
, O +
such O +
as O +
superoxide O +
anion O -
, O +
hydroxyl O +
radical O +
and O +
hydrogen O +
peroxide O +
( O -
H2 O +
O2 O +
) O -
, O +
are O +
generated O +
intra- O +
and O +
extracellularly O +
in O +
the O +
myocardium O +
and O +
endothelium O +
( O -
Hess O +
and O +
Manson O -
, O +
1984 O +
; O +
Lucchesi O -
, O +
1990 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
. O -

These O +
reactive O +
oxygen O +
species O +
are O +
considered O +
important O +
in O +
producing O +
irreversible O +
damage O +
in O +
the O +
ischemia O -
- O -
reperfused O +
heart O +
( O -
Hess O +
and O +
Manson O -
, O +
1984 O +
; O +
Lucchesi O -
, O +
1990 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
. O -

In O +
fact O -
, O +
oxygen O +
radical O +
scavengers O +
and O +
anti O -
- O -
oxidants O +
protect O +
the O +
myocardium O +
against O +
ischemia O -
– O -
reperfusion O +
damage O +
( O -
Hess O +
and O +
Manson O -
, O +
1984 O +
; O +
Lucchesi O -
, O +
1990 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
. O -

We O +
( O -
Hara O +
et O +
al. O -
, O +
1993 O +
; O +
Hara O +
and O +
Abiko O -
, O +
1996 O +
; O +
Kokita O +
and O +
Hara O -
, O +
1996 O +
) O +
have O +
demonstrated O +
that O +
H2 O +
O2 O -
decreases O +
cardiac O +
mechanical O +
function O +
and O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O +
in O +
the O +
isolated O +
perfused O +
rat U-Species +
heart O -
. O -

According O +
to O +
recent O +
physiological O +
studies O -
, O +
H2 O +
O2 O -
increases O +
the O +
intracellular O +
concentration O +
of O +
Na+ O -
( O -
[ O -
Na+ O +
] O -
i O -
) O +
in O +
the O +
myocardium O +
( O -
Yanagida O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
probably O +
because O +
of O +
an O +
increase O +
in O +
Na+ O -
current O +
in O +
cardiac O +
cells O +
( O -
Bhatnagar O +
et O +
al. O -
, O +
1990 O +
; O +
Ward O +
and O +
Giles O -
, O +
1997 O +
) O -
. O -

The O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
activates O +
the O +
Na+ O +
/Ca2 O -
+ O -
exchanger O -
, O +
leading O +
to O +
intracellular O +
Ca2 O -
+ O -
overload O -
, O +
which O +
is O +
responsible O +
for O +
irreversible O +
myocardial O +
derangements O +
( O -
Goldhaber O -
, O +
1996 O +
) O -
. O -

In O +
order O +
to O +
elucidate O +
the O +
mechanisms O +
of O +
action O +
of O +
l O +
-cis O +
-diltiazem O +
responsible O +
for O +
its O +
anti O -
- O -
ischemic O +
effect O +
and O +
to O +
relate O +
its O +
anti O -
- O -
ischemic O +
action O +
to O +
the O +
Ca2 O -
+ O -
channel O +
blocking O +
action O -
, O +
the O +
following O +
two O +
series O +
of O +
experiments O +
were O +
designed O -
. O -

The O +
first O +
series O +
of O +
experiments O +
was O +
performed O +
to O +
determine O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O -
, O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O +
and O +
damage O +
of O +
the O +
cell O +
membrane O -
, O +
and O +
the O +
second O +
series O +
of O +
experiments O +
was O +
carried O +
out O +
to O +
examine O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
. O -

2 O +
Methods O +
The O +
protocol O +
of O +
animal U-Species +
experiments O +
in O +
the O +
present O +
study O +
was O +
approved O +
by O +
the O +
` O -
Asahikawa O +
Medical O +
College O +
Committee O +
on O +
Animal U-Species +
Research O -
' O -
. O -

2.1 O +
Heart O +
perfusion O +
( O -
the O +
first O +
series O +
of O +
experiments O -
) O -

Male O +
Sprague B-Species -
– I-Species -
Dawley I-Species +
rats L-Species -
, O +
weighing O +
310–340 O +
g O +
( O -
9–10 O +
weeks O +
old O -
) O -
, O +
were O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O -

The O +
rats U-Species +
were O +
anesthetized O +
with O +
sodium O +
pentobarbital O +
( O -
50 O +
mg O +
kg−1 O +
, O +
i.p O -
. O -
) O +
20 O +
min O +
after O +
an O +
injection O +
with O +
heparin O +
( O -
1000 O +
u O +
kg−1 O +
, O +
i.p O -
. O -
) O -
. O -

After O +
thoracotomy O -
, O +
the O +
hearts O +
were O +
rapidly O +
removed O -
, O +
and O +
then O +
retrograde O +
perfusion O +
was O +
started O +
using O +
a O +
cannula O +
inserted O +
into O +
the O +
aorta O +
according O +
to O +
the O +
Langendorff O +
technique O -
. O -

The O +
perfusion O +
buffer O +
was O +
a O +
Krebs O -
– O -
Henseleit O +
bicarbonate O +
( O -
KHB O -
) O +
buffer O +
containing O +
( O -
in O +
mM O -
) O -
: O +
NaCl O -
, O +
118 O -
; O +
KCl O -
, O +
4.7 O -
; O +
KH2 O +
PO4 O +
, O +
1.2 O -
; O +
MgSO4 O +
, O +
1.2 O -
; O +
CaCl2 O +
, O +
2.5 O -
; O +
NaHCO3 O +
, O +
25 O -
; O +
and O +
glucose O -
, O +
11 O -
, O +
equilibrated O +
with O +
a O +
gas O +
mixture O +
of O +
95 O -
% O +
O2 O +
+ O -
5 O -
% O +
CO2 O -
and O +
maintained O +
at O +
37 O -
° O -
C O -
. O -

The O +
oxygen O +
tension O +
of O +
the O +
buffer O +
measured O +
by O +
a O +
blood O +
gas O +
analyzer O +
( O -
Model O +
813 O -
, O +
Instrumentation O +
Laboratory O -
, O +
Lexington O -
, O +
USA O -
) O +
was O +
about O +
550 O +
mm O +
Hg O -
. O -

The O +
hearts O -
, O +
mounted O +
in O +
a O +
water O -
- O -
jacketed O +
chamber O +
( O -
37 O -
° O -
C O -
) O -
, O +
were O +
initially O +
perfused O +
at O +
a O +
constant O +
perfusion O +
pressure O +
of O +
80 O +
cm O +
H2 O +
O. O +
About O +
10 O +
min O +
after O +
constant O +
pressure O +
perfusion O -
, O +
perfusion O +
was O +
switched O +
to O +
constant O +
flow O +
perfusion O +
( O -
10 O +
ml O +
min−1 O +
) O -
, O +
using O +
a O +
microtube O +
pump O +
( O -
Eyela O +
MP-3 O -
, O +
Tokyo O -
- O -
Rikakikai O +
Instruments O -
, O +
Tokyo O -
, O +
Japan O -
) O -
, O +
which O +
was O +
maintained O +
until O +
the O +
end O +
of O +
the O +
experiment O -
. O -

The O +
heart O +
rate O +
was O +
kept O +
constant O +
by O +
pacing O +
the O +
heart O +
at O +
300 O +
beats O +
min−1 O -
with O +
an O +
electronic O +
stimulator O +
( O -
3F46 O -
, O +
San O -
- O -
Ei O +
Instruments O -
, O +
Tokyo O -
, O +
Japan O -
) O +
during O +
the O +
course O +
of O +
the O +
study O -
. O -

Rectangular O +
pulses O +
of O +
2 O +
ms O +
in O +
duration O +
with O +
a O +
voltage O +
of O +
6 O +
V O +
( O -
about O +
3 O -
× O +
the O +
threshold O +
voltage O -
) O +
were O +
applied O +
to O +
the O +
left O +
ventricle O +
for O +
pacing O +
of O +
the O +
heart O -
. O -

As O +
indices O +
of O +
mechanical O +
function O -
, O +
left O +
ventricular O +
systolic O +
pressure O -
, O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
and O +
left O +
ventricular O +
developed O +
pressure O +
were O +
used O -
. O -

The O +
values O +
of O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
were O +
determined O +
from O +
the O +
left O +
ventricular O +
pressure O +
curves O +
recorded O +
continuously O +
during O +
the O +
course O +
of O +
the O +
study O -
, O +
and O +
the O +
left O +
ventricular O +
developed O +
pressure O +
value O +
was O +
calculated O +
as O +
left O +
ventricular O +
systolic O +
pressure O +
minus O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O -

For O +
measurement O +
of O +
left O +
ventricular O +
pressure O -
, O +
a O +
saline O -
- O -
filled O +
polyethylene O +
cannula O -
, O +
connected O +
to O +
a O +
pressure O +
transducer O -
, O +
was O +
inserted O +
into O +
the O +
left O +
ventricular O +
cavity O +
via O +
the O +
left O +
atrium O -
. O -

2.2 O +
Experimental O +
protocol O +
( O -
the O +
first O +
series O +
of O +
experiments O -
) O -

The O +
hearts O +
were O +
divided O +
into O +
five O +
groups O -
: O +
vehicle O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
5 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
10 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
groups O -
. O -

In O +
these O +
groups O -
, O +
the O +
hearts O +
were O +
perfused O +
at O +
a O +
constant O +
flow O +
for O +
75 O +
min O +
( O -
stabilization O +
period O +
for O +
20 O +
min O +
and O +
observation O +
period O +
for O +
55 O +
min O -
) O -
. O -

d O +
-cis O +
-Diltiazem O -
, O +
l O +
-cis O +
-diltiazem O +
or O +
vehicle O +
( O -
KHB O +
buffer O +
for O +
both O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
solutions O -
) O +
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O -
for O +
45 O +
min O +
from O +
10 O +
min O +
after O +
the O +
start O +
of O +
observation O +
period O -
. O -

The O +
final O +
concentration O +
of O +
d O +
-cis O +
-diltiazem O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
15 O +
μM O +
and O +
that O +
of O +
l O +
-cis O +
-diltiazem O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
5 O -
, O +
10 O +
or O +
15 O +
μM. O +
H2 O +
O2 O -
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O -
for O +
3.5 O +
min O +
from O +
10 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
d O +
-cis O +
-diltiazem O -
, O +
l O +
-cis O +
-diltiazem O +
or O +
vehicle O -
. O -

The O +
final O +
concentration O +
of O +
H2 O +
O2 O -
in O +
the O +
perfusate O +
was O +
set O +
to O +
600 O +
μM. O +
During O +
the O +
observation O +
period O -
, O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
were O +
continuously O +
recorded O +
and O +
the O +
coronary O +
effluent O +
was O +
collected O +
for O +
determination O +
of O +
lactate O +
dehydrogenase O +
( O -
LDH O -
) O +
released O +
from O +
the O +
myocardium O -
. O -

To O +
measure O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
, O +
the O +
hearts O +
were O +
frozen O +
at O +
the O +
end O +
of O +
experiment O +
( O -
45 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
or O +
l O +
-cis O +
-diltiazem O -
) O +
with O +
freezing O +
clamps O +
previously O +
chilled O +
in O +
liquid O +
nitrogen O -
. O -

In O +
addition O -
, O +
some O +
hearts O +
in O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
groups O +
were O +
frozen O +
immediately O +
before O +
H2 O +
O2 O -
infusion O +
( O -
10 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
or O +
l O +
-cis O +
-diltiazem O -
) O -
. O -

The O +
frozen O +
myocardial O +
samples O +
were O +
stored O +
in O +
liquid O +
nitrogen O +
( O -
at O +
−196 O -
° O -
C O -
) O +
until O +
the O +
biochemical O +
analysis O +
was O +
performed O -
. O -

2.3 O +
Biochemical O +
analysis O +
( O -
the O +
first O +
series O +
of O +
experiments O -
) O -

The O +
frozen O +
myocardial O +
sample O +
was O +
pulverized O +
in O +
a O +
mortar O +
cooled O +
with O +
liquid O +
nitrogen O -
. O -

A O +
part O +
of O +
the O +
pulverized O +
tissue O +
powder O +
( O -
about O +
0.8–1.0 O +
g O -
) O +
was O +
weighed O +
and O +
put O +
into O +
an O +
oven O +
overnight O -
, O +
in O +
order O +
to O +
measure O +
the O +
tissue O +
water O +
content O +
and O +
dry O +
weight O +
of O +
the O +
tissue O -
. O -

The O +
remainder O +
of O +
the O +
tissue O +
powder O +
was O +
used O +
for O +
determination O +
of O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O -
. O -

ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
were O +
measured O +
according O +
to O +
standard O +
enzymatic O +
procedures O +
( O -
Bergmeyer O -
, O +
1974a O +
) O -
, O +
using O +
a O +
spectrophotometer O +
( O -
Gilford O +
system O +
2600 O -
, O +
Gilford O +
Instrument O +
Laboratories O -
, O +
Oberlin O -
, O +
USA O -
) O -
. O -

The O +
LDH O +
activity O +
in O +
the O +
coronary O +
effluent O +
was O +
measured O +
spectrophotometrically O +
according O +
to O +
an O +
enzymatic O +
method O +
( O -
Bergmeyer O -
, O +
1974b O +
) O -
, O +
using O +
an O +
LDH O +
assay O +
kit O +
( O -
Sigma O -
, O +
St. O +
Louis O -
, O +
USA O -
) O -
. O -

2.4 O +
Heart O +
perfusion O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O -

Male O +
Sprague B-Species -
– I-Species -
Dawley I-Species +
rats L-Species -
, O +
weighing O +
180–210 O +
g O +
( O -
6–7 O +
weeks O +
old O -
) O -
, O +
were O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O -
. O -

According O +
to O +
the O +
procedure O +
described O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
the O +
isolated O +
hearts O +
were O +
initially O +
perfused O +
by O +
the O +
Langendorff O +
technique O +
at O +
a O +
constant O +
perfusion O +
pressure O +
of O +
80 O +
cm O +
H2 O +
O. O +
About O +
10 O +
min O +
after O +
constant O +
pressure O +
perfusion O -
, O +
perfusion O +
was O +
switched O +
to O +
constant O +
flow O +
perfusion O +
( O -
8.5 O +
ml O +
min−1 O +
) O -
, O +
using O +
a O +
microtube O +
pump O +
( O -
Eyela O +
MP-3 O -
, O +
Tokyo O -
- O -
Rikakikai O +
Instruments O -
) O -
, O +
which O +
was O +
maintained O +
until O +
the O +
end O +
of O +
the O +
experiment O -
. O -

During O +
the O +
first O +
10 O +
min O +
of O +
constant O +
flow O +
perfusion O -
, O +
the O +
hearts O +
were O +
perfused O +
with O +
normal O +
KHB O +
buffer O -
. O -

To O +
obtain O +
23 O +
Na O -
-nuclear O +
magnetic O +
resonance O +
( O -
NMR O -
) O +
spectra O -
, O +
perfusion O +
buffer O +
was O +
then O +
switched O +
to O +
a O +
KHB O +
buffer O +
containing O +
thulium O +
( O -
III O -
) O -
-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis- O -
( O -
methylenephosphonate O -
) O +
[ O -
Tm O -
( O -
DOTP O -
) O -
5− O +
] O +
( O -
a O +
23 O +
Na O -
-NMR O +
shift O +
reagent O -
) O -
, O +
equilibrated O +
with O +
a O +
gas O +
mixture O +
of O +
95 O -
% O +
O2 O +
+ O -
5 O -
% O +
CO2 O -
and O +
maintained O +
at O +
37 O -
° O -
C O -
. O -

The O +
buffer O +
for O +
the O +
study O +
with O +
23 O +
Na O -
-NMR O +
spectra O +
was O +
the O +
same O +
as O +
the O +
normal O +
KHB O +
buffer O -
, O +
except O +
that O +
it O +
contained O +
104 O +
mM O +
NaCl O -
, O +
3.5 O +
mM O +
Na4 O +
HTmDOTP O +
and O +
3.9 O +
mM O +
CaCl2 O +
. O -

The O +
reason O +
for O +
use O +
of O +
3.9 O +
mM O +
CaCl2 O -
was O +
that O +
addition O +
of O +
3.9 O +
mM O +
CaCl2 O -
would O +
produce O +
1 O +
mM O +
free O +
Ca2 O -
+ O -
in O +
the O +
presence O +
of O +
the O +
shift O +
reagent O +
( O -
Buster O +
et O +
al. O -
, O +
1990 O +
) O -
. O -

Although O +
the O +
concentration O +
of O +
free O +
Ca2 O -
+ O -
was O +
lower O +
than O +
that O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O +
( O -
2.5 O +
mM O -
) O -
, O +
it O +
( O -
1 O +
mM O -
) O +
was O +
chosen O +
to O +
avoid O +
precipitation O +
of O +
the O +
shift O +
reagent O +
( O -
Van O +
Emous O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

The O +
heart O +
rate O +
was O +
kept O +
constant O +
by O +
pacing O +
the O +
heart O +
at O +
300 O +
beats O +
min−1 O +
, O +
using O +
a O +
pair O +
of O +
copper O +
electrodes O +
and O +
an O +
electronic O +
stimulator O +
( O -
SEN-3301 O -
, O +
Nihon O +
Kohden O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O -

For O +
measurement O +
of O +
left O +
ventricular O +
pressure O -
, O +
a O +
latex O +
balloon O +
connected O +
to O +
a O +
pressure O +
transducer O +
was O +
inserted O +
into O +
the O +
left O +
ventricular O +
cavity O +
via O +
the O +
left O +
atrium O -
. O -

Before O +
experiments O -
, O +
the O +
balloon O +
was O +
inflated O +
with O +
distilled O +
water O +
to O +
achieve O +
an O +
initial O +
end O -
- O -
diastolic O +
pressure O +
of O +
10 O +
mm O +
Hg O -
; O +
thereafter O -
, O +
the O +
volume O +
was O +
kept O +
constant O +
during O +
the O +
course O +
of O +
the O +
study O -
. O -

The O +
hearts O +
perfused O +
with O +
the O +
buffer O +
were O +
placed O +
inside O +
a O +
glass O +
NMR O +
tube O +
( O -
13.4 O +
mm O +
in O +
internal O +
diameter O -
) O +
that O +
was O +
introduced O +
into O +
the O +
NMR O +
probe O +
placed O +
in O +
a O +
superconducting O +
magnet O -
. O -

Because O +
the O +
internal O +
diameter O +
of O +
the O +
glass O +
NMR O +
tube O +
was O +
small O -
, O +
only O +
small O +
hearts O +
were O +
used O +
for O +
the O +
NMR O +
experiments O -
. O -

Therefore O -
, O +
relatively O +
small O +
rats U-Species +
weighing O +
about O +
200 O +
g O +
were O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O -
. O -

The O +
temperature O +
surrounding O +
the O +
glass O +
NMR O +
tube O +
was O +
maintained O +
at O +
about O +
20 O -
° O -
C O +
by O +
air O +
conditioner O -
, O +
because O +
the O +
apparatus O +
used O +
in O +
the O +
present O +
study O +
is O +
not O +
equipped O +
to O +
provide O +
a O +
temperature O -
- O -
controlled O +
air O +
stream O +
around O +
the O +
NMR O +
tube O -
. O -

Coronary O +
effluent O +
was O +
removed O +
from O +
the O +
NMR O +
glass O +
tube O +
to O +
a O +
level O +
of O +
about O +
10 O +
mm O +
above O +
the O +
heart O -
. O -

Perfusion O +
fluid O +
was O +
not O +
recirculated O -
. O -

2.5 O +
23 O +
Na O +
-NMR O +
measurements O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O +
23 O +
Na O -
-spectra O +
were O +
obtained O +
using O +
a O +
GX-270 O +
spectrometer O +
( O -
JEOL O -
, O +
Tokyo O -
, O +
Japan O -
) O +
at O +
71.32 O +
MHz O +
with O +
a O +
pulse O +
width O +
of O +
90 O -
° O -
, O +
an O +
interpulse O +
delay O +
of O +
0.5 O +
s O -
, O +
a O +
spectral O +
width O +
of O +
3000 O +
Hz O +
and O +
data O +
size O +
of O +
2048 O -
. O -

The O +
spectrometer O +
was O +
equipped O +
with O +
a O +
6.3-T O +
superconducting O +
magnet O +
and O +
an O +
NMR O +
probe O +
( O -
TU O +
( O -
15 O -
) O -
, O +
JEOL O -
) O +
in O +
which O +
the O +
glass O +
NMR O +
tube O +
was O +
placed O -
. O -

Four O +
glass O +
capillaries O -
, O +
each O +
containing O +
1.67 O +
μmol O +
NaCl O +
in O +
the O +
presence O +
of O +
50 O +
mM O +
Tris O +
form O +
of O +
dysprosium O +
triethylenetetraminehexaacetic O +
acid O +
[ O -
Tris3 O +
Dy O -
( O -
TTHA O -
) O -
·3Tris O -
– O -
HCl O -
] O +
( O -
another O +
23 O +
Na O -
-NMR O +
shift O +
reagent O -
) O -
, O +
were O +
placed O +
inside O +
of O +
the O +
NMR O +
tube O +
as O +
an O +
internal O +
standard O -
. O -

The O +
area O +
of O +
each O +
peak O +
in O +
the O +
23 O +
Na O -
-NMR O +
spectra O +
was O +
analyzed O +
by O +
integration O +
after O +
Gaussian O +
and O +
Lorentzian O +
multiplication O +
and O +
baseline O +
correction O +
using O +
JEOL O +
ALICE2 O +
software O +
( O -
JEOL O +
DATUM O -
, O +
Tokyo O -
, O +
Japan O -
) O -
. O -

The O +
[ O -
Na+ O +
] O -
i O -
of O +
the O +
cardiac O +
cells O +
was O +
calculated O +
by O +
a O +
comparison O +
between O +
the O +
peak O +
area O +
of O +
[ O -
Na+ O +
] O -
i O -
and O +
that O +
of O +
the O +
reference O +
solution O +
in O +
the O +
glass O +
capillaries O -
. O -

2.6 O +
Experimental O +
protocol O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O -

The O +
hearts O +
were O +
divided O +
into O +
four O +
groups O -
: O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
tetrodotoxin O +
( O -
3 O +
μM O -
) O +
groups O -
. O -

In O +
these O +
groups O -
, O +
the O +
hearts O +
were O +
perfused O +
with O +
the O +
Tm O -
( O -
DOTP O -
) O -
5− O +
-containing O +
KHB O +
buffer O +
throughout O +
the O +
experiment O +
( O -
stabilization O +
period O +
for O +
10 O +
min O +
and O +
observation O +
period O +
for O +
40 O +
min O -
) O -
. O -

After O +
the O +
stabilization O +
period O -
, O +
d O +
-cis O +
-diltiazem O -
, O +
l O +
-cis O +
-diltiazem O +
or O +
vehicle O +
( O -
KHB O +
buffer O +
for O +
both O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O -
) O +
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
for O +
40 O +
min O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
. O -

The O +
final O +
concentration O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
15 O +
μM O +
and O +
the O +
final O +
concentration O +
of O +
tetrodotoxin O +
in O +
the O +
perfusate O +
was O +
set O +
to O +
3 O +
μM. O +
H2 O +
O2 O -
was O +
infused O +
into O +
the O +
aortic O +
cannula O +
at O +
a O +
constant O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O -
for O +
4 O +
min O +
from O +
10 O +
min O +
after O +
the O +
start O +
of O +
infusion O +
of O +
l O +
-cis O +
-diltiazem O -
, O +
d O +
-cis O +
-diltiazem O +
or O +
tetrodotoxin O -
. O -

The O +
final O +
concentration O +
of O +
H2 O +
O2 O -
in O +
the O +
perfusate O +
was O +
set O +
to O +
1 O +
mM. O +
Thus O -
, O +
the O +
concentration O +
of O +
H2 O +
O2 O -
used O +
in O +
the O +
second O +
series O +
of O +
experiments O +
was O +
higher O +
than O +
that O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
because O +
in O +
a O +
preliminary O +
experiment O -
, O +
a O +
high O +
concentration O +
of O +
H2 O +
O2 O -
was O +
needed O +
to O +
induce O +
mechanical O +
dysfunction O +
to O +
a O +
degree O +
similar O +
to O +
that O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O -

After O +
the O +
experiment O -
, O +
the O +
hearts O +
were O +
put O +
into O +
an O +
oven O +
( O -
80 O -
° O -
C O -
) O +
for O +
48 O +
h O -
, O +
in O +
order O +
to O +
measure O +
the O +
dry O +
weight O +
of O +
the O +
tissue O -
. O -

The O +
volume O +
of O +
intracellular O +
water O +
was O +
assumed O +
to O +
be O +
2.45 O +
ml O +
g−1 O -
dry O +
weight O +
( O -
Askenasy O +
et O +
al. O -
, O +
1995 O +
) O -
. O -

2.7 O +
Direct O +
effect O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O -
concentration O +
in O +
vitro O +
( O -
another O +
experiment O -
) O +
To O +
determine O +
whether O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
a O +
direct O +
scavenging O +
effect O +
on O +
H2 O +
O2 O +
, O +
the O +
effect O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O -
concentration O +
was O +
investigated O +
and O +
compared O +
with O +
that O +
of O +
dimethylthiourea O -
, O +
which O +
has O +
an O +
H2 O +
O2 O +
-scavenging O +
action O +
( O -
Jackson O +
et O +
al. O -
, O +
1985 O +
) O -
. O -

A O +
mixture O +
of O +
H2 O +
O2 O -
( O -
600 O +
μM O -
) O +
and O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
or O +
that O +
of O +
H2 O +
O2 O -
( O -
600 O +
μM O -
) O +
and O +
dimethylthiourea O +
( O -
10 O +
mM O -
) O +
in O +
0.1 O +
M O +
phosphate O +
buffer O +
( O -
pH O +
7.0 O -
) O +
was O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O -
. O -

The O +
H2 O +
O2 O -
concentration O +
in O +
the O +
buffer O +
was O +
measured O +
according O +
to O +
a O +
spectrophotometric O +
method O +
( O -
Hayashi O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

2.8 O +
Drugs O +
d O +
-cis O +
-Diltiazem O +
( O -
Sigma O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
Tanabe O +
Seiyaku O -
, O +
Osaka O -
, O +
Japan O -
) O +
and O +
tetrodotoxin O +
( O -
Sankyo O -
, O +
Tokyo O -
, O +
Japan O -
) O +
were O +
dissolved O +
in O +
KHB O +
buffer O +
solution O -
. O -

These O +
agents O +
were O +
infused O +
at O +
a O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O +
, O +
using O +
an O +
infusion O +
pump O -
, O +
into O +
the O +
inflow O +
tube O +
connected O +
to O +
the O +
side O +
arm O +
of O +
the O +
aortic O +
cannula O -
. O -

H2 O +
O2 O -
( O -
Nacalai O +
Tesque O -
, O +
Kyoto O -
, O +
Japan O -
) O +
was O +
diluted O +
with O +
saline O +
solution O -
. O -

H2 O +
O2 O -
was O +
also O +
infused O +
into O +
the O +
inflow O +
tube O +
at O +
a O +
flow O +
rate O +
of O +
0.1 O +
ml O +
min−1 O -
using O +
another O +
infusion O +
pump O -
. O -

Dimethylthiourea O +
was O +
purchased O +
from O +
Aldrich O +
Chemical O +
( O -
St. O +
Louis O -
, O +
USA O -
) O -
. O -

The O +
reagents O +
and O +
enzymes O +
used O +
for O +
biochemical O +
analysis O +
were O +
purchased O +
from O +
Sigma O -
. O -

Na4 O +
HTmDOTP O +
was O +
purchased O +
from O +
Magnetic O +
Resonance O +
Solutions O +
( O -
Dallas O -
, O +
USA O -
) O -
. O -

Tris3 O +
Dy O -
( O -
TTHA O -
) O -
·3Tris O -
– O -
HCl O +
( O -
50 O +
mM O -
) O +
was O +
prepared O +
by O +
mixing O +
DyCl3 O +
· O -
6H2 O +
O O +
( O -
Sigma O -
) O +
( O -
50 O +
mM O -
) O +
with O +
H6 O +
TTHA O +
( O -
Sigma O -
) O +
( O -
50 O +
mM O -
) O +
in O +
the O +
Tris O +
buffer O +
( O -
pH O +
7.4 O -
) O -
. O -

2.9 O +
Statistical O +
analysis O +
All O +
values O +
are O +
expressed O +
as O +
means±S.E.M. O +
When O +
changes O +
in O +
left O +
ventricular O +
systolic O +
pressure O -
, O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
, O +
left O +
ventricular O +
developed O +
pressure O -
, O +
LDH O +
release O +
and O +
[ O -
Na+ O +
] O -
i O -
were O +
compared O +
between O +
vehicle O -
- O -
treated O +
and O +
drug O -
- O -
treated O +
groups O -
, O +
statistical O +
analysis O +
was O +
performed O +
with O +
a O +
two O -
- O -
way O +
repeated O +
measures O +
analysis O +
of O +
variance O +
( O -
ANOVA O -
) O +
followed O +
by O +
Dunnett O -
's O +
test O +
for O +
multiple O +
comparisons O -
. O -

If O +
a O +
significant O +
difference O +
was O +
obtained O +
between O +
these O +
groups O -
, O +
further O +
comparisons O +
at O +
each O +
time O +
point O +
were O +
performed O +
by O +
means O +
of O +
Dunnett O -
's O +
test O +
( O -
Fig. O +
1 O -
Figs. O +
3 O -
, O +
4 O +
and O +
6 O +
and O +
8 O +
) O -
. O -

When O +
the O +
tissue O +
levels O +
of O +
energy O +
metabolites O +
in O +
the O +
vehicle O +
group O +
were O +
compared O +
between O +
H2 O +
O2 O +
-untreated O +
and O +
H2 O +
O2 O +
-treated O +
hearts O -
, O +
unpaired O +
Student O -
's O +
t O +
-test O +
was O +
used O +
( O -
Fig. O +
2 O -
Fig. O +
5 O +
) O -
. O -

When O +
the O +
tissue O +
levels O +
of O +
energy O +
metabolites O +
and O +
the O +
H2 O +
O2 O -
concentration O +
were O +
compared O +
between O +
vehicle O -
- O -
treated O +
and O +
drug O -
- O -
treated O +
groups O -
, O +
statistical O +
analysis O +
was O +
performed O +
with O +
a O +
one O -
- O -
way O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O +
for O +
multiple O +
comparisons O +
( O -
Figs. O +
2 O +
and O +
5 O +
, O +
Table O +
1 O -
) O -
. O -

A O +
difference O +
was O +
considered O +
statistically O +
significant O +
at O +
P O +
< O -
0.05 O -
. O -

3 O +
Results O +
3.1 O +
Effects O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
H2 O +
O2 O +
-induced O +
mechanical O +
derangements O +
in O +
the O +
heart O +
Fig. O +
1 O -
shows O +
the O +
effect O +
of O +
various O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O -
, O +
10 O +
or O +
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O -
. O -

Before O +
the O +
start O +
of O +
the O +
infusion O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
0 O -
, O +
5 O +
and O +
10 O +
min O +
in O +
Fig. O +
1 O +
) O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
values O +
of O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
between O +
the O +
vehicle O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
. O -

No O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O -
, O +
10 O +
or O +
15 O +
μM O -
) O +
had O +
a O +
significant O +
action O +
on O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
before O +
H2 O +
O2 O -
infusion O +
( O -
20 O +
min O +
in O +
Fig. O +
1 O +
) O -
. O -

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
produced O +
a O +
temporary O -
, O +
but O +
marked O +
decrease O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
, O +
which O +
was O +
followed O +
by O +
incomplete O +
recovery O +
to O +
the O +
initial O +
level O -
. O -

H2 O +
O2 O -
also O +
produced O +
a O +
marked O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
, O +
which O +
was O +
accompanied O +
by O +
an O +
increase O +
in O +
left O +
ventricular O +
systolic O +
pressure O -
. O -

The O +
decrease O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
induced O +
by O +
H2 O +
O2 O -
was O +
not O +
significantly O +
modified O +
by O +
any O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
P O +
= O -
0.616 O +
by O +
ANOVA O -
) O -
. O -

In O +
contrast O -
, O +
a O +
high O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
significantly O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
although O +
lower O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O +
or O +
10 O +
μM O -
) O +
did O +
not O -
. O -

Fig. O +
2 O -
shows O +
the O +
effects O +
of O +
various O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O -
, O +
10 O +
or O +
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
. O -

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
decreased O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O +
and O +
creatine O +
phosphate O +
and O +
increased O +
the O +
tissue O +
level O +
of O +
AMP O +
( O -
P O +
< O -
0.05 O -
) O -
. O -

These O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O +
were O +
not O +
attenuated O +
by O +
lower O +
concentrations O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
5 O +
or O +
10 O +
μM O -
) O -
. O -

However O -
, O +
a O +
high O +
concentration O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
significantly O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O -

These O +
results O +
suggest O +
that O +
at O +
the O +
concentration O +
of O +
15 O +
μM O -
, O +
l O +
-cis O +
-diltiazem O +
attenuates O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
and O +
metabolic O +
derangements O +
in O +
the O +
heart O -
. O -

Next O -
, O +
the O +
effect O +
of O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
was O +
compared O +
with O +
that O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
. O -

Fig. O +
3 O -
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O -

Before O +
the O +
infusion O +
of O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
0 O -
, O +
5 O +
and O +
10 O +
min O +
in O +
Fig. O +
3 O +
) O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
values O +
of O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
among O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
. O -

Before O +
the O +
H2 O +
O2 O -
infusion O +
( O -
15 O +
and O +
20 O +
min O +
in O +
Fig. O +
3 O +
) O -
, O +
there O +
was O +
a O +
significant O +
decrease O +
in O +
the O +
left O +
ventricular O +
systolic O +
pressure O +
in O +
the O +
d O +
-cis O +
-diltiazem O +
group O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
while O +
there O +
was O +
no O +
decrease O +
in O +
the O +
l O +
-cis O +
-diltiazem O +
group O -
; O +
left O +
ventricular O +
systolic O +
pressure O +
decreased O +
only O +
in O +
the O +
d O +
-cis O +
-diltiazem O +
group O +
( O -
15–55 O +
min O +
in O +
Fig. O +
3 O +
) O -
. O -

As O +
seen O +
in O +
Fig. O +
1 O +
, O +
in O +
the O +
vehicle O +
group O +
H2 O +
O2 O -
decreased O +
left O +
ventricular O +
systolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O +
and O +
increased O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
. O -

It O +
is O +
noteworthy O -
, O +
however O -
, O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuated O +
significantly O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O -

Fig. O +
4 O -
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O -
, O +
which O +
is O +
expressed O +
as O +
left O +
ventricular O +
systolic O +
pressure O +
minus O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O -

Before O +
the O +
infusion O +
of O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
0 O -
, O +
5 O +
and O +
10 O +
min O +
in O +
Fig. O +
4 O +
) O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
left O +
ventricular O +
developed O +
pressure O +
value O +
among O +
vehicle O -
, O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
. O -

Before O +
the O +
H2 O +
O2 O -
infusion O +
( O -
15 O +
and O +
20 O +
min O +
in O +
Fig. O +
4 O +
) O -
, O +
there O +
was O +
a O +
significant O +
decrease O +
in O +
the O +
left O +
ventricular O +
developed O +
pressure O +
in O +
the O +
d O +
-cis O +
-diltiazem O +
group O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
while O +
there O +
was O +
no O +
decrease O +
in O +
the O +
l O +
-cis O +
-diltiazem O +
group O -
; O +
d O +
-cis O +
-diltiazem O +
alone O +
decreased O +
left O +
ventricular O +
developed O +
pressure O +
( O -
15–55 O +
min O +
in O +
Fig. O +
4 O +
) O -
. O -

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
decreased O +
left O +
ventricular O +
developed O +
pressure O +
markedly O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
. O -

l O +
-cis O +
-Diltiazem O +
attenuated O +
significantly O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
whereas O +
d O +
-cis O +
-diltiazem O +
did O +
not O +
attenuate O +
it O -
, O +
probably O +
because O +
of O +
its O +
cardiodepressive O +
action O -
. O -

Thus O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
both O +
left O +
ventricular O +
developed O +
pressure O +
and O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
. O -

Fig. O +
5 O -
shows O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
in O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
groups O +
before O +
H2 O +
O2 O -
infusion O +
( O -
20 O +
min O +
in O +
Fig. O +
4 O +
) O +
and O +
after O +
the O +
H2 O +
O2 O -
infusion O +
( O -
55 O +
min O +
in O +
Fig. O +
4 O +
) O -
. O -

The O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
before O +
H2 O +
O2 O -
infusion O +
were O +
similar O +
among O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
groups O +
( O -
P O +
> O -
0.05 O +
by O +
ANOVA O -
) O -
. O -

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
decreased O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
ADP O +
and O +
creatine O +
phosphate O -
, O +
and O +
increased O +
the O +
tissue O +
level O +
of O +
AMP O +
( O -
P O +
< O -
0.05 O -
) O -
. O -

These O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
energy O +
metabolites O +
induced O +
by O +
H2 O +
O2 O -
were O +
significantly O +
attenuated O +
by O +
d O +
-cis O +
-diltiazem O +
( O -
P O +
< O -
0.01 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O -

l O +
-cis O +
-Diltiazem O +
also O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
the O +
tissue O +
levels O +
of O +
ATP O -
, O +
AMP O +
and O +
creatine O +
phosphate O +
( O -
P O +
< O -
0.01 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
, O +
although O +
it O +
failed O +
to O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
the O +
tissue O +
level O +
of O +
ADP O -
. O -

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
decrease O +
in O +
high O -
- O -
energy O +
phosphates O +
in O +
the O +
heart O -
. O -

Fig. O +
6 O -
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
release O +
of O +
LDH O -
. O -

In O +
the O +
vehicle O -
, O +
d O +
-cis O +
-diltiazem O +
and O +
l O +
-cis O +
-diltiazem O +
groups O -
, O +
there O +
was O +
no O +
significant O +
difference O +
in O +
the O +
release O +
of O +
LDH O +
before O +
H2 O +
O2 O -
infusion O -
. O -

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
produced O +
a O +
marked O +
release O +
of O +
LDH O +
from O +
the O +
myocardium O +
into O +
the O +
effluent O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O -
; O +
the O +
LDH O +
release O +
reached O +
a O +
maximum O +
21.5 O +
min O +
after O +
the O +
end O +
of O +
H2 O +
O2 O -
infusion O +
( O -
35 O +
min O +
in O +
Fig. O +
6 O +
) O -
. O -

The O +
LDH O +
release O +
induced O +
by O +
H2 O +
O2 O -
was O +
significantly O +
attenuated O +
by O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O -

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
damage O +
of O +
the O +
cardiac O +
cell O +
membrane O -
. O -

3.2 O +
Effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
H2 O +
O2 O +
-induced O +
changes O +
in O +
[ O -
Na+ O +
] O -
i O -
Fig. O +
7 O -
shows O +
typical O +
23 O +
Na O -
spectra O +
for O +
the O +
rat U-Species +
heart O +
in O +
the O +
presence O +
of O +
the O +
23 O +
Na O -
shift O +
reagent O +
Tm O -
( O -
DOTP O -
) O -
5− O +
. O -

H2 O +
O2 O -
( O -
1 O +
mM O -
) O +
was O +
added O +
to O +
the O +
heart O +
for O +
4 O +
min O +
( O -
from O +
15 O +
to O +
19 O +
min O +
in O +
Fig. O +
7 O +
) O -
. O -

It O +
is O +
evident O +
that O +
in O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
caused O +
an O +
increase O +
in O +
the O +
peak O +
of O +
[ O -
Na+ O +
] O -
i O -
, O +
which O +
was O +
markedly O +
attenuated O +
by O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
or O +
tetrodotoxin O +
( O -
3 O +
μM O -
) O -
. O -

Fig. O +
8 O -
shows O +
the O +
effects O +
of O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
tetrodotoxin O +
( O -
3 O +
μM O -
) O +
on O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
in O +
myocardial O +
cells O -
. O -

In O +
the O +
vehicle O +
group O -
, O +
H2 O +
O2 O -
( O -
1 O +
mM O -
) O +
increased O +
[ O -
Na+ O +
] O -
i O -
markedly O +
( O -
P O +
< O -
0.001 O +
by O +
ANOVA O -
) O +
and O +
the O +
increase O +
reached O +
a O +
maximum O +
20 O +
min O +
after O +
the O +
end O +
of O +
H2 O +
O2 O -
infusion O +
( O -
34 O +
min O +
in O +
Fig. O +
8 O +
) O -
. O -

The O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
induced O +
by O +
H2 O +
O2 O -
was O +
almost O +
completely O +
inhibited O +
by O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O +
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O -

Tetrodotoxin O +
also O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
( O -
P O +
< O -
0.05 O +
by O +
ANOVA O +
followed O +
by O +
Dunnett O -
's O +
test O -
) O -
. O -

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
intracellular O +
accumulation O +
of O +
intracellular O +
Na+ O -
induced O +
by O +
H2 O +
O2 O +
. O -

In O +
the O +
second O +
series O +
of O +
experiments O -
, O +
we O +
also O +
continuously O +
recorded O +
the O +
mechanical O +
function O +
( O -
left O +
ventricular O +
pressure O -
) O +
of O +
the O +
heart O -
, O +
and O +
similar O +
results O +
as O +
in O +
the O +
first O +
series O +
of O +
experiments O +
( O -
Fig. O +
3 O +
) O +
were O +
obtained O -
: O +
H2 O +
O2 O -
decreased O +
left O +
ventricular O +
systolic O +
pressure O +
and O +
increased O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O -
, O +
and O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
was O +
attenuated O +
by O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
, O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
or O +
tetrodotoxin O +
( O -
data O +
not O +
shown O -
) O -
. O -

If O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
a O +
Na+ O -
channel O +
blocking O +
action O -
, O +
[ O -
Na+ O +
] O -
i O -
in O +
normal O +
cardiac O +
cells O +
( O -
without O +
H2 O +
O2 O +
) O +
should O +
decrease O +
after O +
treatment O +
of O +
the O +
heart O +
with O +
d O +
-cis O +
- O +
or O +
l O +
-cis O +
-diltiazem O -
. O -

However O -
, O +
neither O +
tetrodotoxin O -
, O +
nor O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
changed O +
[ O -
Na+ O +
] O -
i O -
in O +
the O +
normal O +
cardiac O +
cells O -
: O +
[ O -
Na+ O +
] O -
i O -
remained O +
unchanged O +
within O +
the O +
accuracy O +
of O +
the O +
assay O -
. O -

3.3 O +
Effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
concentration O +
of O +
H2 O +
O2 O -
in O +
the O +
buffer O +
solution O +
in O +
vitro O +
We O +
examined O +
whether O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
a O +
direct O +
scavenging O +
effect O +
on O +
H2 O +
O2 O -
in O +
vitro O -
. O -

d O +
-cis O +
- O +
or O +
l O +
-cis O +
-Diltiazem O -
, O +
however O -
, O +
did O +
not O +
modify O +
the O +
H2 O +
O2 O -
concentration O +
in O +
the O +
buffer O +
solution O +
( O -
Table O +
1 O +
) O -
. O -

In O +
contrast O -
, O +
dimethylthiourea O -
, O +
which O +
has O +
a O +
H2 O +
O2 O +
-scavenging O +
action O -
, O +
decreased O +
the O +
H2 O +
O2 O -
concentration O +
markedly O -
. O -

These O +
results O +
suggest O +
that O +
neither O +
d O +
-cis O +
-diltiazem O +
nor O +
l O +
-cis O +
-diltiazem O +
has O +
a O +
direct O +
scavenging O +
action O +
on O +
H2 O +
O2 O -
in O +
vitro O -
. O -

4 O +
Discussion O +
In O +
the O +
present O +
study O -
, O +
we O +
examined O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
myocardial O +
derangements O +
in O +
the O +
isolated O +
perfused O +
rat U-Species +
heart O -
. O -

l O +
-cis O +
-Diltiazem O +
is O +
an O +
optical O +
isomer O +
of O +
d O +
-cis O +
-diltiazem O +
and O +
is O +
about O +
20–100 O +
times O +
less O +
potent O +
than O +
d O +
-cis O +
-diltiazem O +
in O +
its O +
Ca2 O -
+ O -
channel O +
blocking O +
action O +
( O -
Nasa O +
et O +
al. O -
, O +
1992 O +
; O +
Itogawa O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

We O +
used O +
H2 O +
O2 O -
as O +
a O +
substance O +
that O +
may O +
be O +
responsible O +
for O +
ischemic O +
derangements O +
for O +
the O +
following O +
reasons O -
: O +
( O -
1 O -
) O +
H2 O +
O2 O -
and O +
its O +
metabolite O -
, O +
hydroxyl O +
radical O -
, O +
are O +
considered O +
important O +
in O +
the O +
pathogenesis O +
of O +
myocardial O +
damage O +
induced O +
by O +
ischemia O -
– O -
reperfusion O +
( O -
Brown O +
et O +
al. O -
, O +
1988 O +
; O +
Loesser O +
et O +
al. O -
, O +
1991 O +
) O -
; O +
( O -
2 O -
) O +
H2 O +
O2 O -
penetrates O +
the O +
cell O +
membrane O +
and O +
reaches O +
the O +
intracellular O +
site O +
( O -
Fisher O -
, O +
1988 O +
) O -
, O +
and O +
therefore O +
it O +
may O +
produce O +
severe O +
damage O +
to O +
the O +
cell O -
. O -

In O +
the O +
first O +
series O +
of O +
experiments O -
, O +
H2 O +
O2 O -
produced O +
an O +
increase O +
in O +
left O +
ventricular O +
end O -
- O -
diastolic O +
pressure O +
and O +
a O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O +
( O -
i.e. O -
, O +
mechanical O +
dysfunction O -
) O -
, O +
a O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
ATP O +
and O +
creatine O +
phosphate O +
and O +
an O +
increase O +
in O +
the O +
tissue O +
AMP O +
level O +
( O -
i.e. O -
, O +
energy O +
deficiency O -
) O -
, O +
and O +
an O +
increase O +
in O +
LDH O +
release O +
from O +
the O +
myocardium O +
( O -
i.e. O -
, O +
membrane O +
damage O -
) O -
. O -

These O +
alterations O +
induced O +
by O +
H2 O +
O2 O -
were O +
attenuated O +
by O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O -
. O -

In O +
contrast O +
to O +
l O +
-cis O +
-diltiazem O -
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
failed O +
to O +
attenuate O +
the O +
decrease O +
in O +
left O +
ventricular O +
developed O +
pressure O +
induced O +
by O +
H2 O +
O2 O +
, O +
because O +
d O +
-cis O +
-diltiazem O +
has O +
a O +
potent O +
Ca2 O -
+ O -
channel O +
blocking O +
action O -
, O +
leading O +
to O +
a O +
decrease O +
in O +
mechanical O +
function O -
. O -

In O +
fact O -
, O +
the O +
cardiodepressive O +
action O +
of O +
d O +
-cis O +
-diltiazem O +
was O +
observed O +
before O +
H2 O +
O2 O -
infusion O -
. O -

These O +
results O +
suggest O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
protect O +
the O +
myocardium O +
against O +
the O +
H2 O +
O2 O +
-induced O +
derangements O -
, O +
and O +
that O +
their O +
cardioprotective O +
action O +
is O +
not O +
only O +
due O +
to O +
the O +
Ca2 O -
+ O -
channel O +
blocking O +
action O -
. O -

Some O +
radical O +
scavengers O +
or O +
anti O -
- O -
oxidants O +
have O +
been O +
demonstrated O +
to O +
protect O +
the O +
myocardium O +
against O +
oxidative O +
stress O +
( O -
Nakaya O +
et O +
al. O -
, O +
1987 O +
; O +
Weglicki O +
et O +
al. O -
, O +
1990 O +
; O +
Nagy O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

In O +
fact O -
, O +
we O +
have O +
reported O +
that O -
, O +
in O +
the O +
isolated O +
perfused O +
rat U-Species +
heart O -
, O +
catalase O +
( O -
a O +
H2 O +
O2 O -
scavenger O -
) O +
( O -
Hara O +
et O +
al. O -
, O +
1993 O +
) O +
or O +
propofol O +
( O -
an O +
intravenous O +
anesthetic O +
drug O +
with O +
an O +
anti O -
- O -
oxidant O +
action O -
) O +
( O -
Kokita O +
and O +
Hara O -
, O +
1996 O +
) O +
attenuates O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O +
and O +
the O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
. O -

There O +
is O +
evidence O +
to O +
show O +
that O +
d O +
-cis O +
-diltiazem O +
has O +
an O +
anti O -
- O -
oxidant O +
action O +
( O -
Janero O +
et O +
al. O -
, O +
1988 O +
; O +
Mak O +
and O +
Weglicki O -
, O +
1990 O +
; O +
Weglicki O +
et O +
al. O -
, O +
1990 O +
) O -
, O +
whereas O +
there O +
is O +
no O +
information O +
about O +
the O +
anti O -
- O -
oxidant O +
action O +
of O +
l O +
-cis O +
-diltiazem O -
. O -

The O +
concentration O +
of O +
d O +
-cis O +
-diltiazem O +
required O +
for O +
its O +
anti O -
- O -
oxidant O +
action O +
is O +
much O +
higher O +
than O +
that O +
used O +
in O +
the O +
present O +
study O -
; O +
in O +
the O +
sarcolemmal O +
membrane O -
, O +
the O +
concentration O +
required O +
to O +
inhibit O +
50 O -
% O +
of O +
lipid O +
peroxidation O +
( O -
IC50 O +
) O +
induced O +
by O +
oxygen O +
radicals O +
is O +
510 O +
μM O +
( O -
Janero O +
et O +
al. O -
, O +
1988 O +
) O +
or O +
850 O +
μM O +
( O -
Mak O +
and O +
Weglicki O -
, O +
1990 O +
) O -
. O -

In O +
the O +
present O +
study O -
, O +
neither O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
nor O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
modified O +
the O +
H2 O +
O2 O -
concentration O +
in O +
the O +
buffer O +
solution O +
in O +
vitro O -
. O -

It O +
is O +
unlikely O -
, O +
therefore O -
, O +
that O +
the O +
protective O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
derangements O +
is O +
due O +
to O +
the O +
radical O +
scavenging O +
or O +
anti O -
- O -
oxidant O +
effect O -
. O -

According O +
to O +
recent O +
electrophysiological O +
studies O -
, O +
H2 O +
O2 O -
causes O +
an O +
increase O +
in O +
Na+ O -
current O +
in O +
ventricular O +
myocytes O -
, O +
an O +
increase O +
which O +
is O +
blocked O +
by O +
tetrodotoxin O +
( O -
Bhatnagar O +
et O +
al. O -
, O +
1990 O +
; O +
Ward O +
and O +
Giles O -
, O +
1997 O +
) O -
. O -

Ver O +
Donck O +
and O +
Borgers O +
( O -
1991 O -
) O +
have O +
suggested O +
that O +
the O +
reactive O +
oxygen O +
species O +
causes O +
excessive O +
Na+ O -
entry O +
through O +
the O +
fast O +
Na+ O -
channel O -
, O +
leading O +
to O +
intracellular O +
Ca2 O -
+ O -
overload O +
through O +
the O +
Na+ O +
–Ca2 O -
+ O -
exchange O +
system O -
, O +
and O +
hence O +
myocardial O +
damage O -
. O -

In O +
fact O -
, O +
H2 O +
O2 O -
increases O +
intracellular O +
concentrations O +
of O +
both O +
Na+ O -
and O +
Ca2 O -
+ O -
in O +
the O +
myocardium O +
( O -
Yanagida O +
et O +
al. O -
, O +
1995 O +
) O -
. O -

Interestingly O -
, O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
have O +
been O +
demonstrated O +
to O +
block O +
the O +
Na+ O -
channel O +
( O -
Nakajima O +
et O +
al. O -
, O +
1975 O +
; O +
Itogawa O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

Itogawa O +
et O +
al. O +
( O -
1996 O -
) O +
reported O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
inhibited O +
the O +
veratridine O +
( O -
a O +
Na+ O -
channel O +
opener O -
) O -
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
and O +
hypercontracture O +
in O +
rat U-Species +
myocytes O +
at O +
the O +
concentration O +
of O +
10 O +
μM O +
or O +
higher O -
. O -

There O +
is O +
a O +
possibility O -
, O +
therefore O -
, O +
that O +
the O +
beneficial O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
derangements O +
is O +
due O +
to O +
their O +
blocking O +
effect O +
on O +
the O +
Na+ O -
channel O -
. O -

To O +
determine O +
this O +
possibility O -
, O +
we O +
examined O +
the O +
effect O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
in O +
the O +
myocardium O +
using O +
an O +
NMR O +
technique O +
( O -
the O +
second O +
series O +
of O +
experiments O -
) O -
. O -

We O +
used O +
a O +
higher O +
concentration O +
of O +
H2 O +
O2 O -
in O +
the O +
second O +
series O +
of O +
experiments O +
than O +
in O +
the O +
first O +
series O +
of O +
experiments O -
: O +
in O +
the O +
second O +
series O +
of O +
experiments O -
, O +
1 O +
mM O +
H2 O +
O2 O -
was O +
applied O +
for O +
4 O +
min O -
, O +
whereas O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
600 O +
μM O +
H2 O +
O2 O -
was O +
applied O +
for O +
3.5 O +
min O -
. O -

This O +
is O +
because O +
in O +
the O +
second O +
series O +
of O +
experiments O -
, O +
a O +
large O +
amount O +
of O +
H2 O +
O2 O -
was O +
needed O +
to O +
induce O +
mechanical O +
dysfunction O +
to O +
a O +
degree O +
similar O +
to O +
that O +
seen O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O -

The O +
decreased O +
response O +
of O +
the O +
heart O +
to O +
H2 O +
O2 O -
in O +
the O +
second O +
series O +
of O +
experiments O +
may O +
be O +
due O +
to O +
the O +
difference O +
in O +
perfusion O +
conditions O -
, O +
such O +
as O +
lower O +
Ca2 O -
+ O -
concentration O +
and O +
lower O +
temperature O -
, O +
which O +
are O +
determinants O +
of O +
cardioprotection O -
; O +
the O +
concentration O +
of O +
free O +
Ca2 O -
+ O -
( O -
1 O +
mM O -
) O +
in O +
the O +
Tm O -
( O -
DOTP O -
) O -
5− O +
-containing O +
KHB O +
buffer O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O +
was O +
lower O +
than O +
that O +
( O -
2.5 O +
mM O -
) O +
in O +
the O +
KHB O +
buffer O +
( O -
normal O +
KHB O +
buffer O -
) O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
, O +
and O +
the O +
temperature O +
around O +
the O +
NMR O +
tube O +
( O -
about O +
20 O -
° O -
C O -
) O +
used O +
in O +
the O +
second O +
series O +
of O +
experiments O +
was O +
lower O +
that O +
in O +
the O +
water O -
- O -
jacketed O +
chamber O +
( O -
37 O -
° O -
C O -
) O +
used O +
in O +
the O +
first O +
series O +
of O +
experiments O -
. O -

When O +
the O +
membrane O +
is O +
severely O +
damaged O -
, O +
intracellular O +
Na+ O -
resonance O +
collapses O +
and O +
a O +
broad O +
Na+ O -
resonance O +
appears O +
in O +
the O +
23 O +
Na O -
-NMR O +
spectra O +
because O +
of O +
entry O +
of O +
the O +
shift O +
reagent O +
into O +
the O +
cell O -
, O +
and O +
therefore O +
measurement O +
of O +
[ O -
Na+ O +
] O -
i O -
is O +
impossible O +
( O -
Jansen O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

As O +
shown O +
in O +
Fig. O +
7 O +
, O +
however O -
, O +
no O +
broad O +
Na+ O -
resonance O +
was O +
observed O -
, O +
suggesting O +
that O +
the O +
measurement O +
of O +
[ O -
Na+ O +
] O -
i O -
was O +
appropriate O +
in O +
the O +
present O +
study O -
. O -

The O +
results O +
of O +
the O +
second O +
series O +
of O +
experiments O +
indicate O +
that O +
both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuate O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
in O +
the O +
heart O -
. O -

Tetrodotoxin O +
( O -
3 O +
μM O -
) O -
, O +
a O +
specific O +
inhibitor O +
of O +
Na+ O -
channels O +
( O -
Duff O +
et O +
al. O -
, O +
1988 O +
) O -
, O +
also O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
in O +
the O +
heart O +
and O +
the O +
H2 O +
O2 O +
-induced O +
myocardial O +
derangements O -
. O -

Therefore O -
, O +
the O +
protective O +
action O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
may O +
be O +
due O +
to O +
their O +
ability O +
to O +
inhibit O +
the O +
Na+ O -
channel O -
. O -

The O +
above O +
view O +
can O +
be O +
supported O +
by O +
our O +
previous O +
findings O +
that O +
tetrodotoxin O +
( O -
Hara O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
lidocaine O +
( O -
Hara O +
et O +
al. O -
, O +
1993 O +
) O +
and O +
dilazep O +
( O -
Hara O +
and O +
Abiko O -
, O +
1996 O +
) O -
, O +
all O +
of O +
which O +
have O +
a O +
Na+ O -
channel O +
blocking O +
action O -
, O +
are O +
effective O +
in O +
attenuating O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
dysfunction O +
and O +
decrease O +
in O +
the O +
tissue O +
levels O +
of O +
high O -
- O -
energy O +
phosphates O -
. O -

It O +
should O +
be O +
noted O -
, O +
however O -
, O +
that O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
mechanical O +
and O +
metabolic O +
derangements O +
incompletely O -
, O +
even O +
when O +
they O +
attenuated O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
completely O -
. O -

It O +
is O +
possible O +
therefore O +
that O +
the O +
harmful O +
action O +
of O +
H2 O +
O2 O -
on O +
the O +
heart O +
is O +
not O +
only O +
due O +
to O +
activation O +
of O +
the O +
fast O +
Na+ O -
channel O -
, O +
but O +
also O +
due O +
to O +
other O +
mechanisms O -
, O +
such O +
as O +
activation O +
of O +
nonselective O +
cation O +
channels O +
( O -
Jabr O +
and O +
Cole O -
, O +
1995 O +
) O +
and O +
inactivation O +
of O +
creatine O +
kinase O +
( O -
Banerjee O +
et O +
al. O -
, O +
1991 O +
) O -
. O -

According O +
to O +
Nasa O +
et O +
al. O +
( O -
1990 O -
) O +
, O +
d O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
and O +
l O +
-cis O +
-diltiazem O +
( O -
15 O +
μM O -
) O +
are O +
capable O +
of O +
attenuating O +
the O +
myocardial O +
derangements O +
induced O +
by O +
ischemia O -
– O -
reperfusion O +
in O +
the O +
isolated O -
, O +
working O +
rat O +
heart O -
. O -

Therefore O -
, O +
the O +
beneficial O +
action O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
on O +
the O +
H2 O +
O2 O +
-induced O +
changes O +
may O +
contribute O +
to O +
their O +
protective O +
effect O +
on O +
the O +
myocardium O +
against O +
ischemia O -
– O -
reperfusion O +
damage O -
. O -

5 O +
Conclusion O +
Both O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
protect O +
the O +
myocardium O +
against O +
the O +
H2 O +
O2 O +
-induced O +
derangements O +
in O +
the O +
isolated O +
perfused O +
rat O +
heart O -
. O -

The O +
protective O +
action O +
of O +
d O +
-cis O +
- O +
and O +
l O +
-cis O +
-diltiazem O +
may O +
be O +
due O +
to O +
inhibition O +
of O +
the O +
H2 O +
O2 O +
-induced O +
increase O +
in O +
[ O -
Na+ O +
] O -
i O -
, O +
at O +
least O +
in O +
part O -
. O -

Acknowledgements O -

We O +
thank O +
Mr. O +
Mitsutoshi O +
Kusakabe O +
for O +
his O +
help O +
in O +
experiments O +
with O +
NMR O +
technique O -
. O -

We O +
also O +
thank O +
Ms. O +
Min O +
Chen O +
for O +
her O +
valuable O +
help O +
during O +
experiments O -
, O +
Mr. O +
Tadahiko O +
Yokoyama O +
for O +
his O +
technical O +
assistance O -
, O +
and O +
Ms. O +
Miwa O +
Kashu O +
and O +
Ms. O +
Kaori O +
Inaba O +
for O +
their O +
secretarial O +
assistance O -
. O -

l O +
-cis O +
-Diltiazem O +
hydrochloride O +
was O +
kindly O +
supplied O +
by O +
Tanabe O +
Seiyaku O +
( O -
Osaka O -
, O +
Japan O -
) O -
. O +

Cordyceps B-Species +
sinensis I-Species -
( I-Species -
Berk I-Species -
. I-Species -
) L-Species -

Sacc U-Species -
. O -

( O -
family O +
Clavicipitaceae U-Species -
) O +
has O +
long O +
been O +
used O +
in O +
Chinese O +
medicine O +
to O +
treat O +
numerous O +
illnesses O -
, O +
promote O +
longevity O -
, O +
relieve O +
exhaustion O +
and O +
increase O +
athletic O +
prowess O +
( O -
Pegler O -
, O +
Yao O +
& O +
Li O -
, O +
1994 O -
; O +
Steinkraus O +
& O +
Whitfield O -
, O +
1994 O -
; O +
Jones O -
, O +
1993 O -
; O +
Tsunoo O -
, O +
Taketomo O -
, O +
Tsuboi O -
, O +
Kamijio O -
, O +
Nemoto O -
, O +
Sasaki O -
, O +
Uchida O -
, O +
Yamashita O -
, O +
Kinjo O +
& O +
Haung O -
, O +
1995 O +
) O -
. O -

The O +
medicinal O +
preparation O +
from O +
the O +
fruiting O +
bodies O +
of O +
C. B-Species +
sinensis L-Species -
is O +
named O +
dong O -
- O -
chong O -
- O -
xia O -
- O -
cao O +
which O +
translates O +
as O +
winter O +
worm O +
and O +
summer O +
grass O -
. O -

C. B-Species +
sinensis L-Species -
infects O +
the O +
larvae O +
of O +
the O +
sphinx B-Species +
moth L-Species -
, O +
Hepialus B-Species +
armoricanus L-Species +
, O +
found O +
only O +
in O +
the O +
highlands O +
of O +
the O +
Himalayan O +
region O -
, O +
and O +
the O +
larva O +
hibernates O +
underground O +
through O +
the O +
winter O -
. O -

The O +
fungus U-Species +
kills O +
the O +
infected O +
host U-Species +
and O +
grows O +
throughout O +
the O +
cadaver O -
, O +
and O +
in O +
the O +
summer O -
, O +
a O +
rod O -
- O -
like O +
stroma O +
of O +
the O +
fungus U-Species +
grows O +
out O +
from O +
the O +
mummified O +
shell O +
of O +
the O +
dead O +
host U-Species -
. O -

Cordyceps U-Species -
species O +
are O +
generally O +
known O +
as O +
the O +
' O -
caterpillar B-Species +
fungus L-Species -
' O +
due O +
to O +
this O +
characteristic O +
parasitism O +
of O +
the O +
living O +
larvae O +
of O +
insects U-Species +
( O -
Pegler O -
, O +
Yao O +
& O +
Li O -
, O +
1994 O -
; O +
Steinkraus O +
& O +
Whitfield O -
, O +
1994 O -
; O +
Jones O -
, O +
1993 O +
) O -
. O -

A O +
number O +
of O +
bioactive O +
constituents O +
from O +
Cordyceps U-Species -
species O +
have O +
been O +
reported O -
. O -

These O +
include O -
: O +
cordycepin O +
( O -
Cunningham O -
, O +
Herchinson O -
, O +
Manson O +
& O +
Spring O -
, O +
1951 O -
; O +
Kredich O +
& O +
Guarino O -
, O +
1960 O +
) O +
and O +
other O +
antibacterial O +
and O +
antitumor O +
adenosine O +
derivatives O +
( O -
Furuya O -
, O +
Hirotani O +
& O +
Matsuzawa O -
, O +
1983 O +
) O -
, O +
ophicordin O -
, O +
an O +
antifungal O +
agent O +
( O -
Kneifel O -
, O +
Srinivasan O +
& O +
Maiti O -
, O +
1957 O +
) O -
, O +
a O +
polysaccharide O +
shown O +
to O +
have O +
antitumor O +
activity O +
( O -
Miyazaki O -
, O +
Oikawa O +
& O +
Yamada O -
, O +
1977 O -
; O +
Yamada O +
et O +
al. O -
, O +
1984 O -
; O +
Ohmori O -
, O +
Tamura O -
, O +
Tsuru O +
& O +
Nomoto O -
, O +
1986 O +
) O -
, O +
an O +
immunopotentiating O +
galactomannan O -
, O +
and O +
l O +
-tryptophan O +
( O -
Zhang O -
, O +
Zhang O -
, O +
Zhu O +
& O +
Chen O -
, O +
1991 O +
) O -
. O -

A O +
recent O +
report O +
indicated O +
that O +
the O +
fruiting O +
body O +
of O +
C. B-Species +
sinensis L-Species -
contained O +
growth O +
inhibitors O +
against O +
tumor O +
cells O +
( O -
K562 O -
, O +
Vero O -
, O +
Wish O -
, O +
Calu-1 O +
and O +
Raji O -
) O +
other O +
than O +
cordycepin O +
and O +
polysaccharides O +
( O -
Kuo O -
, O +
Ching O -
- O -
Yuang O +
Lin O -
, O +
Wei O -
- O -
Jern O +
Tsai O -
, O +
Wu O -
, O +
Chen O +
& O +
Shiao O -
, O +
1994 O +
) O -
. O -

We O +
report O +
herein O +
the O +
isolation O +
and O +
identification O +
of O +
two O +
antitumor O +
compounds O +
from O +
the O +
mycelia O +
of O +
C. B-Species +
sinensis L-Species +
. O -

Activity O +
guided O +
chemical O +
fractionations O +
of O +
the O +
methanol O +
extract O +
of O +
C. B-Species +
sinensis L-Species +
, O +
led O +
to O +
the O +
isolation O +
of O +
a O +
steroidal O +
glycoside O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
and O +
5α O +
, O -
6α O +
-epoxy-24 O -
( O -
R O +
) O -
-methylcholesta-7,22-dien-3β O +
-ol O +
( O -
2 O +
) O -
. O -

Two O +
previously O +
identified O +
compounds O -
, O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
and O +
22,23-dihydroergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
4 O +
) O +
were O +
also O +
isolated O +
during O +
the O +
fractionation O +
of O +
the O +
methanol O +
extract O +
( O -
Shiao O -
, O +
Lin O -
, O +
Lien O -
, O +
Tzean O +
& O +
Lee O -
, O +
1989 O +
) O -
. O -

These O +
ergosterol O +
derivatives O +
were O +
not O +
active O +
against O +
the O +
tumor O +
cell O +
lines O +
used O +
in O +
this O +
study O -
. O -

2 O +
Results O +
and O +
discussion O +
Compounds O +
3 O -
and O +
4 O +
were O +
identified O +
by O +
1 O +
H O +
NMR O +
spectroscopy O +
as O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
and O +
22,23-dihydroergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
4 O +
) O +
previously O +
isolated O +
from O +
the O +
fruiting O +
body O +
of O +
C. O +
sinensis O -
( O -
Shiao O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

Comparison O +
of O +
the O +
1 O +
H O +
NMR O +
spectra O +
of O +
1a O -
with O +
3 O -
and O +
4 O -
suggests O +
that O +
1a O -
was O +
also O +
a O +
glycoside O +
derivative O +
of O +
a O +
sterol O -
. O -

Compound O +
1a O -
was O +
found O +
to O +
have O +
a O +
[ O -
M+NH4 O +
] O -
+ O -
peak O +
from O +
CI O +
of O +
m O +
/z O +
= O -
608 O +
[ O -
C34 O +
H54 O +
O8 O +
+ O -
NH4 O +
] O -
+ O -
with O +
a O +
prominent O +
fragment O +
ion O +
peak O +
at O +
m O +
/z O -
412 O +
in O +
agreement O +
with O +
the O +
proposed O +
presence O +
of O +
a O +
sugar O +
moiety O +
( O -
C6 O +
H12 O +
O6 O +
) O -
. O -

The O +
observation O +
of O +
six O +
methyl O +
signals O +
in O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
1a O -
at O +
δ O -
0.69 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
7.0 O +
Hz O -
) O -
, O +
0.70 O +
( O -
3H O -
, O +
s O +
) O -
, O +
0.71 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O +
Hz O -
) O -
, O +
0.76 O +
( O -
3H O -
, O +
s O +
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.8 O +
Hz O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.6 O +
Hz O -
) O +
indicates O +
that O +
the O +
sterol O +
fragment O +
of O +
1a O -
is O +
an O +
ergosterol O +
derivative O -
. O -

The O +
doublet O +
at O +
δ O -
4.2 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
) O +
indicates O +
that O +
the O +
attachment O +
of O +
the O +
sugar O +
moiety O +
at O +
C3 O +
is O +
in O +
the O +
β O +
-configuration O +
( O -
Shiao O +
et O +
al. O -
, O +
1989 O -
; O +
Ahmed O -
, O +
Ahmed O +
& O +
Malik O -
, O +
1992 O -
; O +
Wasylyk O -
, O +
Martin O -
, O +
Weinheimer O +
& O +
Alam O -
, O +
1989 O +
) O -
, O +
similar O +
to O +
that O +
of O +
the O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
and O +
22,23-dihydroergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
4 O +
) O +
( O -
Shiao O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

The O +
observation O +
of O +
the O +
two O +
doublets O +
at O +
δ O -
6.39 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
) O +
and O +
6.13 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
) O -
, O +
approximately O +
1 O +
ppm O +
downfield O +
of O +
the O +
H6 O +
and O +
H7 O +
olefinic O +
protons O +
in O +
3 O -
and O +
4 O +
, O +
suggested O +
that O +
the O +
aglycone O +
of O +
1a O -
is O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-diene-3β O +
-ol O +
( O -
1b O +
) O -
. O -

The O +
close O +
comparison O +
of O +
the O +
13 O +
C O +
data O +
of O +
1a O -
with O +
1b O -
listed O +
in O +
Table O +
1 O -
agrees O +
with O +
this O +
proposal O -
. O -

The O +
identity O +
of O +
the O +
sugar O +
moiety O +
in O +
1a O -
was O +
not O +
conclusive O +
from O +
the O +
spectroscopic O +
data O -
. O -

However O +
comparison O +
of O +
the O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
spectra O +
of O +
1a O -
with O +
the O +
spectra O +
of O +
the O +
glucopyranosides O +
3 O -
and O +
4 O -
suggests O +
that O +
1a O -
is O +
also O +
a O +
glucopyranoside O -
. O -

The O +
synthesis O +
of O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
from O +
ergosterol O +
( O -
6 O +
) O +
was O +
carried O +
out O +
as O +
shown O +
in O +
Scheme O +
1 O -
. O -

Deacetylation O +
of O +
5 O -
( O -
Cerný O -
, O +
Pouzar O -
, O +
Drasar O -
, O +
Budesinsky O +
& O +
Havel O -
, O +
1984 O +
) O +
followed O +
by O +
a O +
Diels O -
– O -
Alder O +
addition O +
of O +
singlet O +
O2 O +
( O -
1 O +
Δg O +
) O +
to O +
the O +
diene O +
in O +
ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
( O -
Gunatilaka O -
, O +
Gopichand O -
, O +
Schmitz O +
& O +
Djerassi O -
, O +
1981 O +
) O +
afforded O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O -
. O -

Comparison O +
of O +
the O +
1 O +
H O +
and O +
13 O +
C O +
NMR O +
of O +
the O +
synthesized O +
molecule O +
both O +
confirmed O +
the O +
proposed O +
identity O +
of O +
the O +
sugar O +
moiety O +
and O +
the O +
stereochemistry O +
of O +
the O +
5α O +
, O -
8α O +
-epideoxy O +
functionality O +
in O +
the O +
isolated O +
compound O +
1a O +
. O -

5α O +
, O -
8α O +
-Epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
has O +
previously O +
been O +
isolated O +
from O +
a O +
variety O +
of O +
fungi U-Species +
( O -
including O +
C. B-Species +
sinensis L-Species +
) O +
( O -
Xiao O -
, O +
Liu O +
& O +
Tu O -
, O +
1983 O -
; O +
Takaishi O -
, O +
Adachi O -
, O +
Murakami O -
, O +
Ohashi O -
, O +
Nakano O +
& O +
Tomimatsu O -
, O +
1992 O -
; O +
Tsantrizos O -
, O +
Folkins O -
, O +
Britten O -
, O +
Harpp O -
, O +
Ogilvie O -
, O +
1992 O +
) O -
, O +
lichens U-Species +
( O -
Hirayama O -
, O +
Fujikawa O -
, O +
Yosioka O +
& O +
Kitagawa O -
, O +
1975 O -
; O +
Gonzalez O -
, O +
Barrera O -
, O +
Perez O +
& O +
Padron O -
, O +
1992 O +
) O -
, O +
and O +
marine B-Species +
organisms L-Species +
( O -
Gunatilaka O +
et O +
al. O -
, O +
1981 O -
; O +
Guyot O +
& O +
Durgeat O -
, O +
1981 O +
) O +
and O +
has O +
been O +
shown O +
to O +
have O +
both O +
antitumor O +
( O -
Kahlos O -
, O +
Kangas O +
& O +
Hiltunen O -
, O +
1989 O -
; O +
Kahlos O -
, O +
Hiltunen O +
& O +
Kangas O -
, O +
1989 O -
; O +
Matsueda O -
, O +
Shimoyama O -
, O +
Imaizumi O +
& O +
Tsushima O -
, O +
1982 O -
; O +
Cheng O -
, O +
Nagano O -
, O +
Bang O -
, O +
Ourrison O -
, O +
Beck O -
, O +
1977 O +
) O +
and O +
anti O -
- O -
inflammatory O +
( O -
Yasukawa O +
et O +
al. O -
, O +
1994 O -
, O +
1996 O +
) O +
activity O -
. O -

Formation O +
of O +
1b O -
was O +
shown O +
to O +
be O +
endogenous O +
in O +
fungi U-Species +
and O +
not O +
an O +
artifact O +
of O +
the O +
isolation O +
procedure O +
( O -
Nes O -
, O +
Xu O +
& O +
Haddon O -
, O +
1989 O +
) O -
. O -

The O +
observation O +
of O +
six O +
methyl O +
signals O +
in O +
the O +
1 O +
H O +
NMR O +
spectrum O +
of O +
compound O +
2 O +
, O +
δ O -
0.49 O +
( O -
3H O -
, O +
s O +
) O -
, O +
0.71 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O +
Hz O -
) O -
, O +
0.73 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O +
Hz O -
) O -
, O +
0.81 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.8 O +
Hz O -
) O -
, O +
0.91 O -
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.6 O +
Hz O -
) O -
, O +
0.95 O +
( O -
3H O -
, O +
s O +
) O +
indicates O +
that O +
compound O +
2 O -
is O +
also O +
an O +
ergosterol O +
derivative O -
. O -

The O +
molecular O +
formula O +
for O +
compound O +
2 O -
was O +
determined O +
to O +
be O +
C28 O +
H44 O +
O2 O -
by O +
HRMS O +
( O -
M+ O +
= O -
421.3347 O -
) O -
. O -

The O +
additional O +
oxygen O +
in O +
the O +
molecular O +
formula O +
of O +
2 O -
in O +
comparison O +
to O +
the O +
molecular O +
formula O +
of O +
ergosterol O +
( O -
6 O +
) O +
( O -
C28 O +
H44 O +
O O -
) O +
and O +
the O +
observation O +
in O +
the O +
1 O +
H O +
NMR O +
of O +
a O +
signal O +
at O +
3.50 O +
ppm O +
combined O +
with O +
the O +
loss O +
of O +
an O +
olefinic O +
signal O +
indicates O +
that O +
one O +
of O +
the O +
5,7-diene O +
olefins O +
in O +
6 O -
has O +
been O +
oxidized O +
to O +
the O +
epoxide O -
. O -

The O +
observation O +
of O +
a O +
correlation O +
in O +
the O +
COSY O +
between O +
the O +
trisubstituted O +
epoxy O +
methine O +
signal O +
at O +
3.50 O +
ppm O +
and O +
the O +
olefin O +
methine O +
signal O +
at O +
5.20 O +
ppm O +
is O +
in O +
agreement O +
with O +
this O +
proposal O -
. O -

The O +
observation O +
of O +
cross O -
- O -
peaks O +
in O +
the O +
HMBC O +
between O +
the O +
signal O +
at O +
5.20 O +
ppm O +
with O +
the O +
13 O +
C O +
signals O +
corresponding O +
to O +
C5 O -
, O +
C9 O +
and O +
C14 O +
and O +
the O +
cross O +
peaks O +
for O +
the O +
signal O +
at O +
3.50 O +
ppm O +
with O +
the O +
13 O +
C O +
signals O +
corresponding O +
to O +
C5 O -
, O +
C7 O -
, O +
C8 O +
and O +
C10 O +
indicate O +
the O +
epoxide O +
is O +
in O +
the O +
5,6 O +
position O -
. O -

The O +
downfield O +
chemical O +
shift O +
of O +
the O +
3β O +
-hydroxy O +
methine O +
at O +
3.90 O +
ppm O +
is O +
consistent O +
with O +
the O +
α O -
stereochemistry O +
for O +
the O +
5 O -
, O +
6-epoxy O +
group O +
( O -
Aiello O -
, O +
Fattorusso O -
, O +
Magno O -
, O +
Mayol O +
& O +
Menna O -
, O +
1990 O -
; O +
Isaacs O -
, O +
Berman O +
& O +
Kashman O -
, O +
1991 O -
; O +
Venkateswarlu O -
, O +
Reddy O +
& O +
Rao O -
, O +
1996 O +
) O -
. O -

5α O +
, O +
6α O +
-Epoxy O +
sterols O +
similar O +
to O +
compound O +
2 O +
are O +
unknown O -
. O -

A O +
small O +
number O +
of O +
5α O +
, O +
6α O +
-epoxy O +
sterols O +
have O +
been O +
isolated O +
from O +
marine B-Species +
sponges L-Species +
and O +
corals U-Species +
( O -
Aiello O +
et O +
al. O -
, O +
1990 O -
; O +
Isaacs O -
, O +
Berman O +
& O +
Kashman O -
, O +
1991 O -
; O +
Venkateswarlu O -
, O +
Reddy O +
& O +
Rao O -
, O +
1996 O -
; O +
Kobayashi O +
& O +
Kanda O -
, O +
1991 O +
) O +
and O +
have O +
been O +
shown O +
to O +
have O +
cytotoxic O +
activities O -
. O -

Growth O +
inhibition O +
due O +
to O +
compounds O +
1a O +
, O +
1b O +
, O -
and O +
3 O -
of O +
the O +
malignant O +
cell O +
lines O +
K562 O +
( O -
erythroleukemia O -
) O -
, O +
Jurkat O +
( O -
T O -
- O -
lymphoblastic O -
) O -
, O +
HL-60 O +
( O -
promyelocytic O +
leukemia O -
) O -
, O +
WM1341 O +
( O -
malignant O +
melanoma O -
) O +
and O +
RPMI O +
8226 O +
( O -
multiple O +
myeloma O -
) O +
from O +
the O +
American O +
Tissue O +
Type O +
Collection O +
( O -
ATCC O -
) O +
Rockville O -
, O +
MD O -
, O +
were O +
studied O +
to O +
compare O +
their O +
antitumor O +
activity O -
. O -

The O +
percent O +
inhibition O +
of O +
the O +
proliferation O +
of O +
these O +
five O +
malignant O +
cells O +
lines O +
determined O +
from O +
3 O +
H O -
- O -
thymidine O +
incorporation O +
assays O +
are O +
shown O +
in O +
Fig. O +
1 O -
( O -
a O -
– O -
d O -
) O -
for O +
200 O -
, O +
100 O +
and O +
10 O +
μg O -
/ O -
ml O +
concentrations O +
of O +
compounds O +
3 O +
, O +
1b O +
, O +
and O +
1a O +
. O -

Compound O +
3 O -
which O +
does O +
not O +
contain O +
the O +
5 O -
, O +
8-epoxy O +
functionality O +
showed O +
little O +
to O +
no O +
significant O +
inhibition O +
of O +
proliferation O +
of O +
the O +
tumor O +
cells O -
. O -

Some O +
inhibition O +
of O +
Jurkat O +
and O +
RPMI O +
8226 O +
was O +
detected O +
at O +
200 O +
μg O -
/ O -
ml O -
, O +
the O +
highest O +
concentration O +
in O +
this O +
study O -
. O -

As O +
clearly O +
shown O +
on O +
the O +
graphs O -
, O +
at O +
the O +
lower O +
concentration O -
, O +
the O +
glycoside O +
1a O -
was O +
found O +
to O +
inhibit O +
proliferation O +
of O +
all O +
five O +
malignant O +
cell O +
lines O +
to O +
a O +
greater O +
extent O +
( O -
10–40 O -
% O -
) O +
than O +
the O +
aglycone O +
1b O -
as O +
a O +
control O -
. O -

3 O +
Experimental O +
3.1 O +
General O +
IR O +
spectra O +
were O +
acquired O +
with O +
a O +
Bomen O +
FT O -
- O -
IR O +
Michaelson-100 O +
spectrophotometer O -
. O -

The O +
spectra O +
were O +
obtained O +
either O +
in O +
CHCl3 O -
solution O +
using O +
a O +
0.2 O +
mm O +
thick O +
NaCl O +
cell O -
, O +
or O +
as O +
a O +
solid O +
in O +
KBr O -
, O +
and O +
processed O +
using O +
the O +
Bomen O +
Spectra O +
Calc O +
program O -
. O -

LRMS O +
and O +
HRMS O +
were O +
obtained O +
on O +
a O +
Kratos O -
- O -
AEI O +
model O +
MS-50 O +
spectrometer O -
. O -

All O +
spectra O +
were O +
obtained O +
at O +
an O +
ionization O +
energy O +
of O +
70 O +
eV. O +
1 O +
H O +
NMR O +
spectra O +
were O +
obtained O +
on O +
a O +
Bruker O +
WH-400 O +
spectrometer O -
. O -

13 O +
C O +
and O +
APT O +
were O +
obtained O +
on O +
a O +
Bruker O +
AC-200 O +
spectrometer O -
. O -

HMBC O -
, O +
and O +
HMQC O +
spectra O +
were O +
obtained O +
on O +
a O +
Bruker O +
AMX-500 O +
spectrometer O -
. O -

Silica O +
gel O +
( O -
Art O +
60 O -
, O +
230–400 O +
mesh O -
) O +
for O +
column O +
chromatography O +
( O -
CC O -
) O +
and O +
silica O +
gel O +
( O -
Kieselgel O +
60 O +
F254 O +
) O +
coated O +
on O +
aluminum O +
plates O +
for O +
thin O +
layer O +
chromatography O +
were O +
supplied O +
by O +
Merck O -
. O -

3.2 O +
Fungal U-Species +
material O -

The O +
mycelial O +
sample O +
of O +
C. B-Species +
sinensis L-Species -
was O +
obtained O +
from O +
North O +
American O +
Reishi O -
, O +
Box O +
1780 O -
, O +
Gibsons O -
, O +
British O +
Columbia O -
, O +
Canada O -
, O +
V0N O +
1V0 O -
. O -

3.3 O +
Malignant O +
cell O +
inhibition O +
studies O +
3 O +
H O -
- O -
Thymidine O +
incorporation O +
assays O +
were O +
carried O +
out O +
to O +
determine O +
inhibitory O +
effects O -
. O -

K562 O +
( O -
erythroleukemia O -
) O -
, O +
Jurkat O +
( O -
T O -
- O -
lymphoblastic O -
) O -
, O +
HL-60 O +
( O -
promyelocytic O +
leukemia O -
) O -
, O +
WM1341 O +
( O -
malignant O +
melanoma O -
) O +
and O +
RPMI O +
8226 O +
( O -
multiple O +
myeloma O -
) O +
malignant O +
cell O +
lines O +
were O +
obtained O +
from O +
the O +
American O +
Tissue O +
Type O +
Collection O +
( O -
ATCC O -
) O -
, O +
Rockville O -
, O +
MD O -
. O -

The O +
cell O +
lines O +
were O +
maintained O +
in O +
a O +
medium O +
consisting O +
of O +
RPMI O +
1640 O -
/ O -
FCS O +
10 O -
% O +
at O +
37 O -
° O -
C O +
in O +
an O +
atmosphere O +
of O +
5 O -
% O +
CO2 O +
. O -

Malignant O +
cell O +
lines,106 O -
cells O -
/ O -
ml O +
in O +
96-well O +
round O +
bottom O +
plates O +
( O -
Costar O -
) O -
, O +
were O +
cultured O +
with O +
various O +
concentrations O +
of O +
C. B-Species +
sinensis L-Species -
extracts O +
in O +
a O +
5 O -
% O +
CO2 O +
-air O +
humidified O +
atmosphere O +
at O +
37 O -
° O -
C O -
. O -

After O +
16 O +
h O +
of O +
co O -
- O -
culture O -
, O +
3 O +
H O -
- O -
thymidine O +
( O -
1 O +
MCi O -
/ O -
well O -
, O +
Dupont O -
, O +
Montreal O -
) O +
was O +
added O +
to O +
each O +
well O -
. O -

3 O +
H O -
- O -
Thymidine O +
uptake O +
was O +
measured O +
after O +
6 O +
hours O +
of O +
incubation O +
using O +
a O +
scintillation O +
counter O -
. O -

The O +
inhibitory O +
effect O +
of O +
each O +
extract O +
on O +
tumor O +
cell O +
proliferation O +
was O +
calculated O +
using O +
Eq. O +
1 O +
. O -
( O -
1 O -
) O -

Inhibition O +
percent O +
( O -
% O -
) O +
= O -
Control O +
group O +
( O -
cpm O -
) O -
−Experimental O +
group O +
( O -
cpm O -
) O -
Control O +
group O +
( O -
cpm O -
) O -
×100 O -
3.4 O +
Activity O +
guided O +
fractionation O +
of O +
fungal U-Species +
material O +
The O +
dry O +
mycelium O +
of O +
C. B-Species +
sinensis L-Species -
( O -
150 O +
g O -
) O +
was O +
extracted O +
with O +
MeOH O +
three O +
times O +
( O -
500 O +
ml O -
× O -
3 O -
) O -
. O -

The O +
MeOH O +
extracts O +
were O +
combined O +
and O +
the O +
solvent O +
was O +
removed O +
under O +
reduced O +
pressure O -
. O -

The O +
crude O +
MeOH O +
extract O +
was O +
found O +
to O +
inhibit O +
K562 O +
proliferation O +
by O +
36 O -
% O +
at O +
500 O +
μg O -
/ O -
ml O -
, O +
in O +
the O +
3 O +
H O -
- O -
thymidine O +
incorporation O +
assay O -
. O -

The O +
residue O +
was O +
then O +
redissolved O +
in O +
MeOH O -
/ O -
H2 O +
O O +
( O -
1:1 O -
) O +
and O +
washed O +
with O +
hexanes O -
. O -

Methanol O +
was O +
distilled O +
from O +
the O +
aqueous O +
layer O +
under O +
reduced O +
pressure O -
. O -

The O +
remaining O +
aqueous O +
layer O +
was O +
extracted O +
with O +
EtOAc O -
. O -

Concentration O +
of O +
the O +
combined O +
EtOAc O +
extracts O +
under O +
reduced O +
pressure O +
provided O +
1.57 O +
g O +
of O +
a O +
brown O +
oil O +
( O -
B1 O -
) O -
. O -

This O +
residue O +
was O +
chromatographed O +
on O +
a O +
silica O +
gel O -
- O -
flash O +
column O +
( O -
230–400 O +
mesh O -
, O +
50 O -
× O -
8.0 O +
cm O -
) O -
. O -

The O +
elution O +
was O +
started O +
with O +
CHCl3 O -
and O +
the O +
polarity O +
of O +
solvents O +
was O +
increased O +
stepwise O +
in O +
the O +
following O +
sequence O -
: O +
CHCl3 O +
, O +
CHCl3 O +
/MeOH O +
( O -
8:2 O -
) O -
, O +
CHCl3 O +
/MeOH O +
( O -
5:5 O -
) O -
, O +
CHCl3 O +
/MeOH O +
( O -
2:8 O -
) O +
and O +
MeOH O -
. O -

Fourteen O +
fractions O +
( O -
FA1–FA14 O -
) O +
were O +
collected O +
and O +
dried O +
in O +
vacuo O -
. O -

Only O +
one O +
fraction O +
( O -
FA8 O -
) O +
was O +
found O +
have O +
antitumor O +
activity O -
. O -

Fraction O +
FA8 O +
was O +
further O +
chromatographed O +
on O +
a O +
silicagel O +
flash O -
- O -
column O +
eluted O +
with O +
CHCl3 O +
/MeOH O +
( O -
8:2 O -
) O +
to O +
afford O +
two O +
fractions O +
FB1 O +
and O +
FB2 O +
having O +
an O +
Rf O +
= O -
6.3 O +
and O +
5.4 O -
, O +
respectively O -
. O -

FB1 O +
was O +
a O +
white O +
solid O +
( O -
38 O +
mg O -
) O -
. O -

Recrystallization O +
of O +
FB1 O +
in O +
CHCl3 O -
afforded O +
10 O +
mg O +
of O +
2 O -
as O +
a O +
white O +
powder O -
. O -

Compound O +
2 O -
was O +
found O +
to O +
have O +
61 O -
% O +
antitumor O +
activity O +
against O +
Jurkat O +
cells O +
and O +
36.3 O -
% O +
activity O +
against O +
K562 O +
cells O +
at O +
100 O +
μg O -
/ O -
ml O -
. O -

Fraction O +
FB2 O +
was O +
found O +
to O +
have O +
96 O -
% O +
activity O +
against O +
Jurkat O +
cells O +
and O +
77 O -
% O +
activity O +
against O +
K562 O +
cancer O +
cells O +
at O +
100 O +
μg O -
/ O -
ml O -
. O -

FB2 O +
was O +
further O +
separated O +
by O +
silica O +
gel O +
chromatography O +
eluted O +
with O +
Et2 O +
O O -
: O -
hexanes O -
: O -
MeOH=5:5:1 O +
to O +
afford O +
two O +
fractions O +
FC1 O +
( O -
Rf O +
= O -
6.3 O -
) O +
and O +
3 O +
mg O +
of O +
compound O +
1a O -
( O -
Rf O +
= O -
5.4 O -
) O +
as O +
a O +
white O +
solid O -
. O -

FC1 O +
was O +
further O +
separated O +
by O +
HPLC O +
to O +
give O +
3 O -
and O +
4 O +
. O -

3.4.1 O +
5α O +
, O -
6α O +
-Epoxy-24 O -
( O -
R O +
) O -
-methylcholesta-7,22-dien-3β O -

-ol O +
( O -
2 O +
) O -
. O -

IR O +
( O -
cm−1 O +
, O +
CHCl3 O +
): O +
4685 O -
- O -
3110 O +
( O -
hydroxyl O -
) O -
, O +
2950 O -
, O +
2880 O -
, O +
1673 O -
, O +
1462 O -
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
) O +
δ O +
: O +
0.49 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.72 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.73 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
1.2 O +
( O -
2H O -
, O +
m O +
, O +
H17 O -
, O +
H16 O -
) O -
, O +
1.32 O +
( O -
1H O -
, O +
m O +
, O +
H2 O -
) O -
, O +
1.36 O +
( O -
1H O -
, O +
m O +
, O +
H25 O -
) O -
, O +
1.44–1.48 O +
( O -
4H O -
, O +
m O +
, O +
H11 O -
, O +
H11′ O -
, O +
H15 O -
, O +
H1 O -
) O -
, O +
1.58 O +
( O -
1H O -
, O +
m O +
, O +
H12 O -
) O -
, O +
1.64 O +
( O -
1H O -
, O +
m O +
, O +
H16′ O -
) O -
, O +
1.72 O +
( O -
1H O -
, O +
m O +
, O +
H2′ O -
) O -
, O +
1.75 O +
( O -
1H O -
, O +
m O +
, O +
H24 O -
) O -
, O +
1.81 O +
( O -
1H O -
, O +
m O +
, O +
H14 O -
) O -
, O +
1.85 O +
( O -
1H O -
, O +
m O +
, O +
H9 O -
) O -
, O +
1.94 O +
( O -
1H O -
, O +
m O +
, O +
H20 O -
) O -
, O +
1.95 O +
( O -
1H O -
, O +
m O +
, O +
H4 O -
) O -
, O +
3.5 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
5.1 O -
, O +
H-6 O -
) O -
, O +
3.9 O -
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
, O +
5.09 O -
( O -
1H O -
, O +
m O +
, O +
H-22 O -
) O -
, O +
5.11 O +
( O -
1H O -
, O +
m O +
, O +
H-23 O -
) O -
, O +
5.2 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
) O +
listed O +
in O +
Table O +
2 O -
; O +
LRMS O +
( O -
EI O -
) O +
m O +
/z O -
( O -
rel O -
. O -

int O -
. O -

% O -
): O +
413 O -
[ O -
M+1 O -
] O -
+ O +
, O +
396 O -
[ O -
M−16 O -
] O -
+ O +
; O +
HRMS O +
( O -
EI O -
) O -
: O +
Calculated O +
for O +
C28 O +
H44 O +
O2 O +
: O +
412.33414 O -
; O +
found O -
: O +
412.33477 O -
. O -

3.4.2 O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
IR O +
( O -
cm−1 O +
, O +
CHCl3 O +
): O +
3580–3055 O +
( O -
hydroxyl O -
) O -
, O +
2950 O -
, O +
2873 O -
, O +
1681 O -
, O +
1458 O -
, O +
1371 O -
; O +
[ O -
α O +
] O -
D O -
( O -
25 O -
° O -
C O -
) O -
: O +
−15.6 O -
° O -
; O +
1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
) O +
δ O +
: O +
0.70 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
Me-27 O -
) O -
, O +
0.71 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.72 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
Me-27 O -
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.8 O +
Hz O -
, O +
Me-28 O -
) O -
, O +
0.76 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.6 O +
Hz O -
, O +
Me-21 O -
) O -
, O +
1.0–2.0 O +
( O -
19H O -
, O +
m O +
) O -
, O +
2.1 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.1–3.2 O +
( O -
2H O -
, O +
m O +
, O +
H-2′ O -
, O +
H-3′ O -
) O -
, O +
3.2–3.4 O +
( O -
2H O -
, O +
m O +
, O +
H-4′ O -
, O +
H-5′ O -
) O -
, O +
3.5 O +
( O -
1H O -
, O +
m O +
, O +
H-6a′ O -
) O -
, O +
3.60 O +
( O -
1H O -
, O +
m O +
, O +
H6b′ O -
) O -
, O +
3.85 O +
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
; O +
4.23 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.8 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
5.05 O +
( O -
1H O -
, O +
m O +
, O +
H-22 O -
) O -
, O +
5.09 O +
( O -
1H O -
, O +
m O +
, O +
H-23 O -
) O -
, O +
6.13 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-7 O -
) O -
, O +
6.39 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.5 O +
Hz O -
, O +
H-6 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
): O +
Table O +
2 O +
; O +
LRMS O +
( O -
CIMS O -
) O +
m O +
/z O -
( O -
rel O -
. O -

int O -
. O -
) O -
: O +
608 O -
[ O -
M+NH4 O +
] O -
+ O +
, O +
593 O -
[ O -
M+2 O -
] O -
+ O +
, O +
590 O -
[ O -
M O -
] O -
+ O +
, O +
412 O -
[ O -
M−178 O -
] O -
+ O +
; O +
HRMS O +
( O -
DCIMS O -
) O -
: O +
Calculated O +
for O +
C34 O +
H54 O +
O8 O +
+ O -
NH+ O +
4 O +
: O +
608.41624 O -
; O +
found O -
: O +
608.41572 O -
. O -

3.5 O +
Synthesis O +
of O +
1a O -
from O +
ergosterol O +
( O -
6 O +
) O +
All O +
reactions O +
were O +
carried O +
out O +
under O +
nitrogen O +
atmosphere O +
in O +
flame O -
- O -
dried O +
glassware O +
unless O +
otherwise O +
stated O -
. O -

3.5.1 O +
2,3,4,6-Tetra O -
- O -
O O +
-acetyl-3-O O -
- O -
β O +
-d O +
-glucopyranosyl O -
- O -
ergosta-6,22-dien-5α O +
, O +
8α O +
-epidioxy-3β O +
-ol O +
( O -
5 O +
) O +
To O +
a O +
stirring O +
solution O +
of O +
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
α O +
-d O +
-glucosyl O +
trichloroacetimidate O +
( O -
0.172 O +
g O -
, O +
0.4 O +
mmol O -
) O +
in O +
10 O +
ml O +
dry O +
CH2 O +
Cl2 O -
was O +
added O +
4 O +
Å O +
molecular O +
sieves O +
( O -
1 O +
g O -
) O +
followed O +
by O +
ergosterol O +
( O -
6 O +
) O +
( O -
0.2 O +
g O -
, O +
0.5 O +
mmol O -
) O +
as O +
a O +
solid O +
powder O -
. O -

The O +
solution O +
was O +
cooled O +
to O +
0 O -
° O -
C O +
prior O +
to O +
the O +
dropwise O +
addition O +
of O +
BF3 O +
.Et2 O -

O O +
( O -
0.4 O +
ml O +
of O +
stock O +
30 O +
μl O +
in O +
2.5 O +
ml O +
CH2 O +
Cl2 O +
) O -
. O -

Upon O +
the O +
addition O +
of O +
BF3 O +
.Et2 O -

O O +
the O +
solution O +
turned O +
pink O -
, O +
then O +
quickly O +
returned O +
to O +
a O +
clear O +
colourless O +
solution O -
. O -

After O +
10 O +
min O +
the O +
solution O +
was O +
allowed O +
to O +
warm O +
slowly O +
to O +
room O +
temperature O -
. O -

The O +
reaction O +
was O +
quenched O +
with O +
the O +
addition O +
of O +
Et3 O +
N O +
( O -
60 O +
μl O -
) O +
after O +
40 O +
min O -
. O -

The O +
clear O +
solution O +
was O +
diluted O +
with O +
CH2 O +
Cl2 O +
, O +
filtered O +
to O +
remove O +
the O +
molecular O +
sieves O +
and O +
washed O +
twice O +
with O +
H2 O +
O. O +
The O +
organic O +
layer O +
was O +
concentrated O +
under O +
reduced O +
pressure O -
. O -

Column O +
chromatography O +
eluted O +
with O +
5 O -
% O +
MeOH O +
in O +
CHCl3 O -
afforded O +
5 O -
( O -
0.0466 O -
, O +
mmol O -
) O +
in O +
16 O +
% O +
yield O +
( O -
Rf O +
= O -
0.78 O -
, O +
15 O +
% O +
MeOH O +
in O +
CHCl3 O +
) O +
followed O +
by O +
unreacted O +
starting O +
material O +
( O -
0.1192 O +
g O -
, O +
300 O +
mmol O -
) O +
( O -
Rf O +
= O -
0.66 O -
, O +
15 O +
% O +
MeOH O +
in O +
CHCl3 O +
) O -
. O -

1 O +
H O +
NMR O +
( O -
400 O +
MHz O -
, O +
CDCl3 O +
) O +
δ O +
: O +
0.59 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.80 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.86 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.9 O -
, O +
Me-28 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-21 O -
) O -
, O +
1.7–2.0 O +
( O -
18H O -
, O +
m O +
) O +
1.98 O +
( O -
3H O -
, O +
s O +
) O -
, O +
1.99 O +
( O -
3H O -
, O +
s O +
) O -
, O +
2.01 O +
( O -
3H O -
, O +
s O +
) O -
, O +
2.03 O +
( O -
3H O -
, O +
s O +
) O -
, O +
2.21 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.40 O -
( O -
1H O -
, O +
m O +
) O -
, O +
3.56 O +
( O -
1H O -
, O +
m O +
, O +
H-3 O -
) O -
, O +
3.66 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.10 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.24 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.60 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.7 O -
, O +
H-1′ O -
) O -
, O +
4.94 O +
( O -
1H O -
, O +
m O +
) O -
, O +
5.04 O +
( O -
1H O -
, O +
m O +
) O -
, O +
5.18 O +
( O -
3H O -
, O +
m O +
, O +
H-22 O -
, O +
H-23 O -
) O -
, O +
5.36 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
5.55 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
) O +
12.0 O -
, O +
16.1 O -
, O +
17.6 O -
, O +
19.2 O -
, O +
19.6 O -
, O +
19.6 O -
, O +
19.9 O -
, O +
20.5 O -
, O +
20.6 O -
, O +
20.7 O -
, O +
21.0 O -
, O +
22.9 O -
, O +
28.2 O -
, O +
29.7 O -
, O +
33.0 O -
, O +
33.0 O -
, O +
37.1 O -
, O +
37.4 O -
, O +
38.2 O -
, O +
39.0 O -
, O +
40.3 O -
, O +
42.8 O -
, O +
46.1 O -
, O +
54.5 O -
, O +
55.7 O -
, O +
62.0 O -
, O +
68.5 O -
, O +
71.4 O -
, O +
71.7 O -
, O +
72.8 O -
, O +
78.6 O -
, O +
99.5 O -
, O +
116.1 O -
, O +
119.9 O -
, O +
131.9 O -
, O +
135.4 O -
, O +
139.0 O -
, O +
141.6 O -
, O +
169.2 O -
, O +
169.3 O -
, O +
170.3 O -
, O +
170.6 O -
. O -

3.5.2 O +
Ergosteryl-3-O O +
-β O +
-d O +
-glucopyranoside O +
( O -
3 O +
) O +
To O +
a O +
stirring O +
solution O +
of O +
5 O -
( O -
0.0564 O +
g O -
, O +
0.078 O +
mmol O -
) O +
in O +
20 O +
ml O +
MeOH O +
was O +
added O +
3 O +
ml O +
Et3 O +
N O +
and O +
0.5 O +
ml O +
H2 O +
O. O +
After O +
stirring O +
for O +
48 O +
h O +
the O +
solvent O +
was O +
removed O +
under O +
reduced O +
pressure O -
. O -

The O +
residue O +
was O +
applied O +
to O +
a O +
silica O +
gel O +
column O -
, O +
and O +
eluted O +
with O +
15 O -
% O +
MeOH O +
in O +
CHCl3 O -
( O -
Rf O +
= O -
20.6 O -
) O +
to O +
afford O +
a O +
white O +
solid O -
. O -

Recrystallization O +
from O +
MeOH O +
provided O +
3 O -
( O -
0.0351 O +
g O -
, O +
0.063 O +
mmol O -
) O +
in O +
81 O -
% O +
yield O +
as O +
small O +
white O +
needles O -
. O -

IR O +
( O -
cm−1 O +
, O -
CHCl3 O +
): O +
3400 O -
, O +
2950 O -
, O +
2875 O -
, O +
1681 O -
, O +
1458 O -
, O +
1371 O -
; O +
1 O +
H O +
NMR O +
( O -
400 O +
MHz O -
, O +
DMSO O -
) O +
δ O +
: O +
0.58 O +
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.79 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
-27 O -
) O -
, O +
0.80 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.7 O -
, O +
Me-26 O +
or O +
-27 O -
) O -
, O +
0.86 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
0.88 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.9 O -
, O +
Me-28 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.5 O -
, O +
Me-21 O -
) O -
, O +
1.24 O +
( O -
2H O -
, O +
m O +
) O +
1.45 O +
( O -
1H O -
, O +
m O +
) O -
, O +
1.6 O +
( O -
1H O -
, O +
m O +
) O +
1.68 O +
( O -
1H O -
, O +
m O +
) O -
, O +
1.85 O +
( O -
2H O -
, O +
m O +
) O -
, O +
2.0 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.18 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.54 O +
( O -
1H O -
, O +
m O +
) O -
, O +
2.98 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.13 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.14 O +
( O -
1H O -
, O +
m O +
) O -
, O +
3.3 O +
( O -
1H O -
, O +
bs O -
) O -
, O +
3.46 O +
( O -
2H O -
, O +
m O +
) O -
, O +
3.61 O +
( O -
1H O -
, O +
m O +
) O -
, O +
4.24 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
7.7 O +
Hz O -
, O +
H-1′ O -
) O -
, O +
5.20 O -
( O -
2H O -
, O +
m O +
, O +
H-22 O -
, O +
H-23 O -
) O -
, O +
5.34 O +
( O -
1H O -
, O +
m O +
, O +
H-7 O -
) O -
, O +
5.52 O +
( O -
1H O -
, O +
m O +
, O +
H-6 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
, O -
): O +
Table O +
2 O +
. O -

3.5.3 O +
5α O +
, O -
8α O +
-Epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-d O +
-glucopyranoside O +
( O -
1a O +
) O +
To O +
a O +
solution O +
of O +
3 O -
( O -
0.0211 O +
g O -
, O +
0.038 O +
mmol O -
) O +
in O +
20 O +
ml O +
dry O +
EtOH O +
was O +
added O +
2 O +
drops O +
of O +
a O +
10 O -
% O +
solution O +
of O +
eosin O +
in O +
EtOH O -
. O -

Oxygen O +
was O +
bubbled O +
through O +
the O +
solution O -
. O -

The O +
reaction O +
vessel O +
was O +
then O +
placed O +
in O +
a O +
silver O +
dewa O +
and O +
irradiated O +
with O +
a O +
500 O +
W O +
tungsten O +
lamp O -
. O -

Water O +
was O +
circulated O +
into O +
the O +
dewar O +
to O +
maintain O +
room O +
temperature O +
for O +
the O +
reaction O -
. O -

After O +
3 O +
h O +
the O +
solution O +
was O +
concentrated O +
under O +
reduced O +
pressure O -
, O +
with O +
the O +
resulting O +
residue O +
applied O +
to O +
a O +
silica O +
gel O +
column O +
what O +
we O +
eluted O +
with O +
15 O -
% O +
MeOH O +
in O +
CHCl3 O -
to O +
afford O +
1a O -
( O -
0.0138 O +
g O -
, O +
0.023 O +
mmol O -
) O +
in O +
62 O -
% O +
yield O +
as O +
a O +
white O +
solid O -
. O -

IR,1 O +
H,13 O +
C O +
and O +
LRMS O +
were O +
identical O +
to O +
spectra O +
of O +
1a O -
isolated O +
from O +
the O +
mycelia O +
of O +
C. B-Species +
sinensis L-Species +
. O -

3.5.4 O +
Synthesis O +
of O +
5α O +
, O -
8α O +
-epidioxy-24 O -
( O -
R O +
) O -
-methylcholesta-6,22-dien-3β O +
-ol O +
( O -
1b O +
) O +
( O -
ergosterol O +
peroxide O -
) O +
from O +
ergosterol O +
( O -
6 O +
) O +
Following O +
the O +
same O +
procedure O +
as O +
used O +
for O +
the O +
preparation O +
of O +
1a O -
from O +
3 O +
, O +
ergosterol O +
( O -
6 O +
) O +
( O -
0.1040 O +
g O +
, O +
0.26 O +
mmol O -
) O +
was O +
oxidized O -
, O +
then O +
purified O +
by O +
silica O +
gel O +
column O +
eluted O +
with O +
15 O -
% O +
EtOAc O +
in O +
CH2 O +
Cl2 O -
to O +
afford O +
1b O +
( O -
0.0932 O +
g O -
, O +
0.22 O +
mmol O -
) O +
in O +
85 O -
% O +
yield O +
as O +
a O +
white O +
solid O -
. O -

1 O +
H O +
NMR O +
( O -
500 O +
MHz O -
, O +
CDCl3 O +
) O +
0.61 O -
( O -
3H O -
, O +
s O +
, O +
Me-18 O -
) O -
, O +
0.67 O +
( O -
3H O -
, O +
s O +
, O +
Me-19 O -
) O -
, O +
0.907 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.67 O +
Hz O -
, O +
Me-26 O +
or O +
27 O -
) O -
, O +
0.913 O -
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.71 O +
Hz O -
, O +
Me-26 O +
or O +
-27 O -
) O -
, O +
0.99 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.78 O +
Hz O -
, O +
Me-28 O -
) O -
, O +
1.00 O +
( O -
3H O -
, O +
d O -
, O +
J O +
= O -
6.49 O -
, O +
Me-21 O -
) O -
, O +
1.1–2.0 O +
( O -
20H O -
, O +
m O +
) O -
, O +
3.92 O +
( O -
m O -
, O +
1H O -
, O +
H-3 O -
) O -
, O +
5.14 O +
( O -
1H O -
, O +
m O +
, O +
H-23 O -
) O -
, O +
5.25 O +
( O -
1H O -
, O +
m O +
, O +
H-22 O -
) O -
, O +
5.95 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.37 O +
Hz O -
, O +
H-6 O -
) O -
, O +
6.29 O +
( O -
1H O -
, O +
d O -
, O +
J O +
= O -
8.47 O +
Hz O -
, O +
H-7 O -
) O -
; O +
13 O +
C O +
NMR O +
( O -
50 O +
MHz O -
, O +
CDCl3 O +
): O +
Table O +
2 O +
. O -

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
North O +
American O +
Reishi O +
Inc. O -
, O +
British O +
Columbia O -
. O -

We O +
also O +
thank O +
Dr O +
S. O +
G. O +
Withers O +
for O +
providing O +
2,3,4,6-tetra O -
- O -
O O +
-acetyl O -
- O -
α O +
-d O +
-glucosyltrichloroacetimidate O -
. O +

The O +
biosynthesis O +
of O +
the O +
vitamin O +
biotin O -
, O +
a O +
cofactor O +
in O +
biological O +
carboxylation O +
reactions O -
, O +
occurs O +
in O +
micro B-Species -
- I-Species -
organisms L-Species +
and O +
plants U-Species +
and O +
involves O +
at O +
least O +
four O +
different O +
enzymes O +
( O -
Eisenberg O -
, O +
1973 O -
; O +
Gloeckler O +
et O +
al O +
. O -
, O +
1990 O -
; O +
Baldet O +
et O +
al O +
. O -
, O +
1993 O -
) O +
. O -

Because O +
biotin O +
synthesis O +
is O +
unique O +
to O +
plants U-Species +
and O +
microorganisms U-Species -
, O +
enzymes O +
of O +
this O +
pathway O +
are O +
potential O +
targets O +
for O +
the O +
development O +
of O +
antimicrobial O +
drugs O +
and O +
herbicides O +
( O -
Rendina O +
et O +
al O +
. O -
, O +
1999 O -
) O +
. O -

One O +
of O +
these O +
enzymes O +
is O +
7,8-diaminopelargonic O +
acid O +
synthase O +
( O -
DAPA O +
synthase O -
) O -
, O +
an O +
aminotransferase O +
that O +
catalyses O +
the O +
antepenultimate O +
step O +
in O +
this O +
pathway O -
: O +
the O +
conversion O +
of O +
7-keto-8-aminopelargonic O +
acid O +
( O -
KAPA O -
) O +
to O +
7,8-diaminopelargonic O +
acid O +
( O -
DAPA O -
) O +
( O -
Figure O +
1 O -
) O -
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O -

DAPA O +
synthase O +
from O +
Escherichia B-Species +
coli L-Species -
is O +
a O +
homodimer O +
with O +
a O +
molecular O +
mass O +
of O +
94 O +
kDa O +
( O -
Stoner O +
& O +
Eisenberg O +
1975a O -
) O -
and O +
contains O +
429 O +
residues O +
per O +
monomer O +
( O -
Otsuka O +
et O +
al O +
. O -
, O +
1988 O -
) O +
. O -

It O +
is O +
unique O +
among O +
aminotransferases O +
in O +
that O +
it O +
uses O +
S O +
-adenosyl O -
- O -
l O +
-methionine O +
( O -
SAM O -
) O +
as O +
amino O +
group O +
donor O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O -

DAPA O +
synthase O +
uses O +
pyridoxal-5′-phosphate O +
( O -
PLP O -
) O +
as O +
cofactor O +
and O +
hence O +
belongs O +
to O +
the O +
family O +
of O +
vitamin O +
B6 O +
-dependent O +
aminotransferases O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O -

In O +
general O +
terms O -
, O +
the O +
mechanism O +
of O +
vitamin O +
B6 O +
-dependent O +
enzymes O +
is O +
rather O +
well O +
understood O +
( O -
John O -
, O +
1995 O -
; O +
Hayashi O -
, O +
1995 O -
) O -
and O +
it O +
is O +
expected O +
that O +
DAPA O +
synthase O +
follows O +
the O +
established O +
overall O +
scheme O +
of O +
PLP O +
catalysis O +
( O -
Figure O +
2 O -
) O +
. O -

PLP O +
binds O +
covalently O +
to O +
the O +
active O +
site O +
lysine O +
residue O +
through O +
a O +
Schiff O +
base O +
linkage O +
( O -
the O +
internal O +
aldimine O -
) O -
. O -

Upon O +
binding O +
of O +
SAM O -
, O +
the O +
substrate O +
for O +
the O +
first O +
part O +
of O +
the O +
catalytic O +
cycle O -
, O +
an O +
external O +
aldimine O +
is O +
formed O +
between O +
the O +
substrate O +
and O +
the O +
cofactor O +
through O +
a O +
transaldimination O +
process O -
. O -

The O +
reaction O +
proceeds O +
through O +
deprotonation O +
of O +
the O +
former O +
Cα O -
carbon O +
of O +
the O +
substrate O -
, O +
leading O +
to O +
the O +
quinonoid O +
intermediate O +
followed O +
by O +
protonation O +
of O +
the O +
C-4′ O +
carbon O -
. O -

It O +
has O +
been O +
shown O +
for O +
aspartate O +
aminotransferase O +
that O +
the O +
lysine O +
residue O +
previously O +
covalently O +
bound O +
to O +
the O +
cofactor O +
acts O +
as O +
proton O +
acceptor O +
and O +
donor O +
in O +
these O +
steps O +
( O -
Gehring O -
, O +
1984 O -
; O +
Julin O +
et O +
al O +
. O -
, O +
1989 O -
) O +
. O -

Hydrolysis O +
of O +
the O +
resulting O +
ketimine O +
intermediate O +
gives O +
the O +
keto O +
acid O +
of O +
the O +
first O +
substrate O +
SAM O +
and O +
pyridoxamine O +
phosphate O +
bound O +
to O +
the O +
enzyme O +
by O +
non O -
- O -
covalent O +
bonds O -
. O -

The O +
second O +
half O +
of O +
the O +
catalytic O +
cycle O +
is O +
in O +
principle O +
a O +
reversal O +
of O +
the O +
first O +
steps O -
. O -

KAPA O -
, O +
the O +
second O +
substrate O -
, O +
binds O +
and O +
receives O +
the O +
amino O +
group O +
from O +
pyridoxamine O +
phosphate O +
as O +
the O +
PLP O -
- O -
enzyme O +
complex O +
is O +
regenerated O -
. O -

Thus O -
, O +
both O +
substrates O +
have O +
to O +
be O +
accommodated O +
in O +
the O +
same O +
active O +
site O -
, O +
despite O +
differences O +
in O +
size O +
and O +
chemical O +
properties O -
. O -

Although O +
KAPA O +
bears O +
an O +
amino O +
group O -
, O +
DAPA O +
synthase O +
uses O +
KAPA O +
only O +
as O +
an O +
amino O +
group O +
acceptor O -
, O +
not O +
as O +
an O +
amino O +
group O +
donor O -
, O +
i.e. O +
KAPA O +
is O +
not O +
transaminated O +
by O +
DAPA O +
synthase O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975b O -
) O +
. O -

The O +
three O -
- O -
dimensional O +
structures O +
of O +
more O +
than O +
20 O +
different O +
PLP O -
- O -
dependent O +
enzymes O +
have O +
been O +
determined O +
( O -
for O +
a O +
recent O +
review O -
, O +
see O +
Jansonius O +
1998 O +
) O -
. O -

Christen O +
and O +
co O -
- O -
workers O +
organised O +
PLP O -
- O -
dependent O +
enzymes O +
into O +
three O +
different O +
families O -
, O +
α O -
, O +
β O +
and O +
γ O -
, O +
based O +
on O +
the O +
chemical O +
characteristics O +
of O +
the O +
catalysed O +
reaction O +
and O +
attempted O +
to O +
correlate O +
these O +
with O +
amino O +
acid O +
sequence O +
families O +
( O -
Alexander O +
et O +
al O +
. O -
, O +
1994 O -
) O +
. O -

The O +
aminotransferases O +
belong O +
to O +
the O +
α O -
- O -
family O -
, O +
which O +
hosts O +
enzymes O +
acting O +
on O +
the O +
carbon O +
atom O +
adjacent O +
to O +
the O +
amino O +
group O +
of O +
the O +
substrate O -
. O -

Another O +
classification O +
based O +
on O +
fold O +
types O +
and O +
sequence O +
comparisons O +
was O +
introduced O +
by O +
Grishin O +
et O +
al. O -
( O -
1995 O -
) O +
. O -

So O +
far O -
, O +
five O +
different O +
folds O +
that O +
can O +
bind O +
PLP O +
have O +
been O +
observed O +
and O +
it O +
has O +
been O +
proposed O +
on O +
the O +
basis O +
of O +
sequence O +
analysis O +
that O +
additional O +
hitherto O +
unknown O +
PLP O -
- O -
binding O +
folds O +
might O +
exist O +
( O -
Grishin O +
et O +
al O +
. O -
, O +
1995 O -
) O +
. O -

Most O +
aminotransferases O +
of O +
known O +
structure O +
belong O +
to O +
fold O +
type O +
I O -
, O +
first O +
described O +
for O +
aspartate O +
aminotransferase O +
( O -
Ford O +
et O +
al O +
. O -
, O +
1980 O -
) O +
. O -

This O +
structural O +
family O +
is O +
characterised O +
by O +
a O +
large O +
domain O +
folded O +
into O +
a O +
central O +
β O -
- O -
sheet O -
, O +
with O +
surrounding O +
loops O +
and O +
helices O +
forming O +
most O +
of O +
the O +
PLP O +
binding O +
site O +
and O +
a O +
smaller O +
domain O +
partly O +
involved O +
in O +
substrate O +
binding O -
. O -

Exceptions O +
are O +
d O +
-amino O +
acid O +
aminotransferase O +
( O -
Sugio O +
et O +
al O +
. O -
, O +
1995 O -
) O -
and O +
branched O +
chain O +
aminotransferase O +
( O -
Okada O +
et O +
al O +
. O -
, O +
1997 O -
) O +
, O +
which O +
fold O +
in O +
a O +
completely O +
different O +
manner O -
. O -

Sequence O +
analysis O +
suggested O +
that O +
DAPA O +
synthase O +
may O +
belong O +
to O +
the O +
aminotransferase O +
subclass O +
III O +
of O +
the O +
PLP O +
fold O +
type O +
I O +
family O +
( O -
Metha O +
et O +
al O +
. O -
, O +
1993 O -
) O +
, O +
which O +
includes O +
a O +
number O +
of O +
enzymes O +
of O +
known O +
structure O -
: O +
ω O -
- O -
aminotransferase O +
( O -
Watanabe O +
et O +
al O +
. O -
, O +
1989 O -
) O +
, O +
ornithine O +
aminotransferase O +
( O -
Shah O +
et O +
al O +
. O -
, O +
1997 O -
, O +
Shen O +
et O +
al O +
. O -
, O +
1998 O -
) O +
, O +
2,2-dialkylglycine O +
decarboxylase O +
( O -
Toney O +
et O +
al O +
. O -
, O +
1993 O -
, O +
1995 O -
) O -
and O +
glutamate O +
semialdehyde O +
aminomutase O +
( O -
Hennig O +
et O +
al O +
. O -
, O +
1997 O -
) O +
. O -

Here O +
we O +
report O +
the O +
three O -
- O -
dimensional O +
structure O +
of O +
DAPA O +
synthase O +
from O +
E. B-Species +
coli L-Species -
at O +
1.8 O +
Å O +
resolution O -
. O -

The O +
structure O +
analysis O +
reveals O +
that O +
this O +
enzyme O +
indeed O +
is O +
a O +
member O +
of O +
the O +
aspartate O +
aminotransferase O +
family O +
of O +
vitamin O +
B6 O +
-dependent O +
enzymes O -
. O -

A O +
multiple O +
structure O +
alignment O +
suggests O +
that O +
at O +
least O +
six O +
subclasses O -
, O +
which O +
are O +
structurally O +
and O +
evolutionary O +
closely O +
related O -
, O +
exist O +
in O +
this O +
family O -
. O -

Furthermore O -
, O +
the O +
structure O +
of O +
a O +
ternary O +
complex O +
of O +
DAPA O +
synthase O +
with O +
the O +
substrate O +
KAPA O -
, O +
bound O +
to O +
the O +
PLP O +
form O +
of O +
the O +
enzyme O -
, O +
is O +
presented O -
. O -

This O +
structure O +
forms O +
the O +
basis O +
for O +
mechanistic O +
considerations O -
, O +
in O +
particular O +
with O +
respect O +
to O +
substrate O +
recognition O -
. O -

Results O +
Structure O +
determination O +
The O +
structure O +
of O +
DAPA O +
synthase O +
was O +
determined O +
to O +
1.8 O +
Å O +
resolution O -
. O -

Despite O +
non O -
- O -
isomorphism O +
between O +
crystals O +
of O +
DAPA O +
synthase O -
, O +
two O +
heavy O -
- O -
atom O +
derivatives O +
containing O +
mercury O +
and O +
platinum O -
, O +
respectively O -
, O +
were O +
identified O +
after O +
extensive O +
screening O -
. O -

However O -
, O +
the O +
phases O +
derived O +
from O +
these O +
derivatives O +
were O +
not O +
of O +
sufficient O +
quality O +
to O +
allow O +
tracing O +
of O +
the O +
polypeptide O +
chain O -
. O -

Therefore O +
multiple O +
anomalous O +
dispersion O +
techniques O -
, O +
using O +
mercury O -
- O -
derivatised O +
crystals O +
were O +
employed O +
to O +
obtain O +
phase O +
information O +
( O -
for O +
data O +
collection O +
and O +
phasing O +
statistics O +
see O +
Table O +
1 O +
) O -
. O -

The O +
initial O +
map O +
at O +
2.0 O +
Å O +
resolution O -
, O +
calculated O +
after O +
solvent O +
flattening O +
and O +
2-fold O +
non O -
- O -
crystallographic O +
averaging O -
, O +
was O +
of O +
excellent O +
quality O +
( O -
Figure O +
3 O -
( O -
a O -
) O -
) O -
and O +
the O +
polypeptide O +
chain O +
could O +
be O +
readily O +
built O +
into O +
the O +
electron O +
density O -
. O -

After O +
a O +
few O +
refinement O +
cycles O -
, O +
most O +
of O +
the O +
side O -
- O -
chains O +
had O +
been O +
assigned O -
. O -

However O -
, O +
native O +
crystals O +
diffracted O +
to O +
higher O +
resolution O +
( O -
1.8 O +
Å O -
) O +
and O +
it O +
was O +
desirable O +
to O +
use O +
these O +
data O +
for O +
the O +
refinement O -
. O -

Because O +
of O +
the O +
non O -
- O -
isomorphism O +
between O +
crystals O -
, O +
molecular O +
replacement O +
was O +
necessary O +
for O +
finding O +
the O +
correct O +
orientation O +
of O +
the O +
molecule O +
in O +
the O +
native O +
crystal O -
. O -

The O +
solution O +
was O +
verified O +
by O +
strong O +
and O +
well O +
defined O +
density O +
for O +
the O +
cofactor O -
, O +
PLP O -
, O +
which O +
had O +
been O +
excluded O +
from O +
the O +
search O +
model O -
. O -

Two O -
- O -
fold O +
non O -
- O -
crystallographic O +
symmetry O +
was O +
applied O +
in O +
the O +
subsequent O +
refinement O -
, O +
but O +
released O +
in O +
the O +
very O +
last O +
stages O +
causing O +
a O +
slight O +
drop O +
in O +
the O +
free O +
R O +
-value O -
. O -

Figure O +
3 O -
( O -
b O -
) O -
shows O +
a O +
part O +
of O +
the O +
final O +
2F O +
o O +
−F O +
c O -
electron O +
density O +
map O -
, O +
with O +
the O +
refined O +
model O +
superimposed O -
. O -

The O +
final O +
model O +
contains O +
all O +
but O +
one O +
residue O -
, O +
556 O +
water O +
molecules O -
, O +
two O +
PLP O +
molecules O +
covalently O +
linked O +
to O +
Lys274 O +
in O +
each O +
chain O +
and O +
two O +
Na+ O +
. O -

Only O +
the O +
backbone O +
is O +
modelled O +
for O +
the O +
C O -
- O -
terminal O +
residue O +
in O +
both O +
chains O +
( O -
Glu429 O -
) O -
, O +
since O +
the O +
side O -
- O -
chains O +
were O +
disordered O -
. O -

The O +
side O -
- O -
chains O +
in O +
the O +
loop O +
region O +
between O +
residues O +
180 O +
and O +
192 O +
are O +
badly O +
ordered O -
, O +
and O +
in O +
one O +
of O +
the O +
monomers O +
residue O +
183 O +
is O +
not O +
included O +
in O +
the O +
model O -
, O +
since O +
no O +
electron O +
density O +
corresponding O +
to O +
its O +
main O -
- O -
chain O +
atoms O +
was O +
observed O -
. O -

In O +
both O +
chains O +
residue O +
Trp14 O -
, O +
which O +
is O +
positioned O +
in O +
the O +
interior O +
of O +
the O +
protein O -
, O +
was O +
built O +
as O +
a O +
leucine O +
residue O -
, O +
judged O +
by O +
the O +
electron O +
density O +
and O +
the O +
local O +
environment O +
of O +
the O +
side O -
- O -
chain O -
. O -

This O +
replacement O +
was O +
later O +
supported O +
by O +
N O -
- O -
terminal O +
amino O +
acid O +
sequencing O -
. O -

The O +
model O +
was O +
refined O +
to O +
a O +
final O +
R O +
-factor O +
of O +
17.5 O +
% O +
and O +
a O +
free O +
R O +
-factor O +
of O +
22.6 O +
% O -
. O -

A O +
summary O +
of O +
the O +
refinement O +
statistics O +
is O +
shown O +
in O +
Table O +
2 O +
. O -

Two O +
residues O -
, O +
Trp53 O +
and O +
Ile213 O -
, O +
which O +
both O +
are O +
well O +
defined O +
in O +
the O +
electron O +
density O +
map O -
, O +
appear O +
in O +
the O +
disallowed O +
region O +
of O +
the O +
Ramachandran O +
plot O +
for O +
each O +
subunit O -
. O -

Trp53 O +
is O +
involved O +
in O +
substrate O +
binding O +
and O +
Ile213 O +
is O +
found O +
at O +
a O +
sharp O +
turn O +
in O +
the O +
beginning O +
of O +
a O +
β O -
- O -
strand O +
that O +
takes O +
the O +
chain O +
into O +
the O +
cofactor O +
binding O +
region O -
. O -

The O +
structure O +
of O +
the O +
monomer O +
The O +
monomer O +
of O +
DAPA O +
synthase O +
consists O +
of O +
two O +
domains O +
( O -
Figure O +
4 O -
( O -
a O -
) O -
) O +
, O -
a O +
small O +
domain O +
comprising O +
the O +
N O -
- O -
and O +
C O -
- O -
terminal O +
parts O +
of O +
the O +
polypeptide O +
chain O +
( O -
residues O +
1–49 O +
and O +
330–429 O -
) O +
and O +
a O +
large O +
domain O +
formed O +
by O +
the O +
intervening O +
residues O +
containing O +
the O +
cofactor O +
binding O +
site O -
. O -

A O +
topological O +
description O +
of O +
the O +
structure O +
of O +
DAPA O +
synthase O +
is O +
presented O +
in O +
Figure O +
4 O -
( O -
b O -
) O +
. O -

The O +
large O +
domain O +
starts O +
with O +
a O +
helix O -
- O -
loop O -
- O -
helix O +
segment O +
formed O +
by O +
helices O +
α2 O +
and O +
α3 O -
, O +
which O +
takes O +
the O +
chain O +
over O +
the O +
surface O +
of O +
the O +
molecule O +
to O +
the O +
beginning O +
of O +
a O +
seven O -
- O -
stranded O +
β O -
- O -
sheet O -
, O +
the O +
central O +
feature O +
of O +
this O +
domain O -
, O +
which O +
is O +
typical O +
of O +
aminotransferases O +
( O -
Ford O +
et O +
al O +
. O -
, O +
1980 O -
) O +
. O -

The O +
order O +
of O +
the O +
strands O +
is O +
β4 O -
, O +
β10 O -
, O +
β9 O -
, O +
β8 O -
, O +
β7 O -
, O +
β5 O +
and O +
β6 O -
, O +
where O +
all O +
except O +
β10 O +
are O +
parallel O +
to O +
each O +
other O -
. O -

Towards O +
the O +
exterior O +
of O +
the O +
molecule O +
the O +
sheet O +
is O +
covered O +
by O +
two O +
helices O -
, O +
α5 O +
and O +
α6 O -
, O +
and O +
the O +
loop O +
between O +
strands O +
β8 O +
and O +
β9 O -
. O -

The O +
sheet O +
is O +
further O +
shielded O +
from O +
the O +
solvent O +
by O +
helices O +
α3 O +
and O +
α8 O -
, O +
which O +
pack O +
almost O +
perpendicular O +
to O +
the O +
strands O +
in O +
the O +
β O -
- O -
sheet O -
. O -

Helix O +
α4 O +
and O +
the O +
extended O +
loop O +
between O +
β5 O +
and O +
β6 O +
pack O +
against O +
the O +
sheet O +
on O +
the O +
opposite O +
side O +
and O +
are O +
involved O +
in O +
subunit O -
- O -
subunit O +
interactions O -
. O -

Helices O +
α7-α8 O +
form O +
a O +
helix O -
- O -
loop O -
- O -
helix O +
segment O -
, O +
which O +
follows O +
after O +
the O +
seven O -
- O -
stranded O +
β O -
- O -
sheet O +
and O +
completes O +
the O +
large O +
domain O -
. O -

The O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
folds O +
into O +
a O +
β O -
- O -
sheet O +
which O +
is O +
packed O +
against O +
three O +
helices O +
α9 O -
, O +
α10 O +
and O +
α11 O -
, O +
on O +
one O +
side O -
. O -

The O +
other O +
side O +
of O +
the O +
sheet O +
is O +
turned O +
against O +
the O +
large O +
domain O -
, O +
so O +
that O +
a O +
crevice O +
is O +
formed O +
between O +
the O +
two O +
domains O -
, O +
which O +
accommodates O +
the O +
active O +
site O -
. O -

The O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
starts O +
with O +
an O +
α O -
- O -
helix O +
followed O +
by O +
three O +
short O +
β O -
- O -
strands O -
, O +
β1 O -
, O +
β2 O +
and O +
β3 O -
, O +
folded O +
into O +
an O +
anti O -
- O -
parallel O +
β O -
- O -
sheet O -
, O +
and O +
then O +
proceeds O +
into O +
the O +
large O +
domain O +
via O -
a O +
connecting O +
peptide O +
segment O -
. O -

This O +
β O -
- O -
sheet O +
is O +
positioned O +
between O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
and O +
the O +
large O +
domain O +
and O +
provides O +
one O +
wall O +
of O +
the O +
active O +
site O -
. O -

The O +
N O -
- O -
terminal O +
β O -
- O -
sheet O +
is O +
extended O +
by O +
a O +
very O +
short O +
strand O -
, O +
created O +
by O +
residues O +
located O +
between O +
strand O +
β13 O +
and O +
helix O +
α10 O +
in O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
domain O -
. O -

Following O +
this O +
interaction O +
the O +
polypeptide O +
chain O +
proceeds O +
back O +
into O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O -
, O +
extending O +
its O +
β O -
- O -
sheet O +
by O +
a O +
short O +
anti O -
- O -
parallel O +
β O -
- O -
strand O +
interaction O +
to O +
strand O +
β13 O +
( O -
Figure O +
4 O -
( O -
b O -
) O -
) O +
. O -

Most O +
of O +
the O +
interactions O +
between O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
and O +
the O +
large O +
domain O +
involve O +
strand O +
β11 O -
, O +
the O +
loop O +
following O +
that O +
strand O +
and O +
the O +
loop O +
between O +
β13 O +
and O +
α11 O -
. O -

Arg360 O +
in O +
strand O +
β11 O +
interacts O +
through O +
its O +
side O -
- O -
chain O +
with O +
the O +
main O -
- O -
chain O +
carbonyl O +
groups O +
of O +
residues O +
Gly219 O +
and O +
Met220 O -
, O +
situated O +
in O +
the O +
loop O +
region O +
between O +
β7 O +
and O +
α6 O +
in O +
the O +
large O +
domain O -
. O -

Arg253 O +
in O +
the O +
large O +
domain O +
interacts O +
via O -
its O +
side O -
- O -
chain O +
with O +
the O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atoms O +
of O +
Pro401 O +
found O +
between O +
strand O +
β13 O +
and O +
helix O +
α11 O -
, O +
and O +
Ala364 O +
between O +
strands O +
β11 O +
and O +
β12 O -
. O -

It O +
is O +
also O +
hydrogen O +
bonded O +
through O +
its O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atom O +
to O +
the O +
phenolic O +
hydroxyl O +
group O +
of O +
Tyr403 O -
. O -

Ile56 O -
, O +
found O +
in O +
the O +
domain O +
interconnection O +
region O -
, O +
provides O +
a O +
main O -
- O -
chain O -
- O -
main O -
- O -
chain O +
interaction O +
with O +
Tyr403 O +
in O +
the O +
small O +
domain O -
. O -

Finally O -
, O +
the O +
side O -
- O -
chain O +
hydroxyl O +
group O +
of O +
Tyr403 O +
is O +
within O +
hydrogen O +
bonding O +
distance O +
of O +
the O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atom O +
of O +
Phe251 O +
in O +
the O +
loop O +
between O +
β8 O +
and O +
β9 O -
. O -

All O +
residues O +
involved O +
in O +
this O +
interface O +
except O +
Tyr403 O +
and O +
Ala364 O +
are O +
either O +
conserved O +
or O +
invariant O +
within O +
the O +
DAPA O +
synthases O +
( O -
Figure O +
4 O -
( O -
c O -
) O -
) O +
. O -

The O +
domain O -
- O -
domain O +
interface O +
between O +
the O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
and O +
the O +
large O +
domain O +
involves O +
hydrogen O +
bond O +
interactions O +
between O +
the O +
main O -
- O -
chain O +
atoms O +
of O +
the O +
C O -
- O -
terminal O +
residues O +
of O +
strand O +
β1 O -
, O +
Ala32 O +
and O +
Gly34 O -
, O +
and O +
main O -
- O -
chain O +
atoms O +
of O +
Tyr59 O +
and O +
the O +
side O -
- O -
chain O +
of O +
Asn60 O -
, O +
which O +
precede O +
helix O +
α2 O +
in O +
the O +
large O +
domain O -
. O -

Tyr17 O -
, O +
located O +
in O +
the O +
loop O +
between O +
α1 O +
and O +
β1 O -
, O +
is O +
hydrogen O -
- O -
bonded O +
through O +
its O +
phenolic O +
oxygen O +
to O +
the O +
side O -
- O -
chain O +
of O +
Asp147 O -
, O +
which O +
is O +
part O +
of O +
the O +
extended O +
loop O +
between O +
strands O +
β5 O +
and O +
β6 O +
of O +
the O +
large O +
domain O -
. O -

Furthermore O -
, O +
two O +
of O +
the O +
residues O +
involved O +
in O +
the O +
domain O +
interconnection O -
, O +
Ser50 O +
and O +
Trp53 O -
, O +
interact O +
through O +
the O +
side O -
- O -
chain O +
hydroxyl O +
and O +
main O -
- O -
chain O +
carbonyl O +
oxygen O +
atom O -
, O +
respectively O -
, O +
with O +
the O +
guanidinium O +
group O +
of O +
Arg253 O +
located O +
between O +
strands O +
β8 O +
and O +
β9 O -
. O -

These O +
three O +
residues O +
and O +
Gly34 O +
are O +
invariant O +
throughout O +
the O +
sequenced O +
DAPA O +
synthases O +
( O -
Figure O +
4 O -
( O -
c O -
) O -
) O +
. O -

The O +
DAPA O +
synthase O +
dimer O +
In O +
the O +
crystal O -
, O +
a O +
homodimer O +
of O +
DAPA O +
synthase O +
( O -
Figure O +
5 O -
) O -
is O +
found O +
with O +
the O +
subunits O +
related O +
by O +
a O +
2-fold O +
non O -
- O -
crystallographic O +
axis O -
. O -

This O +
finding O +
is O +
consistent O +
with O +
solution O +
studies O +
that O +
showed O +
that O +
DAPA O +
synthase O +
is O +
active O +
in O +
dimeric O +
form O +
( O -
Stoner O +
& O +
Eisenberg O -
, O +
1975a O -
) O +
. O -

Upon O +
dimerisation O -
, O +
an O +
area O +
of O +
5240 O +
Å2 O -
per O +
subunit O +
is O +
buried O -
, O +
which O +
corresponds O +
to O +
27 O +
% O +
of O +
the O +
total O +
solvent O -
- O -
accessible O +
area O -
. O -

The O +
overall O +
dimension O +
of O +
the O +
dimer O +
is O +
85 O +
Å O -
× O +
60 O +
Å O -
× O -
60 O +
Å. O +
Both O +
subunits O +
are O +
involved O +
in O +
building O +
up O +
the O +
two O +
identical O +
active O +
sites O +
of O +
the O +
DAPA O +
synthase O +
dimer O -
, O +
which O +
are O +
positioned O +
approximately O +
20 O +
Å O +
apart O -
. O -

The O +
pattern O +
of O +
subunit O -
- O -
subunit O +
interactions O +
is O +
extensive O +
and O +
residues O +
from O +
both O +
domains O +
are O +
involved O +
in O +
these O +
interactions O -
. O -

In O +
the O +
large O +
domain O +
helix O +
α2 O +
lines O +
up O +
with O +
and O +
packs O +
against O +
α2 O +
from O +
the O +
other O +
monomer O -
, O +
and O +
both O +
form O +
the O +
top O +
of O +
the O +
molecule O -
, O +
as O +
shown O +
in O +
Figure O +
5 O +
. O -

The O +
extended O +
loop O +
following O +
helix O +
α2 O +
protrudes O +
into O +
the O +
neighbouring O +
subunit O -
, O +
forming O +
several O +
strong O +
interactions O +
with O +
loop O +
regions O +
from O +
both O +
domains O +
of O +
that O +
subunit O -
. O -

Helix O +
α3 O -
, O +
which O +
covers O +
the O +
central O +
β O -
- O -
sheet O +
of O +
its O +
own O +
subunit O -
, O +
interacts O +
with O +
residues O +
from O +
the O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
from O +
the O +
other O +
subunit O -
. O -

Helix O +
α4 O +
and O +
the O +
loop O +
between O +
β5 O +
and O +
β6 O -
, O +
which O +
protrude O +
from O +
the O +
central O +
β O -
- O -
sheet O +
region O -
, O +
pack O +
against O +
the O +
corresponding O +
residues O +
in O +
the O +
second O +
monomer O +
at O +
an O +
angle O +
of O +
approximately O +
90 O -
° O -
, O +
mainly O +
through O +
hydrophobic O +
interactions O -
. O -

Furthermore O -
, O +
the O +
top O +
end O +
of O +
this O +
part O +
of O +
the O +
sheet O +
involving O +
strands O +
β4 O -
, O +
β10 O +
and O +
β11 O -
, O +
including O +
PLP O +
binding O +
residue O +
Lys274 O -
, O +
and O +
connecting O +
loops O +
form O +
interactions O +
with O +
the O +
other O +
subunit O +
of O +
DAPA O +
synthase O -
, O +
in O +
particular O +
with O +
helices O +
α7 O +
and O +
α8 O -
. O -

Dimer O +
interactions O +
formed O +
by O +
the O +
small O +
domain O +
are O +
almost O +
exclusively O +
made O +
up O +
of O +
the O +
N O -
- O -
terminal O +
part O +
in O +
which O +
the O +
N O -
- O -
terminal O +
helix O +
and O +
the O +
following O +
loop O +
folds O +
over O +
the O +
surface O +
of O +
the O +
second O +
monomer O -
. O -

The O +
loop O +
between O +
helix O +
α2 O +
and O +
α3 O +
is O +
of O +
central O +
importance O +
for O +
the O +
subunit O -
- O -
subunit O +
interactions O -
. O -

It O +
interacts O +
with O +
residues O +
located O +
in O +
helix O +
α1 O -
, O +
in O +
the O +
loop O +
between O +
helix O +
α1 O +
and O +
strand O +
β1 O -
, O +
in O +
strand O +
β1 O -
, O +
in O +
the O +
domain O +
interconnection O +
region O -
, O +
in O +
the O +
loop O +
between O +
strands O +
β9 O +
and O +
β10 O -
, O +
and O +
in O +
the O +
loop O +
between O +
helix O +
α10 O +
and O +
strand O +
β13 O +
of O +
the O +
second O +
subunit O -
. O -

The O +
pyridoxal-5′-phosphate O +
binding O +
site O +
The O +
electron O +
density O +
for O +
the O +
cofactor O +
is O +
very O +
well O +
defined O +
and O +
shows O +
clearly O +
that O +
PLP O +
is O +
covalently O +
bound O +
to O +
the O +
active O +
site O +
Lys274 O +
( O -
Figure O +
3 O -
( O -
b O -
) O -
) O +
. O -

The O +
PLP O +
binding O +
site O +
is O +
located O +
between O +
the O +
two O +
domains O +
of O +
the O +
monomer O +
at O +
the O +
interface O +
of O +
the O +
two O +
subunits O +
( O -
Figure O +
6 O -
) O +
. O -

Residues O +
from O +
both O +
subunits O +
are O +
involved O +
in O +
cofactor O +
binding O -
, O +
although O +
each O +
active O +
site O +
cleft O +
is O +
mainly O +
made O +
up O +
of O +
one O +
monomer O -
. O -

The O +
lysine O +
residue O +
covalently O +
attached O +
to O +
PLP O +
is O +
located O +
on O +
the O +
loop O +
between O +
strands O +
β9 O +
and O +
β10 O -
, O +
and O +
points O +
towards O +
the O +
interior O +
of O +
the O +
protein O +
so O +
that O +
PLP O +
is O +
found O +
on O +
the O +
side O +
of O +
the O +
β O -
- O -
sheet O +
facing O +
the O +
second O +
subunit O +
in O +
the O +
dimer O -
. O -

The O +
cofactor O +
is O +
bound O +
at O +
the O +
bottom O +
of O +
the O +
active O +
site O -
, O +
with O +
its O +
re O -
side O +
facing O +
the O +
solvent O -
. O -

The O +
oxygen O +
atoms O +
of O +
the O +
phosphate O +
group O +
interact O +
with O +
the O +
main O -
- O -
chain O +
amides O +
of O +
Gly112 O +
and O +
Ser113 O -
, O +
and O +
the O +
side O -
- O -
chain O +
of O +
Ser113 O -
, O +
located O +
at O +
the O +
N O +
terminus O +
of O +
helix O +
α4 O -
, O +
thus O +
anchoring O +
PLP O +
firmly O +
to O +
the O +
enzyme O -
. O -

The O +
negative O +
charges O +
on O +
the O +
phosphate O +
oxygen O +
atoms O +
are O +
partly O +
neutralised O +
by O +
the O +
positive O +
dipole O +
charge O +
of O +
helix O +
α4 O -
. O -

Further O -
, O +
Thr309 O +
from O +
the O +
other O +
subunit O +
forms O +
a O +
hydrogen O +
bond O +
interaction O +
through O +
its O +
main O -
- O -
chain O +
amide O +
to O +
one O +
of O +
the O +
phosphate O +
oxygen O +
atoms O -
. O -

Several O +
well O +
ordered O +
water O +
molecules O +
within O +
hydrogen O +
bond O +
distance O +
of O +
the O +
phosphate O +
oxygen O +
atoms O +
are O +
also O +
found O +
in O +
the O +
active O +
site O +
of O +
the O +
holo O -
- O -
enzyme O -
. O -

The O +
carboxyl O +
group O +
of O +
Asp245 O +
is O +
within O +
hydrogen O +
bonding O +
distance O +
of O +
the O +
pyridine O +
nitrogen O -
. O -

This O +
indicates O +
either O +
that O +
the O +
carboxyl O +
side O -
- O -
chain O +
is O +
protonated O +
and O +
can O +
form O +
a O +
hydrogen O +
bond O +
to O +
the O +
nitrogen O +
atom O +
or O +
that O +
this O +
nitrogen O +
is O +
protonated O -
. O -

The O +
aspartic O +
acid O +
side O -
- O -
chain O +
is O +
kept O +
in O +
place O +
by O +
interactions O +
with O +
the O +
main O -
- O -
chain O +
amide O +
of O +
residue O +
Ile247 O +
and O +
with O +
the O +
side O -
- O -
chain O +
of O +
His145 O -
. O -

No O +
direct O +
interactions O +
with O +
protein O +
atoms O +
are O +
found O +
for O +
the O +
phenolic O +
hydroxyl O +
group O -
, O +
O-3′ O -
, O +
of O +
the O +
cofactor O -
. O -

There O +
are O -
, O +
however O -
, O +
water O -
- O -
mediated O +
contacts O +
to O +
the O +
side O -
- O -
chain O +
of O +
Glu211 O +
and O +
the O +
main O -
- O -
chain O +
amide O +
of O +
Ala217 O -
. O -

The O +
pyridine O +
ring O +
of O +
PLP O +
is O +
sandwiched O +
between O +
the O +
side O -
- O -
chain O +
of O +
Tyr144 O +
protruding O +
from O +
the O +
active O +
site O -
, O +
which O +
stacks O +
perpendicular O +
to O +
the O +
ring O -
, O +
and O +
Ile247 O -
, O +
which O +
provides O +
support O +
from O +
the O +
si O -
side O +
of O +
the O +
ring O +
facing O +
the O +
protein O -
. O -

Binding O +
of O +
the O +
substrate O +
KAPA O +
The O +
electron O +
density O +
map O +
for O +
the O +
ternary O +
complex O +
was O +
continuous O +
except O +
for O +
a O +
few O +
disordered O +
loop O +
regions O +
at O +
the O +
surface O +
of O +
the O +
molecule O -
. O -

These O +
regions O +
comprise O +
residues O +
160–168 O +
and O +
300–301 O +
in O +
each O +
subunit O +
with O +
no O +
electron O +
density O +
for O +
the O +
backbone O -
. O -

As O +
in O +
the O +
crystals O +
of O +
the O +
holoenzyme O -
, O +
the O +
loop O +
comprising O +
residues O +
180–192 O +
has O +
weak O +
electron O +
density O -
, O +
with O +
disordered O +
side O -
- O -
chains O +
for O +
residues O +
180–192 O +
and O +
no O +
electron O +
density O +
for O +
the O +
backbone O +
of O +
residues O +
183–184 O -
. O -

The O +
C O -
- O -
terminal O +
residue O +
was O +
not O +
modelled O +
because O +
of O +
very O +
weak O +
electron O +
density O -
. O -

The O +
stereochemistry O +
of O +
the O +
refined O +
model O +
is O +
reasonable O +
( O -
Table O +
2 O -
) O +
. O -

The O +
Ramachandran O +
plot O +
showed O +
one O +
outlier O -
, O +
residue O +
Ile213 O -
, O +
with O +
well O +
defined O +
electron O +
density O -
. O -

This O +
residue O +
is O +
also O +
found O +
in O +
the O +
disallowed O +
region O +
of O +
the O +
Ramachandran O +
plot O +
for O +
the O +
model O +
of O +
the O +
holoenzyme O -
. O -

The O +
most O +
characteristic O +
feature O +
of O +
the O +
initial O +
electron O +
density O +
map O +
for O +
the O +
ternary O +
complex O +
was O +
the O +
clear O +
and O +
well O +
defined O +
difference O +
electron O +
density O +
in O +
the O +
active O +
site O +
close O +
to O +
the O +
PLP O +
molecule O -
. O -

A O +
KAPA O +
molecule O +
could O +
be O +
modelled O +
straightforwardly O +
into O +
this O +
difference O +
density O -
. O -

Refinement O +
gave O +
similar O +
B O +
-factors O +
for O +
the O +
atoms O +
of O +
the O +
substrate O +
to O +
those O +
for O +
surrounding O +
protein O +
atoms O -
, O +
indicating O +
high O +
occupancy O +
of O +
the O +
substrate O +
in O +
the O +
active O +
site O -
. O -

The O +
initial O +
difference O +
electron O +
density O +
for O +
bound O +
KAPA O +
is O +
shown O +
in O +
Figure O +
3 O -
( O -
c O -
) O +
. O -

The O +
substrate O +
is O +
bound O +
in O +
a O +
rather O +
bent O +
fashion O +
in O +
the O +
active O +
site O +
cleft O -
, O +
with O +
the O +
carboxyl O +
tail O +
close O +
to O +
the O +
entrance O +
of O +
the O +
cleft O +
and O +
the O +
polar O +
head O +
group O +
close O +
to O +
the O +
re O -
face O +
of O +
the O +
cofactor O +
at O +
the O +
bottom O +
of O +
the O +
active O +
site O +
( O -
Figure O +
7 O -
) O +
. O -

The O +
polar O +
head O -
/ O -
tail O +
groups O +
anchor O +
the O +
substrate O +
to O +
the O +
protein O +
through O +
salt O +
bridges O +
and O +
hydrogen O +
bonds O -
, O +
while O +
the O +
hydrophobic O +
carbon O +
chain O +
packs O +
with O +
hydrophobic O +
amino O +
acid O +
side O -
- O -
chains O +
in O +
the O +
active O +
site O +
pocket O -
. O -

The O +
carboxyl O +
group O +
of O +
KAPA O +
forms O +
a O +
salt O +
bridge O +
with O +
the O +
side O -
- O -
chain O +
of O +
the O +
invariant O +
Arg391 O -
. O -

One O +
of O +
the O +
oxygen O +
atoms O +
of O +
this O +
carboxyl O +
groups O +
is O +
also O +
within O +
hydrogen O +
bonding O +
distance O +
of O +
the O +
Nϵ O -
atom O +
of O +
the O +
side O -
- O -
chain O +
of O +
Trp52 O -
. O -

The O +
aliphatic O +
carbon O +
atoms O +
of O +
the O +
KAPA O +
molecule O +
form O +
van O +
der O +
Waals O -
' O +
interactions O +
with O +
the O +
side O -
- O -
chains O +
of O +
residues O +
Tyr17 O -
, O +
Trp53 O -
, O +
Tyr144 O +
and O +
Phe393 O -
. O -

The O +
7-keto O +
oxygen O +
atom O +
of O +
KAPA O +
forms O +
a O +
hydrogen O +
bond O +
to O +
the O +
Nϵ O -
atom O +
of O +
Lys274 O -
, O +
which O +
is O +
covalently O +
linked O +
to O +
the O +
PLP O +
in O +
this O +
ternary O +
complex O -
. O -

The O +
N8 O +
nitrogen O +
atom O +
of O +
the O +
substrate O +
is O +
held O +
in O +
position O +
through O +
hydrogen O +
bonds O +
formed O +
to O +
the O +
hydroxyl O +
group O +
of O +
Tyr17 O -
, O +
and O +
the O +
peptide O +
oxygen O +
of O +
Gly307 O -
. O -

The O +
terminal O +
methyl O +
group O +
of O +
KAPA O +
forms O +
a O +
hydrophobic O +
contact O +
with O +
the O +
side O -
- O -
chain O +
of O +
Trp52 O -
. O -

Very O +
few O +
significant O +
conformational O +
changes O +
occur O +
upon O +
binding O +
of O +
the O +
substrate O -
. O -

The O +
largest O +
changes O +
involve O +
only O +
side O -
- O -
chain O +
movements O -
. O -

They O +
include O +
the O +
side O -
- O -
chain O +
of O +
Tyr17 O -
, O +
which O +
shifts O +
towards O +
the O +
KAPA O +
substrate O -
. O -

The O +
guanidinium O +
group O +
of O +
the O +
side O -
- O -
chain O +
of O +
Arg391 O +
moves O +
about O +
3 O +
Å O +
in O +
order O +
to O +
form O +
a O +
tight O +
salt O +
bridge O +
to O +
the O +
carboxyl O +
group O +
of O +
KAPA O -
. O -

The O +
most O +
pronounced O +
conformational O +
change O +
involves O +
the O +
side O -
- O -
chain O +
of O +
Trp53 O -
, O +
which O +
adopts O +
a O +
position O +
perpendicular O +
to O +
its O +
location O +
in O +
the O +
unliganded O +
protein O -
. O -

This O +
conformational O +
change O +
has O +
as O +
a O +
consequence O +
that O +
this O +
residue O -
, O +
which O +
had O +
been O +
one O +
of O +
the O +
outliers O +
in O +
the O +
Ramachandran O +
plot O +
for O +
the O +
holoenzyme O -
, O +
is O +
now O +
located O +
in O +
a O +
favourable O +
region O +
of O +
the O +
Ramachandran O +
plot O -
. O -

The O +
metal O +
binding O +
site O +
A O +
strong O +
peak O +
in O +
electron O +
density O +
( O -
11 O +
times O +
the O +
standard O +
deviation O +
of O +
a O +
F O +
o O +
−F O +
c O -
electron O +
density O +
map O -
) O +
was O +
found O +
located O +
close O +
to O +
a O +
tight O +
turn O +
between O +
helix O +
α3 O +
and O +
strand O +
β4 O -
, O +
formed O +
by O +
residues O +
96 O +
to O +
100 O -
. O -

Observed O +
distances O +
to O +
surrounding O +
protein O +
atoms O +
( O -
2.3 O +
to O +
2.6 O +
Å O -
) O +
were O +
not O +
consistent O +
with O +
a O +
water O +
molecule O +
in O +
this O +
position O -
. O -

On O +
the O +
basis O +
of O +
peak O +
height O -
, O +
ligand O +
distance O +
and O +
geometry O -
, O +
this O +
difference O +
density O +
was O +
modelled O +
as O +
a O +
sodium O +
ion O -
. O -

Binding O +
of O +
a O +
potassium O +
ion O +
at O +
this O +
site O +
was O +
excluded O -
, O +
since O +
it O +
is O +
not O +
present O +
in O +
the O +
crystallisation O +
solution O -
, O +
whereas O +
sodium O +
is O +
present O +
in O +
high O +
concentration O +
as O +
a O +
buffer O +
counterion O +
( O -
> O -
50 O +
mM O -
) O -
. O -

The O +
ligands O +
to O +
the O +
Na+ O -
form O +
a O +
close O +
to O +
octahedral O +
coordination O +
sphere O -
, O +
with O +
oxygen O +
atoms O +
provided O +
by O +
main O -
- O -
chain O +
carbonyl O +
groups O +
of O +
residues O +
Val96 O -
, O +
Thr99 O -
, O +
Pro100 O +
and O +
Leu103 O +
( O -
Figure O +
8) O +
. O -

Additional O +
ligands O +
are O +
the O +
side O -
- O -
chain O +
of O +
Thr99 O +
and O +
a O +
water O +
molecule O -
. O -

Binding O +
sites O +
for O +
monovalent O +
metal O +
ions O +
have O +
been O +
observed O +
in O +
other O +
vitamin O +
B6 O +
-dependent O +
enzymes O -
, O +
for O +
instance O +
2,2-dialkylglycine O +
decarboxylase O +
( O -
Toney O +
et O +
al O +
. O -
, O +
1993 O -
, O +
1995 O -
) O -
and O +
tryptophanase O +
( O -
Isupov O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O -

The O +
metal O +
binding O +
site O +
observed O +
in O +
DAPA O +
synthase O +
is O +
identical O +
to O +
site O +
II O +
in O +
the O +
decarboxylase O -
, O +
with O +
the O +
same O +
set O +
of O +
ligands O -
, O +
four O +
carbonyl O +
oxygen O +
atoms O -
, O +
a O +
threonine O +
side O -
- O -
chain O +
and O +
a O +
water O +
molecule O -
. O -

Because O +
this O +
metal O +
binding O +
site O +
is O +
remote O +
from O +
the O +
active O +
site O +
( O -
> O -
20 O +
Å O -
) O -
, O +
its O +
role O +
is O +
likely O +
to O +
be O +
structural O +
rather O +
than O +
catalytic O -
. O -

Crystal O +
packing O +
DAPA O +
synthase O +
crystals O +
grown O +
under O +
the O +
same O +
conditions O +
occur O +
in O +
two O +
space O +
groups O -
, O +
C O +
2 O +
and O +
P O +
21 O +
, O +
with O +
cell O +
dimensions O +
a O +
= O -
130 O +
Å O -
, O +
b O +
= O -
57.5 O +
Å O -
, O +
c O +
= O -
117 O +
Å O +
and O +
β=110 O -
° O -
, O +
and O +
a O +
= O -
58.5 O +
Å O -
, O +
b O +
= O -
55.6 O +
Å O -
, O +
c O +
= O -
117 O +
Å O +
and O +
β=96.9 O -
° O -
, O +
respectively O +
( O -
Käck O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O -

It O +
was O +
evident O +
that O +
the O +
two O +
space O +
groups O +
were O +
closely O +
related O +
as O +
the O +
crystal O +
lattice O +
could O +
change O +
from O +
C O +
2 O +
to O +
P O +
21 O -
during O +
data O +
collection O -
. O -

This O +
transition O +
can O +
be O +
triggered O +
by O +
cooling O +
the O +
crystal O +
from O +
room O +
temperature O +
to O +
4 O -
° O -
C O -
. O -

Further O -
, O +
the O +
native O +
Patterson O +
map O +
obtained O +
from O +
the O +
P O +
21 O -
crystals O +
had O +
two O +
peaks O +
very O +
close O +
to O +
( O -
1 O -
/ O -
2,1 O -
/ O -
2,1 O -
/ O -
2 O -
) O -
, O +
indicating O +
a O +
pseudo O +
symmetry O +
in O +
the O +
packing O +
pattern O +
( O -
Käck O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O -

A O +
slight O +
rearrangement O +
of O +
the O +
molecules O +
in O +
the O +
crystal O +
disrupts O +
the O +
perfect O +
alignment O +
between O +
the O +
2-fold O +
molecular O +
axes O +
relating O +
the O +
monomers O +
and O +
the O +
crystallographic O +
dyad O +
and O +
shifts O +
its O +
positions O +
from O +
exactly O +
( O -
1 O -
/ O -
4 O -
, O +
y O +
, O +
0 O -
) O +
and O +
( O -
3 O -
/ O -
4 O -
, O +
y O +
, O +
0 O -
) O -
, O +
resulting O +
in O +
a O +
change O +
from O +
space O +
group O +
C O +
2 O +
to O +
P O +
21 O +
( O -
Figure O +
9 O -
) O +
. O -

The O +
relationship O +
between O +
the O +
two O +
space O +
groups O +
can O +
be O +
described O +
as O +
X O +
C O +
2= O +
−X O +
P O +
21 O +
−Z O +
P O +
21 O +
, O +
Y O +
C O +
2 O -
= O -
Y O +
P O +
21 O +
, O +
Z O +
C O +
2=2X O +
P O +
21 O +
. O -

Discussion O +
Structural O +
relationships O +
between O +
vitamin O +
B6 O -
enzymes O +
of O +
fold O +
type O +
I O +
In O +
order O +
to O +
analyse O +
structural O +
relationships O +
within O +
the O +
PLP O +
fold O +
type O +
I O +
family O -
, O +
a O +
general O +
search O +
of O +
the O +
Protein O +
Data O +
Bank O +
for O +
PLP O -
- O -
dependent O +
enzymes O +
topologically O +
similar O +
to O +
DAPA O +
synthase O +
was O +
performed O -
, O +
followed O +
by O +
a O +
multiple O +
structural O +
alignment O +
between O +
these O +
( O -
see O +
Materials O +
and O +
Methods O +
for O +
details O -
) O -
. O -

Ten O +
different O +
enzymes O +
aligned O +
with O +
DAPA O +
synthase O +
( O -
Table O +
3 O -
) O +
. O -

The O +
pairwise O +
amino O +
acid O +
identities O +
of O +
structurally O +
aligned O +
elements O +
are O +
presented O +
in O +
Table O +
4 O +
. O -

Furthermore O -
, O +
the O +
relationships O +
based O +
on O +
the O +
structural O +
similarities O +
between O +
these O +
enzymes O +
are O +
presented O +
in O +
Figure O +
10 O -
( O -
a O -
) O -
( O -
see O +
Materials O +
and O +
Methods O +
for O +
details O -
) O -
. O -

Although O +
the O +
enzymes O +
in O +
the O +
fold O +
type O +
I O +
class O +
of O +
the O +
vitamin O +
B6 O -
enzyme O +
superfamily O +
share O +
the O +
same O +
overall O +
fold O -
, O +
only O +
five O +
elements O +
of O +
secondary O +
structure O +
could O +
be O +
structurally O +
aligned O +
between O +
all O +
of O +
them O -
. O -

These O +
elements O +
correspond O +
to O +
strands O +
β4 O -
, O +
β6 O -
, O +
β7 O -
, O +
β8 O +
and O +
β9 O -
, O +
as O +
defined O +
for O +
DAPA O +
synthase O +
Figure O +
10 O -
( O -
b O -
) O +
. O -

A O +
slight O +
difference O +
in O +
the O +
twist O +
of O +
the O +
sheet O +
in O +
the O +
different O +
enzymes O +
prevents O +
alignment O +
of O +
the O +
two O +
outmost O +
strands O +
of O +
the O +
sheet O -
, O +
even O +
though O +
they O +
are O +
present O +
in O +
all O +
structures O -
. O -

Genuinely O +
different O +
areas O +
are O +
loops O +
involved O +
in O +
substrate O +
binding O +
and O +
subunit O -
- O -
subunit O +
interactions O -
. O -

According O +
to O +
the O +
multiple O +
structural O +
alignment O +
these O +
11 O +
enzymes O +
can O +
be O +
divided O +
into O +
six O +
different O +
subclasses O +
( O -
Figure O +
10 O -
( O -
a O -
) O -
and O +
Table O +
3 O +
) O -
. O -

The O +
largest O +
subclass O +
includes O +
DAPA O +
synthase O -
, O +
2,2-dialkylglycine O +
decarboxylase O -
, O +
glutamate O +
semialdehyde O +
aminomutase O +
and O +
human U-Species +
ornithine O +
aminotransferase O -
, O +
and O +
corresponds O +
to O +
aminotransferases O +
subclass O +
III O +
in O +
Grishin O -
's O +
classification O +
( O -
Grishin O +
et O +
al O +
. O -
, O +
1995 O -
) O +
. O -

Aromatic O +
amino O +
acid O +
aminotransferase O +
and O +
aspartate O +
aminotransferase O +
make O +
up O +
the O +
members O +
of O +
aminotransferases O +
subclass O +
I O -
, O +
and O +
phosphoserine O +
aminotransferase O +
is O +
the O +
only O +
representative O +
of O +
the O +
aminotransferase O +
subclass O +
V. O +
There O +
are O +
no O +
coordinates O +
released O +
in O +
the O +
PDB O +
database O +
for O +
enzymes O +
that O +
might O +
belong O +
to O +
aminotransferase O +
subclass O +
II O +
as O +
defined O +
by O +
Grishin O +
et O +
al O +
. O -

( O -
1995 O -
) O +
. O -

A O +
structure O -
- O -
based O +
classification O +
of O +
the O +
fold O +
type O +
I O +
enzymes O +
outside O +
the O +
aminotransferase O +
subclasses O +
had O +
not O +
been O +
addressed O +
earlier O -
. O -

In O +
our O +
comparison O -
, O +
tyrosine O +
phenol O -
- O -
lyase O +
and O +
tryptophan O +
indole O -
- O -
lyase O +
form O +
a O +
distinct O +
class O +
( O -
the O +
tyrosine O +
phenol O -
- O -
lyase O +
subclass O -
) O -
. O -

Cystathionine O +
β O -
- O -
lyase O +
shows O +
sequence O +
identities O +
in O +
the O +
range O +
of O +
26 O +
% O +
to O +
32 O +
% O +
to O +
metathione O +
γ O -
- O -
lyase O -
, O +
cystathionine O +
γ O -
- O -
lyase O -
, O +
O O +
-acetyl O -
- O -
l O +
-homoserine O +
sulfhydrylase O -
, O +
O O +
-succinylhomoserine O +
sulphfhydrylase O -
, O +
and O +
cystathionine O +
γ O -
- O -
synthase O -
, O +
indicating O +
that O +
they O +
belong O +
to O +
the O +
same O +
structural O +
subclass O +
( O -
the O +
cystathionine O +
β O -
- O -
lyase O +
subclass O -
) O -
. O -

The O +
larger O +
prokaryotic U-Species +
ornithine O +
decarboxylase O +
is O +
the O +
sole O +
representative O +
of O +
its O +
subclass O +
so O +
far O -
. O -

There O +
is O +
a O +
striking O +
correlation O +
between O +
the O +
structure O +
of O +
the O +
N O -
- O -
terminal O +
part O +
of O +
the O +
polypeptide O +
chain O +
and O +
the O +
subclass O +
definition O +
obtained O +
from O +
the O +
multiple O +
structure O +
alignment O +
within O +
this O +
family O -
. O -

The O +
structure O +
of O +
this O +
chain O +
segment O +
is O +
rather O +
different O +
between O +
the O +
subclasses O -
, O +
but O +
similar O +
within O +
a O +
given O +
subclass O +
( O -
Figure O +
11 O -
) O +
. O -

For O +
instance O -
, O +
the O +
N O -
- O -
terminal O +
β O -
- O -
meander O +
followed O +
by O +
a O +
helix O +
as O +
described O +
for O +
DAPA O +
synthase O +
holds O +
for O +
all O +
enzymes O +
in O +
subclass O +
III O +
( O -
Figure O +
11 O -
( O -
a O -
) O -
) O +
. O -

In O +
the O +
tyrosine O +
phenol O -
- O -
lyase O +
subclass O +
a O +
helix O +
folds O +
over O +
the O +
hinge O +
region O +
and O +
covers O +
one O +
end O +
of O +
the O +
C O -
- O -
terminal O +
β O -
- O -
sheet O -
. O -

This O +
leaves O +
the O +
entrance O +
to O +
the O +
active O +
site O +
more O +
open O +
than O +
in O +
the O +
subclass O +
III O +
enzymes O -
. O -

An O +
N O -
- O -
terminal O +
arm O +
extends O +
outside O +
the O +
catalytic O +
dimer O +
and O +
is O +
involved O +
in O +
a O +
four O -
- O -
stranded O +
( O -
-sheet O +
built O +
up O +
by O +
two O +
strands O +
from O +
each O +
subunit O +
mediating O +
tetramer O +
formation O +
( O -
Antson O +
et O +
al O +
. O -
, O +
1993 O -
) O +
( O -
Figure O +
11 O -
( O -
b O -
) O -
) O +
. O -

In O +
cystathionine O -
- O -
β O -
- O -
lyase O +
( O -
Figure O +
11 O -
( O -
c O -
) O -
) O -
the O +
N O -
- O -
terminus O +
protrudes O +
out O +
from O +
the O +
monomer O +
into O +
the O +
active O +
site O +
of O +
the O +
other O +
monomer O +
in O +
the O +
catalytic O +
dimer O +
and O +
then O +
turns O +
back O +
and O +
folds O +
into O +
an O +
α O -
- O -
helix O +
which O +
packs O +
against O +
the O +
outside O +
of O +
the O +
hinge O +
between O +
the O +
domains O +
in O +
its O +
original O +
subunit O -
. O -

Some O +
of O +
the O +
residues O +
in O +
the O +
N O -
- O -
terminal O +
segment O +
are O +
also O +
involved O +
in O +
tetramer O +
formation O -
. O -

In O +
the O +
aspartate O +
aminotransferase O +
and O +
aromatic O +
amino O +
acid O +
aminotransferase O +
the O +
N O +
terminus O +
starts O +
on O +
the O +
surface O +
of O +
the O +
second O +
subunit O +
and O +
then O +
crosses O +
over O +
the O +
active O +
site O +
cleft O +
before O +
joining O +
the O +
small O +
domain O -
. O -

The O +
N O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
forms O +
an O +
α O -
- O -
helix O +
which O +
lines O +
the O +
active O +
site O +
entrance O +
and O +
contributes O +
with O +
a O +
β O -
- O -
strand O +
interaction O +
to O +
the O +
C O -
- O -
terminal O +
β O -
- O -
sheet O +
( O -
Figure O +
11 O -
( O -
d O -
) O -
) O +
. O -

Ornithine O +
decarboxylase O +
is O +
a O +
larger O +
PLP O -
- O -
dependent O +
enzyme O +
of O +
which O +
only O +
parts O -
, O +
domain O +
three O +
and O +
domain O +
four O -
, O +
correspond O +
to O +
the O +
fold O +
type O +
I O +
enzymes O -
. O -

The O +
small O +
domain O +
is O +
built O +
up O +
solely O +
by O +
domain O +
four O -
, O +
corresponding O +
to O +
the O +
C O -
- O -
terminal O +
part O +
of O +
the O +
small O +
domain O +
in O +
the O +
smaller O +
fold O +
type O +
I O +
enzymes O -
. O -

The O +
N O -
- O -
terminal O +
domains O +
consist O +
of O +
one O +
independently O +
folded O +
domain O +
followed O +
by O +
a O +
long O +
linker O +
connecting O +
it O +
to O +
the O +
PLP O +
binding O +
domain O +
three O +
( O -
Figure O +
11 O -
( O -
f O -
) O -
) O +
. O -

Finally O -
, O +
the O +
subclass O +
V O +
enzymes O +
seem O +
to O +
lack O +
the O +
N O -
- O -
terminal O +
domain O +
completely O -
. O -

The O +
polypeptide O +
chain O +
starts O +
at O +
the O +
domain O +
linker O +
region O +
and O +
enters O +
the O +
large O +
domain O +
directly O +
( O -
Figure O +
11 O -
( O -
e O -
) O -
) O +
. O -

The O +
active O +
site O -
: O +
similarities O +
and O +
differences O +
in O +
the O +
fold O +
type O +
I O +
enzymes O +
The O +
active O +
site O +
and O +
in O +
particular O +
the O +
pyridine O +
ring O +
of O +
the O +
PLP O +
cofactor O +
of O +
the O +
fold O +
type O +
I O +
enzymes O +
of O +
known O +
3-D O +
structure O +
superpose O +
very O +
well O +
( O -
Figure O +
12 O -
) O +
. O -

The O +
maximum O +
distance O +
from O +
the O +
Schiff O -
- O -
base O +
nitrogen O +
atom O +
in O +
DAPA O +
synthase O +
to O +
the O +
corresponding O +
atom O +
of O +
related O +
enzymes O +
is O +
1.4 O +
Å O +
( O -
ornithine O +
decarboxylase O +
and O +
phosphoserine O +
amino O +
transferase O -
) O -
, O +
and O +
that O +
for O +
the O +
pyridine O +
nitrogen O +
is O +
1.4 O +
Å O +
( O -
phosphoserine O +
amino O +
transferase O -
) O -
. O -

The O +
residues O +
participating O +
in O +
binding O +
of O +
the O +
cofactor O +
are O +
presented O +
in O +
Table O +
5 O +
. O -

It O +
is O +
notable O +
that O -
, O +
despite O +
the O +
similar O +
position O +
of O +
the O +
cofactor O +
in O +
the O +
active O +
site O +
( O -
Figure O +
12 O -
) O +
, O +
the O +
loop O +
between O +
strands O +
β9 O +
and O +
β10 O +
carrying O +
the O +
active O +
site O +
lysine O +
residue O +
is O +
not O +
structurally O +
conserved O -
. O -

In O +
all O +
aminotransferase O +
subclass O +
III O +
enzymes O +
this O +
loop O +
is O +
shorter O -
, O +
with O +
the O +
consequence O +
that O +
the O +
lysine O +
residue O +
is O +
positioned O +
out O +
of O +
register O +
with O +
the O +
corresponding O +
lysine O +
in O +
the O +
enzymes O +
belonging O +
to O +
the O +
other O +
subclasses O +
( O -
Figure O +
12 O -
) O +
. O -

This O +
suggests O +
a O +
deletion O +
of O +
one O +
amino O +
acid O +
in O +
the O +
ancestral O +
subclass O +
III O +
aminotransferase O -
. O -

The O +
Nϵ O -
atom O +
of O +
the O +
lysine O +
side O -
- O -
chain O -
, O +
however O -
, O +
is O +
found O +
at O +
approximately O +
the O +
same O +
position O -
. O -

The O +
aspartic O +
acid O +
residue O +
which O +
corresponds O +
to O +
Asp245 O +
in O +
DAPA O +
synthase O +
is O +
the O +
only O +
structurally O +
conserved O +
residue O +
in O +
this O +
enzyme O +
family O -
. O -

This O +
amino O +
acid O +
forms O +
a O +
salt O +
bridge O -
/ O -
hydrogen O +
bond O +
with O +
the O +
pyridine O +
nitrogen O +
and O +
was O +
proposed O +
to O +
provide O +
one O +
of O +
the O +
key O +
interactions O +
for O +
the O +
regulation O +
of O +
the O +
pK O +
a O -
of O +
the O +
aldimine O +
nitrogen O +
( O -
Hayashi O -
, O +
1995 O -
; O +
John O -
, O +
1995 O -
) O +
. O -

Stabilisation O +
of O +
this O +
interaction O +
is O +
provided O +
by O +
a O +
non O -
- O -
conserved O +
pattern O +
of O +
hydrogen O +
bonds O +
to O +
surrounding O +
residues O -
, O +
except O +
in O +
the O +
case O +
of O +
ornithine O +
decarboxylase O +
and O +
tryptophanase O +
in O +
which O +
the O +
aspartic O +
acid O +
only O +
interacts O +
with O +
the O +
pyridine O +
nitrogen O +
of O +
PLP O -
. O -

In O +
DAPA O +
synthase O -
, O +
glutamate O +
semialdehyde O +
aminomutase O +
and O +
dialkylglycine O +
decarboxylase O +
a O +
histidine O +
residue O +
forms O +
a O +
hydrogen O +
bond O +
to O +
one O +
of O +
the O +
carboxyl O +
oxygen O +
atoms O +
of O +
the O +
aspartic O +
acid O -
. O -

Similar O +
interactions O +
are O +
provided O +
by O +
a O +
histidine O +
from O +
a O +
different O +
loop O +
in O +
the O +
aspartate O +
and O +
aromatic O +
amino O +
acid O +
aminotransferases O -
. O -

In O +
the O +
subclass O +
III O +
and O +
V O +
enzymes O -
, O +
the O +
main O -
- O -
chain O +
amide O +
of O +
the O +
second O +
residue O +
following O +
the O +
aspartic O +
acid O +
is O +
within O +
hydrogen O +
bonding O +
distance O +
( O -
< O -
3.3 O +
Å O -
) O +
to O +
the O +
carboxyl O +
group O +
of O +
this O +
aspartic O +
acid O +
whereas O +
in O +
cystathionine O +
β O -
- O -
lyase O -
, O +
phosphoserine O +
aminotransferase O +
and O +
tyrosine O +
phenol O -
- O -
lyase O +
the O +
side O -
- O -
chain O +
of O +
this O +
residue O +
( O -
Thr O -
/ O -
Ser O -
) O +
provides O +
an O +
interaction O +
with O +
the O +
same O +
group O -
. O -

In O +
all O +
enzymes O +
except O +
DAPA O +
synthase O -
, O +
the O +
protein O +
provides O +
a O +
hydrogen O +
bond O +
partner O +
to O +
the O +
phenolic O +
oxygen O -
, O +
O-3′ O -
, O +
of O +
the O +
pyridine O +
ring O -
. O -

The O +
nature O +
and O +
strength O +
of O +
this O +
interaction O +
might O +
influence O +
the O +
pK O +
a O -
of O +
the O +
resulting O +
Schiff O +
base O +
of O +
the O +
cofactor O +
with O +
the O +
catalytic O +
lysine O +
residue O +
( O -
Goldberg O +
et O +
al O +
. O -
, O +
1991 O -
; O +
Inoue O +
et O +
al O +
. O -
, O +
1991 O -
) O +
. O -

As O +
described O -
, O +
a O +
water O -
- O -
mediated O +
interaction O +
with O +
a O +
glutamic O +
acid O +
residue O +
replaces O +
this O +
interaction O +
in O +
DAPA O +
synthase O -
. O -

A O +
structural O +
feature O +
distinguishing O +
the O +
subclass O +
III O +
aminotransferases O +
from O +
other O +
fold O +
type O +
I O +
PLP O +
enzymes O +
is O +
the O +
stacking O +
interactions O +
with O +
the O +
re O -
face O +
of O +
the O +
pyridine O +
ring O +
of O +
PLP O -
. O -

All O +
enzymes O +
of O +
known O +
structure O +
have O +
aromatic O +
residues O +
in O +
this O +
position O -
, O +
corresponding O +
to O +
Tyr144 O +
in O +
DAPA O +
synthase O -
. O -

However O -
, O +
in O +
the O +
subclass O +
III O +
aminotransferases O +
the O +
aromatic O +
residue O +
packs O +
nearly O +
perpendicular O +
to O +
the O +
pyridine O +
ring O +
of O +
the O +
cofactor O -
, O +
while O +
in O +
the O +
other O +
fold O +
type O +
I O +
enzymes O +
the O +
stacking O +
is O +
close O +
to O +
parallel O -
. O -

It O +
has O +
been O +
proposed O +
for O +
aspartate O +
aminotransferase O +
that O +
the O +
parallel O +
stacking O -
, O +
which O +
is O +
optimised O +
from O +
nearly O +
parallel O +
to O +
parallel O +
in O +
the O +
external O +
aldimine O +
complex O -
, O +
increases O +
the O +
electron O +
withdrawing O +
effect O +
of O +
the O +
cofactor O +
and O +
favours O +
the O +
formation O +
of O +
the O +
quinonoid O +
intermediate O +
( O -
Ford O +
et O +
al O +
. O -
, O +
1980 O -
; O +
Hayashi O +
et O +
al O +
. O -
, O +
1990 O -
) O +
. O -

In O +
the O +
aminotransferase O +
subclass O +
III O +
enzymes O -
, O +
the O +
stacking O +
residue O +
is O +
part O +
of O +
the O +
loop O +
between O +
strands O +
β5 O +
and O +
β6 O -
, O +
which O +
narrows O +
the O +
active O +
site O +
entrance O -
. O -

With O +
this O +
conformation O +
of O +
the O +
polypeptide O +
backbone O -
, O +
the O +
aromatic O +
residue O +
would O +
clash O +
with O +
the O +
main O +
chain O +
if O +
it O +
packed O +
parallel O +
to O +
the O +
ring O -
. O -

In O +
the O +
other O +
fold O +
type O +
I O +
enzymes O +
the O +
loop O +
is O +
replaced O +
by O +
a O +
short O +
helix O +
beginning O +
immediately O +
after O +
the O +
aromatic O +
residue O -
. O -

This O +
difference O +
in O +
backbone O +
conformation O +
enables O +
a O +
parallel O +
stacking O +
to O +
the O +
pyridine O +
ring O +
of O +
the O +
cofactor O +
and O +
leaves O +
the O +
active O +
site O +
much O +
more O +
open O -
. O -

In O +
tryptophanase O -
, O +
cystathionine O +
β O -
- O -
lyase O +
and O +
tyrosine O +
phenol O -
- O -
lyase O +
the O +
active O +
site O +
entrance O +
is O +
instead O +
restricted O +
by O +
a O +
loop O +
protruding O +
from O +
the O +
β O -
- O -
sheet O +
in O +
the O +
small O +
domain O +
whereas O +
the O +
other O +
enzymes O +
simply O +
have O +
a O +
wider O +
active O +
site O +
entrance O -
. O -

Human U-Species +
ornithine O +
decarboxylase O +
is O +
an O +
exception O -
, O +
having O +
an O +
extra O +
C O -
- O -
terminal O +
domain O +
packing O +
against O +
the O +
active O +
site O +
cleft O -
. O -

There O +
are O +
two O +
distinct O +
positions O +
of O +
the O +
phosphate O +
group O +
of O +
PLP O -
; O +
one O +
for O +
the O +
subclass O +
I O +
aminotransferases O +
and O +
one O +
for O +
all O +
the O +
others O +
fold O +
type O +
I O +
PLP O +
enzymes O +
( O -
Figure O +
12 O -
) O +
. O -

This O +
is O +
caused O +
by O +
interactions O +
of O +
phosphate O +
oxygen O +
atoms O +
with O +
an O +
arginine O +
residue O +
( O -
Arg266 O +
in O +
aspartate O +
aminotransferase O -
) O +
which O +
result O +
in O +
a O +
different O +
tilt O +
of O +
the O +
cofactor O +
in O +
aspartate O +
and O +
aromatic O +
amino O +
acid O +
aminotransferases O +
in O +
relation O +
to O +
the O +
other O +
fold O +
type O +
I O +
enzymes O -
. O -

Substrate O +
recognition O +
In O +
order O +
to O +
locate O +
the O +
active O +
site O +
in O +
DAPA O +
synthase O -
, O +
the O +
crystal O +
structure O +
of O +
a O +
ternary O +
complex O +
of O +
the O +
enzyme O +
with O +
PLP O +
and O +
KAPA O +
was O +
determined O +
( O -
Figure O +
7 O -
) O +
. O -

This O +
complex O +
is O +
unproductive O -
, O +
since O +
it O +
combines O +
the O +
PLP O +
form O +
of O +
the O +
cofactor O +
with O +
the O +
amino O +
group O +
acceptor O +
KAPA O -
, O +
which O +
in O +
the O +
catalytic O +
reaction O +
reacts O +
with O +
the O +
pyridoxamine O +
form O +
of O +
the O +
enzyme O -
. O -

Since O +
KAPA O +
is O +
an O +
amino O +
acid O -
, O +
the O +
question O +
arises O +
as O +
to O +
why O +
it O +
does O +
not O +
act O +
as O +
amino O +
donor O +
in O +
the O +
reaction O -
, O +
i.e. O +
react O +
with O +
the O +
PLP O +
form O +
of O +
the O +
enzyme O -
. O -

The O +
structure O +
of O +
the O +
ternary O +
complex O +
provides O +
an O +
immediate O +
answer O -
. O -

In O +
order O +
to O +
react O +
with O +
the O +
C-4′ O +
carbon O +
atom O +
of O +
the O +
cofactor O +
to O +
form O +
the O +
internal O +
aldimine O -
, O +
the O +
N8 O +
amino O +
group O +
of O +
KAPA O +
must O +
bind O +
very O +
closely O +
to O +
this O +
part O +
of O +
the O +
cofactor O +
in O +
an O +
orientation O +
favourable O +
for O +
the O +
reaction O +
to O +
occur O -
. O -

In O +
the O +
complex O -
, O +
the O +
N8 O +
amino O +
group O +
is O +
bound O +
tightly O +
to O +
protein O +
main O -
- O -
chain O +
and O +
side O -
- O -
chain O +
atoms O +
in O +
such O +
a O +
manner O +
that O +
it O +
points O +
away O +
from O +
the O +
internal O +
aldimine O +
group O -
, O +
thus O +
preventing O +
transamination O +
( O -
Figure O +
7 O -
) O +
. O -

The O +
observed O +
binding O +
of O +
KAPA O +
does O +
however O +
position O +
the O +
seven O -
- O -
carbon O +
atom O +
of O +
KAPA O +
close O +
to O +
the O +
aldimine O +
and O +
thereby O +
facilitates O +
transfer O +
of O +
an O +
amino O +
group O +
to O +
this O +
carbon O +
atom O -
, O +
which O +
would O +
yield O +
the O +
product O -
, O +
7,8-diaminopelargonic O +
acid O -
. O -

An O +
important O +
conclusion O +
to O +
be O +
drawn O +
from O +
the O +
structure O +
of O +
the O +
ternary O +
complex O +
is O +
that O +
in O +
DAPA O +
synthase O -
, O +
as O +
opposed O +
to O +
other O +
enzymes O +
of O +
this O +
class O +
of O +
vitamin O +
B6 O +
-dependent O +
enzymes O -
, O +
no O +
domain O -
- O -
domain O +
rotation O +
occurs O +
upon O +
substrate O +
binding O -
. O -

The O +
absence O +
of O +
such O +
large O -
- O -
scale O +
conformational O +
changes O +
is O +
not O +
unique O +
for O +
DAPA O +
synthase O +
but O +
has O +
also O +
been O +
shown O +
for O +
another O +
enzyme O +
in O +
this O +
family O -
, O +
human U-Species +
ornithine O +
aminotransferase O +
( O -
Shah O +
et O +
al O +
. O -
, O +
1997 O -
) O +
. O -

The O +
substrate O +
reacting O +
with O +
the O +
PLP O +
form O +
of O +
the O +
enzyme O +
is O +
SAM O +
and O +
the O +
active O +
site O -
, O +
as O +
seen O +
in O +
the O +
holoenzyme O +
should O +
therefore O +
be O +
poised O +
to O +
bind O +
SAM O -
. O -

The O +
outer O +
part O +
of O +
the O +
active O +
site O +
pocket O +
is O +
quite O +
open O +
and O +
there O +
are O +
several O +
areas O +
which O +
could O +
provide O +
hydrophobic O +
interactions O +
with O +
the O +
adenine O +
ring O +
and O +
still O +
leave O +
space O +
for O +
the O +
sugar O +
moiety O -
. O -

Therefore O -
, O +
modelling O +
the O +
binding O +
site O +
of O +
SAM O +
in O +
DAPA O +
synthase O +
is O +
highly O +
speculative O +
and O +
a O +
reliable O +
model O +
for O +
the O +
enzyme O -
- O -
PLP O -
- O -
SAM O +
complex O +
will O +
have O +
to O +
await O +
a O +
crystal O +
structure O +
determination O -
. O -

A O +
more O +
detailed O +
discussion O +
of O +
the O +
reaction O +
mechanism O +
of O +
DAPA O +
synthase O +
will O +
require O +
structural O +
information O +
from O +
this O +
and O +
other O +
complexes O +
along O +
the O +
reaction O +
pathway O -
, O +
in O +
combination O +
with O +
the O +
results O +
from O +
site O -
- O -
directed O +
mutagenesis O +
experiments O -
. O -

Materials O +
and O +
methods O +
Crystallisation O +
DAPA O +
synthase O +
was O +
expressed O -
, O +
purified O +
and O +
crystallised O +
as O +
described O +
( O -
Käck O +
et O +
al O +
. O -
, O +
1998 O -
) O +
, O +
with O +
one O +
modification O +
in O +
the O +
crystallisation O +
protocol O -
. O -

After O +
one O +
week O +
of O +
equilibration O -
, O +
micro O -
- O -
seeding O +
was O +
employed O +
to O +
increase O +
the O +
reproducibility O +
of O +
crystal O +
formation O -
. O -

At O +
the O +
same O +
time O -
, O +
20–40 O +
μl O +
of O +
4 O +
M O +
sodium O +
chloride O +
was O +
added O +
to O +
the O +
well O +
solution O -
. O -

Crystals O +
of O +
the O +
ternary O +
complex O +
DAPA O +
synthase O -
- O -
PLP O -
- O -
KAPA O +
were O +
prepared O +
by O +
soaking O +
crystals O +
of O +
the O +
holoenzyme O +
overnight O +
in O +
5 O +
mM O +
KAPA O -
, O +
25 O +
% O +
PEG-4000 O -
, O +
20 O +
% O +
MPD O -
, O +
100 O +
mM O +
Hepes O +
( O -
pH O +
7.5 O -
) O -
. O -

The O +
substrate O +
KAPA O +
was O +
synthesised O +
as O +
described O +
( O -
Nudelman O +
et O +
al O +
. O -
, O +
1998 O -
) O +
. O -

Data O +
collection O -
, O +
phasing O +
and O +
model O +
building O +
The O +
cell O +
dimensions O +
differed O +
slightly O +
between O +
crystals O -
, O +
reflecting O +
non O -
- O -
isomorphism O +
between O +
crystals O -
. O -

A O +
large O +
number O +
of O +
different O +
heavy O +
atoms O +
were O +
screened O +
in O +
order O +
to O +
find O +
a O +
useful O +
derivative O -
. O -

Finally O -
, O +
crystals O +
soaked O +
for O +
24 O +
hours O +
at O +
4 O -
° O -
C O +
in O +
25 O +
% O +
polyethylene O +
glycol O +
4000 O -
, O +
22 O +
% O +
2-methyl-2,4 O +
pentanediol O +
and O +
5 O +
mM O +
ethyl O +
mercury O +
thiosalicylate O +
( O -
EMTS O -
) O +
or O +
K2 O +
Pt O -
( O -
NO2 O +
) O -
4 O -
at O +
pH O +
7.5 O +
were O +
isomorphous O +
enough O +
to O +
allow O +
identification O +
of O +
the O +
heavy O -
- O -
atom O +
sites O -
. O -

However O -
, O +
neither O +
the O +
multiple O +
isomorphous O +
replacement O +
electron O +
density O +
map O +
nor O +
the O +
2-fold O +
averaged O +
electron O +
density O +
map O +
was O +
interpretable O -
. O -

Multiple O +
anomalous O +
difference O +
data O +
were O +
therefore O +
collected O +
on O +
a O +
EMTS O -
- O -
soaked O +
crystal O +
with O +
cell O +
dimensions O +
a O +
= O -
58.50 O +
Å O -
, O +
b O +
= O -
56.63 O +
Å O -
, O +
c O +
= O -
121.7 O +
Å O +
and O +
β=96.14 O -
° O -
, O +
space O +
group O +
P O +
21 O +
, O +
at O +
beamline O +
BM O +
14 O +
at O +
the O +
ESRF O +
in O +
Grenoble O -
. O -

Data O +
were O +
collected O +
at O +
three O +
different O +
wavelengths O -
, O +
λ1 O +
( O -
peak O -
) O -
=0.9918 O +
Å O -
, O +
λ2 O +
( O -
inflection O +
point O -
) O -
=1.007 O +
Å O +
and O +
λ3 O +
( O -
high O +
energy O +
remote O -
) O -
=0.8265 O +
Å O +
at O +
100 O +
K O +
to O +
2.0 O +
Å O +
resolution O -
. O -

Data O +
processing O +
and O +
scaling O +
were O +
performed O +
with O +
the O +
programs O +
Denzo O +
and O +
Scalepack O +
( O -
Otwinowski O -
, O +
1993 O -
) O +
. O -

Eight O +
mercury O +
sites O +
were O +
identified O +
by O +
visual O +
inspection O +
of O +
the O +
difference O +
Patterson O +
maps O +
and O +
using O +
difference O +
Fourier O +
methods O +
( O -
for O +
phasing O +
statistics O +
see O +
Table O +
1 O +
) O -
. O -

The O +
five O +
strongest O +
peaks O +
coincided O +
with O +
the O +
binding O +
sites O +
determined O +
earlier O -
, O +
while O +
three O +
minor O +
sites O +
differed O +
in O +
their O +
positions O -
, O +
compared O +
to O +
those O +
previously O +
derived O -
. O -

A O +
map O +
calculated O +
after O +
refinement O +
of O +
the O +
parameters O +
of O +
the O +
mercury O +
positions O +
using O +
mlphare O +
( O -
Otwinowski O -
, O +
1991 O -
) O -
and O +
solvent O +
flattening O +
by O +
DM O +
( O -
Cowtan O +
& O +
Main O -
, O +
1996 O -
) O -
was O +
of O +
excellent O +
quality O -
, O +
and O +
backbone O +
tracing O +
and O +
sequence O +
assignment O +
( O -
Otsuka O +
et O +
al O +
. O -
, O +
1988 O -
) O -
were O +
straighforward O +
for O +
the O +
whole O +
protein O +
except O +
for O +
two O +
mobile O +
regions O +
containing O +
residues O +
160 O +
to O +
183 O +
and O +
298 O +
to O +
304 O -
, O +
respectively O -
; O +
2-fold O +
averaging O +
did O +
not O +
improve O +
the O +
map O +
significantly O -
. O -

The O +
model O +
was O +
refined O +
using O +
XPLOR O +
( O -
Brünger O +
et O +
al O +
. O -
, O +
1987 O -
) O -
with O +
NCS O +
constraints O +
to O +
R O +
free O +
= O -
35.9 O +
% O +
and O +
R O +
= O -
30.4 O +
% O +
without O +
including O +
mercury O +
atoms O -
. O -

A O +
native O +
data O +
set O +
was O +
collected O +
using O +
a O +
300 O +
mm O +
MAR O +
image O +
plate O +
detector O +
( O -
MAR O +
research O +
Hamburg O -
) O +
at O +
beam O +
line O +
X11 O +
at O +
EMBL O +
in O +
Hamburg O +
to O +
1.8 O +
Å O +
resolution O +
( O -
for O +
data O +
collection O +
statistics O +
see O +
Table O +
1 O +
) O -
. O -

The O +
cell O -
- O -
dimensions O +
of O +
this O +
crystal O +
were O +
a O +
= O -
58.3 O +
Å O -
, O +
b O +
= O -
55.6 O +
Å O -
, O +
c O +
= O -
120.9 O +
Å O +
and O +
β=97.0 O -
° O -
, O +
space O +
group O +
P O +
21 O +
. O -

Diffraction O +
data O +
for O +
the O +
ternary O +
complex O +
DAPA O +
synthase O -
- O -
PLP O -
- O -
KAPA O +
were O +
collected O +
at O +
100 O +
K O +
to O +
2.7 O +
Å O +
on O +
a O +
Mar O +
Research O +
image O +
plate O +
mounted O +
on O +
a O +
Rikagu O +
rotating O +
anode O +
operating O +
at O +
50 O +
kV O +
and O +
90 O +
mA. O +
Data O +
were O +
processed O +
and O +
scaled O +
using O +
Denzo O +
and O +
Scalepack O +
software O +
package O +
( O -
Otwinowski O -
, O +
1993 O -
) O +
. O -

Data O +
collection O +
statistics O +
are O +
given O +
in O +
Table O +
1 O +
. O -

The O +
cell O -
- O -
dimensions O +
of O +
this O +
crystal O +
were O +
a O +
= O -
58.0 O +
Å O -
, O +
b O +
= O -
55.9 O +
Å O -
, O +
c O +
= O -
120.8 O +
Å O +
and O +
β=95.7 O -
° O -
. O -

Refinement O +
Because O +
of O +
non O -
- O -
isomorphism O +
between O +
the O +
crystals O -
, O +
molecular O +
replacement O +
had O +
to O +
be O +
used O +
in O +
order O +
to O +
find O +
the O +
position O +
of O +
the O +
native O +
enzyme O +
in O +
the O +
unit O +
cell O -
. O -

The O +
program O +
AMORE O +
( O -
Navaza O -
, O +
1994 O -
) O -
was O +
used O +
for O +
this O +
task O +
with O +
the O +
dimer O +
as O +
the O +
search O +
molecule O -
. O -

Before O +
refinement O -
, O +
the O +
same O +
set O +
of O +
reflections O +
( O -
in O +
total O +
5 O +
% O +
of O +
the O +
reflection O +
data O -
) O +
were O +
set O +
aside O +
to O +
monitor O +
R O +
free O +
. O -

The O +
top O +
solution O +
( O -
correlation O +
coefficient=76.7 O +
% O -
) O +
gave O +
an O +
R O +
free O -
of O +
37.5 O +
% O +
after O +
an O +
initial O +
rigid O +
body O +
refinement O +
to O +
2.5 O +
Å O +
resolution O +
using O +
the O +
program O +
XPLOR O +
( O -
Brünger O +
et O +
al O +
. O -
, O +
1987 O -
) O +
. O -

A O +
clear O +
and O +
strong O +
difference O +
density O +
was O +
found O +
at O +
the O +
position O +
of O +
the O +
cofactor O -
, O +
PLP O -
, O +
which O +
had O +
not O +
been O +
included O +
in O +
the O +
model O -
, O +
confirming O +
that O +
this O +
was O +
the O +
correct O +
solution O -
. O -

After O +
rigid O +
body O +
refinement O +
the O +
structure O +
was O +
rebuilt O +
using O +
the O +
program O +
O O +
( O -
Jones O +
et O +
al O +
. O -
, O +
1991 O -
) O -
and O +
refined O +
using O +
the O +
maximum O +
likelihood O +
method O +
as O +
implemented O +
in O +
Refmac O +
( O -
Murshudov O +
et O +
al O +
. O -
, O +
1997 O -
) O -
with O +
strong O +
NCS O +
restraints O +
giving O +
R O +
= O -
35.4 O +
% O +
and O +
R O +
free O +
= O -
36.4 O +
% O +
after O +
the O +
first O +
round O +
of O +
refinement O -
. O -

On O +
the O +
basis O +
of O +
a O +
sigma O -
- O -
weighted O +
electron O +
density O +
map O +
calculated O +
subsequently O -
, O +
residues O +
162 O -
- O -
180 O +
and O +
residues O +
298 O -
- O -
303 O +
missing O +
from O +
the O +
previous O +
model O +
could O +
be O +
modelled O -
. O -

After O +
the O +
second O +
round O +
of O +
refinement O +
PLP O +
was O +
included O +
in O +
the O +
model O -
. O -

In O +
subsequent O +
refinement O +
runs O +
the O +
loop O +
region O +
between O +
residue O +
181 O +
and O +
191 O +
was O +
built O -
. O -

In O +
one O +
of O +
the O +
subunits O +
residue O +
183 O +
is O +
still O +
not O +
included O +
in O +
the O +
final O +
model O -
. O -

Eighty O +
water O +
molecules O +
were O +
included O +
after O +
each O +
refinement O +
cycle O +
using O +
the O +
program O +
arp O +
( O -
Lamzin O +
& O +
Wilson O -
, O +
1993 O -
) O +
, O +
resulting O +
in O +
a O +
final O +
number O +
of O +
556 O +
water O +
molecules O +
of O +
which O +
about O +
two O +
thirds O +
follow O +
the O +
NCS O -
. O -

All O +
solvent O +
sites O +
were O +
inspected O +
manually O -
. O -

Non O -
- O -
crystallographic O +
restraints O +
were O +
used O +
until O +
the O +
last O +
stages O +
of O +
the O +
refinement O -
, O +
their O +
release O +
resulted O +
in O +
a O +
slight O +
drop O +
of O +
the O +
free O +
R O -
value O -
. O -

The O +
quality O +
of O +
the O +
final O +
model O +
was O +
assessed O +
with O +
PROCHECK O +
( O -
Laskowski O +
et O +
al O +
. O -
, O +
1993 O -
) O +
. O -

The O +
structure O +
of O +
the O +
ternary O +
complex O +
was O +
determined O +
to O +
2.7 O +
Å O +
by O +
difference O +
Fourier O +
methods O -
. O -

Initial O +
phases O +
were O +
calculated O +
from O +
the O +
refined O +
model O +
of O +
the O +
holoenzyme O -
, O +
with O +
the O +
water O +
molecules O +
and O +
the O +
sodium O +
ions O +
excluded O -
. O -

A O +
KAPA O +
molecule O +
was O +
fitted O +
into O +
the O +
difference O +
electron O +
density O +
found O +
in O +
the O +
active O +
site O +
close O +
to O +
the O +
PLP O +
cofactor O -
; O +
5 O +
% O +
of O +
the O +
reflection O +
data O +
were O +
excluded O +
from O +
the O +
refinement O +
and O +
used O +
to O +
calculate O +
the O +
free O +
R O -
value O -
. O -

The O +
model O +
of O +
the O +
ternary O +
complex O +
was O +
refined O +
using O +
Refmac O +
( O -
Murshudov O +
et O +
al O +
. O -
, O +
1997 O -
) O +
, O +
starting O +
in O +
the O +
first O +
cycle O +
as O +
a O +
rigid O +
body O +
refinement O -
. O -

Cycles O +
of O +
refinement O +
were O +
followed O +
by O +
manual O +
intervention O +
using O +
the O +
graphics O +
program O +
O O +
( O -
Jones O +
et O +
al O +
. O -
, O +
1991 O -
) O +
. O -

The O +
final O +
model O +
contains O +
94 O +
water O +
molecules O +
and O +
two O +
sodium O +
ions O -
, O +
refinement O +
statistics O +
are O +
given O +
in O +
Table O +
2 O +
. O -

Structural O +
alignments O +
and O +
database O +
searches O +
The O +
program O +
TOP O +
( O -
Lu O -
, O +
1996 O -
) O -
was O +
used O +
for O +
searching O +
the O +
Protein O +
Data O +
Bank O +
with O +
the O +
large O +
domain O +
of O +
the O +
refined O +
model O +
of O +
DAPA O +
synthase O +
as O +
probe O +
and O +
for O +
subsequent O +
superpositions O -
. O -

Exclusion O +
of O +
mutant O +
structures O +
and O +
complexes O +
resulted O +
in O +
15 O +
different O +
PLP O +
enzymes O +
with O +
identical O +
topology O -
. O -

Five O +
of O +
these O +
were O +
structures O +
of O +
aspartate O +
aminotransferases O +
from O +
different O +
sources O -
. O -

As O +
these O +
enzymes O +
are O +
very O +
similar O -
, O +
only O +
one O +
of O +
these O -
, O +
the O +
E. B-Species +
coli L-Species -
enzyme O -
, O +
was O +
included O +
in O +
the O +
subsequent O +
multiple O +
structure O +
alignment O -
. O -

For O +
the O +
same O +
reason O -
, O +
only O +
one O +
of O +
the O +
two O +
structures O +
of O +
phosphoserine O +
aminotransferase O -
, O +
deposited O +
in O +
the O +
Protein O +
Data O +
Bank O +
was O +
used O +
in O +
the O +
following O +
multiple O +
structural O +
alignment O -
. O -

Generally O -
, O +
the O +
internal O +
aldimine O +
form O +
of O +
the O +
enzymes O +
was O +
used O +
in O +
this O +
comparison O -
. O -

The O +
domain O -
- O -
domain O +
orientation O +
as O +
compared O +
with O +
DAPA O +
synthase O +
varies O +
substantially O +
between O +
different O +
enzymes O -
, O +
from O +
27 O -
° O +
rotation O +
for O +
aspartate O +
aminotransferase O +
to O +
6 O -
° O +
rotation O +
for O +
ornithine O +
aminotransferase O -
. O -

In O +
order O +
to O +
extend O +
the O +
structural O +
alignment O +
and O +
comparison O +
to O +
the O +
whole O +
subunit O +
of O +
these O +
enzymes O -
, O +
a O +
second O +
topological O +
alignment O +
was O +
carried O +
out O +
using O +
the O +
small O +
domain O +
of O +
DAPA O +
synthase O +
as O +
search O +
model O -
. O -

The O +
superposed O +
large O +
and O +
small O +
domains O +
were O +
then O +
artificially O +
connected O +
with O +
the O +
same O +
rotation O +
as O +
in O +
DAPA O +
synthase O -
. O -

This O +
set O +
of O +
enzyme O +
models O +
formed O +
the O +
basis O +
for O +
the O +
multiple O +
structural O +
alignment O +
using O +
the O +
program O +
MAPS O +
( O -
G. O +
Lu O -
, O +
unpublished O -
) O -
. O -

In O +
this O +
program O -
, O +
an O +
initial O +
alignment O +
is O +
carried O +
out O +
using O +
the O +
same O +
algorithm O +
as O +
in O +
TOP O +
( O -
Lu O -
, O +
1996 O -
) O +
. O -

The O +
program O +
then O +
proceeds O +
by O +
minimising O +
a O +
target O +
function O +
made O +
up O +
by O +
the O +
sum O +
of O +
pairwise O +
distances O +
between O +
equivalent O +
Cα O -
atoms O -
. O -

Segments O +
identified O +
as O +
structurally O +
equivalent O +
must O +
fulfil O +
certain O +
criteria O -
: O +
( O -
i O -
) O +
consist O +
of O +
at O +
least O +
three O +
consecutive O +
residues O -
; O +
( O -
ii O -
) O +
the O +
distance O +
between O +
aligned O +
Cα O +
—Cα O -
atoms O +
should O +
not O +
exceed O +
3.8 O +
Å O -
; O +
and O +
( O -
iii O -
) O +
the O +
side O -
- O -
chain O +
should O +
point O +
in O +
a O +
similar O +
direction O +
( O -
the O +
angles O +
formed O +
by O +
the O +
Cα O +
—Cβ O -
bond O +
between O +
equivalent O +
residues O +
should O +
not O +
exceed O +
50 O -
° O -
) O -
. O -

The O +
result O +
of O +
the O +
multiple O +
alignment O +
is O +
presented O +
in O +
terms O +
of O +
aligned O +
residues O +
between O +
all O +
proteins O +
and O +
an O +
alignment O +
score O +
of O +
r.m.s. O -
/ O -
( O -
N O +
match O +
/N O +
average O +
) O -
a O -
( O -
structure O +
diversity O +
factor O -
) O -
, O +
where O +
a O -
is O +
chosen O +
empirically O +
as O +
1.5 O -
. O -

The O +
structure O +
diversity O +
score O +
can O +
be O +
used O +
to O +
illustrate O +
the O +
structural O +
and O +
possibly O +
evolutionary O +
relationships O +
between O +
the O +
aligned O +
enzymes O -
. O -

Protein O +
data O +
bank O +
accession O +
Number O -

The O +
atomic O +
coordinates O +
and O +
observed O +
structure O +
factor O +
amplitudes O +
have O +
been O +
deposited O +
with O +
the O +
Protein O +
Data O +
Bank O -
, O +
Brookhaven O -
, O +
with O +
accession O +
codes O +
1qj5 O -
, O +
1qj5sf O +
for O +
the O +
enzyme O -
- O -
PLP O +
and O +
1qj3 O -
, O +
r1qj3sf O +
for O +
the O +
enzyme O -
- O -
PLP O -
- O -
KAPA O +
complex O -
, O +
respectively O -
. O -

Acknowledgements O -

We O +
thank O +
Ivan O +
M. O +
Turner O +
Sr O +
for O +
excellent O +
technical O +
assistance O +
and O +
Tom O +
Milller O +
for O +
carrying O +
out O +
the O +
N O -
- O -
terminal O +
sequencing O -
. O -

We O +
acknowledge O +
access O +
to O +
synchrotron O +
radiation O +
at O +
the O +
ESRF O -
, O +
Grenoble O -
, O +
France O -
, O +
and O +
thank O +
Dr O +
Andy O +
Thompson O +
at O +
beamline O +
BM14 O +
for O +
assistance O +
and O +
advice O +
with O +
data O +
collection O -
. O -

We O +
also O +
acknowledge O +
access O +
to O +
beamline O +
X11 O -
, O +
EMBL O +
outstation O -
, O +
c O -
/ O -
o O +
DESY O -
, O +
Hamburg O -
. O -

This O +
work O +
was O +
supported O +
by O +
the O +
Swedish O +
Agricultural O +
Research O +
Council O +
and O +
the O +
Swedish O +
Natural O +
Science O +
Research O +
Council O -
. O +

Stilbenes O +
occur O +
naturally O +
in O +
a O +
number O +
of O +
plant U-Species +
families O +
[ O -
1 O -
] O -
but O +
grapes U-Species +
and O +
related O +
products O +
are O +
considered O +
the O +
most O +
important O +
dietary O +
sources O +
of O +
these O +
substances O +
[ O -
2,3 O -
] O +
. O -

Trans O +
-resveratrol O +
and O +
the O +
3-O O -
- O -
β O -
- O -
glucoside O +
of O +
trans O +
-resveratrol O -
, O +
trans O +
-piceid O -
, O +
were O +
recently O +
identified O +
in O +
wine O +
[ O -
4–6 O -
] O +
. O -

Another O +
compound O +
3′-OH O -
- O -
trans O +
-piceid O +
( O -
trans O +
-astringin O -
) O +
has O +
recently O +
been O +
reported O +
to O +
be O +
a O +
constituent O +
of O +
Vitis B-Species +
vinifera L-Species -
cells O +
[ O -
7 O -
] O -
( O -
Fig. O +
1 O -
) O -
. O -

The O +
beneficial O +
role O +
that O +
moderate O +
wine O +
consumption O +
may O +
have O +
in O +
preventing O +
cardiovascular O +
disease O +
is O +
still O +
under O +
debate O +
[ O -
8 O -
] O +
, O +
and O +
great O +
interest O +
has O +
been O +
focused O +
on O +
stilbenes O -
. O -

Trans- O +
astringin O +
has O +
been O +
reported O +
to O +
have O +
antioxidant O +
properties O -
, O +
inhibiting O +
in O +
particular O +
the O +
oxidation O +
of O +
human U-Species +
LDL O +
in O +
vitro O +
[ O -
9 O -
] O +
, O +
but O +
its O +
occurrence O +
in O +
wine O +
has O +
never O +
been O +
reported O -
. O -

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
develop O +
a O +
simple O +
and O +
sensitive O +
method O +
to O +
determine O +
this O +
occurrence O -
. O -

A O +
HPLC O +
method O +
coupled O +
with O +
fluorimetric O +
detection O +
was O +
developed O +
for O +
this O -
. O -

2 O +
Experimental O +
Methanol O +
and O +
acetic O +
acid O +
were O +
purchased O +
from O +
Carlo O +
Erba O +
( O -
Val O +
de O +
Reuil O -
, O +
France O -
) O +
and O +
Merck O +
( O -
Nogent O +
sur O +
Marne O -
, O +
France O -
) O -
. O -

Trans O +
-astringin O +
was O +
obtained O +
from O +
cell O +
suspension O +
cultures O +
[ O -
10 O -
] O -
and O +
identified O +
unambiguously O +
by O +
MS O +
and O +
NMR O +
as O +
previously O +
described O +
[ O -
7 O -
] O +
. O -

The O +
fluorescence O +
properties O +
of O +
trans O +
-astringin O +
were O +
determined O +
with O +
the O +
1064 O +
Hewlett O -
- O -
Packard O +
spectrofluorimeter O -
. O -

Calibration O +
was O +
performed O +
with O +
solutions O +
of O +
different O +
concentrations O +
of O +
trans O +
-astringin O +
obtained O +
by O +
suitable O +
dilution O +
of O +
methanolic O +
solution O +
at O +
10 O +
mg O -
/ O -
l O -
. O -

Standard O +
solutions O +
were O +
stored O +
at O +
−20 O -
° O -
C O +
and O +
protected O +
from O +
light O -
. O -

The O +
linear O +
regression O +
was O +
Y O +
= O -
499.9x O +
−0.8 O +
( O -
r O +
= O -
0.999 O -
; O +
CV<4.71 O -
) O -
. O -

2.1 O +
HPLC O +
analysis O +
A O +
Hewlett O -
- O -
Packard O +
Model O +
1100 O +
with O +
two O +
low O +
pressure O +
pumps O +
and O +
a O +
1064 O +
Hewlett O -
- O -
Packard O +
fluorimetric O +
detector O +
coupled O +
to O +
an O +
HP O +
Chem O +
Station O +
were O +
used O +
for O +
solvent O +
delivery O +
system O +
and O +
detection O -
. O -

A O +
Hewlett O -
- O -
Packard O +
column O -
, O +
packed O +
with O +
Nucleosil O +
100 O +
C18 O -
, O +
250 O -
× O -
4 O +
mm O -
, O +
5 O +
μm O +
particle O +
size O +
was O +
used O +
for O +
the O +
stationary O +
phase O -
. O -

The O +
eluents O +
were O +
for O +
solvent O +
A O -
, O +
an O +
aqueous O +
solution O +
of O +
20 O +
mM O -
acetic O +
acid O -
, O +
and O +
for O +
solvent O +
B O -
, O +
methanol O +
( O -
HPLC O +
grade O -
) O -
; O +
both O +
were O +
filtered O +
through O +
0.45 O +
μm O +
Millipore O +
filters O -
. O -

Elution O +
was O +
performed O +
with O +
the O +
following O +
gradient O -
: O +
0–5 O +
min O +
98 O -
% O +
solvent O +
A O -
; O +
5–12 O +
min O +
from O +
98 O +
to O +
93 O -
% O +
solvent O +
A O -
; O +
12–18 O +
min O +
from O +
93 O +
to O +
89 O -
% O +
A O -
; O +
18–28 O +
min O +
from O +
89 O +
to O +
85 O -
% O +
A O -
; O +
28–38 O +
min O +
from O +
85 O +
to O +
70 O -
% O -
; O +
38–48 O +
min O +
from O +
70 O +
to O +
60 O -
% O -
; O +
48–55 O +
min O +
from O +
60 O +
to O +
50 O -
% O +
A O -
, O +
55–75 O +
min O +
50 O -
% O +
A. O -

The O +
flow O +
rate O +
was O +
0.5 O +
ml O -
/ O -
min O -
. O -

Ten O +
French O +
wines O +
( O -
5 O +
red O -
, O +
5 O +
white O -
) O +
from O +
the O +
South O +
of O +
France O +
were O +
analyzed O -
. O -

Wine O +
samples O +
were O +
directly O +
injected O +
into O +
the O +
HPLC O +
system O +
after O +
dilution O +
in O +
bi O -
- O -
distilled O +
water O +
and O +
filtration O +
( O -
Millex O -
- O -
FH13 O -
; O +
Millipore O -
; O +
St. O +
Quentin O -
, O +
Yvelines O -
, O +
France O -
) O -
. O -

Dilution O +
of O +
1 O -
/ O -
3 O +
was O +
used O -
, O +
and O +
20 O +
μl O +
were O +
injected O -
. O -

3 O +
Results O +
and O +
discussion O +
The O +
maximum O +
excitation O +
and O +
emission O +
wavelength O +
in O +
a O +
methanolic O +
solution O +
as O +
well O +
as O +
in O +
a O +
mixture O +
of O +
20 O +
mM O -
methanol O -
– O -
acetic O +
acid O +
( O -
v O -
/ O -
v O -
, O +
50:50 O -
) O +
( O -
the O +
composition O +
of O +
the O +
trans O +
-astringin O +
gradient O +
was O +
measured O +
when O +
in O +
the O +
spectrofluorimeter O +
cell O -
) O +
were O +
298 O +
and O +
400 O +
nm O +
respectively O -
. O -

The O +
threshold O +
of O +
detection O +
was O +
defined O +
as O +
the O +
amount O +
of O +
the O +
compound O +
resulting O +
in O +
a O +
peak O +
10-fold O +
higher O +
than O +
the O +
standard O +
deviation O +
of O +
the O +
baseline O +
noise O -
. O -

This O +
was O +
found O +
to O +
be O +
0.03 O +
mg O -
/ O -
l O -
. O -

Chromatograms O +
of O +
trans O +
-astringin O +
and O +
of O +
a O +
red O +
wine O +
sample O +
monitored O +
by O +
fluorescence O +
detection O +
are O +
reported O +
in O +
Fig. O +
2A O +
and O +
B O -
. O -

The O +
retention O +
time O +
was O +
53.7 O +
min O -
. O -

The O +
HPLC O +
separation O +
and O +
the O +
good O +
resolution O +
of O +
the O +
peak O +
without O +
interference O +
allowed O +
the O +
identification O +
of O +
the O +
trans O +
-astringin O -
. O -

A O +
co O -
- O -
chromatographic O +
analysis O +
was O +
also O +
performed O -
; O +
it O +
confirmed O +
the O +
identification O +
of O +
trans O +
-astringin O +
by O +
HPLC O +
with O +
fluorimetric O +
detection O -
. O -

The O +
chromatogram O +
of O +
the O +
wine O +
in O +
which O +
trans O +
-astringin O +
was O +
added O +
is O +
reported O +
in O +
Fig. O +
2C O +
. O -

This O +
progressive O +
gradient O +
run O +
developed O +
here O +
has O +
allowed O +
the O +
analysis O +
of O +
other O +
stilbenes O -
: O +
trans O +
-resveratrol O -
, O +
trans O +
-piceid O +
[ O -
11 O -
] O +
, O +
and O +
other O +
phenolic O +
compounds O +
such O +
as O +
( O -
+ O -
) O -
-catechin O -
, O +
tyrosol O -
, O +
gentisic O +
acid O +
[ O -
12 O -
] O +
. O -

The O +
standard O +
methanolic O +
solution O +
of O +
trans O +
-astringin O +
was O +
stable O +
for O +
at O +
least O +
30 O +
days O +
at O +
−20 O -
° O -
C O +
in O +
the O +
dark O -
. O -

When O +
this O +
solution O +
was O +
exposed O +
to O +
wide O -
- O -
spectrum O +
fluorescent O +
lighting O +
at O +
a O +
light O +
intensity O +
of O +
40 O +
μmol O +
m−2 O -
s−1 O -
at O +
25 O -
° O -
C O -
, O +
no O +
degradation O +
of O +
trans O +
-astringin O +
was O +
observed O +
during O +
the O +
first O +
two O +
h O -
, O +
corresponding O +
to O +
the O +
time O +
of O +
analysis O -
. O -

Therefore O -
, O +
trans O +
-astringin O +
can O +
be O +
handled O +
in O +
the O +
laboratory O +
without O +
very O +
stringent O +
precautions O -
. O -

We O +
found O +
low O +
levels O +
of O +
trans O +
-astringin O +
in O +
the O +
wine O +
analyzed O -
, O +
and O +
the O +
results O +
were O +
confirmed O +
by O +
mass O +
spectrometry O -
. O -

Trans O +
-astringin O +
was O +
extracted O +
from O +
red O +
wine O +
and O +
FAB O -
- O -
MS O +
spectra O +
showed O +
a O +
[ O -
MH O -
] O -
+ O -
peak O +
at O +
m O -
/ O -
z O +
407 O +
( O -
C20 O +
H22 O +
O9 O -
requires O +
406 O -
) O -
. O -

In O +
this O +
research O -
, O +
trans O +
-astringin O +
is O +
reported O +
for O +
the O +
first O +
time O +
to O +
be O +
present O +
in O +
both O +
red O +
and O +
white O +
wines O -
. O -

Concentrations O +
ranged O +
from O +
0.09 O +
mg O -
/ O -
l O +
to O +
0.29 O +
mg O -
/ O -
l O +
for O +
red O +
wines O +
and O +
from O +
0.10 O +
mg O -
/ O -
l O +
to O +
0.22 O +
mg O -
/ O -
l O +
for O +
white O +
wines O -
. O -

To O +
study O +
the O +
reproducibility O -
, O +
the O +
same O +
red O +
and O +
white O +
wine O +
samples O +
were O +
analyzed O +
on O +
five O +
different O +
days O -
. O -

The O +
CV O +
obtained O +
were O +
less O +
than O +
4.72 O -
% O +
for O +
red O +
wines O +
and O +
less O +
than O +
4.23 O -
% O +
for O +
white O +
wines O -
. O -

Fluorimetric O +
detection O +
evidenced O +
low O +
levels O +
of O +
trans O +
-astringin O +
in O +
wine O -
. O -

As O +
already O +
described O +
by O +
Pezet O +
et O +
al. O +
[ O -
13 O -
] O -
for O +
trans- O +
resveratrol O +
and O +
pterostilbene O -
, O +
the O +
use O +
of O +
a O +
fluorimetric O +
detector O +
is O +
well O +
adapted O +
to O +
the O +
low O +
concentrations O +
of O +
stilbenes O +
in O +
wines O -
. O -

In O +
particular O -
, O +
no O +
prior O +
treatment O +
of O +
the O +
wine O +
sample O +
is O +
required O -
. O -

For O +
the O +
ten O +
French O +
wines O +
analyzed O +
here O -
, O +
no O +
large O +
differences O +
were O +
observed O +
between O +
red O +
and O +
white O +
wines O -
, O +
but O +
analysis O +
of O +
more O +
samples O +
of O +
commercial O +
wine O +
is O +
needed O +
to O +
estimate O +
the O +
dietary O +
impact O +
and O +
bioavailability O +
of O +
the O +
trans O +
-astringin O +
in O +
the O +
wines O +
of O +
world O -
. O -

4 O +
Conclusion O +
The O +
present O +
method O +
for O +
the O +
analysis O +
of O +
trans O +
-astringin O +
in O +
wine O +
combines O +
the O +
simplicity O +
of O +
direct O +
HPLC O +
injection O +
with O +
the O +
sensitivity O +
of O +
fluorescence O +
detection O -
. O -

Acknowledgements O +
The O +
authors O +
thank O +
Ray O +
Cooke O +
for O +
revising O +
the O +
English O +
manuscript O +
and O +
F. O +
Gasc O +
for O +
glassware O +
expertise O -
. O +

DNA O +
topoisomerases O +
are O +
the O +
enzymes O +
which O +
regulate O +
the O +
state O +
of O +
DNA O +
topology O -
. O -

The O +
enzymes O +
are O -
, O -
therefore O -
, O +
important O +
for O +
DNA O +
metabolism O -
, O +
such O +
as O +
replication O -
, O +
recombination O +
and O +
transcription O -
) O -

Nidulalin O -
A O -
( O -
1 O -
) O -
2 O +
and O +
its O +
derivatives O -
, O +
F390B O -
( O -
2 O -
) O +
and O +
C O -
( O -
3 O -
) O -
, O +
were O +
isolated O +
from O +
Penicillium B-Species +
sp. L-Species +
as O +
potent O +
cytotoxic O +
agents O -
( O -
Figure O +
1 O -
) O -
.3 O +
Nidulalin O +
A O -
, O +
a O +
major O +
metabolite O +
of O +
the O +
producing O +
strain O -
, O +
showed O +
potent O +
inhibitory O +
activity O +
against O -
DNA O +
topoisomerase O +
II O -
( O -
Topo O +
II O -
) O +
in O +
vitro.4 O +
The O +
antitumor O +
activity O +
of O +
nidulalin O +
A O +
against O +
Colon O +
26 O +
routine O -
adenocarcinoma O +
was O +
evaluated O +
in O +
vivo O -
, O +
however O -
, O +
no O +
antitumor O +
effect O +
was O +
observed O -
. O -

Further O +
investigation O -
revealed O +
that O +
rapid O +
hydrolysis O +
and O +
decarboxylation O +
of O +
the O +
methyl O +
ester O +
moiety O +
of O +
1 O +
by O +
esterases O +
in O +
murine U-Species -
plasma O +
gave O +
an O +
inactive O +
xanthone O +
derivative O +
4 O -
, O +
which O +
was O +
identical O +
to O +
the O +
compound O +
derived O +
from O +
1 O +
by O -
alkaline O +
hydrolysis O -
. O -

This O +
result O +
prompted O +
us O +
to O +
synthesize O +
stable O +
analogs O +
against O +
hydrolysis O -
. O -

In O +
this O -
communication O -
, O +
we O +
report O +
synthesis O +
and O +
antitumor O +
activity O +
of O +
derivatives O +
of O +
nidulalin O +
A O +
with O +
amide O +
moieties O +
in O -
place O +
of O +
the O +
methoxycarbonyl O +
group O -
. O -

Figure O +
1 O -
MeO2C O +
ORe O -
Nidulalin O +
A O -
( O -
1 O -
) O +
RI O -
= O -
R2 O -
= O -
H O -
F390B O -
( O -
2 O -
) O +
R~=H O -
, O +
R2 O -
= O -
Ac O -
F390C O -
( O -
3 O -
) O +
RI O -
= O -
OH O -
, O +
R2 O -
= O -
H O -
4 O -
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O -

PII O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00440 O -
- O -
0 O -
2654 O -
S. O +
Sato O +
et O +
al. O +
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
2653 O -
- O -
2656 O -
Synthesis O -
The O +
syntheses O +
of O +
amide O +
analogs O +
of O +
nidulalin O +
A O +
are O +
outlined O +
in O +
Scheme O +
1 O -
. O -

Direct O +
amidation O +
by O -
methylamine O +
in O +
MeOH O +
afforded O +
approximately O +
4:3 O +
mixture O +
of O +
lactams O +
10a O +
and O +
10b O +
via O +
Michael O +
addition O -
followed O +
by O +
intramolecular O +
aminolysis O -
( O -
Scheme O +
2 O -
) O -
. O -

To O +
avoid O +
lactam O +
formation O -
, O +
nidulalin O +
A O +
was O +
reduced O +
by O -
NaBH4 O +
in O +
MeOH O +
to O +
give O +
a O +
tetrahydroxanthone O +
derivative O +
5 O +
in O +
87 O -
% O +
yield,5 O +
which O +
was O +
treated O +
with O +
1N O +
NaOH O -
followed O +
by O +
acetylation O +
with O +
acetic O +
anhydride O +
in O +
pyridine O +
to O +
give O +
carboxylic O +
acid O +
6 O -
. O -

Condensation O +
of O +
6 O +
with O -
various O +
amines O -
, O +
including O +
ammonia O -
, O +
methylamine O -
, O +
dimethylamine O -
, O +
2-aminoethanol O -
, O +
and O +
pyrrolidine O -
, O +
via O +
acid O -
chloride O +
followed O +
by O +
acetylation O +
of O +
a O +
hydroxyl O +
group O -
, O +
which O +
was O +
generated O +
during O +
amine O +
treatment O -
, O +
gave O -
corresponding O +
amides O +
7a O -
- O -
e O -
, O +
respectively O -
. O -

Oxidation O +
of O +
7a O +
with O +
SeOz O +
in O +
dioxane O +
at O +
65 O +
gave O +
a O -
dihydroxanthone O +
derivative O +
8a O +
in O +
18 O -
% O +
yield O -
. O -

In O +
the O +
same O +
manner O -
, O +
7h O -
- O -
e O +
were O +
converted O +
to O +
8h O -
- O -
e O -
, O +
respectively O -
. O -

The O +
acetyl O +
groups O +
of O +
8a O -
- O -
e O +
were O +
removed O +
by O +
alkaline O +
hydrolysis O +
to O +
give O +
amide O +
analogs O +
9a O -
- O -
e O -
, O +
respectively.6 O -
Scheme O +
1 O -
H O -
~ O -
a O -
" O -
Me,"~ O +
b'c O +
" O -
M~-O~. O +
Y O -
M O -
87 O -
% O -
~ O +
, O -
^,,- O -
, O +
7- O +
i O -
.. O -
91 O -
% O -
.. O -

_ O +
.=. O +
, O -
~w O -
~ O -
v2'~ O -
' O +
OH O -
I'-IU2U O +
OAc O -
Nidulalin O +
A O -
( O -
1 O -
) O -

5 O -
6 O -
65 O -
- O -
97 O +
Yo O -
ROC O +
( O -
~Ac O -
17 O -
- O -
35o O +
Me O -
" O +
" O -
~ O +
-ROo~ O +
OTAc O -
quan O -
. O -

7a O +
R O -
= O -
NH2 O -
8a O +
R O -
= O -
NH2 O -
9a O +
R O -
= O -
NH2 O -
7b O +
R O -
= O -
NHMe O -
8b O +
R O -
= O -
NHMe O -
9b O +
R O -
= O -
NHMe O -
7R O -
= O -
NMe2 O -
8c O +
R O -
= O -
NMe2 O -
9c O +
R O -
= O -
NMe2 O -
7d O +
R O -
= O -
NHCH2CH2OAc O -
8d O +
R O -
= O -
NHCH2CH2OAc O -
9d O +
R O -
= O -
NHCH2CH2OH O -
a O -
) O +
NaBH4 O -
, O +
MeOH O -
, O +
5 O +
b O -
) O +
1N O +
NaOH O -
, O +
5 O +
c O -
) O +
Ac20 O -
, O +
pyridine O -
, O +
rt O +
d O -
) O +
SOCI2 O -
, O +
cat O -
. O -

DMF O -
, O +
CH2CI2 O -
, O +
rt O -
e O -
) O +
aq O -
. O -

amines O -
, O +
5 O +
f O -
) O +
Ac20 O -
, O +
pyridine O -
, O +
rt O +
g O -
) O +
SeO2 O -
, O +
dioxane O -
, O +
65 O +
h O -
) O -

1N O +
NaOH O -
, O +
MeOH O -
, O +
5 O -
Scheme O +
2 O -
a O -
1 O -
a O -
) O +
MeNH2 O -
, O +
MeOH O -
, O +
rt O -
+ O -
M O -
M O -
Me O -
O O -
/ O -
j O +
OH O -
10a O -
10b O -
S. O +
Sato O +
et O +
al. O +
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
2653 O -
- O -
2656 O -
2655 O -
Result O +
and O +
Discussion O -
To O +
test O +
the O +
stability O -
, O +
the O +
amide O +
derivatives O +
were O +
treated O +
with O +
murine U-Species +
plasma O -
. O -

The O +
inactive O +
compound O +
4 O -
was O +
not O +
detected O +
by O +
HPLC O +
analyses O -
, O +
and O +
it O +
was O +
revealed O +
that O +
the O +
amide O +
analogs O +
were O +
stable O +
against O +
esterases O -
] O -
The O +
biological O +
activities O +
of O +
the O +
semisynthetic O +
compounds O +
of O +
nidulalin O +
A O +
are O +
shown O +
in O +
Table O +
1 O -
. O -

The O +
amide O -
derivatives O +
9a O -
- O -
e O +
retained O +
cytotoxic O +
activity O +
against O +
both O +
human U-Species +
and O +
murine U-Species +
cancer O +
cell O +
lines O +
in O +
vitro O -
. O -

9a O -
inhibited O +
Topo O +
II O +
in O +
dose O +
dependent O +
manner O +
with O +
IC~0 O +
value O +
of O +
29gM. O +
Furthermore O -
, O +
9a O +
possessed O +
weak O -
inhibitory O +
activity O +
against O +
topoisomerase O +
I O -
( O -
Topo O +
I O -
) O +
with O +
ICs0 O +
value O +
of O +
631.tM. O +
In O +
spite O +
of O +
decreased O +
activity O -
against O +
Topo O +
II O -
, O +
cytotoxicity O +
of O +
9a O +
was O +
comparable O +
to O +
that O +
of O +
1 O -
. O -

Lactam O +
10a O +
inhibited O +
neither O +
Topo O +
I O +
nor O -
Topo O +
II O +
since O +
a O +
conjugated O +
dienone O +
moiety O +
was O +
required O +
for O +
inhibitory O +
activity O +
against O +
Topo O +
II.4 O +
The O -
reason O +
for O +
the O +
discrepancy O +
between O +
cytotoxicity O +
and O +
inhibitory O +
activity O +
against O +
Topo O +
I O +
and O +
Topo O +
II O +
of O +
these O -
compounds O +
is O +
not O +
clear O -
. O -

There O +
might O +
be O +
other O +
mechanisms O +
for O +
cytotoxicity O +
of O +
these O +
analogs O +
or O +
instability O +
of O -
1 O +
in O +
cell O +
culture O +
might O +
decrease O +
its O +
cytotoxicity O -
. O -

Table O +
1 O -
. O -

Biological O +
Activities O +
of O +
Nidulalin O +
A O +
Derivatives O +
in O +
vitro O -
Cytotoxicitya O -
Inhibitory O +
Activity O -
ICso O -
( O -
gM O -
) O -
IC,0 O -
( O -
gM O -
) O -
Compound O -
HCT-116 O -
K562 O -
P388 O -
Topo O +
Ib O -
Topo O +
IIc O -
9a O -
0.33 O -
0.59 O -
0.052 O -
63 O -
29 O -
9b O -
1.13 O -
2.26 O -
0.24 O -
> O -
300 O -
132 O -
9 O +
e O -
0.79 O -
0.98 O -
0.15 O -
ndd O -
nd O -
9d O -
7.88 O -
10.61 O -
2.67 O -
102 O -
23 O -
9e O -
1.64 O -
1.52 O -
0.56 O -
nd O -
nd O -
10a O -
19.6 O -
6.31 O -
nd O -
> O -
300 O -
> O -
300 O -
l O -
( O -
Nidulalin O +
A O -
) O -
0.14 O -
0.32 O -
0.024 O -
172 O -
2.2 O -
a O -
) O +
Cells O +
were O +
treated O +
with O +
each O +
compound O +
for O +
72 O +
hours O -
. O -

Cell O +
viability O +
was O +
evaluated O +
by O +
MTT O +
assay O -
, O +
b O -
) O +
Relaxation O +
assay O +
of O -
Topo O +
I O +
was O +
performed O +
as O +
shown O +
in O +
ref O -
. O -

8 O -
. O +
c O -
) O +
Decatenation O +
assay O +
of O +
Topo O +
II O +
was O +
performed O +
as O +
shown O +
in O +
ref O -
. O -

9 O -
. O +
d O -
) O +
not O +
determined O -
Table O +
2 O -
. O -

Antitumor O +
Activity O +
of O +
9a O +
in O +
vivo O -
Compound O -
Route O -
IR O -
( O -
% O -
) O -
a O -
( O -
dose O -
) O -
9a O -
iv O -
42b O -
( O -
10mg O -
/ O -
Kg O -
) O -
1 O -
iv O -
24 O -
( O -
20mg O -
/ O -
Kg O -
) O -
a O -
) O +
Tumor O +
growth O +
suppression O +
was O +
determined O +
as O +
shown O +
in O -
note O +
10 O -
. O -

b O -
) O +
P<0.01 O +
by O +
T O -
- O -
test O -
Antitumor O +
activity O +
of O +
9a O +
was O +
evaluated O +
against O -
Colon O +
26 O +
murine U-Species +
tumor O +
model O +
in O +
vivo O -
( O -
Table O +
2 O -
) O -
. O -

9a O -
, O +
at O +
a O -
dose O +
of O +
10mg O -
/ O -
Kg O -
, O +
showed O +
moderate O +
antitumor O +
activity O -
in O +
this O +
model O -
, O +
while O +
1 O +
showed O +
only O +
marginal O +
effect O -
even O +
at O +
a O +
higher O +
dose O +
( O -
20mg O -
/ O -
Kg O -
) O -
. O -

From O +
above O +
results O -
, O -
it O +
is O +
demonstrated O +
that O +
the O +
methoxycarbonyl O +
group O -
modified O +
nidulalin O +
A O +
analogs O +
are O +
stable O +
against O +
esterases O +
and O +
effective O +
in O +
murine U-Species +
tumor O +
model O +
in O +
vivo O -
. O -

Further O -
evaluation O +
of O +
antitumor O +
activity O +
and O +
synthesis O +
of O +
other O +
stable O +
analogs O +
are O +
underway O -
. O -

Acknowledgement O -

: O +
We O +
thank O +
Dr. O +
Yukio O +
Iino O -
, O +
Toshimi O +
Mizukoshi O -
, O +
Uno O +
Tagami O -
, O +
and O +
Reiko O +
Yuji O +
for O -
measurement O +
of O +
NMR O +
and O +
mass O +
spectra O -
. O -

We O +
are O +
also O +
grateful O +
to O +
Yumiko O +
Fukuda O +
for O +
skillful O +
technical O -
assistance O -
. O -

2656 O -
S. O +
Sato O +
et O +
al. O +
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
2653 O -
- O -
2656 O +

Phytosterol O +
supplements O +
decrease O +
serum O +
cholesterol O +
and O +
may O +
reduce O +
the O +
risk O +
of O +
cardiovascular O +
disease O +
[ O -
1 O -
] O +
. O -

In O +
a O +
feeding O +
trial O +
involving O +
a O +
stanol O -
- O -
supplemented O +
margarine O +
spread O +
[ O -
2 O -
] O +
, O +
a O +
method O +
was O +
needed O +
for O +
sensitive O +
and O +
precise O +
determination O +
of O +
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O +
in O +
human U-Species +
serum O -
. O -

Quantitation O +
of O +
serum O +
sterols O +
and O +
stanols O +
( O -
5,6-dihydrosterols O -
) O +
is O +
complicated O +
by O +
the O +
presence O +
of O +
numerous O +
other O +
lipids O +
and O +
low O +
concentrations O +
( O -
0.2–13 O +
μg O -
/ O -
ml O -
) O +
of O +
the O +
analytes O +
relative O +
to O +
cholesterol O +
( O -
∼1500–3000 O +
μg O -
/ O -
ml O -
) O -
. O -

A O +
method O +
[ O -
3,4 O -
] O -
previously O +
reported O +
for O +
measurement O +
of O +
phytosterols O -
, O +
stanols O -
, O +
and O +
cholesterol O +
metabolites O +
[ O -
5 O -
] O -
lacked O +
sufficient O +
detail O +
about O +
preparation O +
of O +
serum O +
samples O -
, O +
chromatographic O +
conditions O -
, O +
and O +
analytical O +
sensitivity O -
, O +
and O +
was O +
not O +
readily O +
reproduced O -
. O -

Other O +
reports O +
[ O -
6,7 O -
] O -
do O +
not O +
include O +
validation O +
of O +
the O +
separation O +
and O +
quantification O +
of O +
phytosterols O +
and O +
stanols O +
as O +
well O +
as O +
cholesterol O +
metabolites O +
( O -
e.g. O +
desmosterol O -
, O +
lathosterol O -
) O -
. O -

Sample O +
clean O -
- O -
up O +
was O +
not O +
reported O +
in O +
some O +
of O +
the O +
published O +
methods O -
, O +
and O +
others O +
used O +
thin O -
- O -
layer O +
chromatography O -
. O -

Carryover O +
and O +
column O -
/ O -
injector O +
contamination O +
are O +
problems O +
in O +
the O +
absence O +
of O +
serum O +
sample O +
clean O -
- O -
up O +
prior O +
to O +
chromatography O -
. O -

Very O +
polar O +
compounds O +
( O -
e.g. O +
phospholipids O -
) O +
are O +
an O +
important O +
consideration O +
in O +
sterol O +
analysis O +
when O +
semi O -
- O -
polar O +
or O +
polar O +
stationary O +
phases O +
are O +
employed O -
, O +
especially O +
when O +
analyzing O +
a O +
large O +
number O +
of O +
samples O -
. O -

A O +
60-m O +
capillary O +
column O +
with O +
a O +
moderately O +
polar O +
stationary O +
phase O +
( O -
14 O -
% O +
cyanopropylphenyl–86 O -
% O +
dimethylpolysiloxane O -
) O +
was O +
used O -
, O +
and O +
a O +
one O -
- O -
step O +
solid O -
- O -
phase O +
extraction O +
was O +
added O +
to O +
remove O +
highly O +
polar O +
compounds O +
from O +
the O +
saponified O +
total O +
lipid O +
extract O -
. O -

Epicholesterol O +
was O +
used O +
as O +
an O +
internal O +
standard O -
. O -

Since O +
the O +
primary O +
concern O +
was O +
to O +
detect O +
changes O +
in O +
low O +
levels O +
of O +
serum O +
sterols O +
and O +
stanols O +
as O +
a O +
result O +
of O +
dietary O +
supplementation O -
, O +
we O +
required O +
a O +
very O +
precise O +
assay O -
. O -

Consequently O -
, O +
numerous O +
quality O +
control O +
measures O +
were O +
implemented O -
. O -

In O +
this O +
paper O +
we O +
give O +
a O +
detailed O +
description O +
of O +
the O +
methodology O +
and O +
quality O +
control O +
employed O +
for O +
the O +
precise O +
quantitative O +
analysis O +
of O +
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O +
in O +
human O +
serum O -
. O -

2 O +
Experimental O +
2.1 O +
Materials O +
2.1.1 O +
Chemicals O +
Epicholesterol O +
was O +
obtained O +
from O +
Steraloids O +
( O -
Wilton O -
, O +
NH O -
, O +
USA O -
) O -
. O -

Beta O -
- O -
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
fucosterol O -
, O +
lathosterol O -
, O +
lanosterol O -
, O +
and O +
desmosterol O -
, O +
cholestanol O -
, O +
squalene O -
, O +
pyrogallol O -
, O +
cyclohexane O -
, O +
and O +
pyridine O +
were O +
purchased O +
from O +
Sigma O +
Chemical O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O -

Campestanol O +
was O +
from O +
Research O +
Plus O +
( O -
Bayonne O -
, O +
NJ O -
, O +
USA O -
) O -
, O +
and O +
bis O -
( O -
trimethylsilyl O -
) O -
trifluoroacetamide O +
with O +
1 O -
% O +
trimethylchlorosilane O +
( O -
BSTFA O +
w O -
/ O -
1 O -
% O +
TMCS O -
) O +
was O +
obtained O +
from O +
Alltech O +
Associates O +
( O -
Deerfield O -
, O +
IL O -
, O +
USA O -
) O -
. O -

Hexane O -
, O +
chloroform O -
, O +
methanol O -
, O +
isopropanol O -
, O +
sodium O +
chloride O +
( O -
ACS O +
grade O -
) O -
, O +
and O +
potassium O +
hydroxide O +
( O -
NF O -
/ O -
FCC O +
grade O -
) O +
were O +
from O +
Fisher O +
Scientific O +
( O -
Fairlawn O -
, O +
NJ O -
, O +
USA O -
) O -
. O -

Absolute O +
ethanol O +
was O +
obtained O +
from O +
AAPER O +
Alcohol O +
and O +
Chemical O +
( O -
Shelbyville O -
, O +
KY O -
, O +
USA O -
) O -
. O -

All O +
solvents O +
were O +
HPLC O +
grade O +
and O +
used O +
without O +
further O +
purification O -
. O -

2.1.2 O +
Serum O +
samples O +
Serum O +
samples O +
( O -
1–2 O +
ml O -
) O +
frozen O +
in O +
2-ml O +
cryovials O +
were O +
obtained O +
from O +
a O +
human U-Species +
feeding O +
trial O +
conducted O +
at O +
Pennsylvania O +
State O +
University O +
( O -
University O +
Park O -
, O +
PA O -
, O +
USA O -
) O +
and O +
Pennington O +
Biomedical O +
Research O +
Center O +
( O -
Baton O +
Rouge O -
, O +
LA O -
, O +
USA O -
) O -
. O -

Subjects O +
consumed O +
a O +
stanol O -
- O -
supplemented O +
margarine O +
that O +
provided O +
3 O +
g O +
per O +
day O +
stanols O +
and O +
16 O +
g O +
per O +
day O +
fat O +
in O +
a O +
controlled O +
feeding O +
trial O -
; O +
details O +
of O +
the O +
study O +
are O +
reported O +
elsewhere O +
[ O -
2 O -
] O +
. O -

Serum O +
samples O +
were O +
stored O +
at O +
−80 O -
° O -
C O +
until O +
analyzed O -
. O -

2.2 O +
Instrumentation O +
2.2.1 O +
Gas O +
chromatography O +
Gas O +
chromatography O +
was O +
performed O +
with O +
a O +
Perkin O +
Elmer O +
GC O +
Autosystem O -
™ O +
( O -
Perkin O +
Elmer O -
, O +
Norwalk O -
, O +
CT O -
, O +
USA O -
) O -
, O +
an O +
Rtx O -
® O +
-1701 O +
( O -
14 O -
% O +
cyanopropylphenyl–86 O -
% O +
dimethylpolysiloxane O -
) O +
capillary O +
column O +
( O -
60-m O -
× O -
0.25-mm O +
I.D. O -
, O +
0.25-μm O +
film O +
thickness O -
; O +
Restek O -
, O +
Bellefonte O -
, O +
PA O -
, O +
USA O -
) O -
, O +
and O +
a O +
flame O +
ionization O +
detector O +
with O +
hydrogen O +
( O -
45 O +
ml O -
/ O -
min O -
) O +
and O +
air O +
( O -
450 O +
ml O -
/ O -
min O -
) O +
as O +
fuel O +
source O -
. O -

Hydrogen O +
at O +
1.18 O +
ml O -
/ O -
min O +
was O +
the O +
carrier O +
gas O -
. O -

Operating O +
conditions O +
were O -
: O +
injection O +
temperature O -
, O +
280 O -
° O -
C O -
; O +
detector O +
temperature O -
, O +
280 O -
° O -
C O -
; O +
oven O +
temperature O -
, O +
265 O -
° O -
C O -
; O +
split O +
ratio O -
, O +
9:1 O +
( O -
split O +
vent O +
flow O +
9.44 O +
ml O -
/ O -
min O -
) O -
; O +
injection O +
volume O -
, O +
1 O +
μl O -
; O +
head O +
pressure O +
21 O +
p.s.i O -
. O -

Detector O +
signal O +
output O +
was O +
monitored O +
by O +
computer O +
( O -
Dell O +
Dimension O +
XPS O +
D233 O -
; O +
Dell O +
Computer O -
, O +
Round O +
Rock O -
, O +
TX O -
, O +
USA O -
) O +
and O +
all O +
chromatograms O +
and O +
data O +
were O +
generated O +
and O +
processed O +
using O +
Turbochrom O -
™ O +
Workstation O +
version O +
6.0.2.1 O +
software O +
( O -
Perkin O +
Elmer O -
) O -
. O -

2.3 O +
Quality O +
control O +
measures O +
2.3.1 O +
Preparation O +
of O +
glassware O +
All O +
glassware O +
( O -
and O +
other O +
labware O -
, O +
such O +
as O +
stir O +
bars O +
and O +
spatulas O -
) O +
was O +
scrupulously O +
cleaned O +
and O +
rinsed O +
with O +
distilled O +
deionized O +
water O +
and O +
acetone O -
, O +
then O +
immediately O +
before O +
use O -
, O +
rinsed O +
with O +
chloroform O -
, O +
then O +
ethanol O -
, O +
and O +
allowed O +
to O +
air O +
dry O -
. O -

All O +
glass O +
test O +
tubes O +
were O +
silanized O +
with O +
5 O -
% O +
dimethyldicholorosilane O +
in O +
hexane O +
( O -
Sigma O -
) O -
. O -

2.3.2 O +
Other O +
measures O +
to O +
prevent O +
contamination O +
Since O +
sterols O +
are O +
ubiquitous O +
in O +
the O +
lab O +
( O -
e.g. O +
in O +
skin O +
secretions O -
, O +
rubber O +
septa O -
, O +
vegetable U-Species +
oils O +
and O +
fats O -
) O -
, O +
and O +
because O +
the O +
levels O +
of O +
these O +
compounds O +
in O +
serum O +
are O +
low O +
( O -
ng O +
to O +
μg O -
/ O -
ml O -
) O -
, O +
it O +
is O +
essential O +
to O +
prevent O +
sample O +
contamination O +
to O +
preclude O +
falsely O +
elevated O +
values O +
of O +
the O +
analytes O -
. O -

Precautions O +
against O +
cross O -
- O -
contamination O +
are O +
especially O +
necessary O +
in O +
laboratories O +
where O +
vegetable U-Species +
oils O +
or O +
other O +
materials O +
containing O +
significant O +
levels O +
of O +
phytosterols O +
are O +
analyzed O -
. O -

Tight O +
control O +
of O +
measuring O +
volumes O +
and O +
weights O +
is O +
essential O +
to O +
ensure O +
the O +
precision O +
and O +
accuracy O +
of O +
the O +
assay O +
in O +
the O +
ng O +
to O +
μg O +
range O -
. O -

2.3.3 O +
Calibration O +
of O +
pipettes O +
and O +
balances O +
For O +
all O +
critical O +
volume O +
measurements O +
( O -
e.g. O +
standard O +
solutions O -
, O +
serum O +
aliquots O +
taken O +
for O +
analysis O -
) O -
, O +
automatic O +
pipettes O +
were O +
carefully O +
calibrated O +
for O +
accuracy O +
and O +
precision O +
immediately O +
before O +
use O -
, O +
using O +
the O +
solvent O +
of O +
the O +
solution O +
to O +
be O +
dispensed O +
( O -
e.g. O +
chloroform O +
or O +
ethanol O +
for O +
standards O -
, O +
water O +
for O +
serum O -
) O -
, O +
and O +
a O +
five O -
- O -
decimal O +
place O +
analytical O +
balance O -
, O +
calibrated O +
with O +
certified O +
standard O +
weights O -
. O -

The O +
pipetter O +
was O +
held O +
in O +
the O +
hand O +
5 O +
min O +
to O +
warm O +
it O +
to O +
a O +
constant O +
temperature O +
before O +
calibration O -
. O -

To O +
determine O +
accuracy O -
, O +
the O +
weighed O +
volumes O +
were O +
compared O +
to O +
the O +
expected O +
mass O -
, O +
determined O +
from O +
the O +
density O +
of O +
the O +
liquid O +
at O +
the O +
measured O +
temperature O +
of O +
the O +
liquid O +
aliquoted O +
[ O -
8 O -
] O +
. O -

For O +
preparing O +
standard O +
mixtures O +
and O +
for O +
performing O +
standard O +
additions O +
to O +
serum O +
samples O -
, O +
volumetric O +
pipettes O +
were O +
used O -
. O -

2.3.4 O +
Preparation O +
of O +
standard O +
solutions O +
2.3.4.1 O +
Internal O +
standard O +
Test O +
tubes O +
containing O +
internal O +
standard O +
were O +
prepared O +
in O +
batches O -
. O -

Epicholesterol O +
( O -
3 O +
mg O -
) O +
was O +
weighed O +
to O +
the O +
nearest O +
0.01 O +
mg O +
into O +
a O +
1-l O +
volumetric O +
flask O -
, O +
brought O +
to O +
volume O +
with O +
absolute O +
ethanol O -
, O +
and O +
thoroughly O +
mixed O -
. O -

The O +
solution O +
was O +
dispensed O +
in O +
1.6-ml O +
aliquots O +
into O +
each O +
of O +
approximately O +
one O -
- O -
hundred O +
25 O -
× O -
150 O +
mm O +
glass O +
test O +
tubes O +
using O +
a O +
bottle O -
- O -
top O +
dispenser O +
that O +
had O +
been O +
calibrated O +
for O +
accuracy O +
and O +
precision O +
( O -
Section O +
2.3.3 O +
) O -
, O +
yielding O +
5 O +
μg O +
epicholesterol O +
per O +
tube O +
( O -
the O +
exact O +
amount O +
of O +
internal O +
standard O +
was O +
calculated O +
for O +
the O +
exact O +
weights O +
and O +
volumes O +
measured O -
) O -
. O -

The O +
tubes O +
were O +
capped O +
under O +
nitrogen O +
and O +
stored O +
at O +
< O -
10 O -
° O -
C O +
for O +
up O +
to O +
2 O +
months O -
. O -

Immediately O +
prior O +
to O +
use O -
, O +
the O +
solvent O +
was O +
evaporated O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O -

2.3.4.2 O +
Reference O +
and O +
calibration O +
standards O +
For O +
each O +
component O -
, O +
a O +
6 O +
μg O -
/ O -
ml O +
stock O +
standard O +
solution O +
was O +
made O -
. O -

Three O +
mg O +
of O +
component O +
was O +
weighed O +
to O +
the O +
nearest O +
0.01 O +
mg O +
and O +
diluted O +
to O +
500 O +
ml O +
in O +
a O +
volumetric O +
flask O -
, O +
using O +
absolute O +
ethanol O +
for O +
sterols O +
and O +
chloroform O +
for O +
stanols O -
. O -

Calibration O +
standard O +
solutions O +
containing O +
30 O +
μg O -
/ O -
ml O +
of O +
the O +
analyte O +
and O +
50 O +
μg O -
/ O -
ml O +
epicholesterol O +
were O +
prepared O +
in O +
batches O -
. O -

Solvent O +
was O +
evaporated O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
, O +
then O +
the O +
mixture O +
was O +
derivatized O +
with O +
1 O +
ml O +
pyridine O -
/ O -
BSTFA O +
as O +
described O +
for O +
samples O +
( O -
Section O +
2.4.4 O +
) O -
. O -

The O +
solution O +
was O +
distributed O +
among O +
ten O +
autosampler O +
vials O +
with O +
volume O +
reduction O +
inserts O +
( O -
∼100 O +
μl O -
/ O -
vial O -
) O +
and O +
stored O +
at O +
−60 O -
° O -
C O -
. O -

These O +
standards O +
were O +
used O +
to O +
determine O +
calibration O +
factors O +
and O +
to O +
check O +
instrument O +
calibration O +
throughout O +
the O +
study O -
. O -

Two O +
reference O +
standard O +
mixtures O +
were O +
prepared O +
and O +
run O +
with O +
each O +
batch O +
of O +
samples O +
to O +
determine O +
run O -
- O -
specific O +
retention O +
times O +
for O +
the O +
analytes O -
. O +
' O -

Reference O +
A O -
' O +
contained O +
5 O +
μg O -
/ O -
ml O +
each O +
of O +
sitosterol O -
, O +
lathosterol O -
, O +
campestanol O -
, O +
stigmasterol O -
, O +
and O +
sitostanol O -
. O +
' O -

Reference O +
B O -
' O +
contained O +
5 O +
μg O -
/ O -
ml O +
each O +
of O +
desmosterol O -
, O +
campesterol O -
, O +
lanosterol O -
, O +
and O +
fucosterol O -
. O -

2.3.5 O +
Preparation O +
of O +
quality O +
control O +
material O +
Accutrol O -
™ O +
Human U-Species +
Serum O +
( O -
normal O -
, O +
lyophilized O -
, O +
# O -
A2034 O -
; O +
Sigma O -
) O +
was O +
used O +
as O +
a O +
control O +
material O -
. O -

No O +
standard O +
serum O +
with O +
certified O +
or O +
reference O +
values O +
for O +
phytosterols O +
could O +
be O +
found O -
, O +
and O +
homogeneous O +
fortification O +
of O +
the O +
serum O +
with O +
sitostanol O +
was O +
not O +
feasible O -
. O -

Because O +
of O +
the O +
potential O +
heterogeneity O +
of O +
reconstituted O +
aliquots O +
of O +
lyophilized O +
serum O +
( O -
due O +
to O +
variable O +
loss O +
of O +
dried O +
material O +
during O +
reconstitution O -
) O -
, O +
and O +
because O +
we O +
required O +
a O +
large O +
number O +
of O +
homogeneous O +
aliquots O +
to O +
adequately O +
monitor O +
assay O +
precision O -
, O +
we O +
prepared O +
a O +
composite O +
of O +
reconstituted O +
Accutrol O -
™ O +
serum O +
and O +
dispensed O +
a O +
batch O +
of O +
380 O +
1.25-ml O +
aliquots O -
. O -

One O -
- O -
hundred O +
vials O +
of O +
the O +
lyophilized O +
Accutrol O -
™ O +
serum O +
( O -
from O +
the O +
same O +
lot O -
) O +
were O +
reconstituted O +
and O +
combined O -
. O -

In O +
batches O +
of O +
ten O +
at O +
a O +
time O -
, O +
vials O +
were O +
removed O +
from O +
the O +
refrigerator O +
and O +
each O +
was O +
reconstituted O +
with O +
5 O +
ml O +
of O +
distilled O +
deionized O +
water O -
, O +
mixed O +
well O -
, O +
and O +
allowed O +
to O +
stand O +
for O +
10–20 O +
min O +
at O +
room O +
temperature O +
( O -
20–23 O -
° O -
C O -
) O -
, O +
then O +
placed O +
in O +
the O +
refrigerator O +
( O -
2–4 O -
° O -
C O -
) O -
. O -

Within O +
3 O +
days O -
, O +
a O +
composite O +
of O +
the O +
reconstituted O +
serum O +
was O +
made O +
in O +
a O +
walk O -
- O -
in O +
cold O +
room O +
( O -
7 O -
° O -
C O -
) O -
. O -

As O +
much O +
as O +
possible O +
of O +
it O +
was O +
transferred O +
from O +
each O +
of O +
the O +
100 O +
serum O +
vials O +
to O +
a O +
500-ml O +
glass O +
reagent O +
bottle O -
, O +
which O +
was O +
then O +
covered O +
and O +
stirred O +
at O +
medium O -
– O -
high O +
speed O +
for O +
1 O +
h. O +
The O +
serum O +
was O +
then O +
dispensed O +
in O +
1.25-ml O +
aliquots O +
into O +
380 O +
2-ml O +
microcentrifuge O +
tubes O +
in O +
batches O +
of O +
ten O +
at O +
a O +
time O -
, O +
using O +
a O +
new O +
pipette O +
tip O +
after O +
every O +
ten O +
samples O -
. O -

The O +
tubes O +
were O +
stored O +
at O +
−80 O -
° O -
C O -
. O -

2.4 O +
Sample O +
preparation O +
2.4.1 O +
Total O +
lipid O +
extraction O +
Serum O +
samples O +
were O +
thawed O +
overnight O +
( O -
12–20 O +
h O -
) O +
at O +
2–4 O -
° O -
C O +
then O +
mixed O +
thoroughly O -
. O -

Using O +
a O +
calibrated O +
pipetter O -
, O +
0.90 O +
ml O +
serum O +
was O +
dispensed O +
into O +
a O +
test O +
tube O +
containing O +
the O +
internal O +
standard O +
( O -
5 O +
μg O +
epicholesterol O -
) O -
. O -

Total O +
lipid O +
was O +
extracted O +
by O +
a O +
modified O +
Folch O +
procedure O +
[ O -
9 O -
] O +
, O +
using O +
chloroform O -
– O -
methanol O +
( O -
2:1 O -
, O +
v O -
/ O -
v O -
) O +
followed O +
by O +
a O +
0.9 O -
% O +
saline O +
wash O -
, O +
as O +
follows O -
. O -

After O +
mixing O +
the O +
sample O -
, O +
0.9 O +
ml O +
of O +
methanol O +
was O +
added O -
, O +
then O +
tubes O +
were O +
capped O +
and O +
vortexed O +
at O +
high O +
speed O +
for O +
15 O +
s. O +
Samples O +
were O +
then O +
shaken O +
for O +
10 O +
min O +
on O +
an O +
orbital O +
shaker O +
at O +
300 O +
rpm O -
. O -

If O +
phases O +
separated O +
before O +
orbital O +
shaking O -
, O +
the O +
tubes O +
were O +
first O +
shaken O +
briefly O +
by O +
hand O -
. O -

Chloroform O +
( O -
2 O -
× O -
9.0 O +
ml O -
) O +
and O +
6.75 O +
ml O +
0.9 O -
% O +
( O -
w O -
/ O -
v O -
) O +
aqueous O +
sodium O +
chloride O +
were O +
added O -
, O +
tubes O +
were O +
capped O +
tightly O +
and O +
vortex O +
mixed O +
at O +
high O +
speed O +
for O +
15 O +
s O -
, O +
then O +
shaken O +
at O +
300 O +
rpm O +
on O +
the O +
orbital O +
shaker O +
for O +
10 O +
min O +
( O -
if O +
phases O +
began O +
to O +
separate O +
before O +
orbital O +
shaking O -
, O +
tubes O +
were O +
first O +
shaken O +
by O +
hand O +
for O +
a O +
few O +
seconds O +
to O +
remix O -
) O -
. O -

Samples O +
were O +
then O +
centrifuged O +
at O +
200 O +
g O -
at O +
20 O -
° O -
C O +
for O +
10 O +
min O +
to O +
facilitate O +
phase O +
separation O -
. O -

2.4.2 O +
Saponification O +
The O +
chloroform O +
( O -
lower O -
) O +
layer O +
from O +
each O +
total O +
lipid O +
extraction O +
was O +
transferred O +
to O +
a O +
25 O -
× O -
150 O +
mm O +
test O +
tube O -
. O -

Care O +
was O +
taken O +
not O +
to O +
transfer O +
any O +
of O +
the O +
emulsion O +
or O +
solid O +
material O +
at O +
the O +
interface O +
between O +
the O +
upper O +
and O +
lower O +
phases O -
, O +
by O +
pushing O +
out O +
any O +
material O +
that O +
entered O +
the O +
pipette O +
tip O +
before O +
drawing O +
in O +
the O +
chloroform O +
solution O -
. O -

A O +
new O +
pipette O +
tip O +
was O +
used O +
for O +
each O +
sample O -
. O -

The O +
total O +
lipid O +
extract O +
was O +
saponified O +
by O +
a O +
modification O +
of O +
a O +
method O +
previously O +
described O +
by O +
Thompson O +
and O +
Merola O +
[ O -
10 O -
] O +
. O -

Solvent O +
was O +
evaporated O +
completely O +
from O +
the O +
total O +
lipid O +
extract O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O -

Ethanol O +
with O +
3 O -
% O +
( O -
w O -
/ O -
v O -
) O +
pyrogallol O +
( O -
8 O +
ml O -
) O +
was O +
added O +
to O +
each O +
sample O -
. O -

Tubes O +
were O +
capped O +
and O +
vortexed O +
at O +
high O +
speed O +
for O +
10 O +
s O -
, O +
then O +
0.5 O +
ml O +
of O +
1.28 O +
g O -
/ O -
ml O +
aqueous O +
potassium O +
hydroxide O +
was O +
added O -
. O -

Tubes O +
were O +
capped O +
tightly O -
, O +
vortexed O +
for O +
10 O +
s O +
at O +
high O +
speed O -
, O +
sonicated O +
for O +
30 O +
s O -
, O +
then O +
heated O +
in O +
a O +
test O +
tube O +
rack O +
in O +
a O +
85–89 O -
° O -
C O +
water O +
bath O +
for O +
30 O +
min O -
, O +
ensuring O +
that O +
the O +
bottom O +
half O +
of O +
the O +
tubes O +
were O +
immersed O -
. O -

Tubes O +
( O -
in O +
rack O -
) O +
were O +
shaken O +
and O +
inverted O +
vigorously O +
after O +
1 O -
, O +
2 O -
, O +
5 O -
, O +
10 O -
, O +
15 O -
, O +
20 O -
, O +
25 O -
, O +
and O +
30 O +
min O +
of O +
heating O +
( O -
a O +
second O +
test O +
tube O +
rack O +
was O +
held O +
firmly O +
over O +
the O +
top O +
during O +
shaking O +
to O +
hold O +
the O +
tubes O -
) O -
. O -

The O +
capped O +
tubes O +
were O +
sonicated O +
again O +
for O +
30 O +
s O -
, O +
cooled O +
under O +
running O +
tap O +
water O -
, O +
then O +
slowly O +
opened O -
. O -

Cyclohexane O +
( O -
20 O +
ml O -
) O -
, O +
then O +
12 O +
ml O +
distilled O +
deionized O +
water O +
were O +
added O +
to O +
each O +
sample O -
. O -

Tubes O +
were O +
recapped O -
, O +
shaken O +
vigorously O +
for O +
a O +
few O +
seconds O -
, O +
then O +
rocked O +
15 O +
min O +
on O +
a O +
platform O +
mixer O +
at O +
maximum O +
speed O +
( O -
Thermolyne O +
Vari O -
- O -
Mix O +
platform O +
mixer O -
; O +
Barnstead O -
/ O -
Thermolyne O +
No. O +
48725 O -
) O -
. O -

No O +
residual O +
material O +
was O +
evident O +
in O +
the O +
bottom O +
or O +
on O +
the O +
sides O +
of O +
tubes O +
after O +
shaking O -
. O -

Samples O +
were O +
centrifuged O +
at O +
200 O +
g O -
at O +
20 O -
° O -
C O +
for O +
10 O +
min O +
to O +
accelerate O +
phase O +
separation O -
. O -

For O +
each O +
sample O -
, O +
17.0 O +
ml O +
( O -
2 O -
× O -
8.5 O +
ml O -
) O +
of O +
the O +
cyclohexane O +
( O -
upper O -
) O +
layer O +
was O +
transferred O +
to O +
a O +
25 O -
× O -
150 O +
mm O +
test O +
tube O -
, O +
with O +
care O +
taken O +
not O +
to O +
include O +
any O +
of O +
the O +
black O -
, O +
aqueous O +
phase O -
. O -

Cyclohexane O +
was O +
evaporated O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O -

Chloroform O +
( O -
0.5 O +
ml O -
) O +
was O +
added O +
to O +
each O +
sample O -
, O +
then O +
samples O +
were O +
vortexed O +
for O +
10 O +
s O +
at O +
high O +
speed O -
. O -

2.4.3 O +
Solid O -
- O -
phase O +
extraction O +
A O +
modification O +
of O +
the O +
method O +
of O +
Kaluzny O +
et O +
al. O +
[ O -
11 O -
] O -
was O +
used O +
to O +
separate O +
the O +
neutral O +
lipid O +
fraction O +
( O -
containing O +
sterols O +
and O +
stanols O -
) O +
from O +
more O +
polar O +
lipids O -
. O -

Bond O +
Elute O +
LRC O -
® O -
aminopropyl O +
solid O -
- O -
phase O +
extraction O +
( O -
SPE O -
) O +
cartridges O +
10 O +
ml O -
/ O -
500 O +
mg O +
( O -
Varian O +
Associates O -
, O +
Harbor O +
City O -
, O +
CA O -
, O +
USA O -
) O +
were O +
used O -
. O -

The O +
SPE O +
cartridges O +
were O +
attached O +
to O +
a O +
vacuum O +
manifold O +
( O -
Visaprep O +
DL O -
™ O -
; O +
Supelco O -
, O +
Bellefonte O -
, O +
PA O -
, O +
USA O -
) O +
set O +
at O +
slightly O +
less O +
than O +
1″ O +
Hg O +
with O +
valves O +
closed O -
. O -

Cartridges O +
were O +
conditioned O +
with O +
4 O +
ml O +
hexane O -
, O +
which O +
was O +
discarded O -
. O -

A O +
16 O -
× O -
125 O +
mm O +
glass O +
test O +
tube O +
was O +
placed O +
under O +
each O +
outlet O -
. O -

With O +
vacuum O +
valves O +
closed O +
and O +
using O +
a O +
new O +
pipette O +
tip O +
for O +
each O +
sample O -
, O +
sample O +
was O +
transferred O +
into O +
the O +
SPE O +
cartridge O -
, O +
directly O +
onto O +
the O +
adsorbent O -
, O +
repeating O +
until O +
as O +
much O +
as O +
possible O +
had O +
been O +
transferred O -
. O -

With O +
vacuum O +
set O +
at O +
slightly O +
less O +
than O +
1″ O +
Hg O -
, O +
valves O +
were O +
opened O +
one O +
by O +
one O +
until O +
the O +
sample O +
solution O +
had O +
just O +
completely O +
entered O +
the O +
adsorbent O -
, O +
then O +
turned O +
off O +
until O +
all O +
cartridges O +
had O +
been O +
set O -
. O -

Elution O +
solvent O +
( O -
chloroform O -
– O -
isopropanol O -
, O +
2:1 O -
, O +
v O -
/ O -
v O -
, O +
0.5 O +
ml O -
) O +
was O +
added O +
to O +
each O +
cartridge O -
. O -

The O +
solvent O +
was O +
then O +
drawn O +
under O +
vacuum O +
through O +
the O +
cartridges O +
one O +
at O +
a O +
time O +
until O +
it O +
reached O +
just O +
above O +
the O +
column O +
bed O -
, O +
then O +
valve O +
was O +
closed O +
until O +
all O +
samples O +
had O +
been O +
taken O +
to O +
this O +
stage O -
. O -

An O +
additional O +
3.5 O +
ml O +
of O +
the O +
elution O +
solvent O +
was O +
added O +
to O +
each O +
tube O -
, O +
then O +
all O +
valves O +
were O +
opened O +
and O +
the O +
solvent O +
was O +
allowed O +
to O +
pass O +
completely O +
( O -
dropwise O -
) O +
through O +
the O +
cartridges O -
. O -

The O +
vacuum O +
was O +
then O +
increased O +
to O +
draw O +
the O +
columns O +
dry O +
( O -
∼8″ O +
Hg O +
for O +
at O +
least O +
2 O +
min O -
) O -
. O -

2.4.4 O +
Derivatization O +
Solvent O +
was O +
completely O +
evaporated O +
from O +
samples O +
at O +
60 O -
° O -
C O +
with O +
a O +
stream O +
of O +
nitrogen O -
. O -

Freshly O +
prepared O +
derivatization O +
reagent O +
( O -
pyridine O -
– O -
BSTFA O +
with O +
1 O -
% O +
TMCS O -
, O +
1:1 O -
, O +
v O -
/ O -
v O -
) O -
, O +
100 O +
μl O -
, O +
was O +
pipetted O +
into O +
each O +
tube O +
and O +
vortex O +
mixed O +
for O +
10 O +
s. O -

The O +
reagent O +
was O +
then O +
carefully O +
swirled O +
around O +
and O +
∼2″ O +
up O +
the O +
sides O +
of O +
each O +
tube O -
. O -

Tubes O +
were O +
allowed O +
to O +
stand O +
at O +
least O +
1 O +
min O -
, O +
vortex O +
mixed O +
for O +
3 O +
s O -
, O +
then O +
allowed O +
to O +
stand O +
again O +
for O +
at O +
least O +
1 O +
min O -
. O -

Each O +
sample O +
was O +
transferred O +
using O +
a O +
9″ O +
glass O +
pasteur O +
pipette O +
into O +
a O +
100-μl O +
limited O +
volume O +
insert O +
in O +
an O +
autosampler O +
vial O -
, O +
sealed O +
with O +
a O +
PTFE O -
/ O -
silicone O +
septum O +
cap O -
, O +
and O +
stored O +
at O +
< O -
10 O -
° O -
C O +
until O +
assayed O +
by O +
GC O +
( O -
within O +
1 O +
week O -
) O -
. O -

2.4.5 O +
GC O +
analysis O +
and O +
quantitation O +
Analyte O +
retention O +
times O +
were O +
determined O +
using O +
commercially O +
available O +
standards O -
. O -

Analysis O +
of O +
selected O +
serum O +
samples O +
without O +
added O +
epicholesterol O +
internal O +
standard O +
confirmed O +
lack O +
of O +
sample O +
constituents O +
that O +
co O -
- O -
eluted O +
with O +
the O +
internal O +
standard O -
. O -

In O +
routine O +
assays O -
, O +
component O +
peaks O +
were O +
identified O +
by O +
the O +
adjusted O +
retention O +
time O -
, O +
which O +
compensated O +
for O +
any O +
shifts O +
in O +
expected O +
retention O +
times O +
based O +
on O +
that O +
of O +
the O +
internal O +
standard O +
[ O -
12 O -
] O +
. O -

A O +
relative O +
search O +
window O +
( O -
based O +
on O +
a O +
percent O +
of O +
the O +
absolute O +
retention O +
time O -
) O +
was O +
then O +
applied O +
to O +
the O +
adjusted O +
retention O +
time O +
as O +
the O +
criteria O +
for O +
identification O -
. O -

The O +
size O +
of O +
the O +
relative O +
search O +
window O +
was O +
determined O +
based O +
on O +
the O +
degree O +
of O +
absolute O +
retention O +
time O +
shift O +
that O +
was O +
expected O +
during O +
a O +
run O +
and O +
the O +
proximity O +
of O +
other O +
peaks O +
expected O +
in O +
the O +
samples O -
. O -

After O +
determining O +
the O +
method O +
was O +
linear O +
over O +
the O +
expected O +
concentration O +
ranges O +
( O -
below O -
) O -
, O +
analytes O +
were O +
quantified O +
based O +
on O +
a O +
single O +
point O +
response O +
factor O +
( O -
RF O -
) O -
:RF O +
= O -
RC O -
/RIS O -
MC O -
/MIS O -
where O +
R O +
C O -
is O +
the O +
peak O +
area O +
for O +
the O +
component O -
, O +
R O +
IS O -
is O +
the O +
peak O +
area O +
for O +
the O +
internal O +
standard O -
, O +
M O +
C O -
is O +
the O +
amount O +
of O +
component O +
and O +
M O +
IS O -
is O +
the O +
amount O +
of O +
internal O +
standard O +
added O +
to O +
the O +
sample O -
. O -

For O +
each O +
analyte O -
, O +
the O +
RF O +
was O +
determined O +
at O +
3 O +
μg O +
as O +
the O +
average O +
of O +
triplicate O +
analysis O +
of O +
standards O -
. O -

In O +
samples O -
, O +
each O +
component O +
( O -
M O +
C O +
) O +
was O +
determined O +
using O +
the O +
response O +
factor O +
for O +
that O +
component O +
and O +
R O +
C O -
and O +
R O +
IS O -
determined O +
from O +
the O +
GC O +
analysis O -
. O -

Baseline O +
events O +
( O -
timed O +
events O +
in O +
the O +
instrument O +
method O +
which O +
effect O +
integration O +
of O +
peaks O -
) O +
were O +
set O +
up O +
in O +
the O +
standard O +
( O -
routine O -
) O +
Turbochrom O -
™ O +
method O +
file O +
based O +
on O +
optimal O +
consistency O +
of O +
peak O +
integration O +
for O +
the O +
control O +
sample O -
. O -

In O +
sample O +
runs O -
, O +
individual O +
attention O +
was O +
paid O +
to O +
the O +
chromatograms O +
to O +
avoid O +
and O +
correct O +
any O +
obvious O +
integration O +
problems O +
( O -
usually O +
as O +
a O +
result O +
of O +
small O +
peak O +
size O +
and O +
interfering O +
peaks O -
) O -
, O +
by O +
modifying O +
baseline O +
events O +
as O +
necessary O -
. O -

2.5 O +
Linearity O -
, O +
limit O +
of O +
detection O -
, O +
and O +
limit O +
of O +
quantitation O +
studies O +
The O +
expected O +
concentration O +
ranges O +
for O +
desmosterol O -
, O +
lathosterol O -
, O +
campesterol O -
, O +
sitosterol O -
, O +
stigmasterol O -
, O +
campestanol O -
, O +
sitostanol O -
, O +
lanosterol O -
, O +
and O +
fucosterol O +
were O +
tested O +
for O +
linearity O -
. O -

For O +
each O +
compound O -
, O +
standard O +
solutions O +
were O +
made O +
at O +
four O +
or O +
five O +
different O +
concentrations O +
between O +
0.05 O +
μg O -
/ O -
ml O +
and O +
25 O +
μg O -
/ O -
ml O -
. O -

Each O +
standard O +
solution O +
was O +
derivatized O +
and O +
assayed O +
in O +
duplicate O +
at O +
all O +
concentrations O -
, O +
except O +
in O +
quintuplicate O +
at O +
0.75 O +
μg O -
/ O -
ml O +
for O +
desmosterol O -
, O +
lanosterol O -
, O +
fucosterol O -
, O +
campestanol O -
, O +
and O +
sitostanol O +
and O +
at O +
5 O +
μg O -
/ O -
ml O +
for O +
campesterol O -
, O +
sitosterol O -
, O +
and O +
stigmasterol O -
. O -

For O +
each O +
compound O -
, O +
a O +
linear O +
regression O +
was O +
performed O +
on O +
the O +
data O +
( O -
component O -
/ O -
internal O +
standard O +
area O +
ratio O +
vs. O +
component O -
/ O -
internal O +
standard O +
mass O +
ratio O -
) O -
. O -

All O +
curves O +
were O +
linear O -
, O +
above O +
the O +
limit O +
of O +
detection O -
, O +
in O +
the O +
concentration O +
range O +
tested O +
( O -
r O +
2 O +
= O -
0.99 O +
or O +
greater O +
in O +
all O +
cases O -
) O -
. O -

The O +
method O +
limit O +
of O +
detection O +
( O -
MLOD O -
) O +
and O +
limit O +
of O +
quantitation O +
( O -
MLOQ O -
) O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O +
were O +
determined O +
from O +
results O +
of O +
the O +
repeated O +
analyses O +
( O -
n O +
= O -
55 O -
) O +
of O +
0.9-ml O +
aliquots O +
of O +
the O +
Accutrol O -
™ O +
control O +
serum O +
composite O -
. O -

For O +
each O +
component O -
, O +
the O +
MLOD O +
was O +
calculated O +
as O +
three O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O +
and O +
the O +
MLOQ O +
was O +
estimated O +
as O +
ten O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O +
of O +
the O +
55 O +
measurements O -
. O -

Since O +
sitostanol O +
and O +
campestanol O +
were O +
not O +
present O +
in O +
the O +
control O +
serum O +
and O +
lanosterol O +
and O +
stigmasterol O +
were O +
barely O +
detectable O -
, O +
the O +
MLODs O +
and O +
MLOQs O +
for O +
these O +
components O +
were O +
determined O +
by O +
analysis O +
of O +
the O +
Accutrol O -
™ O +
serum O +
spiked O +
with O +
known O +
amounts O +
of O +
standards O -
, O +
as O +
follows O -
. O -

A O +
chloroform O +
solution O +
containing O +
0.5 O +
μg O -
/ O -
ml O +
of O +
stigmasterol O -
, O +
sitostanol O -
, O +
and O +
lanosterol O +
and O +
1 O +
μg O -
/ O -
ml O +
of O +
campestanol O +
was O +
prepared O -
. O -

One O +
ml O +
of O +
the O +
solution O +
was O +
added O +
to O +
each O +
of O +
seven O +
0.9-ml O +
Accutrol O -
™ O +
composite O +
aliquots O -
, O +
which O +
were O +
then O +
assayed O +
as O +
described O +
above O -
, O +
except O +
for O +
the O +
volume O +
of O +
chloroform O +
added O +
during O +
the O +
total O +
lipid O +
extraction O +
which O +
was O +
reduced O +
by O +
the O +
volume O +
of O +
standard O +
added O -
. O -

MLOD O +
was O +
calculated O +
as O +
three O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O -
, O +
and O +
MLOQ O +
was O +
calculated O +
as O +
ten O +
times O +
the O +
standard O +
deviation O +
of O +
the O +
mean O +
of O +
the O +
seven O +
measurements O -
. O -

We O +
also O +
checked O +
the O +
method O +
performance O +
in O +
assaying O +
smaller O +
serum O +
aliquots O -
, O +
which O +
may O +
be O +
of O +
interest O +
when O +
the O +
sample O +
volume O +
is O +
limited O -
. O -

Seven O +
0.5-ml O +
and O +
seven O +
0.25-ml O +
aliquots O +
of O +
the O +
control O +
serum O +
composite O +
unspiked O +
and O +
spiked O +
with O +
sitostanol O -
, O +
campestanol O -
, O +
stigmasterol O -
, O +
and O +
lanosterol O +
in O +
amounts O +
near O +
the O +
MLOQ O +
determined O +
for O +
analysis O +
of O +
0.9 O +
ml O +
serum O +
were O +
assayed O -
. O -

A O +
chloroform O +
solution O +
of O +
sitostanol O -
, O +
campestanol O -
, O +
stigmasterol O -
, O +
and O +
lanosterol O +
was O +
added O +
to O +
three O +
0.25 O +
ml O +
and O +
three O +
0.5-ml O +
aliquots O +
of O +
the O +
Accutrol O -
™ O +
control O +
composite O +
such O +
that O +
final O +
concentrations O +
were O +
1 O +
μg O -
/ O -
ml O +
campestanol O +
and O +
0.5 O +
μg O -
/ O -
ml O +
sitostanol O -
, O +
stigmasterol O -
, O +
and O +
lanosterol O -
. O -

Additionally O -
, O +
seven O +
serum O +
samples O +
from O +
a O +
clinical O +
feeding O +
trial O +
[ O -
2 O -
] O +
, O +
in O +
which O +
sitostanol O +
was O +
detected O -
, O +
were O +
re O -
- O -
assayed O +
in O +
0.25-ml O +
aliquots O +
and O +
compared O +
to O +
the O +
results O +
from O +
analysis O +
of O +
the O +
0.9-ml O +
aliquots O -
. O -

2.6 O +
Recovery O +
studies O +
Recovery O +
analysis O +
was O +
based O +
on O +
fortification O +
of O +
samples O +
of O +
the O +
control O +
serum O +
composite O -
. O -

For O +
the O +
analytes O +
not O +
present O +
in O +
the O +
control O +
material O -
, O +
fortification O +
was O +
performed O +
at O +
four O +
different O +
concentrations O +
and O +
reported O +
for O +
all O +
concentrations O +
at O +
or O +
above O +
the O +
MLOQ O +
determined O +
for O +
the O +
individual O +
compounds O -
. O -

For O +
the O +
compounds O +
present O +
in O +
the O +
control O +
serum O -
, O +
samples O +
were O +
fortified O +
at O +
one O +
concentration O -
, O +
which O +
was O +
approximately O +
the O +
same O +
as O +
that O +
determined O +
from O +
analysis O +
of O +
the O +
control O +
serum O -
. O -

For O +
these O +
samples O -
, O +
the O +
values O +
calculated O +
for O +
the O +
unfortified O +
control O +
sample O +
analyzed O +
and O +
chromatographed O +
in O +
the O +
same O +
assay O +
were O +
subtracted O +
from O +
the O +
fortified O +
control O +
sample O +
values O +
to O +
determine O +
recovery:%R O -
= O -
Mfc O -
−Mc O -
Mf O -
×100 O -
where O +
% O -
R O -
is O +
percent O +
recovery O -
, O +
M O +
fc O -
is O +
the O +
raw O +
amount O +
in O +
μg O +
of O +
component O +
determined O +
in O +
the O +
fortified O +
sample O -
, O +
M O +
c O -
is O +
the O +
raw O +
amount O +
in O +
μg O +
of O +
component O +
in O +
the O +
unfortified O +
material O -
, O +
and O +
M O +
f O -
is O +
the O +
fortification O +
amount O +
in O +
μg O -
. O -

2.6.1 O +
Precision O +
studies O +
For O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
desmosterol O -
, O +
and O +
lanosterol O -
, O +
precision O +
was O +
evaluated O +
from O +
the O +
results O +
of O +
repeated O +
analyses O +
of O +
the O +
control O +
sample O +
( O -
Accutrol O -
™ O -
) O -
. O -

For O +
sitostanol O -
, O +
campestanol O -
, O +
and O +
stigmasterol O -
, O +
precision O +
was O +
estimated O +
from O +
repeated O +
analyses O +
of O +
the O +
control O +
composite O +
spiked O +
with O +
a O +
standard O +
mixture O +
of O +
these O +
components O -
. O -

2.7 O +
Routine O +
quality O +
control O +
Prior O +
to O +
analysis O +
of O +
unknown O +
samples O -
, O +
three O +
assay O +
batches O +
of O +
5–13 O +
aliquots O +
of O +
the O +
serum O +
control O +
material O +
( O -
Section O +
2.3.5 O -
) O -
were O +
analyzed O +
over O +
a O +
period O +
of O +
2 O +
weeks O -
. O -

A O +
control O +
chart O +
showing O +
the O +
mean O +
and O +
tolerance O +
limits O +
( O -
±3 O +
times O +
the O +
standard O +
deviation O -
) O +
was O +
established O +
for O +
each O +
analyte O +
and O +
used O +
to O +
monitor O +
subsequent O +
assays O +
( O -
[ O -
13 O -
] O +
, O +
pp O -
. O -

130–132 O -
) O -
. O -

An O +
aliquot O +
of O +
the O +
control O +
serum O +
composite O +
was O +
assayed O +
with O +
each O +
batch O +
of O +
samples O -
. O -

3 O +
Results O +
and O +
discussion O +
3.1 O +
Chromatograms O +
Representative O +
chromatograms O +
for O +
standards O -
, O +
the O +
control O +
serum O -
, O +
and O +
a O +
serum O +
sample O +
from O +
the O +
diet O +
intervention O +
( O -
which O +
contained O +
sitostanol O +
and O +
campestanol O -
) O +
are O +
shown O +
in O +
Fig. O +
1 O -
. O -

3.2 O +
Retention O +
times O +
and O +
response O +
factors O +
Table O +
1 O -
summarizes O +
the O +
retention O +
times O -
, O +
relative O +
retention O +
times O -
, O +
and O +
response O +
factors O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
desmosterol O -
, O +
lathosterol O -
, O +
and O +
also O +
lanosterol O -
, O +
fucosterol O -
, O +
and O +
squalene O +
using O +
the O +
present O +
method O -
. O -

Whereas O +
absolute O +
retention O +
times O +
sometimes O +
varied O +
up O +
to O +
0.2 O +
min O -
. O -

( O -
e.g. O +
from O +
slight O +
changes O +
in O +
column O +
activity O +
and/or O +
head O +
pressure O -
) O -
, O +
relative O +
retention O +
times O +
were O +
consistent O +
within O +
0.02 O +
min O +
across O +
runs O -
. O -

3.3 O +
Linearity O -
, O +
limits O +
of O +
detection O -
, O +
limits O +
of O +
quantitation O -
, O +
and O +
analytical O +
ranges O +
Table O +
2 O -
summarizes O +
the O +
method O +
linear O +
range O -
, O +
limit O +
of O +
detection O +
( O -
MLOD O -
) O -
, O +
and O +
limit O +
of O +
quantitation O +
( O -
MLOQ O -
) O +
for O +
each O +
component O +
( O -
sitosterol O -
, O +
campesterol O -
, O +
stigmasterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
desmosterol O -
, O +
lathosterol O -
, O +
lanosterol O -
) O +
in O +
the O +
present O +
study O -
. O -

The O +
method O +
enabled O +
detection O +
of O +
all O +
components O +
at O +
concentrations O +
of O +
< O -
0.4 O +
μg O -
/ O -
ml O +
( O -
< O -
1 O +
μmol O -
/ O -
l O -
) O -
. O -

The O +
greatest O +
sensitivity O +
was O +
for O +
sitostanol O +
( O -
0.05 O +
μg O -
/ O -
ml O -
; O +
0.1 O +
μmol O -
/ O -
l O -
) O +
and O +
the O +
least O +
for O +
campesterol O +
and O +
campestanol O +
( O -
0.4 O +
μg O -
/ O -
ml O -
; O +
1 O +
μmol O -
/ O -
l O -
) O -
. O -

The O +
decreased O +
sensitivity O +
for O +
campesterol O +
and O +
campestanol O +
was O +
largely O +
due O +
to O +
interfering O +
peaks O +
in O +
the O +
region O +
which O +
limited O +
the O +
reliability O +
of O +
peak O +
area O +
estimates O +
at O +
low O +
analyte O +
levels O -
. O -

The O +
MLOQ O +
ranged O +
from O +
0.2 O +
μg O -
/ O -
ml O +
( O -
0.5 O +
μmol O -
/ O -
l O -
) O +
for O +
sitostanol O +
to O +
1.2 O +
μg O -
/ O -
ml O +
( O -
3 O +
μmol O -
/ O -
l O -
) O +
for O +
campesterol O +
and O +
campestanol O -
. O -

Response O +
was O +
linear O +
in O +
the O +
range O +
analyzed O +
for O +
each O +
component O +
( O -
MLOQ O +
to O +
10 O +
or O +
25 O +
μg O -
/ O -
ml O -
) O -
. O -

The O +
statistically O +
determined O +
MLOD O +
and O +
MLOQ O +
( O -
defined O +
as O +
three O +
and O +
ten O +
times O +
the O +
standard O +
deviation O +
of O +
replicates O -
, O +
respectively O -
; O +
13 O -
, O +
p. O +
80 O -
) O +
included O +
effects O +
of O +
inconsistent O +
automated O +
peak O +
integration O +
due O +
to O +
background O +
interferences O -
. O -

The O +
statistically O +
determined O +
MLOQ O +
for O +
lanosterol O +
was O +
0.1 O +
μg O -
/ O -
ml O -
, O +
and O +
lanosterol O +
was O +
present O +
in O +
the O +
unfortified O +
control O +
serum O +
at O +
approximately O +
this O +
level O -
. O -

However O -
, O +
uncertainty O +
in O +
quantitation O +
of O +
lanosterol O +
occurred O +
due O +
to O +
occasional O +
incomplete O +
resolution O +
from O +
a O +
nearby O +
peak O -
, O +
and O +
the O +
results O +
for O +
55 O +
analyses O +
of O +
the O +
control O +
material O +
and O +
control O +
material O +
spiked O +
with O +
various O +
levels O +
of O +
lanosterol O +
( O -
Table O +
4 O +
) O +
suggested O +
that O +
the O +
practical O +
MLOQ O +
was O +
somewhat O +
higher O +
than O +
0.1 O +
μg O -
/ O -
ml O -
. O -

Therefore O -
, O +
the O +
MLOQ O +
and O +
MLOD O +
for O +
lanosterol O +
reported O +
in O +
Table O +
2 O -
are O +
estimated O +
based O +
on O +
these O +
practical O +
findings O -
. O -

3.4 O +
Recovery O +
Recovery O +
of O +
spiked O +
standards O +
is O +
shown O +
in O +
Table O +
3 O -
and O +
appeared O +
quantitative O +
for O +
lathosterol O -
, O +
campesterol O -
, O +
sitosterol O -
, O +
sitostanol O -
, O +
campestanol O -
, O +
lanosterol O -
, O +
and O +
stigmasterol O -
. O -

Recovery O +
of O +
fortified O +
desmosterol O +
was O +
74 O -
% O -
. O -

The O +
reason O +
for O +
this O +
result O +
is O +
unknown O -
; O +
we O +
did O +
not O +
attempt O +
to O +
repeat O +
the O +
experiment O -
. O -

3.5 O +
Precision O +
Table O +
4 O -
summarizes O +
the O +
mean O -
, O +
standard O +
deviation O -
, O +
and O +
relative O +
standard O +
deviation O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
desmosterol O -
, O +
lathosterol O -
, O +
and O +
lanosterol O +
concentrations O +
assayed O +
in O +
the O +
control O +
material O +
over O +
the O +
course O +
of O +
23 O +
assay O +
batches O +
by O +
two O +
analysts O +
over O +
a O +
2-month O +
period O -
. O -

Because O +
sitostanol O -
, O +
campestanol O -
, O +
and O +
stigmasterol O +
are O +
not O +
components O +
of O +
the O +
Accutrol O -
™ O +
serum O +
and O +
could O +
not O +
be O +
readily O +
and O +
homogeneously O +
fortified O -
, O +
no O +
control O +
data O +
were O +
generated O +
for O +
these O +
compounds O -
. O -

For O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O -
, O +
the O +
standard O +
deviation O +
over O +
all O +
analyses O +
ranged O +
from O +
0.02 O +
μg O -
/ O -
ml O +
( O -
lanosterol O -
) O +
to O +
0.12 O +
μg O -
/ O -
ml O +
( O -
campesterol O -
) O -
. O -

The O +
within O -
- O -
assay O +
standard O +
deviations O +
were O +
similar O +
to O +
the O +
overall O +
RSD O +
for O +
all O +
components O -
. O -

The O +
relative O +
standard O +
deviation O +
for O +
lanosterol O +
was O +
much O +
higher O +
than O +
for O +
other O +
components O +
( O -
14 O -
% O -
) O -
, O +
due O +
to O +
the O +
low O +
concentration O +
in O +
the O +
control O +
sample O +
( O -
0.1 O +
μg O -
/ O -
ml O -
) O -
. O -

Quality O +
control O +
charts O +
for O +
lathosterol O +
and O +
campesterol O +
in O +
the O +
control O +
serum O +
are O +
shown O +
in O +
Fig. O +
2 O -
. O -

3.6 O +
Method O +
performance O +
in O +
assay O +
of O +
smaller O +
volumes O +
of O +
serum O +
Table O +
5 O -
shows O +
data O +
from O +
the O +
analyses O +
of O +
fortified O +
( O -
sitostanol O -
, O +
campestanol O -
, O +
lanosterol O -
, O +
stigmasterol O -
) O +
and O +
unfortified O +
0.25- O -
, O +
0.5- O -
, O +
and O +
0.9-ml O +
aliquots O +
of O +
the O +
control O +
serum O +
composite O -
. O -

All O +
compounds O +
were O +
fortified O +
at O +
concentrations O +
near O +
the O +
MLOQ O +
determined O +
for O +
analysis O +
of O +
0.9 O +
ml O +
( O -
Table O +
2 O +
) O -
. O -

Results O +
for O +
sitosterol O -
, O +
campesterol O -
, O +
lathosterol O -
, O +
desmosterol O -
, O +
sitostanol O -
, O +
and O +
campestanol O +
were O +
similar O +
for O +
all O +
volumes O +
analyzed O -
, O +
suggesting O +
that O +
for O +
these O +
components O -
, O +
sensitivity O +
and O +
precision O +
are O +
not O +
compromised O +
by O +
assaying O +
as O +
low O +
as O +
0.25 O +
ml O -
. O -

In O +
the O +
fortified O +
serum O -
, O +
however O -
, O +
lanosterol O +
and O +
stigmasterol O +
that O +
were O +
measured O +
in O +
the O +
0.9-ml O +
aliquots O +
were O +
undetectable O +
in O +
the O +
smaller O +
aliquots O -
. O -

Table O +
6 O -
summarizes O +
results O +
from O +
analyses O +
of O +
0.25- O +
and O +
0.9-ml O +
aliquots O +
of O +
seven O +
sitostanol O -
- O -
containing O +
serum O +
samples O +
( O -
from O +
the O +
feeding O +
trial O -
) O -
, O +
which O +
were O +
analyzed O +
to O +
compare O +
the O +
sensitivity O +
of O +
the O +
method O +
in O +
measuring O +
naturally O +
occurring O +
( O -
i.e. O +
unfortified O -
) O +
sitostanol O +
in O +
smaller O +
and O +
larger O +
sample O +
volumes O -
. O -

The O +
0.25-ml O +
assay O +
failed O +
to O +
detect O +
sitostanol O +
in O +
four O +
of O +
the O +
seven O +
samples O +
and O +
lanosterol O +
in O +
all O +
seven O +
samples O -
. O -

For O +
sitosterol O +
( O -
mean O +
2.24 O +
μg O -
/ O -
ml O -
) O -
, O +
stigmasterol O +
( O -
not O +
detected O -
) O +
and O +
campestanol O +
( O -
not O +
detected O -
) O +
results O +
were O +
similar O +
in O +
both O +
analyses O -
. O -

For O +
campesterol O -
, O +
lathosterol O -
, O +
and O +
desmosterol O -
, O +
results O +
were O +
somewhat O +
lower O +
( O -
3–25 O -
% O +
on O +
average O -
) O +
for O +
the O +
0.25-ml O +
aliquots O -
. O -

These O +
results O +
suggest O +
that O +
in O +
a O +
range O +
of O +
actual O +
serum O +
samples O +
the O +
sensitivity O +
of O +
the O +
analysis O +
may O +
be O +
reduced O +
when O +
0.25-ml O +
vs. O +
0.9-ml O +
is O +
assayed O -
, O +
especially O +
for O +
lanosterol O +
and O +
sitostanol O -
. O -

4 O +
Conclusions O +
A O +
sensitive O +
and O +
precise O +
method O +
was O +
developed O +
for O +
quantitation O +
of O +
phytosterols O -
, O +
stanols O -
, O +
and O +
selected O +
cholesterol O +
metabolites O +
in O +
human U-Species +
serum O -
. O -

Analytes O +
were O +
detected O +
at O +
levels O +
of O +
120 O +
ng O -
/ O -
ml O +
to O +
6 O +
μg O -
/ O -
ml O +
with O +
standard O +
deviations O +
of O +
0.02 O +
to O +
0.12 O +
μg O -
/ O -
ml O -
. O -

We O +
have O +
communicated O +
the O +
method O +
in O +
detail O +
to O +
facilitate O +
its O +
reproduction O +
in O +
other O +
laboratories O -
. O -

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
Fleischmann O -
's O +
Tablespread O +
Company O -
. O -

We O +
gratefully O +
acknowledge O +
technical O +
advice O +
from O +
Dr. O +
Robert O +
Whiton O +
in O +
evaluating O +
method O +
performance O +
parameters O +
and O +
chromatography O +
issues O -
. O +

The O +
majority O +
of O +
adult O +
cancers O +
are O +
carcinomas O +
of O +
epithelial O +
origin O +
with O +
lung O -
, O +
colon O -
, O +
and O +
uterus O +
as O +
the O +
primary O +
sites O -
, O +
which O +
reflects O +
a O +
selective O +
vulnerability O +
of O +
these O +
tissues O +
to O +
carcinogenic O +
insult O +
as O +
a O +
result O +
of O +
frequent O +
exposure O +
to O +
external O +
environment O -
. O -

Indeed O -
, O +
it O +
is O +
estimated O +
that O +
up O +
to O +
80 O +
to O +
90 O -
% O +
of O +
all O +
cancers O +
are O +
attributable O +
to O +
environmental O +
risk O +
factors O -
, O +
including O +
chemicals O -
, O +
radiations O -
, O +
and O +
viruses O -
. O -

The O +
notion O +
that O +
a O +
majority O +
of O +
human U-Species +
cancers O +
have O +
an O +
environmental O +
origin O +
implies O +
an O +
optimistic O +
outlook O +
in O +
terms O +
of O +
cancer O +
prevention O +
since O +
most O +
cancer O -
- O -
causing O +
substances O +
are O +
introduced O +
into O +
the O +
environment O +
by O +
human U-Species +
activities O +
and O +
are O +
hence O -
, O +
controllable O +
or O +
removable O -
. O -

The O +
elimination O +
of O +
environmental O +
carcinogens O +
or O +
at O +
least O +
avoiding O +
exposure O +
to O +
them O +
offers O +
the O +
opportunity O +
to O +
prevent O +
most O +
cancers O -
, O +
which O +
is O +
a O +
basis O +
of O +
primary O +
prevention O -
. O -

Recent O +
advances O +
in O +
our O +
understanding O +
at O +
the O +
cellular O +
and O +
molecular O +
levels O +
of O +
carcinogenesis O +
have O +
led O +
to O +
the O +
development O +
of O +
a O +
new O +
promising O +
strategy O +
for O +
cancer O +
prevention O -
, O +
that O +
is O -
, O +
chemoprevention O +
[ O -
1–3 O -
] O +
. O -

Chemoprevention O +
is O +
defined O +
as O +
the O +
use O +
of O +
specific O +
chemical O +
substances O +
( O -
natural O +
or O +
synthetic O -
) O +
or O +
their O +
mixtures O +
to O +
suppress O -
, O +
retard O -
, O +
or O +
reverse O +
the O +
process O +
of O +
carcinogenesis O -
. O -

It O +
is O +
one O +
of O +
the O +
novel O +
approaches O +
of O +
controlling O +
cancer O +
alternative O +
to O +
therapy O +
that O +
has O +
some O +
limitations O +
and O +
drawbacks O +
in O +
the O +
treatment O +
of O +
patients U-Species -
. O -

The O +
term O +
chemoprevention O +
was O +
initially O +
coined O +
by O +
Michael O +
Sporn O +
who O +
utilized O +
retinoids O +
to O +
halt O +
experimental O +
carcinogenesis O +
[ O -
4 O -
] O +
. O -

Since O +
we O +
are O +
all O +
exposed O +
in O +
greater O +
or O +
lesser O +
degree O +
to O +
environmental O +
carcinogens O +
from O +
diverse O +
sources O -
, O +
it O +
is O +
important O +
to O +
find O +
a O +
way O +
to O +
neutralize O +
these O +
carcinogens O +
or O +
protect O +
against O +
deleterious O +
effects O +
they O +
exert O -
. O -

In O +
this O +
respect O -
, O +
chemoprevention O +
offers O +
a O +
realistic O +
promise O +
of O +
reducing O +
the O +
incidence O +
of O +
human U-Species +
cancer O -
. O -

The O +
primary O +
goal O +
of O +
chemoprevention O +
research O +
is O +
to O +
identify O +
effective O +
agents O +
and/or O +
develop O +
efficient O +
strategies O +
for O +
clinical O +
trials O +
and O +
ultimately O -
, O +
application O +
to O +
human U-Species +
populations O -
. O -

In O +
order O +
to O +
better O +
practice O +
the O +
chemoprevention O -
, O +
one O +
must O +
precisely O +
understand O +
the O +
nature O +
and O +
mechanisms O +
of O +
carcinogenesis O -
. O -

2 O +
Molecular O +
basis O +
of O +
chemoprevention O +
Carcinogenesis O +
is O +
characterized O +
by O +
a O +
complex O +
process O +
that O +
involves O +
a O +
series O +
of O +
individual O +
steps O -
. O -

From O +
the O +
stand O +
point O +
of O +
the O +
experimental O +
carcinogenesis O +
in O +
rodents U-Species -
, O +
tumor O +
development O +
has O +
been O +
generally O +
considered O +
to O +
consist O +
of O +
three O +
distinct O +
steps O -
— O -
initiation O -
, O +
promotion O -
, O +
and O +
progression O +
as O +
depicted O +
in O +
Fig. O +
1 O -
. O -

Initiation O +
is O +
an O +
irreversible O +
event O +
that O +
begins O +
when O +
the O +
cells O +
in O +
normal O +
tissues O +
are O +
exposed O +
to O +
a O +
carcinogen O +
and O +
their O +
genomic O +
DNA O +
undergoes O +
damage O +
that O +
remains O +
unrepaired O +
or O +
misrepaired O -
. O -

In O +
case O +
of O +
chemically O -
- O -
induced O +
carcinogenesis O -
, O +
initiation O +
involves O +
uptake O +
of O +
a O +
given O +
carcinogenic O +
agent O +
with O +
subsequent O +
distribution O +
and O +
transport O +
to O +
organs O +
and O +
tissues O +
where O +
metabolism O +
occurs O -
, O +
the O +
interaction O +
of O +
a O +
reactive O +
metabolite O +
with O +
cellular O +
DNA O +
with O +
subsequent O +
structural O +
alterations O +
in O +
the O +
DNA O +
molecule O -
, O +
and O +
final O +
fixation O +
of O +
the O +
genotoxic O +
damage O +
to O +
cause O +
mutation O -
. O -

The O +
resulting O +
somatic O +
mutation O +
in O +
a O +
damaged O +
cell O +
can O +
be O +
reproduced O +
during O +
mitosis O -
, O +
which O +
gives O +
rise O +
to O +
a O +
clone O +
of O +
mutated O +
cells O -
. O -

Promotion O +
is O +
expansion O +
of O +
the O +
damaged O +
cells O +
to O +
form O +
an O +
actively O +
proliferating O +
multi O -
- O -
cellular O +
premalignant O +
tumor O +
cell O +
population O -
. O -

Progression O +
is O +
the O +
irreversible O +
process O +
which O +
produces O +
a O +
new O +
clone O +
of O +
tumor O +
cells O +
with O +
increased O +
proliferative O +
capacity O -
, O +
invasiveness O -
, O +
and O +
metastatic O +
potential O -
. O -

Conventional O +
classification O +
of O +
chemopreventive O +
agents O -
, O +
first O +
proposed O +
by O +
Wattenberg O +
[ O -
5 O -
] O +
, O +
is O +
based O +
on O +
the O +
underlying O +
mechanisms O +
by O +
which O +
they O +
exert O +
protective O +
effects O +
in O +
a O +
specific O +
stage O +
of O +
multi O -
- O -
step O +
carcinogenesis O -
. O -

According O +
to O +
this O +
system O -
, O +
chemopreventers O +
are O +
subdivided O +
into O +
two O +
major O +
categories O -
, O +
i.e. O -
, O +
blocking O +
agents O +
and O +
suppressing O +
agents O +
( O -
Fig. O +
2 O -
) O -
. O -

Blocking O +
agents O +
are O +
typically O +
those O +
compounds O +
that O +
can O +
inhibit O +
initiation O +
either O +
by O +
inhibiting O +
the O +
formation O +
of O +
carcinogens O +
from O +
precursor O +
molecules O +
or O +
reactive O +
metabolites O +
from O +
the O +
parent O +
carcinogens O -
, O +
or O +
by O +
preventing O +
the O +
ultimate O +
electrophilic O +
and O +
carcinogenic O +
species O +
from O +
interacting O +
with O +
critical O +
cellular O +
target O +
molecules O -
, O +
such O +
as O +
DNA O -
, O +
RNA O -
, O +
and O +
proteins O -
. O -

Suppressing O +
agents O +
are O +
considered O +
to O +
inhibit O +
malignant O +
expression O +
of O +
initiated O +
cells O -
, O +
in O +
either O +
the O +
promotion O +
or O +
the O +
progression O +
stage O -
. O -

Certain O +
chemopreventive O +
agents O +
( O -
e.g. O -
, O +
curcumin O +
and O +
resveratrol O -
) O +
have O +
more O +
than O +
one O +
defined O +
mechanism O +
of O +
action O -
, O +
and O +
hence O -
, O +
possess O +
both O +
blocking O +
and O +
suppressive O +
properties O +
[ O -
6 O -
] O +
. O -

A O +
vast O +
variety O +
of O +
chemical O +
compounds O +
have O +
been O +
identified O +
to O +
elicit O +
pronounced O +
chemopreventive O +
effects O +
and O +
many O +
of O +
them O +
are O +
of O +
plant U-Species +
origin O +
that O +
are O +
present O +
naturally O +
in O +
our O +
daily O +
foods O +
or O +
have O +
been O +
used O +
for O +
traditional O +
herbal U-Species +
medication O +
[ O -
7–9 O -
] O +
. O -

Some O +
spices U-Species +
or O +
herbs U-Species +
contain O +
bioactive O +
phenolic O +
substances O +
with O +
potent O +
antimutagenic O +
and O +
anticarcinogenic O +
properties O -
. O -

3 O +
Some O +
novel O +
strategies O +
applicable O +
for O +
identifying O +
chemopreventive O +
phytochemicals O +
Numerous O +
phenolic O +
substances O +
present O +
in O +
fruits U-Species +
and O +
vegetables U-Species +
or O +
in O +
medicinal O +
plants U-Species +
have O +
been O +
found O +
to O +
retain O +
potential O +
cancer O +
chemopreventive O +
activities O -
. O -

For O +
most O +
of O +
known O +
chemopreventive O +
phytochemicals O -
, O +
however O -
, O +
their O +
protective O +
effects O +
are O +
based O +
solely O +
on O +
the O +
results O +
from O +
animal U-Species +
tests O -
. O -

Unfortunately O -
, O +
however O -
, O +
the O +
predictive O +
capability O +
of O +
the O +
majority O +
of O +
animal U-Species +
model O +
studies O +
in O +
the O +
evaluation O +
of O +
cancer O +
chemopreventive O +
agents O +
for O +
use O +
in O +
humans U-Species +
is O +
uncertain O +
and O +
often O +
limited O -
. O -

The O +
efficacy O -
, O +
as O +
well O +
as O +
the O +
safety O +
of O +
selected O +
phytochemicals O +
with O +
promising O +
chemopreventive O +
potential O +
should O +
be O +
validated O +
through O +
properly O -
- O -
designed O +
and O +
well O -
- O -
controlled O +
clinical O +
intervention O +
trials O -
. O -

The O +
use O +
of O +
a O +
reliable O +
biomarker O +
as O +
an O +
early O +
surrogate O +
endpoint O +
is O +
pivotal O +
in O +
conducting O +
prospective O +
chemopreventive O +
trials O -
. O -

There O +
have O +
been O +
extensive O +
studies O +
conducted O +
during O +
the O +
past O +
two O +
decades O +
to O +
search O +
for O +
potential O +
naturally O +
occurring O +
cancer O +
chemopreventive O +
agents O +
and O +
some O +
of O +
them O +
hold O +
promise O +
for O +
human U-Species +
use O -
. O -

Antioxidant O +
vitamins O +
or O +
their O +
synthetic O +
derivatives O +
have O +
been O +
frequently O +
investigated O +
for O +
their O +
possible O +
chemopreventive O +
efficacy O +
among O +
normal O +
or O +
high O +
risk O +
( O -
e.g. O -
, O +
smokers O -
, O +
asbestos O +
workers O -
, O +
etc O -
. O -
) O +
populations O -
. O -

While O +
there O +
has O +
been O +
substantial O +
body O +
of O +
evidence O +
from O +
both O +
experimental O +
and O +
epidemiologic O +
studies O +
supporting O +
the O +
beneficial O +
effects O +
of O +
fruits U-Species +
and O +
vegetables U-Species -
, O +
which O +
are O +
good O +
sources O +
of O +
antioxidant O +
vitamins O -
, O +
the O +
chemopreventive O +
effects O +
of O +
dietary O +
supplementation O +
of O +
individual O +
vitamins O +
or O +
their O +
mixtures O +
remain O +
controversial O +
at O +
the O +
present O +
time O -
. O -

We O +
have O +
lessons O +
from O +
the O +
large O -
- O -
scale O +
randomized O -
, O +
double O -
- O -
blind O -
, O +
placebo O -
- O -
controlled O +
Alpha O -
- O -
Tocopherol O -
, O +
Beta O -
- O -
Carotene O +
( O -
ATBC O -
) O +
Cancer O +
Prevention O +
Study O +
that O +
was O +
conducted O +
with O +
about O +
30,000 O +
Finnish O +
male B-Species +
smokers L-Species +
under O +
the O +
joint O +
sponsorship O +
of O +
the O +
US O +
National O +
Cancer O +
Institute O +
and O +
the O +
National O +
Public O +
Health O +
Institute O +
in O +
Finland O -
. O -

In O +
this O +
particular O +
trial O -
, O +
a O +
daily O +
intake O +
of O +
20 O +
mg O +
of O +
beta O -
- O -
carotene O +
was O +
not O +
protective O +
against O +
lung O +
cancer O -
. O -

On O +
the O +
contrary O -
, O +
the O +
cumulative O +
incidence O +
and O +
the O +
mortality O +
of O +
lung O +
cancer O +
increased O -
, O +
compared O +
with O +
those O +
observed O +
among O +
people O +
in O +
the O +
placebo O +
control O +
group O +
[ O -
10 O -
] O +
. O -

The O +
results O +
of O +
this O +
study O +
were O +
contradictory O +
to O +
the O +
beneficial O +
effects O +
of O +
beta O -
- O -
carotene O +
demonstrated O +
in O +
the O +
previous O +
intervention O +
trials O -
, O +
as O +
well O +
as O +
laboratory O +
studies O -
. O -

Nonetheless O -
, O +
the O +
unexpected O +
negative O +
finding O +
in O +
the O +
ATBC O +
study O +
is O +
not O +
surprising O +
and O +
may O +
not O +
be O +
fortuitous O -
. O -

Since O +
the O +
subjects O +
who O +
participated O +
in O +
this O +
study O +
were O +
relatively O +
old O +
( O -
50 O +
to O +
69 O +
years O +
of O +
age O -
) O +
with O +
a O +
smoking O +
habit O -
, O +
it O +
seems O +
likely O +
that O +
the O +
majority O +
of O +
them O +
already O +
had O +
mutated O +
genes O +
( O -
e.g. O -
, O +
p53 O -
tumor O -
- O -
suppressor O +
or O +
ras O +
-oncogenes O -
) O +
or O +
premalignant O +
lesions O +
before O +
starting O +
beta O -
- O -
carotene O +
supplementation O -
, O +
as O +
a O +
result O +
of O +
cigarette O +
smoking O -
. O -

If O +
it O +
is O +
the O +
case O -
, O +
one O +
may O +
not O +
expect O +
the O +
beneficial O +
effects O +
of O +
beta O -
- O -
carotene O +
that O +
is O +
most O +
active O +
in O +
early O +
stages O +
of O +
carcinogenesis O -
. O -

Excess O +
amount O +
of O +
beta O -
- O -
carotene O +
might O +
have O +
met O +
the O +
substantial O +
growth O +
requirement O +
of O +
rapidly O +
proliferating O +
cancerous O +
cells O -
, O +
thereby O +
stimulating O +
their O +
growth O +
rather O +
than O +
suppressing O +
it O -
. O -

In O +
support O +
of O +
this O +
assumption O -
, O +
post O -
- O -
initiation O +
application O +
of O +
this O +
compound O +
stimulated O +
the O +
mammary O +
carcinogenesis O +
in O +
rodents U-Species +
[ O -
11 O -
] O +
. O -

Similarly O -
, O +
dietary O +
supplementation O +
of O +
beta O -
- O -
carotene O +
enhanced O +
the O +
development O +
of O +
papillomas O +
in O +
mice O +
[ O -
12 O -
] O +
, O +
probably O +
via O +
stimulation O +
of O +
the O +
promotion O +
of O +
carcinogenesis O -
. O -

Besides O +
antioxidative O +
vitamins O -
, O +
fruits U-Species +
and O +
vegetables U-Species +
contain O +
countless O +
phytochemicals O +
of O +
less O +
nutritional O +
value O +
but O +
with O +
substantial O +
chemopreventive O +
potential O -
. O -

However O -
, O +
few O +
population O -
- O -
based O +
chemoprevention O +
trials O +
with O +
non O -
- O -
vitamin O +
phytochemicals O +
have O +
been O +
conducted O -
. O -

Rational O +
and O +
successful O +
implementation O +
of O +
chemopreventive O +
strategies O +
rely O +
on O +
the O +
precise O +
understanding O +
of O +
underlying O +
molecular O +
mechanisms O -
. O -

Alterations O +
of O +
carcinogen O +
metabolism O +
and O +
subsequent O +
DNA O +
adduction O +
may O +
represent O +
an O +
important O +
mechanism O +
by O +
which O +
a O +
given O +
phytochemical O +
modulates O +
chemically O -
- O -
induced O +
carcinogenesis O +
in O +
the O +
initiation O +
stage O -
. O -

Modulation O +
of O +
carcinogen O +
metabolism O +
is O +
often O +
considered O +
by O +
many O +
investigators O +
as O +
a O +
mechanistic O +
basis O +
for O +
protective O +
effects O +
of O +
many O +
types O +
of O +
chemopreventive O +
phytochemicals O -
. O -

However O -
, O +
carcinogen O -
- O -
metabolizing O +
enzymes O +
in O +
general O +
have O +
dual O +
roles O +
and O +
preventive O +
modulation O +
of O +
metabolism O -
, O +
i.e. O -
, O +
suppression O +
of O +
activation O +
or O +
acceleration O +
of O +
detoxification O +
of O +
one O +
carcinogen O -
, O +
may O +
alter O +
the O +
fate O +
of O +
other O +
xenobiotics O +
and O +
endogenous O +
compounds O +
[ O -
13–15 O -
] O +
, O +
which O +
may O +
limit O +
its O +
utilization O +
as O +
a O +
criterion O +
in O +
identifying O +
or O +
defining O +
new O +
chemopreventive O +
agents O -
. O -

Furthermore O -
, O +
inhibition O +
of O +
initiation O +
is O +
unlikely O +
to O +
be O +
a O +
practical O +
approach O +
to O +
chemoprevention O -
, O +
since O +
there O +
are O +
diverse O +
types O +
of O +
initiators O +
present O +
in O +
our O +
environment O +
and O +
it O +
is O +
not O +
feasible O +
to O +
find O +
a O +
chemopreventive O +
agent O +
that O +
can O +
nullify O +
the O +
initiating O +
activities O +
of O +
all O +
the O +
carcinogens O +
to O +
which O +
we O +
are O +
exposed O -
. O -

Therefore O -
, O +
recent O +
chemopreventive O +
strategies O +
are O +
more O +
concerned O +
with O +
identifying O +
substances O +
with O +
antiproliferative O +
or O +
antiprogressive O +
activities O +
that O +
can O +
suppress O +
the O +
transformation O +
of O +
initiated O +
or O +
precancerous O +
cells O +
to O +
malignant O +
ones O -
, O +
rather O +
than O +
search O +
for O +
anti O -
- O -
initiators O -
. O -

Chemopreventive O +
agents O +
that O +
fall O +
into O +
this O +
category O +
include O +
modulators O +
of O +
signal O +
transduction O -
, O +
inhibitors O +
of O +
oncogene O +
activation O -
, O +
inhibitors O +
of O +
polyamine O +
metabolism O -
, O +
enhancers O +
of O +
gap O +
junctional O +
intercellular O +
communication O -
, O +
inhibitors O +
of O +
angiogenesis O -
, O +
etc O -
. O -

[ O -
16 O -
] O +
. O -

Recently O -
, O +
considerable O +
attention O +
has O +
been O +
focused O +
on O +
dietary O +
and/or O +
pharmacological O +
manipulation O +
of O +
apoptosis O +
as O +
a O +
novel O +
and O +
promising O +
strategy O +
for O +
cancer O +
chemoprevention O -
, O +
as O +
well O +
as O +
therapy O +
[ O -
17–19 O -
] O +
. O -

The O +
maintenance O +
of O +
homeostasis O +
in O +
normal O +
mammalian U-Species +
tissues O +
reflects O +
a O +
critical O +
balance O +
between O +
cell O +
proliferation O +
and O +
cell O +
death O +
via O +
apoptosis O -
. O -

In O +
contrast O -
, O +
apoptosis O +
may O +
be O +
inhibited O +
or O +
perturbed O +
in O +
tumors O +
in O +
which O +
the O +
rate O +
of O +
cell O +
proliferation O +
exceeds O +
that O +
of O +
cell O +
loss O -
. O -

If O +
misregulation O +
of O +
apoptosis O +
results O +
in O +
a O +
failure O +
of O +
tissue O +
size O +
regulation O -
, O +
which O +
eventually O +
leads O +
to O +
the O +
malignant O +
transformation O -
, O +
apoptotic O +
cell O +
death O +
could O +
be O +
induced O +
to O +
augment O +
interventions O +
designed O +
to O +
suppress O +
or O +
reverse O +
the O +
development O +
of O +
cancer O -
. O -

Indeed O -
, O +
various O +
chemopreventive O +
and O +
chemotherapeutic O +
agents O +
are O +
now O +
known O +
to O +
exert O +
their O +
antiproliferative O +
or O +
cytostatic O +
effects O +
by O +
inducing O +
apoptosis O +
in O +
( O -
pre O -
) O -
malignant O +
cells O +
[ O -
17–23 O -
] O +
. O -

Selected O +
chemopreventive O +
vitamins O +
or O +
phytochemicals O +
have O +
the O +
propensity O +
to O +
suppress O +
or O +
retard O +
the O +
growth O +
of O +
cancer O +
cells O +
in O +
this O +
way O +
[ O -
[ O -
17 O -
, O +
24 O -
, O +
25 O -
] O +
, O +
and O +
more O +
examples O +
in O +
this O +
review O -
] O -
. O -

Suppression O +
of O +
prostaglandin O +
synthesis O +
through O +
selective O +
inhibition O +
of O +
cyclooxygenase-2 O +
( O -
COX-2 O -
) O +
is O +
another O +
promising O +
strategy O +
applicable O +
to O +
identification O +
and O +
development O +
of O +
chemopreventive O +
drugs O -
. O -

Prostaglandins O +
are O +
known O +
to O +
play O +
crucial O +
roles O +
in O +
pathogenesis O +
of O +
malignancy O -
, O +
particularly O +
in O +
colon O +
carcinogenesis O +
and O +
certain O +
nonsteroidal O +
anti O -
- O -
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O -
, O +
such O +
as O +
aspirin O -
, O +
piroxicam O -
, O +
and O +
sulindac O -
, O +
have O +
protective O +
effects O +
on O +
experimental O +
carcinogenesis O +
[ O -
26 O -
, O +
27 O -
] O +
. O -

Furthermore O -
, O +
epidemiologic O +
data O +
indicate O +
a O +
reduced O +
risk O +
of O +
colorectal O +
cancer O +
among O +
individuals O +
who O +
intake O +
aspirin O +
or O +
other O +
NSAIDs O +
on O +
a O +
regular O +
basis O +
[ O -
28 O -
] O +
. O -

Moreover O -
, O +
in O +
patients U-Species +
with O +
familial O +
adenomatous O +
polyposis O -
, O +
the O +
NSAID O +
sulindac O +
caused O +
marked O +
regression O +
of O +
polyps O +
and O +
prevented O +
their O +
recurrence O +
[ O -
29 O -
] O +
. O -

Selected O +
NSAIDs O +
have O +
been O +
reported O +
to O +
suppress O +
growth O +
and O +
proliferation O +
of O +
cancer O +
cells O +
by O +
inducing O +
apoptosis O +
[ O -
30–32 O -
] O +
. O -

Some O +
phenolic O +
substances O +
derived O +
from O +
Zingiberaceae U-Species +
( O -
ginger U-Species +
family O -
) O +
plants O +
have O +
potent O +
anti O -
- O -
inflammatory O +
activity O +
and O +
induce O +
apoptosis O +
in O +
human U-Species +
cancer O +
cell O +
lines O +
[ O -
[ O -
33–36 O -
] O +
; O +
vide O +
infra O -
] O -
. O -

4 O +
Selected O +
chemopreventive O +
dietary O +
and/or O +
medicinal O +
phenolic O +
substances O +
4.1 O +
Capsaicin O +
Capsaicin O +
( O -
trans O +
-8-methyl O -
- O -
N O +
-vanillyl-6-nonenamide O -
; O +
structure O +
shown O +
in O +
Fig. O +
3 O -
) O +
is O +
a O +
principal O +
pungent O +
ingredient O +
present O +
in O +
hot O +
red U-Species +
and O +
chili B-Species +
peppers L-Species +
that O +
belong O +
to O +
the O +
plant O +
genus O +
Capsicum U-Species -
( O -
Solanaceae U-Species -
) O -
. O -

The O +
compound O +
has O +
been O +
tested O +
by O +
many O +
investigators O +
for O +
its O +
effects O +
on O +
experimental O +
carcinogenesis O +
and O +
mutagenesis O +
[ O -
for O +
review O -
, O +
see O +
Refs O -
. O -

[ O -
37 O -
, O +
38 O -
] O +
and O +
references O +
therein O -
] O -
. O -

Data O +
in O +
the O +
literature O +
indicate O +
that O +
capsaicin O +
has O +
a O +
dual O +
role O +
in O +
carcinogenic O +
and O +
mutagenic O +
processes O +
and O +
its O +
effects O +
in O +
some O +
degree O +
relies O +
on O +
the O +
doses O -
, O +
routes O +
of O +
administration O -
, O +
and O +
types O +
of O +
tissues O +
affected O -
. O -

Although O +
the O +
previous O +
studies O +
were O +
mainly O +
focused O +
on O +
evaluation O +
of O +
carcinogenic O +
or O +
co O -
- O -
carcinogenic O +
potential O +
of O +
capsaicin O +
in O +
hot B-Species +
peppers L-Species +
in O +
consideration O +
of O +
its O +
irritancy O -
, O +
the O +
compound O +
has O +
recently O +
been O +
reported O +
to O +
retain O +
protective O +
properties O +
against O +
experimental O +
carcinogenesis O +
and O +
mutagenesis O +
[ O -
37 O -
, O +
38 O -
] O +
. O -

In O +
several O +
instances O -
, O +
it O +
has O +
been O +
demonstrated O +
that O +
capsaicin O +
modulates O +
microsomal O +
cytochrome O +
P O +
450-dependent O +
monooxygenase O +
activities O -
, O +
thereby O +
affecting O +
metabolism O +
of O +
carcinogens O +
and O +
other O +
xenobiotics O +
[ O -
39–45 O -
] O +
. O -

Capsaicin O +
was O +
found O +
to O +
interact O +
with O +
rat U-Species +
hepatic O +
mixed O -
- O -
function O +
oxidases O +
as O +
revealed O +
by O +
prolongation O +
of O +
pentobarbital O +
or O +
hexobarbital O +
sleeping O +
time O +
[ O -
39–41 O -
] O +
and O +
inhibition O +
of O +
ethylmorphine O +
demethylase O +
activity O -
, O +
as O +
well O +
as O +
production O +
of O +
a O +
type O +
I O +
spectral O +
change O +
[ O -
39 O -
] O +
. O -

The O +
compound O +
also O +
suppresses O +
the O +
activity O +
of O +
rat U-Species +
epidermal O +
aryl O +
hydrocarbon O +
hydroxylase O +
[ O -
42 O -
] O +
that O +
is O +
responsible O +
for O +
the O +
biotransformation O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O +
and O +
other O +
polyaromatic O +
hydrocarbons O -
. O -

Metabolism O +
and O +
subsequent O +
covalent O +
DNA O +
binding O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O +
in O +
human U-Species +
and O +
murine U-Species +
keratinocytes O +
were O +
attenuated O +
by O +
capsaicin O +
[ O -
42 O -
] O +
. O -

Taken O +
together O -
, O +
the O +
above O +
findings O +
suggest O +
that O +
capsaicin O +
can O +
influence O +
the O +
initiating O +
activities O +
of O +
certain O +
chemical O +
carcinogens O +
through O +
modulation O +
of O +
their O +
metabolic O +
activation O +
and/or O +
detoxification O -
. O -

Benzo O -
[ O -
a O -
] O -
pyrene O -
- O -
induced O +
pulmonary O +
tumor O +
in O +
mice U-Species +
was O +
inhibited O +
by O +
capsaicin O +
treatment O +
[ O -
43 O -
] O +
. O -

Capsaicin O +
displayed O +
inhibitory O +
effects O +
on O +
metabolism O -
, O +
mutagenicity O +
and/or O +
covalent O +
DNA O +
binding O +
of O +
aflatoxin O +
B1 O +
[ O -
44 O -
] O +
and O +
the O +
tobacco U-Species -
- O -
specific O +
nitrosamine O -
, O +
4- O -
( O -
methylnitrosamino O -
) O -
-1- O -
( O -
3-pyridyl O -
) O -
-1-butanone O +
( O -
NNK O -
) O +
[ O -
45–47 O -
] O +
. O -

Capsaicin O +
and O +
its O +
saturated O +
analog O +
dihydrocapsaicin O +
( O -
Fig. O +
3 O -
for O +
chemical O +
structures O -
) O +
have O +
been O +
shown O +
to O +
inhibit O +
cytochrome O +
P O +
450 O +
2E1 O +
[ O -
48 O -
, O +
49 O -
] O +
, O +
an O +
isoform O +
that O +
catalyzes O +
metabolic O +
activation O -
, O +
as O +
well O +
as O +
detoxification O +
of O +
many O +
low O +
molecular O +
weight O +
carcinogens O -
. O -

In O +
agreement O +
with O +
these O +
findings O -
, O +
both O +
compounds O +
inhibited O +
the O +
mutagenicity O +
and/or O +
tumorigenicity O +
of O +
vinyl O +
carbamate O +
and O +
dimethylnitrosamine O +
[ O -
49 O -
] O +
, O +
which O +
are O +
preferentially O +
activated O +
by O +
cytochrome O +
P O +
450 O +
2E1 O -
. O -

In O +
another O +
study O -
, O +
capsaicin O +
ameliorated O +
the O +
peroxidative O +
changes O +
in O +
rat U-Species +
hepatic O +
and O +
pulmonary O +
tissues O +
induced O +
by O +
chloroform O -
, O +
carbon O +
tetrachloride O -
, O +
or O +
dichloromethane O +
[ O -
50 O -
] O +
. O -

Cytochrome O +
P O +
450 O +
2E1 O +
again O +
plays O +
a O +
role O +
in O +
activation O +
of O +
these O +
halogenated O +
hydrocarbons O -
. O -

Capsaicin O +
pretreatment O +
also O +
protects O +
against O +
the O +
free O +
radical O -
- O -
induced O +
pulmonary O +
damage O +
in O +
rats U-Species +
exposed O +
to O +
such O +
gaseous O +
chemical O +
irritants O +
as O +
sulfur O +
dioxide O +
and O +
nitrogen O +
dioxide O +
[ O -
51 O -
] O +
. O -

It O +
has O +
been O +
reported O +
that O +
intraperitoneal O +
administration O +
of O +
capsaicin O +
attenuates O +
cyclophosphamide O -
- O -
induced O +
chromosomal O +
aberrations O +
and O +
DNA O +
breaks O +
in O +
mice U-Species +
[ O -
52 O -
] O +
. O -

Although O +
topical O +
application O +
of O +
capsaicin O +
can O +
initially O +
induce O +
ear O +
edema O +
in O +
mice U-Species +
[ O -
53 O -
] O +
, O +
subsequent O +
reapplications O +
of O +
the O +
compound O +
suppressed O +
the O +
inflammatory O +
response O +
[ O -
54 O -
] O +
. O -

Carrageenan O -
- O -
induced O +
inflammation O +
in O +
rats U-Species +
was O +
also O +
ameliorated O +
by O +
capsaicin O +
treatment O +
[ O -
55 O -
] O +
. O -

Furthermore O -
, O +
capsaicin O +
was O +
found O +
to O +
inhibit O +
platelet O +
aggregation O +
[ O -
56–58 O -
] O +
. O -

Another O +
study O -
, O +
however O -
, O +
has O +
demonstrated O +
the O +
stimulation O +
of O +
prostaglandin O +
biosynthesis O +
by O +
capsaicin O +
[ O -
59 O -
] O +
. O -

The O +
observed O +
antiplatelet O +
or O +
anti O -
- O -
inflammatory O +
effects O +
of O +
capsaicin O +
appears O +
to O +
be O +
associated O +
with O +
its O +
interference O +
with O +
phospholipase O +
A2 O +
[ O -
60 O -
] O +
, O +
a O +
key O +
enzyme O +
mediating O +
the O +
inflammatory O +
process O -
. O -

Since O +
tumor O +
promotion O +
is O +
related O +
to O +
inflammation O +
which O +
can O +
stimulate O +
the O +
proliferation O +
of O +
initiated O +
cells O -
, O +
it O +
would O +
be O +
of O +
interest O +
to O +
determine O +
if O +
capsaicin O +
could O +
act O +
as O +
an O +
anti O -
- O -
tumor O +
promoting O +
agent O -
. O -

Capsaicin O +
was O +
found O +
to O +
antagonize O +
the O +
mouse O +
ear O +
edema O +
induced O +
by O +
croton O +
oil O +
[ O -
61 O -
] O +
, O +
lending O +
further O +
support O +
to O +
the O +
above O +
idea O -
. O -

Our O +
preliminary O +
study O +
indicates O +
that O +
topical O +
application O +
of O +
capsaicin O +
along O +
with O +
phorbol O +
ester O +
onto O +
shaven O +
backs O +
of O +
ICR B-Species +
mice L-Species -
, O +
after O +
initiation O +
with O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O -
, O +
transiently O +
increased O +
the O +
skin O +
tumor O +
formation O -
, O +
but O +
the O +
overall O +
papillomagenesis O +
did O +
not O +
increase O +
[ O -
62 O -
] O +
. O -

Apparently O -
, O +
some O +
of O +
the O +
tumors O +
became O +
slightly O +
regressed O +
after O +
12 O +
weeks O +
of O +
post O -
- O -
initiation O -
. O -

Epithelial O +
thickening O +
and O +
appearance O +
of O +
atypical O +
cells O +
caused O +
by O +
combination O +
of O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O +
and O +
phorbol O +
ester O +
were O +
also O +
reduced O +
by O +
capsaicin O +
treatment O -
. O -

According O +
to O +
a O +
recent O +
study O +
by O +
Morre O +
et O +
al. O +
[ O -
63 O -
] O +
, O +
capsaicin O +
preferentially O +
repressed O +
the O +
growth O +
of O +
some O +
transformed O +
cells O +
of O +
human U-Species +
origin O -
, O +
including O +
HeLa O -
, O +
ovarian O +
carcinoma O -
, O +
mammary O +
adenocarcinoma O -
, O +
and O +
promyelocytic O +
leukemia O +
( O -
HL-60 O -
) O +
cells O +
in O +
culture O -
. O -

The O +
inhibition O +
of O +
cell O +
survival O +
was O +
associated O +
with O +
induction O +
of O +
apoptosis O +
as O +
revealed O +
by O +
characteristic O +
morphological O +
changes O +
and O +
appearance O +
of O +
fragmented O +
nuclear O +
DNA O +
[ O -
63 O -
] O +
. O -

The O +
capsaicin O -
- O -
induced O +
growth O +
inhibition O +
and O +
apoptosis O +
in O +
the O +
aforementioned O +
cells O +
were O +
correlated O +
with O +
inhibition O +
of O +
plasma O +
membrane O +
NADH O +
oxidase O +
activity O +
[ O -
63 O -
] O +
. O -

The O +
same O +
investigators O +
have O +
subsequently O +
observed O +
the O +
similar O +
findings O +
with O +
human U-Species +
and O +
mouse U-Species +
melanoma O +
cell O +
lines O +
in O +
terms O +
of O +
growth O +
inhibition O -
, O +
apoptosis O +
induction O -
, O +
and O +
inhibition O +
of O +
plasma O +
membrane O +
NADH O +
oxidase O +
[ O -
64 O -
] O +
. O -

Interestingly O -
, O +
direct O +
injection O +
of O +
capsaicin O +
into O +
the O +
B16 B-Species +
mouse L-Species +
melanoma O +
transplanted O +
in O +
C57BL B-Species -
/ I-Species -
6 I-Species +
mice L-Species +
significantly O +
blunted O +
the O +
growth O +
of O +
tumors O +
[ O -
64 O -
] O +
. O -

Capsaicin O -
- O -
induced O +
apoptosis O +
has O +
been O +
suggested O +
to O +
be O +
regulated O +
by O +
Bcl-2 O +
and O +
the O +
protein O +
phosphatase O -
, O +
calcineurin O +
[ O -
65 O -
] O +
. O -

In O +
another O +
study O -
, O +
capsaicin O -
- O -
induced O +
apoptotic O +
death O +
of O +
cultured O +
human U-Species +
gastric O +
cancer O +
cells O -
, O +
which O +
appeared O +
to O +
be O +
mediated O +
via O +
overexpression O +
of O +
the O +
p53 O -
tumor O +
suppressor O +
gene O +
and/or O +
c O -
- O -
myc O -
proto O -
- O -
oncogene O +
[ O -
66 O -
] O +
. O -

One O +
of O +
the O +
important O +
cellular O +
mediators O +
of O +
cellular O +
processes O +
in O +
response O +
to O +
diversified O +
extracellular O +
stimuli O +
including O +
oxidants O -
, O +
UV O -
, O +
mitogens O -
, O +
cytokines O -
, O +
viruses O -
, O +
tumor O +
necrosis O +
factor O -
- O -
α O +
( O -
TNF O -
- O -
α O -
) O -
, O +
interleukin-1 O +
( O -
IL-1 O -
) O -
, O +
etc O -
. O +
is O +
a O +
nuclear O +
transcription O +
factor O +
NF O -
- O -
κB O +
[ O -
67–71 O -
] O +
. O -

Upon O +
activation O +
by O +
external O +
signals O -
, O +
NF O -
- O -
κB O +
is O +
migrated O +
to O +
the O +
nucleus O +
where O +
it O +
binds O +
to O +
a O +
specific O +
segment O +
of O +
DNA O -
, O +
thereby O +
triggering O +
expression O +
of O +
a O +
variety O +
of O +
rapid O -
- O -
response O +
genes O +
involved O +
in O +
some O +
important O +
physiological O +
reactions O -
, O +
such O +
as O +
inflammation O -
, O +
cell O +
adhesion O -
, O +
viral O +
replication O -
, O +
immune O +
response O -
, O +
and O +
proliferation O -
. O -

Reactive O +
oxygen O +
species O +
( O -
ROS O -
) O +
has O +
been O +
suggested O +
as O +
a O +
second O +
messenger O +
in O +
a O +
signal O +
transduction O +
pathway O +
for O +
activation O +
of O +
NF O -
- O -
κB O +
[ O -
72 O -
, O +
73 O -
] O +
. O -

According O +
to O +
the O +
study O +
of O +
Singh O +
et O +
al. O +
[ O -
74 O -
] O +
, O +
capsaicin O +
abrogates O +
the O +
activation O +
of O +
NF O -
- O -
κB O +
by O +
TPA O -
, O +
as O +
well O +
as O +
by O +
TNF O -
- O -
α O -
, O +
which O +
may O +
provide O +
a O +
mechanistic O +
basis O +
for O +
the O +
possible O +
anti O -
- O -
tumor O +
promoting O +
activity O +
of O +
capsaicin O -
. O -

Another O +
eukaryotic O +
transcription O +
factor O +
that O +
is O +
responsive O +
to O +
ROS O +
and O +
is O +
hence O -
, O +
regulated O +
by O +
cellular O +
redox O +
status O +
is O +
activator O +
protein O +
1 O +
( O -
AP-1 O -
) O +
[ O -
67 O -
] O +
. O -

The O +
regulation O +
of O +
AP-1 O +
in O +
response O +
to O +
external O +
stimuli O +
is O +
considered O +
to O +
be O +
mediated O +
by O +
members O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
family O -
, O +
among O +
which O +
c O -
- O -
jun O +
-N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
; O +
also O +
known O +
as O +
stress O -
- O -
activated O +
protein O +
kinase O +
abbreviated O +
as O +
SAPK O -
) O +
and O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O -
ERK O -
) O +
isoforms O +
are O +
best O +
characterized O -
. O -

There O +
is O +
some O +
evidence O +
that O +
JNK O +
and O +
ERK O +
exert O +
opposite O +
effects O +
on O +
apoptosis O +
[ O -
75 O -
] O +
. O -

Capsaicin O +
induced O +
apoptosis O +
in O +
cultured O +
Jurkat O +
cells O +
through O +
generation O +
of O +
ROS O +
[ O -
76 O -
] O +
. O -

When O +
treated O +
to O +
these O +
cells O +
at O +
a O +
concentration O +
of O +
300 O +
μM O -
, O +
capsaicin O +
rapidly O +
activated O +
JNK O -
: O +
the O +
activity O +
was O +
detectable O +
as O +
early O +
as O +
5 O +
min O +
after O +
the O +
treatment O -
, O +
while O +
ERK O +
activity O +
was O +
not O +
affected O +
under O +
the O +
same O +
experimental O +
conditions O +
[ O -
76 O -
] O +
. O -

Despite O +
the O +
activation O +
of O +
JNK O +
by O +
capsaicin O -
, O +
there O +
was O +
no O +
induction O +
of O +
AP-1 O +
activity O -
. O -

On O +
the O +
contrary O -
, O +
capsaicin O +
blocked O +
the O +
TPA O -
- O -
induced O +
AP-1 O +
activation O +
[ O -
76 O -
] O +
. O -

The O +
latter O +
finding O -
, O +
together O +
with O +
the O +
previous O +
observation O +
by O +
Singh O +
et O +
al. O +
[ O -
74 O -
] O +
on O +
suppression O +
of O +
TPA O -
- O -
induced O +
NF O -
- O -
κB O +
activation O +
by O +
capsaicin O -
, O +
may O +
provide O +
important O +
molecular O +
basis O +
for O +
anti O -
- O -
tumor O +
promoting O +
potential O +
of O +
this O +
vanilloid O -
. O -

4.2 O +
Gingerol O +
and O +
paradol O +
Ginger U-Species +
( O -
Zingiber B-Species +
officinale I-Species -
Roscoe L-Species -
, O +
Zingiberaceae U-Species -
) O +
is O +
among O +
the O +
most O +
frequently O +
and O +
heavily O +
consumed O +
dietary O +
condiments O +
throughout O +
the O +
world O -
. O -

Besides O +
its O +
extensive O +
use O +
as O +
a O +
spice O -
, O +
the O +
rhizome O +
of O +
ginger U-Species +
has O +
also O +
been O +
used O +
in O +
traditional O +
oriental O +
herbal O +
medicine O +
for O +
the O +
management O +
of O +
such O +
symptoms O +
as O +
common O +
cold O -
, O +
digestive O +
disorders O -
, O +
rheumatism O -
, O +
neurologia O -
, O +
colic O +
and O +
motion O -
- O -
sickness O -
. O -

The O +
oleoresin O +
from O +
rhizomes O +
of O +
ginger U-Species +
contains O +
[ O -
6 O -
] O -
-gingerol O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-5-hydroxy-3-decanone O -
) O +
and O +
its O +
homologs O +
as O +
pungent O +
ingredients O +
that O +
have O +
been O +
found O +
to O +
possess O +
many O +
interesting O +
pharmacological O +
and O +
physiological O +
activities O -
, O +
such O +
as O +
anti O -
- O -
inflammatory O -
, O +
analgesic O -
, O +
antipyretic O -
, O +
antihepatotoxic O -
, O +
and O +
cardiotonic O +
effects O +
[ O -
77 O -
, O +
78 O -
] O +
. O -

The O +
chemical O +
structure O +
of O +
[ O -
6 O -
] O -
-gingerol O +
that O +
is O +
known O +
as O +
a O +
major O +
pungent O +
and O +
pharmacologically O +
active O +
principle O +
of O +
ginger U-Species +
is O +
shown O +
in O +
Fig. O +
3 O +
. O -

Gingerol O +
has O +
been O +
found O +
to O +
possess O +
substantial O +
antioxidant O +
activity O +
as O +
determined O +
by O +
inhibition O +
of O +
phospholipid O +
peroxidation O +
induced O +
by O +
the O +
FeCl3 O +
–ascorbate O +
system O +
[ O -
79 O -
] O +
. O -

The O +
antioxidative O +
properties O +
of O +
gingerol O +
and O +
other O +
constituents O +
of O +
ginger U-Species +
have O +
been O +
confirmed O +
in O +
various O +
in O +
vitro O +
and O +
in O +
vivo O +
test O +
systems O +
[ O -
80 O -
, O +
81 O -
] O +
. O -

Gingerol O +
also O +
exerts O +
an O +
inhibitory O +
effect O +
on O +
xanthine O +
oxidase O +
[ O -
82 O -
] O +
responsible O +
for O +
generation O +
of O +
superoxide O +
anion O -
. O -

Guh O +
et O +
al. O +
[ O -
83 O -
] O +
reported O +
concentration O -
- O -
dependent O +
inhibition O +
by O +
gingerol O +
of O +
arachidonic O +
acid O -
- O -
induced O +
platelet O +
aggregation O +
and O +
formation O +
of O +
thromboxane O +
B2 O -
and O +
prostaglandin O +
D2 O +
. O -

The O +
compound O +
also O +
completely O +
abolished O +
phosphoinositide O +
breakdown O +
induced O +
by O +
arachidonic O +
acid O -
. O -

Gingerol O -
, O +
shogaol O +
and O +
other O +
structurally O -
- O -
related O +
substances O +
in O +
ginger U-Species +
inhibit O +
prostaglandin O +
and O +
leukotriene O +
biosynthesis O +
through O +
suppression O +
of O +
5-lipoxygenase O +
or O +
prostaglandin O +
synthetase O +
[ O -
84–87 O -
] O +
. O -

Since O +
tumor O +
promotion O +
is O +
closely O +
associated O +
with O +
inflammation O +
and O +
oxidative O +
stress O -
, O +
it O +
is O +
likely O +
that O +
a O +
compound O +
with O +
a O +
strong O +
inhibitory O +
effect O +
on O +
the O +
arachidonic O +
acid O +
metabolism O +
would O +
have O +
anti O -
- O -
tumor O +
promoting O +
potential O -
. O -

In O +
line O +
with O +
this O +
notion O -
, O +
our O +
recent O +
study O +
has O +
demonstrated O +
that O +
gingerol O +
protects O +
TPA O -
- O -
induced O +
ear O +
edema O -
, O +
epidermal O +
ornithine O +
decarboxylase O +
( O -
ODC O -
) O +
activity O -
, O +
and O +
skin O +
tumor O +
promotion O +
in O +
female O +
ICR B-Species +
mice L-Species +
[ O -
88 O -
] O +
. O -

Furthermore O -
, O +
topical O +
application O +
of O +
the O +
ginger U-Species +
extract O +
30 O +
min O +
prior O +
to O +
TPA O +
led O +
to O +
dramatic O +
protection O +
against O +
DMBA O -
- O -
initiated O +
skin O +
carcinogenesis O +
in O +
SENCAR B-Species +
mice L-Species +
[ O -
89 O -
] O +
and O +
suppressed O +
TPA O -
- O -
caused O +
induction O +
of O +
epidermal O +
ODC O +
and O +
its O +
mRNA O +
expression O -
, O +
as O +
well O +
as O +
cyclooxygenase O +
( O -
COX O -
) O +
and O +
lipoxygenase O +
activities O +
[ O -
89 O -
] O +
. O -

Azoxymethane O -
- O -
induced O +
intestinal O +
carcinogenesis O +
in O +
rats U-Species +
was O +
significantly O +
suppressed O +
by O +
dietary O +
administration O +
of O +
gingerol O +
[ O -
90 O -
] O +
. O -

Gingerol O +
was O +
reported O +
as O +
one O +
of O +
the O +
most O +
active O +
constituents O +
contained O +
in O +
traditional O +
oriental O +
herbal O +
medication O -
, O +
` O -
Keishi O -
- O -
ka O -
- O -
kei O -
- O -
to O -
' O +
that O +
exhibited O +
substantial O +
inhibitory O +
effects O +
on O +
pulmonary O +
metastasis O +
in O +
mice U-Species +
transplanted O +
with O +
B16F10 O +
melanoma O +
cells O +
[ O -
91 O -
] O +
. O -

[ O -
6 O -
] O -
-Paradol O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-3-decanone O -
; O +
Fig. O +
3 O +
) O -
, O +
a O +
pungent O +
compound O +
isolated O +
from O +
the O +
seeds O +
of O +
Grains B-Species +
of I-Species +
Paradise L-Species +
( O -
Aframomum B-Species +
melegueta I-Species -
Roscoe L-Species -
, O +
Zingiberaceae U-Species -
) O -
, O +
as O +
well O +
as O +
from O +
the O +
rhizome O +
of O +
ginger U-Species -
, O +
also O +
attenuated O +
promotion O +
of O +
skin O +
carcinogenesis O +
and O +
TPA O -
- O -
induced O +
ear O +
edema O +
in O +
female O +
ICR B-Species +
mice L-Species +
[ O -
92 O -
] O +
. O -

Both O +
[ O -
6 O -
] O -
-gingerol O +
and O +
[ O -
6 O -
] O -
-paradol O +
induce O +
apoptosis O +
in O +
HL-60 O +
cells O +
[ O -
36 O -
] O +
. O -

4.3 O +
Curcumin O +
Curcumin O +
( O -
diferuloylmethane O -
; O +
Fig. O +
4 O -
) O +
is O +
a O +
yellow O +
odorless O +
pigment O +
isolated O +
from O +
the O +
rhizome O +
of O +
turmeric U-Species +
( O -
Curcuma B-Species +
longa I-Species -
L. L-Species -
, O +
Zingiberaceae U-Species -
) O -
. O -

Curcumin O +
possesses O +
anti O -
- O -
inflammatory O +
and O +
antioxidant O +
properties O +
[ O -
93–102 O -
] O +
. O -

This O +
yellow O -
- O -
coloured O +
compound O +
inhibits O +
mutagenicity O +
of O +
certain O +
chemical O +
carcinogens O +
[ O -
103–105 O -
] O +
and O +
also O +
hampers O +
their O +
covalent O +
DNA O +
binding O +
in O +
vivo O +
[ O -
106 O -
] O +
, O +
as O +
well O +
as O -
, O +
in O +
vitro O +
[ O -
107 O -
, O +
108 O -
] O +
. O -

Curcumin O +
also O +
protected O +
against O +
chemically O -
- O -
induced O +
liver O +
damage O +
in O +
experimental O +
animals U-Species +
[ O -
109 O -
, O +
110 O -
] O +
. O -

Its O +
anticarcinogenic O +
activity O +
was O +
evaluated O +
in O +
many O +
animal U-Species +
tumor O +
models O +
[ O -
reviewed O +
in O +
Refs O -
. O -

[ O -
111–113 O -
] O +
] O -
. O -

One O +
of O +
the O +
most O +
prominent O +
effects O +
curcumin O +
exerts O +
on O +
experimental O +
carcinogenesis O +
is O +
its O +
capability O +
to O +
inhibit O +
tumor O +
promotion O +
[ O -
113–116 O -
] O +
. O -

Thus O -
, O +
curcumin O +
was O +
reported O +
to O +
alleviate O +
TPA O -
- O -
induced O +
skin O +
tumor O +
promotion O +
and O +
epidermal O +
ODC O +
mRNA O +
expression O +
[ O -
115 O -
] O +
, O +
as O +
well O +
as O -
, O +
ODC O +
activity O +
[ O -
114 O -
] O +
. O -

Topical O +
application O +
of O +
curcumin O +
onto O +
dorsal O +
skins O +
of O +
mice O +
significantly O +
inhibited O +
epidermal O +
COX O +
and O +
lipoxygenase O +
[ O -
117 O -
] O +
. O -

Colonic O +
mucosal O +
COX O +
and O +
lipoxygenase O +
activities O +
were O +
suppressed O +
by O +
dietary O +
curcumin O -
, O +
which O +
appears O +
to O +
account O +
for O +
its O +
chemopreventive O +
effects O +
on O +
colon O +
carcinogenesis O -
. O -

Likewise O -
, O +
F344 B-Species +
rats L-Species +
fed O +
curcumin O +
in O +
the O +
diet O +
exhibited O +
reduced O +
catalytic O +
activities O +
of O +
phospholipase O +
A2 O -
and O +
phospholipase O +
Cγ1 O +
that O +
are O +
involved O +
in O +
arachidonic O +
acid O +
release O +
from O +
cellular O +
phospholipid O +
[ O -
118 O -
] O +
. O -

It O +
also O +
attenuates O +
oxidative O +
DNA O +
damage O +
in O +
mouse U-Species +
epidermis O +
[ O -
116 O -
] O +
and O +
in O +
cultured O +
mouse U-Species +
fibroblast O +
cells O +
[ O -
119 O -
] O +
. O -

The O +
compound O +
was O +
found O +
to O +
suppress O +
the O +
generation O +
of O +
ROS O +
including O +
superoxide O +
and O +
hydrogen O +
peroxide O +
in O +
peritoneal O +
macrophages O +
[ O -
120 O -
, O +
121 O -
] O +
. O -

Its O +
antioxidant O +
effects O +
were O +
confirmed O +
in O +
various O +
systems O -
. O -

It O +
is O +
of O +
interest O +
to O +
note O +
that O +
tetrahydrocurcumin O -
, O +
that O +
is O +
one O +
of O +
the O +
plausible O +
metabolites O +
of O +
curcumin O -
, O +
exhibits O +
stronger O +
antioxidative O +
[ O -
102 O -
] O +
and O +
anti O -
- O -
inflammatory O +
[ O -
97 O -
] O +
activities O +
than O +
does O +
curcumin O -
. O -

Curcumin O +
inhibits O +
lipopolysaccharide- O +
and O +
interferon O -
- O -
γ O -
- O -
induced O +
production O +
of O +
nitric O +
oxide O +
in O +
macrophages O +
[ O -
122 O -
] O +
or O +
nitrite O +
in O +
mouse U-Species +
peritoneal O +
cells O +
[ O -
123 O -
] O +
, O +
possibly O +
by O +
suppression O +
of O +
nitric O +
oxide O +
synthase O -
. O -

More O +
recently O -
, O +
Chan O +
et O +
al. O +
[ O -
124 O -
] O +
have O +
reported O +
the O +
inhibition O +
by O +
curcumin O +
of O +
inducible O +
nitric O +
oxide O +
synthase O +
gene O +
expression O +
in O +
isolated O +
BALB B-Species -
/ I-Species -
c I-Species +
mouse L-Species +
peritoneal O +
macrophages O +
and O +
also O +
in O +
the O +
livers O +
of O +
lipopolysaccharide O -
- O -
injected O +
mice U-Species -
. O -

TPA O -
- O -
induced O +
protein O +
kinase O +
C O +
activation O +
and O +
c O -
- O -
jun O -
expression O +
were O +
markedly O +
suppressed O +
by O +
curcumin O +
in O +
mouse U-Species +
fibroblast O +
cells O +
[ O -
125 O -
] O +
. O -

When O +
applied O +
topically O +
on O +
the O +
dorsal O +
side O +
of O +
mouse U-Species +
skin O -
, O +
curcumin O +
significantly O +
inhibited O +
expression O +
of O +
such O +
proto O -
- O -
oncogenes O +
as O +
c O -
- O -
fos O +
, O +
c O -
- O -
jun O +
, O +
and O +
c O -
- O -
myc O +
[ O -
126 O -
] O +
. O -

Curcumin O +
also O +
exhibited O +
inhibitory O +
effects O +
on O +
epidermal O +
growth O +
factor O +
( O -
EGF O -
) O +
receptor O +
kinase O +
activity O +
in O +
cultured O +
human U-Species +
epidermoid O +
carcinoma O +
A431 O +
[ O -
127 O -
] O +
or O +
NIH3T3 O +
cells O +
[ O -
128 O -
] O +
. O -

Other O +
types O +
of O +
protein O +
kinases O +
were O +
also O +
found O +
to O +
be O +
inhibited O +
by O +
this O +
compound O +
in O +
a O +
non O -
- O -
competitive O +
manner O +
[ O -
129 O -
] O +
. O -

The O +
pleiotropic O +
effects O +
of O +
curcumin O +
appear O +
to O +
be O +
mediated O +
at O +
least O +
in O +
part O +
through O +
inhibition O +
of O +
transcription O +
factors O +
[ O -
130 O -
] O +
. O -

According O +
to O +
a O +
recent O +
study O +
by O +
Huang O +
et O +
al. O +
[ O -
131 O -
] O +
, O +
curcumin O +
suppresses O +
TPA O -
- O -
responsive O +
element O -
- O -
binding O +
activity O +
of O +
c O -
- O -
Jun O -
/ O -
AP-1 O -
, O +
which O +
may O +
account O +
for O +
the O +
anti O -
- O -
tumor O +
promoting O +
effect O +
of O +
this O +
chemopreventive O +
agent O -
. O -

More O +
recently O -
, O +
curcumin O +
has O +
been O +
reported O +
to O +
inhibit O +
TNF O -
- O -
α O -
- O -
induced O +
binding O +
of O +
AP-1 O +
to O +
DNA O +
in O +
bovine U-Species +
aortic O +
endothelial O +
cells O +
[ O -
132 O -
] O +
. O -

Besides O +
interfering O +
with O +
AP-1 O +
activation O -
, O +
curcumin O +
has O +
been O +
shown O +
to O +
suppress O +
the O +
activation O +
of O +
NF O -
- O -
κB O +
[ O -
133 O -
] O +
that O +
is O +
another O +
important O +
eukaryotic O +
transcription O +
factor O -
. O -

The O +
suppression O +
of O +
protein O +
kinases O -
, O +
ODC O -
, O +
and O +
nuclear O +
transcription O +
factors O +
by O +
curcumin O +
suggests O +
that O +
this O +
phenolic O +
compound O +
can O +
act O +
as O +
a O +
cytostatic O +
agent O +
by O +
interfering O +
with O +
certain O +
signal O +
transduction O +
pathways O +
that O +
are O +
critical O +
for O +
cell O +
growth O +
and O +
proliferation O -
. O -

Indeed O -
, O +
curcumin O +
possesses O +
antiproliferative O +
activity O +
[ O -
134 O -
, O +
135 O -
] O +
and O +
the O +
capability O +
of O +
inducing O +
programmed O +
death O +
or O +
apoptosis O +
in O +
cancer O +
cells O +
[ O -
34 O -
, O +
35 O -
] O +
. O -

Furthermore O -
, O +
curcumin O +
exhibited O +
synergistic O +
effects O +
on O +
induction O +
of O +
differentiation O +
in O +
HL-60 O +
cells O +
when O +
combined O +
with O +
all O -
- O -
trans O -
retinoic O +
acid O +
or O +
1α,25-dihydroxyvitamin O +
D3 O +
[ O -
113 O -
] O +
. O -

It O +
also O +
has O +
a O +
strong O +
inhibitory O +
effect O +
on O +
farnesyl O +
protein O +
transferase O +
[ O -
136 O -
] O +
that O +
plays O +
a O +
crucial O +
role O +
in O +
functional O +
activation O +
of O +
Ras O +
protein O -
. O -

A O +
recent O +
study O +
by O +
Ciolino O +
et O +
al. O +
[ O -
137 O -
] O +
has O +
revealed O +
inhibition O +
of O +
cytochrome O +
P O +
450 O +
1A1 O +
activity O +
and O +
formation O +
of O +
carcinogen O -
- O -
DNA O +
adducts O +
in O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O -
- O -
treated O +
human U-Species +
mammary O +
epithelial O +
carcinoma O +
( O -
MCF-7 O -
) O +
cells O +
by O +
competitively O +
binding O +
to O +
the O +
aryl O +
hydrocarbon O +
receptor O -
. O -

Besides O +
preventing O +
malignant O +
transformation O -
, O +
the O +
compound O +
has O +
antimetastatic O +
potential O +
as O +
demonstrated O +
by O +
suppression O +
of O +
matrix O +
metalloproteinase-9 O +
in O +
the O +
human U-Species +
hepatocellular O +
carcinoma O +
cell O +
line O +
[ O -
138 O -
] O +
. O -

4.4 O +
Diarylheptanoids O +
structurally O -
- O -
related O +
to O +
curcuminoids O +
Diarylheptanoids O +
structurally O -
- O -
related O +
to O +
curcumin O +
are O +
present O +
in O +
certain O +
plants U-Species +
of O +
ginger U-Species +
family O +
( O -
Zingiberaceae U-Species -
) O +
and O +
have O +
been O +
reported O +
to O +
possess O +
a O +
strong O +
anti O -
- O -
inflammatory O +
activity O -
. O -

For O +
instance O -
, O +
yakuchinone O +
A O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-7-phenyl-3-heptanone O -
) O +
and O +
yakuchinone O +
B O +
( O -
1- O -
[ O -
4′-hydroxy-3′-methoxyphenyl O -
] O -
-7-phenylhept-1-en-3-one O -
) O +
which O +
are O +
present O +
in O +
Alpinia B-Species +
oxyphylla I-Species -
Miquel L-Species +
have O +
been O +
reported O +
to O +
be O +
strong O +
inhibitors O +
of O +
prostaglandin O +
biosynthesis O +
in O +
vitro O +
[ O -
85 O -
, O +
87 O -
] O +
. O -

Like O +
curcumin O -
, O +
these O +
substances O +
have O +
a O +
diarylheptanoid O +
moiety O +
with O +
a O +
carbonyl O +
functional O +
group O +
( O -
refer O +
to O +
the O +
structures O +
in O +
Fig. O +
4 O +
) O +
and O +
are O +
hence O -
, O +
anticipated O +
to O +
exhibit O +
potential O +
cancer O +
chemopreventive O +
activities O -
. O -

Results O +
of O +
our O +
recent O +
study O +
showed O +
that O +
topical O +
application O +
of O +
the O +
methanol O +
extract O +
of O +
A. B-Species +
oxyphylla L-Species -
to O +
the O +
dorsal O +
epidermis O +
of O +
mice U-Species +
during O +
the O +
process O +
of O +
tumor O +
promotion O +
markedly O +
suppressed O +
the O +
papilloma O +
formation O +
[ O -
33 O -
] O +
. O -

The O +
extract O +
also O +
attenuated O +
the O +
mouse U-Species +
ear O +
edema O +
induced O +
by O +
the O +
tumor O +
promoter O -
, O +
TPA O +
[ O -
33 O -
] O +
. O -

Subsequent O +
studies O +
have O +
revealed O +
that O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O -
, O +
major O +
pungent O +
ingredients O +
derived O +
from O +
A. B-Species +
oxyphylla L-Species +
, O +
can O +
act O +
as O +
anti O -
- O -
tumor O +
promoters O +
as O +
determined O +
by O +
their O +
ability O +
to O +
suppress O +
phorbol O +
ester O -
- O -
induced O +
ODC O +
activation O +
and O +
papilloma O +
formation O +
in O +
mouse U-Species +
skin O +
[ O -
139 O -
, O +
140 O -
] O +
. O -

TPA O -
- O -
stimulated O +
superoxide O +
generation O +
and O +
TNF O -
- O -
α O +
production O +
in O +
HL-60 O +
cells O +
and O +
on O +
DNA O +
binding O +
of O +
AP-1 O +
in O +
NIH3T3 O +
cells O +
were O +
also O +
suppressed O +
by O +
the O +
above O +
compounds O +
[ O -
139 O -
, O +
140 O -
] O +
. O -

Furthermore O -
, O +
both O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O +
induce O +
apoptotic O +
death O +
in O +
HL-60 O +
cells O -
, O +
which O +
accounts O +
for O +
their O +
antiproliferative O +
activity O +
[ O -
139 O -
] O +
. O -

Phenolic O +
diarylheptanoids O +
from O +
Alpinia B-Species +
officinarum I-Species -
Hance L-Species +
( O -
Zingiberaceae U-Species -
) O -
, O +
structurally O +
analogous O +
to O +
yakuchinone O +
A O +
and O +
yakuchinone O +
B O -
, O +
and O +
non O -
- O -
phenolic O +
diarylheptanoids O +
present O +
in O +
a O +
Thai O +
medicinal O +
plant O -
, O +
Curcuma B-Species +
xanthorrhiza L-Species -
( O -
Zingiberaceae U-Species -
) O -
, O +
also O +
exhibit O +
strong O +
anti O -
- O -
inflammatory O +
effects O +
[ O -
86 O -
, O +
141 O -
] O +
. O -

Certain O +
diarylheptanoids O +
isolated O +
from O +
the O +
seeds O +
of O +
Alpinia B-Species +
blepharocalyx I-Species -
K. I-Species +
Schum L-Species +
mitigated O +
collagen- O -
, O +
arachidonic O +
acid- O +
and O +
adenosine O +
diphosphate O -
- O -
induced O +
platelet O +
aggregation O +
of O +
human U-Species +
blood O +
[ O -
142 O -
] O +
and O +
suppressed O +
nitric O +
oxide O +
production O +
in O +
lipopolysaccharide O -
- O -
activated O +
murine U-Species +
macrophages O +
in O +
vitro O +
[ O -
143 O -
] O +
. O -

Bioassay O -
- O -
directed O +
fractionation O +
of O +
the O +
ethanol O +
extract O +
of O +
Curcuma B-Species +
zedoaria L-Species -
( O -
Zingiberaceae U-Species -
) O +
afforded O +
demethoxy- O +
and O +
bisdemethoxycurcumin O -
, O +
as O +
well O +
as O +
curcumin O -
, O +
which O +
were O +
cytotoxic O +
against O +
human U-Species +
ovarian O +
cancer O +
cells O +
[ O -
144 O -
] O +
. O -

The O +
same O +
diarylheptanoids O +
were O +
also O +
found O +
in O +
C. B-Species +
longa I-Species -
L. L-Species +
and O +
displayed O +
topoisomerase O +
I O +
and O +
II O +
inhibitory O +
activity O +
[ O -
145 O -
] O +
. O -

It O +
will O +
be O +
worthwhile O +
investigating O +
chemopreventive O +
effects O +
of O +
these O +
novel O +
diarylheptanoids O -
, O +
particularly O +
with O +
regard O +
to O +
their O +
anti O -
- O -
tumor O +
promotional O +
potential O -
. O -

4.5 O +
Resveratrol O +
Resveratrol O +
( O -
3,5,4′-trihydroxy O -
- O -
trans O +
-stilbene O -
; O +
Fig. O +
5 O -
) O -
, O +
a O +
phytoalexin O +
present O +
in O +
grapes U-Species +
and O +
other O +
plants U-Species -
, O +
has O +
potent O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
activities O +
which O +
have O +
been O +
considered O +
to O +
be O +
responsible O +
for O +
beneficial O +
effects O +
of O +
red O +
wine O +
consumption O +
on O +
coronary O +
heart O +
disease O +
[ O -
146–148 O -
] O +
. O -

This O +
triphenolic O +
stilbene O +
has O +
been O +
suggested O +
as O +
a O +
potential O +
cancer O +
chemopreventive O +
agent O +
based O +
on O +
its O +
striking O +
inhibitory O +
effects O +
on O +
diverse O +
cellular O +
events O +
associated O +
with O +
tumor O +
initiation O -
, O +
promotion O -
, O +
and O +
progression O +
[ O -
149 O -
] O +
. O -

Resveratrol O +
has O +
been O +
reported O +
to O +
be O +
a O +
potent O +
inhibitor O +
of O +
hepatic O +
cytochrome O +
P O +
450-linked O +
alkoxyresorufin O +
O O +
-dealkylase O +
activities O +
[ O -
150 O -
] O +
responsible O +
for O +
oxidative O +
metabolism O +
of O +
many O +
carcinogenic O +
polynuclear O +
aromatic O +
carcinogens O -
. O -

It O +
also O +
induces O +
phase-2 O +
detoxification O +
enzymes O -
, O +
such O +
as O +
NAD O -
( O -
P O -
) O -
H O -
: O +
quinone O +
oxidoreductase O +
[ O -
149 O -
] O +
. O -

Recent O +
work O +
by O +
Uenobe O +
et O +
al. O +
[ O -
151 O -
] O +
demonstrated O +
an O +
antimutagenic O +
activity O +
of O +
resveratrol O +
against O +
the O +
foodborne O +
heterocyclic O +
amine O -
, O +
3-amino-1,4-dimethyl-5H O -
- O -
pyrido O -
[ O -
4,3-b O +
] O -
indole O +
( O -
Trp O -
- O -
P-1 O -
) O +
in O +
bacteria U-Species -
. O -

Resveratrol O +
attenuated O +
PC12 O +
cell O +
death O +
induced O +
by O +
ter O +
-butyl O +
hydroperoxide O +
in O +
the O +
presence O +
of O +
ferric O +
ion O +
[ O -
152 O -
] O +
or O +
by O +
ethanol O +
[ O -
153 O -
] O +
, O +
and O +
was O +
found O +
to O +
be O +
protective O +
against O +
cytotoxicity O +
and O +
NF O -
- O -
κB O +
activation O +
induced O +
by O +
oxidized O +
lipoproteins O +
in O +
PC12 O +
cells O +
[ O -
154 O -
, O +
155 O -
] O +
. O -

In O +
addition O -
, O +
the O +
compound O +
inhibited O +
growth O +
of O +
human U-Species +
breast O +
epithelial O +
cells O +
in O +
culture O +
[ O -
156 O -
] O +
. O -

Proliferation O +
of O +
K-562 O +
human U-Species +
erythroleukemia O +
cells O +
and O +
P-815 O +
murine U-Species +
mastocytoma O +
cells O +
was O +
also O +
suppressed O +
by O +
resveratrol O +
treatment O -
, O +
which O +
might O +
be O +
associated O +
with O +
inhibition O +
of O +
ribonucleotide O +
reductase O +
[ O -
157 O -
] O +
. O -

One O +
of O +
the O +
plausible O +
mechanisms O +
that O +
could O +
account O +
for O +
the O +
chemopreventive O +
activity O +
of O +
resveratrol O +
is O +
suppression O +
of O +
prostaglandin O +
biosynthesis O +
catalyzed O +
COX O -
. O -

Prostaglandins O +
are O +
known O +
to O +
play O +
pivotal O +
roles O +
in O +
pathogenesis O +
of O +
malignancy O -
, O +
particularly O +
in O +
colon O +
and O +
mammary O +
carcinogenesis O +
and O +
suppression O +
of O +
prostaglandin O +
biosynthesis O +
through O +
selective O +
inhibition O +
of O +
COX O +
is O +
hence O -
, O +
now O +
regarded O +
as O +
an O +
important O +
cancer O +
chemopreventive O +
strategy O -
. O -

Resveratrol O +
was O +
shown O +
to O +
inhibit O +
COX-1 O +
activity O +
in O +
microsomes O +
derived O +
from O +
sheep U-Species +
seminal O +
vesicles O +
[ O -
149 O -
] O +
. O -

More O +
recently O -
, O +
Subbaramaiah O +
et O +
al. O +
[ O -
158 O -
] O +
have O +
reported O +
that O +
resveratrol O +
inhibits O +
the O +
catalytic O +
activity O +
of O +
the O +
inducible O +
isozyme O +
COX-2 O +
in O +
cultured O +
human U-Species +
mammary O +
epithelial O +
cells O +
with O +
and O +
without O +
TPA O +
treatment O -
. O -

Likewise O -
, O +
human U-Species +
recombinant O +
COX-2 O +
expressed O +
in O +
baculovirus O +
was O +
inhibited O +
by O +
resveratrol O +
[ O -
158 O -
] O +
. O -

Besides O +
inhibiting O +
the O +
catalytic O +
activity O +
of O +
COX-2 O -
, O +
the O +
compound O +
also O +
blocked O +
TPA O -
- O -
mediated O +
induction O +
of O +
cox O +
-2 O +
mRNA O +
in O +
cultured O +
human U-Species +
mammary O +
epithelial O +
cells O +
through O +
repression O +
of O +
AP-1-dependent O +
transactivation O +
[ O -
158 O -
] O +
. O -

More O +
recently O -
, O +
topical O +
application O +
of O +
resveratrol O +
onto O +
dorsal O +
skin O +
of O +
CD-1 B-Species +
mice L-Species +
led O +
to O +
profound O +
attenuation O +
of O +
oxidative O +
stress O +
and O +
expression O +
of O +
epidermal O +
TGF O -
- O -
β1 O +
and O +
c O -
- O -
fos O -
induced O +
by O +
TPA O -
, O +
but O +
the O +
induction O +
of O +
cox O +
-1 O -
, O +
cox O +
-2 O -
, O +
c O -
- O -
myc O +
, O +
c O -
- O -
jun O -
and O +
TNF O -
- O -
α O +
mRNAs O +
was O +
not O +
affected O +
[ O -
159 O -
] O +
. O -

As O +
mentioned O +
earlier O -
, O +
some O +
anti O -
- O -
inflammatory O +
chemopreventive O +
agents O +
have O +
been O +
found O +
to O +
suppress O +
growth O +
and O +
proliferation O +
of O +
transformed O +
cells O +
through O +
induction O +
of O +
programmed O +
death O +
or O +
apoptosis O +
[ O -
30–32 O -
] O +
. O -

Although O +
resveratrol O +
exerts O +
anti O -
- O -
inflammatory O +
effects O +
through O +
selective O +
suppression O +
of O +
COX-2 O -
, O +
little O +
information O +
is O +
available O +
in O +
the O +
literature O +
in O +
regards O +
to O +
its O +
apoptosis O -
- O -
inducing O +
capability O +
in O +
tumor O +
cells O -
. O -

Mgbonyebi O +
et O +
al. O +
[ O -
156 O -
] O +
reported O +
the O +
growth O +
inhibition O +
by O +
resveratrol O +
of O +
several O +
types O +
of O +
human U-Species +
breast O +
epithelial O +
cells O -
, O +
which O +
was O +
independent O +
of O +
estrogen O +
receptor O +
status O +
of O +
the O +
cells O -
. O -

Although O +
the O +
antiproliferative O +
activity O +
of O +
resveratrol O +
was O +
demonstrated O +
[ O -
156 O -
] O +
, O +
the O +
mode O +
of O +
cell O +
death O +
induced O +
by O +
this O +
phytochemical O +
was O +
not O +
clarified O +
in O +
the O +
above O +
investigation O -
. O -

Suppression O +
of O +
HL-60 O +
cells O +
by O +
resveratrol O +
was O +
shown O +
to O +
be O +
mediated O +
via O +
induction O +
of O +
apoptosis O +
as O +
determined O +
by O +
nuclear O +
fragmentation O -
, O +
chromatin O +
condensation O -
, O +
a O +
time O -
- O -
related O +
increase O +
in O +
the O +
frequency O +
of O +
subdiploid O +
( O -
apoptotic O -
) O +
cells O -
, O +
and O +
internucleosomal O +
DNA O +
fragmentation O +
[ O -
160 O -
] O +
. O -

Besides O +
suppression O +
of O +
proliferation O -
, O +
the O +
compound O +
induced O +
differentiation O +
of O +
HL-60 O +
cells O +
at O +
concentrations O +
as O +
low O +
as O +
30 O +
μM O -
, O +
which O +
appears O +
to O +
be O +
associated O +
with O +
reversible O +
cell O +
cycle O +
arrest O +
at O +
the O +
S O -
- O -
phase O +
check O +
point O +
[ O -
161 O -
] O +
. O -

Moreover O -
, O +
resveratrol O +
was O +
found O +
to O +
induce O +
apoptosis O +
in O +
HL-60 O +
cells O +
by O +
triggering O +
the O +
CD95 O +
signaling O +
system O +
[ O -
162 O -
] O +
. O -

The O +
growth O +
of O +
estrogen O -
- O -
dependent O +
T47D O +
breast O +
carcinoma O +
cells O +
was O +
also O +
suppressed O +
by O +
resveratrol O +
treatment O +
[ O -
162 O -
] O +
. O -

The O +
latter O +
finding O +
is O +
contradictory O +
to O +
the O +
result O +
of O +
a O +
previous O +
work O +
by O +
Gehm O +
et O +
al. O +
[ O -
163 O -
] O +
, O +
who O +
demonstrated O +
stimulation O +
of O +
T47D O +
cell O +
proliferation O +
by O +
resveratrol O +
through O +
interaction O +
with O +
the O +
estrogen O +
receptor O -
. O -

The O +
exact O +
reason O +
for O +
this O +
discrepancy O +
remains O +
unknown O -
. O -

In O +
another O +
study O -
, O +
resveratrol O +
caused O +
estrogen O +
mimic O +
induction O +
of O +
prolactin O +
secretion O +
in O +
the O +
immortalized O +
pituitary O +
cell O +
line O +
PR1 O -
, O +
but O +
it O +
exhibited O +
neither O +
estrogen O +
receptor O +
binding O +
nor O +
growth O +
stimulatory O +
activity O +
in O +
these O +
cells O +
[ O -
164 O -
] O +
. O -

4.6 O +
Epigallocatechin O +
gallate O +
Epidemiologic O -
, O +
as O +
well O +
as O +
laboratory O +
studies O -
, O +
have O +
revealed O +
that O +
increased O +
consumption O +
of O +
green B-Species +
tea L-Species +
has O +
been O +
associated O +
with O +
reduced O +
frequencies O +
of O +
several O +
types O +
of O +
malignant O +
tumors O +
[ O -
165–169 O -
] O +
. O -

Among O +
many O +
polyphenolic O +
compounds O +
isolated O +
from O +
green B-Species +
tea L-Species -
, O +
( O -
− O -
) O -
-epigallocatechin O +
gallate O +
( O -
EGCG O -
; O +
Fig. O +
5 O +
) O +
is O +
believed O +
to O +
be O +
a O +
key O +
active O +
constituent O +
in O +
terms O +
of O +
cancer O +
chemopreventive O +
potential O +
[ O -
113 O -
, O +
165 O -
, O +
170–172 O -
] O +
. O -

The O +
strong O +
antioxidative O +
activity O +
retained O +
in O +
this O +
polyphenol O +
has O +
been O +
confirmed O +
in O +
numerous O +
in O +
vivo O +
and O +
in O +
vitro O +
studies O +
[ O -
173–186 O -
] O +
, O +
which O +
appears O +
to O +
contribute O +
in O +
part O +
to O +
the O +
antimutagenic O +
and O +
anticarcinogenic O +
effects O +
of O +
green B-Species +
tea L-Species -
. O -

Thus O -
, O +
pretreatment O +
of O +
SENCAR B-Species +
mice L-Species +
with O +
EGCG O +
significantly O +
ameliorated O +
TPA O -
- O -
induced O +
infiltration O +
and O +
diminished O +
the O +
formation O +
of O +
hydrogen O +
peroxide O +
and O +
oxidized O +
DNA O +
bases O +
including O +
8-hydroxy-2′-deoxyguanosine O +
( O -
8-OH O -
- O -
dG O -
) O +
and O +
5-hydroxymethyl-2′-deoxyuridine O +
in O +
the O +
skin O +
[ O -
174 O -
] O +
. O -

Likewise O -
, O +
TPA O -
- O -
induced O +
oxidative O +
DNA O +
base O +
modification O +
was O +
inhibited O +
dose O -
- O -
dependently O +
by O +
EGCG O +
in O +
cultured O +
HeLa O +
cells O +
[ O -
175 O -
] O +
. O -

EGCG O +
and O +
structurally O -
- O -
related O +
green B-Species +
tea L-Species +
catechins O +
were O +
found O +
to O +
be O +
stronger O +
inhibitors O +
of O +
lipid O +
peroxidation O +
in O +
rat O +
liver O +
homogenates O +
than O +
such O +
antioxidants O +
as O +
glutathione O -
, O +
ascorbic O +
acid O -
, O +
tocopherol O -
, O +
butylated O +
hydroxytoluene O -
, O +
and O +
butylated O +
hydroxyanisole O +
[ O -
176 O -
] O +
. O -

The O +
antioxidant O +
activities O +
of O +
theaflavins O +
and O +
thearubigin O +
purified O +
from O +
the O +
infusion O +
of O +
black B-Species +
tea L-Species +
leaves O +
were O +
lower O +
than O +
those O +
of O +
green B-Species +
tea L-Species +
polyphenols O +
[ O -
176 O -
] O +
, O +
although O +
the O +
total O +
lyophilized O +
infusion O +
products O +
of O +
green B-Species +
tea L-Species +
and O +
black B-Species +
tea L-Species +
leaves O +
were O +
equally O +
active O -
. O -

EGCG O +
exhibited O +
a O +
strong O +
inhibitory O +
effect O +
on O +
Cu2 O -
+ O +
-mediated O +
oxidation O +
of O +
low O +
density O +
lipoprotein O +
( O -
LDL O -
) O +
in O +
vitro O +
and O +
was O +
again O +
more O +
potent O +
than O +
theaflavin O -
, O +
α O -
- O -
tocopherol O -
, O +
and O +
butylated O +
hydroxytoluene O +
in O +
this O +
regard O +
[ O -
177 O -
] O +
. O -

Kidney O +
slices O +
from O +
rats U-Species +
subjected O +
to O +
oral O +
administration O +
of O +
EGCG O +
( O -
50 O +
mg O -
/ O -
kg O +
body O +
weight O -
) O +
for O +
7 O +
days O +
or O +
fed O +
3 O -
% O +
green B-Species +
tea L-Species +
leaf O +
powder O +
for O +
50 O +
days O +
exhibited O +
lesser O +
extent O +
of O +
ter O +
-butyl O +
hydroperoxide O -
- O -
induced O +
lipid O +
peroxidation O -
, O +
compared O +
with O +
the O +
control O +
animals U-Species +
[ O -
178 O -
] O +
. O -

EGCG O -
, O +
as O +
well O +
as O +
green B-Species +
tea L-Species +
given O +
to O +
rats U-Species +
in O +
drinking O +
water O +
was O +
protective O +
against O +
hepatotoxicity O +
and O +
liver O +
nuclear O +
8-OH O -
- O -
dG O +
formation O +
induced O +
by O +
the O +
carcinogen O +
2-nitropropane O +
[ O -
179 O -
] O +
. O -

Pentachlorophenol O -
- O -
induced O +
hepatic O +
8-OH O -
- O -
dG O +
formation O +
in O +
male O +
B6C3F1 B-Species -
mice L-Species +
was O +
reduced O +
by O +
oral O +
administration O +
of O +
EGCG O +
[ O -
180 O -
] O +
. O -

Peroxynitrite O -
- O -
mediated O +
formation O +
of O +
8-OH O -
- O -
dG O +
in O +
calf U-Species +
thymus O +
DNA O +
and O +
nitration O +
of O +
tyrosine O +
to O +
3-nitrotyrosine O +
were O +
suppressed O +
by O +
EGCG O +
[ O -
181 O -
] O +
. O -

Strand O +
scission O +
in O +
Escherichia B-Species +
coli I-Species -
pUC18 L-Species +
plasmid O +
DNA O +
by O +
gamma O -
- O -
ray O +
or O +
beta O -
- O -
ray O +
was O +
inhibited O +
in O +
the O +
presence O +
of O +
EGCG O -
, O +
which O +
might O +
be O +
attributable O +
to O +
its O +
hydroxyl O +
radical O +
scavenging O +
effect O +
[ O -
182 O -
, O +
183 O -
] O +
. O -

Among O +
the O +
tea U-Species +
flavonoids O +
tested O -
, O +
EGCG O +
exerted O +
the O +
most O +
pronounced O +
protection O +
against O +
oxidation O +
of O +
LDL O +
as O +
revealed O +
by O +
prolongation O +
of O +
the O +
oxidation O +
time O +
[ O -
184 O -
] O +
. O -

The O +
EGCG O +
was O +
found O +
to O +
block O +
the O +
production O +
of O +
ROS O +
derived O +
from O +
NADPH O -
- O -
cytochrome O +
P O +
450-mediated O +
oxidation O +
of O +
the O +
cooked O +
meat O +
carcinogen O -
, O +
2-amino-3-methylimidazo O -
[ O -
4,5-f O +
] O -
quinoline O +
( O -
IQ O -
) O +
[ O -
185 O -
] O +
. O -

The O +
EGCG O +
and O +
epigallocatechin O +
were O +
found O +
to O +
inhibit O +
xanthine O +
oxidase O +
[ O -
186 O -
] O +
. O -

The O +
EGCG O +
has O +
also O +
been O +
reported O +
to O +
attenuate O +
the O +
nitric O +
oxide O +
production O +
[ O -
187 O -
, O +
188 O -
] O +
, O +
which O +
appears O +
to O +
be O +
mediated O +
through O +
suppression O +
of O +
inducible O +
nitric O +
oxide O +
synthase O +
( O -
iNOS O -
) O +
or O +
its O +
mRNA O +
expression O +
[ O -
187 O -
, O +
189 O -
] O +
. O -

The O +
electrophorectic O +
mobility O +
shift O +
assay O +
revealed O +
that O +
EGCG O +
blunted O +
activation O +
of O +
NF O -
- O -
κB O +
responsible O +
for O +
iNOS O +
induction O +
[ O -
187 O -
] O +
. O -

These O +
results O +
indicate O +
that O +
EGCG O +
inhibits O +
the O +
binding O +
of O +
NF O -
- O -
κB O +
to O +
iNOS O +
promoter O -
, O +
thereby O +
hampering O +
the O +
transcription O +
of O +
iNOS O +
gene O -
. O -

Interferon O -
- O -
gamma O +
and O +
lipopolysaccharide O -
- O -
induced O +
nitrite O +
production O +
in O +
mouse U-Species +
peritoneal O +
cells O +
was O +
also O +
inhibited O +
by O +
EGCG O +
[ O -
190 O -
] O +
. O -

The O +
chemopreventive O +
effects O +
of O +
EGCG O +
and O +
other O +
structurally O -
- O -
related O +
green B-Species +
tea L-Species +
polyphenols O +
have O +
been O +
investigated O +
using O +
diverse O +
rodent U-Species +
tumor O +
models O +
( O -
recently O +
reviewed O +
in O +
Ref O -
. O -

[ O -
191 O -
] O +
) O -
. O -

Thus O -
, O +
EGCG O +
exhibited O +
protective O +
effects O +
against O +
N O +
-ethyl O -
- O -
N O +
′-nitrosoguanidine O -
- O -
induced O +
murine U-Species +
duodenum O +
carcinogenesis O +
[ O -
165 O -
, O +
192 O -
, O +
193 O -
] O +
, O +
N O +
-methyl O -
- O -
N O +
′-nitrosoguanidine O -
- O -
induced O +
rat U-Species +
gastric O +
carcinogenesis O +
[ O -
193 O -
, O +
194 O -
] O +
, O +
diethylnitrosamine O -
- O -
initiated O +
and O +
phenobarbital O -
- O -
promoted O +
formation O +
of O +
hepatic O +
preneoplastic O +
foci O +
in O +
male O +
F344 B-Species +
rats L-Species +
[ O -
195 O -
] O +
, O +
mouse U-Species +
skin O +
carcinogenesis O +
[ O -
170 O -
, O +
196–200 O -
] O +
, O +
tobacco U-Species -
- O -
specific O +
nitrosamine O -
- O -
induced O +
mouse U-Species +
pulmonary O +
tumorigenesis O +
[ O -
[ O -
201 O -
] O +
, O +
reviewed O +
in O +
Ref O -
. O -

[ O -
202 O -
] O +
] O -
, O +
rat U-Species +
sarcoma O +
induction O +
following O +
subcutaneous O +
injection O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O +
[ O -
203 O -
] O +
, O +
and O +
spontaneous O +
hepatoma O +
formation O +
in O +
C3H B-Species -
/ I-Species -
HeNCrj I-Species +
mice L-Species +
[ O -
204 O -
] O +
. O -

One O +
of O +
the O +
most O +
plausible O +
mechanisms O +
underlying O +
the O +
chemopreventive O +
activity O +
of O +
EGCG O +
is O +
suppression O +
of O +
promotion O +
of O +
carcinogenesis O +
[ O -
170 O -
, O +
193 O -
, O +
196 O -
, O +
197 O -
] O +
examined O +
in O +
animals U-Species +
and O +
also O +
in O +
cultured O +
cells O +
[ O -
205 O -
] O +
. O -

Thus O -
, O +
EGCG O +
has O +
been O +
reported O +
to O +
influence O +
some O +
biochemical O +
events O +
related O +
to O +
tumor O +
promotion O -
, O +
such O +
as O +
suppression O +
of O +
mouse U-Species +
epidermal O +
ODC O +
activity O +
induced O +
by O +
TPA O +
[ O -
197 O -
] O +
or O +
okadaic O +
acid O +
[ O -
170 O -
] O +
, O +
inhibition O +
of O +
protein O +
kinase O +
C O +
activation O +
induced O +
by O +
teleocidin O +
[ O -
171 O -
] O +
or O +
TPA O +
[ O -
206 O -
] O +
, O +
attenuation O +
of O +
okadaic O +
acid O -
- O -
stimulated O +
production O +
of O +
TNF O -
- O -
α O +
and O +
its O +
mRNA O +
expression O +
in O +
cultured O +
BALB O -
/ O -
3T3 O +
cells O +
[ O -
172 O -
, O +
207 O -
] O +
, O +
inhibition O +
of O +
binding O +
of O +
tumor O +
promoters O +
to O +
the O +
particulate O +
fraction O +
of O +
mouse U-Species +
skin O +
[ O -
170 O -
] O +
or O +
to O +
its O +
receptor O +
protein O +
kinase O +
C O +
[ O -
206 O -
] O +
, O +
mitigation O +
of O +
TPA O -
- O -
induced O +
oxidative O +
damage O +
in O +
mouse U-Species +
skin O +
[ O -
174 O -
] O +
and O +
cultured O +
cells O +
[ O -
175 O -
] O +
, O +
enhancement O +
of O +
gap O +
junctional O +
intercellular O +
communication O +
[ O -
208 O -
] O +
. O -

The O +
ODC O +
activity O +
in O +
gastric O +
mucosal O +
cells O +
of O +
N O +
-methyl O -
- O -
N O +
′-nitrosoguanidine O -
- O -
treated O +
rats U-Species +
was O +
also O +
reduced O +
by O +
oral O +
administration O +
of O +
EGCG O +
[ O -
194 O -
] O +
. O -

TPA O -
- O -
induced O +
expression O +
of O +
ODC O +
gene O -
, O +
protein O +
kinase O +
C O +
gene O -
, O +
and O +
c O -
- O -
myc O -
proto O -
- O -
oncogene O +
in O +
mouse U-Species +
skin O +
was O +
all O +
repressed O +
by O +
topical O +
application O +
of O +
EGCG O +
[ O -
209 O -
] O +
. O -

Likewise O -
, O +
increases O +
in O +
the O +
transcript O +
level O +
of O +
epidermal O +
IL-1α O +
gene O +
in O +
SENCAR B-Species +
mice L-Species +
treated O +
with O +
different O +
types O +
of O +
tumor O +
promoters O +
were O +
suppressed O +
by O +
topical O +
pretreatment O +
with O +
EGCG O +
[ O -
210 O -
] O +
. O -

In O +
contrast O -
, O +
EGCG O +
alone O +
stimulated O +
the O +
production O +
of O +
IL-1α O +
and O +
its O +
mRNA O +
expression O +
in O +
human U-Species +
peripheral O +
blood O +
mononuclear O +
cells O +
in O +
culture O +
[ O -
211 O -
] O +
. O -

EGCG O +
abrogated O +
TPA O -
- O -
induced O +
activation O +
of O +
protein O +
kinase O +
C O -
, O +
c O -
- O -
jun O -
expression O -
, O +
and O +
transformation O +
in O +
cultured O +
mouse U-Species +
fibroblasts O +
in O +
culture O +
[ O -
212 O -
] O +
. O -

Very O +
recently O -
, O +
Dong O +
et O +
al. O +
[ O -
213 O -
] O +
reported O +
that O +
EGCG O +
and O +
theaflavins O +
inhibited O +
EGF- O +
or O +
TPA O -
- O -
induced O +
transformation O +
of O +
JB6 B-Species +
mouse L-Species +
epidermal O +
cell O +
line O +
which O +
was O +
associated O +
with O +
their O +
repression O +
of O +
AP-1-dependent O +
transcriptional O +
activity O +
and O +
its O +
DNA O +
binding O +
activity O -
. O -

The O +
inhibition O +
of O +
AP-1 O +
activation O +
by O +
these O +
substances O +
appears O +
to O +
be O +
mediated O +
via O +
down O -
- O -
regulation O +
of O +
JNK O -
, O +
but O +
not O +
the O +
ERK O +
pathway O +
[ O -
213 O -
] O +
. O -

The O +
anticarcinogenic O -
, O +
as O +
well O +
as O +
antigenotoxic O +
activities O +
of O +
EGCG O +
have O +
been O +
confirmed O +
in O +
many O +
other O +
in O +
vivo O +
and O +
in O +
vitro O +
bioassays O +
( O -
extensively O +
reviewed O +
in O +
Ref O -
. O -

[ O -
192 O -
] O +
and O +
see O +
references O +
therein O -
) O +
although O +
some O +
studies O +
revealed O +
no O +
protective O +
effects O +
[ O -
214 O -
] O +
. O -

Besides O +
inhibiting O +
the O +
tumor O +
promotion O -
, O +
EGCG O +
administered O +
intraperitoneally O +
and O +
the O +
green B-Species +
tea L-Species +
polyphenol O +
fraction O +
given O +
orally O +
or O +
intraperitoneally O +
caused O +
growth O +
inhibition O +
and/or O +
regression O +
of O +
experimentally O +
induced O +
skin O +
papillomas O +
in O +
mice U-Species +
[ O -
198 O -
] O +
. O -

Topically O +
applied O +
green B-Species +
tea L-Species +
polyphenol O +
fraction O +
also O +
inhibited O +
the O +
progression O +
of O +
papillomas O +
to O +
squamous O +
cell O +
carcinoma O +
[ O -
199 O -
] O +
. O -

Similarly O -
, O +
i.p O -
. O -

injection O +
of O +
this O +
polyphenol O +
caused O +
growth O +
inhibition O +
and O +
regression O +
of O +
tumors O +
arising O +
from O +
human U-Species +
prostate O +
cancer O +
cells O -
, O +
PC-3 O +
and O +
LNCaP O +
104-R O -
, O +
subcutaneously O +
inoculated O +
into O +
nude O +
mice U-Species +
[ O -
215 O -
] O +
. O -

Other O +
structurally O -
- O -
related O +
catechins O -
, O +
such O +
as O +
( O -
− O -
) O -
-epicatechin O +
gallate O -
, O +
were O +
not O +
active O +
in O +
this O +
respect O -
. O -

EGCG O +
also O +
effectively O +
suppressed O +
the O +
growth O +
of O +
human U-Species +
mammary O +
cancer O +
cells O +
( O -
MCF-7 O -
) O +
in O +
athymic O +
mice U-Species +
[ O -
215 O -
] O +
. O -

In O +
line O +
with O +
these O +
in O +
vivo O +
findings O -
, O +
EGCG O +
downregulated O +
the O +
aberrant O +
hyperproliferation O +
of O +
c O -
- O -
myc O -
oncogene O -
- O -
transfected O +
mouse U-Species +
mammary O +
epithelial O +
cells O +
as O +
demonstrated O +
by O +
its O +
ability O +
to O +
suppress O +
the O +
anchorage O -
- O -
independent O +
growth O +
of O +
these O +
cells O +
in O +
soft O +
agar O +
[ O -
216 O -
] O +
. O -

Aberrant O +
hyperproliferation O +
of O +
spontaneously O +
immortalized O +
murine U-Species +
mammary O +
epithelial O +
cells O +
subjected O +
to O +
initiation O +
with O +
a O +
chemical O +
carcinogen O +
or O +
by O +
oncogene O +
transfection O +
and O +
their O +
subsequent O +
growth O +
in O +
syngenic O +
mice U-Species +
were O +
also O +
blocked O +
by O +
EGCG O +
treatment O +
[ O -
217 O -
] O +
. O -

In O +
contrast O +
to O +
the O +
above O +
positive O +
findings O -
, O +
EGCG O +
given O +
as O +
a O +
diet O +
to O +
female O +
Sprague B-Species -
– I-Species -
Dawley I-Species +
rats L-Species +
during O +
the O +
late O +
promotion O +
or O +
progression O +
stages O +
of O +
7,12-dimethylbenz O -
[ O -
a O -
] O -
anthracene O -
- O -
initiated O +
mammary O +
carcinogenesis O +
exhibited O +
no O +
significant O +
protective O +
effects O +
[ O -
218 O -
] O +
. O -

There O +
have O +
been O +
a O +
series O +
of O +
papers O +
published O -
, O +
which O +
deal O +
with O +
the O +
growth O +
inhibitory O +
or O +
antiproliferative O +
activities O +
of O +
green B-Species +
tea L-Species +
polyphenols O +
in O +
numerous O +
types O +
of O +
tumor O +
cells O +
[ O -
[ O -
219 O -
, O +
220 O -
] O +
, O +
and O +
vide O +
infra O -
] O -
. O -

Like O +
other O +
chemopreventive O +
phytochemicals O +
listed O +
above O -
, O +
the O +
growth O +
inhibitory O +
effects O +
of O +
EGCG O +
in O +
cancer O +
cells O +
appears O +
in O +
part O +
to O +
be O +
mediated O +
via O +
apoptosis O -
. O -

Hibasami O +
et O +
al. O +
[ O -
221 O -
] O +
reported O +
that O +
human U-Species +
lymphoid O +
leukemia O +
Molt O +
4B O +
cells O +
exposed O +
to O +
EGCG O +
underwent O +
programmed O +
death O +
as O +
determined O +
by O +
appearance O +
of O +
DNA O +
ladder O +
on O +
agarose O +
gel O +
electrophoresis O -
. O -

Other O +
green B-Species +
tea L-Species +
polyphenols O -
, O +
such O +
as O +
epigallocatechin O +
and O +
epicatechin O +
gallate O -
, O +
also O +
inhibited O +
growth O +
of O +
Molt O +
4B O +
cells O +
via O +
induction O +
of O +
apoptotic O +
death O +
[ O -
221 O -
, O +
222 O -
] O +
. O -

Each O +
of O +
these O +
polyphenols O +
exhibited O +
an O +
inhibitory O +
effect O +
on O +
the O +
growth O +
of O +
human U-Species +
lung O +
cancer O +
cell O +
line O +
PC-9 O -
, O +
possibly O +
through O +
arrest O +
of O +
the O +
cell O +
cycle O +
in O +
the O +
G2 O +
/M O +
phase O +
[ O -
166 O -
, O +
223 O -
] O +
. O -

In O +
a O +
subsequent O +
study O -
, O +
the O +
apoptosis O -
- O -
inducing O +
activity O +
of O +
EGCG O +
in O +
PC-9 O +
cells O +
has O +
been O +
found O +
to O +
be O +
synergistically O +
enhanced O +
by O +
combined O +
treatment O +
with O +
other O +
chemopreventive O +
agents O -
, O +
including O +
sulindac O +
and O +
tamoxifen O +
[ O -
224 O -
] O +
. O -

In O +
another O +
study O -
, O +
EGCG O +
induced O +
apoptosis O +
of O +
human U-Species +
epidermoid O +
carcinoma O +
cell O +
line O +
( O -
A431 O -
) O -
, O +
human U-Species +
carcinoma O +
keratinocyte O +
cell O +
line O +
( O -
HaCaT O -
) O -
, O +
human U-Species +
prostate O +
carcinoma O +
cell O +
line O +
( O -
DU145 O -
) O -
, O +
and O +
mouse U-Species +
lymphoma O +
cell O +
line O +
( O -
L5178Y O -
) O +
and O +
its O +
apoptosis O +
inducing O +
activity O +
was O +
related O +
to O +
the O +
cell O +
cycle O +
arrest O +
in O +
the O +
G0 O +
–G1 O -
phase O +
[ O -
225 O -
] O +
. O -

Antiproliferative O +
activity O +
of O +
EGCG O +
against O +
A431 O +
cells O +
has O +
been O +
attributed O +
to O +
its O +
suppression O +
of O +
EGF O +
binding O +
to O +
its O +
receptor O +
and O +
subsequent O +
autophosphorylation O +
of O +
the O +
EGF O +
receptor O +
required O +
for O +
EGF O +
signaling O +
[ O -
226 O -
] O +
. O -

The O +
EGCG O +
and O +
epigallocatechin O +
treated O +
to O +
Ehrlich O +
ascites O +
tumor O +
cells O +
caused O +
significant O +
reduction O +
in O +
cell O +
viability O +
[ O -
227 O -
] O +
. O -

While O +
epigallocatechin O +
suppressed O +
the O +
tyrosine O +
phosphorylation O +
of O +
42 O +
kDa O +
and O +
45 O +
kDa O +
proteins O +
in O +
treated O +
cells O -
, O +
EGCG O +
was O +
not O +
inhibitory O +
on O +
the O +
protein O +
tyrosine O +
kinase O +
activity O +
[ O -
227 O -
] O +
. O -

The O +
growth O +
of O +
premalignant O +
and O +
malignant O +
cells O +
derived O +
respectively O +
from O +
dysplastic O +
leukoplakia O +
and O +
squamous O +
carcinoma O +
of O +
oral O +
epithelial O +
origin O +
was O +
also O +
inhibited O +
by O +
EGCG O -
, O +
which O +
was O +
considered O +
to O +
be O +
associated O +
with O +
cell O +
cycle O +
arrest O +
in O +
the O +
G1 O -
phase O +
[ O -
228 O -
, O +
229 O -
] O +
. O -

The O +
malignant O +
oral O +
epithelium O +
was O +
less O +
responsive O +
to O +
EGCG O +
than O +
normal O +
and O +
dysplastic O +
cells O +
[ O -
229 O -
] O +
. O -

Treatment O +
of O +
benzo O -
[ O -
a O -
] O -
pyrene O -
- O -
initiated O +
human U-Species +
mammary O +
epithelial O +
184-B5 O +
cells O +
with O +
EGCG O +
led O +
to O +
increases O +
in O +
sub O +
G0 O -
population O +
and O +
apoptotic O +
cell O +
death O -
, O +
which O +
might O +
account O +
for O +
suppression O +
of O +
aberrant O +
proliferation O +
in O +
these O +
cells O +
[ O -
230 O -
] O +
. O -

Human U-Species +
stomach O +
KATO O +
III O +
cells O +
also O +
underwent O +
apoptotic O +
death O +
when O +
exposed O +
to O +
EGCG O +
[ O -
231 O -
] O +
. O -

When O +
different O +
types O +
of O +
polyphenols O +
derived O +
from O +
green B-Species +
tea L-Species +
extracts O +
were O +
treated O +
to O +
human O +
lung O +
and O +
colon O +
cancer O +
cell O +
lines O -
, O +
EGCG O +
and O +
epigallocatechin O +
exhibited O +
strong O +
growth O +
inhibitory O +
effects O +
followed O +
by O +
epicatechin O +
gallate O +
and O +
epicatechin O +
[ O -
232 O -
] O +
. O -

The O +
incubation O +
of O +
the O +
human O +
lung O +
tumor O +
cell O +
line O +
H661 O +
with O +
EGCG O +
resulted O +
in O +
apoptosis O -
, O +
which O +
was O +
considered O +
to O +
be O +
mediated O +
by O +
hydrogen O +
peroxide O +
produced O +
by O +
this O +
polyphenol O +
[ O -
232 O -
] O +
. O -

EGCG O +
was O +
proven O +
to O +
be O +
the O +
most O +
potent O +
green B-Species +
tea L-Species +
catechin O +
in O +
terms O +
of O +
suppressing O +
the O +
growth O +
of O +
several O +
human U-Species +
prostate O +
cancer O +
cell O +
lines O -
, O +
including O +
LNCaP O -
, O +
PC-3 O -
, O +
and O +
DU145 O +
[ O -
233 O -
] O +
. O -

The O +
selective O +
inhibition O +
of O +
5α O -
- O -
reductase O +
by O +
EGCG O +
suggests O +
that O +
its O +
antiproliferative O +
activity O +
against O +
prostate O +
cancer O +
cells O +
is O +
mediated O +
via O +
modulation O +
of O +
androgen O +
action O +
[ O -
234 O -
] O +
. O -

The O +
antiproliferative O +
and O +
apoptosis O -
- O -
inducing O +
effects O +
of O +
EGCG O +
were O +
shown O +
to O +
be O +
specific O +
for O +
tumor O +
cells O +
[ O -
225 O -
, O +
235 O -
] O +
, O +
which O +
was O +
partly O +
associated O +
with O +
its O +
differential O +
modulation O +
of O +
c O -
- O -
myc O -
and O +
c O -
- O -
fos O -
expression O +
[ O -
235 O -
] O +
. O -

EGCG O +
also O +
possesses O +
a O +
potential O +
antimetastatic O +
activity O +
as O +
revealed O +
by O +
inhibition O +
of O +
matrix O +
metalloproteinase O +
activity O +
in O +
mouse U-Species +
Lewis O +
lung O +
carcinoma O +
cells O +
[ O -
236 O -
] O +
. O -

Furthermore O -
, O +
administration O +
of O +
EGCG O +
inhibited O +
metastasis O +
of O +
mouse U-Species +
B16 O +
melanoma O +
cells O +
[ O -
237 O -
] O +
. O -

Adhesion O +
of O +
mouse O +
lung O +
carcinoma O +
cells O +
to O +
endothelial O +
cells O +
was O +
also O +
inhibited O +
by O +
EGCG O +
[ O -
238 O -
] O +
. O -

It O +
also O +
reduced O +
the O +
lifespan O +
of O +
cultured O +
monoblastoid O +
leukemia O +
and O +
HT29 O +
colon O +
adenocarcinoma O +
cells O +
through O +
direct O +
inactivation O +
of O +
telomerase O +
[ O -
239 O -
] O +
, O +
an O +
enzyme O +
essential O +
for O +
unlocking O +
the O +
proliferation O +
of O +
cancer O +
cells O -
. O -

5 O +
Concluding O +
remarks O +
A O +
wide O +
variety O +
of O +
phenolic O +
substances O +
present O +
in O +
dietary O +
and O +
medicinal O +
plants U-Species +
possess O +
striking O +
antioxidative O +
and O +
anti O -
- O -
inflammatory O +
properties O -
, O +
which O +
to O +
some O +
extent O -
, O +
contribute O +
to O +
their O +
cancer O +
chemopreventive O +
potential O -
. O -

Examples O +
are O +
pungent O +
vanilloids O +
in O +
red B-Species +
pepper L-Species +
and O +
ginger U-Species -
, O +
and O +
diarylheptanoids O +
isolated O +
from O +
certain O +
medicinal O +
plants U-Species +
of O +
ginger U-Species +
family O -
. O -

These O +
phenolic O +
substances O +
have O +
the O +
ability O +
to O +
inhibit O +
mouse U-Species +
skin O +
tumor O +
promotion O +
and O +
to O +
abrogate O +
various O +
biochemical O +
processes O +
induced O +
or O +
mediated O +
by O +
the O +
tumor O +
promoters O +
including O +
TPA O +
and O +
okadaic O +
acid O -
. O -

They O +
also O +
induce O +
apoptosis O +
in O +
premalignant O +
or O +
cancerous O +
cells O -
. O -

Resveratrol O -
, O +
a O +
phytoalexin O +
present O +
in O +
grapes U-Species +
and O +
red O +
wine O +
and O +
EGCG O -
, O +
one O +
of O +
the O +
major O +
antioxidative O +
polyphenols O +
contained O +
in O +
green B-Species +
tea L-Species -
, O +
have O +
been O +
shown O +
to O +
possess O +
a O +
broad O +
spectrum O +
of O +
anticarcinogenic O +
effects O -
. O -

Recent O +
studies O +
have O +
revealed O +
that O +
resveratrol O +
and O +
EGCG O +
suppress O +
growth O +
and O +
proliferation O +
of O +
various O +
types O +
of O +
tumor O +
cells O +
via O +
induction O +
of O +
apoptosis O +
or O +
arrest O +
of O +
a O +
specific O +
phase O +
of O +
the O +
cell O +
cycle O -
. O -

Most O +
of O +
the O +
naturally O +
occurring O +
chemopreventive O +
phenolics O +
exert O +
multifacet O +
action O -
, O +
and O +
any O +
clinical O +
applications O +
using O +
these O +
substances O +
should O +
be O +
based O +
on O +
the O +
precise O +
understanding O +
of O +
the O +
physiologically O +
relevant O +
action O +
mechanism O -
( O -
s O -
) O -
. O -

Acknowledgements O +
This O +
work O +
was O +
supported O +
by O +
a O +
grant O +
from O +
Korea O +
Science O +
Engineering O +
Foundation O +
through O +
the O +
Research O +
Center O +
for O +
New O +
Drug O +
Development O +
of O +
Seoul O +
National O +
University O +
and O +
also O +
by O +
a O +
grant O +
for O +
' O -
98 O +
Good O +
Health O +
R&D O +
project O +
( O -
HMP-96-D-2 O -
- O -
1034 O -
) O +
sponsored O +
by O +
the O +
Ministry O +
of O +
Health O +
and O +
Welfare O -
, O +
Republic O +
of O +
Korea O -
. O +

Guillain O -
- O -
Barré O +
syndrome O +
( O -
GBS O -
) O +
is O +
an O +
acute O +
immune O -
- O -
mediated O +
polyradiculoneuropathy O -
. O -

An O +
infection O +
often O +
precedes O +
the O +
onset O +
of O +
GBS O -
. O -

Although O +
a O +
subtype O +
with O +
primary O +
axonal O +
degeneration O +
has O +
recently O +
been O +
reported O +
[ O -
1 O -
] O +
, O +
the O +
predominant O +
pathogenetic O +
process O +
is O +
considered O +
to O +
be O +
demyelination O -
. O -

Gangliosides O +
are O +
surface O +
membrane O +
antigens O +
distributed O +
predominantly O +
in O +
the O +
nervous O +
system O -
. O -

Antiganglioside O +
antibodies O +
are O +
frequently O +
elevated O +
in O +
the O +
acute O +
phase O +
sera O +
of O +
GBS O +
[ O -
2–4 O -
] O +
. O -

Among O +
the O +
gangliosides O -
, O +
LM1 O +
( O -
sialosylneolactotetraosylceramide O -
) O +
is O +
the O +
predominant O +
one O +
in O +
the O +
peripheral O +
nerve O +
myelin O +
[ O -
5 O -
] O +
. O -

Anti O -
- O -
LM1 O +
antibody O +
may O +
therefore O +
be O +
related O +
to O +
the O +
pathogenesis O +
of O +
GBS O -
. O -

In O +
this O +
paper O -
, O +
we O +
investigate O +
the O +
presence O +
of O +
the O +
anti O -
- O -
LM1 O +
antibody O +
in O +
the O +
serum O +
of O +
patients U-Species +
with O +
GBS O +
and O +
the O +
clinical O +
and O +
electrophysiological O +
features O +
of O +
GBS O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Patients U-Species -
' O +
sera O +
Serum O +
samples O +
were O +
obtained O +
from O +
140 O +
consecutive O +
patients U-Species +
with O +
acute O +
GBS O +
within O +
two O +
weeks O +
of O +
the O +
onset O +
of O +
neurologic O +
symptoms O -
, O +
24 O +
normal O +
controls O +
and O +
147 O +
disease O +
controls O -
, O +
which O +
included O +
patients U-Species +
with O +
chronic O +
inflammatory O +
demyelinating O +
polyneuropathy O +
( O -
CIDP O -
) O -
, O +
33 O -
; O +
Miller O +
Fisher O +
syndrome O +
( O -
MFS O -
) O -
, O +
47 O -
; O +
other O +
neuropathies O -
, O +
7 O -
; O +
multiple O +
sclerosis O -
, O +
13 O -
; O +
collagen O +
disease O -
, O +
13 O -
; O +
myasthenia O +
gravis O -
, O +
6 O +
and O +
other O +
neurodegenerative O +
disease O -
, O +
28 O -
. O -

All O +
the O +
patients U-Species +
with O +
GBS O +
met O +
the O +
clinical O +
criteria O +
defined O +
by O +
Asbury O +
and O +
Cornblath O +
[ O -
6 O -
] O +
. O -

Except O +
for O +
the O +
subjects U-Species +
with O +
degenerative O +
disorders O +
and O +
normal O +
controls O -
, O +
the O +
serum O +
samples O +
were O +
collected O +
during O +
the O +
acute O +
phase O +
or O +
relapse O -
. O -

2.2 O +
Enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
An O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O +
was O +
performed O +
as O +
described O +
elsewhere O +
[ O -
2 O -
] O -
to O +
investigate O +
the O +
serum O +
anti O -
- O -
LM1 O +
antibodies O -
. O -

Ninety O -
- O -
six O -
- O -
well O +
Linbro O +
microtiter O +
plates O +
( O -
Flow O +
Laboratories O -
, O +
McLean O -
, O +
VA O -
, O +
USA O -
) O +
were O +
used O -
. O -

Each O +
well O +
was O +
coated O +
with O +
0.2 O +
μg O +
of O +
antigen O -
, O +
with O +
an O +
uncoated O +
well O +
being O +
used O +
as O +
the O +
control O -
. O -

After O +
incubation O +
with O +
1 O -
% O +
bovine U-Species +
serum O +
albumin O +
( O -
BSA O -
) O +
in O +
phosphate O -
- O -
buffered O +
saline O +
( O -
PBS O -
) O -
, O +
serum O +
diluted O +
1:40 O +
with O +
1 O -
% O +
BSA O +
in O +
PBS O +
was O +
added O +
to O +
each O +
well O +
and O +
the O +
plate O +
was O +
incubated O +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O +
After O +
each O +
well O +
had O +
been O +
washed O +
with O +
0.1 O -
% O +
BSA O +
in O +
PBS O -
, O +
peroxidase O -
- O -
conjugated O +
anti O -
- O -
human O +
IgM O +
or O +
IgG O +
antibody O +
( O -
Cappel O -
, O +
West O +
Chester O -
, O +
PA O -
, O +
USA O -
) O -
, O +
diluted O +
1:200 O +
and O +
1:500 O -
, O +
respectively O -
, O +
with O +
1 O -
% O +
BSA O +
in O +
PBS O -
, O +
was O +
added O +
to O +
each O +
well O +
and O +
the O +
plate O +
was O +
incubated O +
at O +
room O +
temperature O +
for O +
1.5 O +
h. O -

The O +
wells O +
then O +
were O +
washed O +
with O +
0.1 O -
% O +
BSA O +
in O +
PBS O +
and O +
a O +
color O +
reaction O +
was O +
obtained O +
by O +
incubation O +
with O +
200 O +
μl O +
of O +
orthophenylenediamine O +
dihydrochloride O +
( O -
40 O +
mg O -
/ O -
dl O +
of O +
phosphate O -
– O -
citrate O +
buffer O -
, O +
pH O +
5.0 O -
) O +
at O +
room O +
temperature O +
for O +
2 O +
min O -
. O -

The O +
reaction O +
was O +
stopped O +
by O +
the O +
addition O +
of O +
8 O +
N O +
H2 O +
SO4 O +
, O +
after O +
which O +
the O +
optical O +
density O +
( O -
OD O -
, O +
492 O +
nm O -
) O +
was O +
read O +
with O +
an O +
ELISA O +
reader O +
( O -
Bio O -
- O -
Rad O -
, O +
Hercules O -
, O +
CA O -
, O +
USA O -
) O -
. O -

Each O +
OD O +
value O +
was O +
corrected O +
by O +
subtracting O +
the O +
OD O +
of O +
a O +
control O +
well O +
that O +
had O +
been O +
processed O +
the O +
same O +
way O -
. O -

Serum O +
with O +
an O +
OD O +
of O +
more O +
than O +
the O +
mean+3 O +
SD O +
of O +
the O +
ODs O +
of O +
the O +
24 O +
normal O +
controls O +
was O +
considered O +
positive O -
. O -

Each O +
serum O +
sample O +
positive O +
for O +
the O +
anti O -
- O -
LM1 O +
antibody O +
was O +
diluted O +
serially O +
from O +
1:40 O +
to O +
1:5120 O +
and O +
ELISA O +
was O +
preformed O +
as O +
described O -
. O -

Anti O -
- O -
LM1 O +
antibody O +
titer O +
was O +
expressed O +
as O +
the O +
maximal O +
dilution O +
factor O +
that O +
gave O +
a O +
corrected O +
OD O +
of O +
more O +
than O +
0.1 O -
. O -

Serum O +
samples O +
with O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
were O +
assayed O +
for O +
antibodies O +
to O +
several O +
other O +
gangliosides O +
such O +
as O +
GM1 O -
, O +
GM2 O -
, O +
GM3 O -
, O +
GM1b O -
, O +
GD1a O -
, O +
GD1b O -
, O +
GD3 O -
, O +
GalNAc O -
- O -
GD1a O -
, O +
GT1b O +
and O +
GQ1b O -
, O +
and O +
serum O +
samples O +
of O +
all O +
patients U-Species +
with O +
GBS O +
were O +
assayed O +
for O +
anti O -
- O -
GQ1b O +
IgG O +
antibodies O -
. O -

Antibodies O +
against O +
those O +
gangliosides O +
were O +
investigated O +
by O +
the O +
use O +
of O +
ELISA O +
as O +
described O +
previously O +
[ O -
2 O -
] O +
. O -

2.3 O +
Thin O -
- O -
layer O +
chromatogram O +
immunostaining O +
Thin O -
- O -
layer O +
chromatogram O +
( O -
TLC O -
) O +
immunostaining O +
was O +
performed O +
as O +
described O +
elsewhere O +
[ O -
2 O -
] O -
to O +
confirm O +
the O +
serum O +
antibody O +
reactivities O +
with O +
gangliosides O -
. O -

2.4 O +
Clinical O +
features O +
The O +
clinical O +
and O +
electrophysiological O +
features O +
of O +
GBS O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
were O +
investigated O -
. O -

The O +
clinical O +
grade O +
was O +
determined O +
as O +
described O +
by O +
Hughes O +
et O +
al. O +
[ O -
7 O -
] O +
. O -

Patients U-Species +
were O +
classified O +
electrophysiologically O +
as O +
having O +
either O +
acute O +
inflammatory O +
demyelinating O +
polyradiculoneuropathy O +
( O -
AIDP O -
) O -
, O +
with O +
or O +
without O +
axonal O +
degeneration O +
( O -
AD O -
) O -
, O +
acute O +
motor O +
axonal O +
neuropathy O -
, O +
or O +
acute O +
motor O +
and O +
sensory O +
axonal O +
neuropathy O +
according O +
to O +
the O +
criteria O +
described O +
by O +
Rees O +
et O +
al. O +
[ O -
8 O -
] O +
. O -

Patients U-Species +
who O +
had O +
insufficient O +
evidence O +
of O +
demyelination O +
or O +
axonal O +
degeneration O +
were O +
labeled O +
as O +
unclassifiable O -
. O -

2.5 O +
Statistical O +
analysis O +
The O +
difference O +
in O +
the O +
percentages O +
of O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O -
- O -
positive O +
cases O +
among O +
GBS O +
patients U-Species +
with O +
or O +
without O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
was O +
analyzed O +
using O +
the O +
Fisher O -
's O +
exact O +
test O -
. O -

3 O +
Results O +
3.1 O +
Investigation O +
of O +
serum O +
antiganglioside O +
antibodies O +
Seven O +
patients U-Species +
with O +
GBS O -
, O +
one O +
with O +
CIDP O +
and O +
two O +
with O +
MFS O +
had O +
the O +
IgG O +
anti O -
- O -
LM1 O +
antibody O +
in O +
the O +
serum O +
( O -
Fig. O +
1 O -
) O -
. O -

All O +
the O +
patients U-Species +
with O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
titers O +
of O +
1:160 O +
or O +
more O +
were O +
GBS O +
patients U-Species -
. O -

The O +
IgM O +
anti O -
- O -
LM1 O +
antibody O +
was O +
detected O +
in O +
only O +
two O +
patients U-Species -
, O +
one O +
with O +
GBS O +
and O +
the O +
other O +
with O +
MFS O -
. O -

The O +
binding O +
of O +
the O +
patients U-Species -
' O +
antibody O +
to O +
LM1 O +
was O +
confirmed O +
by O +
TLC O -
- O -
immunostaining O +
( O -
Fig. O +
2 O -
) O -
. O -

Follow O -
- O -
up O +
serum O +
samples O +
were O +
available O +
from O +
three O +
patients U-Species +
( O -
patients U-Species +
3 U-Species -
, O +
4 U-Species +
and O +
5 U-Species -
) O -
. O -

Anti O -
- O -
LM1 O +
IgG O +
antibody O +
titer O +
decreased O +
over O +
the O +
course O +
of O +
the O +
disease O +
in O +
each O +
patient U-Species -
; O +
1:80 O +
on O +
day O +
2 O +
of O +
neurological O +
onset O +
and O +
1:40 O +
on O +
day O +
7 O +
in O +
patient B-Species +
3 L-Species -
; O +
1:160 O +
on O +
day O +
3 O -
, O +
1:80 O +
on O +
day O +
12 O +
and O +
< O -
1:40 O +
on O +
day O +
25 O +
in O +
patient B-Species +
4 L-Species -
; O +
1:640 O +
on O +
day O +
2 O +
and O +
< O -
1:40 O +
on O +
day O +
22 O +
in O +
patient B-Species +
5 L-Species -
. O -

No O +
anti O -
- O -
LM1 O +
antibody O +
was O +
detected O +
either O +
in O +
the O +
normal O +
or O +
in O +
the O +
disease O +
controls O +
other O +
than O +
CIDP O +
and O +
MFS O -
. O -

Six O +
of O +
seven O +
GBS O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
also O +
had O +
antibodies O +
against O +
other O +
gangliosides O -
. O -

In O +
particular O -
, O +
five O +
patients U-Species +
had O +
the O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O +
( O -
Table O +
1 O -
) O -
. O -

The O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O +
was O +
detected O +
in O +
14 O +
of O +
the O +
140 O +
serum O +
samples O +
of O +
patients U-Species +
with O +
GBS O -
. O -

The O +
percentage O +
of O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O -
- O -
positive O +
cases O +
was O +
significantly O +
higher O +
in O +
GBS O +
cases O +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
than O +
in O +
those O +
without O +
it O +
( O -
P O +
< O -
0.001 O -
) O -
. O -

3.2 O +
Clinical O +
features O +
of O +
GBS O +
patients U-Species +
with O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
Of O +
the O +
seven O +
cases O +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O -
, O +
respiratory O +
tract O +
infection O +
preceded O +
the O +
onset O +
of O +
GBS O +
in O +
five O +
patients U-Species +
and O +
gastrointestinal O +
tract O +
infection O +
in O +
two O +
patients U-Species -
. O -

All O +
the O +
five O +
patients U-Species +
in O +
whom O +
the O +
onset O +
of O +
GBS O +
was O +
preceded O +
by O +
respiratory O +
tract O +
infection O +
had O +
anti O -
- O -
GQ1b O +
IgG O +
antibodies O -
. O -

Four O +
of O +
those O +
five O +
patients U-Species +
had O +
ophthalmoplegia O -
. O -

One O +
of O +
the O +
two O +
patients U-Species +
( O -
patient B-Species +
7 L-Species -
) O +
with O +
preceding O +
gastrointestinal O +
infection O +
had O +
an O +
antibody O +
to O +
Campylobacter B-Species +
jejuni L-Species -
( O -
C. B-Species +
jejuni L-Species +
) O -
. O -

Electrophysiological O +
examinations O +
showed O +
that O +
four O +
of O +
the O +
seven O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
were O +
of O +
the O +
AIDP O +
type O +
and O +
one O +
patient U-Species +
( O -
patient B-Species +
7 L-Species -
) O +
was O +
of O +
the O +
AIDP O +
type O +
with O +
axonal O +
damage O -
. O -

In O +
the O +
remaining O +
two O +
patients U-Species -
, O +
no O +
abnormal O +
findings O +
were O +
seen O +
electrophysiologically O -
. O -

Plasmapheresis O +
was O +
performed O +
for O +
all O +
those O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O -
. O -

One O +
month O +
after O +
the O +
onset O +
of O +
neuropathy O -
, O +
six O +
patients U-Species +
had O +
recovered O +
to O +
clinical O +
Grade O +
1 O -
, O +
whereas O +
only O +
patient B-Species +
7 L-Species +
still O +
had O +
Grade O +
4 O -
. O -

4 O +
Discussion O +
We O +
detected O +
the O +
IgG O +
antibody O +
to O +
LM1 O +
in O +
the O +
sera O +
of O +
7 O +
out O +
of O +
140 O +
( O -
5 O -
% O -
) O +
GBS O +
patients U-Species -
, O +
1 O +
out O +
of O +
33 O +
( O -
3.0 O -
% O -
) O +
CIDP O +
patients U-Species -
, O +
and O +
2 O +
out O +
of O +
47 O +
( O -
4.3 O -
% O -
) O +
MFS O +
patients U-Species -
. O -

The O +
IgM O +
antibody O +
to O +
LM1 O +
was O +
found O +
only O +
in O +
two O +
patients U-Species -
, O +
each O +
with O +
GBS O +
and O +
MFS O -
. O -

The O +
sera O +
of O +
patients U-Species +
with O +
other O +
diseases O +
and O +
of O +
the O +
normal O +
controls O +
did O +
not O +
contain O +
anti O -
- O -
LM1 O +
antibodies O -
. O -

Several O +
research O +
groups O +
have O +
found O +
serum O +
anti O -
- O -
LM1 O +
antibodies O +
in O +
patients U-Species +
with O +
demyelinating O +
neuropathies O +
[ O -
9–11 O -
] O +
, O +
however O -
, O +
the O +
results O +
are O +
conflicting O -
. O -

Fredman O +
et O +
al. O +
[ O -
9 O -
] O -
reported O +
that O +
43 O -
% O +
of O +
GBS O +
patients U-Species -
, O +
67 O -
% O +
of O +
CIDP O +
patients U-Species +
and O +
20 O -
% O +
of O +
the O +
normal O +
controls O +
had O +
anti O -
- O -
LM1 O +
antibodies O -
, O +
mostly O +
of O +
the O +
IgG O +
type O -
. O -

Ilyas O +
et O +
al. O +
[ O -
10 O -
] O -
reported O +
that O +
23 O -
% O +
of O +
GBS O +
patients U-Species +
and O +
2.3 O -
% O +
of O +
the O +
disease O +
and O +
normal O +
controls O +
had O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O -
, O +
but O +
no O +
significant O +
elevation O +
of O +
anti O -
- O -
LM1 O +
IgM O +
antibody O +
titers O +
was O +
detected O -
. O -

Yuki O +
et O +
al. O +
[ O -
11 O -
] O -
found O +
the O +
IgG O +
antibody O +
to O +
LM1 O +
in O +
8 O -
% O +
of O +
GBS O +
patients U-Species -
, O +
3 O -
% O +
of O +
CIDP O +
patients U-Species +
and O +
5 O -
% O +
of O +
MFS O +
patients U-Species -
, O +
and O +
the O +
IgM O +
antibody O +
to O +
LM1 O +
in O +
13 O -
% O +
of O +
GBS O +
patients U-Species -
, O +
7 O -
% O +
of O +
CIDP O +
patients U-Species +
and O +
7 O -
% O +
of O +
MFS O +
patients U-Species -
. O -

These O +
differences O +
in O +
results O +
could O +
have O +
been O +
caused O +
by O +
differences O +
in O +
the O +
cut O -
- O -
off O +
levels O +
of O +
the O +
methods O +
used O +
and O +
in O +
the O +
immunogenetic O +
background O -
. O -

We O +
then O +
investigated O +
the O +
clinical O +
and O +
electrophysiological O +
features O +
of O +
GBS O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O -
, O +
which O +
have O +
never O +
been O +
reported O +
so O +
far O -
. O -

Considering O +
that O +
LM1 O +
is O +
the O +
predominant O +
ganglioside O +
in O +
the O +
peripheral O +
nerve O +
myelin O -
, O +
the O +
anti O -
- O -
LM1 O +
antibody O +
can O +
possibly O +
play O +
a O +
role O +
as O +
a O +
demyelinating O +
factor O +
in O +
the O +
pathogenesis O +
of O +
GBS O -
. O -

Of O +
the O +
seven O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
in O +
this O +
study O -
, O +
demyelination O +
was O +
confirmed O +
in O +
five O -
, O +
and O +
two O +
patients U-Species +
were O +
labeled O +
as O +
unclassifiable O -
. O -

Only O +
patient B-Species +
7 L-Species -
, O +
subsequent O +
to O +
C. B-Species +
jejuni L-Species -
infection O -
, O +
had O +
electrophysiological O +
findings O +
suggestive O +
of O +
axonal O +
damage O +
in O +
addition O +
to O +
demyelination O -
. O -

GBS O +
patients U-Species +
subsequent O +
to O +
C. B-Species +
jejuni L-Species -
infection O +
have O +
been O +
reported O +
to O +
frequently O +
have O +
axonal O +
degeneration O +
[ O -
8 O -
] O +
. O -

In O +
patient B-Species +
7 L-Species -
, O +
some O +
other O +
factor O +
induced O +
by O +
the O +
preceding O +
C. B-Species +
jejuni L-Species -
infection O +
might O +
also O +
be O +
elevated O +
to O +
cause O +
axonal O +
damage O -
. O -

Except O +
for O +
patient B-Species +
7 I-Species -
, L-Species +
all O +
patients U-Species +
with O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
exhibited O +
good O +
recovery O -
, O +
being O +
classified O +
Grade O +
1 O +
within O +
one O +
month O +
of O +
the O +
onset O +
of O +
neuropathy O -
. O -

The O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
might O +
be O +
a O +
demyelinating O +
factor O -
, O +
not O +
being O +
associated O +
with O +
axonal O +
degeneration O -
. O -

Five O +
of O +
the O +
seven O +
GBS O +
patients U-Species +
with O +
an O +
elevated O +
anti O -
- O -
LM1 O +
IgG O +
antibody O +
titer O +
also O +
had O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O +
elevation O -
. O -

This O +
percentage O +
is O +
significantly O +
higher O +
than O +
that O +
in O +
the O +
GBS O +
patient U-Species +
group O +
without O +
the O +
anti O -
- O -
LM1 O +
IgG O +
antibody O -
. O -

The O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O +
is O +
specifically O +
and O +
very O +
frequently O +
found O +
in O +
patients U-Species +
with O +
MFS O +
and O +
GBS O +
with O +
ophthalmoplegia O +
[ O -
12,13 O -
] O +
. O -

As O +
ganglioside O +
GQ1b O +
is O +
localized O +
in O +
the O +
paranodal O +
regions O +
of O +
the O +
human U-Species +
cranial O +
nerves O +
innervating O +
the O +
extraocular O +
muscles O -
, O +
it O +
could O +
be O +
a O +
causative O +
factor O +
of O +
ophthalmoplegia O +
in O +
MFS O +
and O +
GBS O +
[ O -
13 O -
] O +
. O -

Because O +
the O +
carbohydrate O +
structure O +
of O +
LM1 O +
is O +
quite O +
different O +
from O +
that O +
of O +
GQ1b O +
( O -
Table O +
2 O -
) O -
, O +
coexistence O +
of O +
antibody O +
activities O +
against O +
LM1 O +
and O +
GQ1b O +
can O -
not O +
be O +
explained O +
by O +
cross O -
- O -
reactivity O -
. O -

Most O +
of O +
the O +
patients U-Species +
with O +
elevated O +
titers O +
of O +
anti O -
- O -
GQ1b O +
IgG O +
antibody O +
have O +
the O +
antecedent O +
respiratory O +
tract O +
infections O +
( O -
Kusunoki O +
et O +
al. O -
, O +
unpublished O +
observation O -
) O -
. O -

The O +
data O +
in O +
this O +
study O +
show O +
that O +
all O +
five O +
patients U-Species +
with O +
both O +
the O +
anti O -
- O -
LM1 O +
and O +
anti O -
- O -
GQ1b O +
IgG O +
antibodies O +
in O +
the O +
serum O +
had O +
a O +
respiratory O +
tract O +
infection O +
before O +
the O +
onset O +
of O +
neuropathy O -
. O -

This O +
is O +
in O +
striking O +
contrast O +
to O +
antibodies O +
to O +
GM1 O +
and O +
GalNAc O -
- O -
GD1a O -
, O +
which O +
are O +
elevated O +
mainly O +
subsequent O +
to O +
gastrointestinal O +
tract O +
infections O +
[ O -
2,14 O -
] O +
. O -

Elevated O +
titers O +
of O +
both O +
anti O -
- O -
GQ1b O +
and O +
anti O -
- O -
LM1 O +
antibodies O +
may O +
be O +
associated O +
with O +
some O +
unknown O +
infectious O +
agent O -
( O -
s O -
) O +
affecting O +
the O +
respiratory O +
tract O -
. O -

Direct O +
evidence O +
that O +
anti O -
- O -
LM1 O +
antibodies O +
cause O +
demyelination O +
has O +
not O +
yet O +
been O +
shown O -
. O -

Although O +
the O +
anti O -
- O -
LM1 O +
antibody O +
is O +
present O +
in O +
only O +
about O +
5 O -
% O +
of O +
GBS O +
patients U-Species -
, O +
it O +
is O +
still O +
an O +
important O +
clue O +
to O +
understanding O +
the O +
pathogenetic O +
mechanisms O +
of O +
demyelination O +
in O +
a O +
subset O +
of O +
GBS O +
cases O -
. O -

Further O +
studies O +
are O +
needed O +
to O +
see O +
whether O +
it O +
is O +
actually O +
a O +
demyelinating O +
factor O +
or O +
not O -
. O -

Acknowledgments O +
This O +
work O +
was O +
supported O +
in O +
part O +
by O +
a O +
Grant O -
- O -
in O -
- O -
Aid O +
for O +
Scientific O +
Research O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O +
and O +
Culture O +
of O +
Japan O +
( O -
10670576 O -
) O -
, O +
and O +
by O +
a O +
Research O +
Grant O +
for O +
Neuroimmunological O +
Diseases O +
from O +
the O +
Ministry O +
of O +
Health O +
and O +
Welfare O +
of O +
Japan O -
. O -

We O +
thank O +
Ms O +
R. O +
Mashiko O +
and O +
Ms O +
H. O +
Mashiko O +
for O +
their O +
technical O +
assistance O -
. O -

We O +
also O +
thank O +
Drs O +
K. O +
Ikeguchi O -
, O +
K. O +
Fujiwara O -
, O +
Y. O +
Yasukawa O -
, O +
K. O +
Ohta O -
, O +
N. O +
Shima O +
and O +
K. O +
Arimura O +
for O +
providing O +
us O +
with O +
the O +
clinical O +
information O +
of O +
the O +
patients U-Species -
. O +

Chalcone O +
synthase O +
( O -
CHS O -
, O +
E.C. O +
2.3.1.74 O -
) O +
catalyzes O +
the O +
first O +
reaction O +
of O +
flavonoid O +
biosynthesis O +
and O +
stilbene O +
synthase O +
( O -
STS O -
, O +
E.C. O +
2.3.1.95 O -
) O +
catalyzes O +
biosynthesis O +
of O +
stilbene O +
backbone O +
of O +
stilbene O -
- O -
type O +
phytoalexins O -
. O -

CHS O +
and O +
STS O +
are O +
similar O +
both O +
in O +
mechanistic O +
and O +
structural O +
aspects O +
and O +
are O +
representative O +
members O +
of O +
the O +
CHS O +
superfamily O +
[ O -
1 O -
] O +
. O -

CHS O +
and O +
STS O +
are O +
homodimers O +
of O +
identical O +
subunits O +
of O +
43 O +
kDa O +
and O +
catalyze O +
repetitive O +
decarboxylative O +
condensation O +
of O +
a O +
p O +
-coumaroyl O +
residue O +
with O +
three O +
C2 O +
-units O +
from O +
malonyl O -
- O -
CoA. O +
Although O +
both O +
enzymes O +
share O +
common O +
starting O +
materials O +
with O +
identical O +
stoichiometry O +
and O +
apparently O +
use O +
the O +
same O +
condensation O +
mechanism O +
up O +
to O +
the O +
common O +
tetraketide O +
intermediate O -
, O +
CHS O +
and O +
STS O +
catalyze O +
different O +
ring O +
closure O +
reactions O +
involving O +
different O +
atoms O +
to O +
give O +
rise O +
to O +
different O +
products O -
, O +
naringenin O +
chalcone O +
and O +
resveratrol O -
, O +
respectively O +
( O -
Fig. O +
1 O +
) O -
. O -

The O +
amino O +
acid O +
homology O +
between O +
these O +
two O +
enzymes O +
is O +
more O +
than O +
65 O -
% O -
, O +
and O +
a O +
phylogenetic O +
analysis O +
showed O +
a O +
higher O +
homology O +
between O +
CHS O +
and O +
STS O +
from O +
related O +
plants U-Species +
than O +
among O +
CHSs O +
and O +
STSs O -
, O +
suggesting O +
that O +
STSs O +
have O +
evolved O +
from O +
CHSs O +
several O +
times O +
independently O +
[ O -
2 O -
] O +
. O -

It O +
has O +
been O +
demonstrated O +
that O -
, O +
under O +
certain O +
in O +
vitro O +
conditions O -
, O +
CHS O +
produces O +
not O +
only O +
naringenin O +
chalcone O +
but O +
also O +
triacetic O +
acid O +
lactone O +
( O -
TAL O -
) O +
and O +
styrylpyrone O +
as O +
early O +
release O +
( O -
derailment O -
) O +
byproducts O +
[ O -
3,4 O -
] O +
. O -

TAL O +
was O +
also O +
detected O +
from O +
the O +
reaction O +
products O +
by O +
fatty O +
acid O +
synthase O +
[ O -
5 O -
] O -
and O +
certain O +
polyketide O +
synthases O +
[ O -
6,7 O -
] O +
. O -

On O +
the O +
other O +
hand O -
, O +
such O +
derailment O +
products O +
have O +
not O +
been O +
observed O +
in O +
the O +
reaction O +
catalyzed O +
by O +
STS O +
[ O -
8 O -
] O +
. O -

Using O +
purified O +
Pueraria B-Species +
lobata L-Species -
( O -
kudzu U-Species -
) O +
CHS O +
and O +
Arachis B-Species +
hypogaea L-Species -
( O -
peanut U-Species -
) O +
STS O +
that O +
was O +
overexpressed O +
in O +
Escherichia B-Species +
coli L-Species +
, O +
we O +
have O +
detected O +
bisnoryangonin O +
( O -
BNY O -
, O +
the O +
derailed O +
lactone O +
after O +
two O +
condensations O -
) O +
and O +
p O +
-coumaroyltriacetic O +
acid O +
lactone O +
( O -
CTAL O -
, O +
the O +
derailed O +
lactone O +
after O +
three O +
condensations O -
) O +
from O +
the O +
reaction O +
products O +
produced O +
by O +
either O +
CHS O +
or O +
STS O -
. O -

Furthermore O -
, O +
we O +
found O +
a O +
cross O -
- O -
reaction O +
between O +
CHS O +
and O +
STS O -
, O +
i.e. O +
resveratrol O +
production O +
by O +
CHS O +
and O +
naringenin O +
production O +
by O +
STS O +
in O +
small O +
but O +
detectable O +
amounts O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Cloning O +
Transcription O +
of O +
STS O +
was O +
induced O +
by O +
cutting O +
peanut U-Species +
seedlings O +
( O -
Sakata O -
, O +
Japan O -
) O +
into O +
slices O +
( O -
1 O +
mm O +
thick O -
) O +
that O +
had O +
been O +
immersed O +
in O +
water O +
for O +
3 O +
days O +
[ O -
9 O -
] O +
. O -

The O +
slices O +
were O +
then O +
left O +
overnight O +
in O +
water O +
at O +
25 O -
° O -
C O +
in O +
darkness O -
. O -

Total O +
RNA O +
was O +
prepared O +
by O +
the O +
phenol O +
method O -
. O -

cDNA O +
was O +
synthesized O +
using O +
an O +
oligo O +
dT O -
- O -
Xba O +
I O +
primer O +
( O -
5′-GTC O +
GAC O +
TCT O +
AGA O +
( O -
T O -
) O -
15 O +
-3′ O -
) O +
and O +
PCR O -
- O -
amplified O +
with O +
primers O +
designed O +
from O +
the O +
published O +
A. B-Species +
hypogaea L-Species -
STS O +
sequence O +
[ O -
10 O -
] O +
; O +
the O +
forward O +
primer O +
( O -
5′-CAT O +
CCA O +
TG O -
G O +
TGT O +
CTG O +
TGA O +
GTG O +
AAT O +
TC-3′ O -
) O +
and O +
the O +
reverse O +
primer O +
( O -
5′-GTA O +
TTA O -
TAT O +
GGC O +
CAT O +
GCT O +
GCG O +
GAG-3′ O -
) O -
. O -

The O +
forward O +
primer O +
carries O +
an O +
Nco O +
I O +
site O +
suitable O +
for O +
cloning O +
into O +
the O +
expression O +
vector O -
, O +
pET-3d O -
. O -

The O +
resulting O +
PCR O +
product O +
was O +
first O +
blunt O -
- O -
ligated O +
into O +
the O +
Sma O +
I O +
site O +
of O +
pBluescriptIISK O -
( O -
+ O -
) O +
( O -
MBI O +
Fermentas O -
) O -
, O +
rescued O +
by O +
Nco O +
I O -
/ O -
Bam O +
HI O +
digestion O -
, O +
and O +
ligated O +
into O +
the O +
Nco O +
I O -
/ O -
Bam O +
HI O +
restricted O +
vector O +
pET-3d O +
to O +
give O +
pET-3d O -
/ O -
STS O -
. O -

The O +
Nco O +
I O +
digestion O +
was O +
carried O +
out O +
in O +
the O +
presence O +
of O +
EtBr O +
( O -
40 O +
μg O -
/ O -
ml O -
) O +
to O +
obtain O +
the O +
1.2-kb O +
full O -
- O -
length O +
cDNA O +
because O +
of O +
the O +
presence O +
of O +
another O +
Nco O +
I O +
site O +
in O +
the O +
coding O +
region O -
. O -

DNA O +
sequencing O +
was O +
carried O +
out O +
on O +
both O +
strands O +
with O +
several O +
forward O +
and O +
reverse O +
primers O +
using O +
the O +
Dye O +
Terminator O +
Cycle O +
Sequencing O +
kit O +
from O +
Applied O +
Biosystems O +
( O -
CA O -
, O +
USA O -
) O -
. O -

Construction O +
of O +
pET-3d O -
/ O -
CHS O +
using O +
similar O +
methods O +
has O +
been O +
described O +
[ O -
11 O -
] O +
. O -

2.2 O +
Protein O +
expression O +
and O +
purification O +
E. B-Species +
coli I-Species -
BL21 I-Species -
( I-Species -
DE3 I-Species -
) I-Species -
pLysE L-Species +
cells O +
transformed O +
with O +
either O +
pET-3d O -
/ O -
CHS O +
or O +
pET-3d O -
/ O -
STS O +
were O +
grown O +
at O +
37 O -
° O -
C O +
in O +
LB O +
medium O +
containing O +
50 O +
μg O -
/ O -
ml O +
ampicillin O +
and O +
25 O +
μg O -
/ O -
ml O +
chloramphenicol O +
and O +
induced O +
with O +
0.4 O +
mM O +
IPTG O -
. O -

After O +
an O +
induction O +
period O +
of O +
4 O +
h O +
at O +
37 O -
° O -
C O -
, O +
the O +
cells O +
were O +
harvested O -
, O +
washed O +
and O +
suspended O +
in O +
buffer O +
A O +
( O -
10 O +
mM O +
potassium O +
phosphate O +
( O -
KPi O -
) O +
buffer O +
( O -
pH O +
7.5 O -
) O -
, O +
2 O +
mM O +
DTT O -
) O -
. O -

Following O +
sonication O +
( O -
10 O +
s O +
×10 O -
) O +
on O +
ice O +
and O +
centrifugation O +
( O -
12 O +
000 O -
× O -
g O +
, O +
4 O -
° O -
C O -
, O +
15 O +
min O -
) O -
, O +
soluble O +
fractions O +
were O +
obtained O -
. O -

After O +
( O -
NH4 O +
) O -
2 O +
SO4 O -
precipitation O +
( O -
30–80 O -
% O +
saturation O -
) O -
, O +
CHS O +
was O +
purified O +
to O +
apparent O +
homogeneity O +
by O +
successive O +
chromatography O +
procedures O -
: O +
( O -
1 O -
) O +
DEAE O -
- O -
Toyopearl O +
( O -
TOSOH O -
, O +
Tokyo O -
, O +
Japan O -
) O +
anion O +
exchange O +
chromatography O +
using O +
a O +
linear O +
gradient O +
of O +
NaCl O +
( O -
0–500 O +
mM O -
) O +
in O +
buffer O +
A O -
, O +
( O -
2 O -
) O +
Bio O -
- O -
Gel O +
hydroxyapatite O +
( O -
Bio O -
- O -
Rad O -
) O +
using O +
a O +
linear O +
gradient O +
of O +
10–300 O +
mM O +
KPi O +
( O -
pH O +
7.5 O -
) O +
containing O +
2 O +
mM O +
DTT O +
and O +
( O -
3 O -
) O +
chromatofocusing O +
on O +
polybuffer O +
exchanger O +
( O -
PBE94 O -
, O +
Pharmacia O -
) O +
pre O -
- O -
equilibrated O +
with O +
25 O +
mM O +
imidazole O -
- O -
HCl O +
( O -
pH O +
7.4 O -
) O -
, O +
2 O +
mM O +
DTT O +
and O +
eluted O +
with O +
Polybuffer74-HCl O +
( O -
pH O +
5.0 O -
) O -
, O +
2 O +
mM O +
DTT O -
. O -

STS O +
was O +
similarly O +
purified O +
after O +
successive O +
DEAE O +
ion O +
exchange O +
and O +
hydroapatite O +
chromatography O +
steps O -
. O -

Protein O +
contents O +
were O +
determined O +
with O +
Bradford O -
's O +
dye O +
method O +
( O -
Bio O -
- O -
Rad O -
) O +
[ O -
12 O -
] O +
, O +
using O +
bovine U-Species +
serum O +
albumin O +
as O +
standard O -
. O -

Expression O +
and O +
purification O +
of O +
P. B-Species +
lobata L-Species -
CHS O +
and O +
A. B-Species +
hypogaea L-Species -
STS O +
as O +
thioredoxin O -
- O -
HisTag O +
fusion O +
proteins O +
( O -
Trx O -
- O -
CHS O +
and O +
Trx O -
- O -
STS O -
) O +
used O +
in O +
the O +
LC O -
- O -
MS O +
analysis O +
of O +
cross O -
- O -
reaction O +
will O +
be O +
described O +
elsewhere O -
. O -

2.3 O +
Enzyme O +
assay O +
For O +
both O +
CHS O +
and O +
STS O -
, O +
the O +
reaction O +
mixture O +
( O -
0.1 O +
ml O -
) O +
contained O +
appropriate O +
amounts O +
of O +
protein O +
( O -
2–5 O +
μg O +
of O +
purified O +
enzyme O -
) O -
, O +
0.1 O +
mM O +
p O +
-coumaroyl O -
- O -
CoA O +
and O +
16.8 O +
μM O +
[ O -
2 O -
- O -
14 O +
C O -
] O -
malonyl O -
- O -
CoA O +
( O -
2.2 O +
GBq O -
/ O -
mmol O -
, O +
NEN O -
) O +
in O +
0.1 O +
M O +
KPi O +
buffer O +
( O -
pH O +
7.5 O -
) O +
( O -
K2 O +
HPO4 O +
/KH2 O +
PO4 O +
) O +
containing O +
2 O +
mM O +
DTT O -
. O -

After O +
incubation O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O -
, O +
50 O +
μl O +
of O +
50 O -
% O +
acetic O +
acid O +
was O +
added O +
and O +
the O +
reaction O +
products O +
were O +
extracted O +
with O +
200 O +
μl O +
of O +
ethyl O +
acetate O -
. O -

A O +
portion O +
( O -
50 O +
μl O -
) O +
of O +
the O +
extract O +
was O +
analyzed O +
by O +
TLC O +
on O +
RP18 O +
plate O +
( O -
Merck O -
) O +
with O +
methanol O -
: O -
H2 O +
O O -
: O -
acetic O +
acid O +
( O -
60:40:1 O -
) O +
as O +
solvent O +
and O +
the O +
radioactive O +
products O +
were O +
quantified O +
with O +
an O +
Imaging O +
Plate O +
analyzer O +
( O -
BAS2000 O -
, O +
Fuji O -
) O -
. O -

Authentic O +
compounds O -
, O +
TAL O +
( O -
R O +
f O +
= O -
0.65 O -
, O +
Tokyo O +
Kasei O -
) O -
, O +
resveratrol O +
( O -
R O +
f O +
= O -
0.50 O -
, O +
Sigma O -
) O +
and O +
naringenin O +
( O -
R O +
f O +
= O -
0.32 O -
, O +
Nacalai O +
tesque O -
) O +
were O +
used O +
as O +
internal O +
standards O +
to O +
identify O +
the O +
products O -
. O -

The O +
specific O +
enzyme O +
activity O +
was O +
expressed O +
in O +
pmol O +
of O +
the O +
product O +
produced O -
/ O -
s O -
/ O -
mg O +
( O -
pkat O -
/ O -
mg O -
) O -
. O -

2.4 O +
Identification O +
of O +
bisnoryangonin O +
and O +
p O +
-coumaroyltriacetic O +
acid O +
lactone O +
For O +
identification O +
of O +
BNY O -
, O +
the O +
ethyl O +
acetate O -
- O -
extracted O +
products O +
produced O +
by O +
STS O +
and O +
CHS O +
were O +
first O +
separated O +
by O +
HPLC O -
. O -

The O +
column O +
( O -
5 O +
μm O -
, O +
4.6 O +
mm O +
I.D. O +
×150 O +
mm O -
, O +
ODS80Ts O -
, O +
TOSOH O -
) O +
was O +
washed O +
at O +
a O +
flow O +
rate O +
of O +
0.6 O +
ml O -
/ O -
min O +
at O +
40 O -
° O -
C O +
with O +
45 O -
% O +
methanol O +
in O +
H2 O +
O O +
containing O +
1 O -
% O +
acetic O +
acid O +
for O +
10 O +
min O +
and O +
then O +
the O +
concentration O +
of O +
methanol O +
was O +
increased O +
to O +
55 O -
% O +
during O +
the O +
next O +
30 O +
min O -
. O -

Detection O +
was O +
with O +
an O +
UV O +
monitor O +
at O +
254 O +
nm O -
. O -

The O +
peak O +
at O +
R O +
t O +
= O -
16.3 O +
min O +
was O +
collected O +
and O -
, O +
after O +
evaporation O +
of O +
the O +
solvent O -
, O +
the O +
residues O +
were O +
dissolved O +
in O +
methanol O +
and O +
reacted O +
with O +
trimethylsilyldiazomethane O +
in O +
the O +
dark O +
for O +
30 O +
min O +
at O +
22 O -
° O -
C O -
. O -

The O +
resulting O +
sample O +
was O +
subjected O +
to O +
GC O -
- O -
MS O +
( O -
Hewlett O +
Packard O +
5890 O +
coupled O +
with O +
JEOL O +
JMS O -
- O -
SX102A O -
) O +
analysis O +
using O +
a O +
DB5 O +
column O +
( O -
0.25 O +
mm O +
I.D. O +
×30 O +
m O -
, O +
film O +
thickness O +
0.25 O +
μm O -
, O +
J O +
and O +
W O -
) O +
at O +
200 O -
° O -
C O +
to O +
250 O -
° O -
C O +
( O -
10 O -
° O -
C O -
/ O -
min O -
) O -
. O -

The O +
retention O +
time O +
and O +
mass O +
spectrum O +
were O +
found O +
to O +
be O +
identical O +
to O +
those O +
of O +
authentic O +
yangonin O -
: O +
GC O -
, O +
R O +
t O +
= O -
22 O +
min O -
; O +
EIMS O +
( O -
70 O +
eV O -
, O +
m O +
/z O +
) O -
, O +
258 O +
( O -
M+ O +
) O -
, O +
230 O -
, O +
187 O -
. O -

Production O +
of O +
CTAL O +
by O +
CHS O +
and O +
STS O +
was O +
confirmed O +
by O +
LC O -
- O -
MS O +
( O -
see O +
below O -
) O -
. O -

CTAL O -
: O +
Multi O -
- O -
stage O +
LC O -
- O -
APCIMS O -
, O +
MS O +
m O +
/z O -
273.1 O +
[ O -
M+H O -
] O -
+ O +
, O +
271.1 O +
[ O -
M−H O -
] O -
− O +
, O +
MS O -
/ O -
MS O +
( O -
precursor O +
ion O +
of O +
m O +
/z O -
271.1 O -
) O +
227.2 O +
[ O -
M−H−CO2 O +
] O -
− O +
, O +
MS O -
/ O -
MS O -
/ O -
MS O +
( O -
transitions O +
m O +
/z O -
271.1>227.2 O -
) O +
185.2 O +
[ O -
M−H−CO2 O +
−CH2 O +
CO O -
] O -
− O +
. O -

2.5 O +
Cross O -
- O -
reaction O +
The O +
enzyme O +
reaction O +
was O +
carried O +
out O +
under O +
the O +
same O +
conditions O +
as O +
described O +
above O +
except O +
that O +
the O +
reaction O +
volume O +
was O +
1 O +
ml O +
and O +
about O +
50 O +
μg O +
of O +
enzyme O +
( O -
10–40 O +
pkat O -
/ O -
mg O -
) O +
was O +
used O -
. O -

Radioactive O +
products O +
thus O +
obtained O +
were O +
redissolved O +
in O +
500 O +
μl O +
of O +
50 O -
% O +
aqueous O +
methanol O +
containing O +
1 O -
% O +
acetic O +
acid O +
in O +
which O +
authentic O +
resveratrol O +
( O -
1.5 O +
μg O -
) O +
and O +
naringenin O +
( O -
2 O +
μg O -
) O +
were O +
added O -
. O -

Using O +
a O +
Hitachi O +
655 O +
HPLC O +
system O +
and O +
ODS-80Ts O +
column O +
( O -
TOSOH O -
) O -
, O +
the O +
radioactive O +
products O +
were O +
separated O +
with O +
isocratic O +
elution O +
with O +
50 O -
% O +
aqueous O +
methanol O +
containing O +
1 O -
% O +
acetic O +
acid O +
for O +
30 O +
min O -
. O -

Radioactivity O +
of O +
each O +
0.5 O +
ml O +
fraction O +
was O +
measured O +
with O +
a O +
β O -
- O -
scintillation O +
counter O +
and O +
the O +
fractions O +
corresponding O +
to O +
main O +
product O +
( O -
naringenin O +
for O +
CHS O +
and O +
resveratrol O +
for O +
STS O -
) O +
and O +
cross O -
- O -
reaction O +
product O +
( O -
resveratrol O +
for O +
CHS O +
and O +
naringenin O +
for O +
STS O -
) O +
were O +
collected O -
. O -

For O +
carrier O +
dilution O +
analysis O -
, O +
recrystallization O +
of O +
the O +
radioactive O +
products O +
with O +
carrier O +
compounds O +
was O +
performed O +
at O +
least O +
four O +
times O +
in O +
two O +
different O +
solvent O +
systems O +
( O -
methanol O +
and O +
ethyl O +
acetate O -
/ O -
hexane O -
) O +
and O +
specific O +
radioactivity O +
was O +
measured O +
after O +
each O +
recrystallization O +
step O -
. O -

The O +
identity O +
of O +
the O +
cross O -
- O -
reaction O +
products O +
was O +
further O +
confirmed O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O -
. O -

First O -
, O +
the O +
CHS O +
and O +
STS O +
reaction O +
products O +
were O +
methylated O +
with O +
trimethylsilyldiazomethane O +
and O +
analyzed O +
by O +
GC O -
- O -
MS O +
as O +
described O +
above O -
. O -

From O +
the O +
methylated O +
CHS O +
reaction O +
products O -
, O +
a O +
peak O +
of O +
m O +
/z O +
= O -
256 O +
( O -
R O +
t O +
= O -
12.99 O +
min O -
) O +
corresponding O +
to O +
dimethylresveratrol O +
was O +
detected O +
with O +
mono- O +
( O -
m O +
/z O -
286 O -
) O -
, O +
di- O +
( O -
m O +
/z O -
300 O -
) O +
and O +
trimethylnaringenin O +
( O -
m O +
/z O -
314 O -
) O -
. O -

Likewise O -
, O +
a O +
peak O +
of O +
m O +
/z O +
= O -
300 O +
( O -
R O +
t O +
= O -
15.35 O +
min O -
) O +
corresponding O +
to O +
dimethylnaringenin O +
was O +
detected O +
from O +
the O +
methylated O +
STS O +
reaction O +
mixture O +
together O +
with O +
di- O +
( O -
m O +
/z O -
256 O -
) O +
and O +
trimethylresveratrol O +
( O -
m O +
/z O -
270 O -
) O -
. O -

For O +
LC O -
- O -
MS O +
analysis O -
, O +
Trx O -
- O -
CHS O +
( O -
11 O +
mg O -
, O +
250 O +
pkat O -
) O +
or O +
Trx O -
- O -
STS O +
( O -
9.5 O +
mg O -
, O +
160 O +
pkat O -
) O +
was O +
incubated O +
with O +
0.1 O +
mM O +
p O +
-coumaroyl O -
- O -
CoA O +
and O +
0.3 O +
mM O +
malonyl O -
- O -
CoA O +
in O +
50 O +
ml O +
of O +
0.1 O +
M O +
KPi O +
buffer O +
( O -
pH O +
7.4 O -
) O +
containing O +
1 O +
mM O +
DTT O +
for O +
40 O +
min O +
at O +
37 O -
° O -
C O -
. O -

At O +
the O +
end O +
of O +
incubation O -
, O +
the O +
pH O +
was O +
raised O +
to O +
9 O +
with O +
1 O +
N O +
NaOH O -
, O +
and O +
the O +
reaction O +
mixture O +
was O +
further O +
incubated O +
at O +
37 O -
° O -
C O +
for O +
another O +
10 O +
min O +
to O +
complete O +
chemical O +
transformation O +
of O +
naringenin O +
chalcone O +
to O +
naringenin O +
[ O -
13 O -
] O +
. O -

The O +
ethyl O +
acetate O +
extract O +
was O +
dried O +
over O +
Na2 O +
SO4 O -
and O +
the O +
solvent O +
was O +
removed O +
under O +
vacuum O +
at O +
30 O -
° O -
C O -
. O -

The O +
remaining O +
products O +
were O +
analyzed O +
by O +
LC O -
- O -
MS O +
( O -
Thermoquest O +
LCQ O -
) O +
as O +
previously O +
described O +
[ O -
14 O -
] O +
. O -

Resveratrol O -
: O +
LC O -
- O -
APCIMS O +
( O -
positive O -
) O -
, O +
229.1 O +
[ O -
M+H O -
] O -
+ O +
, O +
MS O -
/ O -
MS O +
( O -
precursor O +
ion O +
at O +
229 O -
) O +
m O +
/z O -
( O -
rel O -
. O -

% O -
) O +
211 O +
( O -
65 O -
) O -
, O +
135 O +
( O -
100 O -
) O -
, O +
119 O +
( O -
12 O -
) O -
, O +
107 O +
( O -
11 O -
) O -
. O -

Naringenin O -
: O +
LC O -
- O -
APCIMS O +
( O -
positive O -
) O -
, O +
273.2 O +
[ O -
M+H O -
] O -
+ O +
, O +
MS O -
/ O -
MS O +
( O -
precursor O +
ion O +
at O +
273 O -
) O +
m O +
/z O -
( O -
rel O -
. O -

% O -
) O +
171 O +
( O -
18 O -
) O -
, O +
153 O +
( O -
80 O -
) O -
, O +
147 O +
( O -
100 O -
) O -
. O -

3 O +
Results O +
3.1 O +
Sequence O +
of O +
A. B-Species +
hypogaea L-Species -
STS O +
When O +
the O +
deduced O +
amino O +
acid O +
sequence O +
of O +
Japanese B-Species +
peanut L-Species +
STS O +
cloned O +
in O +
this O +
study O +
( O -
Accession O +
number O -
: O +
AB027606 O -
) O +
was O +
compared O +
to O +
the O +
published O +
peanut U-Species +
STS O +
sequence O +
( O -
Swiss O -
- O -
Prot O +
P20178 O -
) O +
[ O -
10 O -
] O +
, O +
8 O +
out O +
of O +
389 O +
amino O +
acids O +
were O +
found O +
to O +
be O +
different O -
. O -

Those O +
are O +
Ser-46 O +
corresponding O +
to O +
Gly-46 O +
in O +
Ref O -
. O -

[ O -
10 O -
] O +
, O +
Ser-195 O +
to O +
Ala-195 O -
, O +
Ser-202 O +
to O +
Asn-202 O -
, O +
Leu-236 O +
to O +
Ile-236 O -
, O +
Asp-281 O +
to O +
Gly-281 O -
, O +
Pro-304 O +
to O +
Leu-304 O -
, O +
Glu-315 O +
to O +
Gln-315 O +
and O +
Ala-356 O +
to O +
Thr-356 O -
. O -

This O +
difference O +
in O +
amino O +
acid O +
sequence O +
probably O +
reflects O +
different O +
origins O +
of O +
the O +
plant U-Species +
materials O +
used O -
. O -

3.2 O +
Purification O +
of O +
CHS O +
and O +
STS O +
Purification O +
of O +
CHS O +
and O +
STS O +
overexpressed O +
in O +
E. B-Species +
coli L-Species -
is O +
summarized O +
in O +
Table O +
1 O +
. O -

Typical O +
experiments O +
yielded O +
0.3–0.4 O +
mg O +
of O +
apparently O +
homogeneous O +
enzymes O +
from O +
300 O +
ml O +
bacteria U-Species +
culture O +
( O -
Fig. O +
2A O +
) O -
. O -

Recovery O +
was O +
10–30 O -
% O +
with O +
about O +
10-fold O +
enrichment O -
. O -

3.3 O +
Identification O +
of O +
BNY O +
and O +
p O +
-coumaroyltriacetic O +
acid O +
lactone O +
Production O +
of O +
BNY O +
and O +
CTAL O +
by O +
STS O +
as O +
well O +
as O +
by O +
CHS O +
was O +
clearly O +
visualized O +
by O +
TLC O +
( O -
Fig. O +
2B O +
) O -
. O -

The O +
TLC O +
spots O +
were O +
identified O +
with O +
non O -
- O -
labeled O +
carrier O +
compounds O +
( O -
resveratrol O +
and O +
naringenin O -
) O +
and O +
with O +
parallel O +
experiment O +
using O +
p O +
-coumaroyltriacetic O +
acid O +
synthase O +
which O +
has O +
been O +
recently O +
cloned O +
from O +
Hydrangea B-Species +
macrophylla L-Species -
and O +
shown O +
to O +
produce O +
CTAL O +
and O +
BNY O +
as O +
the O +
main O +
product O +
and O +
a O +
major O +
byproduct O -
, O +
respectively O +
[ O -
14 O -
] O +
. O -

Further O -
, O +
the O +
identity O +
of O +
BNY O +
and O +
CTAL O +
was O +
unambiguously O +
determined O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O -
. O -

The O +
production O +
of O +
these O +
derailment O +
products O +
by O +
CHS O +
and O +
STS O +
were O +
dependent O +
on O +
the O +
presence O +
of O +
sulfhydryl O +
reagents O +
such O +
as O +
DTT O +
in O +
the O +
reaction O +
mixture O -
, O +
consistent O +
with O +
the O +
earlier O +
report O +
with O +
CHS O +
[ O -
3 O -
] O +
. O -

It O +
was O +
thought O +
that O +
sulfhydryl O +
reagent O +
would O +
act O +
as O +
an O +
acceptor O +
to O +
the O +
enzyme O -
- O -
bound O +
triketide O +
( O -
or O +
tetraketide O -
) O +
intermediate O +
in O +
a O +
non O -
- O -
enzymatic O +
trans O +
-esterification O +
to O +
form O +
unstable O +
thiol O +
adduct O -
, O +
which O +
should O +
be O +
immediately O +
converted O +
to O +
the O +
corresponding O +
pyrone O +
[ O -
3 O -
] O +
. O -

In O +
agreement O +
with O +
this O +
notion O -
, O +
DTT O +
showed O +
apparently O +
parallel O +
effects O +
on O +
formation O +
of O +
BNY O +
and O +
CTAL O -
. O -

However O -
, O +
the O +
requirement O +
of O +
the O +
sulfhydryl O +
reagent O +
was O +
not O +
absolute O -
, O +
as O +
these O +
byproducts O +
were O +
still O +
detectable O +
when O +
the O +
enzyme O +
reaction O +
was O +
carried O +
out O +
in O +
the O +
absence O +
of O +
DTT O +
( O -
data O +
not O +
shown O -
) O -
. O -

Acidification O +
of O +
the O +
reaction O +
mixture O +
to O +
pH<5 O +
greatly O +
enhanced O +
the O +
amounts O +
of O +
BNY O +
and O +
CTAL O +
detected O +
on O +
TLC O -
. O -

These O +
results O +
suggest O +
that O +
the O +
majority O +
of O +
these O +
compounds O -
, O +
both O +
being O +
pyrone O +
derivatives O -
, O +
are O +
present O +
in O +
the O +
reaction O +
mixture O +
as O +
free O +
acids O +
at O +
neutral O +
pH O -
, O +
thus O +
poorly O +
extractable O +
by O +
ethyl O +
acetate O -
, O +
and O +
that O +
lactonization O +
to O +
form O +
pyrone O +
ring O +
is O +
non O -
- O -
enzymatic O -
. O -

Similar O +
pH O -
- O -
dependence O +
of O +
extraction O +
of O +
pyrone O +
derivatives O +
was O +
also O +
reported O +
recently O +
by O +
others O +
[ O -
15 O -
] O +
. O -

Whereas O +
CTAL O +
was O +
a O +
major O +
byproduct O +
of O +
the O +
CHS O +
reaction O -
, O +
BNY O +
was O +
a O +
major O +
byproduct O +
of O +
the O +
STS O +
reaction O +
( O -
Fig. O +
2B O +
) O -
. O -

3.4 O +
Cross O -
- O -
reaction O +
When O +
the O +
reaction O +
products O +
produced O +
by O +
purified O +
recombinant O +
enzyme O +
were O +
analyzed O +
by O +
HPLC O -
, O +
a O +
small O +
radioactive O +
peak O +
corresponding O +
to O +
resveratrol O +
( O -
R O +
t O +
= O -
10 O +
min O -
) O +
was O +
detected O +
in O +
the O +
CHS O +
products O +
and O +
a O +
peak O +
corresponding O +
to O +
naringenin O +
( O -
R O +
t O +
= O -
20 O +
min O -
) O +
was O +
detected O +
in O +
the O +
STS O +
products O +
( O -
Fig. O +
3 O +
) O -
. O -

Cross O -
- O -
reaction O +
was O +
verified O +
by O +
carrier O +
dilution O +
analysis O -
. O -

Successive O +
rounds O +
of O +
recrystallization O +
of O +
radioactive O +
products O +
in O +
the O +
presence O +
of O +
non O -
- O -
labeled O +
compounds O +
gave O +
crystals O +
of O +
constant O +
specific O +
radioactivity O -
. O -

For O +
resveratrol O +
produced O +
by O +
CHS O -
, O +
the O +
specific O +
radioactivity O +
was O +
8200 O +
dpm O -
/ O -
mmol O +
( O -
methanol O -
) O -
, O +
7300 O +
( O -
methanol O -
) O -
, O +
7000 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O +
and O +
6700 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O -
, O +
and O +
for O +
naringenin O +
produced O +
by O +
STS O -
, O +
it O +
was O +
8900 O +
dpm O -
/ O -
mmol O +
( O -
methanol O -
) O -
, O +
7900 O +
( O -
methanol O -
) O -
, O +
7500 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O +
and O +
8300 O +
( O -
ethyl O +
acetate O -
/ O -
hexane O -
) O -
. O -

The O +
cross O -
- O -
reaction O +
was O +
determined O +
to O +
be O +
2.7–4.2 O -
% O +
( O -
resveratrol O -
/ O -
naringenin O -
) O +
for O +
CHS O +
and O +
1.4–2.3 O -
% O +
( O -
naringenin O -
/ O -
resveratrol O -
) O +
for O +
STS O -
. O -

The O +
cross O -
- O -
reaction O +
was O +
further O +
confirmed O +
by O +
GC O -
- O -
MS O +
and O +
LC O -
- O -
MS O +
analyses O -
. O -

The O +
retention O +
time O -
, O +
molecular O +
mass O +
and O +
major O +
daughter O +
ions O +
in O +
MS O -
/ O -
MS O +
were O +
indistinguishable O +
to O +
those O +
of O +
authentic O +
compounds O +
and O +
those O +
found O +
in O +
the O +
literature O +
[ O -
16 O -
] O +
. O -

Trx O +
fusion O +
enzymes O +
were O +
indistinguishable O +
from O +
the O +
native O +
enzymes O +
with O +
regard O +
to O +
the O +
pattern O +
of O +
byproduct O +
production O +
and O +
kinetic O +
parameters O +
( O -
data O +
not O +
shown O -
) O -
. O -

4 O +
Discussion O +
CHS O +
purified O +
from O +
plants U-Species +
was O +
shown O +
to O +
produce O +
styrylpyrones O +
and O +
other O +
minor O +
byproducts O +
in O +
certain O +
in O +
vitro O +
conditions O +
[ O -
3,4 O -
] O +
. O -

In O +
the O +
present O +
study O -
, O +
we O +
showed O +
that O -
, O +
like O +
CHS O -
, O +
purified O +
recombinant O +
peanut U-Species +
STS O +
produced O +
not O +
only O +
BNY O -
, O +
a O +
styrylpyrone O -
, O +
but O +
also O +
CTAL O -
, O +
the O +
recently O +
found O +
derailment O +
product O +
at O +
the O +
stage O +
of O +
tetraketide O +
intermediate O +
[ O -
14 O -
] O +
. O -

This O +
was O +
not O +
unexpected O +
since O +
it O +
has O +
been O +
thought O +
that O +
CHS O +
and O +
STS O +
catalyze O +
identical O +
condensation O +
steps O +
leading O +
to O +
the O +
linear O +
tetraketide O +
intermediate O +
prior O +
to O +
different O +
cyclization O +
steps O +
[ O -
1 O -
] O +
. O -

Detection O +
of O +
BNY O +
and O +
CTAL O +
from O +
the O +
STS O +
reaction O +
products O +
provides O +
an O +
unequivocal O +
evidence O +
for O +
this O +
notion O -
. O -

Under O +
the O +
conditions O +
employed O -
, O +
CHS O +
produces O +
more O +
byproducts O +
than O +
STS O +
( O -
Figs. O +
2B O +
and O +
3 O +
) O -
. O -

This O +
may O +
reflect O +
the O +
more O +
loosely O +
structured O +
active O +
site O +
of O +
CHS O +
compared O +
with O +
that O +
of O +
STS O -
, O +
in O +
vitro O -
, O +
which O +
allows O +
to O +
a O +
greater O +
extent O +
premature O +
thioester O +
exchange O +
with O +
sulfhydryl O +
reagent O +
present O +
in O +
the O +
reaction O +
mixture O +
or O +
thioester O +
hydrolysis O +
by O +
water O +
to O +
give O +
derailment O +
products O -
. O -

CHS O +
is O +
believed O +
to O +
be O +
present O +
in O +
the O +
cell O +
as O +
a O +
part O +
of O +
multi O -
- O -
enzyme O +
complex O +
of O +
flavonoid O +
biosynthesis O +
including O +
polyketide O +
reductase O -
, O +
chalcone O +
isomerase O +
and O +
other O +
modifying O +
enzymes O +
to O +
achieve O +
' O -
metabolite O +
channeling O -
' O +
[ O -
1,17 O -
] O +
. O -

Cyclization O +
steps O +
in O +
CHS O +
and O +
STS O +
are O +
different O -
; O +
Dieckmann O +
condensation O +
leading O +
to O +
naringenin O +
chalcone O +
in O +
CHS O +
and O +
aldol O +
condensation O +
to O +
stilbene O +
in O +
STS O -
. O -

Nonetheless O -
, O +
CHS O +
and O +
STS O +
produce O +
counterpart O +
products O +
in O +
low O +
amounts O +
( O -
2–4 O -
% O +
of O +
main O +
products O -
) O +
which O +
could O +
not O +
be O +
detected O +
by O +
routine O +
assays O -
. O -

The O +
possibility O +
that O +
the O +
cross O -
- O -
reaction O +
products O +
were O +
formed O +
during O +
work O -
- O -
up O +
by O +
chemical O +
transformation O +
was O +
thought O +
to O +
be O +
unlikely O +
based O +
on O +
the O +
following O -
. O -

First O -
, O +
although O +
the O +
corresponding O +
chemical O +
transformations O +
are O +
known O -
, O +
they O +
are O +
normally O +
carried O +
out O +
under O +
harsh O +
conditions O +
unlike O +
the O +
work O -
- O -
up O +
procedures O +
used O +
in O +
this O +
study O -
. O -

For O +
example O -
, O +
the O +
Dieckmann O +
condensation O +
of O +
methyl O +
ester O +
of O +
7-phenyl-3,5,7-trioxoheptanoic O +
acid O +
to O +
corresponding O +
acylphloroglucinol O +
required O +
a O +
prolonged O +
incubation O +
under O +
strongly O +
basic O +
conditions O -
, O +
such O +
as O +
2 O +
M O +
KOH O +
[ O -
18 O -
] O +
. O -

Even O +
though O +
aldol O +
condensation O +
of O +
triketo O +
acids O +
can O +
proceed O +
in O +
weakly O +
acidic O +
( O -
pH O +
5 O -
) O +
aqueous O +
buffer O -
, O +
the O +
products O +
are O +
fairly O +
stable O +
β O -
- O -
resorcylic O +
acids O +
[ O -
18 O -
] O +
. O -

Decarboxylation O +
of O +
aromatic O +
carboxylic O +
acids O +
such O +
as O +
conversion O +
of O +
6-styryl O -
- O -
β O -
- O -
resorcylic O +
acid O +
to O +
pinosylvin O +
and O +
of O +
orsellinic O +
acid O +
to O +
orcinol O +
have O +
been O +
achieved O +
either O +
by O +
heat O +
( O -
180 O -
° O -
C O -
) O +
[ O -
18,19 O -
] O +
, O +
by O +
alcoholic O +
KOH O +
[ O -
20 O -
] O -
or O +
by O +
a O +
decarboxylase O +
[ O -
21 O -
] O +
. O -

It O +
should O +
be O +
noted O +
that O +
stilbene O +
carboxylic O +
acids O -
, O +
though O +
found O +
in O +
nature O +
[ O -
22 O -
] O +
, O +
have O +
not O +
been O +
detected O +
from O +
the O +
STS O +
reaction O +
mixture O -
. O -

Secondly O -
, O +
neither O +
naringenin O +
nor O +
resveratrol O +
was O +
detected O +
after O +
using O +
an O +
identical O +
work O -
- O -
up O +
procedure O +
in O +
the O +
reaction O +
mixture O +
produced O +
by O +
p O +
-coumaroyltriacetic O +
acid O +
synthase O +
( O -
CTAS O -
) O -
, O +
which O +
catalyzes O -
, O +
like O +
CHS O +
and O +
STS O -
, O +
three O +
condensation O +
reactions O +
between O +
p O +
-coumaroyl O -
- O -
CoA O +
and O +
malonyl O -
- O -
CoA O +
to O +
triketo O +
acid O +
but O +
does O +
not O +
catalyze O +
any O +
cyclization O +
reaction O +
[ O -
14 O -
] O +
. O -

This O +
suggested O +
that O +
lactonization O +
of O +
the O +
free O +
triketo O +
acid O +
predominates O +
during O +
work O -
- O -
up O +
to O +
give O +
CTAL O +
as O +
a O +
major O +
byproduct O +
( O -
Fig. O +
1 O +
) O +
and O -
, O +
therefore O -
, O +
we O +
concluded O +
that O +
the O +
cross O -
- O -
reaction O +
of O +
CHS O +
and O +
STS O +
was O +
most O +
likely O +
enzymatic O +
of O +
nature O -
. O -

One O +
reasonable O +
interpretation O +
for O +
this O +
seemingly O +
unnatural O +
cross O -
- O -
reaction O +
is O +
that O +
parts O +
of O +
heterologously O +
overexpressed O +
enzymes O +
are O +
in O +
unnatural O +
conformational O +
states O +
and O +
these O +
misfolded O -
, O +
yet O +
soluble O +
enzymes O +
are O +
responsible O +
for O +
the O +
observed O +
cross O -
- O -
reaction O -
. O -

Overexpression O +
in O +
E. B-Species +
coli L-Species -
often O +
leads O +
to O +
misfolding O +
especially O +
for O +
membrane O -
- O -
associated O +
eukaryotic U-Species +
proteins O -
, O +
as O +
bacteria U-Species +
lack O +
an O +
intracellular O +
membrane O +
environment O +
that O +
may O +
be O +
necessary O +
for O +
efficient O +
and O +
accurate O +
folding O +
[ O -
23 O -
] O +
. O -

Both O +
CHS O +
and O +
STS O +
are O +
shown O +
to O +
be O +
weakly O +
membrane O -
- O -
associated O +
in O +
the O +
plant U-Species +
cells O +
[ O -
24,25 O -
] O -
and O +
CHS O +
is O +
associated O +
with O +
other O +
enzymes O +
involved O +
in O +
the O +
flavonoid O +
biosynthesis O +
pathway O +
[ O -
17 O -
] O +
. O -

However O -
, O +
an O +
attempt O +
to O +
resolve O +
conformational O +
heterogeneity O +
using O +
hydroxyapatite O +
chromatography O +
was O +
unsuccessful O -
, O +
as O +
cross O -
- O -
reaction O +
activities O +
were O +
co O -
- O -
purified O +
with O +
the O +
natural O +
activities O +
( O -
data O +
not O +
shown O -
) O -
. O -

Another O +
intriguing O +
and O +
probably O +
more O +
conceivable O +
possibility O +
is O +
that O +
CHS O +
and O +
STS O +
possess O +
intrinsic O +
potential O +
to O +
catalyze O +
cross O -
- O -
reaction O +
possibly O +
due O +
to O +
conformational O +
flexibility O +
of O +
their O +
active O +
sites O -
, O +
and O +
that O +
this O +
intrinsic O -
, O +
yet O +
' O -
cryptic O -
' O +
capability O +
of O +
these O +
enzymes O +
to O +
perform O +
the O +
cross O -
- O -
reaction O +
was O +
manifested O +
under O +
non O -
- O -
optimal O +
folding O +
conditions O +
during O +
bacterial U-Species +
overexpression O -
. O -

Our O +
recent O +
finding O +
that O +
cross O -
- O -
reaction O +
of O +
CHS O +
and O +
STS O +
expressed O +
in O +
eukaryotic U-Species +
systems O +
( O -
yeasts U-Species +
and O +
insect U-Species +
cells O -
) O +
apparently O +
decreased O +
as O +
compared O +
to O +
the O +
cross O -
- O -
reaction O +
found O +
in O +
this O +
study O +
with O +
bacterial U-Species +
expression O +
system O +
seems O +
to O +
support O +
this O +
idea O +
( O -
Sankawa O -
, O +
unpublished O +
data O -
) O -
. O -

In O +
line O +
with O +
this O +
idea O -
, O +
it O +
should O +
be O +
noted O +
that O +
cyclization O +
steps O +
in O +
CHS O +
and O +
STS O +
are O +
proposed O +
to O +
be O +
under O +
pure O +
topological O +
control O +
[ O -
8 O -
] O +
. O -

Indeed O -
, O +
the O +
recently O +
solved O +
crystal O +
structure O +
of O +
alfalfa U-Species +
( O -
Medicago B-Species +
sativa L-Species +
) O +
CHS O +
by O +
Ferrer O +
et O +
al. O +
did O +
not O +
reveal O +
apparent O +
functional O +
amino O +
acids O +
in O +
the O +
cyclization O +
pocket O +
that O +
might O +
participate O +
in O +
a O +
specific O +
CHS O -
- O -
type O +
cyclization O +
reaction O +
[ O -
26 O -
] O +
. O -

The O +
authors O -
, O +
therefore O -
, O +
proposed O +
that O +
alterations O +
in O +
the O +
surface O +
topology O +
of O +
the O +
cyclization O +
pockets O +
of O +
CHS O +
and O +
STS O +
may O +
affect O +
the O +
stereochemistry O +
of O +
the O +
cyclization O +
reactions O -
. O -

Based O +
on O +
phylogenetic O +
analysis O -
, O +
Schröder O +
et O +
al. O +
[ O -
2 O -
] O -
proposed O +
different O +
STSs O +
evolved O +
from O +
CHSs O +
independently O +
several O +
times O +
by O +
a O +
limited O +
number O +
of O +
amino O +
acid O +
exchanges O -
. O -

However O -
, O +
consensus O +
( O -
signature O -
) O +
amino O +
acid O +
sequences O +
characteristic O +
to O +
CHS O +
or O +
to O +
STS O +
have O +
yet O +
to O +
be O +
recognized O -
. O -

It O +
may O +
result O +
from O +
the O +
insufficient O +
number O +
of O +
STS O +
sequences O +
available O +
( O -
6 O +
entries O +
in O +
Swiss O -
- O -
Prot O -
) O -
. O -

On O +
the O +
other O +
hand O -
, O +
STS O +
conceivably O +
gained O +
its O +
new O +
activity O +
by O +
changing O +
active O +
site O +
geometry O +
rather O +
than O +
by O +
introducing O +
a O +
few O +
new O +
functional O +
amino O +
acids O +
in O +
the O +
active O +
site O +
of O +
STS O -
. O -

A O +
closely O +
related O +
case O +
can O +
be O +
found O +
in O +
chemical O +
diversity O +
of O +
higher O +
plant U-Species +
fatty O +
acids O -
, O +
where O +
independent O -
, O +
multiple O +
evolution O +
of O +
oleate O +
12-hydroxylase O +
from O +
oleate O +
12-desaturase O +
was O +
proposed O -
. O -

Site O -
- O -
directed O +
mutagenesis O +
studies O +
involving O +
as O +
few O +
as O +
seven O +
amino O +
acids O +
suggested O +
that O +
catalytic O +
plasticity O +
in O +
these O +
two O +
enzymes O +
is O +
achieved O +
by O +
changing O +
active O +
site O +
geometry O +
leading O +
to O +
different O +
partitioning O +
of O +
a O +
common O +
intermediate O +
into O +
different O +
reaction O +
products O +
[ O -
27 O -
] O +
. O -

Clearly O -
, O +
further O +
studies O +
with O +
regard O +
to O +
the O +
origin O +
of O +
the O +
cross O -
- O -
reaction O +
of O +
CHS O +
and O +
STS O +
overexpressed O +
in O +
E. B-Species +
coli L-Species -
are O +
warranted O -
. O -

Acknowledgements O +
The O +
authors O +
are O +
grateful O +
to O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O +
of O +
Japan O +
for O +
Grants O -
- O -
in O +
Aid O +
for O +
Scientific O +
Research O +
( O -
B O -
) O +
( O -
No. O +
09044212 O -
) O +
and O +
( O -
C O -
) O +
( O -
No. O +
10680564 O -
) O -
. O -

D O -
.- O -
Y. O +
Suh O +
thanks O +
the O +
Tokyo O +
Biochemistry O +
Research O +
Foundation O +
for O +
a O +
fellowship O +
( O -
TBRF-98 O -
- O -
10 O -
) O -
. O +

There O +
are O +
currently O +
several O +
potent O +
fungal U-Species +
inhibitors O +
of O +
serine O +
palmitoyl- O -
transferase O +
( O -
3-ketosphinganine O +
synthase O -
) O +
[ O -
palmitoyl O -
- O -
CoA O -
: O +
L O -
- O -
serine O +
C O -
- O -
pal- O -
mitoyltransferase O +
( O -
decarboxylating O -
) O -
; O +
EC O +
2.31.50 O -
] O -
, O +
the O +
first O +
enzyme O +
in O +
the O -
de O +
novo O +
biosynthesis O +
of O +
ceramides O +
and O +
more O +
complex O +
sphingolipids O -
. O -

1'2 O +
In O -
t O +
A. O +
H. O +
Merrill O -
, O +
Jr. O +
and O +
E. O +
Wang O -
, O +
Methods O +
Enzymol O -
. O +
51 O -
, O +
427 O +
( O -
1992 O -
) O -
. O -

2 O +
R. O +
C. O +
Dickson O -
, O +
R. O +
L. O +
Lester O -
, O +
and O +
M. O +
Marek O -
, O +
Methods O +
Enzymol O -
. O -

311 O +
[ O -
1 O -
] O +
1999 O +
( O -
this O +
volume O -
) O -
. O -

Copyright O +
© O +
1999 O +
by O +
Academic O +
Press O -
All O +
rights O +
of O +
reproduction O +
in O +
any O +
form O +
reserved O -
. O -

0076 O -
- O -
6879 O -
/ O -
99 O +
$ O -
30.00 O +
METHODS O +
IN O +
ENZYMOLOGY O -
, O +
VOL O -
. O -

311 O -
is O +
measured O +
when O -
casamino O +
acids O +
are O +
omitted O +
from O +
the O +
sphingolipid O +
inhibition O +
assay O +
and O +
the O -
comparatively O +
poor O +
activity O +
that O +
australifungin O +
demonstrates O +
in O +
medium O -
that O +
contains O +
serum O +
or O +
peptone O -
. O -

In O +
addition O +
to O +
the O +
loss O +
in O +
potency O -
, O +
caution O -
is O +
also O +
advised O +
when O +
using O +
australifungin O +
in O +
assays O +
that O +
employ O +
trace O -
amounts O +
of O +
sphingoid O +
bases O -
; O +
high O +
concentrations O +
of O +
australifungin O +
can O +
result O -
in O +
nonspecific O +
inhibition O +
due O +
to O +
sequestration O +
of O +
the O +
sphingoid O +
base O -
. O -

Serine O +
Palmitolytransferase O +
Inhibitors O -
Viridiofungins O +
are O +
at O +
least O +
five O -
- O -
fold O +
less O +
potent O +
and O +
are O +
not O +
as O +
specific O -
for O +
serine O +
palmitoyltransferase O +
inhibition O +
as O +
the O +
sphingofungin O -
/ O -
myriocin O -
class O +
of O +
compounds O -
. O -

Viridiofungins O +
are O +
known O +
to O +
inhibit O +
squalene O +
synthase O -
, O -
geranyl O +
geranyltransferase O -
, O +
and O +
other O +
enzymes O +
that O +
are O +
sensitive O +
to O +
di- O +
and O -
tricarboxylic O +
acids O -
, O +
albeit O +
at O +
higher O +
concentrations O +
than O +
required O +
for O +
serine O -
palmitoyltransferase O +
inhibition O -
. O -

Because O +
of O +
this O +
difference O +
in O +
enzyme O +
sensi- O -
tivity O -
, O +
viridiofungin O +
A O +
showed O +
selective O +
inhibition O +
of O +
sphingolipid O +
synthesis O -
in O +
labeling O +
studies O +
in O +
C. B-Species +
albicans L-Species -
, O +
with O +
no O +
evidence O +
for O +
inhibition U-Species +
of O +
sterol O -
synthesis O +
at O +
growth O +
inhibitory O +
concentrations O +
of O +
drug O -
. O -

7'22 O +
For O +
unknown O -
reasons O -
, O +
viridiofungins O +
lack O +
in O +
vitro O +
activity O +
against O +
Saccharomyces U-Species +
serine O -
palmitoyltransferase O +
and O +
do O +
not O +
inhibit O +
sphingolipid O +
synthesis O +
in O +
this O +
yeast U-Species -
, O -
although O +
they O +
do O +
inhibit O +
the O +
mammalian U-Species +
enzyme O +
and O +
appear O +
to O +
be O +
selective O -
for O +
sphingolipid O +
inhibition O +
in O +
HepG2 O +
cells O -
. O -

2t~ O +
A. O +
H. O +
Merrill O -
, O +
Jr. O -
, O +
D. O +
C. O +
Liotta O -
, O +
and O +
R. O +
T. O +
Riley O -
, O +
Trends O +
Cell O +
Biol O -
. O -

6 O -
, O +
218 O +
( O -
1996 O -
) O -
. O -

3o O +
R. O +
T. O +
Riley O +
et O +
al. O -
, O +
J. O +
Food O +
Protect O -
. O -

57 O -
, O +
638 O +
( O -
1994 O -
) O -
. O -

INHIBITORS O +
OF O +
SPHINGOLIPID O +
BIOSYNTHESIS O +
348 O +
[ O -
36 O -
] O -
Inositol O +
Phosphoceramide O +
Synthase O +
Inhibitors O -
Unlike O +
inhibitors O +
to O +
earlier O +
steps O +
in O +
sphingolipid O +
synthesis O -
, O +
khafrefungin O -
and O +
rustmicin O +
do O +
not O +
have O +
any O +
detectable O +
effect O +
on O +
lipid O +
synthesis O +
in O +
mam- B-Species -
malian L-Species +
cells O +
( O -
unpublished O +
data O +
and O +
Ref O -
. O +
13 O -
) O -
, O +
and O +
rustmicin O +
and O +
aureobasidin O -
A O +
have O +
been O +
nontoxic O +
in O +
animal U-Species +
studies O -
, O +
a4'31 O +
supporting O +
the O +
idea O +
that O +
inositol O -
phosphoceramide O +
synthase O +
is O +
a O +
fungal U-Species +
selective O +
target O -
. O -

Khafrefungin O +
was O -
lytic O +
to O +
washed O +
red O +
blood O +
cells O +
at O +
12.5 O +
to O +
25 O -
/ O -
xg O -
/ O -
ml O -
. O -

However O -
, O +
this O +
toxicity O -
may O +
be O +
due O +
to O +
the O +
detergent O -
- O -
like O +
properties O +
of O +
the O +
compound O -
. O -

Although O -
all O +
three O +
inositol O +
phosphoceramide O +
synthase O +
inhibitors O +
are O +
very O +
potent O +
in O -
vitro O +
( O -
picomolar O +
to O +
low O +
nanomolar O -
) O -
, O +
substantially O +
higher O +
concentrations O +
are O -
required O +
to O +
kill O +
fungi U-Species -
. O -

In O +
the O +
case O +
of O +
rustmicin O -
, O +
two O +
factors O +
that O +
limit O +
whole O -
cell O +
activity O +
were O +
identified O -
: O +
efflux O +
via O +
multidrug O +
transporters O +
and O +
chemical O -
instability O -
. O -

TM O +
Even O +
at O +
its O +
optimal O +
pH O +
of O +
5.5 O -
, O +
rustmicin O +
degrades O +
relatively O -
rapidly O +
in O +
aqueous O +
media O -
. O -

Despite O +
these O +
limitations O -
, O +
concentrations O +
of O +
rust- O -
micin O +
that O +
are O +
required O +
to O +
completely O +
inhibit O +
phosphosphingolipid O +
synthesis O -
and O +
accumulate O +
ceramide O +
in O +
fungi U-Species +
are O +
achieved O +
easily O -
. O -

Acknowledgments O -

We O +
thank O +
M. O +
Zweerink O +
and O -
BS O -
: O -
MIE O +
00110948 O +
S0076 O -
- O -
6879 O -
( O -
00 O -
) O -
11094 O -
- O -
8 O +
10.1016 O -
/ O -
S0076 O -
- O -
6879 O -
( O -
00 O -
) O -
11094 O -
- O -
8 O -
Section O +
II O -
. O -

inhibitors O +
of O +
sphingolipid O +
biosynthesis O -
[ O -
35 O -
] O +
Isolation O +
and O +
characterization O +
of O +
novel O +
inhibitors O +
of O +
sphingolipid O +
synthesis O -
: O +
Australifungin O -
, O +
viridiofungins O -
, O +
rustmicin O -
, O +
and O +
khafrefungin O +
Suzanne O +
M. O +
Mandala O -
Guy O +
H. O +
Harris O -
Publisher O +
Summary O +
Sphingolipid O +
synthesis O +
is O +
an O +
essential O +
process O +
in O +
yeast U-Species +
and O +
the O +
pathogenic O +
fungi U-Species +
that O +
cause O +
life O -
- O -
threatening O +
human U-Species +
infections O +
such O +
as O +
candidiasis O -
, O +
aspergillosis O -
, O +
and O +
cryptococcosis O -
. O -

Although O +
many O +
steps O +
in O +
the O +
human U-Species +
and O +
fungal U-Species +
sphingolipid O +
biosynthetic O +
pathway O +
are O +
similar O -
, O +
there O +
are O +
several O +
enzymes O +
found O +
uniquely O +
in O +
fungi U-Species +
that O +
are O +
potential O +
targets O +
for O +
the O +
development O +
of O +
nontoxic O +
therapeutic O +
antifungals O -
. O -

In O +
the O +
screening O +
program O -
, O +
it O +
has O +
been O +
found O +
that O +
natural O +
products O +
are O +
a O +
rich O +
source O +
of O +
structurally O +
diverse O +
inhibitors O +
of O +
sphingolipid O +
synthesis O -
. O -

Natural O +
product O +
inhibitors O +
to O +
four O +
different O +
enzymes O +
that O +
affect O +
sphingolipid O +
synthesis O +
have O +
been O +
discovered O -
: O +
sphingofungins O -
, O +
lipoxamycin O -
, O +
myriocin O -
/ O -
ISP1 O -
, O +
and O +
viridiofungins O +
inhibit O +
serine O +
palmitoyltransferase O -
; O +
fumonisin O +
B1 O +
and O +
australifungin O -
, O +
inhibit O +
ceramide O +
synthase O -
; O +
aureobasidins O -
, O +
khafrefungin O -
, O +
and O +
rustmicin O +
inhibit O +
inositol O +
phosphoceramide O +
synthase O -
; O +
and O +
minimoidin O +
inhibits O +
the O +
fatty O +
acid O +
elongation O +
pathway O -
. O -

Most O +
of O +
these O +
compounds O +
have O +
fungicidal O +
activity O +
against O +
a O +
broad O +
spectrum O +
of O +
pathogenic O +
fungi U-Species -
, O +
but O +
only O +
the O +
inhibitors O +
of O +
inositol O +
phosphoceramide O +
are O +
fungal U-Species +
selective O -
; O +
compounds O +
that O +
inhibit O +
early O +
biosynthetic O +
steps O +
show O +
comparable O +
activity O +
against O +
orthologous O +
mammalian U-Species +
enzymes O -
. O -

This O +
chapter O +
describes O +
a O +
method O +
to O +
identify O +
sphingolipid O +
inhibitors O +
and O +
detailed O +
protocol O +
for O +
the O +
isolation O +
of O +
australifungin O -
. O -

More O +
abbreviated O +
descriptions O +
of O +
the O +
isolation O +
of O +
viridiofungins O -
, O +
khafrefungin O -
, O +
and O +
rustmicin O +
are O +
also O +
included O -
. O +

The O +
protein O +
mediator O +
known O +
as O +
macrophage O +
migration O +
inhibitory O +
factor O +
( O -
MIF O -
) O +
has O +
emerged O +
to O +
play O +
a O -
central O +
role O +
in O +
the O +
control O +
of O +
the O +
host O +
inflammatory O +
and O +
immune O +
response O -
. O -

Described O +
originally O +
as O +
a O +
lymphocyte O -
" O -
activity O -
" O +
responsible O +
for O +
inhibiting O +
the O +
random O +
migration O +
of O +
macrophages O +
in O +
vitro O -
, O -
l'z O +
MIF O +
has O +
been O +
shown O +
to O +
be O -
released O +
from O +
the O +
anterior O +
pituitary O +
gland O +
during O +
stress O +
and O +
to O +
be O +
critically O +
involved O +
in O +
the O +
toxic O +
response O +
to O -
septic O +
shock.3 O +
Macrophages O -
, O +
T O +
cells O -
, O +
and O +
eosinophils O +
release O +
MIF O +
in O +
response O +
to O +
pro O -
- O -
inflammatory O +
stimuli O -
, O +
and O -
the O +
expression O +
of O +
MIF O +
is O +
required O +
for O +
T O -
- O -
cell O +
activation O +
and O +
antibody O +
production O +
by O +
B O +
cells.4'5 O +
More O +
recent O +
studies O -
have O +
shown O +
that O +
macrophages O +
and O +
T O +
cells O +
can O +
secrete O +
MIF O +
in O +
response O +
to O +
glucocorticoid O +
stimulation O -
, O +
and O +
that O -
once O +
released O -
, O +
MIF O +
can O +
" O -
override O -
" O +
the O +
immuno O -
- O -
suppressive O +
effects O +
of O +
steroids O +
on O +
cytokine O +
production O +
and O -
cellular O +
activation.4'5 O -
Studies O +
performed O +
in O +
models O +
of O +
the O +
inflammatory O +
and O +
immune O +
response O +
indicate O +
that O +
MIF O +
acts O -
extracellularly O +
by O +
stimulating O +
the O +
specific O +
response O +
of O +
target O +
cells O -
. O -

In O +
1996 O +
however O -
, O +
Rorsman O +
et O +
al. O +
reported O +
that O -
recombinant O +
MIF O +
( O -
rMIF O -
) O +
catalyzes O +
a O +
tautomerization O +
reaction O -
, O +
converting O +
the O +
non O -
- O -
naturally O +
occurring O +
D O -
- O -
isomer O -
of O +
dopachrome O +
( O -
2-carboxy-2,3-dihydroindole-5,6-quinone O -
) O +
to O +
dihydroxyindole O +
carboxylic O +
acid O +
( O -
DHICA O -
) O -
.6 O -
Intriguingly O -
, O +
subsequent O +
elucidation O +
of O +
the O +
three O -
- O -
dimensional O +
crystal O +
structure O +
of O +
MIF O +
revealed O +
it O +
to O +
exhibit O -
significant O +
three O -
- O -
dimensional O +
( O -
but O +
not O +
primary O +
sequence O -
) O +
homology O +
with O +
two O +
bacterial O +
isomerases O -
, O +
4- O -
oxalocrotonate O +
tautomerase O +
and O +
5-carboxymethyl-2-hydroxymuconate O +
isomerase.7 O -
- O -
9 O +
These O +
proteins O +
share O +
with O -
MIF O +
an O +
apparently O +
conserved O +
active O +
site O +
structure O +
that O +
consists O +
of O +
a O +
hydrophobic O +
cleft O +
bearing O +
an O +
active O +
site O -
proline O -
. O -

More O +
recently O -
, O +
Rorsman O +
and O +
colleagues O +
have O +
proposed O +
that O +
MIF O +
acts O +
physiologically O +
to O +
catalyze O +
the O -
keto O -
- O -
enol O +
tautomerization O +
of O +
p O -
- O -
hydroxyphenylpyruvate O +
and O +
phenylpyruvate.lFinally O -
, O +
the O +
presence O +
of O +
the O +
CXXC O -
* O -
Present O +
Address O -
: O +
Chemical O +
Development O -
, O +
New O +
Product O +
Research O -
, O +
R. O +
W. O +
Johnson O +
pharmaceutical O +
Research O +
Institute O -
, O +
Route O +
202 O -
, O -
Raritan O -
, O +
NJ O +
08869 O -
0960 O -
- O -
894X O -
/ O -
99 O -
/ O -
$ O +
- O +
see O +
front O +
matter O +
1999 O +
Elsevier O +
Science O +
Ltd. O +
All O +
rights O +
reserved O -
. O -

PII O -
: O +
S0960 O -
- O -
894X O -
( O -
99 O -
) O -
00561 O -
- O -
2 O -
3194 O -
X. O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O -
motif O +
in O +
MIF O +
has O +
prompted O +
yet O +
additional O +
studies O +
which O +
suggest O +
that O +
MIF O +
may O +
function O +
as O +
a O +
physiologically- O -
relevant O +
protein O -
- O -
thiol O +
oxidoreductase.~ O -
These O +
observations O +
notwithstanding O -
, O +
the O +
precise O +
relationship O +
between O +
MIF O -
's O +
enzymatic O -
and O -
immunological O +
activities O +
remain O +
unclear O -
. O -

In O +
two O +
separate O +
studies O -
, O +
the O +
creation O +
of O +
an O +
enzymatically O -
- O -
inactive O +
form O -
of O +
MIF O +
by O +
site O -
- O -
directed O +
mutagenesis O +
shows O +
the O +
protein O +
retains O +
full O +
glucocorticoid O -
- O -
regulatory O +
activity,12 O +
but O +
loses O -
neutrophil O +
priming O +
activity O -
) O -
3 O +
In O +
an O +
effort O +
to O +
further O +
explore O +
the O +
mechanism O +
of O +
action O +
of O +
MIF O +
in O +
biological O -
systems O -
, O +
we O +
have O +
endeavored O +
to O +
identify O +
potential O +
small O +
molecule O +
inhibitors O +
of O +
MIF O -
's O +
isomerization O +
activity O -
. O -

We O -
report O +
herein O +
a O +
study O +
of O +
MIF O +
substrate O +
analogs O +
which O +
inhibit O +
dopachrome O +
tautomerization O +
at O +
concentrations O -
tenfold O +
less O +
than O +
substrate O -
. O -

Such O +
inhibitors O +
may O +
prove O +
useful O +
in O +
the O +
study O +
of O +
MIF O +
structure O +
function O +
relationships O -
and O +
also O +
assist O +
in O +
the O +
development O +
of O +
small O +
molecules O +
that O +
can O +
be O +
specifically O +
targeted O +
to O +
MIF O +
for O -
pharmacological O +
purposes O -
. O -

Materials O +
and O +
Methods O -
Reagents O -
. O -

All O +
chemicals O +
were O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MA O -
) O +
or O +
Aldrich O +
( O -
Milwaukee O -
, O +
WI O -
) O -
. O -

Pure O -
, O +
bioactive O -
recombinant O +
human U-Species +
MIF O +
was O +
prepared O +
by O +
expression O +
in O +
E. B-Species +
coli L-Species +
following O +
methods O +
described O +
previously O -
) O -
4 O -
Preparation O +
of O +
MIF O +
Substrates O +
and O +
Analogs O -
. O -

The O +
MIF O -
- O -
substrates O +
lb-4b O +
( O -
Table O +
1 O -
) O +
and O +
the O +
test O -
inhibitors O +
5b O -
- O -
llb O +
were O +
prepared O +
by O +
oxidizing O +
their O +
precursors O +
la-4a O +
and O +
5a-10a O +
with O +
soCum O +
periodate,7'8 O +
as O -
shown O +
in O +
Scheme O +
1 O -
. O -

Compounds O +
7a O +
and O +
8a O +
were O +
prepared O +
from O +
5a O +
and O +
6a O +
by O +
an O +
esterification O +
procedure.8 O -

The O -
oxidation O +
was O +
performed O +
10 O +
min O +
prior O +
to O +
the O +
tautomerization O +
assay O +
and O +
the O +
dopachrome O +
compounds O +
were O +
tested O -
without O +
further O +
purification O -
. O -

The O +
test O +
compounds O +
11 O -
- O -
13 O +
( O -
Table O +
1 O -
) O +
were O +
obtained O +
from O +
Aldrich O -
. O -

Compd O -
D O -
/ O -
L O -
RI O -
R2 O -
R3 O -
R1 O -
, O -
. O -

O O -
~ O -
R2 O -
HO O -
~ O -
R2 O -
NalO4 O -
HO O +
I.,~ O -
/ O -
Iql~23 O -
HO O -
/ O -
~-~. O -
/ O -
-N O +
R3 O -
a O -
b O -
1 O -
2 O -
3 O -
4 O -
5 O -
6 O -
7 O -
8 O -
9 O -
l0 O -
D O -
L O -
L O -
DL O -
L O -
DL O -
L O -
DL O -
DL O -
DL O -
H O -
H O -
H O -
H O -
H O -
H O -
H O -
H O -
OH O -
OH O -
H O -
H O -
H O -
H O -
Me O -
Me O -
Me O -
Me O -
H O -
H O -
CO2H O -
CO2H O -
CO2Me O -
CO2Me O -
CO2H O -
CO2H O -
CO2Me O -
CO2Me O -
CO2H O -
CH3 O -
Scheme O +
1 O -
Dopachrome O +
Tautomerization O +
Assay O -
. O -

The O +
DOPA O -
- O -
related O +
precursors O +
( O -
la-10a O -
) O +
were O +
prepared O +
as O +
10 O -
mM O +
stock O +
solutions O +
in O +
MIF O +
assay O +
buffer O +
( O -
10 O +
mM O +
sodium O +
phosphate O -
, O +
pH O +
6.0 O -
) O -
. O -

Thirty O +
minutes O +
before O +
the O -
tautomerization O +
assay O -
, O +
1.0 O +
mL O +
of O +
each O +
stock O +
solution O +
was O +
diluted O +
with O +
7 O +
mL O +
of O +
assay O +
buffer O -
, O +
and O +
1.0 O +
mL O +
of O -
sodium O +
periodate O +
stock O +
solution O +
( O -
20 O +
mM O +
in O +
water O -
) O +
was O +
added O +
to O +
initiate O +
the O +
oxidation O +
of O +
the O +
precursors O -
, O +
thus O -
generating O +
each O +
respective O +
dopachrome O +
derivative O +
( O -
lb-10b O -
) O -
) O -
5 O +
After O +
10 O +
min O -
, O +
1 O +
mL O +
of O +
methionine O +
( O -
20 O +
mM O +
in O -
X O -
, O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O -
3195 O -
water O -
) O +
was O +
added O +
to O +
react O +
with O +
the O +
excess O +
periodate O -
. O -

The O +
dopachrome O +
compounds O +
were O +
generated O +
as O +
orange O -
solutions O +
at O +
a O +
final O +
concentration O +
of O +
1 O +
mM. O +
Test O +
inhibitors O +
11 O -
- O -
13 O +
were O +
prepared O +
as O +
10 O +
~M O +
stock O +
solution O +
and O -
diluted O +
to O +
1 O +
mM O +
solution O +
with O +
assay O +
buffer O +
before O +
the O +
assay O -
. O -

To O +
perform O +
the O +
tautomerization O +
assay O -
, O +
0.5 O +
mL O +
of O -
the O +
1 O +
mM O +
solution O +
of O +
the O +
MIF O -
- O -
substrate O +
( O -
lb O -
, O +
2b O -
, O +
3b O -
, O +
or O +
4b O -
) O +
was O +
mixed O +
with O +
0.5 O +
mL O +
of O +
assay O +
buffer O -
. O -

After O +
the O -
Table O +
1 O -
. O -

Inhibition O +
of O +
MIF O +
tautomerase O +
activity O +
by O +
test O +
compounds O -
No. O -
Structure O -
5b O -
L- O +
HO O +
~ O -
/ O -
~N O -
" O +
" O -
CO2H O -
6b O -
7b O -
8b O -
9b O -
10b O -
11 O -
12 O -
13 O -
DL- O -
DL- O +
HOAL'~' O -
/ O -
L O -
~ O -
N O -
" O +
" O -
CO2H O -
O O -

~e O -
L- O +
HO O +
~'~"~" O -
/ O -
~N~ O +
" O -
CO2Me O -
DL- O +
HO O +
~ O -
/ O -
t"~ O -
/ O -
X~'N O -
" O +
" O -
CO2Me O -
OH O -
OH O -
OH O -
OH3 O -
O O -
Conc O -
. O -

of O +
test O +
compounds O +
( O -
mM O -
) O -
0.5 O -
0.5 O -
0.5 O -
0.5 O -
0.5 O -
0.25 O -
0.125 O -
0.06 O -
0.5 O -
0.25 O -
0.125 O -
0.06 O -
0.5 O -
0.25 O -
0.125 O -
0.02 O -
0.5 O -
0.5 O -
% O +
inhibition O -
' O -
29 O -
35 O -
45 O -
34 O -
100 O -
98 O -
41 O -
9 O -
92 O -
88 O -
54 O -
22 O -
98 O -
79 O -
54 O -
21 O -
a0.5 O +
mM O +
of O +
3b O +
was O +
used O +
as O +
MIF O -
- O -
substrate O +
in O +
this O +
assay O -
. O -

3196 O -
X. O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O -
background O +
rate O +
was O +
monitored O -
, O +
10 O +
I.tL O +
of O +
recombinant O +
MIF O +
solution O +
from O +
a O +
20 O +
mg O -
/ O -
mL O +
stock O +
was O +
added O -
. O -

The O -
decrease O +
in O +
absorbance O +
( O -
~ O -
, O +
= O +
475 O +
nm O -
) O +
at O +
1 O +
min O +
following O +
addition O +
of O +
MIF O +
was O +
measured O +
as O +
an O +
index O +
of O -
tautomerase O +
activity O -
, O +
For O +
the O +
inhibitory O +
assay O -
, O +
0.5 O +
mL O +
of O +
the O +
1 O +
mM O +
solution O +
of O +
the O +
MIF O -
- O -
substrate O +
( O -
3b O -
) O +
was O +
mixed O -
with O +
0.5 O +
mL O +
of O +
the O +
1 O +
mM O +
solution O +
of O +
one O +
of O +
the O +
test O +
inhibitors O +
( O -
5b-10b O +
and O +
11 O -
- O -
13 O -
) O -
, O +
followed O +
by O +
addition O +
of O +
10 O -
mL O +
of O +
recombinant O +
MIF O +
stock O +
solution O +
( O -
20 O +
mg O -
/ O -
mL O -
) O -
. O -

Compounds O +
9b O -
, O +
10b O -
, O +
and O +
12 O +
were O +
tested O +
at O +
final O -
concentrations O +
of O +
0.25 O +
mM O -
, O +
0.125 O +
mM O -
, O +
and O +
0.06 O +
mM O +
in O +
addition O +
to O +
the O +
standard O +
0.5 O +
mM O +
assay O -
. O -

The O +
percent O -
inhibition O +
of O +
the O +
decrease O +
in O +
absorbance O +
( O -
~ O -
, O +
= O +
475 O +
nm O -
) O +
at O +
1 O +
min O +
in O +
the O +
presence O +
of O +
inhibitors O +
was O +
calculated O +
from O -
the O +
spectrophotometric O +
data O +
by O +
standard O +
methods.6 O -
Results O +
and O +
Discussion O -
Tautomerization O +
of O +
an O +
orange O +
colored O +
solution O +
of O +
D O -
- O -
dopachrome O +
( O -
lb O -
) O +
by O +
MIF O +
produces O +
the O +
non O -
- O -
colored O -
DHICA.6 O +
This O +
conversion O +
can O +
be O +
quantitated O +
spectrophotometrically O +
by O +
measuring O +
the O +
rate O +
of O +
decrease O +
of O +
the O -
iminochrome O +
absorbance O +
at O +
a O +
wavelength O +
of O +
475 O +
nm O -
. O -

The O +
methyl O +
ester O +
derivatives O +
of O +
D- O +
( O -
or O +
L- O -
) O +
dopachrome O -
were O +
found O +
to O +
be O +
better O +
substrates O +
for O +
this O +
reaction O +
than O +
dopachromes O +
( O -
lb O +
and O +
2b O -
) O -
. O -

In O +
our O +
study O +
L O -
- O -
dopachrome O -
methyl O +
ester O +
3b O +
was O +
used O +
as O +
a O +
test O +
substrate O +
for O +
the O +
identification O +
of O +
compounds O +
with O +
the O +
ability O +
to O +
inhibit O +
the O -
tautomerization O +
reaction O -
. O -

The O +
dopachrome O +
tautomerization O +
by O +
MIF O +
may O +
occur O +
by O +
two O +
different O +
pathways O +
as O +
shown O +
in O +
Scheme O +
2 O -
. O -

The O +
first O +
proceeds O +
via O +
the O +
initial O +
conversion O +
of O +
dopachrome O +
to O +
indolidine O +
14 O +
and O +
subsequent O +
rearrangement O +
to O +
an O -
indole O -
. O -

A O +
possible O +
alternative O +
pathway O +
involves O +
the O +
formation O +
of O +
quinone O +
methide O +
intermediate O +
15 O +
which O +
is O +
then O -
transformed O +
further O +
into O +
an O +
indole O -
. O -

H O +
H O -
O O -
H O -
H O +
H O -
O O -
H O -
H O +
H O -
. O -

HO~ O -
" O -
11 O -
... O -
L O -

/ O -
/ O -
'--CO2R O -
HO O -
/ O +
~ O +
~N O -
14 O -
HO O -
~ O -
H O -
f O -
O O -
/ O -
'~-.,J--~ O +
N~ O +
" O -
CO2R O -
H O -
15 O -
Scheme O +
2 O -
HO O -
~ O -
co2R O -
HO O -
/ O -
~ O +
~N O -
iH O -
Understanding O +
the O +
mechanism O +
of O +
MIF O +
catalyzed O +
substrate O +
tautomerization O +
is O +
helpful O +
in O +
the O +
design O +
and O -
search O +
of O +
MIF O +
inhibitors O -
. O -

Initial O +
molecular O +
modeling O +
studies O +
have O +
suggested O +
that O +
the O +
pathway O +
through O +
indolidine O -
14 O +
might O +
be O +
favored O -
, O +
while O +
comparison O +
to O +
structurally O +
related O +
tautomerases O +
and O +
more O +
recent O +
mechanistic O +
data O -
have O +
favored O +
the O +
quinone O +
methide O +
pathway O -
. O -

16,17 O +
It O +
is O +
known O +
that O +
s O -
- O -
methyl O +
quinone O +
methide O +
have O +
UV O +
and O +
visible O -
X. O +
Zhang O -
, O +
R. O +
Bucala O -
/ O -
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O +
3193 O -
- O -
3198 O -
3197 O -
spectra O +
which O +
are O +
easily O +
distinguished O +
from O +
the O +
corresponding O +
dopachrome O +
spectra.~ O -

When O +
5b-41b O +
were O -
exposed O +
to O +
MIF O -
, O +
no O +
change O +
of O +
their O +
spectra O +
was O +
observed O -
. O -

This O +
observation O +
supports O +
the O +
indolidine O +
pathway O -
described O +
above O +
and O +
suggests O +
that O +
R O -
- O -
proton O +
extraction O +
is O +
the O +
initial O +
step O +
in O +
dopachrome O +
tautomerization O +
by O +
MIF O -
. O -

L- O +
and O +
DL-~-methyl O +
dopachrome O +
( O -
Sb O +
and O +
6b O -
) O +
and O +
their O +
methyl O +
esters O +
( O -
7b O +
and O +
8b O -
) O -
, O +
when O +
present O +
at O +
the O -
same O +
concentration O +
( O -
0.5 O +
mM O -
) O +
as O +
the O +
MIF O -
- O -
substrate O +
3b O -
, O +
each O +
displayed O +
a O +
moderate O +
inhibitory O +
effect O +
on O +
MIF O -
tautomerase O +
activity O -
, O +
with O +
the O +
esters O +
showing O +
slightly O +
higher O +
activity O +
than O +
the O +
free O +
acids O +
as O +
shown O +
in O +
Table O +
1 O -
. O -

The O -
moderate O +
inhibitory O +
activity O +
of O +
or O -
- O -
substituted O +
dopachromes O +
may O +
result O +
from O +
the O +
competition O +
with O +
MIF O -
- O -
substrate O -
3b O +
for O +
the O +
active O +
site O +
of O +
MIF O +
protein O -
. O -

To O +
identify O +
inhibitors O +
with O +
higher O +
activity O -
, O +
we O +
needed O +
to O +
design O +
compounds O +
with O +
stronger O +
binding O -
affinity O +
or O +
even O +
ones O +
capable O +
of O +
binding O +
covalently O +
to O +
the O +
MIF O +
protein O +
thereby O +
blocking O +
the O +
active O +
site O +
and O -
possibly O +
changing O +
the O +
secondary O +
structure O +
of O +
MIF O -
. O -

As O +
proposed O +
in O +
Scheme O +
3 O -
, O +
dopachromes O +
with O +
a O +
leaving O +
group O +
at O +
~l O -
- O -
position O +
may O +
form O +
a O +
very O +
reactive O -
intermediate O +
16 O +
following O +
et O -
- O -
deprotonation O +
by O +
MIF O -
. O -

Compound O +
16 O +
may O +
react O +
with O +
nucleophilic O +
residues O +
of O +
the O -
MIF O +
protein O +
to O +
form O +
a O +
covalent O +
bond O +
with O +
the O +
protein O -
. O -

Our O +
data O +
have O +
indeed O +
shown O +
that O +
9b O -
, O +
10b O -
, O +
and O +
11 O +
all O -
displayed O +
strong O +
inhibition O +
on O +
MIF O +
tautomerase O +
activity O +
( O -
Table O +
1 O -
) O -
. O -

Particularly O -
, O +
compounds O +
9b O -
, O +
lOb O -
, O +
and O +
11 O +
all O -
showed O +
about O +
50 O -
% O +
inhibition O +
even O +
at O +
a O +
concentration O +
four O +
times O +
less O +
than O +
that O +
of O +
MIF O -
- O -
substrate O -
. O -

Further O -
, O +
10b O -
and O +
11 O +
showed O +
activity O +
at O +
a O +
concentration O +
ten O +
times O +
less O +
than O +
that O +
of O +
MIF O -
- O -
substrate O -
. O -

Studies O +
of O +
the O +
proposed O -
MIF O -
- O -
covalent O +
complexes O +
( O -
MIF-10b O +
or O +
11 O -
) O +
by O +
mass O +
spectrometry O +
were O -
, O +
however O -
, O +
inconclusive O -
. O -

Detailed O -
elucidation O +
of O +
the O +
nature O +
of O +
enhanced O +
binding O +
of O +
these O +
inhibitors O +
to O +
MIF O +
requires O +
further O +
study O -
. O -

H O -
H O -
MIF O -
O~~X- O -
HO~~N O -
H O -
R O -
HOI~ O +
-N O -
R O -
HOI~ O +
-N O -
HO O -
16 O -
Scheme O +
3 O -
Finally O -
, O +
we O +
examined O +
acyclic O +
compounds O +
containing O +
some O +
structural O +
features O +
similar O +
to O +
the O +
active O +
MIF O -
substrates O -
/ O -
inhibitors O -
. O -

Thus O -
, O +
compounds O +
12 O +
and O +
13 O +
were O +
tested O +
and O +
found O +
to O +
be O +
inactive O +
in O +
the O +
MIF O -
tautomerization O +
assay O -
. O -

We O +
have O +
identified O +
several O +
inhibitors O +
of O +
MIF O +
tautomerase O +
activity O -
. O -

This O +
discovery O +
should O +
lead O +
to O +
the O -
development O +
of O +
inhibitors O +
of O +
MIF O +
biological O +
activities O +
and O +
the O +
development O +
of O +
agents O +
for O +
the O +
treatment O +
of O +
MIF O -
related O +
diseases O -
. O -

Acknowledgments O -
: O +
These O +
studies O +
were O +
supported O +
by O +
NIH O +
grant O +
AI35931 O -
. O -

3198 O -
X. O +
Zhang O -
, O +
R. O +
Bucala O +
/ O +
Bioorg O -
. O -

Med O -
. O -

Chem O -
. O -

Lett O -
. O -

9 O +
( O -
1999 O -
) O -
3193 O -
- O -
3198 O +

Parasitic U-Species +
diseases O +
caused O +
by O +
helminths U-Species +
afflict O +
billions O +
of O +
people U-Species +
worldwide O +
and O +
are O +
among O +
the O +
main O +
causes O +
of O +
morbidity O +
and O +
mortality O +
resulting O +
from O +
infectious O +
disease O -
. O -

Such O +
diseases O +
in O +
animals U-Species +
also O +
have O +
major O +
economic O +
consequences O -
. O -

Recent O +
information O +
about O +
the O +
basic O +
biochemistry O +
and O +
the O +
immunological O +
responses O +
of O +
infected O +
hosts O +
to O +
parasitic U-Species +
helminths U-Species +
and O +
their O +
eggs O +
has O +
led O +
to O +
increased O +
interest O +
in O +
parasite O +
glycoconjugates O -
, O +
since O +
they O +
are O +
the O +
major O +
focus O +
of O +
the O +
immune O +
response O +
( O -
for O +
reviews O -
, O +
see O +
[ O -
1–4 O -
] O +
) O -
. O -

However O -
, O +
only O +
a O +
few O +
helminth U-Species +
carbohydrate O +
structures O +
have O +
sofar O +
been O +
structurally O +
characterized O -
. O -

A O +
typical O +
feature O +
of O +
helminth U-Species +
infections O +
is O +
the O +
induction O +
of O +
specific O +
IgE O +
[ O -
5,6 O -
] O -
and O +
this O +
is O +
the O +
result O +
of O +
a O +
T O -
- O -
helper-2 O +
( O -
Th2 O -
) O +
response O -
. O -

In O +
the O +
presence O +
of O +
antigen O +
this O +
IgE O +
triggers O +
the O +
activation O +
and O +
proliferation O +
of O +
mast O +
cells O +
and O +
eosinophils O +
( O -
i.e. O +
type O +
I O +
hypersensitivity O +
reactions O -
) O -
. O -

The O +
exact O +
implications O +
of O +
these O +
IgE O +
responses O -
, O +
however O -
, O +
are O +
still O +
unclear O -
. O -

Several O +
studies O +
have O +
shown O +
that O +
high O +
parasite U-Species +
specific O +
IgE O +
levels O +
are O +
associated O +
with O +
resistance O +
to O +
reinfection O -
, O +
suggesting O +
a O +
protective O +
role O +
for O +
IgE O +
[ O -
6–9 O -
] O +
. O -

However O -
, O +
very O +
little O +
is O +
known O +
about O +
the O +
structures O +
of O +
the O +
parasite U-Species +
antigens O +
that O +
induce O +
these O +
IgE O +
responses O -
. O -

N O -
- O -
glycans O +
carrying O +
a O +
' O -
core O +
α1→3-Fuc O -
' O +
( O -
R O -
- O -
GlcNAcβ1→4 O -
( O -
Fucα1→3 O -
) O -
GlcNAcβ1-Asn O -
) O +
or O +
a O +
' O -
core O +
β1→2-Xyl O -
' O +
( O -
Xylβ1→2Manβ1→4GlcNAcβ1-R O -
) O +
are O +
found O +
on O +
many O +
plant U-Species -
, O +
insect U-Species +
and O +
mollusc U-Species -
, O +
but O +
not O +
mammalian U-Species -
, O +
glycoproteins O +
[ O -
10–14 O -
] O +
, O +
and O +
can O +
contribute O +
to O +
the O +
allergenicity O +
and O +
IgE O +
cross O -
- O -
reactivity O +
between O +
extracts O +
of O +
these O +
organisms O +
[ O -
15–17 O -
] O +
. O -

Recently O +
it O +
has O +
been O +
reported O +
that O +
the O +
ruminant O +
nematode U-Species +
Haemonchus B-Species +
contortus L-Species -
expresses O +
glycoproteins O +
carrying O +
core O +
α1→3-Fuc O +
residues O +
[ O -
18 O -
] O +
, O +
and O +
that O +
both O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
epitopes O +
have O +
been O +
observed O +
on O +
egg O +
glycoproteins U-Species +
of O +
the O +
human U-Species +
schistosomes U-Species -
, O +
Schistosoma B-Species +
mansoni L-Species -
and O +
Schistosoma B-Species +
japonicum L-Species +
[ O -
19 O -
] O +
. O -

Thus O -
, O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
epitopes O +
might O +
contribute O +
to O +
the O +
IgE O +
response O +
observed O +
in O +
helminth U-Species +
infections O -
. O -

To O +
identify O +
the O +
possible O +
presence O +
of O +
such O +
epitopes O +
in O +
other O +
helminths U-Species -
, O +
we O +
have O +
analyzed O +
the O +
glycoproteins O +
of O +
different O +
parasitic U-Species +
helminths U-Species -
, O +
and O +
also O +
of O +
the O +
free O +
living O +
nematode U-Species +
Caenorhabditis B-Species +
elegans L-Species -
in O +
Western O +
blots O +
using O +
immunopurified O +
core O +
α1→3-Fuc O +
specific O +
and O +
β1→2-Xyl O +
specific O +
antibodies O +
[ O -
20 O -
] O +
. O -

The O +
results O +
show O +
that O +
core O +
α1→3-fucosylation O +
and O +
β1→2-xylosylation O +
are O +
common O +
glycan O +
modifications O +
occurring O +
in O +
many O +
different O +
helminths U-Species -
. O -

In O +
addition O -
, O +
we O +
report O +
that O +
glycans O +
carrying O +
core O +
α1→3-Fuc O +
are O +
recognized O +
by O +
IgE O +
antibodies O +
from O +
sheep U-Species +
infected O +
with O +
H. B-Species +
contortus L-Species -
and O +
mice U-Species +
infected O +
with O +
S. B-Species +
mansoni L-Species +
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Antigen O +
preparations O +
and O +
sera O +
Honeybee U-Species +
venom O +
phospholipase O +
A2 O +
( O -
PLA2 O -
) O +
and O +
cucurbita U-Species +
ascorbate O +
oxidase O +
were O +
purchased O +
from O +
Sigma O -
. O -

Adult O +
H. B-Species +
contortus L-Species -
were O +
obtained O +
post O +
mortem O +
from O +
the O +
abomasum O +
of O +
sheep U-Species +
experimentally O +
infected O +
with O +
20 O +
000 O +
L3 O +
larvae O -
. O -

H. B-Species +
contortus L-Species -
excretory O +
secretory O +
( O -
ES O -
) O +
products O +
were O +
obtained O +
as O +
described O +
before O +
[ O -
21 O -
] O +
. O -

Sheep U-Species +
antisera O +
were O +
collected O +
28 O +
days O +
after O +
infection O +
from O +
two O +
sheep U-Species -
, O +
experimentally O +
infected O +
with O +
the O +
H. B-Species +
contortus L-Species -
larvae O -
. O -

The O +
preparation O +
of O +
extracts O +
of O +
adult O +
Dirofilaria B-Species +
immitis L-Species +
, O +
Hymenolepis B-Species +
diminuta L-Species +
, O +
Fasciola B-Species +
hepatica L-Species +
, O +
S. B-Species +
mansoni L-Species +
, O +
S. B-Species +
japonicum L-Species -
and O +
Schistosoma B-Species +
haematobium L-Species -
was O +
described O +
previously O +
[ O -
22 O -
] O +
. O -

Extracts O +
of O +
C. B-Species +
elegans L-Species -
were O +
generated O +
by O +
resuspending O +
the O +
worm U-Species +
pellets O +
in O +
SDS O -
- O -
PAGE O +
buffer O -
, O +
followed O +
by O +
incubation O +
for O +
10 O +
min O +
at O +
100 O -
° O -
C O -
. O -

Insoluble O +
material O +
was O +
removed O +
by O +
centrifugation O -
. O -

Trichinella B-Species +
spiralis L-Species +
, O +
Toxocara B-Species +
canis L-Species -
and O +
cercariae U-Species +
of O +
Trichobilharzia B-Species +
ocellata L-Species -
were O +
resuspended O +
in O +
100 O +
μl O +
PBS O +
including O +
the O +
protease O +
inhibitors O +
Pefabloc O +
( O -
1 O +
mg O -
/ O -
ml O -
) O -
, O +
EDTA O +
( O -
0,5 O +
mg O -
/ O -
ml O -
) O -
, O +
leupeptin O +
( O -
10 O +
μg O -
/ O -
ml O -
) O -
, O +
pepstatin O +
( O -
10 O +
μg O -
/ O -
ml O -
) O -
, O +
aprotinin O +
( O -
1 O +
μg O -
/ O -
ml O -
) O +
( O -
Boehringer O +
Mannheim O -
) O -
, O +
and O +
homogenized O +
with O +
a O +
polytron O -
. O -

Triton O +
X-100 O +
( O -
1 O -
% O -
) O +
was O +
added O -
, O +
and O +
the O +
mixture O +
incubated O +
on O +
ice O +
for O +
20 O +
min O -
. O -

After O +
addition O +
of O +
SDS O -
- O -
PAGE O +
buffer O +
and O +
incubation O +
for O +
10 O +
min O +
at O +
100 O -
° O -
C O -
, O +
insoluble O +
material O +
was O +
removed O +
by O +
centrifugation O -
. O -

2.2 O +
Preparation O +
of O +
antisera O +
The O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
specific O +
antisera O +
were O +
prepared O +
as O +
described O +
previously O +
[ O -
20 O -
] O +
. O -

Briefly O -
, O +
antiserum O +
raised O +
against O +
horseradish U-Species +
peroxidase O +
was O +
fractionated O +
on O +
an O +
affinity O +
column O +
of O +
honeybee U-Species +
PLA2 O -
, O +
resulting O +
in O +
serum O +
fractions O +
specific O +
for O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O -
, O +
respectively O -
. O -

Antisera O +
were O +
tested O +
for O +
their O +
specificity O +
as O +
described O -
. O -

2.3 O +
SDS O -
- O -
PAGE O +
and O +
Western O +
blotting O +
Helminth U-Species +
extracts O +
( O -
approximately O +
20–40 O +
μg O +
of O +
protein O -
) O +
and O +
controls O +
were O +
separated O +
by O +
SDS O -
/ O -
PAGE O +
on O +
15 O -
% O +
gels O +
using O +
the O +
Mini O -
- O -
Protean O +
II O +
system O +
( O -
BioRad O -
) O -
. O -

Western O +
blotting O +
and O +
antibody O +
reactions O +
were O +
performed O +
essentially O +
as O +
described O +
previously O +
[ O -
23 O -
] O +
. O -

For O +
detection O +
of O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
containing O +
glycoproteins O -
, O +
rabbit U-Species +
polyclonal O +
anti O -
- O -
core O +
α1→3-Fuc O +
or O +
anti O -
- O -
β1→2-Xyl O +
specific O +
antibodies O +
were O +
used O +
as O +
the O +
first O +
antibody O +
and O +
goat U-Species +
anti O -
- O -
rabbit U-Species +
( O -
IgG O -
/ O -
IgM O -
) O +
peroxidase O +
conjugate O +
( O -
TAGO O -
, O +
Inc. O +
Immunodiagnostic O +
reagents O -
) O +
as O +
the O +
second O +
antibody O -
. O -

For O +
detection O +
of O +
mouse U-Species +
IgE O +
( O -
Fig. O +
4 O +
) O +
the O +
blots O +
were O +
incubated O +
overnight O +
with O +
1:2 O +
diluted O +
mouse U-Species +
serum O +
followed O +
by O +
incubation O +
with O +
rabbit U-Species +
anti O -
- O -
mouse U-Species +
IgE O +
peroxidase O +
conjugate O +
( O -
Nordic O -
, O +
the O +
Netherlands O -
) O +
for O +
1 O +
h O +
at O +
room O +
temperature O -
. O -

Bound O +
antibodies O +
were O +
visualized O +
using O +
0.6 O +
mg O -
/ O -
ml O +
chloronaphtol O +
in O +
TBS O +
containing O +
0.03 O -
% O +
H2 O +
O2 O +
. O -

2.4 O +
ELISA O +
ELISA O +
was O +
performed O +
as O +
the O +
ES O +
specific O +
ELISA O +
described O +
previously O +
[ O -
24 O -
] O +
. O -

Plates O +
were O +
coated O +
with O +
H. B-Species +
contortus L-Species -
ES O -
, O +
PLA2 O -
, O +
Arabidopsis B-Species +
thaliana L-Species +
, O +
A. B-Species +
thaliana L-Species +
cgl O +
, O +
and O +
human U-Species +
transferrin O -
. O -

Competitive O +
glycoproteins O +
were O +
added O +
to O +
the O +
sheep U-Species +
serum O +
in O +
a O +
final O +
concentration O +
range O +
of O +
80 O +
to O +
0.026 O +
μg O -
/ O -
ml O -
. O -

Zero O +
% O +
inhibition O +
was O +
defined O +
as O +
the O +
OD O +
value O +
of O +
serum O +
without O +
competitive O +
glycoproteins O -
, O +
and O +
100 O -
% O +
inhibition O +
as O +
the O +
OD O +
value O +
measured O +
with O +
80 O +
μg O -
/ O -
ml O +
autologous O +
glycoproteins O -
. O -

The O +
monosaccharides O +
D O -
- O -
Glc O -
, O +
L O -
- O -
Fuc O -
, O +
D O -
- O -
Xyl O +
or O +
L O -
- O -
Xyl O +
were O +
added O +
to O +
the O +
sheep U-Species +
serum O +
in O +
a O +
final O +
concentration O +
range O +
of O +
0.01 O +
to O +
1.4 O +
M. O -
3 O +
Results O +
3.1 O +
Specificity O +
of O +
the O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
specific O +
antisera O +
The O +
antisera O +
used O +
in O +
this O +
study O +
were O +
raised O +
against O +
the O +
plant U-Species +
glycoprotein O +
horseradish U-Species +
peroxidase O -
, O +
which O +
carries O +
glycans O +
shown O +
in O +
Fig. O +
1 O +
. O -

Fractionation O +
of O +
this O +
antiserum O +
on O +
an O +
affinity O +
column O +
of O +
honeybee U-Species +
venom O +
phospholipase O +
A2 O +
( O -
PLA2 O -
) O +
resulted O +
in O +
serum O +
fractions O +
highly O +
specific O +
for O +
either O +
the O +
core O +
α1→3-Fuc O -
, O +
or O +
β1→2-Xyl O -
, O +
respectively O -
. O -

To O +
confirm O +
their O +
specificity O +
purified O +
antibodies O +
were O +
tested O +
with O +
many O +
different O +
plant O +
and O +
mammalian U-Species +
glycoproteins O -
, O +
containing O +
either O +
a O +
core O +
α1→3-Fuc O +
or O +
a O +
β1→2-Xyl O -
, O +
or O +
no O +
core O +
modification O +
[ O -
20 O -
] O +
. O -

Furthermore O -
, O +
both O +
antisera O +
reacted O +
strongly O +
with O +
glycoproteins O +
isolated O +
from O +
the O +
leaves O +
of O +
A. B-Species +
thaliana L-Species -
( O -
Figs. O +
2 O -
, O +
4C O +
and O +
D O +
) O -
, O +
the O +
N O -
- O -
glycans O +
of O +
which O +
have O +
been O +
fully O +
identified O +
recently O +
and O +
shown O +
to O +
consist O +
of O +
high O +
mannose O -
- O -
type O +
N O -
- O -
glycans O +
and O +
complex O -
- O -
type O +
core O +
α1→3-fucosylated O +
and O +
β1→2-xylosylated O +
N O -
- O -
glycans O +
[ O -
25 O -
] O +
. O -

No O +
other O +
complex O -
- O -
type O +
modifications O +
have O +
been O +
demonstrated O +
in O +
A. B-Species +
thaliana L-Species +
[ O -
25 O -
] O +
. O -

The O +
antisera O +
did O +
not O +
bind O +
to O +
glycoproteins O +
of O +
the O +
cgl O -
mutant O +
of O +
A. B-Species +
thaliana L-Species +
, O +
lacking O +
N O +
-acetylglucosaminyltransferase O +
I O -
, O +
and O +
thus O +
lacking O +
the O +
expression O +
of O +
the O +
core O +
α3-fucosylated O +
and O +
β2-xylosylated O +
N O -
- O -
glycans O +
[ O -
26 O -
] O -
( O -
Figs. O +
2 O -
, O +
4C O +
and O +
D O +
) O -
. O -

Importantly O -
, O +
the O +
results O +
in O +
Fig. O +
2 O -
show O +
that O +
no O +
cross O -
- O -
reactivity O +
was O +
observed O +
of O +
the O +
core O +
α1→3-Fuc O +
antiserum O +
with O +
LPS O +
from O +
Helicobacter B-Species +
pylori I-Species -
strain I-Species +
O3 L-Species -
, O +
containing O +
Galβ1→4 O -
( O -
Fucα1→3 O -
) O -
GlcNAc O +
( O -
Lex O +
, O +
[ O -
27 O -
] O +
) O -
, O +
sialyl O -
- O -
Lex O -
containing O +
α1 O +
-acid O +
glycoprotein O +
( O -
AGP O -
) O +
derived O +
from O +
patients U-Species +
suffering O +
from O +
rheumatoid O +
arthritis O +
[ O -
28 O -
] O +
, O +
core O +
α1→6-fucosylated O +
human U-Species +
IgG O -
, O +
or O +
neoglycoprotein O +
containing O +
GalNAcβ1→4 O -
( O -
Fucα1→3 O -
) O -
GlcNAc O +
( O -
LDNF O -
) O +
units O -
, O +
indicating O +
that O +
the O +
core O +
α1→3-Fuc O +
specific O +
antiserum O +
does O +
not O +
recognize O +
other O +
Fucα1→3GlcNAc O +
moieties O +
found O +
in O +
the O +
core O +
or O +
outer O +
antennae O +
of O +
N- O +
or O +
O O -
- O -
linked O +
glycans O -
. O -

3.2 O +
Core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
residues O +
on O +
protein O -
- O -
linked O +
glycans O +
of O +
different O +
helminths U-Species +
The O +
presence O +
of O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
residues O +
on O +
protein O -
- O -
linked O +
glycans O +
of O +
different O +
helminths U-Species +
was O +
determined O +
by O +
Western O +
blotting O -
, O +
using O +
the O +
affinity O +
purified O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
specific O +
antisera O +
[ O -
20 O -
] O +
. O -

The O +
extracts O +
were O +
derived O +
from O +
adult O +
helminths U-Species -
, O +
except O +
the O +
extract O +
of O +
T. B-Species +
ocellata L-Species +
, O +
which O +
was O +
derived O +
from O +
cercariae U-Species -
. O -

In O +
addition O +
to O +
the O +
adult O +
stages O -
, O +
soluble O +
antigens O +
were O +
tested O +
from O +
H. B-Species +
contortus L-Species -
( O -
i.e. O +
excretory O -
/ O -
secretory O +
( O -
ES O -
) O +
antigens O -
) O +
and O +
S. B-Species +
mansoni L-Species -
( O -
soluble O +
egg O +
antigens O +
( O -
SE O -
) O -
) O -
. O -

The O +
extracts O +
from O +
most O +
helminths U-Species +
tested O +
contained O +
many O +
glycoproteins O +
that O +
reacted O +
moderate O +
to O +
strongly O +
with O +
the O +
core O +
α1→3-Fuc O +
specific O +
antibodies O -
, O +
whereas O +
reaction O +
of O +
H. B-Species +
diminuta L-Species +
, O +
F. B-Species +
hepatica L-Species -
and O +
T. B-Species +
canis L-Species -
glycoproteins O +
was O +
less O +
abundant O +
( O -
Fig. O +
3 O +
, O +
upper O +
panel O -
) O -
. O -

The O +
β1→2-Xyl O +
specific O +
antiserum O +
showed O +
binding O +
to O +
glycoproteins O +
of O +
some O +
of O +
the O +
extracts O -
, O +
i.e. O +
of O +
C. B-Species +
elegans L-Species +
, O +
S. B-Species +
mansoni L-Species +
, O +
S. B-Species +
haematobium L-Species +
, O +
S. B-Species +
mansoni L-Species -
SE O +
antigens O -
, O +
D. B-Species +
immitis L-Species +
, O +
T. B-Species +
canis L-Species +
, O +
and O +
of O +
cercariae U-Species +
of O +
T. B-Species +
ocellata L-Species +
, O +
whereas O +
no O +
binding O +
was O +
observed O +
with O +
the O +
other O +
parasite U-Species +
derived O +
samples O +
( O -
Fig. O +
3 O +
, O +
lower O +
panel O -
) O -
. O -

3.3 O +
IgE O +
in O +
sera O +
of O +
S. O +
mansoni O -
infected O +
mice U-Species +
cross O -
- O -
reacts O +
with O +
A. B-Species +
thaliana L-Species -
glycoproteins O +
We O +
next O +
sought O +
to O +
determine O +
whether O +
infection O +
of O +
mice U-Species +
with O +
S. B-Species +
mansoni L-Species -
results O +
in O +
IgE O +
to O +
core O +
α1→3-fucosylated O +
and/or O +
β1→2-xylosylated O +
N O -
- O -
glycans O -
. O -

Western O +
blots O +
containing O +
proteins O +
of O +
S. B-Species +
mansoni L-Species +
, O +
A. B-Species +
thaliana L-Species +
[ O -
25 O -
] O -
and O +
the O +
cgl O -
mutant O +
of O +
A. B-Species +
thaliana L-Species -
lacking O +
the O +
core O +
antigens O +
[ O -
26 O -
] O +
, O +
were O +
analyzed O +
using O +
different O +
antibodies O -
. O -

IgE O +
from O +
pooled O +
sera O +
of O +
mice U-Species +
experimentally O +
infected O +
with O +
S. B-Species +
mansoni L-Species -
binds O +
to O +
several O +
S. B-Species +
mansoni L-Species -
proteins O -
, O +
in O +
contrast O +
to O +
IgE O +
from O +
normal O +
mouse U-Species +
serum O +
that O +
showed O +
no O +
reactivity O -
. O -

IgE O +
from O +
the O +
infected O +
mice U-Species +
serum O +
cross O -
- O -
reacted O +
with O +
many O +
proteins O +
of O +
A. B-Species +
thaliana L-Species +
, O +
but O +
not O +
with O +
the O +
cgl O -
mutant O -
, O +
indicating O +
that O +
the O +
antibodies O +
specifically O +
recognize O +
complex O -
- O -
type O +
glycans O +
carrying O +
a O +
core O +
α1→3-Fuc O +
or O +
β1→2-Xyl O +
residue O +
( O -
Fig. O +
4 O +
) O -
. O -

We O +
also O +
could O +
detect O +
a O +
weak O +
binding O +
of O +
the O +
IgE O +
antibodies O +
from O +
infected O +
mice U-Species +
with O +
honeybee U-Species +
PLA2 O +
( O -
data O +
not O +
shown O -
) O -
, O +
suggesting O +
that O +
the O +
core O -
- O -
linked O +
α1→3-Fuc O +
is O +
an O +
epitope O +
for O +
IgE O +
of O +
S. B-Species +
mansoni L-Species -
infected O +
mice U-Species -
. O -

3.4 O +
IgE O +
in O +
sera O +
from O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species +
recognizes O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O +
Sera O +
from O +
sheep U-Species +
infected O +
with O +
H. B-Species +
contortus L-Species -
were O +
analyzed O +
by O +
ELISA O -
. O -

The O +
results O +
in O +
Fig. O +
5A O -
show O +
that O +
IgE O +
in O +
serum O +
of O +
infected O +
sheep U-Species +
recognizes O +
H. B-Species +
contortus L-Species -
ES O +
glycoproteins O -
, O +
honeybee U-Species +
PLA2 O +
and O +
A. B-Species +
thaliana L-Species -
glycoproteins O -
, O +
and O +
did O +
not O +
recognize O +
human U-Species +
transferrin O +
or O +
glycoproteins O +
from O +
the O +
cgl O -
mutant O +
of O +
A. B-Species +
thaliana L-Species -
lacking O +
the O +
core O +
antigens O -
. O -

In O +
contrast O -
, O +
binding O +
of O +
IgG O +
antibodies O +
from O +
the O +
infected O +
sheep U-Species +
sera O +
to O +
A. B-Species +
thaliana L-Species -
and O +
PLA2 O +
proteins O +
was O +
hardly O +
detectable O -
, O +
whereas O +
IgG O +
binding O +
was O +
observed O +
to O +
many O +
H. B-Species +
contortus L-Species -
ES O +
proteins O +
( O -
Fig. O +
5A O +
, O +
[ O -
29 O -
] O +
) O -
. O -

These O +
results O +
suggest O +
that O +
IgE O +
from O +
the O +
sera O +
of O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species +
recognizes O +
the O +
core O +
α1→3-Fuc O +
epitope O +
that O +
occurs O +
on O +
both O +
plant U-Species +
glycoproteins O +
and O +
honeybee U-Species +
PLA2 O -
. O -

To O +
further O +
validate O +
this O +
possibility O -
, O +
inhibition O +
experiments O +
were O +
performed O +
( O -
Fig. O +
5B O -
, O +
C O +
) O -
. O -

It O +
was O +
shown O +
that O +
PLA2 O +
could O +
block O +
the O +
binding O +
of O +
IgE O +
from O +
infected O +
sheep U-Species +
to O +
ES O -
. O -

Similarly O -
, O +
ES O +
could O +
block O +
the O +
binding O +
of O +
this O +
IgE O +
to O +
PLA2 O -
, O +
whereas O +
human U-Species +
transferrin O +
lacking O +
the O +
core O +
fucose O +
did O +
not O +
block O +
the O +
IgE O +
binding O -
. O -

Binding O +
of O +
sheep U-Species +
IgE O +
to O +
H. B-Species +
contortus L-Species -
ES O +
was O +
inhibited O +
to O +
80 O -
% O +
by O +
L O -
- O -
Fuc O +
at O +
a O +
concentration O +
of O +
1 O +
M O -
, O +
whereas O +
the O +
same O +
concentrations O +
of O +
D O -
- O -
Xyl O -
, O +
L O -
- O -
Xyl O +
or O +
D O -
- O -
Glc O +
showed O +
only O +
25 O -
% O +
inhibition O +
in O +
the O +
same O +
experiment O +
( O -
data O +
not O +
shown O -
) O -
. O -

These O +
results O +
demonstrate O +
that O +
an O +
important O +
part O +
of O +
the O +
ES O +
specific O +
IgE O +
in O +
the O +
sera O +
of O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species +
recognizes O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O -
. O -

4 O +
Discussion O +
We O +
report O +
in O +
this O +
study O +
that O +
IgE O +
from O +
serum O +
of O +
S. B-Species +
mansoni L-Species -
infected O +
mice U-Species +
and O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species +
cross O -
- O -
reacts O +
with O +
A. B-Species +
thaliana L-Species -
glycoproteins O +
that O +
carry O +
core O +
α1→3-fucosylated O +
and O +
β1→2-xylosylated O +
N O -
- O -
glycans O -
. O -

In O +
contrast O -
, O +
IgE O +
from O +
these O +
sera O +
did O +
not O +
bind O +
to O +
glycoproteins O +
of O +
the O +
cgl O -
mutant O +
of O +
A. B-Species +
thaliana L-Species +
, O +
that O +
lack O +
the O +
core O +
antigens O +
and O +
other O +
complex O -
- O -
type O +
glycan O +
modifications O +
[ O -
14,25,26 O -
] O +
. O -

These O +
results O +
indicate O +
that O +
the O +
core O +
α1→3-Fuc O +
and/or O +
the O +
β1→2-Xyl O +
residues O +
are O +
epitopes O +
for O +
both O +
IgE O +
from O +
S. B-Species +
mansoni L-Species -
infected O +
mice U-Species +
and O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species -
. O -

It O +
has O +
been O +
reported O +
that O +
the O +
human U-Species +
schistosome U-Species +
S. B-Species +
mansoni L-Species -
synthesizes O +
glycoproteins O +
carrying O +
both O +
core O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
residues O +
[ O -
19 O -
] O +
, O +
which O +
was O +
confirmed O +
by O +
our O +
studies O +
using O +
the O +
affinity O +
purified O +
α1→3-Fuc O +
and O +
β1→2-Xyl O +
specific O +
antibodies O -
. O -

Since O +
these O +
core O +
antigens O +
do O +
not O +
occur O +
in O +
mammals U-Species +
they O +
may O +
induce O +
the O +
generation O +
of O +
anti O -
- O -
glycan O +
antibodies O +
during O +
schistosome U-Species +
infection O -
. O -

We O +
can O -
not O +
deduce O +
from O +
our O +
data O +
whether O +
one O +
or O +
both O +
of O +
the O +
core O +
antigens O +
in O +
A. B-Species +
thaliana L-Species -
are O +
involved O +
in O +
binding O +
of O +
IgE O +
from O +
S. B-Species +
mansoni L-Species -
infected O +
mice U-Species -
. O -

In O +
contrast O -
, O +
the O +
ruminant O +
nematode U-Species +
H. B-Species +
contortus L-Species -
contains O +
glycoproteins O +
carrying O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O +
but O +
no O +
evidence O +
was O +
presented O +
for O +
the O +
presence O +
of O +
a O +
β1→2-Xyl O +
( O -
[ O -
18 O -
] O +
, O +
this O +
study O -
) O -
. O -

This O +
suggests O +
that O +
the O +
core O +
α1→3-Fuc O +
is O +
likely O +
to O +
be O +
the O +
A. B-Species +
thaliana L-Species -
epitope O +
that O +
reacted O +
with O +
IgE O +
from O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species -
. O -

Evidence O +
is O +
presented O +
using O +
both O +
ELISA O +
and O +
competitive O +
ELISA O +
that O +
the O +
core O +
α1→3-Fuc O +
residue O +
indeed O +
is O +
a O +
major O +
epitope O +
recognized O +
by O +
parasite U-Species +
specific O +
IgE O +
from O +
serum O +
of O +
H. B-Species +
contortus L-Species -
infected O +
sheep U-Species -
. O -

Importantly O -
, O +
hardly O +
any O +
IgG O +
reactivity O +
to O +
this O +
core O +
antigen O +
was O +
demonstrable O +
in O +
these O +
sera O -
. O -

In O +
contrast O -
, O +
IgM O +
or O +
IgG O +
antibodies O +
have O +
been O +
demonstrated O +
in O +
sera O +
of O +
parasite U-Species +
infected O +
hosts O +
to O +
other O +
parasite U-Species +
derived O +
carbohydrate O +
components O +
( O -
[ O -
30 O -
] O +
; O +
Van O +
Remoortere O +
et O +
al. O -
, O +
manuscript O +
in O +
preparation O -
) O -
. O -

This O +
suggests O +
that O +
the O +
core O +
α1→3-Fuc O +
epitope O +
preferentially O +
triggers O +
a O +
Th2 O +
response O +
leading O +
to O +
the O +
production O +
of O +
IgE O -
, O +
although O +
we O +
can O -
not O +
rule O +
out O +
the O +
possibility O +
that O +
the O +
core O +
fucose O +
specific O +
IgE O +
is O +
a O +
product O +
rather O +
than O +
an O +
inducer O +
of O +
a O +
Th2 O +
response O -
. O -

Interestingly O -
, O +
several O +
T O +
cell O +
clones O +
have O +
been O +
identified O +
from O +
bee U-Species +
venom O +
sensitized O +
subjects U-Species +
which O +
proliferate O +
in O +
response O +
to O +
honeybee U-Species +
PLA2 O +
but O +
not O +
to O +
its O +
non O -
- O -
glycosylated O +
variants O -
, O +
providing O +
evidence O +
for O +
the O +
involvement O +
of O +
an O +
N O -
- O -
glycan O +
in O +
T O +
cell O +
recognition O +
[ O -
31 O -
] O +
. O -

It O +
will O +
be O +
important O +
to O +
establish O +
whether O +
the O +
core O +
α-1→3-Fuc O +
antigen O +
is O +
involved O +
in O +
these O +
immunological O +
processes O -
. O -

Recently O +
it O +
has O +
been O +
demonstrated O +
that O +
vaccination O +
of O +
sheep U-Species +
with O +
ES O +
antigens O +
of O +
H. B-Species +
contortus L-Species -
induces O +
protection O +
against O +
challenge O +
infection O +
and O +
that O +
this O +
protection O +
is O +
correlated O +
with O +
IgE O +
rather O +
than O +
with O +
IgG O +
[ O -
32 O -
] O +
. O -

It O +
thus O +
appears O +
that O +
the O +
core O +
α1→3-Fuc O +
antigen O +
may O +
be O +
an O +
important O +
protective O +
antigen O +
in O +
H. B-Species +
contortus L-Species -
infections O -
, O +
and O +
perhaps O +
other O +
helminth U-Species +
infections O -
. O -

To O +
identify O +
the O +
possible O +
presence O +
of O +
core O -
- O -
fucosylated O +
and O +
core O -
- O -
xylosylated O +
epitopes O +
in O +
other O +
helminths U-Species +
we O +
analyzed O +
different O +
species O -
. O -

Our O +
results O +
show O +
that O +
many O +
helminths U-Species +
from O +
different O +
orders O +
of O +
the O +
phyla U-Species +
Platyhelminthes U-Species +
and O +
Nematodes U-Species +
synthesize O +
glycoproteins O +
containing O +
core O +
α1→3-fucosylated O +
N O -
- O -
glycans O -
. O -

In O +
addition O +
several O +
of O +
these O +
organisms O +
also O +
synthesize O +
N O -
- O -
glycans O +
containing O +
β1→2-Xyl O -
. O -

Remarkably O -
, O +
only O +
small O +
amounts O +
of O +
β1→2-Xyl O +
were O +
found O +
on O +
glycoproteins O +
of O +
adult O +
S. B-Species +
japonicum L-Species +
, O +
whereas O +
the O +
related O +
S. B-Species +
mansoni L-Species -
and O +
S. B-Species +
haematobium L-Species -
showed O +
many O +
β1→2-xylosylated O +
glycoproteins O -
. O -

Recent O +
data O +
from O +
Khoo O +
et O +
al. O +
[ O -
19 O -
] O -
described O +
the O +
presence O +
of O +
β1→2-xylosylated O +
N O -
- O -
glycans O +
in O +
egg O +
glycoproteins O +
of O +
S. B-Species +
japonicum L-Species +
. O -

It O +
may O +
be O +
possible O +
that O +
in O +
S. B-Species +
japonicum L-Species -
β1→2-xylosylation O +
is O +
stage O +
specific O -
. O -

Alternatively O -
, O +
the O +
plant U-Species +
specific O +
antiserum O +
may O +
be O +
unable O +
to O +
bind O +
some O +
core O +
β1→2-Xyl O +
residues O -
, O +
due O +
to O +
masking O +
of O +
the O +
epitope O -
, O +
e.g. O +
by O +
the O +
presence O +
of O +
multiple O +
core O +
fucose O +
residues O +
[ O -
19 O -
] O -
or O +
other O +
modifications O -
. O -

Cross O -
- O -
reactivity O +
has O +
been O +
observed O +
for O +
many O +
years O +
in O +
immunoassays O +
of O +
plant U-Species -
, O +
arthropod U-Species +
and O +
mollusc U-Species +
extracts O +
[ O -
33–35 O -
] O +
. O -

Part O +
of O +
this O +
cross O -
- O -
reactivity O +
is O +
caused O +
by O +
conserved O +
proteins O -
, O +
as O +
profilins O +
in O +
plants U-Species +
[ O -
36 O -
] O +
, O +
and O +
tropomyosins O +
in O +
crustacea U-Species +
and O +
mollusca U-Species +
[ O -
37 O -
] O +
. O -

In O +
addition O -
, O +
cross O -
- O -
reactivity O +
between O +
several O +
parasitic U-Species +
helminths U-Species -
, O +
and O +
between O +
helminths U-Species +
and O +
molluscs U-Species +
has O +
been O +
reported O +
[ O -
38–40 O -
] O +
. O -

The O +
highly O +
antigenic O +
core O +
α1→3-Fuc O +
and/or O +
β1→2-Xyl O +
in O +
N O -
- O -
glycans O -
, O +
that O +
are O +
conserved O +
among O +
many O +
invertebrates U-Species +
and O +
plants U-Species -
, O +
have O +
been O +
shown O +
to O +
contribute O +
to O +
such O +
cross O -
- O -
reactions O +
[ O -
35,41 O -
] O +
. O -

In O +
some O +
cases O +
it O +
has O +
been O +
established O +
that O +
IgE O +
antibodies O +
from O +
patients U-Species +
allergic O +
for O +
honeybee U-Species +
venom O +
or O +
plant U-Species +
substances O +
such O +
as O +
cereal U-Species +
flour O +
proteins O +
bind O +
to O +
core O +
α1→3-Fuc O +
and/or O +
β1→2-Xyl O +
containing O +
N O -
- O -
glycans O +
[ O -
15–17 O -
] O +
. O -

Our O +
results O +
indicate O +
that O +
the O +
core O +
α1→3-Fuc O +
structure O +
is O +
commonly O +
found O +
on O +
helminth U-Species +
glycoproteins O +
and O +
that O +
IgE O +
antibodies O +
from O +
helminth U-Species +
infected O +
hosts O +
bind O +
to O +
this O +
glycan O +
epitope O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
description O +
of O +
an O +
antigen O +
that O +
may O +
be O +
important O +
in O +
the O +
induction O +
of O +
both O +
helminth U-Species -
- O -
mediated O +
Th2-type O +
immunity O +
and O +
in O +
allergic O +
reactions O -
. O -

Recognition O +
of O +
putative O +
features O +
common O +
to O +
helminths U-Species +
presumably O +
informs O +
the O +
host O +
immune O +
system O +
that O +
a O +
stereotypic O +
type O +
2 O +
cytokine O +
response O +
will O +
be O +
more O +
protective O +
than O +
a O +
type O +
1 O +
or O +
type O +
0 O -
. O -

It O +
has O +
been O +
hypothesized O +
previously O +
that O +
some O +
of O +
these O +
helminth U-Species +
features O +
are O +
shared O +
with O +
allergens O +
and O +
may O +
be O +
responsible O +
for O +
the O +
obviously O +
maladaptive O +
responses O +
made O +
to O +
non O -
- O -
threatening O +
molecules O +
as O +
pollen O +
antigens O +
and O +
bee U-Species +
venom O +
phospholipase O +
[ O -
42 O -
] O +
. O -

This O +
stresses O +
the O +
importance O +
of O +
the O +
conserved O +
core O +
α1→3-Fuc O +
epitope O +
as O +
a O +
potential O +
' O -
pan O +
allergen O -
' O +
[ O -
41 O -
] O +
. O -

Interestingly O -
, O +
several O +
studies O +
have O +
shown O +
an O +
inverse O +
relationship O +
between O +
exposure O +
to O +
helminth U-Species +
infections O +
and O +
the O +
incidence O +
of O +
allergies O +
[ O -
43–45 O -
] O +
. O -

It O +
is O +
exciting O +
to O +
consider O +
the O +
possibility O +
that O +
detailed O +
knowledge O +
of O +
the O +
parasite U-Species +
structures O +
involved O +
in O +
Th2 O +
activation O +
and O +
IgE O +
induction O +
and O +
a O +
better O +
understanding O +
of O +
the O +
mechanism O +
by O +
which O +
they O +
evoke O +
these O +
immune O +
responses O +
may O +
lead O +
to O +
novel O +
therapies O +
against O +
both O +
parasitic U-Species +
diseases O +
and O +
atopic O +
disorders O -
. O -

Acknowledgments O +
We O +
gratefully O +
acknowledge O +
Ms. O +
A. O +
van O +
Tetering O +
for O +
technical O +
assistance O +
in O +
part O +
of O +
the O +
work O -
. O -

We O +
thank O +
Dr. O +
A.M. O +
Deelder O +
( O -
Dept O -
. O -

of O +
Parasitology O -
, O +
Leiden O -
, O +
The O +
Netherlands O -
) O +
for O +
serum O +
from O +
schistosome U-Species +
infected O +
mice U-Species -
, O +
Dr. O +
H. O +
Bakker O +
( O -
CPRO O -
- O -
DLO O -
, O +
Wageningen O -
, O +
The O +
Netherlands O -
) O +
for O +
extracts O +
of O +
A. B-Species +
thaliana L-Species +
, O +
Dr. O +
H. O +
van O +
Luenen O +
( O -
NKI O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
C. B-Species +
elegans L-Species +
, O +
Drs O -
. O -

A.K. O +
Nyame O +
( O -
University O +
of O +
Oklahoma O -
, O +
USA O -
) O -
, O +
Y. O +
Rombouts O +
( O -
RIVM O -
, O +
Bilthoven O -
, O +
The O +
Netherlands O -
) O -
, O +
and O +
M. O +
de O +
Jong O -
- O -
Brink O +
( O -
Dept O -
. O -

of O +
Neurobiology O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
parasites U-Species +
and O +
parasite U-Species +
extracts O -
, O +
Drs O +
A. O +
van O +
Remoortere O +
( O -
Dept O -
. O +
of O +
Medical O +
Chemistry O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
gift O +
of O +
neoglycoprotein O -
, O +
Dr. O +
B. O +
Appelmelk O +
( O -
Dept O -
. O +
of O +
Medical O +
Microbiology O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
H. O +
pylori O -
LPS O -
, O +
and O +
Dr. O +
W. O +
van O +
Dijk O +
( O -
Dept O -
. O +
of O +
Medical O +
Chemistry O -
, O +
VU O -
, O +
Amsterdam O -
, O +
The O +
Netherlands O -
) O +
for O +
AGP O -
. O -

We O +
thank O +
Dr. O +
P. O +
Lerouge O +
( O -
CNRS O -
, O +
Rouen O -
, O +
France O -
) O +
for O +
stimulating O +
discussions O +
and O +
Dr. O +
A.W. O +
Cornelissen O +
( O -
Dept O -
. O -

of O +
Parasitology O -
, O +
Utrecht O -
, O +
The O +
Netherlands O -
) O +
for O +
critical O +
reading O +
of O +
the O +
manuscript O -
. O -

L.V. O +
was O +
supported O +
by O +
a O +
grant O +
from O +
The O +
Technology O +
Foundation O +
( O -
STW O -
, O +
The O +
Netherlands O -
; O +
project O -
: O +
UDG55.3762 O -
) O -
. O -

Collaboration O +
between O +
Drs O -
. O -

I. O +
van O +
Die O +
and O +
R. O +
Cummings O +
was O +
facilitated O +
by O +
a O +
NATO O +
Collaborative O +
Research O +
Grant O +
( O -
CRG972098 O -
) O -
. O +

It O +
is O +
now O +
well O +
established O +
that O +
there O +
are O +
two O +
isozymes O +
of O +
prostaglandin O +
( O -
PG O -
) O -
-forming O +
cyclooxygenase O -
; O +
constitutive O +
cyclooxygenase-1 O +
and O +
inducible O +
cyclooxygenase-2 O +
[ O -
1,2 O -
] O +
. O -

MC3T3-E1 U-Species +
cell O +
cloned O +
from O +
newborn O +
mouse U-Species +
calvaria O +
is O +
an O +
osteogenic O +
cell O +
line O +
which O +
differentiates O +
into O +
an O +
osteoblast O +
[ O -
3,4 O -
] O +
. O -

Much O +
earlier O +
our O +
extensive O +
studies O +
demonstrated O +
the O +
production O +
of O +
E2 O +
as O +
a O +
major O +
arachidonate O +
metabolite O +
in O +
this O +
cell O +
line O +
[ O -
5 O -
] O -
and O +
the O +
induction O +
of O +
cyclooxygenase O +
by O +
various O +
bioregulators O +
[ O -
5–9 O -
] O +
. O -

Later O +
the O +
induced O +
enzyme O +
in O +
MC3T3-E1 U-Species +
cells O +
was O +
identified O +
as O +
cyclooxygenase-2 O +
[ O -
8–10 O -
] O +
. O -

Previously O +
humulon O +
( O -
( O -
R O +
) O -
-3,5,6-trihydroxy-4,6-bis O -
( O -
3-methyl-2-butenyl O -
) O -
-2- O -
( O -
3-methyl-1-oxobutyl O -
) O -
-2,4-cyclohexadien-1-one O -
) O +
( O -
Fig. O +
1 O +
) O +
isolated O +
from O +
hop U-Species +
( O -
Humulus B-Species +
lupulus L-Species -
L. O -
) O +
extract O +
was O +
found O +
as O +
an O +
inhibitor O +
of O +
bone O +
resorption O +
( O -
IC50 O +
: O +
5.9 O +
nM O -
) O +
[ O -
11 O -
] O +
. O -

We O +
noted O +
this O +
activity O +
of O +
humulon O -
, O +
and O +
were O +
interested O +
in O +
a O +
possible O +
inhibitory O +
or O +
suppressive O +
effect O +
of O +
humulon O +
on O +
cyclooxygenase-2 O +
leading O +
to O +
a O +
decreased O +
production O +
of O +
PGE2 O +
as O +
a O +
bone O +
resorption O +
factor O +
[ O -
12 O -
] O +
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
Humulon O +
was O +
purified O +
from O +
hop U-Species +
paste O +
as O +
described O +
previously O +
[ O -
11 O -
] O +
, O +
and O +
the O +
purified O +
material O +
was O +
dissolved O +
in O +
dimethyl O +
sulfoxide O +
at O +
a O +
concentration O +
of O +
10 O +
mM. O +
MC3T3-E1 U-Species +
cells O +
were O +
cultured O +
as O +
described O +
previously O +
[ O -
5 O -
] O +
. O -

Confluent O +
cultures O +
were O +
usually O +
obtained O +
on O +
the O +
4th O +
day O -
. O -

Then O -
, O +
the O +
medium O +
was O +
changed O +
to O +
α O -
- O -
MEM O +
( O -
Life O +
Technologies O -
, O +
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O +
supplemented O +
with O +
2 O -
% O +
newborn O +
bovine U-Species +
serum O +
( O -
Irvine O +
Scientific O -
, O +
Santa O +
Ana O -
, O +
CA O -
, O +
USA O -
) O +
and O +
a O +
compound O +
to O +
be O +
tested O -
. O -

At O +
indicated O +
time O +
intervals O -
, O +
the O +
cells O +
were O +
scraped O +
from O +
dishes O +
and O +
subjected O +
to O +
various O +
assays O +
described O +
below O -
. O -

2.2 O +
Assays O +
of O +
cyclooxygenase-1 O +
and O +
-2 O +
activities O +
For O +
cyclooxygenase-1 O +
preparation O -
, O +
lyophilized O +
powder O +
of O +
sheep U-Species +
seminal O +
vesicle O +
microsomes O +
( O -
Eldan O +
Technologies O -
, O +
Jerusalem O -
, O +
Israel O -
) O +
was O +
suspended O +
in O +
20 O +
mM O +
phosphate O +
buffer O +
( O -
pH O +
7.4 O -
) O +
containing O +
5 O +
mM O +
tryptophan O -
. O -

For O +
cyclooxygenase-2 O +
preparation O -
, O +
5 O -
× O -
107 O -
MC3T3-E1 U-Species +
cells O +
were O +
incubated O +
with O +
100 O +
nM O +
phorbol O +
12-myristate O +
13-acetate O +
and O +
100 O +
nM O +
A23187 O +
for O +
9 O +
h. O +
The O +
cells O +
were O +
subjected O +
to O +
sonic O +
disruption O -
, O +
and O +
centrifuged O +
at O +
180 O +
000 O -
× O -
g O -
for O +
50 O +
min O -
. O -

The O +
resultant O +
pellet O +
was O +
collected O +
as O +
the O +
microsomal O +
fraction O -
, O +
and O +
suspended O +
in O +
1 O +
ml O +
of O +
20 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
7.4 O -
) O +
containing O +
5 O +
mM O +
tryptophan O -
. O -

The O +
enzyme O +
assay O +
was O +
performed O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O -

2.3 O +
Cyclooxygenase-2 O +
induction O +
MC3T3-E1 U-Species +
cells O +
( O -
2.2 O -
× O -
106 O -
cells O -
) O +
were O +
incubated O +
with O +
tumor O +
necrosis O +
factor O +
α O +
( O -
TNFα O -
) O +
( O -
10–20 O +
ng O -
/ O -
ml O -
) O -
. O -

For O +
determination O +
of O +
PGE2 O +
synthesis O -
, O +
aliquots O +
were O +
removed O +
from O +
the O +
culture O +
medium O +
( O -
1 O +
ml O -
) O +
of O +
3 O -
× O -
105 O -
MC3T3-E1 U-Species +
cells O -
, O +
and O +
subjected O +
to O +
radioimmunoassay O +
for O +
PGE2 O +
as O +
described O +
previously O +
[ O -
5 O -
] O +
. O -

For O +
catalytic O +
activity O +
assay O -
, O +
the O +
cells O +
were O +
scraped O +
from O +
the O +
dishes O -
, O +
suspended O +
in O +
200 O +
μl O +
of O +
20 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
7.4 O -
) O +
containing O +
5 O +
mM O +
tryptophan O -
, O +
and O +
subjected O +
to O +
sonication O -
. O -

Aliquots O +
( O -
1–30 O +
μl O -
) O +
of O +
the O +
sonicate O +
were O +
incubated O +
with O +
10 O +
μM O +
[ O -
1 O -
- O -
14 O +
C O -
] O -
arachidonic O +
acid O +
( O -
2.1 O +
GBq O -
/ O -
mmol O -
, O +
Amersham O +
Pharmacia O +
Biotech O -
, O +
Bucks O -
, O +
UK O -
) O +
for O +
2 O +
min O +
at O +
24 O -
° O -
C O +
in O +
a O +
100-μl O +
mixture O +
containing O +
100 O +
mM O +
Tris O -
– O -
HCl O +
( O -
pH O +
8.0 O -
) O -
, O +
2 O +
μM O +
hematin O -
, O +
and O +
5 O +
mM O +
tryptophan O -
. O -

The O +
reaction O +
products O +
were O +
separated O +
by O +
thin O -
- O -
layer O +
chromatography O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O -

Total O +
RNA O +
was O +
extracted O +
from O +
MC3T3-E1 U-Species +
cells O +
using O +
ISOGEN O +
( O -
Nippon O +
Gene O -
, O +
Tokyo O -
, O +
Japan O -
) O +
and O +
subjected O +
to O +
Northern O +
blot O +
analysis O +
for O +
cyclooxygenase-2 O +
and O +
β O -
- O -
actin O +
mRNA O +
as O +
described O +
previously O +
[ O -
8 O -
] O +
. O -

2.4 O +
Reporter O +
gene O +
assay O +
A O +
DNA O +
fragment O +
( O -
nucleotides O +
−815 O +
to O +
+ O -
123 O -
) O +
was O +
prepared O +
from O +
the O +
5′-flanking O +
region O +
of O +
the O +
mouse U-Species +
cyclooxygenase-2 O +
gene O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
, O +
and O +
was O +
inserted O +
into O +
the O +
luciferase O +
plasmid O +
pGL3 O +
Basic O +
( O -
Promega O -
, O +
Madison O -
, O +
WI O -
, O +
USA O -
) O -
. O -

The O +
complementary O +
oligonucleotide O +
with O +
a O +
specific O +
sequence O +
of O +
glucocorticoid O +
response O +
element O +
( O -
5′-AGAGGATCTGTACA O -
GGATGTTCT O -
AGAT-3′ O -
; O +
consensus O +
sequence O +
of O +
the O +
glucocorticoid O +
response O +
element O +
is O +
underlined O -
) O +
was O +
synthesized O +
essentially O +
by O +
the O +
same O +
method O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O -

The O +
oligonucleotide O +
of O +
the O +
glucocorticoid O +
response O +
element O -
, O +
NFκB O +
response O +
element O +
[ O -
9 O -
] O -
or O +
NF O -
- O -
IL6 O +
response O +
element O +
[ O -
9 O -
] O -
was O +
inserted O +
in O +
front O +
of O +
the O +
herpes B-Species +
simplex I-Species +
virus L-Species +
thymidine O +
kinase O +
gene O +
[ O -
13 O -
] O -
of O +
the O +
tk O -
- O -
pGL3 O +
vector O +
[ O -
14 O -
] O +
. O -

For O +
the O +
transfection O +
of O +
luciferase O +
plasmid O -
, O +
7.8 O -
× O -
105 O -
confluent O +
cells O +
were O +
treated O +
with O +
pGL3 O +
plasmid O +
DNA O +
( O -
3 O +
μg O -
) O -
, O +
standard O +
β O -
- O -
galactosidase O +
DNA O +
( O -
1.5 O +
μg O -
) O -
, O +
and O +
13.5 O +
μl O +
of O +
Trans O +
IT O -
™ O -
-LT1 O +
( O -
Takara O -
, O +
Tokyo O -
, O +
Japan O -
) O +
in O +
2.3 O +
ml O +
of O +
serum O -
- O -
free O +
α O -
- O -
MEM O +
for O +
4 O +
h O +
at O +
37 O -
° O -
C O -
. O -

After O +
transfection O +
the O +
medium O +
was O +
changed O +
to O +
5 O +
ml O +
of O +
α O -
- O -
MEM O +
with O +
10 O -
% O +
fetal O +
bovine U-Species +
serum O +
( O -
Life O +
Technologies O -
, O +
Gaithersburg O -
, O +
MD O -
, O +
USA O -
) O -
, O +
and O +
the O +
transfected O +
cells O +
were O +
further O +
incubated O +
for O +
3 O +
days O -
. O -

The O +
medium O +
was O +
changed O +
to O +
α O -
- O -
MEM O +
described O +
above O -
. O -

After O +
12 O +
h O +
the O +
cells O +
were O +
scraped O +
from O +
the O +
dishes O -
, O +
and O +
the O +
luciferase O +
assay O +
was O +
performed O +
as O +
described O +
previously O +
[ O -
9 O -
] O +
. O -

The O +
results O +
were O +
normalized O +
with O +
β O -
- O -
galactosidase O +
activity O -
. O -

3 O +
Results O +
We O +
investigated O +
the O +
possibility O +
that O +
humulon O +
suppressed O +
the O +
TNFα O -
- O -
mediated O +
induction O +
of O +
cyclooxygenase-2 O -
. O -

When O +
MC3T3-E1 U-Species +
cells O +
were O +
incubated O +
with O +
10 O +
ng O -
/ O -
ml O +
TNFα O +
in O +
the O +
presence O +
of O +
humulon O +
for O +
12 O +
h O -
, O +
the O +
amount O +
of O +
released O +
PGE2 O +
decreased O +
depending O +
on O +
the O +
concentration O +
of O +
humulon O +
with O +
an O +
IC50 O -
of O +
about O +
30 O +
nM O +
( O -
Fig. O +
2A O +
) O -
. O -

As O +
shown O +
in O +
Fig. O +
2C O +
, O +
the O +
cyclooxygenase O +
activity O +
of O +
the O +
TNFα O -
- O -
treated O +
cells O +
was O +
reduced O +
by O +
humulon O +
dose O -
- O -
dependently O -
. O -

Furthermore O -
, O +
Northern O +
blot O +
analysis O +
showed O +
that O +
the O +
addition O +
of O +
humulon O +
suppressed O +
the O +
TNFα O -
- O -
induced O +
increase O +
of O +
cyclooxygenase-2 O +
mRNA O +
( O -
Fig. O +
2E O +
) O -
. O -

For O +
analysis O +
of O +
the O +
promoter O +
activity O -
, O +
a O +
luciferase O +
vector O +
of O +
cyclooxygenase-2 O +
gene O +
was O +
constructed O -
, O +
and O +
transfected O +
to O +
MC3T3-E1 U-Species +
cells O +
by O +
the O +
lipofection O +
method O -
. O -

The O +
luciferase O +
activity O +
of O +
the O +
cell O +
lysate O +
was O +
measured O +
12 O +
h O +
after O +
the O +
addition O +
of O +
10 O +
ng O -
/ O -
ml O +
TNFα O +
in O +
the O +
presence O +
of O +
various O +
concentrations O +
of O +
humulon O +
( O -
Fig. O +
2 O -
G O +
) O -
. O -

Since O +
the O +
same O +
range O +
of O +
humulon O +
concentration O +
was O +
required O +
for O +
the O +
decrease O +
in O +
the O +
PGE2 O +
release O -
, O +
enzyme O +
activity O -
, O +
mRNA O +
level O +
and O +
promoter O +
activity O -
, O +
we O +
presumed O +
that O +
the O +
induction O +
of O +
cyclooxygenase-2 O +
by O +
TNFα O +
was O +
inhibited O +
at O +
the O +
step O +
of O +
transcription O -
. O -

Then O -
, O +
we O +
examined O +
whether O +
or O +
not O +
humulon O +
inhibited O +
the O +
catalytic O +
activities O +
of O +
cyclooxygenases-1 O +
and O +
-2 O -
. O -

As O +
shown O +
in O +
Fig. O +
3 O +
, O +
the O +
cyclooxygenase-1 O +
activity O +
was O +
hardly O +
affected O +
by O +
humulon O +
below O +
10 O +
μM O -
, O +
whereas O +
the O +
cyclooxygenase-2 O +
activity O +
was O +
inhibited O +
with O +
an O +
IC50 O -
value O +
of O +
about O +
1.6 O +
μM. O +
Thus O -
, O +
the O +
catalytic O +
activity O +
of O +
cyclooxygenase-2 O +
was O +
inhibited O +
by O +
humulon O -
, O +
but O +
its O +
IC50 O -
was O +
higher O +
by O +
about O +
two O +
orders O +
of O +
magnitude O +
than O +
the O +
IC50 O -
of O +
the O +
cyclooxygenase-2 O +
suppression O -
. O -

As O +
reported O +
preliminarily O +
earlier O +
[ O -
15 O -
] O +
, O +
the O +
TNFα O -
- O -
dependent O +
cyclooxygenase-2 O +
induction O +
in O +
MC3T3-E1 U-Species +
cells O +
was O +
suppressed O +
by O +
dexamethasone O +
which O +
is O +
well O +
known O +
as O +
a O +
potent O +
anti O -
- O -
inflammatory O +
drug O +
and O +
a O +
suppressor O +
of O +
cyclooxygenase-2 O +
induction O +
in O +
most O +
cells O +
[ O -
1,2 O -
] O +
. O -

We O +
investigated O +
the O +
effect O +
of O +
dexamethasone O +
in O +
MC3T3-E1 U-Species +
cells O -
. O -

When O +
the O +
cells O +
were O +
incubated O +
with O +
20 O +
ng O -
/ O -
ml O +
TNFα O +
for O +
12 O +
h O -
, O +
the O +
amount O +
of O +
released O +
PGE2 O +
( O -
Fig. O +
2B O +
) O +
and O +
the O +
cyclooxygenase-2 O +
activity O +
( O -
Fig. O +
2D O +
) O +
decreased O +
depending O +
on O +
the O +
concentration O +
of O +
added O +
dexamethasone O +
( O -
IC50 O +
: O +
1 O +
nM O -
) O -
. O -

As O +
shown O +
in O +
Fig. O +
2F O +
, O +
the O +
cyclooxygenase-2 O +
mRNA O +
level O +
was O +
also O +
decreased O +
in O +
the O +
presence O +
of O +
dexamethasone O -
. O -

The O +
TNFα O -
- O -
dependent O +
luciferase O +
activity O +
was O +
also O +
decreased O +
by O +
dexamethasone O +
with O +
an O +
IC50 O -
of O +
about O +
1 O +
nM O +
( O -
Fig. O +
2H O +
) O -
. O -

These O +
data O +
indicated O +
that O +
dexamethasone O +
suppressed O +
the O +
cyclooxygenase-2 O +
induction O +
by O +
reducing O +
its O +
mRNA O +
level O +
in O +
MC3T3-E1 U-Species +
cells O -
. O -

Our O +
previous O +
work O +
with O +
MC3T3-E1 U-Species +
cells O +
demonstrated O +
the O +
involvement O +
of O +
NFκB O +
and O +
NF O -
- O -
IL6 O +
as O +
transcription O +
factors O +
in O +
the O +
cyclooxygenase-2 O +
induction O +
by O +
TNFα O +
[ O -
9 O -
] O +
. O -

We O +
investigated O +
whether O +
or O +
not O +
humulon O +
and O +
dexamethasone O +
functioned O +
with O +
the O +
aid O +
of O +
NFκB O +
( O -
nucleotides O +
−401 O +
to O +
−393 O -
) O +
and O +
NF O -
- O -
IL6 O +
( O -
nucleotides O +
−138 O +
to O +
−130 O -
) O +
response O +
elements O -
. O -

As O +
shown O +
in O +
Fig. O +
4 O +
, O +
we O +
constructed O +
a O +
luciferase O +
vector O +
containing O +
thymidine O +
kinase O +
gene O +
and O +
NFκB O +
or O +
NF O -
- O -
IL6 O +
response O +
element O -
. O -

Each O +
vector O +
was O +
transfected O +
to O +
MC3T3-E1 U-Species +
cells O -
, O +
and O +
the O +
luciferase O +
activity O +
was O +
measured O -
. O -

Both O +
humulon O +
and O +
dexamethasone O +
decreased O +
the O +
luciferase O +
activity O +
induced O +
by O +
TNFα O -
. O -

Thus O -
, O +
the O +
suppressive O +
effect O +
of O +
humulon O +
and O +
dexamethasone O +
on O +
the O +
cyclooxygenase-2 O +
induction O +
was O +
attributable O +
presumably O +
to O +
NFκB O +
or O +
NF O -
- O -
IL6 O +
or O +
both O -
. O -

To O +
investigate O +
whether O +
or O +
not O +
humulon O +
bound O +
to O +
glucocorticoid O +
receptor O -
, O +
we O +
used O +
RU486 O +
as O +
a O +
glucocorticoid O +
receptor O +
antagonist O +
[ O -
16 O -
] O +
. O -

The O +
TNFα O -
- O -
dependent O +
PGE2 O +
production O +
decreased O +
by O +
dexamethasone O +
was O +
reversed O +
by O +
RU486 O +
dose O -
- O -
dependently O +
( O -
Fig. O +
5A O +
) O -
. O -

However O -
, O +
the O +
decreased O +
PGE2 O +
production O +
by O +
humulon O +
was O +
not O +
affected O +
by O +
RU486 O +
( O -
Fig. O +
5A O +
) O -
. O -

Then O -
, O +
we O +
constructed O +
a O +
luciferase O +
vector O +
containing O +
thymidine O +
kinase O +
gene O +
and O +
glucocorticoid O +
response O +
element O +
( O -
Fig. O +
5B O +
) O -
. O -

The O +
vector O +
was O +
transfected O +
to O +
MC3T3-E1 U-Species +
cells O -
, O +
and O +
the O +
luciferase O +
activity O +
of O +
the O +
cell O +
lysate O +
was O +
measured O +
12 O +
h O +
after O +
the O +
addition O +
of O +
TNFα O +
plus O +
dexamethasone O +
or O +
humulon O -
. O -

As O +
shown O +
in O +
Fig. O +
5B O +
, O +
the O +
addition O +
of O +
dexamethasone O +
increased O +
luciferase O +
activity O +
of O +
MC3T3-E1 U-Species +
cells O +
by O +
16–18 O +
fold O -
. O -

Therefore O -
, O +
dexamethasone O +
bound O +
to O +
the O +
glucocorticoid O +
receptor O +
and O +
then O +
to O +
the O +
glucocorticoid O +
response O +
element O -
. O -

In O +
contrast O -
, O +
when O +
the O +
transfected O +
cells O +
were O +
incubated O +
with O +
humulon O -
, O +
the O +
luciferase O +
activity O +
was O +
not O +
increased O -
. O -

These O +
data O +
suggested O +
that O +
the O +
humulon O -
- O -
dependent O +
suppression O +
of O +
cyclooxygenase-2 O +
induction O +
was O +
not O +
mediated O +
by O +
glucocorticoid O +
receptor O -
. O -

4 O +
Discussion O +
As O +
for O +
the O +
inhibitors O +
of O +
cyclooxygenase O +
induction O +
other O +
than O +
glucocorticoid O -
, O +
a O +
recent O +
paper O +
reported O +
a O +
cyclooxygenase-2 O +
transcription O +
in O +
phorbol O +
ester O -
- O -
treated O +
human U-Species +
epithelial O +
cells O +
inhibited O +
by O +
resveratrol O -
, O +
which O +
is O +
a O +
phytoalexin O +
found O +
in O +
grapes U-Species +
and O +
other O +
foods O +
[ O -
17 O -
] O +
. O -

The O +
compound O +
reduced O +
both O +
the O +
enzyme O +
activity O +
and O +
the O +
gene O +
transcription O +
at O +
a O +
concentration O +
in O +
the O +
order O +
of O +
10 O +
μM. O +
Resveratrol O +
also O +
blocked O +
cyclooxygenase-2 O +
activation O +
by O +
protein O +
kinase O +
C O -
- O -
α O -
, O +
ERK1 O -
, O +
and O +
c O -
- O -
Jun O +
[ O -
17 O -
] O +
. O -

In O +
addition O -
, O +
sodium O +
salicylate O +
and O +
aspirin O +
at O +
pharmacological O +
concentrations O +
( O -
0.1–100 O +
μM O -
) O +
inhibited O +
cyclooxygenase-2 O +
transcription O +
induced O +
by O +
phorbol O +
ester O -
, O +
interleukin-1β O -
, O +
and O +
lipopolysaccharide O +
( O -
LPS O -
) O +
[ O -
18 O -
] O +
. O -

It O +
is O +
established O +
that O +
glucocorticoid O +
binds O +
to O +
its O +
intracellular O +
receptor O +
migrating O +
into O +
nucleus O +
and O +
the O +
steroid O -
- O -
receptor O +
complex O +
binds O +
to O +
a O +
glucocorticoid O +
response O +
element O +
of O +
the O +
promoter O +
region O +
of O +
target O +
gene O +
[ O -
19 O -
] O +
. O -

Inoue O +
and O +
others O +
reported O +
that O +
the O +
activation O +
of O +
the O +
cyclooxygenase-2 O +
gene O +
promoter O +
by O +
LPS O +
was O +
suppressed O +
by O +
glucocorticoid O -
, O +
and O +
the O +
suppression O +
was O +
enhanced O +
by O +
transfection O +
of O +
the O +
glucocorticoid O +
receptor O +
cDNA O +
to O +
vascular O +
endothelial O +
cells O +
[ O -
20 O -
] O +
. O -

However O -
, O +
there O +
is O +
no O +
typical O +
sequence O +
for O +
glucocorticoid O +
response O +
element O +
within O +
1.2 O +
kb O +
upstream O +
in O +
cyclooxygenase-2 O +
gene O +
promoter O +
[ O -
1,2 O -
] O +
. O -

One O +
of O +
the O +
two O +
NFκB O +
sites O +
( O -
nucleotides O +
–223 O +
to O +
–214 O -
) O +
was O +
involved O +
in O +
both O +
the O +
LPS O -
- O -
induced O +
human U-Species +
cyclooxygenase-2 O +
gene O +
expression O +
in O +
U937 B-Species +
cells L-Species +
and O +
its O +
suppression O +
by O +
dexamethasone O +
and O +
herbimycin O +
A O +
[ O -
21 O -
] O +
. O -

In O +
conclusion O -
, O +
our O +
results O +
demonstrated O +
that O +
humulon O +
has O +
a O +
glucocorticoid O -
- O -
like O +
suppression O +
activity O +
in O +
TNFα O -
- O -
induced O +
cyclooxygenase-2 O +
transcription O +
and O +
its O +
signal O +
transduction O +
may O +
be O +
independent O +
from O +
glucocorticoid O +
receptor O -
. O -

However O -
, O +
these O +
results O +
required O +
further O +
investigations O +
of O +
a O +
detailed O +
molecular O +
mechanism O +
and O +
of O +
in O +
vivo O +
anti O -
- O -
inflammatory O +
action O +
of O +
humulon O -
. O -

Acknowledgements O -

We O +
thank O +
Dr. O +
H. O +
Kondoh O +
of O +
Osaka O +
University O +
for O +
providing O +
the O +
herpes B-Species +
simplex I-Species +
virus L-Species +
thymidine O +
kinase O +
gene O -
; O +
Dr. O +
Y. O +
Taketani O +
of O +
the O +
University O +
of O +
Tokushima O +
for O +
providing O +
tk O -
- O -
pGL3 O +
vector O -
; O +
and O +
Mr. O +
H. O +
Kurobe O +
for O +
technical O +
assistance O -
. O -

This O +
work O +
was O +
supported O +
by O +
grants O -
- O -
in O -
- O -
aid O +
for O +
scientific O +
research O +
from O +
the O +
Ministry O +
of O +
Education O -
, O +
Science O -
, O +
Sports O +
and O +
Culture O +
of O +
Japan O -
, O +
the O +
Japanese O +
Foundation O +
of O +
Metabolism O +
and O +
Disease O -
, O +
and O +
the O +
Japan O +
Foundation O +
for O +
Applied O +
Enzymology O -
. O +

Butea B-Species +
monosperma L-Species -
( O -
Fabaceae O -
) O +
is O +
a O +
medium O +
sized O +
tree O +
native O +
of O +
the O +
mountainous O +
regions O +
of O +
India O +
and O +
Burma O +
and O +
now O +
grows O +
wild O +
throughout O +
India O +
( O -
Anonymous O -
, O +
1988 O +
) O -
. O -

The O +
bark O +
is O +
reported O +
to O +
possess O +
antitumour O +
and O +
antiulcer O +
properties O +
( O -
Anonymous O -
, O +
1988 O +
) O -
, O +
while O +
stem O +
bark O +
possess O +
antifungal O +
activity O +
( O -
Bandara O +
et O +
al. O -
, O +
1989 O -
; O +
1990 O +
) O -
. O -

The O +
root O +
bark O +
is O +
used O +
as O +
an O +
aphrodisiac O -
, O +
analgesic O +
and O +
anthelmintic O +
( O -
Anonymous O -
, O +
1988 O +
) O -
, O +
whereas O +
the O +
leaves O +
possess O +
antimicrobial O +
property O +
( O -
Zaffar O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

The O +
flowers O +
are O +
used O +
for O +
the O +
treatment O +
of O +
liver O +
disorders O +
( O -
Wagner O +
et O +
al. O -
, O +
1986 O +
) O +
and O +
the O +
seeds O +
as O +
anthelmintic O +
( O -
Lal O +
et O +
al. O -
, O +
1978 O +
) O -
. O -

Flavonoids O +
from O +
flowers O +
( O -
Gupta O +
et O +
al. O -
, O +
1970 O +
) O -
, O +
stem O +
bark O +
( O -
Bandara O +
et O +
al. O -
, O +
1990 O +
) O +
and O +
nitrogenous O +
compounds O +
from O +
the O +
seeds O +
( O -
Guha O +
et O +
al. O -
, O +
1990 O -
; O +
Mehta O +
and O +
Bokadia O -
, O +
1981 O +
) O +
have O +
been O +
reported O +
earlier O -
. O -

During O +
the O +
course O +
of O +
investigation O +
on O +
the O +
yellow O +
dye O +
from O +
the O +
flowers O -
, O +
it O +
was O +
of O +
interest O +
to O +
work O +
on O +
the O +
stems O +
as O +
relatively O +
few O +
compounds O +
have O +
been O +
reported O +
from O +
it O -
. O -

This O +
report O +
describes O +
the O +
characterisation O +
of O +
a O +
new O +
euphane O +
and O +
a O +
new O +
lipid O +
derivative O -
. O -

2 O +
Results O +
and O +
discussion O +
Compounds O +
1–5 O -
were O +
isolated O +
from O +
the O +
stems O +
of O +
B. B-Species +
monosperma L-Species +
. O -

Compound O +
1 O +
was O +
obtained O +
as O +
colourless O +
needles O -
. O -

Its O +
IR O +
spectrum O +
bands O +
corresponded O +
to O +
OH O +
( O -
3480 O +
cm−1 O +
) O -
, O +
terminal O +
unsaturated O +
CH2 O -
( O -
1610 O -
, O +
880 O +
cm−1 O +
) O +
and O +
gem O +
dimethyl O +
( O -
1380 O -
, O +
1360 O +
cm−1 O +
) O +
functions O -
. O -

An O +
[ O -
M O -
] O -
+ O -
at O +
m O -
/ O -
z O -
428 O +
suggested O +
the O +
molecular O +
formula O +
as O +
C30 O +
H52 O +
O. O +
Its O +
1 O +
H O +
NMR O +
spectrum O +
exhibited O +
signals O +
due O +
to O +
five O +
quaternary O +
methyls O +
( O -
δ O -
0.79 O -
, O +
0.83 O -
, O +
0.94 O -
, O +
0.96 O -
, O +
1.04 O -
) O -
, O +
a O +
vinylic O +
methyl O +
( O -
δ O -
1.62 O -
) O -
, O +
and O +
a O +
secondary O +
methyl O +
( O -
δ O -
1.08 O -
) O +
indicative O +
of O +
a O +
tetracyclic O +
triterpene O +
skeleton O +
( O -
Hemmert O +
et O +
al. O -
, O +
1966 O +
) O -
. O -

Two O +
broad O +
singlets O +
at O +
δ O -
4.56 O +
and O +
4.68 O -
, O +
each O +
integrating O +
for O +
one O +
proton O -
, O +
corresponded O +
to O +
the O +
methine O +
protons O +
of O +
an O +
olefinic O +
methylene O +
group O +
( O -
Jagodzinska O +
et O +
al. O -
, O +
1985 O +
) O +
which O +
in O +
conjunction O +
with O +
a O +
broad O +
singlet O +
at O +
δ O -
1.62 O +
suggested O +
the O +
existence O +
of O +
a O +
isopropylidene O +
group O -
. O -

This O +
was O +
also O +
substantiated O +
by O +
the O +
appearance O +
of O +
signals O +
at O +
δ O -
151.0 O +
and O +
109.30 O +
in O +
the O +
13 O +
C O +
NMR O +
spectrum O +
for O +
> O -
CCH2 O -
grouping O +
( O -
Schneider O +
and O +
Agrawal O -
, O +
1984 O +
) O -
. O -

A O +
multiplet O +
at O +
δ O -
3.34 O +
( O -
W O +
1 O -
/ O -
2 O +
= O -
7 O +
Hz O -
) O +
was O +
assigned O +
to O +
a O +
methine O +
proton O +
with O +
an O +
axially O +
oriented O +
C-3 O +
OH O +
group O +
( O -
Jolad O +
et O +
al. O -
, O +
1981 O -
; O +
Nakanishi O +
et O +
al. O -
, O +
1986 O +
) O -
. O -

There O +
is O +
a O +
remarkable O +
similarity O +
in O +
the O +
13 O +
C O +
NMR O +
chemical O +
shifts O +
of O +
euphenol O +
and O +
lanosterol O +
except O +
for O +
those O +
of O +
C-12 O -
, O +
C-15 O -
, O +
C-16 O +
and O +
C-19 O +
( O -
Knight O -
, O +
1974 O +
) O -
. O -

This O +
excludes O +
1 O -
to O +
be O +
included O +
under O +
lanosterol O +
series O -
. O -

Such O +
difference O +
is O +
also O +
seen O +
in O +
euphane O +
and O +
tirucallane O +
triterpenoids O +
( O -
Jolad O +
et O +
al. O -
, O +
1981 O -
; O +
Bhakuni O +
et O +
al. O -
, O +
1987 O -
; O +
Singh O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

The O +
chemical O +
shift O +
range O +
of O +
the O +
methyl O +
protons O +
except O +
for O +
vinylic O +
CH3 O -
suggested O +
a O +
euphane O +
or O +
tirucallane O +
skeleton O +
( O -
differing O +
C-20 O +
stereochemistry O -
) O +
in O +
1 O +
, O +
and O +
a O +
( O -
+ O -
) O +
optical O +
rotation O +
37.8 O -
° O +
of O +
1 O -
indicated O +
that O +
it O +
belonged O +
to O +
euphane O +
rather O +
than O +
tirucallane O +
series O +
( O -
Itoh O +
et O +
al. O -
, O +
1976 O +
) O -
. O -

In O +
the O +
MS O +
of O +
1 O +
, O +
the O +
loss O +
of O +
CH3 O -
and O +
H2 O +
O O +
from O +
[ O -
M O -
] O -
+ O -
was O +
seen O +
at O +
m O -
/ O -
z O -
413 O +
and O +
410 O -
. O -

The O +
formation O +
of O +
a O +
fragment O +
ion O +
at O +
m O -
/ O -
z O -
316 O +
[ O -
M O -
- O -
side O +
chain O +
( O -
C8 O +
H15 O +
) O -
–H O -
] O -
+ O -
suggested O +
the O +
presence O +
of O +
a O +
monounsaturated O +
side O +
chain O +
( O -
Wyllie O +
and O +
Djerassi O -
, O +
1968 O +
) O +
and O +
the O +
existence O +
of O +
OH O +
group O +
in O +
the O +
tetracyclic O +
system O -
. O -

Compound O +
1 O -
on O +
treatment O +
with O +
Ac2 O +
O O -
/ O -
pyridine O +
afforded O +
an O +
acetate O +
( O -
1a O +
) O -
, O +
C32 O +
H54 O +
O2 O +
, O +
whose O +
1 O +
H O +
NMR O +
spectrum O +
was O +
similar O +
to O +
1 O -
except O +
for O +
the O +
appearance O +
of O +
a O +
new O +
signal O +
at O +
δ O -
2.04 O +
and O +
downfield O +
shifted O +
C-3 O +
methine O +
by O +
1.11 O +
ppm O -
. O -

In O +
the O +
13 O +
C O +
NMR O +
spectrum O +
of O +
1 O +
, O +
the O +
appearance O +
of O +
C-18 O -
, O +
C-20 O +
and O +
C-21 O +
at O +
15.4 O -
, O +
35.6 O +
and O +
19.3 O +
also O +
established O +
the O +
euphane O +
skeleton O +
( O -
Wehrli O +
and O +
Nishida O -
, O +
1979 O -
; O +
Knight O -
, O +
1974 O +
) O -
. O -

The O +
13 O +
C O +
NMR O +
spectral O +
data O +
of O +
1 O -
( O -
Table O +
1 O -
) O +
were O +
analysed O +
by O +
analogy O +
with O +
the O +
reported O +
values O +
for O +
euphane O +
and O +
other O +
related O +
triterpenoids O +
( O -
Wehrli O +
et O +
al. O -
, O +
1979 O -
; O +
Knight O -
, O +
1974 O -
; O +
Singh O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

These O +
data O +
led O +
to O +
characterise O +
1 O -
as O +
3α O -
- O -
hydroxyeuph-25-ene O -
. O -

Compound O +
4 O -
showed O +
IR O +
bands O +
at O +
3438 O +
( O -
OH O -
) O -
, O +
1730 O +
( O -
CO O -
) O -
, O +
1670 O +
( O -
tetrasubstituted O -
) O +
( O -
Nakanishi O +
and O +
Solomon O -
, O +
1977 O +
) O -
, O +
1386 O +
( O -
Me O -
) O +
and O +
720 O +
cm−1 O -
( O -
straight O +
chain O -
) O -
. O -

It O +
was O +
assigned O +
the O +
molecular O +
formula O +
C26 O +
H48 O +
O3 O -
( O +
[ O -
M O -
] O -
+ O -
= O +
408 O +
and O +
elemental O +
analysis O -
) O -
. O -

Successive O +
loss O +
of O +
two O +
H2 O +
O O +
molecules O +
was O +
seen O +
at O +
m O -
/ O -
z O -
390 O +
and O +
372 O -
, O +
whereas O +
the O +
location O +
of O +
these O +
OH O +
groups O +
was O +
assigned O +
at O +
C-2 O +
and O +
C-14 O +
since O +
significant O +
α O -
- O -
fission O +
ions O +
were O +
appeared O +
at O +
m O -
/ O -
z O -
311 O -
, O +
281 O -
, O +
127 O -
, O +
97 O +
and O +
351 O -
, O +
321 O -
, O +
87 O -
, O +
57 O -
, O +
respectively O -
. O -

The O +
other O +
diagnostic O +
α O -
- O -
fission O +
ions O +
at O +
m O -
/ O -
z O -
225 O -
, O +
211 O -
, O +
197 O -
, O +
183 O +
together O +
with O +
ß O -
- O -
fission O +
ions O +
involving O +
McLafferty O +
rearrangement O +
( O -
Budzikiewicz O +
et O +
al. O -
, O +
1964 O +
) O +
at O +
m O -
/ O -
z O -
226 O +
and O +
182 O +
located O +
the O +
keto O +
group O +
at O +
C-8 O -
. O -

The O +
abundant O +
ions O +
at O +
m O -
/ O -
z O -
83 O +
and O +
325 O +
indicated O +
the O +
presence O +
of O +
a O +
cyclohexyl O +
moiety O +
at O +
the O +
end O +
carbon O +
atom O +
( O -
Bhakuni O +
and O +
Shukla O -
, O +
1992 O +
) O -
. O -

The O +
tetrasubstituted O +
double O +
bond O +
along O +
with O +
the O +
two O +
methyl O +
groups O +
were O +
assigned O +
at O +
C-11,12 O +
since O +
significant O +
ions O +
were O +
seen O +
at O +
m O -
/ O -
z O -
307 O -
, O +
253 O -
, O +
155 O +
and O +
101 O -
. O -

These O +
data O +
suggested O +
the O +
structure O +
of O +
4 O -
as O +
2,14-dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane O +
which O +
was O +
also O +
in O +
full O +
accord O +
with O +
its O +
1 O +
H O +
NMR O +
( O -
see O +
Section O +
3 O +
) O -
. O -

Compounds O +
2 O +
, O +
3 O -
and O +
5 O -
were O +
identified O +
as O +
nonacosanoic O +
acid O -
, O +
stigmasterol O +
and O +
stigmasterol O -
- O -
ßD O +
-glucopyranoside O -
, O +
respectively O -
, O +
by O +
comparison O +
with O +
authentic O +
samples O -
. O -

The O +
straight O +
chain O +
alcohols O +
having O +
a O +
cyclohexane O +
moiety O +
are O +
not O +
commonly O +
found O +
in O +
nature O -
. O -

3 O +
Experimental O +
3.1 O +
General O +
Mps O -
: O +
uncorrected O -
; O +
IR O -
: O +
KBr O -
; O +
1 O +
H O +
NMR O -
: O +
Bruker O +
( O -
200 O +
MHz O -
) O +
in O +
CDCl3 O +
, O +
chemical O +
shifts O +
in O +
δ O -
( O -
ppm O -
) O +
with O +
TMS O +
as O +
internal O +
standard O -
; O +
13 O +
C O +
NMR O -
: O +
75 O +
MHz O -
, O +
CDCl3 O +
; O +
EIMS O -
: O +
70 O +
ev O -
; O +
TLC O -
: O +
silica O +
gel O +
G O -
; O +
CC O -
: O +
silica O +
gel O +
( O -
Merk O -
, O +
60–120 O +
mesh O -
) O -
. O -

Spots O +
were O +
detected O +
by O +
exposure O +
to O +
I2 O -
vapour O -
. O -

The O +
homogeneity O +
of O +
the O +
isolates O +
was O +
checked O +
on O +
TLC O +
in O +
at O +
least O +
two O +
solvent O +
systems O -
. O -

3.2 O +
Plant O +
material O +
The O +
stems O +
of O +
B. B-Species +
monosperma L-Species -
were O +
collected O +
from O +
the O +
local O +
area O +
and O +
identified O +
in O +
our O +
Botany O +
Department O +
where O +
a O +
voucher O +
specimen O +
has O +
been O +
maintained O -
. O -

3.3 O +
Extraction O +
and O +
isolation O +
Dried O +
and O +
powdered O +
stems O +
( O -
2.8 O +
kg O -
) O +
were O +
extracted O +
with O +
MeOH O +
( O -
5 O -
× O -
11 O +
l O -
) O +
and O +
the O +
combined O +
extract O +
concentrated O +
to O +
500 O +
ml O -
. O -

After O +
the O +
addition O +
of O +
water O +
( O -
500 O +
ml O -
) O -
, O +
the O +
extract O +
was O +
fractionated O +
with O +
n O +
-hexane O +
( O -
5 O -
× O -
200 O +
ml O -
, O +
7.33 O +
g O -
) O -
, O +
EtOAc O +
( O -
5 O -
× O -
200 O +
ml O -
, O +
13.34 O +
g O -
) O +
and O +
n O +
-BuOH O +
( O -
5 O -
× O -
200 O +
ml O -
, O +
33.2 O +
g O -
) O -
. O -

A O +
portion O +
( O -
6.1 O +
g O -
) O +
of O +
the O +
hexane O +
fraction O +
was O +
chromatographed O +
over O +
silica O +
gel O +
( O -
300 O +
g O -
) O -
, O +
eluting O +
with O +
varying O +
proportions O +
of O +
hexane O -
, O +
EtOAc O +
and O +
MeOH O +
to O +
provide O +
compounds O +
1 O -
( O -
50 O +
mg O -
) O -
, O +
2 O -
( O -
61 O +
mg O -
) O -
, O +
3 O -
( O -
68 O +
mg O -
) O -
, O +
4 O -
( O -
25 O +
mg O -
) O +
and O +
5 O -
( O -
46 O +
mg O -
) O -
. O -

The O +
fractions O +
collected O +
were O +
100 O +
ml O +
each O +
and O +
monitored O +
by O +
TLC O -
. O -

3.4 O +
3α O -
- O -
Hydroxyeuph-25-ene O +
( O -
1 O +
) O +
Removal O +
of O +
solvent O +
from O +
the O +
fractions O +
65–68 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
95:5 O -
) O +
gave O +
a O +
residue O -
, O +
mp O +
180–82 O -
° O -
C O -
, O -
α O -
D O -
+ O -
37.8 O -
° O +
( O -
CHCl3 O +
) O -
. O -

IR O -
: O +
γ O +
max O -
cm−1 O +
: O +
3480 O -
, O +
2930 O -
, O +
1610 O -
, O +
1450 O -
, O +
1360 O -
, O +
1244 O -
, O +
1110 O -
, O +
1014 O -
, O +
880 O -
; O +
1 O +
H O +
NMR O -
: O +
δ O -
0.79 O +
( O -
3H O -
, O +
s O +
, O +
19-H3 O +
) O -
, O +
0.83 O +
( O -
3H O -
, O +
s O +
, O +
18-H3 O +
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
29-H3 O +
) O -
, O +
0.96 O +
( O -
3H O -
, O +
s O +
, O +
28-H3 O +
) O -
, O +
1.04 O +
( O -
3H O -
, O +
s O +
, O +
30-H3 O +
) O -
, O +
1.08 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
21-H3 O +
) O -
, O +
1.62 O -
( O -
3H O -
, O +
s O +
, O +
27-H3 O +
) O -
, O +
1.90 O +
( O -
1H O -
, O +
m O +
, O +
20-H O -
) O -
, O +
2.36 O +
( O -
2H O -
, O +
m O +
, O +
24-H2 O +
) O -
, O +
3.34 O +
( O -
1H O -
, O +
m O +
, O +
W O +
1 O -
/ O -
2 O +
= O -
7 O +
Hz O -
, O +
3ß O -
- O -
H O -
) O -
, O +
4.56 O -
, O +
4.68 O -
, O +
( O -
2H O -
, O +
each O +
br O +
s O +
, O +
26-H2 O +
) O -
; O +
MS O +
m O -
/ O -
z O -
( O -
rel O -
. O -

int O -
. O -
) O -
: O +
428 O +
[ O -
M O -
] O -
+ O -
( O -
C30 O +
H52 O +
O O -
, O +
67 O -
) O -
, O +
413 O +
[ O -
M O +
− O +
Me O -
] O -
+ O +
( O -
19 O -
) O -
, O +
410 O +
[ O -
M O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
5 O -
) O -
, O +
395 O +
[ O -
M O +
− O +
Me O -
– O -
H2 O +
O O -
] O -
+ O +
( O -
5 O -
) O -
, O +
387 O +
[ O -
M O +
− O +
41 O -
] O -
+ O +
( O -
6 O -
) O -
, O +
317 O +
[ O -
M O +
− O +
sc O -
] O -
+ O +
( O -
15 O -
) O -
, O +
316 O +
[ O -
M O +
− O +
sc O -
– O -
H O -
] O -
+ O +
( O -
18 O -
) O -
, O +
301 O +
[ O -
316 O +
− O +
Me O -
] O -
+ O +
( O -
5 O -
) O -
, O +
298 O +
[ O -
316 O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
5 O -
) O -
, O +
286 O +
[ O -
301 O +
− O +
Me O -
] O -
+ O +
( O -
5 O -
) O -
, O +
196 O +
( O -
5 O -
) O -
, O +
194 O +
( O -
8) O -
, O +
178 O +
[ O -
196 O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
18 O -
) O -
, O +
179 O +
[ O -
194 O +
− O +
Me O -
] O -
+ O +
( O -
10 O -
) O -
, O +
161 O +
( O -
12 O -
) O -
, O +
128 O +
( O -
5 O -
) O -
, O +
111 O +
( O -
20 O -
) O -
, O +
110 O +
( O -
15 O -
) O -
, O +
95 O +
( O -
100 O -
) O -
, O +
81 O +
( O -
80 O -
) O -
, O +
69 O +
( O -
75 O -
) O -
. O -

3.5 O +
Monoacetate O +
( O -
1a O +
) O +
of O +
1 O -
Compound O +
1 O -
( O -
25 O +
mg O -
) O +
was O +
acetylated O +
with O +
C5 O +
H5 O +
N O -
– O -
Ac2 O +
O O +
( O -
1 O +
ml O +
each O -
) O -
, O +
overnight O +
at O +
room O +
temperature O -
. O -

The O +
usual O +
work O -
- O -
up O +
yielded O +
1a O +
, O +
mp O +
205 O -
° O -
C O -
, O +
20 O +
mg O -
. O -

IR O +
γ O +
max O -
cm−1 O +
: O +
2940 O -
, O +
2856 O -
, O +
1738 O -
, O +
1640 O -
, O +
1460 O -
, O +
1374 O -
, O +
1245 O -
, O +
1020 O -
, O +
978 O -
, O +
880 O -
; O +
1 O +
H O +
NMR O -
: O +
δ O -
0.79 O +
( O -
3H O -
, O +
s O +
, O +
19-H3 O +
) O -
, O +
0.84 O +
( O -
3H O -
, O +
s O +
, O +
18-H3 O +
) O -
, O +
0.94 O +
( O -
3H O -
, O +
s O +
, O +
29-H3 O +
) O -
, O +
0.97 O +
( O -
3H O -
, O +
s O +
, O +
28-H3 O +
) O -
, O +
1.03 O +
( O -
3H O -
, O +
s O +
, O +
30-H3 O +
) O -
, O +
1.08 O +
( O -
3H O -
, O +
d O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
21-H3 O +
) O -
, O +
1.68 O +
( O -
3H O -
, O +
s O +
, O +
27-H3 O +
) O -
, O +
1.90 O +
( O -
1H O -
, O +
m O +
, O +
20-H O -
) O -
, O +
2.04 O +
( O -
3H O -
, O +
s O +
, O +
OAc O -
) O -
, O +
2.36 O +
( O -
2H O -
, O +
m O +
, O +
24-H2 O +
) O -
, O +
4.45 O +
( O -
1H O -
, O +
m O +
, O +
W O +
1 O -
/ O -
2 O +
= O -
7 O +
Hz O -
, O +
3ßH O -
) O -
, O +
4.56 O -
, O +
4.68 O +
( O -
2H O -
, O +
each O +
br O +
s O +
, O +
26-H2 O +
) O -
; O +
MS O +
m O -
/ O -
z O -
( O -
rel O -
. O -

int O -
. O -
) O -
: O +
470 O +
[ O -
M O -
] O -
+ O -
( O -
C32 O +
H54 O +
O2 O +
, O +
11 O -
) O -
, O +
455 O +
( O -
4 O -
) O -
, O +
429 O +
( O -
5 O -
) O -
, O +
410 O +
( O -
2 O -
) O -
, O +
359 O +
( O -
5 O -
) O -
, O +
257 O +
( O -
5 O -
) O -
, O +
238 O +
( O -
5 O -
) O -
, O +
236 O +
( O -
4 O -
) O -
, O +
188 O +
( O -
100 O -
) O -
, O +
176 O +
( O -
15 O -
) O -
, O +
161 O +
( O -
17 O -
) O -
, O +
160 O +
( O -
21 O -
) O -
, O +
111 O +
( O -
20 O -
) O -
, O +
110 O +
( O -
15 O -
) O -
, O +
95 O +
( O -
60 O -
) O -
, O +
81 O +
( O -
80 O -
) O -
, O +
69 O +
( O -
40 O -
) O -
, O +
55 O +
( O -
50 O -
) O -
, O +
43 O +
( O -
98 O -
) O -
. O -

3.6 O +
Nonacosanoic O +
acid O +
( O -
2 O +
) O +
Fractions O +
71–75 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
95:5 O -
) O +
eluates O +
yielded O +
a O +
residue O -
, O +
mp O +
68–70 O -
° O -
C O -
, O +
identified O +
by O +
co O -
- O -
TLC O -
, O +
MS O -
, O +
1 O +
H O +
NMR O -
. O -

3.7 O +
Stigmasterol O +
( O -
3 O +
) O +
Fractions O +
90–95 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
95:5 O -
) O +
eluates O +
when O +
freed O +
of O +
the O +
solvent O +
provided O +
3 O +
, O +
mp O +
160 O -
° O -
C O -
, O +
identified O +
by O +
co O -
- O -
TLC O -
, O +
MS O -
, O +
IR O -
, O +
1 O +
H O +
NMR O -
. O -

3.8 O +
2,14-Dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane O +
( O -
4 O +
) O +
Elimination O +
of O +
solvent O +
from O +
the O +
fractions O +
221–226 O +
of O +
hexane O -
– O -
EtOAc O +
( O -
1:1 O -
) O +
eluates O +
furnished O +
4 O +
, O +
mp O +
83–84 O -
° O -
C O -
. O -

IR O +
γ O +
max O -
cm−1 O +
: O +
3438 O -
, O +
2920 O -
, O +
2850 O -
, O +
1730 O -
, O +
1670 O -
, O +
1450 O -
, O +
1386 O -
, O +
1180 O -
, O +
1110 O -
, O +
1052 O -
, O +
720 O -
; O +
1 O +
H O +
NMR O -
: O +
δ O -
0.88 O +
( O -
3H O -
, O +
t O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
18-H3 O +
) O -
, O +
1.25 O +
( O -
10H O -
, O +
br O +
s O +
, O +
5 O +
× O +
CH2 O +
) O -
, O +
1.50 O +
( O -
10H O -
, O +
br O +
s O +
, O +
cyclohexyl O +
( O -
CH2 O +
) O -
5 O +
) O -
, O +
1.64 O +
( O -
1H O -
, O +
m O +
, O +
1′ O +
-H O -
) O -
, O +
1.60 O +
( O -
6H O -
, O +
s O +
, O +
11-H3 O +
, O +
12-H3 O -
) O -
, O +
1.90 O +
( O -
4H O -
, O +
m O +
, O +
3-H2 O +
, O +
15-H2 O +
) O -
, O +
2.02 O +
( O -
2H O -
, O +
m O +
, O +
1-H2 O +
) O -
, O +
2.35 O +
( O -
4H O -
, O +
t O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
7-H2 O +
, O +
9-H2 O +
) O -
, O +
2.45 O +
( O -
2H O -
, O +
t O +
, O +
J O +
= O -
6 O +
Hz O -
, O +
10-H2 O +
) O -
, O +
2.48 O +
( O -
2H O -
, O +
d O +
, O +
J O +
= O -
5 O +
Hz O -
, O +
13-H2 O +
) O -
, O +
3.64 O +
( O -
1H O -
, O +
m O +
, O +
2-H O -
) O -
, O +
3.94 O +
( O -
1H O -
, O +
m O +
, O +
14-H O -
) O -
; O +
MS O +
m O -
/ O -
z O -
( O -
rel O -
. O -

int O -
. O -
) O -
: O +
408 O +
[ O -
M O -
] O -
+ O -
( O -
C26 O +
H48 O +
O3 O +
, O +
2 O -
) O -
, O +
390 O -
[ O -
M O +
− O +
H2 O +
O O -
] O -
+ O +
( O -
7 O -
) O -
, O +
372 O +
[ O -
M O +
− O +
2H2 O +
O O -
] O -
+ O +
( O -
7 O -
) O -
, O +
393 O +
[ O -
M O +
− O +
Me O -
] O -
+ O +
( O -
3 O -
) O -
, O +
378 O +
[ O -
M O +
−2 O +
× O +
Me O -
] O -
+ O +
( O -
3 O -
) O -
, O +
351 O +
( O -
4 O -
) O -
, O +
325 O +
( O -
5 O -
) O -
, O +
321 O +
( O -
3 O -
) O -
, O +
311 O +
( O -
4 O -
) O -
, O +
307 O +
( O -
5 O -
) O -
, O +
281 O +
( O -
4 O -
) O -
, O +
253 O +
( O -
5 O -
) O -
, O +
226 O +
( O -
6 O -
) O -
, O +
225 O +
( O -
5 O -
) O -
, O +
211 O +
( O -
7 O -
) O -
, O +
197 O +
( O -
6 O -
) O -
, O +
183 O +
( O -
10 O -
) O -
, O +
182 O +
( O -
7 O -
) O -
, O +
155 O +
( O -
4 O -
) O -
, O +
127 O +
( O -
19 O -
) O -
, O +
101 O +
( O -
6 O -
) O -
, O +
97 O +
( O -
90 O -
) O -
, O +
87 O +
( O -
12 O -
) O -
, O +
83 O +
( O -
65 O -
) O -
, O +
57 O +
( O -
100 O -
) O +
( O -
Found O -
: O +
C O -
, O +
76.40 O -
; O +
H O -
, O +
11.82 O -
. O -

C26 O +
H48 O +
O3 O -
requires O -
: O +
C O -
, O +
76.47 O -
; O +
H O -
, O +
11.76 O -
% O -
) O -
. O -

3.9 O +
Stigmasterol O -
- O -
ßD O +
-glucopyranoside O +
( O -
5 O +
) O +
Removal O +
of O +
solvent O +
from O +
290–301 O +
fractions O +
of O +
MeOH O -
– O -
EtOAc O +
( O -
2:98 O -
) O +
eluates O +
gave O +
5 O +
, O +
mp O +
263–65 O -
° O -
C O -
, O +
identified O +
by O +
MS O -
, O +
1 O +
H O +
NMR O +
and O +
hydrolysis O +
products O -
. O -

Acknowledgements O +
One O +
of O +
the O +
authors O +
( O -
M. O +
Mishra O -
) O +
is O +
grateful O +
to O +
the O +
Director O -
, O +
CIMAP O +
for O +
the O +
award O +
of O +
a O +
Junior O +
Research O +
Fellowship O -
. O +

Arachidonic O +
acid O +
( O -
AA O -
) O +
is O +
metabolized O +
to O +
form O +
four O +
different O +
epoxides O +
( O -
namely O +
5,6- O -
, O +
8,9- O -
, O +
11,12- O -
, O +
14,15-EET O -
) O +
via O +
the O +
cytochrome O +
P-450 O +
monooxygenase O +
( O -
epoxygenase O -
) O +
pathway O +
[ O -
1 O -
] O +
. O -

14,15-EET O +
is O +
found O +
in O +
the O +
urine O +
[ O -
2 O -
] O -
and O +
produced O +
by O +
platelets O +
and O +
endothelial O +
cells O +
[ O -
3,4 O -
] O +
. O -

The O +
occurrence O +
of O +
14,15-EET O +
and O +
other O +
EETs O +
in O +
tissues O +
and O +
various O +
cell O +
types O +
leads O +
to O +
the O +
hypothesis O +
that O +
these O +
substances O +
may O +
be O +
stored O +
in O +
cells O +
by O +
conjugative O +
protein O +
binding O +
or O +
by O +
incorporation O +
into O +
membrane O +
phospholipids O +
( O -
PL O -
) O +
[ O -
5 O -
] O +
. O -

The O +
stored O +
form O +
of O +
EETs O +
can O +
be O +
released O +
upon O +
activation O +
of O +
specific O +
phospholipase O -
, O +
for O +
example O -
, O +
phospholipase O +
A2 O -
( O -
PLA2 O +
) O +
or O +
phospholipase O +
C O +
( O -
PLC O -
) O -
, O +
by O +
neuronal O -
, O +
hormonal O +
or O +
chemical O +
stimulation O +
[ O -
6,7 O -
] O +
. O -

Of O +
the O +
various O +
systems O +
in O +
which O -
, O +
epoxygenase O +
and O +
its O +
epoxides O +
( O -
EETs O -
) O +
have O +
studied O -
, O +
the O +
kidney O +
seems O +
to O +
be O +
a O +
major O +
organ O +
for O +
production O +
and O +
action O +
of O +
the O +
EETs O -
. O -

The O +
main O +
forms O +
of O +
EETs O +
found O +
in O +
the O +
kidney O +
and O +
in O +
urine O +
are O +
8,9- O +
and O +
14,15-EET O +
[ O -
2 O -
] O +
. O -

The O +
levels O +
of O +
EETs O +
in O +
the O +
kidney O +
seemed O +
to O +
vary O +
as O +
a O +
function O +
of O +
renal O +
pathology O +
[ O -
8–10 O -
] O +
. O -

In O +
the O +
kidney O -
, O +
certain O +
EETs O +
and O +
their O +
dihydroxyeicosatrienoic O +
acid O +
metabolites O +
( O -
diols O +
or O +
DHETs O -
) O +
have O +
prominent O +
biological O +
functions O -
, O +
such O +
as O -
: O +
inhibition O +
of O +
Na+ O +
/K+ O -
ATPase O +
[ O -
11 O -
] O -
and O +
suppression O +
of O +
vasopressin O +
( O -
AVP O -
) O +
action O +
on O +
rabbit U-Species +
kidney O +
cortical O +
collecting O +
duct O +
( O -
CCD O -
) O +
[ O -
9 O -
] O +
. O -

With O +
our O +
previous O +
reports O +
[ O -
12,13 O -
] O +
, O +
it O +
is O +
conceivable O +
that O +
14,15-EET O +
and O +
its O +
metabolite O +
( O -
14,15-DHET O -
) O +
may O +
play O +
an O +
important O +
role O +
in O +
maintaining O +
blood O +
pressure O -
, O +
modulating O +
renal O +
function O -
, O +
and O +
regulating O +
monocyte O +
adhesion O -
. O -

In O +
other O +
systems O -
, O +
Malcolm O +
and O +
Fitzpatrick O +
reported O +
that O +
14,15-EET O +
inhibited O +
Ca+2 O -
entry O +
into O +
cells O +
[ O -
14 O -
] O +
. O -

We O +
had O +
shown O +
that O +
14,15-EET O +
can O +
enhance O +
monocyte O +
attachment O +
to O +
endothelium O +
and O +
decrease O +
the O +
mean O +
arterial O +
blood O +
pressure O +
in O +
normal O +
and O +
spontaneously O +
hypertensive O +
rats U-Species +
[ O -
12,13 O -
] O +
. O -

Catella O +
et O +
al. O +
[ O -
15 O -
] O -
reported O +
high O +
amounts O +
of O +
14,15-EET O +
in O +
the O +
urine O +
of O +
patients U-Species +
with O +
pregnancy O -
- O -
induced O +
hypertension O -
, O +
suggesting O +
a O +
possible O +
role O +
of O +
14,15-EET O +
in O +
blood O +
pressure O +
regulation O -
. O -

These O +
wide O +
varieties O +
of O +
biological O +
function O +
suggest O +
that O +
14,15-EET O +
may O +
act O +
through O +
specific O +
receptors O +
and O +
signal O +
transduction O +
pathways O -
. O -

In O +
this O +
study O -
, O +
we O +
have O +
identified O +
a O +
population O +
of O +
specific O +
high O +
affinity O +
binding O +
sites O +
for O +
14,15-EET O +
in O +
GPM U-Species +
cells O +
that O +
may O +
be O +
associated O +
with O +
receptors O -
. O -

This O +
population O +
of O +
14,15-EET O +
binding O +
sites O +
in O +
GPM U-Species +
cells O +
was O +
down O +
regulated O +
by O +
cholera O +
toxin O +
or O +
dibutyryl O -
- O -
cAMP O +
that O +
suggested O +
a O +
postreceptor O +
mechanism O +
coupled O +
to O +
PKA O -
- O -
dependent O +
signal O +
transduction O +
pathway O -
. O -

2 O +
Materials O +
and O +
methods O +
2.1 O +
Materials O +
White B-Species +
Hartley I-Species +
guinea I-Species +
pigs L-Species +
weighing O +
250 O +
to O +
350 O +
g O +
were O +
obtained O +
from O +
Taconic O +
Farms O +
( O -
Germantown O -
, O +
NY O -
, O +
USA O -
) O -
. O -

Percoll O -
, O +
HEPES O -
, O +
deoxyribonuclease O -
, O +
cholera O +
toxin O -
, O +
pertussis O +
toxin O -
, O +
sodium O +
bicarbonate O +
( O -
a O +
cell O +
culture O +
grade O -
) O -
, O +
Tris O -
- O -
base O -
, O +
chymotrypsin O +
( O -
type O +
IS O +
and O +
type O +
II O -
) O -
, O +
papain O -
, O +
pronase O +
E O -
, O +
proteinase O +
K O -
, O +
and O +
dibutyryl O +
cAMP O +
were O +
purchased O +
from O +
Sigma O +
( O -
St. O +
Louis O -
, O +
MO O -
, O +
USA O -
) O -
. O -

The O +
gelatin O +
was O +
obtained O +
from O +
Fisher O +
Scientific O +
( O -
Fairlawn O -
, O +
NJ O -
, O +
USA O -
) O -
. O -

H-89 O +
and O +
K252a O +
were O +
from O +
LC O +
Laboratories O +
( O -
Woburn O -
, O +
MA O -
, O +
USA O -
) O -
. O -

Hank O -
's O +
Balanced O +
Salt O +
Solution O +
( O -
HBSS O -
) O +
and O +
horse U-Species +
serums O +
were O +
obtained O +
from O +
GIBCO O +
( O -
Grand O +
Island O -
, O +
NY O -
, O +
USA O -
) O -
, O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
( O -
100 O +
Ci O -
/ O -
mmole O -
) O +
and O +
14,15-EET O +
was O +
synthesized O +
and O +
purified O +
by O +
RP O -
, O +
reversed O +
phase O -
- O -
HPLC O -
, O +
as O +
previously O +
described O +
[ O -
16 O -
] O +
. O -

2.2 O +
Harvest O +
and O +
purification O +
of O +
guinea B-Species +
pig L-Species +
monocytes O +
Female O +
white B-Species +
Hartley I-Species +
guinea I-Species +
pigs L-Species +
( O -
250–350 O +
g O -
) O +
were O +
injected O +
intraperitoneally O +
( O -
i.p O -
. O -
) O +
with O +
0.5 O +
ml O +
horse U-Species +
serum O +
twice O +
a O +
week O +
for O +
2 O +
weeks O -
, O +
and O +
afterwards O -
, O +
once O +
weekly O -
. O -

After O +
a O +
minimum O +
of O +
48 O +
h O +
from O +
the O +
last O +
injection O -
, O +
the O +
cells O +
were O +
harvested O +
by O +
peritoneal O +
lavage O -
. O -

The O +
animals O +
were O +
anesthetized O +
with O +
metofane O +
and O +
a O +
20 O +
g O +
× O +
2″ O +
( O -
Surflo O -
) O +
Teflon O +
intercath O +
was O +
inserted O +
into O +
the O +
peritoneal O +
cavity O -
. O -

The O +
cavity O +
was O +
washed O +
with O +
20 O +
ml O +
of O +
Hank O -
's O +
buffered O +
saline O +
solution O +
without O +
calcium O +
or O +
magnesium O +
( O -
HBSS O -
) O -
, O +
containing O +
5 O +
mM O +
HEPES O -
, O +
pH O +
7.3 O +
and O +
10 O +
Units O -
/ O -
ml O +
of O +
heparin O -
. O -

The O +
collected O +
cells O +
were O +
centrifuged O +
at O +
275 O +
× O +
g O -
for O +
5 O +
min O -
, O +
washed O +
and O +
resuspended O +
in O +
4 O +
ml O +
of O +
HBSS O +
containing O +
10 O -
% O +
gelatin O +
and O +
5 O +
mg O +
deoxyribonuclease O +
( O -
HBSS O -
- O -
GD O -
) O -
. O -

Hypotonic O +
lysis O +
removed O +
contaminating O +
red O +
blood O +
cells O -
. O -

Four O +
milliliters O +
of O +
aliquots O +
of O +
the O +
cell O +
suspension O +
were O +
layered O +
on O +
top O +
of O +
a O +
Percoll O +
density O +
gradient O +
and O +
centrifuged O +
at O +
1600 O +
× O +
g O -
for O +
30 O +
min O -
. O -

The O +
discontinuous O +
density O +
gradient O +
was O +
prepared O +
by O +
overlaying O +
successive O +
layers O +
of O +
86 O -
% O -
, O +
76 O -
% O -
, O +
64 O -
% O -
, O +
and O +
45 O -
% O +
isotonic O +
Percoll O +
containing O +
0.03 O +
mg O -
/ O -
ml O +
deoxyribonuclease O +
to O +
give O +
the O +
following O +
densities O -
: O +
A O -
: O +
1.06 O -
, O +
B O -
: O +
1.08 O -
, O +
C O -
: O +
1.09 O -
, O +
D O -
: O +
1.10 O +
g O -
/ O -
ml O +
[ O -
17,18 O -
] O +
. O -

The O +
four O +
bands O +
of O +
cells O +
were O +
collected O +
at O +
the O +
interface O +
of O +
the O +
different O +
density O +
layers O -
, O +
and O +
to O +
remove O +
any O +
remaining O +
Percoll O -
, O +
each O +
was O +
diluted O +
1:4 O +
with O +
HBSS O -
- O -
GD O -
, O +
centrifuged O -
, O +
washed O +
once O -
, O +
and O +
resuspended O +
in O +
HBSS O -
- O -
GD O -
. O -

Differential O +
counts O +
were O +
obtained O +
using O +
slide O +
preparation O +
stained O +
with O +
Diff O +
Quick O +
( O -
American O +
Scientific O -
) O -
. O -

From O +
this O +
procedure O +
we O +
could O +
collect O +
the O +
lymphocytes O +
and O +
monocytes O -
, O +
A O +
and O +
B O +
bands O -
, O +
respectively O -
. O -

Eosinophils O +
were O +
collected O +
mainly O +
from O +
the O +
C O +
and O +
D O +
bands O +
[ O -
17,18 O -
] O +
. O -

Cell O +
viability O +
was O +
determined O +
by O +
trypan O +
blue O +
exclusion O +
and O +
found O +
to O +
be O +
> O -
99 O -
% O -
. O -

2.3 O +
Radioligand O +
binding O +
assays O +
All O +
assays O +
were O +
performed O +
in O +
duplicate O +
with O +
intact O +
GPM U-Species +
cells O +
suspended O +
in O +
HBSS O +
buffer O -
, O +
pH O +
7.4 O +
containing O +
10 O +
mM O +
CaCl2 O -
and O +
10 O +
mM O +
MgCl2 O -
at O +
a O +
final O +
volume O +
of O +
250 O +
μl O -
. O -

In O +
the O +
saturation O +
binding O +
experiment O -
, O +
GPM U-Species +
cells O +
( O -
106 O -
cells O -
) O +
were O +
added O +
to O +
polypropylene O +
tubes O +
( O -
12 O +
× O +
75 O +
mm O -
) O +
and O +
incubated O +
at O +
4 O -
° O -
C O +
for O +
4 O +
min O +
with O +
increasing O +
concentrations O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
( O -
0.4 O +
nM–30 O +
nM O -
) O +
in O +
the O +
presence O +
or O +
absence O +
of O +
20 O +
μM O +
unlabeled O +
14,15-EET O -
. O -

For O +
nonsaturation O +
experiments O -
, O +
1000-fold O +
excess O +
of O +
unlabeled O +
14,15-EET O +
was O +
used O -
. O -

Bound O +
and O +
free O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
were O +
separated O +
by O +
centrifugation O +
at O +
2000 O +
rev. O -
/ O -
min O -
, O +
4 O -
° O -
C O +
for O +
2 O +
min O -
. O -

Pellets O +
were O +
washed O +
with O +
250 O +
μl O +
of O +
HBSS O +
twice O +
and O +
centrifuged O +
at O +
2000 O +
rev. O -
/ O -
min O -
, O +
4 O -
° O -
C O +
for O +
2 O +
min O -
. O -

Pellets O +
were O +
taken O +
up O +
in O +
200 O +
μl O +
20 O -
% O +
NaOH O -
, O +
heated O +
on O +
40 O -
° O -
C O +
water O +
bath O +
with O +
constant O +
shaking O -
, O +
and O +
then O +
taken O +
up O +
in O +
4.8 O +
ml O +
of O +
scintillation O +
liquid O -
. O -

The O +
radioactivity O +
was O +
measured O +
by O +
a O +
Beckman O +
7500 O +
Scintillation O +
Counter O +
after O +
equilibration O +
for O +
13 O +
to O +
18 O +
h O +
in O +
5 O +
ml O +
of O +
scintillation O +
fluid O -
. O -

The O +
competition O +
studies O +
of O +
[ O -
3 O +
H O -
] O -
14,15-EET O +
specific O +
binding O +
to O +
guinea O +
pig O +
mononuclear O +
cells O +
was O +
conducted O +
by O +
incubating O +
GPM U-Species +
cells O +
( O -
106 O -
cells O -
) O +
with O +
2 O +
nM O +
of O +
[ O -
3 O +
H O -
] O +
14,15-EET O +
in O +
the O +
presence O +
of O +
various O +
concentrations O +
( O -
10−11 O -
to O +
10−4 O -
M O -
) O +
of O +
stereo O +
isomers O +
and O +
analogs O +
of O +
14,15-EET O -
. O -

For O +
the O +
experiments O +
on O +
the O +
effects O +
of O +
proteases O +
( O -
chymotrypsin O -
, O +
papain O -
, O +
pronase O +
E O -
, O +
and O +
Proteinase O +
K O -
) O -
, O +
cholera O +
toxin O -
, O +
pertussis O +
toxin O -
, O +
dibutyryl O +
cAMP O -
, O +
and O +
H-89 O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM U-Species +
cells O -
, O +
the O +
cells O +
were O +
pretreated O +
with O +
one O +
of O +
the O +
following O +
group O +
of O +
agents O -
: O +
1 O -
) O +
proteases O +
( O -
chymotrypsin O -
- O -
type O +
IS O +
and O +
type O +
II O -
, O +
papain O -
, O +
pronase O +
E O +
and O +
proteinase O +
K O -
, O +
100 O +
μg O -
/ O -
ml O -
) O +
at O +
37 O -
° O -
C O +
for O +
20 O +
min O -
; O +
2 O -
) O +
cholera O +
toxin O +
( O -
25–200 O +
μg O -
/ O -
ml O -
) O +
and O +
pertussis O +
toxin O +
( O -
20–200 O +
ng O -
/ O -
ml O -
) O +
at O +
37 O -
° O -
C O +
for O +
2 O +
h O -
; O +
3 O -
) O +
dibutyryl O +
cAMP O +
( O -
DBcAMP O -
) O +
( O -
10–100 O +
nM O -
) O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O -
; O +
4 O -
) O +
H-89 O +
( O -
0.01–1 O +
μm O -
) O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O -
, O +
then O +
in O +
the O +
presence O +
of O +
DBcAMP O +
( O -
100 O +
nM O -
) O +
at O +
37 O -
° O -
C O +
for O +
another O +
30 O +
min O -
, O +
separately O +
before O +
the O +
binding O +
assay O -
. O -

The O +
pretreated O +
GPM U-Species +
cells O +
were O +
centrifuged O +
at O +
1000 O +
rev. O -
/ O -
min O -
, O +
at O +
4 O -
° O -
C O +
for O +
5 O +
min O -
, O +
washed O +
with O +
HBSS O +
buffer O -
, O +
centrifuged O -
, O +
and O +
resuspended O +
in O +
HBSS O +
before O +
the O +
binding O +
assay O -
. O -

2.4 O +
cAMP O +
and O +
cGMP O +
determination O +
GPM U-Species +
cells O +
( O -
4 O +
× O +
106 O +
) O +
were O +
preincubated O +
with O +
or O +
without O +
400 O +
μM O +
of O +
IBMX O +
for O +
5 O +
min O +
before O +
the O +
addition O +
of O +
14,15-EET O +
( O -
0.1–100 O +
μM O -
) O -
. O -

The O +
assays O +
were O +
incubated O +
for O +
another O +
10 O +
min O +
at O +
37 O -
° O -
C O +
and O +
terminated O +
by O +
addition O +
of O +
ethanol O +
( O -
its O +
final O +
concentration O +
was O +
65 O -
% O -
) O -
. O -

The O +
cell O +
debris O +
was O +
removed O +
by O +
centrifugation O +
and O +
the O +
supernatant O +
was O +
dried O +
under O +
vacuum O +
and O +
redissolved O +
in O +
0.05 O +
M O +
acetate O +
buffer O +
for O +
further O +
determination O +
of O +
cAMP O +
and O +
cGMP O +
by O +
RIA O +
kit O +
( O -
Amersham O +
Corp. O -
, O +
Arlington O +
Heights O -
, O +
IL O -
, O +
USA O -
) O -
. O -

2.5 O +
Statistical O +
analysis O +
Experimental O +
results O +
were O +
summarized O +
as O +
mean O +
values O +
± O +
SEM O -
. O -

Data O +
were O +
analyzed O +
using O +
one O -
- O -
way O +
ANOVA O +
through O +
the O +
Sigma O +
stat O +
program O +
( O -
Jandel O +
Scientific O -
) O -
. O -

Difference O +
between O +
groups O +
was O +
then O +
determined O +
using O +
the O +
Bonferroni O -
's O +
t O +
-test O -
. O -

When O +
the O +
test O +
of O +
the O +
normality O +
failed O -
, O +
Dunn O -
's O +
test O +
of O +
ANOVA O +
by O +
ranks O +
was O +
used O -
. O -

Groups O +
were O +
deemed O +
to O +
be O +
significantly O +
different O +
from O +
one O +
another O +
when O +
P O -
< O +
0.05 O -
. O -

3 O +
Results O +
3.1 O +
Binding O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
to O +
GPM U-Species +
cells O +
The O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
to O +
GPM U-Species +
cells O +
was O +
time O +
dependent O +
and O +
cell O +
concentration O +
dependent O +
( O -
Fig. O +
1A O +
and O +
B O -
) O +
. O -

Maximum O +
binding O +
at O +
4 O -
° O -
C O +
was O +
reached O +
at O +
4 O +
min O +
with O +
the O +
cell O +
density O +
of O +
2 O +
× O +
106 O -
cells O -
/ O -
ml O -
. O -

Cell O +
bound O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
was O +
readily O +
dissociated O +
in O +
a O +
time O -
- O -
dependent O +
fashion O +
when O +
1000-fold O +
higher O +
concentration O +
of O +
unlabeled O +
of O +
14 O -
( O -
R O +
) O -
, O +
15 O -
( O -
S O +
) O -
-EET O -
, O +
or O +
14 O -
( O -
S O +
) O -
, O +
15 O -
( O -
R O +
) O -
-EET O +
was O +
added O +
to O +
the O +
reaction O +
mixture O +
with O +
14 O -
( O -
R O +
) O -
, O -
15 O -
( O -
S O +
) O -
-EET O +
more O +
effective O +
than O +
the O +
14 O -
( O -
S O +
) O -
, O -
15 O -
( O -
R O +
) O -
-EET O +
( O -
Fig. O +
2 O -
) O +
. O -

The O +
displacement O +
of O +
bound O +
radioligand O +
reached O +
maximum O +
( O -
66 O -
% O -
) O +
in O +
5 O +
min O +
after O +
the O +
addition O +
of O +
unlabeled O +
14 O -
( O -
R O -
) O -
, O +
15 O -
( O -
S O -
) O -
-EET O -
. O -

The O +
saturability O +
of O +
the O +
specific O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
was O +
shown O +
by O +
incubating O +
the O +
GPM U-Species +
cells O +
with O +
increasing O +
concentrations O +
of O +
radioligand O +
in O +
the O +
presence O +
or O +
absence O +
of O +
20 O +
μM O +
unlabeled O +
14,15-EET O -
. O -

As O +
shown O +
in O +
Fig. O +
3A O +
, O -
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM U-Species +
cells O +
was O +
saturable O +
and O +
of O +
high O +
affinity O -
. O -

Nonspecific O +
binding O +
increased O +
linearly O +
with O +
increasing O +
concentration O +
of O +
ligand O -
. O -

Total O +
binding O +
also O +
increased O +
with O +
increasing O +
concentration O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O -
. O -

This O +
showed O +
that O +
nonspecific O +
binding O +
was O +
of O +
high O +
capacity O -
, O +
nonsaturable O +
and O +
low O +
affinity O +
whereas O +
specific O +
binding O +
was O +
of O +
low O +
capacity O -
, O +
saturable O -
, O +
and O +
high O +
affinity O -
. O -

Scatchard O +
analysis O +
of O +
specific O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM U-Species +
cells O +
( O -
Fig. O +
3B O -
) O -
shows O +
that O +
the O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
binding O +
sites O +
in O +
GPM U-Species +
cells O +
belong O +
to O +
a O +
high O +
affinity O +
population O -
. O -

The O +
dissociation O +
constant O +
( O -
K O +
d O +
) O +
is O +
35.06 O +
± O +
1.73 O +
nM O +
( O -
n O -
= O +
4 O -
) O -
, O +
and O +
the O +
maximum O +
number O +
of O +
binding O +
sites O +
( O -
B O +
max O +
) O +
was O +
estimated O +
to O +
be O +
2.36 O +
± O +
0.31 O +
pmol O -
/ O -
106 O -
cells O +
and O +
the O +
number O +
of O +
binding O +
sites O +
per O +
cell O +
calculated O +
to O +
be O +
1.42 O +
± O +
0.19 O +
× O +
106 O -
sites O -
/ O -
cell O +
( O -
n O -
= O +
4 O -
) O -
. O -

3.2 O +
Competition O +
studies O +
of O +
[ O -
3 O +
H O -
] O -
14,15-EET O +
specific O +
binding O +
to O +
guinea B-Species +
pig L-Species +
mononuclear O +
cells O +
by O +
14,15-EET O +
stereoisomers O +
and O +
other O +
EETs O +
To O +
examine O +
the O +
specificity O +
of O +
the O +
binding O +
sites O +
for O +
[ O -
3 O +
H O -
] O -
14,15-EET O -
, O +
we O +
conducted O +
competition O +
binding O +
studies O +
with O +
stereoisomers O +
and O +
analogs O +
of O +
14,15-EET O +
and O +
other O +
EETs O -
. O -

As O +
shown O +
in O +
Fig. O +
4 O +
, O -
14 O -
( O -
R O +
) O -
, O +
15 O -
( O -
S O +
) O -
-EET O +
was O +
an O +
effective O +
competing O +
ligand O +
with O +
a O +
K O +
i O -
of O +
226.3 O +
nM O +
followed O +
by O +
11 O -
( O -
R O +
) O -
, O -
12 O -
( O -
S O +
) O -
-EET O -
, O +
14 O -
( O -
S O +
) O -
, O -
15 O -
( O -
R O +
) O -
-EET O -
, O +
14,15 O +
thia O -
( O -
S O +
) O -
-ET O -
, O +
and O +
14,15-aza O -
( O -
N O +
) O -
-ET O +
with O +
K O +
i O -
of O +
595.1 O +
nM O -
, O +
612.5 O +
nM O -
, O +
3.54 O +
μM O -
, O +
and O +
5 O +
μM O -
, O +
respectively O -
. O -

3.3 O +
Effects O +
of O +
protease O +
enzymes O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
on O +
GPM U-Species +
cells O +
Preincubation O +
of O +
the O +
intact O +
GPM U-Species +
cells O +
with O +
100 O +
μg O -
/ O -
ml O +
of O +
various O +
protease O +
enzymes O +
such O +
as O -
: O +
chymotrypsin O -
- O -
type O +
IS O +
and O +
type O +
II O -
, O +
papain O -
, O +
pronase O +
E O -
, O +
and O +
proteinase O +
K O +
at O +
37 O -
° O -
C O +
for O +
20 O +
min O +
led O +
to O +
significant O +
reduction O +
of O +
binding O +
( O -
n O -
= O +
3 O -
) O +
( O -
Fig. O +
5 O -
) O +
. O -

Papain O +
produced O +
the O +
most O +
reduction O +
( O -
51.60 O -
% O -
) O +
on O +
the O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
to O +
its O +
receptor O +
followed O +
by O +
proteinase O +
K O +
( O -
47.14 O -
% O -
) O -
, O +
chymotrypsin O -
- O -
type O +
II O +
( O -
42.04 O -
% O -
) O -
, O +
chymotrypsin O -
- O -
type O +
IS O +
( O -
27.33 O -
% O -
) O -
, O +
and O +
pronase O +
E O +
( O -
15.98 O -
% O -
) O -
, O +
respectively O -
. O -

These O +
data O +
suggest O +
that O +
14,15-EET O +
binding O +
sites O +
of O +
the O +
intact O +
GPM U-Species +
cells O +
are O +
protein O +
in O +
nature O -
. O -

3.4 O +
Effects O +
of O +
cholera O +
toxin O +
and O +
pertussis O +
toxin O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
on O +
GPM U-Species +
cells O +
The O +
effects O +
of O +
cholera O +
toxin O +
and O +
pertussis O +
toxin O -
, O +
agents O +
known O +
to O +
enhance O +
cAMP O +
levels O -
, O +
were O +
tested O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
in O +
GPM U-Species +
cells O -
. O -

GPM U-Species +
cells O +
were O +
pretreated O +
with O +
cholera O +
toxin O +
( O -
25–200 O +
μg O -
/ O -
ml O -
) O +
and O +
pertussis O +
toxin O +
( O -
20–200 O +
ng O -
/ O -
ml O -
) O +
separately O +
at O +
37 O -
° O -
C O +
for O +
2 O +
h O -
, O +
followed O +
by O +
radioligand O +
binding O +
assay O -
. O -

14,15-EET O +
receptor O +
binding O +
was O +
decreased O +
58.99 O +
± O +
6.37 O -
% O +
by O +
cholera O +
toxin O +
( O -
200 O +
μg O -
/ O -
ml O -
) O +
( O -
Fig. O +
6A O -
) O -
and O +
40.50 O +
± O +
3.78 O -
% O +
by O +
pertussis O +
toxin O +
( O -
200 O +
ng O -
/ O -
ml O -
) O +
( O -
data O +
not O +
shown O -
) O -
. O -

Thus O -
, O +
agents O +
that O +
increase O +
intracellular O +
cAMP O +
level O +
can O +
effectively O +
down O +
regulate O +
14,15-EET O +
receptor O +
binding O -
. O -

The O +
down O +
regulation O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
binding O +
in O +
GPM U-Species +
cells O +
by O +
cholera O +
toxin O +
( O -
200 O +
μg O -
/ O -
ml O -
) O +
is O +
shown O +
by O +
the O +
decrease O +
of O +
number O +
of O +
binding O +
sites O +
( O -
B O +
max O +
, O +
32.0 O -
% O +
decrease O -
) O +
on O +
the O +
cell O +
surface O +
without O +
changing O +
the O +
dissociation O +
constant O +
( O -
K O +
d O +
) O +
( O -
Fig. O +
6B O -
) O +
. O -

3.5 O +
Effects O +
of O +
dibutyryl O +
cAMP O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
on O +
GPM U-Species +
cells O +
We O +
pretreated O +
GPM U-Species +
cells O +
with O +
various O +
concentrations O +
of O +
dibutyryl O +
cAMP O +
( O -
DBcAMP O -
) O +
at O +
37 O -
° O -
C O +
for O +
30 O +
min O +
followed O +
by O +
the O +
radioligand O +
binding O +
assays O +
as O +
described O -
. O -

Similar O +
to O +
the O +
effect O +
of O +
cholera O +
toxin O -
, O +
a O +
significant O +
reduction O +
of O +
specific O +
binding O +
( O -
> O -
35 O -
% O +
reduction O -
) O +
for O +
[ O -
3 O +
H O -
] O +
14,15-EET O +
was O +
observed O +
after O +
the O +
cells O +
were O +
treated O +
with O +
DBcAMP O -
. O -

The O +
reduction O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
to O +
GPM U-Species +
cells O +
was O +
dose O -
- O -
dependent O +
with O +
respect O +
to O +
DBcAMP O +
( O -
Fig. O +
7A O -
) O -
and O +
maximum O +
response O +
was O +
reached O +
at O +
100 O +
nM. O +
Scatchard O +
analysis O +
revealed O +
that O +
the O +
number O +
of O +
the O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
sites O +
( O -
B O +
max O +
) O +
in O +
GPM U-Species +
cell O +
surface O +
was O +
decreased O +
by O +
19.1 O -
% O +
after O +
incubation O +
with O +
100 O +
nM O +
of O +
DBcAMP O +
without O +
changing O +
the O +
K O +
d O +
( O -
Fig. O +
7B O -
) O -
in O +
the O +
same O +
fashion O +
as O +
the O +
treatment O +
with O +
cholera O +
toxin O -
. O -

3.6 O +
Effect O +
of O +
protein O +
kinase O +
inhibitors O +
on O +
the O +
reduction O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
in O +
GPM U-Species +
cells O +
by O +
DBcAMP O +
Because O +
pretreatment O +
of O +
GPM U-Species +
cells O +
with O +
DBcAMP O +
or O +
cholera O +
toxin O +
resulted O +
in O +
the O +
down O +
regulation O +
of O +
14,15-EET O +
binding O +
site O +
density O -
, O +
we O +
further O +
examined O +
whether O +
this O +
effect O +
was O +
due O +
to O +
activation O +
of O +
PKA O -
. O -

GPM U-Species +
cells O +
were O +
incubated O +
with O +
various O +
concentrations O +
of O +
PKA O +
inhibitor O -
, O +
H-89 O +
[ O -
19 O -
] O +
, O +
at O +
37 O -
° O -
C O +
for O +
10 O +
min O +
before O +
the O +
pretreatment O +
of O +
DBcAMP O +
( O -
100 O +
nM O -
) O +
at O +
37 O -
° O -
C O +
for O +
an O +
30 O +
min O -
. O -

The O +
cells O +
were O +
washed O +
with O +
HBSS O +
once O +
and O +
resuspended O +
in O +
HBSS O -
. O -

Low O +
doses O +
of O +
H-89 O +
( O -
0.01 O +
μM O -
) O +
alone O +
showed O +
a O +
slightly O +
decrease O +
in O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
but O +
a O +
higher O +
dose O +
( O -
0.1–1.0 O +
μM O -
) O +
showed O +
significant O +
increases O +
as O +
compared O +
with O +
controls O +
( O -
untreated O +
GPM U-Species +
cells O -
) O -
. O -

However O -
, O +
when O +
GPM U-Species +
cells O +
were O +
pretreated O +
with O +
H-89 O +
from O +
0.1 O +
to O +
1.0 O +
μM O +
before O +
treatment O +
with O +
DBcAMP O -
, O +
H-89 O +
readily O +
reversed O +
the O +
down O +
regulatory O +
response O +
of O +
DBcAMP O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
in O +
GPM U-Species +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
Fig. O +
8) O +
. O -

Under O +
similar O +
conditions O -
, O +
K252a O +
( O -
a O +
protein O +
kinase O +
C O +
inhibitor O -
) O +
could O +
not O +
reverse O +
the O +
downward O +
regulatory O +
effect O +
of O +
DBcAMP O +
on O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
binding O +
in O +
GPM U-Species +
cells O -
. O -

3.7 O +
Effects O +
of O +
14,15-EET O +
on O +
the O +
level O +
of O +
cAMP O +
and O +
cGMP O +
in O +
intact O +
GPM U-Species +
cells O +
Because O +
cholera O +
toxin O +
and O +
cAMP O +
both O +
are O +
able O +
to O +
down O +
regulate O +
the O +
14,15-EET O +
receptor O +
binding O -
, O +
the O +
effects O +
of O +
14,15-EET O +
on O +
the O +
intracellular O +
levels O +
of O +
cAMP O +
or O +
cGMP O +
were O +
examined O -
. O -

GPM U-Species +
cells O +
were O +
preincubated O +
with O +
or O +
without O +
400 O +
μM O +
of O +
IBMX O +
for O +
5 O +
min O +
at O +
37 O -
° O -
C O +
and O +
incubated O +
with O +
various O +
concentrations O +
of O +
14,15-EET O +
( O -
0.01–100 O +
μM O -
) O +
for O +
additional O +
10 O +
min O -
. O -

We O +
found O +
that O +
14,15-EET O +
can O +
indeed O +
induce O +
an O +
increase O +
of O +
intracellular O +
level O +
of O +
cAMP O +
in O +
GPM U-Species +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
( O -
0.1 O +
to O +
100 O +
μM O -
) O +
( O -
Fig. O +
9 O -
) O +
. O -

Maximal O +
effect O +
on O +
the O +
increase O +
of O +
cAMP O +
in O +
GPM U-Species +
cells O +
required O +
the O +
presence O +
of O +
IBMX O -
, O +
a O +
phospodiesterase O +
inhibitor O -
. O -

When O +
the O +
cells O +
were O +
pretreated O +
with O +
100 O +
μM O +
of O +
14,15-EET O -
, O +
there O +
was O +
a O +
nearly O +
12-fold O +
increase O +
in O +
intracellular O +
level O +
of O +
cAMP O -
, O +
from O +
2.67 O +
pmol O -
/ O -
106 O -
cells O +
( O -
without O +
14,15-EET O -
) O +
to O +
32.42 O +
pmol O -
/ O -
106 O -
cells O +
( O -
pretreated O +
with O +
100 O +
μM O +
of O +
14,15-EET O -
) O -
. O -

However O -
, O +
under O +
similar O +
conditions O -
, O +
14,15-EET O +
had O +
no O +
effect O +
on O +
the O +
levels O +
of O +
cGMP O +
in O +
GPM U-Species +
cells O +
in O +
the O +
presence O +
of O +
IBMX O -
. O -

4 O +
Discussion O +
14,15-epoxyeicosatrienoic O +
acid O +
( O -
14,15-EET O -
) O +
was O +
originally O +
found O +
to O +
produce O +
by O +
platelets O +
and O +
subsequently O +
by O +
endothelial O +
cells O +
[ O -
3,4 O -
] O +
. O -

Our O +
earlier O +
data O +
showed O +
that O +
a O +
profound O +
increase O +
in O +
EET O +
( O -
especially O +
14,15-EET O -
) O +
generation O +
in O +
endothelial O +
cells O +
( O -
EC O -
) O +
after O +
exposure O +
to O +
240 O +
mg O -
/ O -
dl O +
low O -
- O -
density O +
lipoprotein O +
( O -
LDL O -
) O -
-cholesterol O -
. O -

Subsequent O +
data O +
showed O +
that O +
14,15-EET O +
induced O +
an O +
8-fold O +
increase O +
of O +
U-937 U-Species +
cell O +
adhesion O +
to O +
cultured O +
human U-Species +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVEC U-Species -
) O +
as O +
compared O +
with O +
non O -
- O -
treated O +
control O +
[ O -
13 O -
] O +
. O -

These O +
results O +
support O +
the O +
notion O +
that O +
14,15-EET O +
may O +
mediate O +
the O +
atherogenic O +
LDL O +
induced O +
enhancement O +
of O +
U-937 U-Species +
cells O -
' O +
adhesion O +
on O +
HUVEC U-Species +
[ O -
20 O -
] O +
. O -

Because O +
endothelial O +
cells O +
derived O +
from O +
human U-Species +
umbilical O +
veins O +
( O -
HUVE U-Species -
) O +
do O +
not O +
possess O +
any O +
specific O +
binding O +
for O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
that O +
suggested O +
a O +
lack O +
of O +
14,15-EET O +
receptors O +
in O +
endothelium O +
[ O -
21,22 O -
] O +
, O +
the O +
enhancement O +
of O +
monocyte O +
adhesion O +
by O +
14,15-EET O +
may O +
act O +
through O +
a O +
receptor O +
and O +
the O +
activation O +
of O +
a O +
signal O +
transduction O +
mechanism O +
in O +
monocytes O -
. O -

In O +
this O +
report O -
, O +
we O +
have O +
identified O +
and O +
characterized O +
a O +
population O +
of O +
specific O +
high O +
affinity O +
binding O +
sites O +
for O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
in O +
GPM U-Species +
cells O +
and O +
found O +
the O +
ligand O +
binding O +
is O +
high O +
affinity O +
with O +
a O +
K O +
d O -
of O +
35.06 O +
± O +
1.73 O +
nM O +
and O +
B O +
max O -
of O +
2.36 O +
± O +
0.32 O +
pmol O -
/ O -
106 O -
cells O -
. O -

The O +
calculated O +
number O +
of O +
binding O +
sites O +
per O +
cell O +
was O +
1.42 O +
± O +
0.19 O +
× O +
106 O -
sites O -
/ O -
cell O -
. O -

This O +
binding O +
site O +
is O +
stereospecific O +
for O +
14 O -
( O -
R O +
) O -
, O +
15 O -
( O -
S O +
) O -
-EET O +
and O +
has O +
less O +
affinity O +
toward O +
other O +
EETs O +
and O +
11 O -
( O -
R O +
) O -
, O +
12 O -
( O -
S O +
) O -
-EET O +
( O -
Fig. O +
4 O -
) O +
. O -

The O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
-14,15-EET O +
to O +
GPM U-Species +
cells O +
is O +
reversible O +
( O -
Fig. O +
2 O -
) O -
and O +
protease O +
sensitive O +
which O +
showed O +
that O +
this O +
binding O +
site O +
is O +
associated O +
with O +
a O +
protein O +
species O +
( O -
Fig. O +
5 O -
) O +
. O -

The O +
rapid O +
time O +
course O +
of O +
radioligand O +
binding O +
in O +
the O +
cold O +
temperature O +
and O +
the O +
reversibility O +
suggested O +
that O +
the O +
binding O +
be O +
not O +
likely O +
due O +
to O +
the O +
esterification O +
of O +
14,15-EET O +
into O +
the O +
membrane O +
phospholipids O -
. O -

14,15-EET O +
binding O +
in O +
GPM U-Species +
cells O +
is O +
attenuated O +
by O +
cholera O +
toxin O +
or O +
pertussis O +
toxin O +
without O +
changing O +
the O +
dissociation O +
constant O +
( O -
K O +
d O +
) O -
. O -

Because O +
both O +
cholera O +
toxin O +
and O +
pertussis O +
toxin O +
activate O +
adenyl O +
cyclase O +
and O +
report O +
to O +
increase O +
intracellular O +
cAMP O +
[ O -
23 O -
] O +
, O +
we O +
found O +
that O +
addition O +
of O +
dibutyryl O +
cAMP O +
( O -
DBcAMP O -
) O +
can O +
reduce O +
the O +
binding O +
of O +
[ O -
3 O +
H O -
] O -
- O +
14,15-EET O +
on O +
GPM U-Species +
cells O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
by O +
reducing O +
the O +
cell O +
surface O +
receptor O +
density O +
( O -
B O +
max O +
) O +
without O +
changing O +
the O +
dissociation O +
constant O +
( O -
K O +
d O +
) O +
( O -
Fig. O +
7A O +
and O +
B O -
) O +
. O -

However O +
pertussis O +
toxin O +
was O +
less O +
effective O +
as O +
compared O +
with O +
cholera O +
toxin O +
probably O +
due O +
to O +
the O +
fact O +
it O +
is O +
less O +
effective O +
in O +
increasing O +
intracellular O +
cAMP O +
level O +
in O +
GPM U-Species +
cells O -
. O -

These O +
results O +
suggest O +
that O +
the O +
reagents O +
that O +
elevated O +
intracellular O +
cAMP O +
levels O +
in O +
GPM U-Species +
cells O +
down O +
regulate O +
14,15-EET O +
binding O +
and O +
the O +
binding O +
sites O +
are O +
likely O +
associated O +
with O +
a O +
functional O +
receptor O -
. O -

The O +
fact O +
that O +
the O +
down O +
regulation O +
of O +
14,15-EET O +
receptor O +
binding O +
induced O +
by O +
cAMP O +
can O +
be O +
reversed O +
by O +
a O +
PKA O +
inhibitor O -
, O +
H-89 O -
, O +
further O +
suggest O +
these O +
processes O +
may O +
be O +
mediated O +
through O +
the O +
activation O +
of O +
PKA O +
linked O +
signal O +
transduction O +
pathway O -
. O -

The O +
high O +
concentration O +
( O -
μM O +
range O -
) O +
of O +
14,15-EET O +
required O +
to O +
increase O +
the O +
level O +
of O +
cAMP O +
possibly O +
due O +
to O +
phosphodiesterase O +
in O +
GPM U-Species +
cells O +
being O +
active O +
that O +
cAMP O +
could O +
not O +
accumulate O +
even O +
in O +
the O +
presence O +
of O +
IBMX O -
. O -

Another O +
possibility O +
is O +
due O +
to O +
GPM U-Species +
cells O +
that O +
might O +
have O +
different O +
types O +
of O +
phosphodiesterase O +
that O +
IBMX O +
can O -
not O +
effectively O +
inhibit O -
. O -

Although O +
it O +
seems O +
clear O +
that O +
14,15-EET O +
transduction O +
system O +
involves O +
cAMP O +
mediation O +
and O +
a O +
PKA O -
- O -
dependent O +
mechanism O -
, O +
the O +
precise O +
details O +
of O +
the O +
process O -
, O +
i.e. O +
whether O +
down O +
regulation O +
is O +
secondary O +
to O +
phosphorylation O +
of O +
receptor O +
protein O +
or O +
by O +
internalization O +
require O +
further O +
investigation O -
. O +

Salvia U-Species -
is O +
an O +
important O +
genus O +
consisting O +
of O +
ca O +
900 O +
species O +
in O +
the O +
family O +
Lamiaceae O +
( O -
formerly O +
Labiatae O -
) O +
and O +
some O +
species O +
of O +
Salvia U-Species -
have O +
been O +
cultivated O +
worldwide O +
for O +
use O +
in O +
folk O +
medicines O +
and O +
for O +
culinary O +
purposes O -
. O -

The O +
dried O +
root O +
of O +
Salvia B-Species +
miltiorrhiza L-Species -
( O -
Chinese O +
Danshen O -
) O -
, O +
for O +
example O -
, O +
has O +
been O +
used O +
extensively O +
for O +
the O +
treatment O +
of O +
coronary O +
heart O +
disease O -
, O +
cerebrovascular O +
disease O -
, O +
hepatitis O -
, O +
hepatocirrhosis O -
, O +
chronic O +
renal O +
failure O -
, O +
dysmenorrhea O +
and O +
neuroasthenic O +
insomnia O +
( O -
Li O -
, O +
1998 O +
) O -
. O -

Studies O +
on O +
the O +
chemical O +
constituents O +
of O +
Salvia U-Species -
have O +
been O +
mainly O +
confined O +
to O +
the O +
diterpenoids O +
and O +
the O +
tanshinones O +
( O -
Chang O +
et O +
al. O -
, O +
1990 O -
; O +
Zhang O +
et O +
al. O -
, O +
1990 O +
) O +
and O +
several O +
reviews O +
on O +
these O +
components O +
have O +
now O +
been O +
published O +
( O -
Prokopenko O +
and O +
Litvinenko O -
, O +
1980 O -
; O +
Kong O -
, O +
1989 O -
; O +
Tang O +
and O +
Eisenbrand O -
, O +
1992 O -
; O +
Al O -
- O -
Hazimi O +
and O +
Miana O -
, O +
1994 O -
; O +
Rodriguez O -
- O -
Hahn O +
et O +
al. O -
, O +
1995 O -
; O +
Ulubelen O +
and O +
Topcu O -
, O +
1998 O +
) O -
. O -

However O -
, O +
in O +
recent O +
years O +
much O +
attention O +
has O +
been O +
directed O +
to O +
the O +
biologically O +
active O -
, O +
water O -
- O -
soluble O +
components O +
in O +
the O +
dried O +
root O +
decoction O +
used O +
in O +
traditional O +
medicine O +
( O -
Zhang O +
and O +
Liu O -
, O +
1996 O +
) O -
. O -

These O +
studies O -
, O +
particularly O +
in O +
China O -
, O +
have O +
led O +
to O +
the O +
isolation O +
and O +
identification O +
of O +
a O +
host O +
of O +
caffeic O +
acid O +
derived O +
metabolites O +
( O -
Li O -
, O +
1998 O +
) O -
, O +
many O +
of O +
which O +
possess O +
a O +
variety O +
of O +
biological O +
activities O +
including O +
antioxidant O -
, O +
antiplatelet O -
, O +
antitumor O +
and O +
antiviral O +
activity O +
( O -
see O +
Table O +
1 O -
) O -
. O -

This O +
review O +
is O +
written O +
to O +
take O +
into O +
account O +
of O +
the O +
rapid O +
development O +
in O +
the O +
phytochemistry O +
and O +
therapeutical O +
applications O +
of O +
species O +
of O +
Salvia U-Species +
. O -

2 O +
Phenolic O +
acids O +
The O +
polar O +
phenolic O +
acids O +
constitute O +
the O +
major O +
part O +
of O +
the O +
water O -
- O -
soluble O +
components O +
of O +
the O +
Salvia U-Species -
decoction O -
. O -

Most O +
of O +
the O +
phenolic O +
acids O +
identified O +
so O +
far O +
are O +
those O +
from O +
the O +
Chinese O +
Danshen O -
, O +
S. B-Species +
miltiorrhiza L-Species +
, O +
S. B-Species +
chinensis L-Species -
and O +
S. B-Species +
yunnanensis L-Species -
and O +
the O +
compounds O +
unique O +
to O +
Salvia U-Species -
are O +
consequently O +
designated O +
salvianolic O +
acids O +
A O -
– O -
K O +
or O +
yunnaneic O +
acids O +
A O -
– O -
H O +
to O +
reflect O +
their O +
origin O +
( O -
see O +
Table O +
2 O -
) O -
. O -

Apart O +
from O +
a O +
few O +
simple O +
benzoic O +
acids O +
such O +
as O +
4-hydroxybenzoic O +
acid O +
( O -
Wang O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
3,4-dihydroxybenzoic O +
acid O +
or O +
protocatechuic O +
acid O +
( O -
Wu O +
et O +
al. O -
, O +
1999a O +
) O -
, O +
3-methoxy-4-hydroxybenzoic O +
acid O +
or O +
vanillic O +
acid O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
2,4-dimethoxybenzoic O +
acid O +
( O -
Topcu O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
an O +
ether O +
linked O +
dimer O +
of O +
hexyl O +
4-hydroxybenzoate O +
or O +
di O -
( O -
4-hexyloxycarbonylphenyl O -
) O -
ether O +
( O -
Ulubelen O +
et O +
al. O -
, O +
1995 O +
) O +
and O +
two O +
coumarins O +
6,7-dihydroxycoumarin O +
( O -
esculetin O -
) O +
( O -
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O +
and O +
7-methoxycoumarin O +
( O -
herniarin O -
) O +
( O -
El O -
- O -
Missiry O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
the O +
majority O +
of O +
the O +
phenolic O +
acids O +
in O +
Salvia B-Species -
species L-Species +
are O +
exclusively O +
those O +
of O +
caffeic O +
acid O +
( O -
1 O +
) O +
derivatives O -
, O +
which O +
are O +
unique O +
to O +
Salvia U-Species -
except O +
for O +
rosmarinic O +
acid O +
( O -
2 O +
) O +
and O +
lithospermic O +
acid O +
( O -
9 O +
) O +
( O -
see O +
Fig. O +
1 O -
for O +
chemical O +
structures O -
) O -
. O -

2.1 O +
Caffeic O +
acid O +
metabolites O +
Caffeic O +
acid O +
plays O +
a O +
central O +
role O +
in O +
the O +
biochemistry O +
of O +
Lamiaceae U-Species +
and O +
occurs O +
predominantly O +
in O +
the O +
dimer O +
form O +
as O +
rosmarinic O +
acid O +
( O -
Gerhardt O +
and O +
Schroeter O -
, O +
1983 O +
) O -
. O -

In O +
the O +
Salvia B-Species -
species L-Species +
the O +
caffeic O +
acid O +
is O +
the O +
building O +
block O +
of O +
a O +
variety O +
of O +
the O +
plant O +
metabolites O +
from O +
the O +
more O +
simple O +
monomers O +
to O +
multiple O +
condensation O +
products O +
to O +
give O +
rise O +
to O +
a O +
variety O +
of O +
oligomers O -
. O -

The O +
trimers O +
and O +
tetramers O +
are O +
more O +
interesting O +
from O +
the O +
therapeutic O +
point O +
of O +
view O +
as O +
they O +
have O +
been O +
shown O +
to O +
possess O +
significant O +
biological O +
activities O -
. O -

2.1.1 O +
Caffeic O +
acid O +
monomers O +
The O +
monomers O +
that O +
are O +
frequently O +
present O +
in O +
Salvia U-Species -
are O +
represented O +
by O +
caffeic O +
acid O +
itself O +
and O +
3- O -
( O -
3,4-dihydroxyphenyl O -
) O -
lactic O +
acid O +
( O -
3 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O -
. O -

The O +
latter O +
compound O -
, O +
also O +
known O +
as O +
danshensu O +
( O -
Chinese O +
word O +
to O +
mean O +
literally O +
the O +
element O +
of O +
Danshen O -
) O +
was O +
first O +
isolated O +
from O +
S. B-Species +
miltiorrhiza L-Species -
( O -
Yang O +
and O +
Zhang O -
, O +
1981 O +
) O +
and O +
found O +
to O +
be O +
a O +
coronary O +
vasodilator O +
and O +
to O +
scavenge O +
the O +
free O +
oxygen O +
radicals O +
generated O +
during O +
ischemia O -
- O -
reperfusion O +
injury O +
in O +
the O +
myocardium O +
as O +
effectively O +
as O +
superoxide O +
dismutase O +
( O -
SOD O -
) O +
( O -
Zhao O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

The O +
amide O +
of O +
3 O +
, O +
3- O -
( O -
3,4-dihydroxyphenyl O -
) O -
lactamide O +
( O -
4 O +
) O -
, O +
also O +
found O +
in O +
S. B-Species +
miltiorrhiza L-Species +
, O +
had O +
been O +
reported O +
to O +
possess O +
radical O +
scavenging O +
activity O +
greater O +
than O +
ascorbic O +
acid O +
( O -
Kang O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

Other O +
monomeric O +
derivatives O +
including O +
ferulic O +
acid O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O -
, O +
isoferulic O +
acid O +
( O -
Ai O +
and O +
Li O -
, O +
1992 O +
) O +
and O +
two O +
caffeic O +
acid O +
esters O +
mono O -
- O -
feruloyl O -
- O -
R O +
, O -
R O +
- O -
( O -
+ O -
) O -
-tartaric O +
acid O +
( O -
6 O +
) O +
( O -
Qian O +
et O +
al. O -
, O +
1993 O +
) O +
and O +
chlorogenic O +
acid O +
( O -
5-caffeoylquinic O +
acid O -
) O +
( O -
7 O +
) O +
( O -
Kokkalou O +
and O +
Kapetanidis O -
, O +
1988 O +
) O +
have O +
also O +
been O +
described O +
as O +
Salvia U-Species -
constituents O -
. O -

The O +
identification O +
of O +
mono O -
- O -
feruloyl O -
- O -
R O +
, O -
R O +
- O -
( O -
+ O -
) O -
-tartaric O +
acid O +
has O +
been O +
corroborated O +
by O +
chemical O +
synthesis O -
, O +
along O +
with O +
its O +
two O +
S O +
, O -
S O +
- O -
( O -
- O -
) O -
- O +
and O +
R O +
, O -
S O +
- O -
( O -
meso O +
) O -
-isomers O -
. O -

Chlorogenic O +
acid O -
, O +
despite O +
being O +
common O +
and O +
widespread O +
in O +
fruits O -
, O +
is O +
surprisingly O +
uncommon O +
in O +
Lamiaceae U-Species -
, O +
which O +
is O +
generally O +
dominated O +
by O +
rosmarinic O +
acid O +
( O -
Gerhardt O +
and O +
Schroeter O -
, O +
1983 O +
) O -
. O -

Caffeic O +
acids O +
esterified O +
with O +
sugars O +
are O +
quite O +
common O +
in O +
nature O +
and O +
those O +
identified O +
in O +
Salvia U-Species -
are O +
discussed O +
under O +
Phenolic O +
Glycosides O -
( O -
see O +
below O -
) O -
. O -

2.1.2 O +
Caffeic O +
acid O +
dimers O +
Rosmarinic O +
acid O +
( O -
2 O +
) O +
is O +
the O +
most O +
abundant O +
caffeic O +
acid O +
dimer O +
in O +
Salvia B-Species -
species L-Species +
( O -
Ai O +
and O +
Li O -
, O +
1988 O -
; O +
Cuvelier O +
et O +
al. O -
, O +
1994 O -
; O +
Lu O +
and O +
Foo O -
, O +
1999 O +
) O +
and O +
has O +
been O +
reported O +
to O +
be O +
the O +
major O +
phenolic O +
compound O +
responsible O +
for O +
the O +
high O +
antioxidant O +
activity O +
of O +
Salvia U-Species -
samples O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

There O +
have O +
been O +
many O +
publications O +
on O +
rosmarinic O +
acid O +
dealing O +
with O +
its O +
detection O +
and O +
quantitative O +
estimation O +
in O +
various O +
Salvia U-Species -
preparations O +
( O -
Janicsak O +
and O +
Mathe O -
, O +
1997 O -
; O +
Yuan O +
et O +
al. O -
, O +
1998 O -
; O +
Areias O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
its O +
biochemical O +
production O +
in O +
cell O +
cultures O +
( O -
Morimoto O +
et O +
al. O -
, O +
1994 O +
) O +
or O +
chemical O +
synthesis O +
( O -
Eicher O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
its O +
metabolism O +
in O +
rats U-Species +
( O -
Nakazawa O +
and O +
Ohsawa O -
, O +
1998 O +
) O -
. O -

Other O +
types O +
of O +
dimers O +
identified O +
in O +
Salvia U-Species -
include O +
przewalskinic O +
acid O +
A O +
( O -
8 O +
) O +
from O +
the O +
Tibetan O +
sage O +
S. B-Species +
przewalskii L-Species -
( O -
Lu O +
et O +
al. O -
, O +
1991 O +
) O -
, O +
salvianolic O +
acid O +
G O +
( O -
11 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1991 O +
) O +
and O +
the O +
stilbenoid O +
salvianolic O +
acid O +
F O +
or O +
2- O -
( O -
3,4-dihydroxystyryl O -
) O -
caffeic O +
acid O +
( O -
12 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1996 O +
) O +
both O +
from O +
S. B-Species +
miltiorrhiza L-Species +
. O -

The O +
dihydrobenzofuran O +
compound O +
przewalskinic O +
acid O +
A O +
is O +
apparently O +
related O +
to O +
lithospermic O +
acid O +
( O -
9 O +
) O +
and O +
salvianolic O +
acid O +
B O +
or O +
lithospermic O +
acid O +
B O +
( O -
10 O +
) O -
, O +
whereas O +
salvianolic O +
acid O +
G O -
, O +
with O +
a O +
dibenzooxepin O +
skeleton O -
, O +
is O +
the O +
first O +
of O +
its O +
kind O +
found O +
in O +
Salvia U-Species +
. O -

Salvianolic O +
acid O +
F O -
, O +
which O +
has O +
been O +
synthesised O +
by O +
Dalla O +
and O +
Cotelle O +
( O -
1999 O -
) O +
, O +
is O +
a O +
decarboxylated O +
caffeic O +
acid O +
dimer O -
. O -

In O +
addition O -
, O +
Ulubelen O +
and O +
co O -
- O -
workers O +
( O -
1996 O -
) O -
have O +
reported O +
the O +
existence O +
of O +
two O +
isomeric O +
caffeic O +
acid O +
ester O +
dimers O +
linked O +
by O +
ether O +
bond O -
, O +
namely O +
the O +
dioctyl O +
3-O O +
-3′-di O -
- O -
cis O +
- O +
and O +
di O -
- O -
trans O +
-isoferulate O +
( O -
14 O +
, O +
15 O +
) O +
in O +
S. B-Species +
forskahlei L-Species +
. O -

2.1.3 O +
Caffeic O +
acid O +
trimers O +
Trimers O +
derived O +
from O +
caffeic O +
acid O +
constitute O +
the O +
largest O +
group O +
of O +
metabolites O +
in O +
Salvia U-Species -
. O -

They O +
include O +
compounds O +
such O +
as O +
lithospermic O +
acid O +
( O -
9 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O -
, O +
salvianolic O +
acids O +
H O +
( O -
16 O +
) O +
( O -
Zhang O +
and O +
Li O -
, O +
1993 O +
) O -
, O +
I O +
( O -
17 O +
) O +
( O -
Zhang O +
and O +
Li O -
, O +
1994 O +
) O -
, O +
J O +
( O -
18 O +
) O +
( O -
Ai O +
et O +
al. O -
, O +
1994 O +
) O +
and O +
K O +
( O -
19 O +
) O +
( O -
Tezuka O +
et O +
al. O -
, O +
1998 O -
; O +
Lu O +
and O +
Foo O -
, O +
1999 O +
) O -
, O +
sagecoumarin O +
( O -
20 O +
) O +
( O -
Lu O +
et O +
al. O -
, O +
1999 O +
) O -
, O +
three O +
decarboxylated O +
forms O +
of O +
salvianolic O +
acids O +
A O +
( O -
13 O +
) O +
( O -
Li O +
et O +
al. O -
, O +
1984 O +
) O -
, O +
C O +
( O -
21 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O +
) O +
and O +
isosalvianolic O +
acid O +
C O +
( O -
22 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O +
as O +
well O +
as O +
yunnaneic O +
acids O +
C O +
( O -
24 O +
) O -
, O +
D O +
( O -
25 O +
) O -
, O +
E O +
( O -
26 O +
) O +
and O +
F O +
( O -
27 O +
) O +
( O -
Tanaka O +
et O +
al. O -
, O +
1996 O -
; O +
1997 O +
) O -
. O -

These O +
last O +
mentioned O +
are O +
apparent O +
Diels O -
– O -
Alder O +
adducts O +
of O +
caffeic O +
acids O -
. O -

Lithospermic O +
acid O +
and O +
both O +
its O +
mono O -
- O -
and O +
dimethyl O +
esters O +
were O +
the O +
active O +
components O +
that O +
inhibited O +
adenylate O +
cyclase O +
( O -
Kohda O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

In O +
addition O -
, O +
dimethyl O +
lithospermate O +
was O +
also O +
shown O +
to O +
be O +
a O +
stronger O +
radical O +
scavenger O +
than O +
ascorbic O +
acid O +
( O -
Kang O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

The O +
new O +
member O +
of O +
the O +
salvianolic O +
acid O +
series O +
is O +
salvianolic O +
acid O +
K O +
and O +
its O +
presence O +
has O +
been O +
detected O +
by O +
LC O -
– O -
MS O +
in O +
10 O +
Salvia B-Species -
species L-Species +
( O -
Kasimu O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

Salvianolic O +
acid O +
A O -
, O +
the O +
stilbenoid O +
caffeic O +
acid O +
trimer O +
has O +
been O +
shown O +
to O +
possess O +
a O +
strong O +
oxygen O +
free O +
radical O +
scavenging O +
activity O +
( O -
Huang O +
and O +
Zhang O -
, O +
1992 O -
; O +
Li O +
et O +
al. O -
, O +
1995 O +
) O +
which O +
may O +
be O +
the O +
basis O +
for O +
some O +
of O +
its O +
biological O +
activities O +
( O -
see O +
Table O +
1 O +
) O -
. O -

Salvianolic O +
acid O +
A O +
is O +
apparently O +
not O +
very O +
stable O +
and O +
its O +
reactivity O +
has O +
been O +
demonstrated O +
by O +
its O +
conversion O +
to O +
salvianolic O +
acid O +
C O +
on O +
a O +
TLC O +
plate O +
that O +
was O +
impregnated O +
with O +
2 O -
% O +
of O +
formic O +
acid O +
solution O -
. O -

This O +
suggested O +
that O +
salvianolic O +
acid O +
C O -
, O +
a O +
benzofuran O +
compound O -
, O +
was O +
likely O +
a O +
cyclization O +
product O +
of O +
salvianolic O +
acid O +
A O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O +
) O -
. O -

Isosalvianolic O +
acid O +
C O -
, O +
a O +
second O +
depside O +
to O +
salvianolic O +
acid O +
G O +
with O +
a O +
dibenzooxepin O +
skeleton O -
, O +
has O +
been O +
identified O +
only O +
in O +
S. B-Species +
chinensis L-Species -
along O +
with O +
salvianolic O +
acid O +
D O +
( O -
23 O +
) O +
( O -
Qian O +
and O +
Li O -
, O +
1992 O +
) O -
, O +
the O +
latter O +
could O +
be O +
considered O +
as O +
an O +
abridged O +
caffeic O +
acid O +
trimer O +
that O +
was O +
first O +
found O +
in O +
S. B-Species +
miltiorrhiza L-Species -
( O -
Ai O +
and O +
Li O -
, O +
1992 O +
) O -
. O -

Yunnaneic O +
acids O +
C O +
and O +
D O +
both O +
of O +
which O +
contain O +
the O +
bicyclo O -
[ O -
2.2.2 O -
] O -
octane O +
core O +
structure O +
appear O +
to O +
be O +
the O +
Diels O -
– O -
Alder O +
adducts O +
involving O +
the O +
double O +
bond O +
of O +
the O +
caffeic O +
acid O +
and O +
the O +
phenol O +
ring O +
or O +
its O +
quinone O +
form O +
in O +
a O +
rosmarinic O +
acid O +
moiety O -
. O -

Further O +
oxidation O +
of O +
yunnaneic O +
acid O +
C O +
resulted O +
in O +
the O +
formation O +
of O +
yunnaneic O +
acid O +
E O +
while O +
the O +
addition O +
of O +
an O +
acetyl O +
group O +
to O +
the O +
bicyclo O -
[ O -
2.2.2 O -
] O -
octa-1,2-dione O +
skeleton O +
in O +
yunnaneic O +
acid O +
C O +
led O +
to O +
yunnaneic O +
acid O +
F. O -
2.1.4 O +
Caffeic O +
acid O +
tetramers O +
Caffeic O +
acid O +
tetramers O +
are O +
in O +
effect O +
dimerised O +
rosmarinic O +
acids O +
as O +
in O +
salvianolic O +
acids O +
B O +
( O -
10 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1988 O +
) O -
, O +
E O +
( O -
28 O +
) O +
( O -
Ai O +
and O +
Li O -
, O +
1992 O +
) O +
and O +
L O +
( O -
32 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
2001b O +
) O -
, O +
rabdosiin O +
( O -
29 O +
) O -
, O +
yunnaneic O +
acids O +
G O +
( O -
30 O +
) O +
and O +
H O +
( O -
31 O +
) O +
( O -
Tanaka O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
and O +
sagerinic O +
acid O +
( O -
33 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
1999 O +
) O -
. O -

Distribution O +
of O +
salvianolic O +
acid O +
E O +
is O +
more O +
restricted O +
and O +
has O +
been O +
reported O +
only O +
in O +
S. B-Species +
miltiorrhiza L-Species -
while O +
salvianolic O +
acid O +
B O -
, O +
which O +
is O +
also O +
known O +
as O +
lithospermic O +
acid O +
B O -
, O +
is O +
more O +
common O +
in O +
Salvia B-Species -
species L-Species +
and O +
occurs O +
mainly O +
as O +
potassium O -
, O +
ammonium O +
or O +
magnesium O +
salts O -
. O -

These O +
salts O +
constitute O +
largely O +
the O +
most O +
important O +
bioactive O +
Salvia U-Species -
components O +
in O +
sage U-Species +
( O -
see O +
Table O +
1 O +
) O -
. O -

Three O +
methyl O +
esters O +
of O +
lithospermic O +
acid O +
B O -
, O +
namely O +
the O +
9′- O +
and O +
9‴-monomethyl O +
lithospermate O +
B O +
and O +
dimethyl O +
lithospermate O +
B O -
, O +
have O +
been O +
found O +
recently O +
in O +
Tibetan B-Species +
sage L-Species +
together O +
with O +
other O +
known O +
polyphenolic O +
compounds O +
( O -
Wu O +
et O +
al. O -
, O +
1999b O +
) O -
. O -

In O +
addition O +
to O +
the O +
yunnaneic O +
acids O +
C O +
to O +
F O +
mentioned O +
above O -
, O +
Tanaka O +
et O +
al. O +
( O -
1997 O -
) O -
have O +
also O +
identified O +
three O +
oxidatively O +
cyclized O +
rosmarinic O +
acid O +
dimers O +
with O +
a O +
1,2-dihydronaphthalene O +
core O +
comprising O +
of O +
rabdosiin O -
, O +
yunnaneic O +
acids O +
G O +
and O +
H O +
in O +
S. B-Species +
yunnanesis L-Species -
. O -

Most O +
recently O -
, O +
salvianolic O +
acid O +
L O -
, O +
an O +
isomer O +
of O +
rabdosiin O +
or O +
yunnaneic O +
acid O +
G O -
, O +
has O +
been O +
found O +
in O +
S. B-Species +
officinalis L-Species +
. O -

In O +
addition O -
, O +
a O +
more O +
structurally O +
interesting O +
new O +
type O +
of O +
[ O -
2 O -
+ O -
2 O -
] O -
-rosmarinic O +
acid O +
dimer O +
is O +
sagerinic O +
acid O +
reported O +
in O +
S. B-Species +
officinalis L-Species +
, O +
which O +
contained O +
a O +
cyclobutane O +
ring O +
in O +
the O +
μ O -
- O -
truxinate O +
form O -
. O -

Sagerinic O +
acid O +
is O +
the O +
first O +
example O +
of O +
a O +
natural O +
[ O -
2 O -
+ O -
2 O -
] O -
-dimers O +
of O +
caffeic O +
acid O +
esters O -
. O -

2.1.5 O +
Higher O +
caffeic O +
acid O +
oligomers O +
Yunnaneic O +
acids O +
A O +
( O -
34 O +
) O +
and O +
B O +
( O -
35 O +
) O +
found O +
in O +
S. B-Species +
yunnanesis L-Species -
( O -
Tanaka O +
et O +
al. O -
, O +
1996 O +
) O +
are O +
the O +
only O +
known O +
hexamers O +
of O +
caffeic O +
acid O -
. O -

These O +
two O +
compounds O +
could O +
be O +
formed O +
by O +
spiroacetal O +
bonding O +
between O +
yunnaneic O +
acid O +
C O +
( O -
24 O +
) O +
and O +
yunnaneic O +
acid O +
D O +
( O -
25 O +
) O +
or O +
between O +
two O +
molecules O +
of O +
24 O +
. O -

The O +
presence O +
of O +
these O +
Diels O -
– O -
Alder O +
type O +
adducts O +
in O +
S. B-Species +
yunnanesis L-Species -
indicates O +
the O +
complexity O +
in O +
the O +
biochemistry O +
of O +
plant O +
metabolism O -
. O -

2.2 O +
Phenolic O +
glycosides O +
The O +
phenolic O +
glycosides O +
are O +
apparently O +
not O +
very O +
common O +
in O +
Salvia U-Species -
and O +
rosmarinic O +
acid O +
3′-glucoside1 O -
1 O +
Unless O +
otherwise O +
mentioned O -
, O +
common O +
sugars O +
glucose O -
, O +
galactose O -
, O +
xylose O -
, O +
arabinose O -
, O +
rhamnose O -
, O +
fructose O +
and O +
apiose O +
denote O +
β O -
- O -
d O +
-glucopyranose O -
, O +
β O -
- O -
d O +
-galactopyranose O -
, O +
β O -
- O -
d O +
-xylopyranose O -
, O +
α O -
- O -
l O +
-arabiopyranose O -
, O +
α O -
- O -
l O +
-rhamnopyranose O -
, O +
β O -
- O -
d O +
-fructofuranose O +
and O +
β O -
- O -
d O +
-apiofuranose O -
, O +
respectively O -
. O -

( O -
salviaflaside O -
) O +
( O -
36 O +
) O +
and O +
its O +
methyl O +
ester O +
( O -
Zhao O +
et O +
al. O -
, O +
1996a O +
) O +
as O +
well O +
as O +
the O +
cis O -
and O +
trans O +
-p O +
-coumaric O +
acid O +
4-O O +
- O -
( O -
2-O O +
-apiosyl O -
) O -
glucosides O +
( O -
37 O +
, O +
38 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
2000 O +
) O +
are O +
the O +
only O +
examples O +
of O +
the O +
glycosylated O +
phenolic O +
acids O -
. O -

In O +
contrast O +
the O +
phenolic O +
acids O +
esterified O +
with O +
sugars O -
, O +
in O +
which O +
the O +
phenolic O +
acids O +
serve O +
as O +
acylating O +
agents O +
to O +
give O +
rise O +
to O +
acylated O +
sugars O -
, O +
are O +
more O +
common O -
. O -

These O +
acylated O +
sugars O +
include O +
6-O O +
-feruloyl O -
- O -
α- O +
and O +
β O -
- O -
glucose O +
( O -
39 O +
, O +
40 O +
) O +
( O -
Wang O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
1-O O +
- O -
( O -
2,3,4-trihydroxy-3-methyl O -
) O -
butyl-6-O O +
-feruloylglucoside O +
( O -
41 O +
) O +
( O -
Wang O +
et O +
al. O -
, O +
2000 O +
) O -
, O +
6-O O +
-caffeoyl-1-O O +
-fructosyl O -
- O -
α O -
- O -
glucoside O +
( O -
42 O +
) O -
, O +
1-O O +
-caffeoyl-6-O O +
-apiosylglucoside O +
( O -
43 O +
) O -
, O +
1-O O +
-p O +
-hydroxybenzoyl-6-O O +
-apiosylglucoside O +
( O -
44 O +
) O -
, O +
all O +
from O +
S. B-Species +
officinalis L-Species -
( O -
Wang O +
et O +
al. O -
, O +
1999 O +
) O -
, O +
and O +
prionitisides O +
A O +
( O -
45 O +
) O +
and O +
B O +
( O -
46 O +
) O +
from O +
S. B-Species +
prionitis L-Species +
. O -

The O +
structures O +
of O +
prionitisides O +
A O +
and O +
B O +
were O +
elucidated O +
as O +
2- O -
( O -
3,4-dihydroxyphenyl O -
) O -
-3-glucosyloxycarbonyl-4,6-dihydroxybenzofuran O +
and O +
2- O -
( O -
3,4-dihydroxyphenyl O -
) O -
-3-rutinosyloxy O +
carbonyl-4,6-dihydroxybenzofuran O -
, O +
respectively O +
( O -
Zhao O +
et O +
al. O -
, O +
1996b O +
) O -
. O -

Several O +
phenolic O +
acetophenone O +
glycosides O +
have O +
been O +
also O +
identified O +
in O +
S. B-Species +
officinalis L-Species -
and O +
these O +
include O +
4-hydroxyacetophenone O +
4-O O +
-glucoside O +
( O -
picein O -
) O +
( O -
47 O +
) O -
, O +
4-hydroxyacetophenone O +
4-O O +
- O -
( O -
6-O O +
-apiosyl O -
) O -
glucoside O +
( O -
48 O +
) O -
, O +
4-hydroxyacetophenone O +
4-O O +
- O -
( O -
2-O O +
- O -
( O -
5-O O +
-syringoylapiosyl O -
) O -
glucoside O -
) O +
( O -
49 O +
) O +
( O -
Wang O +
et O +
al. O -
, O +
2000 O +
) O -
. O -

Also O +
present O +
in O +
S. B-Species +
officinalis L-Species -
are O +
glycosides O +
of O +
neolignans O +
namely O +
1-hydroxypinoresinol O +
1-O O +
-glucoside O +
( O -
50 O +
) O -
, O +
isolariciresinol O +
3α O -
- O -
O O +
-glucoside O +
( O -
51 O +
) O +
and O +
2- O -
( O -
3-methoxy-4-glucosyloxyphenyl O -
) O -
-3-hydroxymethyl-5- O -
( O -
3-hydroxypropyl O -
) O -
-7-methoxy-2,3-dihydrobenzofuran O +
( O -
52 O -
) O +
( O -
Wang O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

In O +
addition O -
, O +
two O +
related O +
isolariciresinol O +
compounds O +
feruloyl O -
- O -
secoisolariciresinol O +
12-methylmyristate O +
( O -
53 O +
) O +
( O -
Powell O +
and O +
Plattner O -
, O +
1976 O +
) O +
and O +
secoisolariciresinol O +
di O -
( O -
12-methylmyristate O -
) O +
( O -
54 O +
) O +
( O -
Plattner O +
and O +
Powell O -
, O +
1978 O +
) O +
and O +
a O +
structurally O +
related O +
compound O +
to O +
52 O -
2- O -
( O -
3-methoxy-4-hydroxyphenyl O -
) O -
-5- O -
( O -
3-hydroxypropyl O -
) O -
-7-methoxybenzofuran-3-carbaldehyde O +
( O -
55 O +
) O +
( O -
Yang O +
et O +
al. O -
, O +
1991 O +
) O +
have O +
been O +
reported O +
in O +
the O +
seed O +
of O +
S. B-Species +
plebeia L-Species -
and O +
in O +
the O +
root O +
of O +
S. B-Species +
miltiorrhiza L-Species -
, O -
respectively O -
. O -

Compound O +
55 O -
has O +
also O +
been O +
produced O +
synthetically O +
( O -
Kuo O +
and O +
Wu O -
, O +
1996 O +
) O +
and O +
shown O +
to O +
be O +
a O +
novel O +
adenosine O +
A1 O +
receptor O +
ligand O -
. O -

3 O +
Flavonoids O +
Flavonoids O +
are O +
widely O +
distributed O +
in O +
species O +
of O +
Salvia U-Species -
( O -
Sagdullaeva O +
and O +
Khazanovich O -
, O +
1972 O -
; O +
Smirnova O +
et O +
al. O -
, O +
1974b O -
; O +
Adzet O +
et O +
al. O -
, O +
1987 O -
; O +
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O -
, O +
being O +
mostly O +
present O +
as O +
flavones O -
, O +
flavonols O +
and O +
their O +
glycosides O +
( O -
see O +
Tables O +
3 O +
and O +
4 O -
) O -
. O -

The O +
6-hydroxylated O +
flavones O +
have O +
been O +
reported O +
to O +
be O +
of O +
particularly O +
taxonomic O +
significance O +
to O +
this O +
genus O +
( O -
Tomas O -
- O -
Barberan O +
and O +
Wollenweber O -
, O +
1990 O +
) O -
. O -

3.1 O +
Flavone O +
and O +
flavonol O +
aglycones O +
The O +
majority O +
of O +
flavonoids O +
are O +
flavones O +
of O +
apigenin O +
( O -
5,7,4′-trihydroxyflavone O -
) O +
( O -
56 O +
) O +
and O +
luteolin O +
( O -
5,7,3′,4′-tetrahydroxyflavone O -
) O +
( O -
60 O +
) O +
and O +
their O +
corresponding O +
6-hydroxylated O +
derivatives O -
. O -

The O +
methyl O +
ethers O +
of O +
flavones O +
are O +
widely O +
distributed O +
in O +
the O +
leaves O +
of O +
Salvia U-Species -
or O +
in O +
the O +
exudate O +
from O +
aerial O +
parts O +
( O -
Wollenweber O -
, O +
1974 O -
; O +
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O -

The O +
etherification O +
of O +
apigenin O +
seemed O +
to O +
occur O +
preferably O +
on O +
the O +
phenolic O +
7-OH O +
while O +
the O +
catechol O +
B O -
- O -
ring O +
of O +
luteolin O +
is O +
etherified O +
before O +
the O +
A O -
- O -
ring O -
. O -

Thus O +
apigenin O +
7-methyl O +
ether O +
( O -
genkwanin O -
) O +
( O -
57 O +
) O +
and O +
7,4′-dimethyl O +
ether O +
( O -
59 O +
) O +
are O +
common O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O +
while O +
the O +
4′-methyl O +
ether O +
( O -
acacetin O -
) O +
( O -
58 O +
) O +
has O +
been O +
found O +
only O +
in O +
S. B-Species +
nicolsoniana L-Species -
( O -
Pereda O -
- O -
Miranda O +
and O +
Delgado O -
, O +
1986 O +
) O +
and O +
S. B-Species +
yosgadensis L-Species -
( O -
Topcu O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

Likewise O -
, O +
luteolin O +
3′-methyl O +
ether O +
( O -
chrysoeriol O -
) O +
( O -
62 O +
) O +
and O +
4′-methyl O +
ether O +
( O -
diosmetin O -
) O +
( O -
63 O +
) O +
are O +
more O +
frequently O +
encountered O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O -
; O +
Topcu O +
et O +
al. O -
, O +
1995 O +
) O -
, O +
followed O +
by O +
7-methyl O +
ether O +
( O -
61 O +
) O +
and O +
7,3′,4′-trimethyl O +
ether O +
( O -
66 O +
) O +
( O -
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O -
. O -

Luteolin O +
7,4′-dimethyl O +
ether O +
( O -
64 O +
) O +
( O -
Miski O +
et O +
al. O -
, O +
1983 O +
) O +
and O +
3′,4′-dimethyl O +
ether O +
( O -
65 O +
) O +
( O -
Pereda O -
- O -
Miranda O +
and O +
Delgado O -
, O +
1986 O +
) O +
have O +
only O +
been O +
reported O +
once O +
before O +
in O +
S. B-Species +
palaestina L-Species -
and O +
S. B-Species +
nicolsoniana L-Species +
, O +
respectively O -
. O -

The O +
6-hydroxyflavones O +
are O +
the O +
flavonoids O +
that O +
characterise O +
species O +
of O +
Salvia U-Species +
. O -

They O +
include O +
a O +
variety O +
of O +
6-hydroxylated O +
apigenin O +
and O +
luteolin O +
derivatives O -
, O +
with O +
6-hydroxyapigenin-6,7-dimethyl O +
ether O +
( O -
cirsimaritin O -
) O +
( O -
69 O +
) O -
, O +
6,7,4′-trimethyl O +
ether O +
( O -
salvigenin O -
) O +
( O -
72 O +
) O -
, O +
and O +
6-hydroxyluteolin O +
6-methyl O +
ether O +
( O -
nepetin O +
or O +
eupafolin O -
) O +
( O -
75 O +
) O -
, O +
6,7-dimethyl O +
ether O +
( O -
cirsiliol O -
) O +
( O -
77 O +
) O -
, O +
6,7,4′-trimethyl O +
ether O +
( O -
eupatorin O -
) O +
( O -
81 O +
) O +
and O +
6,7,3′,4′-tetramethyl O +
ether O +
( O -
83 O +
) O +
being O +
the O +
most O +
common O +
( O -
Tomas O -
- O -
Lorente O +
et O +
al. O -
, O +
1988 O -
; O +
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O -

6-Hydroxyapigenin O +
( O -
scutellarein O -
) O +
itself O +
( O -
67 O +
) O +
was O +
only O +
detected O +
in O +
sage U-Species +
extracts O +
by O +
HPLC O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
other O +
6-hydroxyapigenin O +
methyl O +
ethers O +
including O +
6-methyl O +
ether O +
( O -
hispidulin O -
) O +
( O -
68 O +
) O -
, O +
6,4′-dimethyl O +
ether O +
( O -
pectolinarigenin O -
) O +
( O -
70 O +
) O -
, O +
7,4′-dimethyl O +
ether O +
( O -
71 O +
) O +
and O +
5,6,7,4′-tetramethyl O +
ether O +
( O -
5-methoxysalvigenin O -
) O +
( O -
73 O +
) O +
were O +
reported O +
only O +
occasionally O -
, O +
as O +
were O +
the O +
6-hydroxyluteolin O +
7-methyl O +
ether O +
( O -
pedalitin O -
) O +
( O -
76 O +
) O -
, O +
6,3′-dimethyl O +
ether O +
( O -
jaceosidin O -
) O +
( O -
78 O +
) O -
, O +
7,4′-dimethyl O +
ether O +
( O -
nuchensin O -
) O +
( O -
79 O +
) O -
, O +
6,7,3′-trimethyl O +
ether O +
( O -
cirsilineol O -
) O +
( O -
80 O +
) O +
and O +
6,3′,4′-trimethyl O +
ether O +
( O -
eupatilin O -
) O +
( O -
82 O +
) O -
. O -

Cirsimaritin O +
was O +
reported O +
to O +
have O +
a O +
high O +
anti O -
- O -
microbial O +
activity O +
against O +
several O +
bacteria O +
strains O +
( O -
Miski O +
et O +
al. O -
, O +
1983 O +
) O +
while O +
hispidulin O +
possessed O +
antihepatotoxic O +
activity O +
( O -
Oshima O +
et O +
al. O -
, O +
1984 O +
) O -
. O -

In O +
a O +
more O +
recent O +
report O +
( O -
Viola O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
the O +
sedative O -
- O -
depressant O +
property O +
for O +
cirsiliol O +
was O +
described O -
. O -

An O +
unusual O +
flavone O +
which O +
lacks O +
the O +
5-OH O +
group O -
, O +
namely O +
6,7,3′,4′-tetramethoxyflavone O +
( O -
74 O +
) O -
, O +
was O +
described O +
by O +
Miski O +
et O +
al. O +
( O -
1983 O -
) O +
. O -

The O +
8-hydroxylated O +
flavones O +
are O +
rare O +
in O +
Salvia U-Species +
, O +
with O +
8-hydroxyapigenin O +
7-methyl O +
ether O +
( O -
salvitin O -
) O +
( O -
85 O +
) O +
being O +
the O +
only O +
representative O +
found O +
in O +
S. B-Species +
plebeia L-Species -
( O -
Gupta O +
et O +
al. O -
, O +
1975 O +
) O +
while O +
8-hydroxyapigenin O +
( O -
isoscutellarein O -
) O +
( O -
84 O +
) O +
itself O +
was O +
detected O +
by O +
HPLC O +
in O +
sage U-Species +
samples O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

The O +
four O +
dihydroflavones O +
that O +
have O +
been O +
described O +
to O +
date O +
in O +
Salvia U-Species -
include O +
5-hydroxy-7-methoxyflavanone O +
( O -
86 O +
) O +
( O -
Gonzalez O +
et O +
al. O -
, O +
1989 O +
) O -
, O +
5,7-dihydroxy-4′-methoxyflavanone O +
( O -
isosakuranetin O +
or O +
narigenin-4′-methyl O +
ether O -
) O +
( O -
87 O +
) O +
( O -
Pereda O -
- O -
Miranda O +
and O +
Delgado O -
, O +
1986 O +
) O -
, O +
5,7,3′-trihydroxy-4′-methoxyflavanone O +
( O -
hesperetin O -
) O +
( O -
88 O +
) O +
( O -
Cuvelier O +
et O +
al. O -
, O +
1996 O +
) O +
and O +
5,3′-dihydroxy-7,4′-dimethoxyflavanone O +
( O -
89 O +
) O -
. O -

The O +
last O +
mentioned O +
compound O +
was O +
also O +
found O +
to O +
possess O +
coronary O +
dilator O +
activity O +
( O -
Chen O +
et O +
al. O -
, O +
1986 O +
) O -
. O -

Flavonols O +
are O +
mostly O +
those O +
of O +
kaempferol O +
( O -
5,7,4′-trihydroxyflavonol O -
) O +
and O +
quercetin O +
( O -
5,7,3′,4′-tetrahydroxyflavonol O -
) O +
methyl O +
ethers O -
. O -

Kaempferol O +
( O -
90 O +
) O +
itself O +
was O +
present O +
in O +
S. B-Species +
farinacea L-Species -
( O -
Kamel O +
et O +
al. O -
, O +
1992 O +
) O +
and O +
S. B-Species +
folium L-Species -
( O -
Tamas O +
et O +
al. O -
, O +
1986 O +
) O +
while O +
quercetin O +
was O +
only O +
reported O +
in O +
S. B-Species +
dorrii L-Species -
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O -

Kaempferol O +
3-methyl O +
ether O +
( O -
isokaempferide O -
) O +
( O -
91 O +
) O -
, O +
3,7-dimethyl O +
ether O +
( O -
kumatakenin O -
) O +
( O -
92 O +
) O +
and O +
quercetin O +
3-methyl O +
ether O +
( O -
94 O +
) O -
, O +
3′-methyl O +
ether O +
( O -
isorhamnetin O -
) O +
( O -
95 O +
) O -
, O +
3,3′-dimethyl O +
ether O +
( O -
96 O +
) O +
and O +
3,7,4′-trimethyl O +
ether O +
( O -
ayanin O -
) O +
( O -
97 O +
) O +
are O +
also O +
known O +
Salvia U-Species -
constituents O +
( O -
Topcu O +
et O +
al. O -
, O +
1996 O -
; O +
Gökdil O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

Kaempferol-3-methyl O +
ether O -
, O +
together O +
with O +
seven O +
other O +
flavones O +
were O +
identified O +
in O +
S. B-Species +
yosgadensis L-Species -
( O -
Topcu O +
et O +
al. O -
, O +
1996 O +
) O -
. O -

Quercetin O +
3,7,3′,4′-tetramethyl O +
ether O -
, O +
or O +
retusin O +
( O -
98 O +
) O +
was O +
identified O +
by O +
TLC O +
in O +
S. B-Species +
glutinosa L-Species -
( O -
Wollenweber O -
, O +
1974 O +
) O -
. O -

6-Hydroxylated O +
flavonols O +
are O +
mostly O +
confined O +
to O +
6-hydroxykaempferol O +
derivatives O +
and O +
include O +
6-hydroxykaempferol O +
3,6-dimethyl O +
ether O +
( O -
99 O +
) O +
( O -
Gökdil O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
3,6,4′-trimethyl O +
ether O +
( O -
santin O -
) O +
( O -
100 O +
) O +
( O -
Ulubelen O +
and O +
Tuzlaci O -
, O +
1990 O +
) O +
and O +
interestingly O +
the O +
5,6-dimethyl O +
ether O +
( O -
101 O +
) O +
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O -
. O -

Compound O +
101 O -
is O +
one O +
of O +
the O +
only O +
two O +
flavone O +
5-methyl O +
ethers O +
known O +
to O +
Salvia B-Species -
species L-Species -
, O +
the O +
other O +
being O +
6-hydroxygalangin O +
5,6-dimethyl O +
ether O +
( O -
102 O +
) O +
found O +
in O +
S. B-Species +
columbariae L-Species -
( O -
Wollenweber O +
et O +
al. O -
, O +
1992 O +
) O +
which O +
is O +
also O +
the O +
only O +
one O +
galangin O +
( O -
5,7-dihydroxyflavonol O -
) O +
compound O +
reported O +
in O +
Salvia U-Species +
. O -

No O +
corresponding O +
6-hydroxyquercetin O +
derivatives O +
have O +
been O +
described O +
so O +
far O +
in O +
Salvia U-Species +
. O -

3.2 O +
Flavone O +
and O +
flavonol O +
glycosides O +
Flavone O +
O O +
-glycosides O +
are O +
apparently O +
common O +
in O +
Salvia U-Species -
and O +
most O +
of O +
them O +
are O +
flavone O +
7-glycosides O +
represented O +
by O +
apigenin O +
7-glucoside O +
( O -
cosmosiin O -
) O +
( O -
103 O +
) O -
, O +
luteolin O +
7-glucoside O +
( O -
cinaroside O -
) O +
( O -
110 O +
) O +
and O +
their O +
corresponding O +
7-glucuronides O +
( O -
104 O +
, O +
111 O +
) O -
. O -

There O +
are O +
several O +
apigenins O +
glycosylated O +
with O +
two O +
or O +
more O +
sugars O +
and O +
among O +
these O +
are O +
apigenin O +
7,4′-diglucoside O +
( O -
105 O +
) O +
( O -
Takeda O +
et O +
al. O -
, O +
1994 O +
) O -
, O +
apigenin O +
7-cellobioside O +
( O -
107 O +
) O +
( O -
Veitch O +
et O +
al. O -
, O +
1998 O +
) O -
, O +
apigenin O +
7-rutinoside O +
( O -
108 O +
) O +
( O -
Kokkalou O +
and O +
Kapetanidis O -
, O +
1988 O +
) O +
and O +
apigenin O +
7-cellobioside-4′-glucoside O +
( O -
109 O +
) O +
( O -
Veitch O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

The O +
latter O +
compound O +
is O +
the O +
only O +
trisaccharide O +
of O +
flavones O +
and O +
together O +
with O +
apigenin O +
7,4′-diglucoside O +
are O +
the O +
only O +
two O +
apigenin O +
derivatives O +
in O +
which O +
two O +
phenolic O +
hydroxyl O +
groups O +
are O +
glycosylated O -
. O -

Apigenin O +
7,4′-diglucoside O +
occurred O +
as O +
a O +
co O -
- O -
pigment O +
in O +
the O +
blue O +
flower O +
of O +
S. B-Species +
patens L-Species -
( O -
Takeda O +
et O +
al. O -
, O +
1994 O +
) O -
. O -

Other O +
flavone O +
disaccharides O +
like O +
apigenin O +
7-cellobioside O +
and O +
apigenin O +
7-cellobioside-4′-glucoside O +
present O +
in O +
Salvia U-Species -
flowers O +
could O +
very O +
well O +
serve O +
as O +
co O -
- O -
pigments O +
( O -
Veitch O +
et O +
al. O -
, O +
1998 O +
) O -
. O -

Compared O +
to O +
apigenin O -
, O +
luteolin O +
glycosides O +
appeared O +
to O +
be O +
more O +
common O -
. O -

Luteolin O +
3′-glucuronide O +
( O -
112 O +
) O +
was O +
present O +
in O +
S. B-Species +
officinalis L-Species -
( O -
Lu O +
and O +
Foo O -
, O +
2000 O +
) O +
while O +
luteolin O +
4′-glucuronide O +
( O -
113 O +
) O +
was O +
found O +
in O +
S. B-Species +
lavandulifolia L-Species -
along O +
with O +
other O +
flavonoids O +
( O -
Canigueral O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

The O +
3′-OH O +
of O +
luteolin O +
is O +
often O +
methylated O +
and O +
thus O +
chrysoeriol O +
glycosides O +
such O +
as O +
7-glucoside O +
( O -
114 O +
) O -
, O +
7-glucuronide O +
( O -
115 O +
) O +
and O +
7-xyloside O +
( O -
116 O +
) O +
have O +
been O +
frequently O +
reported O +
in O +
Salvia U-Species -
( O -
Smirnova O +
et O +
al. O -
, O +
1974b O -
; O +
Abdalla O +
et O +
al. O -
, O +
1983 O +
) O -
. O -

Several O +
luteolin O +
disaccharides O +
have O +
been O +
identified O +
in O +
Salvia U-Species -
and O +
these O +
include O +
luteolin O +
3′-glucoside-7-glucuronide O +
( O -
117 O +
) O +
( O -
Abdalla O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
7-rutinoside O +
( O -
118 O +
) O +
( O -
Kokkalou O +
and O +
Kapetanidis O -
, O +
1988 O -
; O +
Tomas O -
- O -
Lorente O +
et O +
al. O -
, O +
1988 O +
) O -
, O +
7-cellobioside O +
( O -
119 O +
) O +
( O -
Abdalla O -
, O +
1984 O +
) O +
and O +
5-rutinoside O +
( O -
127 O +
) O +
( O -
Zarzuelo O +
et O +
al. O -
, O +
1995 O +
) O -
. O -

The O +
6-hydroxyflavone O +
glycosides O -
, O +
like O +
their O +
aglycones O -
, O +
are O +
also O +
important O +
constituents O +
of O +
Salvia U-Species -
. O -

While O +
6-hydroxyapigenin O +
glycosides O +
are O +
exclusively O +
those O +
of O +
6-methylated O +
derivatives O +
such O +
as O +
6-methoxyapigenin O +
7-glucoside O +
( O -
homoplantagenin O -
) O +
( O -
120 O +
) O +
and O +
7-glucuronide O +
( O -
121 O +
) O -
, O +
salvigenin O +
5-glucoside O +
( O -
122 O +
) O +
( O -
Abdalla O +
et O +
al. O -
, O +
1983 O -
; O +
Ulubelen O +
and O +
Topcu O -
, O +
1984 O +
) O -
, O +
the O +
corresponding O +
6-hydroxyluteolin O +
glycosides O +
are O +
evenly O +
distributed O +
between O +
those O +
that O +
are O +
methylated O +
and O +
unmethylated O -
, O +
thus O +
6-hydroxyluteolin O +
7-glucoside O +
( O -
123 O +
) O +
and O +
7-glucuronide O +
( O -
124 O +
) O +
( O -
Lu O +
and O +
Foo O -
, O +
2000 O +
) O -
, O +
6-methoxyluteolin O +
7-glucoside O +
( O -
nepitrin O -
) O +
( O -
125 O +
) O -
, O +
7-glucuronide O +
( O -
126 O +
) O +
( O -
Abdalla O +
et O +
al. O -
, O +
1983 O +
) O -
, O +
6-hydroxyluteolin O +
5-glucoside O +
( O -
128 O +
) O +
( O -
Ulubelen O +
et O +
al. O -
, O +
1981 O +
) O +
and O +
6-methoxyluteolin O +
7-methyl O +
ether-5-glucoside O +
( O -
129 O +
) O +
( O -
Saleh O +
and O +
Sabri O -
, O +
1980 O +
) O +
have O +
all O +
been O +
found O +
in O +
Salvia U-Species +
. O -

Another O +
compound O -
, O +
identified O +
as O +
acetylpectolinarin O +
by O +
Smirnova O +
et O +
al. O +
( O -
1974a O -
) O +
, O +
could O +
likely O +
be O +
6-methoxyapigenin O +
4′-methyl O +
ether-7-rutinoside O -
, O +
as O +
its O +
acidic O +
hydrolysis O +
gave O +
pectolinarigenin O +
( O -
6-hydroxyapigenin O +
6,4′-dimethyl O +
ether O -
) O +
together O +
with O +
glucose O +
and O +
rhamnose O -
. O -

Flavone O +
C O +
-glycosides O +
are O +
widespread O +
in O +
nature O +
and O +
those O +
present O +
in O +
Salvia U-Species -
are O +
mostly O +
those O +
of O +
apigenin O +
including O +
apigenin O +
8-C O +
-glucoside O +
( O -
vitexin O -
) O +
( O -
130 O +
) O +
and O +
apigenin O +
8-C O +
-arabinoside O +
( O -
schaftoside O -
) O +
( O -
131 O +
) O +
from O +
S. B-Species +
blepharophylla L-Species -
( O -
Bisio O +
et O +
al. O -
, O +
1997 O +
) O +
and O +
the O +
more O +
common O +
apigenin O +
6,8-di O -
- O -
C O +
-glucoside O +
( O -
vicenin-2 O -
) O +
( O -
132 O +
) O +
( O -
Abdalla O -
, O +
1984 O -
; O +
Lu O +
and O +
Foo O -
, O +
2000 O +
) O -
. O -

Luteolin O +
6,8-di O -
- O -
C O +
-glucoside O +
( O -
133 O +
) O +
from O +
S. B-Species +
aegypteacae L-Species -
( O -
Abdalla O -
, O +
1984 O +
) O +
is O +
the O +
only O +
example O +
of O +
luteolin O +
C O +
-glycosides O +
reported O -
. O -

The O +
flavonol O +
glycosides O +
found O +
in O +
Salvia U-Species -
are O +
exclusively O +
those O +
of O +
the O +
3-glycosides O -
. O -

There O +
are O +
three O +
kaempferol O +
glycosides O +
known O +
but O +
they O +
cover O +
a O +
range O +
of O +
compounds O +
from O +
mono- O +
to O +
triglycoside O +
which O +
are O +
exemplified O +
by O +
kaempferol O +
3-glucoside O +
( O -
astragalin O -
) O +
( O -
134 O +
) O +
in O +
S. B-Species +
cavaleriei L-Species -
( O -
Zhao O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
3-robinoside O +
( O -
141 O +
) O +
and O +
3- O -
( O -
2,6-dirhamnosylglucoside O -
) O +
or O +
3- O -
( O -
2 O -
G O +
-rhamnosylrutinoside O -
) O +
( O -
135 O +
) O +
in O +
S. B-Species +
farnacea L-Species -
( O -
Kamel O +
et O +
al. O -
, O +
1992 O +
) O -
. O -

The O +
quercetin O +
glycosides O +
also O +
include O +
their O +
methyl O +
ethers O -
, O +
thus O +
in O +
addition O +
to O +
the O +
more O +
common O +
3-glucoside O +
( O -
isoquercitrin O -
) O +
( O -
137 O +
) O -
, O +
3-glucuronide O +
( O -
miquelianin O -
) O +
( O -
138 O +
) O +
and O +
3-robinoside O +
( O -
142 O +
) O -
, O +
all O +
of O +
which O +
occur O +
in O +
S. B-Species +
blepharophylla L-Species -
( O -
Bisio O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
rhamnetin O +
( O -
quercetin O +
7-methyl O +
ether O -
) O +
3-glucoside O +
( O -
139 O +
) O +
from O +
S. B-Species +
blepharophylla L-Species -
( O -
Bisio O +
et O +
al. O -
, O +
1997 O +
) O -
, O +
isorhamnetin O +
( O -
quercetin O +
3′-methyl O +
ether O -
) O +
3-galactoside O +
( O -
140 O +
) O +
and O +
3- O -
( O -
2 O -
G O +
-rhamnosylrutinoside O -
) O +
( O -
136 O +
) O +
both O +
from O +
S. B-Species +
farinacea L-Species -
( O -
Kamel O +
et O +
al. O -
, O +
1992 O +
) O +
have O +
also O +
been O +
reported O -
. O -

3.3 O +
Anthocyanins O +
The O +
anthocyanins O +
are O +
particularly O +
abundant O +
in O +
the O +
red O +
or O +
purple O +
flowers O +
of O +
Salvia U-Species -
( O -
Asen O -
, O +
1961 O -
; O +
Shibata O +
et O +
al. O -
, O +
1966 O -
; O +
Cornu O +
and O +
Paynot O -
, O +
1969 O -
; O +
Albulescu O +
and O +
Gavrila O -
- O -
Dinu O -
, O +
1981 O -
; O +
Zhang O +
et O +
al. O -
, O +
1997 O +
) O -
. O -

Salvia U-Species -
anthocyanins O +
( O -
see O +
Table O +
5 O -
) O +
were O +
first O +
studied O +
by O +
Willstätter O +
and O +
Bolton O +
( O -
1916 O -
) O -
and O +
the O +
pigment O +
known O +
as O +
salvianin O +
was O +
identified O +
as O +
pelargonidin O +
diglucoside O +
with O +
caffeic O +
acid O +
and O +
malonic O +
acid O +
substituents O -
. O -

Subsequent O +
investigations O +
led O +
to O +
the O +
first O +
structural O +
assignment O +
of O +
salvianin O +
as O +
pelargonidin O +
3- O -
( O -
6-caffeoylglucoside O -
) O -
-5-glucoside O +
( O -
145 O +
) O +
( O -
Birkofer O +
et O +
al. O -
, O +
1965 O +
) O -
, O +
but O +
this O +
structure O +
was O +
later O +
revised O +
to O +
pelargonidin O +
3- O -
( O -
6-caffeoylglucoside O -
) O -
-5- O -
( O -
4,6-dimalonylglucoside O -
) O +
( O -
143 O +
) O +
( O -
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

The O +
earlier O +
structure O +
was O +
revised O +
because O +
plant O +
pigments O +
were O +
extracted O +
with O +
alcohols O +
which O +
were O +
acidified O +
with O +
mineral O +
acids O +
causing O +
hydrolysis O +
of O +
the O +
labile O +
malonyl O +
moiety O +
( O -
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O +
) O -
. O -

The O +
mono- O +
and O +
bis O -
- O -
demalonyl O +
derivatives O +
of O +
salvianin O +
( O -
144 O +
, O +
145 O +
) O +
have O +
also O +
been O +
identified O +
( O -
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O -
; O +
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

Furthermore O -
, O +
the O +
caffeoyl O +
group O +
in O +
salvianin O +
can O +
be O +
replaced O +
by O +
a O +
p O +
-coumaroyl O +
group O -
, O +
leading O +
to O +
the O +
corresponding O +
pelargonidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
4,6-dimalonylglucoside O -
) O +
or O +
monardaein O +
( O -
146 O +
) O +
and O +
its O +
demalonated O +
derivatives O +
( O -
147 O +
, O +
148 O +
) O +
( O -
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O +
) O -
. O -

Likewise O -
, O +
the O +
pelargonidin O +
aglycone O +
can O +
be O +
replaced O +
by O +
cyanidin O -
, O +
delphinidin O +
and O +
even O +
malvidin O -
, O +
so O +
the O +
respective O +
cyanidin O +
and O +
delphinidin O +
3- O -
( O -
caffeoylglucoside O -
) O -
-5- O -
( O -
dimalonylglucosides O -
) O +
( O -
149 O +
, O +
155 O +
) O +
or O +
3- O -
( O -
p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
dimalonylglucosides O -
) O +
( O -
152 O +
, O +
158 O +
) O +
and O +
their O +
demalonated O +
derivatives O +
( O -
150 O +
, O +
151 O +
, O +
153 O +
, O +
154 O +
, O +
156 O +
, O +
157 O +
, O +
159 O +
, O +
160 O +
) O +
have O +
all O +
been O +
identified O +
in O +
scarlet O -
, O +
purple O +
and O +
blue O +
flowers O +
of O +
Salvia U-Species -
( O -
Takeda O +
et O +
al. O -
, O +
1986 O -
; O +
Tomas O -
- O -
Barberan O +
et O +
al. O -
, O +
1987 O -
; O +
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

Malvidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
6-malonylglucoside O -
) O +
( O -
salviamalvin O -
) O +
( O -
162 O +
) O -
, O +
along O +
with O +
malonylawobanin O +
( O -
159 O +
) O -
, O +
have O +
been O +
isolated O +
from O +
the O +
blue O +
flowers O +
of O +
S. B-Species +
farinacea L-Species -
( O -
Kondo O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

Studies O +
on O +
the O +
distribution O +
pattern O +
of O +
anthocyanins O +
in O +
10 O +
species O +
of O +
Salvia U-Species -
showed O +
that O +
the O +
red O -
, O +
scarlet O +
and O +
pink O -
- O -
coloured O +
flower O +
varieties O +
contained O +
pelargonidin O -
, O +
the O +
blue O +
ones O +
the O +
delphinidin O +
and O +
the O +
amethyst- O +
and O +
grape O -
- O -
violet O -
- O -
colored O +
ones O +
were O +
the O +
cyanidin O +
derivatives O +
( O -
Haque O +
et O +
al. O -
, O +
1981 O +
) O -
. O -

An O +
acetylated O +
anthocyanin O -
, O +
delphinidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
4-acetyl-6-malonylglucoside O -
) O +
( O -
161 O +
) O +
together O +
with O +
its O +
parent O +
compound O +
have O +
been O +
reported O +
in O +
the O +
blue O +
petals O +
of O +
S. B-Species +
uliginosa L-Species -
( O -
Ishikawa O +
et O +
al. O -
, O +
1999 O +
) O -
. O -

An O +
example O +
of O +
a O +
stable O +
complex O +
of O +
anthocyanins O +
with O +
flavonoids O +
as O +
co O -
- O -
pigments O +
is O +
a O +
blue O +
pigment O +
found O +
in O +
the O +
blue O +
flowers O +
of O +
S. B-Species +
patens L-Species +
. O -

The O +
pigment O +
is O +
composed O +
of O +
delphinidin O +
3- O -
( O -
6-p O +
-coumaroylglucoside O -
) O -
-5- O -
( O -
6-malonylglucoside O -
) O +
( O -
malonylawobanin O -
) O +
( O -
159 O +
) O -
, O +
apigenin O +
7,4′-diglucoside O +
( O -
105 O +
) O +
and O +
magnesium O +
cation O +
( O -
Takeda O +
et O +
al. O -
, O +
1994 O +
) O -
. O -

3.4 O +
Proanthocyanidins O +
Proanthocyanidins O -
, O +
or O +
condensed O +
tannins O -
, O +
have O +
been O +
reported O +
in O +
Salvia B-Species -
species L-Species +
( O -
Brieskorn O -
, O +
1949 O -
; O +
Savin O +
and O +
Ivanic O -
, O +
1973 O -
; O +
Murko O +
and O +
Baldasar O -
, O +
1977 O +
) O -
. O -

The O +
so O -
- O -
called O +
salviatannin O +
( O -
164 O +
) O +
has O +
only O +
been O +
investigated O +
with O +
UV O +
and O +
IR O +
and O +
deduced O +
to O +
be O +
based O +
on O +
catechin O +
( O -
163 O +
) O +
which O +
gave O +
catechol O +
and O +
catechuic O +
acid O +
after O +
alkali O +
pyrolysis O +
( O -
Murko O +
et O +
al. O -
, O +
1974 O +
) O -
. O -

Later O -
, O +
salviatannin O +
was O +
also O +
detected O +
by O +
paper O +
chromatography O +
followed O +
by O +
spraying O +
color O +
reagent O +
( O -
Hu O -
, O +
1982 O +
) O +
or O +
analysed O +
by O +
absorption O +
onto O +
hide O +
powder O +
followed O +
by O +
gravimetry O +
( O -
Karuza O -
- O -
Stojakovic O +
et O +
al. O -
, O +
1989 O +
) O -
. O -

The O +
tannins O +
present O +
in O +
Salvia U-Species -
intravenous O +
preparations O +
could O +
be O +
removed O +
by O +
passing O +
through O +
a O +
polyamide O +
column O +
( O -
Hu O -
, O +
1982 O +
) O +
or O +
by O +
precipitation O +
with O +
5 O -
% O +
gelatin O +
solutions O +
followed O +
by O +
filtration O +
( O -
Ren O +
et O +
al. O -
, O +
1986 O +
) O -
. O -

4 O +
Conclusion O +
Salvia B-Species -
species L-Species +
commonly O +
called O +
sages U-Species +
are O +
widely O +
used O +
in O +
traditional O +
medicine O +
and O +
are O +
a O +
rich O +
source O +
of O +
polyphenolic O +
flavonoids O +
and O +
phenolic O +
acids O -
. O -

Flavones O -
, O +
flavonols O +
and O +
their O +
glycosides O +
constitute O +
the O +
majority O +
of O +
flavonoids O +
present O -
. O -

Malonylated O +
anthocyanins O +
are O +
abundant O +
in O +
red O +
to O +
blue O +
Salvia U-Species -
flowers O +
while O +
the O +
presence O +
of O +
proanthocyanidins O +
( O -
condensed O +
tannins O -
) O +
in O +
Salvia U-Species -
have O +
not O +
been O +
demonstrated O +
conclusively O -
. O -

The O +
phenolic O +
acids O +
are O +
exclusively O +
those O +
based O +
on O +
caffeic O +
acid O +
building O +
block O +
with O +
compounds O +
formed O +
from O +
two O +
to O +
four O +
or O +
more O +
caffeic O +
acid O +
units O -
. O -

The O +
depsides O +
formed O +
from O +
these O +
are O +
believed O +
to O +
be O +
responsible O +
for O +
the O +
many O +
biological O +
activities O +
in O +
the O +
sage U-Species +
decoction O +
used O +
in O +
traditional O +
medicine O -
. O -

In O +
addition O +
to O +
the O +
dried O +
root O -
, O +
the O +
aerial O +
part O +
of O +
sage U-Species +
has O +
been O +
shown O +
to O +
also O +
contain O +
a O +
rich O +
source O +
of O +
polar O +
polyphenols O +
including O +
flavonoids O +
and O +
phenolic O +
acids O +
which O +
could O +
potentially O +
be O +
used O +
also O +
as O +
herbal O +
materials O -
. O +

Daphnia U-Species +
are O +
an O +
important O +
and O +
widely O +
studied O +
model O +
species O +
in O +
ecological O +
and O +
toxicological O +
studies O +
throughout O +
the O +
world O +
and O +
an O +
official O +
( O -
OECD O -
) O +
recommended O +
test O +
organism O -
. O -

Their O +
small O +
size O -
, O +
wide O +
distribution O +
and O +
easy O +
growth O +
conditions O +
make O +
this O +
organism O +
ideal O +
for O +
functional O +
genomics O +
based O +
studies O -
, O +
including O +
metabolic O +
profiling O +
and O +
transcriptomics O -
. O -

In O +
this O +
study O +
we O +
used O +
an O +
integrated O +
systems O +
approach O +
in O +
which O +
transcriptomic O -
, O +
metabolomic O +
and O +
energetic O +
responses O +
of O -
juvenile O +
( O -
4days O +
old O -
) O +
daphnids U-Species +
were O +
evaluated O +
in O +
response O +
to O +
exposure O +
to O +
two O +
poly O -
aromatic O +
hydrocarbons O +
( O -
pyrene O +
and O +
fluoranthene O -
) O +
and O +
binary O +
mixtures O +
thereof O -
. O -

In O +
addition O -
, O +
these O +
responses O +
were O +
linked O +
to O +
responses O +
measured O +
during O +
chronic O +
experiments O +
( O -
21days O -
) O +
assessing O +
survival O -
, O +
growth O +
and O +
reproductive O +
traits O -
. O -

Custom O +
Daphnia B-Species +
magna L-Species +
microarrays O +
were O +
used O +
to O +
assess O +
transcriptomic O +
changes O -
. O -

Hierarchical O +
cluster O +
analysis O +
did O +
not O +
result O +
in O +
a O +
clear O +
distinction O +
between O +
the O +
single O +
compounds O +
suggesting O +
similar O +
molecular O +
modes O +
of O +
action O -
. O -

Cluster O +
analysis O +
with O +
both O +
the O +
single O +
compounds O +
and O +
the O +
binary O +
mixture O +
treatments O +
resulted O +
in O +
a O +
separation O +
of O +
treatments O +
based O +
on O +
differences O +
in O +
toxic O +
ratios O +
rather O +
than O +
component O +
differences O -
. O -

Changes O +
in O +
the O +
metabolic O +
profiles O +
of O +
the O +
organisms O +
were O +
investigated O +
using O +
Nuclear O +
Magnetic O +
Resonance O +
Spectroscopy O +
and O +
Gas O +
and O +
Liquid O +
Chromatography O +
Mass O +
Spectrometry O -
. O -

These O +
multivariate O +
metabolomic O +
datasets O +
were O +
analyzed O +
with O +
Principal O +
Components O +
Analysis O +
and O +
Partial O +
Least O +
Squares O +
Discriminant O +
Analysis O -
. O -

The O +
major O +
metabolite O +
changes O +
responsible O +
for O +
the O +
differences O +
observed O +
indicated O +
a O +
disturbance O +
in O +
aminosugar O +
metabolism O +
in O +
all O +
cases O -
. O -

The O +
study O +
demonstrates O +
the O +
potential O +
of O +
' O -
omics O -
' O +
to O +
provide O +
screening O +
tools O +
for O +
monitoring O +
of O +
the O +
freshwater O +
environment O -
-- O -
in O +
invertebrate U-Species +
species O -
-- O -
which O +
is O +
reasonably O +
rapid O -
, O +
cost O -
- O -
effective O +
and O +
has O +
the O +
potential O +
to O +
greatly O +
increase O +
the O +
amount O +
of O +
information O +
obtained O +
from O +
aquatic O +
toxicology O +
testing O -
. O +

Molecular O +
cloning O +
and O +
biochemical O +
characterization O +
of O +
a O +
truncated O -
, O +
secreted O +
member O +
of O +
the O +
human U-Species +
family O +
of O +
Ca2 O -
+ O -
-activated O +
Cl- O +
channels O -
. O -

A O +
novel O +
family O +
of O +
chloride O +
channel O +
proteins O +
has O +
recently O +
been O +
discovered O +
including O +
two O +
bovine U-Species +
( O -
Lu O -
- O -
ECAM-1 O -
, O +
bCLCA1 O -
) O -
, O +
one O +
murine U-Species +
( O -
mCLCA1 O -
) O -
, O +
and O +
two O +
human U-Species +
( O -
hCLCA1 O +
and O +
hCLCA2 O -
) O +
members O -
. O -

Here O -
, O +
we O +
describe O +
the O +
cloning O -
, O +
expression O -
, O +
and O +
molecular O +
characterization O +
of O +
a O +
truncated O +
human U-Species +
homolog O -
, O +
tentatively O +
named O +
hCLCA3 O -
. O -

It O +
was O +
cloned O +
from O +
a O +
human U-Species +
spleen O +
cDNA O +
library O +
and O +
is O +
expressed O +
in O +
numerous O +
tissues O +
including O +
lung O -
, O +
trachea O -
, O +
spleen O -
, O +
thymus O -
, O +
and O +
mammary O +
gland O +
as O +
determined O +
by O +
reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O -
. O -

Unlike O +
all O +
previously O +
known O +
CLCA O +
family O +
members O +
which O +
consistently O +
encode O +
an O +
approximately O +
125-kDa O +
transmembrane O +
protein O +
that O +
is O +
cleaved O +
to O +
form O +
a O +
heterodimer O +
of O +
two O +
proteins O +
of O +
approximately O +
90 O +
and O +
35 O +
kDa O -
, O +
the O +
3.6-kb O +
hCLCA3 O +
mRNA O +
encodes O +
a O +
37-kDa O +
glycoprotein O +
that O +
corresponds O +
to O +
the O +
N O -
- O -
terminal O +
extracellular O +
domain O +
of O +
its O +
homologs O -
. O -

Moreover O -
, O +
when O +
expressed O +
in O +
human U-Species +
embryonic O +
kidney O +
293 O +
or O +
Chinese O +
hamster O +
ovary O +
cells O -
, O +
this O +
37-kDa O +
glycoprotein O +
is O +
secreted O +
into O +
the O +
culture O +
supernatant O -
. O -

These O +
observations O +
suggest O +
that O +
hCLCA3 O +
is O +
a O +
structurally O +
divergent O +
member O +
of O +
the O +
CLCA O +
family O +
of O +
proteins O +
and O +
that O +
it O +
does O +
not O +
act O +
as O +
a O +
channel O +
protein O +
but O +
has O +
distinct O -
, O +
yet O +
unidentified O +
functions O -
. O -

Yeast U-Species +
mutants O +
affecting O +
possible O +
quality O +
control O +
of O +
plasma O +
membrane O +
proteins O -
. O -

Mutations O +
gef1 O -
, O +
stp22 O -
, O +
STP26 O -
, O +
and O +
STP27 O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species +
were O +
identified O +
as O +
suppressors O +
of O +
the O +
temperature O -
- O -
sensitive O +
alpha O -
- O -
factor O +
receptor O +
( O -
mutation O +
ste2 O -
- O -
3 O -
) O +
and O +
arginine O +
permease O +
( O -
mutation O +
can1 O -
( O -
ts O -
) O -
) O -
. O -

These O +
suppressors O +
inhibited O +
the O +
elimination O +
of O +
misfolded O +
receptors O +
( O -
synthesized O +
at O +
34 O +
degrees O +
C O -
) O +
as O +
well O +
as O +
damaged O +
surface O +
receptors O +
( O -
shifted O +
from O +
22 O +
to O +
34 O +
degrees O +
C O -
) O -
. O -

The O +
stp22 O +
mutation O +
( O -
allelic O +
to O +
vps23 O +
[ O -
M. O +
Babst O +
and O +
S. O +
Emr O -
, O +
personal O +
communication O -
] O +
and O +
the O +
STP26 O +
mutation O +
also O +
caused O +
missorting O +
of O +
carboxypeptidase O +
Y O -
, O +
and O +
ste2 O -
- O -
3 O +
was O +
suppressed O +
by O +
mutations O +
vps1 O -
, O +
vps8 O -
, O +
vps10 O -
, O +
and O +
vps28 O +
but O +
not O +
by O +
mutation O +
vps3 O -
. O -

In O +
the O +
stp22 O +
mutant O -
, O +
both O +
the O +
mutant O +
and O +
the O +
wild O -
- O -
type O +
receptors O +
( O -
tagged O +
with O +
green O +
fluorescent O +
protein O +
[ O -
GFP O -
] O -
) O +
accumulated O +
within O +
an O +
endosome O -
- O -
like O +
compartment O +
and O +
were O +
excluded O +
from O +
the O +
vacuole O -
. O -

GFP O -
- O -
tagged O +
Stp22p O +
also O +
accumulated O +
in O +
this O +
compartment O -
. O -

Upon O +
reaching O +
the O +
vacuole O -
, O +
cytoplasmic O +
domains O +
of O +
both O +
mutant O +
and O +
wild O -
- O -
type O +
receptors O +
appeared O +
within O +
the O +
vacuolar O +
lumen O -
. O -

Stp22p O +
and O +
Gef1p O +
are O +
similar O +
to O +
tumor O +
susceptibility O +
protein O +
TSG101 O +
and O +
voltage O -
- O -
gated O +
chloride O +
channel O -
, O +
respectively O -
. O -

These O +
results O +
identify O +
potential O +
elements O +
of O +
plasma O +
membrane O +
quality O +
control O +
and O +
indicate O +
that O +
cytoplasmic O +
domains O +
of O +
membrane O +
proteins O +
are O +
translocated O +
into O +
the O +
vacuolar O +
lumen O -
. O -

Apg13p O +
and O +
Vac8p O +
are O +
part O +
of O +
a O +
complex O +
of O +
phosphoproteins O +
that O +
are O +
required O +
for O +
cytoplasm O +
to O +
vacuole O +
targeting O -
. O -

We O +
have O +
been O +
studying O +
protein O +
components O +
that O +
function O +
in O +
the O +
cytoplasm O +
to O +
vacuole O +
targeting O +
( O -
Cvt O -
) O +
pathway O +
and O +
the O +
overlapping O +
process O +
of O +
macroautophagy O -
. O -

The O +
Vac8 O +
and O +
Apg13 O +
proteins O +
are O +
required O +
for O +
the O +
import O +
of O +
aminopeptidase O +
I O +
( O -
API O -
) O +
through O +
the O +
Cvt O +
pathway O -
. O -

We O +
have O +
identified O +
a O +
protein O -
- O -
protein O +
interaction O +
between O +
Vac8p O +
and O +
Apg13p O +
by O +
both O +
two O -
- O -
hybrid O +
and O +
co O -
- O -
immunoprecipitation O +
analysis O -
. O -

Subcellular O +
fractionation O +
of O +
API O +
indicates O +
that O +
Vac8p O +
and O +
Apg13p O +
are O +
involved O +
in O +
the O +
vesicle O +
formation O +
step O +
of O +
the O +
Cvt O +
pathway O -
. O -

Kinetic O +
analysis O +
of O +
the O +
Cvt O +
pathway O +
and O +
autophagy O +
indicates O +
that O -
, O +
although O +
Vac8p O +
is O +
essential O +
for O +
Cvt O +
transport O -
, O +
it O +
is O +
less O +
important O +
for O +
autophagy O -
. O -

In O +
vivo O +
phosphorylation O +
experiments O +
demonstrate O +
that O +
both O +
Vac8p O +
and O +
Apg13p O +
are O +
phosphorylated O +
proteins O -
, O +
and O +
Apg13p O +
phosphorylation O +
is O +
regulated O +
by O +
changing O +
nutrient O +
conditions O -
. O -

Although O +
Apg13p O +
interacts O +
with O +
the O +
serine O -
/ O -
threonine O +
kinase O +
Apg1p O -
, O +
this O +
protein O +
is O +
not O +
required O +
for O +
phosphorylation O +
of O +
either O +
Vac8p O +
or O +
Apg13p O -
. O -

Subcellular O +
fractionation O +
experiments O +
indicate O +
that O +
Apg13p O +
and O +
a O +
fraction O +
of O +
Apg1p O +
are O +
membrane O -
- O -
associated O -
. O -

Vac8p O +
and O +
Apg13p O +
may O +
be O +
part O +
of O +
a O +
larger O +
protein O +
complex O +
that O +
includes O +
Apg1p O +
and O +
additional O +
interacting O +
proteins O -
. O -

Together O -
, O +
these O +
components O +
may O +
form O +
a O +
protein O +
complex O +
that O +
regulates O +
the O +
conversion O +
between O +
Cvt O +
transport O +
and O +
autophagy O +
in O +
response O +
to O +
changing O +
nutrient O +
conditions O -
. O -

Mdv1p O +
is O +
a O +
WD O +
repeat O +
protein O +
that O +
interacts O +
with O +
the O +
dynamin O -
- O -
related O +
GTPase O -
, O +
Dnm1p O -
, O +
to O +
trigger O +
mitochondrial O +
division O -
. O -

Mitochondrial O +
fission O +
is O +
mediated O +
by O +
the O +
dynamin O -
- O -
related O +
GTPase O -
, O +
Dnm1p O -
, O +
which O +
assembles O +
on O +
the O +
mitochondrial O +
outer O +
membrane O +
into O +
punctate O +
structures O +
associated O +
with O +
sites O +
of O +
membrane O +
constriction O +
and O +
fission O -
. O -

We O +
have O +
identified O +
additional O +
nuclear O +
genes O +
required O +
for O +
mitochondrial O +
fission O -
, O +
termed O +
MDV O +
( O -
for O +
mitochondrial O +
division O -
) O -
. O -

MDV1 O +
encodes O +
a O +
predicted O +
soluble O +
protein O -
, O +
containing O +
a O +
coiled O -
- O -
coil O +
motif O +
and O +
seven O +
COOH O -
- O -
terminal O +
WD O +
repeats O -
. O -

Genetic O +
and O +
two O -
- O -
hybrid O +
analyses O +
indicate O +
that O +
Mdv1p O +
interacts O +
with O +
Dnm1p O +
to O +
mediate O +
mitochondrial O +
fission O -
. O -

In O +
addition O -
, O +
Mdv1p O +
colocalizes O +
with O +
Dnm1p O +
in O +
fission O -
- O -
mediating O +
punctate O +
structures O +
on O +
the O +
mitochondrial O +
outer O +
membrane O -
. O -

Whereas O +
localization O +
of O +
Mdv1p O +
to O +
these O +
structures O +
requires O +
Dnm1p O -
, O +
localization O +
of O +
Mdv1p O +
to O +
mitochondrial O +
membranes O +
does O +
not O -
. O -

This O +
indicates O +
that O +
Mdv1p O +
possesses O +
a O +
Dnm1p O -
- O -
independent O +
mitochondrial O +
targeting O +
signal O -
. O -

Dnm1p O -
- O -
independent O +
targeting O +
of O +
Mdv1p O +
to O +
mitochondria O +
requires O +
MDV2 O -
. O -

Our O +
data O +
indicate O +
that O +
MDV2 O +
also O +
functions O +
separately O +
to O +
regulate O +
the O +
assembly O +
of O +
Dnm1p O +
into O +
punctate O +
structures O -
. O -

In O +
contrast O -
, O +
Mdv1p O +
is O +
not O +
required O +
for O +
the O +
assembly O +
of O +
Dnm1p O -
, O +
but O +
Dnm1p O -
- O -
containing O +
punctate O +
structures O +
lacking O +
Mdv1p O +
are O +
not O +
able O +
to O +
complete O +
division O -
. O -

Our O +
studies O +
suggest O +
that O +
mitochondrial O +
fission O +
is O +
a O +
multi O -
- O -
step O +
process O +
in O +
which O +
Mdv2p O +
regulates O +
the O +
assembly O +
of O +
Dnm1p O +
into O +
punctate O +
structures O +
and O +
together O +
with O +
Mdv1p O +
functions O +
later O +
during O +
fission O +
to O +
facilitate O +
Dnm1p O -
- O -
dependent O +
mitochondrial O +
membrane O +
constriction O +
and/or O +
division O -
. O -

PEX11alpha O +
is O +
required O +
for O +
peroxisome O +
proliferation O +
in O +
response O +
to O +
4-phenylbutyrate O +
but O +
is O +
dispensable O +
for O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
alpha O -
- O -
mediated O +
peroxisome O +
proliferation O -
. O -

The O +
PEX11 O +
peroxisomal O +
membrane O +
proteins O +
promote O +
peroxisome O +
division O +
in O +
multiple O +
eukaryotes O -
. O -

As O +
part O +
of O +
our O +
effort O +
to O +
understand O +
the O +
molecular O +
and O +
physiological O +
functions O +
of O +
PEX11 O +
proteins O -
, O +
we O +
disrupted O +
the O +
mouse U-Species +
PEX11alpha O +
gene O -
. O -

Overexpression O +
of O +
PEX11alpha O +
is O +
sufficient O +
to O +
promote O +
peroxisome O +
division O -
, O +
and O +
a O +
class O +
of O +
chemicals O +
known O +
as O +
peroxisome O +
proliferating O +
agents O +
( O -
PPAs O -
) O +
induce O +
the O +
expression O +
of O +
PEX11alpha O +
and O +
promote O +
peroxisome O +
division O -
. O -

These O +
observations O +
led O +
to O +
the O +
hypothesis O +
that O +
PPAs O +
induce O +
peroxisome O +
abundance O +
by O +
enhancing O +
PEX11alpha O +
expression O -
. O -

The O +
phenotypes O +
of O +
PEX11alpha O -
( O -
- O -
/ O -
- O -
) O +
mice U-Species +
indicate O +
that O +
this O +
hypothesis O +
remains O +
valid O +
for O +
a O +
novel O +
class O +
of O +
PPAs O +
that O +
act O +
independently O +
of O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
alpha O +
( O -
PPARalpha O -
) O +
but O +
is O +
not O +
valid O +
for O +
the O +
classical O +
PPAs O +
that O +
act O +
as O +
activators O +
of O +
PPARalpha O -
. O -

Furthermore O -
, O +
we O +
find O +
that O +
PEX11alpha O -
( O -
- O -
/ O -
- O -
) O +
mice U-Species +
have O +
normal O +
peroxisome O +
abundance O +
and O +
that O +
cells O +
lacking O +
both O +
PEX11alpha O +
and O +
PEX11beta O -
, O +
a O +
second O +
mammalian O +
PEX11 O +
gene O -
, O +
have O +
no O +
greater O +
defect O +
in O +
peroxisome O +
abundance O +
than O +
do O +
cells O +
lacking O +
only O +
PEX11beta O -
. O -

Finally O -
, O +
we O +
report O +
the O +
identification O +
of O +
a O +
third O +
mammalian O +
PEX11 O +
gene O -
, O +
PEX11gamma O -
, O +
and O +
show O +
that O +
it O +
too O +
encodes O +
a O +
peroxisomal O +
protein O -
. O -

Functional O +
proteomic O +
analysis O +
of O +
human O +
nucleolus O -
. O -

The O +
notion O +
of O +
a O +
" O -
plurifunctional O -
" O +
nucleolus O +
is O +
now O +
well O +
established O -
. O -

However O -
, O +
molecular O +
mechanisms O +
underlying O +
the O +
biological O +
processes O +
occurring O +
within O +
this O +
nuclear O +
domain O +
remain O +
only O +
partially O +
understood O -
. O -

As O +
a O +
first O +
step O +
in O +
elucidating O +
these O +
mechanisms O +
we O +
have O +
carried O +
out O +
a O +
proteomic O +
analysis O +
to O +
draw O +
up O +
a O +
list O +
of O +
proteins O +
present O +
within O +
nucleoli O +
of O +
HeLa O +
cells O -
. O -

This O +
analysis O +
allowed O +
the O +
identification O +
of O +
213 O +
different O +
nucleolar O +
proteins O -
. O -

This O +
catalog O +
complements O +
that O +
of O +
the O +
271 O +
proteins O +
obtained O +
recently O +
by O +
others O -
, O +
giving O +
a O +
total O +
of O +
approximately O +
350 O +
different O +
nucleolar O +
proteins O -
. O -

Functional O +
classification O +
of O +
these O +
proteins O +
allowed O +
outlining O +
several O +
biological O +
processes O +
taking O +
place O +
within O +
nucleoli O -
. O -

Bioinformatic O +
analyses O +
permitted O +
the O +
assignment O +
of O +
hypothetical O +
functions O +
for O +
43 O +
proteins O +
for O +
which O +
no O +
functional O +
information O +
is O +
available O -
. O -

Notably O -
, O +
a O +
role O +
in O +
ribosome O +
biogenesis O +
was O +
proposed O +
for O +
31 O +
proteins O -
. O -

More O +
generally O -
, O +
this O +
functional O +
classification O +
reinforces O +
the O +
plurifunctional O +
nature O +
of O +
nucleoli O +
and O +
provides O +
convincing O +
evidence O +
that O +
nucleoli O +
may O +
play O +
a O +
central O +
role O +
in O +
the O +
control O +
of O +
gene O +
expression O -
. O -

Finally O -
, O +
this O +
analysis O +
supports O +
the O +
recent O +
demonstration O +
of O +
a O +
coupling O +
of O +
transcription O +
and O +
translation O +
in O +
higher O +
eukaryotes O -
. O -

Genomic O +
structure O -
, O +
gene O +
expression O -
, O +
and O +
promoter O +
analysis O +
of O +
human U-Species +
multidrug O +
resistance O -
- O -
associated O +
protein O +
7 O -
. O -

The O +
multidrug O +
resistance O -
- O -
associated O +
protein O +
( O -
MRP O -
) O +
subfamily O +
transporters O +
associated O +
with O +
anticancer O +
drug O +
efflux O +
are O +
attributed O +
to O +
the O +
multidrug O -
- O -
resistance O +
of O +
cancer O +
cells O -
. O -

The O +
genomic O +
organization O +
of O +
human U-Species +
multidrug O +
resistance O -
- O -
associated O +
protein O +
7 O +
( O -
MRP7 O -
) O +
was O +
identified O -
. O -

The O +
human U-Species +
MRP7 O +
gene O -
, O +
consisting O +
of O +
22 O +
exons O +
and O +
21 O +
introns O -
, O +
greatly O +
differs O +
from O +
other O +
members O +
of O +
the O +
human U-Species +
MRP O +
subfamily O -
. O -

A O +
splicing O +
variant O +
of O +
human U-Species +
MRP7 O -
, O +
MRP7A O -
, O +
expressed O +
in O +
most O +
human U-Species +
tissues O -
, O +
was O +
also O +
characterized O -
. O -

The O +
1.93-kb O +
promoter O +
region O +
of O +
MRP7 O +
was O +
isolated O +
and O +
shown O +
to O +
support O +
luciferase O +
activity O +
at O +
a O +
level O +
4- O +
to O +
5-fold O +
greater O +
than O +
that O +
of O +
the O +
SV40 O +
promoter O -
. O -

Basal O +
MRP7 O +
gene O +
expression O +
was O +
regulated O +
by O +
2 O +
regions O +
in O +
the O +
5'-flanking O +
region O +
at O +
-1,780 O -
- O -
1,287 O +
bp O -
, O +
and O +
at O +
-611 O +
to O +
-208 O +
bp O -
. O -

In O +
Madin O -
- O -
Darby O +
canine O +
kidney O +
( O -
MDCK O -
) O +
cells O -
, O +
MRP7 O +
promoter O +
activity O +
was O +
increased O +
by O +
226 O -
% O +
by O +
genotoxic O +
2-acetylaminofluorene O +
and O +
347 O -
% O +
by O +
the O +
histone O +
deacetylase O +
inhibitor O -
, O +
trichostatin O +
A. O +
The O +
protein O +
was O +
expressed O +
in O +
the O +
membrane O +
fraction O +
of O +
transfected O +
MDCK O +
cells O -
. O -

YMR313c O -
/ O -
TGL3 O +
encodes O +
a O +
novel O +
triacylglycerol O +
lipase O +
located O +
in O +
lipid O +
particles O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species -
. O -

Previous O +
work O +
from O +
our O +
laboratory O +
( O -
Athenstaedt O -
, O +
K. O -
, O +
Zweytick O -
, O +
D. O -
, O +
Jandrositz O -
, O +
A. O -
, O +
Kohlwein O -
, O +
S. O +
D. O -
, O +
and O +
Daum O -
, O +
G. O +
( O -
1999 O -
) O +
J. O +
Bacteriol O -
. O -

181 O -
, O +
6441 O -
- O -
6448 O -
) O +
showed O +
that O +
the O +
gene O +
product O +
of O +
YMR313c O +
( O -
named O +
Tgl3p O -
) O +
is O +
a O +
component O +
of O +
yeast U-Species +
lipid O +
particles O -
, O +
and O +
deletion O +
of O +
this O +
gene O +
led O +
to O +
an O +
increase O +
in O +
the O +
cellular O +
level O +
of O +
triacylglycerols O +
( O -
TAG O -
) O -
. O -

These O +
observations O +
suggested O +
that O +
TGL3 O +
may O +
encode O +
a O +
TAG O +
lipase O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species -
. O -

Here O +
we O +
demonstrate O +
by O +
cell O +
fractionation O +
and O +
by O +
microscopic O +
inspection O +
of O +
a O +
strain O +
bearing O +
a O +
Tgl3p O -
- O -
GFP O +
hybrid O +
that O +
this O +
polypeptide O +
is O +
highly O +
enriched O +
in O +
the O +
lipid O +
particle O +
fraction O +
but O +
virtually O +
absent O +
from O +
other O +
organelles O -
. O -

The O +
entire O +
TAG O +
lipase O +
activity O +
of O +
lipid O +
particles O +
is O +
attributed O +
to O +
Tgl3p O -
, O +
because O +
the O +
activity O +
in O +
this O +
organelle O +
is O +
completely O +
absent O +
in O +
a O +
Deltatgl3 O +
deletion O +
mutant O -
, O +
whereas O +
it O +
is O +
significantly O +
enhanced O +
in O +
a O +
strain O +
overexpressing O +
Tgl3p O -
. O -

A O +
His6-tagged O +
Tgl3p O +
hybrid O +
purified O +
close O +
to O +
homogeneity O +
from O +
a O +
yeast U-Species +
strain O +
overexpressing O +
this O +
fusion O +
protein O +
exhibited O +
high O +
TAG O +
lipase O +
activity O -
. O -

Most O +
importantly O -
, O +
experiments O +
in O +
vivo O +
using O +
the O +
fatty O +
acid O +
synthesis O +
inhibitor O +
cerulenin O +
demonstrated O +
that O +
deletion O +
of O +
TGL3 O +
resulted O +
in O +
a O +
decreased O +
mobilization O +
of O +
TAG O +
from O +
lipid O +
particles O -
. O -

The O +
amino O +
acid O +
sequence O +
deduced O +
from O +
the O +
open O +
reading O +
frame O +
YMR313c O +
contains O +
the O +
consensus O +
sequence O +
motif O +
GXSXG O +
typical O +
for O +
lipolytic O +
enzymes O -
. O -

Otherwise O -
, O +
Tgl3p O +
has O +
no O +
significant O +
sequence O +
homology O +
to O +
other O +
lipases O +
identified O +
so O +
far O -
. O -

In O +
summary O -
, O +
our O +
data O +
identified O +
Tgl3p O +
as O +
a O +
novel O +
yeast U-Species +
TAG O +
lipase O +
at O +
the O +
molecular O +
level O +
and O +
by O +
function O +
in O +
vivo O +
and O +
in O +
vitro O -
. O -

Biochemical O +
features O +
of O +
the O +
MHC O -
- O -
related O +
protein O +
1 O +
consistent O +
with O +
an O +
immunological O +
function O -
. O -

MHC O -
- O -
related O +
protein O +
( O -
MR O -
) O -
1 O +
is O +
an O +
MHC O +
class O +
I O -
- O -
related O +
molecule O +
encoded O +
on O +
chromosome O +
1 O +
that O +
is O +
highly O +
conserved O +
among O +
mammals O +
and O +
is O +
more O +
closely O +
related O +
to O +
classical O +
class O +
I O +
molecules O +
than O +
are O +
other O +
nonclassical O +
class O +
I O +
family O +
members O -
. O -

In O +
this O +
report O -
, O +
we O +
show O +
for O +
the O +
first O +
time O +
that O +
both O +
mouse U-Species +
and O +
human U-Species +
MR1 O +
molecules O +
can O +
associate O +
with O +
the O +
peptide O -
- O -
loading O +
complex O +
and O +
can O +
be O +
detected O +
at O +
low O +
levels O +
at O +
the O +
surface O +
of O +
transfected O +
cells O -
. O -

We O +
also O +
report O +
the O +
production O +
of O +
recombinant O +
human U-Species +
MR1 O +
molecules O +
in O +
insect O +
cells O +
using O +
highly O +
supplemented O +
media O +
and O +
provide O +
evidence O +
that O +
the O +
MR1 O +
H O +
chain O +
can O +
assume O +
a O +
folded O +
conformation O +
and O +
is O +
stoichiometrically O +
associated O +
with O +
beta O -
( O -
2 O -
) O -
-microglobulin O -
, O +
similar O +
to O +
class O +
I O +
molecules O -
. O -

Cumulatively O -
, O +
these O +
findings O +
demonstrate O +
that O +
surface O +
expression O +
of O +
MR1 O +
is O +
possible O +
but O +
may O +
be O +
limited O +
by O +
a O +
specific O +
ligand O +
or O +
associated O +
molecule O -
. O -

BRL1 O +
and O +
BRL3 O +
are O +
novel O +
brassinosteroid O +
receptors O +
that O +
function O +
in O +
vascular O +
differentiation O +
in O +
Arabidopsis U-Species -
. O -

Plant O +
steroid O +
hormones O -
, O +
brassinosteroids O +
( O -
BRs O -
) O -
, O +
are O +
perceived O +
by O +
the O +
plasma O +
membrane O -
- O -
localized O +
leucine O -
- O -
rich O -
- O -
repeat O -
- O -
receptor O +
kinase O +
BRI1 O -
. O -

Based O +
on O +
sequence O +
similarity O -
, O +
we O +
have O +
identified O +
three O +
members O +
of O +
the O +
BRI1 O +
family O -
, O +
named O +
BRL1 O -
, O +
BRL2 O +
and O +
BRL3 O -
. O -

BRL1 O +
and O +
BRL3 O -
, O +
but O +
not O +
BRL2 O -
, O +
encode O +
functional O +
BR O +
receptors O +
that O +
bind O +
brassinolide O -
, O +
the O +
most O +
active O +
BR O -
, O +
with O +
high O +
affinity O -
. O -

In O +
agreement O -
, O +
only O +
BRL1 O +
and O +
BRL3 O +
can O +
rescue O +
bri1 O +
mutants O +
when O +
expressed O +
under O +
the O +
control O +
of O +
the O +
BRI1 O +
promoter O -
. O -

While O +
BRI1 O +
is O +
ubiquitously O +
expressed O +
in O +
growing O +
cells O -
, O +
the O +
expression O +
of O +
BRL1 O +
and O +
BRL3 O +
is O +
restricted O +
to O +
non O -
- O -
overlapping O +
subsets O +
of O +
vascular O +
cells O -
. O -

Loss O -
- O -
of O -
- O -
function O +
of O +
brl1 O +
causes O +
abnormal O +
phloem O -
: O -
xylem O +
differentiation O +
ratios O +
and O +
enhances O +
the O +
vascular O +
defects O +
of O +
a O +
weak O +
bri1 O +
mutant O -
. O -

bri1 O +
brl1 O +
brl3 O +
triple O +
mutants O +
enhance O +
bri1 O +
dwarfism O +
and O +
also O +
exhibit O +
abnormal O +
vascular O +
differentiation O -
. O -

Thus O -
, O +
Arabidopsis U-Species +
contains O +
a O +
small O +
number O +
of O +
BR O +
receptors O +
that O +
have O +
specific O +
functions O +
in O +
cell O +
growth O +
and O +
vascular O +
differentiation O -
. O -

Molecular O +
cloning O -
, O +
expression O +
and O +
immunolocalization O +
of O +
a O +
novel O +
human U-Species +
cementum O -
- O -
derived O +
protein O +
( O -
CP-23 O -
) O -
. O -

Cementum O +
is O +
a O +
unique O +
mineralized O +
connective O +
tissue O +
that O +
covers O +
the O +
root O +
surfaces O +
of O +
the O +
teeth O -
. O -

The O +
cementum O +
is O +
critical O +
for O +
appropriate O +
maturation O +
of O +
the O +
periodontium O -
, O +
both O +
during O +
development O +
as O +
well O +
as O +
that O +
associated O +
with O +
regeneration O +
of O +
periodontal O +
tissues O -
, O +
IU O -
; O +
however O -
, O +
one O +
major O +
impediment O +
to O +
understand O +
the O +
molecular O +
mechanisms O +
that O +
regulate O +
periodontal O +
regeneration O +
is O +
the O +
lack O +
of O +
cementum O +
markers O -
. O -

Here O +
we O +
report O +
on O +
the O +
identification O +
and O +
characterization O +
of O +
one O +
such O +
differentially O +
human U-Species +
expressed O +
gene O -
, O +
termed O +
" O -
cementum O +
protein-23 O -
" O +
( O -
CP-23 O -
) O +
that O +
appears O +
to O +
be O +
periodontal O +
ligament O +
and O +
cementum O -
- O -
specific O -
. O -

We O +
screened O +
human U-Species +
cementum O +
tumor O -
- O -
derived O +
cDNA O +
libraries O +
by O +
transient O +
expression O +
in O +
COS-7 O +
cells O +
and O +
" O -
panning O -
" O +
with O +
a O +
rabbit U-Species +
polyclonal O +
antibody O +
against O +
a O +
cementoblastoma O +
conditioned O +
media O -
- O -
derived O +
protein O +
( O -
CP O -
) O -
. O -

One O +
isolated O +
cDNA O -
, O +
CP-23 O -
, O +
was O +
expressed O +
in O +
E. B-Species +
coli L-Species +
and O +
polyclonal O +
antibodies O +
against O +
the O +
recombinant O +
human U-Species +
CP-23 O +
were O +
produced O -
. O -

Expression O +
of O +
CP-23 O +
protein O +
by O +
cells O +
of O +
the O +
periodontium O +
was O +
examined O +
by O +
Northern O +
blot O +
and O +
in O +
situ O +
hybridization O -
. O -

Expression O +
of O +
CP-23 O +
transcripts O +
in O +
human U-Species +
cementoblastoma O -
- O -
derived O +
cells O -
, O +
periodontal O +
ligament O +
cells O -
, O +
human U-Species +
gingival O +
fibroblasts O +
and O +
alveolar O +
bone O -
- O -
derived O +
cells O +
was O +
determined O +
by O +
RT O -
- O -
PCR O -
. O -

Our O +
results O +
show O +
that O +
we O +
have O +
isolated O +
a O +
1374-bp O +
human U-Species +
cDNA O +
containing O +
an O +
open O +
reading O +
frame O +
that O +
encodes O +
a O +
polypeptide O +
with O +
247 O +
amino O +
acid O +
residues O -
, O +
with O +
a O +
predicted O +
molecular O +
mass O +
of O +
25.9 O +
kDa O +
that O +
represents O +
CP O +
species O -
. O -

The O +
recombinant O +
human U-Species +
CP-23 O +
protein O +
cross O -
- O -
reacted O +
with O +
antibodies O +
against O +
CP O +
and O +
type O +
X O +
collagen O -
. O -

Immunoscreening O +
of O +
human U-Species +
periodontal O +
tissues O +
revealed O +
that O +
CP-23 O +
gene O +
product O +
is O +
localized O +
to O +
the O +
cementoid O +
matrix O +
of O +
cementum O +
and O +
cementoblasts O +
throughout O +
the O +
entire O +
surface O +
of O +
the O +
root O -
, O +
cell O +
subpopulations O +
of O +
the O +
periodontal O +
ligament O +
as O +
well O +
as O +
cells O +
located O +
paravascularly O +
to O +
the O +
blood O +
vessels O +
into O +
the O +
periodontal O +
ligament O -
. O -

Furthermore O -
, O +
98 O -
% O +
of O +
putative O +
cementoblasts O +
and O +
15 O -
% O +
of O +
periodontal O +
ligament O +
cells O +
cultured O +
in O +
vitro O +
expressed O +
CP-23 O +
gene O +
product O -
. O -

Cementoblastoma O +
cells O +
and O +
periodontal O +
ligament O +
cells O +
contained O +
a O +
5.0 O +
kb O +
CP-23 O +
mRNA O -
. O -

In O +
situ O +
hybridization O +
showed O +
strong O +
expression O +
of O +
CP-23 O +
mRNA O +
on O +
cementoblast O -
, O +
cell O +
subpopulations O +
of O +
the O +
periodontal O +
ligament O +
and O +
cells O +
located O +
around O +
blood O +
vessels O +
into O +
the O +
periodontal O +
ligament O -
. O -

Our O +
results O +
demonstrate O +
that O +
CP-23 O +
represents O +
a O +
novel O -
, O +
tissue O -
- O -
specific O -
- O -
gene O +
product O +
being O +
expressed O +
by O +
periodontal O +
ligament O +
subpopulations O +
and O +
cementoblasts O -
. O -

These O +
findings O +
offer O +
the O +
possibility O +
to O +
determine O +
the O +
cellular O +
and O +
molecular O +
events O +
that O +
regulate O +
the O +
cementogenesis O +
process O +
during O +
root O +
development O -
. O -

Furthermore O -
, O +
it O +
might O +
provide O +
new O +
venues O +
for O +
the O +
design O +
of O +
translational O +
studies O +
aimed O +
at O +
achieving O +
predictable O +
new O +
cementogenesis O +
and O +
regeneration O +
of O +
the O +
periodontal O +
tissues O -
. O -

Nuclear O +
localisation O +
of O +
endogenous O +
SUMO-1-modified O +
PDGF O -
- O -
C O +
in O +
human U-Species +
thyroid O +
tissue O +
and O +
cell O +
lines O -
. O -

We O +
investigated O +
post O -
- O -
translational O +
modification O +
and O +
subcellular O +
localisation O +
of O +
endogenous O +
platelet O -
- O -
derived O +
growth O +
factor O -
- O -
C O +
( O -
PDGF O -
- O -
C O -
) O +
in O +
human U-Species +
thyroid O +
papillary O +
carcinomas O +
( O -
PTC O -
) O -
, O +
non O -
- O -
neoplastic O +
thyroid O +
tissues O -
, O +
and O +
a O +
selection O +
of O +
cultured O +
cell O +
lines O -
. O -

PDGF O -
- O -
C O +
expressed O +
nuclear O +
localisation O +
in O +
95 O -
% O +
of O +
all O +
tested O +
cell O +
types O +
in O +
culture O +
and O +
in O +
10 O -
% O +
of O +
the O +
thyrocytes O +
from O +
both O +
PTC O +
and O +
non O -
- O -
neoplastic O +
tissue O -
. O -

The O +
cell O +
lines O +
expressed O +
two O +
forms O +
of O +
full O -
- O -
length O +
PDGF O -
- O -
C O -
, O +
approximately O +
39 O +
and O +
approximately O +
55 O +
kDa O -
, O +
in O +
cell O +
membrane O +
and O +
cytosol O -
, O +
while O +
the O +
approximately O +
55 O +
kDa O +
form O +
dominated O +
in O +
the O +
nucleus O +
where O +
it O +
was O +
partly O +
chromatin O -
- O -
associated O -
. O -

The O +
approximately O +
55 O +
kDa O +
form O +
was O +
post O -
- O -
translationally O +
modified O +
by O +
SUMO-1 O -
. O -

The O +
putative O +
PDGF O -
- O -
C O +
SUMOylation O +
site O +
is O +
the O +
surface O +
exposed O +
( O -
314 O -
) O -
lysine O +
part O +
of O +
a O +
positively O +
charged O +
loop O +
( O -
( O -
312 O -
) O -
RPKTGVRGLHK O -
( O -
322 O -
) O -
) O +
with O +
characteristics O +
of O +
a O +
nuclear O +
localisation O +
signal O -
. O -

The O +
tissue O +
thyrocytes O +
expressed O +
a O +
non O -
- O -
SUMOylated O +
approximately O +
43 O +
kDa O +
and O +
the O +
55 O +
kDa O +
PDGF O -
- O -
C. O -

The O +
SUMO-1 O +
modified O +
approximately O +
55 O +
kDa O +
PDGF O -
- O -
C O +
expression O +
was O +
low O +
in O +
PTC O +
where O +
the O +
approximately O +
43 O +
kDa O +
PDGF O -
- O -
C O +
dominated O -
. O -

This O +
is O +
in O +
contrast O +
to O +
non O -
- O -
neoplastic O +
tissue O +
and O +
cultured O +
cells O +
where O +
the O +
SUMOylated O +
approximately O +
55 O +
kDa O +
PDGF O -
- O -
C O +
was O +
strongly O +
expressed O -
. O -

Our O +
data O +
provide O +
novel O +
evidence O +
for O +
nuclear O +
localisation O +
of O +
PDGF O -
- O -
C O -
, O +
post O -
- O -
translational O +
modification O +
by O +
SUMOylation O +
and O +
the O +
expression O +
of O +
a O +
novel O +
form O +
of O +
PDGF O -
- O -
C O +
in O +
human U-Species +
papillary O +
thyroid O +
carcinomas O -
. O -

Shugoshin O +
collaborates O +
with O +
protein O +
phosphatase O +
2A O +
to O +
protect O +
cohesin O -
. O -

Sister O +
chromatid O +
cohesion O -
, O +
mediated O +
by O +
a O +
complex O +
called O +
cohesin O -
, O +
is O +
crucial O -
-- O -
particularly O +
at O +
centromeres O -
-- O -
for O +
proper O +
chromosome O +
segregation O +
in O +
mitosis O +
and O +
meiosis O -
. O -

In O +
animal O +
mitotic O +
cells O -
, O +
phosphorylation O +
of O +
cohesin O +
promotes O +
its O +
dissociation O +
from O +
chromosomes O -
, O +
but O +
centromeric O +
cohesin O +
is O +
protected O +
by O +
shugoshin O +
until O +
kinetochores O +
are O +
properly O +
captured O +
by O +
the O +
spindle O +
microtubules O -
. O -

However O -
, O +
the O +
mechanism O +
of O +
shugoshin O -
- O -
dependent O +
protection O +
of O +
cohesin O +
is O +
unknown O -
. O -

Here O +
we O +
find O +
a O +
specific O +
subtype O +
of O +
serine O -
/ O -
threonine O +
protein O +
phosphatase O +
2A O +
( O -
PP2A O -
) O +
associating O +
with O +
human U-Species +
shugoshin O -
. O -

PP2A O +
colocalizes O +
with O +
shugoshin O +
at O +
centromeres O +
and O +
is O +
required O +
for O +
centromeric O +
protection O -
. O -

Purified O +
shugoshin O +
complex O +
has O +
an O +
ability O +
to O +
reverse O +
the O +
phosphorylation O +
of O +
cohesin O +
in O +
vitro O -
, O +
suggesting O +
that O +
dephosphorylation O +
of O +
cohesin O +
is O +
the O +
mechanism O +
of O +
protection O +
at O +
centromeres O -
. O -

Meiotic O +
shugoshin O +
of O +
fission O +
yeast U-Species +
also O +
associates O +
with O +
PP2A O -
, O +
with O +
both O +
proteins O +
collaboratively O +
protecting O +
Rec8-containing O +
cohesin O +
at O +
centromeres O -
. O -

Thus O -
, O +
we O +
have O +
revealed O +
a O +
conserved O +
mechanism O +
of O +
centromeric O +
protection O +
of O +
eukaryotic O +
chromosomes O +
in O +
mitosis O +
and O +
meiosis O -
. O -

Identification O +
and O +
characterization O +
of O +
a O +
novel O +
zinc O +
finger O +
protein O +
( O -
HZF1 O -
) O +
gene O +
and O +
its O +
function O +
in O +
erythroid O +
and O +
megakaryocytic O +
differentiation O +
of O +
K562 O +
cells O -
. O -

A O +
novel O +
zinc O +
finger O +
protein O +
( O -
HZF1 O -
) O +
gene O +
was O +
identified O +
and O +
characterized O +
by O +
screening O +
a O +
human U-Species +
bone O +
marrow O +
cDNA O +
library O -
, O +
using O +
a O +
new O +
expression O +
sequence O +
tag O +
probe O +
that O +
contains O +
sequences O +
encoding O +
zinc O +
finger O +
motifs O -
. O -

There O +
are O +
at O +
least O +
three O +
transcripts O +
that O +
may O +
result O +
from O +
different O +
splicing O +
of O +
the O +
pre O -
- O -
mRNA O -
, O +
but O +
the O +
differences O +
among O +
them O +
are O +
only O +
involved O +
in O +
5 O -
' O +
non O -
- O -
translation O +
region O +
of O +
HZF1 O +
mRNA O -
. O -

HZF1 O +
gene O +
contains O +
four O +
exons O +
and O +
three O +
introns O -
. O -

The O +
putative O +
protein O +
consists O +
of O +
670 O +
amino O -
- O -
acid O +
residues O +
including O +
15 O +
typical O +
C2H2 O +
and O +
2 O +
C2RH O +
zinc O +
finger O +
motifs O -
. O -

This O +
structure O +
characterization O +
of O +
HZF1 O +
and O +
the O +
nuclear O +
location O +
of O +
the O +
protein O +
suggest O +
that O +
HZF1 O +
may O +
function O +
as O +
a O +
transcription O +
factor O -
. O -

HZF1 O +
mRNA O +
expression O +
was O +
detected O +
in O +
ubiquitous O +
tissues O +
and O +
various O +
hematopoietic O +
cell O +
lines O -
. O -

Increased O +
HZF1 O +
mRNA O +
expression O +
was O +
observed O +
following O +
erythroid O +
differentiation O +
of O +
K562 O +
cells O +
induced O +
by O +
hemin O +
or O +
megakaryocytic O +
differentiation O +
of O +
K562 O +
cells O +
induced O +
by O +
phorbol O +
myristate O +
acetate O +
( O -
PMA O -
) O -
. O -

Both O +
of O +
the O +
antisense O +
method O +
and O +
RNA O +
interference O +
assay O +
revealed O +
that O +
repression O +
of O +
the O +
intrinsic O +
expression O +
of O +
HZF1 O +
blocked O +
the O +
hemin O -
- O -
induced O +
erythroid O +
differentiation O +
and O +
reduced O +
the O +
PMA O -
- O -
induced O +
megakaryocytic O +
differentiation O +
of O +
K562 O +
cells O -
, O +
which O +
suggested O +
that O +
HZF1 O +
play O +
important O +
roles O +
in O +
erythroid O +
and O +
megakaryocytic O +
differentiation O -
. O -

Reversible O +
lysine O +
acetylation O +
controls O +
the O +
activity O +
of O +
the O +
mitochondrial O +
enzyme O +
acetyl O -
- O -
CoA O +
synthetase O +
2 O -
. O -

We O +
report O +
that O +
human U-Species +
acetyl O -
- O -
CoA O +
synthetase O +
2 O +
( O -
AceCS2 O -
) O +
is O +
a O +
mitochondrial O +
matrix O +
protein O -
. O -

AceCS2 O +
is O +
reversibly O +
acetylated O +
at O +
Lys-642 O +
in O +
the O +
active O +
site O +
of O +
the O +
enzyme O -
. O -

The O +
mitochondrial O +
sirtuin O +
SIRT3 O +
interacts O +
with O +
AceCS2 O +
and O +
deacetylates O +
Lys-642 O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

Deacetylation O +
of O +
AceCS2 O +
by O +
SIRT3 O +
activates O +
the O +
acetyl O -
- O -
CoA O +
synthetase O +
activity O +
of O +
AceCS2 O -
. O -

This O +
report O +
identifies O +
the O +
first O +
acetylated O +
substrate O +
protein O +
of O +
SIRT3 O -
. O -

Our O +
findings O +
show O +
that O +
a O +
mammalian O +
sirtuin O +
directly O +
controls O +
the O +
activity O +
of O +
a O +
metabolic O +
enzyme O +
by O +
means O +
of O +
reversible O +
lysine O +
acetylation O -
. O -

Because O +
the O +
activity O +
of O +
a O +
bacterial O +
ortholog O +
of O +
AceCS2 O -
, O +
called O +
ACS O -
, O +
is O +
controlled O +
via O +
deacetylation O +
by O +
a O +
bacterial O +
sirtuin O +
protein O -
, O +
our O +
observation O +
highlights O +
the O +
conservation O +
of O +
a O +
metabolic O +
regulatory O +
pathway O +
from O +
bacteria O +
to O +
humans U-Species -
. O -

Detection O +
of O +
autoantibodies O +
to O +
the O +
BTB O -
- O -
kelch O +
protein O +
KLHL7 O +
in O +
cancer O +
sera O -
. O -

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
search O +
for O +
novel O +
targets O +
of O +
autoantibodies O +
in O +
patients O +
with O +
paraneoplastic O +
neurological O +
syndromes O +
( O -
PNS O -
) O -
. O -

PNS O +
are O +
mediated O +
by O +
immune O +
reactions O +
against O +
autoantigen O -
( O -
s O -
) O +
shared O +
by O +
the O +
cancer O +
cells O +
and O +
the O +
nervous O +
system O -
. O -

By O +
serological O +
screening O +
of O +
a O +
rat U-Species +
cerebellum O +
cDNA O +
expression O +
library O +
using O +
anti O -
- O -
Hu O -
- O -
positive O +
sera O +
from O +
three O +
patients O +
with O +
paraneoplastic O +
encephalomyelitis O +
( O -
PEM O -
) O -
, O +
we O +
identified O +
an O +
open O +
reading O +
frame O +
encoding O +
an O +
isoform O +
of O +
the O +
BTB O -
- O -
kelch O +
protein O +
KLHL7 O -
. O -

Immunohistochemical O +
studies O +
demonstrated O +
that O +
the O +
KLHL7 O +
protein O +
is O +
expressed O +
in O +
the O +
nuclei O +
of O +
neurones O -
, O +
but O +
not O +
in O +
other O +
tissues O +
including O +
various O +
cancers O -
. O -

However O -
, O +
the O +
KLHL7 O +
protein O +
was O +
detected O +
in O +
the O +
nuclei O +
of O +
cancer O +
cell O +
lines O -
. O -

Antibodies O +
to O +
KLHL7 O +
were O +
detected O +
by O +
an O +
immunoprecipitation O +
assay O +
in O +
sera O +
from O +
12 O +
of O +
254 O +
( O -
4.7 O -
% O -
) O +
patients O +
with O +
various O +
cancers O +
and O +
2 O +
of O +
170 O +
blood O +
donors O +
( O -
1.2 O -
% O -
) O -
. O -

None O +
of O +
50 O +
sera O +
from O +
patients O +
with O +
multiple O +
sclerosis O +
were O +
positive O +
for O +
KLHL7 O +
antibodies O -
. O -

Sixteen O +
patients O +
with O +
classical O +
PNS O +
and O +
anti O -
- O -
Hu O +
or O +
anti O -
- O -
Yo O +
antibodies O +
were O +
also O +
negative O +
for O +
KLHL7 O +
antibodies O -
. O -

Seven O +
cancer O +
patients O +
with O +
KLHL7 O +
antibodies O +
had O +
various O +
signs O +
of O +
neurological O +
disease O +
that O +
could O +
be O +
related O +
to O +
cancer O -
, O +
whereas O +
the O +
remaining O +
five O +
seropositive O +
cancer O +
patients O +
had O +
no O +
clinical O +
signs O +
of O +
possible O +
PNS O -
. O -

The O +
present O +
results O +
indicate O +
that O +
KLHL7 O +
antibodies O +
are O +
associated O +
with O +
various O +
cancers O -
, O +
and O +
in O +
some O +
patients O +
also O +
with O +
neurological O +
disease O -
. O -

Whether O +
KLHL7 O +
antibodies O +
can O +
be O +
used O +
as O +
paraneoplastic O +
markers O +
for O +
PNS O +
remains O +
to O +
be O +
determined O -
. O -

Quantitative O +
phosphoproteomics O +
of O +
early O +
elicitor O +
signaling O +
in O +
Arabidopsis U-Species -
. O -

Perception O +
of O +
general O +
elicitors O +
by O +
plant O +
cells O +
initiates O +
signal O +
transduction O +
cascades O +
that O +
are O +
regulated O +
by O +
protein O +
phosphorylation O -
. O -

The O +
earliest O +
signaling O +
events O +
occur O +
within O +
minutes O +
and O +
include O +
ion O +
fluxes O +
across O +
the O +
plasma O +
membrane O -
, O +
activation O +
of O +
MAPKs O -
, O +
and O +
the O +
formation O +
of O +
reactive O +
oxygen O +
species O -
. O -

The O +
phosphorylation O +
events O +
that O +
regulate O +
these O +
signaling O +
cascades O +
are O +
largely O +
unknown O -
. O -

Here O +
we O +
present O +
a O +
mass O +
spectrometry O -
- O -
based O +
quantitative O +
phosphoproteomics O +
approach O +
that O +
identified O +
differentially O +
phosphorylated O +
sites O +
in O +
signaling O +
and O +
response O +
proteins O +
from O +
Arabidopsis U-Species +
cells O +
treated O +
with O +
either O +
flg22 O +
or O +
xylanase O -
. O -

Our O +
approach O +
was O +
sensitive O +
enough O +
to O +
quantitate O +
phosphorylation O +
on O +
low O +
abundance O +
signaling O +
proteins O +
such O +
as O +
calcium O -
- O -
dependent O +
protein O +
kinases O +
and O +
receptor O -
- O -
like O +
kinase O +
family O +
members O -
. O -

With O +
this O +
approach O +
we O +
identified O +
one O +
or O +
more O +
differentially O +
phosphorylated O +
sites O +
in O +
76 O +
membrane O -
- O -
associated O +
proteins O +
including O +
a O +
number O +
of O +
defense O -
- O -
related O +
proteins O -
. O -

Our O +
data O +
on O +
phosphorylation O +
indicate O +
a O +
high O +
degree O +
of O +
complexity O +
at O +
the O +
level O +
of O +
post O -
- O -
translational O +
modification O +
as O +
exemplified O +
by O +
the O +
complex O +
modification O +
patterns O +
of O +
respiratory O +
burst O +
oxidase O +
protein O +
D. O +
Furthermore O +
the O +
data O +
also O +
suggest O +
that O +
protein O +
translocation O +
and O +
vesicle O +
traffic O +
are O +
important O +
aspects O +
of O +
early O +
signaling O +
and O +
defense O +
in O +
response O +
to O +
general O +
elicitors O -
. O -

Our O +
study O +
presents O +
the O +
largest O +
quantitative O +
Arabidopsis U-Species +
phosphoproteomics O +
data O +
set O +
to O +
date O +
and O +
provides O +
a O +
new O +
resource O +
that O +
can O +
be O +
used O +
to O +
gain O +
novel O +
insight O +
into O +
plant O +
defense O +
signal O +
transduction O +
and O +
early O +
defense O +
response O -
. O -

An O +
endoplasmic O +
reticulum O +
transmembrane O +
prolyl O +
4-hydroxylase O +
is O +
induced O +
by O +
hypoxia O +
and O +
acts O +
on O +
hypoxia O -
- O -
inducible O +
factor O +
alpha O -
. O -

Prolyl O +
4-hydroxylases O +
( O -
P4Hs O -
) O +
act O +
on O +
collagens O +
( O -
C O -
- O -
P4Hs O -
) O +
and O +
the O +
oxygen O -
- O -
dependent O +
degradation O +
domains O +
( O -
ODDDs O -
) O +
of O +
hypoxia O -
- O -
inducible O +
factor O +
alpha O +
subunits O +
( O -
HIF O -
- O -
P4Hs O -
) O +
leading O +
to O +
degradation O +
of O +
the O +
latter O -
. O -

We O +
report O +
data O +
on O +
a O +
human U-Species +
P4H O +
possessing O +
a O +
transmembrane O +
domain O +
( O -
P4H O -
- O -
TM O -
) O -
. O -

Its O +
gene O +
is O +
also O +
found O +
in O +
zebrafish U-Species +
but O +
not O +
in O +
flies U-Species +
and O +
nematodes U-Species -
. O -

Its O +
sequence O +
more O +
closely O +
resembles O +
those O +
of O +
the O +
C O -
- O -
P4Hs O +
than O +
the O +
HIF O -
- O -
P4Hs O -
, O +
but O +
it O +
lacks O +
the O +
peptide O +
substrate O -
- O -
binding O +
domain O +
of O +
the O +
C O -
- O -
P4Hs O -
. O -

P4H O -
- O -
TM O +
levels O +
in O +
cultured O +
cells O +
are O +
increased O +
by O +
hypoxia O -
, O +
and O +
P4H O -
- O -
TM O +
is O +
N O -
- O -
glycosylated O +
and O +
is O +
located O +
in O +
endoplasmic O +
reticulum O +
membranes O +
with O +
its O +
catalytic O +
site O +
inside O +
the O +
lumen O -
, O +
a O +
location O +
differing O +
from O +
those O +
of O +
the O +
HIF O -
- O -
P4Hs O -
. O -

Despite O +
this O -
, O +
P4H O -
- O -
TM O +
overexpression O +
in O +
cultured O +
neuroblastoma O +
cells O +
reduced O +
HIF O -
- O -
alpha O +
ODDD O +
reporter O +
construct O +
levels O -
, O +
and O +
its O +
small O +
interfering O +
RNA O +
increased O +
HIF-1alpha O +
protein O +
level O -
, O +
in O +
the O +
same O +
way O +
as O +
those O +
of O +
HIF O -
- O -
P4Hs O -
. O -

Furthermore O -
, O +
recombinant O +
P4H O -
- O -
TM O +
hydroxylated O +
the O +
two O +
critical O +
prolines O +
in O +
HIF-1alpha O +
ODDD O +
in O +
vitro O -
, O +
with O +
a O +
preference O +
for O +
the O +
C O -
- O -
terminal O +
proline O -
, O +
whereas O +
it O +
did O +
not O +
hydroxylate O +
any O +
prolines O +
in O +
recombinant O +
type O +
I O +
procollagen O +
chains O -
. O -

A O +
mechanism O +
for O +
asymmetric O +
segregation O +
of O +
age O +
during O +
yeast U-Species +
budding O -
. O -

Ageing O +
and O +
the O +
mortality O +
that O +
ensues O +
are O +
sustainable O +
for O +
the O +
species O +
only O +
if O +
age O +
is O +
reset O +
in O +
newborns O -
. O -

In O +
budding O +
yeast U-Species -
, O +
buds O +
are O +
made O +
young O +
whereas O +
ageing O +
factors O -
, O +
such O +
as O +
carbonylated O +
proteins O +
and O +
DNA O +
circles O -
, O +
remain O +
confined O +
to O +
the O +
ageing O +
mother O +
cell O -
. O -

The O +
mechanisms O +
of O +
this O +
confinement O +
and O +
their O +
relevance O +
are O +
poorly O +
understood O -
. O -

Here O +
we O +
show O +
that O +
a O +
septin O -
- O -
dependent O -
, O +
lateral O +
diffusion O +
barrier O +
forms O +
in O +
the O +
nuclear O +
envelope O +
and O +
limits O +
the O +
translocation O +
of O +
pre O -
- O -
existing O +
nuclear O +
pores O +
into O +
the O +
bud O -
. O -

The O +
retention O +
of O +
DNA O +
circles O +
within O +
the O +
mother O +
cell O +
depends O +
on O +
the O +
presence O +
of O +
the O +
diffusion O +
barrier O +
and O +
on O +
the O +
anchorage O +
of O +
the O +
circles O +
to O +
pores O +
mediated O +
by O +
the O +
nuclear O +
basket O -
. O -

In O +
accordance O +
with O +
the O +
diffusion O +
barrier O +
ensuring O +
the O +
asymmetric O +
segregation O +
of O +
nuclear O +
age O -
- O -
determinants O -
, O +
the O +
barrier O +
mutant O +
bud6Delta O +
fails O +
to O +
properly O +
reset O +
age O +
in O +
buds O -
. O -

Our O +
data O +
involve O +
septin O -
- O -
dependent O +
diffusion O +
barriers O +
in O +
the O +
confinement O +
of O +
ageing O +
factors O +
to O +
one O +
daughter O +
cell O +
during O +
asymmetric O +
cell O +
division O -
. O -

H2A.Bbd O -
: O +
an O +
X O -
- O -
chromosome O -
- O -
encoded O +
histone O +
involved O +
in O +
mammalian O +
spermiogenesis O -
. O -

Despite O +
the O +
identification O +
of O +
H2A.Bbd O +
as O +
a O +
new O +
vertebrate O -
- O -
specific O +
replacement O +
histone O +
variant O +
several O +
years O +
ago O -
, O +
and O +
despite O +
the O +
many O +
in O +
vitro O +
structural O +
characterizations O +
using O +
reconstituted O +
chromatin O +
complexes O +
consisting O +
of O +
this O +
variant O -
, O +
the O +
existence O +
of O +
H2A.Bbd O +
in O +
the O +
cell O +
and O +
its O +
location O +
has O +
remained O +
elusive O -
. O -

Here O -
, O +
we O +
report O +
that O +
the O +
native O +
form O +
of O +
this O +
variant O +
is O +
present O +
in O +
highly O +
advanced O +
spermiogenic O +
fractions O +
of O +
mammalian O +
testis O +
at O +
the O +
time O +
when O +
histones O +
are O +
highly O +
acetylated O +
and O +
being O +
replaced O +
by O +
protamines O -
. O -

It O +
is O +
also O +
present O +
in O +
the O +
nucleosomal O +
chromatin O +
fraction O +
of O +
mature O +
human U-Species +
sperm O -
. O -

The O +
ectopically O +
expressed O +
non O -
- O -
tagged O +
version O +
of O +
the O +
protein O +
is O +
associated O +
with O +
micrococcal O +
nuclease O -
- O -
refractory O +
insoluble O +
fractions O +
of O +
chromatin O +
and O +
in O +
mouse U-Species +
( O -
20T1 O -
/ O -
2 O -
) O +
cell O +
line O -
, O +
H2A.Bbd O +
is O +
enriched O +
at O +
the O +
periphery O +
of O +
chromocenters O -
. O -

The O +
exceedingly O +
rapid O +
evolution O +
of O +
this O +
unique O +
X O -
- O -
chromosome O -
- O -
linked O +
histone O +
variant O +
is O +
shared O +
with O +
other O +
reproductive O +
proteins O +
including O +
those O +
associated O +
with O +
chromatin O +
in O +
the O +
mature O +
sperm O +
( O -
protamines O -
) O +
of O +
many O +
vertebrates O -
. O -

This O +
common O +
rate O +
of O +
evolution O +
provides O +
further O +
support O +
for O +
the O +
functional O +
and O +
structural O +
involvement O +
of O +
this O +
protein O +
in O +
male O +
gametogenesis O +
in O +
mammals O -
. O -

HERC2 O +
coordinates O +
ubiquitin O -
- O -
dependent O +
assembly O +
of O +
DNA O +
repair O +
factors O +
on O +
damaged O +
chromosomes O -
. O -

Regulatory O +
ubiquitylation O +
is O +
emerging O +
as O +
an O +
important O +
mechanism O +
to O +
protect O +
genome O +
integrity O +
in O +
cells O +
exposed O +
to O +
DNA O +
damage O -
. O -

However O -
, O +
the O +
spectrum O +
of O +
known O +
ubiquitin O +
regulators O +
of O +
the O +
DNA O +
damage O +
response O +
( O -
DDR O -
) O +
is O +
limited O +
and O +
their O +
functional O +
interplay O +
is O +
poorly O +
understood O -
. O -

Here O -
, O +
we O +
identify O +
HERC2 O +
as O +
a O +
factor O +
that O +
regulates O +
ubiquitin O -
- O -
dependent O +
retention O +
of O +
repair O +
proteins O +
on O +
damaged O +
chromosomes O -
. O -

In O +
response O +
to O +
ionising O +
radiation O +
( O -
IR O -
) O -
, O +
HERC2 O +
forms O +
a O +
complex O +
with O +
RNF8 O -
, O +
a O +
ubiquitin O +
ligase O +
involved O +
in O +
the O +
DDR O -
. O -

The O +
HERC2-RNF8 O +
interaction O +
requires O +
IR O -
- O -
inducible O +
phosphorylation O +
of O +
HERC2 O +
at O +
Thr O +
4827 O -
, O +
which O +
in O +
turn O +
binds O +
to O +
the O +
forkhead O -
- O -
associated O +
( O -
FHA O -
) O +
domain O +
of O +
RNF8 O -
. O -

Mechanistically O -
, O +
we O +
provide O +
evidence O +
that O +
HERC2 O +
facilitates O +
assembly O +
of O +
the O +
ubiquitin O -
- O -
conjugating O +
enzyme O +
Ubc13 O +
with O +
RNF8 O -
, O +
thereby O +
promoting O +
DNA O +
damage O -
- O -
induced O +
formation O +
of O +
Lys O +
63-linked O +
ubiquitin O +
chains O -
. O -

We O +
also O +
show O +
that O +
HERC2 O +
interacts O +
with O -
, O +
and O +
maintains O +
the O +
levels O +
of O -
, O +
RNF168 O -
, O +
another O +
ubiquitin O +
ligase O +
operating O +
downstream O +
of O +
RNF8 O +
( O -
Refs O +
7 O -
, O +
8) O -
. O -

Consequently O -
, O +
knockdown O +
of O +
HERC2 O +
abrogates O +
ubiquitin O -
- O -
dependent O +
retention O +
of O +
repair O +
factors O +
such O +
as O +
53BP1 O -
, O +
RAP80 O +
and O +
BRCA1 O -
. O -

Together O +
with O +
the O +
increased O +
radiosensitivity O +
of O +
HERC2-depleted O +
cells O -
, O +
these O +
results O +
uncover O +
a O +
regulatory O +
layer O +
in O +
the O +
orchestration O +
of O +
protein O +
interactions O +
on O +
damaged O +
chromosomes O +
and O +
they O +
underscore O +
the O +
role O +
of O +
ubiquitin O -
- O -
mediated O +
signalling O +
in O +
genome O +
maintenance O -
. O -

Characterization O +
of O +
a O +
putative O +
3-deoxy O -
- O -
D O -
- O -
manno-2-octulosonic O +
acid O +
( O -
Kdo O -
) O +
transferase O +
gene O +
from O +
Arabidopsis B-Species +
thaliana L-Species -
. O -

The O +
structures O +
of O +
the O +
pectic O +
polysaccharide O +
rhamnogalacturonan O +
II O +
( O -
RG O -
- O -
II O -
) O +
pectin O +
constituent O +
are O +
remarkably O +
evolutionary O +
conserved O +
in O +
all O +
plant O +
species O -
. O -

At O +
least O +
12 O +
different O +
glycosyl O +
residues O +
are O +
present O +
in O +
RG O -
- O -
II O -
. O -

Among O +
them O +
is O +
the O +
seldom O +
eight O -
- O -
carbon O +
sugar O +
3-deoxy O -
- O -
d O -
- O -
manno O -
- O -
octulosonic O +
acid O +
( O -
Kdo O -
) O +
whose O +
biosynthetic O +
pathway O +
has O +
been O +
shown O +
to O +
be O +
conserved O +
between O +
plants O +
and O +
Gram O -
- O -
negative O +
bacteria O -
. O -

Kdo O +
is O +
formed O +
in O +
the O +
cytosol O +
by O +
the O +
condensation O +
of O +
phosphoenol O +
pyruvate O +
with O +
d O -
- O -
arabinose-5-P O +
and O +
then O +
activated O +
by O +
coupling O +
to O +
cytidine O +
monophosphate O +
( O -
CMP O -
) O +
prior O +
to O +
its O +
incorporation O +
in O +
the O +
Golgi O +
apparatus O +
by O +
a O +
Kdo O +
transferase O +
( O -
KDTA O -
) O +
into O +
the O +
nascent O +
polysaccharide O +
RG O -
- O -
II O -
. O -

To O +
gain O +
new O +
insight O +
into O +
RG O -
- O -
II O +
biosynthesis O +
and O +
function O -
, O +
we O +
isolated O +
and O +
characterized O +
null O +
mutants O +
for O +
the O +
unique O +
putative O +
KDTA O +
( O -
AtKDTA O -
) O +
encoded O +
in O +
the O +
Arabidopsis U-Species +
genome O -
. O -

We O +
provide O +
evidence O +
that O -
, O +
in O +
contrast O +
to O +
mutants O +
affecting O +
the O +
RG O -
- O -
II O +
biosynthesis O -
, O +
the O +
extinction O +
of O +
the O +
AtKDTA O +
gene O +
expression O +
does O +
not O +
result O +
in O +
any O +
developmental O +
phenotype O +
in O +
the O +
AtkdtA O +
plants O -
. O -

Furthermore O -
, O +
the O +
structure O +
of O +
RG O -
- O -
II O +
from O +
the O +
null O +
mutants O +
was O +
not O +
altered O +
and O +
contained O +
wild O -
- O -
type O +
amount O +
of O +
Rha O -
- O -
alpha O -
( O -
1 O -
- O -
5 O -
) O -
Kdo O +
side O +
chain O -
. O -

The O +
cellular O +
localization O +
of O +
AtKDTA O +
was O +
investigated O +
by O +
using O +
laser O +
scanning O +
confocal O +
imaging O +
of O +
the O +
protein O +
fused O +
to O +
green O +
fluorescent O +
protein O -
. O -

In O +
agreement O +
with O +
its O +
cellular O +
prediction O -
, O +
the O +
fusion O +
protein O +
was O +
demonstrated O +
to O +
be O +
targeted O +
to O +
the O +
mitochondria O -
. O -

These O +
data O -
, O +
together O +
with O +
data O +
deduced O +
from O +
sequence O +
analyses O +
of O +
higher O +
plant O +
genomes O -
, O +
suggest O +
that O +
AtKDTA O +
encodes O +
a O +
putative O +
KDTA O +
involved O +
in O +
the O +
synthesis O +
of O +
a O +
mitochondrial O +
not O +
yet O +
identified O +
lipid O +
A O -
- O -
like O +
molecule O +
rather O +
than O +
in O +
the O +
synthesis O +
of O +
the O +
cell O +
wall O +
RG O -
- O -
II O -
. O -

Arginine O +
metabolism O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species -
: O +
subcellular O +
localization O +
of O +
the O +
enzymes O -
. O -

Subcellular O +
localization O +
of O +
enzymes O +
of O +
arginine O +
metabolism O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species +
was O +
studied O +
by O +
partial O +
fractionation O +
and O +
stepwise O +
homogenization O +
of O +
spheroplast O +
lysates O -
. O -

These O +
enzymes O +
could O +
clearly O +
be O +
divided O +
into O +
two O +
groups O -
. O -

The O +
first O +
group O +
comprised O +
the O +
five O +
enzymes O +
of O +
the O +
acetylated O +
compound O +
cycle O -
, O +
i.e. O -
, O +
acetylglutamate O +
synthase O -
, O +
acetylglutamate O +
kinase O -
, O +
acetylglutamyl O -
- O -
phosphate O +
reductase O -
, O +
acetylornithine O +
aminotransferase O -
, O +
and O +
acetylornithine O -
- O -
glutamate O +
acetyltransferase O -
. O -

These O +
enzymes O +
were O +
exclusively O +
particulate O -
. O -

Comparison O +
with O +
citrate O +
synthase O +
and O +
cytochrome O +
oxidase O -
, O +
and O +
results O +
from O +
isopycnic O +
gradient O +
analysis O -
, O +
suggested O +
that O +
these O +
enzymes O +
were O +
associated O +
with O +
the O +
mitochondria O -
. O -

By O +
contrast O -
, O +
enzymatic O +
activities O +
going O +
from O +
ornithine O +
to O +
arginine O -
, O +
i.e. O -
, O +
arginine O +
pathway O -
- O -
specific O +
carbamoylphosphate O +
synthetase O -
, O +
ornithine O +
carbamoyltransferase O -
, O +
argininosuccinate O +
synthetase O -
, O +
and O +
argininosuccinate O +
lyase O -
, O +
and O +
the O +
two O +
first O +
catabolic O +
enzymes O -
, O +
arginase O +
and O +
ornithine O +
aminotransferase O -
, O +
were O +
in O +
the O +
" O -
soluble O -
" O +
fraction O +
of O +
the O +
cell O -
. O -

Identification O +
and O +
characterization O +
of O +
the O +
missing O +
pyrimidine O +
reductase O +
in O +
the O +
plant O +
riboflavin O +
biosynthesis O +
pathway O -
. O -

Riboflavin O +
( O -
vitamin O +
B₂ O -
) O +
is O +
the O +
precursor O +
of O +
the O +
flavin O +
coenzymes O +
flavin O +
mononucleotide O +
and O +
flavin O +
adenine O +
dinucleotide O -
. O -

In O +
Escherichia B-Species +
coli L-Species +
and O +
other O +
bacteria O -
, O +
sequential O +
deamination O +
and O +
reduction O +
steps O +
in O +
riboflavin O +
biosynthesis O +
are O +
catalyzed O +
by O +
RibD O -
, O +
a O +
bifunctional O +
protein O +
with O +
distinct O +
pyrimidine O +
deaminase O +
and O +
reductase O +
domains O -
. O -

Plants O +
have O +
two O +
diverged O +
RibD O +
homologs O -
, O +
PyrD O +
and O +
PyrR O -
; O +
PyrR O +
proteins O +
have O +
an O +
extra O +
carboxyl O -
- O -
terminal O +
domain O +
( O -
COG3236 O -
) O +
of O +
unknown O +
function O -
. O -

Arabidopsis U-Species +
( O -
Arabidopsis B-Species +
thaliana L-Species -
) O +
PyrD O +
( O -
encoded O +
by O +
At4g20960 O -
) O +
is O +
known O +
to O +
be O +
a O +
monofunctional O +
pyrimidine O +
deaminase O -
, O +
but O +
no O +
pyrimidine O +
reductase O +
has O +
been O +
identified O -
. O -

Bioinformatic O +
analyses O +
indicated O +
that O +
plant O +
PyrR O +
proteins O +
have O +
a O +
catalytically O +
competent O +
reductase O +
domain O +
but O +
lack O +
essential O +
zinc O -
- O -
binding O +
residues O +
in O +
the O +
deaminase O +
domain O -
, O +
and O +
that O +
the O +
Arabidopsis U-Species +
PyrR O +
gene O +
( O -
At3g47390 O -
) O +
is O +
coexpressed O +
with O +
riboflavin O +
synthesis O +
genes O -
. O -

These O +
observations O +
imply O +
that O +
PyrR O +
is O +
a O +
pyrimidine O +
reductase O +
without O +
deaminase O +
activity O -
. O -

Consistent O +
with O +
this O +
inference O -
, O +
Arabidopsis U-Species +
or O +
maize U-Species +
( O -
Zea B-Species +
mays L-Species -
) O +
PyrR O +
( O -
At3g47390 O +
or O +
GRMZM2G090068 O -
) O +
restored O +
riboflavin O +
prototrophy O +
to O +
an O +
E. B-Species +
coli L-Species +
ribD O +
deletant O +
strain O +
when O +
coexpressed O +
with O +
the O +
corresponding O +
PyrD O +
protein O +
( O -
At4g20960 O +
or O +
GRMZM2G320099 O -
) O +
but O +
not O +
when O +
expressed O +
alone O -
; O +
the O +
COG3236 O +
domain O +
was O +
unnecessary O +
for O +
complementing O +
activity O -
. O -

Furthermore O -
, O +
recombinant O +
maize U-Species +
PyrR O +
mediated O +
NAD O -
( O -
P O -
) O -
H O -
- O -
dependent O +
pyrimidine O +
reduction O +
in O +
vitro O -
. O -

Import O +
assays O +
with O +
pea U-Species +
( O -
Pisum B-Species +
sativum L-Species -
) O +
chloroplasts O +
showed O +
that O +
PyrR O +
and O +
PyrD O +
are O +
taken O +
up O +
and O +
proteolytically O +
processed O -
. O -

Ablation O +
of O +
the O +
maize U-Species +
PyrR O +
gene O +
caused O +
early O +
seed O +
lethality O -
. O -

These O +
data O +
argue O +
that O +
PyrR O +
is O +
the O +
missing O +
plant O +
pyrimidine O +
reductase O -
, O +
that O +
it O +
is O +
plastid O +
localized O -
, O +
and O +
that O +
it O +
is O +
essential O -
. O -

The O +
role O +
of O +
the O +
COG3236 O +
domain O +
remains O +
mysterious O -
; O +
no O +
evidence O +
was O +
obtained O +
for O +
the O +
possibility O +
that O +
it O +
catalyzes O +
the O +
dephosphorylation O +
that O +
follows O +
pyrimidine O +
reduction O -
. O -

Heptahelical O +
protein O +
PQLC2 O +
is O +
a O +
lysosomal O +
cationic O +
amino O +
acid O +
exporter O +
underlying O +
the O +
action O +
of O +
cysteamine O +
in O +
cystinosis O +
therapy O -
. O -

Cystinosin O -
, O +
the O +
lysosomal O +
cystine O +
exporter O +
defective O +
in O +
cystinosis O -
, O +
is O +
the O +
founding O +
member O +
of O +
a O +
family O +
of O +
heptahelical O +
membrane O +
proteins O +
related O +
to O +
bacteriorhodopsin O +
and O +
characterized O +
by O +
a O +
duplicated O +
motif O +
termed O +
the O +
PQ O +
loop O -
. O -

PQ O -
- O -
loop O +
proteins O +
are O +
more O +
frequent O +
in O +
eukaryotes O +
than O +
in O +
prokaryotes O -
; O +
except O +
for O +
cystinosin O -
, O +
their O +
molecular O +
function O +
remains O +
elusive O -
. O -

In O +
this O +
study O -
, O +
we O +
report O +
that O +
three O +
yeast U-Species +
PQ O -
- O -
loop O +
proteins O +
of O +
unknown O +
function O -
, O +
Ypq1 O -
, O +
Ypq2 O -
, O +
and O +
Ypq3 O -
, O +
localize O +
to O +
the O +
vacuolar O +
membrane O +
and O +
are O +
involved O +
in O +
homeostasis O +
of O +
cationic O +
amino O +
acids O +
( O -
CAAs O -
) O -
. O -

We O +
also O +
show O +
that O +
PQLC2 O -
, O +
a O +
mammalian O +
PQ O -
- O -
loop O +
protein O +
closely O +
related O +
to O +
yeast U-Species +
Ypq O +
proteins O -
, O +
localizes O +
to O +
lysosomes O +
and O +
catalyzes O +
a O +
robust O -
, O +
electrogenic O +
transport O +
that O +
is O +
selective O +
for O +
CAAs O +
and O +
strongly O +
activated O +
at O +
low O +
extracytosolic O +
pH. O +
Heterologous O +
expression O +
of O +
PQLC2 O +
at O +
the O +
yeast U-Species +
vacuole O +
rescues O +
the O +
resistance O +
phenotype O +
of O +
an O +
ypq2 O +
mutant O +
to O +
canavanine O -
, O +
a O +
toxic O +
analog O +
of O +
arginine O +
efficiently O +
transported O +
by O +
PQLC2 O -
. O -

Finally O -
, O +
PQLC2 O +
transports O +
a O +
lysine O -
- O -
like O +
mixed O +
disulfide O +
that O +
serves O +
as O +
a O +
chemical O +
intermediate O +
in O +
cysteamine O +
therapy O +
of O +
cystinosis O -
, O +
and O +
PQLC2 O +
gene O +
silencing O +
trapped O +
this O +
intermediate O +
in O +
cystinotic O +
cells O -
. O -

We O +
conclude O +
that O +
PQLC2 O +
and O +
Ypq1 O -
- O -
3 O +
proteins O +
are O +
lysosomal O -
/ O -
vacuolar O +
exporters O +
of O +
CAAs O +
and O +
suggest O +
that O +
small O -
- O -
molecule O +
transport O +
is O +
a O +
conserved O +
feature O +
of O +
the O +
PQ O -
- O -
loop O +
protein O +
family O -
, O +
in O +
agreement O +
with O +
its O +
distant O +
similarity O +
to O +
SWEET O +
sugar O +
transporters O +
and O +
to O +
the O +
mitochondrial O +
pyruvate O +
carrier O -
. O -

The O +
elucidation O +
of O +
PQLC2 O +
function O +
may O +
help O +
improve O +
cysteamine O +
therapy O -
. O -

It O +
may O +
also O +
clarify O +
the O +
origin O +
of O +
CAA O +
abnormalities O +
in O +
Batten O +
disease O -
. O -

GOLPH3L O +
antagonizes O +
GOLPH3 O +
to O +
determine O +
Golgi O +
morphology O -
. O -

GOLPH3 O +
is O +
a O +
phosphatidylinositol-4-phosphate O +
( O -
PI4P O -
) O +
effector O +
that O +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
Golgi O +
architecture O +
and O +
anterograde O +
trafficking O -
. O -

GOLPH3 O +
does O +
so O +
through O +
its O +
ability O +
to O +
link O +
trans O -
- O -
Golgi O +
membranes O +
to O +
F O -
- O -
actin O +
via O +
its O +
interaction O +
with O +
myosin O +
18A O +
( O -
MYO18A O -
) O -
. O -

GOLPH3 O +
also O +
is O +
known O +
to O +
be O +
an O +
oncogene O +
commonly O +
amplified O +
in O +
human U-Species +
cancers O -
. O -

GOLPH3L O +
is O +
a O +
GOLPH3 O +
paralogue O +
found O +
in O +
all O +
vertebrate O +
genomes O -
, O +
although O +
previously O +
it O +
was O +
largely O +
uncharacterized O -
. O -

Here O +
we O +
demonstrate O +
that O +
although O +
GOLPH3 O +
is O +
ubiquitously O +
expressed O +
in O +
mammalian O +
cells O -
, O +
GOLPH3L O +
is O +
present O +
in O +
only O +
a O +
subset O +
of O +
tissues O +
and O +
cell O +
types O -
, O +
particularly O +
secretory O +
tissues O -
. O -

We O +
show O +
that O -
, O +
like O +
GOLPH3 O -
, O +
GOLPH3L O +
binds O +
to O +
PI4P O -
, O +
localizes O +
to O +
the O +
Golgi O +
as O +
a O +
consequence O +
of O +
its O +
PI4P O +
binding O -
, O +
and O +
is O +
required O +
for O +
efficient O +
anterograde O +
trafficking O -
. O -

Surprisingly O -
, O +
however O -
, O +
we O +
find O +
that O +
perturbations O +
of O +
GOLPH3L O +
expression O +
produce O +
effects O +
on O +
Golgi O +
morphology O +
that O +
are O +
opposite O +
to O +
those O +
of O +
GOLPH3 O +
and O +
MYO18A O -
. O -

GOLPH3L O +
differs O +
critically O +
from O +
GOLPH3 O +
in O +
that O +
it O +
is O +
largely O +
unable O +
to O +
bind O +
to O +
MYO18A O -
. O -

Our O +
data O +
demonstrate O +
that O +
despite O +
their O +
similarities O -
, O +
unexpectedly O -
, O +
GOLPH3L O +
antagonizes O +
GOLPH3 O -
/ O -
MYO18A O +
at O +
the O +
Golgi O -
. O -

Molecular O +
cloning O +
of O +
a O +
novel O +
human U-Species +
cDNA O +
encoding O +
a O +
zinc O +
finger O +
protein O +
that O +
binds O +
to O +
the O +
interleukin-3 O +
promoter O -
. O -

The O +
CT O -
/ O -
GC O -
- O -
rich O +
region O +
( O -
-76 O +
to O +
-47 O -
) O +
is O +
one O +
transcriptional O +
regulatory O +
region O +
of O +
the O +
interleukin-3 O +
( O -
IL-3 O -
) O +
gene O +
which O +
confers O +
basic O +
transcriptional O +
activity O +
and O +
responds O +
to O +
trans O -
- O -
activation O +
by O +
human U-Species +
T O -
- O -
cell O +
leukemia O +
virus O +
type O +
I O -
- O -
encoded O +
Tax O -
. O -

We O +
isolated O +
three O +
types O +
of O +
cDNAs O +
encoding O +
Cys2 O -
/ O -
His2-type O +
zinc O +
finger O +
proteins O +
that O +
bind O +
to O +
this O +
region O -
. O -

Two O +
were O +
identical O +
to O +
known O +
transcription O +
factors O -
, O +
EGR1 O +
and O +
EGR2 O -
, O +
and O +
the O +
other O +
clone O -
, O +
named O +
DB1 O -
, O +
encoded O +
a O +
novel O +
protein O +
of O +
516 O +
amino O +
acids O +
with O +
six O +
zinc O +
finger O +
motifs O -
. O -

DB1 O +
mRNA O +
was O +
present O +
in O +
human U-Species +
tissues O -
, O +
ubiquitously O -
. O -

Two O +
constitutive O +
transcripts O +
of O +
4.0 O +
and O +
4.8 O +
kb O +
in O +
length O +
were O +
present O +
in O +
Jurkat O +
cells O -
. O -

Electrophoretic O +
mobility O +
shift O +
assay O -
, O +
with O +
specific O +
antibodies O -
, O +
showed O +
that O +
DB1 O +
constitutively O +
binds O +
to O +
this O +
region O +
whereas O +
EGR1 O +
binds O +
in O +
a O +
T O -
- O -
cell O +
activation O -
- O -
dependent O +
manner O -
. O -

Overexpression O +
of O +
DB1 O +
in O +
Jurkat O +
cells O +
had O +
no O +
detectable O +
effect O +
on O +
the O +
transcription O +
activity O +
of O +
the O +
IL-3 O +
promoter O -
, O +
in O +
a O +
transient O -
- O -
transfection O +
assay O -
. O -

EGR1 O +
and O +
EGR2 O +
increased O +
IL-3 O +
promoter O +
activity O +
when O +
the O +
transfected O +
cells O +
were O +
stimulated O +
with O +
phorbol-12-myristate-13-acetate O +
and O +
A23187 O -
. O -

When O +
DB1 O +
was O +
cotransfected O +
with O +
a O +
Tax O +
expression O +
vector O -
, O +
transcription O +
activity O +
of O +
the O +
IL-3 O +
promoter O +
induced O +
by O +
Tax O +
was O +
significantly O +
increased O -
, O +
while O +
EGR1 O +
and O +
EGR2 O +
were O +
without O +
effect O -
. O -

These O +
results O +
suggest O +
that O +
EGR1 O +
has O +
a O +
role O +
in O +
inducible O +
transcription O +
of O +
the O +
IL-3 O +
gene O -
, O +
while O +
DB1 O +
sustains O +
basal O +
transcriptional O +
activity O +
and O +
also O +
cooperates O +
with O +
Tax O +
to O +
activate O +
the O +
IL-3 O +
promoter O -
. O -

Sequence O +
analysis O +
of O +
203 O +
kilobases O +
from O +
Saccharomyces B-Species +
cerevisiae L-Species +
chromosome O +
VII O -
. O -

The O +
nucleotide O +
sequences O +
of O +
five O +
major O +
regions O +
from O +
chromosome O +
VII O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species +
have O +
been O +
determined O +
and O +
analysed O -
. O -

These O +
regions O +
represent O +
203 O +
kilobases O +
corresponding O +
to O +
approximately O +
one O -
- O -
fifth O +
of O +
the O +
complete O +
yeast U-Species +
chromosome O +
VII O -
. O -

Two O +
fragments O +
originate O +
from O +
the O +
left O +
arm O +
of O +
this O +
chromosome O -
. O -

The O +
first O +
one O +
of O +
about O +
15.8 O +
kb O +
starts O +
approximately O +
75 O +
kb O +
from O +
the O +
left O +
telomere O +
and O +
is O +
bordered O +
by O +
the O +
SK18 O +
chromosomal O +
marker O -
. O -

The O +
second O +
fragment O +
covers O +
the O +
72.6 O +
kb O +
region O +
between O +
the O +
chromosomal O +
markers O +
CYH2 O +
and O +
ALG2 O -
. O -

On O +
the O +
right O +
chromosomal O +
arm O +
three O +
regions O -
, O +
a O +
70.6 O +
kb O +
region O +
between O +
the O +
MSB2 O +
and O +
the O +
KSS1 O +
chromosomal O +
markers O +
and O +
two O +
smaller O +
regions O +
dominated O +
by O +
the O +
KRE11 O +
marker O +
and O +
another O +
one O +
in O +
the O +
vicinity O +
of O +
the O +
SER2 O +
marker O +
were O +
sequenced O -
. O -

We O +
found O +
a O +
total O +
of O +
114 O +
open O +
reading O +
frames O +
( O -
ORFs O -
) O -
, O +
13 O +
of O +
which O +
were O +
completely O +
overlapping O +
with O +
larger O +
ORFs O +
running O +
in O +
the O +
opposite O +
direction O -
. O -

A O +
total O +
of O +
44 O +
yeast U-Species +
genes O -
, O +
the O +
physiological O +
functions O +
of O +
which O +
are O +
known O -
, O +
could O +
be O +
precisely O +
mapped O +
on O +
this O +
chromosome O -
. O -

Of O +
the O +
remaining O +
57 O +
ORFs O -
, O +
26 O +
shared O +
sequence O +
homologies O +
with O +
known O +
genes O -
, O +
among O +
which O +
were O +
13 O +
other O +
S. B-Species +
cerevisiae L-Species +
genes O +
and O +
five O +
genes O +
from O +
other O +
organisms O -
. O -

No O +
homology O +
with O +
any O +
sequence O +
in O +
the O +
databases O +
could O +
be O +
found O +
for O +
31 O +
ORFs O -
. O -

Furthermore O -
, O +
five O +
Ty O +
elements O +
were O +
found O -
, O +
one O +
of O +
which O +
may O +
not O +
be O +
functional O +
due O +
to O +
a O +
frame O +
shift O +
in O +
its O +
Ty1B O +
amino O +
acid O +
sequence O -
. O -

The O +
five O +
chromosomal O +
regions O +
harboured O +
five O +
potential O +
ARS O +
elements O +
and O +
one O +
sigma O +
element O +
together O +
with O +
eight O +
tRNA O +
genes O +
and O +
two O +
snRNAs O -
, O +
one O +
of O +
which O +
is O +
encoded O +
by O +
an O +
intron O +
of O +
a O +
protein O -
- O -
coding O +
gene O -
. O -

A O +
single O +
precursor O +
protein O +
for O +
ferrochelatase O -
- O -
I O +
from O +
Arabidopsis U-Species +
is O +
imported O +
in O +
vitro O +
into O +
both O +
chloroplasts O +
and O +
mitochondria O -
. O -

Ferrochelatase O +
is O +
the O +
last O +
enzyme O +
of O +
heme O +
biosynthesis O +
and O +
in O +
higher O +
plants O +
is O +
found O +
in O +
both O +
chloroplasts O +
and O +
mitochondria O -
. O -

We O +
have O +
isolated O +
cDNAs O +
for O +
two O +
isoforms O +
of O +
ferrochelatase O +
from O +
Arabidopsis B-Species +
thaliana L-Species -
, O +
both O +
of O +
which O +
are O +
imported O +
into O +
isolated O +
chloroplasts O -
. O -

In O +
this O +
paper O +
we O +
show O +
that O +
ferrochelatase O -
- O -
I O +
is O +
also O +
imported O +
into O +
isolated O +
pea U-Species +
mitochondria O +
with O +
approximately O +
the O +
same O +
efficiency O +
as O +
into O +
chloroplasts O -
. O -

Processing O +
of O +
the O +
precursor O +
was O +
observed O +
with O +
both O +
chloroplast O +
stroma O +
and O +
mitochondrial O +
matrix O +
extracts O -
. O -

This O +
was O +
inhibited O +
by O +
EDTA O -
, O +
indicating O +
it O +
was O +
due O +
to O +
the O +
specific O +
processing O +
proteases O -
. O -

The O +
specificity O +
of O +
import O +
was O +
verified O +
by O +
the O +
fact O +
that O +
the O +
mitochondrial O +
preparation O +
did O +
not O +
import O +
the O +
precursor O +
of O +
the O +
light O -
- O -
harvesting O +
chlorophyll O +
a O -
/ O -
b O +
protein O +
precursor O +
or O +
the O +
precursor O +
of O +
porphobilinogen O +
deaminase O -
, O +
an O +
earlier O +
enzyme O +
of O +
tetrapyrrole O +
biosynthesis O -
, O +
both O +
of O +
which O +
are O +
exclusively O +
chloroplast O -
- O -
located O -
. O -

Furthermore O -
, O +
import O +
of O +
ferrochelatase O -
- O -
I O +
precursor O +
into O +
mitochondria O +
was O +
inhibited O +
by O +
valinomycin O -
, O +
but O +
this O +
had O +
no O +
effect O +
on O +
its O +
import O +
into O +
chloroplasts O -
. O -

Thus O +
a O +
single O +
precursor O +
molecule O +
is O +
recognized O +
by O +
the O +
import O +
machinery O +
of O +
the O +
two O +
organelles O -
. O -

The O +
implications O +
for O +
the O +
targeting O +
of O +
ferrochelatase O +
in O +
a O +
possible O +
protective O +
role O +
against O +
photooxidative O +
stress O +
are O +
discussed O -
. O -

Screening O +
for O +
glycosylphosphatidylinositol O +
( O -
GPI O -
) O -
-dependent O +
cell O +
wall O +
proteins O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species -
. O -

Open O +
reading O +
frames O +
in O +
the O +
genome O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species +
were O +
screened O +
for O +
potential O +
glycosylphosphatidylinositol O +
( O -
GPI O -
) O -
-attached O +
proteins O -
. O -

The O +
identification O +
of O +
putative O +
GPI O -
- O -
attached O +
proteins O +
was O +
based O +
on O +
three O +
criteria O -
: O +
the O +
presence O +
of O +
a O +
GPI O -
- O -
attachment O +
signal O +
sequence O -
, O +
a O +
signal O +
sequence O +
for O +
secretion O +
and O +
a O +
serine- O +
or O +
threonine O -
- O -
rich O +
sequence O -
. O -

In O +
all O -
, O +
53 O +
ORFs O +
met O +
these O +
three O +
criteria O +
and O +
38 O +
were O +
further O +
analyzed O +
as O +
follows O -
. O -

The O +
sequence O +
encoding O +
the O +
40 O +
C O -
- O -
terminal O +
amino O +
acids O +
of O +
each O +
was O +
fused O +
with O +
the O +
structural O +
gene O +
for O +
a O +
reporter O +
protein O +
consisting O +
of O +
a O +
secretion O +
signal O -
, O +
alpha O -
- O -
galactosidase O +
and O +
a O +
hemagglutinin O +
( O -
HA O -
) O +
epitope O -
, O +
and O +
examined O +
for O +
the O +
ability O +
to O +
become O +
incorporated O +
into O +
the O +
cell O +
wall O -
. O -

On O +
this O +
basis O -
, O +
14 O +
of O +
fusion O +
proteins O +
were O +
classified O +
as O +
GPI O -
- O -
dependent O +
cell O +
wall O +
proteins O +
because O +
cells O +
expressing O +
these O +
fusion O +
proteins O -
: O +
( O -
i O -
) O +
had O +
high O +
levels O +
of O +
alpha O -
- O -
galactosidase O +
activity O +
on O +
their O +
surface O -
; O +
( O -
ii O -
) O +
released O +
significant O +
amounts O +
of O +
the O +
fusion O +
proteins O +
from O +
the O +
membrane O +
on O +
treatment O +
with O +
phosphatidylinositol O -
- O -
specific O +
phospholipase O +
C O +
( O -
PI O -
- O -
PLC O -
) O -
; O +
and O +
( O -
iii O -
) O +
released O +
fusion O +
proteins O +
from O +
the O +
cell O +
wall O +
following O +
treatment O +
with O +
laminarinase O -
. O -

Of O +
the O +
14 O +
identified O +
putative O +
GPI O -
- O -
dependent O +
cell O +
wall O +
proteins O -
, O +
12 O +
had O +
novel O +
ORFs O +
adjacent O +
to O +
their O +
GPI O -
- O -
attachment O +
signal O +
sequence O -
. O -

Amino O +
acid O +
sequence O +
alignment O +
of O +
the O +
C O -
- O -
terminal O +
sequences O +
of O +
the O +
12 O +
ORFs O -
, O +
together O +
with O +
those O +
of O +
known O +
cell O +
wall O +
proteins O -
, O +
reveals O +
some O +
sequence O +
similarities O +
among O +
them O -
. O -

This O +
can O +
translate O +
into O +
global O +
effects O +
on O +
cellular O +
health O +
and O +
differentiation O +
state O -
. O -

Recently O -
, O +
several O +
reports O +
have O +
identified O +
crucial O +
roles O +
for O +
miRNAs O +
in O +
controlling O +
the O +
production O -
, O +
differentiation O -
, O +
and O +
health O +
of O +
myelinating O +
cells O +
of O +
the O +
mammalian O +
nervous O +
system O -
. O -

As O +
single O +
miRNAs O +
are O +
often O +
predicted O +
to O +
target O +
up O +
to O +
hundreds O +
of O +
individual O +
transcripts O -
, O +
miRNAs O +
are O +
able O +
to O +
broadly O +
affect O +
the O +
overall O +
protein O +
expression O +
state O +
of O +
the O +
cell O -
. O -

In O +
this O +
review O -
, O +
we O +
will O +
discuss O +
how O +
individual O +
miRNAs O +
regulate O +
these O +
various O +
processes O -
, O +
and O +
also O +
how O +
miRNA O +
production O +
in O +
general O +
is O +
required O +
for O +
several O +
stages O +
of O +
myelin O +
generation O +
and O +
maintenance O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
class O +
of O +
small O +
( O -
approx O -
. O +
22 O +
nt O -
) O +
noncoding O +
RNAs O +
that O +
are O +
capable O +
of O +
post O -
- O -
transcriptionally O +
silencing O +
mRNAs O +
that O +
contain O +
sequences O +
complementary O +
to O +
the O +
miRNAs O -
' O +
7- O +
to O +
8-bp O +
' O -
seed O -
' O +
sequence O -
. O -

MicroRNAs O +
in O +
oligodendrocyte O +
and O +
Schwann O +
cell O +
differentiation O -
. O -

Identification O +
of O +
blood O +
microRNAs O +
associated O +
to O +
Parkinsońs O +
disease O -
. O -

While O +
miR-1 O -
, O +
miR-22 O -
* O +
and O +
miR-29 O +
expression O +
levels O +
allowed O +
to O +
distinguish O +
non O -
- O -
treated O +
PD O +
from O +
healthy O +
subjects O -
, O +
miR-16 O -
- O -
2 O -
* O -
, O +
miR-26a2 O -
* O +
and O +
miR30a O +
differentiated O +
treated O +
from O +
untreated O +
patients O -
. U-Species -

They O +
form O +
two O +
groups O +
according O +
to O +
their O +
expression O +
profile O +
in O +
control O -
, O +
non O -
- O -
treated O -
, O +
early O -
- O -
onset O +
and O +
treated O +
Parkinson O -
's O +
disease O +
subjects O -
. O -

A O +
set O +
of O +
six O +
differentially O +
expressed O +
microRNAs O +
were O +
identified O -
. O -

The O +
present O +
study O +
demonstrates O +
that O +
blood O +
samples O +
can O +
be O +
used O +
as O +
a O +
source O +
of O +
miRNA O +
identification O +
associated O +
to O +
Parkinson O -
's O +
disease O +
( O -
PD O -
) O -
. O -

This O +
study O +
is O +
innovative O +
in O +
contributing O +
to O +
the O +
development O +
of O +
effective O +
PD O +
biomarkers O -
. O -

Our O +
data O +
suggests O +
that O +
down O -
- O -
regulation O +
of O +
miRNA-128 O +
may O +
contribute O +
to O +
glioma O +
and O +
GBM O -
, O +
in O +
part O -
, O +
by O +
coordinately O +
up O -
- O -
regulating O +
ARP5 O +
( O -
ANGPTL6 O -
) O -
, O +
Bmi-1 O +
and O +
E2F-3a O -
, O +
resulting O +
in O +
the O +
proliferation O +
of O +
undifferentiated O +
GBM O +
cells O -
. O -

Addition O +
of O +
exogenous O +
miRNA-128 O +
to O +
CRL-1690 O +
and O +
CRL-2610 O +
GBM O +
cell O +
lines O +
( O -
a O -
) O +
restored O +
' O -
homeostatic O -
' O +
ARP5 O +
( O -
ANGPTL6 O -
) O -
, O +
Bmi-1 O +
and O +
E2F-3a O +
expression O -
, O +
and O +
( O -
b O -
) O +
significantly O +
decreased O +
the O +
proliferation O +
of O +
CRL-1690 O +
and O +
CRL-2610 O +
cell O +
lines O -
. O -

Three O +
bioinformatics O -
- O -
verified O +
miRNA-128 O +
targets O -
, O +
angiopoietin O -
- O -
related O +
growth O +
factor O +
protein O +
5 O +
( O -
ARP5 O -
; O +
ANGPTL6 O -
) O -
, O +
a O +
transcription O +
suppressor O +
that O +
promotes O +
stem O +
cell O +
renewal O +
and O +
inhibits O +
the O +
expression O +
of O +
known O +
tumor O +
suppressor O +
genes O +
involved O +
in O +
senescence O +
and O +
differentiation O -
, O +
Bmi-1 O -
, O +
and O +
a O +
transcription O +
factor O +
critical O +
for O +
the O +
control O +
of O +
cell O -
- O -
cycle O +
progression O -
, O +
E2F-3a O -
, O +
were O +
found O +
to O +
be O +
up O -
- O -
regulated O -
. O -

The O +
down O -
- O -
regulation O +
of O +
miRNA-128 O +
was O +
found O +
to O +
inversely O +
correlate O +
with O +
WHO O +
tumor O +
grade O -
. O -

High O +
density O +
micro O -
- O -
RNA O +
( O -
miRNA O -
) O +
arrays O -
, O +
fluorescent O -
- O -
reporter O +
miRNA O +
assay O +
and O +
Northern O +
miRNA O +
dot O -
- O -
blot O +
analysis O +
show O +
that O +
a O +
brain O -
- O -
enriched O +
miRNA-128 O +
is O +
significantly O +
down O -
- O -
regulated O +
in O +
glioblastoma O +
multiforme O +
( O -
GBM O -
) O +
and O +
in O +
GBM O +
cell O +
lines O +
when O +
compared O +
to O +
age O -
- O -
matched O +
controls O -
. O -

Micro O -
- O -
RNA-128 O +
( O -
miRNA-128 O -
) O +
down O -
- O -
regulation O +
in O +
glioblastoma O +
targets O +
ARP5 O +
( O -
ANGPTL6 O -
) O -
, O +
Bmi-1 O +
and O +
E2F-3a O -
, O +
key O +
regulators O +
of O +
brain O +
cell O +
proliferation O -
. O -

This O +
reveals O +
a O +
previously O +
unrecognized O +
signaling O +
cascade O +
involved O +
in O +
meningioma O +
tumor O +
development O +
and O +
highlights O +
a O +
novel O +
molecular O +
interaction O +
between O +
miR-200a O +
and O +
Wnt O +
signaling O -
, O +
thereby O +
providing O +
insights O +
into O +
novel O +
therapies O +
for O +
meningiomas O -
. O -

A O +
direct O +
correlation O +
was O +
found O +
between O +
the O +
downregulation O +
of O +
miR-200a O +
and O +
the O +
upregulation O +
of O +
beta O -
- O -
catenin O +
in O +
human U-Species +
meningioma O +
samples O -
. O -

Thus O -
, O +
miR-200a O +
appears O +
to O +
act O +
as O +
a O +
multifunctional O +
tumor O +
suppressor O +
miRNA O +
in O +
meningiomas O +
through O +
effects O +
on O +
the O +
E O -
- O -
cadherin O +
and O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
signaling O +
pathways O -
. O -

miR-200a O +
was O +
found O +
to O +
directly O +
target O +
beta O -
- O -
catenin O +
mRNA O -
, O +
thereby O +
inhibiting O +
its O +
translation O +
and O +
blocking O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
signaling O -
, O +
which O +
is O +
frequently O +
involved O +
in O +
cancer O -
. O -

Downregulation O +
of O +
miR-200a O +
in O +
meningiomas O +
and O +
arachnoidal O +
cells O +
resulted O +
in O +
increased O +
expression O +
of O +
beta O -
- O -
catenin O +
and O +
cyclin O +
D1 O +
involved O +
in O +
cell O +
proliferation O -
. O -

Upregulation O +
of O +
miR-200a O +
decreased O +
the O +
expression O +
of O +
transcription O +
factors O +
ZEB1 O +
and O +
SIP1 O -
, O +
with O +
consequent O +
increased O +
expression O +
of O +
E O -
- O -
cadherin O -
, O +
an O +
adhesion O +
protein O +
associated O +
with O +
cell O +
differentiation O -
. O -

Elevated O +
levels O +
of O +
miR-200a O +
inhibited O +
meningioma O +
cell O +
growth O +
in O +
culture O +
and O +
in O +
a O +
tumor O +
model O +
in O +
vivo O -
. O -

Meningiomas O -
, O +
one O +
of O +
the O +
most O +
common O +
human U-Species +
brain O +
tumors O -
, O +
are O +
derived O +
from O +
arachnoidal O +
cells O +
associated O +
with O +
brain O +
meninges O -
, O +
are O +
usually O +
benign O -
, O +
and O +
are O +
frequently O +
associated O +
with O +
neurofibromatosis O +
type O +
2 O -
. O +
Here O -
, O +
we O +
define O +
a O +
typical O +
human U-Species +
meningioma O +
microRNA O +
( O -
miRNA O -
) O +
profile O +
and O +
characterize O +
the O +
effects O +
of O +
one O +
downregulated O +
miRNA O -
, O +
miR-200a O -
, O +
on O +
tumor O +
growth O -
. O -

Downregulated O +
microRNA-200a O +
in O +
meningiomas O +
promotes O +
tumor O +
growth O +
by O +
reducing O +
E O -
- O -
cadherin O +
and O +
activating O +
the O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
signaling O +
pathway O -
. O -

In O +
neurodegenerative O +
disorders O +
such O +
as O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
, O +
brain O +
miRNA O +
profiles O +
are O +
altered O -
; O +
thus O +
miRNA O +
dysfunction O +
could O +
be O +
both O +
a O +
cause O +
and O +
a O +
consequence O +
of O +
disease O -
. O -

These O +
small O +
non O -
- O -
coding O +
RNA O +
regulators O +
are O +
highly O +
enriched O +
in O +
brain O +
where O +
they O +
play O +
key O +
roles O +
in O +
neuronal O +
development O -
, O +
plasticity O +
and O +
disease O -
. O -

Normal O +
brain O +
development O +
and O +
function O +
depends O +
on O +
microRNA O +
( O -
miRNA O -
) O +
networks O +
to O +
fine O +
tune O +
the O +
balance O +
between O +
the O +
transcriptome O +
and O +
proteome O +
of O +
the O +
cell O -
. O -

Neuronal O +
microRNA O +
deregulation O +
in O +
response O +
to O +
Alzheimer O -
's O +
disease O +
amyloid O -
- O -
beta O -
. O -

Bioinformatic O +
analysis O +
predicts O +
that O +
the O +
deregulated O +
miRNAs O +
are O +
likely O +
to O +
affect O +
target O +
genes O +
present O +
in O +
prominent O +
neuronal O +
pathways O +
known O +
to O +
be O +
disrupted O +
in O +
AD O -
. O +
Remarkably O -
, O +
we O +
also O +
found O +
that O +
the O +
miRNA O +
deregulation O +
in O +
hippocampal O +
cultures O +
was O +
paralleled O +
in O +
vivo O +
by O +
a O +
deregulation O +
in O +
the O +
hippocampus O +
of O +
Abeta42-depositing O +
APP23 O +
mice U-Species -
, O +
at O +
the O +
onset O +
of O +
Abeta O +
plaque O +
formation O -
. O -

Time O -
- O -
course O +
assays O +
of O +
neuronal O +
Abeta O +
treatments O +
show O +
that O +
Abeta O +
is O +
in O +
fact O +
a O +
powerful O +
regulator O +
of O +
miRNA O +
levels O +
as O +
the O +
response O +
of O +
certain O +
mature O +
miRNAs O +
is O +
extremely O +
rapid O -
. O -

We O +
used O +
sensitive O +
TaqMan O +
low O +
density O +
miRNA O +
arrays O +
( O -
TLDA O -
) O +
on O +
murine U-Species +
primary O +
hippocampal O +
cultures O +
to O +
show O +
that O +
about O +
half O +
of O +
all O +
miRNAs O +
tested O +
were O +
down O -
- O -
regulated O +
in O +
response O +
to O +
Abeta O +
peptides O -
. O -

Our O +
study O +
dissects O +
the O +
complexity O +
of O +
human U-Species +
AD O +
pathology O -
, O +
and O +
addresses O +
the O +
hypothesis O +
that O +
amyloid O -
- O -
beta O +
( O -
Abeta O -
) O +
itself O -
, O +
a O +
known O +
causative O +
factor O +
of O +
AD O -
, O +
causes O +
neuronal O +
miRNA O +
deregulation O -
, O +
which O +
could O +
contribute O +
to O +
the O +
pathomechanisms O +
of O +
AD O -
. O -

In O +
addition O -
, O +
the O +
miRNA O +
deregulation O +
in O +
hippocampal O +
cultures O +
and O +
APP23 O +
hippocampus O +
overlaps O +
with O +
those O +
obtained O +
in O +
human U-Species +
AD O +
studies O -
. O -

Taken O +
together O -
, O +
our O +
findings O +
suggest O +
that O +
neuronal O +
miRNA O +
deregulation O +
in O +
response O +
to O +
an O +
insult O +
by O +
Abeta O +
may O +
be O +
an O +
important O +
factor O +
contributing O +
to O +
the O +
cascade O +
of O +
events O +
leading O +
to O +
AD O -
. O -

Isolation O +
and O +
characterization O +
of O +
a O +
novel O +
pituitary O +
tumor O +
apoptosis O +
gene O -
. O -

We O +
report O +
the O +
isolation O +
of O +
a O +
novel O +
differentially O +
methylated O +
chromosome O +
22 O +
CpG O +
island O -
- O -
associated O +
gene O +
( O -
C22orf3 O -
) O -
. O -

To O +
determine O +
mechanisms O +
for O +
pituitary O +
neoplasia O +
we O +
used O +
methylation O -
- O -
sensitive O +
arbitrarily O +
primed O -
- O -
PCR O +
to O +
isolate O +
novel O +
genes O +
that O +
are O +
differentially O +
methylated O +
relative O +
to O +
normal O +
pituitary O -
. O -

Sodium O +
bisulfite O +
sequencing O +
of O +
individual O +
adenomas O +
showed O +
that O +
6 O +
of O +
30 O +
( O -
20 O -
% O -
) O +
that O +
failed O +
to O +
express O +
pituitary O +
tumor O +
apoptosis O +
gene O +
( O -
PTAG O -
) O +
were O +
methylated O -
; O +
however O -
, O +
genetic O +
change O +
as O +
determined O +
by O +
loss O +
of O +
heterozygosity O +
and O +
sequence O +
analysis O +
was O +
not O +
apparent O +
in O +
the O +
remaining O +
tumors O +
that O +
failed O +
to O +
express O +
this O +
gene O -
. O -

Sodium O +
bisulfite O +
sequencing O +
of O +
pooled O +
tumor O +
cohorts O -
, O +
used O +
in O +
the O +
isolation O +
of O +
this O +
gene O -
, O +
showed O +
that O +
only O +
a O +
proportion O +
of O +
the O +
adenomas O +
within O +
the O +
pools O +
were O +
methylated O -
; O +
however O -
, O +
expression O +
analysis O +
by O +
quantitative O +
RT O -
- O -
PCR O +
of O +
individual O +
adenoma O +
irrespective O +
of O +
subtype O +
showed O +
the O +
majority O +
( O -
30 O +
of O +
38 O -
; O +
79 O -
% O -
) O +
failed O +
to O +
express O +
this O +
gene O +
relative O +
to O +
normal O +
pituitary O -
. O -

Enforced O +
expression O +
of O +
C22orf3 O +
in O +
AtT20 O +
cells O +
had O +
no O +
measurable O +
effects O +
on O +
cell O +
proliferation O +
or O +
viability O -
; O +
however O -
, O +
in O +
response O +
to O +
bromocriptine O +
challenge O +
( O -
10 O -
- O -
40 O +
microm O -
) O +
cells O +
expressing O +
this O +
gene O +
showed O +
a O +
significantly O +
augmented O +
apoptotic O +
response O +
as O +
determined O +
by O +
both O +
acridine O +
orange O +
staining O +
and O +
TUNEL O +
labeling O -
. O -

In O +
those O +
cases O +
where O +
the O +
CpG O +
island O +
of O +
these O +
genes O +
was O +
methylated O +
it O +
was O +
invariably O +
associated O +
with O +
loss O +
of O +
transcript O +
expression O -
. O -

In O +
addition O -
, O +
in O +
time O +
course O +
experiments O -
, O +
direct O +
measurement O +
of O +
active O +
caspases O +
by O +
fluorochrome O -
- O -
labeled O +
inhibition O +
of O +
caspases O -
, O +
showed O +
an O +
augmented O +
increase O +
( O -
approximately O +
2.4 O +
fold O -
) O +
in O +
active O +
caspases O +
in O +
response O +
to O +
bromocriptine O +
challenge O +
in O +
cells O +
expressing O +
C22orf3 O +
relative O +
to O +
those O +
harboring O +
an O +
empty O +
vector O +
control O -
. O -

The O +
apoptotic O +
response O +
to O +
bromocriptine O +
challenge O +
was O +
inhibited O +
in O +
coincubation O +
experiments O +
with O +
the O +
general O +
caspase O +
inhibitor O +
z O -
- O -
VAD O -
- O -
fmk O -
. O -

The O +
pituitary O +
tumor O +
derivation O +
and O +
its O +
role O +
in O +
apoptosis O +
of O +
this O +
gene O +
led O +
us O +
to O +
assign O +
the O +
acronym O +
PTAG O +
to O +
this O +
gene O +
and O +
its O +
protein O +
product O -
. O -

The O +
ability O +
of O +
cells O -
, O +
showing O +
reduced O +
expression O +
of O +
PTAG O -
, O +
to O +
evade O +
or O +
show O +
a O +
blunted O +
apoptotic O +
response O +
may O +
underlie O +
oncogenic O +
transformation O +
in O +
both O +
the O +
pituitary O +
and O +
other O +
tumor O +
types O -
. O -

It O +
has O +
been O +
recently O +
demonstrated O +
that O +
herpesviruses O +
encode O +
miRNAs O +
to O +
control O +
the O +
post O -
- O -
transcriptional O +
regulation O +
of O +
expression O +
from O +
their O +
own O +
genomes O +
and O +
possibly O +
that O +
of O +
their O +
host O -
, O +
thus O +
adding O +
an O +
additional O +
layer O +
of O +
complexity O +
to O +
the O +
physiological O +
cross O -
- O -
talk O +
between O +
host O +
and O +
pathogen O -
. O -

MicroRNAs O +
are O +
small O +
non O -
- O -
coding O +
RNAs O +
approximately O +
22 O +
nt O +
long O +
that O +
modulate O +
gene O +
expression O +
in O +
animals O +
and O +
plants O -
. O -

Co O -
- O -
expression O +
of O +
host O +
and O +
viral O +
microRNAs O +
in O +
porcine U-Species +
dendritic O +
cells O +
infected O +
by O +
the O +
pseudorabies O +
virus O -
. O -

Almost O +
95 O -
% O +
of O +
reads O +
mapped O +
to O +
the O +
draft O +
pig U-Species +
genome O +
sequence O +
and O +
pig U-Species +
miRNAs O +
previously O +
annotated O +
in O +
dedicated O +
databases O +
were O +
detected O +
by O +
sequence O +
alignment O -
. O -

An O +
average O +
of O +
2 O +
million O +
reads O +
per O +
sample O +
with O +
a O +
size O +
of O +
21 O -
- O -
24 O +
nucleotides O +
was O +
obtained O +
from O +
six O +
libraries O +
representing O +
three O +
biological O +
replicates O +
of O +
infected O +
and O +
mock O -
- O -
infected O +
DCs O -
. O -

A O +
catalogue O +
of O +
porcine U-Species +
and O +
viral O +
miRNAs O -
, O +
expressed O +
eight O +
hours O +
post O -
- O -
infection O -
, O +
was O +
established O +
by O +
deep O +
sequencing O -
. O -

The O +
present O +
study O +
focussed O +
on O +
the O +
interactions O +
between O +
porcine U-Species +
dendritic O +
cells O +
( O -
DCs O -
) O +
and O +
the O +
Pseudorabies O +
virus O +
( O -
PRV O -
) O -
, O +
an O +
alpha O -
- O -
herpesvirus O +
causing O +
Aujeszky O -
's O +
disease O +
in O +
pigs U-Species -
. O -

In O +
silico O +
prediction O +
allowed O +
the O +
identification O +
of O +
unknown O +
porcine U-Species +
as O +
well O +
as O +
of O +
five O +
miRNAs O +
transcribed O +
by O +
the O +
Large O +
Latency O +
Transcript O +
( O -
LLT O -
) O +
of O +
PRV O -
. O -

The O +
gene O +
target O +
prediction O +
of O +
the O +
viral O +
miRNAs O +
and O +
the O +
Ingenuity O +
Pathway O +
Analysis O +
of O +
differentially O +
expressed O +
pig U-Species +
miRNAs O +
were O +
conducted O +
to O +
contextualize O +
the O +
identified O +
small O +
RNA O +
molecules O +
and O +
functionally O +
characterize O +
their O +
involvement O +
in O +
the O +
post O -
- O -
transcriptional O +
regulation O +
of O +
gene O +
expression O -
. O -

The O +
results O +
support O +
a O +
role O +
for O +
PRV O +
miRNAs O +
in O +
the O +
maintenance O +
of O +
the O +
host O +
cell O +
latency O +
state O +
through O +
the O +
down O -
- O -
regulation O +
of O +
immediate O -
- O -
early O +
viral O +
genes O +
which O +
is O +
similar O +
to O +
other O +
herpesviruses O -
. O -

The O +
differentially O +
expressed O +
swine U-Species +
miRNAs O +
identified O +
a O +
unique O +
network O +
of O +
target O +
genes O +
with O +
highly O +
significant O +
functions O +
in O +
the O +
development O +
and O +
function O +
of O +
the O +
nervous O +
system O +
and O +
in O +
infectious O +
mechanisms O -
, O +
suggesting O +
that O +
the O +
modulation O +
of O +
both O +
host O +
and O +
viral O +
miRNAs O +
is O +
necessary O +
for O +
the O +
establishment O +
of O +
PRV O +
latency O -
. O -

The O +
RAKE O +
assay O +
is O +
theoretically O +
versatile O +
and O +
may O +
be O +
used O +
for O +
other O +
applications O -
, O +
such O +
as O +
viral O +
gene O +
profiling O -
. O -

Furthermore O -
, O +
we O +
demonstrate O +
that O +
miRNAs O +
can O +
be O +
isolated O +
and O +
profiled O +
from O +
formalin O -
- O -
fixed O +
paraffin O -
- O -
embedded O +
tissue O -
, O +
which O +
opens O +
up O +
new O +
opportunities O +
for O +
analyses O +
of O +
small O +
RNAs O +
from O +
archival O +
human U-Species +
tissue O -
. O -

RAKE O +
offers O +
unique O +
advantages O +
for O +
specificity O +
over O +
northern O +
blots O +
or O +
other O +
microarray O -
- O -
based O +
expression O +
profiling O +
platforms O -
. O -

We O +
show O +
that O +
the O +
RAKE O +
assay O +
is O +
sensitive O +
and O +
specific O +
for O +
miRNAs O +
and O +
is O +
ideally O +
suited O +
for O +
rapid O +
expression O +
profiling O +
of O +
all O +
known O +
miRNAs O -
. O -

We O +
used O +
RAKE O +
to O +
study O +
human U-Species +
cell O +
lines O +
and O +
brain O +
tumors O -
. O -

The O +
technique O +
is O +
termed O +
the O +
RNA O -
- O -
primed O -
, O +
array O -
- O -
based O +
Klenow O +
enzyme O +
( O -
RAKE O -
) O +
assay O -
, O +
because O +
it O +
involves O +
on O -
- O -
slide O +
application O +
of O +
the O +
Klenow O +
fragment O +
of O +
DNA O +
polymerase O +
I O +
to O +
extend O +
unmodified O +
miRNAs O +
hybridized O +
to O +
immobilized O +
DNA O +
probes O -
. O -

We O +
describe O +
a O +
new O +
method O +
for O +
high O -
- O -
throughput O +
miRNA O +
detection O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
regulatory O +
RNAs O +
that O +
serve O +
fundamental O +
biological O +
roles O +
across O +
eukaryotic O +
species O -
. O -

Microarray O -
- O -
based O -
, O +
high O -
- O -
throughput O +
gene O +
expression O +
profiling O +
of O +
microRNAs O -
. O -

Brain O +
cells O +
maintain O +
distinct O +
populations O +
of O +
miRNAs O +
that O +
support O +
physiologically O +
normal O +
patterns O +
of O +
expression O -
, O +
however O -
, O +
certain O +
miRNA O +
abundances O +
are O +
significantly O +
altered O +
in O +
neurodegenerative O +
disorders O +
such O +
as O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O -

Here O +
we O +
provide O +
evidence O +
in O +
human U-Species +
neural O +
( O -
HN O -
) O +
cells O +
of O +
an O +
aluminum O -
- O -
sulfate- O +
and O +
reactive O +
oxygen O +
species O +
( O -
ROS O -
) O -
-mediated O +
up O -
- O -
regulation O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
sensitive O +
miRNA-146a O +
that O +
down O -
- O -
regulates O +
the O +
expression O +
of O +
complement O +
factor O +
H O +
( O -
CFH O -
) O -
, O +
an O +
important O +
repressor O +
of O +
inflammation O -
. O -

Characterization O +
of O +
an O +
NF O -
- O -
kappaB O -
- O -
regulated O -
, O +
miRNA-146a O -
- O -
mediated O +
down O -
- O -
regulation O +
of O +
complement O +
factor O +
H O +
( O -
CFH O -
) O +
in O +
metal O -
- O -
sulfate O -
- O -
stressed O +
human U-Species +
brain O +
cells O -
. O -

Micro O +
RNAs O +
( O -
miRNAs O -
) O +
represent O +
a O +
family O +
of O +
small O +
ribonucleic O +
acids O +
( O -
RNAs O -
) O +
that O +
are O +
post O -
- O -
transcriptional O +
regulators O +
of O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
complexity O -
. O -

An O +
NF O -
- O -
kappaB O -
- O -
containing O +
miRNA-146a O -
- O -
promoter O -
- O -
luciferase O +
reporter O +
construct O +
transfected O +
into O +
HN O +
cells O +
showed O +
significant O +
up O -
- O -
regulation O +
of O +
miRNA-146a O +
after O +
aluminum O -
- O -
sulfate O +
treatment O +
that O +
corresponded O +
to O +
decreased O +
CFH O +
gene O +
expression O -
. O -

These O +
data O +
suggest O +
that O +
( O -
1 O -
) O +
as O +
in O +
AD O +
brain O -
, O +
NF O -
- O -
kappaB O -
- O -
sensitive O -
, O +
miRNA-146a O -
- O -
mediated O -
, O +
modulation O +
of O +
CFH O +
gene O +
expression O +
may O +
contribute O +
to O +
inflammatory O +
responses O +
in O +
aluminum O -
- O -
stressed O +
HN O +
cells O -
, O +
and O +
( O -
2 O -
) O +
underscores O +
the O +
potential O +
of O +
nanomolar O +
aluminum O +
to O +
drive O +
genotoxic O +
mechanisms O +
characteristic O +
of O +
neurodegenerative O +
disease O +
processes O -
. O -

This O +
NF O -
- O -
kappaB O -
- O -
miRNA-146a O -
- O -
CFH O +
signaling O +
circuit O +
is O +
known O +
to O +
be O +
similarly O +
affected O +
by O +
Abeta42 O +
peptides O +
and O +
in O +
AD O +
brain O -
. O -

These O +
aluminum O -
- O -
sulfate O -
- O -
inducible O +
events O +
were O +
not O +
observed O +
in O +
parallel O +
experiments O +
using O +
iron- O -
, O +
magnesium- O -
, O +
or O +
zinc O -
- O -
sulfate O -
- O -
stressed O +
HN O +
cells O -
. O -

A O +
specific O +
subset O +
of O +
five O +
miRNAs O +
revealed O +
by O +
in O +
silico O +
target O +
prediction O +
was O +
significantly O +
overexpressed O +
in O +
NFA O +
samples O -
; O +
three O +
miRs O +
( O -
miR-128a O -
, O +
miR-155 O -
, O +
and O +
miR-516a-3p O -
) O +
targeted O +
the O +
3'-untranslated O +
region O +
of O +
the O +
Wee1 O +
transcript O -
, O +
and O +
exogenous O +
overexpression O +
of O +
these O +
miRs O +
inhibited O +
Wee1 O +
protein O +
expression O +
and O +
HeLa O +
cell O +
proliferation O -
. O -

RESULTS O -
: O +
Wee1 O +
protein O +
expression O +
was O +
decreased O +
in O +
NFAs O +
and O +
GH O -
- O -
producing O +
tumors O +
with O +
or O +
without O +
prolactin O +
production O -
, O +
but O +
no O +
change O +
in O +
mRNA O +
expression O +
was O +
observed O +
with O +
qRT O -
- O -
PCR O -
. O -

CONCLUSIONS O -
: O +
To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
suggesting O +
that O +
regulation O +
of O +
Wee1 O +
kinase O +
by O +
miRs O +
may O +
be O +
linked O +
to O +
pituitary O +
tumorigenesis O -
. O -

CONTEXT O -
: O +
The O +
tumorigenic O +
mechanisms O +
involved O +
in O +
pituitary O +
adenomas O -
, O +
especially O +
of O +
nonfunctional O +
pituitary O +
adenomas O +
( O -
NFAs O -
) O -
, O +
remains O +
unclear O -
. O -

Down O -
- O -
regulation O +
of O +
Wee1 O +
kinase O +
by O +
a O +
specific O +
subset O +
of O +
microRNA O +
in O +
human U-Species +
sporadic O +
pituitary O +
adenomas O -
. O -

OBJECTIVE O -
: O +
Our O +
objective O +
was O +
to O +
examine O +
the O +
expression O +
of O +
Wee1 O +
in O +
pituitary O +
tumors O +
and O +
to O +
identify O +
microRNAs O +
( O -
miRs O -
) O +
that O +
can O +
regulate O +
its O +
expression O -
. O -

Various O +
cell O +
cycle O +
inhibitors O +
have O +
been O +
found O +
to O +
be O +
underexpressed O +
in O +
pituitary O +
tumors O -
; O +
however O -
, O +
Wee1 O +
kinase O -
, O +
a O +
nuclear O +
protein O +
that O +
delays O +
mitosis O +
and O +
was O +
recently O +
recognized O +
as O +
a O +
tumor O +
suppressor O +
gene O -
, O +
has O +
not O +
been O +
previously O +
investigated O +
in O +
pituitary O +
tumors O -
. O -

Identification O +
of O +
miRs O +
targeting O +
the O +
Wee1 O +
3'-untranslated O +
region O +
was O +
performed O +
by O +
miR O +
array O +
followed O +
by O +
expression O +
analysis O +
of O +
identified O +
miRs O +
using O +
qRT O -
- O -
PCR O -
. O -

DESIGN O -
: O +
Expression O +
of O +
Wee1 O +
was O +
examined O +
by O +
immunohistochemistry O +
and O +
quantitative O +
real O -
- O -
time O +
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
. O -

PATIENTS U-Species -
: O +
A O +
total O +
of O +
57 O +
pituitary O +
tissue O +
samples O +
including O +
27 O +
NFAs O -
, O +
15 O +
GH O -
- O -
producing O +
adenomas O +
with O +
or O +
without O +
prolactin O +
overproduction O -
, O +
and O +
15 O +
normal O +
pituitary O +
glands O +
were O +
analyzed O -
. O -

Dual O -
- O -
luciferase O +
assay O +
and O +
transient O +
transfection O +
of O +
miRs O +
into O +
Hela O +
cells O +
followed O +
by O +
immunoblot O +
analysis O +
of O +
Wee1 O +
protein O +
and O +
cell O +
proliferation O +
analysis O +
were O +
carried O +
out O -
. O -

In O +
this O +
review O +
article O -
, O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
role O +
and O +
function O +
of O +
miRNAs O +
in O +
the O +
regulation O +
of O +
genes O +
involved O +
in O +
neurological O +
and O +
neurodegenerative O +
diseases O +
will O +
be O +
discussed O -
, O +
with O +
a O +
focus O +
on O +
the O +
fragile O +
X O +
syndrome O -
, O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
and O +
prion O +
disease O -
. O -

Likely O +
to O +
play O +
a O +
central O +
role O +
in O +
health O +
and O +
disease O -
, O +
a O +
dysfunctional O +
miRNA O -
- O -
based O +
regulation O +
of O +
gene O +
expression O +
may O +
represent O +
the O +
main O +
etiologic O +
factor O +
underlying O +
diseases O +
affecting O +
major O +
organs O -
, O +
such O +
as O +
the O +
brain O -
. O -

MicroRNAs O +
as O +
a O +
molecular O +
basis O +
for O +
mental O +
retardation O -
, O +
Alzheimer O -
's O +
and O +
prion O +
diseases O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O -
, O +
approximately O +
21- O +
to O +
23-nucleotide O +
( O -
nt O -
) O +
non O -
- O -
coding O +
RNA O +
species O +
that O +
act O +
as O +
key O +
regulators O +
of O +
gene O +
expression O +
along O +
a O +
central O +
and O +
well O -
- O -
defined O +
cellular O +
process O +
known O +
as O +
RNA O +
silencing O -
, O +
and O +
involving O +
the O +
recognition O +
and O +
translational O +
control O +
of O +
specific O +
messenger O +
RNA O +
( O -
mRNAs O -
) O -
. O -

Generated O +
through O +
the O +
well O -
- O -
orchestrated O +
and O +
sequential O +
processing O +
of O +
miRNA O +
precursor O +
molecules O -
, O +
mature O +
miRNAs O +
are O +
subsequently O +
incorporated O +
into O +
miRNA O -
- O -
containing O +
ribonucleoprotein O +
effector O +
complexes O +
to O +
regulate O +
mRNA O +
translation O +
through O +
the O +
recognition O +
of O +
specific O +
binding O +
sites O +
of O +
imperfect O +
complementarity O +
located O +
mainly O +
in O +
the O +
3 O -
' O +
untranslated O +
region O -
. O -

Predicted O +
to O +
regulate O +
up O +
to O +
90 O -
% O +
of O +
the O +
genes O +
in O +
humans U-Species -
, O +
miRNAs O +
may O +
thus O +
control O +
cellular O +
processes O +
in O +
all O +
cells O +
and O +
tissues O +
of O +
the O +
human U-Species +
body O -
. O -

High O +
levels O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
also O +
significantly O +
correlated O +
with O +
the O +
proliferation O +
marker O +
Ki-67 O +
( O -
P<0.0001 O -
) O -
. O -

High O +
levels O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
were O +
more O +
frequently O +
observed O +
in O +
macroadenomas O +
than O +
in O +
microadenomas O +
( O -
P<0.05 O -
) O -
. O -

Overexpression O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
was O +
observed O +
in O +
39 O -
% O +
( O -
38 O -
/ O -
98 O -
) O +
of O +
pituitary O +
adenomas O +
compared O +
with O +
normal O +
adenohypophysial O +
tissue O +
and O +
was O +
frequently O +
found O +
in O +
adenomas O +
including O +
prolactin O +
( O -
PRL O -
) O -
, O +
adrenocorticotrophic O +
hormone O -
, O +
or O +
follicle O -
- O -
stimulating O +
hormone O -
/ O -
luteinizing O +
hormone O +
and O +
in O +
null O +
cell O +
adenomas O -
, O +
but O +
relatively O +
rare O +
in O +
growth O +
hormone O +
( O -
GH O -
) O +
and O +
mixed O +
GH O -
/ O -
PRL O +
adenomas O -
. O -

High O -
- O -
mobility O +
group O +
A2 O +
expression O +
was O +
significantly O +
associated O +
with O +
tumor O +
invasion O +
( O -
P<0.05 O -
) O +
and O +
was O +
significantly O +
higher O +
in O +
grade O +
IV O +
than O +
in O +
grades O +
I O -
, O +
II O -
, O +
and O +
III O +
adenomas O +
( O -
P<0.05 O -
) O -
. O -

However O -
, O +
no O +
studies O +
have O +
investigated O +
the O +
clinical O +
significance O +
of O +
high O -
- O -
mobility O +
group O +
A2 O +
and O +
its O +
relationship O +
to O +
the O +
let-7 O +
miRNA O +
family O +
in O +
human U-Species +
pituitary O +
adenomas O -
. O -

Using O +
immunohistochemistry O -
, O +
we O +
analyzed O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
with O +
respect O +
to O +
various O +
clinicopathologic O +
factors O +
in O +
98 O +
pituitary O +
adenomas O -
. O -

Recent O +
studies O +
report O +
that O +
high O -
- O -
mobility O +
group O +
A2 O +
is O +
negatively O +
regulated O +
by O +
the O +
let-7 O +
microRNAs O +
( O -
miRNAs O -
) O +
family O +
in O +
vitro O -
. O -

The O +
development O +
of O +
pituitary O +
adenomas O +
in O +
high O -
- O -
mobility O +
group O +
A2 O +
transgenic B-Species +
mice L-Species +
showed O +
that O +
high O -
- O -
mobility O +
group O +
A2 O +
may O +
be O +
involved O +
in O +
pituitary O +
tumorigenesis O -
. O -

Overexpression O +
of O +
HMGA2 O +
relates O +
to O +
reduction O +
of O +
the O +
let-7 O +
and O +
its O +
relationship O +
to O +
clinicopathological O +
features O +
in O +
pituitary O +
adenomas O -
. O -

High O -
- O -
mobility O +
group O +
A2 O +
is O +
highly O +
expressed O +
during O +
embryogenesis O +
and O +
in O +
various O +
benign O +
and O +
malignant O +
tumors O -
. O -

Real O -
- O -
time O +
quantitative O +
RT O -
- O -
PCR O +
analysis O +
was O +
carried O +
out O +
to O +
evaluate O +
the O +
expression O +
of O +
let-7 O +
in O +
55 O +
pituitary O +
adenomas O -
. O -

Subsequently O -
, O +
decreased O +
expression O +
of O +
let-7 O +
was O +
confirmed O +
in O +
23 O +
of O +
55 O +
( O -
42 O -
% O -
) O +
adenomas O +
and O +
was O +
correlated O +
with O +
high O -
- O -
grade O +
tumors O +
( O -
P<0.05 O -
) O -
. O -

An O +
inverse O +
correlation O +
between O +
let-7 O +
and O +
high O -
- O -
mobility O +
group O +
A2 O +
expression O +
was O +
evident O +
( O -
R=-0.33 O -
, O +
P<0.05 O -
) O -
. O -

These O +
findings O +
support O +
a O +
causal O +
link O +
between O +
let-7 O +
and O +
high O -
- O -
mobility O +
group O +
A2 O +
whereby O +
loss O +
of O +
let-7 O +
expression O +
induces O +
high O -
- O -
mobility O +
group O +
A2 O +
upregulation O +
that O +
represents O +
an O +
important O +
mechanism O +
in O +
pituitary O +
tumorigenesis O +
and O +
progression O -
. O -

The O +
proliferation O +
inhibition O +
and O +
induced O +
apoptosis O +
by O +
this O +
recombinant O +
with O +
an O +
apoptosis O +
ratio O +
of O +
21.89 O -
% O +
in O +
U87 O +
cell O +
were O +
also O +
observed O -
. O -

The O +
results O +
of O +
Western O +
blot O +
indicated O +
the O +
expression O +
of O +
Flag O +
of O +
No O +
1 O +
recombinant O +
plasmid O +
group O +
was O +
inhibited O +
heavily O +
with O +
a O +
34.3 O -
% O +
expression O +
level O +
by O +
compared O +
with O +
control O +
group O -
. O -

The O +
expressed O +
Flag O +
protein O +
was O +
detected O +
by O +
Western O +
blot O +
to O +
evaluate O +
the O +
inhibition O +
effect O +
of O +
targeting O +
sequences O -
. O -

The O +
confirmed O +
pGCSIL O -
- O -
GFP O +
recombinants O +
by O +
combining O +
with O +
pEGFP O -
- O -
miR-221 O +
were O +
transfected O +
into O +
293 O -
T O +
cells O +
seperately O -
. O -

RESULTS O -
: O +
The O +
resulting O +
recombinants O +
were O +
confirmed O +
by O +
sequencing O +
which O +
demonstrated O +
that O +
the O +
recombinant O +
plasmids O +
contained O +
the O +
correct O +
sequences O +
of O +
designed O +
transcript O +
templates O -
. O -

Then O +
a O +
recombinant O +
with O +
the O +
highest O +
anti O -
- O -
miR-221 O +
effect O +
was O +
screened O +
and O +
transfected O +
into O +
U87 O +
glioma O +
cell O -
, O +
and O +
its O +
anti O -
- O -
tumor O +
effect O +
was O +
evaluated O +
by O +
MTT O +
and O +
FCM O -
. O -

[ O -
Construction O +
and O +
screening O +
an O +
effective O +
anti O -
- O -
miR-221 O +
RNAi O +
vector O +
in O +
vitro O -
] O -
. O -

OBJECTIVE O -
: O +
To O +
construct O +
and O +
screen O +
an O +
effective O +
anti O -
- O -
miR-221 O +
vector O +
of O +
siRNA O -
. O -

METHODS O -
: O +
Four O +
hairpin O +
structure O +
of O +
siRNA O +
transcript O +
templates O +
targeting O +
miR-221 O +
and O +
a O +
negative O +
control O +
were O +
synthesized O -
, O +
then O +
ligated O +
with O +
pGCSIL O -
- O -
GFP O +
vector O +
and O +
a O +
pEGFP O -
- O -
miR-221 O +
which O +
express O +
pre O -
- O -
miR-221 O +
was O +
also O +
constructed O -
. O -

All O +
the O +
recombinants O +
were O +
sequenced O -
. O -

CONCLUSION O -
: O +
The O +
anti O -
- O -
miR-221 O +
expression O +
siRNA O +
espression O +
recombinants O +
were O +
constructed O +
successfully O -
, O +
and O +
one O +
sequence O +
with O +
the O +
highest O +
inhibition O +
efficiency O +
was O +
screened O +
out O -
, O +
which O +
could O +
inhibit O +
U87 O +
cell O +
proliferation O +
and O +
induce O +
cell O +
apoptosis O -
, O +
and O +
could O +
be O +
used O +
to O +
suppress O +
target O +
gene O +
for O +
further O +
study O +
in O +
tumor O +
biology O -
. O -

Expression O +
profiling O +
showed O +
strong O +
miRNA O +
and O +
isomiR O +
expression O +
deregulation O +
in O +
HD O -
, O +
most O +
being O +
common O +
to O +
both O +
FC O +
and O +
ST O -
. O -

Around O +
80 O -
- O -
90 O -
% O +
of O +
the O +
miRNAs O +
presented O +
modifications O +
in O +
the O +
3'-terminus O +
mainly O +
in O +
the O +
form O +
of O +
trimming O +
and/or O +
as O +
nucleotide O +
addition O +
variants O -
, O +
while O +
the O +
5'-terminus O +
of O +
the O +
miRNAs O +
was O +
specially O +
protected O +
from O +
changes O -
. O -

Deep O +
sequencing O +
revealed O +
length O +
and O +
sequence O +
heterogeneity O +
( O -
IsomiRs O -
) O +
for O +
the O +
vast O +
majority O +
of O +
miRNAs O -
. O -

More O +
than O +
80 O -
% O +
of O +
the O +
small O -
- O -
RNAs O +
were O +
annotated O +
as O +
microRNAs O +
( O -
miRNAs O -
) O +
in O +
all O +
samples O -
. O -

We O +
have O +
applied O +
the O +
Illumina O +
massively O +
parallel O +
sequencing O +
to O +
deeply O +
analyze O +
the O +
small O +
RNA O +
populations O +
of O +
two O +
different O +
forebrain O +
areas O -
, O +
the O +
frontal O +
cortex O +
( O -
FC O -
) O +
and O +
the O +
striatum O +
( O -
ST O -
) O +
of O +
healthy O +
individuals O +
and O +
individuals O +
with O +
HD O -
. O -

Huntington O +
disease O +
( O -
HD O -
) O +
is O +
a O +
neurodegenerative O +
disorder O +
that O +
predominantly O +
affects O +
neurons O +
of O +
the O +
forebrain O -
. O -

A O +
myriad O +
of O +
miRNA O +
variants O +
in O +
control O +
and O +
Huntington O -
's O +
disease O +
brain O +
regions O +
detected O +
by O +
massively O +
parallel O +
sequencing O -
. O -

Our O +
results O +
show O +
that O +
miRNA O +
variability O +
is O +
a O +
ubiquitous O +
phenomenon O +
in O +
the O +
adult O +
human U-Species +
brain O -
, O +
which O +
may O +
influence O +
gene O +
expression O +
in O +
physiological O +
and O +
pathological O +
conditions O -
. O -

The O +
putative O +
targets O +
of O +
deregulated O +
miRNAs O +
and O +
seed O -
- O -
region O +
IsomiRs O +
strongly O +
suggest O +
that O +
their O +
altered O +
expression O +
contributes O +
to O +
the O +
aberrant O +
gene O +
expression O +
in O +
HD O -
. O -

The O +
analysis O +
of O +
the O +
upstream O +
regulatory O +
regions O +
in O +
co O -
- O -
regulated O +
miRNAs O +
suggests O +
a O +
role O +
for O +
RE1-Silencing O +
Transcription O +
Factor O +
( O -
REST O -
) O +
and O +
P53 O +
in O +
miRNAs O +
downregulation O +
in O +
HD O -
. O -

Moreover O -
, O +
LPS O +
stimulation O +
decreased O +
expression O +
of O +
microRNAs O +
( O -
miRNA O -
) O -
--miR-17 O -
- O -
5 O -
, O +
miR-20a O -
, O +
and O +
miR-93 O -
- O -
-which O +
target O +
MICA O -
, O +
implicating O +
a O +
novel O +
role O +
for O +
miRNAs O +
in O +
NKG2D O +
ligand O +
expression O -
. O -

However O -
, O +
it O +
was O +
not O +
sufficient O +
for O +
surface O +
protein O +
expression O -
, O +
which O +
was O +
controlled O +
posttranscriptionally O +
via O +
a O +
separate O +
pathway O +
involving O +
the O +
ataxia O +
telangiectasia O +
mutated O -
/ O -
ataxia O +
telangiectasia O +
and O +
Rad3 O +
related O +
kinases O -
. O -

Thus O -
, O +
TLR O +
stimulation O +
allows O +
expression O +
of O +
NKG2D O +
ligands O +
through O +
multiple O +
pathways O -
, O +
including O +
downmodulation O +
of O +
specific O +
miRNAs O -
. O -

In O +
this O +
paper O -
, O +
we O +
clarify O +
that O +
LPS O -
, O +
which O +
ligates O +
TLR-4 O -
, O +
preferentially O +
upregulated O +
MICA O +
and O +
not O +
MICB O -
; O +
CL097 O -
, O +
which O +
ligates O +
TLR-7 O -
/ O -
8 O -
, O +
upregulated O +
both O +
MICA O +
and O +
MICB O -
; O +
and O +
polyinosinic O -
- O -
polycytidylic O +
acid O -
, O +
which O +
ligates O +
TLR-3 O -
, O +
upregulated O +
neither O -
. O -

However O -
, O +
NKG2D O +
ligands O +
can O +
also O +
be O +
induced O +
on O +
human U-Species +
macrophages O +
by O +
TLR O +
stimulation O -
, O +
which O +
has O +
been O +
far O +
less O +
studied O -
. O -

This O +
finding O +
suggests O +
that O +
increased O +
levels O +
of O +
MICA O +
mRNA O +
following O +
LPS O +
stimulation O +
resulted O +
from O +
increased O +
transcription O -
. O -

To O +
probe O +
how O +
LPS O +
stimulation O +
triggers O +
MICA O +
expression O -
, O +
we O +
determined O +
that O +
the O +
stability O +
of O +
MICA O +
mRNA O +
was O +
much O +
longer O +
than O +
that O +
of O +
MICB O +
mRNA O -
, O +
but O +
neither O +
was O +
changed O +
by O +
LPS O +
stimulation O -
. O -

Multiple O +
mechanisms O +
downstream O +
of O +
TLR-4 O +
stimulation O +
allow O +
expression O +
of O +
NKG2D O +
ligands O +
to O +
facilitate O +
macrophage O -
/ O -
NK O +
cell O +
crosstalk O -
. O -

This O +
establishes O +
recognition O +
of O +
" O -
induced O +
self O -
" O +
as O +
an O +
important O +
strategy O +
for O +
surveillance O +
of O +
infections O +
or O +
tumor O +
transformation O -
. O -

The O +
activating O +
receptor O +
NKG2D O +
recognizes O +
proteins O +
that O +
are O +
not O +
normally O +
expressed O +
at O +
the O +
surface O +
of O +
most O +
cells O +
but O +
are O +
expressed O +
during O +
a O +
cellular O +
" O -
stress O -
" O +
response O +
( O -
e.g. O -
, O +
upon O +
induction O +
of O +
the O +
DNA O +
damage O +
pathway O -
) O -
. O -

MicroRNA O +
in O +
Situ O +
Hybridization O +
in O +
the O +
Human U-Species +
Entorhinal O +
and O +
Transentorhinal O +
Cortex O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
key O +
roles O +
in O +
gene O +
expression O +
regulation O +
in O +
both O +
healthy O +
and O +
disease O +
brains O -
. O -

To O +
better O +
understand O +
those O +
roles O -
, O +
it O +
is O +
necessary O +
to O +
characterize O +
the O +
miRNAs O +
that O +
are O +
expressed O +
in O +
particular O +
cell O +
types O +
under O +
a O +
range O +
of O +
conditions O -
. O -

In O +
situ O +
hybridization O +
( O -
ISH O -
) O +
can O +
demonstrate O +
cell- O +
and O +
lamina O -
- O -
specific O +
patterns O +
of O +
miRNA O +
expression O +
that O +
would O +
be O +
lost O +
in O +
tissue O -
- O -
level O +
expression O +
profiling O -
. O -

In O +
the O +
present O +
study O -
, O +
ISH O +
was O +
performed O +
with O +
special O +
focus O +
on O +
the O +
human U-Species +
entorhinal O +
cortex O +
( O -
EC O -
) O +
and O +
transentorhinal O +
cortex O +
( O -
TEC O -
) O -
. O -

The O +
TEC O +
is O +
the O +
area O +
of O +
the O +
cerebral O +
cortex O +
that O +
first O +
develops O +
neurofibrillary O +
tangles O +
in O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O -

However O -
, O +
the O +
reason O +
for O +
TEC O -
's O +
special O +
vulnerability O +
to O +
AD O -
- O -
type O +
pathology O +
is O +
unknown O -
. O -

MiRNA O +
ISH O +
was O +
performed O +
on O +
three O +
human U-Species +
brains O +
with O +
well O -
- O -
characterized O +
clinical O +
and O +
pathological O +
parameters O -
. O -

Locked O +
nucleic O +
acid O +
ISH O +
probes O +
were O +
used O +
referent O +
to O +
miR-107 O -
, O +
miR-124 O -
, O +
miR-125b O -
, O +
and O +
miR-320 O -
. O -

In O +
order O +
to O +
correlate O +
the O +
ISH O +
data O +
with O +
AD O +
pathology O -
, O +
the O +
ISH O +
staining O +
was O +
compared O +
with O +
near O -
- O -
adjacent O +
slides O +
processed O +
using O +
Thioflavine O +
stains O -
. O -

MiRNA O +
ISH O +
is O +
among O +
the O +
first O +
methods O +
to O +
show O +
special O +
staining O +
characteristics O +
of O +
cells O +
and O +
laminae O +
of O +
the O +
human U-Species +
TEC O -
. O -

As O +
with O +
other O +
areas O +
of O +
brain O -
, O +
the O +
TEC O +
and O +
EC O +
have O +
characteristic O +
miRNA O +
expression O +
patterns O -
. O -

Not O +
all O +
neurons O +
or O +
cortical O +
lamina O +
stain O +
with O +
equal O +
intensity O +
for O +
individual O +
miRNAs O -
. O -

Our O +
in O +
vitro O +
results O +
suggested O +
that O +
Aβ42 O +
oligomer O -
- O -
induced O +
miR-106b O +
leads O +
to O +
impairment O +
in O +
TGF O -
- O -
β O +
signaling O +
through O +
TβR O +
II O -
, O +
concomitant O +
with O +
retinoic O +
acid O -
- O -
induced O +
neurodegeneration O +
in O +
SH O -
- O -
SY5Y O +
cells O -
. O -

These O +
results O +
show O +
that O +
TβR O +
II O +
is O +
a O +
functional O +
target O +
of O +
miR-106b O +
and O +
that O +
miR-106b O +
may O +
influence O +
TGF O -
- O -
β O +
signaling O -
, O +
thereby O +
contributing O +
to O +
the O +
pathogenesis O +
of O +
AD O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
abundantly O +
expressed O +
in O +
the O +
brain O +
and O +
play O +
an O +
important O +
role O +
in O +
disorders O +
of O +
the O +
brain O -
, O +
including O +
Alzheimer O -
's O +
diseases O +
( O -
AD O -
) O -
. O -

miR-106b O +
aberrantly O +
expressed O +
in O +
a O +
double O +
transgenic B-Species +
mouse L-Species +
model O +
for O +
Alzheimer O -
's O +
disease O +
targets O +
TGF O -
- O -
β O +
type O +
II O +
receptor O -
. O -

However O -
, O +
it O +
is O +
unclear O +
whether O +
miRNAs O +
involved O +
in O +
AD O +
pathogenesis O +
by O +
regulating O +
TGF O -
- O -
β O +
signaling O -
. O -

Growing O +
body O +
of O +
evidence O +
suggests O +
that O +
the O +
TGF O -
- O -
β O +
signaling O +
pathway O +
plays O +
a O +
key O +
role O +
in O +
the O +
pathogenesis O +
of O +
AD O -
. O -

Sequence O +
analysis O +
revealed O +
two O +
putative O +
binding O +
sites O +
for O +
miR-106b O +
in O +
the O +
3 O -
' O +
UTR O +
of O +
the O +
TβR O +
II O +
mRNA O -
. O -

Here O +
we O +
found O +
that O +
miR-106b O +
and O +
TGF O -
- O -
β O +
type O +
II O +
receptor O +
( O -
TβR O +
II O -
) O +
were O +
aberrantly O +
expressed O +
in O +
APPswe O -
/ O -
PS∆E9 O +
mice U-Species +
( O -
a O +
double O +
transgenic B-Species +
mouse L-Species +
model O +
for O +
AD O -
) O -
. O -

After O +
induced O +
neurodifferentiation O +
with O +
all O -
- O -
trans O +
retinoic O +
acid O -
, O +
we O +
observed O +
significant O +
neurodegeneration O +
in O +
SH O -
- O -
SY5Y O +
cells O +
stably O +
transfected O +
with O +
miR-106b O -
. O -

Our O +
results O +
showed O +
that O +
the O +
expression O +
of O +
miR-106b O +
was O +
inversely O +
correlated O +
with O +
TβR O +
II O +
protein O +
levels O +
and O +
miR-106b O +
can O +
directly O +
inhibit O +
the O +
TβR O +
II O +
translation O +
in O +
vitro O -
. O -

Exposure O +
of O +
SH O -
- O -
SY5Y O +
cells O +
to O +
Aβ42 O +
oligomers O +
led O +
to O +
the O +
expression O +
of O +
miR-106b O +
was O +
first O +
increased O +
and O +
then O +
decreased O +
and O +
TβR O +
II O +
levels O +
reduced O -
. O -

Western O +
blot O +
analysis O +
revealed O +
unchanged O +
total O +
Smad2 O -
/ O -
3 O +
protein O +
levels O -
, O +
but O +
reduced O +
phospho O -
- O -
Smad2 O -
/ O -
3 O +
( O -
p O -
- O -
Smad2 O -
/ O -
3 O -
) O +
and O +
increased O +
Smad6 O -
/ O -
7 O +
protein O +
levels O +
in O +
the O +
miR-106b O +
stably O +
transfected O +
cell O +
line O -
. O -

Nuclear O +
factor O +
TDP-43 O +
can O +
affect O +
selected O +
microRNA O +
levels O -
. O -

TDP-43 O +
has O +
recently O +
been O +
described O +
as O +
the O +
major O +
component O +
of O +
the O +
inclusions O +
found O +
in O +
the O +
brain O +
of O +
patients U-Species +
with O +
a O +
variety O +
of O +
neurodegenerative O +
diseases O -
, O +
such O +
as O +
frontotemporal O +
lobar O +
degeneration O +
and O +
amyotrophic O +
lateral O +
sclerosis O -
. O -

Apart O +
from O +
its O +
involvement O +
in O +
transcription O -
, O +
splicing O +
and O +
mRNA O +
stability O -
, O +
TDP-43 O +
has O +
also O +
been O +
described O +
as O +
a O +
Drosha O -
- O -
associated O +
protein O -
. O -

TDP-43 O +
is O +
a O +
ubiquitous O +
protein O +
whose O +
specific O +
functions O +
are O +
probably O +
crucial O +
to O +
establishing O +
its O +
pathogenic O +
role O -
. O -

Here O +
we O +
report O +
for O +
the O +
first O +
time O +
which O +
changes O +
occur O +
in O +
the O +
total O +
miRNA O +
population O +
following O +
TDP-43 O +
knockdown O +
in O +
culture O +
cells O -
. O -

However O -
, O +
our O +
knowledge O +
of O +
the O +
role O +
of O +
TDP-43 O +
in O +
the O +
microRNA O +
( O -
miRNA O -
) O +
synthesis O +
pathway O +
is O +
limited O +
to O +
the O +
association O +
mentioned O +
above O -
. O -

Interestingly O -
, O +
both O +
miRNAs O +
are O +
capable O +
of O +
binding O +
directly O +
to O +
TDP-43 O +
in O +
different O +
positions O -
: O +
within O +
the O +
miRNA O +
sequence O +
itself O +
( O -
let-7b O -
) O +
or O +
in O +
the O +
hairpin O +
precursor O +
( O -
miR-663 O -
) O -
. O -

In O +
particular O -
, O +
we O +
have O +
observed O +
that O +
let-7b O +
and O +
miR-663 O +
expression O +
levels O +
are O +
down- O +
and O +
upregulated O -
, O +
respectively O -
. O -

Using O +
microarray O +
data O +
and O +
real O -
- O -
time O +
PCR O +
we O +
have O +
also O +
identified O +
several O +
candidate O +
transcripts O +
whose O +
expression O +
levels O +
are O +
selectively O +
affected O +
by O +
these O +
TDP-43-miRNA O +
interactions O -
. O -

CONCLUSIONS O -
: O +
These O +
results O +
demonstrate O +
that O +
tissue O -
- O -
specific O +
miRNAs O +
may O +
serve O +
as O +
diagnostically O +
sensitive O +
plasma O +
biomarkers O +
of O +
tissue O +
injury O -
. O -

The O +
miR-124 O +
concentration O +
increased O +
in O +
the O +
plasma O +
of O +
rats U-Species +
8 O +
h O +
after O +
surgery O +
to O +
produce O +
brain O +
injury O +
and O +
peaked O +
at O +
24 O +
h O -
, O +
while O +
the O +
miR-122 O +
and O +
miR-133a O +
concentrations O +
remained O +
at O +
baseline O +
values O -
. O -

Furthermore O -
, O +
miR-122 O +
exhibited O +
a O +
diagnostic O +
sensitivity O +
superior O +
to O +
that O +
of O +
ALT O +
when O +
the O +
results O +
were O +
correlated O +
to O +
the O +
liver O +
histopathologic O +
results O -
. O -

Plasma O +
MicroRNAs O +
as O +
sensitive O +
and O +
specific O +
biomarkers O +
of O +
tissue O +
injury O -
. O -

BACKGROUND O -
: O +
MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O -
, O +
small O +
noncoding O +
RNAs O -
. O -

Because O +
of O +
their O +
size O -
, O +
abundance O -
, O +
tissue O +
specificity O -
, O +
and O +
relative O +
stability O +
in O +
plasma O -
, O +
miRNAs O +
hold O +
promise O +
as O +
unique O +
accessible O +
biomarkers O +
to O +
monitor O +
tissue O +
injury O -
. O -

METHODS O -
: O +
We O +
investigated O +
the O +
use O +
of O +
liver- O -
, O +
muscle- O +
and O +
brain O -
- O -
specific O +
miRNAs O +
as O +
circulating O +
biomarkers O +
of O +
tissue O +
injury O -
. O -

We O +
used O +
a O +
highly O +
sensitive O +
quantitative O +
PCR O +
assay O +
to O +
measure O +
specific O +
miRNAs O +
( O -
miR-122 O -
, O +
miR-133a O -
, O +
and O +
miR-124 O -
) O +
in O +
plasma O +
samples O +
from O +
rats U-Species +
treated O +
with O +
liver O +
or O +
muscle O +
toxicants O +
and O +
from O +
a O +
rat U-Species +
surgical O +
model O +
of O +
stroke O -
. O -

RESULTS O -
: O +
We O +
observed O +
increases O +
in O +
plasma O +
concentrations O +
of O +
miR-122 O -
, O +
miR-133a O -
, O +
and O +
miR-124 O +
corresponding O +
to O +
injuries O +
in O +
liver O -
, O +
muscle O -
, O +
and O +
brain O -
, O +
respectively O -
. O -

miR-122 O +
and O +
miR-133a O +
illustrated O +
specificity O +
for O +
liver O +
and O +
muscle O +
toxicity O -
, O +
respectively O -
, O +
because O +
they O +
were O +
not O +
detectable O +
in O +
the O +
plasma O +
of O +
animals O +
with O +
toxicity O +
to O +
the O +
other O +
organ O -
. O -

This O +
result O +
contrasted O +
with O +
the O +
results O +
for O +
alanine O +
aminotransferase O +
( O -
ALT O -
) O +
and O +
aspartate O +
aminotransferase O -
, O +
which O +
were O +
both O +
increased O +
with O +
either O +
organ O +
toxicity O -
. O -

Meanwhile O -
, O +
3NP O +
rats U-Species +
showed O +
dynamic O +
changes O +
in O +
the O +
miRNA O +
profiles O +
during O +
disease O +
development O +
and O +
a O +
few O +
miRNAs O +
with O +
altered O +
expression O -
. O -

In O +
10-week O -
- O -
old O +
R6 O -
/ O -
2 O +
mice U-Species -
, O +
downregulation O +
was O +
dominant O +
in O +
the O +
miRNA O +
expressions O +
and O +
the O +
level O +
of O +
Drosha O +
decreased O +
concomitantly O -
. O -

Nine O +
miRNAs O +
( O -
miR-22 O -
, O +
miR-29c O -
, O +
miR-128 O -
, O +
miR-132 O -
, O +
miR-138 O -
, O +
miR-218 O -
, O +
miR-222 O -
, O +
miR-344 O -
, O +
and O +
miR-674 O -
* O -
) O +
were O +
commonly O +
down O -
- O -
regulated O +
in O +
both O +
the O +
12-month O -
- O -
old O +
YAC128 O +
and O +
10-week O -
- O -
old O +
R6 O -
/ O -
2 O +
mice U-Species -
. O -

Concomitantly O -
, O +
the O +
expressions O +
of O +
Drosha O -
- O -
DGCR8 O -
, O +
Exportin-5 O -
, O +
and O +
Dcp1 O +
were O +
increased O +
at O +
5months O -
, O +
and O +
the O +
expression O +
of O +
Dicer O +
was O +
decreased O +
at O +
12 O +
months O -
. O -

YAC128 O +
mice U-Species +
showed O +
upregulation O -
- O -
dominant O +
miRNA O +
expressions O +
at O +
5 O +
months O +
and O +
downregulation O -
- O -
dominant O +
expressions O +
at O +
12 O +
months O -
. O -

After O +
characterizing O +
the O +
phenotypes O +
by O +
behavioral O +
tests O +
and O +
histological O +
analyses O -
, O +
we O +
profiled O +
striatal O +
miRNAs O +
using O +
a O +
miRNA O +
microarray O +
and O +
we O +
measured O +
the O +
key O +
molecules O +
involved O +
in O +
miRNA O +
biogenesis O +
and O +
function O -
. O -

Here O -
, O +
we O +
analyzed O +
the O +
miRNA O +
expression O +
and O +
miRNA O +
regulators O +
in O +
two O +
transgenic O +
models O +
of O +
HD O -
, O +
YAC128 O +
and O +
R6 O -
/ O -
2 O +
mice U-Species -
, O +
and O +
in O +
a O +
3-nitropropionic O +
acid O +
( O -
3NP O -
) O -
-induced O +
striatal O +
degeneration O +
rat U-Species +
model O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
short O +
RNA O +
molecules O +
regulating O +
gene O +
expression O -
, O +
and O +
are O +
implicated O +
in O +
a O +
variety O +
of O +
diseases O +
including O +
HD O -
. O +
However O -
, O +
the O +
profiles O +
and O +
regulation O +
of O +
miRNAs O +
in O +
HD O +
are O +
not O +
fully O +
understood O -
. O -

Huntington O -
's O +
disease O +
( O -
HD O -
) O +
is O +
a O +
genetic O +
neurodegenerative O +
disease O +
caused O +
by O +
abnormal O +
CAG O +
expansion O -
. O -

Altered O +
microRNA O +
regulation O +
in O +
Huntington O -
's O +
disease O +
models O -
. O -

This O +
information O +
should O +
aid O +
in O +
future O +
studies O +
on O +
therapeutic O +
application O +
of O +
miRNAs O +
in O +
HD O -
. O -

Our O +
results O +
show O +
that O +
transgenic O +
HD O +
mice U-Species +
have O +
abnormal O +
miRNA O +
biogenesis O -
. O -

To O +
our O +
knowledge O -
, O +
this O +
is O +
the O +
first O +
report O +
of O +
miRNA O +
profiles O +
in O +
A. O +
cantonensis O -
, O +
which O +
may O +
represent O +
a O +
new O +
platform O +
for O +
studying O +
regulation O +
of O +
genes O +
and O +
their O +
networks O +
in O +
A. O +
cantonensis O -
. O -

Nucleotide O +
bias O +
analysis O +
showed O +
that O +
uracil O +
was O +
the O +
prominent O +
nucleotide O -
, O +
particularly O +
at O +
positions O +
of O +
1 O -
, O +
10 O -
, O +
14 O -
, O +
17 O +
and O +
22 O -
, O +
approximately O +
at O +
the O +
beginning O -
, O +
middle O +
and O +
the O +
end O +
of O +
the O +
conserved O +
miRNAs O -
. O -

No O +
new O +
miRNA O +
sequence O +
was O +
found O -
. O -

A O +
total O +
of O +
8861,260 O +
and O +
10,957,957 O +
high O +
quality O +
reads O +
with O +
20 O +
and O +
23 O +
conserved O +
miRNAs O +
were O +
obtained O +
in O +
females O +
and O +
males O -
, O +
respectively O -
. O -

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
and O +
characterize O +
miRNAs O +
of O +
female O +
and O +
male O +
adults O +
of O +
A. O +
cantonensis O +
by O +
Solexa O +
deep O +
sequencing O -
. O -

They O +
have O +
been O +
identified O +
in O +
a O +
diverse O +
range O +
of O +
organisms O -
. O -

microRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O +
small O +
non O -
- O -
coding O +
RNAs O +
that O +
play O +
crucial O +
roles O +
in O +
gene O +
expression O +
regulation O -
, O +
cellular O +
function O +
and O +
defense O -
, O +
homeostasis O +
and O +
pathogenesis O -
. O -

Angiostrongylus O +
cantonensis O +
causes O +
eosinophilic O +
meningitis O +
and O +
eosinophilic O +
pleocytosis O +
in O +
humans U-Species +
and O +
is O +
of O +
significant O +
socio O -
- O -
economic O +
importance O +
globally O -
. O -

Angiostrongylus O +
cantonensis O -
: O +
Identification O +
and O +
characterization O +
of O +
microRNAs O +
in O +
male O +
and O +
female O +
adults O -
. O -

However O -
, O +
none O +
of O +
these O +
individuals O +
reported O +
here O +
have O +
epilepsy O -
, O +
although O +
two O +
have O +
an O +
abnormal O +
EEG O -
. O -

CONCLUSIONS O -
: O +
The O +
phenotype O +
of O +
chromosome O +
15q13.2q13.3 O +
BP4-BP5 O +
microdeletion O -
/ O -
duplication O +
syndrome O +
may O +
include O +
features O +
of O +
autism O +
spectrum O +
disorder O -
, O +
a O +
variety O +
of O +
neuropsychiatric O +
disorders O -
, O +
and O +
cognitive O +
impairment O -
. O -

Recognition O +
of O +
this O +
broader O +
phenotype O +
has O +
implications O +
for O +
clinical O +
diagnostic O +
testing O +
and O +
efforts O +
to O +
understand O +
the O +
underlying O +
aetiology O +
of O +
this O +
syndrome O -
. O -

PATIENTS U-Species -
: O +
DNA O +
samples O +
from O +
1445 O +
unrelated O +
patients U-Species +
submitted O +
consecutively O +
for O +
clinical O +
array O +
comparative O +
genomic O +
hybridisation O +
( O -
CGH O -
) O +
testing O +
at O +
Children B-Species -
's L-Species +
Hospital O +
Boston O +
and O +
DNA O +
samples O +
from O +
1441 O +
individuals O +
with O +
autism O +
from O +
751 O +
families O +
in O +
the O +
Autism O +
Genetic O +
Resource O +
Exchange O +
( O -
AGRE O -
) O +
repository O -
. O -

RESULTS O -
: O +
We O +
report O +
the O +
clinical O +
features O +
of O +
five O +
patients U-Species +
with O +
a O +
BP4-BP5 O +
deletion O -
, O +
three O +
with O +
a O +
BP4-BP5 O +
duplication O -
, O +
and O +
two O +
with O +
an O +
overlapping O +
but O +
smaller O +
duplication O +
identified O +
by O +
whole O +
genome O +
high O +
resolution O +
oligonucleotide O +
array O +
CGH O -
. O -

Microdeletion O -
/ O -
duplication O +
at O +
15q13.2q13.3 O +
among O +
individuals O +
with O +
features O +
of O +
autism O +
and O +
other O +
neuropsychiatric O +
disorders O -
. O -

BACKGROUND O -
: O +
Segmental O +
duplications O +
at O +
breakpoints O +
( O -
BP4-BP5 O -
) O +
of O +
chromosome O +
15q13.2q13.3 O +
mediate O +
a O +
recurrent O +
genomic O +
imbalance O +
syndrome O +
associated O +
with O +
mental O +
retardation O -
, O +
epilepsy O -
, O +
and/or O +
electroencephalogram O +
( O -
EEG O -
) O +
abnormalities O -
. O -

BP4-BP5 O +
covers O +
approximately O +
1.5 O +
Mb O +
( O -
chr15:28.719 O -
- O -
30.298 O +
Mb O -
) O +
and O +
includes O +
six O +
reference O +
genes O +
and O +
1 O +
miRNA O +
gene O -
, O +
while O +
the O +
smaller O +
duplications O +
cover O +
approximately O +
500 O +
kb O +
( O -
chr15:28.902 O -
- O -
29.404 O +
Mb O -
) O +
and O +
contain O +
three O +
reference O +
genes O +
and O +
one O +
miRNA O +
gene O -
. O -

Cognitive O +
impairment O +
varied O +
from O +
moderate O +
mental O +
retardation O +
to O +
normal O +
IQ O +
with O +
learning O +
disability O -
. O -

These O +
BP4-BP5 O +
deletion O +
cases O +
exhibit O +
minor O +
dysmorphic O +
features O -
, O +
significant O +
expressive O +
language O +
deficits O -
, O +
and O +
a O +
spectrum O +
of O +
neuropsychiatric O +
impairments O +
that O +
include O +
autism O +
spectrum O +
disorder O -
, O +
attention O +
deficit O +
hyperactivity O +
disorder O -
, O +
anxiety O +
disorder O -
, O +
and O +
mood O +
disorder O -
. O -

The O +
BP4-BP5 O +
deletion O +
and O +
duplication O +
events O +
span O +
CHRNA7 O -
, O +
a O +
candidate O +
gene O +
for O +
seizures O -
. O -

The O +
KIAA0226 O +
gene O +
encodes O +
a O +
protein O +
that O +
we O +
named O +
rundataxin O -
, O +
with O +
two O +
conserved O +
domains O -
: O +
an O +
N O -
- O -
terminal O +
RUN O +
domain O +
and O +
a O +
C O -
- O -
terminal O +
domain O +
containing O +
a O +
diacylglycerol O +
binding O -
- O -
like O +
motif O -
. O -

Mutation O +
screening O +
of O +
all O +
coding O +
sequences O +
revealed O +
a O +
single O +
nucleotide O +
deletion O -
, O +
2927delC O -
, O +
in O +
exon O +
19 O +
of O +
the O +
KIAA0226 O +
gene O -
, O +
which O +
results O +
in O +
a O +
frame O +
shift O +
of O +
the O +
C O -
- O -
terminal O +
domain O +
( O -
p O -
. O -
Ala943ValfsX146 O -
) O -
. O -

The O +
rundataxin O +
pathway O +
appears O +
therefore O +
distinct O +
from O +
the O +
ataxia O +
pathways O +
involving O +
deficiency O +
in O +
mitochondrial O +
or O +
nuclear O +
proteins O +
and O +
broadens O +
the O +
range O +
of O +
mechanisms O +
leading O +
to O +
recessive O +
ataxias O -
. O -

The O +
closest O +
paralogue O +
of O +
rundataxin O -
, O +
the O +
plekstrin O +
homology O +
domain O +
family O +
member O +
M1 O -
, O +
has O +
been O +
shown O +
to O +
colocalize O +
with O +
Rab7 O -
, O +
a O +
small O +
GTPase O +
associated O +
with O +
late O +
endosomes O -
/ O -
lysosomes O -
, O +
suggesting O +
that O +
rundataxin O +
may O +
also O +
be O +
associated O +
with O +
vesicular O +
trafficking O +
and O +
signalling O +
pathways O +
through O +
its O +
RUN O +
and O +
diacylglycerol O +
binding O -
- O -
like O +
domains O -
. O -

The O +
three O +
patients U-Species +
presented O +
with O +
childhood O +
onset O +
gait O +
and O +
limb O +
ataxia O -
, O +
dysarthria O +
and O +
had O +
limited O +
walking O +
without O +
aid O +
into O +
their O +
teenage O +
years O -
. O -

We O +
have O +
identified O +
a O +
novel O +
form O +
of O +
recessive O +
ataxia O +
that O +
segregates O +
in O +
three O +
children U-Species +
of O +
a O +
large O +
consanguineous O +
Saudi O +
Arabian O +
family O -
. O -

Linkage O +
studies O +
allowed O +
us O +
to O +
identify O +
a O +
single O +
locus O +
that O +
segregated O +
with O +
the O +
disease O +
on O +
chromosome O +
3q28-qter O -
. O -

Two O +
patients B-Species +
developed L-Species +
epilepsy O +
at O +
7 O +
months O +
without O +
relapse O +
after O +
treatment O -
, O +
and O +
mental O +
retardation O -
. O -

Rundataxin O -
, O +
a O +
novel O +
protein O +
with O +
RUN O +
and O +
diacylglycerol O +
binding O +
domains O -
, O +
is O +
mutant O +
in O +
a O +
new O +
recessive O +
ataxia O -
. O -

A O +
novel O +
microRNA O +
and O +
transcription O +
factor O +
mediated O +
regulatory O +
network O +
in O +
schizophrenia O -
. O -

Previous O +
studies O +
have O +
suggested O +
that O +
changes O +
in O +
gene O +
expression O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
etiology O +
of O +
schizophrenia O -
, O +
and O +
that O +
microRNAs O +
( O -
miRNAs O -
) O +
and O +
transcription O +
factors O +
( O -
TFs O -
) O +
are O +
primary O +
regulators O +
of O +
this O +
gene O +
expression O -
. O -

BACKGROUND O -
: O +
Schizophrenia O +
is O +
a O +
complex O +
brain O +
disorder O +
with O +
molecular O +
mechanisms O +
that O +
have O +
yet O +
to O +
be O +
elucidated O -
. O -

We O +
hypothesized O +
that O +
miRNAs O +
and O +
TFs O +
might O +
play O +
combinatory O +
regulatory O +
roles O +
for O +
schizophrenia O +
genes O +
and O -
, O +
thus O -
, O +
explored O +
miRNA O -
- O -
TF O +
regulatory O +
networks O +
in O +
schizophrenia O -
. O -

So O +
far O -
, O +
several O +
miRNA O -
- O -
TF O +
mediated O +
regulatory O +
modules O +
have O +
been O +
verified O -
. O -

Our O +
evaluation O +
revealed O +
that O +
these O +
observed O +
FFLs O +
were O +
significantly O +
enriched O +
in O +
schizophrenia O +
genes O -
. O -

RESULTS O -
: O +
We O +
identified O +
32 O +
feed O -
- O -
forward O +
loops O +
( O -
FFLs O -
) O +
among O +
our O +
compiled O +
schizophrenia O -
- O -
related O +
miRNAs O -
, O +
TFs O +
and O +
genes O -
. O -

By O +
converging O +
the O +
FFLs O +
and O +
mutual O +
feedback O +
loops O -
, O +
we O +
constructed O +
a O +
novel O +
miRNA O -
- O -
TF O +
regulatory O +
network O +
for O +
schizophrenia O -
. O -

Our O +
analysis O +
revealed O +
EGR3 O +
and O +
hsa O -
- O -
miR-195 O +
were O +
core O +
regulators O +
in O +
this O +
regulatory O +
network O -
. O -

We O +
next O +
proposed O +
a O +
model O +
highlighting O +
EGR3 O +
and O +
miRNAs O +
involved O +
in O +
signaling O +
pathways O +
and O +
regulatory O +
networks O +
in O +
the O +
nervous O +
system O -
. O -

It O +
represents O +
the O +
first O +
investigation O +
of O +
a O +
miRNA O -
- O -
TF O +
regulatory O +
network O +
for O +
a O +
complex O +
disease O -
, O +
as O +
demonstrated O +
in O +
schizophrenia O -
. O -

CONCLUSIONS O -
: O +
This O +
study O +
provides O +
many O +
insights O +
on O +
the O +
regulatory O +
mechanisms O +
of O +
genes O +
involved O +
in O +
schizophrenia O -
. O -

Finally O -
, O +
we O +
suggested O +
several O +
single O +
nucleotide O +
polymorphisms O +
( O -
SNPs O -
) O +
located O +
on O +
miRNAs O -
, O +
their O +
target O +
sites O -
, O +
and O +
TFBSs O -
, O +
which O +
may O +
have O +
an O +
effect O +
in O +
schizophrenia O +
gene O +
regulation O -
. O -

MicroRNA O +
expression O +
in O +
ACTH O -
- O -
producing O +
pituitary O +
tumors O -
: O +
up O -
- O -
regulation O +
of O +
microRNA-122 O +
and O +
-493 O +
in O +
pituitary O +
carcinomas O -
. O -

Real O -
- O -
time O +
RT O -
- O -
PCR O +
and O +
in O +
situ O +
hybridization O +
were O +
used O +
to O +
confirm O +
and O +
independently O +
validate O +
miRNAs O +
that O +
were O +
significantly O +
up O -
- O -
regulated O +
or O +
down O -
- O -
regulated O +
between O +
the O +
pituitary O +
tissues O -
. O -

We O +
used O +
miRNA O +
profiling O +
with O +
1,145 O +
probes O +
to O +
study O +
miRNA O +
expression O +
in O +
normal O +
anterior O +
pituitary O +
( O -
6 O +
cases O -
) O -
, O +
adrenocorticotropin O +
( O -
ACTH O -
) O -
-producing O +
adenomas O +
( O -
8 O +
cases O -
) O -
, O +
and O +
ACTH O -
- O -
producing O +
pituitary O +
carcinomas O +
( O -
two O +
cases O -
) O -
. O -

The O +
expression O +
of O +
miRNAs O +
in O +
pituitary O +
carcinomas O +
has O +
not O +
been O +
previously O +
examined O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
involved O +
in O +
cell O +
proliferation O -
, O +
differentiation O -
, O +
and O +
apoptosis O -
, O +
and O +
can O +
function O +
as O +
tumor O +
suppressor O +
genes O +
or O +
oncogenes O -
. O -

MiRNA-493 O +
was O +
also O +
up O -
- O -
regulated O +
in O +
carcinomas O +
compared O +
to O +
ACTH O +
adenomas O -
. O -

Analysis O +
of O +
genes O +
that O +
miRNA-493 O +
interacts O +
with O +
included O +
LGALS3 O +
and O +
RUNX2 O +
( O +
http://microrna.sanger.ac.uk O +
) O +
both O +
of O +
which O +
have O +
been O +
shown O +
to O +
have O +
roles O +
in O +
pituitary O +
tumor O +
cell O +
growth O -
. O -

There O +
were O +
more O +
miRNAs O +
up- O +
( O -
188 O -
) O +
or O +
down O -
- O -
regulated O +
( O -
160 O -
) O +
between O +
adenomas O +
and O +
normal O +
pituitaries O +
compared O +
to O +
carcinomas O +
and O +
normal O +
pituitaries O +
( O -
92 O +
up- O +
and O +
91 O +
down O -
- O -
regulated O -
) O +
or O +
between O +
carcinomas O +
and O +
adenomas O +
( O -
46 O +
up- O +
and O +
52 O +
down O -
- O -
regulated O -
) O -
. O -

Both O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
and O +
in O +
situ O +
hybridization O +
showed O +
significant O +
up O -
- O -
regulation O +
of O +
miRNA-122 O +
between O +
pituitary O +
carcinomas O +
and O +
adenomas O -
. O -

These O +
results O +
provide O +
information O +
about O +
marker O +
miRNAs O +
that O +
may O +
lead O +
to O +
further O +
insights O +
into O +
the O +
regulation O +
of O +
pituitary O +
tumor O +
growth O +
and O +
development O -
. O -

Vascular O +
injury O +
triggers O +
dedifferentiation O +
and O +
cytoskeletal O +
remodeling O +
of O +
smooth O +
muscle O +
cells O +
( O -
SMCs O -
) O -
, O +
culminating O +
in O +
vessel O +
occlusion O -
. O -

MicroRNAs O +
miR-143 O +
and O +
miR-145 O +
modulate O +
cytoskeletal O +
dynamics O +
and O +
responsiveness O +
of O +
smooth O +
muscle O +
cells O +
to O +
injury O -
. O -

Serum O +
response O +
factor O +
( O -
SRF O -
) O +
and O +
its O +
coactivator O -
, O +
myocardin O -
, O +
play O +
a O +
central O +
role O +
in O +
the O +
control O +
of O +
smooth O +
muscle O +
phenotypes O +
by O +
regulating O +
the O +
expression O +
of O +
cytoskeletal O +
genes O -
. O -

We O +
show O +
that O +
SRF O +
and O +
myocardin O +
regulate O +
a O +
cardiovascular O -
- O -
specific O +
microRNA O +
( O -
miRNA O -
) O +
cluster O +
encoding O +
miR-143 O +
and O +
miR-145 O -
. O -

To O +
assess O +
the O +
functions O +
of O +
these O +
miRNAs O +
in O +
vivo O -
, O +
we O +
systematically O +
deleted O +
them O +
singly O +
and O +
in O +
combination O +
in O +
mice U-Species -
. O -

Mice U-Species +
lacking O +
both O +
miR-143 O +
and O +
miR-145 O +
are O +
viable O +
and O +
do O +
not O +
display O +
overt O +
abnormalities O +
in O +
smooth O +
muscle O +
differentiation O -
, O +
although O +
they O +
show O +
a O +
significant O +
reduction O +
in O +
blood O +
pressure O +
due O +
to O +
reduced O +
vascular O +
tone O -
. O -

Remarkably O -
, O +
however O -
, O +
neointima O +
formation O +
in O +
response O +
to O +
vascular O +
injury O +
is O +
profoundly O +
impeded O +
in O +
mice U-Species +
lacking O +
these O +
miRNAs O -
, O +
due O +
to O +
disarray O +
of O +
actin O +
stress O +
fibers O +
and O +
diminished O +
migratory O +
activity O +
of O +
SMCs O -
. O -

These O +
abnormalities O +
reflect O +
the O +
regulation O +
of O +
a O +
cadre O +
of O +
modulators O +
of O +
SRF O +
activity O +
and O +
actin O +
dynamics O +
by O +
miR-143 O +
and O +
miR-145 O -
. O -

Thus O -
, O +
miR-143 O +
and O +
miR-145 O +
act O +
as O +
integral O +
components O +
of O +
the O +
regulatory O +
network O +
whereby O +
SRF O +
controls O +
cytoskeletal O +
remodeling O +
and O +
phenotypic O +
switching O +
of O +
SMCs O +
during O +
vascular O +
disease O -
. O -

Plasma O +
concentrations O +
of O +
miR-124 O +
were O +
significantly O +
elevated O +
at O +
6 O +
h O -
, O +
and O +
remained O +
elevated O +
at O +
48 O +
h O +
after O +
MCAO O +
introduction O -
. O -

Thus O -
, O +
plasma O +
concentration O +
of O +
miR-124 O +
provides O +
a O +
promising O +
candidate O +
biomarker O +
for O +
early O +
detection O +
of O +
cerebral O +
infarction O -
. O -

In O +
this O +
study O -
, O +
miRNA O +
array O +
analysis O +
in O +
various O +
tissues O +
showed O +
that O +
miR-124 O +
is O +
almost O +
exclusively O +
expressed O +
in O +
the O +
central O +
nervous O +
system O +
and O +
neuronal O +
cells O -
, O +
suggesting O +
that O +
it O +
might O +
be O +
useful O +
as O +
a O +
potential O +
biomarker O +
for O +
neurological O +
diseases O -
. O -

We O +
examined O +
whether O +
plasma O +
concentrations O +
of O +
brain O -
- O -
specific O +
miRNA O +
can O +
serve O +
as O +
a O +
biomarker O +
for O +
cerebral O +
infarction O -
, O +
where O +
the O +
cerebral O +
infarction O +
was O +
modeled O +
by O +
middle O +
cerebral O +
artery O +
occlusion O +
( O -
MCAO O -
) O +
in O +
the O +
rat U-Species -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O +
small O +
RNAs O +
that O +
play O +
an O +
important O +
role O +
in O +
various O +
physiological O +
processes O +
by O +
downregulating O +
target O +
genes O -
. O -

Recently O -
, O +
plasma O +
miRNAs O +
have O +
been O +
investigated O +
as O +
biomarkers O +
for O +
various O +
diseases O -
. O -

Plasma O +
miR-124 O +
as O +
a O +
biomarker O +
for O +
cerebral O +
infarction O -
. O -

METHODS O -
: O +
Surgical O +
outcome O +
data O +
were O +
prospectively O +
collected O +
for O +
2 O +
to O +
11 O +
years O +
in O +
161 O +
consecutive O +
patients U-Species +
with O +
MTLE O -
/ O +
HS O -
. O +
Eighty O +
patients U-Species +
underwent O +
an O +
ATL O +
and O +
81 O +
an O +
SA O -
. O +
Seizure O +
control O +
achieved O +
with O +
each O +
technique O +
was O +
compared O +
using O +
the O +
Engel O +
classification O +
scheme O -
. O -

Postoperative O +
memory O +
testing O +
was O +
performed O +
in O +
86 O +
patients U-Species +
( O -
53 O -
% O -
) O -
. O -

At O +
the O +
last O +
follow O +
up O -
, O +
72 O -
% O +
of O +
the O +
patients U-Species +
who O +
had O +
undergone O +
an O +
ATL O +
( O -
mean O +
follow O +
up O +
6.7 O +
years O -
) O +
and O +
71 O -
% O +
of O +
those O +
who O +
had O +
undergone O +
an O +
SA O +
( O -
mean O +
follow O +
up O +
4.5 O +
years O -
) O +
were O +
seizure O +
free O +
( O -
Engle O +
Class O +
IA O -
) O -
. O -

Estimated O +
survival O +
in O +
patients U-Species +
in O +
Engel O +
Classes O +
I O -
, O +
IA O -
, O +
and O +
I O +
and O +
II O +
combined O +
did O +
not O +
differ O +
between O +
the O +
two O +
surgical O +
techniques O -
. O -

Preoperatively O -
, O +
58 O -
% O +
of O +
the O +
patients U-Species +
had O +
verbal O +
memory O +
scores O +
one O +
standard O +
deviation O +
( O -
SD O -
) O +
below O +
the O +
normal O +
mean O -
. O -

One O +
third O +
of O +
the O +
patients U-Species +
with O +
preoperative O +
scores O +
in O +
the O +
normal O +
range O +
worsened O +
after O +
surgery O -
, O +
although O +
this O +
outcome O +
was O +
not O +
related O +
to O +
the O +
surgical O +
technique O -
. O -

In O +
contrast O -
, O +
one O +
third O +
of O +
those O +
whose O +
preoperative O +
scores O +
were O +
less O +
than O +
-1 O +
SD O +
experienced O +
improvement O +
after O +
surgery O -
. O -

Nine O +
( O -
18 O -
% O -
) O +
of O +
the O +
50 O +
patients U-Species +
whose O +
left O +
side O +
had O +
been O +
surgically O +
treated O +
improved O +
their O +
verbal O +
memory O +
scores O +
by O +
more O +
than O +
one O +
SD O -
. O +
Seven O +
( O -
78 O -
% O -
) O +
of O +
these O +
nine O +
underwent O +
an O +
SA O +
( O -
p O +
= O +
0.05 O -
) O -
. O -

OBJECT O -
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
seizure O +
and O +
memory O +
outcome O +
in O +
patients U-Species +
with O +
medically O +
refractory O +
mesial O +
temporal O +
lobe O +
epilepsy O +
due O +
to O +
hippocampal O +
sclerosis O +
( O -
MTLE O -
/ O -
HS O -
) O +
treated O +
using O +
an O +
anterior O +
temporal O +
lobectomy O +
( O -
ATL O -
) O +
or O +
a O +
selective O +
amygdalohippocampectomy O +
( O -
SA O -
) O -
. O -

Seizure O +
and O +
memory O +
outcome O +
following O +
temporal O +
lobe O +
surgery O -
: O +
selective O +
compared O +
with O +
nonselective O +
approaches O +
for O +
hippocampal O +
sclerosis O -
. O -

Preliminary O +
data O +
suggest O +
that O +
postoperative O +
verbal O +
memory O +
scores O +
may O +
improve O +
in O +
patients U-Species +
who O +
undergo O +
selective O +
resection O +
of O +
a O +
sclerotic O +
hippocampus O +
in O +
the O +
dominant O +
temporal O +
lobe O -
. O -

CONCLUSIONS O -
: O +
Both O +
ATL O +
and O +
SA O +
can O +
lead O +
to O +
similar O +
favorable O +
seizure O +
control O +
in O +
patients U-Species +
with O +
MTLE O -
/ O -
HS O -
. O -

These O +
data O +
suggest O +
a O +
role O +
for O +
HSV-1-induced U-Species +
miRNA-146a O +
in O +
the O +
evasion O +
of O +
HSV-1 U-Species +
from O +
the O +
complement O +
system O -
, O +
and O +
the O +
activation O +
of O +
key O +
elements O +
of O +
the O +
arachidonic O +
acid O +
cascade O +
known O +
to O +
contribute O +
to O +
Alzheimer O -
- O -
type O +
neuropathological O +
change O -
. O -

A O +
known O +
miRNA-146a O +
target O +
in O +
the O +
brain O -
, O +
complement O +
factor O +
H O -
, O +
was O +
downregulated O -
. O -

Expression O +
of O +
cytoplasmic O +
phospholipase O +
A2 O -
, O +
the O +
inducible O +
prostaglandin O +
synthase O +
cyclooxygenase-2 O -
, O +
and O +
the O +
neuroinflammatory O +
cytokine O +
interleukin-1beta O +
were O +
each O +
upregulated O -
. O -

We O +
report O +
that O +
infection O +
of O +
human U-Species +
primary O +
neural O +
cells O +
with O +
a O +
high O +
phenotypic O +
reactivator O +
HSV-1 U-Species +
( O -
17syn+ O -
) O +
induces O +
upregulation O +
of O +
a O +
brain O -
- O -
enriched O +
microRNA O +
( O -
miRNA O -
) O -
-146a O +
that O +
is O +
associated O +
with O +
proinflammatory O +
signaling O +
in O +
stressed O +
brain O +
cells O +
and O +
Alzheimer O -
's O +
disease O -
. O -

Herpes B-Species +
simplex I-Species +
virus I-Species +
type-1 I-Species +
( I-Species -
HSV-1 L-Species -
) O +
infection O +
of O +
human U-Species +
brain O +
cells O +
induces O +
changes O +
in O +
gene O +
expression O +
favorable O +
to O +
the O +
propagation O +
of O +
the O +
infecting O +
agent O +
and O +
detrimental O +
to O +
the O +
function O +
of O +
the O +
host O +
cells O -
. O -

HSV-1 U-Species +
infection O +
of O +
human U-Species +
brain O +
cells O +
induces O +
miRNA-146a O +
and O +
Alzheimer O -
- O -
type O +
inflammatory O +
signaling O -
. O -

This O +
study O +
reveals O +
the O +
occurrence O +
of O +
novel O +
mechanisms O +
of O +
HIF O +
regulation O -
, O +
which O +
might O +
contribute O +
to O +
developing O +
novel O +
strategies O +
for O +
therapeutic O +
intervention O +
of O +
HIF O -
- O -
related O +
pathologies O -
, O +
including O +
heart O +
attack O -
, O +
cancer O -
, O +
and O +
stroke O -
. O -

One O +
remarkable O +
hit O +
was O +
the O +
argonaute O +
1 O +
( O -
ago1 O -
) O +
gene O -
, O +
a O +
central O +
element O +
of O +
the O +
microRNA O +
( O -
miRNA O -
) O +
translational O +
silencing O +
machinery O -
. O -

Further O +
studies O +
confirmed O +
the O +
physiological O +
role O +
of O +
the O +
miRNA O +
machinery O +
in O +
HIF O -
- O -
dependent O +
transcription O -
. O -

After O +
3 O +
rounds O +
of O +
selection O -
, O +
30 O +
genes O +
emerged O +
as O +
critical O +
HIF O +
regulators O +
in O +
hypoxia O -
, O +
most O +
of O +
which O +
had O +
not O +
been O +
previously O +
associated O +
with O +
HIF O +
biology O -
. O -

The O +
list O +
of O +
genes O +
includes O +
components O +
of O +
chromatin O +
remodeling O +
complexes O -
, O +
transcription O +
elongation O +
factors O -
, O +
and O +
translational O +
regulators O -
. O -

Molecular O +
mechanisms O +
that O +
mediate O +
oxygen O -
- O -
dependent O +
HIF O +
regulation O +
operate O +
at O +
the O +
level O +
of O +
the O +
alpha O +
subunit O -
, O +
controlling O +
protein O +
stability O -
, O +
subcellular O +
localization O -
, O +
and O +
transcriptional O +
coactivator O +
recruitment O -
. O -

We O +
have O +
conducted O +
an O +
unbiased O +
genome O -
- O -
wide O +
RNA O +
interference O +
( O -
RNAi O -
) O +
screen O +
in O +
Drosophila O +
cells O +
aimed O +
to O +
the O +
identification O +
of O +
genes O +
required O +
for O +
HIF O +
activity O -
. O -

Drosophila O +
genome O -
- O -
wide O +
RNAi O +
screen O +
identifies O +
multiple O +
regulators O +
of O +
HIF O -
- O -
dependent O +
transcription O +
in O +
hypoxia O -
. O -

Hypoxia O -
- O -
inducible O +
factors O +
( O -
HIFs O -
) O +
are O +
a O +
family O +
of O +
evolutionary O +
conserved O +
alpha O -
- O -
beta O +
heterodimeric O +
transcription O +
factors O +
that O +
induce O +
a O +
wide O +
range O +
of O +
genes O +
in O +
response O +
to O +
low O +
oxygen O +
tension O -
. O -

Follow O +
up O +
functional O +
enrichment O +
analysis O +
of O +
these O +
FFLs O +
uncovered O +
some O +
functions O +
important O +
to O +
carcinogenesis O +
but O +
also O +
some O +
unique O +
functions O +
specific O +
to O +
the O +
FFLs O +
we O +
identified O -
. O -

Transcriptional O +
aberrations O +
may O +
play O +
a O +
vital O +
role O +
in O +
the O +
etiology O +
of O +
glioblastoma O -
, O +
which O +
might O +
be O +
caused O +
by O +
both O +
genomic O +
alterations O +
and O +
other O +
regulation O +
molecules O -
. O -

Illustrating O +
the O +
functions O +
being O +
disturbed O +
during O +
carcinogenesis O +
and O +
how O +
they O +
are O +
deregulated O +
is O +
very O +
important O +
for O +
us O +
to O +
understand O +
its O +
underlying O +
mechanism O -
. O -

We O +
searched O +
glioblastoma O -
- O -
specific O +
regulatory O +
networks O +
by O +
integrating O +
glioblastoma O +
related O +
miRNAs O -
, O +
TFs O +
and O +
genes O -
, O +
and O +
identified O +
54 O +
feed O -
- O -
forward O +
loops O +
( O -
FFLs O -
) O -
. O -

In O +
this O +
study O -
, O +
we O +
investigated O +
possible O +
cooperative O +
deregulation O +
of O +
microRNAs O +
( O -
miRNAs O -
) O +
and O +
transcription O +
factors O +
( O -
TFs O -
) O +
in O +
glioblastoma O -
, O +
under O +
the O +
hypothesis O +
that O +
miRNAs O +
and O +
TFs O +
might O +
have O +
a O +
combinational O +
regulatory O +
effect O +
on O +
glioblastoma O +
genes O -
. O -

Glioblastoma O +
is O +
the O +
most O +
common O +
and O +
most O +
lethal O +
brain O +
tumour O +
in O +
humans U-Species -
. O -

Gene O +
regulation O +
in O +
glioblastoma O -
: O +
a O +
combinatorial O +
analysis O +
of O +
microRNAs O +
and O +
transcription O +
factors O -
. O -

These O +
data O +
support O +
the O +
hypothesis O +
that O +
patterns O +
of O +
miRNA O +
expression O +
in O +
cortical O +
GM O +
may O +
contribute O +
to O +
AD O +
pathogenetically O -
, O +
because O +
the O +
aggregate O +
change O +
in O +
miRNA O +
expression O +
observed O +
early O +
in O +
the O +
disease O +
would O +
be O +
predicted O +
to O +
cause O +
profound O +
changes O +
in O +
gene O +
expression O -
. O -

Patterns O +
of O +
microRNA O +
expression O +
in O +
normal O +
and O +
early O +
Alzheimer O -
's O +
disease O +
human U-Species +
temporal O +
cortex O -
: O +
white O +
matter O +
versus O +
gray O +
matter O -
. O -

MicroRNA O +
( O -
miRNA O -
) O +
expression O +
was O +
assessed O +
in O +
human U-Species +
cerebral O +
cortical O +
gray O +
matter O +
( O -
GM O -
) O +
and O +
white O +
matter O +
( O -
WM O -
) O +
in O +
order O +
to O +
provide O +
the O +
first O +
insights O +
into O +
the O +
difference O +
between O +
GM O +
and O +
WM O +
miRNA O +
repertoires O +
across O +
a O +
range O +
of O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O +
pathology O -
. O -

RNA O +
was O +
isolated O +
separately O +
from O +
GM O +
and O +
WM O +
portions O +
of O +
superior O +
and O +
middle O +
temporal O +
cerebral O +
cortex O +
( O -
N O +
= O +
10 O +
elderly O +
females O -
, O +
postmortem O +
interval O +
< O +
4 O +
h O -
) O -
. O -

miRNA O +
profiling O +
experiments O +
were O +
performed O +
using O +
state O -
- O -
of O -
- O -
the O -
- O -
art O +
Exiqon O -
( O -
© O -
) O +
LNA O -
- O -
microarrays O -
. O -

A O +
subset O +
of O +
miRNAs O +
that O +
appeared O +
to O +
be O +
strongly O +
expressed O +
according O +
to O +
the O +
microarrays O +
did O +
not O +
appear O +
to O +
be O +
conventional O +
miRNAs O +
according O +
to O +
Northern O +
blot O +
analyses O -
. O -

Some O +
well O -
- O -
characterized O +
miRNAs O +
were O +
substantially O +
enriched O +
in O +
WM O +
as O +
expected O -
. O -

However O -
, O +
most O +
of O +
the O +
miRNA O +
expression O +
variability O +
that O +
correlated O +
with O +
the O +
presence O +
of O +
early O +
AD O -
- O -
related O +
pathology O +
was O +
seen O +
in O +
GM O -
. O -

We O +
confirm O +
that O +
downregulation O +
of O +
a O +
set O +
of O +
miRNAs O +
in O +
GM O +
( O -
including O +
several O +
miR-15 O -
/ O -
107 O +
genes O +
and O +
miR-29 O +
paralogs O -
) O +
correlated O +
strongly O +
with O +
the O +
density O +
of O +
diffuse O +
amyloid O +
plaques O +
detected O +
in O +
adjacent O +
tissue O -
. O -

A O +
few O +
miRNAs O +
were O +
differentially O +
expressed O +
in O +
WM O -
, O +
including O +
miR-212 O +
that O +
is O +
downregulated O +
in O +
AD O +
and O +
miR-424 O +
which O +
is O +
upregulated O +
in O +
AD O -
. O -

The O +
expression O +
of O +
certain O +
miRNAs O +
correlates O +
with O +
other O +
miRNAs O +
across O +
different O +
cases O -
, O +
and O +
particular O +
subsets O +
of O +
miRNAs O +
are O +
coordinately O +
expressed O +
in O +
relation O +
to O +
AD O -
- O -
related O +
pathology O -
. O -

Leukodystrophy O +
and O +
gene O +
therapy O +
with O +
a O +
dimmer O +
switch O -
. O -

The O +
authors O +
reviewed O +
the O +
records O +
of O +
nineteen O +
consecutive O +
children U-Species +
with O +
newly O +
diagnosed O +
IIH O +
in O +
order O +
to O +
compare O +
demographic O +
characteristics O -
, O +
clinical O +
pictures O +
and O +
ophthalmologic O +
aspects O +
as O +
optic O +
disc O +
evaluation O +
and O +
visual O +
field O +
evaluation O -
, O +
as O +
well O +
as O +
treatment O +
modalities O +
and O +
follow O +
up O -
. O -

Beside O +
obesity O +
and O +
female O +
gender O -
, O +
potential O +
alternative O +
risk O +
factors O +
remains O +
to O +
be O +
investigated O -
, O +
which O +
need O +
a O +
good O +
collaboration O +
between O +
neuro O -
- O -
ophthalmologists O +
and O +
pediatric O +
neurologists O -
. O -

Idiopathic O +
intracranial O +
hypertension O +
( O -
IIH O -
) O +
is O +
a O +
clinical O +
condition O +
characterized O +
by O +
elevated O +
intracranial O +
pressure O +
and O +
absence O +
of O +
clinical O -
, O +
laboratory O +
or O +
radiographic O +
evidence O +
of O +
central O +
nervous O +
system O +
infection O -
, O +
vascular O +
malformation O -
, O +
intracranial O +
space O +
occupying O +
lesion O +
or O +
hydrocephalus O -
. O -

In O +
the O +
last O +
years O +
the O +
raising O +
understanding O +
of O +
pediatric O +
IIH O -
, O +
especially O +
concerning O +
its O +
demographics O +
and O +
epidemiology O -
, O +
has O +
brought O +
up O +
to O +
a O +
redefinition O +
of O +
diagnostic O +
criteria O +
and O +
reevaluation O +
of O +
pathogenesis O +
and O +
treatment O -
. O -

Pediatric O +
idiopathic O +
intracranial O +
hypertension O -
: O +
clinical O +
and O +
demographic O +
features O -
. O -

Although O +
microRNAs O +
are O +
expressed O +
extensively O +
in O +
the O +
central O +
nervous O +
system O +
in O +
physiological O +
and O +
pathological O +
conditions O -
, O +
their O +
expression O +
in O +
neurological O +
disorder O +
of O +
epilepsy O +
has O +
not O +
been O +
well O +
characterized O -
. O -

Expression O +
profile O +
of O +
microRNAs O +
in O +
rat U-Species +
hippocampus O +
following O +
lithium O -
- O -
pilocarpine O -
- O -
induced O +
status O +
epilepticus O -
. O -

Rat U-Species +
MicroRNA O +
array O +
and O +
differential O +
analysis O +
had O +
detected O +
19 O +
up O -
- O -
regulated O +
microRNAs O +
and O +
7 O +
down O -
- O -
regulated O +
microRNAs O +
in O +
rat U-Species +
hippocampus O -
, O +
and O +
four O +
randomly O +
selected O +
deregulated O +
microRNAs O +
( O -
microRNA-34a O -
, O +
microRNA-22 O -
, O +
microRNA-125a O -
, O +
microRNA-21 O -
) O +
were O +
confirmed O +
by O +
qRT O -
- O -
PCR O -
, O +
then O +
their O +
expression O +
alterations O +
in O +
rat U-Species +
peripheral O +
blood O +
were O +
analyzed O -
. O -

Here O +
we O +
investigated O +
microRNA O +
expression O +
pattern O +
in O +
post O +
status O +
epilepticus O +
rats U-Species +
( O -
24h O +
after O +
status O -
) O -
. O -

Thus O -
, O +
our O +
results O +
have O +
not O +
only O +
characterized O +
the O +
microRNA O +
expression O +
profile O +
in O +
post O +
status O +
epilepticus O +
rat U-Species +
hippocampus O +
but O +
also O +
demonstrated O +
that O +
some O +
rat U-Species +
hippocampal O +
microRNAs O +
were O +
probably O +
associated O +
with O +
rat U-Species +
peripheral O +
blood O +
microRNAs O -
. O -

We O +
found O +
that O +
these O +
four O +
deregulated O +
microRNAs O +
were O +
also O +
differentially O +
expressed O +
in O +
rat U-Species +
peripheral O +
blood O -
, O +
and O +
trends O +
for O +
their O +
blood O +
expression O +
alterations O +
were O +
just O +
the O +
same O +
as O +
their O +
counterparts O +
in O +
rat U-Species +
hippocampus O -
. O -

Moreover O -
, O +
targets O +
of O +
these O +
deregulated O +
microRNAs O +
were O +
analyzed O +
using O +
bioinformatics O +
and O +
the O +
identified O +
enriched O +
MAPK O +
pathway O +
and O +
long O -
- O -
term O +
potentiation O +
pathway O +
might O +
have O +
been O +
involved O +
in O +
molecular O +
mechanisms O +
concerning O +
neuronal O +
death O -
, O +
inflammation O +
and O +
epileptogenesis O -
. O -

Remarks O +
are O +
also O +
provided O +
to O +
point O +
out O +
the O +
unanswered O +
questions O +
and O +
to O +
outline O +
the O +
new O +
directions O +
for O +
the O +
future O +
research O +
of O +
the O +
field O -
. O -

Speculations O +
on O +
the O +
development O +
of O +
miRNAs O +
as O +
potential O +
therapeutic O +
targets O +
are O +
also O +
presented O -
. O -

These O +
small O +
molecules O +
act O +
by O +
repressing O +
the O +
expression O +
of O +
either O +
the O +
proapoptotic O +
or O +
antiapoptotic O +
genes O +
to O +
produce O +
antiapoptotic O +
or O +
proapoptotic O +
effects O -
. O -

Appealing O +
evidence O +
has O +
been O +
accumulating O +
for O +
the O +
involvement O +
of O +
miRNAs O +
in O +
human U-Species +
diseases O +
associated O +
with O +
apoptotic O +
cell O +
death O +
and O +
the O +
potential O +
of O +
miRNAs O +
as O +
novel O +
therapeutic O +
targets O +
for O +
the O +
treatment O +
of O +
the O +
diseases O -
. O -

The O +
importance O +
of O +
miRNAs O +
has O +
steadily O +
gained O +
appreciation O +
and O +
miRNA O +
biology O +
has O +
exploded O +
into O +
a O +
massive O +
swell O +
of O +
interest O +
with O +
enormous O +
range O +
and O +
potential O +
in O +
almost O +
every O +
biological O +
discipline O +
because O +
of O +
their O +
widespread O +
expression O +
and O +
diverse O +
functions O +
in O +
both O +
animals O +
and O +
humans U-Species -
. O -

It O +
has O +
been O +
established O +
that O +
miRNAs O +
are O +
critical O +
regulators O +
of O +
apoptosis O +
of O +
various O +
cell O +
types O -
. O -

Tremendous O +
efforts O +
have O +
been O +
made O +
to O +
improve O +
our O +
understanding O +
of O +
the O +
molecular O +
mechanisms O +
and O +
signaling O +
pathways O +
involved O +
in O +
apoptosistic O +
cell O +
death O -
. O -

Once O +
ignored O +
completely O +
or O +
overlooked O +
as O +
cellular O +
detritus O -
, O +
microRNAs O +
( O -
miRNAs O -
) O +
that O +
were O +
discovered O +
only O +
a O +
decade O +
ago O -
, O +
have O +
recently O +
taken O +
many O +
by O +
surprise O -
. O -

MicroRNA O -
: O +
A O +
matter O +
of O +
life O +
or O +
death O -
. O -

Progressive O +
cell O +
loss O +
due O +
to O +
apoptosis O +
is O +
a O +
pathological O +
hallmark O +
implicated O +
in O +
a O +
wide O +
spectrum O +
of O +
degenerative O +
diseases O +
such O +
as O +
heart O +
disease O -
, O +
atherosclerotic O +
arteries O +
and O +
hypertensive O +
vessels O -
, O +
Alzheimer O -
's O +
disease O +
and O +
other O +
neurodegenerative O +
disorders O -
. O -

This O +
editorial O +
aims O +
to O +
convey O +
this O +
message O +
and O +
to O +
boost O +
up O +
the O +
research O +
interest O +
by O +
providing O +
a O +
timely O -
, O +
comprehensive O +
overview O +
on O +
regulation O +
of O +
apoptosis O +
by O +
miRNAs O +
and O +
a O +
synopsis O +
on O +
the O +
pathophysiologic O +
implications O +
of O +
this O +
novel O +
regulatory O +
network O +
based O +
on O +
the O +
currently O +
available O +
data O +
in O +
the O +
literature O -
. O -

It O +
begins O +
with O +
a O +
brief O +
introduction O +
to O +
apoptosis O +
and O +
miRNAs O -
, O +
followed O +
by O +
the O +
description O +
of O +
the O +
fundamental O +
aspects O +
of O +
miRNA O +
biogenesis O +
and O +
action O -
, O +
and O +
the O +
role O +
of O +
miRNAs O +
in O +
regulating O +
apoptosis O +
of O +
cancer O +
cells O +
and O +
cardiovascular O +
cells O -
. O -

The O +
accurate O +
diagnosis O +
of O +
brain O +
malignancies O +
is O +
essential O +
for O +
selection O +
of O +
proper O +
treatment O -
. O -

A O +
recurring O +
challenge O +
for O +
brain O +
pathologists O +
is O +
to O +
diagnose O +
whether O +
a O +
brain O +
malignancy O +
is O +
a O +
primary O +
tumor O +
or O +
a O +
metastasis O +
from O +
some O +
other O +
tissue O -
. O -

MiR-92b O +
and O +
miR-9 O -
/ O -
9 O -
* O +
are O +
specifically O +
expressed O +
in O +
brain O +
primary O +
tumors O +
and O +
can O +
be O +
used O +
to O +
differentiate O +
primary O +
from O +
metastatic O +
brain O +
tumors O -
. O -

These O +
microRNAs O +
thus O +
represent O +
excellent O +
biomarkers O +
for O +
brain O +
primary O +
tumors O -
. O -

By O +
considering O +
the O +
expression O +
of O +
only O +
these O +
two O +
microRNAs O -
, O +
it O +
is O +
possible O +
to O +
distinguish O +
between O +
primary O +
and O +
metastatic O +
brain O +
tumors O +
with O +
very O +
high O +
accuracy O -
. O -

Using O +
microRNA O +
expression O +
profiling O -
, O +
we O +
found O +
that O +
hsa O -
- O -
miR-92b O +
and O +
hsa O -
- O -
miR-9 O -
/ O -
hsa O -
- O -
miR-9 O -
* O +
are O +
over O -
- O -
expressed O -
, O +
specifically O +
in O +
brain O +
primary O +
tumors O -
, O +
as O +
compared O +
to O +
primary O +
tumors O +
from O +
other O +
tissues O +
and O +
their O +
metastases O +
to O +
the O +
brain O -
. O -

MicroRNAs O +
are O +
a O +
class O +
of O +
small O +
non O -
- O -
coding O +
RNA O +
species O +
that O +
regulate O +
gene O +
expression O -
; O +
many O +
exhibit O +
tissue O -
- O -
specific O +
expression O +
and O +
are O +
misregulated O +
in O +
cancer O -
. O -

Previous O +
reports O +
have O +
found O +
that O +
hsa O -
- O -
miR-92b O +
and O +
hsa O -
- O -
miR-9 O -
/ O -
hsa O -
- O -
miR-9 O -
* O +
are O +
expressed O +
more O +
strongly O +
in O +
developing O +
neurons O +
and O +
brain O +
than O +
in O +
adult O +
brain O -
. O -

Thus O -
, O +
their O +
specific O +
over O -
- O -
expression O +
in O +
brain O +
primary O +
tumors O +
supports O +
a O +
functional O +
role O +
for O +
these O +
microRNAs O +
or O +
a O +
link O +
between O +
neuronal O +
stem O +
cells O +
and O +
brain O +
tumorigenesis O -
. O -

These O +
results O +
are O +
the O +
first O +
to O +
demonstrate O +
that O +
levels O +
of O +
human U-Species +
APP O +
can O +
be O +
regulated O +
by O +
miRNAs O -
. O -

Over O -
- O -
expression O +
of O +
these O +
miRNAs O -
, O +
but O +
not O +
control O +
miRNAs O -
, O +
results O +
in O +
translational O +
repression O +
of O +
APP O +
mRNA O +
and O +
significantly O +
reduces O +
APP O +
protein O +
levels O -
. O -

Here O +
we O +
test O +
the O +
hypothesis O +
that O +
APP O +
protein O +
levels O +
can O +
be O +
regulated O +
by O +
miRNAs O -
, O +
evolutionarily O +
conserved O +
small O +
noncoding O +
RNA O +
molecules O +
that O +
play O +
an O +
important O +
role O +
in O +
regulating O +
gene O +
expression O -
. O -

Utilizing O +
human U-Species +
cell O +
lines O -
, O +
we O +
demonstrate O +
that O +
miRNAs O +
hsa O -
- O -
mir-106a O +
and O +
hsa O -
- O -
mir-520c O +
bind O +
to O +
their O +
predicted O +
target O +
sequences O +
in O +
the O +
APP O +
3'UTR O +
and O +
negatively O +
regulate O +
reporter O +
gene O +
expression O -
. O -

ABSTRACT O -
: O +
A O +
number O +
of O +
studies O +
have O +
shown O +
that O +
increased O +
APP O +
levels O -
, O +
resulting O +
from O +
either O +
a O +
genomic O +
locus O +
duplication O +
or O +
alteration O +
in O +
APP O +
regulatory O +
sequences O -
, O +
can O +
lead O +
to O +
development O +
of O +
early O -
- O -
onset O +
dementias O -
, O +
including O +
Alzheimer O -
's O +
disease O +
( O -
AD O -
) O -
. O -

Therefore O -
, O +
understanding O +
how O +
APP O +
levels O +
are O +
regulated O +
could O +
provide O +
valuable O +
insight O +
into O +
the O +
genetic O +
basis O +
of O +
AD O +
and O +
illuminate O +
novel O +
therapeutic O +
avenues O +
for O +
AD O -
. O -

MicroRNAs O +
can O +
regulate O +
human U-Species +
APP O +
levels O -
. O -

MicroRNA O +
expression O +
profiling O +
for O +
molecular O +
classification O +
of O +
pediatric O +
brain O +
tumors O -
. O -

The O +
transcription O +
factor O +
REST O +
silences O +
neuronal O +
gene O +
expression O +
in O +
non O -
- O -
neuronal O +
cells O -
. O -

The O +
bifunctional O +
microRNA O +
miR-9 O -
/ O -
miR-9 O -
* O +
regulates O +
REST O +
and O +
CoREST O +
and O +
is O +
downregulated O +
in O +
Huntington O -
's O +
disease O -
. O -

Polyglutamine O +
expansions O +
in O +
huntingtin O -
, O +
which O +
causes O +
Huntington O -
's O +
disease O +
( O -
HD O -
) O -
, O +
abrogates O +
REST O -
- O -
huntingtin O +
binding O -
. O -

In O +
neurons O -
, O +
the O +
protein O +
is O +
sequestered O +
in O +
the O +
cytoplasm O +
in O +
part O +
through O +
binding O +
to O +
huntingtin O -
. O -

In O +
this O +
work O -
, O +
we O +
found O +
that O +
levels O +
of O +
several O +
microRNAs O +
( O -
miRNAs O -
) O +
with O +
upstream O +
RE1 O +
sites O +
are O +
decreased O +
in O +
HD O +
patient U-Species +
cortices O +
relative O +
to O +
healthy O +
controls O -
. O -

Consequently O -
, O +
REST O +
translocates O +
to O +
the O +
nucleus O -
, O +
occupies O +
RE1 O +
repressor O +
sequences O +
and O +
decreases O +
neuronal O +
gene O +
expression O -
. O -

Interestingly O -
, O +
one O +
of O +
these O -
, O +
the O +
bifunctional O +
brain O +
enriched O +
miR-9 O -
/ O -
miR-9 O -
* O -
, O +
targets O +
two O +
components O +
of O +
the O +
REST O +
complex O -
: O +
miR-9 O +
targets O +
REST O +
and O +
miR-9 O -
* O +
targets O +
CoREST O -
. O -

These O +
data O +
provide O +
evidence O +
for O +
a O +
double O +
negative O +
feedback O +
loop O +
between O +
the O +
REST O +
silencing O +
complex O +
and O +
the O +
miRNAs O +
it O +
regulates O -
. O -

Specificity O -
, O +
duplex O +
degradation O +
and O +
subcellular O +
localization O +
of O +
antagomirs O -
. O -

Finally O -
, O +
we O +
show O +
that O +
antagomirs O -
, O +
although O +
incapable O +
of O +
silencing O +
miRNAs O +
in O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
when O +
injected O +
systemically O -
, O +
efficiently O +
target O +
miRNAs O +
when O +
injected O +
locally O +
into O +
the O +
mouse U-Species +
cortex O -
. O -

Our O +
data O +
further O +
validate O +
the O +
effectiveness O +
of O +
antagomirs O +
in O +
vivo O +
and O +
should O +
facilitate O +
future O +
studies O +
to O +
silence O +
miRNAs O +
for O +
functional O +
analysis O +
and O +
in O +
clinically O +
relevant O +
settings O -
. O -

We O +
demonstrate O +
that O +
antagomirs O +
harbor O +
optimized O +
phosphorothioate O +
modifications O -
, O +
require O +
> O -
19-nt O +
length O +
for O +
highest O +
efficiency O +
and O +
can O +
discriminate O +
between O +
single O +
nucleotide O +
mismatches O +
of O +
the O +
targeted O +
miRNA O -
. O -

Degradation O +
of O +
different O +
chemically O +
protected O +
miRNA O -
/ O -
antagomir O +
duplexes O +
in O +
mouse U-Species +
livers O +
and O +
localization O +
of O +
antagomirs O +
in O +
a O +
cytosolic O +
compartment O +
that O +
is O +
distinct O +
from O +
processing O +
( O -
P O -
) O -
-bodies O +
indicates O +
a O +
degradation O +
mechanism O +
independent O +
of O +
the O +
RNA O +
interference O +
( O -
RNAi O -
) O +
pathway O -
. O -

We O +
recently O +
demonstrated O +
silencing O +
miRNA O +
function O +
in O +
mice U-Species +
using O +
chemically O +
modified O +
and O +
cholesterol O -
- O -
conjugated O +
RNAs O +
termed O +
' O -
antagomirs O -
' O -
. O -

Here O -
, O +
we O +
further O +
characterize O +
the O +
properties O +
and O +
function O +
of O +
antagomirs O +
in O +
mice U-Species -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
an O +
abundant O +
class O +
of O +
20 O -
- O -
23-nt O +
long O +
regulators O +
of O +
gene O +
expression O -
. O -

The O +
study O +
of O +
miRNA O +
function O +
in O +
mice U-Species +
and O +
potential O +
therapeutic O +
approaches O +
largely O +
depend O +
on O +
modified O +
oligonucleotides O -
. O -

Altered O +
microRNAs O +
in O +
STHdh O -
( O -
Q111 O -
) O -
/ O -
Hdh O -
( O -
Q111 O -
) O +
cells O -
: O +
miR-146a O +
targets O +
TBP O -
. O -

We O +
studied O +
expression O +
of O +
90 O +
miRNAs O +
in O +
STHdh O -
( O -
Q111 O -
) O -
/ O -
Hdh O -
( O -
Q111 O -
) O +
cells O -
, O +
a O +
model O +
for O +
Huntington O -
's O +
disease O +
and O +
compared O +
with O +
that O +
obtained O +
in O +
STHdh O -
( O -
Q7 O -
) O -
/ O -
Hdh O -
( O -
Q7 O -
) O +
cells O -
. O -

Fifteen O +
miRNAs O +
were O +
down O +
regulated O +
and O +
12 O +
miRNAs O +
were O +
up O +
regulated O +
more O +
than O +
2-fold O -
. O -

Such O +
changes O +
were O +
statistically O +
significant O -
. O -

One O +
hundred O +
and O +
forty O -
- O -
two O +
genes O +
are O +
experimentally O +
known O +
targets O +
of O +
these O +
altered O +
miRNAs O -
. O -

Using O +
luciferase O +
reporter O +
assays O +
with O +
3'-UTRs O +
of O +
TBP O -
, O +
over O -
- O -
expression O +
and O +
inhibition O +
of O +
miR-146a O -
, O +
we O +
showed O +
that O +
miR-146a O +
targets O +
TBP O -
. O -

It O +
has O +
been O +
predicted O +
that O +
miR-146a O +
may O +
target O +
Tata O +
Binding O +
Protein O +
( O -
TBP O -
) O -
. O -

Regulation O +
of O +
TBP O +
by O +
miR-146a O +
may O +
contribute O +
to O +
HD O +
pathogenesis O -
. O -

Many O +
of O +
these O +
pathways O +
were O +
first O +
identified O +
in O +
genetic O +
screens O +
in O +
Drosophila U-Species +
and O +
other O +
lower O +
organisms O -
. O -

In O +
the O +
last O +
20 O +
years O -
, O +
it O +
has O +
become O +
clear O +
that O +
developmental O +
genes O +
and O +
their O +
regulators O -
, O +
noncoding O +
RNAs O +
including O +
microRNAs O +
and O +
long O -
- O -
noncoding O +
RNAs O -
, O +
within O +
signaling O +
pathways O +
play O +
a O +
critical O +
role O +
in O +
the O +
pathogenesis O +
of O +
cancer O -
. O -

Genes O +
and O +
pathways O +
expressed O +
during O +
embryonic O +
development O -
, O +
including O +
the O +
Notch O -
, O +
Wnt O -
/ O -
β O -
- O -
Catenin O -
, O +
TGF O -
- O -
β O -
/ O -
BMP O -
, O +
Shh O -
/ O -
Patched O -
, O +
and O +
Hippo O +
pathways O +
are O +
mutated O -
, O +
lost O -
, O +
or O +
aberrantly O +
regulated O +
in O +
a O +
wide O +
variety O +
of O +
human U-Species +
cancers O -
, O +
including O +
skin O -
, O +
breast O -
, O +
blood O -
, O +
and O +
brain O +
cancers O -
, O +
including O +
medulloblastoma O -
. O -

Mammalian O +
orthologs O +
were O +
subsequently O +
identified O +
and O +
genes O +
within O +
the O +
pathways O +
cloned O +
and O +
found O +
to O +
regulate O +
cell O +
growth O -
. O -

Cerebellum O +
development O +
and O +
medulloblastoma O -
. O -

Medulloblastoma O -
, O +
the O +
most O +
common O +
malignant O +
nervous O +
system O +
tumor O +
in O +
childhood O -
, O +
are O +
thought O +
to O +
arise O +
from O +
disruptions O +
in O +
cerebellar O +
development O +
[ O -
reviewed O +
by O +
Marino O -
, O +
S. O +
( O -
2005 O -
) O -
] O -
. O -

These O +
biochemical O +
pathways O +
affect O +
cell O +
fate O +
determination O -
, O +
axis O +
formation O -
, O +
and O +
patterning O +
during O +
development O +
and O +
regulate O +
tissue O +
homeostasis O +
and O +
regeneration O +
in O +
adults O -
. O -

In O +
this O +
chapter O -
, O +
we O +
will O +
review O +
the O +
development O +
of O +
the O +
cerebellar O +
cortex O -
, O +
highlighting O +
signaling O +
pathways O +
of O +
potential O +
relevance O +
to O +
tumorigenesis O -
. O -

Defining O +
the O +
extracellular O +
cues O +
and O +
intracellular O +
signaling O +
pathways O +
that O +
control O +
cerebellar O +
neurogenesis O -
, O +
especially O +
granule O +
cell O +
progenitor O +
( O -
GCP O -
) O +
proliferation O +
and O +
differentiation O +
has O +
been O +
useful O +
for O +
developing O +
models O +
to O +
unravel O +
the O +
mechanisms O +
underlying O +
medulloblastoma O +
formation O +
and O +
growth O -
. O -

This O +
is O -
, O +
to O +
our O +
knowledge O -
, O +
the O +
first O +
case O +
of O +
this O +
kind O +
found O +
in O +
Argentina O +
and O +
is O +
additional O +
evidence O +
that O +
HAM O -
/ O -
TSP O +
solely O +
related O +
to O +
HTLV O -
- O -
II O +
infection O +
occurs O +
in O +
HTLV O -
- O -
I O -
- O -
negative O +
subjects O -
. O -

A O +
case O +
of O +
neurological O +
disease O +
featuring O +
human U-Species +
T O +
lymphocyte O +
virus O -
- O -
associated O +
myelopathy O -
/ O -
tropical O +
spastic O +
paraparesis O +
( O -
HAM O -
/ O -
TSP O -
) O +
was O +
diagnosed O +
by O +
serological O +
( O -
Western O +
blot O -
) O +
and O +
molecular O +
( O -
polymerase O +
chain O +
reaction O -
) O +
criteria O +
as O +
related O +
to O +
human U-Species +
T O +
lymphocyte O +
virus O +
( O -
HTLV O -
) O -
-II O +
infection O -
. O -

A O +
possible O +
case O +
of O +
myelopathy O -
/ O -
tropical O +
spastic O +
paraparesis O +
in O +
an O +
Argentinian O +
woman U-Species +
with O +
human U-Species +
T O +
lymphocyte O +
virus O +
type O +
II O -
. O -

Co O -
- O -
suppression O +
of O +
miR-221 O -
/ O -
222 O +
directly O +
resulted O +
in O +
the O +
up O -
- O -
regulation O +
of O +
p27Kip1 O +
in O +
the O +
tested O +
cells O -
, O +
consequently O -
, O +
affects O +
their O +
growth O +
potential O +
by O +
reducing O +
a O +
G1 O +
to O +
S O +
shift O +
in O +
the O +
cell O +
cycle O -
. O -

Consistently O -
, O +
miR-221 O -
/ O -
222 O +
knocked O -
- O -
down O +
through O +
antisense O +
2'-OME O -
- O -
oligonucleotides O +
increased O +
p27Kip1 O +
in O +
U251 O +
glioma O +
subcutaneous O +
mice U-Species +
and O +
strongly O +
reduced O +
tumor O +
growth O +
in O +
vivo O +
through O +
up O +
regulation O +
of O +
p27Kip1 O -
. O -

Our O +
results O +
suggest O +
that O +
miR-221 O -
/ O -
222 O +
is O +
a O +
regulator O +
of O +
the O +
tumor O +
suppressor O +
gene O +
p27Kip1 O -
, O +
and O +
co O -
- O -
suppression O +
of O +
miR-221 O -
/ O -
222 O +
expression O +
in O +
advanced O +
gliomas O +
may O +
inhibit O +
glioma O +
cell O +
proliferation O +
by O +
a O +
mechanism O +
involving O +
the O +
up O -
- O -
regulation O +
of O +
p27Kip1 O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

Co O -
- O -
suppression O +
of O +
miR-221 O -
/ O -
222 O +
cluster O +
suppresses O +
human U-Species +
glioma O +
cell O +
growth O +
by O +
targeting O +
p27kip1 O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

MicroRNAs O +
are O +
short O +
regulatory O +
RNAs O +
that O +
negatively O +
modulate O +
protein O +
expression O +
at O +
a O +
post O -
- O -
transcriptional O +
level O -
. O -

Emerging O +
evidence O +
suggests O +
that O +
altered O +
regulation O +
of O +
miRNA O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
several O +
types O +
of O +
cancers O -
. O -

In O +
the O +
current O +
study O -
, O +
an O +
inverse O +
relationship O +
between O +
the O +
expression O +
of O +
miR-221 O -
/ O -
miR-222 O +
and O +
the O +
cell O +
cycle O +
inhibitor O +
p27Kip1 O +
was O +
identified O +
in O +
U251 O +
glioma O +
cells O -
. O -

The O +
mRNA O +
expression O +
of O +
the O +
RNases O +
Drosha O +
and O +
Dicer O -
, O +
cofactor O +
Pasha O -
, O +
and O +
the O +
pre O -
- O -
miRNA O +
transporter O +
exportin-5 O -
, O +
which O +
modulate O +
miRNA O +
biogenesis O -
, O +
were O +
not O +
altered O +
after O +
transient O +
middle O +
cerebral O +
artery O +
occlusion O -
. O -

Thus O -
, O +
the O +
present O +
studies O +
indicate O +
a O +
critical O +
role O +
of O +
miRNAs O +
in O +
controlling O +
mRNA O +
transcription O +
and O +
translation O +
in O +
the O +
postischemic O +
brain O -
. O -

Bioinformatics O +
analysis O +
indicated O +
a O +
correlation O +
between O +
miRNAs O +
altered O +
to O +
several O +
mRNAs O +
known O +
to O +
mediate O +
inflammation O -
, O +
transcription O -
, O +
neuroprotection O -
, O +
receptors O +
function O -
, O +
and O +
ionic O +
homeostasis O -
. O -

Of O +
those O -
, O +
17 O +
showed O +
> O -
5 O +
fold O +
change O -
. O -

In O +
silico O +
analysis O +
showed O +
sequence O +
complementarity O +
of O +
eight O +
miRNAs O +
induced O +
after O +
focal O +
ischemia O +
to O +
877 O +
promoters O +
indicating O +
the O +
possibility O +
of O +
noncoding O +
RNA O -
- O -
induced O +
activation O +
of O +
gene O +
expression O -
. O -

Antagomir O -
- O -
mediated O +
prevention O +
of O +
mir-145 O +
expression O +
led O +
to O +
an O +
increased O +
protein O +
expression O +
of O +
its O +
downstream O +
target O +
superoxide O +
dismutase-2 O +
in O +
the O +
postischemic O +
brain O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
approximately O +
22 O +
nucleotides O +
long O -
, O +
noncoding O +
RNAs O +
that O +
control O +
cellular O +
function O +
by O +
either O +
degrading O +
mRNAs O +
or O +
arresting O +
their O +
translation O -
. O -

Transient O +
focal O +
ischemia O +
induces O +
extensive O +
temporal O +
changes O +
in O +
rat U-Species +
cerebral O +
microRNAome O -
. O -

Of O +
the O +
238 O +
miRNAs O +
evaluated O -
, O +
8 O +
showed O +
increased O +
and O +
12 O +
showed O +
decreased O +
expression O +
at O +
least O +
at O +
4 O +
out O +
of O +
5 O +
reperfusion O +
time O +
points O +
studied O +
between O +
3 O +
h O +
and O +
3 O +
days O +
compared O +
with O +
sham O -
. O -

To O +
understand O +
their O +
functional O +
significance O +
in O +
ischemic O +
pathophysiology O -
, O +
we O +
profiled O +
miRNAs O +
in O +
adult O +
rat U-Species +
brain O +
as O +
a O +
function O +
of O +
reperfusion O +
time O +
after O +
transient O +
middle O +
cerebral O +
artery O +
occlusion O -
. O -

The O +
therapy O +
employed O -
, O +
in O +
a O +
single O +
baculoviral O +
vector O -
, O +
a O +
glial O +
fibrillary O +
acidic O +
protein O +
( O -
GFAP O -
) O +
gene O +
promoter O +
and O +
the O +
repeated O +
target O +
sequences O +
of O +
three O +
miRNAs O +
that O +
are O +
enriched O +
in O +
astrocytes O +
but O +
downregulated O +
in O +
glioblastoma O +
cells O +
to O +
control O +
the O +
expression O +
of O +
the O +
herpes O +
simplex O +
virus O +
thymidine O +
kinase O +
( O -
HSVtk O -
) O +
gene O -
. O -

This O +
resulted O +
in O +
significantly O +
improved O +
in O +
vivo O +
selectivity O +
over O +
the O +
use O +
of O +
a O +
control O +
vector O +
without O +
miRNA O +
regulation O -
, O +
enabling O +
effective O +
elimination O +
of O +
human U-Species +
glioma O +
xenografts O +
while O +
producing O +
negligible O +
toxic O +
effects O +
on O +
normal O +
astrocytes O -
. O -

In O +
the O +
context O +
of O +
cancer O +
suicide O +
gene O +
therapy O -
, O +
this O +
approach O +
may O +
lead O +
to O +
cytotoxic O +
effects O +
in O +
both O +
cancer O +
and O +
nontarget O +
normal O +
cells O -
. O -

Considering O +
microRNA O +
( O -
miRNA O -
) O +
function O +
in O +
post O -
- O -
transcriptional O +
regulation O +
of O +
gene O +
expression O -
, O +
we O +
have O +
developed O +
a O +
viral O +
vector O +
platform O +
combining O +
cellular O +
promoter O -
- O -
based O +
transcriptional O +
targeting O +
with O +
miRNA O +
regulation O +
for O +
a O +
glioma O +
suicide O +
gene O +
therapy O +
in O +
the O +
mouse U-Species +
brain O -
. O -

Thus O -
, O +
incorporating O +
miRNA O +
regulation O +
into O +
a O +
transcriptional O +
targeting O +
vector O +
adds O +
an O +
extra O +
layer O +
of O +
security O +
to O +
prevent O +
off O -
- O -
target O +
transgene O +
expression O +
and O +
should O +
be O +
useful O +
for O +
the O +
development O +
of O +
gene O +
delivery O +
vectors O +
with O +
high O +
targeting O +
specificity O +
for O +
cancer O +
therapy O -
. O -

Transcriptional O +
targeting O +
using O +
a O +
tissue O -
- O -
specific O +
cellular O +
promoter O +
is O +
proving O +
to O +
be O +
a O +
powerful O +
means O +
for O +
restricting O +
transgene O +
expression O +
in O +
targeted O +
tissues O -
. O -

Combinatorial O +
control O +
of O +
suicide O +
gene O +
expression O +
by O +
tissue O -
- O -
specific O +
promoter O +
and O +
microRNA O +
regulation O +
for O +
cancer O +
therapy O -
. O -

The O +
possible O +
use O +
of O +
RNAi O +
in O +
the O +
treatment O +
of O +
spinocerebellar O +
ataxia O +
or O +
amyotrophic O +
lateral O +
sclerosis O -
, O +
with O +
its O +
advantages O +
and O +
pitfalls O +
and O +
possible O +
extensions O +
to O +
other O +
diseases O +
are O +
discussed O -
. O -

RNAi O +
has O +
moved O +
from O +
a O +
purely O +
experimental O +
technique O +
to O +
the O +
stage O +
of O +
potential O +
clinical O +
applications O -
. O -

RNAi O +
utilises O +
cellular O +
machinery O +
associated O +
with O +
the O +
processing O +
of O +
naturally O +
occurring O +
micro O +
RNA O +
( O -
miRNAs O -
) O -
. O -

RNAi O +
has O +
both O +
admirers O +
and O +
detractors O -
, O +
but O +
is O +
undeniably O +
a O +
technique O +
with O +
great O +
potential O -
, O +
which O +
has O +
come O +
a O +
long O +
way O +
in O +
the O +
short O +
time O +
since O +
its O +
discovery O -
. O -

RNA O +
interference O +
has O +
become O +
the O +
tool O +
of O +
choice O +
to O +
analyse O +
the O +
loss O -
- O -
of O -
- O -
function O +
of O +
individual O +
genes O +
and O +
has O +
been O +
exploited O +
to O +
identify O +
complex O +
regulatory O +
pathways O +
following O +
genomic O +
screening O -
. O -

Design O +
of O +
shRNAs O +
for O +
RNAi O -
- O -
A O +
lesson O +
from O +
pre O -
- O -
miRNA O +
processing O -
: O +
possible O +
clinical O +
applications O -
. O -

The O +
cellular O +
processing O +
of O +
shRNAs O +
shares O +
common O +
features O +
with O +
the O +
biogenesis O +
of O +
naturally O +
occurring O +
miRNA O +
such O +
as O +
cleavage O +
by O +
nuclear O +
RNase O +
Drosha O -
, O +
export O +
from O +
the O +
nucleus O -
, O +
processing O +
by O +
a O +
cytoplasmic O +
RNase O +
Dicer O -
, O +
and O +
incorporation O +
into O +
the O +
RNA O -
- O -
induced O +
silencing O +
complex O +
( O -
RISC O -
) O -
. O -

Each O +
step O +
has O +
a O +
crucial O +
influence O +
on O +
the O +
efficiency O +
of O +
RNAi O +
and O +
their O +
consideration O +
should O +
be O +
a O +
part O +
of O +
a O +
standard O +
experimental O +
design O -
. O -

More O +
recently O +
an O +
introduction O +
of O +
short O +
approximately O +
22 O +
nucleotide O +
RNA O +
duplexes O +
has O +
become O +
the O +
standard O +
in O +
short O -
- O -
term O +
experiments O -
, O +
but O +
is O +
insufficient O +
for O +
long O -
- O -
term O +
knock O -
- O -
down O +
assays O -
. O -

Long O -
- O -
term O +
expression O +
of O +
siRNAs O +
has O +
been O +
achieved O +
by O +
in O +
vivo O +
transcription O +
from O +
plasmids O +
coding O +
for O +
short O +
hairpin O +
RNAs O +
( O -
shRNAs O -
) O -
. O -

Effective O +
use O +
of O +
RNAi O +
requires O +
detailed O +
knowledge O +
of O +
the O +
individual O +
steps O +
and O +
the O +
proteins O +
involved O -
, O +
as O +
well O +
as O +
the O +
similarities O +
and O +
distinctions O +
between O +
miRNA O +
and O +
siRNA O +
pathways O -
. O -

RNAi O +
was O +
originally O +
induced O +
by O +
the O +
introduction O +
of O +
long O +
double O +
stranded O +
RNAs O +
( O -
dsRNAs O -
) O +
into O +
cells O +
in O +
which O +
the O +
RNA O +
was O +
cleaved O +
into O +
short O +
RNAs O +
which O +
effectively O +
interfered O +
with O +
a O +
transcription O +
of O +
cognate O +
mRNA O -
. O -

[ O -
AD O -
- O -
FTLD O +
spectrum O -
-- O -
new O +
findings O +
on O +
risk O +
genes O +
in O +
neurodegenerative O +
diseases O -
] O -
. O -

Our O +
microarray O +
based O +
analysis O +
of O +
microRNA O +
expression O +
in O +
rat U-Species +
cerebral O +
cortex O +
after O +
traumatic O +
brain O +
injury O +
has O +
shown O +
that O +
some O +
microRNA O +
such O +
as O +
miR-21 O +
could O +
be O +
involved O +
in O +
the O +
intricate O +
process O +
of O +
TBI O +
course O -
. O -

Furthermore O -
, O +
we O +
revealed O +
global O +
up O -
- O -
regulation O +
of O +
miR-21 O +
expression O +
within O +
all O +
the O +
four O +
time O +
points O +
post O +
injury O -
. O -

Our O +
research O +
revealed O +
that O +
136 O +
miRNAs O +
were O +
expressing O +
at O +
6 O +
h O +
post O +
injury O -
, O +
in O +
which O +
13 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
14 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
; O +
118 O +
miRNAs O +
were O +
expressing O +
at O +
24 O +
h O +
post O +
injury O -
, O +
in O +
which O +
4 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
23 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
; O +
149 O +
miRNAs O +
were O +
expressing O +
at O +
48 O +
h O +
post O +
injury O -
, O +
in O +
which O +
16 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
11 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
; O +
and O +
203 O +
miRNAs O +
were O +
expressing O +
at O +
72 O +
h O +
post O +
injury O -
, O +
in O +
which O +
19 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
up O -
- O -
regulated O -
, O +
and O +
5 O +
miRNAs O +
were O +
more O +
than O +
2-fold O +
down O -
- O -
regulated O -
. O -

The O +
qRT O -
- O -
PCR O +
results O +
indicated O +
good O +
consistency O +
with O +
the O +
results O +
of O +
the O +
microarray O +
method O -
. O -

Finally O -
, O +
we O +
utilized O +
qRT O -
- O -
PCR O +
methods O +
to O +
verify O +
the O +
microarray O +
results O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
very O +
important O +
regulators O +
of O +
biological O +
processes O +
such O +
as O +
development O -
, O +
cellular O +
differentiation O -
, O +
and O +
tumor O +
generation O -
. O -

MiRNA O +
microarray O +
has O +
been O +
found O +
to O +
be O +
a O +
high O +
throughput O +
global O +
analysis O +
tool O +
for O +
detecting O +
miRNA O +
expression O +
profiling O -
, O +
and O +
miRNA O +
expression O +
profiling O +
will O +
facilitate O +
the O +
study O +
of O +
the O +
biological O +
function O +
of O +
miRNAs O -
. O -

In O +
this O +
report O -
, O +
we O +
describe O +
the O +
miRNA O +
expression O +
level O +
in O +
rat U-Species +
cerebral O +
cortex O +
after O +
traumatic O +
brain O +
injury O +
using O +
microarray O +
method O -
. O -

We O +
choose O +
several O +
time O +
points O +
post O +
brain O +
injury O -
: O +
6 O +
h O -
, O +
24 O +
h O -
, O +
48 O +
h O +
and O +
72 O +
h O -
, O +
respectively O -
, O +
to O +
reveal O +
differential O +
expression O +
of O +
miRNAs O +
in O +
rat U-Species +
brain O +
cortex O +
compared O +
with O +
control O +
groups O -
. O -

Microarray O +
based O +
analysis O +
of O +
microRNA O +
expression O +
in O +
rat U-Species +
cerebral O +
cortex O +
after O +
traumatic O +
brain O +
injury O -
. O -

Ectopic O +
expression O +
of O +
miR-29b O +
decreased O +
hPGRN O +
expression O +
at O +
the O +
both O +
mRNA O +
and O +
protein O +
levels O -
. O -

To O +
examine O +
the O +
direct O +
effect O +
of O +
manipulating O +
endogenous O +
miR-29b O +
on O +
hPGRN O +
expression O -
, O +
we O +
established O +
a O +
stable O +
NIH3T3 O +
cell O +
line O +
that O +
expresses O +
hPGRN O +
under O +
the O +
control O +
of O +
the O +
cytomegalovirus O +
promoter O -
. O -

Endogenous O +
hPGRN O +
in O +
HEK O +
293 O +
cells O +
was O +
also O +
regulated O +
by O +
miR-29b O -
. O -

Conversely O -
, O +
knockdown O +
of O +
endogenous O +
miR-29b O +
with O +
locked O +
nucleic O +
acid O +
increased O +
the O +
production O +
and O +
secretion O +
of O +
hPGRN O +
in O +
NIH3T3 O +
cells O -
. O -

How O +
progranulin O +
( O -
PGRN O -
) O +
expression O +
is O +
regulated O +
is O +
largely O +
unknown O -
. O -

Progranulin O +
deficiency O +
is O +
thought O +
to O +
cause O +
some O +
forms O +
of O +
frontotemporal O +
dementia O +
( O -
FTD O -
) O -
, O +
a O +
major O +
early O -
- O -
onset O +
age O -
- O -
dependent O +
neurodegenerative O +
disease O -
. O -

miR-29b O +
downregulates O +
the O +
expression O +
of O +
luciferase O +
through O +
hPGRN O +
or O +
mouse U-Species +
PGRN O +
( O -
mPGRN O -
) O +
3'UTRs O -
, O +
and O +
the O +
regulation O +
was O +
abolished O +
by O +
mutations O +
in O +
the O +
miR-29b O +
binding O +
site O -
. O -

We O +
identified O +
an O +
evolutionarily O +
conserved O +
binding O +
site O +
for O +
microRNA-29b O +
( O -
miR-29b O -
) O +
in O +
the O +
3 O -
' O +
untranslated O +
region O +
( O -
3'UTR O -
) O +
of O +
the O +
human U-Species +
PGRN O +
( O -
hPGRN O -
) O +
mRNA O -
. O -

MicroRNA-29b O +
regulates O +
the O +
expression O +
level O +
of O +
human U-Species +
progranulin O -
, O +
a O +
secreted O +
glycoprotein O +
implicated O +
in O +
frontotemporal O +
dementia O -
. O -

These O +
findings O +
identify O +
miR-29b O +
as O +
a O +
novel O +
posttranscriptional O +
regulator O +
of O +
PGRN O +
expression O -
, O +
raising O +
the O +
possibility O +
that O +
miR-29b O +
or O +
other O +
miRNAs O +
might O +
be O +
targeted O +
therapeutically O +
to O +
increase O +
hPGRN O +
levels O +
in O +
some O +
FTD O +
patients U-Species -
. O -

We O +
studied O +
the O +
expression O +
of O +
selected O +
miRNAs O +
following O +
infection O +
of O +
CBA O +
mice U-Species +
with O +
Plasmodium O +
berghei O +
ANKA O +
( O -
PbA O -
) O -
, O +
which O +
causes O +
cerebral O +
malaria O +
( O -
CM O -
) O -
, O +
or O +
Plasmodium O +
berghei O +
K173 O +
( O -
PbK O -
) O -
, O +
which O +
causes O +
severe O +
malaria O +
but O +
without O +
cerebral O +
complications O -
, O +
termed O +
non O -
- O -
CM O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
posttranscriptional O +
regulatory O +
molecules O +
that O +
have O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
immune O +
responses O -
, O +
but O +
their O +
role O +
in O +
the O +
immune O +
response O +
to O +
Plasmodium O +
infection O +
is O +
unknown O -
. O -

Differential O +
MicroRNA O +
Expression O +
in O +
Experimental O +
Cerebral O +
and O +
Noncerebral O +
Malaria O -
. O -

To O +
investigate O +
the O +
involvement O +
of O +
let-7i O -
, O +
miR-27a O -
, O +
and O +
miR-150 O +
in O +
CM O -
- O -
resistant O +
mice U-Species -
, O +
we O +
assessed O +
the O +
expression O +
levels O +
in O +
gamma O +
interferon O +
knockout O +
( O -
IFN O -
- O -
γ O -
( O -
- O -
/ O -
- O -
) O -
) O +
mice U-Species +
on O +
a O +
C57BL O -
/ O -
6 O +
genetic O +
background O -
. O -

In O +
contrast O -
, O +
no O +
miRNA O +
changes O +
were O +
detected O +
in O +
the O +
heart O -
, O +
an O +
organ O +
with O +
no O +
known O +
pathology O +
during O +
acute O +
malaria O -
. O -

We O +
identified O +
three O +
miRNAs O +
that O +
were O +
differentially O +
expressed O +
in O +
the O +
brain O +
of O +
PbA O -
- O -
infected O +
CBA O +
mice U-Species -
: O +
let7i O -
, O +
miR-27a O -
, O +
and O +
miR-150 O -
. O -

The O +
differential O +
expression O +
profiles O +
of O +
selected O +
miRNAs O +
( O -
let-7i O -
, O +
miR-27a O -
, O +
miR-150 O -
, O +
miR-126 O -
, O +
miR-210 O -
, O +
and O +
miR-155 O -
) O +
were O +
analyzed O +
in O +
mouse U-Species +
brain O +
and O +
heart O +
tissue O +
by O +
quantitative O +
reverse O +
transcription O -
- O -
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
. O -

Our O +
data O +
suggest O +
that O +
in O +
the O +
CBA O +
mouse U-Species +
at O +
least O -
, O +
miRNA O +
may O +
have O +
a O +
regulatory O +
role O +
in O +
the O +
pathogenesis O +
of O +
severe O +
malaria O -
. O -

Overexpression O +
of O +
these O +
three O +
miRNAs O +
during O +
PbA O -
, O +
but O +
not O +
PbK O -
, O +
infection O +
in O +
WT O +
mice U-Species +
may O +
be O +
critical O +
for O +
the O +
triggering O +
of O +
the O +
neurological O +
syndrome O +
via O +
regulation O +
of O +
their O +
potential O +
downstream O +
targets O -
. O -

The O +
expression O +
of O +
let-7i O -
, O +
miR-27a O -
, O +
and O +
miR-150 O +
was O +
unchanged O +
in O +
both O +
wild O -
- O -
type O +
( O -
WT O -
) O +
and O +
IFN O -
- O -
γ O -
( O -
- O -
/ O -
- O -
) O +
mice U-Species +
following O +
infection O -
. O -

[ O -
Genetic O +
and O +
molecular O +
abnormalities O +
of O +
glioblastomas O +
( O -
GBM O -
) O -
] O -
. O -

This O +
presentation O +
reports O +
a O +
series O +
of O +
data O +
dealing O +
with O +
recurrent O +
genetic O +
abnormalities O +
and O +
gene O +
expression O +
profiles O +
that O +
characterize O +
primary O +
glioblastomas O +
and O +
secondary O +
glioblastomas O +
resulting O +
from O +
the O +
transformation O +
of O +
low O +
grade O +
tumors O +
( O -
grade O +
II O +
and O +
III O +
astrocytomas O +
and O +
oligodendrogliomas O -
) O -
. O -

Finally O -
, O +
a O +
short O +
description O +
of O +
exosomes O +
as O +
vectors O +
of O +
tumor O +
information O +
will O +
be O +
presented O -
. O -

The O +
most O +
recent O +
aspects O +
of O +
the O +
concept O +
of O +
tumor O +
stem O +
cells O +
that O +
may O +
explain O +
the O +
relentless O +
growth O +
of O +
GBM O +
will O +
be O +
reported O -
. O -

Molecular O +
features O +
of O +
tumor O +
neoangiogenesis O +
will O +
be O +
described O -
. O -

Epigenetic O +
alterations O +
and O +
deregulation O +
of O +
gene O +
expression O +
by O +
microRNAs O +
( O -
miRs O -
) O +
will O +
be O +
also O +
included O -
. O -

Some O +
aspects O +
of O +
tumor O +
predisposition O +
will O +
be O +
also O +
discussed O -
. O -

In O +
an O +
effort O +
to O +
shed O +
light O +
on O +
consequences O +
mediated O +
by O +
p53 O +
inactivation O +
in O +
gliomas O -
, O +
we O +
established O +
the O +
Tet O -
- O -
On O +
system O +
for O +
p53 O +
in O +
the O +
LN O -
- O -
Z308 O +
glioblastoma O +
cell O +
line O -
. O -

p53 O +
is O +
activated O +
upon O +
various O +
kinds O +
of O +
cellular O +
stress O +
leading O +
to O +
apoptosis O +
or O +
cell O +
cycle O +
arrest O -
, O +
but O +
is O +
also O +
implicated O +
in O +
complex O +
biological O +
processes O +
such O +
as O +
inhibition O +
of O +
angiogenesis O +
and O +
metastasis O -
. O -

Oxygen O +
deprivation O -
, O +
an O +
important O +
cellular O +
stress O -
, O +
revealed O +
MIC-1 O +
as O +
an O +
anoxia O +
responsive O +
gene O +
in O +
glioblastoma O +
cell O +
lines O -
. O -

The O +
macrophage O +
inhibitory O +
cytokine-1 O +
( O -
MIC-1 O -
) O +
gene O +
was O +
identified O +
as O +
a O +
most O +
prominent O +
p53 O +
target O +
gene O +
upon O +
gene O +
expression O +
profiling O -
. O -

Furthermore O -
, O +
ectopic O +
expression O +
of O +
MIC-1 O +
in O +
LN O -
- O -
Z308 O +
cell O +
line O +
completely O +
abolished O +
its O +
inherent O +
tumorigenicity O +
in O +
nude B-Species +
mice L-Species -
, O +
while O +
proliferation O +
in O +
vitro O +
was O +
not O +
affected O -
. O -

MIC-1 O +
up O -
- O -
regulation O +
by O +
anoxia O +
is O +
mediated O +
through O +
an O +
alternative O -
, O +
p53 O +
and O +
hypoxia O +
inducible O +
factor O +
1 O +
( O -
HIF-1 O -
) O +
independent O +
pathway O -
. O -

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
MIC-1 O +
is O +
an O +
important O +
downstream O +
mediator O +
of O +
p53 O +
function O -
, O +
while O +
acting O +
itself O +
as O +
an O +
intercessor O +
of O +
cellular O +
stress O +
signaling O +
and O +
exerting O +
anti O -
- O -
tumorigenic O +
activities O -
. O -

In O +
the O +
present O +
experimental O +
model O +
MIC-1 O +
may O +
exert O +
its O +
anti O -
- O -
tumorigenic O +
properties O +
via O +
a O +
paracrine O +
mechanism O +
mediated O +
by O +
host O +
cells O +
in O +
vivo O -
. O -

Human U-Species +
astrocytic O +
brain O +
tumors O +
select O +
for O +
mutations O +
in O +
the O +
p53 O +
tumor O +
suppressor O +
gene O +
early O +
in O +
malignant O +
progression O -
. O -

Anoxia O +
induces O +
macrophage O +
inhibitory O +
cytokine-1 O +
( O -
MIC-1 O -
) O +
in O +
glioblastoma O +
cells O +
independently O +
of O +
p53 O +
and O +
HIF-1 O -
. O -

Reduction O +
of O +
miR-21 O +
induces O +
glioma O +
cell O +
apoptosis O +
via O +
activating O +
caspase O +
9 O +
and O +
3 O -
. O -
Extensive O +
data O +
indicate O +
that O +
miR-21 O +
plays O +
a O +
critical O +
role O +
in O +
gliomagenesis O -
, O +
however O -
, O +
knowledge O +
is O +
limited O +
on O +
the O +
mechanism O +
of O +
action O +
of O +
miR-21 O -
, O +
including O +
cell O +
proliferation O -
, O +
apoptosis O -
, O +
and O +
migration O -
. O -

Moreover O -
, O +
reduction O +
of O +
miR-21 O +
activated O +
caspase O +
9 O +
and O +
3 O -
, O +
which O +
may O +
be O +
mediated O +
by O +
modulating O +
multiple O +
potential O +
target O +
genes O -
, O +
such O +
as O +
TIMP3 O -
. O -

In O +
this O +
study O -
, O +
we O +
showed O +
that O +
down O -
- O -
regulation O +
of O +
miR-21 O +
expression O +
by O +
antisense O +
oligonucleotides O +
inhibited O +
glioma O +
cell O +
proliferation O +
and O +
induced O +
cell O +
apoptosis O -
. O -

Together O -
, O +
these O +
findings O +
indicate O +
that O +
miR-21 O +
plays O +
a O +
key O +
role O +
in O +
regulating O +
cell O +
apoptosis O +
in O +
gliomas O +
and O +
may O +
serve O +
as O +
a O +
target O +
for O +
effective O +
therapies O -
. O -

Membership O +
in O +
this O +
group O +
is O +
defined O +
based O +
on O +
sequence O +
similarity O +
near O +
the O +
mature O +
miRNAs O -
' O +
5 O -
' O +
end O -
: O +
all O +
include O +
the O +
sequence O +
AGCAGC O -
. O -

Here O +
we O +
provide O +
an O +
overview O +
of O +
the O +
following O -
: O +
( O -
1 O -
) O +
the O +
evolution O +
of O +
miR-15 O -
/ O -
107 O +
group O +
member O +
genes O -
; O +
( O -
2 O -
) O +
the O +
expression O +
levels O +
of O +
miRNAs O +
in O +
mammalian O +
tissues O -
; O +
( O -
3 O -
) O +
evidence O +
for O +
overlapping O +
gene O -
- O -
regulatory O +
functions O +
by O +
different O +
miRNAs O -
; O +
( O -
4 O -
) O +
the O +
normal O +
biochemical O +
pathways O +
regulated O +
by O +
miR-15 O -
/ O -
107 O +
group O +
miRNAs O -
; O +
and O +
( O -
5 O -
) O +
the O +
roles O +
played O +
by O +
these O +
miRNAs O +
in O +
human U-Species +
diseases O -
. O -

While O +
all O +
vertebrates O +
studied O +
to O +
date O +
express O +
miR-15a O -
, O +
miR-15b O -
, O +
miR-16 O -
, O +
miR-103 O -
, O +
and O +
miR-107 O -
, O +
mammals O +
alone O +
are O +
known O +
to O +
express O +
miR-195 O -
, O +
miR-424 O -
, O +
miR-497 O -
, O +
miR-503 O -
, O +
and O +
miR-646 O -
. O -

Phylogeny O +
of O +
this O +
group O +
of O +
miRNAs O +
is O +
incomplete O -
; O +
thus O -
, O +
a O +
definitive O +
taxonomic O +
classification O +
( O -
e.g. O -
, O +
designation O +
as O +
a O +
" O -
superfamily O -
" O -
) O +
is O +
currently O +
not O +
possible O -
. O -

We O +
present O +
data O +
on O +
the O +
expression O +
of O +
all O +
known O +
miR-15 O -
/ O -
107 O +
group O +
members O +
in O +
human U-Species +
cerebral O +
cortical O +
gray O +
matter O +
and O +
white O +
matter O +
using O +
new O +
miRNA O +
profiling O +
microarrays O -
. O -

Multiple O +
different O +
miRNAs O +
in O +
the O +
miR-15 O -
/ O -
107 O +
group O +
are O +
expressed O +
at O +
moderate O +
to O +
high O +
levels O +
in O +
human U-Species +
tissues O -
. O -

The O +
miR-15 O -
/ O -
107 O +
group O +
of O +
microRNA O +
genes O -
: O +
evolutionary O +
biology O -
, O +
cellular O +
functions O -
, O +
and O +
roles O +
in O +
human U-Species +
diseases O -
. O -

The O +
miR-15 O -
/ O -
107 O +
group O +
of O +
microRNA O +
( O -
miRNA O -
) O +
gene O +
is O +
increasingly O +
appreciated O +
to O +
serve O +
key O +
functions O +
in O +
humans U-Species -
. O -

These O +
miRNAs O +
regulate O +
gene O +
expression O +
involved O +
in O +
cell O +
division O -
, O +
metabolism O -
, O +
stress O +
response O -
, O +
and O +
angiogenesis O +
in O +
vertebrate O +
species O -
. O -

The O +
miR-15 O -
/ O -
107 O +
group O +
has O +
also O +
been O +
implicated O +
in O +
human U-Species +
cancers O -
, O +
cardiovascular O +
disease O +
and O +
neurodegenerative O +
disease O -
, O +
including O +
Alzheimer O -
's O +
disease O -
. O -

In O +
conclusion O -
, O +
the O +
miR-15 O -
/ O -
107 O +
group O +
of O +
miRNA O +
genes O +
is O +
a O +
fascinating O +
topic O +
of O +
study O +
for O +
evolutionary O +
biologists O -
, O +
miRNA O +
biochemists O -
, O +
and O +
clinically O +
oriented O +
translational O +
researchers O +
alike O -
. O -

We O +
show O +
new O +
data O +
from O +
cultured O +
H4 O +
cancer O +
cells O +
that O +
demonstrate O +
similarities O +
in O +
mRNAs O +
targeted O +
by O +
miR-16 O +
and O +
miR-103 O +
and O +
also O +
support O +
the O +
importance O +
of O +
the O +
mature O +
miRNAs O -
' O +
5 O -
' O +
seed O +
region O +
in O +
mRNA O +
target O +
recognition O -
. O -

There O +
is O +
extensive O +
overlap O +
in O +
the O +
mRNAs O +
targeted O +
by O +
miR-15 O -
/ O -
107 O +
group O +
members O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
small O +
noncoding O +
RNAs O +
comprising O +
21 O -
- O -
23 O +
nucleotides O +
that O +
regulate O +
gene O +
expression O +
by O +
transcriptionally O +
repressing O +
their O +
complementary O +
mRNAs O -
. O -

Let-7 O +
microRNA O +
inhibits O +
the O +
proliferation O +
of O +
human U-Species +
glioblastoma O +
cells O -
. O -

Transfection O +
of O +
let-7 O +
miRNA O +
reduced O +
expression O +
of O +
pan O -
- O -
RAS O -
, O +
N O -
- O -
RAS O -
, O +
and O +
K O -
- O -
RAS O +
in O +
the O +
glioblastoma O +
cells O -
. O -

Human U-Species +
glioblastoma O +
cells O +
( O -
U251 O +
or O +
U87 O +
cells O -
) O +
were O +
transfected O +
with O +
let-7 O +
miRNA O +
and O +
assayed O +
for O +
in O -
- O -
vitro O +
proliferation O -
, O +
migration O -
, O +
and O +
in O -
- O -
vivo O +
tumor O +
formation O -
. O -

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
anti O -
- O -
tumorigenic O +
effect O +
of O +
let-7 O +
miRNA O +
in O +
glioblastoma O +
cells O -
. O -

In O +
particular O -
, O +
let-7 O +
miRNA O +
has O +
been O +
postulated O +
to O +
function O +
as O +
a O +
tumor O +
suppressor O +
in O +
various O +
cancer O +
cells O -
, O +
but O +
not O +
yet O +
in O +
glioblastoma O -
. O -

These O +
results O +
indicate O +
that O +
let-7 O +
miRNA O +
has O +
an O +
anti O -
- O -
tumorigenic O +
effect O +
on O +
glioblastoma O +
cells O -
, O +
and O +
suggest O +
possible O +
use O +
of O +
let-7 O +
miRNA O +
for O +
treating O +
glioblastoma O -
. O -

However O -
, O +
let-7 O +
miRNA O +
exerted O +
no O +
effect O +
on O +
the O +
proliferation O +
of O +
normal O +
human U-Species +
astrocytes O -
. O -

Let-7 O +
miRNA O +
also O +
reduced O +
the O +
in O -
- O -
vitro O +
proliferation O +
and O +
migration O +
of O +
the O +
cells O -
, O +
and O +
reduced O +
the O +
sizes O +
of O +
the O +
tumors O +
produced O +
after O +
transplantation O +
into O +
nude B-Species +
mice L-Species -
. O -

MiRNAs O +
microarray O +
analysis O +
results O +
showed O +
that O +
125 O +
miRNAs O +
were O +
detected O +
in O +
the O +
hippocampus O +
of O +
lithium O -
- O -
pilocarpine O -
- O -
induced O +
TLE O +
rats U-Species +
and O +
normal O +
rats U-Species -
. O -

To O +
understand O +
the O +
role O +
of O +
miRNAs O +
in O +
the O +
molecular O +
mechanisms O +
of O +
temporal O +
lobe O +
epilepsy O +
( O -
TLE O -
) O -
, O +
we O +
investigated O +
the O +
changes O +
in O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
profiles O +
of O +
chronic O +
TLE O +
rat U-Species +
models O -
. O -

Temporal O +
lobe O +
epilepsy O +
induces O +
differential O +
expression O +
of O +
hippocampal O +
miRNAs O +
including O +
let-7e O +
and O +
miR-23a O -
/ O -
b O -
. O -

let-7e O +
was O +
detected O +
down O -
- O -
regulated O +
expression O +
at O +
0h O -
, O +
1h O -
, O +
6h O -
, O +
2days O -
, O +
7days O -
, O +
50days O +
after O +
SE O +
and O +
up O -
- O -
regulated O +
expression O +
at O +
12h O -
, O +
24h O -
, O +
10days O -
, O +
30days O +
after O +
SE O -
, O +
which O +
was O +
significantly O +
up O -
- O -
regulated O +
expression O +
at O +
24h O +
after O +
SE O +
( O -
10.49 O +
folds O -
, O +
P<0.01 O -
) O -
. O -

miR-23a O -
/ O -
b O +
was O +
detected O +
down O -
- O -
regulated O +
at O +
0h O -
, O +
1h O -
, O +
6h O -
, O +
12h O -
, O +
2days O -
, O +
7days O -
, O +
10days O -
, O +
30days O +
after O +
SE O +
and O +
significantly O +
up O -
- O -
regulated O +
at O +
24h O +
( O -
4.49 O +
folds O +
P<0.01 O -
) O -
, O +
50d O +
( O -
2.4 O +
folds O -
, O +
P<0.01 O -
) O +
after O +
SE O -
. O +
TLE O +
alters O +
the O +
expression O +
levels O +
of O +
a O +
subset O +
of O +
miRNAs O +
in O +
the O +
hippocampus O +
and O +
these O +
deregulated O +
miRNAs O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
epilepsy O +
directly O +
or O +
indirectly O -
. O -

Compared O +
with O +
normal O +
rats U-Species +
( O -
control O +
group O -
) O -
, O +
23 O +
of O +
the O +
125 O +
miRNAs O +
were O +
expressed O +
differentially O +
in O +
TLE O +
rats U-Species +
including O +
5 O +
down O -
- O -
regulated O +
miRNAs O +
( O -
let-7e O +
included O -
) O +
and O +
18 O +
up O -
- O -
regulated O +
miRNAs O +
( O -
miR-23a O -
/ O -
b O +
included O -
) O -
. O -

Furthermore O -
, O +
let-7e O +
and O +
miR-23a O -
/ O -
b O +
analysis O +
in O +
rat U-Species +
hippocampus O +
were O +
performed O +
by O +
real O -
- O -
time O +
quantitative O +
polymerase O +
chain O +
reaction O +
at O +
0h O -
, O +
1h O -
, O +
6h O -
, O +
12h O -
, O +
24h O -
, O +
2days O -
, O +
7days,10days O -
, O +
30days,50days O +
after O +
induction O +
of O +
status O +
epilepticus O +
( O -
SE O -
) O -
. O -

Also O +
the O +
temporal O +
change O +
of O +
the O +
let-7e O +
and O +
miR-23a O -
/ O -
b O +
expression O +
in O +
the O +
epileptogenesis O +
indicated O +
their O +
underlying O +
functions O +
on O +
TLE O -
. O -

The O +
findings O +
also O +
indicate O +
that O +
allopregnanolone O +
and O +
perhaps O +
other O +
neurosteroid O -
- O -
like O +
compounds O +
might O +
represent O +
potential O +
biomarkers O +
or O +
therapies O +
for O +
multiple O +
sclerosis O -
. O -

These O +
multi O -
- O -
platform O +
studies O +
point O +
to O +
impaired O +
neurosteroidogenesis O +
in O +
both O +
multiple O +
sclerosis O +
and O +
experimental O +
autoimmune O +
encephalomyelitis O -
. O -

Allopregnanolone O +
treatment O +
of O +
the O +
experimental O +
autoimmune O +
encephalomyelitis O +
mouse U-Species +
model O +
limited O +
the O +
associated O +
neuropathology O -
, O +
including O +
neuroinflammation O -
, O +
myelin O +
and O +
axonal O +
injury O +
and O +
reduced O +
neurobehavioral O +
deficits O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

Levels O +
of O +
important O +
neurosteroids O -
, O +
including O +
allopregnanolone O -
, O +
were O +
suppressed O +
in O +
the O +
white O +
matter O +
of O +
patients U-Species +
with O +
multiple O +
sclerosis O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

Induction O +
of O +
the O +
murine U-Species +
micro O -
- O -
RNAs O -
, O +
miR-338 O +
and O +
miR-155 O -
, O +
accompanied O +
by O +
diminished O +
expression O +
of O +
neurosteroidogenic O +
enzymes O +
and O +
allopregnanolone O -
, O +
was O +
also O +
observed O +
in O +
the O +
brains O +
of O +
mice U-Species +
with O +
experimental O +
autoimmune O +
encephalomyelitis O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

Analysis O +
of O +
the O +
neurosteroidogenic O +
pathways O +
targeted O +
by O +
micro O -
- O -
RNAs O +
revealed O +
suppression O +
of O +
enzyme O +
transcript O +
and O +
protein O +
levels O +
in O +
the O +
white O +
matter O +
of O +
patients U-Species +
with O +
multiple O +
sclerosis O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

This O +
was O +
confirmed O +
by O +
firefly O -
/ O -
Renilla O +
luciferase O +
micro O -
- O -
RNA O +
target O +
knockdown O +
experiments O +
( O -
P O +
< O +
0.05 O -
) O +
and O +
detection O +
of O +
specific O +
micro O -
- O -
RNAs O +
by O +
in O +
situ O +
hybridization O +
in O +
the O +
brains O +
of O +
patients U-Species +
with O +
or O +
without O +
multiple O +
sclerosis O -
. O -

These O +
observations O +
were O +
verified O +
using O +
the O +
in O +
vivo O +
multiple O +
sclerosis O +
model O -
, O +
experimental O +
autoimmune O +
encephalomyelitis O -
. O -

Brains O +
of O +
patients U-Species +
with O +
or O +
without O +
multiple O +
sclerosis O +
demonstrated O +
differential O +
expression O +
of O +
multiple O +
micro O -
- O -
RNAs O -
, O +
but O +
expression O +
of O +
three O +
neurosteroid O +
synthesis O +
enzyme O -
- O -
specific O +
micro O -
- O -
RNAs O +
( O -
miR-338 O -
, O +
miR-155 O +
and O +
miR-491 O -
) O +
showed O +
a O +
bias O +
towards O +
induction O +
in O +
patients U-Species +
with O +
multiple O +
sclerosis O +
( O -
P O +
< O +
0.05 O -
) O -
. O -

High O -
- O -
throughput O +
technologies O +
have O +
led O +
to O +
advances O +
in O +
the O +
recognition O +
of O +
disease O +
pathways O +
and O +
their O +
underlying O +
mechanisms O -
. O -

To O +
investigate O +
the O +
impact O +
of O +
micro O -
- O -
RNAs O +
on O +
the O +
disease O +
process O +
in O +
multiple O +
sclerosis O -
, O +
a O +
prototypic O +
inflammatory O +
neurological O +
disorder O -
, O +
we O +
examined O +
cerebral O +
white O +
matter O +
from O +
patients U-Species +
with O +
or O +
without O +
the O +
disease O +
by O +
micro O -
- O -
RNA O +
profiling O -
, O +
together O +
with O +
confirmatory O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
analysis O -
, O +
immunoblotting O +
and O +
gas O +
chromatography O -
- O -
mass O +
spectrometry O -
. O -

Impaired O +
neurosteroid O +
synthesis O +
in O +
multiple O +
sclerosis O -
. O -

This O +
review O +
reports O +
the O +
current O +
knowledge O +
of O +
microRNA O +
( O -
miRNA O -
) O +
expression O +
in O +
pituitary O +
adenomas O -
, O +
focusing O +
on O +
recent O +
microarray O +
data O -
. O -

Moreover O -
, O +
a O +
discussion O +
is O +
provided O +
concerning O +
the O +
possible O +
role O +
of O +
validated O +
and O +
putative O +
targets O +
of O +
the O +
most O +
dysregulated O +
miRNA O +
in O +
pituitary O +
adenoma O +
pathogenesis O -
. O -

MicroRNAs O +
and O +
possible O +
role O +
in O +
pituitary O +
adenoma O -
. O -

These O +
findings O +
indicate O +
that O +
miR-107 O +
contributes O +
to O +
GRN O +
expression O +
regulation O +
with O +
implications O +
for O +
brain O +
disorders O -
. O -

In O +
brain O +
tissue O +
subjacent O +
to O +
1.0 O +
mm O +
depth O +
controlled O +
cortical O +
impact O -
, O +
surviving O +
hippocampal O +
neurons O +
show O +
decreased O +
miR-107 O +
with O +
augmentation O +
of O +
neuronal O +
GRN O +
expression O -
. O -

We O +
also O +
tested O +
a O +
mouse U-Species +
model O +
where O +
miR-107 O +
has O +
been O +
shown O +
to O +
be O +
down O -
- O -
regulated O -
. O -

However O -
, O +
GRN O +
regulation O +
expression O +
is O +
poorly O +
understood O -
. O -

A O +
high O -
- O -
throughput O +
experimental O +
microRNA O +
assay O +
showed O +
that O +
GRN O +
is O +
the O +
strongest O +
target O +
for O +
miR-107 O +
in O +
human U-Species +
H4 O +
neuroglioma O +
cells O -
. O -

miR-107 O +
has O +
been O +
implicated O +
in O +
Alzheimer O -
's O +
disease O +
pathogenesis O -
, O +
and O +
sequence O +
elements O +
in O +
the O +
open O +
reading O +
frame O -
- O -
rather O +
than O +
the O +
3 O -
' O +
untranslated O +
region O -
- O -
of O +
GRN O +
mRNA O +
are O +
recognized O +
by O +
miR-107 O +
and O +
are O +
highly O +
conserved O +
among O +
vertebrate O +
species O -
. O -

To O +
better O +
understand O +
the O +
mechanism O +
of O +
this O +
interaction O -
, O +
FLAG O -
- O -
tagged O +
Argonaute O +
constructs O +
were O +
used O +
following O +
miR-107 O +
transfection O -
. O -

miR-107 O +
regulates O +
granulin O -
/ O -
progranulin O +
with O +
implications O +
for O +
traumatic O +
brain O +
injury O +
and O +
neurodegenerative O +
disease O -
. O -

Granulin O +
( O -
GRN O -
, O +
or O +
progranulin O -
) O +
is O +
a O +
protein O +
involved O +
in O +
wound O +
repair O -
, O +
inflammation O -
, O +
and O +
neoplasia O -
. O -

GRN O +
has O +
also O +
been O +
directly O +
implicated O +
in O +
frontotemporal O +
dementia O +
and O +
may O +
contribute O +
to O +
Alzheimer O -
's O +
disease O +
pathogenesis O -
. O -

GRN O +
mRNA O +
interacts O +
preferentially O +
with O +
Argonaute O +
2 O -
. O +
In O +
vitro O +
and O +
in O +
vivo O +
studies O +
indicate O +
that O +
regulation O +
of O +
GRN O +
by O +
miR-107 O +
may O +
be O +
functionally O +
important O -
. O -

Glucose O +
supplementation O +
in O +
cultured O +
cells O +
that O +
leads O +
to O +
increased O +
miR-107 O +
levels O +
also O +
results O +
in O +
decreased O +
GRN O +
expression O -
, O +
including O +
changes O +
in O +
cell O +
compartmentation O +
and O +
decreased O +
secretion O +
of O +
GRN O +
protein O -
. O -

This O +
effect O +
was O +
eliminated O +
following O +
miR-107 O +
transfection O -
. O -

Many O +
miRNA O +
targets O +
have O +
been O +
computationally O +
predicted O +
but O +
only O +
a O +
limited O +
number O +
of O +
these O +
were O +
experimentally O +
validated O -
. O -

However O -
, O +
interactions O +
between O +
miRNAs O +
and O +
their O +
targets O +
are O +
complex O +
and O +
very O +
often O +
there O +
are O +
numerous O +
putative O +
miRNA O +
recognition O +
sites O +
in O +
mRNAs O -
. O -

Therefore O -
, O +
it O +
is O +
of O +
particular O +
interest O +
to O +
reliably O +
predict O +
potential O +
miRNA O +
targets O +
which O +
might O +
be O +
involved O +
in O +
these O +
diseases O -
. O -

Both O +
the O +
deregulation O +
of O +
genes O +
controlled O +
by O +
miRNAs O +
and O +
the O +
altered O +
miRNA O +
expression O +
have O +
been O +
linked O +
to O +
many O +
disorders O -
, O +
including O +
cancer O -
, O +
cardiovascular O -
, O +
metabolic O +
and O +
neurodegenerative O +
diseases O -
. O -

In O +
this O +
review O -
, O +
currently O +
available O +
and O +
frequently O +
used O +
computational O +
tools O +
for O +
miRNA O +
target O +
prediction O -
, O +
i.e. O -
, O +
PicTar O -
, O +
TargetScan O -
, O +
DIANA O -
- O -
microT O -
, O +
miRanda O -
, O +
rna22 O +
and O +
PITA O +
are O +
outlined O +
and O +
various O +
practical O +
aspects O +
of O +
miRNA O +
target O +
analysis O +
are O +
extensively O +
discussed O -
. O -

Hence O -
, O +
finding O +
a O +
functional O +
miRNA O +
target O +
is O +
still O +
a O +
challenging O +
task O -
. O -

Although O +
a O +
variety O +
of O +
miRNA O +
target O +
prediction O +
algorithms O +
are O +
available O -
, O +
results O +
of O +
their O +
application O +
are O +
often O +
inconsistent O -
. O -

microRNAs O +
( O -
miRNAs O -
) O +
are O +
endogenous O +
non O -
- O -
coding O +
RNAs O +
that O +
control O +
gene O +
expression O +
at O +
the O +
posttranscriptional O +
level O -
. O -

These O +
small O +
regulatory O +
molecules O +
play O +
a O +
key O +
role O +
in O +
the O +
majority O +
of O +
biological O +
processes O +
and O +
their O +
expression O +
is O +
also O +
tightly O +
regulated O -
. O -

Practical O +
Aspects O +
of O +
microRNA O +
Target O +
Prediction O -
. O -

Moreover O -
, O +
the O +
performance O +
of O +
three O +
algorithms O +
( O -
PicTar O -
, O +
TargetScan O +
and O +
DIANA O -
- O -
microT O -
) O +
is O +
both O +
demonstrated O +
and O +
evaluated O +
by O +
performing O +
an O +
in O -
- O -
depth O +
analysis O +
of O +
miRNA O +
interactions O +
with O +
mRNAs O +
derived O +
from O +
genes O +
triggering O +
hereditary O +
neurological O +
disorders O +
known O +
as O +
trinucleotide O +
repeat O +
expansion O +
diseases O +
( O -
TREDs O -
) O -
, O +
such O +
as O +
Huntington O -
's O +
disease O +
( O -
HD O -
) O -
, O +
a O +
number O +
of O +
spinocerebellar O +
ataxias O +
( O -
SCAs O -
) O -
, O +
and O +
myotonic O +
dystrophy O +
type O +
1 O +
( O -
DM1 O -
) O -
. O -

Our O +
study O +
shows O +
that O +
one O +
aspect O +
of O +
miR-155 O +
function O +
is O +
the O +
promotion O +
of O +
T O +
cell O -
- O -
dependent O +
tissue O +
inflammation O -
, O +
suggesting O +
that O +
miR-155 O +
might O +
be O +
a O +
promising O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
autoimmune O +
disorders O -
. O -

miR-155 O +
functions O +
in O +
the O +
hematopoietic O +
compartment O +
to O +
promote O +
the O +
development O +
of O +
inflammatory O +
T O +
cells O +
including O +
the O +
T O +
helper O +
17 O +
( O -
Th17 O -
) O +
cell O +
and O +
Th1 O +
cell O +
subsets O -
. O -

Furthermore O -
, O +
the O +
major O +
contribution O +
of O +
miR-155 O +
to O +
EAE O +
was O +
CD4 O -
( O -
+ O -
) O +
T O +
cell O +
intrinsic O -
, O +
whereas O +
miR-155 O +
was O +
also O +
required O +
for O +
optimum O +
dendritic O +
cell O +
production O +
of O +
cytokines O +
that O +
promoted O +
Th17 O +
cell O +
formation O -
. O -

Here O -
, O +
we O +
have O +
investigated O +
the O +
role O +
of O +
miR-155 O +
during O +
an O +
autoimmune O +
inflammatory O +
disease O -
. O -

Consistent O +
with O +
a O +
positive O +
role O +
for O +
miR-155 O +
in O +
mediating O +
inflammatory O +
responses O -
, O +
Mir155 O -
( O -
- O -
/ O -
- O -
) O +
mice U-Species +
were O +
highly O +
resistant O +
to O +
experimental O +
autoimmune O +
encephalomyelitis O +
( O -
EAE O -
) O -
. O -

MicroRNA-155 O +
promotes O +
autoimmune O +
inflammation O +
by O +
enhancing O +
inflammatory O +
T O +
cell O +
development O -
. O -

Mammalian O +
noncoding O +
microRNAs O +
( O -
miRNAs O -
) O +
are O +
a O +
class O +
of O +
gene O +
regulators O +
that O +
have O +
been O +
linked O +
to O +
immune O +
system O +
function O -
. O -

miR-15a O +
and O +
miR-16 O -
- O -
1 O +
in O +
cancer O -
: O +
discovery O -
, O +
function O +
and O +
future O +
perspectives O -
. O -

Expression O +
of O +
these O +
miRNAs O +
inhibits O +
cell O +
proliferation O -
, O +
promotes O +
apoptosis O +
of O +
cancer O +
cells O -
, O +
and O +
suppresses O +
tumorigenicity O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
encoded O +
by O +
the O +
miR-15 O -
/ O -
16 O +
cluster O +
are O +
known O +
to O +
act O +
as O +
tumor O +
suppressors O -
. O -

Down O -
- O -
regulation O +
of O +
these O +
miRNAs O +
has O +
been O +
reported O +
in O +
chronic O +
lymphocytic O +
lymphoma O +
( O -
CLL O -
) O -
, O +
pituitary O +
adenomas O -
, O +
and O +
prostate O +
carcinoma O -
. O -

miR-15a O +
and O +
miR-16 O -
- O -
1 O +
function O +
by O +
targeting O +
multiple O +
oncogenes O -
, O +
including O +
BCL2 O -
, O +
MCL1 O -
, O +
CCND1 O -
, O +
and O +
WNT3A O -
. O -

This O +
review O +
summarizes O +
the O +
discovery O -
, O +
functions O -
, O +
and O +
clinical O +
relevance O +
of O +
these O +
miRNAs O +
in O +
cancer O -
, O +
particularly O +
CLL O -
. O -

During O +
experimental O +
autoimmune O +
encephalomyelitis O +
( O -
EAE O -
) O -
, O +
miR-124 O +
was O +
downregulated O +
in O +
activated O +
microglia O -
. O -

Peripheral O +
administration O +
of O +
miR-124 O +
in O +
EAE O +
caused O +
systemic O +
deactivation O +
of O +
macrophages O -
, O +
reduced O +
activation O +
of O +
myelin O -
- O -
specific O +
T O +
cells O +
and O +
marked O +
suppression O +
of O +
disease O -
. O -

Conversely O -
, O +
knockdown O +
of O +
miR-124 O +
in O +
microglia O +
and O +
macrophages O +
resulted O +
in O +
activation O +
of O +
these O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O -
. O -

These O +
findings O +
identify O +
miR-124 O +
both O +
as O +
a O +
key O +
regulator O +
of O +
microglia O +
quiescence O +
in O +
the O +
central O +
nervous O +
system O +
and O +
as O +
a O +
previously O +
unknown O +
modulator O +
of O +
monocyte O +
and O +
macrophage O +
activation O -
. O -

MicroRNA-124 O +
promotes O +
microglia O +
quiescence O +
and O +
suppresses O +
EAE O +
by O +
deactivating O +
macrophages O +
via O +
the O +
C O -
/ O -
EBP O -
- O -
α O -
- O -
PU.1 O +
pathway O -
. O -

MicroRNAs O +
are O +
a O +
family O +
of O +
regulatory O +
molecules O +
involved O +
in O +
many O +
physiological O +
processes O -
, O +
including O +
differentiation O +
and O +
activation O +
of O +
cells O +
of O +
the O +
immune O +
system O -
. O -

We O +
found O +
that O +
brain O -
- O -
specific O +
miR-124 O +
is O +
expressed O +
in O +
microglia O +
but O +
not O +
in O +
peripheral O +
monocytes O +
or O +
macrophages O -
. O -

When O +
overexpressed O +
in O +
macrophages O -
, O +
miR-124 O +
directly O +
inhibited O +
the O +
transcription O +
factor O +
CCAAT O -
/ O -
enhancer O -
- O -
binding O +
protein O -
- O -
α O +
( O -
C O -
/ O -
EBP O -
- O -
α O -
) O +
and O +
its O +
downstream O +
target O +
PU.1 O -
, O +
resulting O +
in O +
transformation O +
of O +
these O +
cells O +
from O +
an O +
activated O +
phenotype O +
into O +
a O +
quiescent O +
CD45 O -
( O -
low O -
) O -
, O +
major O +
histocompatibility O +
complex O +
( O -
MHC O -
) O +
class O +
II O -
( O -
low O -
) O +
phenotype O +
resembling O +
resting O +
microglia O -
. O -

Molecular O +
and O +
cellular O +
neurobiological O +
studies O +
of O +
the O +
miRNAs O +
in O +
neurodegeneration O +
represent O +
the O +
exploration O +
of O +
a O +
new O +
Frontier O +
of O +
miRNAs O +
biology O +
and O +
the O +
potential O +
development O +
of O +
new O +
diagnostic O +
tests O +
and O +
genetic O +
therapies O +
for O +
neurodegenerative O +
diseases O -
. O -

MiRNA O +
studies O +
in O +
neurobiology O +
showed O +
their O +
involvement O +
in O +
synaptic O +
plasticity O +
and O +
brain O +
diseases O -
. O -

In O +
this O +
review O +
, O -
correlations O +
between O +
miRNA O -
- O -
mediated O +
gene O +
silencing O +
and O +
Alzheimer O -
's O -
, O +
Parkinson O -
's O -
, O +
and O +
other O +
neurodegenerative O +
diseases O +
will O +
be O +
discussed O -
. O -

In O +
few O +
years O +
our O +
understanding O +
of O +
microRNA O +
( O -
miRNA O -
) O +
biogenesis O -
, O +
molecular O +
mechanisms O +
by O +
which O +
miRNAs O +
regulate O +
gene O +
expression O -
, O +
and O +
the O +
functional O +
roles O +
of O +
miRNAs O +
has O +
been O +
expanded O -
. O -

Interestingly O -
, O +
numerous O +
miRNAs O +
are O +
expressed O +
in O +
a O +
spatially O +
and O +
temporally O +
controlled O +
manner O +
in O +
the O +
nervous O +
system O -
, O +
suggesting O +
that O +
their O +
posttrascriptional O +
regulation O +
may O +
be O +
particularly O +
relevant O +
in O +
neural O +
development O +
and O +
function O -
. O -

Searching O +
for O +
MIND O -
: O +
microRNAs O +
in O +
neurodegenerative O +
diseases O -
. O -

In O +
gliomas O -
, O +
microRNA-21 O +
( O -
miR-21 O -
) O +
levels O +
have O +
been O +
reported O +
to O +
be O +
elevated O +
and O +
their O +
knockdown O +
is O +
associated O +
with O +
increased O +
apoptotic O +
activity O -
. O -

We O +
hypothesized O +
that O +
suppression O +
of O +
miR-21 O +
might O +
sensitize O +
gliomas O +
for O +
cytotoxic O +
tumor O +
therapy O -
. O -

With O +
the O +
use O +
of O +
locked O +
nucleic O +
acid O +
( O -
LNA O -
) O -
-antimiR-21 O +
oligonucleotides O -
, O +
bimodal O +
imaging O +
vectors O -
, O +
and O +
neural O +
precursor O +
cells O +
( O -
NPC O -
) O +
expressing O +
a O +
secretable O +
variant O +
of O +
the O +
cytotoxic O +
agent O +
tumor O +
necrosis O +
factor O -
- O -
related O +
apoptosis O +
inducing O +
ligand O +
( O -
S O -
- O -
TRAIL O -
) O -
, O +
we O +
show O +
that O +
the O +
combined O +
suppression O +
of O +
miR-21 O +
and O +
NPC O -
- O -
S O -
- O -
TRAIL O +
leads O +
to O +
a O +
synergistic O +
increase O +
in O +
caspase O +
activity O +
and O +
significantly O +
decreased O +
cell O +
viability O +
in O +
human U-Species +
glioma O +
cells O +
in O +
vitro O -
. O -

This O +
phenomenon O +
persists O +
in O +
vivo O -
, O +
as O +
we O +
observed O +
complete O +
eradication O +
of O +
LNA O -
- O -
antimiR-21-treated O +
gliomas O +
subjected O +
to O +
the O +
presence O +
of O +
NPC O -
- O -
S O -
- O -
TRAIL O +
in O +
the O +
murine U-Species +
brain O -
. O -

Our O +
results O +
reveal O +
the O +
efficacy O +
of O +
miR-21 O +
antagonism O +
in O +
murine U-Species +
glioma O +
models O +
and O +
implicate O +
miR-21 O +
as O +
a O +
target O +
for O +
therapeutic O +
intervention O -
. O -

Furthermore O -
, O +
our O +
findings O +
provide O +
the O +
basis O +
for O +
developing O +
combination O +
therapies O +
using O +
miRNA O +
modulation O +
and O +
cytotoxic O +
tumor O +
therapies O -
. O -

MicroRNA-21 O +
knockdown O +
disrupts O +
glioma O +
growth O +
in O +
vivo O +
and O +
displays O +
synergistic O +
cytotoxicity O +
with O +
neural O +
precursor O +
cell O +
delivered O +
S O -
- O -
TRAIL O +
in O +
human U-Species +
gliomas O -
. O -

Mounting O +
evidence O +
indicates O +
that O +
microRNAs O +
( O -
miRNA O -
) O +
might O +
play O +
a O +
fundamental O +
role O +
in O +
tumorigenesis O -
, O +
controlling O +
cell O +
proliferation O +
and O +
apoptosis O -
. O -

Despite O +
the O +
development O +
of O +
new O +
glioma O +
therapies O +
that O +
allow O +
for O +
tumor O -
- O -
targeted O +
in O +
situ O +
delivery O +
of O +
cytotoxic O +
drugs O -
, O +
tumor O +
resistance O +
to O +
apoptosis O +
remains O +
a O +
key O +
impediment O +
to O +
effective O +
treatment O -
. O -

CONCLUSIONS O -
: O +
The O +
irregularity O +
of O +
prolactin O +
secretion O +
in O +
patients U-Species +
with O +
NPG O +
is O +
not O +
dependant O +
on O +
the O +
presence O +
of O +
a O +
pituitary O +
tumour O +
which O +
suggests O +
that O +
a O +
hypothalamic O +
dysfunction O +
underlies O +
this O +
condition O -
. O -

An O +
irregular O +
secretion O +
and O +
a O +
higher O +
daily O +
mass O +
production O +
of O +
prolactin O +
in O +
patients U-Species +
with O +
NPG O +
could O +
explain O +
both O +
galactorrhea O +
and O +
infertility O -
. O -

BACKGROUND O -
: O +
Abnormal O +
frequency O +
and O +
pulse O +
amplitud O +
of O +
prolactin O +
secretion O +
in O +
micro O +
and O +
macroprolactinomas O +
has O +
been O +
atributed O +
to O +
a O +
dysfunctional O +
tumoral O +
lactotrope O -
. O -

[ O -
Irregular O +
secretion O +
of O +
prolactin O +
in O +
infertile O +
women U-Species +
with O +
normoprolactinemic O +
galactorrhea O -
] O -
. O -

The O +
regularity O +
of O +
prolactin O +
secretion O +
has O +
not O +
been O +
studied O +
with O +
cuantitative O +
methods O +
in O +
patients U-Species +
with O +
normoprolactinemic O +
galactorrhea O +
( O -
NPG O -
) O +
which O +
could O +
be O +
considered O +
an O +
entity O +
that O +
precedes O +
non O +
tumoral O +
and O +
tumoral O +
hyperprolactinemia O -
. O -

Previous O +
evidence O +
suggests O +
that O +
non O +
tumoral O +
hyperprolactinemia O +
is O +
caused O +
by O +
a O +
hypothalamic O +
dysfunction O -
. O -

PATIENTS U-Species +
AND O +
METHODS O -
: O +
A O +
transversal O -
- O -
comparative O +
study O +
was O +
carried O +
out O +
in O +
6 O +
infertile O +
women U-Species +
with O +
normoprolactinemic O +
galactorrhea O +
and O +
4 O +
healthy O +
women U-Species +
as O +
controls O -
. O -

Objective O -
: O +
To O +
analyze O +
the O +
24-hour O +
prolactin O +
secretion O +
pattern O +
and O +
its O +
secretion O +
regularity O +
in O +
a O +
group O +
of O +
infertile O +
women U-Species +
with O +
normoprolactinemic O +
galatorea O -
. O -

RESULTS O -
: O +
Blunting O +
of O +
the O +
nyctohemeral O +
rythm O +
and O +
nocturn O +
hyperprolactinaemia O +
occurred O +
in O +
patients U-Species +
with O +
normoprolactinemic O +
galactorrhea O +
( O -
NPG O -
) O -
. O -

The O +
24 O +
hour O +
prolactin O +
profile O -
, O +
the O +
ratio O +
night O +
time O +
mean O +
concentration O -
/ O -
daytime O +
mean O +
concentrattion O +
( O -
NM O -
/ O -
DM O +
ratio O -
) O +
and O +
apparent O +
entropy O +
( O -
Ap O +
En O -
, O +
Ap O +
En O +
ratio O -
) O +
were O +
compared O +
in O +
the O +
two O +
groups O -
. O -

Higher O +
irregularity O +
of O +
prolactin O +
secretion O +
was O +
found O +
in O +
patients U-Species +
with O +
NPG O +
( O -
ApEn O -
: O +
0.853 O +
+ O -
/- O +
0.158 O +
vs O +
0.608 O +
+ O -
/- O +
0.171 O -
, O +
p=0.04 O -
; O +
Ap O +
En O +
ratio O -
: O +
0.839 O +
+ O -
/- O +
0.11 O +
vs O +
0.661 O +
+ O -
/- O +
0.14 O -
; O +
p=0.04 O -
) O -
. O -

NM O -
/ O -
DM O +
ratio O +
was O +
lower O +
in O +
patients U-Species +
with O +
NPG O +
than O +
in O +
controls O +
( O -
1.28 O +
+ O -
/- O +
0.25 O +
vs. O +
1.75 O +
+ O -
/- O +
0.05 O -
; O +
p= O +
0.01 O -
) O -
. O -

We O +
therefore O +
sought O +
to O +
determine O +
whether O +
microRNA O +
targets O +
could O +
be O +
engineered O +
into O +
VSV O +
to O +
ameliorate O +
its O +
neuropathogenicity O -
. O -

Using O +
a O +
panel O +
of O +
recombinant O +
VSVs O +
incorporating O +
microRNA O +
target O +
sequences O +
corresponding O +
to O +
neuron O -
- O -
specific O +
or O +
control O +
microRNAs O +
( O -
in O +
forward O +
and O +
reverse O +
orientations O -
) O -
, O +
we O +
tested O +
viral O +
replication O +
kinetics O +
in O +
cell O +
lines O +
treated O +
with O +
microRNA O +
mimics O -
, O +
neurotoxicity O +
after O +
direct O +
intracerebral O +
inoculation O +
in O +
mice U-Species -
, O +
and O +
antitumor O +
efficacy O -
. O -

Compared O +
to O +
picornaviruses O +
and O +
adenoviruses O -
, O +
the O +
engineered O +
VSVs O +
were O +
relatively O +
resistant O +
to O +
microRNA O -
- O -
mediated O +
inhibition O -
, O +
but O +
neurotoxicity O +
could O +
nevertheless O +
be O +
ameliorated O +
significantly O +
using O +
this O +
approach O -
, O +
without O +
compromise O +
to O +
antitumor O +
efficacy O -
. O -

Neurotoxicity O +
was O +
most O +
profoundly O +
reduced O +
in O +
a O +
virus O +
carrying O +
four O +
tandem O +
copies O +
of O +
a O +
neuronal O +
mir125 O +
target O +
sequence O +
inserted O +
in O +
the O +
3'-untranslated O +
region O +
of O +
the O +
viral O +
polymerase O +
( O -
L O -
) O +
gene O -
. O -

Attenuation O +
of O +
vesicular O +
stomatitis O +
virus O +
encephalitis O +
through O +
microRNA O +
targeting O -
. O -

Vesicular O +
stomatitis O +
virus O +
( O -
VSV O -
) O +
has O +
long O +
been O +
regarded O +
as O +
a O +
promising O +
recombinant O +
vaccine O +
platform O +
and O +
oncolytic O +
agent O +
but O +
has O +
not O +
yet O +
been O +
tested O +
in O +
humans U-Species +
because O +
it O +
causes O +
encephalomyelitis O +
in O +
rodents O +
and O +
primates O -
. O -

Recent O +
studies O +
have O +
shown O +
that O +
specific O +
tropisms O +
of O +
several O +
viruses O +
could O +
be O +
eliminated O +
by O +
engineering O +
microRNA O +
target O +
sequences O +
into O +
their O +
genomes O -
, O +
thereby O +
inhibiting O +
spread O +
in O +
tissues O +
expressing O +
cognate O +
microRNAs O -
. O -

Alteration O +
of O +
miRNA O +
expression O +
by O +
disease O +
and O +
insult O +
also O +
holds O +
the O +
potential O +
for O +
improved O +
diagnostic O +
tools O -
. O -

Finally O -
, O +
miRNAs O +
have O +
been O +
shown O +
to O +
control O +
cellular O +
proliferation O +
and O +
specification O -
, O +
suggesting O +
that O +
manipulation O +
of O +
miRNAs O +
in O +
cultured O +
cells O +
could O +
result O +
in O +
more O +
convenient O +
generation O +
of O +
pure O +
cell O +
populations O +
for O +
transplantation O -
. O -

miRNAs O +
appear O +
to O +
be O +
dysregulated O +
in O +
a O +
number O +
of O +
neurodegenerative O +
diseases O -
, O +
developmental O +
disorders O -
, O +
and O +
as O +
a O +
result O +
of O +
stroke O -
. O -

MicroRNAS O +
( O -
miRNAs O -
) O +
have O +
been O +
suggested O +
to O +
play O +
important O +
roles O +
in O +
the O +
central O +
nervous O +
system O +
during O +
development O +
as O +
well O +
as O +
disease O -
. O -

The O +
therapeutic O +
potential O +
of O +
microRNAs O +
in O +
nervous O +
system O +
damage O -
, O +
degeneration O -
, O +
and O +
repair O -
. O -

Artificial O +
miRNAs O +
have O +
also O +
been O +
generated O +
for O +
the O +
repression O +
of O +
specific O +
transcripts O -
. O -

Both O +
viral O +
delivery O +
and O +
administration O +
of O +
modified O +
oligonucleotides O +
mimicking O +
or O +
inhibiting O +
specific O +
miRNAs O +
have O +
been O +
effective O +
in O +
model O +
systems O -
. O -

Recent O +
findings O +
suggest O +
that O +
it O +
may O +
eventually O +
be O +
possible O +
to O +
treat O +
some O +
neurological O +
disorders O +
by O +
restoring O +
or O +
inhibiting O +
miRNAs O +
altered O +
by O +
disease O +
pathology O -
. O -

Each O +
miRNA O +
has O +
the O +
ability O +
to O +
regulate O +
hundreds O +
of O +
messenger O +
RNA O +
transcripts O -
, O +
both O +
by O +
causing O +
degradation O +
of O +
the O +
mRNA O +
and O +
by O +
inhibition O +
of O +
protein O +
translation O -
. O -

MicroRNA-210 O +
as O +
a O +
novel O +
blood O +
biomarker O +
in O +
acute O +
cerebral O +
ischemia O -
. O -

MicroRNA-210 O +
( O -
miR-210 O -
) O -
, O +
a O +
master O +
and O +
pleiotropic O +
hypoxia O -
- O -
microRNA O -
, O +
plays O +
multiple O +
roles O +
in O +
brain O +
ischemia O -
. O -

However O -
, O +
miR-210 O +
expression O +
and O +
its O +
function O +
in O +
humans U-Species +
have O +
not O +
been O +
explored O -
. O -

The O +
aim O +
of O +
our O +
study O +
is O +
to O +
evaluate O +
the O +
correlation O +
of O +
blood O +
miR-210 O +
with O +
clinical O +
findings O +
in O +
acute O +
ischemic O +
stroke O -
. O -

Blood O +
samples O +
were O +
obtained O +
from O +
stroke O +
patients U-Species +
( O -
n=112 O -
) O +
and O +
healthy O +
controls O +
( O -
n= O +
60 O -
) O -
. O -

MiR-210 O +
was O +
measured O +
at O +
within O +
3 O -
, O +
7 O +
and O +
14 O +
days O +
after O +
stroke O +
using O +
a O +
quantitative O +
PCR O +
technique O -
. O -

Stroke O +
severity O +
and O +
clinical O +
outcome O +
were O +
evaluated O +
by O +
NIHSS O +
and O +
modified O +
Rankin O +
Score O -
. O -

Both O +
blood O +
and O +
brain O +
miR-210 O +
in O +
ischemic O +
mice U-Species +
was O +
examined O +
and O +
the O +
correlation O +
was O +
investigated O -
. O -

Compared O +
to O +
healthy O +
controls O -
, O +
blood O +
miRNA-210 O +
was O +
significantly O +
decreased O +
in O +
stroke O +
patients U-Species +
( O -
0.93 O +
vs. O +
1.36 O -
; O +
P=0.001 O -
) O -
, O +
especially O +
at O +
7 O +
days O +
( O -
0.56 O +
vs. O +
1.36 O -
; O +
P=0.001 O -
) O +
and O +
14 O +
days O +
of O +
stroke O +
onset O +
( O -
0.50 O +
vs. O +
1.36 O -
; O +
P=0.001 O -
) O -
. O -

The O +
cut O +
off O +
point O +
of O +
miR-210 O +
in O +
diagnosis O +
was O +
0.505 O +
with O +
88.3 O +
per O +
cent O +
sensitivity O -
. O -

MiR-210 O +
level O +
in O +
stroke O +
patients U-Species +
with O +
good O +
outcome O +
was O +
significantly O +
higher O +
than O +
patients U-Species +
with O +
poor O +
outcome O +
( O -
1.2 O +
vs. O +
0.44 O -
; O +
P=0.012 O -
) O -
. O -

The O +
correlation O +
between O +
blood O +
and O +
brain O +
miR-210 O +
in O +
ischemic O +
mice U-Species +
was O +
positive O +
( O -
R2=0.57 O -
, O +
P=0.001 O -
) O -
. O -

Blood O +
miR-210 O +
is O +
a O +
novel O +
sensitive O +
biomarker O +
for O +
clinical O +
diagnosis O +
and O +
prognosis O +
in O +
acute O +
cerebral O +
ischemia O -
. O -

Out O +
of O +
the O +
5 O +
positive O +
samples O -
, O +
one O +
was O +
an O +
HTLV O -
, O +
three O +
HTLV-1 O +
and O +
one O +
HTLV-2 O -
. O -

These O +
blood O +
donors O +
were O +
residents O +
of O +
Posadas O -
, O +
Eldorado O +
and O +
Oberá O -
, O +
with O +
no O +
risk O +
antecedents O -
. O -

This O +
study O +
demonstrates O +
the O +
presence O +
of O +
HTLV-1 O -
/ O -
2 O +
in O +
a O +
population O +
of O +
Misiones O +
with O +
a O +
prevalence O +
rate O +
similar O +
to O +
those O +
reported O +
among O +
blood O +
donors O +
from O +
non O -
- O -
endemic O +
areas O -
. O -

[ O -
Seroprevalence O +
of O +
HTLV-1 O -
/ O -
2 O +
in O +
blood O +
donors O +
from O +
Misiones O +
Province O -
] O -
. O -

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
estimate O +
the O +
seroprevalence O +
of O +
HTLV-1 O -
/ O -
2 O +
in O +
a O +
blood O +
donor O +
population O +
from O +
Misiones O +
province O -
. O -

They O +
are O +
transmitted O +
through O +
sex O +
contact O -
, O +
parenterally O +
and O +
from O +
mother O +
to O +
child U-Species -
. O -

HTLV-1 O -
/ O -
2 O +
screening O +
was O +
performed O +
with O +
ELISA O +
and O +
particle O +
agglutination O -
, O +
and O +
reactive O +
samples O +
were O +
confirmed O +
by O +
Western O +
Blot O -
. O -

A O +
total O +
of O +
6912 O +
accepted O +
blood O +
donations O +
in O +
2008 O +
were O +
analyzed O -
. O -

It O +
is O +
endemic O +
worldwide O -
, O +
including O +
the O +
North O +
of O +
Argentina O +
where O +
both O +
associated O +
diseases O +
have O +
also O +
been O +
detected O -
. O -

Human U-Species +
T O -
- O -
cell O +
Lymphotropic O +
viruses O +
type O +
1 O +
( O -
HTLV-1 O -
) O -
, O +
the O +
first O +
human U-Species +
oncoretrovirus O +
to O +
be O +
discovered O -
, O +
is O +
the O +
etiologic O +
agent O +
of O +
Adult O +
T O -
- O -
cell O +
Leukemia O +
( O -
ATL O -
) O +
and O +
HTLV-1 O +
Associated O +
Mielopathy O +
or O +
Tropical O +
Spastic O +
Paraparesis O +
( O -
HAM O -
/ O -
TSP O -
) O -
. O -

Both O +
retroviruses O +
are O +
endemic O +
in O +
native O +
populations O +
of O +
The O +
Americas O -
, O +
Africa O +
and O +
at O -
- O -
risk O +
populations O -
. O -

No O +
etiologic O +
role O +
has O +
been O +
described O +
for O +
HTLV-2 O -
, O +
although O +
it O +
has O +
been O +
associated O +
with O +
HAM O -
/ O -
TSP O -
- O -
like O +
neurologic O +
syndromes O -
. O -

From O +
the O +
total O -
, O +
5 O +
samples O +
resulted O +
seropositive O +
with O +
a O +
final O +
prevalence O +
of O +
0.00072 O -
. O -

Furthermore O -
, O +
in O +
patient O +
samples O +
expression O +
of O +
miR O +
124a O +
is O +
significantly O +
decreased O -
. O -

Our O +
data O +
strongly O +
indicate O +
that O +
CDK6 O +
is O +
regulated O +
by O +
microRNA O +
124 O +
in O +
medulloblastoma O +
and O +
that O +
miR O +
124 O +
modulates O +
medulloblastoma O +
cell O +
growth O -
. O -

We O +
hypothesized O +
that O +
CDK6 O +
expression O +
is O +
also O +
regulated O +
by O +
microRNAs O +
in O +
medulloblastoma O -
. O -

Genomic O +
amplification O +
accounts O +
for O +
some O -
, O +
but O +
not O +
all O +
of O +
the O +
CDK6 O +
over O -
- O -
expression O -
. O -

Expression O +
of O +
miR O +
124a O +
was O +
significantly O +
decreased O +
in O +
medulloblastoma O +
cells O +
compared O +
to O +
normal O +
adult O +
cerebellum O -
. O -

We O +
identified O +
putative O +
miR O +
sites O +
in O +
the O +
CDK6 O +
including O +
microRNA O +
124a O -
, O +
a O +
brain O +
enriched O +
microRNA O -
. O -

Additionally O -
, O +
re O -
- O -
expression O +
of O +
miR O +
124a O +
in O +
medulloblastoma O +
cells O +
decreased O +
expression O +
of O +
CDK6 O +
protein O -
. O -

Functional O +
association O +
between O +
miR O +
124a O +
and O +
CDK6 O +
in O +
medulloblastoma O +
was O +
established O +
using O +
luciferase O +
assays O -
. O -

Transfection O +
of O +
miR O +
124 O +
significantly O +
decreases O +
medulloblastoma O +
cell O +
growth O +
but O +
does O +
not O +
alter O +
apoptosis O -
. O -

Regulation O +
of O +
cyclin O +
dependent O +
kinase O +
6 O +
by O +
microRNA O +
124 O +
in O +
medulloblastoma O -
. O -

Despite O +
recent O +
advances O +
in O +
treatment O +
medulloblastoma O +
continues O +
to O +
remain O +
a O +
vexing O +
problem O -
. O -

Recently O +
increased O +
expression O +
of O +
cyclin O +
dependent O +
kinase O +
6 O +
( O -
CDK6 O -
) O +
was O +
identified O +
as O +
an O +
adverse O +
prognostic O +
marker O +
in O +
medulloblastoma O -
. O -

CONCLUSIONS O -
: O +
The O +
study O +
suggests O +
that O +
spatial O +
orientation O +
memory O +
relies O +
on O +
the O +
integrity O +
of O +
the O +
right O +
hippocampus O -
. O -

Nevertheless O -
, O +
further O +
studies O +
are O +
necessary O +
to O +
confirm O +
this O +
hypothesis O -
. O -

The O +
subjects O +
were O +
submitted O +
to O +
a O +
neuropsychologic O +
evaluation O +
through O +
the O +
Route O +
Learning O +
Test O +
and O +
the O +
Childhood O +
Home O +
Test O +
in O +
the O +
preoperative O +
period O -
. O -

The O +
statistical O +
analysis O +
was O +
performed O +
using O +
the O +
Kruskal O -
- O -
Wallis O -
, O +
analysis O +
of O +
variance O -
, O +
χ O -
, O +
and O +
Mann O -
- O -
Whitney O +
U O +
tests O -
. O -

RESULTS O -
: O +
There O +
was O +
no O +
significant O +
difference O +
in O +
performance O +
in O +
the O +
remote O +
visuospatial O +
memory O +
( O -
as O +
measured O +
by O +
the O +
Childhood O +
Home O +
Test O -
) O +
across O +
the O +
groups O +
( O -
LTLE O -
, O +
RTLE O -
, O +
and O +
control O -
) O -
. O -

Concerning O +
the O +
spatial O +
orientation O +
memory O -
, O +
however O -
, O +
there O +
was O +
a O +
significant O +
difference O +
between O +
the O +
LTLE O +
and O +
controls O +
as O +
compared O +
with O +
the O +
RTLE O +
group O +
( O -
P<0.001 O -
) O -
, O +
the O +
latter O +
showing O +
a O +
poorer O +
performance O -
. O -

However O -
, O +
evaluations O +
of O +
the O +
right O +
hippocampal O +
functions O +
have O +
not O +
been O +
consistent O -
. O -

In O +
ablative O +
interventions O -
, O +
neuropsychologic O +
testing O +
of O +
memory O +
is O +
a O +
crucial O +
step O -
. O -

METHODS O -
: O +
A O +
controlled O +
study O +
of O +
patients U-Species +
with O +
left O +
( O -
LTLE O -
) O +
or O +
right O +
( O -
RTLE O -
) O +
TLE O -
. O -

AIM O -
: O +
To O +
assess O +
the O +
hippocampal O +
function O +
in O +
remote O +
orientation O +
and O +
visuospatial O +
memory O +
in O +
patients U-Species +
with O +
refractory O +
temporal O +
epilepsy O -
. O -

INTRODUCTION O -
: O +
In O +
temporal O +
lobe O +
epilepsy O +
( O -
TLE O -
) O -
, O +
about O +
30 O -
% O +
of O +
the O +
patients U-Species +
do O +
not O +
achieve O +
adequate O +
pharmacologic O +
control O +
of O +
refractory O +
crises O -
, O +
and O +
surgery O +
becomes O +
an O +
alternative O -
. O -

Route O +
Learning O +
Performance O -
: O +
Is O +
it O +
a O +
Hippocampus O +
Function O -
? O -

Thrombolytic O +
therapy O +
involving O +
recombinant O +
tissue O +
plasminogen O +
activator O +
( O -
rtPA O -
) O +
has O +
been O +
shown O +
to O +
be O +
beneficial O +
only O +
when O +
used O +
within O +
4.5 O +
hours O +
of O +
onset O +
of O +
acute O +
ischemic O +
stroke O -
. O -

There O +
are O +
two O +
major O +
types O +
of O +
stroke O -
: O +
cerebral O +
ischemia O +
caused O +
by O +
obstruction O +
of O +
blood O +
vessels O +
in O +
the O +
brain O +
and O +
haemorrhagic O +
stroke O +
that O +
is O +
triggered O +
by O +
the O +
disruption O +
of O +
blood O +
vessels O -
. O -

Stroke O +
is O +
one O +
of O +
the O +
leading O +
causes O +
of O +
death O +
and O +
disability O +
worldwide O -
. O -

microRNAs O +
in O +
stroke O +
pathogenesis O -
. O -

Although O +
the O +
biochemistry O +
of O +
stroke O +
and O +
related O +
diseases O +
is O +
quite O +
well O +
understood O -
, O +
the O +
knowledge O +
on O +
the O +
molecular O +
mechanisms O +
underlying O +
these O +
diseases O +
is O +
still O +
at O +
its O +
infancy O -
. O -

microRNAs O +
that O +
form O +
a O +
unique O +
class O +
of O +
endogenous O +
riboregulators O +
of O +
gene O +
function O -
, O +
offer O +
tremendous O +
potential O +
in O +
unraveling O +
the O +
mechanisms O +
underlying O +
stroke O +
pathogenesis O -
. O -

rtPA O +
treatment O +
beyond O +
this O +
time O +
window O +
has O +
been O +
found O +
to O +
be O +
unsuitable O +
and O +
usually O +
resulting O +
in O +
haemorrhagic O +
transformation O -
. O -

Stroke O +
is O +
a O +
multifactorial O +
disease O +
that O +
forms O +
a O +
possible O +
end O +
state O +
for O +
majority O +
of O +
patients U-Species +
suffering O +
from O +
diabetes O -
, O +
atherosclerosis O +
and O +
hypertension O +
which O +
are O +
known O +
risk O +
factors O -
. O -

microRNA O +
expression O +
also O +
reflects O +
the O +
response O +
of O +
individuals O +
to O +
drugs O +
and O +
therapy O -
. O -

Several O +
microRNAs O +
and O +
their O +
target O +
genes O -
, O +
known O +
to O +
be O +
involved O +
in O +
endothelial O +
dysfunction O -
, O +
dysregulation O +
of O +
neurovascular O +
integrity O -
, O +
edema O +
formation O -
, O +
pro O -
- O -
apoptosis O -
, O +
inflammation O +
and O +
extra O -
- O -
cellular O +
matrix O +
remodeling O +
contribute O +
to O +
the O +
critical O +
processes O +
in O +
the O +
pathogenesis O +
of O +
stroke O -
. O -

In O +
this O +
review O -
, O +
we O +
will O +
also O +
be O +
discussing O +
the O +
role O +
of O +
microRNAs O +
as O +
possible O +
diagnostic O +
and O +
prognostic O +
biomarkers O +
as O +
well O +
as O +
potential O +
therapeutic O +
targets O +
in O +
stroke O +
pathogenesis O -
. O -

Mutations O +
in O +
ABHD12 O +
cause O +
the O +
neurodegenerative O +
disease O +
PHARC O -
: O +
An O +
inborn O +
error O +
of O +
endocannabinoid O +
metabolism O -
. O -

Previously O -
, O +
we O +
mapped O +
this O +
Refsum O -
- O -
like O +
disorder O +
to O +
a O +
16 O +
Mb O +
region O +
on O +
chromosome O +
20 O -
. O -

Polyneuropathy O -
, O +
hearing O +
loss O -
, O +
ataxia O -
, O +
retinitis O +
pigmentosa O -
, O +
and O +
cataract O +
( O -
PHARC O -
) O +
is O +
a O +
neurodegenerative O +
disease O +
marked O +
by O +
early O -
- O -
onset O +
cataract O +
and O +
hearing O +
loss O -
, O +
retinitis O +
pigmentosa O -
, O +
and O +
involvement O +
of O +
both O +
the O +
central O +
and O +
peripheral O +
nervous O +
systems O -
, O +
including O +
demyelinating O +
sensorimotor O +
polyneuropathy O +
and O +
cerebellar O +
ataxia O -
. O -

Our O +
findings O +
show O +
that O +
ABHD12 O +
performs O +
essential O +
functions O +
in O +
both O +
the O +
central O +
and O +
peripheral O +
nervous O +
systems O +
and O +
the O +
eye O -
. O -

Any O +
future O +
drug O -
- O -
mediated O +
interference O +
with O +
this O +
enzyme O +
should O +
consider O +
the O +
potential O +
risk O +
of O +
long O -
- O -
term O +
adverse O +
effects O -
. O -

Here O +
we O +
report O +
that O +
mutations O +
in O +
the O +
ABHD12 O +
gene O +
cause O +
PHARC O +
disease O +
and O +
we O +
describe O +
the O +
clinical O +
manifestations O +
in O +
a O +
total O +
of O +
19 O +
patients U-Species +
from O +
four O +
different O +
countries O -
. O -

The O +
ABHD12 O +
enzyme O +
was O +
recently O +
shown O +
to O +
hydrolyze O +
2-arachidonoyl O +
glycerol O +
( O -
2-AG O -
) O -
, O +
the O +
main O +
endocannabinoid O +
lipid O +
transmitter O +
that O +
acts O +
on O +
cannabinoid O +
receptors O +
CB1 O +
and O +
CB2 O -
. O -

Our O +
data O +
therefore O +
represent O +
an O +
example O +
of O +
an O +
inherited O +
disorder O +
related O +
to O +
endocannabinoid O +
metabolism O -
. O -

The O +
endocannabinoid O +
system O +
is O +
involved O +
in O +
a O +
wide O +
range O +
of O +
physiological O +
processes O +
including O +
neurotransmission O -
, O +
mood O -
, O +
appetite O -
, O +
pain O +
appreciation O -
, O +
addiction O +
behavior O -
, O +
and O +
inflammation O -
, O +
and O +
several O +
potential O +
drugs O +
targeting O +
these O +
pathways O +
are O +
in O +
development O +
for O +
clinical O +
applications O -
. O -

These O +
cellular O +
responses O +
are O +
mediated O +
by O +
augmented O +
expression O +
of O +
the O +
direct O +
targets O +
of O +
miR-10b O -
, O +
including O +
BCL2L11 O -
/ O -
Bim O -
, O +
TFAP2C O -
/ O -
AP-2γ O -
, O +
CDKN1A O -
/ O -
p21 O -
, O +
and O +
CDKN2A O -
/ O -
p16 O -
, O +
which O +
normally O +
protect O +
cells O +
from O +
uncontrolled O +
growth O -
. O -

Analysis O +
of O +
The O +
Cancer O +
Genome O +
Atlas O +
expression O +
data O +
set O +
reveals O +
a O +
strong O +
positive O +
correlation O +
between O +
numerous O +
genes O +
sustaining O +
cellular O +
growth O +
and O +
miR-10b O +
levels O +
in O +
human U-Species +
glioblastomas O -
, O +
while O +
proapoptotic O +
genes O +
anticorrelate O +
with O +
the O +
expression O +
of O +
miR-10b O -
. O -

Molecular O +
functions O +
of O +
these O +
miRNAs O +
in O +
gliomagenesis O +
are O +
mainly O +
unknown O -
. O -

We O +
show O +
that O +
inhibition O +
of O +
miR-10b O -
, O +
a O +
miRNA O +
not O +
expressed O +
in O +
human U-Species +
brain O +
and O +
strongly O +
upregulated O +
in O +
both O +
low O -
- O -
grade O +
and O +
high O -
- O -
grade O +
gliomas O -
, O +
reduces O +
glioma O +
cell O +
growth O +
by O +
cell O -
- O -
cycle O +
arrest O +
and O +
apoptosis O -
. O -

Human U-Species +
glioma O +
growth O +
is O +
controlled O +
by O +
microRNA-10b O -
. O -

MicroRNA O +
( O -
miRNA O -
) O +
expression O +
profiling O +
studies O +
revealed O +
a O +
number O +
of O +
miRNAs O +
dysregulated O +
in O +
the O +
malignant O +
brain O +
tumor O +
glioblastoma O -
. O -

Altogether O -
, O +
our O +
experiments O +
validate O +
an O +
important O +
role O +
of O +
miR-10b O +
in O +
gliomagenesis O -
, O +
reveal O +
a O +
novel O +
mechanism O +
of O +
miR-10b O -
- O -
mediated O +
regulation O -
, O +
and O +
suggest O +
the O +
possibility O +
of O +
its O +
future O +
use O +
as O +
a O +
therapeutic O +
target O +
in O +
gliomas O -
. O -

Furthermore O -
, O +
survival O +
of O +
glioblastoma O +
patients U-Species +
expressing O +
high O +
levels O +
of O +
miR-10 O +
family O +
members O +
is O +
significantly O +
reduced O +
in O +
comparison O +
to O +
patients U-Species +
with O +
low O +
miR-10 O +
levels O -
, O +
indicating O +
that O +
miR-10 O +
may O +
contribute O +
to O +
glioma O +
growth O +
in O +
vivo O -
. O -

Finally O -
, O +
inhibition O +
of O +
miR-10b O +
in O +
a O +
mouse U-Species +
model O +
of O +
human U-Species +
glioma O +
results O +
in O +
significant O +
reduction O +
of O +
tumor O +
growth O -
. O -

MRI O +
scan O +
showed O +
an O +
area O +
of O +
encephalomalacia O +
in O +
the O +
left O +
temporal O +
lobe O -
, O +
as O +
well O +
as O +
post O -
- O -
surgical O +
changes O +
in O +
the O +
left O +
frontal O +
area O -
. O -

He O +
presented O +
with O +
status O +
epilepticus O +
every O +
two O +
or O +
three O +
months O -
, O +
and O +
required O +
long O +
periods O +
of O +
hospitalization O +
on O +
each O +
occasion O +
for O +
post O -
- O -
ictal O +
confusion O +
and O +
aphasia O -
. O -

He O +
continued O +
to O +
have O +
frequent O +
seizures O +
despite O +
treatment O +
with O +
multiple O +
combinations O +
of O +
antiepileptic O +
medications O -
. O -

EEG O +
telemetry O +
recorded O +
multiple O +
seizures O -
, O +
all O +
with O +
a O +
clear O +
focus O +
in O +
the O +
left O +
temporal O +
area O -
. O -

Scalp O +
EEG O +
showed O +
continuous O +
spikes O +
and O +
polyspikes O +
and O +
persistent O +
slowing O +
in O +
the O +
left O +
temporal O +
area O -
, O +
as O +
well O +
as O +
spikes O +
in O +
the O +
left O +
frontal O +
area O -
. O -

CASE O +
REPORT O -
: O +
We O +
report O +
a O +
case O +
of O +
a O +
75-year O -
- O -
old O +
right O -
- O -
handed O +
man U-Species +
who O +
underwent O +
a O +
left O +
fronto O -
- O -
temporal O +
craniotomy O +
for O +
resection O +
of O +
a O +
suprasellar O +
meningioma O +
in O +
2002 O -
. O -

Immediately O +
following O +
hospital O +
discharge O -
, O +
he O +
began O +
to O +
experience O +
complex O +
partial O +
seizures O -
. O -

BACKGROUND O -
: O +
Epilepsy O +
surgery O +
is O +
increasingly O +
well O -
- O -
supported O +
as O +
an O +
effective O +
treatment O +
for O +
patients U-Species +
with O +
intractable O +
epilepsy O -
. O -

It O +
is O +
most O +
often O +
performed O +
on O +
younger O +
patients U-Species +
and O +
the O +
safety O +
and O +
efficacy O +
of O +
epilepsy O +
surgery O +
in O +
elderly O +
patients U-Species +
are O +
not O +
frequently O +
described O -
. O -

Epilepsy O +
surgery O +
in O +
the O +
elderly O -
: O +
an O +
unusual O +
case O +
of O +
a O +
75-year O -
- O -
old O +
man U-Species +
with O +
recurrent O +
status O +
epilepticus O -
. O -

In O +
addition O -
, O +
few O +
cases O +
with O +
such O +
a O +
malignant O +
evolution O +
of O +
temporal O +
lobe O +
epilepsy O +
have O +
been O +
described O +
in O +
this O +
age O +
group O -
. O -

A O +
left O +
anteromesial O +
temporal O +
lobectomy O +
was O +
performed O +
with O +
intraoperative O +
electrocorticography O -
. O -

Neuropsychological O +
testing O +
showed O +
bilateral O +
memory O +
impairment O +
with O +
no O +
significant O +
cognitive O +
decline O +
expected O +
after O +
unilateral O +
temporal O +
lobe O +
resection O -
. O -

CONCLUSIONS O -
: O +
This O +
is O +
one O +
of O +
the O +
oldest O +
patients U-Species +
reported O +
in O +
the O +
literature O +
with O +
epilepsy O +
surgery O +
and O +
supports O +
the O +
possibility O +
of O +
epilepsy O +
surgery O +
in O +
elderly O +
patients U-Species +
for O +
particular O +
cases O -
. O -

Since O +
surgery O -
, O +
the O +
patient U-Species +
was O +
not O +
seizure O -
- O -
free O +
( O -
Engel O +
class O +
II O -
- O -
b O -
) O -
, O +
but O +
had O +
no O +
further O +
episodes O +
of O +
status O +
epilepticus O +
in O +
one O +
year O +
and O +
two O +
months O +
of O +
follow O -
- O -
up O -
. O -

Adult O -
- O -
onset O +
autosomal O +
dominant O +
leukodystrophy O -
: O +
linking O +
nuclear O +
envelope O +
to O +
myelin O -
. O -

Aberrant O +
expression O +
of O +
miRNAs O +
can O +
lead O +
to O +
diseases O -
, O +
including O +
cancer O -
. O -

Expression O +
of O +
many O +
miRNAs O +
in O +
the O +
de O -
- O -
differentiated O +
brain O +
tumor O +
cancer O +
stem O +
cells O +
resembles O +
that O +
of O +
neural O +
stem O +
cells O -
. O -

MicroRNAs O -
: O +
regulators O +
of O +
oncogenesis O +
and O +
stemness O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
are O +
essential O +
post O -
- O -
transcriptional O +
regulators O +
that O +
determine O +
cell O +
identity O +
and O +
fate O -
. O -

In O +
this O +
issue O +
of O +
BMC O +
Medicine O -
, O +
Silber O +
et O +
al O +
provide O +
evidence O +
of O +
the O +
expression O +
of O +
such O +
miRNAs O +
and O +
their O +
potential O +
to O +
mediate O +
differentiation O +
in O +
both O +
stem O +
cell O +
populations O -
. O -

In O +
this O +
commentary O -
, O +
we O +
discuss O +
the O +
known O +
functions O +
of O +
miRNAs O +
in O +
cancer O +
and O +
stem O +
cells O -
, O +
their O +
therapeutic O +
potential O +
and O +
how O +
the O +
findings O +
of O +
Silber O +
et O +
al O +
provide O +
insight O +
into O +
the O +
role O +
of O +
miR-124 O -
/ O -
miR-137 O +
dysregulation O +
in O +
glioblastomas O -
. O -

The O +
emerging O +
role O +
of O +
epigenetics O +
in O +
stroke O -
: O +
II O -
. O +
RNA O +
regulatory O +
circuitry O -
. O -

These O +
non O -
- O -
protein O -
- O -
coding O +
RNAs O +
( O -
ncRNAs O -
) O +
include O +
subclasses O +
that O +
are O +
well O +
known O -
, O +
such O +
as O +
transfer O +
RNAs O +
and O +
ribosomal O +
RNAs O -
, O +
as O +
well O +
as O +
those O +
that O +
have O +
more O +
recently O +
been O +
characterized O -
, O +
such O +
as O +
microRNAs O -
, O +
small O +
nucleolar O +
RNAs O -
, O +
and O +
long O +
ncRNAs O -
. O -

In O +
this O +
review O -
, O +
we O +
examine O +
the O +
role O +
of O +
these O +
novel O +
ncRNAs O +
in O +
the O +
nervous O +
system O +
and O +
highlight O +
emerging O +
evidence O +
that O +
implicates O +
RNA O -
- O -
based O +
networks O +
in O +
the O +
molecular O +
pathogenesis O +
of O +
stroke O -
. O -

Recent O +
scientific O +
advances O +
have O +
demonstrated O +
the O +
existence O +
of O +
extensive O +
RNA O -
- O -
based O +
regulatory O +
networks O +
involved O +
in O +
orchestrating O +
nearly O +
every O +
cellular O +
process O +
in O +
health O +
and O +
various O +
disease O +
states O -
. O -

This O +
previously O +
hidden O +
layer O +
of O +
functional O +
RNAs O +
is O +
derived O +
largely O +
from O +
non O -
- O -
protein O -
- O -
coding O +
DNA O +
sequences O +
that O +
constitute O +
more O +
than O +
98 O -
% O +
of O +
the O +
genome O +
in O +
humans U-Species -
. O -

These O +
novel O +
approaches O +
for O +
neural O +
cell- O +
and O +
tissue O -
- O -
selective O +
reprogramming O +
of O +
epigenetic O +
regulatory O +
mechanisms O +
are O +
likely O +
to O +
promote O +
more O +
effective O +
neuroprotective O +
and O +
neural O +
regenerative O +
responses O +
for O +
safeguarding O +
and O +
even O +
restoring O +
central O +
nervous O +
system O +
function O -
. O -

We O +
also O +
describe O +
RNA O +
editing O -
, O +
a O +
related O +
epigenetic O +
mechanism O +
that O +
is O +
partly O +
responsible O +
for O +
generating O +
the O +
exquisite O +
degrees O +
of O +
environmental O +
responsiveness O +
and O +
molecular O +
diversity O +
that O +
characterize O +
ncRNAs O -
. O -

In O +
addition O -
, O +
we O +
discuss O +
the O +
development O +
of O +
future O +
therapeutic O +
strategies O +
for O +
locus O -
- O -
specific O +
and O +
genome O -
- O -
wide O +
regulation O +
of O +
genes O +
and O +
functional O +
gene O +
networks O +
through O +
the O +
modulation O +
of O +
RNA O +
transcription O -
, O +
posttranscriptional O +
RNA O +
processing O +
( O -
eg O -
, O +
RNA O +
modifications O -
, O +
quality O +
control O -
, O +
intracellular O +
trafficking O -
, O +
and O +
local O +
and O +
long O -
- O -
distance O +
intercellular O +
transport O -
) O -
, O +
and O +
RNA O +
translation O -
. O -

These O +
results O +
indicate O +
that O +
miRNAs O +
are O +
differentially O +
expressed O +
in O +
C. B-Species +
elegans L-Species +
PD O +
models O +
and O +
suggest O +
a O +
role O +
for O +
these O +
molecules O +
in O +
disease O +
pathogenesis O -
. O -

Here O -
, O +
we O +
show O +
that O +
12 O +
specific O +
miRNAs O +
are O +
differentially O +
regulated O +
in O +
the O +
animals O +
overexpressing O +
alpha O -
- O -
synuclein O -
, O +
five O +
in O +
cat-1 O -
, O +
and O +
three O +
in O +
the O +
pdr-1 O +
mutants O -
. O -

The O +
family O +
of O +
miR-64 O +
and O +
miR-65 O +
are O +
co O -
- O -
underexpressed O +
in O +
the O +
alpha O -
- O -
synuclein O +
transgenic O +
and O +
cat-1 O +
strains O -
, O +
and O +
members O +
of O +
let-7 O +
family O +
co O -
- O -
underexpressed O +
in O +
the O +
alpha O -
- O -
synuclein O +
and O +
pdr-1 O +
strains O -
; O +
mdl-1 O +
and O +
ptc-1 O +
genes O +
are O +
target O +
candidates O +
for O +
miR-64 O +
and O +
miR-65 O +
and O +
are O +
overexpressed O +
in O +
alpha O -
- O -
synuclein O +
transgenic O +
as O +
well O +
as O +
miR-64 O -
/ O -
65 O +
( O -
tm3711 O -
) O +
knockout O +
animals O -
. O -

MicroRNAs O +
( O -
miRNAs O -
) O +
play O +
an O +
important O +
role O +
in O +
human U-Species +
brain O +
development O +
and O +
maintenance O -
. O -

To O +
search O +
for O +
miRNAs O +
that O +
may O +
be O +
involved O +
in O +
the O +
pathogenesis O +
of O +
Parkinsons O +
disease O +
( O -
PD O -
) O -
, O +
we O +
utilized O +
miRNA O +
microarrays O +
to O +
identify O +
potential O +
gene O +
expression O +
changes O +
in O +
115 O +
annotated O +
miRNAs O +
in O +
PD O -
- O -
associated O +
Caenorhabditis B-Species +
elegans L-Species +
models O +
that O +
either O +
overexpress O +
human U-Species +
A53 O -
T O +
alpha O -
- O -
synuclein O +
or O +
have O +
mutations O +
within O +
the O +
vesicular O +
catecholamine O +
transporter O +
( O -
cat-1 O -
) O +
or O +
parkin O +
( O -
pdr-1 O -
) O +
ortholog O -
. O -

Global O +
microRNA O +
expression O +
profiling O +
of O +
Caenorhabditis B-Species +
elegans L-Species +
Parkinson O -
's O +
disease O +
models O -
. O -

A O +
series O +
of O +
novel O +
and O +
established O +
medulloblastoma O +
defects O +
were O +
detected O +
( O -
MYC O +
amplification O +
( O -
n O +
= O +
4 O -
) O -
, O +
17q21.31 O +
high O -
- O -
level O +
gain O +
( O -
n O +
= O +
1 O -
) O -
; O +
9p21.1-p21.3 O +
( O -
n O +
= O +
1 O -
) O +
and O +
6q23.1 O +
( O -
n O +
= O +
1 O -
) O +
homozygous O +
deletion O -
) O -
. O -

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
We O +
performed O +
a O +
SNP O -
- O -
array O +
based O +
genome O -
- O -
wide O +
copy O +
number O +
analysis O +
in O +
medulloblastoma O +
cell O +
lines O -
, O +
to O +
identify O +
regions O +
of O +
genomic O +
amplification O +
and O +
homozygous O +
deletion O -
, O +
which O +
may O +
harbour O +
critical O +
disease O +
genes O -
. O -

Most O +
notably O -
, O +
a O +
novel O +
recurrent O +
region O +
of O +
genomic O +
amplification O +
at O +
8q24.22-q24.23 O +
was O +
identified O +
( O -
n O +
= O +
2 O -
) O -
, O +
and O +
selected O +
for O +
further O +
investigation O -
. O -

Amplification O +
and O +
overexpression O +
of O +
Hsa O -
- O -
miR-30b O -
, O +
Hsa O -
- O -
miR-30d O +
and O +
KHDRBS3 O +
at O +
8q24.22-q24.23 O +
in O +
medulloblastoma O -
. O -

The O +
identification O +
of O +
critical O +
genes O +
involved O +
in O +
its O +
pathogenesis O +
will O +
be O +
central O +
to O +
advances O +
in O +
our O +
understanding O +
of O +
its O +
molecular O +
basis O -
, O +
and O +
the O +
development O +
of O +
improved O +
therapeutic O +
approaches O -
. O -

BACKGROUND O -
: O +
Medulloblastoma O +
is O +
the O +
most O +
common O +
malignant O +
brain O +
tumour O +
of O +
childhood O -
. O -

Of O +
these O -
, O +
only O +
expression O +
of O +
hsa O -
- O -
miR-30b O -
, O +
hsa O -
- O -
miR-30d O +
and O +
KHDRBS3 O +
correlated O +
with O +
copy O +
number O +
status O -
, O +
and O +
all O +
three O +
of O +
these O +
transcripts O +
also O +
displayed O +
evidence O +
of O +
elevated O +
expression O +
in O +
sub O -
- O -
sets O +
of O +
primary O +
medulloblastomas O -
, O +
measured O +
relative O +
to O +
the O +
normal O +
cerebellum O -
. O -

Additional O +
analysis O +
by O +
interphase O +
fluorescence O +
in O +
situ O +
hybridisation O +
( O -
iFISH O -
) O -
, O +
PCR O -
- O -
based O +
mapping O +
and O +
SNP O -
- O -
array O +
revealed O +
this O +
novel O +
amplification O +
at O +
8q24.22-q24.23 O +
is O +
independent O +
of O +
MYC O +
amplification O +
at O +
8q24.21 O -
, O +
and O +
is O +
unique O +
to O +
medulloblastoma O +
in O +
over O +
800 O +
cancer O +
cell O +
lines O +
assessed O +
from O +
different O +
tumour O +
types O -
, O +
suggesting O +
it O +
contains O +
key O +
genes O +
specifically O +
involved O +
in O +
medulloblastoma O +
development O -
. O -

Detailed O +
mapping O +
identified O +
a O +
3Mb O +
common O +
minimal O +
region O +
of O +
amplification O +
harbouring O +
3 O +
coding O +
genes O +
( O -
ZFAT1 O -
, O +
LOC286094 O -
, O +
KHDRBS3 O -
) O +
and O +
two O +
genes O +
encoding O +
micro O -
- O -
RNAs O +
( O -
hsa O -
- O -
miR-30b O -
, O +
hsa O -
- O -
miR-30d O -
) O -
. O -

Our O +
findings O +
suggest O +
critical O +
roles O +
for O +
these O +
genes O +
in O +
medulloblastoma O +
development O -
, O +
and O +
further O +
support O +
the O +
contribution O +
of O +
micro O -
- O -
RNA O +
species O +
to O +
medulloblastoma O +
pathogenesis O -
. O -

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
These O +
data O +
implicate O +
hsa O -
- O -
miR-30b O -
, O +
hsa O -
- O -
miR-30d O +
and O +
KHDRBS3 O +
as O +
putative O +
oncogenic O +
target O -
( O -
s O -
) O +
of O +
a O +
novel O +
recurrent O +
medulloblastoma O +
amplicon O +
at O +
8q24.22-q24.23 O -
. O -

PURPOSE O +
Medulloblastomas O +
are O +
heterogeneous O +
tumors O +
that O +
collectively O +
represent O +
the O +
most O +
common O +
malignant O +
brain O +
tumor O +
in O +
children U-Species -
. O -

Integrative O +
genomic O +
analysis O +
of O +
medulloblastoma O +
identifies O +
a O +
molecular O +
subgroup O +
that O +
drives O +
poor O +
clinical O +
outcome O -
. O -

We O +
reveal O +
the O +
relative O +
contribution O +
of O +
each O +
subgroup O +
to O +
clinical O +
outcome O +
as O +
a O +
whole O +
and O +
show O +
that O +
a O +
previously O +
unidentified O +
molecular O +
subgroup O -
, O +
characterized O +
genetically O +
by O +
c O -
- O -
MYC O +
copy O +
number O +
gains O +
and O +
transcriptionally O +
by O +
enrichment O +
of O +
photoreceptor O +
pathways O +
and O +
increased O +
miR-183∼96∼182 O +
expression O -
, O +
is O +
associated O +
with O +
significantly O +
lower O +
rates O +
of O +
event O -
- O -
free O +
and O +
overall O +
survivals O -
. O -

Results O +
Identified O +
are O +
six O +
molecular O +
subgroups O +
of O +
medulloblastoma O -
, O +
each O +
with O +
a O +
unique O +
combination O +
of O +
numerical O +
and O +
structural O +
chromosomal O +
aberrations O +
that O +
globally O +
influence O +
mRNA O +
and O +
miRNA O +
expression O -
. O -

CONCLUSION O +
Our O +
results O +
detail O +
the O +
complex O +
genomic O +
heterogeneity O +
of O +
medulloblastomas O +
and O +
identify O +
a O +
previously O +
unrecognized O +
molecular O +
subgroup O +
with O +
poor O +
clinical O +
outcome O +
for O +
which O +
more O +
effective O +
therapeutic O +
strategies O +
should O +
be O +
developed O -
. O -

PATIENTS U-Species +
AND O +
METHODS O +
We O +
profiled O +
the O +
mRNA O +
transcriptome O +
of O +
194 O +
medulloblastomas O +
and O +
performed O +
high O -
- O -
density O +
single O +
nucleotide O +
polymorphism O +
array O +
and O +
miRNA O +
analysis O +
on O +
115 O +
and O +
98 O +
of O +
these O -
, O +
respectively O -
. O -

To O +
understand O +
the O +
molecular O +
characteristics O +
underlying O +
their O +
heterogeneity O +
and O +
to O +
identify O +
whether O +
such O +
characteristics O +
represent O +
risk O +
factors O +
for O +
patients U-Species +
with O +
this O +
disease O -
, O +
we O +
performed O +
an O +
integrated O +
genomic O +
analysis O +
of O +
a O +
large O +
series O +
of O +
primary O +
tumors O -
. O -

We O +
additionally O +
validated O +
our O +
findings O +
in O +
three O +
previously O +
published O +
independent O +
medulloblastoma O +
data O +
sets O -
. O -

Non O -
- O -
negative O +
matrix O +
factorization O -
- O -
based O +
clustering O +
of O +
mRNA O +
expression O +
data O +
was O +
used O +
to O +
identify O +
molecular O +
subgroups O +
of O +
medulloblastoma O -
; O +
DNA O +
copy O +
number O -
, O +
miRNA O +
profiles O -
, O +
and O +
clinical O +
outcomes O +
were O +
analyzed O +
for O +
each O -
. O -

The O +
reason O +
why O +
a O +
mild O +
TBI O +
results O +
in O +
varying O +
clinical O +
symptoms O +
is O +
currently O +
unknown O -
. O -

Based O +
on O +
evidence O +
that O +
microRNA O +
species O +
in O +
peripheral O +
blood O +
mononuclear O +
cells O +
( O -
PBMCs O -
) O +
may O +
reflect O +
molecular O +
alterations O +
in O +
neurodegenerative O +
disorders O -
, O +
it O +
can O +
be O +
hypothesized O +
that O +
at O +
early O -
, O +
preclinical O +
phases O +
of O +
the O +
disease O -
, O +
PBMC O +
may O +
provide O +
an O +
ideal O +
and O +
clinically O +
assessable O +
" O -
window O -
" O +
into O +
the O +
brain O -
. O -

Patients U-Species +
who O +
have O +
sustained O +
a O +
mild O +
traumatic O +
brain O +
injury O +
( O -
TBI O -
) O +
from O +
both O +
civilian O +
and O +
military O +
populations O +
exhibit O +
clinical O +
symptoms O +
of O +
varying O +
severity O +
with O +
minimal O +
to O +
profound O +
impact O +
on O +
their O +
daily O +
functioning O -
. O -

Although O +
most O +
patients U-Species +
make O +
a O +
full O +
recovery O -
, O +
a O +
subgroup O +
of O +
mild O +
TBI O +
patients U-Species +
develop O +
cognitive O -
, O +
somatic O -
, O +
and O +
neurobehavioral O +
sequelae O +
that O +
generally O +
resolve O +
over O +
3 O +
to O +
6 O +
months O -
; O +
a O +
smaller O +
subgroup O +
develop O +
persisting O +
symptoms O -
. O -

Personalized O +
medicine O +
in O +
traumatic O +
brain O +
injury O -
. O -

Thus O -
, O +
it O +
is O +
conceivable O +
that O +
changes O +
in O +
the O +
expression O +
profile O +
of O +
clinically O +
accessible O +
biological O +
indices O +
( O -
biomarkers O -
) O -
, O +
such O +
as O +
microRNA O +
in O +
PBMC O -
, O +
may O +
reflect O +
molecular O +
alterations O +
following O +
TBI O +
that O +
contribute O +
to O +
the O +
onset O +
and O +
progression O +
of O +
TBI O +
phenotypes O +
including O +
chronic O +
traumatic O +
encephalopathy O -
. O -

It O +
is O +
possible O +
that O +
the O +
availability O +
of O +
TBI O +
biomarkers O +
may O +
provide O +
potential O +
elements O +
with O +
clinical O +
relevance O +
to O +
prevention O -
, O +
prognosis O -
, O +
and O +
treatment O +
of O +
postconcussive O +
disorders O -
. O -

This O +
opportunistic O +
mycosis O +
infection O +
presented O +
with O +
clinically O +
totally O +
nonspecific O +
signs O +
and O +
symptoms O +
of O +
CNS O +
affection O -
. O -

Therefore O -
, O +
we O +
suspected O +
affection O +
of O +
CNS O +
with O +
SLE O -
. O -

Even O +
though O +
all O +
diagnostic O +
procedures O +
were O +
made O +
on O +
time O +
and O +
that O +
adequate O +
antifungal O +
and O +
supportive O +
agents O +
were O +
applied O +
very O +
early O +
after O +
the O +
infection O +
onset O -
, O +
the O +
outcome O +
was O +
fatal O -
. O -

Because O +
of O +
infective O +
diathesis O +
in O +
patients U-Species +
with O +
SLE O -
, O +
which O +
present O +
with O +
common O +
and O +
opportunistic O +
infections O -
, O +
and O +
due O +
to O +
high O +
mortality O +
rates O +
caused O +
by O +
these O +
infections O -
, O +
we O +
have O +
tried O +
to O +
emphasise O +
the O +
importance O +
of O +
taking O +
adequate O +
specimens O +
early O +
after O +
infection O +
outcome O +
for O +
these O +
rare O +
infective O +
agents O +
like O +
C. O +
neophormans O -
. O -

It O +
was O +
meningitis O +
caused O +
by O +
C. O +
neoformans O -
. O -

Reports O +
from O +
Europe O +
are O +
very O +
rare O -
, O +
and O +
this O +
case O +
is O +
the O +
one O +
of O +
that O +
kind O +
in O +
Croatia O -
. O -

In O +
recent O +
medical O +
literature O +
are O +
dominant O +
cases O +
reported O +
in O +
Asia O -
. O -

Systemic O +
erythematosus O +
lupus O +
( O -
SLE O -
) O +
is O +
a O +
disease O +
with O +
wide O +
range O +
of O +
clinical O +
manifestations O -
, O +
signs O +
and O +
symptoms O -
. O -

[ O -
Cryptococcal O +
meningitis O +
as O +
a O +
diagnostic O +
problem O +
in O +
a O +
patient U-Species +
with O +
SLE O -
-- O -
case O +
report O -
] O -
. O -

Very O +
important O +
cause O +
of O +
death O +
in O +
patients U-Species +
with O +
SLE O +
is O +
infection O -
. O -

Disease O +
outcome O +
depends O +
mostly O +
on O +
the O +
affection O +
of O +
kidneys O +
and O +
central O +
nervous O +
system O +
by O +
the O +
disease O -
. O -

During O +
one O +
of O +
the O +
disease O +
flares O +
the O +
patient U-Species +
was O +
hospitalized O +
an O +
opportunistic O +
infection O +
developed O -
. O -

As O +
an O +
outcome O +
of O +
the O +
combined O +
effect O +
of O +
disease O +
and O +
immunosuppressive O +
agents O +
used O +
in O +
the O +
treatment O +
of O +
the O +
disease O -
, O +
the O +
patient U-Species +
had O +
increased O +
infective O +
diathesis O +
( O -
repeated O +
infections O +
caused O +
by O +
S. O +
enteritidis O -
-- O -
urinary O +
infections O +
and O +
sepsis O -
) O -
. O -

In O +
this O +
case O +
report O +
we O +
have O +
presented O +
a O +
patient U-Species +
with O +
SLE O +
who O +
initially O +
had O +
severe O +
renal O +
affection O -
, O +
but O +
also O +
complications O +
of O +
immunosuppressive O +
therapy O +
that O +
was O +
administered O -
. O -

Infections O +
are O +
very O +
common O +
among O +
these O +
patients U-Species +
due O +
to O +
aggressive O +
immunosuppressive O +
treatment O +
that O +
is O +
needed O +
for O +
the O +
disease O +
inflammatory O +
activity O +
control O -
. O -

Because O +
of O +
lupus O +
nephropathy O -
, O +
in O +
the O +
early O +
phase O +
of O +
the O +
disease O +
we O +
administered O +
aggressive O +
immunosuppressive O +
therapy O +
( O -
combined O +
parenteral O +
therapy O +
of O +
glucocorticoides O +
and O +
cyclophosphamide O -
) O -
. O -

Even O +
though O +
the O +
disease O +
was O +
accidentally O +
diagnosed O -
, O +
it O +
had O +
a O +
severe O +
clinical O +
progress O -
. O -

Isolation O +
and O +
characterization O +
of O +
MAT O +
genes O +
in O +
the O +
symbiotic O +
ascomycete O +
Tuber B-Species +
melanosporum L-Species -
. O +

* O +
The O +
genome O +
of O +
Tuber B-Species +
melanosporum L-Species +
has O +
recently O +
been O +
sequenced O -
. O -

Here O -
, O +
we O +
used O +
this O +
information O +
to O +
identify O +
genes O +
involved O +
in O +
the O +
reproductive O +
processes O +
of O +
this O +
edible O +
fungus O -
. O -

The O +
sequenced O +
strain O +
( O -
Mel28 O -
) O +
possesses O +
only O +
one O +
of O +
the O +
two O +
master O +
genes O +
required O +
for O +
mating O -
, O +
that O +
is O -
, O +
the O +
gene O +
that O +
codes O +
for O +
the O +
high O +
mobility O +
group O +
( O -
HMG O -
) O +
transcription O +
factor O +
( O -
MAT1 O -
- O -
2 O -
- O -
1 O -
) O -
, O +
whereas O +
it O +
lacks O +
the O +
gene O +
that O +
codes O +
for O +
the O +
protein O +
containing O +
the O +
alpha O -
- O -
box- O +
domain O +
( O -
MAT1 O -
- O -
1 O -
- O -
1 O -
) O -
, O +
suggesting O +
that O +
this O +
fungus O +
is O +
heterothallic O -
. O -

* O +
A O +
PCR O -
- O -
based O +
approach O +
was O +
initially O +
employed O +
to O +
screen O +
truffles O +
for O +
the O +
presence O +
of O +
the O +
MAT1 O -
- O -
2 O -
- O -
1 O +
gene O +
and O +
amplify O +
the O +
conserved O +
regions O +
flanking O +
the O +
mating O +
type O +
( O -
MAT O -
) O +
locus O -
. O -

The O +
MAT1 O -
- O -
1 O -
- O -
1 O +
gene O +
was O +
finally O +
identified O +
using O +
primers O +
designed O +
from O +
the O +
conserved O +
regions O +
of O +
strains O +
that O +
lack O +
the O +
MAT1 O -
- O -
2 O -
- O -
1 O +
gene O -
. O -

* O +
Mating O +
type O -
- O -
specific O +
primer O +
pairs O +
were O +
developed O +
to O +
screen O +
asci O +
and O +
gleba O +
from O +
truffles O +
of O +
different O +
origins O +
and O +
to O +
genotype O +
single O +
ascospores O +
within O +
the O +
asci O -
. O -

These O +
analyses O +
provided O +
definitive O +
evidence O +
that O +
T. B-Species +
melanosporum L-Species +
is O +
a O +
heterothallic O +
species O +
with O +
a O +
MAT O +
locus O +
that O +
is O +
organized O +
similarly O +
to O +
those O +
of O +
ancient O +
fungal O +
lineages O -
. O -

* O +
A O +
greater O +
understanding O +
of O +
the O +
reproductive O +
mechanisms O +
that O +
exist O +
in O +
Tuber O +
spp O -
. O +
allows O +
for O +
optimization O +
of O +
truffle O +
plantation O +
management O +
strategies O -
. O +

Microtubule O +
dynamics O +
in O +
mitosis O +
in O +
Aspergillus B-Species +
nidulans L-Species -
. O +

Mitosis O +
in O +
Aspergillus B-Species +
nidulans L-Species +
is O +
very O +
rapid O -
, O +
requiring O +
less O +
than O +
5 O +
min O +
at O +
37 O +
^0C O +
in O +
germlings O +
( O -
Bergen O +
and O +
Morris O -
, O +
1983 O -
) O -
. O -

In O +
this O +
time O +
the O +
cytoplasmic O +
microtubules O +
( O -
MTs O -
) O +
must O +
disassemble O -
, O +
the O +
mitotic O +
spindle O +
assemble O -
, O +
function O +
and O +
disassemble O -
, O +
and O +
cytoplasmic O +
MTs O +
reassemble O -
. O -

It O +
follows O +
that O +
cytoplasmic O +
MTs O +
must O +
be O +
extremely O +
dynamic O +
in O +
this O +
period O +
and O +
we O +
were O +
interested O -
, O +
in O +
particular O -
, O +
in O +
examining O +
the O +
processes O +
of O +
MT O +
disassembly O +
in O +
prophase O +
and O +
reassembly O +
in O +
anaphase O +
and O +
telophase O -
. O -

We O +
observed O +
a O +
diploid O +
strain O +
that O +
expressed O +
GFP O -
- O -
alpha O -
- O -
tubulin O -
. O -

We O +
used O +
a O +
spinning O +
disk O +
confocal O +
microscope O +
that O +
allowed O +
rapid O +
image O +
capture O -
, O +
which O +
proved O +
necessary O +
because O +
microtubule O +
dynamics O +
were O +
extremely O +
rapid O -
. O -

We O +
found O -
, O +
for O +
the O +
first O +
time O -
, O +
that O +
microtubule O +
severing O +
occurs O +
in O +
prophase O +
in O +
a O +
filamentous O +
fungus O +
and O +
that O +
catastrophe O +
rather O +
than O +
nucleation O +
limits O +
astral O +
microtubule O +
growth O -
. O +

Morphological O +
redescriptions O +
of O +
four O +
marine O +
ciliates O +
( O -
Ciliophora O -
: O +
Cyrtophorida O -
: O +
Dysteriidae O -
) O +
from O +
Qingdao O -
, O +
China O -
. O +

The O +
morphology O +
and O +
infraciliature O +
of O +
four O +
marine O +
cyrtophorid O +
ciliates O +
isolated O +
from O +
Qingdao O -
, O +
China O -
, O +
were O +
investigated O -
. O -

Based O +
on O +
the O +
present O +
work O +
and O +
on O +
previous O +
data O -
, O +
improved O +
diagnoses O +
for O +
three O +
rarely O +
known O +
species O +
are O +
provided O -
: O +
( O -
1 O -
) O +
Mirodysteria O +
decora O -
; O +
small O -
- O -
sized O +
marine O +
Mirodysteria O +
about O +
35 O -
- O -
60 O +
x O +
25 O -
- O -
35 O +
mum O +
in O +
vivo O -
, O +
oval O +
in O +
outline O -
; O +
body O +
surface O +
with O +
two O +
or O +
three O +
conspicuous O +
dorsal O +
spines O +
and O +
one O +
caudal O +
spine O -
; O +
three O +
right O +
kineties O -
, O +
the O +
rightmost O +
one O +
extending O +
dorso O -
- O -
apically O -
; O +
left O +
frontal O +
kineties O +
reduced O -
, O +
each O +
consisting O +
of O +
three O +
basal O +
bodies O +
only O -
; O +
podite O +
subcaudally O +
positioned O -
; O +
two O +
ventrally O +
located O +
contractile O +
vacuoles O -
. O -

( O -
2 O -
) O +
Dysteria O +
legumen O -
; O +
body O +
oval O +
with O +
two O +
longitudinal O +
grooves O +
on O +
different O +
plates O -
; O +
six O +
right O +
kineties O -
, O +
the O +
rightmost O +
two O +
of O +
which O +
extend O +
dorso O -
- O -
apically O -
; O +
two O +
left O +
frontal O +
kineties O +
and O +
two O +
ventrally O +
located O +
contractile O +
vacuoles O -
. O -

( O -
3 O -
) O +
Dysteria O +
proraefrons O -
; O +
body O +
about O +
60x35 O +
mum O +
in O +
vivo O -
; O +
six O +
right O +
kineties O -
, O +
the O +
two O +
rightmost O +
of O +
which O +
extend O +
dorso O -
- O -
apically O +
and O +
the O +
leftmost O +
one O +
is O +
considerably O +
shortened O -
; O +
three O +
left O +
frontal O +
kineties O -
; O +
two O +
ventrally O +
located O +
contractile O +
vacuoles O -
. O -

A O +
population O +
of O +
D. B-Species +
derouxi L-Species +
with O +
eight O +
or O +
nine O +
right O +
kineties O +
is O +
also O +
briefly O +
described O -
. O -

The O +
current O +
investigation O +
further O +
demonstrates O +
high O +
diversity O +
and O +
cosmopolitan O +
distribution O +
of O +
this O +
highly O +
specialized O +
group O +
of O +
benthic O +
ciliates O -
. O +

Auxin O +
depletion O +
in O +
barley U-Species +
plants O +
under O +
high O -
- O -
temperature O +
conditions O +
represses O +
DNA O +
proliferation O +
in O +
organelles O +
and O +
nuclei O +
via O +
transcriptional O +
alterations O -
. O +

Many O +
plant O +
species O +
are O +
susceptible O +
to O +
high O -
- O -
temperature O +
( O -
HT O -
) O +
injury O +
during O +
reproductive O +
development O -
. O -

We O +
recently O +
demonstrated O +
that O +
HT O +
represses O +
the O +
expression O +
of O +
YUCCA O +
auxin O +
biosynthesis O +
genes O +
and O +
reduces O +
endogenous O +
auxin O +
in O +
the O +
developing O +
anthers O +
of O +
barley U-Species +
and O +
Arabidopsis O -
. O -

Here O -
, O +
we O +
show O +
that O +
DNA O +
proliferation O +
in O +
mitochondria O -
, O +
chloroplasts O +
and O +
nuclei O +
of O +
developing O +
panicles O +
is O +
inhibited O +
with O +
increasing O +
temperatures O +
in O +
barley U-Species -
. O -

Following O +
DNA O +
proliferation O +
suppression O -
, O +
terminal O +
abnormalities O +
were O +
observed O +
in O +
the O +
organelles O +
of O +
anther O +
wall O +
cells O -
, O +
including O +
mitochondrial O +
swelling O +
and O +
overdevelopment O +
of O +
chloroplasts O -
. O -

Comprehensive O +
transcriptome O +
analyses O +
using O +
both O +
reproductive O +
organs O +
and O +
vegetative O +
tissues O +
showed O +
high O +
and O +
positive O +
pairwise O +
correlations O +
between O +
the O +
expression O +
profiles O +
of O +
auxin O -
- O -
induced O +
genes O -
, O +
DNA O +
replication O -
- O -
related O +
genes O +
and O +
mitochondrial O -
- O -
related O +
genes O -
. O -

In O +
contrast O -
, O +
the O +
expression O +
profiles O +
of O +
auxin O -
- O -
repressed O +
protein O +
genes O +
and O +
photosynthesis- O -
/ O -
chloroplast O -
- O -
related O +
genes O +
were O +
negatively O +
correlated O +
with O +
those O +
of O +
the O +
previously O +
mentioned O +
genes O -
. O -

Under O +
HT O +
conditions O -
, O +
the O +
former O +
was O +
repressed O +
and O +
the O +
latter O +
was O +
up O -
- O -
regulated O +
in O +
the O +
developing O +
panicles O -
. O -

Furthermore O -
, O +
application O +
of O +
exogenous O +
auxin O +
promoted O +
the O +
expression O +
of O +
DNA O +
replication O -
- O -
related O +
genes O +
under O +
HT O +
conditions O -
, O +
inducing O +
anther O +
cell O +
proliferation O -
. O -

These O +
suggest O +
that O +
compromised O +
auxin O +
biosynthesis O -
/ O -
IAA O +
level O +
under O +
HT O +
condition O +
results O +
in O +
nuclear O +
and O +
organellar O +
DNA O +
proliferation O +
arrest O +
due O +
to O +
co O -
- O -
transcriptional O +
alterations O -
. O +

Separating O +
parental O +
environment O +
from O +
seed O +
size O +
effects O +
on O +
next O +
generation O +
growth O +
and O +
development O +
in O +
Arabidopsis O -
. O +

Plant O +
growth O +
and O +
development O +
is O +
profoundly O +
influenced O +
by O +
environmental O +
conditions O +
that O +
laboratory O +
experimentation O +
typically O +
attempts O +
to O +
control O -
. O -

However O -
, O +
growth O +
conditions O +
are O +
not O +
uniform O +
between O +
or O +
even O +
within O +
laboratories O +
and O +
the O +
extent O +
to O +
which O +
these O +
differences O +
influence O +
plant O +
growth O +
and O +
development O +
is O +
unknown O -
. O -

Experiments O +
with O +
wild O -
- O -
type O +
Arabidopsis B-Species +
thaliana L-Species +
were O +
designed O +
to O +
quantify O +
the O +
influences O +
of O +
parental O +
environment O +
and O +
seed O +
size O +
on O +
growth O +
and O +
development O +
in O +
the O +
next O +
generation O -
. O -

A O +
single O +
lot O +
of O +
seed O +
was O +
planted O +
in O +
six O +
environmental O +
chambers O +
and O +
grown O +
to O +
maturity O -
. O -

The O +
seed O +
produced O +
was O +
mechanically O +
sieved O +
into O +
small O +
and O +
large O +
size O +
classes O +
then O +
grown O +
in O +
a O +
common O +
environment O +
and O +
subjected O +
to O +
a O +
set O +
of O +
assays O +
spanning O +
the O +
life O +
cycle O -
. O -

Analysis O +
of O +
variance O +
demonstrated O +
that O +
seed O +
size O +
effects O +
were O +
particularly O +
significant O +
early O +
in O +
development O -
, O +
affecting O +
primary O +
root O +
growth O +
and O +
gravitropism O -
, O +
but O +
also O +
flowering O +
time O -
. O -

Parental O +
environment O +
affected O +
progeny O +
germination O +
time O -
, O +
flowering O +
and O +
weight O +
of O +
seed O +
the O +
progeny O +
produced O -
. O -

In O +
some O +
cases O -
, O +
the O +
parental O +
environment O +
affected O +
the O +
magnitude O +
of O +
( O -
interacted O +
with O -
) O +
the O +
observed O +
seed O +
size O +
effects O -
. O -

These O +
data O +
indicate O +
that O +
life O +
history O +
circumstances O +
of O +
the O +
parental O +
generation O +
can O +
affect O +
growth O +
and O +
development O +
throughout O +
the O +
life O +
cycle O +
of O +
the O +
next O +
generation O +
to O +
an O +
extent O +
that O +
should O +
be O +
considered O +
when O +
performing O +
genetic O +
studies O -
. O +

Minimum O +
hydraulic O +
safety O +
leads O +
to O +
maximum O +
water O -
- O -
use O +
efficiency O +
in O +
a O +
forage O +
grass O -
. O +

Understanding O +
how O +
water O -
- O -
use O +
regulation O +
relates O +
to O +
biomass O +
accumulation O +
is O +
imperative O +
for O +
improving O +
crop O +
production O +
in O +
water O -
- O -
limited O +
environments O -
. O -

Here O -
, O +
we O +
examine O +
how O +
the O +
vulnerability O +
of O +
xylem O +
to O +
water O +
stress O -
- O -
induced O +
cavitation O +
and O +
the O +
coordination O +
between O +
water O +
transport O +
capacity O +
and O +
assimilation O +
( O -
A O -
) O +
influences O +
diurnal O +
water O -
- O -
use O +
efficiency O +
( O -
WUE O -
) O +
and O +
dry O -
- O -
matter O +
production O +
in O +
Lolium B-Species +
perenne L-Species +
L. O +
- O +
a O +
commercial O +
forage O +
grass O -
. O -

Plants O +
were O +
exposed O +
to O +
a O +
range O +
of O +
water O +
stresses O -
, O +
causing O +
up O +
to O +
90 O -
% O +
leaf O +
death O -
, O +
by O +
withholding O +
water O +
and O +
then O +
rewatering O +
to O +
observe O +
the O +
recovery O +
process O -
. O -

Leaf O +
hydraulic O +
conductance O +
( O -
K O -
( O -
leaf O -
) O +
) O +
declined O +
to O +
50 O -
% O +
of O +
maximum O +
at O +
a O +
leaf O +
water O +
potential O +
( O -
psi O -
( O -
leaf O -
) O +
) O +
of O +
-1 O +
MPa O -
, O +
whereas O +
complete O +
stomatal O +
closure O +
occurred O +
well O +
after O +
this O +
point O -
, O +
at O +
-2.35 O +
MPa O -
, O +
providing O +
no O +
protection O +
against O +
hydraulic O +
dysfunction O -
. O -

Instantaneous O +
A O +
remained O +
maximal O +
until O +
> O -
70 O -
% O +
of O +
hydraulic O +
conductivity O +
had O +
been O +
lost O -
. O -

Post O -
- O -
stress O +
rewatering O +
showed O +
that O +
95 O -
% O +
loss O +
of O +
K O -
( O -
leaf O -
) O +
could O +
be O +
incurred O +
before O +
the O +
recovery O +
of O +
gas O +
exchange O +
exceeded O +
1 O +
d O -
, O +
with O +
a O +
rapid O +
transition O +
to O +
leaf O +
death O +
after O +
this O +
point O -
. O -

Plants O +
exposed O +
to O +
sustained O +
soil O +
water O +
deficits O +
through O +
restricted O +
nightly O +
watering O +
regimes O +
did O +
not O +
suffer O +
cumulative O +
losses O +
in O +
K O -
( O -
leaf O -
) O +
; O +
instead O -
, O +
psi O -
( O -
leaf O -
) O +
and O +
gas O +
exchange O +
recovered O +
diurnally O -
. O -

The O +
effect O +
was O +
improved O +
WUE O +
during O +
the O +
day O +
and O +
optimal O +
psi O -
( O -
leaf O -
) O +
during O +
the O +
night O +
for O +
the O +
maintenance O +
of O +
growth O -
. O +

Cotterillia B-Species +
bromelicola I-Species +
nov. I-Species +
gen. I-Species -
, I-Species +
nov. I-Species +
spec L-Species -
. O -
, O +
a O +
gonostomatid O +
ciliate O +
( O -
Ciliophora O -
, O +
Hypotricha O -
) O +
from O +
tank O +
bromeliads O +
( O -
Bromeliaceae O -
) O +
with O +
de O +
novo O +
originating O +
dorsal O +
kineties O -
. O +

Cotterillia B-Species +
bromelicola I-Species +
nov. I-Species +
gen. I-Species -
, I-Species +
nov. I-Species +
spec L-Species -
. O -

was O +
discovered O +
in O +
the O +
tanks O +
of O +
the O +
Mexican O +
bromeliad O +
Tillandsia B-Species +
heterophylla L-Species -
. O -

Its O +
morphology O -
, O +
ontogenesis O -
, O +
and O +
18S O +
rDNA O +
were O +
studied O +
with O +
standard O +
methods O -
. O -

Cotterillia U-Species +
has O +
many O +
cirral O +
rows O +
on O +
both O +
sides O +
of O +
the O +
body O -
. O -

Uniquely O -
, O +
and O +
thus O +
used O +
to O +
diagnose O +
the O +
new O +
genus O +
Cotterillia U-Species -
, O +
it O +
has O +
dorsal O +
kineties O +
originating O +
de O +
novo O -
, O +
producing O +
neokinetal O +
waves O +
where O +
the O +
parental O +
dorsal O +
kineties O +
reorganize O +
to O +
& O -
quot;combined O +
rows&quot O -
; O -
, O +
consisting O +
of O +
dorsal O +
bristles O +
anteriorly O +
and O +
of O +
cirri O +
posteriorly O -
. O -

Thus O -
, O +
up O +
to O +
four O +
generations O +
of O +
bristles O +
and O +
cirri O +
occur O +
on O +
the O +
dorsal O +
body O +
surface O -
. O -

Cotterillia B-Species +
bromelicola L-Species +
has O +
a O +
gonostomatid O +
body O +
and O +
adoral O +
zone O +
of O +
membranelles O -
, O +
while O +
the O +
dense O +
ciliature O +
and O +
the O +
neokinetal O +
waves O +
resemble O +
kahliellid O +
hypotrichs O -
. O -

However O -
, O +
the O +
de O +
novo O +
origin O +
of O +
anlage O +
1 O +
and O +
the O +
molecular O +
analyses O +
show O +
convincingly O +
that O +
Cotterillia U-Species +
belongs O +
to O +
the O +
Gonostomatidae O +
Small O +
and O +
Lynn O -
, O +
1985 O -
, O +
for O +
which O +
an O +
improved O +
diagnosis O +
is O +
provided O -
. O -

Thus O -
, O +
neokinetal O +
waves O +
originated O +
several O +
times O +
independently O -
. O -

The O +
molecular O +
differences O +
between O +
Trachelostyla O -
, O +
Gonostomum O -
, O +
and O +
Cotterillia U-Species +
are O +
small O +
(= O -
< O +
5 O -
% O -
) O +
compared O +
to O +
their O +
distinct O +
morphologies O +
and O +
ontogeneses O -
, O +
suggesting O +
that O +
the O +
18S O +
rDNA O +
underestimates O +
generic O +
diversity O -
. O -

Our O +
study O +
emphasizes O +
the O +
need O +
of O +
combined O +
morphological O -
, O +
ontogenetic O -
, O +
and O +
molecular O +
investigations O +
to O +
unravel O +
the O +
complex O +
phylogeny O +
and O +
evolution O +
of O +
hypotrich O +
ciliates O -
. O +

The O +
first O +
vitellogenin O +
receptor O +
from O +
a O +
Lepidopteran O +
insect O -
: O +
molecular O +
characterization O -
, O +
expression O +
patterns O +
and O +
RNA O +
interference O +
analysis O -
. O +

The O +
vitellogenin O +
receptor O +
( O -
VgR O -
) O +
belongs O +
to O +
the O +
low O -
- O -
density O +
lipoprotein O +
receptor O +
( O -
LDLR O -
) O +
superfamily O -
, O +
and O +
is O +
an O +
important O +
carrier O +
for O +
the O +
uptake O +
of O +
vitellogenin O +
( O -
Vg O -
) O +
into O +
developing O +
oocytes O +
of O +
all O +
oviparous O +
species O -
. O -

The O +
first O +
full O -
- O -
length O +
message O +
for O +
a O +
VgR O +
from O +
a O +
Lepidopteran O +
insect O +
was O +
cloned O +
and O +
sequenced O +
from O +
the O +
ovary O +
of O +
Spodoptera B-Species +
litura I-Species +
Fabricius L-Species +
( O -
GenBank O +
accession O +
no. O +
GU983858 O -
) O -
. O -

The O +
coding O +
region O +
consisted O +
of O +
5370 O +
bp O +
flanked O +
by O +
a O +
49 O +
bp O +
5'-untranslated O +
region O +
( O -
UTR O -
) O +
and O +
a O +
177 O +
bp O +
3'-UTR O -
, O +
which O +
encoded O +
a O +
1798-residue O +
protein O +
with O +
a O +
predicted O +
molecular O +
weight O +
( O -
MW O -
) O +
of O +
201.69 O +
kDa O -
. O -

S. B-Species +
litura L-Species +
VgR O +
( O -
SlVgR O -
) O -
comprised O +
two O +
ligand O +
binding O +
sites O +
with O +
four O +
LDLR O +
class O +
A O +
repeats O +
in O +
the O +
first O +
domain O +
and O +
seven O +
in O +
the O +
second O +
domain O -
, O +
an O +
epidermal O +
growth O +
factor O -
- O -
like O +
domain O +
containing O +
an O +
LDLR O +
class O +
B O +
repeat O +
and O +
a O +
YWXD O +
motif O -
, O +
a O +
transmembrane O +
domain O +
and O +
a O +
cytoplasmic O +
domain O -
. O -

A O +
phylogenetic O +
relationship O +
placed O +
SlVgR O +
as O +
a O +
separate O +
group O +
from O +
the O +
other O +
insects O -
. O -

SlVgR O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
was O +
specifically O +
expressed O +
in O +
the O +
ovarian O +
tissues O -
. O -

The O +
developmental O +
expression O +
patterns O +
showed O +
that O +
VgR O +
mRNA O +
was O +
first O +
transcribed O +
in O +
6 O -
( O -
th O -
) O +
day O +
female O +
pupae O +
and O +
the O +
maximum O +
level O +
of O +
VgR O +
mRNA O +
appeared O +
in O +
36-h O -
- O -
old O +
adults O -
. O -

Immunoblot O +
analysis O +
detected O +
an O +
ovary O -
- O -
specific O +
VgR O +
protein O +
with O +
a O +
MW O +
of O +
-200 O +
kDa O -
, O +
whose O +
development O +
profiles O +
were O +
consistent O +
with O +
VgR O +
mRNA O +
expression O +
patterns O -
. O -

RNA O +
inteference O +
( O -
RNAi O -
) O +
specifically O +
disrupted O +
the O +
VgR O +
gene O +
by O +
injection O +
of O +
3 O +
or O +
5 O +
mug O +
VgR O +
double O -
- O -
stranded O +
RNA O +
per O +
insect O +
in O +
4 O -
( O -
th O -
) O +
or O +
6 O -
( O -
th O -
) O +
day O +
pupae O -
. O -

RNAi O +
of O +
SlVgR O +
led O +
to O +
a O +
phenotype O +
characterized O +
by O +
high O +
Vg O +
accumulation O +
in O +
the O +
haemolymph O -
, O +
low O +
Vg O +
deposition O +
in O +
the O +
ovary O +
and O +
the O +
failure O +
of O +
insect O +
spawning O -
. O -

These O +
results O +
mean O +
that O +
VgR O +
is O +
critical O +
for O +
binding O +
Vg O +
and O +
transporting O +
it O +
into O +
the O +
oocytes O +
of O +
the O +
insect O +
ovary O -
, O +
thus O +
playing O +
an O +
important O +
role O +
in O +
insect O +
reproduction O -
. O +

Rapid O +
detection O +
of O +
Newcastle B-Species +
disease I-Species +
virus L-Species +
replication O +
in O +
embryonated O +
chicken U-Species +
eggs O +
using O +
quantitative O +
real O +
time O +
polymerase O +
chain O +
reaction O -
. O +

Newcastle B-Species +
disease I-Species +
virus L-Species +
( O -
NDV U-Species -
) O -
, O +
an O +
avian O +
paramyxovirus O -
, O +
is O +
an O +
economically O +
important O +
disease O +
of O +
poultry U-Species +
globally O -
. O -

Rapid O +
methods O +
to O +
detect O +
and O +
differentiate O +
the O +
virus O +
are O +
important O +
to O +
curtail O +
the O +
spread O +
of O +
this O +
virus O -
. O -

Nucleic O +
acid O +
based O +
detection O +
methods O +
are O +
routinely O +
employed O +
for O +
diagnosis O +
that O +
suffer O +
from O +
the O +
disadvantage O +
of O +
failure O +
to O +
discriminate O +
viable O +
virus O +
and O +
non O -
- O -
infectious O +
genome O -
. O -

However O -
, O +
virus O +
isolation O +
remains O +
the O +
gold O +
standard O +
for O +
diagnosis O +
of O +
field O +
outbreaks O -
. O -

The O +
sensitivity O +
of O +
virus O +
isolation O +
was O +
combined O +
with O +
nucleic O +
acid O +
based O +
detection O +
methods O +
so O +
that O +
the O +
time O +
taken O +
for O +
confirmatory O +
diagnosis O +
could O +
be O +
considerably O +
reduced O +
while O +
increasing O +
sensitivity O -
. O -

Quantitative O +
real O +
time O +
reverse O +
transcription O +
polymerase O +
chain O +
reaction O +
( O -
qRT O -
- O -
PCR O -
) O +
and O +
conventional O +
RT O -
- O -
PCR O +
techniques O +
were O +
compared O +
for O +
the O +
detection O +
of O +
NDV U-Species +
genome O +
replication O +
in O +
9 O -
- O -
11-day O -
- O -
old O +
embryonated O +
chicken U-Species +
eggs O +
( O -
ECE O -
) O +
using O +
the O +
nucleoprotein O +
( O -
NP O -
) O +
gene O +
of O +
the O +
virus O +
as O +
a O +
target O -
. O -

The O +
results O +
suggest O +
that O +
at O +
least O +
two O +
to O +
fourfold O +
increase O +
in O +
cycle O +
threshold O +
( O -
C O -
( O -
t O -
) O -
) O +
values O +
over O +
the O +
baseline O +
C O -
( O -
t O -
) O +
value O +
of O +
samples O +
lacking O +
infectious O +
virus O -
, O +
would O +
indicate O +
live O +
NDV U-Species +
replication O -
. O -

The O +
limit O +
of O +
detection O +
of O +
NDV U-Species +
replication O +
using O +
qRT O -
- O -
PCR O +
was O +
1x10 O -
( O -
4.0 O -
) O +
mean O +
embryo O +
infective O +
doses O +
( O -
EID O -
( O -
50 O -
) O -
) O -
. O -

The O +
earliest O +
time O +
point O +
when O +
live O +
virus O +
replication O +
was O +
detectable O +
by O +
qRT O -
- O -
PCR O +
or O +
RT O -
- O -
PCR O +
was O +
30h O +
post O -
- O -
inoculation O +
in O +
ECE O -
. O +

Ste50 O +
adaptor O +
protein O +
governs O +
sexual O +
differentiation O +
of O +
Cryptococcus B-Species +
neoformans L-Species +
via O +
the O +
pheromone O -
- O -
response O +
MAPK O +
signaling O +
pathway O -
. O +

The O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
pathways O +
control O +
diverse O +
cellular O +
functions O +
in O +
pathogenic O +
fungi O -
, O +
including O +
sexual O +
differentiation O -
, O +
stress O +
response O -
, O +
and O +
maintenance O +
of O +
cell O +
wall O +
integrity O -
. O -

Here O +
we O +
characterized O +
a O +
Cryptococcus B-Species +
neoformans L-Species +
gene O -
, O +
which O +
is O +
homologous O +
to O +
the O +
yeast O +
Ste50 O +
that O +
is O +
known O +
to O +
play O +
an O +
important O +
role O +
in O +
mating O +
pheromone O +
response O +
and O +
stress O +
response O +
as O +
an O +
adaptor O +
protein O +
to O +
the O +
Ste11 O +
MAPK O +
kinase O +
kinase O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species -
. O -

The O +
C. B-Species +
neoformans L-Species +
Ste50 O +
was O +
not O +
involved O +
in O +
any O +
of O +
the O +
stress O +
responses O +
or O +
virulence O +
factor O +
production O +
( O -
capsule O +
and O +
melanin O -
) O +
that O +
are O +
controlled O +
by O +
the O +
HOG O +
and O +
Ras O -
/ O -
cAMP O +
signaling O +
pathways O -
. O -

However O -
, O +
Ste50 O +
was O +
required O +
for O +
mating O +
in O +
both O +
serotype U-Species +
A O +
and O +
serotype B-Species +
D I-Species +
C. I-Species +
neoformans L-Species +
strains O -
. O -

The O +
ste50Delta O +
mutant O +
was O +
completely O +
defective O +
in O +
cell O -
- O -
cell O +
fusion O +
and O +
mating O +
pheromone O +
production O -
. O -

Double O +
mutation O +
of O +
the O +
STE50 O +
gene O +
blocked O +
increased O +
production O +
of O +
pheromone O +
and O +
the O +
hyper O -
- O -
filamentation O +
phenotype O +
of O +
cells O +
deleted O +
of O +
the O +
CRG1 O +
gene O -
, O +
which O +
encodes O +
the O +
RGS O +
protein O +
that O +
negatively O +
regulates O +
pheromone O +
responsive O +
G O -
- O -
protein O +
signaling O +
via O +
the O +
MAPK O +
pathway O -
. O -

Regardless O +
of O +
the O +
presence O +
of O +
the O +
basidiomycota O -
- O -
specific O +
SH3 O +
domains O +
of O +
Ste50 O +
that O +
are O +
known O +
to O +
be O +
required O +
for O +
full O +
virulence O +
of O +
Ustilago B-Species +
maydis L-Species -
, O +
Ste50 O +
was O +
dispensable O +
for O +
virulence O +
of O +
C. B-Species +
neoformans L-Species +
in O +
a O +
murine O +
model O +
of O +
cryptococcosis O -
. O -

In O +
conclusion O -
, O +
the O +
Ste50 O +
adaptor O +
protein O +
controls O +
sexual O +
differentiation O +
of O +
C. B-Species +
neoformans L-Species +
via O +
the O +
pheromone O -
- O -
responsive O +
MAPK O +
pathway O +
but O +
is O +
not O +
required O +
for O +
virulence O -
. O +

The O +
role O +
of O +
abscisic O +
acid O +
and O +
water O +
stress O +
in O +
root O +
herbivore O -
- O -
induced O +
leaf O +
resistance O -
. O +

* O +
Herbivore O -
- O -
induced O +
systemic O +
resistance O +
occurs O +
in O +
many O +
plants O +
and O +
is O +
commonly O +
assumed O +
to O +
be O +
adaptive O -
. O -

The O +
mechanisms O +
triggered O +
by O +
leaf O -
- O -
herbivores O +
that O +
lead O +
to O +
systemic O +
resistance O +
are O +
largely O +
understood O -
, O +
but O +
it O +
remains O +
unknown O +
how O +
and O +
why O +
root O +
herbivory O +
also O +
increases O +
resistance O +
in O +
leaves O -
. O -

* O +
To O +
resolve O +
this O -
, O +
we O +
investigated O +
the O +
mechanism O +
by O +
which O +
the O +
root O +
herbivore O +
Diabrotica B-Species +
virgifera L-Species +
induces O +
resistance O +
against O +
lepidopteran O +
herbivores O +
in O +
the O +
leaves O +
of O +
Zea B-Species +
mays L-Species -
. O -

* O +
Diabrotica B-Species +
virgifera L-Species +
infested O +
plants O +
suffered O +
less O +
aboveground O +
herbivory O +
in O +
the O +
field O +
and O +
showed O +
reduced O +
growth O +
of O +
Spodoptera B-Species +
littoralis L-Species +
caterpillars O +
in O +
the O +
laboratory O -
. O -

Root O +
herbivory O +
did O +
not O +
lead O +
to O +
a O +
jasmonate O -
- O -
dependent O +
response O +
in O +
the O +
leaves O -
, O +
but O +
specifically O +
triggered O +
water O +
loss O +
and O +
abscisic O +
acid O +
( O -
ABA O -
) O +
accumulation O -
. O -

The O +
induction O +
of O +
ABA O +
by O +
itself O +
was O +
partly O +
responsible O +
for O +
the O +
induction O +
of O +
leaf O +
defenses O -
, O +
but O +
not O +
for O +
the O +
resistance O +
against O +
S. B-Species +
littoralis L-Species -
. O -

Root O -
- O -
herbivore O +
induced O +
hydraulic O +
changes O +
in O +
the O +
leaves O -
, O +
however O -
, O +
were O +
crucial O +
for O +
the O +
increase O +
in O +
insect O +
resistance O -
. O -

* O +
We O +
conclude O +
that O +
the O +
induced O +
leaf O +
resistance O +
after O +
root O +
feeding O +
is O +
the O +
result O +
of O +
hydraulic O +
changes O -
, O +
which O +
reduce O +
the O +
quality O +
of O +
the O +
leaves O +
for O +
chewing O +
herbivores O -
. O -

This O +
finding O +
calls O +
into O +
question O +
whether O +
root O -
- O -
herbivore O +
induced O +
leaf O -
- O -
resistance O +
is O +
an O +
evolved O +
response O -
. O +

Introduced O +
brown B-Species +
trout L-Species +
alter O +
native O +
acanthocephalan O +
infections O +
in O +
native O +
fish O -
. O -

1 O -
. O -

Native O +
parasite O +
acquisition O +
provides O +
introduced O +
species O +
with O +
the O +
potential O +
to O +
modify O +
native O +
host O -
- O -
parasite O +
dynamics O +
by O +
acting O +
as O +
parasite O +
reservoirs O +
( O -
with O +
the O +
' O -
spillback O -
' O +
of O +
infection O +
increasing O +
the O +
parasite O +
burdens O +
of O +
native O +
hosts O -
) O +
or O +
sinks O +
( O -
with O +
the O +
' O -
dilution O -
' O +
of O +
infection O +
decreasing O +
the O +
parasite O +
burdens O +
of O +
native O +
hosts O -
) O +
of O +
infection O -
. O -

2 O -
. O -

In O +
New O +
Zealand O -
, O +
negative O +
correlations O +
between O +
the O +
presence O +
of O +
introduced O +
brown B-Species +
trout L-Species +
( O -
Salmo B-Species +
trutta L-Species -
) O +
and O +
native O +
parasite O +
burdens O +
of O +
the O +
native O +
roundhead B-Species +
galaxias L-Species +
( O -
Galaxias B-Species +
anomalus L-Species -
) O +
have O +
been O +
observed O -
, O +
suggesting O +
that O +
parasite O +
dilution O +
is O +
occurring O -
. O -

3 O -
. O -

We O +
used O +
a O +
multiple O -
- O -
scale O +
approach O +
combining O +
field O +
observations O -
, O +
experimental O +
infections O +
and O +
dynamic O +
population O +
modelling O +
to O +
investigate O +
whether O +
native O +
Acanthocephalus O +
galaxii O +
acquisition O +
by O +
brown B-Species +
trout L-Species +
alters O +
host O -
- O -
parasite O +
dynamics O +
in O +
native O +
roundhead B-Species +
galaxias L-Species -
. O -

4 O -
. O +
Field O +
observations O +
demonstrated O +
higher O +
infection O +
intensity O +
in O +
introduced O +
trout O +
than O +
in O +
native B-Species +
galaxias L-Species -
, O +
but O +
only O +
small O -
, O +
immature O +
A. O +
galaxii O +
were O +
present O +
in O +
trout U-Species -
. O -

Experimental O +
infections O +
also O +
demonstrated O +
that O +
A. O +
galaxii O +
does O +
not O +
mature O +
in O +
trout U-Species -
, O +
although O +
parasite O +
establishment O +
and O +
initial O +
growth O +
were O +
similar O +
in O +
the O +
two O +
hosts O -
. O -

Taken O +
together O -
, O +
these O +
results O +
support O +
the O +
hypothesis O +
that O +
trout U-Species +
may O +
serve O +
as O +
an O +
infection O +
sink O +
for O +
the O +
native O +
parasite O -
. O -

5 O -
. O -

However O -
, O +
dynamic O +
population O +
modelling O +
predicts O +
that O +
A. O +
galaxii O +
infections O +
in O +
native O +
galaxias U-Species +
should O +
at O +
most O +
only O +
be O +
slightly O +
reduced O +
by O +
dilution O +
in O +
the O +
presence O +
of O +
trout U-Species -
. O -

Rather O -
, O +
model O +
exploration O +
indicates O +
parasite O +
densities O +
in O +
galaxias U-Species +
are O +
highly O +
sensitive O +
to O +
galaxias U-Species +
predation O +
on O +
infected O +
amphipods O -
, O +
and O +
to O +
relative O +
abundances O +
of O +
galaxias U-Species +
and O +
trout U-Species -
. O -

Hence O -
, O +
trout U-Species +
presence O +
may O +
instead O +
reduce O +
parasite O +
burdens O +
in O +
galaxias U-Species +
by O +
either O +
reducing O +
galaxias U-Species +
density O +
or O +
by O +
altering O +
galaxias U-Species +
foraging O +
behaviour O -
. O +

Host O +
phylogeography O +
and O +
beta O +
diversity O +
in O +
avian O +
haemosporidian O +
( O -
Plasmodiidae O -
) O +
assemblages O +
of O +
the O +
Lesser O +
Antilles O -
. O +

1 O -
. O -

We O +
estimated O +
the O +
correlation O +
between O +
host O +
phylogeographical O +
structure O +
and O +
beta O +
diversity O +
of O +
avian O +
haemosporidian O +
assemblages O +
of O +
passerine O +
birds O +
to O +
determine O +
the O +
degree O +
to O +
which O +
parasite O +
communities O +
change O +
with O +
host O +
evolution O -
, O +
expressed O +
as O +
genetic O +
divergence O +
between O +
island O +
populations O -
, O +
and O +
we O +
investigated O +
whether O +
differences O +
among O +
islands O +
in O +
the O +
haemosporidia O +
of O +
a O +
particular O +
host O +
species O +
reflect O +
beta O +
diversity O +
in O +
the O +
entire O +
parasite O +
assemblage O -
, O +
beta O +
diversity O +
in O +
vectors O -
, O +
turnover O +
of O +
bird O +
species O +
and/or O +
geographical O +
distance O -
. O -

2 O -
. O -

We O +
used O +
Mantel O +
tests O +
to O +
assess O +
the O +
significance O +
of O +
partial O +
correlations O +
between O +
host O +
nucleotide O +
difference O +
( O -
based O +
on O +
cytochrome O +
b O -
) O +
and O +
haemosporidian O +
( O -
Haemoproteus O +
spp O -
. O +
and O +
Plasmodium O +
spp O -
. O -
) O +
mitochondrial O +
lineage O +
beta O +
diversity O +
within O +
a O +
given O +
host O +
species O +
and O +
between O +
Plasmodium O +
mitochondrial O +
lineage O +
beta O +
diversity O +
and O +
mosquito O +
and O +
bird O +
species O +
beta O +
diversity O +
( O -
or O +
turnover O -
) O -
. O -

Three O +
abundant O +
and O +
widespread O +
host O +
species O +
( O -
Tiaris B-Species +
bicolor L-Species -
, O +
Coereba B-Species +
flaveola L-Species +
and O +
Loxigilla B-Species +
noctis L-Species -
/ O -
barbadensis U-Species -
) O +
were O +
included O +
in O +
the O +
study O -
. O -

Haemosporidian O +
lineage O +
beta O +
diversity O +
among O +
nine O +
islands O +
was O +
assessed O +
using O +
the O +
Chao O -
- O -
Jaccard O -
, O +
Chao O -
- O -
Sorensen O +
and O +
Morisita O -
- O -
Horn O +
indices O +
of O +
community O +
similarity O -
. O -

Beta O +
diversity O +
indices O +
of O +
mosquito O +
species O +
and O +
turnover O +
of O +
bird O +
species O +
were O +
calculated O +
from O +
data O +
in O +
published O +
records O +
and O +
field O +
guides O -
. O -

3 O -
. O -

In O +
Loxigilla O +
spp O -
. O -
, O +
we O +
found O +
a O +
positive O +
correlation O +
with O +
geographical O +
distance O +
and O +
an O +
unexpected O +
negative O +
correlation O +
between O +
haemosporidian O +
beta O +
diversity O +
and O +
host O +
genetic O +
distance O -
. O -

Tiaris B-Species +
bicolor L-Species +
exhibited O +
a O +
significant O +
positive O +
correlation O +
between O +
haemosporidian O +
beta O +
diversity O +
and O +
beta O +
diversity O +
within O +
the O +
entire O +
parasite O +
assemblage O -
. O -

We O +
did O +
not O +
find O +
significant O +
correlations O +
between O +
parasite O +
beta O +
diversity O +
and O +
mosquito O +
beta O +
diversity O +
or O +
bird O +
species O +
turnover O -
. O -

4 O -
. O -

Host O +
phylogeographical O +
structure O +
does O +
not O +
appear O +
to O +
drive O +
within O -
- O -
host O +
beta O +
diversity O +
of O +
haemosporidian O +
lineages O -
. O -

Instead O -
, O +
the O +
array O +
of O +
parasites O +
on O +
one O +
host O +
can O +
reflect O +
the O +
haemosporidian O +
assemblage O +
on O +
other O +
hosts O -
. O +

Analysis O +
of O +
expressed O +
sequence O +
tags O +
from O +
Maize B-Species +
mosaic I-Species +
rhabdovirus L-Species -
- O -
infected O +
gut O +
tissues O +
of O +
Peregrinus B-Species +
maidis L-Species +
reveals O +
the O +
presence O +
of O +
key O +
components O +
of O +
insect O +
innate O +
immunity O -
. O +

The O +
corn B-Species +
planthopper L-Species -
, O +
Peregrinus B-Species +
maidis L-Species -
, O +
causes O +
direct O +
feeding O +
damage O +
to O +
plants O +
and O +
transmits O +
Maize B-Species +
mosaic I-Species +
rhabdovirus I-Species +
( I-Species -
MMV L-Species -
) O +
in O +
a O +
persistent O -
- O -
propagative O +
manner O -
. O -

MMV U-Species +
must O +
cross O +
several O +
insect O +
tissue O +
layers O +
for O +
successful O +
transmission O +
to O +
occur O -
, O +
and O +
the O +
gut O +
serves O +
as O +
an O +
important O +
barrier O +
for O +
rhabdovirus O +
transmission O -
. O -

In O +
order O +
to O +
facilitate O +
the O +
identification O +
of O +
proteins O +
that O +
may O +
interact O +
with O +
MMV U-Species +
either O +
by O +
facilitating O +
acquisition O +
or O +
responding O +
to O +
virus O +
infection O -
, O +
we O +
generated O +
and O +
analysed O +
the O +
gut O +
transcriptome O +
of O +
P. B-Species +
maidis L-Species -
. O -

From O +
two O +
normalized O +
cDNA O +
libraries O -
, O +
we O +
generated O +
a O +
P. B-Species +
maidis L-Species +
gut O +
transcriptome O +
composed O +
of O +
20,771 O +
expressed O +
sequence O +
tags O +
( O -
ESTs O -
) O -
. O -

Assembly O +
of O +
the O +
sequences O +
yielded O +
1860 O +
contigs O +
and O +
14,032 O +
singletons O -
, O +
and O +
biological O +
roles O +
were O +
assigned O +
to O +
5793 O +
( O -
36 O -
% O -
) O -
. O -

Comparison O +
of O +
P. B-Species +
maidis L-Species +
ESTs O +
with O +
other O +
insect O +
amino O +
acid O +
sequences O +
revealed O +
that O +
P. B-Species +
maidis L-Species +
shares O +
greatest O +
sequence O +
similarity O +
with O +
another O +
hemipteran O -
, O +
the O +
brown B-Species +
planthopper L-Species +
Nilaparvata B-Species +
lugens L-Species -
. O -

We O +
identified O +
202 O +
P. B-Species +
maidis L-Species +
transcripts O +
with O +
putative O +
homology O +
to O +
proteins O +
associated O +
with O +
insect O +
innate O +
immunity O -
, O +
including O +
those O +
implicated O +
in O +
the O +
Toll O -
, O +
Imd O -
, O +
JAK O -
/ O -
STAT O -
, O +
Jnk O +
and O +
the O +
small O -
- O -
interfering O +
RNA O -
- O -
mediated O +
pathways O -
. O -

Sequence O +
comparisons O +
between O +
our O +
P. B-Species +
maidis L-Species +
gut O +
EST O +
collection O +
and O +
the O +
currently O +
available O +
National O +
Center O +
for O +
Biotechnology O +
Information O +
EST O +
database O +
collection O +
for O +
Ni B-Species -
. L-Species -

lugens U-Species +
revealed O +
that O +
a O +
pathogen O +
recognition O +
receptor O +
in O +
the O +
Imd O +
pathway O -
, O +
peptidoglycan O +
recognition O +
protein O -
- O -
long O +
class O +
( O -
PGRP O -
- O -
LC O -
) O -
, O +
is O +
present O +
in O +
these O +
two O +
members O +
of O +
the O +
family O +
Delphacidae O -
; O +
however O -
, O +
these O +
recognition O +
receptors O +
are O +
lacking O +
in O +
the O +
model O +
hemipteran O +
Acyrthosiphon B-Species +
pisum L-Species -
. O -

In O +
addition O -
, O +
we O +
identified O +
sequences O +
in O +
the O +
P. B-Species +
maidis L-Species +
gut O +
transcriptome O +
that O +
share O +
significant O +
amino O +
acid O +
sequence O +
similarities O +
with O +
the O +
rhabdovirus O +
receptor O +
molecule O -
, O +
acetylcholine O +
receptor O +
( O -
AChR O -
) O -
, O +
found O +
in O +
other O +
hosts O -
. O -

This O +
EST O +
analysis O +
sheds O +
new O +
light O +
on O +
immune O +
response O +
pathways O +
in O +
hemipteran O +
guts O +
that O +
will O +
be O +
useful O +
for O +
further O +
dissecting O +
innate O +
defence O +
response O +
pathways O +
to O +
rhabdovirus O +
infection O -
. O +

Proteomics O +
of O +
cryoprotective O +
dehydration O +
in O +
Megaphorura B-Species +
arctica L-Species +
Tullberg O +
1876 O +
( O -
Onychiuridae O -
: O +
Collembola O -
) O -
. O +

The O +
Arctic B-Species +
springtail L-Species -
, O +
Megaphorura B-Species +
arctica L-Species +
Tullberg O +
1876 O +
( O -
Onychiuridae O -
: O +
Collembola O -
) O -
, O +
is O +
one O +
of O +
the O +
few O +
organisms O +
known O +
to O +
survive O +
the O +
extreme O +
stresses O +
of O +
its O +
environment O +
by O +
using O +
cryoprotective O +
dehydration O -
. O -

We O +
have O +
undertaken O +
a O +
proteomics O +
study O +
comparing O +
M. B-Species +
arctica L-Species -
, O +
acclimated O +
at O +
-2 O -
^ O -
0C O -
, O +
the O +
temperature O +
known O +
to O +
induce O +
the O +
production O +
of O +
the O +
anhydroprotectant O +
trehalose O +
in O +
this O +
species O -
, O +
and O +
-6 O -
^ O -
0C O -
, O +
the O +
temperature O +
at O +
which O +
trehalose O +
expression O +
plateaus O -
, O +
against O +
control O +
animals O +
acclimated O +
at O +
+ O -
5 O -
^ O -
0C O -
. O -

Using O +
difference O +
gel O +
electrophoresis O -
, O +
and O +
liquid O +
chromatography O +
tandem O +
mass O +
spectrometry O -
, O +
we O +
identified O +
three O +
categories O +
of O +
differentially O +
expressed O +
proteins O +
with O +
specific O +
functions O -
, O +
up O -
- O -
regulated O +
in O +
both O +
the O +
-2 O -
^ O -
0C O +
and O +
-6 O -
^ O -
0C O +
animals O -
, O +
that O +
were O +
involved O +
in O +
metabolism O -
, O +
membrane O +
transport O +
and O +
protein O +
folding O -
. O -

Proteins O +
involved O +
in O +
cytoskeleton O +
organisation O +
were O +
only O +
up O -
- O -
regulated O +
in O +
the O +
-6 O -
^ O -
0C O +
animals O -
. O +

Genetic O +
analysis O +
of O +
the O +
xenobiotic O +
resistance O -
- O -
associated O +
ABC O +
gene O +
subfamilies O +
of O +
the O +
Lepidoptera O -
. O +

Some O +
ATP O -
- O -
binding O +
cassette O +
( O -
ABC O -
) O +
transporters O +
of O +
subfamilies O +
B O -
, O +
C O +
and O +
G O +
confer O +
resistance O +
to O +
xenobiotics O +
including O +
insecticides O -
. O -

We O +
identified O +
genes O +
of O +
these O +
subfamilies O +
expressed O +
by O +
the O +
lepidopterans O +
Trichoplusia B-Species +
ni L-Species +
and O +
Bombyx B-Species +
mori L-Species -
. O -

The O +
B. B-Species +
mori L-Species +
genome O +
includes O +
eight O -
, O +
six O +
and O +
13 O +
ABC O -
- O -
B O -
, O +
-C O +
and O +
-G O +
genes O -
, O +
respectively O -
, O +
which O +
encode O +
P O -
- O -
glycoprotein O -
, O +
multidrug O +
resistance O +
protein O -
, O +
MRP O -
, O +
and O +
breast O +
cancer O +
resistance O +
protein O -
, O +
BCRP O -
, O +
homologues O -
. O -

Among O +
the O +
ABC O -
- O -
C O +
and O +
-G O +
subfamilies O -
, O +
gene O +
duplication O +
contributes O +
to O +
protein O +
diversity O -
. O -

We O +
have O +
identified O +
three O +
ABC O -
- O -
B O +
and O +
two O +
ABC O -
- O -
C O +
T. B-Species +
ni L-Species +
genes O -
. O -

Analyses O +
of O +
the O +
T. B-Species +
ni L-Species +
MRP O +
( O -
TrnMRP O -
) O +
revealed O +
unique O +
features O -
, O +
including O +
the O +
potential O +
for O +
TrnMRP4 O +
hyperglycosylation O +
and O +
the O +
alternative O +
splicing O +
of O +
TrnMRP1 O -
. O -

Taken O +
together O -
, O +
these O +
attributes O +
of O +
moth O +
multidrug O +
resistance O -
- O -
associated O +
ABCs O +
may O +
confer O +
distinct O +
functional O +
capacities O +
to O +
xenobiotic O +
efflux O -
. O +

El O +
Nino O +
in O +
the O +
warm O +
tropics O -
: O +
local O +
sea O +
temperature O +
predicts O +
breeding O +
parameters O +
and O +
growth O +
of O +
blue B-Species -
- I-Species -
footed I-Species +
boobies L-Species -
. O +

1 O -
. O -

There O +
is O +
increasing O +
interest O +
in O +
the O +
impacts O +
of O +
El O +
Nino O +
Southern O +
Oscillation O +
( O -
ENSO O -
) O +
on O +
reproduction O +
of O +
apical O +
predators O +
such O +
as O +
seabirds O +
and O +
marine O +
mammals O -
. O -

Long O -
- O -
term O +
studies O +
documenting O +
ENSO O +
effects O +
on O +
reproduction O +
of O +
seabirds O +
in O +
the O +
warm O +
tropics O +
are O +
scarce O -
, O +
and O +
differential O +
sensitivity O +
of O +
breeding O +
parameters O +
to O +
ENSO O +
has O +
rarely O +
been O +
explored O -
. O -

2 O -
. O +
Analysis O +
of O +
18 O +
years O +
of O +
breeding O +
data O +
from O +
a O +
colony O +
of O +
the O +
blue B-Species -
- I-Species -
footed I-Species +
booby L-Species +
Sula B-Species +
nebouxii L-Species +
( O -
Milne O -
- O -
Edwards O -
) O +
showed O +
a O +
delay O +
in O +
onset O +
of O +
breeding O +
when O +
the O +
global O +
Southern O +
Oscillation O +
Index O +
was O +
negative O -
; O +
each O +
unit O +
of O +
the O +
atmospheric O +
pressure O +
differential O +
( O -
hPa O -
) O +
across O +
the O +
Pacific O +
Ocean O +
meant O +
a O +
delay O +
of O +
7 O +
days O -
. O -

3 O -
. O +
ENSO O +
conditions O +
also O +
produced O +
declines O +
in O +
breeding O +
participation O -
, O +
clutch O +
size O -
, O +
brood O +
size O -
, O +
hatching O +
success O +
and O +
fledging O +
success O -
, O +
especially O +
when O +
surface O +
waters O +
surrounding O +
the O +
colony O +
were O +
warmer O +
during O +
winter O +
and O +
spring O -
. O -

Each O +
additional O +
degree O +
( O -
^0C O -
) O +
of O +
water O +
temperature O +
produced O +
a O +
reduction O +
of O +
0.45 O +
fledglings O +
per O +
nest O -
. O -

Different O +
breeding O +
parameters O +
were O +
sensitive O +
to O +
ENSO O +
indices O +
in O +
different O +
blocks O +
of O +
months O -
. O -

4 O -
. O -

Warming O +
of O +
local O +
waters O +
during O +
the O +
winter O +
was O +
associated O +
with O +
decline O +
in O +
ocean O +
productivity O +
in O +
the O +
current O +
year O +
and O +
the O +
following O +
year O -
, O +
consistent O +
with O +
ENSO O +
impacts O +
on O +
breeding O +
parameters O +
being O +
mediated O +
by O +
effects O +
on O +
local O +
productivity O +
and O +
prey O +
availability O -
. O -

However O -
, O +
there O +
was O +
no O +
evidence O +
of O +
lagged O +
effects O +
of O +
ENSO O +
on O +
any O +
breeding O +
parameter O -
. O -

5 O -
. O -

Comparison O +
of O +
5 O +
years O +
revealed O +
that O +
when O +
local O +
surface O +
waters O +
were O +
warm O -
, O +
chicks O +
grew O +
more O +
slowly O -
, O +
but O +
no O +
effects O +
of O +
ENSO O +
on O +
weight O +
and O +
size O +
of O +
eggs O +
were O +
evident O +
in O +
data O +
of O +
9 O +
and O +
7 O +
years O -
, O +
respectively O -
. O -

6 O -
. O -

Our O +
findings O +
extend O +
evidence O +
of O +
impacts O +
of O +
ENSO O +
on O +
seabird O +
reproduction O +
to O +
the O +
eastern O +
tropical O +
Pacific O +
and O +
indicate O +
that O +
several O +
breeding O +
parameters O +
of O +
blue B-Species -
- I-Species -
footed I-Species +
boobies L-Species +
( O -
but O +
not O +
egg O +
size O -
) O +
are O +
affected O +
in O +
the O +
short O +
term O +
by O +
ENSO O +
conditions O -
, O +
particularly O +
by O +
local O +
anomalies O +
in O +
sea O +
surface O +
temperature O +
associated O +
with O +
decline O +
in O +
ocean O +
productivity O -
. O +

Amnibacterium B-Species +
kyonggiense I-Species +
gen. I-Species +
nov. I-Species -
, I-Species +
sp. I-Species +
nov. L-Species -
, O +
a O +
new O +
member O +
of O +
the O +
family O +
Microbacteriaceae O -
. O +

A O +
Gram O -
- O -
positive O -
, O +
non O -
- O -
motile O +
bacterium O -
, O +
designated O +
KSL51201 B-Species -
- I-Species -
037 I-Species -
( I-Species -
T L-Species -
) O -
, O +
was O +
isolated O +
from O +
Anyang O +
stream O -
, O +
Republic O +
of O +
Korea O -
, O +
and O +
was O +
characterized O +
using O +
a O +
polyphasic O +
taxonomic O +
approach O -
. O -

Comparative O +
16S O +
rRNA O +
gene O +
sequence O +
analysis O +
showed O +
that O +
strain O +
KSL51201 B-Species -
- I-Species -
037 I-Species -
( I-Species -
T L-Species -
) O +
belonged O +
to O +
the O +
family O +
Microbacteriaceae O +
of O +
the O +
class O +
Actinobacteria O +
and O +
exhibited O +
96.9 O +
% O +
gene O +
sequence O +
similarity O +
to O +
Labedella B-Species +
gwakjiensis I-Species +
KSW2 I-Species -
- I-Species -
17 I-Species -
( I-Species -
T L-Species -
) O -
, O +
96.0 O +
% O +
to O +
Leifsonia B-Species +
ginsengi I-Species +
wged11 I-Species -
( I-Species -
T L-Species -
) O +
and O +
95.9 O +
% O +
to O +
Microterricola B-Species +
viridarii I-Species +
KV-677 I-Species -
( I-Species -
T L-Species -
) O -
. O -

The O +
G+C O +
content O +
of O +
the O +
genomic O +
DNA O +
was O +
72.7 O +
mol% O -
. O -

Strain O +
KSL51201 B-Species -
- I-Species -
037 I-Species -
( I-Species -
T L-Species -
) O +
had O +
l-2,4-diaminobutyric O +
acid O +
as O +
the O +
diagnostic O +
cell O -
- O -
wall O +
diamino O +
acid O -
, O +
MK-11 O +
and O +
MK-12 O +
as O +
the O +
major O +
menaquinones O -
, O +
anteiso O -
- O -
C O -
( O -
15 O +
: O +
0 O -
) O +
( O -
47.8 O +
% O -
) O +
and O +
iso O -
- O -
C O -
( O -
16 O +
: O +
0 O -
) O +
( O -
24.0 O +
% O -
) O +
as O +
the O +
major O +
fatty O +
acids O +
and O +
phosphatidylglycerol O +
and O +
three O +
unknown O +
phospholipids O +
as O +
the O +
major O +
polar O +
lipids O -
. O -

On O +
the O +
basis O +
of O +
phenotypic O +
and O +
genotypic O +
properties O +
and O +
phylogenetic O +
distinctiveness O -
, O +
it O +
is O +
suggested O +
that O +
strain O +
KSL51201 B-Species -
- I-Species -
037 I-Species -
( I-Species -
T L-Species -
) O +
represents O +
a O +
novel O +
species O +
of O +
a O +
new O +
genus O +
in O +
the O +
family O +
Microbacteriaceae O +
for O +
which O +
the O +
name O +
Amnibacterium B-Species +
kyonggiense I-Species +
gen. I-Species +
nov. I-Species -
, I-Species +
sp. I-Species +
nov. L-Species +
is O +
proposed O -
. O -

The O +
type O +
strain O +
of O +
the O +
type O +
species O +
is O +
KSL51201 B-Species -
- I-Species -
037 I-Species -
( I-Species -
T L-Species -
) O +
( O -
= O -
KEMC O +
51201 O -
- O -
037 O -
( O -
T O -
) O -
=JCM O +
16463 O -
( O -
T O -
) O -
) O -
. O +

Nocardioides B-Species +
caricicola I-Species +
sp. I-Species +
nov. L-Species -
, O +
an O +
endophytic O +
bacterium O +
isolated O +
from O +
a O +
halophyte O -
, O +
Carex B-Species +
scabrifolia L-Species +
Steud O -
. O +

A O +
Gram O -
- O -
staining O -
- O -
positive O -
, O +
coccoid O +
to O +
rod O -
- O -
shaped O +
bacterium O -
, O +
designated O +
strain O +
YC6903 U-Species -
( O -
T O -
) O -
, O +
was O +
isolated O +
from O +
a O +
halophytic O +
plant O +
( O -
Carex B-Species +
scabrifolia L-Species +
Steud O -
. O -
) O +
collected O +
from O +
sand O +
dunes O +
at O +
Namhae O +
Island O -
, O +
Korea O -
, O +
and O +
its O +
taxonomic O +
position O +
was O +
investigated O +
by O +
using O +
a O +
polyphasic O +
approach O -
. O -

Strain O +
YC6903 U-Species -
( O -
T O -
) O +
grew O +
optimally O +
at O +
30 O +
^0C O +
and O +
at O +
pH O +
8.0 O -
. O -

Phylogenetic O +
analysis O +
based O +
on O +
16S O +
rRNA O +
gene O +
sequences O +
indicated O +
that O +
strain O +
YC6903 U-Species -
( O -
T O -
) O +
belongs O +
to O +
the O +
genus O +
Nocardioides O +
in O +
the O +
family O +
Nocardioidaceae O -
. O -

Strain O +
YC6903 U-Species -
( O -
T O -
) O +
was O +
related O +
most O +
closely O +
to O +
Nocardioides B-Species +
pyridinolyticus I-Species +
OS4 L-Species -
( O -
T O -
) O +
( O -
97.0 O +
% O +
16S O +
rRNA O +
gene O +
sequence O +
similarity O -
) O -
, O +
Nocardioides B-Species +
dokdonensis I-Species +
FR1436 L-Species -
( O -
T O -
) O +
( O -
96.6 O +
% O -
) O -
, O +
Nocardioides B-Species +
aquiterrae I-Species +
GW-9 L-Species -
( O -
T O -
) O +
( O -
96.6 O +
% O -
) O +
and O +
Nocardioides B-Species +
hankookensis I-Species +
DS-30 L-Species -
( O -
T O -
) O +
( O -
96.6 O +
% O -
) O -
. O -

The O +
cell O -
- O -
wall O +
peptidoglycan O +
contained O +
LL O -
- O -
diaminopimelic O +
acid O +
and O +
MK-8 O -
( O -
H O -
( O -
4 O -
) O -
) O +
was O +
the O +
major O +
respiratory O +
quinone O -
. O -

The O +
mean O +
( O -
+ O -
/-SD O -
) O +
level O +
of O +
DNA O -
- O -
DNA O +
relatedness O +
between O +
strain O +
YC6903 U-Species -
( O -
T O -
) O +
and O +
N. B-Species +
pyridinolyticus I-Species +
OS4 L-Species -
( O -
T O -
) O +
was O +
53.5+ O -
/ O -
-5.5 O +
% O -
. O -

The O +
predominant O +
cellular O +
fatty O +
acid O +
of O +
strain O +
YC6903 U-Species -
( O -
T O -
) O +
was O +
iso O -
- O -
C O -
( O -
16 O +
: O +
0 O -
) O +
( O -
28.9 O +
% O -
) O -
. O -

The O +
DNA O +
G+C O +
content O +
was O +
71.7 O +
mol% O -
. O -

Phenotypic O -
, O +
phylogenetic O +
and O +
chemotaxonomic O +
data O +
indicated O +
that O +
strain O +
YC6903 U-Species -
( O -
T O -
) O +
represents O +
a O +
novel O +
species O +
of O +
the O +
genus O +
Nocardioides O -
, O +
for O +
which O +
the O +
name O +
Nocardioides B-Species +
caricicola I-Species +
sp. I-Species +
nov. L-Species +
is O +
proposed O -
. O -

The O +
type O +
strain O +
is O +
YC6903 U-Species -
( O -
T O -
) O +
( O -
= O -
KACC O +
13778 O -
( O -
T O -
) O +
= O -
DSM O +
22177 O -
( O -
T O -
) O -
) O -
. O +

Staphylococcus B-Species +
aureus L-Species +
ClpC O +
divergently O +
regulates O +
capsule O +
via O +
sae O +
and O +
codY O +
in O +
strain O +
newman U-Species +
but O +
activates O +
capsule O +
via O +
codY O +
in O +
strain O +
UAMS-1 U-Species +
and O +
in O +
strain O +
Newman U-Species +
with O +
repaired O +
saeS. O +
ClpC O +
is O +
an O +
ATPase O +
chaperone O +
found O +
in O +
most O +
Gram O -
- O -
positive O +
low O -
- O -
GC O +
bacteria O -
. O -

It O +
has O +
been O +
recently O +
reported O +
that O +
ClpC O +
affected O +
virulence O +
gene O +
expression O +
in O +
Staphylococcus B-Species +
aureus L-Species -
. O -

Here O +
we O +
report O +
that O +
ClpC O +
regulates O +
transcription O +
of O +
the O +
cap O +
operon O +
and O +
accumulation O +
of O +
capsule O -
, O +
a O +
major O +
virulence O +
factor O +
for O +
S. B-Species +
aureus L-Species -
. O -

As O +
virulence O +
genes O +
are O +
regulated O +
by O +
a O +
complex O +
regulatory O +
network O +
in O +
S. B-Species +
aureus L-Species -
, O +
we O +
have O +
used O +
capsule O +
as O +
a O +
model O +
to O +
understand O +
this O +
regulation O -
. O -

By O +
microarray O +
analyses O +
of O +
strain O +
Newman U-Species -
, O +
we O +
found O +
that O +
ClpC O +
strongly O +
activates O +
transcription O +
of O +
the O +
sae O +
operon O -
, O +
whose O +
products O +
are O +
known O +
to O +
negatively O +
regulate O +
capsule O +
synthesis O +
in O +
this O +
strain O -
. O -

Further O +
studies O +
indicated O +
that O +
ClpC O +
repressed O +
capsule O +
production O +
by O +
activating O +
the O +
sae O +
operon O +
in O +
strain O +
Newman U-Species -
. O -

Interestingly O -
, O +
the O +
clpC O +
gene O +
cloned O +
into O +
a O +
multiple O -
- O -
copy O +
plasmid O +
vector O +
exhibited O +
an O +
activation O +
phenotype O -
, O +
suggesting O +
that O +
ClpC O +
overexpression O +
has O +
a O +
net O +
positive O +
effect O -
. O -

In O +
the O +
absence O +
of O +
sae O +
function O -
, O +
by O +
either O +
deletion O +
or O +
correction O +
of O +
a O +
native O +
mutation O +
within O +
saeS O -
, O +
we O +
found O +
that O +
ClpC O +
had O +
a O +
positive O +
effect O +
on O +
capsule O +
production O -
. O -

Indeed O -
, O +
in O +
the O +
UAMS-1 U-Species +
strain O -
, O +
which O +
does O +
not O +
have O +
the O +
saeS O +
mutation O -
, O +
ClpC O +
functioned O +
as O +
an O +
activator O +
of O +
capsule O +
production O -
. O -

Our O +
microarray O +
analyses O +
of O +
strain O +
Newman U-Species +
also O +
revealed O +
that O +
CodY O -
, O +
a O +
repressor O +
of O +
capsule O +
production O -
, O +
was O +
repressed O +
by O +
ClpC. O +
Using O +
genetic O +
approaches O -
, O +
we O +
showed O +
that O +
CodY O +
functioned O +
downstream O +
of O +
ClpC O -
, O +
leading O +
to O +
capsule O +
activation O +
both O +
in O +
Newman U-Species +
and O +
in O +
UAMS-1 U-Species -
. O -

Thus O -
, O +
ClpC O +
functions O +
in O +
two O +
opposite O +
pathways O +
in O +
capsule O +
regulation O +
in O +
strain O +
Newman U-Species +
but O +
functions O +
as O +
a O +
positive O +
activator O +
in O +
strain O +
UAMS-1 U-Species -
. O +

Characterizing O +
the O +
role O +
of O +
the O +
microtubule O +
binding O +
protein O +
Bim1 O +
in O +
Cryptococcus B-Species +
neoformans L-Species -
. O +

During O +
sexual O +
development O +
the O +
human U-Species +
fungal O +
pathogen O +
Cryptococcus B-Species +
neoformans L-Species +
undergoes O +
a O +
developmental O +
transition O +
from O +
yeast O -
- O -
form O +
growth O +
to O +
filamentous O +
growth O -
. O -

This O +
transition O +
requires O +
cellular O +
restructuring O +
to O +
form O +
a O +
filamentous O +
dikaryon O -
. O -

Dikaryotic O +
growth O +
also O +
requires O +
tightly O +
controlled O +
nuclear O +
migration O +
to O +
ensure O +
faithful O +
replication O +
and O +
dissemination O +
of O +
genetic O +
material O +
to O +
spore O +
progeny O -
. O -

Although O +
the O +
gross O +
morphological O +
changes O +
that O +
take O +
place O +
during O +
dikaryotic O +
growth O +
are O +
largely O +
known O -
, O +
the O +
molecular O +
underpinnings O +
that O +
control O +
this O +
process O +
are O +
uncharacterized O -
. O -

Here O +
we O +
identify O +
and O +
characterize O +
a O +
C. B-Species +
neoformans L-Species +
homolog O +
of O +
the O +
Saccharomyces B-Species +
cerevisiae L-Species +
BIM1 O +
gene O -
, O +
and O +
establish O +
the O +
importance O +
of O +
BIM1 O +
for O +
proper O +
filamentous O +
growth O +
of O +
C. B-Species +
neoformans L-Species -
. O -

Deletion O +
of O +
BIM1 O +
leads O +
to O +
truncated O +
sexual O +
development O +
filaments O -
, O +
a O +
severe O +
defect O +
in O +
diploid O +
formation O -
, O +
and O +
a O +
block O +
in O +
monokaryotic O +
fruiting O -
. O -

Our O +
findings O +
lead O +
to O +
a O +
model O +
consistent O +
with O +
a O +
critical O +
role O +
for O +
BIM1 O +
in O +
both O +
filament O +
integrity O +
and O +
nuclear O +
congression O +
that O +
is O +
mediated O +
through O +
the O +
microtubule O +
cytoskeleton O -
. O +

Improved O +
nitrogen O +
nutrition O +
enhances O +
root O +
uptake O -
, O +
root O -
- O -
to O -
- O -
shoot O +
translocation O +
and O +
remobilization O +
of O +
zinc O +
( O -
( O -
65 O -
) O +
Zn O -
) O +
in O +
wheat O -
. O +

This O +
study O +
focussed O +
on O +
the O +
effect O +
of O +
increasing O +
nitrogen O +
( O -
N O -
) O +
supply O +
on O +
root O +
uptake O +
and O +
root O -
- O -
to O -
- O -
shoot O +
translocation O +
of O +
zinc O +
( O -
Zn O -
) O +
as O +
well O +
as O +
retranslocation O +
of O +
foliar O -
- O -
applied O +
Zn O +
in O +
durum B-Species +
wheat L-Species +
( O -
Triticum B-Species +
durum L-Species -
) O -
. O -

Nutrient O +
solution O +
experiments O +
were O +
conducted O +
to O +
examine O +
the O +
root O +
uptake O +
and O +
root O -
- O -
to O -
- O -
shoot O +
translocation O +
of O +
( O -
65 O -
) O +
Zn O +
in O +
seedlings O +
precultured O +
with O +
different O +
N O +
supplies O -
. O -

In O +
additional O +
experiments O -
, O +
the O +
effect O +
of O +
varied O +
N O +
nutrition O +
on O +
retranslocation O +
of O +
foliar O -
- O -
applied O +
( O -
65 O -
) O +
Zn O +
was O +
tested O +
at O +
both O +
the O +
vegetative O +
and O +
generative O +
stages O -
. O -

When O +
N O +
supply O +
was O +
increased O -
, O +
the O +
( O -
65 O -
) O +
Zn O +
uptake O +
by O +
roots O +
was O +
enhanced O +
by O +
up O +
to O +
threefold O +
and O +
the O +
( O -
65 O -
) O +
Zn O +
translocation O +
from O +
roots O +
to O +
shoots O +
increased O +
by O +
up O +
to O +
eightfold O -
, O +
while O +
plant O +
growth O +
was O +
affected O +
to O +
a O +
much O +
smaller O +
degree O -
. O -

Retranslocation O +
of O +
( O -
65 O -
) O +
Zn O +
from O +
old O +
into O +
young O +
leaves O +
and O +
from O +
flag O +
leaves O +
to O +
grains O +
also O +
showed O +
marked O +
positive O +
responses O +
to O +
increasing O +
N O +
supply O -
. O -

The O +
results O +
demonstrate O +
that O +
the O +
N O -
- O -
nutritional O +
status O +
of O +
wheat O +
affects O +
major O +
steps O +
in O +
the O +
route O +
of O +
Zn O +
from O +
the O +
growth O +
medium O +
to O +
the O +
grain O -
, O +
including O +
its O +
uptake O -
, O +
xylem O +
transport O +
and O +
remobilization O +
via O +
phloem O -
. O -

Thus O -
, O +
N O +
is O +
a O +
critical O +
player O +
in O +
the O +
uptake O +
and O +
accumulation O +
of O +
Zn O +
in O +
plants O -
, O +
which O +
deserves O +
special O +
attention O +
in O +
biofortification O +
of O +
food O +
crops O +
with O +
Zn O -
. O +

UreA O -
, O +
the O +
major O +
urea O -
/ O -
H+ O +
symporter O +
in O +
Aspergillus B-Species +
nidulans L-Species -
. O +

We O +
report O +
here O +
the O +
characterization O +
of O +
UreA O -
, O +
a O +
high O -
- O -
affinity O +
urea O -
/ O -
H+ O +
symporter O +
of O +
Aspergillus B-Species +
nidulans L-Species -
. O -

The O +
deletion O +
of O +
the O +
encoding O +
gene O +
abolishes O +
urea O +
transport O +
at O +
low O +
substrate O +
concentrations O -
, O +
suggesting O +
that O +
in O +
these O +
conditions O +
UreA O +
is O +
the O +
sole O +
transport O +
system O +
specific O +
for O +
urea O +
in O +
A. B-Species +
nidulans L-Species -
. O -

The O +
ureA O +
gene O +
is O +
not O +
inducible O +
by O +
urea O +
or O +
its O +
precursors O -
, O +
but O +
responds O +
to O +
nitrogen O +
metabolite O +
repression O -
, O +
necessitating O +
for O +
its O +
expression O +
the O +
AreA O +
GATA O +
factor O -
. O -

In O +
contrast O +
to O +
what O +
was O +
observed O +
for O +
other O +
transporters O +
in O +
A. B-Species +
nidulans L-Species -
, O +
repression O +
by O +
ammonium O +
is O +
also O +
operative O +
during O +
the O +
isotropic O +
growth O +
phase O -
. O -

The O +
activity O +
of O +
UreA O +
is O +
down O -
- O -
regulated O +
post O -
- O -
translationally O +
by O +
ammonium O -
- O -
promoted O +
endocytosis O -
. O -

A O +
number O +
of O +
homologues O +
of O +
UreA O +
have O +
been O +
identified O +
in O +
A. B-Species +
nidulans L-Species +
and O +
other O +
Aspergilli O -
, O +
which O +
cluster O +
in O +
four O +
groups O -
, O +
two O +
of O +
which O +
contain O +
the O +
urea O +
transporters O +
characterized O +
so O +
far O +
in O +
fungi O +
and O +
plants O -
. O -

This O +
phylogeny O +
may O +
have O +
arisen O +
by O +
gene O +
duplication O +
events O -
, O +
giving O +
place O +
to O +
putative O +
transport O +
proteins O +
that O +
could O +
have O +
acquired O +
novel O -
, O +
still O +
unidentified O +
functions O -
. O +

Linking O +
disease O +
and O +
community O +
ecology O +
through O +
behavioural O +
indicators O -
: O +
immunochallenge O +
of O +
white B-Species -
- I-Species -
footed I-Species +
mice L-Species +
and O +
its O +
ecological O +
impacts O -
. O +

1 O -
. O -

Pathogens O +
and O +
immune O +
challenges O +
can O +
induce O +
changes O +
in O +
host O +
phenotype O +
in O +
ways O +
that O +
indirectly O +
impact O +
important O +
community O +
interactions O -
, O +
including O +
those O +
that O +
affect O +
host O -
- O -
pathogen O +
interactions O -
. O -

2 O -
. O -

To O +
explore O +
host O +
behavioural O +
response O +
to O +
immune O +
challenge O -
, O +
we O +
exposed O +
wild O +
white B-Species -
- I-Species -
footed I-Species +
mice L-Species +
( O -
Peromyscus B-Species +
leucopus L-Species -
) O +
to O +
an O +
immunogen O +
from O +
an O +
endemic O -
, O +
zoonotic O +
pathogen O -
, O +
the O +
spirochete O +
Borrelia B-Species +
burgdorferi L-Species -
. O -

White B-Species -
- I-Species -
footed I-Species +
mice L-Species +
are O +
a O +
major O +
reservoir O +
host O +
of O +
Lyme O +
disease O +
( O -
LD O -
) O +
spirochetes O +
in O +
northeastern O +
USA O +
and O +
an O +
abundant O +
member O +
of O +
forest O +
communities O -
. O -

The O +
activity O +
patterns O -
, O +
foraging O +
behaviour O -
, O +
and O +
space O +
use O +
of O +
white B-Species -
- I-Species -
footed I-Species +
mice L-Species +
have O +
implications O +
for O +
population O +
growth O +
rates O +
of O +
community O +
members O +
upon O +
which O +
mice O +
incidentally O +
prey O +
( O -
i.e. O +
gypsy O +
moths O +
and O +
native O +
thrushes O -
) O -
, O +
as O +
well O +
as O +
potentially O +
determining O +
host O -
- O -
vector O +
encounter O +
rates O +
and O +
human U-Species +
risk O +
of O +
LD O -
. O -

3 O -
. O -

Immunochallenge O +
led O +
to O +
specific O +
humoral O +
( O -
antibody O -
) O +
and O +
cellular O +
( O -
i.e. O +
elevated O +
neutrophils O +
and O +
eosinophils O -
) O +
immune O +
responses O -
, O +
supporting O +
use O +
of O +
the O +
immunogen O +
as O +
a O +
surrogate O +
for O +
pathogenic O +
infection O -
. O -

4 O -
. O -

Immunochallenged O +
mice O +
had O +
reduced O +
wheel O -
- O -
running O +
activity O +
early O +
in O +
the O +
night O +
when O +
measured O +
in O +
the O +
lab O -
. O -

However O -
, O +
mouse O +
activity O -
, O +
as O +
measured O +
by O +
track O +
plates O +
in O +
natural O +
field O +
experiments O -
, O +
did O +
not O +
differ O +
between O +
mice O +
exposed O +
to O +
the O +
immunogen O +
and O +
unexposed O +
mice O -
. O -

5 O -
. O -

Foraging O +
behaviour O +
of O +
wild O +
mice O +
in O +
the O +
field O +
- O +
assessed O +
with O +
giving O -
- O -
up O +
densities O +
of O +
seed O +
at O +
artificial O +
feeding O +
stations O +
- O +
was O +
affected O +
by O +
exposure O +
to O +
the O +
immunogen O -
. O -

Whereas O +
immunochallenge O +
did O +
not O +
influence O +
whether O +
foraging O +
mice O +
gained O +
information O +
on O +
patch O +
quality O +
while O +
foraging O -
, O +
it O +
led O +
to O +
reductions O +
in O +
predator O +
avoidance O +
during O +
foraging O -
, O +
suggesting O +
that O +
the O +
proportion O +
of O +
space O +
used O +
by O +
foraging O +
mice O +
may O +
be O +
greater O +
as O +
a O +
result O +
of O +
immunochallenge O -
. O -

This O +
increased O +
space O +
use O +
is O +
predicted O +
to O +
increase O +
encounter O +
rates O +
with O +
patchily O +
distributed O +
LD O +
vectors O +
( O -
ticks O -
) O +
and O +
with O +
incidental O +
prey O +
items O -
. O -

6 O -
. O -

Thus O -
, O +
immunochallenge O +
in O +
white B-Species -
- I-Species -
footed I-Species +
mice L-Species -
, O +
and O +
potentially O +
pathogenic O +
infection O -
, O +
have O +
the O +
potential O +
to O +
indirectly O +
impact O +
community O +
interactions O -
, O +
including O +
those O +
important O +
for O +
pathogen O +
transmission O -
. O +

Regulation O +
and O +
function O +
of O +
Escherichia B-Species +
coli L-Species +
sugar O +
efflux O +
transporter O +
A O +
( O -
SetA O -
) O +
during O +
glucose O -
- O -
phosphate O +
stress O -
. O +

Accumulation O +
of O +
certain O +
nonmetabolizable O +
sugar O -
- O -
phosphates O +
( O -
including O +
alpha O -
- O -
methyl O +
glucoside-6-phosphate O -
) O +
in O +
Escherichia O +
coli O +
is O +
growth O +
inhibitory O +
and O +
elicits O +
the O +
glucose O -
- O -
phosphate O +
stress O +
response O -
. O -

The O +
transcription O +
factor O +
SgrR O +
activates O +
transcription O +
of O +
the O +
small O +
RNA O +
SgrS O +
under O +
stress O +
conditions O -
. O -

SgrS O +
represses O +
translation O +
of O +
mRNAs O +
encoding O +
sugar O +
transporters O -
. O -

The O +
sgrR O +
and O +
sgrS O +
genes O +
are O +
located O +
directly O +
upstream O +
of O +
setA O -
, O +
and O +
this O +
gene O +
organization O +
is O +
conserved O +
in O +
numerous O +
enteric O +
species O -
, O +
prompting O +
the O +
hypothesis O +
that O +
SetA O +
contributes O +
to O +
the O +
glucose O -
- O -
phosphate O +
stress O +
response O -
. O -

SetA O +
is O +
a O +
proton O +
motive O +
force O -
- O -
driven O +
efflux O +
pump O +
capable O +
of O +
transporting O +
various O +
sugars O +
and O +
sugar O +
analogs O +
in O +
vitro O -
. O -

This O +
study O +
demonstrates O +
that O +
setA O +
expression O +
is O +
induced O +
in O +
response O +
to O +
glucose O -
- O -
phosphate O +
stress O -
, O +
and O +
this O +
requires O +
SgrR. O +
Under O +
stress O +
conditions O -
, O +
setA O +
is O +
cotranscribed O +
with O +
sgrS O +
from O +
the O +
sgrS O +
promoter O -
. O -

A O +
setA O +
mutant O +
exhibits O +
a O +
growth O +
defect O +
under O +
stress O +
conditions O +
that O +
can O +
be O +
complemented O +
by O +
setA O +
in O +
trans O -
, O +
suggesting O +
that O +
SetA O +
contributes O +
to O +
the O +
optimal O +
cellular O +
recovery O +
from O +
stress O -
. O -

Despite O +
previous O +
in O +
vitro O +
evidence O +
that O +
SetA O +
can O +
promote O +
efflux O +
of O +
the O +
stress O -
- O -
causing O +
glucose O +
analog O +
alpha O -
- O -
methyl O +
glucoside O -
, O +
in O +
vivo O +
data O +
in O +
this O +
study O +
indicate O +
that O +
SetA O +
is O +
not O +
the O +
major O +
efflux O +
pump O +
responsible O +
for O +
removal O +
of O +
alpha O -
- O -
methyl O +
glucoside O +
under O +
stress O +
conditions O -
. O +

Functional O +
analysis O +
of O +
molybdopterin O +
biosynthesis O +
in O +
mycobacteria O +
identifies O +
a O +
fused O +
molybdopterin O +
synthase O +
in O +
Mycobacterium B-Species +
tuberculosis L-Species -
. O +

Most O +
mycobacterial O +
species O +
possess O +
a O +
full O +
complement O +
of O +
genes O +
for O +
the O +
biosynthesis O +
of O +
molybdenum O +
cofactor O +
( O -
MoCo O -
) O -
. O -

However O -
, O +
a O +
distinguishing O +
feature O +
of O +
members O +
of O +
the O +
Mycobacterium O +
tuberculosis O +
complex O +
is O +
their O +
possession O +
of O +
multiple O +
homologs O +
associated O +
with O +
the O +
first O +
two O +
steps O +
of O +
the O +
MoCo O +
biosynthetic O +
pathway O -
. O -

A O +
mutant O +
of O +
M. B-Species +
tuberculosis L-Species +
lacking O +
the O +
moaA1-moaD1 O +
gene O +
cluster O +
and O +
a O +
derivative O +
in O +
which O +
moaD2 O +
was O +
also O +
deleted O +
were O +
significantly O +
impaired O +
for O +
growth O +
in O +
media O +
containing O +
nitrate O +
as O +
a O +
sole O +
nitrogen O +
source O -
, O +
indicating O +
a O +
reduced O +
availability O +
of O +
MoCo O +
to O +
support O +
the O +
assimilatory O +
function O +
of O +
the O +
MoCo O -
- O -
dependent O +
nitrate O +
reductase O -
, O +
NarGHI O -
. O -

However O -
, O +
the O +
double O +
mutant O +
displayed O +
residual O +
respiratory O +
nitrate O +
reductase O +
activity O -
, O +
suggesting O +
that O +
it O +
retains O +
the O +
capacity O +
to O +
produce O +
MoCo O -
. O -

The O +
M. B-Species +
tuberculosis L-Species +
moaD O +
and O +
moaE O +
homologs O +
were O +
further O +
analyzed O +
by O +
expressing O +
these O +
genes O +
in O +
mutant O +
strains O +
of O +
M. B-Species +
smegmatis L-Species +
that O +
lacked O +
one O +
or O +
both O +
of O +
the O +
sole O +
molybdopterin O +
( O -
MPT O -
) O +
synthase O -
- O -
encoding O +
genes O -
, O +
moaD2 O +
and O +
moaE2 O -
, O +
and O +
were O +
unable O +
to O +
grow O +
on O +
nitrate O -
, O +
presumably O +
as O +
a O +
result O +
of O +
the O +
loss O +
of O +
MoCo O -
- O -
dependent O +
nitrate O +
assimilatory O +
activity O -
. O -

Expression O +
of O +
M. B-Species +
tuberculosis L-Species +
moaD2 O +
in O +
the O +
M. B-Species +
smegmatis L-Species +
moaD2 O +
mutant O +
and O +
of O +
M. B-Species +
tuberculosis L-Species +
moaE1 O +
or O +
moaE2 O +
in O +
the O +
M. B-Species +
smegmatis L-Species +
moaE2 O +
mutant O +
restored O +
nitrate O +
assimilation O -
, O +
confirming O +
the O +
functionality O +
of O +
these O +
genes O +
in O +
MPT O +
synthesis O -
. O -

Expression O +
of O +
M. B-Species +
tuberculosis L-Species +
moaX O +
also O +
restored O +
MoCo O +
biosynthesis O +
in O +
M. B-Species +
smegmatis L-Species +
mutants O +
lacking O +
moaD2 O -
, O +
moaE2 O -
, O +
or O +
both O -
, O +
thus O +
identifying O +
MoaX O +
as O +
a O +
fused O +
MPT O +
synthase O -
. O -

By O +
implicating O +
multiple O +
synthase O -
- O -
encoding O +
homologs O +
in O +
MoCo O +
biosynthesis O -
, O +
these O +
results O +
suggest O +
that O +
important O +
cellular O +
functions O +
may O +
be O +
served O +
by O +
their O +
expansion O +
in O +
M. B-Species +
tuberculosis L-Species -
. O -

The O +
nodulation O +
of O +
alfalfa O +
by O +
the O +
acid O -
- O -
tolerant O +
Rhizobium B-Species +
sp. I-Species +
strain I-Species +
LPU83 L-Species +
does O +
not O +
require O +
sulfated O +
forms O +
of O +
lipochitooligosaccharide O +
nodulation O +
signals O -
. O +

The O +
induction O +
of O +
root O +
nodules O +
by O +
the O +
majority O +
of O +
rhizobia O +
has O +
a O +
strict O +
requirement O +
for O +
the O +
secretion O +
of O +
symbiosis O -
- O -
specific O +
lipochitooligosaccharides O +
( O -
nodulation O +
factors O +
[ O -
NFs O -
] O -
) O -
. O -

The O +
nature O +
of O +
the O +
chemical O +
substitution O +
on O +
the O +
NFs O +
depends O +
on O +
the O +
particular O +
rhizobium O +
and O +
contributes O +
to O +
the O +
host O +
specificity O +
imparted O +
by O +
the O +
NFs O -
. O -

We O +
present O +
here O +
a O +
description O +
of O +
the O +
genetic O +
organization O +
of O +
the O +
nod O +
gene O +
cluster O +
and O +
the O +
characterization O +
of O +
the O +
chemical O +
structure O +
of O +
the O +
NFs O +
associated O +
with O +
the O +
broad O -
- O -
host O -
- O -
range O +
Rhizobium B-Species +
sp. I-Species +
strain I-Species +
LPU83 L-Species -
, O +
a O +
bacterium O +
capable O +
of O +
nodulating O +
at O +
least O +
alfalfa U-Species -
, O +
bean O -
, O +
and O +
Leucena B-Species +
leucocephala L-Species -
. O -

The O +
nod O +
gene O +
cluster O +
was O +
located O +
on O +
the O +
plasmid O +
pLPU83b O -
. O -

The O +
organization O +
of O +
the O +
cluster O +
showed O +
synteny O +
with O +
those O +
of O +
the O +
alfalfa U-Species -
- O -
nodulating O +
rhizobia O -
, O +
Sinorhizobium B-Species +
meliloti L-Species +
and O +
Sinorhizobium B-Species +
medicae L-Species -
. O -

Interestingly O -
, O +
the O +
strongest O +
sequence O +
similarity O +
observed O +
was O +
between O +
the O +
partial O +
nod O +
sequences O +
of O +
Rhizobium B-Species +
mongolense I-Species +
USDA I-Species +
1844 L-Species +
and O +
the O +
corresponding O +
LPU83 U-Species +
nod O +
genes O +
sequences O -
. O -

The O +
phylogenetic O +
analysis O +
of O +
the O +
intergenic O +
region O +
nodEG O +
positions O +
strain O +
LPU83 U-Species +
and O +
the O +
type O +
strain O +
R. B-Species +
mongolense I-Species +
1844 L-Species +
in O +
the O +
same O +
branch O -
, O +
which O +
indicates O +
that O +
Rhizobium B-Species +
sp. I-Species +
strain I-Species +
LPU83 L-Species +
might O +
represent O +
an O +
early O +
alfalfa U-Species -
- O -
nodulating O +
genotype O -
. O -

The O +
NF O +
chemical O +
structures O +
obtained O +
for O +
the O +
wild O -
- O -
type O +
strain O +
consist O +
of O +
a O +
trimeric O -
, O +
tetrameric O -
, O +
and O +
pentameric O +
chitin O +
backbone O +
that O +
shares O +
some O +
substitutions O +
with O +
both O +
alfalfa- O +
and O +
bean O -
- O -
nodulating O +
rhizobia O -
. O -

Remarkably O -
, O +
while O +
in O +
strain O +
LPU83 U-Species +
most O +
of O +
the O +
NFs O +
were O +
sulfated O +
in O +
their O +
reducing O +
terminal O +
residue O -
, O +
none O +
of O +
the O +
NFs O +
isolated O +
from O +
the O +
nodH O +
mutant O +
LPU83-H U-Species +
were O +
sulfated O -
. O -

The O +
evidence O +
obtained O +
supports O +
the O +
notion O +
that O +
the O +
sulfate O +
decoration O +
of O +
NFs O +
in O +
LPU83 U-Species +
is O +
not O +
necessary O +
for O +
alfalfa U-Species +
nodulation O -
. O +

Plantazolicin O -
, O +
a O +
novel O +
microcin O +
B17 O -
/ O -
streptolysin O +
S O -
- O -
like O +
natural O +
product O +
from O +
Bacillus B-Species +
amyloliquefaciens I-Species +
FZB42 L-Species -
. O +

Here O +
we O +
report O +
on O +
a O +
novel O +
thiazole O -
/ O -
oxazole O -
- O -
modified O +
microcin O +
( O -
TOMM O -
) O +
from O +
Bacillus B-Species +
amyloliquefaciens I-Species +
FZB42 L-Species -
, O +
a O +
Gram O -
- O -
positive O +
soil O +
bacterium O -
. O -

This O +
organism O +
is O +
well O +
known O +
for O +
stimulating O +
plant O +
growth O +
and O +
biosynthesizing O +
complex O +
small O +
molecules O +
that O +
suppress O +
the O +
growth O +
of O +
bacterial O +
and O +
fungal O +
plant O +
pathogens O -
. O -

Like O +
microcin O +
B17 O +
and O +
streptolysin O +
S O -
, O +
the O +
TOMM O +
from O +
B. B-Species +
amyloliquefaciens I-Species +
FZB42 L-Species +
undergoes O +
extensive O +
posttranslational O +
modification O +
to O +
become O +
a O +
bioactive O +
natural O +
product O -
. O -

Our O +
data O +
show O +
that O +
the O +
modified O +
peptide O +
bears O +
a O +
molecular O +
mass O +
of O +
1,335 O +
Da O +
and O +
displays O +
antibacterial O +
activity O +
toward O +
closely O +
related O +
Gram O -
- O -
positive O +
bacteria O -
. O -

A O +
cluster O +
of O +
12 O +
genes O +
that O +
covers O +
-10 O +
kb O +
is O +
essential O +
for O +
the O +
production O -
, O +
modification O -
, O +
export O -
, O +
and O +
self O -
- O -
immunity O +
of O +
this O +
natural O +
product O -
. O -

We O +
have O +
named O +
this O +
compound O +
plantazolicin O +
( O -
PZN O -
) O -
, O +
based O +
on O +
the O +
association O +
of O +
several O +
producing O +
organisms O +
with O +
plants O +
and O +
the O +
incorporation O +
of O +
azole O +
heterocycles O -
, O +
which O +
derive O +
from O +
Cys O -
, O +
Ser O -
, O +
and O +
Thr O +
residues O +
of O +
the O +
precursor O +
peptide O -
. O +

Mismatch O +
repair O +
modulation O +
of O +
MutY O +
activity O +
drives O +
Bacillus B-Species +
subtilis L-Species +
stationary O -
- O -
phase O +
mutagenesis O -
. O +

Stress O -
- O -
promoted O +
mutations O +
that O +
occur O +
in O +
nondividing O +
cells O +
( O -
adaptive O +
mutations O -
) O +
have O +
been O +
implicated O +
strongly O +
in O +
causing O +
genetic O +
variability O +
as O +
well O +
as O +
in O +
species O +
survival O +
and O +
evolutionary O +
processes O -
. O -

Oxidative O +
stress O -
- O -
induced O +
DNA O +
damage O +
has O +
been O +
associated O +
with O +
generation O +
of O +
adaptive O +
His O -
( O -
+ O -
) O +
and O +
Met O -
( O -
+ O -
) O +
but O +
not O +
Leu O -
( O -
+ O -
) O +
revertants O +
in O +
strain B-Species +
Bacillus I-Species +
subtilis I-Species +
YB955 I-Species +
( I-Species -
hisC952 I-Species +
metB5 I-Species +
leuC427 L-Species -
) O -
. O -

Here O +
we O +
report O +
that O +
an O +
interplay O +
between O +
MutY O +
and O +
MutSL O +
( O -
mismatch O +
repair O +
system O +
[ O -
MMR O -
] O -
) O +
plays O +
a O +
pivotal O +
role O +
in O +
the O +
production O +
of O +
adaptive O +
Leu O -
( O -
+ O -
) O +
revertants O -
. O -

Essentially O -
, O +
the O +
genetic O +
disruption O +
of O +
MutY O +
dramatically O +
reduced O +
the O +
reversion O +
frequency O +
to O +
the O +
leu O +
allele O +
in O +
this O +
model O +
system O -
. O -

Moreover O -
, O +
the O +
increased O +
rate O +
of O +
adaptive O +
Leu O -
( O -
+ O -
) O +
revertants O +
produced O +
by O +
a O +
MutSL B-Species +
knockout I-Species +
strain L-Species +
was O +
significantly O +
diminished O +
following O +
mutY O +
disruption O -
. O -

Interestingly O -
, O +
although O +
the O +
expression O +
of O +
mutY O +
took O +
place O +
during O +
growth O +
and O +
stationary O +
phase O +
and O +
was O +
not O +
under O +
the O +
control O +
of O +
RecA O -
, O +
PerR O -
, O +
or O +
sigma O -
( O -
B O -
) O -
, O +
a O +
null O +
mutation O +
in O +
the O +
mutSL O +
operon O +
increased O +
the O +
expression O +
of O +
mutY O +
several O +
times O -
. O -

Thus O -
, O +
in O +
starved O +
cells O -
, O +
saturation O +
of O +
the O +
MMR O +
system O +
may O +
induce O +
the O +
expression O +
of O +
mutY O -
, O +
disturbing O +
the O +
balance O +
between O +
MutY O +
and O +
MMR O +
proteins O +
and O +
aiding O +
in O +
the O +
production O +
of O +
types O +
of O +
mutations O +
detected O +
by O +
reversion O +
to O +
leucine O +
prototrophy O -
. O -

In O +
conclusion O -
, O +
our O +
results O +
support O +
the O +
idea O +
that O +
MMR O +
regulation O +
of O +
the O +
mutagenic O -
/ O -
antimutagenic O +
properties O +
of O +
MutY O +
promotes O +
stationary O -
- O -
phase O +
mutagenesis O +
in O +
B. B-Species +
subtilis L-Species +
cells O -
. O +

Structural O +
and O +
functional O +
analysis O +
of O +
the O +
type O +
III O +
secretion O +
system O +
from O +
Pseudomonas B-Species +
fluorescens I-Species +
Q8r1 I-Species -
- I-Species -
96 L-Species -
. O +

Pseudomonas B-Species +
fluorescens I-Species +
Q8r1 I-Species -
- I-Species -
96 L-Species +
represents O +
a O +
group O +
of O +
rhizosphere O +
strains O +
responsible O +
for O +
the O +
suppressiveness O +
of O +
agricultural O +
soils O +
to O +
take O -
- O -
all O +
disease O +
of O +
wheat O -
. O -

It O +
produces O +
the O +
antibiotic O +
2,4-diacetylphloroglucinol O +
and O +
aggressively O +
colonizes O +
the O +
roots O +
of O +
cereal O +
crops O -
. O -

In O +
this O +
study O -
, O +
we O +
analyzed O +
the O +
genome O +
of O +
Q8r1 B-Species -
- I-Species -
96 L-Species +
and O +
identified O +
a O +
type O +
III O +
protein O +
secretion O +
system O +
( O -
T3SS O -
) O +
gene O +
cluster O +
that O +
has O +
overall O +
organization O +
similar O +
to O +
that O +
of O +
the O +
T3SS O +
gene O +
cluster O +
of O +
the O +
plant O +
pathogen O +
Pseudomonas B-Species +
syringae L-Species -
. O -

We O +
also O +
screened O +
a O +
collection O +
of O +
30 O +
closely O +
related O +
P. B-Species +
fluorescens I-Species +
strains L-Species +
and O +
detected O +
the O +
T3SS O +
genes O +
in O +
all O +
but O +
one O +
of O +
them O -
. O -

The O +
Q8r1 B-Species -
- I-Species -
96 L-Species +
genome O +
contained O +
ropAA O +
and O +
ropM O +
type O +
III O +
effector O +
genes O -
, O +
which O +
are O +
orthologs O +
of O +
the O +
P. B-Species +
syringae L-Species +
effector O +
genes O +
hopAA1 O -
- O -
1 O +
and O +
hopM1 O -
, O +
as O +
well O +
as O +
a O +
novel O +
type O +
III O +
effector O +
gene O +
designated O +
ropB. O +
These O +
type O +
III O +
effector O +
genes O +
encoded O +
proteins O +
that O +
were O +
secreted O +
in O +
culture O +
and O +
injected O +
into O +
plant O +
cells O +
by O +
both O +
P. B-Species +
syringae L-Species +
and O +
Q8r1 B-Species -
- I-Species -
96 L-Species +
T3SSs O -
. O -

The O +
Q8r1 B-Species -
- I-Species -
96 L-Species +
T3SS O +
was O +
expressed O +
in O +
the O +
rhizosphere O -
, O +
but O +
mutants O +
lacking O +
a O +
functional O +
T3SS O +
were O +
not O +
altered O +
in O +
their O +
rhizosphere O +
competence O -
. O -

The O +
Q8r1 B-Species -
- I-Species -
96 L-Species +
type O +
III O +
effectors O +
RopAA O -
, O +
RopB O -
, O +
and O +
RopM O +
were O +
capable O +
of O +
suppressing O +
the O +
hypersensitive O +
response O +
and O +
production O +
of O +
reactive O +
oxygen O +
species O -
, O +
two O +
plant O +
immune O +
responses O -
. O +

A O +
cis O -
- O -
encoded O +
antisense O +
small O +
RNA O +
regulated O +
by O +
the O +
HP0165-HP0166 O +
two O -
- O -
component O +
system O +
controls O +
expression O +
of O +
ureB O +
in O +
Helicobacter B-Species +
pylori L-Species -
. O +

Expression O +
of O +
urease O +
is O +
essential O +
for O +
gastric O +
colonization O +
by O +
Helicobacter B-Species +
pylori L-Species -
. O -

The O +
increased O +
level O +
of O +
urease O +
in O +
gastric O +
acidity O +
is O +
due O -
, O +
in O +
part O -
, O +
to O +
acid O +
activation O +
of O +
the O +
two O -
- O -
component O +
system O +
( O -
TCS O -
) O +
consisting O +
of O +
the O +
membrane O +
sensor O +
HP0165 O +
and O +
its O +
response O +
regulator O -
, O +
HP0166 O -
, O +
which O +
regulates O +
transcription O +
of O +
the O +
seven O +
genes O +
of O +
the O +
urease O +
gene O +
cluster O -
. O -

We O +
now O +
find O +
that O +
there O +
are O +
two O +
major O +
ureAB O +
transcripts O -
: O +
a O +
2.7-kb O +
full O -
- O -
length O +
ureAB O +
transcript O +
and O +
a O +
1.4-kb O +
truncated O +
transcript O +
lacking O +
3 O -
' O +
ureB. O +
Acidic O +
pH O +
( O -
pH O +
4.5 O -
) O +
results O +
in O +
a O +
significant O +
increase O +
in O +
transcription O +
of O +
ureAB O -
, O +
while O +
neutral O +
pH O +
( O -
pH O +
7.4 O -
) O +
increases O +
the O +
truncated O +
1.4-kb O +
transcript O -
. O -

Northern O +
blot O +
analysis O +
with O +
sense O +
RNA O +
and O +
strand O -
- O -
specific O +
oligonucleotide O +
probes O +
followed O +
by O +
5 O -
' O +
rapid O +
amplification O +
of O +
cDNA O +
ends O +
detects O +
an O +
antisense O +
small O +
RNA O +
( O -
sRNA O -
) O +
encoded O +
by O +
the O +
5 O -
' O +
ureB O +
noncoding O +
strand O +
consisting O +
of O +
-290 O +
nucleotides O +
( O -
5'ureB O -
- O -
sRNA O -
) O -
. O -

Deletion O +
of O +
HP0165 O +
elevates O +
the O +
level O +
of O +
the O +
truncated O +
1.4-kb O +
transcript O +
along O +
with O +
that O +
of O +
the O +
5'ureB O -
- O -
sRNA O +
at O +
both O +
pH O +
7.4 O +
and O +
pH O +
4.5 O -
. O -

Overexpression O +
of O +
5'ureB O -
- O -
sRNA O +
increases O +
the O +
1.4-kb O +
transcript O -
, O +
decreases O +
the O +
2.7-kb O +
transcript O -
, O +
and O +
decreases O +
urease O +
activity O -
. O -

Electrophoretic O +
mobility O +
shift O +
assay O +
shows O +
that O +
unphosphorylated O +
HP0166 O +
binds O +
specifically O +
to O +
the O +
5'ureB O -
- O -
sRNA O +
promoter O -
. O -

The O +
ability O +
of O +
the O +
HP0165-HP0166 O +
TCS O +
to O +
both O +
increase O +
and O +
decrease O +
ureB O +
expression O +
at O +
low O +
and O +
high O +
pHs O -
, O +
respectively O -
, O +
facilitates O +
gastric O +
habitation O +
and O +
colonization O +
over O +
the O +
wide O +
range O +
of O +
intragastric O +
pHs O +
experienced O +
by O +
the O +
organism O -
. O +

Effects O +
of O +
deficiency O +
and O +
overdose O +
of O +
group O +
2 O +
sigma O +
factors O +
in O +
triple O +
inactivation O +
strains O +
of O +
Synechocystis B-Species +
sp. I-Species +
strain I-Species +
PCC I-Species +
6803 L-Species -
. O +

Acclimation O +
of O +
cyanobacteria O +
to O +
environmental O +
changes O +
includes O +
major O +
changes O +
in O +
the O +
gene O +
expression O +
patterns O +
partly O +
orchestrated O +
by O +
the O +
replacement O +
of O +
a O +
particular O +
sigma O +
subunit O +
with O +
another O +
in O +
the O +
RNA O +
polymerase O +
holoenzyme O -
. O -

The O +
cyanobacterium O +
Synechocystis B-Species +
sp. I-Species +
strain I-Species +
PCC I-Species +
6803 L-Species +
encodes O +
nine O +
sigma O +
factors O -
, O +
all O +
belonging O +
to O +
the O +
sigma O -
( O -
70 O -
) O +
family O -
. O -

Cyanobacteria O +
typically O +
encode O +
many O +
group O +
2 O +
sigma O +
factors O +
that O +
closely O +
resemble O +
the O +
principal O +
sigma O +
factor O -
. O -

We O +
inactivated O +
three O +
out O +
of O +
the O +
four O +
group O +
2 O +
sigma O +
factors O +
of O +
Synechocystis O +
simultaneously O +
in O +
all O +
possible O +
combinations O +
and O +
found O +
that O +
all O +
triple O +
inactivation O +
strains O +
grow O +
well O +
under O +
standard O +
conditions O -
. O -

Unlike O +
the O +
other O +
strains O -
, O +
the O +
DeltasigBCD O +
strain O -
, O +
which O +
contains O +
SigE O +
as O +
the O +
only O +
functional O +
group O +
2 O +
sigma O +
factor O -
, O +
did O +
not O +
grow O +
faster O +
under O +
mixotrophic O +
than O +
under O +
autotrophic O +
conditions O -
. O -

The O +
SigB O +
and O +
SigD O +
factors O +
were O +
important O +
in O +
low O -
- O -
temperature O +
acclimation O -
, O +
especially O +
under O +
diurnal O +
light O +
rhythm O -
. O -

The O +
DeltasigBCD O -
, O +
DeltasigBCE O -
, O +
and O +
DeltasigBDE O +
strains O +
were O +
sensitive O +
to O +
high O -
- O -
light O -
- O -
induced O +
photoinhibition O -
, O +
indicating O +
a O +
central O +
role O +
of O +
the O +
SigB O +
factor O +
in O +
high O -
- O -
light O +
tolerance O -
. O -

Furthermore O -
, O +
the O +
DeltasigBCE O +
strain O +
( O -
SigD O +
is O +
the O +
only O +
functional O +
group O +
2 O +
sigma O +
factor O -
) O +
appeared O +
to O +
be O +
locked O +
in O +
the O +
high O -
- O -
fluorescence O +
state O +
( O -
state O +
1 O -
) O +
and O +
grew O +
slowly O +
in O +
blue O +
but O +
not O +
in O +
orange O +
or O +
white O +
light O -
. O -

Our O +
results O +
suggest O +
that O +
features O +
of O +
the O +
triple O +
inactivation O +
strains O +
can O +
be O +
categorized O +
as O +
( O -
i O -
) O +
direct O +
consequences O +
of O +
the O +
inactivation O +
of O +
a O +
particular O +
sigma O +
factor O -
( O -
s O -
) O +
and O +
( O -
ii O -
) O +
effects O +
resulting O +
from O +
the O +
higher O +
probability O +
that O +
the O +
remaining O +
group O +
2 O +
sigma O +
factors O +
associate O +
with O +
the O +
RNA O +
polymerase O +
core O -
. O +

Effects O +
of O +
temperature O +
on O +
the O +
development O +
and O +
population O +
growth O +
of O +
the O +
sycamore B-Species +
lace I-Species +
bug L-Species -
, O +
Corythucha B-Species +
ciliata L-Species -
. O +

The O +
sycamore B-Species +
lace I-Species +
bug L-Species -
, O +
Corythucha B-Species +
ciliata L-Species +
( O -
Say O -
) O +
( O -
Hemiptera O -
: O +
Tingidae O -
) O -
, O +
is O +
an O +
important O +
invasive O +
exotic O +
pest O +
of O +
Platanus O +
( O -
Proteales O -
: O +
Platanaceae O -
) O +
trees O +
in O +
China O -
. O -

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
effects O +
of O +
temperature O +
on O +
C. B-Species +
ciliata L-Species +
in O +
the O +
laboratory O +
so O +
that O +
forecasting O +
models O +
based O +
on O +
heat O +
accumulation O +
units O +
could O +
be O +
developed O +
for O +
the O +
pest O -
. O -

Development O +
and O +
fecundity O +
of O +
C. B-Species +
ciliata L-Species +
reared O +
on O +
leaves O +
of O +
London B-Species +
plane I-Species +
tree L-Species +
( O -
Platanus B-Species +
x I-Species +
acerifolia L-Species -
) O +
were O +
investigated O +
at O +
seven O +
constant O +
temperatures O +
( O -
16 O -
, O +
19 O -
, O +
22 O -
, O +
26 O -
, O +
30 O -
, O +
33 O -
, O +
and O +
36 O -
^ O -
0 O +
C O -
) O +
and O +
at O +
a O +
relative O +
humidity O +
of O +
80 O -
% O +
with O +
a O +
photoperiod O +
of O +
14:10 O +
( O -
L O -
: O -
D O -
) O -
. O -

The O +
developmental O +
time O +
was O +
found O +
to O +
significantly O +
decrease O +
with O +
increasing O +
temperature O -
. O -

The O +
developmental O +
time O +
from O +
egg O +
hatching O +
to O +
adult O +
emergence O +
was O +
respectively O +
47.6 O -
, O +
35.0 O -
, O +
24.1 O -
, O +
20.0 O -
, O +
and O +
17.1 O +
days O +
at O +
the O +
temperatures O +
of O +
19 O -
, O +
22 O -
, O +
26 O -
, O +
30 O -
, O +
and O +
33 O -
^ O -
0 O +
C. O +
C. B-Species +
ciliata L-Species +
could O +
not O +
complete O +
full O +
development O +
at O +
16 O -
^ O -
0 O +
and O +
36 O -
^ O -
0 O +
C. O +
The O +
developmental O +
threshold O +
temperature O +
( O -
C O -
) O +
estimated O +
for O +
egg O -
- O -
to O -
- O -
adult O +
was O +
11.17 O -
^ O -
0 O +
C O -
, O +
with O +
a O +
thermal O +
constant O +
of O +
( O -
K O -
) O +
370.57 O +
degree O -
- O -
days O -
. O -

Longevity O +
of O +
females O +
was O +
found O +
to O +
be O +
the O +
shortest O -
, O +
17.7 O +
days O +
at O +
33 O -
^ O -
0 O +
C O +
and O +
the O +
longest O -
, O +
58.9 O +
days O +
at O +
16 O -
^ O -
0 O +
C O -
, O +
and O +
that O +
of O +
males O +
was O +
the O +
shortest O -
, O +
19.7 O +
days O +
at O +
33 O -
^ O -
0 O +
C O +
and O +
the O +
longest O -
, O +
59.7 O +
days O +
at O +
16 O -
^ O -
0 O +
C. O +
Fecundity O +
was O +
the O +
highest O +
at O +
30 O -
^ O -
0 O +
C O -
, O +
being O +
286.8 O +
eggs O +
per O +
female O +
over O +
an O +
oviposition O +
period O +
of O +
8.9 O +
days O -
. O -

Female O +
lifetime O +
fecundity O +
was O +
reduced O +
at O +
other O +
temperatures O -
, O +
being O +
the O +
lowest O +
( O -
87.7 O +
eggs O +
per O +
female O -
) O +
at O +
19 O -
^ O -
0 O +
C. O +
The O +
population O +
trend O +
index O +
( O -
I O -
) O +
of O +
C. B-Species +
ciliata L-Species +
was O +
the O +
highest O +
( O -
130.1 O -
) O +
at O +
30 O -
^ O -
0 O +
C O +
and O +
the O +
lowest O +
( O -
24.9 O -
) O +
at O +
19 O -
^ O -
0 O +
C. O +
Therefore O -
, O +
the O +
optimal O +
developmental O +
temperature O +
for O +
C. B-Species +
ciliata L-Species +
was O +
determined O +
to O +
be O +
30 O -
^ O -
0 O +
C. O +

Adaptation O +
of O +
a O +
Madin O -
- O -
Darby O +
canine U-Species +
kidney O +
cell O +
line O +
to O +
suspension O +
growth O +
in O +
serum O -
- O -
free O +
media O +
and O +
comparison O +
of O +
its O +
ability O +
to O +
produce O +
avian O +
influenza O +
virus O +
to O +
Vero O +
and O +
BHK21 O +
cell O +
lines O -
. O +

Madin O -
- O -
Darby O +
canine U-Species +
kidney O +
( O -
MDCK O -
) O +
cells O +
are O +
currently O +
considered O +
for O +
influenza O +
vaccine O +
manufacturing O -
. O -

A O +
drawback O +
of O +
these O +
cells O +
is O +
their O +
anchorage O +
dependent O +
growth O -
, O +
which O +
greatly O +
complicates O +
process O +
scale O -
- O -
up O -
. O -

In O +
this O +
paper O +
a O +
novel O +
MDCK O +
cell O +
line O +
( O -
MDCK O -
- O -
SFS O -
) O +
is O +
described O +
that O +
grows O +
efficiently O +
in O +
suspension O +
and O +
retained O +
high O +
expression O +
levels O +
of O +
both O +
alpha-2,6 O +
and O +
alpha-2,3 O +
sialic O +
acid O +
receptors O -
, O +
which O +
bind O +
preferably O +
to O +
human O +
and O +
avian O +
influenza O +
viruses O -
, O +
respectively O -
. O -

The O +
production O +
of O +
avian O +
influenza O +
virus O +
by O +
BHK21 O -
, O +
Vero O +
and O +
MDCK O -
- O -
SFS O +
cell O +
lines O +
was O +
compared O -
. O -

Although O +
BHK21 O +
cells O +
consisted O +
of O +
two O +
populations O -
, O +
one O +
of O +
which O +
lacks O +
the O +
alpha-2,3 O +
receptor O -
, O +
they O +
supported O +
the O +
replication O +
of O +
two O +
influenza O +
strains O +
to O +
high O +
titres O -
. O -

However O -
, O +
BHK21 O +
cells O +
are O +
generally O +
not O +
applicable O +
for O +
influenza O +
production O +
since O +
they O +
supported O +
the O +
replication O +
of O +
six O +
further O +
strains O +
poorly O -
. O -

MDCK O -
- O -
SFS O +
cells O +
yielded O +
the O +
highest O +
infectious O +
virus O +
titres O +
and O +
virus O +
genome O +
equivalent O +
concentration O +
for O +
five O +
of O +
the O +
eight O +
influenza O +
strains O +
analyzed O +
and O +
the O +
highest O +
hemagglutination O +
activity O +
for O +
all O +
eight O +
virus O +
strains O -
. O -

Taken O +
together O +
with O +
their O +
suitability O +
for O +
suspension O +
growth O +
this O +
makes O +
the O +
MDCK O -
- O -
SFS O +
cell O +
line O +
potentially O +
useful O +
for O +
large O +
scale O +
influenza O +
virus O +
production O -
. O +

Novel O +
cultured O +
protists O +
identify O +
deep O -
- O -
branching O +
environmental O +
DNA O +
clades O +
of O +
cercozoa O -
: O +
New O +
Genera O +
Tremula O -
, O +
Micrometopion O -
, O +
Minimassisteria O -
, O +
Nudifila O -
, O +
Peregrinia O -
. O +

We O +
describe O +
three O +
new O +
orders O +
of O +
filosan O +
Cercozoa O -
, O +
five O +
new O +
deep O -
- O -
branching O +
genera O -
, O +
eight O +
new O +
species O +
of O +
Thaumatomonas O -
, O +
Reckertia O -
, O +
Spongomonas O -
, O +
Rhogostoma O -
, O +
Agitata O -
, O +
Neoheteromita O +
and O +
Paracercomonas O -
, O +
sequence O +
their O +
18S O +
rDNA O -
, O +
and O +
construct O +
18S O +
rDNA O +
trees O +
for O +
148 O +
Cercozoa O -
. O -

Our O +
phylogeny O +
indicates O +
that O +
Filosa O +
were O +
ancestrally O +
gliding O +
flagellates O -
; O +
non O -
- O -
flagellate O +
filose O +
amoebae O +
evolved O +
from O +
them O +
five O +
times O +
independently O -
. O -

The O +
new O +
genera O +
are O +
more O +
closely O +
related O +
to O +
environmental O +
DNA O +
sequences O +
than O +
cultured O +
organisms O -
. O -

Tremula B-Species +
longifila L-Species -
, O +
a O +
zooflagellate O +
glider O +
on O +
both O +
flagella O +
( O -
unlike O +
other O +
Cercozoa O -
) O -
, O +
is O +
the O +
most O +
divergent O +
filosan O +
( O -
Tremulida O +
ord O -
. O -

n. O -
) O -
. O -

Micrometopion B-Species +
nutans L-Species +
is O +
a O +
eukaryote O -
- O -
eating O +
gliding O +
zooflagellate O +
like O +
Metopion O +
and O +
Metromonas O -
. O -

Minimassisteria B-Species +
diva L-Species +
is O +
a O +
widespread O +
trimorphic O +
marine O +
amoeboflagellate O +
granofilosan O -
. O -

Peregrinia B-Species +
clavideferens L-Species -
, O +
a O +
non O -
- O -
testate O -
, O +
scale O -
- O -
bearing O -
, O +
filose O +
amoeba O -
, O +
branches O +
deeply O +
in O +
Thaumatomonadida O -
, O +
which O +
are O +
probably O +
sisters O +
to O +
Spongomonadida O -
. O -

Nudifila B-Species +
producta L-Species +
is O +
a O +
filose O +
amoeboflagellate O +
related O +
to O +
Clautriavia O +
and O +
Marimonadida O +
( O -
ord O -
. O -

n. O -
, O +
e.g. O +
Pseudopirsonia O -
, O +
Auranticordis O -
) O -
. O -

We O +
substantially O +
revise O +
Imbricatea O -
, O +
now O +
including O +
Spongomonadida O -
, O +
and O +
Thecofilosea O +
to O +
include O +
Phaeodaria O -
. O -

Thecofilosea O +
and O +
Imbricatea O +
and O +
Thecofilosea O +
are O +
sisters O -
, O +
both O +
arguably O +
ancestrally O +
rigid O +
gliding O +
flagellates O +
with O +
ventral O +
pseudopod O -
- O -
emitting O +
grooves O -
. O -

Scale O -
- O -
free O +
Ovulinata B-Species +
parva L-Species +
is O +
sister O +
to O +
Paulinella O -
, O +
so O +
imbricate O +
silica O +
scales O +
can O +
be O +
lost O -
. O -

Internal O +
hollow O +
silica O +
skeletons O +
evolved O +
twice O +
in O +
Thecofilosea O +
( O -
Ebriida O -
, O +
Phaeodaria O -
) O +
or O +
were O +
multiply O +
lost O -
. O -

Protaspa O +
replaces O +
preoccupied O +
' O -
Protaspis O -
' O -
. O +

Functional O +
analysis O +
of O +
a O +
mitochondrial O +
phosphopantetheinyl O +
transferase O +
( O -
PPTase O -
) O +
gene O +
pptB O +
in O +
Aspergillus B-Species +
fumigatus L-Species -
. O +

The O +
mitochondrial O +
phosphopantetheinyl O +
transferase O +
gene O +
pptB O +
of O +
the O +
opportunistic O +
pathogen O +
Aspergillus B-Species +
fumigatus L-Species +
has O +
been O +
identified O +
and O +
characterised O -
. O -

Unlike O +
pptA O -
, O +
which O +
is O +
required O +
for O +
lysine O +
biosynthesis O -
, O +
secondary O +
metabolism O -
, O +
and O +
iron O +
assimilation O -
, O +
pptB O +
is O +
essential O +
for O +
viability O -
. O -

PptB O +
is O +
located O +
in O +
the O +
mitochondria O -
. O -

In O +
vitro O +
expression O +
of O +
pptA O +
and O +
pptB O +
has O +
shown O +
that O +
PptB O +
is O +
specific O +
for O +
the O +
mitochondrial O +
acyl O +
carrier O +
protein O +
AcpA. O +

The O +
second O +
face O +
of O +
a O +
known O +
player O -
: O +
Arabidopsis U-Species +
silencing O +
suppressor O +
AtXRN4 O +
acts O +
organ O -
- O -
specifically O -
. O +

Plant O +
viruses O +
exploit O +
the O +
symplastic O +
transport O +
pathway O +
provided O +
by O +
plasmodesmata O +
by O +
encoding O +
for O +
specialized O +
movement O +
proteins O -
, O +
which O +
interact O +
with O +
host O +
factors O +
to O +
enable O +
viral O +
intracellular O +
and O +
intercellular O +
spread O -
. O -

Stable O +
expression O +
of O +
the O +
Potato B-Species +
leaf I-Species +
roll I-Species +
virus L-Species +
movement O +
protein O +
MP17 O +
in O +
Arabidopsis U-Species +
results O +
in O +
a O +
carbohydrate O +
export O +
block O +
and O +
stunted O +
growth O -
. O -

To O +
identify O +
host O +
factors O +
essential O +
for O +
viral O +
infection O -
, O +
we O +
screened O +
a O +
progeny O +
population O +
of O +
EMS O +
( O -
ethyl O +
methanesulfonate O -
) O -
-mutagenized O +
Arabidopsis U-Species +
expressing O +
a O +
MP17 O -
: O -
GFP O +
fusion O +
for O +
suppressor O +
mutants O +
with O +
restored O +
wild O +
type O -
- O -
like O +
phenotype O -
. O -

Two O +
suppressor O +
mutants O +
showed O +
decreased O +
susceptibility O +
against O +
Turnip B-Species +
mosaic I-Species +
virus L-Species +
and O +
post O -
- O -
transcriptional O +
silencing O +
of O +
MP17 O -
: O -
GFP O +
RNA O +
in O +
source O +
leaves O -
. O -

Map O +
based O +
cloning O +
identified O +
in O +
both O +
lines O +
mutations O +
in O +
XRN4 O +
( O -
Exoribonuclease O +
4 O -
) O -
, O +
which O +
was O +
previously O +
described O +
as O +
a O +
suppressor O +
of O +
transgene O +
silencing O +
in O +
source O +
leaves O -
. O -

Importantly O -
, O +
silencing O +
of O +
MP17 O -
: O -
GFP O +
was O +
not O +
present O +
in O +
cotyledons O +
and O +
roots O +
of O +
the O +
two O +
suppressor O +
mutants O -
, O +
which O +
was O +
confirmed O +
in O +
a O +
third O +
xrn4 O +
T O -
- O -
DNA O +
knock O +
out O +
line O -
. O -

Subsequent O +
analysis O +
of O +
MP17 O -
: O -
GFP O +
transcript O +
stability O +
in O +
xrn2 O +
and O +
xrn3 O +
mutants O +
indicated O +
an O +
essential O +
role O +
of O +
AtXRN2 O +
for O +
silencing O +
suppression O +
in O +
roots O -
/ O -
cotyledons O +
while O +
AtXRN3 O +
appears O +
to O +
act O +
similar O +
to O +
AtXRN4 O +
in O +
source O +
leaves O -
, O +
only O -
. O -

Overall O -
, O +
these O +
findings O +
point O +
towards O +
an O +
organ O -
- O -
specific O +
regulation O +
of O +
gene O +
silencing O +
in O +
Arabidopsis U-Species -
. O +

Ecological O +
trade O -
- O -
offs O +
between O +
jasmonic O +
acid O -
- O -
dependent O +
direct O +
and O +
indirect O +
plant O +
defences O +
in O +
tritrophic O +
interactions O -
. O +

Recent O +
studies O +
on O +
plants O +
genetically O +
modified O +
in O +
jasmonic O +
acid O +
( O -
JA O -
) O +
signalling O +
support O +
the O +
hypothesis O +
that O +
the O +
jasmonate O +
family O +
of O +
oxylipins O +
plays O +
an O +
important O +
role O +
in O +
mediating O +
direct O +
and O +
indirect O +
plant O +
defences O -
. O -

However O -
, O +
the O +
interaction O +
of O +
two O +
modes O +
of O +
defence O +
in O +
tritrophic O +
systems O +
is O +
largely O +
unknown O -
. O -

In O +
this O +
study O -
, O +
we O +
examined O +
the O +
preference O +
and O +
performance O +
of O +
a O +
herbivorous O +
leafminer U-Species +
( O -
Liriomyza B-Species +
huidobrensis L-Species -
) O +
and O +
its O +
parasitic O +
wasp U-Species +
( O -
Opius B-Species +
dissitus L-Species -
) O +
on O +
three O +
tomato U-Species +
genotypes O -
: O +
a O +
wild B-Species -
- I-Species -
type I-Species +
( I-Species -
WT I-Species -
) I-Species +
plant L-Species -
, O +
a O +
JA B-Species +
biosynthesis I-Species +
( I-Species -
spr2 I-Species -
) I-Species +
mutant L-Species -
, O +
and O +
a O +
JA B-Species -
- I-Species -
overexpression I-Species +
35S::prosys I-Species +
plant L-Species -
. O -

Their O +
proteinase O +
inhibitor O +
production O +
and O +
volatile O +
emission O +
were O +
used O +
as O +
direct O +
and O +
indirect O +
defence O +
factors O +
to O +
evaluate O +
the O +
responses O +
of O +
leafminers U-Species +
and O +
parasitoids O -
. O -

Here O -
, O +
we O +
show O +
that O +
although O +
spr2 B-Species +
mutant I-Species +
plants L-Species +
are O +
compromised O +
in O +
direct O +
defence O +
against O +
the O +
larval O +
leafminers U-Species +
and O +
in O +
attracting O +
parasitoids O -
, O +
they O +
are O +
less O +
attractive O +
to O +
adult O +
flies O +
compared O +
with O +
WT B-Species +
plants L-Species -
. O -

Moreover O -
, O +
in O +
comparison O +
to O +
other O +
genotypes O -
, O +
the O +
35S::prosys B-Species +
plant L-Species +
displays O +
greater O +
direct O +
and O +
constitutive O +
indirect O +
defences O -
, O +
but O +
reduced O +
success O +
of O +
parasitism O +
by O +
parasitoids O -
. O -

Taken O +
together O -
, O +
these O +
results O +
suggest O +
that O +
there O +
are O +
distinguished O +
ecological O +
trade O -
- O -
offs O +
between O +
JA O -
- O -
dependent O +
direct O +
and O +
indirect O +
defences O +
in O +
genetically O +
modified O +
plants O +
whose O +
fitness O +
should O +
be O +
assessed O +
in O +
tritrophic O +
systems O +
and O +
under O +
natural O +
conditions O -
. O +

Haplotype O +
analysis O +
of O +
the O +
genes O +
encoding O +
glutamine O +
synthetase O +
plastic O +
isoforms O +
and O +
their O +
association O +
with O +
nitrogen O -
- O -
use- O +
and O +
yield O -
- O -
related O +
traits O +
in O +
bread B-Species +
wheat L-Species -
. O +

Glutamine O +
synthetase O +
( O -
GS O -
) O +
plays O +
a O +
key O +
role O +
in O +
the O +
growth O -
, O +
nitrogen O +
( O -
N O -
) O +
use O +
and O +
yield O +
potential O +
of O +
cereal O +
crops O -
. O -

Investigating O +
the O +
haplotype O +
variation O +
of O +
GS O +
genes O +
and O +
its O +
association O +
with O +
agronomic O +
traits O +
may O +
provide O +
useful O +
information O +
for O +
improving O +
wheat U-Species +
N O -
- O -
use O +
efficiency O +
and O +
yield O -
. O -

We O +
isolated O +
the O +
promoter O +
and O +
coding O +
region O +
sequences O +
of O +
the O +
plastic O +
glutamine O +
synthetase O +
isoform O +
( O -
GS2 O -
) O +
genes O +
located O +
on O +
chromosomes O +
2A O -
, O +
2B O +
and O +
2D O +
in O +
bread B-Species +
wheat L-Species -
. O -

By O +
analyzing O +
nucleotide O +
sequence O +
variations O +
of O +
the O +
coding O +
region O -
, O +
two O -
, O +
six O +
and O +
two O +
haplotypes O +
were O +
distinguished O +
for O +
TaGS2-A1 O +
( O -
a O +
and O +
b O -
) O -
, O +
TaGS2-B1 O +
( O -
a O -
- O -
f O -
) O +
and O +
TaGS2-D1 O +
( O -
a O +
and O +
b O -
) O -
, O +
respectively O -
. O -

By O +
analyzing O +
the O +
frequency O +
data O +
of O +
different O +
haplotypes O +
and O +
their O +
association O +
with O +
N O +
use O +
and O +
agronomic O +
traits O -
, O +
four O +
major O +
and O +
favorable O +
TaGS2 O +
haplotypes O +
( O -
A1b O -
, O +
B1a O -
, O +
B1b O -
, O +
D1a O -
) O +
were O +
revealed O -
. O -

These O +
favorable O +
haplotypes O +
may O +
confer O +
better O +
seedling O +
growth O -
, O +
better O +
agronomic O +
performance O -
, O +
and O +
improved O +
N O +
uptake O +
during O +
vegetative O +
growth O +
or O +
grain O +
N O +
concentration O -
. O -

Our O +
data O +
suggest O +
that O +
certain O +
TaGS2 O +
haplotypes O +
may O +
be O +
valuable O +
in O +
breeding O +
wheat U-Species +
varieties O +
with O +
improved O +
agronomic O +
performance O +
and O +
N O -
- O -
use O +
efficiency O -
. O +

High O +
homologous O +
gene O +
conservation O +
despite O +
extreme O +
autopolyploid O +
redundancy O +
in O +
sugarcane U-Species -
. O +

Modern O +
sugarcane U-Species +
( O -
Saccharum B-Species +
spp L-Species -
. O -
) O +
is O +
the O +
leading O +
sugar O +
crop O +
and O +
a O +
primary O +
energy O +
crop O -
. O -

It O +
has O +
the O +
highest O +
level O +
of O +
' O -
vertical O -
' O +
redundancy O +
( O -
2n=12x=120 O -
) O +
of O +
all O +
polyploid O +
plants O +
studied O +
to O +
date O -
. O -

It O +
was O +
produced O +
about O +
a O +
century O +
ago O +
through O +
hybridization O +
between O +
two O +
autopolyploid O +
species O -
, O +
namely O +
S. B-Species +
officinarum L-Species +
and O +
S. B-Species +
spontaneum L-Species -
. O -

In O +
order O +
to O +
investigate O +
the O +
genome O +
dynamics O +
in O +
this O +
highly O +
polyploid O +
context O -
, O +
we O +
sequenced O +
and O +
compared O +
seven O +
hom O -
( O -
oe O -
) O -
ologous O +
haplotypes O +
( O -
bacterial O +
artificial O +
chromosome O +
clones O -
) O -
. O -

Our O +
analysis O +
revealed O +
a O +
high O +
level O +
of O +
gene O +
retention O +
and O +
colinearity O -
, O +
as O +
well O +
as O +
high O +
gene O +
structure O +
and O +
sequence O +
conservation O -
, O +
with O +
an O +
average O +
sequence O +
divergence O +
of O +
4 O -
% O +
for O +
exons O -
. O -

Remarkably O -
, O +
all O +
of O +
the O +
hom O -
( O -
oe O -
) O -
ologous O +
genes O +
were O +
predicted O +
as O +
being O +
functional O +
( O -
except O +
for O +
one O +
gene O +
fragment O -
) O +
and O +
showed O +
signs O +
of O +
evolving O +
under O +
purifying O +
selection O -
, O +
with O +
the O +
exception O +
of O +
genes O +
within O +
segmental O +
duplications O -
. O -

By O +
contrast O -
, O +
transposable O +
elements O +
displayed O +
a O +
general O +
absence O +
of O +
colinearity O +
among O +
hom O -
( O -
oe O -
) O -
ologous O +
haplotypes O +
and O +
appeared O +
to O +
have O +
undergone O +
dynamic O +
expansion O +
in O +
Saccharum O -
, O +
compared O +
with O +
sorghum O -
, O +
its O +
close O +
relative O +
in O +
the O +
Andropogonea O +
tribe O -
. O -

These O +
results O +
reinforce O +
the O +
general O +
trend O +
emerging O +
from O +
recent O +
studies O +
indicating O +
the O +
diverse O +
and O +
nuanced O +
effect O +
of O +
polyploidy O +
on O +
genome O +
dynamics O -
. O +

Updated O +
hypothesis O +
on O +
the O +
evolution O +
of O +
oligotrichid O +
ciliates O +
( O -
Ciliophora O -
, O +
Spirotricha O -
, O +
Oligotrichida O -
) O +
based O +
on O +
somatic O +
ciliary O +
patterns O +
and O +
ontogenetic O +
data O -
. O +

The O +
two O +
recently O +
established O +
genera O +
Apostrombidium O +
Xu O +
et O +
al. O -
, O +
2009 O +
and O +
Varistrombidium O +
Xu O +
et O +
al. O -
, O +
2009 O +
and O +
the O +
analysis O +
of O +
ontogenetic O +
data O +
in O +
Strombidium O +
constrictum O -
, O +
S. O +
montagnesi O -
, O +
S. O +
wilberti O -
, O +
Omegastrombidium B-Species +
elegans L-Species -
, O +
and O +
Paratontonia O +
gracillima O +
necessitated O +
a O +
revision O +
of O +
the O +
hypothesis O +
about O +
the O +
somatic O +
ciliary O +
pattern O +
evolution O +
in O +
oligotrichid O +
ciliates O -
. O -

As O +
a O +
consequence O -
, O +
the O +
species O -
- O -
rich O +
genus O +
Strombidium O +
was O +
split O -
, O +
establishing O +
two O +
genera O +
for O +
species O +
with O +
a O +
horizontal O +
girdle O +
kinety O +
posterior O +
to O +
the O +
oral O +
primordium O -
: O +
Opisthostrombidium O +
nov. O +
gen. O +
with O +
the O +
extrusome O +
attachment O +
sites O +
along O +
the O +
anterior O +
margin O +
of O +
the O +
girdle O +
kinety O +
and O +
posterior O +
to O +
the O +
oral O +
primordium O +
and O +
Foissneridium O +
nov. O +
gen. O +
with O +
the O +
extrusome O +
attachment O +
sites O +
distinctly O +
apart O +
from O +
the O +
girdle O +
kinety O +
and O +
anterior O +
to O +
the O +
oral O +
primordium O -
. O -

The O +
ontogenetic O +
data O +
revealed O +
that O +
the O +
Omega O -
- O -
shaped O +
girdle O +
kinety O +
pattern O +
evolved O +
convergently O +
from O +
the O +
Pseudotontonia O +
pattern O +
with O +
its O +
horizontal O +
girdle O +
kinety O +
in O +
the O +
tailed O +
genus O +
Paratontonia O +
and O +
from O +
the O +
Novistrombidium O +
pattern O +
with O +
its O +
dextrally O +
spiralled O +
girdle O +
kinety O +
in O +
the O +
tailless O +
genus O +
Omegastrombidium O -
. O -

The O +
somatic O +
ciliary O +
pattern O +
of O +
the O +
latter O +
genus O +
probably O +
gave O +
rise O +
to O +
the O +
patterns O +
of O +
Apostrombidium O +
and O +
Varistrombidium O -
. O +

Identification O +
of O +
a O +
novel O +
mitochondrial O +
protein O -
, O +
short O +
postembryonic O +
roots O +
1 O +
( O -
SPR1 O -
) O -
, O +
involved O +
in O +
root O +
development O +
and O +
iron O +
homeostasis O +
in O +
Oryza B-Species +
sativa L-Species -
. O +

* O +
A O +
rice U-Species +
mutant O -
, O +
Oryza B-Species +
sativa I-Species +
short I-Species +
postembryonic I-Species +
roots L-Species +
1 O +
( O -
Osspr1 U-Species -
) O -
, O +
has O +
been O +
characterized O -
. O -

It O +
has O +
short O +
postembryonic O +
roots O -
, O +
including O +
adventitious O +
and O +
lateral O +
roots O -
, O +
and O +
a O +
lower O +
iron O +
content O +
in O +
its O +
leaves O -
. O -

* O +
OsSPR1 U-Species +
was O +
identified O +
by O +
map O -
- O -
based O +
cloning O -
. O -

It O +
encodes O +
a O +
novel O +
mitochondrial O +
protein O +
with O +
the O +
Armadillo O -
- O -
like O +
repeat O +
domain O -
. O -

* O +
Osspr1 O +
mutants O +
exhibited O +
decreased O +
root O +
cell O +
elongation O -
. O -

The O +
iron O +
content O +
of O +
the O +
mutant O +
shoots O +
was O +
significantly O +
altered O +
compared O +
with O +
that O +
of O +
wild O -
- O -
type O +
shoots O -
. O -

A O +
similar O +
pattern O +
of O +
alteration O +
of O +
manganese O +
and O +
zinc O +
concentrations O +
in O +
shoots O +
was O +
also O +
observed O -
. O -

Complementation O +
of O +
the O +
mutant O +
confirmed O +
that O +
OsSPR1 U-Species +
is O +
involved O +
in O +
post O -
- O -
embryonic O +
root O +
elongation O +
and O +
iron O +
homeostasis O +
in O +
rice O -
. O -

OsSPR1 U-Species +
was O +
found O +
to O +
be O +
ubiquitously O +
expressed O +
in O +
various O +
tissues O +
throughout O +
the O +
plant O -
. O -

The O +
transcript O +
abundance O +
of O +
various O +
genes O +
involved O +
in O +
iron O +
uptake O +
and O +
signaling O +
via O +
both O +
strategies O +
I O +
and O +
II O +
was O +
similar O +
in O +
roots O +
of O +
wild O -
- O -
type O +
and O +
mutant O +
plants O -
, O +
but O +
was O +
higher O +
in O +
the O +
leaves O +
of O +
mutant O +
plants O -
. O -

* O -

Thus O -
, O +
a O +
novel O +
mitochondrial O +
protein O +
that O +
is O +
involved O +
in O +
root O +
elongation O +
and O +
plays O +
a O +
role O +
in O +
metal O +
ion O +
homeostasis O +
has O +
been O +
identified O -
. O +

Morphology O +
and O +
ultrastructure O +
of O +
multiple O +
life O +
cycle O +
stages O +
of O +
the O +
photosynthetic O +
relative O +
of O +
apicomplexa O -
, O +
Chromera B-Species +
velia L-Species -
. O +

Chromera B-Species +
velia L-Species +
is O +
a O +
photosynthetic O +
alga O +
with O +
a O +
secondary O +
plastid O +
that O +
represents O +
the O +
closest O +
known O +
photosynthetic O +
relative O +
of O +
the O +
apicomplexan O +
parasites O -
. O -

The O +
original O +
description O +
of O +
this O +
organism O +
was O +
based O +
on O +
brownish O -
, O +
immotile O +
coccoid O +
cells O -
, O +
which O +
is O +
the O +
predominating O +
stage O +
of O +
C. B-Species +
velia L-Species +
in O +
the O +
culture O -
. O -

Here O +
we O +
provide O +
a O +
detailed O +
light O +
and O +
electron O +
microscopy O +
description O +
of O +
coccoid O +
cells O +
of O +
C. B-Species +
velia L-Species +
and O +
a O +
previously O +
undocumented O +
bi O -
- O -
flagellated O +
stage O +
that O +
is O +
highly O +
motile O +
and O +
moves O +
in O +
a O +
characteristic O +
zig O -
- O -
zag O +
pattern O -
. O -

Transformation O +
from O +
a O +
coccoid O +
into O +
a O +
flagellate O +
stage O +
occurs O +
in O +
exponentially O +
growing O +
cultures O -
, O +
and O +
is O +
accelerated O +
by O +
exposure O +
to O +
light O -
. O -

The O +
C. B-Species +
velia L-Species +
cells O +
contain O +
a O +
pseudoconoid O -
, O +
which O +
is O +
likely O +
homologous O +
to O +
the O +
corresponding O +
structure O +
in O +
the O +
apical O +
complex O +
of O +
Apicomplexa O -
, O +
cortical O +
alveoli O +
subtended O +
by O +
subpellicular O +
microtubules O -
, O +
mitochondrion O +
with O +
tubular O +
cristae O -
, O +
a O +
micropyle O -
, O +
and O +
a O +
distinctive O +
chromerosome O -
, O +
an O +
apparently O +
novel O +
type O +
of O +
extrusion O +
organelle O -
. O -

Ultrastructural O +
analysis O +
of O +
the O +
flagellate O +
supports O +
its O +
close O +
association O +
with O +
colpodellids O +
and O +
apicomplexans O +
and O +
provides O +
important O +
insight O +
into O +
their O +
evolution O -
. O +

Constraints O +
on O +
host O +
choice O -
: O +
why O +
do O +
parasitic O +
birds O +
rarely O +
exploit O +
some O +
common O +
potential O +
hosts O -
? O +

1 O -
. O -

Why O +
are O +
some O +
common O +
and O +
apparently O +
suitable O +
resources O +
avoided O +
by O +
potential O +
users O -
? O -

This O +
interesting O +
ecological O +
and O +
evolutionary O +
conundrum O +
is O +
vividly O +
illustrated O +
by O +
obligate O +
brood O +
parasites O -
. O -

Parasitic O +
birds O +
lay O +
their O +
eggs O +
into O +
nests O +
of O +
a O +
wide O +
range O +
of O +
host O +
species O -
, O +
including O +
many O +
rare O +
ones O -
, O +
but O +
do O +
not O +
parasitize O +
some O +
commonly O +
co O -
- O -
occurring O +
potential O +
hosts O -
. O -

2 O -
. O +
Attempts O +
to O +
explain O +
the O +
absence O +
of O +
parasitism O +
in O +
common O +
potential O +
hosts O +
are O +
limited O +
and O +
typically O +
focused O +
on O +
single O -
- O -
factor O +
explanations O +
while O +
ignoring O +
other O +
potential O +
factors O -
. O -

We O +
tested O +
why O +
thrushes O +
Turdus O +
spp O -
. O +
are O +
extremely O +
rarely O +
parasitized O +
by O +
common B-Species +
cuckoos L-Species +
Cuculus B-Species +
canorus L-Species +
despite O +
breeding O +
commonly O +
in O +
sympatry O +
and O +
building O +
the O +
most O +
conspicuous O +
nests O +
among O +
forest O -
- O -
breeding O +
passerines O -
. O -

3 O -
. O -

No O +
single O +
examined O +
factor O +
explained O +
cuckoo U-Species +
avoidance O +
of O +
thrushes O -
. O -

Life O -
- O -
history O +
traits O +
of O +
all O +
six O +
European O +
thrush O +
species O +
and O +
the O +
10 O +
most O +
frequently O +
used O +
cuckoo U-Species +
hosts O +
in O +
Europe O +
were O +
similar O +
except O +
body O -
/ O -
egg O +
size O -
, O +
nest O +
design O +
and O +
nestling O +
diet O -
. O -

4 O -
. O -

Experiments O +
( O -
n O +
= O +
1211 O -
) O +
in O +
several O +
populations O +
across O +
Europe O +
showed O +
that O +
host O +
defences O +
at O +
egg O -
- O -
laying O +
and O +
incubation O +
stages O +
did O +
not O +
account O +
for O +
the O +
lack O +
of O +
cuckoo U-Species +
parasitism O +
in O +
thrushes O -
. O -

However O -
, O +
cross O -
- O -
fostering O +
experiments O +
disclosed O +
that O +
various O +
factors O +
during O +
the O +
nestling O +
period O +
prevent O +
cuckoos U-Species +
from O +
successfully O +
parasitizing O +
thrushes O -
. O -

Specifically O -
, O +
in O +
some O +
thrush O +
species O -
, O +
the O +
nest O +
cup O +
design O +
forced O +
cuckoo U-Species +
chicks O +
to O +
compete O +
with O +
host O +
chicks O +
with O +
fatal O +
consequences O +
for O +
the O +
parasite O -
. O -

Other O +
species O +
were O +
reluctant O +
to O +
care O +
even O +
for O +
lone O +
cuckoo U-Species +
chicks O -
. O -

5 O -
. O -

Importantly O -
, O +
in O +
an O +
apparently O +
phylogenetically O +
homogenous O +
group O +
of O +
hosts O -
, O +
there O +
were O +
interspecific O +
differences O +
in O +
factors O +
responsible O +
for O +
the O +
absence O +
of O +
cuckoo U-Species +
parasitism O -
. O -

6 O -
. O -

This O +
study O +
highlights O +
the O +
importance O +
of O +
considering O +
multiple O +
potential O +
factors O +
and O +
their O +
interactions O +
for O +
understanding O +
absence O +
of O +
parasitism O +
in O +
potential O +
hosts O +
of O +
parasitic O +
birds O -
. O -

In O +
the O +
present O +
study O -
, O +
comparative O +
and O +
experimental O +
procedures O +
are O +
integrated O -
, O +
which O +
represent O +
a O +
novel O +
approach O +
that O +
should O +
prove O +
useful O +
for O +
the O +
understanding O +
of O +
interspecific O +
ecological O +
relationships O +
in O +
general O -
. O +

Expression O +
and O +
functional O +
characterisation O +
of O +
TNC O -
, O +
a O +
high O -
- O -
affinity O +
nickel O +
transporter O +
from O +
Neurospora B-Species +
crassa L-Species -
. O +

Our O +
previous O +
in O +
silico O +
studies O +
identified O +
a O +
high O -
- O -
affinity O +
nickel O +
transporter O -
, O -
TNC O -
, O +
from O +
the O +
metal O +
transportome O +
of O +
Neurospora B-Species +
crassa L-Species -
. O -

A O +
knockout O +
mutant O +
of O +
the O +
tnc O +
gene O +
in O +
N. B-Species +
crassa L-Species +
failed O +
to O +
transport O +
nickel O -
, O +
showed O +
phenotypic O +
growth O +
defects O +
and O +
diminished O +
urease O +
activity O +
under O +
physiological O +
levels O +
of O +
nickel O -
. O -

Transport O +
assays O +
conducted O +
in O +
wild O +
type O +
and O +
knockout O +
mutant O +
strains O +
showed O +
that O +
TNC O +
transports O +
nickel O +
withhigh O +
affinity O +
but O +
exhibits O +
selectivity O +
for O +
other O +
transition O +
metal O +
ions O +
like O +
cobalt O -
. O -

Heterologous O +
complementation O +
of O +
Schizosaccharomyces B-Species +
pombe L-Species +
nickel O +
uptake O +
mutant O +
by O +
TNC O +
further O +
substantiates O +
its O +
nickel O +
transport O +
function O -
. O -

Transcriptional O +
analysis O +
of O +
the O +
nickel O +
transporter O +
encoding O +
gene O -
, O +
tnc O +
in O +
N. B-Species +
crassa L-Species +
by O +
qRT O -
- O -
PCR O +
showed O +
its O +
constitutive O +
expression O +
in O +
various O +
phases O +
of O +
its O +
life O +
cycle O -
. O -

However O -
, O +
levels O +
of O +
the O +
corresponding O +
protein O +
TNC O +
were O +
down O -
- O -
regulated O +
only O +
by O +
increasing O +
the O +
nickel O -
, O +
but O +
not O +
cobalt O +
concentration O +
in O +
the O +
media O -
. O -

Immunolocalisation O +
data O +
suggested O +
that O +
TNC O +
is O +
distributed O +
in O +
the O +
plasma O +
membrane O +
of O +
N. B-Species +
crassa L-Species -
. O -

Thus O -
, O +
the O +
present O +
study O +
establishes O +
TNC O +
as O +
a O +
functional O +
plasma O +
membrane O +
nickel O +
transporter O +
necessary O +
for O +
physiological O +
acquisition O +
of O +
nickel O +
in O +
the O +
multicellular O +
fungi O +
N. B-Species +
crassa L-Species -
. O +

An O +
Antarctic O +
hypotrichous O +
ciliate O -
, O +
Parasterkiella B-Species +
thompsoni L-Species +
( O -
Foissner O -
) O +
nov. O +
gen. O -
, O +
nov. O +
comb O -
. O -
, O +
recorded O +
in O +
Argentinean O +
peat O -
- O -
bogs O -
: O +
morphology O -
, O +
morphogenesis O -
, O +
and O +
molecular O +
phylogeny O -
. O +

The O +
ciliate O +
Parasterkiella B-Species +
thompsoni L-Species +
( O -
Foissner O -
, O +
1996 O -
) O +
nov. O +
gen. O -
, O +
nov. O +
comb O -
. O +
was O +
originally O +
described O +
from O +
Antarctica O -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
report O +
the O +
morphology O -
, O +
morphogenesis O +
during O +
cell O +
division O -
, O +
and O +
molecular O +
phylogeny O +
inferred O +
from O +
the O +
18S O -
- O -
rDNA O +
sequence O +
of O +
a O +
population O +
isolated O +
from O +
the O +
Rancho O +
Hambre O +
peat O +
bog O -
, O +
Tierra O +
del O +
Fuego O +
Province O +
( O -
Argentina O -
) O -
. O -

The O +
study O +
is O +
based O +
on O +
live O +
and O +
protargol O -
- O -
impregnated O +
specimens O -
. O -

Molecular O +
phylogeny O +
was O +
inferred O +
from O +
trees O +
constructed O +
by O +
means O +
of O +
the O +
maximum O +
parsimony O -
, O +
neighbor O +
joining O -
, O +
and O +
Bayesian O +
analyses O -
. O -

The O +
interphase O +
morphology O +
matches O +
the O +
original O +
description O +
of O +
the O +
species O -
. O -

During O +
the O +
cell O +
division O -
, O +
stomatogenesis O +
begins O +
with O +
the O +
de O +
novo O +
proliferation O +
of O +
two O +
fields O +
of O +
basal O +
bodies O -
, O +
each O +
one O +
left O +
of O +
the O +
postoral O +
ventral O +
cirri O +
and O +
of O +
transverse O +
cirri O -
, O +
which O +
later O +
unify O -
. O -

Primordia O +
IV O -
- O -
VI O +
of O +
the O +
proter O +
develop O +
from O +
disaggregation O +
of O +
cirrus O +
IV O -
/ O -
3 O -
, O +
while O +
primordium O +
IV O +
of O +
the O +
opisthe O +
develops O +
from O +
cirrus O +
IV O -
/ O -
2 O +
and O +
primordia O +
V O +
and O +
VI O +
from O +
cirrus O +
V O -
/ O -
4 O -
. O -

Dorsal O +
morphogenesis O +
occurs O +
in O +
the O +
Urosomoida O +
pattern O -
- O -
that O +
is O -
, O +
the O +
fragmentation O +
of O +
kinety O +
3 O +
is O +
lacking O -
. O -

Three O +
macronuclear O +
nodules O +
are O +
generated O +
before O +
cytokinesis O -
. O -

Phylogenetic O +
analyses O +
consistently O +
placed O +
P. B-Species +
thompsoni L-Species +
within O +
the O +
stylonychines O -
. O -

New O +
data O +
on O +
the O +
morphogenesis O +
of O +
the O +
dorsal O +
ciliature O +
justifies O +
the O +
transference O +
of O +
Sterkiella B-Species +
thompsoni L-Species +
to O +
a O +
new O +
genus O +
Parasterkiella O -
. O +

A O +
nuclear O +
inhibitor O +
of O +
NF O -
- O -
kappaB O +
encoded O +
by O +
a O +
poxvirus O -
. O -

Poxviruses O +
have O +
evolved O +
various O +
strategies O +
to O +
inhibit O +
cytoplasmic O +
events O +
leading O +
to O +
activation O +
of O +
the O +
nuclear O +
factor O +
kappaB O +
( O -
NF O -
- O -
kappaB O -
) O +
signaling O +
pathway O -
, O +
with O +
individual O +
viruses O +
often O +
encoding O +
multiple O +
NF O -
- O -
kappaB O +
inhibitors O -
. O -

Here O -
, O +
the O +
novel O +
orf B-Species +
virus L-Species +
( O -
ORFV U-Species -
) O -
-encoded O +
protein O +
ORFV002 U-Species +
was O +
shown O +
to O +
inhibit O +
nuclear O +
events O +
regulating O +
NF O -
- O -
kappaB O +
transcriptional O +
activity O -
. O -

ORFV002 O +
expression O +
in O +
cell O +
cultures O +
significantly O +
decreased O +
wild O -
- O -
type O -
- O -
virus- O -
, O +
tumor O +
necrosis O +
factor O +
alpha O +
( O -
TNF O -
- O -
alpha O -
) O -
- O -
, O +
and O +
lipopolysaccharide O +
( O -
LPS O -
) O -
-induced O +
NF O -
- O -
kappaB O -
- O -
mediated O +
gene O +
expression O -
. O -

Expression O +
of O +
ORFV002 O +
in O +
cells O -
, O +
while O +
not O +
affecting O +
phosphorylation O +
or O +
nuclear O +
translocation O +
of O +
NF O -
- O -
kappaB O -
- O -
p65 O -
, O +
markedly O +
decreased O +
TNF O -
- O -
alpha- O +
and O +
wild O -
- O -
type O -
- O -
virus O -
- O -
induced O +
acetylation O +
of O +
NF O -
- O -
kappaB O -
- O -
p65 O -
, O +
a O +
p300-mediated O +
nuclear O +
modification O +
of O +
NF O -
- O -
kappaB O -
- O -
p65 O +
that O +
regulates O +
its O +
transactivating O +
activity O -
. O -

ORFV002 O +
was O +
shown O +
to O +
colocalize O +
and O +
interact O +
with O +
NF O -
- O -
kappaB O -
- O -
p65 O -
, O +
and O +
expression O +
of O +
ORFV002 O +
in O +
cell O +
cultures O +
resulted O +
in O +
a O +
reduced O +
interaction O +
of O +
NF O -
- O -
kappaB O -
- O -
p65 O +
with O +
p300 O -
, O +
suggesting O +
that O +
ORFV002 O +
interferes O +
with O +
NF O -
- O -
kappaB O -
- O -
p65 O -
/ O -
p300 O +
association O -
. O -

Deletion O +
of O +
ORFV002 O +
from O +
the O +
OV O -
- O -
IA82 O +
genome O +
had O +
no O +
significant O +
effect O +
on O +
ORFV O +
pathogenesis O +
in O +
sheep O -
, O +
indicating O +
that O +
ORFV002 O +
is O +
nonessential O +
for O +
virus O +
virulence O +
in O +
the O +
natural O +
host O -
. O -

This O +
represents O +
the O +
first O +
description O +
of O +
a O +
nuclear O +
inhibitor O +
of O +
NF O -
- O -
kappaB O +
encoded O +
by O +
a O +
poxvirus O -
. O +

Alphacoronavirus O +
transmissible B-Species +
gastroenteritis I-Species +
virus L-Species +
nsp1 O +
protein O +
suppresses O +
protein O +
translation O +
in O +
mammalian O +
cells O +
and O +
in O +
cell O -
- O -
free O +
HeLa O +
cell O +
extracts O +
but O +
not O +
in O +
rabbit U-Species +
reticulocyte O +
lysate O -
. O +

The O +
nsp1 O +
protein O +
of O +
transmissible B-Species +
gastroenteritis I-Species +
virus L-Species +
( O -
TGEV U-Species -
) O -
, O +
an O +
alphacoronavirus O -
, O +
efficiently O +
suppressed O +
protein O +
synthesis O +
in O +
mammalian O +
cells O -
. O -

Unlike O +
the O +
nsp1 O +
protein O +
of O +
severe B-Species +
acute I-Species +
respiratory I-Species +
syndrome I-Species +
coronavirus L-Species -
, O +
a O +
betacoronavirus O -
, O +
the O +
TGEV U-Species +
nsp1 O +
protein O +
was O +
unable O +
to O +
bind O +
40S O +
ribosomal O +
subunits O +
or O +
promote O +
host O +
mRNA O +
degradation O -
. O -

TGEV U-Species +
nsp1 O +
also O +
suppressed O +
protein O +
translation O +
in O +
cell O -
- O -
free O +
HeLa O +
cell O +
extract O -
; O +
however O -
, O +
it O +
did O +
not O +
affect O +
translation O +
in O +
rabbit U-Species +
reticulocyte O +
lysate O +
( O -
RRL O -
) O -
. O -

Our O +
data O +
suggested O +
that O +
HeLa O +
cell O +
extracts O +
and O +
cultured O +
host O +
cells O -
, O +
but O +
not O +
RRL O -
, O +
contain O +
a O +
host O +
factor O -
( O -
s O -
) O +
that O +
is O +
essential O +
for O +
TGEV U-Species +
nsp1-induced O +
translational O +
suppression O -
. O +

Modification O +
of O +
nonstructural O +
protein O +
1 O +
of O +
influenza B-Species +
A I-Species +
virus L-Species +
by O +
SUMO1 O -
. O -

Nonstructural O +
protein O +
1 O +
( O -
NS1 O -
) O +
is O +
one O +
of O +
the O +
major O +
factors O +
resulting O +
in O +
the O +
efficient O +
infection O +
rate O +
and O +
high O +
level O +
of O +
virulence O +
of O +
influenza B-Species +
A I-Species +
virus L-Species -
. O -

Although O +
consisting O +
of O +
only O +
approximately O +
230 O +
amino O +
acids O -
, O +
NS1 O +
has O +
the O +
ability O +
to O +
interfere O +
with O +
several O +
systems O +
of O +
the O +
host O +
viral O +
defense O -
. O -

In O +
the O +
present O +
study O -
, O +
we O +
demonstrate O +
that O +
NS1 O +
of O +
the O +
highly O +
pathogenic O +
avian O +
influenza U-Species +
A B-Species -
/ I-Species -
Duck I-Species -
/ I-Species -
Hubei I-Species -
/ I-Species -
L-1 I-Species -
/ I-Species -
2004 I-Species +
( I-Species -
H5N1 I-Species -
) I-Species +
virus L-Species +
interacts O +
with O +
human U-Species +
Ubc9 O -
, O +
which O +
is O +
the O +
E2 O +
conjugating O +
enzyme O +
for O +
sumoylation O -
, O +
and O +
we O +
show O +
that O +
SUMO1 O +
is O +
conjugated O +
to O +
H5N1 U-Species +
NS1 O +
in O +
both O +
transfected O +
and O +
infected O +
cells O -
. O -

Furthermore O -
, O +
two O +
lysine O +
residues O +
in O +
the O +
C O +
terminus O +
of O +
NS1 O +
were O +
identified O +
as O +
SUMO1 O +
acceptor O +
sites O -
. O -

When O +
the O +
SUMO1 O +
acceptor O +
sites O +
were O +
removed O +
by O +
mutation O -
, O +
NS1 O +
underwent O +
rapid O +
degradation O -
. O -

Studies O +
of O +
different O +
influenza B-Species +
A I-Species +
virus L-Species +
strains O +
of O +
human U-Species +
and O +
avian O +
origin O +
showed O +
that O +
the O +
majority O +
of O +
viruses O +
possess O +
an O +
NS1 O +
protein O +
that O +
is O +
modified O +
by O +
SUMO1 O -
, O +
except O +
for O +
the O +
recently O +
emerged O +
swine B-Species -
- I-Species -
origin I-Species +
influenza I-Species +
A I-Species +
virus I-Species +
( I-Species -
S I-Species -
- I-Species -
OIV I-Species -
) I-Species +
( I-Species -
H1N1 L-Species -
) O -
. O -

Interestingly O -
, O +
growth O +
of O +
a O +
sumoylation O -
- O -
deficient O +
WSN O +
virus O +
mutant O +
was O +
retarded O +
compared O +
to O +
that O +
of O +
wild O -
- O -
type O +
virus O -
. O -

Together O -
, O +
these O +
results O +
indicate O +
that O +
sumoylation O +
enhances O +
NS1 O +
stability O +
and O +
thus O +
promotes O +
rapid O +
growth O +
of O +
influenza B-Species +
A I-Species +
virus L-Species -
. O +

Novel O +
mutations O +
reveal O +
two O +
important O +
regions O +
in O +
Aspergillus B-Species +
nidulans L-Species +
transcriptional O +
activator O +
MetR. O +
Expression O +
of O +
the O +
sulfur O +
assimilation O +
pathway O +
in O +
Aspergillus B-Species +
nidulans L-Species +
is O +
under O +
control O +
of O +
sulfur O +
metabolite O +
repression O -
, O +
which O +
is O +
composed O +
of O +
scon O +
genes O +
encoding O +
subunits O +
of O +
ubiquitin O +
ligase O +
and O +
the O +
metR O +
gene O +
coding O +
for O +
a O +
transcriptional O +
activator O -
. O -

In O +
this O +
paper O +
we O +
report O +
three O +
dominant O +
suppressors O +
of O +
methionine O +
requirement O +
isolated O +
from O +
a O +
metB3 O +
diploid O +
strain O -
. O -

All O +
three O +
mutations O +
lead O +
to O +
the O +
substitution O +
of O +
phenylalanine O +
48 O +
by O +
serine O +
or O +
leucine O +
in O +
the O +
conserved O +
N O -
- O -
terminal O +
region O +
of O +
the O +
MetR O +
protein O -
. O -

Strains O +
carrying O +
the O +
dominant O +
suppressor O +
mutations O +
exhibit O +
increased O +
activities O +
of O +
homocysteine O +
synthase O +
and O +
sulfur O +
assimilation O +
enzymes O +
as O +
well O +
as O +
elevated O +
levels O +
of O +
the O +
corresponding O +
transcripts O -
. O -

These O +
changes O +
are O +
observed O +
even O +
under O +
conditions O +
of O +
methionine O +
repression O -
, O +
which O +
suggests O +
that O +
the O +
mutated O +
MetR O +
protein O +
may O +
be O +
resistant O +
to O +
inactivation O +
or O +
degradation O +
mediated O +
by O +
sulfur O +
metabolite O +
repression O -
. O -

We O +
also O +
found O +
that O +
a O +
mutant O +
impaired O +
in O +
sulfite O +
reductase O +
activity O -
, O +
known O +
until O +
now O +
as O +
sG8 O -
, O +
has O +
a O +
frameshift O +
which O +
changes O +
41 O +
C O -
- O -
terminal O +
amino O +
acids O -
. O -

Therefore O -
, O +
it O +
is O +
now O +
designated O +
metR18 O -
. O -

This O +
mutant O +
has O +
elevated O +
levels O +
of O +
MetR O -
- O -
regulated O +
transcripts O +
and O +
of O +
activities O +
of O +
sulfur O +
assimilation O +
enzymes O +
( O -
except O +
sulfite O +
reductase O -
) O -
, O +
which O +
can O +
be O +
repressed O +
to O +
the O +
wild O +
type O +
level O +
by O +
exogenous O +
methionine O -
. O -

Thus O -
, O +
metR18 O +
and O +
the O +
three O +
dominant O +
suppressors O +
represent O +
new O +
types O +
of O +
mutations O +
affecting O +
different O +
parts O +
of O +
the O +
A. B-Species +
nidulans L-Species +
MetR O +
protein O -
. O +

Norovirus O +
GII.4 O +
strain O +
antigenic O +
variation O -
. O -

Noroviruses O +
are O +
the O +
principal O +
cause O +
of O +
epidemic O +
gastroenteritis O +
worldwide O -
. O -

Multiple O +
reports O +
have O +
concluded O +
that O +
the O +
major O +
capsid O +
proteins O +
of O +
GII.4 O +
strains O -
, O +
which O +
cause O +
80 O -
% O +
of O +
norovirus O +
infections O +
worldwide O -
, O +
are O +
evolving O +
rapidly O -
, O +
resulting O +
in O +
new O +
epidemic O +
strains O -
. O -

Surrogate O +
neutralization O +
assays O +
using O +
sera O +
from O +
outbreaks O +
and O +
from O +
immunized O +
mice O +
suggest O +
that O -
, O +
as O +
with O +
influenza B-Species +
virus L-Species -
, O +
antigenic O +
variation O +
maintains O +
GII.4 O +
persistence O +
in O +
the O +
face O +
of O +
human U-Species +
population O +
herd O +
immunity O -
. O -

To O +
test O +
this O +
hypothesis O -
, O +
mice O +
were O +
hyperimmunized O +
with O +
virus O -
- O -
like O +
particles O +
( O -
VLPs O -
) O +
representing O +
an O +
early O +
( O -
GII.4 O -
- O -
1987 O -
) O +
and O +
a O +
contemporary O +
( O -
GII.4 O -
- O -
2006 O -
) O +
GII.4 O +
strain O -
. O -

Anti O -
- O -
GII.4 O -
- O -
1987 O +
IgG O +
monoclonal O +
antibodies O +
( O -
MAbs O -
) O +
strongly O +
reacted O +
with O +
GII.4 O +
VLPs O +
derived O +
between O +
only O +
1987 O +
and O +
2002 O -
. O -

Ligand O +
binding O +
blockade O +
was O +
more O +
efficient O +
with O +
GII.4 O -
- O -
1987 O +
and O +
GII.4 O -
- O -
1997 O +
VLPs O +
than O +
with O +
GII.4 O -
- O -
2002 O -
. O -

Anti O -
- O -
GII.4 O -
- O -
2006 O +
IgG O +
MAbs O +
recognized O +
either O +
a O +
broad O +
panel O +
of O +
GII.4 O +
VLPs O +
( O -
1987 O +
to O +
2006 O -
) O +
or O +
a O +
subset O +
of O +
contemporary O +
( O -
2004 O +
to O +
2006 O -
) O +
VLPs O -
. O -

Most O +
2006 O +
antibodies O +
did O +
not O +
recognize O +
or O +
only O +
poorly O +
recognized O +
GII.4 O +
VLPs O +
of O +
2007 O +
or O +
2008 O -
, O +
documenting O +
rapid O +
antigenic O +
evolution O +
of O +
GII.4 O +
capsids O -
. O -

Generally O -
, O +
2006 O +
MAbs O +
blocked O +
homotypic O +
VLP O -
- O -
ligand O +
binding O +
but O +
were O +
unable O +
to O +
block O +
VLPs O +
representing O +
strains O +
primarily O +
circulating O +
during O +
or O +
earlier O +
than O +
2002 O -
. O -

These O +
analyses O +
demonstrate O +
that O +
both O +
subtle O +
and O +
significant O +
evolutionary O +
change O +
has O +
occurred O +
within O +
antibody O +
epitopes O +
between O +
epidemic O +
strains O -
, O +
providing O +
direct O +
evidence O +
that O +
the O +
GII.4 O +
noroviruses O +
are O +
undergoing O +
antigenic O +
variation O -
, O +
likely O +
in O +
response O +
to O +
herd O +
immunity O -
. O -

As O +
with O +
influenza B-Species +
virus L-Species -
, O +
HIV O -
, O +
and O +
hepatitis B-Species +
C I-Species +
virus L-Species -
, O +
norovirus O +
antigenic O +
variation O +
will O +
significantly O +
influence O +
the O +
design O +
of O +
efficacious O +
vaccines O +
and O +
immunotherapeutics O +
against O +
these O +
important O +
human U-Species +
pathogens O -
. O +

Cold O +
stress O +
contributes O +
to O +
aberrant O +
cytokinesis O +
during O +
male O +
meiosis O +
I O +
in O +
a O +
wheat U-Species +
thermosensitive O +
genic O +
male O +
sterile O +
line O -
. O +

The O +
male O +
sterility O +
of O +
a O +
wheat U-Species +
thermosensitive O +
genic O +
male O +
sterile O +
( O -
TGMS O -
) O +
line O +
is O +
strictly O +
controlled O +
by O +
temperature O -
. O -

When O +
the O +
TGMS O +
line O +
BS366 O +
was O +
exposed O +
to O +
10 O +
^0C O +
from O +
the O +
pollen O +
mother O +
cell O +
stage O +
to O +
the O +
meiosis O +
stage O -
, O +
a O +
few O +
pollen O +
grains O +
were O +
formed O +
and O +
devoid O +
of O +
starch O -
. O -

We O +
report O +
here O +
a O +
large O -
- O -
scale O +
transcriptomic O +
study O +
using O +
the O +
Affymetrix O +
wheat U-Species +
GeneChip O +
to O +
follow O +
gene O +
expression O +
in O +
BS366 O +
line O +
anthers O +
in O +
response O +
to O +
cold O +
stress O -
. O -

Notably O -
, O +
many O +
cytoskeletal O +
signaling O +
components O +
were O +
gradually O +
induced O +
in O +
response O +
to O +
cold O +
stress O +
in O +
BS366 O +
line O +
anthers O -
. O -

However O -
, O +
the O +
cytoskeleton O -
- O -
associated O +
genes O +
that O +
play O +
key O +
roles O +
in O +
the O +
dynamic O +
organization O +
of O +
the O +
cytoskeleton O +
were O +
dramatically O +
repressed O -
. O -

Histological O +
studies O +
revealed O +
that O +
the O +
separation O +
of O +
dyads O +
occurred O +
abnormally O +
during O +
male O +
meiosis O +
I O -
, O +
indicating O +
defective O +
male O +
meiotic O +
cytokinesis O -
. O -

Fluorescence O +
labelling O +
and O +
subcellular O +
histological O +
observations O +
revealed O +
that O +
the O +
phragmoplast O +
was O +
defectively O +
formed O +
and O +
the O +
cell O +
plate O +
was O +
abnormally O +
assembled O +
during O +
meiosis O +
I O +
under O +
cold O +
stress O -
. O -

Based O +
on O +
the O +
transcriptomic O +
analysis O +
and O +
observations O +
of O +
characterized O +
histological O +
changes O -
, O +
our O +
results O +
suggest O +
that O +
cold O +
stress O +
repressed O +
transcription O +
of O +
cytoskeleton O +
dynamic O +
factors O +
and O +
subsequently O +
caused O +
the O +
defective O +
cytokinesis O +
during O +
meiosis O +
I. O +
The O +
results O +
may O +
explain O +
the O +
male O +
sterility O +
caused O +
by O +
low O +
temperature O +
in O +
wheat O +
TGMS O +
lines O -
. O +

Social O +
immunity O +
in O +
honeybees U-Species +
( O -
Apis B-Species +
mellifera L-Species -
) O -
: O +
transcriptome O +
analysis O +
of O +
varroa O -
- O -
hygienic O +
behaviour O -
. O +

Honeybees U-Species +
have O +
evolved O +
a O +
social O +
immunity O +
consisting O +
of O +
the O +
cooperation O +
of O +
individuals O +
to O +
decrease O +
disease O +
in O +
the O +
hive O -
. O -

We O +
identified O +
a O +
set O +
of O +
genes O +
involved O +
in O +
this O +
social O +
immunity O +
by O +
analysing O +
the O +
brain O +
transcriptome O +
of O +
highly O +
varroa O -
- O -
hygienic O +
bees O -
, O +
who O +
efficiently O +
detect O +
and O +
remove O +
brood O +
infected O +
with O +
the O +
Varroa O +
destructor O +
mite O -
. O -

The O +
function O +
of O +
these O +
candidate O +
genes O +
does O +
not O +
seem O +
to O +
support O +
a O +
higher O +
olfactory O +
sensitivity O +
in O +
hygienic O +
bees O -
, O +
as O +
previously O +
hypothesized O -
. O -

However O -
, O +
comparing O +
their O +
genomic O +
profile O +
with O +
those O +
from O +
other O +
behaviours O +
suggests O +
a O +
link O +
with O +
brood O +
care O +
and O +
the O +
highly O +
varroa O -
- O -
hygienic O +
Africanized B-Species +
honeybees L-Species -
. O -

These O +
results O +
represent O +
a O +
first O +
step O +
toward O +
the O +
identification O +
of O +
genes O +
involved O +
in O +
social O +
immunity O +
and O +
thus O +
provide O +
first O +
insights O +
into O +
the O +
evolution O +
of O +
social O +
immunity O -
. O +

Introns O -
, O +
alternative O +
splicing O -
, O +
spliced O +
leader O +
trans O -
- O -
splicing O +
and O +
differential O +
expression O +
of O +
pcna O +
and O +
cyclin O +
in O +
Perkinsus B-Species +
marinus L-Species -
. O +

To O +
gain O +
understanding O +
on O +
the O +
structure O +
and O +
regulation O +
of O +
growth O -
- O -
related O +
genes O +
of O +
the O +
parasitic O +
alveolate O +
Perkinsus B-Species +
marinus L-Species -
, O +
we O +
analyzed O +
genes O +
encoding O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O -
pcna O -
) O +
and O +
cyclins O +
( O -
cyclin O -
) O -
. O -

Comparison O +
of O +
the O +
full O -
- O -
length O +
cDNAs O +
with O +
the O +
corresponding O +
genomic O +
sequences O +
revealedtrans O -
- O -
splicing O +
of O +
the O +
mRNAs O +
of O +
these O +
genes O +
with O +
a O +
conserved O +
21 O -
- O -
22 O +
nt O +
spliced O +
leader O -
. O -

Over O +
10 O +
copies O +
of O +
pcna O +
were O +
detected O -
, O +
with O +
identical O +
gene O +
structures O +
and O +
similar O +
nucleotide O +
( O -
nt O -
) O +
sequences O +
( O -
88 O -
- O -
99 O -
% O -
) O -
, O +
encoding O +
largely O +
identical O +
amino O +
acid O +
sequences O +
( O -
aa O -
) O -
. O -

Two O +
distinct O +
types O +
ofcyclin O +
( O -
Pmacyclin1 O +
and O +
Pmacyclin2 O -
) O +
were O +
identified O -
, O +
with O +
66 O -
- O -
69 O -
% O +
nt O +
and O +
81 O -
- O -
85 O -
% O +
aa O +
similarities O -
. O -

Pmacyclin2 O +
was O +
organized O +
in O +
tandem O +
repeats O -
, O +
and O +
was O +
alternatively O +
spliced O -
, O +
giving O +
rise O +
to O +
five O +
subtypes O +
of O +
transcripts O -
. O -

For O +
both O +
pcna O +
and O +
cyclin O +
genes O -
, O +
6 O -
- O -
10 O +
introns O +
were O +
found O -
. O -

Quantitative O +
RT O -
- O -
PCR O +
assays O +
showed O +
that O +
pcna O +
and O +
Pmacyclin2 O +
expression O +
levels O +
were O +
low O +
with O +
small O +
variations O +
during O +
a O +
28-h O +
time O +
course O -
, O +
whereas O +
Pmacyclin1 O +
transcript O +
abundance O +
was O +
10 O -
- O -
100 O +
times O +
higher O -
, O +
and O +
increased O +
markedly O +
during O +
active O +
cell O +
division O -
, O +
suggesting O +
that O +
it O +
is O +
a O +
mitoticcyclinand O +
can O +
be O +
a O +
useful O +
growth O +
marker O +
for O +
this O +
species O -
. O -

The O +
gene O +
structure O +
and O +
expression O +
features O +
along O +
with O +
phylogenetic O +
results O +
position O +
this O +
organism O +
between O +
dinoflagellates O +
and O +
apicomplexans O -
, O +
but O +
its O +
definitive O +
affiliation O +
among O +
alveolates O +
requires O +
further O +
studies O -
. O +

Development O +
Time O +
and O +
Body O +
Size O +
in O +
Eupolyphaga B-Species +
sinensis L-Species +
Along O +
a O +
Latitudinal O +
Gradient O +
From O +
China O -
. O +

The O +
responses O +
of O +
organisms O +
to O +
temperature O +
variations O +
may O +
be O +
via O +
short O +
term O +
responses O +
of O +
the O +
phenotype O +
( O -
phenotypic O +
plasticity O -
) O -
, O +
or O +
they O +
could O +
involve O +
long O -
- O -
term O +
evolutionary O +
change O +
and O +
adaptation O +
( O -
via O +
selection O -
) O +
to O +
the O +
genotype O -
. O -

These O +
could O +
involve O +
changes O +
to O +
the O +
mean O +
size O +
of O +
the O +
animal O +
or O +
to O +
the O +
thermal O +
reaction O +
norm O -
. O -

We O +
examined O +
the O +
effects O +
of O +
various O +
temperatures O +
( O -
of O +
22 O -
, O +
25 O -
, O +
28 O -
, O +
and O +
31 O -
^ O -
0C O -
) O +
on O +
development O +
time O -
, O +
adult O +
body O +
size O +
and O +
preadult O +
survivorship O +
in O +
three O +
populations O +
of O +
the O +
cockroach O -
, O +
Eupolyphaga B-Species +
sinensis L-Species +
( O -
Walker O -
) O -
, O +
collected O +
at O +
different O +
latitudes O -
. O -

We O +
found O +
substantial O +
temperature O -
- O -
induced O +
plasticity O +
in O +
development O +
time O -
, O +
body O +
size O -
, O +
and O +
preadult O +
survivorship O -
, O +
indicating O +
that O +
developmental O +
temperatures O +
have O +
strong O +
impacts O +
on O +
growth O +
and O +
life O +
history O +
traits O +
of O +
E. B-Species +
sinensis L-Species -
. O -

Genetic O +
differences O +
for O +
development O +
time O -
, O +
body O +
size O -
, O +
and O +
preadult O +
survivorship O +
were O +
detected O +
among O +
populations O -
, O +
and O +
the O +
three O +
traits O +
exhibited O +
highly O +
significant O +
variations O +
in O +
the O +
responses O +
of O +
different O +
populations O +
to O +
various O +
temperature O +
conditions O -
, O +
indicating O +
genetic O +
differences O +
among O +
populations O +
in O +
terms O +
of O +
thermal O +
reaction O +
norms O -
. O -

We O +
also O +
found O +
that O +
two O +
populations O +
seem O +
to O +
support O +
the O +
beneficial O +
acclimation O +
hypothesis O +
whereas O +
the O +
third O +
mid O -
- O -
latitude O +
population O +
does O +
not O -
. O -

The O +
results O +
are O +
likely O +
because O +
of O +
differences O +
in O +
season O +
length O +
and O +
voltinism O -
, O +
indicating O +
that O +
not O +
only O +
temperature O +
regime O +
but O +
also O +
its O +
interactions O +
with O +
generation O +
time O +
( O -
and O +
development O +
time O -
) O -
, O +
voltinism O -
, O +
and O +
season O +
length O +
are O +
likely O +
to O +
have O +
considerable O +
effects O +
on O +
insect O +
development O +
time O +
and O +
body O +
size O -
. O -

Overall O -
, O +
changes O +
in O +
development O +
time O -
, O +
body O +
size O -
, O +
and O +
preadult O +
survivorship O +
in O +
E. B-Species +
sinensis L-Species +
can O +
all O +
be O +
regarded O +
as O +
adaptations O +
to O +
changing O +
thermal O +
regimes O -
. O +

Age O +
and O +
Sex O +
Related O +
Responsiveness O +
of O +
Tribolium B-Species +
castaneum L-Species +
( O -
Coleoptera O -
: O +
Tenebrionidae O -
) O +
in O +
Novel O +
Behavioral O +
Bioassays O -
. O +

The O +
hardiness O +
and O +
mobile O +
nature O +
of O +
Tribolium B-Species +
castaneum I-Species +
( I-Species -
Herbst L-Species -
) O +
make O +
them O +
easy O +
to O +
work O +
with O +
but O +
are O +
the O +
same O +
factors O +
that O +
make O +
their O +
responses O +
to O +
behavior O -
- O -
modifying O +
chemical O +
stimuli O +
difficult O +
to O +
evaluate O -
. O -

To O +
overcome O +
these O +
difficulties O +
two O +
bioassays O +
were O +
developed O -
: O +
a O +
two O -
- O -
choice O +
test O +
with O +
airflow O +
and O +
a O +
diffusion O -
- O -
based O +
test O +
to O +
evaluate O +
responses O +
to O +
chemical O +
stimuli O -
. O -

The O +
two O -
- O -
choice O +
assay O +
is O +
excellent O +
for O +
rapidly O +
comparing O +
two O +
stimuli O +
or O +
examining O +
the O +
response O +
to O +
one O +
stimulus O +
against O +
a O +
control O -
. O -

The O +
diffusion O +
assay O +
determines O +
differences O +
in O +
orientation O +
behavior O +
to O +
multiple O +
simultaneous O +
stimuli O +
and O +
can O +
examine O +
other O +
behaviors O +
during O +
exposure O -
. O -

Preparation O +
of O +
individuals O +
for O +
bioassay O +
is O +
also O +
important O -
, O +
because O +
disturbance O +
increases O +
the O +
activity O +
level O +
of O +
individual O +
beetles O +
beyond O +
the O +
duration O +
of O +
the O +
disturbance O -
. O -

The O +
age O +
and O +
the O +
sex O +
of O +
beetles O +
affect O +
responsiveness O +
to O +
chemical O +
cues O -
. O -

These O +
bioassays O +
and O +
a O +
better O +
understanding O +
of O +
T. B-Species +
castaneum L-Species -
's O +
activity O +
have O +
revealed O +
approaches O +
for O +
evaluating O +
its O +
responsiveness O +
to O +
behavior O -
- O -
modifying O +
chemicals O -
. O +

Monoclonal O +
antibody O -
- O -
based O +
triple O +
antibody O +
sandwich O -
- O -
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
and O +
immunocapture O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
for O +
Odontoglossum B-Species +
ringspot I-Species +
virus L-Species +
detection O -
. O +

Odontoglossum B-Species +
ringspot I-Species +
virus L-Species +
( O -
ORSV U-Species -
) O +
infects O +
numerous O +
commercially O +
important O +
orchids O +
and O +
causes O +
significant O +
losses O +
worldwide O -
. O -

The O +
coat O +
protein O +
( O -
CP O -
) O +
gene O +
of O +
ORSV U-Species +
was O +
cloned O +
and O +
expressed O +
in O +
Escherichia B-Species +
coli L-Species +
by O +
using O +
the O +
pET-32a O +
expression O +
vector O -
, O +
and O +
the O +
expression O +
of O +
recombinant O +
protein O +
was O +
confirmed O +
by O +
Western O +
blotting O +
using O +
anti O -
- O -
ORSV U-Species +
antibodies O -
. O -

The O +
recombinant O +
protein O +
was O +
purified O +
using O +
Ni O -
- O -
NTA O +
agarose O -
, O +
and O +
the O +
purified O +
protein O +
was O +
used O +
as O +
an O +
immunogen O +
to O +
produce O +
monoclonal O +
antibodies O +
( O -
MAbs O -
) O +
and O +
polyclonal O +
antibodies O +
( O -
PAbs O -
) O -
. O -

Five O +
murine O +
MAbs O +
against O +
ORSV U-Species +
CP O +
were O +
obtained O -
. O -

Among O +
them O -
, O +
two O +
MAbs O +
( O -
6B4 O +
and O +
1D1 O -
) O +
also O +
reacted O +
with O +
TMV O +
CP O -
. O -

The O +
triple O +
antibody O +
sandwich O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
TAS O -
- O -
ELISA O -
) O +
and O +
immunocapture O +
reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
( O -
IC O -
- O -
RT O -
- O -
PCR O -
) O +
methods O +
using O +
the O +
MAb O +
( O -
8A5 O -
) O +
were O +
then O +
developed O +
for O +
sensitive O -
, O +
specific O -
, O +
and O +
rapid O +
detection O +
of O +
ORSV U-Species -
. O -

TAS O -
- O -
ELISA O +
and O +
IC O -
- O -
RT O -
- O -
PCR O +
could O +
detect O +
ORSV U-Species +
in O +
the O +
infected O +
leaf O +
saps O +
with O +
dilutions O +
of O +
1:10,240 O +
and O +
1:81,920 O +
( O -
w O -
/ O -
v O -
, O +
g O +
mL O -
( O -
-1 O -
) O -
) O -
, O +
respectively O -
. O -

TAS O -
- O -
ELISA O +
and O +
IC O -
- O -
RT O -
- O -
PCR O +
detections O +
indicated O +
that O +
ORSV U-Species +
was O +
prevalent O +
in O +
orchids O +
in O +
the O +
Zhejiang O +
Province O +
of O +
China O -
. O +

A O +
review O +
of O +
the O +
implications O +
of O +
heterozygosity O +
and O +
inbreeding O +
on O +
germplasm O +
biodiversity O +
and O +
its O +
conservation O +
in O +
the O +
silkworm U-Species -
, O +
Bombyx B-Species +
mori L-Species -
. O +

Abstract O +
Silkworm U-Species +
genebanks O +
assume O +
paramount O +
importance O +
as O +
the O +
reservoirs O +
of O +
biodiversity O +
and O +
source O +
of O +
alleles O +
that O +
can O +
be O +
easily O +
retrieved O +
for O +
genetic O +
enhancement O +
of O +
popular O +
breeds O -
. O -

More O +
than O +
4000 O +
Bombyx B-Species +
mori L-Species +
L O +
( O -
Lepidoptera O -
: O +
Bombycidae O -
) O +
strains O +
are O +
currently O +
available O +
and O +
these O +
strains O +
are O +
maintained O +
through O +
continuous O +
sibling O +
mating O -
. O -

This O +
repeated O +
sibling O +
mating O +
makes O +
the O +
populations O +
of O +
each O +
strain O +
more O +
homozygous O -
, O +
but O +
leads O +
to O +
loss O +
of O +
unique O +
and O +
valuable O +
genes O +
through O +
the O +
process O +
of O +
inbreeding O +
depression O -
. O -

Hence O -
, O +
it O +
is O +
essential O +
to O +
maintain O +
a O +
minimal O +
degree O +
of O +
heterozygosity O +
within O +
the O +
population O +
of O +
each O +
silkworm U-Species +
strain O -
, O +
especially O +
in O +
the O +
traditional O +
geographic O +
strains O -
, O +
to O +
avoid O +
such O +
loss O -
. O -

As O +
a O +
result O -
, O +
accurate O +
estimation O +
of O +
genetic O +
diversity O +
is O +
becoming O +
more O +
important O +
in O +
silkworm U-Species +
genetic O +
resources O +
conservation O -
. O -

Application O +
of O +
molecular O +
markers O +
help O +
estimate O +
genetic O +
diversity O +
much O +
more O +
accurately O +
than O +
that O +
of O +
morphological O +
traits O -
. O -

Since O +
a O +
minimal O +
amount O +
of O +
heterozygosity O +
in O +
each O +
silkworm U-Species +
strain O +
is O +
essential O +
for O +
better O +
conservation O +
by O +
avoiding O +
inbreeding O +
depression O -
, O +
this O +
article O +
overviews O +
both O +
theoretical O +
and O +
practical O +
importance O +
of O +
heterozygosity O +
together O +
with O +
impacts O +
of O +
inbreeding O +
depression O +
and O +
the O +
merits O +
and O +
demerits O +
of O +
neutral O +
molecular O +
markers O +
for O +
measurements O +
of O +
both O +
heterozygosity O +
and O +
inbreeding O +
depression O +
in O +
the O +
silkworm U-Species +
Bombyx B-Species +
mori L-Species -
. O +

Evidence O +
for O +
the O +
higher O +
importance O +
of O +
signal O +
size O +
over O +
body O +
size O +
in O +
aposematic O +
signaling O +
in O +
insects O -
. O +

To O +
understand O +
the O +
evolution O +
of O +
warning O +
coloration O -
, O +
it O +
is O +
important O +
to O +
distinguish O +
between O +
different O +
aspects O +
of O +
conspicuous O +
color O +
patterns O -
. O -

As O +
an O +
example O -
, O +
both O +
pattern O +
element O +
size O +
and O +
body O +
size O +
of O +
prey O +
have O +
been O +
shown O +
to O +
enhance O +
the O +
effectiveness O +
of O +
warning O +
signals O -
. O -

However O -
, O +
it O +
is O +
unclear O +
whether O +
the O +
effect O +
of O +
body O +
size O +
is O +
merely O +
a O +
side O +
effect O +
of O +
proportionally O +
increasing O +
pattern O +
elements O -
, O +
or O +
if O +
there O +
is O +
an O +
effect O +
of O +
body O +
size O +
per O +
se O -
. O -

These O +
possibilities O +
were O +
evaluated O +
by O +
offering O +
different O +
sized O +
artificial O +
caterpillars O +
with O +
either O +
fixed O +
or O +
proportionally O +
increasing O +
aposematic O +
color O +
signal O +
elements O +
to O +
wild O +
great B-Species +
tits L-Species -
, O +
Parus B-Species +
major I-Species +
L. L-Species +
( O -
Passeriformes O -
: O +
Paridae O -
) O -
. O -

The O +
birds O -
' O +
hesitation O +
time O +
to O +
attack O +
each O +
" O -
caterpillar O -
" O +
was O +
used O +
as O +
a O +
measure O +
of O +
the O +
warning O +
effect O -
. O -

The O +
hesitation O +
time O +
showed O +
a O +
significant O -
, O +
positive O +
size O -
- O -
dependence O +
with O +
the O +
caterpillars O +
whose O +
pattern O +
elements O +
increased O +
proportionally O +
with O +
their O +
body O +
size O -
. O -

In O +
contrast O -
, O +
no O +
size O +
dependence O +
was O +
found O +
in O +
the O +
larvae O +
with O +
fixed O -
- O -
size O +
signal O +
elements O -
. O -

Such O +
a O +
difference O +
in O +
mortality O +
curves O +
is O +
consistent O +
with O +
the O +
idea O +
that O +
pattern O +
element O +
size O +
is O +
a O +
more O +
important O +
aspect O +
than O +
body O +
size O +
in O +
enhancing O +
a O +
warning O +
signal O -
. O -

Since O +
no O +
evidence O +
of O +
an O +
effect O +
of O +
body O +
size O +
per O +
se O +
on O +
signal O +
efficiency O +
was O +
found O -
, O +
this O +
study O +
does O +
not O +
support O +
the O +
hypothesis O +
that O +
aposematic O +
insects O +
gain O +
more O +
from O +
large O +
size O +
than O +
cryptic O +
ones O -
. O +

Post O -
- O -
egression O +
host O +
tissue O +
feeding O +
is O +
another O +
strategy O +
of O +
host O +
regulation O +
by O +
the O +
Koinobiont O +
wasp O -
, O +
Toxoneuron B-Species +
nigriceps L-Species -
. O +

Koinobiont O +
wasps O +
start O +
their O +
lives O +
as O +
hemolymph O +
feeders O +
inside O +
the O +
host O +
body O -
, O +
but O +
before O +
they O +
egress O +
from O +
the O +
host O +
many O +
become O +
tissue O +
predators O -
. O -

One O +
species O -
, O +
the O +
endoparasitoid O +
Toxoneuron B-Species +
nigriceps L-Species +
Viereck O +
( O -
Hymenoptera O -
: O +
Braconidae O -
) O -
, O +
exhibits O +
the O +
unusual O +
behavior O +
of O +
egressing O +
before O +
initiating O +
tissue O +
predation O -
. O -

After O +
egression O +
from O +
the O +
host O -
, O +
it O +
reinserts O +
its O +
head O +
into O +
the O +
host O +
body O +
to O +
begin O +
tissue O +
feeding O -
. O -

These O +
third O +
instar O +
T. B-Species +
nigriceps L-Species +
larvae O +
show O +
a O +
significant O +
increase O +
in O +
body O +
size O +
and O +
mass O +
after O +
post O -
- O -
egression O +
feeding O -
. O -

Through O +
this O +
project O +
the O +
importance O +
of O +
post O -
- O -
egression O +
feeding O +
in O +
the O +
development O +
of O +
T. B-Species +
nigriceps L-Species +
in O +
its O +
host O +
the O +
tobacco B-Species +
budworm L-Species -
, O +
Heliothis B-Species +
virescens L-Species +
Fabricius O +
( O -
Lepidoptera O -
: O +
Noctuidae O -
) O -
, O +
has O +
been O +
evaluated O -
. O -

The O +
study O +
was O +
conducted O +
by O +
preventing O +
the O +
egressed O +
third O +
instar O +
T. B-Species +
nigriceps L-Species +
larvae O +
from O +
feeding O +
on O +
host O +
tissue O +
and O +
observing O +
whether O +
they O +
could O +
undergo O +
further O +
development O -
. O -

Though O +
some O +
of O +
the O +
larvae O +
that O +
were O +
prevented O +
from O +
post O -
- O -
egression O +
feeding O +
did O +
undergo O +
cocoon O +
formation O -
, O +
pupation O -
, O +
and O +
adult O +
emergence O +
they O +
were O +
inferior O +
in O +
terms O +
of O +
size O -
, O +
body O +
mass O -
, O +
and O +
survival O +
to O +
those O +
that O +
developed O +
from O +
larvae O +
allowed O +
to O +
feeding O +
after O +
egression O -
. O -

Hence O -
, O +
it O +
is O +
concluded O +
that O +
post O -
- O -
egression O +
host O +
tissue O +
feeding O +
is O +
essential O +
for O +
the O +
normal O +
development O +
of O +
T. B-Species +
nigriceps L-Species -
, O +
as O +
the O +
prevention O +
of O +
feeding O +
resulted O +
in O +
significantly O +
lighter O +
and O +
smaller O +
larvae O -
, O +
cocoons O -
, O +
and O +
adults O +
as O +
well O +
as O +
deformed O +
adults O +
and O +
reduced O +
adult O +
survival O -
. O -

Post O -
- O -
egression O +
feeding O +
as O +
a O +
host O +
regulatory O +
strategy O +
is O +
discussed O -
. O +

Transcript O +
analysis O +
and O +
comparative O +
evaluation O +
of O +
shaker O +
and O +
slowmo O +
gene O +
homologues O +
from O +
the O +
European B-Species +
corn I-Species +
borer L-Species -
, O +
Ostrinia B-Species +
nubilalis L-Species -
. O +

The O +
movement O +
and O +
dispersal O +
of O +
larval O +
Lepidoptera O +
impact O +
their O +
survival O +
and O +
distribution O +
within O +
the O +
natural O +
landscape O -
. O -

Homologues O +
of O +
the O +
Drosophila O +
behaviour O -
- O -
linked O +
genes O +
shaker O +
( O -
shkr O -
) O +
and O +
slowmo O +
( O -
slmo O -
) O +
were O +
identified O +
from O +
Ostrinia B-Species +
nubilalis L-Species +
( O -
Lepidoptera O -
: O +
Crambidae O -
) O -
. O -

Onshkr O +
was O +
isolated O +
as O +
a O +
1610-nucleotide O +
( O -
nt O -
) O +
constitutively O +
expressed O +
transcript O +
encoding O +
a O +
membrane O -
- O -
localized O +
469-amino O -
- O -
acid O +
( O -
aa O -
) O +
protein O +
with O +
a O +
conserved O +
tetramerization O +
domain O +
and O +
the O +
six O -
- O -
domain O +
architecture O +
necessary O +
for O +
the O +
molecule O +
to O +
fold O +
into O +
an O +
active O +
K O -
( O -
+ O -
) O +
channel O -
. O -

Three O +
expressed O +
splice O +
variants O +
of O +
682 O -
, O +
970 O +
and O +
1604 O +
nt O +
were O +
identified O +
for O +
the O +
Onslmo O +
gene O -
, O +
and O +
encode O +
predicted O +
141 O +
and O +
228 O +
aa O +
proteins O +
with O +
a O +
conserved O +
protein O +
of O +
relevant O +
evolutionary O +
and O +
lymphoid O +
interest O +
( O -
PRELI O -
) O +
domain O +
that O +
may O +
function O +
in O +
mitochondrial O +
protein O +
sorting O +
and O +
perinuclear O +
protein O +
localization O -
. O -

Onshkr O +
and O +
Onslmo O +
protein O +
sequences O +
aligned O +
within O +
monophyletic O +
lepidopteran O +
groups O -
. O +

Projectin O +
PEVK O +
domain O -
, O +
splicing O +
variants O +
and O +
domain O +
structure O +
in O +
basal O +
and O +
derived O +
insects O -
. O +

The O +
third O +
elastic O +
filament O +
of O +
striated O +
muscles O +
consists O +
of O +
giant O +
proteins O -
: O +
titin O +
( O -
in O +
vertebrates O -
) O +
and O +
kettin O -
/ O -
projectin O +
( O -
in O +
insects O -
) O -
. O -

In O +
all O +
three O +
proteins O -
, O +
elasticity O +
is O +
at O +
least O +
partly O +
associated O +
with O +
the O +
so O -
- O -
called O +
PEVK O +
domain O -
. O -

The O +
projectin O +
PEVK O +
domains O +
of O +
diverse O +
insects O +
are O +
highly O +
divergent O +
compared O +
with O +
an O +
otherwise O +
conserved O +
protein O +
organization O -
. O -

We O +
present O +
the O +
characterization O +
of O +
the O +
PEVK O +
domain O +
in O +
two O +
dragonflies O +
and O +
in O +
human B-Species +
lice L-Species -
. O -

A O +
conserved O +
segment O +
at O +
the O +
end O +
of O +
the O +
PEVK O -
, O +
the O +
NH O -
( O -
2 O -
) O -
-terminal O +
conserved O +
segment-1 O +
( O -
NTCS-1 O -
) O -
, O +
may O +
serve O +
as O +
an O +
anchor O +
point O +
for O +
projectin O +
to O +
either O +
myosin O +
or O +
actin O -
, O +
providing O +
a O +
mechanical O +
link O -
. O -

The O +
analysis O +
of O +
alternative O +
splicing O +
variants O +
identifies O +
the O +
shortest O +
PEVK O +
isoform O +
as O +
the O +
predominant O +
form O +
in O +
the O +
flight O +
muscles O +
of O +
several O +
insects O -
, O +
possibly O +
contributing O +
to O +
myofibrillar O +
stiffness O -
. O +

Clinical O +
management O +
of O +
Staphylococcus B-Species +
aureus L-Species +
bacteraemia O -
. O -

Staphylococcus B-Species +
aureus L-Species +
bacteraemia O +
is O +
one O +
of O +
the O +
most O +
common O +
serious O +
bacterial O +
infections O +
worldwide O -
. O -

In O +
the O +
UK O +
alone O -
, O +
around O +
12,500 O +
cases O +
each O +
year O +
are O +
reported O -
, O +
with O +
an O +
associated O +
mortality O +
of O +
about O +
30 O -
% O -
, O +
yet O +
the O +
evidence O +
guiding O +
optimum O +
management O +
is O +
poor O -
. O -

To O +
date O -
, O +
fewer O +
than O +
1500 O +
patients O +
with O +
S B-Species +
aureus L-Species +
bacteraemia O +
have O +
been O +
recruited O +
to O +
16 O +
controlled O +
trials O +
of O +
antimicrobial O +
therapy O -
. O -

Consequently O -
, O +
clinical O +
practice O +
is O +
driven O +
by O +
the O +
results O +
of O +
observational O +
studies O +
and O +
anecdote O -
. O -

Here O -
, O +
we O +
propose O +
and O +
review O +
ten O +
unanswered O +
clinical O +
questions O +
commonly O +
posed O +
by O +
those O +
managing O +
S B-Species +
aureus L-Species +
bacteraemia O -
. O -

Our O +
findings O +
define O +
the O +
major O +
areas O +
of O +
uncertainty O +
in O +
the O +
management O +
of O +
S B-Species +
aureus L-Species +
bacteraemia O +
and O +
highlight O +
just O +
two O +
key O +
principles O -
. O -

First O -
, O +
all O +
infective O +
foci O +
must O +
be O +
identified O +
and O +
removed O +
as O +
soon O +
as O +
possible O -
. O -

Second O -
, O +
long O -
- O -
term O +
antimicrobial O +
therapy O +
is O +
required O +
for O +
those O +
with O +
persistent O +
bacteraemia O +
or O +
a O +
deep O -
, O +
irremovable O +
focus O -
. O -

Beyond O +
this O -
, O +
the O +
best O +
drugs O -
, O +
dose O -
, O +
mode O +
of O +
delivery O -
, O +
and O +
duration O +
of O +
therapy O +
are O +
uncertain O -
, O +
a O +
situation O +
compounded O +
by O +
emerging O +
S B-Species +
aureus L-Species +
strains O +
that O +
are O +
resistant O +
to O +
old O +
and O +
new O +
antibiotics O -
. O -

We O +
discuss O +
the O +
consequences O +
on O +
clinical O +
practice O -
, O +
and O +
how O +
these O +
findings O +
define O +
the O +
agenda O +
for O +
future O +
clinical O +
research O -
. O +

A O +
new O +
model O +
of O +
Epstein B-Species -
- I-Species -
Barr I-Species +
virus L-Species +
infection O +
reveals O +
an O +
important O +
role O +
for O +
earlylytic O +
viral O +
protein O +
expression O +
in O +
the O +
development O +
of O +
lymphomas O -
. O -

Epstein B-Species -
- I-Species -
Barr I-Species +
virus L-Species +
( O -
EBV U-Species -
) O +
infects O +
cells O +
in O +
latent O +
or O +
lytic O +
forms O -
, O +
but O +
the O +
roleof O +
lytic O +
infection O +
in O +
EBV U-Species -
- O -
induced O +
lymphomas O +
is O +
unclear O -
. O -

Here O -
, O +
we O +
have O +
used O +
anew O +
humanized O +
mouse U-Species +
model O -
, O +
in O +
which O +
both O +
human U-Species +
fetal O +
CD34 O -
( O -
+ O -
) O +
hematopoietic O +
stemcells O +
and O +
thymus O -
/ O -
liver O +
tissue O +
are O +
transplanted O -
, O +
to O +
compare O +
EBV U-Species +
pathogenesis O +
andlymphoma O +
formation O +
following O +
infection O +
with O +
a O +
lytic O +
replication O -
- O -
defectiveBZLF1-deleted O +
( O -
Z O -
- O -
KO O -
) O +
virus O +
or O +
a O +
lytically O +
active O +
BZLF1 O -
( O -
+ O -
) O +
control O -
. O -

Both O +
thecontrol O +
and O +
Z O -
- O -
KO O +
viruses O +
established O +
long O -
- O -
term O +
viral O +
latency O +
in O +
all O +
infectedanimals O -
. O -

The O +
infection O +
appeared O +
well O +
controlled O +
in O +
some O +
animals O -
, O +
but O +
otherseventually O +
developed O +
CD20 O -
( O -
+ O -
) O +
diffuse O +
large O +
B O +
cell O +
lymphomas O +
( O -
DLBCL O -
) O -
. O -

Animalsinfected O +
with O +
the O +
control O +
virus O +
developed O +
tumors O +
more O +
frequently O +
than O +
Z O -
- O -
KOvirus O -
- O -
infected O +
animals O -
. O -

Specific O +
immune O +
responses O +
against O +
EBV U-Species -
- O -
infected O +
B O +
cellswere O +
generated O +
in O +
mice U-Species +
infected O +
with O +
either O +
the O +
control O +
virus O +
or O +
the O +
Z O -
- O -
KOvirus O -
. O -

In O +
both O +
cases O -
, O +
forms O +
of O +
viral O +
latency O +
( O -
type O +
I O +
and O +
type O +
IIB O -
) O +
wereobserved O +
that O +
are O +
less O +
immunogenic O +
than O +
the O +
highly O +
transforming O +
form O +
( O -
type O +
III O -
) O -
commonly O +
found O +
in O +
tumors O +
of O +
immunocompromised O +
hosts O -
, O +
suggesting O +
that O +
immunepressure O +
contributed O +
to O +
the O +
outcome O +
of O +
the O +
infection O -
. O -

These O +
results O +
point O +
to O +
animportant O +
role O +
for O +
lytic O +
EBV U-Species +
infection O +
in O +
the O +
development O +
of O +
B O +
cell O +
lymphomasin O +
the O +
context O +
of O +
an O +
active O +
host O +
immune O +
response O -
. O -

Serine O -
- O -
threonine O +
ubiquitination O +
mediates O +
downregulation O +
of O +
BST-2 O -
/ O -
tetherin O +
and O +
relief O +
of O +
restricted O +
virion O +
release O +
by O +
HIV-1 U-Species +
Vpu O -
. O +

The O +
HIV-1 U-Species +
protein O +
Vpu O +
counteracts O +
the O +
antiviral O +
activity O +
of O +
the O +
innate O +
restriction O +
factor O +
BST-2 O -
/ O -
tetherin O +
by O +
a O +
mechanism O +
that O +
partly O +
depends O +
on O +
its O +
interaction O +
with O +
Beta O -
- O -
TrCP O -
, O +
a O +
substrate O +
adaptor O +
for O +
an O +
SCF O +
( O -
Skp O -
- O -
Cullin O +
1-F O +
box O -
) O +
E3 O +
ubiquitin O +
ligase O +
complex O -
. O -

This O +
suggests O +
that O +
Vpu O +
stimulates O +
the O +
ubiquitination O +
of O +
BST-2 O +
and O +
that O +
this O +
underlies O +
the O +
relief O +
of O +
restriction O -
. O -

Here O -
, O +
we O +
show O +
that O +
Vpu O +
stimulates O +
ubiquitination O +
of O +
BST-2 O -
. O -

Mutation O +
of O +
all O +
potential O +
ubiquitination O +
sites O +
in O +
the O +
cytoplasmic O +
domain O +
of O +
BST-2 O -
, O +
including O +
lysines O -
, O +
cysteines O -
, O +
serines O -
, O +
and O +
threonines O -
, O +
abrogates O +
Vpu O -
- O -
mediated O +
ubiquitination O -
. O -

However O -
, O +
a O +
serine O -
- O -
threonine O -
- O -
serine O +
sequence O +
specifically O +
mediates O +
the O +
downregulation O +
of O +
BST-2 O +
from O +
the O +
cell O +
surface O +
and O +
the O +
optimal O +
relief O +
of O +
restricted O +
virion O +
release O -
. O -

Serine O -
- O -
threonine O +
ubiquitination O +
of O +
BST-2 O +
is O +
likely O +
part O +
of O +
the O +
mechanism O +
by O +
which O +
Vpu O +
counteracts O +
innate O +
defenses O -
. O +

Small O -
- O -
molecule O +
inhibition O +
of O +
human B-Species +
immunodeficiency I-Species +
virus I-Species +
type L-Species +
1 O +
infection O +
by O +
virus O +
capsid O +
destabilization O -
. O +

Human B-Species +
immunodeficiency I-Species +
virus I-Species +
type L-Species +
1 O +
( O -
HIV-1 U-Species -
) O +
infection O +
is O +
dependent O +
on O +
the O +
proper O +
disassembly O +
of O +
the O +
viral O +
capsid O -
, O +
or O +
" O -
uncoating O -
, O -
" O +
in O +
target O +
cells O -
. O -

The O +
HIV-1 O +
capsid O +
consists U-Species +
of O +
a O +
conical O +
multimeric O +
complex O +
of O +
the O +
viral O +
capsid O +
protein O +
( O -
CA O -
) O +
arranged O +
in O +
a O +
hexagonal O +
lattice O -
. O -

Mutations O +
in O +
CA O +
that O +
destabilize O +
the O +
viral O +
capsid O +
result O +
in O +
impaired O +
infection O +
owing O +
to O +
defects O +
in O +
reverse O +
transcription O +
in O +
target O +
cells O -
. O -

We O +
describe O +
here O +
the O +
mechanism O +
of O +
action O +
of O +
a O +
small O +
molecule O +
HIV-1 O +
inhibitor O -
, O +
PF-3450074 O +
( O -
PF74 O -
) O -
, O +
which O +
targets O +
CA O -
. O -

PF74 O +
acts O +
at O +
an O +
early O +
stage O +
of O +
HIV-1 O +
infection O +
and O +
inhibits O +
reverse O +
transcription O +
in O +
target O +
cells O -
. O -

We O +
show O +
that O +
PF74 O +
binds O +
specifically O +
to O +
HIV-1 O +
particles O -
, O +
and O +
substitutions O +
in O +
CA O +
that O +
confer O +
resistance O +
to O +
the O +
compound O +
prevent O +
binding O -
. O -

A O +
single O +
point O +
mutation O +
in O +
CA O +
that O +
stabilizes O +
the O +
HIV-1 O +
core O +
also U-Species +
conferred O +
strong O +
resistance O +
to O +
the O +
virus O +
without O +
inhibiting O +
compound O +
binding O -
. O -

Treatment O +
of O +
HIV-1 O +
particles O +
or O +
purified O +
cores O +
with O +
PF74 O +
destabilized O +
the O +
viral O +
capsid O +
in O +
vitro O -
. O -

Furthermore O -
, O +
the O +
compound O +
induced O +
the O +
rapid O +
dissolution O +
of O +
the O +
HIV-1 O +
capsid O +
in U-Species +
target O +
cells O -
. O -

PF74 O +
antiviral O +
activity O +
was O +
promoted O +
by O +
binding O +
of O +
the O +
host O +
protein O +
cyclophilin O +
A O +
to O +
the O +
HIV-1 O +
capsid O -
, U-Species +
and O +
PF74 O +
and O +
cyclosporine O +
exhibited O +
mutual O +
antagonism O -
. O -

Our O +
data O +
suggest O +
that O +
PF74 O +
triggers O +
premature O +
HIV-1 O +
uncoating O +
in O +
target O +
cells O -
, O +
thereby O +
mimicking O +
the O +
activity O +
of O +
the O +
retrovirus O +
restriction O +
factor O +
TRIM5alpha O -
. O -

This O +
study O +
highlights O +
uncoating O +
as O +
a O +
step O +
in O +
the O +
HIV-1 O +
life O +
cycle U-Species +
that O +
is O +
susceptible O +
to O +
small O +
molecule O +
intervention O -
. O +

Macaque O +
long O -
- O -
term O +
nonprogressors O +
resist O +
superinfection O +
with O +
multiple O +
CD8 O -
+ O +
T O +
cell O +
escape O +
variants O +
of O +
simian B-Species +
immunodeficiency I-Species +
virus L-Species -
. O +

Human B-Species +
immunodeficiency I-Species +
virus L-Species +
( O -
HIV U-Species -
) O -
-positive O +
individuals O +
can O +
be O +
superinfected O +
with O +
different O +
virus O +
strains O -
. O -

Individuals O +
who O +
control O +
an O +
initial O +
HIV U-Species +
infection O +
are O +
therefore O +
still O +
at O +
risk O +
for O +
subsequent O +
infection O +
with O +
divergent O +
viruses O -
, O +
but O +
the O +
barriers O +
to O +
such O +
superinfection O +
remain O +
unclear O -
. O -

Here O +
we O +
tested O +
long O -
- O -
term O +
nonprogressors O -
' O +
( O -
LTNPs O -
' O -
) O +
susceptibility O +
to O +
superinfection O +
using O +
Indian B-Species +
rhesus I-Species +
macaques L-Species +
that O +
express O +
the O +
major O +
histocompatibility O +
complex O +
class O +
I O +
( O -
MHC O -
- O -
I O -
) O +
allele O +
Mamu O -
- O -
B O +
17 O -
, O +
which O +
is O +
associated O +
with O +
control O +
of O +
the O +
pathogenic O +
AIDS O +
virus B-Species +
SIVmac239 L-Species -
. O -

The O +
Mamu O -
- O -
B O +
17-restricted O +
CD8 O -
( O -
+ O -
) O +
T O +
cell O +
repertoire O +
is O +
focused O +
almost O +
entirely O +
on O +
5 O +
epitopes O -
. O -

We O +
engineered O +
a O +
series O +
of O +
SIVmac239 O +
variants O +
bearing O +
mutations O +
in O +
3 O -
, O +
4 O -
, O +
or O +
all O +
5 O +
of O +
these O +
epitopes O +
and O +
used O +
them O +
to O +
serially O +
challenge O +
2 O +
Mamu O -
- O -
B O +
17-positive O +
LTNPs O -
. O -

None O +
of O +
the O +
escape O +
variants O +
caused O +
breakthrough O +
replication O +
in O +
LTNPs O -
, O +
although O +
they O +
readily O +
infected O +
Mamu O -
- O -
B O +
17-negative O +
naive O +
macaques O -
. O -

In O +
vitro O +
competing O +
coculture O +
assays O +
and O +
examination O +
of O +
viral O +
evolution O +
in O +
hosts O +
lacking O +
Mamu O -
- O -
B O +
17 O +
suggested O +
that O +
the O +
mutant O +
viruses O +
had O +
negligible O +
defects O +
in O +
replicative O +
fitness O -
. O -

Both O +
LTNPs O +
maintained O +
robust O +
immune O +
responses O -
, O +
including O +
simian B-Species +
immunodeficiency I-Species +
virus L-Species +
( O -
SIV U-Species -
) O -
-specific O +
CD8 O -
( O -
+ O -
) O +
and O +
CD4 O -
( O -
+ O -
) O +
T O +
cells O +
and O +
neutralizing O +
antibodies O -
. O -

Our O +
results O +
suggest O +
that O +
escape O +
mutations O +
in O +
epitopes O +
bound O +
by O +
" O -
protective O -
" O +
MHC O -
- O -
I O +
molecules O +
may O +
not O +
be O +
sufficient O +
to O +
establish O +
superinfection O +
in O +
LTNPs O -
. O +

Determinants O +
that O +
specify O +
the O +
integration O +
pattern O +
of O +
retrotransposon O +
Tf1 O +
in O +
the O +
fbp1 O +
promoter O +
of O +
Schizosaccharomyces B-Species +
pombe L-Species -
. O +

Long O +
terminal O +
repeat O +
( O -
LTR O -
) O +
retrotransposons O +
are O +
closely O +
related O +
to O +
retroviruses O +
and O -
, O +
as O +
such O -
, O +
are O +
important O +
models O +
for O +
the O +
study O +
of O +
viral O +
integration O +
and O +
target O +
site O +
selection O -
. O -

The O +
transposon O +
Tf1 O +
of O +
Schizosaccharomyces B-Species +
pombe L-Species +
integrates O +
with O +
a O +
strong O +
preference O +
for O +
the O +
promoters O +
of O +
polymerase O +
II O +
( O -
Pol O +
II O -
) O -
-transcribed O +
genes O -
. O -

Previous O +
work O +
in O +
vivo O +
with O +
plasmid O -
- O -
based O +
targets O +
revealed O +
that O +
the O +
patterns O +
of O +
insertion O +
were O +
promoter O +
specific O +
and O +
highly O +
reproducible O -
. O -

To O +
determine O +
which O +
features O +
of O +
promoters O +
are O +
recognized O +
by O +
Tf1 O -
, O +
we O +
studied O +
integration O +
in O +
a O +
promoter O +
that O +
has O +
been O +
characterized O -
. O -

The O +
promoter O +
of O +
fbp1 O +
has O +
two O +
upstream O +
activating O +
sequences O -
, O +
UAS1 O +
and O +
UAS2 O -
. O -

We O +
found O +
that O +
integration O +
was O +
targeted O +
to O +
two O +
windows O -
, O +
one O +
180 O +
nucleotides O +
( O -
nt O -
) O +
upstream O +
and O +
the O +
other O +
30 O +
to O +
40 O +
nt O +
downstream O +
of O +
UAS1 O -
. O -

A O +
series O +
of O +
deletions O +
in O +
the O +
promoter O +
showed O +
that O +
the O +
integration O +
activities O +
of O +
these O +
two O +
regions O +
functioned O +
autonomously O -
. O -

Integration O +
assays O +
of O +
UAS2 O +
and O +
of O +
a O +
synthetic O +
promoter O +
demonstrated O +
that O +
strong O +
promoter O +
activity O +
alone O +
was O +
not O +
sufficient O +
to O +
direct O +
integration O -
. O -

The O +
factors O +
that O +
modulate O +
the O +
transcription O +
activities O +
of O +
UAS1 O +
and O +
UAS2 O +
include O +
the O +
activators O +
Atf1p O -
, O +
Pcr1p O -
, O +
and O +
Rst2p O +
as O +
well O +
as O +
the O +
repressors O +
Tup11p O -
, O +
Tup12p O -
, O +
and O +
Pka1p O -
. O -

Strains O +
lacking O +
each O +
of O +
these O +
proteins O +
revealed O +
that O +
Atf1p O +
alone O +
mediated O +
the O +
sites O +
of O +
integration O -
. O -

These O +
data O +
indicate O +
that O +
Atf1p O +
plays O +
a O +
direct O +
and O +
specific O +
role O +
in O +
targeting O +
integration O +
in O +
the O +
promoter O +
of O +
fbp1 O -
. O +

Replicative O +
and O +
transcriptional O +
activities O +
of O +
hepatitis B-Species +
B I-Species +
virus L-Species +
in O +
patients O +
coinfected O +
with O +
hepatitis U-Species +
B O +
and O +
hepatitis B-Species +
delta I-Species +
viruses L-Species -
. O +

Hepatitis B-Species +
B I-Species +
virus L-Species +
( O -
HBV U-Species -
) O +
and O +
hepatitis B-Species +
delta I-Species +
virus L-Species +
( O -
HDV U-Species -
) O +
interplay O +
was O +
investigated O +
by O +
examining O +
liver O +
and O +
serum O +
samples O +
from O +
21 O +
coinfected O +
and O +
22 O +
HBV U-Species -
- O -
monoinfected O +
patients O +
with O +
chronic O +
liver O +
disease O -
. O -

Different O +
real O -
- O -
time O +
PCR O +
assays O +
were O +
applied O +
to O +
evaluate O +
intrahepatic O +
amounts O +
of O +
HBV U-Species +
DNA O -
, O +
covalently O +
closed O +
circular O +
DNA O +
( O -
cccDNA O -
) O -
, O +
pregenomic O +
RNA O +
( O -
pgRNA O -
) O -
, O +
pre O -
- O -
S O -
/ O -
S O +
RNAs O -
, O +
and O +
HDV U-Species +
RNA O -
. O -

Besides O +
HBV U-Species +
DNA O +
and O +
HDV U-Species +
RNA O +
levels O -
, O +
HBsAg O +
concentrations O +
in O +
the O +
sera O +
were O +
also O +
determined O -
. O -

HDV U-Species -
- O -
coinfected O +
cases O +
showed O +
significantly O +
lower O +
median O +
levels O +
of O +
serum O +
HBV U-Species +
DNA O +
( O -
-5 O +
log O -
) O -
, O +
intrahepatic O +
relaxed O -
- O -
circular O +
DNA O +
( O -
-2 O +
log O -
) O -
, O +
and O +
cccDNA O +
( O -
-2 O +
log O -
) O +
than O +
those O +
of O +
HBV U-Species -
- O -
monoinfected O +
cases O -
. O -

Interestingly O -
, O +
pgRNA O +
and O +
pre O -
- O -
S O -
/ O -
S O +
RNA O +
amounts O +
were O +
significantly O +
lower O +
( O -
both O +
-1 O +
log O -
) O +
in O +
HDV U-Species -
- O -
positive O +
patients O -
, O +
whereas O +
serum O +
HBsAg O +
concentrations O +
were O +
comparable O +
between O +
the O +
two O +
patient O +
groups O -
. O -

Pre O -
- O -
S O -
/ O -
S O +
RNA O +
and O +
HBsAg O +
amounts O +
per O +
cccDNA O +
molecule O +
were O +
higher O +
in O +
HDV U-Species -
- O -
positive O +
patients O +
( O -
3-fold O +
and O +
1 O +
log O -
, O +
respectively O -
) O -
, O +
showing O +
that O +
HBV U-Species +
replication O +
was O +
reduced O -
, O +
whereas O +
synthesis O +
of O +
envelope O +
proteins O +
was O +
not O +
specifically O +
decreased O -
. O -

The O +
ratios O +
of O +
cccDNA O +
to O +
intracellular O +
total O +
HBV U-Species +
DNA O +
showed O +
a O +
larger O +
proportion O +
of O +
cccDNA O +
molecules O +
in O +
HDV U-Species -
- O -
positive O +
cases O -
. O -

For O +
these O +
patients O -
, O +
both O +
intrahepatic O +
and O +
serum O +
HDV U-Species +
RNA O +
amounts O +
were O +
associated O +
with O +
cccDNA O +
but O +
not O +
with O +
HBsAg O +
or O +
HBV O +
DNA O +
levels O -
. O -

Finally O -
, O +
HBV O +
genomes O +
with O +
large O +
deletions O +
in O +
the O +
basal O +
core O +
promoter O -
/ O -
precore O +
region O +
were O +
detected O +
in O +
5 O -
/ O -
21 O +
HDV U-Species -
- O -
positive O +
patients O +
but O +
in O +
no O +
HDV U-Species -
- O -
negative O +
patients O +
and O +
were O +
associated O +
with O +
lower O +
viremia O +
levels O -
. O -

These O +
findings O +
provide O +
significant O +
information O +
about O +
the O +
interference O +
exerted O +
by O +
HDV O +
on O +
HBV U-Species +
replication O +
and O +
transcription O +
activities O +
in O +
the O +
human U-Species +
liver O -
. O +

Lasting O +
effects O +
of O +
maternal O +
behaviour O +
on O +
the O +
distribution O +
of O +
a O +
dispersive O +
stream O +
insect O -
. O +

1 O -
. O -

Predicting O +
population O +
dynamics O +
at O +
large O +
spatial O +
scales O +
requires O +
integrating O +
information O +
about O +
spatial O +
distribution O +
patterns O -
, O +
inter O -
- O -
patch O +
movement O +
rates O +
and O +
within O -
- O -
patch O +
processes O -
. O -

Advective O +
dispersal O +
of O +
aquatic O +
species O +
by O +
water O +
movement O +
is O +
considered O +
paramount O +
to O +
understanding O +
their O +
population O +
dynamics O -
. O -

Rivers O +
are O +
model O +
advective O +
systems O -
, O +
and O +
the O +
larvae O +
of O +
baetid O +
mayflies O +
are O +
considered O +
quintessential O +
dispersers O -
. O -

Egg O +
laying O +
of O +
baetids O +
along O +
channels O +
is O +
patchy O +
and O +
reflects O +
the O +
distribution O +
of O +
oviposition O +
sites O -
, O +
but O +
larvae O +
are O +
assumed O +
to O +
drift O +
frequently O +
and O +
far O -
, O +
thereby O +
erasing O +
patterns O +
created O +
during O +
oviposition O -
. O -

Dispersal O +
kernels O +
are O +
often O +
overestimated O -
, O +
however O -
, O +
and O +
empirical O +
tests O +
of O +
such O +
assumptions O +
are O +
warranted O +
because O +
of O +
the O +
pivotal O +
role O +
distribution O +
patterns O +
can O +
have O +
on O +
populations O -
. O -

2 O -
. O -

We O +
tested O +
empirically O +
whether O +
the O +
egg O +
distribution O +
patterns O +
arising O +
from O +
oviposition O +
behaviours O +
persisted O +
and O +
were O +
reflected O +
in O +
the O +
distribution O +
patterns O +
of O +
larval O +
Baetis B-Species +
rhodani L-Species -
. O -

In O +
field O +
surveys O -
, O +
we O +
tested O +
for O +
associations O +
between O +
egg O +
mass O +
and O +
larval O +
densities O +
over O +
1 O +
km O +
lengths O +
of O +
four O +
streams O -
. O -

A O +
control O +
species O -
, O +
the O +
mayfly O +
Ephemerella O +
ignita O -
, O +
was O +
employed O +
to O +
test O +
for O +
covarying O +
environmental O +
factors O -
. O -

We O +
estimated O +
drift O +
rates O +
directly O +
to O +
test O +
whether O +
larvae O +
dispersed O +
between O +
riffles O +
( O -
patches O +
of O +
high O +
egg O +
mass O +
density O -
) O +
and O +
whether O +
drift O +
rates O +
were O +
density O -
- O -
dependent O +
or O +
density O -
- O -
related O +
- O +
expected O +
outcomes O +
if O +
drift O +
erases O +
patterns O +
established O +
by O +
maternal O +
behaviours O -
. O -

3 O -
. O -

Positive O +
associations O +
between O +
egg O +
masses O +
and O +
larval O +
benthic O +
densities O +
were O +
found O +
for O +
neonate O +
and O +
mid O -
- O -
stage O +
larvae O +
of O +
Baetis O -
, O +
but O +
not O +
the O +
control O +
species O -
, O +
suggesting O +
persistence O +
of O +
the O +
patchy O +
distribution O +
patterns O +
established O +
at O +
oviposition O -
. O -

Drift O +
rates O +
were O +
high O -
, O +
and O +
riffles O +
were O +
net O +
exporters O +
of O +
neonate O +
and O +
mid O -
- O -
stage O +
larvae O -
, O +
but O +
drift O +
rates O +
were O +
unrelated O +
to O +
benthic O +
densities O +
and O +
few O +
drifters O +
reached O +
the O +
next O +
riffle O -
. O -

Riffles O +
were O +
sinks O +
for O +
large O +
larvae O -
, O +
suggesting O +
ontogenetic O +
shifts O +
in O +
habitat O +
use O -
, O +
but O +
little O +
long O -
- O -
distance O +
dispersal O -
. O -

4 O -
. O -

Overall O -
, O +
the O +
results O +
suggest O +
that O +
most O +
neonate O +
and O +
mid O -
- O -
stage O +
larvae O +
of O +
B. B-Species +
rhodani L-Species +
remain O +
close O +
to O +
the O +
natal O +
riffle O -
, O +
and O +
late O -
- O -
stage O +
larvae O +
disperse O +
shorter O +
distances O +
than O +
routinely O +
assumed O -
. O -

The O +
persistence O +
of O +
maternal O +
effects O +
on O +
distribution O +
patterns O +
well O +
into O +
juvenile O +
life O +
of O +
an O +
allegedly O +
iconic O +
disperser O +
suggests O +
that O +
traditional O +
models O +
of O +
how O +
dispersal O +
influences O +
the O +
population O +
dynamics O +
of O +
many O +
lotic O +
invertebrates O +
may O +
be O +
incorrect O -
. O +

Symbiotic O +
Chlorella B-Species +
vulgaris L-Species +
of O +
the O +
ciliate O +
Paramecium B-Species +
bursaria L-Species +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
perialgal O +
vacuole O +
membrane O +
functions O -
. O +

Treatment O +
of O +
symbiotic O +
alga O -
- O -
bearing O +
Paramecium B-Species +
bursaria L-Species +
cells O +
with O +
a O +
protein O +
synthesis O +
inhibitor O -
, O +
cycloheximide O -
, O +
induces O +
synchronous O +
swelling O +
of O +
all O +
perialgal O +
vacuoles O +
at O +
about O +
24h O +
after O +
treatment O +
under O +
a O +
constant O +
light O +
condition O -
. O -

Subsequently O -
, O +
the O +
vacuoles O +
detach O +
from O +
the O +
host O +
cell O +
cortex O -
. O -

The O +
algae O +
in O +
the O +
vacuoles O +
are O +
digested O +
by O +
the O +
host O -
's O +
lysosomal O +
fusion O +
to O +
the O +
vacuoles O -
. O -

To O +
elucidate O +
the O +
timing O +
of O +
algal O +
degeneration O -
, O +
P. B-Species +
bursaria L-Species +
cells O +
were O +
treated O +
with O +
cycloheximide O +
under O +
a O +
constant O +
light O +
condition O -
. O -

Then O +
the O +
cells O +
were O +
observed O +
using O +
transmission O +
electron O +
microscopy O -
. O -

Results O +
show O +
that O +
algal O +
chloroplasts O +
and O +
nuclei O +
degenerated O +
within O +
9h O +
after O +
treatment O -
, O +
but O +
before O +
the O +
synchronous O +
swelling O +
of O +
the O +
perialgal O +
vacuole O +
and O +
appearance O +
of O +
acid O +
phosphatase O +
activity O +
in O +
the O +
perialgal O +
vacuole O +
by O +
lysosomal O +
fusion O -
. O -

Treatment O +
with O +
cycloheximide O +
under O +
a O +
constant O +
dark O +
condition O +
and O +
treatment O +
with O +
chloramphenicol O +
under O +
a O +
constant O +
light O +
condition O +
induced O +
neither O +
synchronous O +
swelling O +
of O +
the O +
vacuoles O +
nor O +
digestion O +
of O +
the O +
algae O +
inside O +
the O +
vacuoles O -
. O -

These O +
results O +
demonstrate O +
that O +
algal O +
proteins O +
synthesized O +
during O +
photosynthesis O +
are O +
necessary O +
to O +
maintain O +
chloroplastic O +
and O +
nuclear O +
structures O -
, O +
and O +
that O +
inhibition O +
of O +
protein O +
synthesis O +
induces O +
rapid O +
lysis O +
of O +
these O +
organelles O -
, O +
after O +
which O +
synchronous O +
swelling O +
of O +
the O +
perialgal O +
vacuole O +
and O +
fusion O +
occur O +
with O +
the O +
host O +
lysosomes O -
. O +

The O +
transcriptional O +
response O +
of O +
Saccharomyces B-Species +
cerevisiae L-Species +
to O +
proapoptotic O +
concentrations O +
of O +
Pichia B-Species +
membranifaciens L-Species +
killer O +
toxin O -
. O +

PMKT O +
( O -
Pichia B-Species +
membranifaciens L-Species +
killer O +
toxin O -
) O +
reportedly O +
has O +
antimicrobial O +
activity O +
against O +
yeasts U-Species +
and O +
filamentous O +
fungi O -
. O -

In O +
previous O +
research O +
we O +
posited O +
that O +
high O +
PMKT O +
concentrations O +
pose O +
a O +
serious O +
challenge O +
for O +
cell O +
survival O +
by O +
disrupting O +
plasma O +
membrane O +
electrochemical O +
gradients O -
, O +
inducing O +
a O +
transcriptional O +
response O +
similar O +
to O +
that O +
of O +
certain O +
stimuli O +
such O +
as O +
hyperosmotic O +
shock O -
. O -

This O +
response O +
was O +
related O +
to O +
the O +
HOG O -
- O -
pathway O +
with O +
Hog1p O +
phosphorylation O +
and O +
a O +
transitional O +
increase O +
in O +
intracellular O +
glycerol O +
accumulation O -
. O -

Such O +
a O +
response O +
was O +
consistent O +
with O +
the O +
notion O +
that O +
the O +
effect O +
induced O +
by O +
high O +
PMKT O +
concentrations O +
lies O +
in O +
an O +
alteration O +
to O +
the O +
ionic O +
homeostasis O +
of O +
the O +
sensitive O +
cell O -
. O -

By O +
contrast O -
, O +
the O +
evidence O +
presented O +
here O +
shows O +
that O +
low O +
PMKT O +
doses O +
lead O +
to O +
a O +
cell O +
death O +
process O +
in O +
Saccharomyces B-Species +
cerevisiae L-Species +
accompanied O +
by O +
cytological O +
and O +
biochemical O +
indicators O +
of O +
apoptotic O +
programmed O +
cell O +
death O -
, O +
namely O -
, O +
the O +
production O +
of O +
reactive O +
oxygen O +
species O -
, O +
DNA O +
strand O +
breaks O -
, O +
metacaspase O +
activation O +
and O +
cytochrome O +
c O +
release O -
. O -

Furthermore O -
, O +
dying O +
cells O +
progressed O +
from O +
an O +
apoptotic O +
state O +
to O +
a O +
secondary O +
necrotic O +
state O -
, O +
and O +
the O +
rate O +
at O +
which O +
this O +
change O +
occurred O +
was O +
proportional O +
to O +
the O +
intensity O +
of O +
the O +
stimulus O -
. O -

We O +
have O +
explored O +
the O +
global O +
gene O +
expression O +
response O +
of O +
S. B-Species +
cerevisiae L-Species +
during O +
that O +
stimulus O -
. O -

The O +
results O +
obtained O +
from O +
DNA O +
microarrays O +
indicate O +
that O +
genes O +
related O +
with O +
an O +
oxidative O +
stress O +
response O +
were O +
induced O +
in O +
response O +
to O +
proapoptotic O +
concentrations O +
of O +
PMKT O -
, O +
showing O +
that O +
the O +
coordinated O +
transcriptional O +
response O +
is O +
not O +
coincident O +
with O +
that O +
obtained O +
when O +
ionophoric O +
concentrations O +
of O +
PMKT O +
are O +
used O -
. O -

By O +
contrast O -
, O +
cwp2Delta O +
mutants O +
showed O +
no O +
signs O +
of O +
apoptosis O -
, O +
indicating O +
that O +
the O +
initial O +
steps O +
of O +
the O +
killer O +
mechanism O +
coincide O +
when O +
proapoptotic O +
( O -
low O -
) O +
or O +
ionophoric O +
( O -
high O -
) O +
PMKT O +
concentrations O +
are O +
used O -
. O -

Additionally O -
, O +
low O +
dosages O +
of O +
PMKT O +
promoted O +
Hog1p O +
phosphorylation O +
and O +
glycerol O +
accumulation O -
. O +

Real O +
time O +
PCR O +
method O +
for O +
simultaneous O +
detection O -
, O +
quantitation O +
and O +
differentiation O +
of O +
capripoxviruses O -
. O +

The O +
genus O +
Capripoxvirus O +
( O -
CaPV O -
) O +
comprises O +
three O +
members O +
namely O -
, O +
sheep B-Species +
poxvirus L-Species +
( O -
SPPV U-Species -
) O -
, O +
goat B-Species +
poxvirus L-Species +
( O -
GTPV U-Species -
) O +
and O +
lumpy B-Species +
skin I-Species +
disease I-Species +
virus L-Species +
( O -
LSDV U-Species -
) O +
affecting O +
sheep U-Species -
, O +
goats U-Species +
and O +
cattle U-Species -
, O +
respectively O -
. O -

CaPV O +
infections O +
produce O +
similar O +
symptoms O +
in O +
sheep U-Species +
and O +
goats U-Species -
, O +
and O +
the O +
three O +
viruses O +
can O -
not O +
be O +
distinguished O +
serologically O -
. O -

Since O +
there O +
are O +
conflicting O +
opinions O +
regarding O +
the O +
host O +
specificity O +
of O +
CaPVs O -
, O +
particularly O +
for O +
goatpox U-Species +
and O +
sheeppox B-Species +
viruses L-Species -
, O +
the O +
development O +
of O +
rapid O +
genotyping O +
tools O +
will O +
facilitate O +
more O +
accurate O +
disease O +
diagnosis O +
and O +
surveillance O +
for O +
better O +
management O +
of O +
capripox O +
outbreaks O -
. O -

This O +
paper O +
describes O +
a O +
species O -
- O -
specific O -
, O +
real O +
time O +
polymerase O +
chain O +
reaction O +
( O -
PCR O -
) O -
, O +
based O +
on O +
unique O +
molecular O +
markers O +
that O +
were O +
found O +
in O +
the O +
G O -
- O -
protein O -
- O -
coupled O +
chemokine O +
receptor O +
( O -
GPCR O -
) O +
gene O +
sequences O +
of O +
CaPVs O -
, O +
that O +
uses O +
dual O +
hybridization O +
probes O +
for O +
their O +
simultaneous O +
detection O -
, O +
quantitation O +
and O +
genotyping O -
. O -

The O +
assay O +
can O +
differentiate O +
between O +
CaPV O +
strains O +
based O +
on O +
differences O +
in O +
the O +
melting O +
point O +
temperature O +
( O -
Tm O -
) O +
obtained O +
after O +
fluorescence O +
melting O +
curve O +
analysis O +
( O -
FMCA O -
) O -
. O -

It O +
is O +
highly O +
sensitive O +
and O +
presents O +
low O +
intra- O +
and O +
inter O -
- O -
run O +
variation O -
. O -

This O +
real O +
time O +
PCR O +
assay O +
will O +
make O +
a O +
significant O +
contribution O +
to O +
CaPV O +
diagnosis O +
and O +
to O +
the O +
better O +
understanding O +
of O +
the O +
epidemiology O +
of O +
CaPVs O +
by O +
enabling O +
rapid O +
genotyping O +
and O +
gene O -
- O -
based O +
classification O +
of O +
viral O +
strains O +
and O +
unequivocal O +
identification O +
of O +
isolates O -
. O +

The O +
Perigord B-Species +
black I-Species +
truffle L-Species +
responds O +
to O +
cold O +
temperature O +
with O +
an O +
extensive O +
reprogramming O +
of O +
its O +
transcriptional O +
activity O -
. O +

The O +
Tuber B-Species +
melanosporum L-Species +
genome O +
has O +
been O +
analysed O +
with O +
the O +
aim O +
of O +
identifying O +
and O +
characterizing O +
the O +
genes O +
involved O +
in O +
the O +
environmental O +
stress O +
response O -
. O -

A O +
whole O +
genome O +
array O +
( O -
7496 O +
genes O -
/ O -
probe O -
) O +
was O +
used O +
to O +
verify O +
the O +
fungal O +
transcriptional O +
profiling O +
upon O +
a O +
cold O +
temperature O +
period O +
( O -
7 O +
days O +
at O +
4 O +
^0C O -
) O -
. O -

A O +
total O +
of O +
423 O +
genes O +
resulted O +
to O +
be O +
differentially O +
expressed O +
in O +
a O +
significant O +
manner O +
( O -
> O -
2.5-fold O -
; O +
p O -
- O -
value<0.05 O -
) O +
in O +
the O +
mycelia O +
exposed O +
to O +
cold O -
, O +
compared O +
to O +
the O +
control O +
ones O -
: O +
187 O +
of O +
these O +
genes O +
were O +
up O -
- O -
regulated O -
, O +
while O +
236 O +
were O +
down O -
- O -
regulated O -
. O -

Sixty O -
- O -
six O +
and O +
fifty O -
- O -
one O +
percent O -
, O +
respectively O -
, O +
of O +
the O +
up- O +
or O +
down O -
- O -
regulated O +
transcripts O +
had O +
no O +
KOG O +
classification O +
and O +
were O +
clustered O +
as O +
unclassified O +
proteins O -
, O +
which O +
was O +
the O +
most O +
abundant O +
category O +
in O +
the O +
both O +
up- O +
and O +
down O -
- O -
regulated O +
genes O -
. O -

A O +
gene O +
subset O -
, O +
containing O +
a O +
range O +
of O +
biological O +
functions O -
, O +
was O +
chosen O +
to O +
validate O +
the O +
microarray O +
experiment O +
through O +
quantitative O +
real O +
time O +
PCR O +
( O -
qRT O -
- O -
PCR O -
) O -
. O -

The O +
analysis O +
confirmed O +
the O +
array O +
data O +
for O +
16 O +
out O +
of O +
22 O +
of O +
the O +
considered O +
genes O -
, O +
confirming O +
that O +
a O +
cold O +
temperature O +
period O +
influences O +
the O +
truffle O +
global O +
gene O +
expression O -
. O -

The O +
expressed O +
genes O -
, O +
which O +
mostly O +
resulted O +
to O +
be O +
genes O +
for O +
heat O +
shock O +
proteins O +
( O -
HSPs O -
) O +
and O +
genes O +
involved O +
in O +
cell O +
wall O +
and O +
lipid O +
metabolism O -
, O +
could O +
be O +
involved O +
in O +
mechanisms O -
, O +
which O +
are O +
responsible O +
for O +
fungal O +
adaptation O -
. O -

Since O +
truffle O +
ascomata O +
develop O +
during O +
the O +
winter O +
period O -
, O +
we O +
hypothesize O +
that O +
these O +
differentially O +
expressed O +
genes O +
may O +
help O +
the O +
truffle O +
to O +
adapt O +
to O +
low O +
temperatures O +
and/or O +
perceive O +
environmental O +
signals O +
that O +
regulate O +
the O +
fructification O -
. O +

The O +
rapid O +
production O +
of O +
high O -
- O -
titer O +
porcine B-Species +
endogenous I-Species +
retrovirus L-Species -
( O -
PERV O -
) O -
-B O +
env O +
pseudotype O +
and O +
construction O +
of O +
an O +
EGFP O -
- O -
expressing O +
replication O +
competent O +
PERV O -
- O -
A O +
vector O -
. O +

Porcine B-Species +
endogenous I-Species +
retroviruses L-Species +
( O -
PERVs U-Species -
) O +
present O +
a O +
unique O +
concern O +
associated O +
with O +
xenotransplantation O +
because O +
they O +
have O +
been O +
shown O +
to O +
infect O +
certain O +
human U-Species +
cells O +
in O +
vitro O +
and O +
it O +
is O +
also O +
difficult O +
to O +
generate O +
herds O +
of O +
pigs U-Species +
free O +
of O +
PERVs U-Species -
. O -

A O +
simple O +
system O +
for O +
the O +
production O +
of O +
high O -
- O -
titer O +
MoMLV O -
- O -
PERV O +
pseudotypes O +
is O +
reported O -
; O +
an O +
EGFP O -
- O -
expressing O +
replication O -
- O -
competent O +
molecular O +
clone O +
that O +
allows O +
direct O +
measurement O +
of O +
titer O +
was O +
also O +
constructed O -
. O -

To O +
improve O +
the O +
MLV O -
- O -
based O +
retroviral U-Species +
vector O +
system O -
, O +
a O +
2.1-kb O +
PERV U-Species -
- O -
B O +
env O +
product O +
was O +
amplified O +
from O +
PK-15 O +
genomic O +
DNA O +
and O +
cloned O +
into O +
the O +
pCL O -
- O -
Eco O +
retroviral O +
vector O -
. O -

The O +
titer O +
of O +
lacZ O +
( O -
PERV B-Species -
- L-Species -
B O -
) O +
from O +
the O +
293 O +
cells O +
was O +
about O +
1.0x10 O -
( O -
4 O -
) O +
CFU O -
/ O -
ml O -
. O -

In O +
contrast O -
, O +
the O +
titer O +
of O +
lacZ O +
( O -
PERV O -
- O -
B O -
) O +
from O +
a O +
conventional O +
murine O +
retroviral U-Species +
vector O +
( O -
split O +
genome O -
) O +
was O +
found O +
to O +
be O +
1.2x10 O -
( O -
2 O -
) O +
CFU O -
/ O -
ml O +
when O +
the O +
PERV B-Species -
- L-Species -
B O +
env O +
expression O +
vector O +
was O +
transfected O +
into O +
TELCeB6 O +
cells O -
, O +
which O +
harbor O +
MFGnlslacZ O +
and O +
the O +
gag O -
- O -
pol O -
- O -
expressing O +
vector O -
. O -

In O +
addition O -
, O +
an O +
infectious O +
PERV B-Species -
- L-Species -
A O +
clone O +
containing O +
enhanced O +
GFP O +
( O -
EGFP O -
) O +
by O +
using O +
a O +
PCR O -
- O -
based O +
method O +
was O +
developed O -
. O -

This O +
EGFP O -
- O -
expressing O +
PERV O -
- O -
A O -
- O -
IRES O -
- O -
EGFP O +
molecular O +
clone O +
was O +
found O +
to O +
be O +
stable O +
genetically O +
on O +
transfection O +
in O +
293 O +
cells O -
. O +

Cross O -
- O -
talk O +
between O +
light O +
and O +
glucose O +
regulation O +
controls O +
toxin O +
production O +
and O +
morphogenesis O +
in O +
Aspergillus B-Species +
nidulans L-Species -
. O +

Light O +
is O +
a O +
major O +
environmental O +
stimulus O +
that O +
has O +
a O +
broad O +
effect O +
on O +
organisms O -
, O +
triggering O +
a O +
cellular O +
response O +
that O +
results O +
in O +
an O +
optimal O +
adaptation O +
enhancing O +
fitness O +
and O +
survival O -
. O -

In O +
fungi O -
, O +
light O +
affects O +
growth O -
, O +
and O +
causes O +
diverse O +
morphological O +
changes O +
such O +
as O +
those O +
leading O +
to O +
reproduction O -
. O -

Light O +
can O +
also O +
affect O +
fungal O +
metabolism O -
, O +
including O +
the O +
biosynthesis O +
of O +
natural O +
products O -
. O -

In O +
this O +
study O +
we O +
show O +
that O +
in O +
Aspergillus B-Species +
nidulans L-Species +
the O +
effect O +
of O +
light O +
on O +
the O +
production O +
of O +
the O +
sterigmatocystin O +
( O -
ST O -
) O +
toxin O +
depends O +
on O +
the O +
glucose O +
concentration O -
. O -

In O +
cultures O +
grown O +
with O +
1 O -
% O +
glucose O +
and O +
exposed O +
to O +
light O -
, O +
ST O +
production O +
was O +
lower O +
than O +
when O +
grown O +
in O +
the O +
dark O -
. O -

This O +
lower O +
ST O +
production O +
coincided O +
with O +
an O +
elevated O +
rate O +
of O +
cellular O +
damage O +
with O +
partial O +
loss O +
of O +
nuclear O +
integrity O +
and O +
vacuolated O +
cytoplasm O -
. O -

However O -
, O +
in O +
cultures O +
grown O +
with O +
2 O -
% O +
glucose O +
these O +
effects O +
were O +
reversed O +
and O +
light O +
enhanced O +
ST O +
production O -
. O -

Glucose O +
abundance O +
also O +
affected O +
the O +
light O -
- O -
dependent O +
subcellular O +
localization O +
of O +
the O +
VeA O +
( O -
velvet O -
) O +
protein O -
, O +
a O +
key O +
regulator O +
necessary O +
for O +
normal O +
light O -
- O -
dependent O +
morphogenesis O +
and O +
secondary O +
metabolism O +
in O +
Aspergilli O +
and O +
other O +
fungal O +
genera O -
. O -

The O +
role O +
of O +
other O +
VeA O -
- O -
associated O +
proteins O -
, O +
particularly O +
the O +
blue O -
- O -
light O -
- O -
sensing O +
proteins O +
LreA O +
and O +
LreB O +
( O -
WC-1 O +
and O +
WC-2 O +
orthologs O -
) O -
, O +
on O +
conidiation O +
could O +
also O +
be O +
modified O +
by O +
the O +
abundance O +
of O +
glucose O -
. O -

We O +
also O +
show O +
that O +
LreA O +
and O +
LreB O -
, O +
as O +
well O +
as O +
the O +
phytochrome O +
FphA O -
, O +
modulate O +
not O +
only O +
the O +
synthesis O +
of O +
sterigmatocystin O -
, O +
but O +
also O +
the O +
production O +
of O +
the O +
antibiotic O +
penicillin O -
. O +

Genome O -
- O -
wide O +
analysis O +
of O +
brain O +
transcriptional O +
changes O +
in O +
honey B-Species +
bee L-Species +
( O -
Apis B-Species +
mellifera L-Species +
L. O -
) O +
queens O +
exposed O +
to O +
carbon O +
dioxide O +
and O +
physical O +
manipulation O -
. O +

Mating O +
is O +
a O +
complex O +
process O +
causing O +
many O +
behavioural O +
and O +
physiological O +
changes O -
, O +
but O +
the O +
factors O +
triggering O +
them O +
and O +
the O +
underlying O +
molecular O +
processes O +
are O +
not O +
well O +
characterized O -
. O -

In O +
the O +
present O +
study O +
we O +
examine O +
the O +
effects O +
of O +
CO O -
( O -
2 O -
) O +
( O -
a O +
commonly O +
used O +
anaesthetic O +
in O +
instrumental O +
insemination O +
that O +
causes O +
changes O +
similar O +
to O +
those O +
occurring O +
after O +
mating O -
) O +
and O +
physical O +
manipulation O +
( O -
which O +
may O +
mimic O +
certain O +
aspects O +
of O +
copulation O -
) O +
on O +
the O +
behavioural O -
, O +
physiological O +
and O +
brain O +
transcriptional O +
changes O +
in O +
honey B-Species +
bee L-Species +
queens O -
. O -

We O +
show O +
that O +
while O +
CO O -
( O -
2 O -
) O +
causes O +
cessation O +
of O +
mating O +
flights O +
and O +
ovary O +
activation O -
, O +
physical O +
manipulation O +
has O +
additional O +
effects O +
on O +
ovary O +
activation O +
and O +
brain O +
transcriptional O +
changes O -
. O -

Comparisons O +
with O +
previous O +
studies O +
of O +
honey B-Species +
bees L-Species +
and O +
female O +
Drosophila U-Species +
indicate O +
that O +
common O +
molecular O +
mechanisms O +
may O +
be O +
responsible O +
for O +
regulating O +
reproductive O +
changes O +
across O +
different O +
mating O +
regimes O +
and O +
insect O +
orders O -
. O +

Identification O +
and O +
expression O +
analysis O +
of O +
the O +
genes O +
involved O +
in O +
serotonin O +
biosynthesis O +
and O +
transduction O +
in O +
the O +
field O +
cricket O +
Gryllus B-Species +
bimaculatus L-Species -
. O +

Serotonin O +
( O -
5-HT O -
) O +
modulates O +
various O +
aspects O +
of O +
behaviours O +
such O +
as O +
aggressive O +
behaviour O +
and O +
circadian O +
behaviour O +
in O +
the O +
cricket O -
. O -

To O +
elucidate O +
the O +
molecular O +
basis O +
of O +
the O +
cricket O +
5-HT O +
system O -
, O +
we O +
identified O +
5-HT O -
- O -
related O +
genes O +
in O +
the O +
field O +
cricket O +
Gryllus B-Species +
bimaculatus I-Species +
DeGeer L-Species -
. O -

Complementary O +
DNA O +
of O +
tryptophan O +
hydroxylase O +
and O +
phenylalanine O -
- O -
tryptophan O +
hydroxylase O -
, O +
which O +
convert O +
tryptophan O +
into O +
5-hydroxy O -
- O -
L O -
- O -
tryptophan O +
( O -
5-HTP O -
) O -
, O +
and O +
that O +
of O +
aromatic O +
L O -
- O -
amino O +
acid O +
decarboxylase O -
, O +
which O +
converts O +
5-HTP O +
into O +
5-HT O -
, O +
were O +
isolated O +
from O +
a O +
cricket O +
brain O +
cDNA O +
library O -
. O -

In O +
addition O -
, O +
four O +
5-HT O +
receptor O +
genes O +
( O -
5-HT O -
( O -
1A O -
) O +
, O +
5-HT O -
( O -
1B O -
) O +
, O +
5-HT O -
( O -
2alpha O -
) O +
, O +
and O +
5-HT O -
( O -
7 O -
) O +
) O +
were O +
identified O -
. O -

Expression O +
analysis O +
of O +
the O +
tryptophan O +
hydroxylase O +
gene O +
TRH O +
and O +
phenylalanine O -
- O -
tryptophan O +
hydroxylase O +
gene O +
TPH O -
, O +
which O +
are O +
selectively O +
involved O +
in O +
neuronal O +
and O +
peripheral O +
5-HT O +
synthesis O +
in O +
Drosophila O -
, O +
suggested O +
that O +
two O +
5-HT O +
synthesis O +
pathways O +
co O -
- O -
exist O +
in O +
the O +
cricket O +
neuronal O +
tissues O -
. O -

The O +
four O +
5-HT O +
receptor O +
genes O +
were O +
expressed O +
in O +
various O +
tissues O +
at O +
differential O +
expression O +
levels O -
, O +
suggesting O +
that O +
the O +
5-HT O +
system O +
is O +
widely O +
distributed O +
in O +
the O +
cricket O -
. O +

Fungal O +
secondary O +
metabolites O +
- O +
strategies O +
to O +
activate O +
silent O +
gene O +
clusters O -
. O -

Filamentous O +
fungi O +
produce O +
a O +
multitude O +
of O +
low O +
molecular O +
weight O +
bioactive O +
compounds O -
. O -

The O +
increasing O +
number O +
of O +
fungal O +
genome O +
sequences O +
impressively O +
demonstrated O +
that O +
their O +
biosynthetic O +
potential O +
is O +
far O +
from O +
being O +
exploited O -
. O -

In O +
fungi O -
, O +
the O +
genes O +
required O +
for O +
the O +
biosynthesis O +
of O +
a O +
secondary O +
metabolite O +
are O +
clustered O -
. O -

Many O +
of O +
these O +
bioinformatically O +
newly O +
discovered O +
secondary O +
metabolism O +
gene O +
clusters O +
are O +
silent O +
under O +
standard O +
laboratory O +
conditions O -
. O -

Consequently O -
, O +
no O +
product O +
can O +
be O +
found O -
. O -

This O +
review O +
summarizes O +
the O +
current O +
strategies O +
that O +
have O +
been O +
successfully O +
applied O +
during O +
the O +
last O +
years O +
to O +
activate O +
these O +
silent O +
gene O +
clusters O +
in O +
filamentous O +
fungi O -
, O +
especially O +
in O +
the O +
genus O +
Aspergillus O -
. O -

The O +
techniques O +
take O +
advantage O +
of O +
genome O +
mining O -
, O +
vary O +
from O +
the O +
simple O +
search O +
for O +
compounds O +
with O +
bioinformatically O +
predicted O +
physicochemical O +
properties O +
up O +
to O +
methods O +
that O +
exploit O +
a O +
probable O +
interaction O +
of O +
microorganisms O -
. O -

Until O +
now O -
, O +
the O +
majority O +
of O +
successful O +
approaches O +
have O +
been O +
based O +
on O +
molecular O +
biology O +
like O +
the O +
generation O +
of O +
gene O +
" O -
knock O +
outs O -
" O -
, O +
promoter O +
exchange O -
, O +
overexpression O +
of O +
transcription O +
factors O +
or O +
other O +
pleiotropic O +
regulators O -
. O -

Moreover O -
, O +
strategies O +
based O +
on O +
epigenetics O +
opened O +
a O +
new O +
avenue O +
for O +
the O +
elucidation O +
of O +
the O +
regulation O +
of O +
secondary O +
metabolite O +
formation O +
and O +
will O +
certainly O +
continue O +
to O +
play O +
a O +
significant O +
role O +
for O +
the O +
elucidation O +
of O +
cryptic O +
natural O +
products O -
. O -

The O +
conditions O +
under O +
which O +
a O +
given O +
gene O +
cluster O +
is O +
naturally O +
expressed O +
are O +
largely O +
unknown O -
. O -

One O +
technique O +
is O +
to O +
attempt O +
to O +
simulate O +
the O +
natural O +
habitat O +
by O +
co O -
- O -
cultivation O +
of O +
microorganisms O +
from O +
the O +
same O +
ecosystem O -
. O -

This O +
has O +
already O +
led O +
to O +
the O +
activation O +
of O +
silent O +
gene O +
clusters O +
and O +
the O +
identification O +
of O +
novel O +
compounds O +
in O +
Aspergillus O +
nidulans B-Species -
. L-Species -

These B-Species +
simulation L-Species +
strategies O +
will O +
help O +
discover O +
new O +
natural O +
products O +
in O +
the O +
future O -
, O +
and O +
may O +
also O +
provide O +
fundamental O +
new O +
insights O +
into O +
microbial O +
communication O -
. O +

The O +
genetic O +
basis O +
for O +
3-ADON O +
and O +
15-ADON O +
trichothecene O +
chemotypes O +
in O +
Fusarium O -
. O -

Certain O +
Fusarium O +
species O +
cause O +
head O +
blight O +
of O +
wheat U-Species +
and O +
other O +
small O +
grains O +
worldwide O +
and O +
produce O +
trichothecene O +
mycotoxins O -
. O -

These O +
mycotoxins O +
can O +
induce O +
toxicoses O +
in O +
animals O +
and O +
humans U-Species +
and O +
can O +
contribute O +
to O +
the O +
ability O +
of O +
some O +
fusaria O +
to O +
cause O +
plant O +
disease O -
. O -

Production O +
of O +
the O +
trichothecene O +
3-acetyldeoxynivalenol O +
( O -
3-ADON O -
) O +
versus O +
15-acetyldeoxynivalenol O +
( O -
15-ADON O -
) O +
is O +
an O +
important O +
phenotypic O +
difference O +
within O +
and O +
among O +
some O +
Fusarium O +
species O -
. O -

However O -
, O +
until O +
now O -
, O +
the O +
genetic O +
basis O +
for O +
this O +
difference O +
in O +
chemotype O +
has O +
not O +
been O +
identified O -
. O -

Here O -
, O +
we O +
identified O +
consistent O +
DNA O +
sequence O +
differences O +
in O +
the O +
coding O +
region O +
of O +
the O +
trichothecene O +
biosynthetic O +
gene O +
TRI8 O +
in O +
3-ADON O +
and O +
15-ADON O +
strains O -
. O -

Functional O +
analyses O +
of O +
the O +
TRI8 O +
enzyme O +
( O -
Tri8 O -
) O +
in O +
F. B-Species +
graminearum L-Species -
, O +
the O +
predominant O +
cause O +
of O +
wheat O +
head O +
blight O +
in O +
North O +
America O +
and O +
Europe O -
, O +
revealed O +
that O +
Tri8 O +
from O +
3-ADON O +
strains O +
catalyzes O +
deacetylation O +
of O +
the O +
trichothecene O +
biosynthetic O +
intermediate O +
3,15-diacetyldeoxynivalenol O +
at O +
carbon O +
15 O +
to O +
yield O +
3-ADON O -
, O +
whereas O +
Tri8 O +
from O +
15-ADON O +
strains O +
catalyzes O +
deacetylation O +
of O +
3,15-diacetyldeoxynivalenol O +
at O +
carbon O +
3 O +
to O +
yield O +
15-ADON O -
. O -

Fusarium O +
strains O +
that O +
produce O +
the O +
trichothecene O +
nivalenol O +
have O +
a O +
Tri8 O +
that O +
functions O +
like O +
that O +
in O +
15-ADON O +
strains O -
. O -

TRI3 O -
, O +
which O +
encodes O +
a O +
trichothecene O +
carbon O +
15 O +
acetyltransferase O -
, O +
was O +
found O +
to O +
be O +
functional O +
in O +
all O +
three O +
chemotypes O -
. O -

Together O -
, O +
our O +
data O +
indicate O +
that O +
differential O +
activity O +
of O +
Tri8 O +
determines O +
the O +
3-ADON O +
and O +
15-ADON O +
chemotypes O +
in O +
Fusarium O -
. O +

Recovery O +
of O +
ectomycorrhiza O +
after O +
' O -
nitrogen O +
saturation O -
' O +
of O +
a O +
conifer O +
forest O -
. O -

Trees O +
reduce O +
their O +
carbon O +
( O -
C O -
) O +
allocation O +
to O +
roots O +
and O +
mycorrhizal O +
fungi O +
in O +
response O +
to O +
high O +
nitrogen O +
( O -
N O -
) O +
additions O -
, O +
which O +
should O +
reduce O +
the O +
N O +
retention O +
capacity O +
of O +
forests O -
. O -

The O +
time O +
needed O +
for O +
recovery O +
of O +
mycorrhizas O +
after O +
termination O +
of O +
N O +
loading O +
remains O +
unknown O -
. O -

Here O -
, O +
we O +
report O +
the O +
long O -
- O -
term O +
impact O +
of O +
N O +
loading O +
and O +
the O +
recovery O +
of O +
ectomycorrhiza O +
after O +
high O +
N O +
loading O +
on O +
a O +
Pinus B-Species +
sylvestris L-Species +
forest O -
. O -

We O +
analysed O +
the O +
N% O +
and O +
abundance O +
of O +
the O +
stable O +
isotope O +
( O -
15 O -
) O +
N O +
in O +
tree O +
needles O +
and O +
soil O -
, O +
soil O +
microbial O +
fatty O +
acid O +
biomarkers O +
and O +
fungal O +
DNA O -
. O -

Needles O +
in O +
N O -
- O -
loaded O +
plots O +
became O +
enriched O +
in O +
( O -
15 O -
) O +
N O -
, O +
reflecting O +
decreased O +
N O +
retention O +
by O +
mycorrhizal O +
fungi O +
and O +
isotopic O +
discrimination O +
against O +
( O -
15 O -
) O +
N O +
during O +
loss O +
of O +
N. O +
Meanwhile O -
, O +
needles O +
in O +
N O -
- O -
limited O +
( O -
control O -
) O +
plots O +
became O +
depleted O +
in O +
( O -
15 O -
) O +
N O -
, O +
reflecting O +
high O +
retention O +
of O +
( O -
15 O -
) O +
N O +
by O +
mycorrhizal O +
fungi O -
. O -

N O +
loading O +
was O +
terminated O +
after O +
20yr O -
. O -

The O +
delta O -
( O -
15 O -
) O +
N O +
and O +
N% O +
of O +
the O +
needles O +
decreased O +
6yr O +
after O +
N O +
loading O +
had O +
been O +
terminated O -
, O +
and O +
approached O +
values O +
in O +
control O +
plots O +
after O +
15yr O -
. O -

This O +
decrease O -
, O +
and O +
the O +
larger O +
contributions O +
compared O +
with O +
N O -
- O -
loaded O +
plots O +
of O +
a O +
fungal O +
fatty O +
acid O +
biomarker O +
and O +
ectomycorrhizal O +
sequences O -
, O +
suggest O +
recovery O +
of O +
ectomycorrhiza O -
. O -

High O +
N O +
loading O +
rapidly O +
decreased O +
the O +
functional O +
role O +
of O +
ectomycorrhiza O +
in O +
the O +
forest O +
N O +
cycle O -
, O +
but O +
significant O +
recovery O +
occurred O +
within O +
6 O -
- O -
15yr O +
after O +
termination O +
of O +
N O +
loading O -
. O +

What O +
determines O +
variation O +
in O +
home O +
range O +
size O +
across O +
spatiotemporal O +
scales O +
in O +
a O +
large O +
browsing O +
herbivore O -
? O +

1 O -
. O -

Most O +
studies O +
of O +
intraspecific O +
variation O +
in O +
home O +
range O +
size O +
have O +
investigated O +
only O +
a O +
single O +
or O +
a O +
few O +
factors O +
and O +
often O +
at O +
one O +
specific O +
scale O -
. O -

However O -
, O +
considering O +
multiple O +
spatial O +
and O +
temporal O +
scales O +
when O +
defining O +
a O +
home O +
range O +
is O +
important O +
as O +
mechanisms O +
that O +
affect O +
variation O +
in O +
home O +
range O +
size O +
may O +
differ O +
depending O +
on O +
the O +
scale O +
under O +
investigation O -
. O -

2 O -
. O -

We O +
aim O +
to O +
quantify O +
the O +
relative O +
effect O +
of O +
various O +
individual O -
, O +
forage O +
and O +
climatic O +
determinants O +
of O +
variation O +
in O +
home O +
range O +
size O +
across O +
multiple O +
spatiotemporal O +
scales O +
in O +
a O +
large O +
browsing O +
herbivore O -
, O +
the O +
moose O +
( O -
Alces B-Species +
alces L-Species -
) O -
, O +
living O +
at O +
the O +
southern O +
limit O +
of O +
its O +
distribution O +
in O +
Norway O -
. O -

3 O -
. O -

Total O +
home O +
range O +
size O +
and O +
core O +
home O +
range O +
areas O +
were O +
estimated O +
for O +
daily O +
to O +
monthly O +
scales O +
in O +
summer O +
and O +
winter O +
using O +
both O +
local O +
convex O +
hull O +
( O -
LoCoH O -
) O +
and O +
fixed O +
kernel O +
home O +
range O +
methods O -
. O -

Variance O +
in O +
home O +
range O +
size O +
was O +
analysed O +
using O +
linear O +
mixed O -
- O -
effects O +
models O +
for O +
repeated O +
measurements O -
. O -

4 O -
. O -

Reproductive O +
status O +
was O +
the O +
most O +
influential O +
individual O -
- O -
level O +
factor O +
explaining O +
variance O +
in O +
moose O +
home O +
range O +
size O -
, O +
with O +
females O +
accompanied O +
by O +
a O +
calf O +
having O +
smaller O +
summer O +
ranges O +
across O +
all O +
scales O -
. O -

Variation O +
in O +
home O +
range O +
size O +
was O +
strongly O +
correlated O +
with O +
spatiotemporal O +
changes O +
in O +
quantity O +
and O +
quality O +
of O +
natural O +
food O +
resources O -
. O -

Home O +
range O +
size O +
decreased O +
with O +
increasing O +
browse O +
density O +
at O +
daily O +
scales O -
, O +
but O +
the O +
relationship O +
changed O +
to O +
positive O +
at O +
longer O +
temporal O +
scales O -
. O -

In O +
contrast O -
, O +
browse O +
quality O +
was O +
consistently O +
negatively O +
correlated O +
with O +
home O +
range O +
size O +
except O +
at O +
the O +
monthly O +
scale O +
during O +
winter O +
when O +
depletion O +
of O +
high O -
- O -
quality O +
forage O +
occurs O -
. O -

Local O +
climate O +
affected O +
total O +
home O +
range O +
size O +
more O +
than O +
core O +
areas O -
. O -

Temperature O -
, O +
precipitation O +
and O +
snow O +
depth O +
influenced O +
home O +
range O +
size O +
directly O +
at O +
short O +
temporal O +
scales O -
. O -

5 O -
. O -

The O +
relative O +
effects O +
of O +
intrinsic O +
and O +
extrinsic O +
determinants O +
of O +
variation O +
in O +
home O +
range O +
size O +
differed O +
with O +
spatiotemporal O +
scale O -
, O +
providing O +
clear O +
evidence O +
that O +
home O +
range O +
size O +
is O +
scale O +
dependent O +
in O +
this O +
large O +
browser O -
. O -

Insight O +
into O +
the O +
behavioural O +
responses O +
of O +
populations O +
to O +
climatic O +
stochasticity O +
and O +
forage O +
variability O +
is O +
essential O +
in O +
view O +
of O +
current O +
and O +
future O +
climate O +
change O -
, O +
especially O +
for O +
populations O +
with O +
thermoregulatory O +
restrictions O +
living O +
at O +
the O +
southern O +
limit O +
of O +
their O +
distribution O -
. O +

Differential O +
responses O +
of O +
Bacillus B-Species +
subtilis L-Species +
rRNA O +
promoters O +
to O +
nutritional O +
stress O -
. O +

The O +
in O +
vivo O +
expression O +
levels O +
of O +
four O +
rRNA O +
promoter O +
pairs O +
( O -
rrnp O -
( O -
1 O -
) O -
p O -
( O -
2 O -
) O -
) O +
of O +
Bacillus B-Species +
subtilis L-Species +
were O +
determined O +
by O +
employing O +
single O -
- O -
copy O +
lacZ O +
fusions O +
integrated O +
at O +
the O +
amyE O +
locus O -
. O -

The O +
rrnO O -
, O +
rrnJ O -
, O +
rrnD O -
, O +
and O +
rrnB O +
promoters O +
displayed O +
unique O +
growth O +
rate O +
regulation O +
and O +
stringent O +
responses O -
. O -

Both O +
lacZ O +
activity O +
and O +
mRNA O +
levels O +
were O +
highest O +
for O +
rrnO O +
under O +
all O +
growth O +
conditions O +
tested O -
, O +
while O +
rrnJ O -
, O +
rrnB O -
, O +
and O +
rrnD O +
showed O +
decreasing O +
levels O +
of O +
activity O -
. O -

During O +
amino O +
acid O +
starvation O +
induced O +
by O +
serine O +
hydroxamate O +
( O -
SHX O -
) O -
, O +
only O +
the O +
strong O +
rrnO O +
and O +
rrnJ O +
promoters O +
demonstrated O +
stringent O +
responses O -
. O -

Under O +
the O +
growth O +
conditions O +
used O -
, O +
the O +
rrn O +
promoters O +
showed O +
responses O +
similar O +
to O +
the O +
responses O +
to O +
carbon O +
source O +
limitation O +
induced O +
by O +
alpha O -
- O -
methyl O +
glucoside O +
( O -
alpha O -
- O -
MG O -
) O -
. O -

The O +
ratio O +
of O +
P2 O +
to O +
P1 O +
transcripts O -
, O +
determined O +
by O +
primer O +
extension O +
analysis O -
, O +
was O +
high O +
for O +
the O +
strong O +
rrnO O +
and O +
rrnJ O +
promoters O -
, O +
while O +
only O +
P2 O +
transcripts O +
were O +
detected O +
for O +
the O +
weak O +
rrnD O +
and O +
rrnB O +
promoters O -
. O -

Cloned O +
P1 O +
or O +
P2 O +
promoter O +
fragments O +
of O +
rrnO O +
or O +
rrnJ O +
were O +
differentially O +
regulated O -
. O -

In O +
wild O -
- O -
type O +
( O -
relA O -
( O -
+ O -
) O -
) O +
and O +
suppressor O +
[ O -
relA O -
( O -
S O -
) O -
] O +
strains O +
under O +
the O +
conditions O +
tested O -
, O +
only O +
P2 O +
responded O +
to O +
carbon O +
source O +
limitation O +
by O +
a O +
decrease O +
in O +
RNA O +
synthesis O -
, O +
correlating O +
with O +
an O +
increase O +
in O +
( O -
p O -
) O -
ppGpp O +
levels O +
and O +
a O +
decrease O +
in O +
the O +
GTP O +
concentration O -
. O -

The O +
weak O +
P1 O +
promoter O +
elements O +
remain O +
relaxed O +
in O +
the O +
three O +
genetic O +
backgrounds O +
[ O -
relA O -
( O -
+ O -
) O -
, O +
relA O -
, O +
relA O -
( O -
S O -
) O -
] O +
in O +
the O +
presence O +
of O +
alpha O -
- O -
MG O -
. O -

During O +
amino O +
acid O +
starvation O -
, O +
P2 O +
was O +
stringently O +
regulated O +
in O +
relA O -
( O -
+ O -
) O +
and O +
relA O -
( O -
S O -
) O +
cells O -
, O +
while O +
only O +
rrnJp O -
( O -
1 O -
) O +
was O +
also O +
regulated O -
, O +
but O +
to O +
a O +
lesser O +
extent O -
. O -

Both O +
the O +
relA O -
( O -
+ O -
) O +
and O +
relA O -
( O -
S O -
) O +
strains O +
showed O +
( O -
p O -
) O -
ppGpp O +
accumulation O +
after O +
alpha O -
- O -
MG O +
treatment O +
but O +
not O +
after O +
SHX O +
treatment O -
. O -

These O +
data O +
reveal O +
the O +
complex O +
nature O +
of O +
B. B-Species +
subtilis L-Species +
rrn O +
promoter O +
regulation O +
in O +
response O +
to O +
stress O -
, O +
and O +
they O +
suggest O +
that O +
the O +
P2 O +
promoters O +
may O +
play O +
a O +
more O +
prominent O +
role O +
in O +
the O +
stringent O +
response O -
. O +

Altered O +
regulation O +
of O +
the O +
OmpF O +
porin O +
by O +
Fis O +
in O +
Escherichia B-Species +
coli L-Species +
during O +
an O +
evolution O +
experiment O +
and O +
between O +
B O +
and O +
K-12 O +
strains O -
. O +

The O +
phenotypic O +
plasticity O +
of O +
global O +
regulatory O +
networks O +
provides O +
bacteria O +
with O +
rapid O +
acclimation O +
to O +
a O +
wide O +
range O +
of O +
environmental O +
conditions O -
, O +
while O +
genetic O +
changes O +
in O +
those O +
networks O +
provide O +
additional O +
flexibility O +
as O +
bacteria O +
evolve O +
across O +
long O +
time O +
scales O -
. O -

We O +
previously O +
identified O +
mutations O +
in O +
the O +
global O +
regulator O -
- O -
encoding O +
gene O +
fis O +
that O +
enhanced O +
organismal O +
fitness O +
during O +
a O +
long O -
- O -
term O +
evolution O +
experiment O +
with O +
Escherichia B-Species +
coli L-Species -
. O -

To O +
gain O +
insight O +
into O +
the O +
effects O +
of O +
these O +
mutations O -
, O +
we O +
produced O +
two O -
- O -
dimensional O +
protein O +
gels O +
with O +
strains O +
carrying O +
different O +
fis O +
alleles O -
, O +
including O +
a O +
beneficial O +
evolved O +
allele O +
and O +
one O +
with O +
an O +
in O -
- O -
frame O +
deletion O -
. O -

We O +
found O +
that O +
Fis O +
controls O +
the O +
expression O +
of O +
the O +
major O +
porin O -
- O -
encoding O +
gene O +
ompF O +
in O +
the O +
E. B-Species +
coli L-Species +
B O -
- O -
derived O +
ancestral O +
strain O +
used O +
in O +
the O +
evolution O +
experiment O -
, O +
a O +
relationship O +
that O +
has O +
not O +
been O +
described O +
before O -
. O -

We O +
further O +
showed O +
that O +
this O +
regulatory O +
connection O +
evolved O +
over O +
two O +
different O +
time O +
scales O -
, O +
perhaps O +
explaining O +
why O +
it O +
was O +
not O +
observed O +
before O -
. O -

On O +
the O +
longer O +
time O +
scale O -
, O +
we O +
showed O +
that O +
this O +
regulation O +
of O +
ompF O +
by O +
Fis O +
is O +
absent O +
from O +
the O +
more O +
widely O +
studied O +
K-12 B-Species +
strain L-Species +
and O +
thus O +
is O +
specific O +
to O +
the O +
B B-Species +
strain L-Species -
. O -

On O +
a O +
shorter O +
time O +
scale O -
, O +
this O +
regulatory O +
linkage O +
was O +
lost O +
during O +
20,000 O +
generations O +
of O +
experimental O +
evolution O +
of O +
the O +
B B-Species +
strain L-Species -
. O -

Finally O -
, O +
we O +
mapped O +
the O +
Fis O +
binding O +
sites O +
in O +
the O +
ompF O +
regulatory O +
region O -
, O +
and O +
we O +
present O +
a O +
hypothetical O +
model O +
of O +
ompF O +
expression O +
that O +
includes O +
its O +
other O +
known O +
regulators O -
. O +

Fur O +
and O +
the O +
novel O +
regulator O +
YqjI O +
control O +
transcription O +
of O +
the O +
ferric O +
reductase O +
gene O +
yqjH O +
in O +
Escherichia B-Species +
coli L-Species -
. O +

Iron O +
acquisition O +
in O +
aerobic O +
habitats O +
is O +
complicated O +
by O +
the O +
low O +
solubility O +
of O +
ferric O +
hydroxides O -
. O -

Siderophores O +
that O +
bind O +
ferric O +
iron O +
with O +
high O +
affinity O +
are O +
used O +
to O +
mobilize O +
iron O -
. O -

The O +
reduction O +
of O +
ferric O +
iron O +
to O +
the O +
ferrous O +
form O +
can O +
be O +
coupled O +
to O +
the O +
release O +
of O +
iron O +
from O +
siderophores O -
. O -

Iron O +
is O +
also O +
stored O +
intracellularly O +
as O +
a O +
ferric O +
mineral O +
in O +
proteins O -
, O +
such O +
as O +
ferritin O -
, O +
and O +
must O +
be O +
reduced O +
during O +
release O -
. O -

In O +
Escherichia B-Species +
coli L-Species -
, O +
the O +
yqjH O +
gene O +
encodes O +
a O +
putative O +
ferric O +
siderophore O +
reductase O +
that O +
is O +
also O +
part O +
of O +
the O +
Fur O +
regulon O -
. O -

Here O +
we O +
show O +
that O +
YqjH O +
has O +
ferric O +
reductase O +
activity O +
and O +
is O +
required O +
for O +
iron O +
homeostasis O +
in O +
E. B-Species +
coli L-Species -
. O -

Divergently O +
transcribed O +
from O +
yqjH O +
is O +
the O +
yqjI O +
gene O -
, O +
which O +
encodes O +
a O +
novel O +
member O +
of O +
the O +
winged O -
- O -
helix O +
family O +
of O +
transcriptional O +
regulators O +
and O +
also O +
contains O +
an O +
N O -
- O -
terminal O +
extension O +
similar O +
to O +
the O +
Ni O -
( O -
2+ O -
) O -
-binding O +
C O -
- O -
terminal O +
tail O +
of O +
SlyD. O +
Deletion O +
of O +
yqjI O +
leads O +
to O +
constitutive O +
high O -
- O -
level O +
activity O +
of O +
the O +
yqjH O +
and O +
yqjI O +
promoters O -
. O -

Purified O +
YqjI O +
binds O +
inverted O +
repeat O +
target O +
sequences O +
within O +
the O +
yqjH O +
and O +
yqjI O +
promoters O -
. O -

We O +
also O +
observed O +
that O +
YqjI O -
- O -
dependent O +
transcriptional O +
repression O +
is O +
reduced O +
when O +
cells O +
are O +
exposed O +
to O +
elevated O +
nickel O +
levels O -
, O +
resulting O +
in O +
increased O +
expression O +
of O +
yqjH O +
and O +
yqjI. O +
YqjI O +
binding O +
to O +
nickel O +
or O +
iron O +
reduces O +
YqjI O +
DNA O -
- O -
binding O +
activity O +
in O +
vitro O -
. O -

Furthermore O -
, O +
we O +
found O +
that O +
elevated O +
nickel O +
stress O +
levels O +
disrupt O +
iron O +
homeostasis O +
in O +
E. B-Species +
coli L-Species +
and O +
that O +
deletion O +
of O +
yqjH O +
increases O +
nickel O +
toxicity O -
. O -

Our O +
results O +
suggest O +
that O +
the O +
YqjI O +
protein O +
controls O +
expression O +
of O +
yqjH O +
to O +
help O +
maintain O +
iron O +
homeostasis O +
under O +
conditions O +
( O -
such O +
as O +
elevated O +
cellular O +
nickel O +
levels O -
) O +
that O +
disrupt O +
iron O +
metabolism O -
. O +

Identification O +
of O +
binary O +
interactions O +
between O +
human B-Species +
cytomegalovirus L-Species +
virion O +
proteins O -
. O +

Human B-Species +
cytomegalovirus L-Species +
( O -
HCMV U-Species -
) O +
virions O +
are O +
composed O +
of O +
a O +
DNA O -
- O -
containing O +
nucleocapsid O +
surrounded O +
by O +
a O +
tegument O +
layer O +
and O +
host O -
- O -
derived O +
lipid O +
envelope O +
studded O +
with O +
virally O +
encoded O +
glycoproteins O -
. O -

These O +
complex O +
virions O +
are O +
estimated O +
to O +
be O +
composed O +
of O +
more O +
than O +
50 O +
viral O +
proteins O -
. O -

Assembly O +
of O +
HCMV U-Species +
virions O +
is O +
poorly O +
understood O -
, O +
especially O +
with O +
respect O +
to O +
acquisition O +
of O +
the O +
tegument O -
; O +
however O -
, O +
it O +
is O +
thought O +
to O +
involve O +
the O +
stepwise O +
addition O +
of O +
virion O +
components O +
through O +
protein O -
- O -
protein O +
interactions O -
. O -

We O +
sought O +
to O +
identify O +
interactions O +
among O +
HCMV U-Species +
virion O +
proteins O +
using O +
yeast U-Species +
two O -
- O -
hybrid O +
analysis O -
. O -

Using O +
33 O +
known O +
capsid O +
and O +
tegument O +
proteins O -
, O +
we O +
tested O +
1,089 O +
pairwise O +
combinations O +
for O +
binary O +
interaction O +
in O +
the O +
two O -
- O -
hybrid O +
assay O -
. O -

We O +
identified O +
24 O +
interactions O +
among O +
HCMV U-Species +
virion O +
proteins O -
, O +
including O +
13 O +
novel O +
interactions O +
among O +
tegument O +
proteins O +
and O +
one O +
novel O +
interaction O +
between O +
capsid O +
proteins O -
. O -

Several O +
of O +
these O +
novel O +
interactions O +
were O +
confirmed O +
by O +
coimmunoprecipitation O +
of O +
protein O +
complexes O +
from O +
transfected O +
cells O -
. O -

In O +
addition O -
, O +
we O +
demonstrate O +
three O +
of O +
these O +
interactions O +
in O +
the O +
context O +
of O +
HCMV U-Species +
infection O -
. O -

This O +
study O +
reveals O +
several O +
new O +
protein O -
- O -
protein O +
interactions O +
among O +
HCMV U-Species +
tegument O +
proteins O -
, O +
some O +
of O +
which O +
are O +
likely O +
important O +
for O +
HCMV U-Species +
replication O +
and O +
pathogenesis O -
. O +

Role O +
of O +
the O +
F1 O +
region O +
in O +
the O +
Escherichia B-Species +
coli L-Species +
aerotaxis O +
receptor O +
Aer O -
. O -

In O +
Escherichia B-Species +
coli L-Species -
, O +
the O +
aerotaxis O +
receptor O +
Aer O +
is O +
an O +
atypical O +
receptor O +
because O +
it O +
senses O +
intracellular O +
redox O +
potential O -
. O -

The O +
Aer O +
sensor O +
is O +
a O +
cytoplasmic O -
, O +
N O -
- O -
terminal O +
PAS O +
domain O +
that O +
is O +
tethered O +
to O +
the O +
membrane O +
by O +
a O +
47-residue O +
F1 O +
linker O -
. O -

Here O +
we O +
investigated O +
the O +
function O -
, O +
topology O -
, O +
and O +
orientation O +
of O +
F1 O +
by O +
employing O +
random O +
mutagenesis O -
, O +
cysteine O +
scanning O -
, O +
and O +
disulfide O +
cross O -
- O -
linking O -
. O -

No O +
native O +
residue O +
was O +
obligatory O +
for O +
function O -
, O +
most O +
deleterious O +
substitutions O +
had O +
radically O +
different O +
side O +
chain O +
properties O -
, O +
and O +
all O +
F1 O +
mutants O +
but O +
one O +
were O +
functionally O +
rescued O +
by O +
the O +
chemoreceptor O +
Tar O -
. O -

Cross O -
- O -
linking O +
studies O +
were O +
consistent O +
with O +
the O +
predicted O +
alpha O -
- O -
helical O +
structure O +
in O +
the O +
N O -
- O -
terminal O +
F1 O +
region O +
and O +
demonstrated O +
trigonal O +
interactions O +
among O +
the O +
F1 O +
linkers O +
from O +
three O +
Aer O +
monomers O -
, O +
presumably O +
within O +
trimer O -
- O -
of O -
- O -
dimer O +
units O -
, O +
as O +
well O +
as O +
binary O +
interactions O +
between O +
subunits O -
. O -

Using O +
heterodimer O +
analyses O -
, O +
we O +
also O +
demonstrated O +
the O +
importance O +
of O +
arginine O +
residues O +
near O +
the O +
membrane O +
interface O -
, O +
which O +
may O +
properly O +
anchor O +
the O +
Aer O +
protein O +
in O +
the O +
membrane O -
. O -

By O +
incorporating O +
these O +
data O +
into O +
a O +
homology O +
model O +
of O +
Aer O -
, O +
we O +
developed O +
a O +
model O +
for O +
the O +
orientation O +
of O +
the O +
Aer O +
F1 O +
and O +
PAS O +
regions O +
in O +
an O +
Aer O +
lattice O +
that O +
is O +
compatible O +
with O +
the O +
known O +
dimensions O +
of O +
the O +
chemoreceptor O +
lattice O -
. O -

We O +
propose O +
that O +
the O +
F1 O +
region O +
facilitates O +
the O +
orientation O +
of O +
PAS O +
and O +
HAMP O +
domains O +
during O +
folding O +
and O +
thereby O +
promotes O +
the O +
stability O +
of O +
the O +
PAS O +
and O +
HAMP O +
domains O +
in O +
Aer O -
. O +

Novel O +
Fusarium O +
head O +
blight O +
pathogens O +
from O +
Nepal O +
and O +
Louisiana O +
revealed O +
by O +
multilocus O +
genealogical O +
concordance O -
. O +

This O +
study O +
was O +
conducted O +
to O +
assess O +
evolutionary O +
relationships O -
, O +
species O +
diversity O +
and O +
trichothecene O +
toxin O +
potential O +
of O +
five O +
Fusarium B-Species +
graminearum I-Species +
complex L-Species +
( O -
FGSC U-Species -
) O +
isolates O +
identified O +
as O +
genetically O +
novel O +
during O +
prior O +
Fusarium O +
head O +
blight O +
( O -
FHB O -
) O +
surveys O +
in O +
Nepal O +
and O +
Louisiana O -
. O -

Results O +
of O +
a O +
multilocus O +
genotyping O +
( O -
MLGT O -
) O +
assay O +
for O +
B O -
- O -
trichothecene O +
species O +
determination O +
indicated O +
these O +
isolates O +
might O +
represent O +
novel O +
species O +
within O +
the O +
FGSC U-Species -
. O -

GCPSR O -
- O -
based O +
phylogenetic O +
analyses O +
of O +
a O +
12-gene O +
dataset O -
, O +
comprising O +
portions O +
of O +
seven O +
loci O +
totaling O +
13.1 O -
kb O +
of O +
aligned O +
DNA O +
sequence O +
data O -
, O +
provided O +
strong O +
support O +
for O +
the O +
genealogical O +
exclusivity O +
of O +
the O +
Nepalese O +
and O +
Louisianan O +
isolates O -
. O -

Accordingly O -
, O +
both O +
species O +
are O +
formally O +
recognized O +
herein O +
as O +
novel O +
FGSC B-Species +
species L-Species -
. O -

Fusarium B-Species +
nepalense L-Species +
was O +
resolved O +
as O +
the O +
sister O +
lineage O +
of O +
Fusarium B-Species +
ussurianum+Fusarium I-Species +
asiaticum L-Species +
within O +
an O +
Asian O +
subclade O +
of O +
the O +
FGSC U-Species -
. O -

Fusarium B-Species +
louisianense L-Species +
was O +
strongly O +
supported O +
as O +
a O +
reciprocally O +
monophyletic O +
sister O +
of O +
Fusarium B-Species +
gerlachii+F. I-Species +
graminearum L-Species -
, O +
suggesting O +
that O +
this O +
subclade O +
might O +
be O +
endemic O +
to O +
North O +
America O -
. O -

Multilocus O +
Bayesian O +
species O +
tree O +
analyses O +
augment O +
these O +
results O +
and O +
provide O +
evidence O +
for O +
a O +
distinct O +
lineage O +
within O +
F. B-Species +
graminearum L-Species +
predominately O +
from O +
the O +
Gulf O +
Coast O +
of O +
Louisiana O -
. O -

As O +
predicted O +
by O +
the O +
MLGT O +
assay O -
, O +
mycotoxin O +
analyses O +
demonstrated O +
that O +
F. B-Species +
nepalense L-Species +
and O +
F. B-Species +
louisianense L-Species +
could O +
produce O +
15ADON O +
and O +
nivalenol O -
, O +
respectively O -
, O +
in O +
planta O -
. O -

In O +
addition O -
, O +
both O +
species O +
were O +
only O +
able O +
to O +
induce O +
mild O +
FHB O +
symptoms O +
on O +
wheat O +
in O +
pathogenicity O +
experiments O -
. O +

Host O +
plant O +
secondary O +
metabolite O +
profiling O +
shows O +
a O +
complex O -
, O +
strain O -
- O -
dependent O +
response O +
of O +
maize U-Species +
to O +
plant O +
growth O -
- O -
promoting O +
rhizobacteria O +
of O +
the O +
genus O +
Azospirillum O -
. O +

Most O +
Azospirillum O +
plant O +
growth O -
- O -
promoting O +
rhizobacteria O +
( O -
PGPR O -
) O +
benefit O +
plant O +
growth O +
through O +
source O +
effects O +
related O +
to O +
free O +
nitrogen O +
fixation O +
and/or O +
phytohormone O +
production O -
, O +
but O +
little O +
is O +
known O +
about O +
their O +
potential O +
effects O +
on O +
plant O +
physiology O -
. O -

These O +
effects O +
were O +
assessed O +
by O +
comparing O +
the O +
early O +
impacts O +
of O +
three O +
Azospirillum O +
inoculant O +
strains O +
on O +
secondary O +
metabolite O +
profiles O +
of O +
two O +
different O +
maize U-Species +
( O -
Zea B-Species +
mays L-Species -
) O +
cultivars O -
. O -

After O +
10d O +
of O +
growth O +
in O +
nonsterile O +
soil O -
, O +
maize U-Species +
methanolic O +
extracts O +
were O +
analyzed O +
by O +
reverse O -
- O -
phase O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
RP O -
- O -
HPLC O -
) O +
and O +
secondary O +
metabolites O +
identified O +
by O +
liquid O +
chromatography O -
/ O -
mass O +
spectrometry O +
( O -
LC O -
/ O -
MS O -
) O +
and O +
nuclear O +
magnetic O +
resonance O +
( O -
NMR O -
) O -
. O -

Seed O +
inoculation O +
resulted O +
in O +
increased O +
shoot O +
biomass O +
( O -
and O +
also O +
root O +
biomass O +
with O +
one O +
strain O -
) O +
of O +
hybrid O +
PR37Y15 O +
but O +
had O +
no O +
stimulatory O +
effect O +
on O +
hybrid O +
DK315 O -
. O -

In O +
parallel O -
, O +
Azospirillum O +
inoculation O +
led O +
to O +
major O +
qualitative O +
and O +
quantitative O +
modifications O +
of O +
the O +
contents O +
of O +
secondary O +
metabolites O -
, O +
especially O +
benzoxazinoids O -
, O +
in O +
the O +
maize U-Species +
plants O -
. O -

These O +
modifications O +
depended O +
on O +
the O +
PGPR O +
strainxplant O +
cultivar O +
combination O -
. O -

Thus O -
, O +
Azospirillum O +
inoculation O +
resulted O +
in O +
early O -
, O +
strain O -
- O -
dependent O +
modifications O +
in O +
the O +
biosynthetic O +
pathways O +
of O +
benzoxazine O +
derivatives O +
in O +
maize U-Species +
in O +
compatible O +
interactions O -
. O -

This O +
is O +
the O +
first O +
study O +
documenting O +
a O +
PGPR O +
effect O +
on O +
plant O +
secondary O +
metabolite O +
profiles O -
, O +
and O +
suggests O +
the O +
establishment O +
of O +
complex O +
interactions O +
between O +
Azospirillum O +
PGPR O +
and O +
maize O -
. O +

Carnivorous O +
planktonic O +
Difflugia O +
( O -
Protista O -
, O +
Amoebina O +
Testacea O -
) O +
and O +
their O +
predators O -
. O +

Four O +
planktonic O +
species O +
of O +
Difflugia O +
co O -
- O -
occurring O +
in O +
a O +
south O +
Chinese O +
reservoir O +
were O +
found O +
to O +
be O +
carnivorous O -
, O +
but O +
the O +
diet O +
was O +
widest O +
in O +
the O +
largest O +
species O +
( O -
D. O +
tuberspinifera O -
) O +
and O +
narrowest O +
in O +
the O +
smallest O +
( O -
D. O +
hydrostatica O -
) O -
. O -

It O +
included O +
rotifers O -
, O +
ciliates O -
, O +
dinoflagellates O -
, O +
floating O +
eggs O -
, O +
and O +
small O +
particles O +
associated O +
with O +
organic O +
debris O -
. O -

Scavenging O +
and O +
cannibalism O +
were O +
also O +
observed O -
. O -

Species O +
with O +
a O +
collared O +
test O +
( O -
D. O +
biwae O -
, O +
D. O +
mulanensis O -
) O +
showed O +
a O +
form O +
of O +
suction O -
- O -
feeding O -
, O +
while O +
species O +
with O +
teeth O +
on O +
the O +
pseudostome O +
used O +
these O -
, O +
together O +
with O +
their O +
pseudopods O -
, O +
as O +
" O -
inverted O +
crown O +
corks O -
" O -
, O +
providing O +
leverage O +
for O +
opening O +
the O +
lorica O +
of O +
their O +
( O -
rotifer O -
) O +
prey O -
. O -

Predators O +
of O +
Difflugia O +
included O +
cyclopoid O +
copepods O -
. O -

In O +
addition O -
, O +
the O +
rotifers O +
Asplanchna O +
priodonta O -
, O +
Ploesoma O +
hudsoni O +
and B-Species -
, I-Species +
occasionally L-Species -
, O +
big O +
ciliates O +
( O -
Stentor O +
sp. O -
) O +
all O +
ingested O +
their O +
prey O +
as O +
a O +
whole O -
. O +

Ca O -
( O -
2+ O -
) O -
-dependent O +
in O +
vivo O +
protein O +
phosphorylation O +
and O +
encystment O +
induction O +
in O +
the O +
ciliated O +
protozoan O +
Colpoda B-Species +
cucullus L-Species -
. O +

Encystment O +
induction O +
of O +
Colpoda B-Species +
cucullus L-Species +
is O +
promoted O +
by O +
an O +
increase O +
in O +
external O +
Ca O -
( O -
2 O -
+ O -
) O +
and O +
overpopulation O +
of O +
Colpoda O +
vegetative O +
cells O -
. O -

Using O +
phos O -
- O -
tag O +
detection O +
assays O -
, O +
the O +
present O +
study O +
revealed O +
that O +
the O +
in O +
vivo O +
phosphorylation O +
level O +
in O +
several O +
proteins O +
[ O -
33 O +
kDa O -
, O +
37 O +
kDa O -
, O +
37.5 O +
kDa O -
, O +
43 O +
kDa O -
, O +
47 O +
kDa O -
, O +
49 O +
kDa O -
, O +
etc O -
. O -
] O +
was O +
raised O +
when O +
the O +
vegetative O +
cells O +
were O +
stimulated O +
by O +
overpopulation O +
to O +
encyst O +
in O +
a O +
medium O +
containing O +
0.1 O +
mM O +
Ca O -
( O -
2 O -
+ O -
) O +
or O +
without O +
the O +
addition O +
of O +
Ca O -
( O -
2 O -
+ O -
) O -
. O -

Both O +
overpopulation O -
- O -
mediated O +
encystment O +
induction O +
and O +
protein O +
phosphorylation O +
were O +
suppressed O +
by O +
the O +
addition O +
of O +
EGTA O -
. O -

Ca O -
( O -
2+ O -
) O -
/ O -
overpopulation O -
- O -
stimulated O +
encystment O +
induction O +
and O +
protein O +
phosphorylation O +
were O +
also O +
suppressed O +
by O +
the O +
addition O +
of O +
BAPTA O -
- O -
AM O -
. O -

These O +
results O +
suggest O +
that O +
the O +
Ca O -
( O -
2 O -
+ O -
) O +
inflow O +
promoted O +
by O +
cell O -
- O -
to O -
- O -
cell O +
stimulation O +
due O +
to O +
overpopulation O +
may O +
activate O +
signaling O +
pathways O +
involving O +
protein O +
phosphorylation O +
and O +
encystment O +
induction O -
. O -

In O +
the O +
presence O +
of O +
cAMP O -
- O -
AM O -
, O +
the O +
phosphorylation O +
levels O +
of O +
33 O +
kDa O -
, O +
37 O +
kDa O -
, O +
37.5 O +
kDa O -
, O +
43 O +
kDa O -
, O +
47 O +
kDa O +
and O +
49 O +
kDa O +
proteins O +
were O +
enhanced O -
, O +
and O +
encystment O +
induction O +
was O +
promoted O -
. O -

Enzyme O +
immunoassays O +
( O -
EIAs O -
) O +
showed O +
that O +
intracellular O +
cAMP O +
concentration O +
was O +
raised O +
prior O +
to O +
encystment O +
when O +
the O +
cells O +
were O +
stimulated O +
by O +
overpopulation O -
. O -

These O +
results O +
suggest O +
that O +
cAMP O -
/ O -
PKA O -
- O -
dependent O +
protein O +
phosphorylation O -
, O +
which O +
is O +
an O +
event O +
on O +
Ca O -
( O -
2+ O -
) O -
-triggered O +
signaling O +
pathways O -
, O +
may O +
be O +
involved O +
in O +
encystment O +
induction O -
. O +

Proposal O +
of O +
Mingxiaea O +
gen. O +
nov. O +
for O +
the O +
anamorphic O +
basidiomycetous O +
yeast U-Species +
species O +
in O +
the O +
Bulleribasidium O +
clade O +
( O -
Tremellales O -
) O +
based O +
on O +
molecular O +
phylogenetic O +
analysis O -
, O +
with O +
six O +
new O +
combinations O +
and O +
four O +
novel O +
species O -
. O +

The O +
distinction O +
and O +
monophyletic O +
property O +
of O +
the O +
basidiomycetous O +
yeast U-Species +
species O +
in O +
the O +
Bulleribasidium O +
clade O +
of O +
the O +
order O +
Tremellales O +
was O +
resolved O +
by O +
molecular O +
phylogenetic O +
analysis O +
based O +
on O +
the O +
combined O +
sequences O +
of O +
the O +
18S O +
rRNA O +
gene O -
, O +
internal O +
transcribed O +
spacer O +
( O -
ITS O -
) O +
region O +
including O +
5.8S O +
rRNA O +
gene O +
and O +
26S O +
rRNA O +
gene O +
D1 O -
/ O -
D2 O +
domain O -
. O -

The O +
addition O +
to O +
the O +
clade O +
of O +
new O +
anamorphic O +
species O +
identified O +
among O +
ballistoconidium O -
- O -
forming O +
yeasts U-Species +
isolated O +
from O +
China O +
confirmed O +
and O +
strengthened O +
the O +
separation O +
of O +
this O +
clade O +
from O +
other O +
clades O +
or O +
lineages O +
in O +
the O +
order O +
Tremellales O -
. O -

A O +
new O +
anamorphic O +
genus O -
, O +
Mingxiaea O +
gen. O +
nov. O +
( O -
type O +
species O +
Mingxiaea O +
variabilis O +
comb O -
. O -

nov. O -
) O +
is O +
therefore O +
proposed O +
to O +
accommodate O +
the O +
anamorphic O +
species O +
in O +
the O +
Bulleribasidium O +
clade O -
. O -

Six O +
new O +
combinations O +
are O +
proposed O +
for O +
the O +
described O +
species O +
of O +
this O +
clade O +
which O +
were O +
formerly O +
assigned O +
to O +
the O +
genus O +
Bullera O -
. O -

Four O +
novel O +
species O +
in O +
the O +
new O +
genus O +
were O +
identified O +
among O +
16 O +
ballistoconidium O -
- O -
forming O +
yeast U-Species +
strains O +
isolated O +
from O +
plant O +
leaves O +
collected O +
in O +
Hainan O +
province O -
, O +
southern O +
China O -
, O +
by O +
D1 O -
/ O -
D2 O +
and O +
ITS O +
sequence O +
analyses O -
. O -

The O +
novel O +
species O +
are O +
described O +
as O +
Mingxiaea O +
sanyaensis O +
sp. O +
nov. O +
( O -
type O +
strain O +
SY-3.23 O -
( O -
T O -
) O +
= O -
AS O +
2 O -
. O +
3623 O -
( O -
T O -
) O +
= O -
CBS O +
11408 O -
( O -
T O -
) O -
) O -
, O +
Mingxiaea O +
hainanensis O +
( O -
type O +
strain O +
WZS-8.13 O -
( O -
T O -
) O +
= O -
AS O +
2.4161 O -
( O -
T O -
) O +
= O -
CBS O +
11409 O -
( O -
T O -
) O -
) O -
, O +
Mingxiaea O +
foliicola O +
( O -
type O +
strain O +
WZS-8.14 O -
( O -
T O -
) O +
= O -
AS O +
2.3518 O -
( O -
T O -
) O +
= O -
CBS O +
11407 O -
( O -
T O -
) O -
) O +
and O +
Mingxiaea O +
wuzhishanensis O +
( O -
type O +
strain O +
WZS-29.8 O -
( O -
T O -
) O +
= O -
AS O +
2.4163 O -
( O -
T O -
) O +
= O -
CBS O +
11411 O -
( O -
T O -
) O -
) O -
. O +

Taxonomy O +
and O +
phylogeny O +
of O +
a O +
new O +
kleptoplastidal O +
dinoflagellate O -
, O +
Gymnodinium B-Species +
myriopyrenoides L-Species +
sp. O +
nov. O +
( O -
Gymnodiniales O -
, O +
Dinophyceae O -
) O -
, O +
and O +
its O +
cryptophyte O +
symbiont O -
. O +

A O +
new O +
kleptoplastidal O +
dinoflagellate O -
, O +
Gymnodinium B-Species +
myriopyrenoides L-Species +
sp. O +
nov. O -
, O +
was O +
described O +
using O +
light O +
microscopy O -
, O +
electron O +
microscopy O +
and O +
phylogengetic O +
analysis O +
based O +
on O +
partial O +
LSU O +
rDNA O +
sequences O -
. O -

Cells O +
were O +
dorsiventrally O +
flattened O -
, O +
elongate O -
- O -
elliptical O +
in O +
ventral O +
view O -
. O -

There O +
was O +
no O +
displacement O +
of O +
the O +
cingulum O +
encircling O +
the O +
anterior O +
part O +
of O +
the O +
cell O -
. O -

The O +
cingulum O +
was O +
curved O +
posteriorly O +
at O +
the O +
terminal O +
junction O +
with O +
the O +
sulcus O -
. O -

The O +
sulcus O +
was O +
generally O +
narrow O +
but O +
expanded O +
in O +
the O +
posterior O +
end O -
. O -

The O +
epicone O +
possessed O +
an O +
apical O +
groove O +
made O +
of O +
one O +
and O +
one O -
- O -
half O +
counterclockwise O +
revolutions O -
. O -

Phylogenetic O +
analysis O +
based O +
on O +
LSU O +
rDNA O +
showed O +
that O +
the O +
sequence O +
of O +
G. B-Species +
myriopyrenoides L-Species +
was O +
included O +
in O +
the O +
Gymnodiniales O +
sensu O +
stricto O +
clade O +
and O +
had O +
special O +
affinities O +
with O +
the O +
species O +
Amphidinium B-Species +
poecilochroum L-Species +
and O +
Gymnodinium B-Species +
acidotum L-Species -
, O +
which O +
also O +
harbor O +
kleptochloroplasts O -
. O -

Phylogenetic O +
analysis O +
based O +
on O +
plastid O -
- O -
encoded O +
SSU O +
rDNA O +
and O +
ultrastructural O +
observations O +
suggested O +
that O +
the O +
symbionts O +
of O +
G. B-Species +
myriopyrenoides L-Species +
were O +
cryptophytes O +
of O +
the O +
genus O +
Chroomonas O +
or O +
Hemiselmis O -
. O -

Organelles O +
including O +
the O +
nucleus O -
, O +
the O +
nucleomorph O -
, O +
mitochondria O -
, O +
Golgi O +
bodies O +
and O +
large O +
chloroplasts O +
remained O +
in O +
the O +
cytoplasm O +
of O +
the O +
symbionts O -
, O +
but O +
not O +
the O +
periplast O -
, O +
ejectosomes O +
or O +
flagellar O +
apparatus O -
. O -

The O +
symbiotic O +
level O +
of O +
G. B-Species +
myriopyrenoides L-Species +
was O +
estimated O +
to O +
be O +
a O +
relatively O +
early O +
stage O +
in O +
the O +
unarmored O +
kleptoplastidal O +
dinoflagellates O -
. O +

Unexpected O +
coregulator O +
range O +
for O +
the O +
global O +
regulator O +
Lrp O +
of O +
Escherichia B-Species +
coli L-Species +
and O +
Proteus B-Species +
mirabilis L-Species -
. O +

The O +
Lrp O -
/ O -
AsnC O +
family O +
of O +
transcription O +
factors O +
links O +
gene O +
regulation O +
to O +
metabolism O +
in O +
bacteria O +
and O +
archaea O -
. O -

Members O +
of O +
this O +
family O -
, O +
collectively O -
, O +
respond O +
to O +
a O +
wide O +
range O +
of O +
amino O +
acids O +
as O +
coregulators O -
. O -

In O +
Escherichia B-Species +
coli L-Species -
, O +
Lrp O +
regulates O +
over O +
200 O +
genes O +
directly O +
and O +
is O +
well O +
known O +
to O +
respond O +
to O +
leucine O +
and O -
, O +
to O +
a O +
somewhat O +
lesser O +
extent O -
, O +
alanine O -
. O -

We O +
focused O +
on O +
Lrp O +
from O +
Proteus B-Species +
mirabilis L-Species +
and O +
E. B-Species +
coli L-Species -
, O +
orthologs O +
with O +
98 O -
% O +
identity O +
overall O +
and O +
identical O +
helix O -
- O -
turn O -
- O -
helix O +
motifs O -
, O +
for O +
which O +
a O +
previous O +
study O +
nevertheless O +
found O +
functional O +
differences O -
. O -

Sequence O +
differences O +
between O +
these O +
orthologs O -
, O +
within O +
and O +
adjacent O +
to O +
the O +
amino O +
acid O -
- O -
responsive O +
RAM O +
domain O -
, O +
led O +
us O +
to O +
test O +
for O +
differential O +
sensitivity O +
to O +
coregulatory O +
amino O +
acids O -
. O -

In O +
the O +
course O +
of O +
this O +
investigation O -
, O +
we O +
found O -
, O +
via O +
in O +
vivo O +
reporter O +
fusion O +
assays O +
and O +
in O +
vitro O +
electrophoretic O +
mobility O +
shift O +
experiments O -
, O +
that O +
E. B-Species +
coli L-Species +
Lrp O +
itself O +
responded O +
to O +
a O +
broader O +
range O +
of O +
amino O +
acids O +
than O +
was O +
previously O +
appreciated O -
. O -

In O +
particular O -
, O +
for O +
both O +
the O +
E. B-Species +
coli L-Species +
and O +
P. B-Species +
mirabilis L-Species +
orthologs O -
, O +
Lrp O +
responsiveness O +
to O +
methionine O +
was O +
similar O +
in O +
magnitude O +
to O +
that O +
to O +
leucine O -
. O -

Both O +
Lrp O +
orthologs O +
are O +
also O +
fairly O +
sensitive O +
to O +
Ile O -
, O +
His O -
, O +
and O +
Thr O -
. O -

These O +
observations O +
suggest O +
that O +
Lrp O +
ties O +
gene O +
expression O +
in O +
the O +
Enterobacteriaceae O +
rather O +
extensively O +
to O +
physiological O +
status O -
, O +
as O +
reflected O +
in O +
amino O +
acid O +
pools O -
. O -

These O +
findings O +
also O +
have O +
substantial O +
implications O +
for O +
attempts O +
to O +
model O +
regulatory O +
architecture O +
from O +
transcriptome O +
measurements O +
or O +
to O +
infer O +
such O +
architecture O +
from O +
genome O +
sequences O -
, O +
and O +
they O +
suggest O +
that O +
even O +
well O -
- O -
studied O +
regulators O +
deserve O +
ongoing O +
exploration O -
. O +

Contrasting O +
covariation O +
of O +
above- O +
and O +
belowground O +
invertebrate O +
species O +
across O +
plant O +
genotypes O -
. O +

1 O -
. O -

Invertebrate O +
species O +
generally O +
do O +
not O +
respond O +
independently O +
to O +
genotypic O +
variation O +
in O +
plants O -
, O +
giving O +
rise O +
to O +
clusters O +
of O +
species O +
that O +
naturally O +
associate O +
with O +
or O +
avoid O +
certain O +
genotypes O -
. O -

This O +
covariation O +
causes O +
coevolution O +
to O +
be O +
diffuse O +
rather O +
than O +
pairwise O -
. O -

Studies O +
on O +
this O +
topic O -
, O +
however O -
, O +
have O +
never O +
considered O +
the O +
belowground O +
invertebrate O +
community O -
, O +
leaving O +
a O +
critical O +
gap O +
in O +
our O +
understanding O -
. O -

2 O -
. O -

We O +
investigated O +
the O +
covariation O +
among O +
naturally O +
colonising O +
above- O +
and O +
belowground O +
invertebrate O +
species O +
across O +
six O +
genetically O +
distinct O +
populations O +
of O +
the O +
dune O +
grass O +
Ammophila B-Species +
arenaria L-Species -
. O -

After O +
having O +
grown O +
from O +
seed O +
in O +
a O +
common O +
garden O -
, O +
plants O +
were O +
randomised O +
in O +
a O +
single O +
field O +
site O +
to O +
exclude O +
all O +
but O +
broad O -
- O -
sense O +
genetic O +
variation O -
. O -

3 O -
. O +
Strong O +
positive O +
covariation O +
across O +
genotypes O +
among O +
both O +
above- O +
and O +
belowground O +
invertebrates O +
was O +
detected O -
, O +
while O +
correlations O +
between O +
these O +
two O +
groups O +
were O +
negative O -
. O -

This O +
clustering O +
of O +
above- O +
and O +
belowground O +
species O +
matched O +
well O +
with O +
order O +
level O +
taxonomy O -
. O -

Host O +
range O -
, O +
trophic O +
level O +
and O +
food O +
type O +
on O +
the O +
other O +
hand O +
did O +
not O +
correspond O +
well O +
with O +
the O +
clusters O -
. O -

Within O +
the O +
cluster O +
of O +
aboveground O +
fauna O -
, O +
subsequent O +
groupings O +
were O +
not O +
related O +
to O +
any O +
phylogenetic O +
or O +
ecological O +
characteristic O -
, O +
although O +
correlations O +
within O +
these O +
subgroups O +
were O +
very O +
high O -
. O -

We O +
furthermore O +
demonstrated O +
significant O +
differences O +
in O +
multiple O +
invertebrate O +
species O +
occurrence O +
between O +
plant O +
genotypes O -
, O +
in O +
general O +
as O +
well O +
as O +
at O +
the O +
above- O +
and O +
belowground O +
level O -
. O -

4 O -
. O -

The O +
observed O +
strong O +
covariation O +
suggests O +
diffuse O +
coevolution O +
between O +
A. B-Species +
arenaria L-Species +
and O +
its O +
associated O +
invertebrate O +
species O -
. O -

The O +
trade O -
- O -
off O +
between O +
root O +
and O +
shoot O +
invertebrates O +
could O +
however O +
hamper O +
directional O +
selection O +
on O +
resistance O +
to O +
either O +
group O -
. O -

5 O -
. O -

Our O +
results O +
clearly O +
demonstrate O +
the O +
need O +
for O +
studies O +
of O +
plant O -
- O -
animal O +
interactions O +
to O +
include O +
the O +
belowground O +
fauna O -
, O +
as O +
this O +
might O +
drastically O +
alter O +
our O +
general O +
conception O +
of O +
how O +
plants O +
and O +
their O +
associated O +
animal O +
communities O +
interact O +
and O +
how O +
these O +
interactions O +
shape O +
the O +
process O +
of O +
evolution O -
. O +

Labeling O +
and O +
enzyme O +
studies O +
of O +
the O +
central O +
carbon O +
metabolism O +
in O +
Metallosphaera B-Species +
sedula L-Species -
. O +

Metallosphaera B-Species +
sedula L-Species +
( O -
Sulfolobales O -
, O +
Crenarchaeota O -
) O +
uses O +
the O +
3-hydroxypropionate O -
/ O -
4-hydroxybutyrate O +
cycle O +
for O +
autotrophic O +
carbon O +
fixation O -
. O -

In O +
this O +
pathway O -
, O +
acetyl O -
- O -
coenzyme O +
A O +
( O -
CoA O -
) O +
and O +
succinyl O -
- O -
CoA O +
are O +
the O +
only O +
intermediates O +
that O +
can O +
be O +
considered O +
common O +
to O +
the O +
central O +
carbon O +
metabolism O -
. O -

We O +
addressed O +
the O +
question O +
of O +
which O +
intermediate O +
of O +
the O +
cycle O +
most O +
biosynthetic O +
routes O +
branch O +
off O -
. O -

We O +
labeled O +
autotrophically O +
growing O +
cells O +
by O +
using O +
4-hydroxy O -
[ O -
1-^1 O -
^ O -
4C O -
] O -
butyrate O +
and O +
[ O -
1,4-^1 O -
^ O -
3C1 O -
] O -
succinate O -
, O +
respectively O -
, O +
as O +
precursors O +
for O +
biosynthesis O -
. O -

The O +
labeling O +
patterns O +
of O +
protein O -
- O -
derived O +
amino O +
acids O +
verified O +
the O +
operation O +
of O +
the O +
proposed O +
carbon O +
fixation O +
cycle O -
, O +
in O +
which O +
4-hydroxybutyrate O +
is O +
converted O +
to O +
two O +
molecules O +
of O +
acetyl O -
- O -
CoA. O +
The O +
results O +
also O +
showed O +
that O +
major O +
biosynthetic O +
flux O +
does O +
not O +
occur O +
via O +
acetyl O -
- O -
CoA O -
, O +
except O +
for O +
the O +
formation O +
of O +
building O +
blocks O +
that O +
are O +
directly O +
derived O +
from O +
acetyl O -
- O -
CoA. O +
Notably O -
, O +
acetyl O -
- O -
CoA O +
is O +
not O +
assimilated O +
via O +
reductive O +
carboxylation O +
to O +
pyruvate O -
. O -

Rather O -
, O +
our O +
data O +
suggest O +
that O +
the O +
majority O +
of O +
anabolic O +
precursors O +
are O +
derived O +
from O +
succinyl O -
- O -
CoA O -
, O +
which O +
is O +
removed O +
from O +
the O +
cycle O +
via O +
oxidation O +
to O +
malate O +
and O +
oxaloacetate O -
. O -

These O +
C4intermediates O +
yield O +
pyruvate O +
and O +
phosphoenolpyruvate O +
( O -
PEP O -
) O -
. O -

Enzyme O +
activities O +
that O +
are O +
required O +
for O +
forming O +
intermediates O +
from O +
succinyl O -
- O -
CoA O +
were O +
detected O -
, O +
including O +
enzymes O +
catalyzing O +
gluconeogenesis O +
from O +
PEP O -
. O -

This O +
study O +
completes O +
the O +
picture O +
of O +
the O +
central O +
carbon O +
metabolism O +
in O +
autotrophic O +
Sulfolobales O +
by O +
connecting O +
the O +
autotrophic O +
carbon O +
fixation O +
cycle O +
to O +
the O +
formation O +
of O +
central O +
carbon O +
precursor O +
metabolites O -
. O +

Density O -
- O -
dependent O +
population O +
dynamics O +
and O +
dispersal O +
in O +
heterogeneous O +
metapopulations O -
. O +

1 O -
. O -

Metapopulation O +
microcosms O +
were O +
constructed O +
to O +
test O +
the O +
effect O +
of O +
four O +
different O +
types O +
of O +
habitat O +
heterogeneity O +
on O +
the O +
dynamics O +
and O +
dispersal O +
in O +
spatially O +
extended O +
systems O -
; O +
homogeneity O -
, O +
spatial O +
heterogeneity O -
, O +
temporal O +
heterogeneity O +
and O +
spatio O -
- O -
temporal O +
heterogeneity O -
. O -

Resources O +
were O +
distributed O +
across O +
discrete O +
habitat O +
patches O +
in O +
bruchid O +
beetle O +
( O -
Callosobruchus B-Species +
maculatus L-Species -
) O +
metapopulations O -
, O +
and O +
long O -
- O -
term O +
time O +
series O +
were O +
recorded O -
. O -

2 O -
. O -

Mathematical O +
models O +
were O +
fitted O +
to O +
the O +
long O -
- O -
term O +
time O +
series O +
from O +
the O +
experimental O +
systems O +
using O +
a O +
maximum O +
likelihood O +
approach O -
. O -

Models O +
were O +
composed O +
of O +
separate O +
birth O -
, O +
death O -
, O +
emigration O +
and O +
immigration O +
terms O +
all O +
of O +
which O +
incorporated O +
stochasticity O +
drawn O +
from O +
different O +
probability O +
distributions O -
. O -

Models O +
with O +
density O -
- O -
dependent O +
and O +
density O -
- O -
independent O +
birth O -
, O +
death O +
and O +
emigration O +
terms O +
were O +
investigated O +
and O -
, O +
in O +
each O +
case O -
, O +
the O +
model O +
that O +
best O +
described O +
the O +
empirical O +
data O +
was O +
identified O -
. O -

3 O -
. O -

At O +
the O +
local O +
scale O -
, O +
population O +
sizes O +
differed O +
between O +
patches O +
depending O +
on O +
the O +
type O +
of O +
heterogeneity O -
. O -

Larger O +
populations O +
were O +
associated O +
with O +
higher O +
resource O +
availabilities O -
. O -

As O +
a O +
result O +
of O +
this O -
, O +
the O +
variation O +
between O +
local O +
population O +
sizes O +
was O +
greatest O +
when O +
there O +
was O +
spatial O +
heterogeneity O +
in O +
which O +
mean O +
resource O +
abundance O +
varied O +
from O +
patch O +
to O +
patch O -
. O -

Variation O +
in O +
population O +
sizes O +
within O +
patches O +
was O +
largest O +
when O +
there O +
was O +
temporal O +
heterogeneity O -
. O -

4 O -
. O +
Density O -
- O -
dependent O +
processes O +
leading O +
to O +
the O +
regulation O +
of O +
local O +
population O +
dynamics O +
in O +
our O +
experimental O +
systems O +
were O +
strongest O +
in O +
homogeneity O +
or O +
temporal O +
heterogeneity O +
treatments O -
. O -

Associated O +
with O +
this O -
, O +
we O +
found O +
that O +
these O +
systems O +
were O +
best O +
described O +
using O +
mathematical O +
models O +
with O +
density O +
dependence O +
acting O +
on O +
mortality O -
. O -

In O +
contrast O -
, O +
spatial O +
and O +
spatio O -
- O -
temporal O +
time O +
series O +
were O +
adequately O +
described O +
using O +
density O -
- O -
independent O +
population O +
processes O -
. O -

5 O -
. O +
Experimental O +
metapopulations O +
showed O +
varying O +
degrees O +
of O +
density O -
- O -
dependent O +
dispersal O -
. O -

Local O +
net O +
dispersal O +
each O +
week O +
was O +
primarily O +
driven O +
by O +
the O +
local O +
population O +
size O +
and O +
secondarily O +
affected O +
by O +
neighbourhood O +
population O +
density O -
. O -

Mathematical O +
population O +
models O +
illustrated O +
the O +
importance O +
of O +
explicit O +
description O +
of O +
density O -
- O -
dependent O +
dispersal O +
in O +
all O +
systems O +
except O +
the O +
homogeneous O +
metapopulations O -
. O +

Predicting O +
diet O +
and O +
consumption O +
rate O +
differences O +
between O +
and O +
within O +
species O +
using O +
gut O +
ecomorphology O -
. O +

1 O -
. O -

Rapid O +
environmental O +
changes O +
and O +
pressing O +
human U-Species +
needs O +
to O +
forecast O +
the O +
consequences O +
of O +
environmental O +
change O +
are O +
increasingly O +
driving O +
ecology O +
to O +
become O +
a O +
predictive O +
science O -
. O -

The O +
need O +
for O +
effective O +
prediction O +
requires O +
both O +
the O +
development O +
of O +
new O +
tools O +
and O +
the O +
refocusing O +
of O +
existing O +
tools O +
that O +
may O +
have O +
previously O +
been O +
used O +
primarily O +
for O +
purposes O +
other O +
than O +
prediction O -
. O -

One O +
such O +
tool O +
that O +
historically O +
has O +
been O +
more O +
descriptive O +
in O +
nature O +
is O +
ecomorphology O +
( O -
the O +
study O +
of O +
relationships O +
between O +
ecological O +
roles O +
and O +
morphological O +
adaptations O +
of O +
species O +
and O +
individuals O -
) O -
. O -

2 O -
. O +
Here O -
, O +
we O +
examine O +
relationships O +
between O +
diet O +
and O +
gut O +
morphology O +
for O +
15 O +
species O +
of O +
brachyuran O +
crabs O -
, O +
a O +
group O +
of O +
pervasive O +
and O +
highly O +
successful O +
consumers O +
for O +
which O +
trophic O +
predictions O +
would O +
be O +
highly O +
valuable O -
. O -

3 O -
. O -

We O +
show O +
that O +
patterns O +
in O +
crab O +
stomach O +
volume O +
closely O +
match O +
some O +
predictions O +
of O +
metabolic O +
theory O +
and O +
demonstrate O +
that O +
individual O +
diet O +
differences O +
and O +
associated O +
morphological O +
variation O +
reflect O -
, O +
at O +
least O +
in O +
some O +
instances O -
, O +
individual O +
choice O +
or O +
diet O +
specialization O -
. O -

4 O -
. O -

We O +
then O +
present O +
examples O +
of O +
how O +
stomach O +
volume O +
can O +
be O +
used O +
to O +
predict O +
both O +
the O +
per O +
cent O +
herbivory O +
of O +
brachyuran O +
crabs O +
and O +
the O +
relative O +
consumption O +
rates O +
of O +
individual O +
crabs O -
. O +

Alcohol O +
dehydrogenase O +
and O +
hydrogenase O +
transcript O +
fluctuations O +
during O +
a O +
day O -
- O -
night O +
cycle O +
in O +
Chlamydomonas B-Species +
reinhardtii L-Species -
: O +
the O +
role O +
of O +
anoxia O -
. O +

* O +
The O +
unicellular O +
green O +
alga O +
Chlamydomonas B-Species +
reinhardtii L-Species +
contains O +
two O +
iron O +
( O -
Fe O -
) O -
-hydrogenases O +
which O +
are O +
responsible O +
for O +
hydrogen O +
production O +
under O +
anoxia O -
. O -

In O +
the O +
present O +
work O +
the O +
patterns O +
of O +
expression O +
of O +
alcohol O +
dehydrogenase O -
, O +
a O +
typical O +
anaerobic O +
gene O +
in O +
plants O -
, O +
of O +
the O +
hydrogenases O +
genes O +
( O -
HYD1 O -
, O +
HYD2 O -
) O +
and O +
of O +
the O +
genes O +
responsible O +
for O +
their O +
maturation O +
( O -
HYDEF O -
, O +
HYDG O -
) O -
, O +
were O +
analysed O -
. O -

* O +
The O +
expression O +
patterns O +
were O +
analysed O +
by O +
real O -
- O -
time O +
reverse O -
- O -
transcription O +
polymerase O +
chain O +
reaction O +
in O +
Chlamydomonas O +
cultures O +
during O +
the O +
day O -
- O -
night O +
cycle O -
, O +
as O +
well O +
as O +
in O +
response O +
to O +
oxygen O +
availability O -
. O -

* O +
The O +
results O +
indicated O +
that O +
ADH1 O -
, O +
HYD1 O -
, O +
HYD2 O -
, O +
HYDEF O +
and O +
HYDG O +
were O +
expressed O +
following O +
precise O +
day O -
- O -
night O +
fluctuations O -
. O -

ADH1 O +
and O +
HYD2 O +
were O +
modulated O +
by O +
the O +
day O -
- O -
night O +
cycle O -
. O -

Low O +
oxygen O +
plays O +
an O +
important O +
role O +
for O +
the O +
induction O +
of O +
HYD1 O -
, O +
HYDEF O +
and O +
HYDG O -
, O +
while O +
ADH1 O +
and O +
HYD2 O +
expression O +
was O +
relatively O +
insensitive O +
to O +
oxygen O +
availability O -
. O -

* O +
The O +
regulation O +
of O +
the O +
anaerobic O +
gene O +
expression O +
in O +
Chlamydomonas O +
is O +
only O +
partly O +
explained O +
by O +
responses O +
to O +
anoxia O -
. O -

The O +
cell O +
cycle O +
and O +
light O -
- O -
dark O +
cycles O +
are O +
equally O +
important O +
elements O +
in O +
the O +
regulatory O +
network O +
modulating O +
the O +
anaerobic O +
response O +
in O +
Chlamydomonas O -
. O +

Analysis O +
of O +
the O +
Fusarium B-Species +
graminearum I-Species +
species I-Species +
complex L-Species +
from O +
wheat U-Species -
, O +
barley U-Species +
and O +
maize U-Species +
in O +
South O +
Africa O +
provides O +
evidence O +
of O +
species O -
- O -
specific O +
differences O +
in O +
host O +
preference O -
. O +

Species O +
identity O +
and O +
trichothecene O +
toxin O +
potential O +
of O +
560 O +
members O +
of O +
the O +
Fusarium B-Species +
graminearum I-Species +
species I-Species +
complex L-Species +
( O -
FGSC U-Species -
) O +
collected O +
from O +
diseased O +
wheat U-Species -
, O +
barley U-Species +
and O +
maize U-Species +
in O +
South O +
Africa O +
was O +
determined O +
using O +
a O +
microsphere O -
- O -
based O +
multilocus O +
genotyping O +
assay O -
. O -

Although O +
three O +
trichothecene O +
types O +
( O -
3-ADON O -
, O +
15-ADON O +
and O +
NIV O -
) O +
were O +
represented O +
among O +
these O +
isolates O -
, O +
strains O +
with O +
the O +
15-ADON O +
type O +
predominated O +
on O +
all O +
three O +
hosts O -
. O -

A O +
significant O +
difference O -
, O +
however O -
, O +
was O +
identified O +
in O +
the O +
composition O +
of O +
FGSC U-Species +
pathogens O +
associated O +
with O +
Gibberella O +
ear O +
rot O +
( O -
GER O -
) O +
of O +
maize U-Species +
as O +
compared O +
to O +
Fusarium O +
head O +
blight O +
( O -
FHB O -
) O +
of O +
wheat U-Species +
or O +
barley U-Species +
( O -
P<0.001 O -
) O -
. O -

F. O +
graminearum B-Species +
accounted L-Species +
for O +
more O +
than O +
85 O -
% O +
of O +
the O +
FGSC O +
isolates U-Species +
associated O +
with O +
FHB O +
of O +
wheat O +
and U-Species +
barley O +
( U-Species -
N=425 O -
) O -
, O +
and O +
was O +
also O +
the O +
dominant O +
species O +
among O +
isolates O +
from O +
maize O +
roots U-Species +
( O -
N=35 O -
) O -
. O -

However O -
, O +
with O +
the O +
exception O +
of O +
a O +
single O +
isolate O +
identified O +
as O +
an O +
interspecific O +
hybrid O +
between O +
Fusariumboothii O +
and U-Species +
F. O +
graminearum B-Species -
, L-Species +
GER O +
of O +
maize O +
( U-Species -
N=100 O -
) O +
was O +
exclusively O +
associated O +
with O +
F. O +
boothii B-Species -
. L-Species -

The O +
predominance O +
of O +
F. O +
graminearum B-Species +
among L-Species +
FHB O +
isolates O -
, O +
and O +
the O +
near O +
exclusivity O +
of O +
F. O +
boothii B-Species +
among L-Species +
GER O +
isolates O -
, O +
was O +
observed O +
across O +
all O +
cultivars O -
, O +
collection O +
dates O -
, O +
and O +
provinces O +
sampled O -
. O -

Because O +
these O +
results O +
suggest O +
a O +
difference O +
in O +
host O +
preference O +
among O +
species O +
of O +
the O +
FGSC O -
, U-Species +
we O +
hypothesize O +
that O +
F. O +
graminearum B-Species +
may L-Species +
be O +
less O +
well O +
adapted O +
to O +
infect O +
maize O +
ears U-Species +
than O +
other O +
members O +
of O +
the O +
FGSC O -
. U-Species +

Molecular O +
structure O +
of O +
the O +
prothoracicotropic O +
hormone O +
gene O +
in O +
the O +
northern B-Species +
house I-Species +
mosquito L-Species -
, O +
Culex B-Species +
pipiens L-Species -
, O +
and O +
its O +
expression O +
analysis O +
in O +
association O +
with O +
diapause O +
and O +
blood O +
feeding O -
. O +

We O +
cloned O +
the O +
gene O +
that O +
encodes O +
prothoracicotropic O +
hormone O +
( O -
PTTH O -
) O +
in O +
the O +
northern B-Species +
house I-Species +
mosquito L-Species -
, O +
Culex B-Species +
pipiens L-Species -
, O +
and O +
investigated O +
its O +
expression O +
profile O +
in O +
short O -
- O -
day O +
( O -
diapause O -
- O -
destined O -
) O +
and O +
long O -
- O -
day O +
( O -
nondiapause O -
- O -
destined O -
) O +
individuals O +
from O +
the O +
fourth O -
- O -
instar O +
larval O +
stage O +
to O +
2 O +
months O +
of O +
adulthood O -
, O +
as O +
well O +
as O +
after O +
a O +
blood O +
meal O -
. O -

The O +
deduced O +
C. B-Species +
pipiens L-Species +
PTTH O +
( O -
Cupip O -
- O -
PTTH O -
) O +
amino O +
acid O +
sequence O +
contains O +
seven O +
cysteines O +
with O +
a O +
specific O +
spacing O +
pattern O -
. O -

Sequence O +
alignment O +
suggests O +
that O +
Cupip O -
- O -
PTTH O +
is O +
23 O -
% O +
identical O +
to O +
Drosophila B-Species +
melanogaster L-Species +
PTTH O -
, O +
but O +
is O +
> O -
= O -
59 O -
% O +
identical O +
to O +
the O +
PTTHs O +
of O +
other O +
mosquitoes O -
. O -

Cupip O -
- O -
PTTH O +
has O +
structural O +
characteristics O +
similar O +
to O +
those O +
of O +
Bombyx B-Species +
mori L-Species +
PTTH O +
and O +
some O +
vertebrate O +
nerve O +
growth O +
factors O +
with O +
cysteine O -
- O -
knot O +
motifs O -
. O -

PTTH O +
transcripts O +
exhibit O +
a O +
daily O +
cycling O +
profile O +
during O +
the O +
final O +
( O -
fourth O -
) O +
larval O +
instar O -
, O +
with O +
peak O +
abundance O +
occurring O +
late O +
in O +
the O +
scotophase O -
. O -

The O +
fourth O -
- O -
larval O +
instar O +
stage O +
is O +
one O +
day O +
longer O +
in O +
short O -
- O -
day O +
larvae O +
than O +
in O +
long O -
- O -
day O +
larvae O -
, O +
resulting O +
in O +
larger O +
larvae O +
and O +
adults O -
. O -

This O +
additional O +
day O +
of O +
larval O +
development O +
is O +
associated O +
with O +
one O +
extra O +
PTTH O +
cycle O -
. O -

No O +
cycling O +
was O +
observed O +
in O +
pupae O -
, O +
but O +
PTTH O +
transcripts O +
were O +
slightly O +
higher O +
in O +
short O -
- O -
day O +
pupae O +
than O +
in O +
long O -
- O -
day O +
pupae O +
throughout O +
much O +
of O +
the O +
pupal O +
stage O -
. O -

PTTH O +
expression O +
persisted O +
at O +
a O +
nearly O +
constant O +
level O +
in O +
diapausing O +
adult O +
females O +
for O +
the O +
first O +
month O +
but O +
then O +
dropped O +
by O +
-50 O -
% O -
, O +
while O +
expression O +
decreased O +
at O +
the O +
beginning O +
of O +
adulthood O +
in O +
nondiapausing O +
females O +
and O +
then O +
remained O +
at O +
a O +
low O +
level O +
as O +
long O +
as O +
the O +
females O +
were O +
denied O +
a O +
blood O +
meal O -
. O -

However O -
, O +
when O +
nondiapausing O +
females O +
were O +
offered O +
a O +
blood O +
meal O -
, O +
PTTH O +
transcripts O +
rose O +
approximately O +
7 O +
fold O +
in O +
2 O +
h O +
and O +
remained O +
elevated O +
for O +
24 O +
h. O +
A O +
few O +
diapausing O +
females O +
( O -
-10 O -
% O -
) O +
will O +
take O +
a O +
blood O +
meal O +
when O +
placed O +
in O +
close O +
proximity O +
to O +
a O +
host O -
, O +
but O +
much O +
of O +
the O +
blood O +
is O +
ejected O +
and O +
such O +
meals O +
do O +
not O +
result O +
in O +
mature O +
eggs O -
. O -

Yet O -
, O +
elevated O +
PTTH O +
mRNA O +
expression O +
was O +
also O +
observed O +
in O +
diapausing O +
females O +
that O +
were O +
force O +
fed O -
. O -

Our O +
results O +
thus O +
point O +
to O +
several O +
distinctions O +
in O +
PTTH O +
expression O +
between O +
short O -
- O -
day O +
and O +
long O -
- O -
day O +
mosquitoes O -
, O +
but O +
both O +
types O +
of O +
females O +
responded O +
to O +
a O +
blood O +
meal O +
by O +
elevating O +
levels O +
of O +
PTTH O +
mRNA O -
. O +

Phylloplane O +
location O +
of O +
glucosinolates O +
in O +
Barbarea O +
spp O -
. O -

( O -
Brassicaceae O -
) O +
and O +
misleading O +
assessment O +
of O +
host O +
suitability O +
by O +
a O +
specialist O +
herbivore O -
. O +

Glucosinolates O +
are O +
plant O +
secondary O +
metabolites O +
used O +
in O +
host O +
plant O +
recognition O +
by O +
insects O +
specialized O +
on O +
Brassicaceae O -
, O +
such O +
as O +
the O +
diamondback B-Species +
moth L-Species +
( O -
DBM U-Species -
) O -
, O +
Plutella B-Species +
xylostella L-Species -
. O -

Their O +
perception O +
as O +
oviposition O +
cues O +
by O +
females O +
would O +
seem O +
to O +
require O +
their O +
occurrence O +
on O +
the O +
leaf O +
surface O -
, O +
yet O +
previous O +
studies O +
have O +
reached O +
opposite O +
conclusions O +
about O +
whether O +
glucosinolates O +
are O +
actually O +
present O +
on O +
the O +
surface O +
of O +
crucifer O +
leaves O -
. O -

DBM U-Species +
oviposits O +
extensively O +
on O +
Barbarea B-Species +
vulgaris L-Species -
, O +
despite O +
its O +
larvae O +
not O +
being O +
able O +
to O +
survive O +
on O +
this O +
plant O +
because O +
of O +
its O +
content O +
of O +
feeding O -
- O -
deterrent O +
saponins O -
. O -

Glucosinolates O +
and O +
saponins O +
in O +
plant O +
tissue O +
and O +
mechanically O +
removed O +
surface O +
waxes O +
from O +
leaves O +
of O +
Barbarea O +
spp O -
. O +
were O +
analyzed O +
with O +
high O -
- O -
performance O +
liquid O +
chromatography O +
( O -
HPLC O -
) O +
and O +
liquid O +
chromatography O -
- O -
mass O +
spectrometry O +
( O -
LC O -
- O -
MS O -
) O -
. O -

Surface O +
waxes O +
from O +
leaves O +
of O +
Barbarea O +
spp O -
. O -

contained O +
glucosinolates O -
, O +
but O +
not O +
feeding O -
- O -
deterrent O +
saponins O -
. O -

Our O +
research O +
is O +
the O +
first O +
to O +
show O +
that O +
glucosinolates O +
are O +
present O +
on O +
the O +
leaf O +
surface O +
of O +
Barbarea O +
spp O -
. O -
, O +
but O +
not O +
in O +
other O +
crucifers O +
investigated O -
, O +
resolving O +
some O +
conflicting O +
results O +
from O +
previous O +
studies O -
. O -

Our O +
research O +
is O +
also O +
the O +
first O +
to O +
quantify O +
glucosinolates O +
on O +
the O +
leaf O +
surface O +
of O +
a O +
crucifer O -
, O +
and O +
to O +
show O +
that O +
the O +
concentrations O +
of O +
glucosinolates O +
found O +
on O +
the O +
leaf O +
surface O +
of O +
Barbarea O +
spp O -
. O +
are O +
sufficient O +
to O +
be O +
perceived O +
by O +
ovipositing O +
DBM U-Species -
. O +

Floret O +
initiation O -
, O +
tissue O +
expansion O +
and O +
carbon O +
availability O +
at O +
the O +
meristem O +
of O +
the O +
sunflower U-Species +
capitulum O +
as O +
affected O +
by O +
water O +
or O +
light O +
deficits O -
. O +

* O +
The O +
co O -
- O -
ordination O +
between O +
floret O +
initiation O +
and O +
meristem O +
expansion O -
, O +
and O +
their O +
relationships O +
with O +
carbon O +
availability O -
, O +
were O +
studied O +
and O +
quantified O +
in O +
sunflower U-Species +
( O -
Helianthus B-Species +
annuus L-Species -
) O +
plants O +
subjected O +
to O +
light O +
or O +
water O +
shortages O -
. O -

* O +
Meristem O +
size O -
, O +
number O +
of O +
floret O +
primordia O -
, O +
primordium O +
size O -
, O +
rate O +
of O +
plant O +
biomass O +
accumulation O -
, O +
leaf O +
area O -
, O +
photosynthetic O +
rate O -
, O +
and O +
soluble O +
sugar O +
content O +
in O +
the O +
capitulum O +
were O +
measured O +
until O +
completion O +
of O +
floret O +
initiation O -
. O -

* O +
Although O +
treatments O +
differentially O +
affected O +
tissue O +
expansion O +
and O +
biomass O +
acquisition O -
, O +
a O +
common O +
relationship O +
between O +
the O +
final O +
number O +
of O +
florets O +
and O +
the O +
rate O +
and O +
duration O +
of O +
meristem O +
expansion O +
was O +
conserved O -
. O -

In O +
the O +
absence O +
of O +
water O +
deficit O -
, O +
changes O +
in O +
relative O +
expansion O +
rate O +
in O +
the O +
meristem O +
paralleled O +
changes O +
in O +
soluble O +
sugar O +
content O -
. O -

Water O +
deficit O +
reduced O +
tissue O +
expansion O +
both O +
in O +
leaves O +
and O +
in O +
the O +
capitulum O -
, O +
and O +
induced O +
the O +
accumulation O +
of O +
soluble O +
sugars O +
in O +
the O +
meristem O -
. O -

Use O +
of O +
these O +
sugars O +
at O +
re O -
- O -
watering O +
was O +
associated O +
with O +
increased O +
meristem O +
growth O +
and O +
higher O +
floret O +
numbers O +
compared O +
with O +
control O +
plants O -
. O -

* O +
Floret O +
initiation O +
and O +
meristem O +
tissue O +
expansion O +
remained O +
strongly O +
co O -
- O -
ordinated O +
under O +
all O +
studied O +
circumstances O -
, O +
and O +
both O +
depended O +
on O +
local O +
carbon O +
availability O +
when O +
water O +
supply O +
was O +
unlimited O -
. O -

Transient O +
water O +
deficits O +
favoured O +
reproductive O +
meristem O +
growth O +
and O +
floret O +
production O -
. O -

Equations O +
accounting O +
for O +
these O +
results O +
constitute O +
a O +
framework O +
for O +
phenotyping O +
the O +
response O +
to O +
drought O -
. O +

Dynamic O +
behaviour O +
of O +
stationary O +
pronuclei O +
during O +
their O +
positioning O +
in O +
Paramecium B-Species +
caudatum L-Species -
. O +

During O +
conjugation O +
of O +
Paramecium B-Species +
caudatum L-Species -
, O +
there O +
are O +
two O +
well O -
- O -
known O +
stages O +
when O +
nuclear O +
migration O +
occurs O -
. O -

What O +
happens O +
to O +
the O +
nuclei O +
is O +
closely O +
related O +
to O +
their O +
localisations O +
in O +
cells O -
. O -

The O +
first O +
of O +
these O +
stages O +
is O +
the O +
entrance O +
of O +
one O +
meiotic O +
product O +
into O +
the O +
paroral O +
region O -
. O -

This O +
nucleus O +
survives O -
, O +
while O +
the O +
remaining O +
three O +
outside O +
this O +
area O +
degenerate O -
. O -

The O +
second O +
stage O +
is O +
the O +
antero O -
- O -
posterior O +
localisation O +
of O +
eight O +
synkaryon O +
division O +
products O -
. O -

Four O +
posterior O +
nuclei O +
are O +
differentiated O +
into O +
macronuclear O +
anlagen O -
, O +
whereas O +
four O +
anterior O +
nuclei O +
remain O +
as O +
the O +
presumptive O +
micronuclei O -
. O -

In O +
this O +
experiment O -
, O +
the O +
process O +
of O +
the O +
third O +
prezygotic O +
division O +
of O +
P. B-Species +
caudatum L-Species +
was O +
studied O +
with O +
the O +
help O +
of O +
protargol O +
staining O -
. O -

Here O -
, O +
a O +
third O +
nuclear O +
migration O +
was O +
discovered O -
. O -

By O +
two O +
spindle O +
turnings O +
and O +
two O +
spindle O +
elongations O -
, O +
stationary O +
pronuclei O +
were O +
positioned O +
near O +
migratory O +
pronuclei O -
. O -

This O +
positioning O +
of O +
stationary O +
pronuclei O +
could O +
shorten O +
the O +
distance O +
for O +
transferred O +
migratory O +
pronuclei O +
to O +
recognise O +
and O +
reach O +
the O +
stationary O +
pronuclei O -
. O -

This O +
fosters O +
the O +
synkaryon O +
formation O +
of O +
P. B-Species +
caudatum L-Species -
. O +

Adaptive O +
trade O -
- O -
offs O +
in O +
juvenile O +
salmonid O +
metabolism O +
associated O +
with O +
habitat O +
partitioning O +
between O +
coho B-Species +
salmon L-Species +
and O +
steelhead B-Species +
trout L-Species +
in O +
coastal O +
streams O -
. O +

1 O -
. O -

Adaptive O +
trade O -
- O -
offs O +
are O +
fundamental O +
to O +
the O +
evolution O +
of O +
diversity O +
and O +
the O +
coexistence O +
of O +
similar O +
taxa O +
and O +
occur O +
when O +
complimentary O +
combinations O +
of O +
traits O +
maximize O +
efficiency O +
of O +
resource O +
exploitation O +
or O +
survival O +
at O +
different O +
points O +
on O +
environmental O +
gradients O -
. O -

2 O -
. O -

Standard O +
metabolic O +
rate O +
( O -
SMR O -
) O +
is O +
a O +
key O +
physiological O +
trait O +
that O +
reflects O +
adaptations O +
to O +
baseline O +
metabolic O +
performance O -
, O +
whereas O +
active O +
metabolism O +
reflects O +
adaptations O +
to O +
variable O +
metabolic O +
output O +
associated O +
with O +
performance O +
related O +
to O +
foraging O -
, O +
predator O +
avoidance O -
, O +
aggressive O +
interactions O +
or O +
migratory O +
movements O -
. O -

Benefits O +
of O +
high O +
SMR O +
and O +
active O +
metabolism O +
may O +
change O +
along O +
a O +
resource O +
( O -
productivity O -
) O +
gradient O -
, O +
indicating O +
that O +
a O +
trade O -
- O -
off O +
exists O +
among O +
active O +
metabolism O -
, O +
resting O +
metabolism O +
and O +
energy O +
intake O -
. O -

3 O -
. O -

We O +
measured O +
and O +
compared O +
SMR O -
, O +
maximal O +
metabolic O +
rate O +
( O -
MMR O -
) O -
, O +
aerobic O +
scope O +
( O -
AS O -
) O -
, O +
swim O +
performance O +
( O -
UCrit O -
) O +
and O +
growth O +
of O +
juvenile O +
hatchery O +
and O +
wild O +
steelhead U-Species +
and O +
coho B-Species +
salmon L-Species +
held O +
on O +
high- O +
and O +
low O -
- O -
food O +
rations O +
in O +
order O +
to O +
better O +
understand O +
the O +
potential O +
significance O +
of O +
variation O +
in O +
SMR O +
to O +
growth O -
, O +
differentiation O +
between O +
species O -
, O +
and O +
patterns O +
of O +
habitat O +
use O +
along O +
a O +
productivity O +
gradient O -
. O -

4 O -
. O -

We O +
found O +
that O +
differences O +
in O +
SMR O -
, O +
MMR O -
, O +
AS O -
, O +
swim O +
performance O +
and O +
growth O +
rate O +
between O +
steelhead B-Species +
trout L-Species +
and O +
coho B-Species +
salmon L-Species +
were O +
reduced O +
in O +
hatchery O -
- O -
reared O +
fish O +
compared O +
with O +
wild O +
fish O -
. O -

Wild O +
steelhead U-Species +
had O +
a O +
higher O +
MMR O -
, O +
AS O -
, O +
swim O +
performance O +
and O +
growth O +
rate O +
than O +
wild O +
coho U-Species -
, O +
but O +
adaptations O +
between O +
species O +
do O +
not O +
appear O +
to O +
involve O +
differences O +
in O +
SMR O +
or O +
to O +
trade O -
- O -
off O +
increased O +
growth O +
rate O +
against O +
lower O +
swim O +
performance O -
, O +
as O +
commonly O +
observed O +
for O +
high O -
- O -
growth O +
strains O -
. O -

Instead O -
, O +
we O +
hypothesize O +
that O +
wild O +
steelhead U-Species +
may O +
be O +
trading O +
off O +
higher O +
growth O +
rate O +
for O +
lower O +
food O +
consumption O +
efficiency O -
, O +
similar O +
to O +
strategies O +
adopted O +
by O +
anadromous O +
vs. O +
resident O +
brook B-Species +
trout L-Species +
and O +
Atlantic B-Species +
salmon L-Species +
vs. O +
brook B-Species +
trout L-Species -
. O -

This O +
highlights O +
potential O +
differences O +
in O +
food O +
consumption O +
and O +
digestion O +
strategies O +
as O +
cryptic O +
adaptations O +
ecologically O +
differentiating O +
salmonid O +
species O -
. O -

5 O -
. O -

We O +
hypothesize O +
that O +
divergent O +
digestive O +
strategies O -
, O +
which O +
are O +
common O +
and O +
well O +
documented O +
among O +
terrestrial O +
vertebrates O -
, O +
may O +
be O +
an O +
important O +
but O +
overlooked O +
aspect O +
of O +
adaptive O +
strategies O +
of O +
juvenile O +
salmonids O -
, O +
and O +
fish O +
in O +
general O -
. O +

Natal O +
conditions O +
alter O +
age O -
- O -
specific O +
reproduction O +
but O +
not O +
survival O +
or O +
senescence O +
in O +
a O +
long O -
- O -
lived O +
bird O +
of O +
prey O -
. O +

1 O -
. O -

Natal O +
conditions O +
and O +
senescence O +
are O +
two O +
major O +
factors O +
shaping O +
life O -
- O -
history O +
traits O +
of O +
wild O +
animals O -
. O -

However O -
, O +
such O +
factors O +
have O +
rarely O +
been O +
investigated O +
together O -
, O +
and O +
it O +
remains O +
largely O +
unknown O +
whether O +
they O +
interact O +
to O +
affect O +
age O -
- O -
specific O +
performance O -
. O -

2 O -
. O -

We O +
used O +
27 O +
years O +
of O +
longitudinal O +
data O +
collected O +
on O +
tawny B-Species +
owls L-Species +
with O +
estimates O +
of O +
prey O +
density O +
( O -
field O +
voles O -
) O +
from O +
Kielder O +
Forest O +
( O -
UK O -
) O +
to O +
investigate O +
how O +
prey O +
density O +
at O +
birth O +
affects O +
ageing O +
patterns O +
in O +
reproduction O +
and O +
survival O -
. O -

3 O -
. O -

Natal O +
conditions O +
experienced O +
by O +
tawny B-Species +
owls L-Species -
, O +
measured O +
in O +
terms O +
of O +
vole O +
density O -
, O +
dramatically O +
varied O +
among O +
cohorts O +
and O +
explained O +
87 O -
% O +
of O +
the O +
deviance O +
in O +
first O -
- O -
year O +
apparent O +
survival O +
( O -
annual O +
estimates O +
ranging O +
from O +
0 O -
* O -
07 O +
to O +
0 O -
* O -
33 O -
) O -
. O -

4 O -
. O -

We O +
found O +
evidence O +
for O +
senescence O +
in O +
survival O +
for O +
females O +
as O +
well O +
as O +
for O +
males O -
. O -

Model O -
- O -
averaged O +
estimates O +
showed O +
that O +
adult O +
survival O +
probability O +
declined O +
linearly O +
with O +
age O +
for O +
females O +
from O +
age O +
1 O -
. O -

In O +
contrast O -
, O +
male O +
survival O +
probability O -
, O +
lower O +
on O +
average O +
than O +
for O +
female O -
, O +
declined O +
after O +
a O +
plateau O +
at O +
age O +
1 O -
- O -
3 O -
. O +
5 O -
. O -

We O +
also O +
found O +
evidence O +
for O +
reproductive O +
senescence O +
( O -
number O +
of O +
offspring O -
) O -
. O -

For O +
females O -
, O +
reproductive O +
performance O +
increased O +
until O +
age O +
9 O +
then O +
declined O -
. O -

Males O +
showed O +
an O +
earlier O +
decline O +
in O +
reproductive O +
performance O +
with O +
an O +
onset O +
of O +
senescence O +
at O +
age O +
3 O -
. O +
6 O -
. O -

Long O -
- O -
lasting O +
effects O +
of O +
natal O +
environmental O +
conditions O +
were O +
sex O +
specific O -
. O -

Female O +
reproductive O +
performance O +
was O +
substantially O +
related O +
to O +
natal O +
conditions O +
( O -
difference O +
of O +
0 O -
* O -
24 O +
fledgling O +
per O +
breeding O +
event O +
between O +
females O +
born O +
in O +
the O +
first O +
or O +
third O +
quartile O +
of O +
vole O +
density O -
) O -
, O +
whereas O +
male O +
performance O +
was O +
not O -
. O -

We O +
found O +
no O +
evidence O +
for O +
tawny B-Species +
owls L-Species +
born O +
in O +
years O +
with O +
low O +
prey O +
density O +
having O +
accelerated O +
rates O +
of O +
senescence O -
. O -

7 O -
. O -

Our O +
results O -
, O +
combined O +
with O +
previous O +
findings O -
, O +
suggest O +
the O +
way O +
natal O +
environmental O +
conditions O +
affect O +
senescence O +
varies O +
not O +
only O +
across O +
species O +
but O +
also O +
within O +
species O +
according O +
to O +
gender O +
and O +
the O +
demographic O +
trait O +
considered O -
. O +

Linking O +
irradiance O -
- O -
induced O +
changes O +
in O +
pit O +
membrane O +
ultrastructure O +
with O +
xylem O +
vulnerability O +
to O +
cavitation O -
. O +

The O +
effect O +
of O +
shading O +
on O +
xylem O +
hydraulic O +
traits O +
and O +
xylem O +
anatomy O +
was O +
studied O +
in O +
hybrid O +
poplar O +
( O -
Populus B-Species +
trichocarpa I-Species +
x I-Species +
deltoides L-Species -
, O +
clone O +
H11 O -
- O -
11 O -
) O -
. O -

Hydraulic O +
measurements O +
conducted O +
on O +
stem O +
segments O +
of O +
3-month O -
- O -
old O +
saplings O +
grown O +
in O +
shaded O +
( O -
SH O -
) O +
or O +
control O +
light O +
( O -
C O -
) O +
conditions O +
indicated O +
that O +
shading O +
resulted O +
in O +
more O +
vulnerable O +
and O +
less O +
efficient O +
xylem O -
. O -

Air O +
is O +
thought O +
to O +
enter O +
vessels O +
through O +
pores O +
in O +
inter O -
- O -
vessel O +
pit O +
membranes O -
, O +
thereby O +
nucleating O +
cavitation O -
. O -

Therefore O -
, O +
we O +
tested O +
if O +
the O +
ultrastructure O +
and/or O +
chemistry O +
of O +
pit O +
membranes O +
differed O +
in O +
SH O +
and O +
C O +
plants O -
. O -

Transmission O +
electron O +
micrographs O +
revealed O +
that O +
pit O +
membranes O +
were O +
thinner O +
in O +
SH O -
, O +
which O +
was O +
paralleled O +
by O +
lower O +
compound O +
middle O +
lamella O +
thickness O -
. O -

Immunolabelling O +
with O +
JIM5 O +
and O +
JIM7 O +
monoclonal O +
antibodies O +
surprisingly O +
indicated O +
that O +
pectic O +
homogalacturonans O +
were O +
not O +
present O +
in O +
the O +
mature O +
pit O +
membrane O +
regardless O +
of O +
the O +
light O +
treatment O -
. O -

Porosity O +
measurements O +
conducted O +
with O +
scanning O +
electron O +
microscopy O +
were O +
significantly O +
affected O +
by O +
the O +
method O +
used O +
for O +
sample O +
dehydration O -
. O -

Drying O +
through O +
a O +
gradual O +
ethanol O +
series O +
seems O +
to O +
be O +
a O +
better O +
alternative O +
to O +
drying O +
directly O +
from O +
a O +
hydrated O +
state O +
for O +
pit O +
membrane O +
observations O +
in O +
poplar O -
. O -

Scanning O +
electron O +
microscopy O +
based O +
estimates O +
of O +
pit O +
membrane O +
porosity O +
probably O +
overestimated O +
real O +
porosity O +
as O +
suggested O +
by O +
the O +
results O +
from O +
the O +
' O -
rare O +
pit O -
' O +
model O -
. O +

Sensing O +
embolism O +
in O +
xylem O +
vessels O -
: O +
the O +
role O +
of O +
sucrose O +
as O +
a O +
trigger O +
for O +
refilling O -
. O +

Refilling O +
of O +
embolized O +
vessels O +
requires O +
a O +
source O +
of O +
water O +
and O +
the O +
release O +
of O +
energy O +
stored O +
in O +
xylem O +
parenchyma O +
cells O -
. O -

Past O +
evidence O +
suggests O +
that O +
embolism O +
presence O +
can O +
trigger O +
a O +
biological O +
response O +
that O +
is O +
switched O +
off O +
upon O +
successful O +
vessel O +
refilling O -
. O -

As O +
embolism O +
formation O +
is O +
a O +
purely O +
physical O +
process O +
and O +
most O +
biological O +
triggers O +
rely O +
on O +
chemical O +
sensors O -
, O +
we O +
hypothesized O +
that O +
accumulation O +
of O +
osmotic O +
compounds O +
in O +
walls O +
of O +
embolized O +
vessels O +
are O +
involved O +
in O +
the O +
embolism O +
sensing O +
mechanism O -
. O -

Analysis O +
of O +
Populus B-Species +
trichocarpa L-Species -
's O +
response O +
to O +
infiltration O +
of O +
sucrose O -
, O +
monosaccharides O -
, O +
polyethylene O +
glycol O +
and O +
potassium O +
chloride O +
into O +
the O +
xylem O +
revealed O +
that O +
only O +
presence O +
of O +
sucrose O +
resulted O +
in O +
a O +
simultaneous O +
physiological O +
and O +
molecular O +
response O +
similar O +
to O +
that O +
induced O +
by O +
embolism O -
. O -

This O +
response O +
included O +
reduction O +
of O +
the O +
starch O +
pool O +
in O +
xylem O +
parenchyma O +
cells O +
and O +
significant O +
correlation O +
of O +
gene O +
expression O +
from O +
aquaporins O -
, O +
amylases O +
and O +
sugar O +
transporter O +
families O -
. O -

The O +
work O +
provides O +
evidence O +
of O +
the O +
ability O +
of O +
plants O +
to O +
sense O +
embolism O +
and O +
suggests O +
that O +
sucrose O +
concentration O +
is O +
the O +
stimulus O +
that O +
allows O +
plants O +
to O +
trigger O +
a O +
biological O +
response O +
to O +
embolism O -
. O +

Light O +
exerts O +
multiple O +
levels O +
of O +
influence O +
on O +
the O +
Arabidopsis U-Species +
wound O +
response O -
. O -

Light O +
plays O +
important O +
roles O +
in O +
modulating O +
plant O +
responses O +
to O +
attack O +
by O +
pests O +
and O +
pathogens O -
. O -

Here O -
, O +
we O +
test O +
the O +
hypothesis O +
that O +
darkness O +
modifies O +
the O +
response O +
to O +
wounding O -
, O +
and O +
examine O +
possible O +
mechanisms O +
for O +
such O +
an O +
effect O -
. O -

We O +
investigated O +
changes O +
in O +
the O +
Arabidopsis U-Species +
transcriptome O +
following O +
a O +
light O -
- O -
dark O +
transition O +
and O +
the O +
response O +
to O +
wounding O +
either O +
in O +
the O +
light O +
or O +
in O +
the O +
dark O -
. O -

The O +
transcriptional O +
response O +
to O +
the O +
light O -
- O -
dark O +
transition O +
strongly O +
resembles O +
responses O +
associated O +
with O +
carbon O +
depletion O -
. O -

The O +
dark O +
shift O +
and O +
wound O +
responses O +
acted O +
largely O +
independently O -
, O +
but O +
more O +
complex O +
interactions O +
were O +
identified O +
at O +
a O +
number O +
of O +
levels O -
. O -

Darkness O +
attenuates O +
the O +
overall O +
transcriptional O +
response O +
to O +
wounding O -
, O +
and O +
we O +
identified O +
genes O +
and O +
physiological O +
processes O -
, O +
such O +
as O +
anthocyanin O +
accumulation O -
, O +
that O +
exhibit O +
light O -
- O -
dependent O +
wound O +
responses O -
. O -

Transcriptional O +
activation O +
of O +
light O -
- O -
dependent O +
wound O -
- O -
induced O +
genes O +
requires O +
a O +
chloroplast O -
- O -
derived O +
signal O +
originating O +
from O +
photosynthetic O +
electron O +
transport O -
. O -

We O +
also O +
present O +
evidence O +
of O +
a O +
role O +
for O +
the O +
circadian O +
clock O +
in O +
modifying O +
wound O +
responses O -
. O -

Our O +
results O +
show O +
that O +
darkness O +
impacts O +
on O +
the O +
wound O +
response O +
at O +
a O +
number O +
of O +
levels O -
, O +
which O +
may O +
imply O +
differences O +
in O +
induced O +
herbivore O +
defences O +
during O +
the O +
day O +
and O +
night O -
. O +

Parallel O +
evolution O +
of O +
cytochrome O +
b O +
mediated O +
bifenazate O +
resistance O +
in O +
the O +
citrus B-Species +
red I-Species +
mite L-Species +
Panonychus B-Species +
citri L-Species -
. O +

Bifenazate O +
is O +
a O +
recently O +
developed O +
acaricide O +
that O +
is O +
mainly O +
used O +
to O +
control O +
spider O +
mites O +
on O +
a O +
variety O +
of O +
crops O -
. O -

Although O +
first O +
thought O +
to O +
be O +
a O +
neurotoxin O -
, O +
genetic O +
evidence O +
obtained O +
from O +
bifenazate O +
resistant O +
Tetranychus B-Species +
urticae L-Species +
strains O +
suggested O +
an O +
alternative O +
mode O +
of O +
action O +
as O +
a O +
Qo O +
pocket O +
inhibitor O +
of O +
the O +
mitochondrial O +
complex O +
III O -
. O -

In O +
this O +
study O -
, O +
we O +
reveal O +
how O +
bifenazate O +
resistance O +
in O +
strains O +
of O +
Panonychus B-Species +
citri L-Species +
is O +
maternally O +
inherited O +
and O +
can O +
confer O +
cross O -
- O -
resistance O +
to O +
the O +
known O +
Qo O +
inhibitor O +
acequinocyl O -
. O -

The O +
mitochondrial O +
genome O +
of O +
P. B-Species +
citri L-Species +
was O +
sequenced O +
and O +
Qo O +
pocket O +
mutations O +
were O +
shown O +
to O +
be O +
linked O +
with O +
the O +
resistant O +
trait O -
. O -

Parallel O +
evolution O +
of O +
cytochrome O +
b O +
mediated O +
bifenazate O +
resistance O +
corroborates O +
the O +
alternative O +
mode O +
of O +
action O +
and O +
yet O +
again O +
illustrates O +
that O +
care O +
should O +
be O +
taken O +
when O +
employing O +
Qo O +
inhibitors O +
as O +
crop O +
protection O +
compounds O -
. O +

European O +
guidelines O +
on O +
the O +
clinical O +
management O +
of O +
HIV-1 U-Species +
tropism O +
testing O -
. O -

Viral O +
tropism O +
is O +
the O +
ability O +
of O +
viruses O +
to O +
enter O +
and O +
infect O +
specific O +
host O +
cells O +
and O +
is O +
based O +
on O +
the O +
ability O +
of O +
viruses O +
to O +
bind O +
to O +
receptors O +
on O +
those O +
cells O -
. O -

Testing O +
for O +
HIV U-Species +
tropism O +
is O +
recommended O +
before O +
prescribing O +
a O +
chemokine O +
receptor O +
blocker O -
. O -

In O +
most O +
European O +
countries O -
, O +
HIV U-Species +
tropism O +
is O +
identified O +
with O +
tropism O +
phenotype O +
testing O -
. O -

New O +
data O +
support O +
genotype O +
analysis O +
of O +
the O +
HIV U-Species +
third O +
hypervariable O +
loop O +
( O -
V3 O -
) O +
for O +
the O +
identification O +
of O +
tropism O -
. O -

The O +
European O +
Consensus O +
Group O +
on O +
clinical O +
management O +
of O +
tropism O +
testing O +
was O +
established O +
to O +
make O +
recommendations O +
to O +
clinicians O +
and O +
clinical O +
virologists O -
. O -

The O +
panel O +
recommends O +
HIV U-Species -
- O -
tropism O +
testing O +
for O +
the O +
following O +
groups O -
: O +
drug O -
- O -
naive O +
patients O +
in O +
whom O +
toxic O +
effects O +
are O +
anticipated O +
or O +
for O +
whom O +
few O +
treatment O +
options O +
are O +
available O -
; O +
patients O +
who O +
have O +
poor O +
tolerability O +
to O +
or O +
toxic O +
effects O +
from O +
current O +
treatment O +
or O +
who O +
have O +
CNS O +
pathology O -
; O +
and O +
patients O +
for O +
whom O +
therapy O +
has O +
failed O +
and O +
a O +
change O +
in O +
treatment O +
is O +
considered O -
. O -

In O +
general O -
, O +
an O +
enhanced O +
sensitivity O +
Trofile O +
assay O +
and O +
V3 O +
population O +
genotyping O +
are O +
the O +
recommended O +
methods O -
. O -

Genotypic O +
methods O +
are O +
anticipated O +
to O +
be O +
used O +
more O +
frequently O +
in O +
the O +
clinical O +
setting O +
because O +
of O +
their O +
greater O +
accessibility O -
, O +
lower O +
cost O -
, O +
and O +
faster O +
turnaround O +
time O +
than O +
other O +
methods O -
. O -

For O +
the O +
interpretation O +
of O +
V3 O +
loop O +
genotyping O -
, O +
clinically O +
validated O +
systems O +
should O +
be O +
used O +
when O +
possible O -
. O -

Laboratories O +
doing O +
HIV U-Species +
tropism O +
tests O +
should O +
have O +
adequate O +
quality O +
assurance O +
measures O -
. O -

Similarly O -
, O +
close O +
collaboration O +
between O +
HIV U-Species +
clinicians O +
and O +
virologists O +
is O +
needed O +
to O +
ensure O +
adequate O +
diagnostic O +
and O +
treatment O +
decisions O -
. O +

Effects O +
of O +
early O +
horn O +
growth O +
on O +
reproduction O +
and O +
hunting O +
mortality O +
in O +
female O +
chamois U-Species -
. O +

1 O -
. O -

Environmental O +
conditions O +
during O +
early O +
development O +
can O +
affect O +
the O +
growth O +
patterns O +
of O +
vertebrates O -
, O +
influencing O +
future O +
survival O +
and O +
reproduction O -
. O -

In O +
long O -
- O -
lived O +
mammals O -
, O +
females O +
that O +
experience O +
poor O +
environmental O +
conditions O +
early O +
in O +
life O +
may O +
delay O +
primiparity O -
. O -

In O +
female O +
bovids O -
, O +
annual O +
horn O +
growth O +
increments O +
may O +
provide O +
a O +
record O +
of O +
age O -
- O -
specific O +
reproduction O +
and O +
body O +
growth O -
. O -

Horn O +
length O -
, O +
however O -
, O +
may O +
also O +
be O +
a O +
criterion O +
used O +
by O +
hunters O +
in O +
selecting O +
animals O +
to O +
harvest O -
, O +
possibly O +
leading O +
to O +
artificial O +
selection O -
. O -

2 O -
. O -

We O +
studied O +
three O +
populations O +
of O +
chamois U-Species +
( O -
Rupicapra B-Species +
rupicapra L-Species -
) O +
in O +
the O +
western O +
Alps O +
to O +
explore O +
the O +
relationships O +
between O +
female O +
horn O +
length O +
and O +
early O +
growth O -
, O +
age O +
of O +
primiparity O +
and O +
age O -
- O -
specific O +
reproduction O -
. O -

We O +
also O +
compared O +
the O +
risk O +
of O +
harvest O +
to O +
reproductive O +
status O +
and O +
horn O +
length O -
. O -

3 O -
. O -

Early O +
horn O +
growth O +
was O +
positively O +
correlated O +
with O +
body O +
mass O +
in O +
pre O -
- O -
reproductive O +
females O +
and O +
with O +
reproduction O +
in O +
very O +
young O +
and O +
senescent O +
adults O -
. O -

Females O +
with O +
strong O +
early O +
horn O +
growth O +
attained O +
primiparity O +
at O +
an O +
earlier O +
age O +
than O +
those O +
with O +
weak O +
early O +
growth O -
. O -

Horn O +
length O +
did O +
not O +
affect O +
hunter O +
selection O -
, O +
but O +
we O +
found O +
a O +
strong O +
hunter O +
preference O +
for O +
nonlactating O +
females O -
. O -

4 O -
. O -

Our O +
research O +
highlights O +
the O +
persistent O +
effects O +
of O +
early O +
development O +
on O +
reproductive O +
performance O +
in O +
mammals O -
. O -

Moderate O +
sport O +
harvests O +
are O +
unlikely O +
to O +
affect O +
the O +
evolution O +
of O +
phenotypic O +
traits O +
and O +
reproductive O +
strategies O +
in O +
female O +
chamois U-Species -
. O -

A O +
policy O +
of O +
penalizing O +
hunters O +
that O +
harvest O +
lactating O +
females O -
, O +
however O -
, O +
may O +
increase O +
the O +
harvest O +
of O +
2-year O -
- O -
old O +
females O -
, O +
which O +
have O +
high O +
reproductive O +
potential O -
. O +

Dissection O +
of O +
the O +
phytohormonal O +
regulation O +
of O +
trichome O +
formation O +
and O +
biosynthesis O +
of O +
the O +
antimalarial O +
compound O +
artemisinin O +
in O +
Artemisia B-Species +
annua I-Species +
plants L-Species -
. O +

* O +
Biosynthesis O +
of O +
the O +
sesquiterpene O +
lactone O +
and O +
potent O +
antimalarial O +
drug O +
artemisinin O +
occurs O +
in O +
glandular O +
trichomes O +
of O +
Artemisia B-Species +
annua I-Species +
plants L-Species +
and O +
is O +
subjected O +
to O +
a O +
strict O +
network O +
of O +
developmental O +
and O +
other O +
regulatory O +
cues O -
. O -

* O +
The O +
effects O +
of O +
three O +
hormones O -
, O +
jasmonate O -
, O +
gibberellin O +
and O +
cytokinin O -
, O +
were O +
studied O +
at O +
the O +
structural O +
and O +
molecular O +
levels O +
in O +
two O +
different O +
A. B-Species +
annua L-Species +
chemotypes O +
by O +
microscopic O +
analysis O +
of O +
gland O +
development O -
, O +
and O +
by O +
targeted O +
metabolite O +
and O +
transcript O +
profiling O -
. O -

Furthermore O -
, O +
a O +
genome O -
- O -
wide O +
cDNA O -
- O -
amplified O +
fragment O +
length O +
polymorphism O +
( O -
AFLP O -
) O -
-based O +
transcriptome O +
profiling O +
was O +
carried O +
out O +
of O +
jasmonate O -
- O -
elicited O +
leaves O +
at O +
different O +
developmental O +
stages O -
. O -

* O +
Although O +
cytokinin O +
and O +
gibberellin O +
positively O +
affected O +
at O +
least O +
one O +
aspect O +
of O +
gland O +
formation O -
, O +
these O +
two O +
hormones O +
did O +
not O +
stimulate O +
artemisinin O +
biosynthesis O -
. O -

Only O +
jasmonate O +
simultaneously O +
promoted O +
gland O +
formation O +
and O +
coordinated O +
transcriptional O +
activation O +
of O +
biosynthetic O +
gene O +
expression O -
, O +
which O +
ultimately O +
led O +
to O +
increased O +
sesquiterpenoid O +
accumulation O +
with O +
chemotype O -
- O -
dependent O +
effects O +
on O +
the O +
distinct O +
pathway O +
branches O -
. O -

Transcriptome O +
profiling O +
revealed O +
a O +
trichome O -
- O -
specific O +
fatty O +
acyl- O +
coenzyme O +
A O +
reductase O -
, O +
trichome O -
- O -
specific O +
fatty O +
acyl O -
- O -
CoA O +
reductase O +
1 O +
( O -
TFAR1 O -
) O -
, O +
the O +
expression O +
of O +
which O +
correlates O +
with O +
trichome O +
development O +
and O +
sesquiterpenoid O +
biosynthesis O -
. O -

* O +
TFAR1 O +
is O +
potentially O +
involved O +
in O +
cuticular O +
wax O +
formation O +
during O +
glandular O +
trichome O +
expansion O +
in O +
leaves O +
and O +
flowers O +
of O +
A. B-Species +
annua I-Species +
plants L-Species -
. O -

Analysis O +
of O +
phytohormone O -
- O -
modulated O +
transcriptional O +
regulons O +
provides O +
clues O +
to O +
dissect O +
the O +
concerted O +
regulation O +
of O +
metabolism O +
and O +
development O +
of O +
plant O +
trichomes O -
. O +

Accumulation O +
of O +
P O -
- O -
bodies O +
in O +
Candida B-Species +
albicans L-Species +
under O +
different O +
stress O +
and O +
filamentous O +
growth O +
conditions O -
. O +

Candida B-Species +
albicans L-Species +
is O +
an O +
opportunistic O +
fungal O +
pathogen O +
that O +
grows O +
as O +
budding O +
yeast O -
, O +
pseudohyphal O -
, O +
and O +
hyphal O +
forms O -
. O -

In O +
response O +
to O +
external O +
signals O -
, O +
C. B-Species +
albicans L-Species +
switches O +
rapidly O +
among O +
these O +
forms O -
. O -

mRNA O -
- O -
containing O +
cytoplasmic O +
granules O -
, O +
termed O +
processing O +
bodies O +
( O -
P O -
- O -
bodies O -
) O -
, O +
have O +
been O +
reported O +
to O +
accumulate O +
under O +
various O +
environmental O +
stress O +
conditions O +
in O +
diverse O +
species O +
from O +
yeast U-Species +
to O +
mammals O -
. O -

Here O -
, O +
we O +
provide O +
the O +
first O +
microscopic O +
and O +
genetic O +
characterization O +
of O +
P O -
- O -
bodies O +
in O +
C. B-Species +
albicans L-Species -
. O -

The O +
core O +
components O +
of O +
P O -
- O -
bodies O -
, O +
including O +
the O +
decapping O +
machinery O +
( O -
Dcp2 O +
and O +
Dhh1 O -
) O -
, O +
5'-3 O -
' O +
exoribonuclease O +
( O -
Kem1 O -
/ O -
Xrn1 O -
) O -
, O +
and O +
the O +
P O -
- O -
body O +
scaffolding O +
protein O +
( O -
Edc3 O -
) O -
, O +
were O +
identified O +
and O +
their O +
localizations O +
with O +
respect O +
to O +
P O -
- O -
bodies O +
were O +
demonstrated O -
. O -

Various O +
growth O +
conditions O -
, O +
including O +
glucose O +
deprivation O -
, O +
hyperosmotic O +
stress O -
, O +
and O +
heat O +
stress O -
, O +
stimulated O +
the O +
accumulation O +
of O +
P O -
- O -
bodies O -
. O -

In O +
addition O -
, O +
we O +
observed O +
P O -
- O -
body O +
aggregation O +
during O +
hyphal O +
development O -
. O -

The O +
deletion O +
mutant O +
strain O +
edc3 O -
/ O -
edc3 O +
had O +
a O +
defect O +
in O +
filamentation O +
and O +
exhibited O +
a O +
dramatic O +
reduction O +
in O +
the O +
number O +
of O +
P O -
- O -
bodies O -
. O -

These O +
results O +
suggest O +
that O +
Edc3 O +
plays O +
an O +
essential O +
role O +
in O +
the O +
assembly O +
and O +
maintenance O +
of O +
P O -
- O -
bodies O +
in O +
C. B-Species +
albicans L-Species -
, O +
and O +
that O +
the O +
switch O +
to O +
filamentous O +
growth O +
appears O +
to O +
accompany O +
P O -
- O -
body O +
accumulation O -
. O +

A O +
heme O +
peroxidase O +
of O +
the O +
ascomyceteous O +
lichen O +
Leptogium B-Species +
saturninum L-Species +
oxidizes O +
high O -
- O -
redox O +
potential O +
substrates O -
. O +

Lichens O +
belonging O +
to O +
the O +
order O +
Peltigerales O +
display O +
strong O +
activity O +
of O +
multi O -
- O -
copper O +
oxidases O +
( O -
e.g. O +
tyrosinase O -
) O +
as O +
well O +
as O +
heme O -
- O -
containing O +
peroxidases O -
. O -

The O +
lichen O +
peroxidase O +
was O +
purified O +
to O +
homogeneity O +
from O +
the O +
thallus O +
of O +
Leptogium B-Species +
saturninum L-Species +
( O -
LsaPOX O -
) O +
by O +
fast O +
protein O +
liquid O +
chromatography O +
and O +
then O +
partially O +
characterized O -
. O -

The O +
oligomeric O +
protein O +
occurs O +
as O +
both O +
79kDa O +
dimeric O +
and O +
42kDa O +
monomeric O +
forms O -
, O +
and O +
displayed O +
broad O +
substrate O +
specificity O -
. O -

In O +
addition O +
to O +
an O +
ability O +
to O +
oxidize O +
classic O +
peroxidase O +
substrates O +
( O -
e.g. O +
2,6-dimethoxyphenol O -
) O -
, O +
the O +
enzyme O +
could O +
convert O +
recalcitrant O +
compounds O +
such O +
as O +
synthetic O +
dyes O +
( O -
e.g. O +
Azure O +
B O +
and O +
Reactive O +
Blue O +
5 O -
) O -
, O +
4-nitrophenol O +
and O +
non O -
- O -
phenolic O +
methoxylated O +
aromatics O +
( O -
e.g. O +
veratryl O +
alcohol O -
) O -
. O -

Comparing O +
LsaPOX O +
with O +
a O +
basidiomycete O +
dye O -
- O -
decolorizing O +
( O -
DyP O -
) O -
-type O +
peroxidase O +
from O +
Auricularia B-Species +
auricula I-Species -
- I-Species -
judae L-Species +
showed O +
that O +
the O +
lichen O +
enzyme O +
has O +
a O +
high O -
- O -
redox O +
potential O -
, O +
with O +
oxidation O +
capabilities O +
ranging O +
between O +
those O +
of O +
known O +
plant O +
and O +
fungal O +
peroxidases O -
. O -

Internal O +
peptide O +
fragments O +
show O +
homology O +
( O -
up O +
to O +
60 O -
% O -
) O +
with O +
putative O +
proteins O +
from O +
free O -
- O -
living O +
ascomycetes O +
( O -
e.g. O +
Penicillium B-Species +
marneffei L-Species +
and O +
Neosartorya B-Species +
fischeri L-Species -
) O -
, O +
but O +
not O +
to O +
sequences O +
of O +
algal O +
or O +
cyanobacterial O +
peptides O +
or O +
to O +
known O +
fungal O -
, O +
bacterial O +
or O +
plant O +
peroxidases O -
. O -

LsaPOX O +
is O +
the O +
first O +
heme O +
peroxidase O +
purified O +
from O +
an O +
ascomyceteous O +
lichen O +
that O +
may O +
help O +
the O +
organism O +
to O +
successfully O +
exploit O +
the O +
extreme O +
micro O -
- O -
environments O +
in O +
which O +
they O +
often O +
grow O -
. O +

Comparative O +
immunofluorescence O +
and O +
ultrastructural O +
analysis O +
of O +
microtubule O +
organization O +
in O +
Uronema O +
sp. O -
, O +
Klebsormidium B-Species +
flaccidum L-Species -
, O +
K. B-Species +
subtilissimum L-Species -
, O +
Stichococcus B-Species +
bacillaris L-Species +
and O +
S. B-Species +
chloranthus L-Species +
( O -
Chlorophyta O -
) O -
. O +

A O +
detailed O +
comparative O +
examination O +
of O +
microtubule O +
( O -
MT O -
) O +
organization O +
in O +
interphase O +
and O +
dividing O +
cells O +
of O +
Uronema O +
sp. O -
, O +
Klebsormidium B-Species +
flaccidum L-Species -
, O +
K. B-Species +
subtilissimum L-Species -
, O +
Stichococcus B-Species +
bacillaris L-Species +
and O +
S. B-Species +
chloranthus L-Species +
was O +
made O +
using O +
tubulin O +
immunofluorescence O +
and O +
transmission O +
electron O +
microscopy O +
( O -
TEM O -
) O -
. O -

During O +
interphase O +
all O +
the O +
species O +
bear O +
a O +
well O -
- O -
organized O +
cortical O +
MT O +
system O -
, O +
consisting O +
of O +
parallel O +
bundles O +
with O +
different O +
orientations O -
. O -

In O +
Uronema O +
sp. O +
the O +
cortical O +
MT O +
bundles O +
are O +
longitudinally O +
oriented O -
, O +
whereas O +
in O +
the O +
other O +
species O +
they O +
are O +
in O +
transverse O +
orientation O +
to O +
the O +
axis O +
of O +
the O +
cells O -
. O -

Considerable O +
differences O +
in O +
MT O +
organization O +
were O +
also O +
observed O +
during O +
stages O +
of O +
mitosis O -
, O +
mainly O +
preprophase O -
, O +
as O +
well O +
as O +
cytokinesis O -
. O -

In O +
Uronema O +
sp. O -
, O +
a O +
particular O +
radial O +
MT O +
assembly O +
is O +
organized O +
during O +
preprophase O -
- O -
early O +
prophase O -
, O +
which O +
was O +
not O +
observed O +
in O +
the O +
other O +
species O -
. O -

In O +
Stichococcus O +
a O +
fine O +
MT O +
ring O +
surrounded O +
the O +
nucleus O +
during O +
preprophase O +
and O +
prophase O -
. O -

An O +
MT O +
ring O -
, O +
together O +
with O +
single O +
cytoplasmic O +
MTs O -
, O +
was O +
also O +
found O +
associated O +
with O +
the O +
developing O +
diaphragm O +
during O +
cytokinesis O +
in O +
Stichococcus O -
. O -

A O +
phycoplast O +
participates O +
in O +
cytokinesis O +
in O +
Uronema O +
sp. O -
, O +
but O +
not O +
in O +
the O +
other O +
species O -
. O -

In O +
Uronema O +
sp. O +
the O +
centrosome O +
functions O +
as O +
a O +
microtubule O +
organizing O +
center O +
( O -
MTOC O -
) O +
during O +
mitosis O -
, O +
but O +
not O +
during O +
interphase O +
and O +
cytokinesis O -
. O -

The O +
phylogenetic O +
significance O +
of O +
these O +
differences O +
is O +
discussed O +
in O +
combination O +
with O +
SSU O -
/ O -
ITS O +
sequencing O +
and O +
other O -
, O +
existing O +
molecular O +
data O -
. O +

Growth O +
and O +
reproductive O +
costs O +
of O +
larval O +
defence O +
in O +
the O +
aposematic O +
lepidopteran O +
Pieris B-Species +
brassicae L-Species -
. O +

1 O -
. O -

Utilization O +
of O +
plant O +
secondary O +
compounds O +
for O +
antipredator O +
defence O +
is O +
common O +
in O +
immature O +
herbivorous O +
insects O -
. O -

Such O +
defences O +
may O +
incur O +
a O +
cost O +
to O +
the O +
animal O -
, O +
either O +
in O +
terms O +
of O +
survival O -
, O +
growth O +
rate O +
or O +
in O +
the O +
reproductive O +
success O -
. O -

2 O -
. O -

A O +
common O +
defence O +
in O +
lepidopterans O +
is O +
the O +
regurgitation O +
of O +
semi O -
- O -
digested O +
material O +
containing O +
the O +
defensive O +
compounds O +
of O +
the O +
food O +
plant O -
, O +
a O +
defence O +
which O +
has O +
led O +
to O +
gut O +
specialization O +
in O +
this O +
order O -
. O -

Regurgitation O +
is O +
often O +
swift O +
in O +
response O +
to O +
cuticular O +
stimulation O +
and O +
deters O +
predators O +
from O +
consuming O +
or O +
parasitizing O +
the O +
larva O -
. O -

The O +
loss O +
of O +
food O +
and O +
other O +
gut O +
material O +
seems O +
likely O +
to O +
impact O +
on O +
fitness O -
, O +
but O +
evidence O +
is O +
lacking O -
. O -

3 O -
. O -

Here O -
, O +
we O +
raised O +
larvae O +
of O +
the O +
common O +
crop O +
pest O +
Pieris B-Species +
brassicae L-Species +
on O +
commercial O +
cabbage U-Species +
leaves O -
, O +
simulated O +
predator O +
attacks O +
throughout O +
the O +
larval O +
period O -
, O +
and O +
measured O +
life O -
- O -
history O +
responses O -
. O -

4 O -
. O -

We O +
found O +
that O +
the O +
probability O +
of O +
survival O +
to O +
pupation O +
decreased O +
with O +
increasing O +
frequency O +
of O +
attacks O -
, O +
but O +
this O +
was O +
because O +
of O +
regurgitation O +
rather O +
than O +
the O +
stimulation O +
itself O -
. O -

There O +
was O +
a O +
growth O +
cost O +
to O +
the O +
defence O +
such O +
that O +
the O +
more O +
regurgitant O +
that O +
individuals O +
produced O +
over O +
the O +
growth O +
period O -
, O +
the O +
smaller O +
they O +
were O +
at O +
pupation O -
. O -

5 O -
. O -

The O +
number O +
of O +
mature O +
eggs O +
in O +
adult O +
females O +
was O +
positively O +
related O +
to O +
pupal O +
mass O -
, O +
but O +
this O +
relationship O +
was O +
only O +
found O +
when O +
individuals O +
were O +
not O +
subjected O +
to O +
a O +
high O +
frequency O +
of O +
predator O +
simulation O -
. O -

This O +
suggests O +
that O +
there O +
might O +
be O +
cryptic O +
fitness O +
costs O +
to O +
common O +
defensive O +
responses O +
that O +
are O +
paid O +
despite O +
apparent O +
growth O +
rate O +
being O +
maintained O -
. O -

6 O -
. O -

Our O +
results O +
demonstrate O +
a O +
clear O +
life O -
- O -
history O +
cost O +
of O +
an O +
antipredator O +
defence O +
in O +
a O +
model O +
pest O +
species O +
and O +
show O +
that O +
under O +
certain O +
conditions O -
, O +
such O +
as O +
high O +
predation O +
threat O -
, O +
the O +
expected O +
relationship O +
between O +
female O +
body O +
size O +
and O +
potential O +
fecundity O +
can O +
be O +
disrupted O -
. O +

Functions O +
of O +
the O +
mitotic O +
B O -
- O -
type O +
cyclins O +
CLB1 O -
, O +
CLB2 O -
, O +
and O +
CLB3 O +
at O +
mitotic O +
exit O +
antagonized O +
by O +
the O +
CDC14 O +
phosphatase O -
. O +

In O +
the O +
budding O +
yeast U-Species +
Saccharomyces B-Species +
cerevisiae L-Species -
, O +
cell O +
cycle O +
progression O +
and O +
cytokinesis O +
at O +
mitotic O +
exit O +
are O +
proposed O +
to O +
be O +
linked O +
by O +
CDC14 O +
phosphatase O +
antagonizing O +
the O +
function O +
of O +
mitotic O +
B O -
- O -
type O +
cyclin O +
( O -
CLBs O -
) O -
. O -

We O +
have O +
isolated O +
a O +
temperature O -
- O -
sensitive O +
mutant O -
, O +
cdc14 O -
( O -
A280V O -
) O -
, O +
with O +
a O +
mutation O +
in O +
the O +
conserved O +
phosphatase O +
domain O -
. O -

Prolonged O +
arrest O +
in O +
the O +
cdc14 O -
( O -
A280V O -
) O +
mutant O +
partially O +
uncoupled O +
cell O +
cycle O +
progression O +
from O +
the O +
completion O +
of O +
cytokinesis O +
as O +
measured O +
by O +
bud O +
re O -
- O -
emergence O -
, O +
in O +
the O +
form O +
of O +
elongated O +
apical O +
projections O -
, O +
and O +
DNA O +
re O -
- O -
replication O -
. O -

In O +
contrast O +
to O +
previous O +
mitotic O +
exit O +
mutants O -
, O +
cdc14 O -
( O -
A280V O -
) O +
mutants O +
displayed O +
a O +
strong O +
bias O +
for O +
the O +
first O +
apical O +
projection O +
to O +
form O +
in O +
the O +
mother O +
cell O +
body O -
. O -

Using O +
cdc14 O -
( O -
A280V O -
) O +
mutant O +
phenotypes O -
, O +
the O +
functions O +
of O +
the O +
B O -
- O -
type O +
cyclins O +
at O +
mitotic O +
exit O +
were O +
investigated O -
. O -

The O +
preference O +
in O +
mother O -
- O -
daughter O +
apical O +
projection O +
formation O +
was O +
observed O +
to O +
be O +
independent O +
of O +
any O +
individual O +
CLB O +
function O -
. O -

However O -
, O +
cdc14 O -
( O -
A280V O -
) O -
clb1Delta O +
cells O +
displayed O +
a O +
pronounced O +
increase O +
in O +
apical O +
projections O -
, O +
while O +
cdc14 O -
( O -
A280V O -
) O -
clb3Delta O +
cells O +
were O +
observed O +
to O +
form O +
round O +
cellular O +
chains O -
. O -

While O +
cdc14 O -
( O -
A280V O -
) O +
cells O +
arrested O +
at O +
mitotic O +
exit O -
, O +
both O +
cdc14 O -
( O -
A280V O -
) O -
clb1Delta O +
and O +
cdc14 O -
( O -
A280V O -
) O -
clb3Delta O +
cells O +
completed O +
cytokinesis O -
, O +
but O +
failed O +
cell O +
separation O -
. O -

cdc14 O -
( O -
A280V O -
) O -
clb2Delta O +
cells O +
displayed O +
a O +
defect O +
in O +
actin O +
ring O +
assembly O -
. O -

These O +
observations O +
differentiate O +
the O +
functions O +
of O +
CLB1 O -
, O +
CLB2 O -
, O +
and O +
CLB3 O +
at O +
mitotic O +
exit O -
, O +
and O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
CLB O +
activities O +
are O +
antagonized O +
by O +
the O +
CDC14 O +
phosphatase O +
in O +
order O +
to O +
couple O +
cell O +
cycle O +
progression O +
with O +
cytokinesis O +
at O +
mitotic O +
exit O -
. O +

PRP8 O +
intein O +
in O +
Ajellomycetaceae O +
family O +
pathogens O -
: O +
sequence O +
analysis O -
, O +
splicing O +
evaluation O +
and O +
homing O +
endonuclease O +
activity O -
. O +

Inteins O +
are O +
intervening O +
sequences O +
that O +
are O +
transcribed O +
and O +
translated O +
with O +
flanking O +
host O +
protein O +
sequences O +
and O +
then O +
self O -
- O -
excised O +
by O +
protein O +
splicing O -
. O -

Bi O -
- O -
functional O +
inteins O +
also O +
contain O +
a O +
homing O +
endonuclease O +
responsible O +
for O +
their O +
genetic O +
mobility O -
. O -

The O +
PRP8 O +
intein O -
, O +
the O +
most O +
widespread O +
among O +
fungi O -
, O +
occurs O +
in O +
important O +
pathogens O +
such O +
as O +
Histoplasma B-Species +
capsulatum L-Species +
and O +
Paracoccidioides B-Species +
brasiliensis L-Species -
, O +
from O +
the O +
Ajellomycetaceae O +
family O -
. O -

Herein O -
, O +
we O +
describe O +
the O +
bi O -
- O -
functional O +
PRP8 O +
intein O +
in O +
two O +
other O +
Ajellomycetacean O +
pathogens O -
, O +
Blastomyces B-Species +
dermatitidis L-Species +
and O +
Emmonsia B-Species +
parva L-Species -
. O -

Sequence O +
analysis O +
and O +
experimental O +
evidence O +
suggest O +
that O +
the O +
homing O +
endonuclease O +
from O +
PbrPRP8 O +
is O +
inactive O -
. O -

The O +
splicing O +
activity O +
of O +
the O +
PRP8 O +
intein O +
from O +
the O +
B. B-Species +
dermatitidis L-Species -
, O +
E. B-Species +
parva L-Species +
and O +
P. B-Species +
brasiliensis I-Species +
species I-Species +
complex L-Species +
was O +
demonstrated O +
in O +
a O +
non O -
- O -
native O +
protein O +
context O +
in O +
Escherichia B-Species +
coli L-Species -
. O -

Since O +
the O +
PRP8 O +
intein O +
is O +
located O +
in O +
a O +
functionally O +
essential O +
nuclear O +
protein O -
, O +
it O +
can O +
be O +
considered O +
a O +
promising O +
therapeutic O +
target O +
for O +
anti O -
- O -
fungal O +
drugs O -
, O +
because O +
inhibition O +
of O +
intein O +
splicing O +
should O +
inhibit O +
proliferation O +
of O +
intein O -
- O -
containing O +
pathogens O -
. O +

Towards O +
a O +
conceptual O +
framework O +
to O +
support O +
one O -
- O -
health O +
research O +
for O +
policy O +
on O +
emerging O +
zoonoses O -
. O +

In O +
the O +
past O +
two O +
decades O +
there O +
has O +
been O +
a O +
growing O +
realisation O +
that O +
the O +
livestock O +
sector O +
was O +
in O +
a O +
process O +
of O +
change O -
, O +
resulting O +
from O +
an O +
expansion O +
of O +
intensive O +
animal O +
production O +
systems O +
and O +
trade O +
to O +
meet O +
a O +
globalised O +
world O -
's O +
increasing O +
demand O +
for O +
livestock O +
products O -
. O -

One O +
unintended O +
consequence O +
has O +
been O +
the O +
emergence O +
and O +
spread O +
of O +
transboundary O +
animal O +
diseases O +
and O -
, O +
more O +
specifically O -
, O +
the O +
resurgence O +
and O +
emergence O +
of O +
zoonotic O +
diseases O -
. O -

Concurrent O +
with O +
changes O +
in O +
the O +
livestock O +
sector O -
, O +
contact O +
with O +
wildlife O +
has O +
increased O -
. O -

This O +
development O +
has O +
increased O +
the O +
risk O +
of O +
transmission O +
of O +
infections O +
from O +
wildlife O +
to O +
human U-Species +
beings O +
and O +
livestock O -
. O -

Two O +
overarching O +
questions O +
arise O +
with O +
respect O +
to O +
the O +
real O +
and O +
perceived O +
threat O +
from O +
emerging O +
infectious O +
diseases O -
: O +
why O +
are O +
these O +
problems O +
arising O +
with O +
increasing O +
frequency O -
, O +
and O +
how O +
should O +
we O +
manage O +
and O +
control O +
them O -
? O -

A O +
clear O +
conceptual O +
research O +
framework O +
can O +
provide O +
a O +
guide O +
to O +
ensure O +
a O +
research O +
strategy O +
that O +
coherently O +
links O +
to O +
the O +
overarching O +
goals O +
of O +
policy O +
makers O -
. O -

We O +
propose O +
such O +
a O +
new O +
framework O +
in O +
support O +
of O +
a O +
research O +
and O +
policy O -
- O -
generation O +
strategy O +
to O +
help O +
to O +
address O +
the O +
challenges O +
posed O +
by O +
emerging O +
zoonoses O -
. O +

The O +
ribonucleotide O +
reductase O +
large O +
subunit O +
( O -
RRM1 O -
) O +
as O +
a O +
predictive O +
factor O +
in O +
patients O +
with O +
cancer O -
. O +

The O +
large O +
subunit O +
of O +
human U-Species +
ribonucleotide O +
reductase O -
, O +
RRM1 O -
, O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O -
, O +
cell O +
migration O -
, O +
tumour O +
and O +
metastasis O +
development O -
, O +
and O +
the O +
synthesis O +
of O +
deoxyribonucleotides O +
for O +
DNA O +
synthesis O -
. O -

It O +
is O +
also O +
a O +
cellular O +
target O +
for O +
the O +
chemotherapeutic O +
agent O -
, O +
gemcitabine O -
. O -

RRM1 O +
has O +
been O +
studied O +
in O +
a O +
large O +
number O +
of O +
patients O +
with O +
different O +
types O +
of O +
cancer O -
, O +
such O +
as O +
non O -
- O -
small O -
- O -
cell O +
lung O +
cancer O -
, O +
pancreatic O +
cancer O -
, O +
breast O +
cancer O -
, O +
and O +
biliary O +
tract O +
cancer O -
, O +
to O +
establish O +
its O +
prognostic O +
or O +
predictive O +
value O +
when O +
patients O +
were O +
treated O +
with O +
gemcitabine O -
, O +
and O +
mRNA O +
expression O +
and O +
genetic O +
variants O +
as O +
determined O +
by O +
genotyping O +
have O +
in O +
some O +
cases O +
been O +
associated O +
with O +
clinical O +
outcome O +
of O +
patients O +
with O +
cancer O -
. O -

Here O -
, O +
we O +
review O +
preclinical O +
and O +
clinical O +
studies O +
of O +
RRM1 O +
assessment O +
and O +
discuss O +
the O +
further O +
steps O +
in O +
the O +
development O +
of O +
this O +
clinically O +
pertinent O +
biomarker O -
. O +

OsEDR1 O +
negatively O +
regulates O +
rice U-Species +
bacterial O +
resistance O +
via O +
activation O +
of O +
ethylene O +
biosynthesis O -
. O +

Rice U-Species +
OsEDR1 O +
is O +
a O +
sequence O +
ortholog O +
of O +
Arabidopsis O +
EDR1 O -
. O -

However O -
, O +
its O +
molecular O +
function O +
is O +
unknown O -
. O -

We O +
show O +
here O +
that O +
OsEDR1-suppressing O -
/ O -
knockout O +
( O -
KO O -
) O +
plants O -
, O +
which O +
developed O +
spontaneous O +
lesions O +
on O +
the O +
leaves O -
, O +
have O +
enhanced O +
resistance O +
to O +
Xanthomonas B-Species +
oryzae I-Species +
pv I-Species -
. L-Species -

oryzae U-Species +
( O -
Xoo U-Species -
) O +
causing O +
bacterial O +
blight O +
disease O -
. O -

This O +
resistance O +
was O +
associated O +
with O +
increased O +
accumulation O +
of O +
salicylic O +
acid O +
( O -
SA O -
) O +
and O +
jasmonic O +
acid O +
( O -
JA O -
) O -
, O +
induced O +
expression O +
of O +
SA- O +
and O +
JA O -
- O -
related O +
genes O +
and O +
suppressed O +
accumulation O +
of O +
1-aminocyclopropane-1-carboxylic O +
acid O +
( O -
ACC O -
) O -
, O +
the O +
direct O +
precursor O +
of O +
ethylene O -
, O +
and O +
expression O +
of O +
ethylene O -
- O -
related O +
genes O -
. O -

OsEDR1-KO O +
plants O +
also O +
showed O +
suppressed O +
production O +
of O +
ethylene O -
. O -

Knockout O +
of O +
OsEDR1 O +
suppressed O +
the O +
ACC O +
synthase O +
( O -
ACS O -
) O +
gene O +
family O -
, O +
which O +
encodes O +
the O +
rate O -
- O -
limiting O +
enzymes O +
of O +
ethylene O +
biosynthesis O +
by O +
catalysing O +
the O +
formation O +
of O +
ACC O -
. O -

The O +
lesion O +
phenotype O +
and O +
enhanced O +
bacterial O +
resistance O +
of O +
the O +
OsEDR1-KO O +
plants O +
was O +
partly O +
complemented O +
by O +
the O +
treatment O +
with O +
ACC O -
. O -

ACC O +
treatment O +
was O +
associated O +
with O +
decreased O +
SA O +
and O +
JA O +
biosynthesis O +
in O +
OsEDR1-KO O +
plants O -
. O -

In O +
contrast O -
, O +
aminoethoxyvinylglycine O -
, O +
the O +
inhibitor O +
of O +
ethylene O +
biosynthesis O -
, O +
promoted O +
expression O +
of O +
SA O +
and O +
JA O +
synthesis O -
- O -
related O +
genes O +
in O +
OsEDR1-KO O +
plants O -
. O -

These O +
results O +
suggest O +
that O +
ethylene O +
is O +
a O +
negative O +
signalling O +
molecule O +
in O +
rice U-Species +
bacterial O +
resistance O -
. O -

In O +
the O +
rice U-Species -
- O -
Xoo U-Species +
interaction O -
, O +
OsEDR1 O +
transcriptionally O +
promotes O +
the O +
synthesis O +
of O +
ethylene O +
that O -
, O +
in O +
turn O -
, O +
suppresses O +
SA- O +
and O +
JA O -
- O -
associated O +
defence O +
signalling O -
. O +

Functional O +
test O +
of O +
the O +
influence O +
of O +
Wolbachia O +
genes O +
on O +
cytoplasmic O +
incompatibility O +
expression O +
in O +
Drosophila B-Species +
melanogaster L-Species -
. O +

Wolbachia O +
are O +
inherited O +
intracellular O +
bacteria O +
that O +
infect O +
a O +
broad O +
range O +
of O +
invertebrate O +
hosts O -
. O -

They O +
commonly O +
manipulate O +
host O +
reproduction O +
in O +
a O +
variety O +
of O +
ways O +
and O +
thereby O +
favour O +
their O +
invasion O +
into O +
host O +
populations O -
. O -

While O +
the O +
biology O +
of O +
Wolbachia O +
has O +
been O +
extensively O +
studied O +
at O +
the O +
ecological O +
and O +
phenotypic O +
level O -
, O +
little O +
is O +
known O +
about O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
interaction O +
between O +
Wolbachia O +
and O +
their O +
hosts O -
. O -

Recent O +
comparative O +
genomics O +
studies O +
of O +
Wolbachia O +
strains O +
have O +
revealed O +
putative O +
candidate O +
genes O +
involved O +
in O +
the O +
expression O +
of O +
cytoplasmic O +
incompatibility O +
( O -
CI O -
) O +
in O +
insects O -
. O -

However O +
the O +
functional O +
testing O +
of O +
these O +
genes O +
is O +
hindered O +
by O +
the O +
lack O +
of O +
available O +
genetic O +
tools O +
in O +
Wolbachia O -
. O -

To O +
circumvent O +
this O +
problem O +
we O +
generated O +
transgenic O +
Drosophila O +
lines O +
expressing O +
various O +
Wolbachia O +
CI O +
candidate O +
genes O +
under O +
the O +
control O +
of O +
the O +
GAL4 O -
/ O -
UAS O +
system O +
in O +
order O +
to O +
evaluate O +
their O +
possible O +
role O +
in O +
Wolbachia O -
- O -
related O +
phenotypes O +
in O +
Drosophila O -
. O -

The O +
expression O +
of O +
a O +
number O +
of O +
these O +
genes O +
in O +
Drosophila B-Species +
melanogaster L-Species +
failed O +
to O +
mimic O +
or O +
alter O +
CI O +
phenotypes O +
across O +
a O +
range O +
of O +
Wolbachia O +
backgrounds O +
or O +
in O +
the O +
absence O +
of O +
Wolbachia O -
. O +

Differential O +
transcription O +
of O +
two O +
highly O +
divergent O +
gut O -
- O -
expressed O +
Bm86 O +
antigen O +
gene O +
homologues O +
in O +
the O +
tick O +
Rhipicephalus B-Species +
appendiculatus L-Species +
( O -
Acari O -
: O +
Ixodida O -
) O -
. O +

The O +
transcriptional O +
control O +
of O +
gene O +
expression O +
is O +
not O +
well O +
documented O +
in O +
the O +
Arthropoda O -
. O -

We O +
describe O +
transcriptional O +
analysis O +
of O +
two O +
exceptionally O +
divergent O +
homologues O +
( O -
Ra86 O -
) O +
of O +
the O +
Bm86 O +
gut O +
antigen O +
from O +
Rhipicephalus B-Species +
appendiculatus L-Species -
. O -

Bm86 O +
forms O +
the O +
basis O +
of O +
a O +
commercial O +
vaccine O +
for O +
the O +
control O +
of O +
Rhipicephalus B-Species +
( I-Species -
Boophilus I-Species -
) I-Species +
microplus L-Species -
. O -

The O +
R. B-Species +
appendiculatus L-Species +
Ra86 O +
proteins O +
contain O +
654 O +
and O +
693 O +
amino O +
acids O -
, O +
with O +
only O +
80 O -
% O +
amino O +
acid O +
sequence O +
identity O -
. O -

Reverse O -
- O -
transcription O +
PCR O +
of O +
gut O +
cDNA O +
showed O +
transcription O +
of O +
only O +
one O +
genotype O +
in O +
individual O +
female O +
ticks O -
. O -

PCR O +
amplification O +
of O +
3 O -
' O +
untranslated O +
sequences O +
from O +
genomic O +
DNA O +
indicated O +
that O +
both O +
variants O +
could O +
be O +
encoded O +
within O +
a O +
single O +
genome O -
. O -

When O +
both O +
variants O +
were O +
present O -
, O +
one O +
of O +
the O +
two O +
Ra86 O +
genotypes O +
was O +
transcriptionally O +
dominant O -
. O +

Surface O +
and O +
flagella O +
morphology O +
of O +
the O +
motile O +
form O +
of O +
Chromera B-Species +
velia L-Species +
revealed O +
by O +
field O -
- O -
emission O +
scanning O +
electron O +
microscopy O -
. O +

Chromera B-Species +
velia L-Species +
( O -
Chromerida O -
; O +
Alveolata O -
) O +
is O +
an O +
autotrophic O +
protist O +
isolated O +
from O +
stony O +
corals O -
. O -

Ch B-Species -
. L-Species -

velia U-Species +
possesses O +
a O +
chloroplast O +
thought O +
to O +
be O +
most O +
closely O +
related O +
to O +
the O +
apicoplasts O +
of O +
non O -
- O -
photosynthetic O +
apicomplexa O -
. O -

Phylogenetic O +
analyses O +
place O +
Ch B-Species -
. L-Species -

velia U-Species +
as O +
a O +
close O +
relative O +
of O +
parasitic O +
apicomplexa O +
and O +
predatory O +
colpodellids O -
. O -

We O +
have O +
used O +
field O -
- O -
emission O +
scanning O +
electron O +
microscopy O +
of O +
cells O +
sputter O -
- O -
coated O +
with O +
gold O +
or O +
chromium O +
and O +
non O -
- O -
coated O +
cells O +
to O +
characterise O +
the O +
surface O +
ultrastructure O +
of O +
the O +
motile O +
form O +
of O +
Ch B-Species -
. L-Species -

velia U-Species -
. O -

In O +
overall O +
morphology O +
the O +
biflagellated O +
Ch B-Species -
. L-Species -

velia U-Species +
cells O +
resemble O +
the O +
colpodellid O +
Colpodella B-Species +
edax L-Species -
, O +
but O +
with O +
some O +
notable O +
differences O -
. O -

The O +
ventral O +
side O +
of O +
the O +
flagellated O +
Ch B-Species -
. L-Species -

velia U-Species +
cell O +
has O +
two O +
grooves O +
extending O +
from O +
the O +
anterior O +
flagella O +
insertion O +
point O +
with O +
a O +
ridge O +
rising O +
towards O +
the O +
anterior O +
apex O +
of O +
the O +
cell O -
. O -

The O +
anterior O +
flagellum O +
is O +
shorter O +
than O +
the O +
posterior O +
flagellum O +
and O +
possesses O +
a O +
distinct O -
, O +
small O +
curved O +
appendage O -
. O -

The O +
insertion O +
point O +
of O +
the O +
anterior O +
flagellum O +
is O +
partly O +
enclosed O +
by O +
a O +
flap O +
extending O +
from O +
the O +
cell O -
. O -

The O +
posterior O +
flagellum O +
is O +
approximately O +
four O +
times O +
the O +
length O +
of O +
the O +
cell O +
and O +
possesses O +
mastigonemes O -
. O -

The O +
combination O +
of O +
coating O +
techniques O +
proved O +
superior O +
to O +
the O +
commonly O +
used O +
gold O +
coating O +
to O +
determine O +
fine O +
surface O +
ultrastructure O -
. O -

This O +
new O +
ultrastructural O +
information O +
for O +
Ch B-Species -
. L-Species -

velia U-Species +
allowed O +
us O +
to O +
emend O +
its O +
diagnosis O -
. O +

Genetic O +
and O +
molecular O +
characterization O +
of O +
a O +
blue O +
light O +
photoreceptor O +
MGWC-1 O +
in O +
Magnaporth B-Species +
oryzae L-Species -
. O +

Three O +
key O +
factors O +
involved O +
in O +
successful O +
plant O +
disease O +
development O +
include O +
the O +
presence O +
of O +
a O +
susceptible O +
host O -
, O +
a O +
virulent O +
pathogen O -
, O +
and O +
a O +
disease O -
- O -
conducive O +
environment O -
. O -

Our O +
understanding O +
of O +
how O +
environmental O +
factors O +
influence O +
disease O -
- O -
conducive O +
or O +
disease O -
- O -
suppressive O +
conditions O -
, O +
and O +
how O +
a O +
pathogen O +
advantageously O +
capitalizes O +
on O +
them O -
, O +
is O +
quite O +
limited O -
. O -

Utilizing O +
the O +
model O +
pathosystem O +
Magnaporthe B-Species +
oryzae L-Species -
- O -
Oryza B-Species +
sativa L-Species -
, O +
we O +
found O +
a O +
significant O +
light O -
- O -
dependent O +
disease O +
suppression O -
. O -

Our O +
genetic O +
data O +
suggest O +
that O +
the O +
blue O -
- O -
light O +
receptor O +
MGWC-1 O +
in O +
M. B-Species +
oryzae L-Species +
is O +
involved O +
in O +
light O -
- O -
dependent O +
disease O +
suppression O +
during O +
the O +
dark O -
- O -
phase O +
( O -
disease O -
- O -
conducive O +
light O +
condition O -
) O +
immediately O +
after O +
pathogen O -
- O -
host O +
contact O -
. O -

Sensing O +
" O -
darkness O -
" O +
is O +
accomplished O +
by O +
MGWC-1 O -
, O +
a O +
blue O -
- O -
light O +
receptor O +
in O +
M. O +
oryzae O -
. O -

To B-Species +
explore L-Species +
the O +
potential O +
molecular O +
mechanisms O +
of O +
light O -
- O -
dependent O +
disease O +
suppression O +
we O +
performed O +
a O +
genome O -
- O -
wide O +
microarray O +
experiment O +
and O +
identified O +
several O +
groups O +
of O +
gene O +
families O +
that O +
are O +
differentially O +
regulated O +
during O +
the O +
light O -
- O -
to O -
- O -
dark O +
transition O -
. O -

Our O +
genetic O +
and O +
molecular O +
data O +
provide O +
insights O +
into O +
how O +
a O +
fungal O +
pathogen O +
utilizes O +
ambient O +
light O +
signals O +
for O +
successful O +
disease O +
development O -
. O +

Determinants O +
of O +
reproductive O +
success O +
in O +
dominant O +
pairs O +
of O +
clownfish O -
: O +
a O +
boosted O +
regression O +
tree O +
analysis O -
. O +

1 O -
. O -

Central O +
questions O +
of O +
behavioural O +
and O +
evolutionary O +
ecology O +
are O +
what O +
factors O +
influence O +
the O +
reproductive O +
success O +
of O +
dominant O +
breeders O +
and O +
subordinate O +
nonbreeders O +
within O +
animal O +
societies O -
? O -

A O +
complete O +
understanding O +
of O +
any O +
society O +
requires O +
that O +
these O +
questions O +
be O +
answered O +
for O +
all O +
individuals O -
. O -

2 O -
. O -

The O +
clown O +
anemonefish O -
, O +
Amphiprion B-Species +
percula L-Species -
, O +
forms O +
simple O +
societies O +
that O +
live O +
in O +
close O +
association O +
with O +
sea O +
anemones O -
, O +
Heteractis B-Species +
magnifica L-Species -
. O -

Here O -
, O +
we O +
use O +
data O +
from O +
a O +
well O -
- O -
studied O +
population O +
of O +
A. B-Species +
percula L-Species +
to O +
determine O +
the O +
major O +
predictors O +
of O +
reproductive O +
success O +
of O +
dominant O +
pairs O +
in O +
this O +
species O -
. O -

3 O -
. O -

We O +
analyse O +
the O +
effect O +
of O +
multiple O +
predictors O +
on O +
four O +
components O +
of O +
reproductive O +
success O -
, O +
using O +
a O +
relatively O +
new O +
technique O +
from O +
the O +
field O +
of O +
statistical O +
learning O -
: O +
boosted O +
regression O +
trees O +
( O -
BRTs O -
) O -
. O -

BRTs O +
have O +
the O +
potential O +
to O +
model O +
complex O +
relationships O +
in O +
ways O +
that O +
give O +
powerful O +
insight O -
. O -

4 O -
. O -

We O +
show O +
that O +
the O +
reproductive O +
success O +
of O +
dominant O +
pairs O +
is O +
unrelated O +
to O +
the O +
presence O -
, O +
number O +
or O +
phenotype O +
of O +
nonbreeders O -
. O -

This O +
is O +
consistent O +
with O +
the O +
observation O +
that O +
nonbreeders O +
do O +
not O +
help O +
or O +
hinder O +
breeders O +
in O +
any O +
way O -
, O +
confirming O +
and O +
extending O +
the O +
results O +
of O +
a O +
previous O +
study O -
. O -

5 O -
. O +
Primarily O -
, O +
reproductive O +
success O +
is O +
negatively O +
related O +
to O +
male O +
growth O +
and O +
positively O +
related O +
to O +
breeding O +
experience O -
. O -

It O +
is O +
likely O +
that O +
these O +
effects O +
are O +
interrelated O +
because O +
males O +
that O +
grow O +
a O +
lot O +
have O +
little O +
breeding O +
experience O -
. O -

These O +
effects O +
are O +
indicative O +
of O +
a O +
trade O -
- O -
off O +
between O +
male O +
growth O +
and O +
parental O +
investment O -
. O -

6 O -
. O -

Secondarily O -
, O +
reproductive O +
success O +
is O +
positively O +
related O +
to O +
female O +
growth O +
and O +
size O -
. O -

In O +
this O +
population O -
, O +
female O +
size O +
is O +
positively O +
related O +
to O +
group O +
size O +
and O +
anemone O +
size O -
, O +
also O -
. O -

These O +
positive O +
correlations O +
among O +
traits O +
likely O +
are O +
caused O +
by O +
variation O +
in O +
site O +
quality O +
and O +
are O +
suggestive O +
of O +
a O +
silver O -
- O -
spoon O +
effect O -
. O -

7 O -
. O -

Noteworthily O -
, O +
whereas O +
reproductive O +
success O +
is O +
positively O +
related O +
to O +
female O +
size O -
, O +
it O +
is O +
unrelated O +
to O +
male O +
size O -
. O -

This O +
observation O +
provides O +
support O +
for O +
the O +
size O +
advantage O +
hypothesis O +
for O +
sex O +
change O -
: O +
both O +
individuals O +
maximize O +
their O +
reproductive O +
success O +
when O +
the O +
larger O +
individual O +
adopts O +
the O +
female O +
tactic O -
. O -

8 O -
. O -

This O +
study O +
provides O +
the O +
most O +
complete O +
picture O +
to O +
date O +
of O +
the O +
factors O +
that O +
predict O +
the O +
reproductive O +
success O +
of O +
dominant O +
pairs O +
of O +
clown O +
anemonefish O +
and O +
illustrates O +
the O +
utility O +
of O +
BRTs O +
for O +
analysis O +
of O +
complex O +
behavioural O +
and O +
evolutionary O +
ecology O +
data O -
. O +

Multiplex O +
RT O -
- O -
PCR O +
for O +
rapid O +
detection O +
and O +
differentiation O +
of O +
class U-Species +
I O +
and O +
class B-Species +
II I-Species +
Newcastle I-Species +
disease I-Species +
viruses L-Species -
. O +

A O +
multiplex O +
RT O -
- O -
PCR O +
was O +
developed O +
for O +
detection O +
and O +
differentiation O +
of O +
class U-Species +
I O +
and O +
class B-Species +
II I-Species +
strains I-Species +
of I-Species +
Newcastle I-Species +
disease I-Species +
virus I-Species +
( I-Species -
NDV L-Species -
) O -
. O -

The O +
method O +
was O +
shown O +
to O +
have O +
high O +
specificity O +
and O +
sensitivity O -
. O -

The O +
results O +
obtained O +
from O +
the O +
multiplex O +
RT O -
- O -
PCR O +
for O +
a O +
total O +
of O +
67 O +
NDV U-Species +
field O +
isolates O +
obtained O +
in O +
2009 O +
were O +
consistent O +
with O +
those O +
obtained O +
by O +
nucleotide O +
sequencing O +
and O +
phylogenetic O +
analysis O -
. O -

A O +
phylogenetic O +
tree O +
based O +
on O +
the O +
partial O +
sequences O +
of O +
the O +
F O +
gene O +
revealed O +
that O +
the O +
67 O +
field O +
isolates O +
of O +
NDV U-Species +
could O +
be O +
divided O +
into O +
two O +
classes O -
. O -

Twenty O -
- O -
seven O +
NDV U-Species +
isolates O +
were O +
grouped O +
into O +
class U-Species +
I O -
, O +
and O +
two O +
genotypes O +
were O +
identified O -
. O -

Most O +
of O +
the O +
class U-Species +
I O +
isolates O +
were O +
determined O +
to O +
be O +
of O +
genotype O +
3 O -
, O +
with O +
the O +
exception O +
of O +
isolate O +
NDV09 B-Species -
- I-Species -
034 L-Species -
, O +
which O +
belonged O +
to O +
genotype O +
2 O -
. O -

Forty O +
class B-Species +
II I-Species +
NDV I-Species +
isolates L-Species +
were O +
divided O +
into O +
three O +
genotypes O -
, O +
namely O +
genotype O +
VII O +
( O -
27 O +
isolates O -
) O -
, O +
genotype O +
I O +
( O -
2 O +
isolates O -
) O +
and O +
genotype O +
II O +
( O -
11 O +
isolates O -
) O -
. O -

Isolates O +
of O +
genotypes O +
I O +
and O +
II O +
in O +
class O +
II O +
were O +
shown O +
to O +
be O +
related O +
to O +
commercial O +
vaccine O +
strains O +
used O +
commonly O +
in O +
China O -
. O -

All O +
isolates O +
of O +
genotype O +
VII O +
were O +
predicted O +
to O +
be O +
virulent O -
, O +
on O +
the O +
basis O +
of O +
the O +
sequence O +
motif O +
at O +
the O +
cleavage O +
site O +
of O +
the O +
F O +
gene O -
. O -

This O +
genotype O +
has O +
become O +
predominantly O +
responsible O +
for O +
most O +
outbreaks O +
of O +
ND O +
in O +
China O +
in O +
recent O +
years O -
. O -

In O +
conclusion O -
, O +
this O +
multiplex O +
RT O -
- O -
PCR O +
provides O +
a O +
new O +
assay O +
for O +
rapid O +
detection O +
and O +
differentiation O +
of O +
both O +
classes O +
of O +
NDV B-Species +
isolates L-Species -
. O +

Comparison O +
of O +
commercial O +
systems O +
for O +
extraction O +
of O +
nucleic O +
acids O +
from O +
DNA O -
/ O -
RNA O +
respiratory O +
pathogens O -
. O +

This O +
study O +
compared O +
six O +
automated O +
nucleic O +
acid O +
extraction O +
systems O +
and O +
one O +
manual O +
kit O +
for O +
their O +
ability O +
to O +
recover O +
nucleic O +
acids O +
from O +
human U-Species +
nasal O +
wash O +
specimens O +
spiked O +
with O +
five O +
respiratory O +
pathogens O -
, O +
representing O +
Gram O -
- O -
positive O +
bacteria O +
( O -
Streptococcus B-Species +
pyogenes L-Species -
) O -
, O +
Gram O -
- O -
negative O +
bacteria O +
( O -
Legionella B-Species +
pneumophila L-Species -
) O -
, O +
DNA O +
viruses O +
( O -
adenovirus O -
) O -
, O +
segmented O +
RNA O +
viruses O +
( O -
human B-Species +
influenza I-Species +
virus L-Species +
A O -
) O -
, O +
and O +
non O -
- O -
segmented O +
RNA O +
viruses O +
( O -
respiratory B-Species +
syncytial I-Species +
virus L-Species -
) O -
. O -

The O +
robots O +
and O +
kit O +
evaluated O +
represent O +
major O +
commercially O +
available O +
methods O +
that O +
are O +
capable O +
of O +
simultaneous O +
extraction O +
of O +
DNA O +
and O +
RNA O +
from O +
respiratory O +
specimens O -
, O +
and O +
included O +
platforms O +
based O +
on O +
magnetic O -
- O -
bead O +
technology O +
( O -
KingFisher O +
mL O -
, O +
Biorobot O +
EZ1 O -
, O +
easyMAG O -
, O +
KingFisher O +
Flex O -
, O +
and O +
MagNA O +
Pure O +
Compact O -
) O +
or O +
glass O +
fiber O +
filter O +
technology O +
( O -
Biorobot O +
MDX O +
and O +
the O +
manual O +
kit O +
Allprep O -
) O -
. O -

All O +
methods O +
yielded O +
extracts O +
free O +
of O +
cross O -
- O -
contamination O +
and O +
RT O -
- O -
PCR O +
inhibition O -
. O -

All O +
automated O +
systems O +
recovered O +
L. B-Species +
pneumophila L-Species +
and O +
adenovirus O +
DNA O +
equivalently O -
. O -

However O -
, O +
the O +
MagNA O +
Pure O +
protocol O +
demonstrated O +
more O +
than O +
4-fold O +
higher O +
DNA O +
recovery O +
from O +
the O +
S. B-Species +
pyogenes L-Species +
than O +
other O +
methods O -
. O -

The O +
KingFisher O +
mL O +
and O +
easyMAG O +
protocols O +
provided O +
1- O +
to O +
3-log O +
wider O +
linearity O +
and O +
extracted O +
3- O +
to O +
4-fold O +
more O +
RNA O +
from O +
the O +
human B-Species +
influenza I-Species +
virus L-Species +
and O +
respiratory B-Species +
syncytial I-Species +
virus L-Species -
. O -

These O +
findings O +
suggest O +
that O +
systems O +
differed O +
in O +
nucleic O +
acid O +
recovery O -
, O +
reproducibility O -
, O +
and O +
linearity O +
in O +
a O +
pathogen O +
specific O +
manner O -
. O +

Detection O +
of O +
Tomato B-Species +
black I-Species +
ring I-Species +
virus L-Species +
by O +
real O -
- O -
time O +
one O -
- O -
step O +
RT O -
- O -
PCR O -
. O -

A O +
TaqMan O -
- O -
based O +
real O -
- O -
time O +
one O -
- O -
step O +
RT O -
- O -
PCR O +
assay O +
was O +
developed O +
for O +
the O +
rapid O +
detection O +
of O +
Tomato B-Species +
black I-Species +
ring I-Species +
virus L-Species +
( O -
TBRV U-Species -
) O -
, O +
a O +
significant O +
plant O +
pathogen O +
which O +
infects O +
a O +
wide O +
range O +
of O +
economically O +
important O +
crops O -
. O -

Primers O +
and O +
a O +
probe O +
were O +
designed O +
against O +
existing O +
genomic O +
sequences O +
to O +
amplify O +
a O +
72 O +
bp O +
fragment O +
from O +
RNA-2 O -
. O -

The O +
assay O +
amplified O +
all O +
isolates O +
of O +
TBRV U-Species +
tested O -
, O +
but O +
no O +
amplification O +
was O +
observed O +
from O +
the O +
RNA O +
of O +
other O +
nepovirus O +
species O +
or O +
healthy O +
host O +
plants O -
. O -

The O +
detection O +
limit O +
of O +
the O +
assay O +
was O +
estimated O +
to O +
be O +
around O +
nine O +
copies O +
of O +
the O +
TBRV U-Species +
target O +
region O +
in O +
total O +
RNA O -
. O -

A O +
comparison O +
with O +
conventional O +
RT O -
- O -
PCR O +
and O +
ELISA O -
, O +
indicated O +
that O +
ELISA O -
, O +
the O +
current O +
standard O +
test O +
method O -
, O +
lacked O +
specificity O +
and O +
reacted O +
to O +
all O +
nepovirus O +
species O +
tested O -
, O +
while O +
conventional O +
RT O -
- O -
PCR O +
was O +
approximately O +
ten O -
- O -
fold O +
less O +
sensitive O +
than O +
the O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
assay O -
. O -

Finally O -
, O +
the O +
real O -
- O -
time O +
RT O -
- O -
PCR O +
assay O +
was O +
tested O +
using O +
five O +
different O +
RT O -
- O -
PCR O +
reagent O +
kits O +
and O +
was O +
found O +
to O +
be O +
robust O +
and O +
reliable O -
, O +
with O +
no O +
significant O +
differences O +
in O +
sensitivity O +
being O +
found O -
. O -

The O +
development O +
of O +
this O +
rapid O +
assay O +
should O +
aid O +
in O +
quarantine O +
and O +
post O -
- O -
border O +
surveys O +
for O +
regulatory O +
agencies O -
. O +

Scales O +
of O +
orientation O -
, O +
directed O +
walks O +
and O +
movement O +
path O +
structure O +
in O +
sharks O -
. O -

1 O -
. O -

Animal O +
search O +
patterns O +
reflect O +
sensory O +
perception O +
ranges O +
combined O +
with O +
memory O +
and O +
knowledge O +
of O +
the O +
surrounding O +
environment O -
. O -

2 O -
. O -

Random O +
walks O +
are O +
used O +
when O +
the O +
locations O +
of O +
resources O +
are O +
unknown O -
, O +
whereas O +
directed O +
walks O +
should O +
be O +
optimal O +
when O +
the O +
location O +
of O +
favourable O +
habitats O +
is O +
known O -
. O -

However O -
, O +
directed O +
walks O +
have O +
been O +
quantified O +
for O +
very O +
few O +
species O -
. O -

3 O -
. O -

We O +
re O -
- O -
analysed O +
tracking O +
data O +
from O +
three O +
shark O +
species O +
to O +
determine O +
whether O +
they O +
were O +
using O +
directed O +
walks O -
, O +
and O +
if O +
so O -
, O +
over O +
which O +
spatial O +
scales O -
. O -

Fractal O +
analysis O +
was O +
used O +
to O +
quantify O +
how O +
movement O +
structure O +
varied O +
with O +
spatial O +
scale O +
and O +
determine O +
whether O +
the O +
sharks O +
were O +
using O +
patches O -
. O -

4 O -
. O +
Tiger O +
sharks O +
performed O +
directed O +
walks O +
at O +
large O +
spatial O +
scales O +
( O -
at O +
least O +
6 O -
- O -
8 O +
km O -
) O -
. O -

Thresher O +
sharks O +
also O +
showed O +
directed O +
movement O +
( O -
at O +
scales O +
of O +
400 O -
- O -
1900 O +
m O -
) O -
, O +
and O +
adult O +
threshers U-Species +
were O +
able O +
to O +
orient O +
at O +
greater O +
scales O +
than O +
juveniles O -
, O +
which O +
may O +
suggest O +
that O +
learning O +
improves O +
the O +
ability O +
to O +
perform O +
directed O +
walks O -
. O -

Blacktip B-Species +
reef I-Species +
sharks L-Species +
had O +
small O +
home O +
ranges O -
, O +
high O +
site O +
fidelity O +
and O +
showed O +
no O +
evidence O +
of O +
oriented O +
movements O +
at O +
large O +
scales O -
. O -

5 O -
. O -

There O +
were O +
inter- O +
and O +
intraspecific O +
differences O +
in O +
path O +
structure O +
and O +
patch O +
size O -
, O +
although O +
most O +
individuals O +
showed O +
scale O -
- O -
dependent O +
movements O -
. O -

Furthermore O -
, O +
some O +
individuals O +
of O +
each O +
species O +
performed O +
movements O +
similar O +
to O +
a O +
correlated O +
random O +
walk O -
. O -

6 O -
. O -

Sharks O +
can O +
perform O +
directed O +
walks O +
over O +
large O +
spatial O +
scales O -
, O +
with O +
scales O +
of O +
movements O +
reflecting O +
site O +
fidelity O +
and O +
home O +
range O +
size O -
. O -

Understanding O +
when O +
and O +
where O +
directed O +
walks O +
occur O +
is O +
crucial O +
for O +
developing O +
more O +
accurate O +
population O -
- O -
level O +
dispersal O +
models O -
. O +

Fluorescent O +
proteins O +
illuminate O +
the O +
structure O +
and O +
function O +
of O +
the O +
hyphal O +
tip O +
apparatus O -
. O +

Fungal O +
hyphae O +
show O +
extreme O +
polarized O +
growth O +
at O +
the O +
tip O -
. O -

Electron O +
microscope O +
studies O +
have O +
revealed O +
a O +
apical O +
body O +
called O +
the O +
Spitzenkorper O +
that O +
is O +
thought O +
to O +
drive O +
polarized O +
growth O -
. O -

Studies O +
of O +
polarized O +
growth O +
in O +
S. B-Species +
cerevisiae L-Species +
have O +
identified O +
the O +
protein O +
components O +
of O +
the O +
polarized O +
growth O +
machinery O -
, O +
that O +
are O +
conserved O +
in O +
other O +
fungi O -
. O -

Fusion O +
of O +
these O +
proteins O +
to O +
GFP O +
and O +
its O +
variants O +
has O +
for O +
the O +
first O +
time O +
allowed O +
the O +
localization O +
of O +
these O +
proteins O +
in O +
real O +
time O +
to O +
the O +
hyphal O +
tip O +
without O +
the O +
need O +
for O +
drastic O +
fixation O +
procedures O -
. O -

Such O +
studies O +
showed O +
that O +
vesicle O -
- O -
associated O +
proteins O +
localize O +
to O +
the O +
Spitzenkorper O +
and O +
identified O +
a O +
second O +
compartment O +
located O +
at O +
the O +
tip O +
surface O +
composed O +
of O +
exocyst O +
and O +
other O +
proteins O +
that O +
mediate O +
the O +
fusion O +
of O +
secretory O +
vesicles O +
with O +
the O +
plasma O +
membrane O -
. O +

Galleria B-Species +
mellonella L-Species +
as O +
model O +
host O +
for O +
the O +
trans O -
- O -
kingdom O +
pathogen O +
Fusarium B-Species +
oxysporum L-Species -
. O +

Fusarium B-Species +
oxysporum L-Species -
, O +
the O +
causal O +
agent O +
of O +
vascular O +
wilt O +
disease O -
, O +
affects O +
a O +
wide O +
range O +
of O +
plant O +
species O +
and O +
can O +
produce O +
disseminated O +
infections O +
in O +
humans U-Species -
. O -

F. B-Species +
oxysporum I-Species +
f. I-Species +
sp. I-Species +
lycopersici I-Species +
isolate I-Species +
FGSC I-Species +
9935 L-Species +
causes O +
disease O +
both O +
on O +
tomato B-Species +
plants L-Species +
and O +
immunodepressed O +
mice U-Species -
, O +
making O +
it O +
an O +
ideal O +
model O +
for O +
the O +
comparative O +
analysis O +
of O +
fungal O +
virulence O +
on O +
plant O +
and O +
animal O +
hosts O -
. O -

Here O +
we O +
tested O +
the O +
ability O +
of O +
FGSC B-Species +
9935 L-Species +
to O +
cause O +
disease O +
in O +
the O +
greater B-Species +
wax I-Species +
moth L-Species +
Galleria B-Species +
mellonella L-Species -
, O +
an O +
invertebrate O +
model O +
host O +
that O +
is O +
widely O +
used O +
for O +
the O +
study O +
of O +
microbial O +
human U-Species +
pathogens O -
. O -

Injection O +
of O +
living O +
but O +
not O +
of O +
heat O -
- O -
killed O +
microconidia O +
into O +
the O +
hemocoel O +
of O +
G. B-Species +
mellonella L-Species +
larvae O +
resulted O +
in O +
dose O -
- O -
dependent O +
killing O +
both O +
at O +
30 O -
^ O -
0C O +
and O +
at O +
37 O -
^ O -
0C O -
. O -

Fluorescence O +
microscopy O +
of O +
larvae O +
inoculated O +
with O +
a O +
F. B-Species +
oxysporum I-Species +
transformant L-Species +
expressing O +
GFP O +
revealed O +
hyphal O +
proliferation O +
within O +
the O +
hemocoel O -
, O +
interaction O +
with O +
G. B-Species +
mellonella L-Species +
hemocytes O -
, O +
and O +
colonization O +
of O +
the O +
killed O +
insects O +
by O +
the O +
fungus O -
. O -

Fungal O +
gene O +
knockout O +
mutants O +
previously O +
tested O +
in O +
the O +
tomato U-Species +
and O +
immunodepressed O +
mouse U-Species +
systems O +
displayed O +
a O +
good O +
correlation O +
in O +
virulence O +
between O +
the O +
Galleria O +
and O +
the O +
mouse U-Species +
model O -
. O -

Thus O -
, O +
Galleria O +
represents O +
a O +
useful O +
non O -
- O -
vertebrate O +
infection O +
model O +
for O +
studying O +
virulence O +
mechanisms O +
of O +
F. B-Species +
oxysporum L-Species +
on O +
animal O +
hosts O -
. O +

Genome O -
- O -
wide O +
inventory O +
of O +
metal O +
homeostasis O -
- O -
related O +
gene O +
products O +
including O +
a O +
functional O +
phytochelatin O +
synthase O +
in O +
the O +
hypogeous O +
mycorrhizal O +
fungus O +
Tuber B-Species +
melanosporum L-Species -
. O +

Ectomycorrhizal O +
fungi O +
are O +
thought O +
to O +
enhance O +
mineral O +
nutrition O +
of O +
their O +
host O +
plants O +
and O +
to O +
confer O +
increased O +
tolerance O +
toward O +
toxic O +
metals O -
. O -

However O -
, O +
a O +
global O +
view O +
of O +
metal O +
homeostasis O -
- O -
related O +
genes O +
and O +
pathways O +
in O +
these O +
organisms O +
is O +
still O +
lacking O -
. O -

Building O +
upon O +
the O +
genome O +
sequence O +
of O +
Tuber B-Species +
melanosporum L-Species +
and O +
on O +
transcriptome O +
analyses O -
, O +
we O +
set O +
out O +
to O +
systematically O +
identify O +
metal O +
homeostasis O -
- O -
related O +
genes O +
in O +
this O +
plant O -
- O -
symbiotic O +
ascomycete O -
. O -

Candidate O +
gene O +
products O +
( O -
101 O -
) O +
were O +
subdivided O +
into O +
three O +
major O +
functional O +
classes O -
: O +
( O -
i O -
) O +
metal O +
transport O +
( O -
58 O -
) O -
; O +
( O -
ii O -
) O +
oxidative O +
stress O +
defence O +
( O -
32 O -
) O -
; O +
( O -
iii O -
) O +
metal O +
detoxification O +
( O -
11 O -
) O -
. O -

The O +
latter O +
class O +
includes O +
a O +
small O -
- O -
size O +
metallothionein O +
( O -
TmelMT O -
) O +
that O +
was O +
functionally O +
validated O +
in O +
yeast U-Species -
, O +
and O +
phytochelatin O +
synthase O +
( O -
TmelPCS O -
) O -
, O +
the O +
first O +
enzyme O +
of O +
this O +
kind O +
to O +
be O +
described O +
in O +
filamentous O +
ascomycetes O -
. O -

Recombinant O +
TmelPCS O +
was O +
shown O +
to O +
support O +
GSH O -
- O -
dependent O -
, O +
metal O -
- O -
activated O +
phytochelatin O +
synthesis O +
in O +
vitro O +
and O +
to O +
afford O +
increased O +
Cd O -
/ O -
Cu O +
tolerance O +
to O +
metal O +
hypersensitive O +
yeast U-Species +
strains O -
. O -

Metal O +
transporters O -
, O +
especially O +
those O +
related O +
to O +
Cu O +
and O +
Zn O +
trafficking O -
, O +
displayed O +
the O +
highest O +
expression O +
levels O +
in O +
mycorrhizae O -
, O +
suggesting O +
extensive O +
translocation O +
of O +
both O +
metals O +
to O +
root O +
cells O +
as O +
well O +
as O +
to O +
fungal O +
metalloenzymes O +
( O -
e.g. O -
, O +
laccase O -
) O +
that O +
are O +
strongly O +
upregulated O +
in O +
symbiotic O +
hyphae O -
. O +

Predation O +
is O +
associated O +
with O +
variation O +
in O +
colour O +
pattern O -
, O +
but O +
not O +
body O +
shape O +
or O +
colour O +
reflectance O -
, O +
in O +
a O +
rainbowfish U-Species +
( O -
Melanotaenia B-Species +
australis L-Species -
) O -
. O +

1 O -
. O -

In O +
freshwater O +
fishes O -
, O +
inter O -
- O -
population O +
variation O +
in O +
male O +
phenotype O +
is O +
often O +
associated O +
with O +
differences O +
in O +
predation O +
intensity O -
, O +
but O +
these O +
effects O +
can O +
be O +
difficult O +
to O +
disentangle O +
from O +
environmental O +
influences O -
. O -

2 O -
. O -

The O +
western B-Species +
rainbowfish L-Species +
Melanotaenia B-Species +
australis L-Species +
exhibits O +
marked O +
sexual O +
dimorphism O +
- O +
females O +
are O +
plain O +
with O +
a O +
slender O +
body O -
, O +
while O +
males O +
have O +
striking O +
coloration O +
and O +
are O +
deeper O +
in O +
the O +
body O -
. O -

Male O +
traits O +
differ O +
in O +
expression O +
among O +
populations O -
, O +
but O +
this O +
has O +
not O +
been O +
described O +
or O +
explored O +
in O +
the O +
literature O -
. O -

3 O -
. O -

This O +
paper O +
describes O +
a O +
study O +
designed O +
to O +
test O +
for O +
geographic O +
structuring O +
of O +
male O +
phenotype O +
in O +
M. B-Species +
australis L-Species +
and O +
to O +
determine O +
whether O +
between O -
- O -
population O +
variation O +
in O +
male O +
phenotype O +
is O +
attributable O +
to O +
variation O +
in O +
predation O +
regime O -
, O +
after O +
accounting O +
for O +
environment O -
. O -

4 O -
. O -

We O +
collected O +
data O +
describing O +
habitat O -
, O +
and O +
the O +
size O -
, O +
activity O +
and O +
abundance O +
of O +
predators O +
at O +
sites O +
containing O +
M. B-Species +
australis L-Species +
populations O -
. O -

We O +
then O +
used O +
photography O -
, O +
spectrometry O +
and O +
geometric O +
morphometrics O +
to O +
describe O +
colour O +
pattern O -
, O +
spectral O +
reflectance O +
and O +
body O +
shape O +
in O +
males O +
from O +
these O +
populations O -
. O -

Finally O -
, O +
we O +
used O +
permutation O -
- O -
based O +
multivariate O +
statistics O +
to O +
partition O +
variance O +
in O +
these O +
traits O +
according O +
to O +
environment O +
and O +
predation O +
regime O -
. O -

5 O -
. O -

Downstream O +
environments O +
posed O +
higher O +
predation O +
risk O +
to O +
M. B-Species +
australis L-Species -
. O -

Furthermore O -
, O +
males O +
from O +
these O +
sites O +
consistently O +
exhibited O +
larger O +
cheek O +
spots O +
and O +
fewer O +
coloured O +
lateral O +
stripes O +
than O +
those O +
from O +
upstream O +
sites O -
. O -

Variation O +
in O +
predation O +
regime O +
accounted O +
for O +
a O +
significant O +
proportion O +
of O +
the O +
total O +
variance O +
in O +
these O +
traits O +
( O -
30 O -
* O -
9 O -
% O -
) O -
, O +
after O +
controlling O +
for O +
the O +
effects O +
of O +
environment O -
. O -

6 O -
. O -

Variation O +
in O +
predation O +
regime O +
did O +
not O +
explain O +
variation O +
in O +
reflectance O +
or O +
shape O -
. O -

Environmental O +
variation O -
, O +
however O -
, O +
explained O +
a O +
significant O +
portion O +
of O +
the O +
total O +
variance O +
in O +
reflectance O +
( O -
74 O -
* O -
9 O -
% O -
) O -
, O +
and O +
there O +
was O +
a O +
strong O +
trend O +
towards O +
it O +
explaining O +
a O +
portion O +
of O +
the O +
total O +
variance O +
in O +
body O +
shape O +
( O -
34 O -
* O -
9 O -
% O -
) O -
. O -

7 O -
. O -

We O +
conclude O +
that O +
natural O +
selection O +
by O +
predators O +
may O +
be O +
an O +
important O +
determinant O +
of O +
the O +
evolution O +
of O +
colour O +
pattern O +
variation O +
in O +
M. B-Species +
australis L-Species -
, O +
but O +
not O +
of O +
that O +
of O +
body O +
shape O +
or O +
colour O +
reflectance O -
. O -

8 O -
. O -

Further O +
study O +
of O +
M. B-Species +
australis L-Species +
will O +
complement O +
existing O +
models O -
, O +
which O +
show O +
complex O +
relationships O +
between O +
predation O +
regime O -
, O +
environment O +
and O +
phenotype O -
. O -

Understanding O +
these O +
relationships O +
is O +
prerequisite O +
to O +
predicting O +
the O +
evolution O +
of O +
phenotypic O +
variation O +
in O +
natural O +
systems O -
. O +

Distribution O +
and O +
localization O +
of O +
microsatellites O +
in O +
the O +
Perigord B-Species +
black I-Species +
truffle L-Species +
genome O +
and O +
identification O +
of O +
new O +
molecular O +
markers O -
. O +

The O +
level O +
of O +
genetic O +
diversity O +
and O +
genetic O +
structure O +
in O +
the O +
Perigord B-Species +
black I-Species +
truffle L-Species +
( O -
Tuber B-Species +
melanosporum I-Species +
Vittad L-Species -
. O -
) O +
has O +
been O +
debated O +
for O +
several O +
years O -
, O +
mainly O +
due O +
to O +
the O +
lack O +
of O +
appropriate O +
genetic O +
markers O -
. O -

Microsatellites O +
or O +
simple O +
sequence O +
repeats O +
( O -
SSRs O -
) O +
are O +
important O +
for O +
the O +
genome O +
organisation O -
, O +
phenotypic O +
diversity O +
and O +
are O +
one O +
of O +
the O +
most O +
popular O +
molecular O +
markers O -
. O -

In O +
this O +
study O -
, O +
we O +
surveyed O +
the O +
T. B-Species +
melanosporum L-Species +
genome O +
( O -
1 O -
) O +
to O +
characterise O +
its O +
SSR O +
pattern O -
; O +
( O -
2 O -
) O +
to O +
compare O +
it O +
with O +
SSR O +
patterns O +
found O +
in O +
48 O +
other O +
fungal O +
and O +
three O +
oomycetes O +
genomes O +
and O +
( O -
3 O -
) O +
to O +
identify O +
new O +
polymorphic O +
SSR O +
markers O +
for O +
population O +
genetics O -
. O -

The O +
T. B-Species +
melanosporum L-Species +
genome O +
is O +
rich O +
in O +
SSRs O +
with O +
22,425 O +
SSRs O +
with O +
mono O -
- O -
nucleotides O +
being O +
the O +
most O +
frequent O +
motifs O -
. O -

SSRs O +
were O +
found O +
in O +
all O +
genomic O +
regions O +
although O +
they O +
are O +
more O +
frequent O +
in O +
non O -
- O -
coding O +
regions O +
( O -
introns O +
and O +
intergenic O +
regions O -
) O -
. O -

Sixty O +
out O +
of O +
135 O +
PCR O -
- O -
amplified O +
mono- O -
, O +
di- O -
, O +
tri- O -
, O +
tetra O -
, O +
penta O -
, O +
and O +
hexa O -
- O -
nucleotides O +
were O +
polymorphic O +
( O -
44 O -
% O -
) O +
within O +
black B-Species +
truffle L-Species +
populations O +
and O +
27 O +
were O +
randomly O +
selected O +
and O +
analysed O +
on O +
139 O +
T. B-Species +
melanosporum L-Species +
isolates O +
from O +
France O -
, O +
Italy O +
and O +
Spain O -
. O -

The O +
number O +
of O +
alleles O +
varied O +
from O +
2 O +
to O +
18 O +
and O +
the O +
expected O +
heterozygosity O +
from O +
0.124 O +
to O +
0.815 O -
. O -

One O +
hundred O +
and O +
thirty O -
- O -
two O +
different O +
multilocus O +
genotypes O +
out O +
of O +
the O +
139 O +
T. B-Species +
melanosporum L-Species +
isolates O +
were O +
identified O +
and O +
the O +
genotypic O +
diversity O +
was O +
high O +
( O -
0.999 O -
) O -
. O -

Polymorphic O +
SSRs O +
were O +
found O +
in O +
UTR O +
regulatory O +
regions O +
of O +
fruiting O +
bodies O +
and O +
ectomycorrhiza O +
regulated O +
genes O -
, O +
suggesting O +
that O +
they O +
may O +
play O +
a O +
role O +
in O +
phenotypic O +
variation O -
. O -

In O +
conclusion O -
, O +
SSRs O +
developed O +
in O +
this O +
study O +
were O +
highly O +
polymorphic O +
and O +
our O +
results O +
showed O +
that O +
T. B-Species +
melanosporum L-Species +
is O +
a O +
species O +
with O +
an O +
important O +
genetic O +
diversity O -
, O +
which O +
is O +
in O +
agreement O +
with O +
its O +
recently O +
uncovered O +
heterothallic O +
mating O +
system O -
. O +

Complete O +
genome O +
sequences O +
of O +
three O +
Erwinia B-Species +
amylovora L-Species +
phages O +
isolated O +
in O +
north O +
america O +
and O +
a O +
bacteriophage O +
induced O +
from O +
an O +
Erwinia B-Species +
tasmaniensis L-Species +
strain O -
. O +

Fire O +
blight O -
, O +
a O +
plant O +
disease O +
of O +
economic O +
importance O +
caused O +
by O +
Erwinia B-Species +
amylovora L-Species -
, O +
may O +
be O +
controlled O +
by O +
the O +
application O +
of O +
bacteriophages O -
. O -

Here O -
, O +
we O +
provide O +
the O +
complete O +
genome O +
sequences O +
and O +
the O +
annotation O +
of O +
three O +
E. B-Species +
amylovora L-Species -
- O -
specific O +
phages O +
isolated O +
in O +
North O +
America O +
and O +
genomic O +
information O +
about O +
a O +
bacteriophage O +
induced O +
by O +
mitomycin O +
C O +
treatment O +
of O +
an O +
Erwinia B-Species +
tasmaniensis L-Species +
strain O +
that O +
is O +
antagonistic O +
for O +
E. B-Species +
amylovora L-Species -
. O -

The O +
American O +
phages O +
resemble O +
two O +
already O -
- O -
described O +
viral O +
genomes O -
, O +
whereas O +
the O +
E. B-Species +
tasmaniensis L-Species +
phage O +
displays O +
a O +
singular O +
genomic O +
sequence O +
in O +
BLAST O +
searches O -
. O +

Prasinoderma O +
singularis O +
sp. O +
nov. O +
( O -
Prasinophyceae O -
, O +
Chlorophyta O -
) O -
, O +
a O +
solitary O +
coccoid O +
Prasinophyte O +
from O +
the O +
South O -
- O -
East O +
Pacific O +
Ocean O -
. O +

During O +
the O +
BIOSOPE O +
cruise O +
in O +
the O +
South O -
- O -
East O +
Pacific O +
Ocean O +
in O +
2004 O -
, O +
several O +
unidentified O +
strains O +
of O +
prasinophytes O +
were O +
isolated O +
into O +
culture O -
. O -

Of O +
these O -
, O +
nine O +
strains O +
composed O +
a O +
group O +
for O +
which O +
the O +
partial O +
18S O +
rRNA O +
gene O +
sequence O +
was O +
related O +
to O +
Prasinoderma B-Species +
coloniale L-Species -
. O -

The O +
ultrastructure O -
, O +
morphology O -
, O +
division O +
process O -
, O +
pigment O +
composition O -
, O +
genome O +
size O +
and O +
molecular O +
genetic O +
phylogeny O +
of O +
these O +
nine O +
strains O +
were O +
investigated O -
, O +
using O +
P. B-Species +
coloniale L-Species +
as O +
a O +
reference O -
. O -

The O +
18S O +
rRNA O +
gene O +
sequence O +
of O +
P. O +
singularis O +
sp. O +
nov. O +
shares O +
only O +
96.9 O -
% O +
of O +
identity O +
with O +
that O +
of O +
P. B-Species +
coloniale L-Species +
and O +
contains O +
a O +
conserved O +
insertion O +
of O +
567bp O +
length O +
not O +
recorded O +
in O +
P. B-Species +
coloniale L-Species -
. O -

When O +
compared O +
to O +
P. B-Species +
coloniale L-Species -
, O +
P. O +
singularis O +
sp. O +
nov. O +
is O +
morphologically O +
characterized O +
by O +
the O +
absence O +
of O +
colonies O -
, O +
smaller O +
cells O +
with O +
a O +
thinner O +
cell O +
wall O -
, O +
and O +
a O +
second O +
cell O +
type O +
with O +
a O +
different O +
cell O +
covering O -
. O +

Regulation O +
of O +
horizontal O +
gene O +
transfer O +
in O +
Bacillus B-Species +
subtilis L-Species +
by O +
activation O +
of O +
a O +
conserved O +
site O -
- O -
specific O +
protease O -
. O +

The O +
mobile O +
genetic O +
element O +
ICEBs1 O +
is O +
an O +
integrative O +
and O +
conjugative O +
element O +
( O -
a O +
conjugative O +
transposon O -
) O +
found O +
in O +
Bacillus B-Species +
subtilis L-Species -
. O -

The O +
RecA O -
- O -
dependent O +
SOS O +
response O +
and O +
the O +
RapI O -
- O -
PhrI O +
cell O +
sensory O +
system O +
activate O +
ICEBs1 O +
gene O +
expression O +
by O +
stimulating O +
cleavage O +
of O +
ImmR O -
, O +
the O +
ICEBs1 O +
immunity O +
repressor O -
, O +
by O +
the O +
protease O +
ImmA. O +
We O +
found O +
that O +
increasing O +
the O +
amount O +
of O +
wild O -
- O -
type O +
ImmA O +
in O +
vivo O +
caused O +
partial O +
derepression O +
of O +
ICEBs1 O +
gene O +
expression O -
. O -

However O -
, O +
during O +
RapI O -
- O -
mediated O +
derepression O +
of O +
ICEBs1 O +
gene O +
expression O -
, O +
ImmA O +
levels O +
did O +
not O +
detectably O +
increase O -
, O +
indicating O +
that O +
RapI O +
likely O +
activates O +
the O +
protease O +
ImmA O +
by O +
increasing O +
its O +
specific O +
activity O -
. O -

We O +
also O +
isolated O +
and O +
characterized O +
mutations O +
in O +
immA O +
( O -
immA O -
( O -
h O -
) O -
) O +
that O +
cause O +
partial O +
derepression O +
of O +
ICEBs1 O +
gene O +
expression O +
in O +
the O +
absence O +
of O +
inducing O +
signals O -
. O -

We O +
obtained O +
two O +
types O +
of O +
immA O -
( O -
h O -
) O +
mutations O -
: O +
one O +
type O +
caused O +
increased O +
amounts O +
of O +
the O +
mutant O +
proteins O +
in O +
vivo O +
but O +
no O +
detectable O +
effect O +
on O +
specific O +
activity O +
in O +
vitro O -
; O +
the O +
other O +
type O +
had O +
no O +
detectable O +
effect O +
on O +
the O +
amount O +
of O +
the O +
mutant O +
protein O +
in O +
vivo O +
but O +
caused O +
increased O +
specific O +
activity O +
of O +
the O +
protein O +
( O -
as O +
measured O +
in O +
vitro O -
) O -
. O -

Together O -
, O +
these O +
findings O +
indicate O +
that O +
derepression O +
of O +
ICEBs1 O +
gene O +
expression O +
is O +
likely O +
caused O +
by O +
an O +
increase O +
in O +
the O +
specific O +
activity O +
of O +
ImmA. O +
Homologs O +
of O +
ImmA O +
and O +
ImmR O +
are O +
found O +
in O +
many O +
mobile O +
genetic O +
elements O -
, O +
so O +
the O +
mechanisms O +
that O +
regulate O +
ImmA O -
- O -
mediated O +
cleavage O +
of O +
ImmR O +
may O +
be O +
widely O +
conserved O -
. O +

Complete O +
genome O +
sequence O +
of O +
strain O +
HTCC2503 U-Species -
T O +
of O +
Parvularcula B-Species +
bermudensis L-Species -
, O +
the O +
type O +
species O +
of O +
the O +
order O +
Parvularculales O +
in O +
the O +
class O +
Alphaproteobacteria O -
. O +

The O +
order O +
Parvularculales O +
represents O +
the O +
seventh O +
order O +
in O +
the O +
class O +
Alphaproteobacteria O -
. O -

Parvularcula B-Species +
bermudensis L-Species -
, O +
the O +
type O +
species O +
of O +
the O +
order O -
, O +
was O +
isolated O +
from O +
the O +
Sargasso O +
Sea O +
using O +
dilution O -
- O -
to O -
- O -
extinction O +
culturing O -
. O -

We O +
present O +
here O +
the O +
complete O +
genome O +
sequence O +
of O +
Parvularcula B-Species +
bermudensis I-Species +
HTCC2503 I-Species -
( I-Species -
T L-Species -
) O -
, O +
which O +
contains O +
genes O +
for O +
carotenoid O +
biosynthesis O -
, O +
dimethylsulfoniopropionate O +
demethylase O -
, O +
and O +
transduction O -
- O -
like O +
gene O +
transfer O +
agents O -
. O +

argC O +
Orthologs O +
from O +
Rhizobiales O +
show O +
diverse O +
profiles O +
of O +
transcriptional O +
efficiency O +
and O +
functionality O +
in O +
Sinorhizobium B-Species +
meliloti L-Species -
. O +

Several O +
factors O +
can O +
influence O +
ortholog O +
replacement O +
between O +
closely O +
related O +
species O -
. O -

We O +
evaluated O +
the O +
transcriptional O +
expression O +
and O +
metabolic O +
performance O +
of O +
ortholog O +
substitution O +
complementing O +
a O +
Sinorhizobium B-Species +
meliloti L-Species +
argC O +
mutant O +
with O +
argC O +
from O +
Rhizobiales O +
( O -
Agrobacterium B-Species +
tumefaciens L-Species -
, O +
Rhizobium B-Species +
etli L-Species -
, O +
and O +
Mesorhizobium B-Species +
loti L-Species -
) O -
. O -

The O +
argC O +
gene O +
is O +
necessary O +
for O +
the O +
synthesis O +
of O +
arginine O -
, O +
an O +
amino O +
acid O +
that O +
is O +
central O +
to O +
protein O +
and O +
cellular O +
metabolism O -
. O -

Strains O +
were O +
obtained O +
carrying O +
plasmids O +
with O +
argC O +
orthologs O +
expressed O +
under O +
the O +
speB O +
and O +
argC O +
( O -
S. B-Species +
meliloti L-Species -
) O +
and O +
lac O +
( O -
Escherichia B-Species +
coli L-Species -
) O +
promoters O -
. O -

Complementation O +
analysis O +
was O +
assessed O +
by O +
growth O -
, O +
transcriptional O +
activity O -
, O +
enzymatic O +
activity O -
, O +
mRNA O +
levels O -
, O +
specific O +
detection O +
of O +
ArgC O +
proteomic O +
protein O -
, O +
and O +
translational O +
efficiency O -
. O -

The O +
argC O +
orthologs O +
performed O +
differently O +
in O +
each O +
complementation O -
, O +
reflecting O +
the O +
diverse O +
factors O +
influencing O +
gene O +
expression O +
and O +
the O +
ability O +
of O +
the O +
ortholog O +
product O +
to O +
function O +
in O +
a O +
foreign O +
metabolic O +
background O -
. O -

Optimal O +
complementation O +
was O +
directly O +
related O +
to O +
sequence O +
similarity O +
with O +
S. B-Species +
meliloti L-Species -
, O +
and O +
was O +
inversely O +
related O +
to O +
species O +
signature O -
, O +
with O +
M. B-Species +
loti L-Species +
argC O +
showing O +
the O +
poorest O +
performance O -
, O +
followed O +
by O +
R. B-Species +
etli L-Species +
and O +
A. B-Species +
tumefaciens L-Species -
. O -

Different O +
copy O +
numbers O +
of O +
genes O +
and O +
amounts O +
of O +
mRNA O +
and O +
protein O +
were O +
produced O -
, O +
even O +
with O +
genes O +
transcribed O +
from O +
the O +
same O +
promoter O -
, O +
indicating O +
that O +
coding O +
sequences O +
play O +
a O +
role O +
in O +
the O +
transcription O +
and O +
translation O +
processes O -
. O -

These O +
results O +
provide O +
relevant O +
information O +
for O +
further O +
genomic O +
analyses O +
and O +
suggest O +
that O +
orthologous O +
gene O +
substitutions O +
between O +
closely O +
related O +
species O +
are O +
not O +
completely O +
functionally O +
equivalent O -
. O +

Complete O +
genome O +
sequence O +
of O +
strain O +
HTCC2170 U-Species -
, O +
a O +
novel O +
member O +
of O +
the O +
genus O +
Maribacter O +
in O +
the O +
family O +
Flavobacteriaceae O -
. O +

Strain O +
HTCC2170 U-Species +
was O +
isolated O +
from O +
surface O +
waters O +
off O +
the O +
Oregon O +
coast O +
using O +
dilution O -
- O -
to O -
- O -
extinction O +
culturing O -
. O -

Here O -
, O +
we O +
present O +
the O +
finished O +
genome O +
sequence O +
of O +
a O +
marine B-Species +
bacterium L-Species -
, O +
Maribacter B-Species +
sp. I-Species +
strain I-Species +
HTCC2170 L-Species -
. O -

Strain O +
sp. O +
HTCC2170 U-Species +
is O +
predicted O +
to O +
be O +
a O +
facultatively O +
aerobic O +
chemoorganotroph O +
that O -
, O +
based O +
on O +
genomic O +
sequence O +
analysis O -
, O +
is O +
capable O +
of O +
macromolecule O +
degradation O +
and O +
anaerobic O +
respiration O -
. O +

Flavobacterium B-Species +
ponti I-Species +
sp. I-Species +
nov. L-Species -
, O +
isolated O +
from O +
seawater O -
. O -

A O +
Gram O -
- O -
stain O -
- O -
negative O -
, O +
non O -
- O -
flagellated O -
, O +
non O -
- O -
gliding O -
, O +
yellow O -
- O -
pigmented O +
and O +
rod O -
- O -
shaped O +
bacterial O +
strain O -
, O +
designated O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O -
, O +
was O +
isolated O +
from O +
seawater O +
of O +
Geoje O +
Island O +
in O +
the O +
South O +
Sea O -
, O +
Korea O -
. O -

Strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
grew O +
optimally O +
at O +
25 O +
^0C O -
, O +
at O +
pH O +
7.0 O -
- O -
8.0 O +
and O +
in O +
the O +
presence O +
of O +
2 O +
% O +
( O -
w O -
/ O -
v O -
) O +
NaCl O -
. O -

Phylogenetic O +
analyses O +
based O +
on O +
16S O +
rRNA O +
gene O +
sequences O +
showed O +
that O +
strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
belonged O +
to O +
the O +
genus O +
Flavobacterium O -
, O +
joining O +
Flavobacterium B-Species +
gelidilacus L-Species +
LMG O +
21477 O -
( O -
T O -
) O +
by O +
a O +
bootstrap O +
resampling O +
value O +
of O +
100 O +
% O -
. O -

Strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
exhibited O +
97.6 O +
% O +
16S O +
rRNA O +
gene O +
sequence O +
similarity O +
to O +
F. B-Species +
gelidilacus L-Species +
LMG O +
21477 O -
( O -
T O -
) O +
and O +
similarities O +
of O +
91.2 O -
- O -
95.2 O +
% O +
to O +
other O +
members O +
of O +
the O +
genus O +
Flavobacterium O -
. O -

Strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
contained O +
MK-6 O +
as O +
the O +
predominant O +
menaquinone O -
. O -

The O +
fatty O +
acid O +
profile O +
of O +
strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
was O +
similar O +
to O +
that O +
of O +
F. B-Species +
gelidilacus L-Species +
LMG O +
21477 O -
( O -
T O -
) O -
. O -

The O +
DNA O +
G+C O +
content O +
of O +
strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
was O +
31.4 O +
mol% O +
and O +
its O +
DNA O -
- O -
DNA O +
relatedness O +
with O +
F. B-Species +
gelidilacus L-Species +
LMG O +
21477 O -
( O -
T O -
) O +
was O +
31 O +
% O -
. O -

Strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
could O +
be O +
distinguished O +
from O +
F. B-Species +
gelidilacus L-Species +
and O +
the O +
other O +
species O +
of O +
the O +
genus O +
Flavobacterium O +
by O +
its O +
phylogenetic O +
and O +
genetic O +
distinctiveness O +
and O +
by O +
several O +
phenotypic O +
properties O -
. O -

On O +
the O +
basis O +
of O +
these O +
data O -
, O +
strain O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
is O +
considered O +
to O +
represent O +
a O +
novel O +
species O +
of O +
the O +
genus O +
Flavobacterium O -
, O +
for O +
which O +
the O +
name O +
Flavobacterium B-Species +
ponti I-Species +
sp. I-Species +
nov. L-Species +
is O +
proposed O -
; O +
the O +
type O +
strain O +
is O +
GSW B-Species -
- I-Species -
R14 L-Species -
( O -
T O -
) O +
( O -
= O -
KCTC O +
22802 O -
( O -
T O -
) O +
= O -
CCUG O +
58402 O -
( O -
T O -
) O -
) O -
. O +

The O +
small O +
GTPase O +
BcCdc42 O +
affects O +
nuclear O +
division O -
, O +
germination O +
and O +
virulence O +
of O +
the O +
gray O +
mold O +
fungus O +
Botrytis B-Species +
cinerea L-Species -
. O +

The O +
small O +
GTPase O +
Cdc42 O +
plays O +
a O +
central O +
role O +
in O +
various O +
processes O +
in O +
eukaryotic O +
cells O +
including O +
growth O -
, O +
differentiation O +
and O +
cytoskeleton O +
organization O -
. O -

Whereas O +
it O +
is O +
essential O +
in O +
the O +
yeast U-Species +
Saccharomyces B-Species +
cerevisiae L-Species -
, O +
its O +
role O +
in O +
filamentous O +
fungi O +
differs O -
, O +
due O +
to O +
the O +
complementing O -
, O +
partly O +
overlapping O +
function O +
of O +
Rac O -
. O -

We O +
analyzed O +
the O +
role O +
of O +
the O +
Cdc42 O +
homologue O +
in O +
the O +
necrotrophic O -
, O +
broad O +
host O +
range O +
pathogen O +
Botrytis B-Species +
cinerea L-Species -
. O -

Deletion O +
mutants O +
of O +
bccdc42 O +
showed O +
various O +
growth O +
abnormalities O -
; O +
the O +
mutants O +
had O +
reduced O +
growth O +
rate O +
and O +
hyphal O +
branching O -
, O +
they O +
produced O +
fewer O +
conidia O -
, O +
which O +
were O +
enlarged O +
and O +
misshapen O +
and O +
had O +
germination O +
defects O -
. O -

Additionally O -
, O +
the O +
mutants O +
were O +
impaired O +
in O +
sclerotia O +
development O -
. O -

Cytological O +
studies O +
indicate O +
that O +
at O +
least O +
part O +
of O +
this O +
phenotype O +
could O +
be O +
attributed O +
to O +
disturbed O +
control O +
of O +
nuclear O +
division O -
: O +
conidia O +
and O +
hyphae O +
of O +
the O +
mutant O +
showed O +
twofold O +
higher O +
nucleus O -
/ O -
cytoplasm O +
ratio O +
compared O +
to O +
wild O +
type O +
cells O -
. O -

Apart O +
from O +
these O +
effects O +
on O +
vegetative O +
growth O +
and O +
differentiation O -
, O +
Deltabccdc42 O +
strains O +
were O +
attenuated O +
in O +
penetration O +
and O +
colonization O +
of O +
host O +
tissue O -
, O +
confirming O +
that O +
BcCdc42 O +
- O +
though O +
being O +
not O +
essential O +
like O +
in O +
yeast U-Species +
- O +
is O +
involved O +
in O +
important O +
developmental O +
processes O +
in O +
B. B-Species +
cinerea L-Species -
. O +

Human U-Species +
resources O +
for O +
health O +
in O +
India O -
. O -

India O +
has O +
a O +
severe O +
shortage O +
of O +
human U-Species +
resources O +
for O +
health O -
. O -

It O +
has O +
a O +
shortage O +
of O +
qualified O +
health O +
workers O +
and O +
the O +
workforce O +
is O +
concentrated O +
in O +
urban O +
areas O -
. O -

Bringing O +
qualified O +
health O +
workers O +
to O +
rural O -
, O +
remote O -
, O +
and O +
underserved O +
areas O +
is O +
very O +
challenging O -
. O -

Many O +
Indians O -
, O +
especially O +
those O +
living O +
in O +
rural O +
areas O -
, O +
receive O +
care O +
from O +
unqualified O +
providers O -
. O -

The O +
migration O +
of O +
qualified O +
allopathic O +
doctors O +
and O +
nurses O +
is O +
substantial O +
and O +
further O +
strains O +
the O +
system O -
. O -

Nurses O +
do O +
not O +
have O +
much O +
authority O +
or O +
say O +
within O +
the O +
health O +
system O -
, O +
and O +
the O +
resources O +
to O +
train O +
them O +
are O +
still O +
inadequate O -
. O -

Little O +
attention O +
is O +
paid O +
during O +
medical O +
education O +
to O +
the O +
medical O +
and O +
public O +
health O +
needs O +
of O +
the O +
population O -
, O +
and O +
the O +
rapid O +
privatisation O +
of O +
medical O +
and O +
nursing O +
education O +
has O +
implications O +
for O +
its O +
quality O +
and O +
governance O -
. O -

Such O +
issues O +
are O +
a O +
result O +
of O +
underinvestment O +
in O +
and O +
poor O +
governance O +
of O +
the O +
health O +
sector O -
-- O -
two O +
issues O +
that O +
the O +
government O +
urgently O +
needs O +
to O +
address O -
. O -

A O +
comprehensive O +
national O +
policy O +
for O +
human U-Species +
resources O +
is O +
needed O +
to O +
achieve O +
universal O +
health O +
care O +
in O +
India O -
. O -

The O +
public O +
sector O +
will O +
need O +
to O +
redesign O +
appropriate O +
packages O +
of O +
monetary O +
and O +
non O -
- O -
monetary O +
incentives O +
to O +
encourage O +
qualified O +
health O +
workers O +
to O +
work O +
in O +
rural O +
and O +
remote O +
areas O -
. O -

Such O +
a O +
policy O +
might O +
also O +
encourage O +
task O -
- O -
shifting O +
and O +
mainstreaming O +
doctors O +
and O +
practitioners O +
who O +
practice O +
traditional O +
Indian O +
medicine O +
( O -
ayurveda O -
, O +
yoga O +
and O +
naturopathy O -
, O +
unani O -
, O +
and O +
siddha O -
) O +
and O +
homoeopathy O +
to O +
work O +
in O +
these O +
areas O +
while O +
adopting O +
other O +
innovative O +
ways O +
of O +
augmenting O +
human U-Species +
resources O +
for O +
health O -
. O -

At O +
the O +
same O +
time O -
, O +
additional O +
investments O +
will O +
be O +
needed O +
to O +
improve O +
the O +
relevance O -
, O +
quantity O -
, O +
and O +
quality O +
of O +
nursing O -
, O +
medical O -
, O +
and O +
public O +
health O +
education O +
in O +
the O +
country O -
. O +

Continuing O +
challenge O +
of O +
infectious O +
diseases O +
in O +
India O -
. O -

In O +
India O -
, O +
the O +
range O +
and O +
burden O +
of O +
infectious O +
diseases O +
are O +
enormous O -
. O -

The O +
administrative O +
responsibilities O +
of O +
the O +
health O +
system O +
are O +
shared O +
between O +
the O +
central O +
( O -
federal O -
) O +
and O +
state O +
governments O -
. O -

Control O +
of O +
diseases O +
and O +
outbreaks O +
is O +
the O +
responsibility O +
of O +
the O +
central O +
Ministry O +
of O +
Health O -
, O +
which O +
lacks O +
a O +
formal O +
public O +
health O +
department O +
for O +
this O +
purpose O -
. O -

Tuberculosis O -
, O +
malaria O -
, O +
filariasis O -
, O +
visceral O +
leishmaniasis O -
, O +
leprosy O -
, O +
HIV U-Species +
infection O -
, O +
and O +
childhood O +
cluster O +
of O +
vaccine O -
- O -
preventable O +
diseases O +
are O +
given O +
priority O +
for O +
control O +
through O +
centrally O +
managed O +
vertical O +
programmes O -
. O -

Control O +
of O +
HIV U-Species +
infection O +
and O +
leprosy O -
, O +
but O +
not O +
of O +
tuberculosis O -
, O +
seems O +
to O +
be O +
on O +
track O -
. O -

Early O +
success O +
of O +
malaria O +
control O +
was O +
not O +
sustained O -
, O +
and O +
visceral O +
leishmaniasis O +
prevalence O +
has O +
increased O -
. O -

Inadequate O +
containment O +
of O +
the O +
vector O +
has O +
resulted O +
in O +
recurrent O +
outbreaks O +
of O +
dengue O +
fever O +
and O +
re O -
- O -
emergence O +
of O +
Chikungunya B-Species +
virus L-Species +
disease O +
and O +
typhus O +
fever O -
. O -

Other O +
infectious O +
diseases O +
caused O +
by O +
faecally O +
transmitted O +
pathogens O +
( O -
enteric O +
fevers O -
, O +
cholera O -
, O +
hepatitis U-Species +
A O +
and O +
E B-Species +
viruses L-Species -
) O +
and O +
zoonoses O +
( O -
rabies O -
, O +
leptospirosis O -
, O +
anthrax O -
) O +
are O +
not O +
in O +
the O +
process O +
of O +
being O +
systematically O +
controlled O -
. O -

Big O +
gaps O +
in O +
the O +
surveillance O +
and O +
response O +
system O +
for O +
infectious O +
diseases O +
need O +
to O +
be O +
addressed O -
. O -

Replication O +
of O +
the O +
model O +
of O +
vertical O +
single O -
- O -
disease O +
control O +
for O +
all O +
infectious O +
diseases O +
will O +
not O +
be O +
efficient O +
or O +
viable O -
. O -

India O +
needs O +
to O +
rethink O +
and O +
revise O +
its O +
health O +
policy O +
to O +
broaden O +
the O +
agenda O +
of O +
disease O +
control O -
. O -

A O +
comprehensive O +
review O +
and O +
redesign O +
of O +
the O +
health O +
system O +
is O +
needed O +
urgently O +
to O +
ensure O +
equity O +
and O +
quality O +
in O +
health O +
care O -
. O -

We O +
recommend O +
the O +
creation O +
of O +
a O +
functional O +
public O +
health O +
infrastructure O +
that O +
is O +
shared O +
between O +
central O +
and O +
state O +
governments O -
, O +
with O +
professional O +
leadership O +
and O +
a O +
formally O +
trained O +
public O +
health O +
cadre O +
of O +
personnel O +
who O +
manage O +
an O +
integrated O +
control O +
mechanism O +
of O +
diseases O +
in O +
districts O +
that O +
includes O +
infectious O +
and O +
non O -
- O -
infectious O +
diseases O -
, O +
and O +
injuries O -
. O +

Negotiating O +
a O +
noisy O -
, O +
information O -
- O -
rich O +
environment O +
in O +
search O +
of O +
cryptic O +
prey O -
: O +
olfactory O +
predators O +
need O +
patchiness O +
in O +
prey O +
cues O -
. O +

1 O -
. O -

Olfactory O +
predator O +
search O +
processes O +
differ O +
fundamentally O +
to O +
those O +
based O +
on O +
vision O -
, O +
particularly O +
when O +
odour O +
cues O +
are O +
deposited O +
rather O +
than O +
airborne O +
or O +
emanating O +
from O +
a O +
point O +
source O -
. O -

When O +
searching O +
for O +
visually O +
cryptic O +
prey O +
that O +
may O +
have O +
moved O +
some O +
distance O +
from O +
a O +
deposited O +
odour O +
cue O -
, O +
cue O +
context O +
and O +
spatial O +
variability O +
are O +
the O +
most O +
likely O +
sources O +
of O +
information O +
about O +
prey O +
location O +
available O +
to O +
an O +
olfactory O +
predator O -
. O -

2 O -
. O -

We O +
tested O +
whether O +
the O +
house B-Species +
mouse L-Species +
( O -
Mus B-Species +
domesticus L-Species -
) O -
, O +
a O +
model O +
olfactory O +
predator O -
, O +
would O +
use O +
cue O +
context O +
and O +
spatial O +
variability O +
when O +
searching O +
for O +
buried O +
food O +
items O -
; O +
specifically O -
, O +
we O +
tested O +
the O +
effect O +
of O +
varying O +
cue O +
patchiness O -
, O +
odour O +
strength O -
, O +
and O +
cue O -
- O -
prey O +
association O +
on O +
mouse U-Species +
foraging O +
success O -
. O -

3 O -
. O -

Within O +
mouse- U-Species +
and O +
predator O -
- O -
proof O +
enclosures O -
, O +
we O +
created O +
grids O +
of O +
100 O +
sand O -
- O -
filled O +
Petri O +
dishes O +
and O +
buried O +
peanut U-Species +
pieces O +
in O +
a O +
set O +
number O +
of O +
these O +
patches O +
to O +
represent O +
visually O +
cryptic O +
' O -
prey O -
' O -
. O -

By O +
adding O +
peanut U-Species +
oil O +
to O +
selected O +
dishes O -
, O +
we O +
varied O +
the O +
spatial O +
distribution O +
of O +
prey O +
odour O +
relative O +
to O +
the O +
distribution O +
of O +
prey O +
patches O +
in O +
each O +
grid O -
, O +
to O +
reflect O +
different O +
levels O +
of O +
cue O +
patchiness O +
( O -
Experiment O +
1 O -
) O -
, O +
odour O +
strength O +
( O -
Experiment O +
2 O -
) O +
and O +
cue O -
- O -
prey O +
association O +
( O -
Experiment O +
3 O -
) O -
. O -

We O +
measured O +
the O +
overnight O +
foraging O +
success O +
of O +
individual O +
mice U-Species +
( O -
percentage O +
of O +
searched O +
patches O +
containing O +
prey O -
) O -
, O +
as O +
well O +
as O +
their O +
foraging O +
activity O +
( O -
percentage O +
of O +
patches O +
searched O -
) O -
, O +
and O +
prey O +
survival O +
( O -
percentage O +
of O +
unsearched O +
prey O +
patches O -
) O -
. O -

4 O -
. O -

Mouse U-Species +
foraging O +
success O +
was O +
highest O +
where O +
odour O +
cues O +
were O +
patchy O +
rather O +
than O +
uniform O +
( O -
Experiment O +
1 O -
) O -
, O +
and O +
where O +
cues O +
were O +
tightly O +
associated O +
with O +
prey O +
location O -
, O +
rather O +
than O +
randomly O +
or O +
uniformly O +
distributed O +
( O -
Experiment O +
3 O -
) O -
. O -

However O -
, O +
when O +
cues O +
at O +
prey O +
patches O +
were O +
ten O +
times O +
stronger O +
than O +
a O +
uniformly O +
distributed O +
weak O +
background O +
odour O -
, O +
mice U-Species +
did O +
not O +
improve O +
their O +
foraging O +
success O +
over O +
that O +
experienced O +
when O +
cues O +
were O +
of O +
uniform O +
strength O +
and O +
distribution O +
( O -
Experiment O +
2 O -
) O -
. O -

5 O -
. O -

These O +
results O +
suggest O +
that O +
spatial O +
variability O +
and O +
cue O +
context O +
are O +
important O +
means O +
by O +
which O +
olfactory O +
predators O +
can O +
use O +
deposited O +
odour O +
cues O +
to O +
locate O +
visually O +
cryptic O +
prey O -
. O -

They O +
also O +
indicate O +
that O +
chemical O +
crypsis O +
can O +
disrupt O +
these O +
search O +
processes O +
as O +
effectively O +
as O +
background O +
matching O +
in O +
visually O +
based O +
predator O -
- O -
prey O +
systems O -
. O +

Comparison O +
of O +
transgene O +
expression O +
in O +
Aedes B-Species +
aegypti L-Species +
generated O +
by O +
mariner O +
Mos1 O +
transposition O +
and O +
PhiC31 O +
site O -
- O -
directed O +
recombination O -
. O +

Transgenic O +
mosquitoes O +
generated O +
by O +
transposable O +
elements O +
( O -
TEs O -
) O +
often O +
poorly O +
express O +
transgenes O +
owing O +
to O +
position O +
effects O -
. O -

To O +
avoid O +
these O +
effects O -
, O +
the O +
PhiC31 O +
site O -
- O -
directed O +
recombination O +
system O +
was O +
used O +
to O +
insert O +
transgenes O +
into O +
a O +
locus O +
favourable O +
for O +
gene O +
expression O +
in O +
Aedes B-Species +
aegypti L-Species -
. O -

We O +
describe O +
phenotypes O +
of O +
mariner O +
Mos1 O +
TE O +
and O +
PhiC31 O +
transgenic O +
mosquitoes O +
expressing O +
the O +
enhanced O +
green O +
fluorescent O +
protein O +
( O -
EGFP O -
) O +
reporter O +
in O +
midguts O +
of O +
blood O -
- O -
fed O +
females O -
. O -

Mosquitoes O +
of O +
nine O +
TE O -
- O -
generated O +
lines O +
[ O -
estimated O +
transformation O +
frequency O +
( O -
TF O -
) O -
: O +
9.3 O -
% O -
] O +
clearly O +
expressed O +
the O +
eye O -
- O -
specific O +
selection O +
marker O +
but O +
only O +
2 O -
/ O -
9 O +
lines O +
robustly O +
expressed O +
the O +
EGFP O +
reporter O -
. O -

The O +
piggyBac O +
TE O -
- O -
generated O +
PhiC31 O +
docking O +
strain O -
, O +
attP26 O -
, O +
supported O +
recombination O +
with O +
attB O +
site O +
containing O +
donors O +
at O +
an O +
estimated O +
TF O +
of O +
1.7 O -
- O -
4.9 O -
% O -
. O -

Using O +
a O +
codon O -
- O -
optimized O +
PhiC31 O +
integrase O +
mutant O +
instead O +
of O +
the O +
' O -
wild O -
- O -
type O -
' O +
enzyme O +
did O +
not O +
affect O +
TF O -
. O -

Site O -
- O -
directed O +
recombination O +
of O +
line O +
attP26 O +
with O +
an O +
attB O -
- O -
containing O +
donor O +
expressing O +
EGFP O +
from O +
the O +
Ae B-Species -
. L-Species -

aegypti U-Species +
carboxypeptidase O +
promoter O +
produced O +
one O +
transgenic O +
line O +
with O +
blood O -
- O -
fed O +
females O +
expressing O +
the O +
reporter O +
in O +
midgut O +
tissue O -
. O -

Docking O +
strain O +
attP26 O +
also O +
supported O +
robust O +
expression O +
of O +
Flock B-Species +
House I-Species +
virus I-Species +
B2 L-Species +
from O +
the O +
Ae B-Species -
. L-Species -

aegypti U-Species +
polyubiquitin O +
promoter O -
. O -

Our O +
data O +
confirm O +
that O +
eye O -
- O -
specific O +
selection O +
marker O +
expression O +
alone O +
is O +
not O +
a O +
reliable O +
indicator O +
for O +
robust O +
gene O -
- O -
of O -
- O -
interest O +
expression O +
in O +
Ae B-Species -
. L-Species -

aegypti U-Species +
and O +
that O +
the O +
PhiC31 O +
system O +
can O +
ensure O +
predictable O +
transgene O +
expression O +
in O +
this O +
mosquito O +
species O -
. O +

Citrate O +
uptake O +
in O +
exchange O +
with O +
intermediates O +
in O +
the O +
citrate O +
metabolic O +
pathway O +
in O +
Lactococcus B-Species +
lactis L-Species +
IL1403 O -
. O +

Carbohydrate O -
/ O -
citrate O +
cometabolism O +
in O +
Lactococcus B-Species +
lactis L-Species +
results O +
in O +
the O +
formation O +
of O +
the O +
flavor O +
compound O +
acetoin O -
. O -

Resting O +
cells O +
of O +
strain O +
IL1403 U-Species -
( O -
pFL3 O -
) O +
rapidly O +
consumed O +
citrate O +
while O +
producing O +
acetoin O +
when O +
substoichiometric O +
concentrations O +
of O +
glucose O +
or O +
l O -
- O -
lactate O +
were O +
present O -
. O -

A O +
proton O +
motive O +
force O +
was O +
generated O +
by O +
electrogenic O +
exchange O +
of O +
citrate O +
and O +
lactate O +
catalyzed O +
by O +
the O +
citrate O +
transporter O +
CitP O +
and O +
proton O +
consumption O +
in O +
decarboxylation O +
reactions O +
in O +
the O +
pathway O -
. O -

In O +
the O +
absence O +
of O +
glucose O +
or O +
l O -
- O -
lactate O -
, O +
citrate O +
consumption O +
was O +
biphasic O -
. O -

During O +
the O +
first O +
phase O -
, O +
hardly O +
any O +
citrate O +
was O +
consumed O -
. O -

In O +
the O +
second O +
phase O -
, O +
citrate O +
was O +
converted O +
rapidly O -
, O +
but O +
without O +
the O +
formation O +
of O +
acetoin O -
. O -

Instead O -
, O +
significant O +
amounts O +
of O +
the O +
intermediates O +
pyruvate O +
and O +
alpha O -
- O -
acetolactate O -
, O +
and O +
the O +
end O +
product O +
acetate O -
, O +
were O +
excreted O +
from O +
the O +
cells O -
. O -

It O +
is O +
shown O +
that O +
the O +
intermediates O +
and O +
acetate O +
are O +
excreted O +
in O +
exchange O +
with O +
the O +
uptake O +
of O +
citrate O +
catalyzed O +
by O +
CitP. O +
The O +
availability O +
of O +
exchangeable O +
substrates O +
in O +
the O +
cytoplasm O +
determines O +
both O +
the O +
rate O +
of O +
citrate O +
consumption O +
and O +
the O +
end O +
product O +
profile O -
. O -

It O +
follows O +
that O +
citrate O +
metabolism O +
in O +
L. B-Species +
lactis L-Species +
IL1403 O -
( O -
pFL3 O -
) O +
splits O +
up O +
in O +
two O +
routes O +
after O +
the O +
formation O +
of O +
pyruvate O -
, O +
one O +
the O +
well O -
- O -
characterized O +
route O +
yielding O +
acetoin O +
and O +
the O +
other O +
a O +
new O +
route O +
yielding O +
acetate O -
. O -

The O +
flux O +
distribution O +
between O +
the O +
two O +
branches O +
changes O +
from O +
85:15 O +
in O +
the O +
presence O +
of O +
l O -
- O -
lactate O +
to O +
30:70 O +
in O +
the O +
presence O +
of O +
pyruvate O -
. O -

The O +
proton O +
motive O +
force O +
generated O +
was O +
greatest O +
in O +
the O +
presence O +
of O +
l O -
- O -
lactate O +
and O +
zero O +
in O +
the O +
presence O +
of O +
pyruvate O -
, O +
suggesting O +
that O +
the O +
pathway O +
to O +
acetate O +
does O +
not O +
generate O +
proton O +
motive O +
force O -
. O +

OsHMA3 O -
, O +
a O +
P1B O -
- O -
type O +
of O +
ATPase O +
affects O +
root O -
- O -
to O -
- O -
shoot O +
cadmium O +
translocation O +
in O +
rice U-Species +
by O +
mediating O +
efflux O +
into O +
vacuoles O -
. O +

* O +
The O +
cadmium O +
( O -
Cd O -
) O +
over O -
- O -
accumulating O +
rice U-Species +
( O -
Oryza B-Species +
sativa L-Species -
) O +
cv B-Species +
Cho I-Species -
- I-Species -
Ko I-Species -
- I-Species -
Koku L-Species +
was O +
previously O +
shown O +
to O +
have O +
an O +
enhanced O +
rate O +
of O +
root O -
- O -
to O -
- O -
shoot O +
Cd O +
translocation O -
. O -

This O +
trait O +
is O +
controlled O +
by O +
a O +
single O +
recessive O +
allele O +
located O +
at O +
qCdT7 O -
. O -

* O +
In O +
this O +
study O -
, O +
using O +
positional O +
cloning O +
and O +
transgenic O +
strategies O -
, O +
heavy O +
metal O +
ATPase O +
3 O +
( O -
OsHMA3 O -
) O +
was O +
identified O +
as O +
the O +
gene O +
that O +
controls O +
root O -
- O -
to O -
- O -
shoot O +
Cd O +
translocation O +
rates O -
. O -

The O +
subcellular O +
localization O +
and O +
Cd O -
- O -
transporting O +
activity O +
of O +
the O +
gene O +
products O +
were O +
also O +
investigated O -
. O -

* O +
The O +
allele O +
of O +
OsHMA3 O +
that O +
confers O +
high O +
root O -
- O -
to O -
- O -
shoot O +
Cd O +
translocation O +
rates O +
( O -
OsHMA3mc O -
) O +
encodes O +
a O +
defective O +
P O -
( O -
1B O -
) O +
-ATPase O +
transporter O -
. O -

OsHMA3 O +
fused O +
to O +
green O +
fluorescent O +
protein O +
was O +
localized O +
to O +
vacuolar O +
membranes O +
in O +
plants O +
and O +
yeast U-Species -
. O -

An O +
OsHMA3 O +
transgene O +
complemented O +
Cd O +
sensitivity O +
in O +
a O +
yeast U-Species +
mutant O +
that O +
lacks O +
the O +
ability O +
to O +
transport O +
Cd O +
into O +
vacuoles O -
. O -

By O +
contrast O -
, O +
OsHMA3mc O +
did O +
not O +
complement O +
the O +
Cd O +
sensitivity O +
of O +
this O +
yeast U-Species +
mutant O -
, O +
indicating O +
that O +
the O +
OsHMA3mc O +
transport O +
function O +
was O +
lost O -
. O -

* O +
We O +
propose O +
that O +
the O +
root O +
cell O +
cytoplasm O +
of O +
Cd O -
- O -
overaccumulating O +
rice B-Species +
plants L-Species +
has O +
more O +
Cd O +
available O +
for O +
loading O +
into O +
the O +
xylem O +
as O +
a O +
result O +
of O +
the O +
lack O +
of O +
OsHMA3-mediated O +
transportation O +
of O +
Cd O +
to O +
the O +
vacuoles O -
. O -

This O +
defect O +
results O +
in O +
Cd O +
translocation O +
to O +
the O +
shoots O +
in O +
higher O +
concentrations O -
. O -

These O +
data O +
demonstrate O +
the O +
importance O +
of O +
vacuolar O +
sequestration O +
for O +
Cd O +
accumulation O +
in O +
rice U-Species -
. O +

Functional O +
and O +
phylogenetic O +
analysis O +
of O +
ureD O +
in O +
Shiga O +
toxin O -
- O -
producing O +
Escherichia B-Species +
coli L-Species -
. O +

Enterohemorrhagic O +
Escherichia B-Species +
coli L-Species +
( O -
EHEC U-Species -
) O +
is O +
a O +
food O -
- O -
borne O +
pathogen O +
that O +
can O +
cause O +
severe O +
health O +
complications O +
and O +
utilizes O +
a O +
much O +
lower O +
infectious O +
dose O +
than O +
other O +
E. B-Species +
coli L-Species +
pathotypes O -
. O -

Despite O +
having O +
an O +
intact O +
ure O +
locus O -
, O +
ureDABCEFG O -
, O +
the O +
majority O +
of O +
EHEC U-Species +
strains O +
are O +
phenotypically O +
urease O +
negative O +
under O +
tested O +
conditions O -
. O -

Urease O +
activity O +
potentially O +
assists O +
with O +
survival O +
fitness O +
by O +
enhancing O +
acid O +
tolerance O +
during O +
passage O +
through O +
the O +
stomach O +
or O +
by O +
aiding O +
with O +
colonization O +
in O +
either O +
human U-Species +
or O +
animal O +
reservoirs O -
. O -

Previously O -
, O +
in O +
the O +
EHEC B-Species +
O157 I-Species -
: I-Species -
H7 L-Species +
Sakai O +
strain O -
, O +
a O +
point O +
mutation O +
in O +
ureD O -
, O +
encoding O +
a O +
urease O +
chaperone O +
protein O -
, O +
was O +
identified O -
, O +
resulting O +
in O +
a O +
substitution O +
of O +
an O +
amber O +
stop O +
codon O +
for O +
glutamine O -
. O -

This O +
single O +
nucleotide O +
polymorphism O +
( O -
SNP O -
) O +
is O +
observed O +
in O +
the O +
majority O +
of O +
EHEC B-Species +
O157 I-Species -
: I-Species -
H7 L-Species +
isolates O +
and O +
correlates O +
with O +
a O +
negative O +
urease O +
phenotype O +
in O +
vitro O -
. O -

We O +
demonstrate O +
that O +
the O +
lack O +
of O +
urease O +
activity O +
in O +
vitro O +
is O +
not O +
solely O +
due O +
to O +
the O +
amber O +
codon O +
in O +
ureD. O +
Our O +
analysis O +
has O +
identified O +
two O +
additional O +
SNPs O +
in O +
ureD O +
affecting O +
amino O +
acid O +
positions O +
38 O +
and O +
205 O -
, O +
in O +
both O +
cases O +
determining O +
whether O +
the O +
encoded O +
amino O +
acid O +
is O +
leucine O +
or O +
proline O -
. O -

Phylogenetic O +
analysis O +
based O +
on O +
Ure O +
protein O +
sequences O +
from O +
a O +
variety O +
of O +
urease O -
- O -
encoding O +
bacteria O +
demonstrates O +
that O +
the O +
proline O +
at O +
position O +
38 O +
is O +
highly O +
conserved O +
among O +
Gram O -
- O -
negative O +
bacteria O -
. O -

Experiments O +
reveal O +
that O +
the O +
L38P O +
substitution O +
enhances O +
urease O +
enzyme O +
activity O -
; O +
however O -
, O +
the O +
L205P O +
substitution O +
does O +
not O -
. O -

Multilocus O +
sequence O +
typing O +
analysis O +
for O +
a O +
variety O +
of O +
Shiga O +
toxin O -
- O -
producing O +
E. B-Species +
coli L-Species +
isolates O +
combined O +
with O +
the O +
ureD O +
sequence O +
reveals O +
that O +
except O +
for O +
a O +
subset O +
of O +
the O +
O157 B-Species -
: I-Species -
H7 L-Species +
strains O -
, O +
neither O +
the O +
in O +
vitro O +
urease O -
- O -
positive O +
phenotype O +
nor O +
the O +
ureD O +
sequence O +
is O +
phylogenetically O +
restricted O -
. O +

Genome O -
- O -
wide O +
identification O +
of O +
Mycobacterium B-Species +
tuberculosis L-Species +
exported O +
proteins O +
with O +
roles O +
in O +
intracellular O +
growth O -
. O +

The O +
exported O +
proteins O +
of O +
Mycobacterium B-Species +
tuberculosis L-Species +
that O +
are O +
localized O +
at O +
the O +
bacterial O +
cell O +
surface O +
or O +
secreted O +
into O +
the O +
environment O +
are O +
ideally O +
situated O +
to O +
interact O +
with O +
host O +
factors O +
and O +
to O +
function O +
in O +
virulence O -
. O -

In O +
this O +
study O -
, O +
we O +
constructed O +
a O +
novel O +
Beta O -
- O -
lactamase O +
reporter O +
transposon O +
and O +
used O +
it O +
directly O +
in O +
M. B-Species +
tuberculosis L-Species +
for O +
genome O -
- O -
wide O +
identification O +
of O +
exported O +
proteins O -
. O -

From O +
177 O +
Beta O -
- O -
lactam O -
- O -
resistant O +
transposon O +
mutants O -
, O +
we O +
identified O +
111 O +
different O +
exported O +
proteins O -
. O -

The O +
majority O +
of O +
these O +
proteins O +
have O +
no O +
known O +
function O -
, O +
and O +
for O +
nearly O +
half O +
of O +
the O +
proteins O -
, O +
our O +
demonstration O +
that O +
they O +
are O +
exported O +
when O +
fused O +
to O +
a O +
Beta O -
- O -
lactamase O +
reporter O +
is O +
the O +
first O +
experimental O +
proof O +
of O +
their O +
extracytoplasmic O +
localization O -
. O -

The O +
transposon O +
mutants O +
in O +
our O +
banked O +
library O +
were O +
of O +
further O +
value O +
as O +
a O +
collection O +
of O +
mutants O +
lacking O +
individual O +
exported O +
proteins O -
. O -

By O +
individually O +
testing O +
each O +
of O +
111 O +
mutants O +
for O +
growth O +
in O +
macrophages O -
, O +
six O +
attenuated O +
mutants O +
with O +
insertions O +
in O +
mce1A O -
, O +
mce1B O -
, O +
mce2F O -
, O +
rv0199 O -
, O +
ctaC O -
, O +
and O +
lppX O +
were O +
identified O -
. O -

Given O +
that O +
much O +
of O +
the O +
M. B-Species +
tuberculosis L-Species +
genome O +
encodes O +
proteins O +
of O +
unknown O +
function O -
, O +
our O +
library O +
of O +
mapped O +
transposon O +
mutants O +
is O +
a O +
valuable O +
resource O +
for O +
efforts O +
in O +
functional O +
genomics O -
. O -

This O +
work O +
also O +
demonstrates O +
the O +
power O +
of O +
a O +
Beta O -
- O -
lactamase O +
reporter O +
transposon O +
that O +
could O +
be O +
applied O +
similarly O +
to O +
other O +
bacterial O +
pathogens O -
. O +

Infraciliature O +
of O +
eight O +
Triplumaria O +
species O +
( O -
Ciliophora O -
, O +
Entodiniomorphida O -
) O +
from O +
Asian B-Species +
elephants L-Species +
with O +
the O +
description O +
of O +
six O +
new O +
species O -
. O +

Intestinal O +
ciliates O +
excreted O +
in O +
the O +
feces O +
of O +
Asian B-Species +
elephants L-Species +
were O +
surveyed O -
. O -

Fourteen O +
species O +
in O +
the O +
order O +
Entodiniomorphida O +
were O +
detected O -
. O -

Nine O +
Triplumaria O +
species O +
in O +
the O +
family O +
Cycloposthiidae O +
were O +
found O -
. O -

Using O +
the O +
silver O +
impregnation O -
, O +
two O +
known O +
species O -
, O +
T. O +
antis O +
and O +
T. O +
dvoinosi O -
, O +
were O +
redescribed O +
and O +
six O +
new O +
species O -
, O +
T. O +
sukuna O +
n. O -

sp. O -
, O +
T. O +
zuze O -

n. O +
sp. O -
, O +
T. O +
solea O -

n. O +
sp. O -

, O +
T. O +
suwako O +
n. O +
sp. O -
, O +
T. O +
fulgora O +
n. O +
sp. O -
, O +
and O +
T. O +
harpagonis O +
n. O +
sp. O -
, O +
were O +
described O -
. O -

T. O +
sukuna O -
, O +
T. O +
zuze O -
, O +
T. O +
solea O -
, O +
and O +
T. O +
suwako O +
have O +
the O +
perivestibular O +
polybrachykinety O +
along O +
the O +
vestibular O +
opening O -
. O -

The O +
buccal O +
infraciliary O +
bands O +
of O +
T. O +
suwako O +
are O +
similar O +
to O +
those O +
of O +
T. B-Species +
selenica L-Species +
found O +
from O +
elephants O +
and O +
the O +
buccal O +
infraciliary O +
bands O +
of O +
T. O +
sukuna O -
, O +
T. O +
zuze O -
, O +
and O +
T. O +
solea O +
are O +
similar O +
to O +
those O +
of O +
T. O +
grypoclunis O +
described O +
from O +
rhinoceroses O -
. O -

T. O +
antis O -
, O +
T. O +
dvoinosi O -
, O +
T. O +
fulgora O -
, O +
and O +
T. O +
harpagonis O +
have O +
the O +
vestibular O +
polybrachykinety O +
extending O +
down O +
inside O +
the O +
vestibulum O +
as O +
found O +
in O +
rumen O +
ciliates O +
in O +
the O +
family O +
Ophryoscolecidae O -
. O -

The O +
caudalial O +
ciliary O +
zones O +
of O +
T. O +
dvoinosi O +
and O +
T. O +
fulgora O +
were O +
retractable O +
as O +
found O +
in O +
rumen O +
ophryoscolecids O -
. O -

Raabena B-Species +
bella L-Species +
and O +
Pseudoentodinium O +
elephantis O +
showed O +
high O +
composition O +
values O +
over O +
30 O -
% O -
. O -

Ciliate O +
densities O +
in O +
the O +
three O +
fecal O +
samples O +
were O +
0.15 O -
, O +
1.09 O -
, O +
and O +
2.07x10 O -
( O -
4 O -
) O -
/ O -
ml O -
. O +

Comparison O +
of O +
seasonal O +
variations O +
in O +
water O -
- O -
use O +
efficiency O +
calculated O +
from O +
the O +
carbon O +
isotope O +
composition O +
of O +
tree O +
rings O +
and O +
flux O +
data O +
in O +
a O +
temperate O +
forest O -
. O +

Tree O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C O +
is O +
often O +
interpreted O +
in O +
terms O +
of O +
intrinsic O +
water O -
- O -
use O +
efficiency O +
( O -
WUE O -
) O +
using O +
a O +
carbon O +
isotope O +
discrimination O +
model O +
established O +
at O +
the O +
leaf O +
level O -
. O -

We O +
examined O +
whether O +
intra O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C O +
could O +
be O +
used O +
to O +
assess O +
variations O +
in O +
intrinsic O +
WUE O +
( O -
W O -
( O -
g O -
) O -
, O +
the O +
ratio O +
of O +
carbon O +
assimilation O +
and O +
stomatal O +
conductance O +
to O +
water O -
) O +
and O +
variations O +
in O +
ecosystem O +
WUE O +
( O -
W O -
( O -
t O -
) O +
, O +
the O +
ratio O +
of O +
C O +
assimilation O +
and O +
transpiration O -
) O +
at O +
a O +
seasonal O +
scale O -
. O -

Intra O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C O +
was O +
measured O +
in O +
30- O +
to O +
60-mum O -
- O -
thick O +
slices O +
in O +
eight O +
oak O +
trees O +
( O -
Quercus B-Species +
petraea L-Species -
) O -
. O -

Canopy O +
W O -
( O -
g O -
) O +
was O +
simulated O +
using O +
a O +
physiologically O +
process O -
- O -
based O +
model O -
. O -

High O +
between O -
- O -
tree O +
variability O +
was O +
observed O +
in O +
the O +
seasonal O +
variations O +
of O +
intra O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C. O +
Six O +
trees O +
showed O +
significant O +
positive O +
correlations O +
between O +
W O -
( O -
g O -
) O +
calculated O +
from O +
intra O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C O +
and O +
canopy O +
W O -
( O -
g O -
) O +
averaged O +
over O +
several O +
days O +
during O +
latewood O +
formation O -
. O -

These O +
results O +
suggest O +
that O +
latewood O +
is O +
a O +
seasonal O +
recorder O +
of O +
W O -
( O -
g O -
) O +
trends O -
, O +
with O +
a O +
temporal O +
lag O +
corresponding O +
to O +
the O +
mixing O +
time O +
of O +
sugars O +
in O +
the O +
phloem O -
. O -

These O +
six O +
trees O +
also O +
showed O +
significant O +
negative O +
correlations O +
between O +
photosynthetic O +
discrimination O +
Delta O +
calculated O +
from O +
intra O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C O -
, O +
and O +
ecosystem O +
W O -
( O -
t O -
) O -
, O +
during O +
latewood O +
formation O -
. O -

Despite O +
the O +
observed O +
between O -
- O -
tree O +
variability O -
, O +
these O +
results O +
indicate O +
that O +
intra O -
- O -
ring O +
delta O -
( O -
13 O -
) O +
C O +
can O +
be O +
used O +
to O +
access O +
seasonal O +
variations O +
in O +
past O +
W O -
( O -
t O -
) O -
. O +

Neuropeptide O +
precursor O +
gene O +
discovery O +
in O +
the O +
Chagas O +
disease O +
vector O +
Rhodnius B-Species +
prolixus L-Species -
. O +

We O +
show O +
a O +
straightforward O +
workflow O +
combining O +
homology O +
search O +
in O +
Rhodnius B-Species +
prolixus L-Species +
genome O +
sequence O +
with O +
cloning O +
by O +
rapid O +
amplification O +
of O +
cDNA O +
ends O +
and O +
mass O +
spectrometry O -
. O -

We O +
have O +
identified O +
32 O +
genes O +
and O +
their O +
transcripts O +
that O +
encode O +
a O +
number O +
of O +
neuropeptide O +
precursors O +
leading O +
to O +
194 O +
putative O +
peptides O -
. O -

We O +
validated O +
by O +
mass O +
spectrometry O +
82 O +
of O +
those O +
predicted O +
neuropeptides O +
in O +
the O +
brain O +
of O +
R. B-Species +
prolixus L-Species +
to O +
achieve O +
the O +
first O +
comprehensive O +
genomic O -
, O +
transcriptomic O +
and O +
neuropeptidomic O +
analysis O +
of O +
an O +
insect O +
disease O +
vector O -
. O -

Comparisons O +
of O +
available O +
insect O +
neuropeptide O +
sequences O +
revealed O +
that O +
the O +
R. B-Species +
prolixus L-Species +
genome O +
contains O +
most O +
of O +
the O +
conserved O +
neuropeptides O +
in O +
insects O -
, O +
many O +
of O +
them O +
displaying O +
specific O +
features O +
at O +
the O +
sequence O +
level O -
. O -

Some O +
gene O +
families O +
reported O +
here O +
are O +
identified O +
for O +
the O +
first O +
time O +
in O +
the O +
order O +
Hemiptera O -
, O +
a O +
highly O +
biodiverse O +
group O +
of O +
insects O +
that O +
includes O +
many O +
human U-Species -
, O +
animal O +
and O +
plant O +
disease O +
agents O -
. O +

Resistance O +
and O +
recovery O +
of O +
soil O +
microbial O +
communities O +
in O +
the O +
face O +
of O +
Alliaria B-Species +
petiolata L-Species +
invasions O -
. O +

Invaders O +
can O +
gain O +
ecological O +
advantages O +
because O +
of O +
their O +
evolutionary O +
novelty O -
, O +
but O +
little O +
is O +
known O +
about O +
how O +
these O +
novel O +
advantages O +
will O +
change O +
over O +
time O +
as O +
the O +
invader O +
and O +
invaded O +
community O +
evolve O +
in O +
response O +
to O +
each O +
other O -
. O -

Invasive O +
plants O +
often O +
gain O +
such O +
an O +
advantage O +
through O +
alteration O +
of O +
soil O +
microbial O +
communities O -
. O -

In O +
soil O +
communities O +
sampled O +
from O +
sites O +
along O +
a O +
gradient O +
of O +
invasion O +
history O +
with O +
Alliaria B-Species +
petiolata L-Species -
, O +
microbial O +
richness O +
tended O +
to O +
decline O -
, O +
but O +
the O +
community O -
's O +
resistance O +
to O +
A. B-Species +
petiolata L-Species -
's O +
effects O +
generally O +
increased O +
with O +
increasing O +
history O +
of O +
invasion O -
. O -

However O -
, O +
sensitive O +
microbial O +
taxa O +
appeared O +
to O +
recover O +
in O +
the O +
two O +
oldest O +
sites O -
, O +
leading O +
to O +
an O +
increase O +
in O +
richness O -
, O +
but O +
consequent O +
decrease O +
in O +
resistance O -
. O -

This O +
may O +
be O +
because O +
of O +
evolutionary O +
changes O +
in O +
the O +
A. B-Species +
petiolata L-Species +
populations O -
, O +
which O +
tend O +
to O +
reduce O +
their O +
investment O +
to O +
allelopathic O +
compounds O +
over O +
time O -
. O -

These O +
results O +
show O +
that O -
, O +
over O +
time O -
, O +
microbial O +
communities O +
can O +
develop O +
resistance O +
to O +
an O +
invasive O +
plant O +
but O +
at O +
the O +
cost O +
of O +
lower O +
richness O -
. O -

However O -
, O +
over O +
longer O +
time O -
- O -
scales O +
evolution O +
in O +
the O +
invasive O +
species O +
may O +
allow O +
for O +
the O +
recovery O +
of O +
soil O +
microbial O +
communities O -
. O +

Streptococcus B-Species +
ursoris I-Species +
sp. I-Species +
nov. L-Species -
, O +
isolated O +
from O +
the O +
oral O +
cavities O +
of O +
bears O -
. O -

Three O +
Gram O -
- O -
positive O -
, O +
catalase O -
- O -
negative O -
, O +
coccus O -
- O -
shaped O +
organisms O +
were O +
isolated O +
from O +
the O +
oral O +
cavities O +
of O +
bears O -
. O -

The O +
isolates O +
were O +
tentatively O +
identified O +
as O +
a O +
streptococcal O +
species O +
based O +
on O +
the O +
results O +
of O +
biochemical O +
tests O -
. O -

Comparative O +
16S O +
rRNA O +
gene O +
sequencing O +
studies O +
confirmed O +
that O +
the O +
organisms O +
were O +
members O +
of O +
the O +
genus O +
Streptococcus O -
, O +
but O +
they O +
did O +
not O +
correspond O +
to O +
any O +
recognized O +
species O +
of O +
the O +
genus O -
. O -

The O +
nearest O +
phylogenetic O +
relative O +
of O +
the O +
new O +
isolates O +
was O +
Streptococcus B-Species +
ratti I-Species +
ATCC I-Species +
19645 L-Species -
( O -
T O -
) O +
( O -
98.6 O +
% O -
) O -
, O +
however O -
, O +
DNA O -
- O -
DNA O +
hybridization O +
analysis O +
showed O +
that O +
the O +
isolates O +
displayed O +
less O +
than O +
15 O +
% O +
DNA O -
- O -
DNA O +
relatedness O +
with O +
the O +
type O +
strain O +
of O +
S. B-Species +
ratti L-Species -
. O -

Colonies O +
of O +
the O +
novel O +
strains O +
grown O +
on O +
mitis O +
salivarius O +
agar O +
showed O +
an O +
extracellular O +
polysaccharide O -
- O -
producing O +
colony O +
morphology O -
. O -

Based O +
on O +
phenotypic O +
and O +
phylogenetic O +
evidence O -
, O +
it O +
is O +
proposed O +
that O +
the O +
novel O +
isolates O +
are O +
classified O +
in O +
the O +
genus O +
Streptococcus O +
as O +
Streptococcus B-Species +
ursoris I-Species +
sp. I-Species +
nov. L-Species +
The O +
type O +
strain O +
of O +
S. B-Species +
ursoris L-Species +
is O +
NUM B-Species +
1615 I-Species -
( I-Species -
T L-Species -
) O +
( O -
= O -
JCM O +
16316 O -
( O -
T O -
) O -
=DSM O +
22768 O -
( O -
T O -
) O -
) O -
. O +

Rarity O -
, O +
life O +
history O +
and O +
scaling O +
of O +
the O +
dynamics O +
in O +
time O +
and O +
space O +
of O +
British O +
birds O -
. O +

1 O -
. O -

Many O +
patterns O +
in O +
macroecology O +
are O +
closely O +
related O +
to O +
the O +
total O +
abundance O +
of O +
a O +
species O +
in O +
a O +
region O -
. O -

Here O +
we O +
show O +
that O +
interspecific O +
differences O +
in O +
the O +
pattern O +
of O +
population O +
fluctuations O +
of O +
British O +
bird O +
species O +
can O +
be O +
predicted O +
from O +
knowledge O +
of O +
their O +
overall O +
abundance O +
and O +
some O +
basic O +
life O -
- O -
history O +
characteristics O -
. O -

2 O -
. O -

We O +
identify O +
a O +
rarity O +
syndrome O +
that O +
arises O +
through O +
an O +
increased O +
stochastic O +
influence O +
on O +
population O +
fluctuations O +
with O +
decreasing O +
population O +
size O -
, O +
mainly O +
resulting O +
from O +
an O +
inverse O +
density O -
- O -
dependent O +
effect O +
of O +
demographic O +
stochasticity O -
. O -

This O +
syndrome O +
involves O +
an O +
increase O +
in O +
the O +
annual O +
changes O +
in O +
population O +
size O +
with O +
increasing O +
rarity O +
in O +
the O +
United O +
Kingdom O -
. O -

3 O -
. O -

The O +
relationship O +
between O +
the O +
magnitude O +
of O +
temporal O +
variation O +
and O +
local O +
mean O +
population O +
size O +
differs O +
between O +
species O +
dependent O +
on O +
their O +
life O +
history O -
, O +
i.e. O +
species O +
with O +
larger O +
clutch O +
size O +
and O +
lower O +
survival O +
tended O +
to O +
have O +
larger O +
annual O +
changes O +
in O +
population O +
size O +
than O +
low O -
- O -
reproducing O +
long O -
- O -
lived O +
species O -
. O -

4 O -
. O -

The O +
probability O +
of O +
local O +
disappearance O +
from O +
a O +
study O +
plot O +
depended O +
on O +
the O +
population O +
size O +
and O +
was O +
hence O +
closely O +
related O +
to O +
the O +
overall O +
abundance O +
of O +
the O +
species O +
in O +
UK O -
. O -

For O +
a O +
given O +
population O +
size O -
, O +
this O +
probability O +
was O +
also O +
related O +
to O +
species O -
- O -
specific O +
life O -
- O -
history O +
characteristics O -
, O +
being O +
higher O +
in O +
species O +
with O +
larger O +
clutch O +
sizes O +
and O +
smaller O +
survival O +
rates O -
. O -

5 O -
. O -

Rareness O +
results O +
in O +
a O +
spatial O +
decoupling O +
of O +
the O +
temporal O +
variation O +
in O +
population O +
size O -
. O -

6 O -
. O -

These O +
patterns O +
show O +
that O +
once O +
a O +
species O +
has O +
become O +
rare O -
, O +
e.g. O +
due O +
to O +
human U-Species +
activities O -
, O +
key O +
population O +
dynamical O +
characteristics O +
will O +
change O +
because O +
of O +
density O -
- O -
dependent O +
stochastic O +
effects O -
, O +
which O +
in O +
turn O +
are O +
dependent O +
on O +
species O -
- O -
specific O +
life O -
- O -
history O +
characteristics O -
. O +

Influence O +
of O +
helix O +
12 O +
of O +
Ultraspiracle O +
on O +
Drosophila B-Species +
melanogaster L-Species +
ecdysone O +
receptor O +
function O -
. O +

Although O +
it O +
has O +
no O +
ligand O -
, O +
helix O +
12 O +
in O +
the O +
ligand O +
binding O +
domain O +
of O +
Ultraspiracle O +
( O -
USP O -
) O +
is O +
locked O +
in O +
an O +
antagonistic O +
position O -
. O -

To O +
investigate O +
whether O +
this O +
position O +
is O +
of O +
functional O +
importance O -
, O +
we O +
enhanced O +
the O +
flexibility O +
of O +
helix O +
12 O +
by O +
mutating O +
two O +
amino O +
acids O +
( O -
259 O -
, O +
located O +
in O +
L1 O -
- O -
3 O +
and O +
F491 O +
in O +
helix O +
12 O -
) O -
. O -

Mutated O +
USP O +
reduces O +
the O +
stability O +
of O +
USP O +
and O +
all O +
isoforms O +
of O +
the O +
ecdysone O +
receptor O +
( O -
EcR O -
) O +
and O +
impairs O +
nuclear O +
localization O +
and O +
DNA O +
binding O +
of O +
EcR O -
/ O -
USP O -
( O -
L259A O -
/ O -
F491 O -
/ O -
A O -
) O -
, O +
resulting O +
in O +
lower O +
levels O +
of O +
basal O +
transcriptional O +
activity O -
. O -

Although O +
the O +
affinity O +
of O +
the O +
ligand O +
ponasterone O +
A O +
to O +
EcR O -
/ O -
USP O -
( O -
L259 O -
/ O -
F491 O -
) O +
is O +
moderately O +
diminished O -
, O +
hormone O -
- O -
induced O +
stimulation O +
of O +
transcriptional O +
activity O +
is O +
normal O -
. O -

Potentiation O +
of O +
the O +
ecdysone O +
response O +
by O +
juvenile O +
hormone O +
( O -
JH O -
) O +
is O +
selectively O +
increased O +
in O +
mutated O +
heterodimers O +
with O +
EcR O -
- O -
B1 O -
, O +
demonstrating O +
that O +
the O +
antagonistic O +
position O +
impairs O +
functional O +
interaction O +
of O +
the O +
EcR O +
complex O +
with O +
JHIII O -
. O +

The O +
rise O +
of O +
chronic O +
non O -
- O -
communicable O +
diseases O +
in O +
southeast O +
Asia O -
: O +
time O +
for O +
action O -
. O +

Southeast O +
Asia O +
faces O +
an O +
epidemic O +
of O +
chronic O +
non O -
- O -
communicable O +
diseases O -
, O +
now O +
responsible O +
for O +
60 O -
% O +
of O +
deaths O +
in O +
the O +
region O -
. O -

The O +
problem O +
stems O +
from O +
environmental O +
factors O +
that O +
promote O +
tobacco U-Species +
use O -
, O +
unhealthy O +
diet O -
, O +
and O +
inadequate O +
physical O +
activity O -
. O -

Disadvantaged O +
populations O +
are O +
the O +
hardest O +
hit O -
, O +
with O +
death O +
rates O +
inversely O +
proportional O +
to O +
a O +
country O -
's O +
gross O +
national O +
income O -
. O -

Families O +
shoulder O +
the O +
financial O +
burden O -
, O +
but O +
entire O +
economies O +
suffer O +
as O +
well O -
. O -

Although O +
attempts O +
to O +
control O +
non O -
- O -
communicable O +
diseases O +
are O +
increasing O -
, O +
more O +
needs O +
to O +
be O +
done O -
. O -

Health O -
- O -
care O +
systems O +
need O +
to O +
be O +
redesigned O +
to O +
deliver O +
chronic O +
care O +
that O +
is O +
founded O +
on O +
existing O +
primary O +
health O -
- O -
care O +
facilities O -
, O +
but O +
supported O +
by O +
good O +
referral O +
systems O -
. O -

Surveillance O +
of O +
key O +
modifiable O +
risk O +
factors O +
is O +
needed O +
to O +
monitor O +
the O +
magnitude O +
of O +
the O +
problem O +
and O +
to O +
study O +
the O +
effects O +
of O +
interventions O -
. O -

All O +
branches O +
of O +
government O +
and O +
all O +
sectors O +
of O +
society O +
have O +
to O +
get O +
involved O +
in O +
establishing O +
environments O +
that O +
are O +
conducive O +
to O +
healthy O +
living O -
. O -

The O +
Association O +
of O +
Southeast O +
Asian O +
Nations O +
is O +
in O +
a O +
unique O +
position O +
to O +
make O +
a O +
united O +
stand O +
against O +
chronic O +
non O -
- O -
communicable O +
diseases O +
in O +
the O +
region O -
. O -

Inaction O +
will O +
affect O +
millions O +
of O +
lives O -
- O -
often O -
, O +
the O +
lives O +
of O +
those O +
who O +
have O +
the O +
least O -
. O +

Health O -
- O -
financing O +
reforms O +
in O +
southeast O +
Asia O -
: O +
challenges O +
in O +
achieving O +
universal O +
coverage O -
. O +

In O +
this O +
sixth O +
paper O +
of O +
the O +
Series O -
, O +
we O +
review O +
health O -
- O -
financing O +
reforms O +
in O +
seven O +
countries O +
in O +
southeast O +
Asia O +
that O +
have O +
sought O +
to O +
reduce O +
dependence O +
on O +
out O -
- O -
of O -
- O -
pocket O +
payments O -
, O +
increase O +
pooled O +
health O +
finance O -
, O +
and O +
expand O +
service O +
use O +
as O +
steps O +
towards O +
universal O +
coverage O -
. O -

Laos O +
and O +
Cambodia O -
, O +
both O +
resource O -
- O -
poor O +
countries O -
, O +
have O +
mostly O +
relied O +
on O +
donor O -
- O -
supported O +
health O +
equity O +
funds O +
to O +
reach O +
the O +
poor O -
, O +
and O +
reliable O +
funding O +
and O +
appropriate O +
identification O +
of O +
the O +
eligible O +
poor O +
are O +
two O +
major O +
challenges O +
for O +
nationwide O +
expansion O -
. O -

For O +
Thailand O -
, O +
the O +
Philippines O -
, O +
Indonesia O -
, O +
and O +
Vietnam O -
, O +
social O +
health O +
insurance O +
financed O +
by O +
payroll O +
tax O +
is O +
commonly O +
used O +
for O +
formal O +
sector O +
employees O +
( O -
excluding O +
Malaysia O -
) O -
, O +
with O +
varying O +
outcomes O +
in O +
terms O +
of O +
financial O +
protection O -
. O -

Alternative O +
payment O +
methods O +
have O +
different O +
implications O +
for O +
provider O +
behaviour O +
and O +
financial O +
protection O -
. O -

Two O +
alternative O +
approaches O +
for O +
financial O +
protection O +
of O +
the O +
non O -
- O -
poor O +
outside O +
the O +
formal O +
sector O +
have O +
emerged O -
- O -
contributory O +
arrangements O +
and O +
tax O -
- O -
financed O +
schemes O -
- O -
with O +
different O +
abilities O +
to O +
achieve O +
high O +
population O +
coverage O +
rapidly O -
. O -

Fiscal O +
space O +
and O +
mobilisation O +
of O +
payroll O +
contributions O +
are O +
both O +
important O +
in O +
accelerating O +
financial O +
protection O -
. O -

Expanding O +
coverage O +
of O +
good O -
- O -
quality O +
services O +
and O +
ensuring O +
adequate O +
human U-Species +
resources O +
are O +
also O +
important O +
to O +
achieve O +
universal O +
coverage O -
. O -

As O +
health O -
- O -
financing O +
reform O +
is O +
complex O -
, O +
institutional O +
capacity O +
to O +
generate O +
evidence O +
and O +
inform O +
policy O +
is O +
essential O +
and O +
should O +
be O +
strengthened O -
. O +

Implementation O +
and O +
validation O +
of O +
a O +
sensitive O +
PCR O +
detection O +
method O +
in O +
the O +
eradication O +
campaign O +
against O +
Aleutian B-Species +
mink I-Species +
disease I-Species +
virus L-Species -
. O +

Aleutian B-Species +
mink I-Species +
disease I-Species +
virus I-Species +
( I-Species -
AMDV L-Species -
) O +
is O +
a O +
severe O +
progressive O +
disease O +
causing O +
multiple O +
different O +
clinical O +
syndromes O +
in O +
mink U-Species -
. O -

In O +
Denmark O -
, O +
the O +
disease O +
is O +
notifiable O +
and O +
under O +
official O +
control O -
. O -

The O +
control O +
programme O -
, O +
based O +
on O +
serological O +
screening O -
, O +
has O +
confined O +
successfully O +
AMDV U-Species +
to O +
the O +
northern O +
part O +
of O +
Denmark O -
. O -

However O -
, O +
re O -
- O -
infections O +
and O +
new O +
introductions O +
of O +
virus O +
into O +
farms O +
require O +
a O +
confirmatory O +
virological O +
test O +
to O +
verify O +
the O +
positive O +
test O +
results O +
of O +
single O +
animals O +
and O +
ultimately O +
to O +
investigate O +
disease O +
transmission O -
. O -

A O +
one O +
step O +
PCR O +
amplifying O +
a O +
374-base O +
fragment O +
of O +
the O +
NS1 O +
gene O +
of O +
AMDV U-Species +
was O +
compared O +
to O +
the O +
counter O -
- O -
current O +
immune O +
electrophoresis O +
( O -
CIE O -
) O +
routinely O +
used O +
in O +
the O +
serological O +
screening O +
programme O -
. O -

Mink U-Species +
organs O +
( O -
n=299 O -
) O +
obtained O +
from O +
55 O +
recently O +
infected O +
farms O +
and O +
8 O +
non O -
- O -
infected O +
farms O +
from O +
2008 O +
to O +
2010 O +
were O +
tested O +
by O +
PCR O -
, O +
and O +
the O +
results O +
were O +
found O +
to O +
have O +
a O +
high O +
correlation O +
with O +
the O +
serological O +
status O +
of O +
the O +
mink U-Species -
. O -

The O +
relative O +
diagnostic O +
sensitivity O +
of O +
the O +
PCR O +
was O +
94.7 O -
% O -
, O +
and O +
the O +
relative O +
diagnostic O +
specificity O +
was O +
97.9 O -
% O +
when O +
read O +
in O +
parallel O +
with O +
the O +
CIE O -
. O -

PCR O +
positive O +
samples O +
were O +
sequenced O +
and O +
phylogenetic O +
analysis O +
revealed O +
high O +
similarity O +
within O +
the O +
analysed O +
AMDV B-Species +
strains L-Species +
and O +
to O +
AMDV B-Species +
strains L-Species +
described O +
previously O -
. O +

Rapid O +
and O +
sensitive O +
detection O +
of O +
infectious B-Species +
hypodermal I-Species +
and I-Species +
hematopoietic I-Species +
necrosis I-Species +
virus L-Species +
by O +
loop O -
- O -
mediated O +
isothermal O +
amplification O +
combined O +
with O +
a O +
lateral O +
flow O +
dipstick O -
. O +

Infectious B-Species +
hypodermal I-Species +
and I-Species +
hematopoietic I-Species +
necrosis I-Species +
virus L-Species +
( O -
IHHNV U-Species -
) O +
is O +
an O +
important O +
shrimp O +
pathogen O +
that O +
causes O +
mortality O +
in O +
Penaeus B-Species +
stylirostris L-Species +
and O +
stunting O +
( O -
called O +
runt O +
deformity O +
syndrome O +
or O +
RDS O -
) O +
in O +
Penaeus B-Species +
vannamei L-Species -
. O -

Loop O -
- O -
mediated O +
isothermal O +
amplification O +
( O -
LAMP O -
) O +
allows O +
rapid O +
amplification O +
of O +
nucleic O +
acids O +
under O +
isothermal O +
conditions O -
. O -

It O +
can O +
be O +
combined O +
with O +
a O +
chromatographic O +
lateral O +
flow O +
dipstick O +
( O -
LFD O -
) O +
for O +
highly O +
specific O -
, O +
rapid O +
and O +
simple O +
visual O +
detection O +
of O +
IHHNV U-Species -
- O -
specific O +
amplicons O -
. O -

Using O +
this O +
protocol O -
, O +
a O +
30-min O +
amplification O +
followed O +
by O +
5 O +
min O +
hybridization O +
with O +
an O +
FITC O -
- O -
labeled O +
DNA O +
probe O +
and O +
5 O +
min O +
LFD O +
resulted O +
in O +
visualization O +
of O +
DNA O +
amplicons O +
trapped O +
at O +
the O +
LFD O +
test O +
line O -
. O -

Thus O -
, O +
10 O +
min O +
for O +
rapid O +
DNA O +
extraction O +
followed O +
by O +
LAMP O +
combined O +
with O +
LFD O +
detection O +
resulted O +
in O +
a O +
total O +
assay O +
time O +
of O +
approximately O +
50 O +
min O -
. O -

Detection O +
sensitivity O +
was O +
comparable O +
to O +
other O +
methods O +
used O +
commonly O +
for O +
nested O +
PCR O +
detection O +
of O +
IHHNV U-Species +
but O +
had O +
the O +
additional O +
advantages O +
of O +
reduced O +
assay O +
time O -
, O +
confirmation O +
of O +
amplicon O +
identity O +
by O +
hybridization O +
and O +
elimination O +
of O +
electrophoresis O +
with O +
carcinogenic O +
ethidium O +
bromide O -
. O +

Methanobacterium O +
arcticum O +
sp. O +
nov. O -
, O +
a O +
methanogenic O +
archaeon O +
from O +
Holocene O +
Arctic O +
permafrost O -
. O +

A O +
mesophilic O -
, O +
non O -
- O -
motile O -
, O +
hydrogenotrophic O -
, O +
rod O -
- O -
shaped O +
methanogen O -
, O +
designated O +
M2 B-Species -
( I-Species -
T L-Species -
) O -
, O +
was O +
isolated O +
from O +
Holocene O +
permafrost O +
sediments O +
of O +
the O +
Kolyma O +
lowland O +
in O +
the O +
Russian O +
Arctic O -
. O -

Cells O +
were O +
3 O -
- O -
6 O +
mum O +
long O +
and O +
0.45 O -
- O -
0.5 O +
mum O +
wide O -
. O -

Strain O +
M2 B-Species -
( I-Species -
T L-Species -
) O +
grew O +
on O +
H O -
( O -
2 O -
) O -
/ O -
CO O -
( O -
2 O -
) O +
and O +
formate O -
. O -

Optimum O +
conditions O +
for O +
growth O +
were O +
37 O -
^ O -
0C O -
, O +
pH O +
6.8 O -
- O -
7.2 O +
and O +
0.1 O +
M O +
NaCl O -
. O -

The O +
DNA O +
G+C O +
content O +
was O +
38.1 O +
mol% O -
. O -

On O +
the O +
basis O +
of O +
16S O +
rRNA O +
gene O +
sequence O +
comparison O +
with O +
known O +
methanogens O -
, O +
strain O +
M2 B-Species -
( I-Species -
T L-Species -
) O +
was O +
affiliated O +
with O +
the O +
genus O +
Methanobacterium O +
and O +
was O +
most O +
closely O +
related O +
to O +
Methanobacterium B-Species +
veterum I-Species +
MK4 I-Species -
( I-Species -
T L-Species -
) O +
and O +
Methanobacterium B-Species +
bryantii L-Species +
DSM B-Species +
863 I-Species -
( I-Species -
T L-Species -
) O +
( O -
both O +
99 O +
% O +
16S O +
rRNA O +
gene O +
sequence O +
similarity O -
) O -
. O -

However O -
, O +
no O +
significant O +
DNA O -
- O -
DNA O +
relatedness O +
was O +
observed O +
between O +
strain O +
M2 B-Species -
( I-Species -
T L-Species -
) O +
and O +
these O +
type O +
strains O -
. O -

We O +
propose O +
that O +
strain O +
M2 B-Species -
( I-Species -
T L-Species -
) O +
represents O +
a O +
novel O +
species O -
, O +
with O +
the O +
name O +
Methanobacterium O +
arcticum O +
sp. O +
nov. O -
, O +
with O +
type O +
strain O +
M2 B-Species -
( I-Species -
T L-Species -
) O +
( O -
= O -
DSM O +
19844 O -
( O -
T O -
) O +
= O -
VKM O +
B-2371 O -
( O -
T O -
) O -
) O -
. O -

PsOr1 O -
, O +
a O +
potential O +
target O +
for O +
RNA O +
interference O -
- O -
based O +
pest O +
management O -
. O -

Insect O +
pests O +
cause O +
billions O +
of O +
dollars O +
in O +
agricultural O +
losses O -
, O +
and O +
attempts O +
to O +
kill O +
them O +
have O +
resulted O +
in O +
growing O +
threats O +
from O +
insecticide O +
resistance O -
, O +
dietary O +
pesticide O +
pollution O +
and O +
environmental O +
destruction O -
. O -

New O +
approaches O +
to O +
control O +
refractory O +
insect O +
pests O +
are O +
therefore O +
needed O -
. O -

The O +
host O -
- O -
plant O +
preferences O +
of O +
insect O +
pests O +
rely O +
on O +
olfaction O +
and O +
are O +
mediated O +
via O +
a O +
seven O +
transmembrane O -
- O -
domain O +
odorant O +
receptor O +
( O -
Or O -
) O +
family O -
. O -

The O +
present O +
study O +
reports O +
the O +
cloning O +
and O +
characterization O +
of O +
PsOr1 O -
, O +
the O +
first O +
candidate O +
member O +
of O +
the O +
Or O +
gene O +
family O +
from O +
Phyllotreta B-Species +
striolata L-Species -
, O +
a O +
devastating O +
beetle O +
pest O +
that O +
causes O +
damage O +
worldwide O -
. O -

PsOr1 O +
is O +
remarkably O +
well O +
conserved O +
with O +
respect O +
to O +
other O +
insect O +
orthologues O -
, O +
including O +
DmOr83b O +
from O +
Drosophila B-Species +
melanogaster L-Species -
. O -

These O +
insect O +
orthologues O +
form O +
an O +
essential O +
non O -
- O -
conventional O +
Or O +
sub O -
- O -
family O +
and O +
may O +
play O +
an O +
important O +
and O +
generalized O +
role O +
in O +
insect O +
olfaction O -
. O -

We O +
designed O +
double O -
- O -
stranded O +
( O -
ds O -
) O +
RNA O +
directly O +
against O +
the O +
PsOr1 O +
gene O +
and O +
exploited O +
RNA O +
interference O +
( O -
RNAi O -
) O +
to O +
control O +
P. B-Species +
striolata L-Species -
. O -

The O +
chemotactic O +
behavioural O +
measurements O +
showed O +
that O +
adult O +
beetles O +
were O +
unable O +
to O +
sense O +
the O +
attractant O +
or O +
repellent O +
odour O +
stimulus O +
after O +
microinjection O +
of O +
dsRNA O +
against O +
PsOr1 O -
. O -

Reverse O +
Transcription O +
( O -
RT O -
) O -
-PCR O +
analysis O +
showed O +
specific O +
down O -
- O -
regulation O +
of O +
mRNA O +
transcript O +
levels O +
for O +
this O +
gene O -
. O -

Furthermore O -
, O +
host O -
- O -
plant O +
preference O +
experiments O +
confirmed O +
that O +
silencing O +
PsOr1 O +
by O +
RNAi O +
treatment O +
impaired O +
the O +
host O -
- O -
plant O +
preferences O +
of O +
P. B-Species +
striolata L-Species +
for O +
cruciferous O +
vegetables O -
. O -

These O +
results O +
demonstrate O +
that O +
this O +
insect O +
control O +
approach O +
of O +
using O +
RNAi O +
to O +
target O +
PsOr1 O +
and O +
its O +
orthologues O +
might O +
be O +
effective O +
in O +
blocking O +
host O -
- O -
plant O -
- O -
seeking O +
behaviours O +
in O +
diverse O +
insect O +
pests O -
. O -

The O +
results O +
also O +
support O +
the O +
theory O +
that O +
this O +
unique O +
receptor O +
type O +
plays O +
an O +
essential O +
general O +
role O +
in O +
insect O +
olfaction O -
. O +

Effective O +
management O +
in O +
clusters O +
of O +
pneumococcal U-Species +
disease O -
: O +
a O +
systematic O +
review O -
. O -

Outbreaks O +
of O +
serious O +
pneumococcal U-Species +
disease O +
can O +
occur O +
with O +
high O +
attack O +
rates O +
in O +
certain O +
settings O -
. O -

We O +
systematically O +
reviewed O +
studies O +
of O +
interventions O +
implemented O +
in O +
pneumococcal U-Species +
clusters O +
and O +
those O +
reporting O +
the O +
effect O +
of O +
antibiotics O +
on O +
carriage O +
reduction O +
to O +
assess O +
the O +
effectiveness O +
of O +
interventions O -
. O -

Evidence O +
was O +
graded O +
according O +
to O +
the O +
Scottish O +
Intercollegiate O +
Guidelines O +
Network O +
system O -
. O -

Of O +
28 O +
identified O +
cluster O +
reports O -
, O +
one O +
showed O +
that O +
administration O +
of O +
antibiotics O +
to O +
close O +
contacts O +
reduced O +
risk O +
of O +
pneumococcal U-Species +
disease O -
. O -

In O +
three O +
of O +
four O +
clusters O +
where O +
rifampicin O +
chemoprophylaxis O +
was O +
used O +
and O +
in O +
four O +
of O +
five O +
clusters O +
where O +
penicillin O +
was O +
used O +
no O +
further O +
cases O +
were O +
seen O +
after O +
intervention O -
. O -

In O +
clusters O +
where O +
pneumococcal U-Species +
polysaccharide O +
vaccine O +
was O +
used O -
, O +
subsequent O +
cases O +
occurred O -
, O +
all O +
within O +
around O +
2 O +
weeks O +
of O +
vaccination O -
, O +
which O +
suggests O +
delayed O +
benefit O +
with O +
this O +
approach O +
( O -
evidence O +
grade O +
D O -
) O -
. O -

Use O +
of O +
infection O +
control O +
measures O +
alone O +
was O +
reported O +
in O +
eight O +
clusters O -
, O +
with O +
no O +
further O +
cases O +
being O +
reported O +
in O +
seven O +
( O -
grade O +
D O -
) O -
. O -

From O +
21 O +
selected O +
carriage O +
studies O -
, O +
large O +
carriage O +
reductions O +
were O +
observed O +
consistently O +
with O +
use O +
of O +
penicillin O +
and O +
azithromycin O -
, O +
with O +
median O +
values O +
being O +
90 O -
% O +
and O +
73 O -
% O -
, O +
respectively O +
( O -
grade O +
C O -
) O -
. O -

The O +
findings O +
were O +
presented O +
to O +
a O +
working O +
group O +
for O +
pneumococcal U-Species +
cluster O +
guidelines O +
and O +
used O +
to O +
develop O +
key O +
recommendations O +
on O +
the O +
management O +
of O +
clusters O +
that O +
supported O +
prompt O +
use O +
of O +
amoxicillin O +
or O +
azithromycin O +
chemoprophylaxis O -
, O +
pneumococcal U-Species +
vaccination O +
for O +
close O +
contacts O -
, O +
and O +
implementation O +
of O +
infection O +
control O +
measures O -
. O +

Bacillus B-Species +
anthracis L-Species +
sin O +
locus O +
and O +
regulation O +
of O +
secreted O +
proteases O -
. O -

Bacillus B-Species +
anthracis L-Species +
shares O +
many O +
regulatory O +
loci O +
with O +
the O +
nonpathogenic O +
Bacillus O +
species O +
Bacillus B-Species +
subtilis L-Species -
. O -

One O +
such O +
locus O +
is O +
sinIR O -
, O +
which O +
in O +
B. B-Species +
subtilis L-Species +
controls O +
sporulation O -
, O +
biofilm O +
formation O -
, O +
motility O -
, O +
and O +
competency O -
. O -

As O +
B. B-Species +
anthracis L-Species +
is O +
not O +
known O +
to O +
be O +
motile O -
, O +
to O +
be O +
naturally O +
competent O -
, O +
or O +
to O +
readily O +
form O +
biofilms O -
, O +
we O +
hypothesized O +
that O +
the O +
B. B-Species +
anthracis L-Species +
sinIR O +
regulon O +
is O +
distinct O +
from O +
that O +
of O +
B. B-Species +
subtilis L-Species -
. O -

A O +
genome O -
- O -
wide O +
expression O +
microarray O +
analysis O +
of O +
B. B-Species +
anthracis L-Species +
parental O +
and O +
sinR O +
mutant O +
strains O +
indicated O +
limited O +
convergence O +
of O +
the O +
B. B-Species +
anthracis L-Species +
and O +
B. B-Species +
subtilis L-Species +
SinR O +
regulons O -
. O -

The O +
B. B-Species +
anthracis L-Species +
regulon O +
includes O +
homologues O +
of O +
some O +
B. B-Species +
subtilis L-Species +
SinR O -
- O -
regulated O +
genes O -
, O +
including O +
the O +
signal O +
peptidase O +
gene O +
sipW O +
near O +
the O +
sinIR O +
locus O +
and O +
the O +
sporulation O +
gene O +
spoIIE O -
. O -

The O +
B. B-Species +
anthracis L-Species +
SinR O +
protein O +
also O +
negatively O +
regulates O +
transcription O +
of O +
genes O +
adjacent O +
to O +
the O +
sinIR O +
locus O +
that O +
are O +
unique O +
to O +
the O +
Bacillus B-Species +
cereus I-Species +
group I-Species +
species L-Species -
. O -

These O +
include O +
calY O +
and O +
inhA1 O -
, O +
structural O +
genes O +
for O +
the O +
metalloproteases O +
camelysin O +
and O +
immune O +
inhibitor O +
A1 O +
( O -
InhA1 O -
) O -
, O +
which O +
have O +
been O +
suggested O +
to O +
be O +
associated O +
with O +
virulence O +
in O +
B. B-Species +
cereus L-Species +
and O +
B. B-Species +
anthracis L-Species -
, O +
respectively O -
. O -

Electrophoretic O +
mobility O +
shift O +
assays O +
revealed O +
direct O +
binding O +
of O +
B. B-Species +
anthracis L-Species +
SinR O +
to O +
promoter O +
DNA O +
from O +
strongly O +
regulated O +
genes O -
, O +
such O +
as O +
calY O +
and O +
sipW O -
, O +
but O +
not O +
to O +
the O +
weakly O +
regulated O +
inhA1 O +
gene O -
. O -

Assessment O +
of O +
camelysin O +
and O +
InhA1 O +
levels O +
in O +
culture O +
supernates O +
from O +
sinR- O -
, O +
inhA1- O -
, O +
and O +
calY O -
- O -
null O +
mutants O +
showed O +
that O +
the O +
concentration O +
of O +
InhA1 O +
in O +
the O +
culture O +
supernatant O +
is O +
inversely O +
proportional O +
to O +
the O +
concentration O +
of O +
camelysin O -
. O -

Our O +
data O +
are O +
consistent O +
with O +
a O +
model O +
in O +
which O +
InhA1 O +
protease O +
levels O +
are O +
controlled O +
at O +
the O +
transcriptional O +
level O +
by O +
SinR O +
and O +
at O +
the O +
posttranslational O +
level O +
by O +
camelysin O -
. O +

Npc1 O +
is O +
involved O +
in O +
sterol O +
trafficking O +
in O +
the O +
filamentous O +
fungus O +
Fusarium B-Species +
graminearum L-Species -
. O +

The O +
ortholog O +
of O +
the O +
human U-Species +
gene O +
NPC1 O +
was O +
identified O +
in O +
the O +
plant O +
pathogenic O -
, O +
filamentous O +
fungus O +
Fusarium B-Species +
graminearum L-Species +
by O +
shared O +
amino O +
acid O +
sequence O -
, O +
protein O +
domain O +
structure O +
and O +
cellular O +
localization O +
of O +
the O +
mature O +
fungal O +
protein O -
. O -

The O +
FusariumNpc1 O +
gene O +
shares O +
34 O -
% O +
amino O +
acid O +
sequence O +
identity O +
and O +
51 O -
% O +
similarity O +
to O +
the O +
human U-Species +
gene O -
, O +
has O +
similar O +
domain O +
structure O +
and O +
is O +
constitutively O +
expressed O -
, O +
although O +
up O -
- O -
regulated O +
in O +
ungerminated O +
macroconidia O +
and O +
ascospores O -
. O -

GFP O -
- O -
tagged O +
Npc1p O +
localizes O +
to O +
the O +
fungal O +
vacuolar O +
membrane O -
. O -

Cultures O +
derived O +
from O +
a O +
Deltanpc1 O +
mutant O +
strain O +
contain O +
significantly O +
more O +
ergosterol O +
than O +
cultures O +
of O +
the O +
wildtype O -
. O -

Staining O +
with O +
the O +
fluorescent O -
, O +
sterol O +
binding O +
dye O +
filipin O -
, O +
shows O +
that O +
ergosterol O +
accumulates O +
in O +
vacuoles O +
of O +
the O +
Deltanpc1 O +
mutant O +
but O +
not O +
the O +
wildtype O +
strain O -
. O -

The O +
Deltanpc1 O +
mutant O +
has O +
a O +
temperature O +
dependent O +
reduction O +
in O +
growth O +
and O +
greater O +
sensitivity O +
to O +
the O +
ergosterol O +
synthesis O +
inhibiting O +
fungicide O +
tebuconazole O +
compared O +
with O +
the O +
wildtype O +
strain O +
or O +
the O +
mutant O +
complemented O +
with O +
wildtype O +
Npc1 O -
. O -

The O +
mutant O +
also O +
is O +
significantly O +
reduced O +
in O +
pathogenicity O +
to O +
wheat U-Species -
. O -

Our O +
results O +
are O +
consistent O +
with O +
the O +
interpretation O +
that O +
Npc1p O +
is O +
important O +
for O +
normal O +
transport O +
of O +
ergosterol O +
from O +
the O +
vacuole O +
and O +
is O +
essential O +
for O +
proper O +
membrane O +
function O +
under O +
particular O +
environmental O +
conditions O -
. O +

Flavobacterium B-Species +
johnsoniae L-Species +
sprB O +
is O +
part O +
of O +
an O +
operon O +
spanning O +
the O +
additional O +
gliding O +
motility O +
genes O +
sprC O -
, O +
sprD O -
, O +
and O +
sprF. O +
Cells O +
of O +
Flavobacterium B-Species +
johnsoniae L-Species +
move O +
rapidly O +
over O +
surfaces O +
by O +
a O +
process O +
known O +
as O +
gliding O +
motility O -
. O -

Gld O +
proteins O +
are O +
thought O +
to O +
comprise O +
the O +
gliding O +
motor O +
that O +
propels O +
cell O +
surface O +
adhesins O -
, O +
such O +
as O +
the O +
669-kDa O +
SprB. O +
A O +
novel O +
protein O +
secretion O +
apparatus O +
called O +
the O +
Por O +
secretion O +
system O +
( O -
PorSS O -
) O +
is O +
required O +
for O +
assembly O +
of O +
SprB O +
on O +
the O +
cell O +
surface O -
. O -

Genetic O +
and O +
molecular O +
analyses O +
revealed O +
that O +
sprB O +
is O +
part O +
of O +
a O +
seven O -
- O -
gene O +
operon O +
spanning O +
29.3 O +
kbp O +
of O +
DNA O -
. O -

In O +
addition O +
to O +
sprB O -
, O +
three O +
other O +
genes O +
of O +
this O +
operon O +
( O -
sprC O -
, O +
sprD O -
, O +
and O +
sprF O -
) O +
are O +
involved O +
in O +
gliding O -
. O -

Mutations O +
in O +
sprB O -
, O +
sprC O -
, O +
sprD O -
, O +
and O +
sprF O +
resulted O +
in O +
cells O +
that O +
failed O +
to O +
form O +
spreading O +
colonies O +
on O +
agar O +
but O +
that O +
exhibited O +
some O +
motility O +
on O +
glass O +
in O +
wet O +
mounts O -
. O -

SprF O +
exhibits O +
some O +
similarity O +
to O +
Porphyromonas B-Species +
gingivalis L-Species +
PorP O -
, O +
which O +
is O +
required O +
for O +
secretion O +
of O +
gingipain O +
protease O +
virulence O +
factors O +
via O +
the O +
P. B-Species +
gingivalis L-Species +
PorSS O -
. O -

F. B-Species +
johnsoniae L-Species +
sprF O +
mutants O +
produced O +
SprB O +
protein O +
but O +
were O +
defective O +
in O +
localization O +
of O +
SprB O +
to O +
the O +
cell O +
surface O -
, O +
suggesting O +
a O +
role O +
for O +
SprF O +
in O +
secretion O +
of O +
SprB. O +
The O +
F. B-Species +
johnsoniae L-Species +
PorSS O +
is O +
involved O +
in O +
secretion O +
of O +
extracellular O +
chitinase O +
in O +
addition O +
to O +
its O +
role O +
in O +
secretion O +
of O +
SprB. O +
SprF O +
was O +
not O +
needed O +
for O +
chitinase O +
secretion O +
and O +
may O +
be O +
specifically O +
required O +
for O +
SprB O +
secretion O +
by O +
the O +
PorSS O -
. O -

Cells O +
with O +
nonpolar O +
mutations O +
in O +
sprC O +
or O +
sprD O +
produced O +
and O +
secreted O +
SprB O +
and O +
propelled O +
it O +
rapidly O +
along O +
the O +
cell O +
surface O -
. O -

Multiple O +
paralogs O +
of O +
sprB O -
, O +
sprC O -
, O +
sprD O -
, O +
and O +
sprF O +
are O +
present O +
in O +
the O +
genome O -
, O +
which O +
may O +
explain O +
why O +
mutations O +
in O +
sprB O -
, O +
sprC O -
, O +
sprD O -
, O +
and O +
sprF O +
do O +
not O +
result O +
in O +
complete O +
loss O +
of O +
motility O +
and O +
suggests O +
the O +
possibility O +
that O +
semiredundant O +
SprB O -
- O -
like O +
adhesins O +
may O +
allow O +
movement O +
of O +
cells O +
over O +
different O +
surfaces O -
. O +

Evaluating O +
aggregation O +
membership O +
and O +
copulatory O +
success O +
in O +
the O +
stink B-Species +
bug L-Species -
, O +
Euschistus O +
conspersus O -
, O +
using O +
field O +
and O +
laboratory O +
experiments O -
. O +

The O +
aggregation O +
and O +
mating O +
behavior O +
of O +
the O +
stink B-Species +
bug L-Species -
, O +
Euschistus O +
conspersus O +
Uhler O +
( O -
Hemiptera O -
: O +
Pentatomidae O -
) O +
was O +
investigated O +
in O +
a O +
series O +
of O +
field O +
and O +
laboratory O +
experiments O -
. O -

Marking O +
of O +
E. O +
conspersus O +
mating O +
in O +
aggregations O +
in O +
the O +
field O +
demonstrated O +
that O +
both O +
sexes O +
mate O +
multiple O +
times O +
within O +
aggregations O +
on O +
successive O +
nights O +
and O +
with O +
different O +
partners O -
, O +
although O +
= O +
20 O -
% O +
of O +
the O +
individuals O +
of O +
both O +
sexes O +
returned O +
to O +
aggregations O +
but O +
did O +
not O +
mate O -
. O -

Further O +
analysis O +
of O +
mating O +
patterns O +
in O +
caged O +
aggregations O +
revealed O +
that O +
heavy O +
males O +
and O +
light O +
females O +
mated O +
more O +
frequently O +
than O +
their O +
respective O +
counterparts O -
. O -

Data O +
are O +
interpreted O +
in O +
terms O +
of O +
elucidating O +
the O +
function O +
of O +
benefits O +
of O +
multiple O +
mating O +
within O +
aggregations O +
for O +
males O +
and O +
females O -
. O +

Ice O -
- O -
cover O +
effects O +
on O +
competitive O +
interactions O +
between O +
two O +
fish O +
species O -
. O -

1 O -
. O -

Variations O +
in O +
the O +
strength O +
of O +
ecological O +
interactions O +
between O +
seasons O +
have O +
received O +
little O +
attention O -
, O +
despite O +
an O +
increased O +
focus O +
on O +
climate O +
alterations O +
on O +
ecosystems O -
. O -

Particularly O -
, O +
the O +
winter O +
situation O +
is O +
often O +
neglected O +
when O +
studying O +
competitive O +
interactions O -
. O -

In O +
northern O +
temperate O +
freshwaters O -
, O +
winter O +
implies O +
low O +
temperatures O +
and O +
reduced O +
food O +
availability O -
, O +
but O +
also O +
strong O +
reduction O +
in O +
ambient O +
light O +
because O +
of O +
ice O +
and O +
snow O +
cover O -
. O -

Here O -
, O +
we O +
study O +
how O +
brown B-Species +
trout L-Species +
[ O -
Salmo B-Species +
trutta L-Species +
( O -
L. O -
) O -
] O +
respond O +
to O +
variations O +
in O +
ice O -
- O -
cover O +
duration O +
and O +
competition O +
with O +
Arctic B-Species +
charr L-Species +
[ O -
Salvelinus B-Species +
alpinus L-Species +
( O -
L. O -
) O -
] O -
, O +
by O +
linking O +
laboratory O -
- O -
derived O +
physiological O +
performance O +
and O +
field O +
data O +
on O +
variation O +
in O +
abundance O +
among O +
and O +
within O +
natural O +
brown B-Species +
trout L-Species +
populations O -
. O -

2 O -
. O -

Both O +
Arctic B-Species +
charr L-Species +
and O +
brown B-Species +
trout L-Species +
reduced O +
resting O +
metabolic O +
rate O +
under O +
simulated O +
ice O -
- O -
cover O +
( O -
darkness O -
) O +
in O +
the O +
laboratory O -
, O +
compared O +
to O +
no O +
ice O +
( O -
6-h O +
daylight O -
) O -
. O -

However O -
, O +
in O +
contrast O +
to O +
brown B-Species +
trout L-Species -
, O +
Arctic B-Species +
charr L-Species +
was O +
able O +
to O +
obtain O +
positive O +
growth O +
rate O +
in O +
darkness O +
and O +
had O +
higher O +
food O +
intake O +
in O +
tank O +
experiments O +
than O +
brown B-Species +
trout L-Species -
. O -

Arctic B-Species +
charr L-Species +
also O +
performed O +
better O +
( O -
lower O +
energy O +
loss O -
) O +
under O +
simulated O +
ice O -
- O -
cover O +
in O +
a O +
semi O -
- O -
natural O +
environment O +
with O +
natural O +
food O +
supply O -
. O -

3 O -
. O -

When O +
comparing O +
brown B-Species +
trout L-Species +
biomass O +
across O +
190 O +
Norwegian O +
lakes O +
along O +
a O +
climate O +
gradient O -
, O +
longer O +
ice O -
- O -
covered O +
duration O +
decreased O +
the O +
biomass O +
only O +
in O +
lakes O +
where O +
brown B-Species +
trout L-Species +
lived O +
together O +
with O +
Arctic B-Species +
charr L-Species -
. O -

We O +
were O +
not O +
able O +
to O +
detect O +
any O +
effect O +
of O +
ice O -
- O -
cover O +
on O +
brown B-Species +
trout L-Species +
biomass O +
in O +
lakes O +
where O +
brown B-Species +
trout L-Species +
was O +
the O +
only O +
fish O +
species O -
. O -

4 O -
. O -

Similarly O -
, O +
a O +
25-year O +
time O +
series O +
from O +
a O +
lake O +
with O +
both O +
brown B-Species +
trout L-Species +
and O +
Arctic B-Species +
charr L-Species +
showed O +
that O +
brown B-Species +
trout L-Species +
population O +
growth O +
rate O +
depended O +
on O +
the O +
interaction O +
between O +
ice O +
breakup O +
date O +
and O +
Arctic B-Species +
charr L-Species +
abundance O -
. O -

High O +
charr U-Species +
abundance O +
was O +
correlated O +
with O +
low O +
trout O +
population O +
growth O +
rate O +
only O +
in O +
combination O +
with O +
long O +
winters O -
. O -

5 O -
. O -

In O +
conclusion O -
, O +
the O +
two O +
species O +
differed O +
in O +
performance O +
under O +
ice O -
, O +
and O +
the O +
observed O +
outcome O +
of O +
competition O +
in O +
natural O +
populations O +
was O +
strongly O +
dependent O +
on O +
duration O +
of O +
the O +
ice O -
- O -
covered O +
period O -
. O -

Our O +
study O +
shows O +
that O +
changes O +
in O +
ice O +
phenology O +
may O +
alter O +
species O +
interactions O +
in O +
Northern O +
aquatic O +
systems O -
. O -

Increased O +
knowledge O +
of O +
how O +
adaptations O +
to O +
winter O +
conditions O +
differ O +
among O +
coexisting O +
species O +
is O +
therefore O +
vital O +
for O +
our O +
understanding O +
of O +
ecological O +
impacts O +
of O +
climate O +
change O -
. O +

Prolixicin O -
: O +
a O +
novel O +
antimicrobial O +
peptide O +
isolated O +
from O +
Rhodnius B-Species +
prolixus L-Species +
with O +
differential O +
activity O +
against O +
bacteria O +
and O +
Trypanosoma B-Species +
cruzi L-Species -
. O +

We O +
identified O +
and O +
characterized O +
the O +
activity O +
of O +
prolixicin O -
, O +
a O +
novel O +
antimicrobial O +
peptide O +
( O -
AMP O -
) O +
isolated O +
from O +
the O +
hemipteran O +
insect O -
, O +
Rhodnius B-Species +
prolixus L-Species -
. O -

Sequence O +
analysis O +
reveals O +
one O +
region O +
of O +
prolixicin O +
that O +
may O +
be O +
related O +
to O +
the O +
diptericin O -
/ O -
attacin O +
family O +
of O +
AMPs O -
. O -

Prolixicin O +
is O +
an O +
11-kDa O +
peptide O +
containing O +
a O +
putative O +
21 O +
amino O +
acid O +
signal O +
peptide O -
, O +
two O +
putative O +
phosphorylation O +
sites O +
and O +
no O +
glycosylation O +
sites O -
. O -

It O +
is O +
produced O +
by O +
both O +
adult O +
fat O +
body O +
and O +
midgut O +
tissues O +
in O +
response O +
to O +
bacterial O +
infection O +
of O +
the O +
haemolymph O +
or O +
the O +
midgut O -
. O -

Unlike O +
most O +
insect O +
antibacterial O +
peptides O -
, O +
the O +
prolixicin O +
gene O +
does O +
not O +
seem O +
to O +
be O +
regulated O +
by O +
NF O -
- O -
kappaB O +
binding O +
sites O -
, O +
but O +
its O +
promoter O +
region O +
contains O +
several O +
GATA O +
sites O -
. O -

Recombinant O +
prolixicin O +
has O +
strong O +
activity O +
against O +
the O +
Gram O -
- O -
negative O +
bacterium O +
Escherichia B-Species +
coli L-Species +
and O +
differential O +
activity O +
against O +
several O +
Gram O -
- O -
negative O +
and O +
Gram O -
- O -
positive O +
bacteria O -
. O -

No O +
significant O +
toxicity O +
was O +
demonstrated O +
against O +
Trypanosoma B-Species +
cruzi L-Species -
, O +
the O +
human U-Species +
parasite O +
transmitted O +
by O +
R. B-Species +
prolixus L-Species -
. O +

Amyotrophic O +
lateral O +
sclerosis O -
. O -

Amyotrophic O +
lateral O +
sclerosis O +
( O -
ALS O -
) O +
is O +
an O +
idiopathic O -
, O +
fatal O +
neurodegenerative O +
disease O +
of O +
the O +
human U-Species +
motor O +
system O -
. O -

In O +
this O +
Seminar O -
, O +
we O +
summarise O +
current O +
concepts O +
about O +
the O +
origin O +
of O +
the O +
disease O -
, O +
what O +
predisposes O +
patients O +
to O +
develop O +
the O +
disorder O -
, O +
and O +
discuss O +
why O +
all O +
cases O +
of O +
ALS O +
are O +
not O +
the O +
same O -
. O -

In O +
the O +
150 O +
years O +
since O +
Charcot O +
originally O +
described O +
ALS O -
, O +
painfully O +
slow O +
progress O +
has O +
been O +
made O +
towards O +
answering O +
these O +
questions O -
. O -

We O +
focus O +
on O +
what O +
is O +
known O +
about O +
ALS O +
and O +
where O +
research O +
is O +
heading O -
- O -
from O +
the O +
small O +
steps O +
of O +
extending O +
longevity O -
, O +
improving O +
therapies O -
, O +
undertaking O +
clinical O +
trials O -
, O +
and O +
compiling O +
population O +
registries O +
to O +
the O +
overarching O +
goals O +
of O +
establishing O +
the O +
measures O +
that O +
guard O +
against O +
onset O +
and O +
finding O +
the O +
triggers O +
for O +
this O +
neurodegenerative O +
disorder O -
. O +

Role O +
of O +
RNase O +
MRP O +
in O +
viral O +
RNA O +
degradation O +
and O +
RNA O +
recombination O -
. O -

RNA O +
degradation O -
, O +
together O +
with O +
RNA O +
synthesis O -
, O +
controls O +
the O +
steady O -
- O -
state O +
level O +
of O +
viral O +
RNAs O +
in O +
infected O +
cells O -
. O -

The O +
endoribonucleolytic O +
cleavage O +
of O +
viral O +
RNA O +
is O +
important O +
not O +
only O +
for O +
viral O +
RNA O +
degradation O +
but O +
for O +
RNA O +
recombination O +
as O +
well O -
, O +
due O +
to O +
the O +
participation O +
of O +
some O +
RNA O +
degradation O +
products O +
in O +
the O +
RNA O +
recombination O +
process O -
. O -

To O +
identify O +
host O +
endoribonucleases O +
involved O +
in O +
degradation O +
of O +
Tomato B-Species +
bushy I-Species +
stunt I-Species +
virus L-Species +
( O -
TBSV U-Species -
) O +
in O +
a O +
Saccharomyces B-Species +
cerevisiae L-Species +
model O +
host O -
, O +
we O +
tested O +
eight O +
known O +
endoribonucleases O -
. O -

Here O +
we O +
report O +
that O +
downregulation O +
of O +
SNM1 O -
, O +
encoding O +
a O +
component O +
of O +
the O +
RNase O +
MRP O -
, O +
and O +
a O +
temperature O -
- O -
sensitive O +
mutation O +
in O +
the O +
NME1 O +
gene O -
, O +
coding O +
for O +
the O +
RNA O +
component O +
of O +
RNase O +
MRP O -
, O +
lead O +
to O +
reduced O +
production O +
of O +
the O +
endoribonucleolytically O +
cleaved O +
TBSV U-Species +
RNA O +
in O +
yeast U-Species -
. O -

We O +
also O +
show O +
that O +
the O +
highly O +
purified O +
yeast U-Species +
RNase O +
MRP O +
cleaves O +
the O +
TBSV U-Species +
RNA O +
in O +
vitro O -
, O +
resulting O +
in O +
TBSV U-Species +
RNA O +
degradation O +
products O +
similar O +
in O +
size O +
to O +
those O +
observed O +
in O +
yeast U-Species +
cells O -
. O -

Knocking O +
down O +
the O +
NME1 O +
homolog O +
in O +
Nicotiana B-Species +
benthamiana L-Species +
also O +
led O +
to O +
decreased O +
production O +
of O +
the O +
cleaved O +
TBSV U-Species +
RNA O -
, O +
suggesting O +
that O +
in O +
plants O -
, O +
RNase O +
MRP O +
is O +
involved O +
in O +
TBSV U-Species +
RNA O +
degradation O -
. O -

Altogether O -
, O +
this O +
work O +
suggests O +
a O +
role O +
for O +
the O +
host O +
endoribonuclease O +
RNase O +
MRP O +
in O +
viral O +
RNA O +
degradation O +
and O +
recombination O -
. O +

Reverse O +
genetics O +
generation O +
of O +
chimeric O +
infectious O +
Junin O -
/ O -
Lassa O +
virus O +
is O +
dependent O +
on O +
interaction O +
of O +
homologous O +
glycoprotein O +
stable O +
signal O +
peptide O +
and O +
G2 O +
cytoplasmic O +
domains O -
. O +

The O +
Arenaviridae O +
are O +
a O +
diverse O +
and O +
globally O +
distributed O +
collection O +
of O +
viruses O +
that O +
are O +
maintained O +
primarily O +
by O +
rodent O +
reservoirs O -
. O -

Junin B-Species +
virus L-Species +
( O -
JUNV U-Species -
) O +
and O +
Lassa B-Species +
virus L-Species +
( O -
LASV U-Species -
) O +
can O +
both O +
cause O +
significant O +
outbreaks O +
of O +
severe O +
and O +
often O +
fatal O +
human U-Species +
disease O +
throughout O +
their O +
respective O +
areas O +
of O +
endemicity O -
. O -

In O +
an O +
effort O +
to O +
improve O +
upon O +
the O +
existing O +
live O +
attenuated O +
JUNV U-Species +
Candid1 O +
vaccine O -
, O +
we O +
generated O +
a O +
genetically O +
homogenous O +
stock O +
of O +
this O +
virus O +
from O +
cDNA O +
copies O +
of O +
the O +
virus O +
S O +
and O +
L O +
segments O +
by O +
using O +
a O +
reverse O +
genetics O +
system O -
. O -

Further O -
, O +
these O +
cDNAs O +
were O +
used O +
in O +
combination O +
with O +
LASV U-Species +
cDNAs O +
to O +
successfully O +
generate O +
two O +
recombinant O +
Candid1 O +
JUNV U-Species -
/ O -
LASV U-Species +
chimeric O +
viruses O +
( O -
via O +
envelope O +
glycoprotein O +
[ O -
GPC O -
] O +
exchange O -
) O -
. O -

It O +
was O +
found O +
that O +
while O +
the O +
GPC O +
extravirion O +
domains O +
were O +
readily O +
exchangeable O -
, O +
homologous O +
stable O +
signal O +
peptide O +
( O -
SSP O -
) O +
and O +
G2 O +
transmembrane O +
and O +
cytoplasmic O +
tail O +
domains O +
were O +
essential O +
for O +
correct O +
GPC O +
maturation O +
and O +
production O +
of O +
infectious O +
chimeric O +
viruses O -
. O -

The O +
switching O +
of O +
the O +
JUNV U-Species +
and O +
LASV U-Species +
G1 O -
/ O -
G2 O +
ectodomains O +
within O +
the O +
Candid1 O +
vaccine O +
background O +
did O +
not O +
alter O +
the O +
attenuated O +
phenotype O +
of O +
the O +
vaccine O +
strain O +
in O +
a O +
lethal O +
mouse U-Species +
model O -
. O -

These O +
recombinant O +
chimeric O +
viruses O +
shed O +
light O +
on O +
the O +
fundamental O +
requirements O +
of O +
arenavirus O +
GPC O +
maturation O +
and O +
may O +
serve O +
as O +
a O +
strategy O +
for O +
the O +
development O +
of O +
bivalent O +
JUNV U-Species +
and O +
LASV U-Species +
vaccine O +
candidates O -
. O +

Titrating O +
the O +
cost O +
of O +
plant O +
toxins O +
against O +
predators O -
: O +
determining O +
the O +
tipping O +
point O +
for O +
foraging O +
herbivores O -
. O +

1 O -
. O -

Foraging O +
herbivores O +
must O +
deal O +
with O +
plant O +
characteristics O +
that O +
inhibit O +
feeding O +
and O +
they O +
must O +
avoid O +
being O +
eaten O -
. O -

Principally O -
, O +
toxins O +
limit O +
food O +
intake O -
, O +
while O +
predation O +
risk O +
alters O +
how O +
long O +
animals O +
are O +
prepared O +
to O +
harvest O +
resources O -
. O -

Each O +
of O +
these O +
factors O +
strongly O +
affects O +
how O +
herbivores O +
use O +
food O +
patches O -
, O +
and O +
both O +
constraints O +
can O +
pose O +
immediate O +
proximate O +
costs O +
and O +
long O -
- O -
term O +
consequences O +
to O +
fitness O -
. O -

2 O -
. O +
Using O +
a O +
generalist O +
mammalian O +
herbivore O -
, O +
the O +
common B-Species +
brushtail I-Species +
possum L-Species +
( O -
Trichosurus B-Species +
vulpecula L-Species -
) O -
, O +
our O +
aim O +
was O +
to O +
quantitatively O +
compare O +
the O +
influence O +
of O +
plant O +
toxin O +
and O +
predation O +
risk O +
on O +
foraging O +
decisions O -
. O -

3 O -
. O -

We O +
performed O +
a O +
titration O +
experiment O +
by O +
offering O +
animals O +
a O +
choice O +
between O +
non O -
- O -
toxic O +
food O +
at O +
a O +
risky O +
patch O +
paired O +
with O +
food O +
with O +
one O +
of O +
five O +
toxin O +
concentrations O +
at O +
a O +
safe O +
patch O -
. O -

This O +
allowed O +
us O +
to O +
identify O +
the O +
tipping O +
point O -
, O +
where O +
the O +
cost O +
of O +
toxin O +
in O +
the O +
safe O +
food O +
patch O +
was O +
equivalent O +
to O +
the O +
perceived O +
predation O +
risk O +
in O +
the O +
alternative O +
patch O -
. O -

4 O -
. O -

At O +
low O +
toxin O +
concentration O -
, O +
animals O +
ate O +
more O +
from O +
the O +
safe O +
than O +
the O +
risky O +
patch O -
. O -

As O +
toxin O +
concentration O +
increased O +
at O +
the O +
safe O +
patch O -
, O +
intake O +
shifted O +
until O +
animals O +
ate O +
mainly O +
from O +
the O +
risky O +
patch O -
. O -

This O +
shift O +
was O +
associated O +
with O +
behavioural O +
changes O -
: O +
animals O +
spent O +
more O +
time O +
and O +
fed O +
longer O +
at O +
the O +
risky O +
patch O -
, O +
while O +
vigilance O +
increased O +
at O +
both O +
risky O +
and O +
safe O +
patches O -
. O -

5 O -
. O -

Our O +
results O +
demonstrate O +
that O +
the O +
variation O +
in O +
toxin O +
concentration O -
, O +
which O +
occurs O +
intraspecifically O +
among O +
plants O -
, O +
can O +
critically O +
influence O +
the O +
relative O +
cost O +
of O +
predation O +
risk O +
on O +
foraging O -
. O -

We O +
show O +
that O +
herbivores O +
quantify O -
, O +
compare O +
and O +
balance O +
these O +
two O +
different O +
but O +
proximate O +
costs O -
, O +
altering O +
their O +
foraging O +
patterns O +
in O +
the O +
process O -
. O -

This O +
has O +
potential O +
ecological O +
and O +
evolutionary O +
implications O +
for O +
the O +
production O +
of O +
plant O +
defence O +
compounds O +
in O +
relation O +
to O +
spatial O +
variation O +
in O +
predation O +
risk O +
to O +
herbivores O -
. O +

The O +
Role O +
of O +
Frass O +
and O +
Cocoon O +
Volatiles O +
in O +
Host O +
Location O +
by O +
Monodontomerus O +
aeneus O -
, O +
a O +
Parasitoid O +
of O +
Megachilid O +
Solitary O +
Bees O -
. O +

Monodontomerus O +
aeneus O +
( O -
Fonscolombe O -
) O +
is O +
a O +
parasitic O +
wasp O +
that O +
oviposits O +
on O +
the O +
prepupae O +
and O +
pupae O +
of O +
Osmia B-Species +
cornuta L-Species +
( O -
Latreille O -
) O +
and O +
other O +
solitary O +
bee O +
species O -
. O -

A O +
two O -
- O -
armed O +
olfactometer O +
was O +
used O +
to O +
test O +
the O +
olfactory O +
attractiveness O +
of O +
O. B-Species +
cornuta L-Species +
prepupae O -
, O +
cocoon O -
, O +
and O +
larval O +
frass O +
to O +
female O +
M. O +
aeneus O -
. O -

Both O +
cocoon O +
and O +
frass O +
attracted O +
the O +
female O +
parasitoids O -
, O +
but O +
frass O +
alone O +
was O +
more O +
attractive O +
than O +
the O +
cocoon O +
and O +
the O +
cocoon O +
with O +
frass O +
was O +
more O +
attractive O +
than O +
frass O +
alone O -
. O -

Female O +
parasitoids O +
were O +
not O +
attracted O +
by O +
the O +
host O +
prepupa O -
. O -

M33 O +
( O -
methanol O -
) O +
was O +
the O +
organic O +
volatile O +
most O +
emitted O +
by O +
cocoons O +
and O +
m61 O +
( O -
acetic O +
acid O -
) O +
was O +
the O +
compound O +
most O +
emitted O +
by O +
frass O -
. O -

However O -
, O +
cocoons O +
showed O +
higher O +
emission O +
for O +
almost O +
all O +
compounds O -
, O +
including O +
m61 O +
( O -
acetic O +
acid O -
) O -
. O -

Although O +
acetic O +
acid O +
alone O +
attracted O +
M. O +
aeneus O -
, O +
a O +
complex O +
volatile O +
signal O +
is O +
probably O +
involved O +
in O +
the O +
attraction O +
process O +
because O +
the O +
ratio O +
of O +
acetic O +
acid O +
and O +
acetaldehyde O +
characteristic O +
of O +
the O +
frass O +
was O +
more O +
attractive O +
than O +
other O +
ratios O -
. O +

Individual O +
differences O +
in O +
reproductive O +
costs O +
examined O +
using O +
multi O -
- O -
state O +
methods O -
. O +

1 O -
. O -

Trade O -
- O -
offs O +
among O +
life O -
- O -
history O +
traits O +
are O +
common O +
because O +
individuals O +
have O +
to O +
partition O +
limited O +
resources O +
between O +
multiple O +
traits O -
. O -

Reproductive O +
costs O +
are O +
generally O +
assumed O +
to O +
be O +
high O -
, O +
resulting O +
in O +
reduced O +
survival O +
and O +
fecundity O +
in O +
the O +
following O +
year O -
. O -

However O -
, O +
it O +
is O +
common O +
to O +
find O +
positive O +
rather O +
than O +
negative O +
correlations O +
between O +
life O -
- O -
history O +
traits O -
. O -

2 O -
. O +
Here O -
, O +
we O +
use O +
a O +
data O +
set O +
from O +
the O +
individual O -
- O -
based O +
study O +
of O +
red B-Species +
deer L-Species +
on O +
the O +
Isle O +
of O +
Rum O +
to O +
examine O +
how O +
these O +
costs O +
vary O +
between O +
individuals O +
and O +
at O +
different O +
ages O -
, O +
using O +
multi O -
- O -
state O +
mark O -
- O -
recapture O +
methodology O -
. O -

3 O -
. O +
Females O +
that O +
had O +
reproduced O +
frequently O +
in O +
the O +
past O +
incurred O +
lower O +
costs O +
of O +
reproduction O +
in O +
terms O +
of O +
survival O +
in O +
the O +
following O +
year O +
and O +
were O +
more O +
likely O +
to O +
reproduce O +
in O +
two O +
consecutive O +
years O -
. O -

Older O +
individuals O +
and O +
those O +
that O +
had O +
not O +
reproduced O +
frequently O +
exhibited O +
higher O +
costs O -
. O -

4 O -
. O -

These O +
results O +
highlight O +
the O +
importance O +
of O +
considering O +
heterogeneity O +
and O +
individual O +
quality O +
when O +
examining O +
trade O -
- O -
offs O +
and O +
demonstrate O +
the O +
effectiveness O +
of O +
using O +
detailed O +
long O -
- O -
term O +
data O +
sets O +
to O +
explore O +
life O -
- O -
history O +
strategies O +
using O +
multi O -
- O -
state O +
mark O -
- O -
recapture O +
models O -
. O +

Phr1p O -
, O +
a O +
glycosylphosphatidylinsitol O -
- O -
anchored O +
Beta O -
( O -
1,3 O -
) O -
-glucanosyltransferase O +
critical O +
for O +
hyphal O +
wall O +
formation O -
, O +
localizes O +
to O +
the O +
apical O +
growth O +
sites O +
and O +
septa O +
in O +
Candida B-Species +
albicans L-Species -
. O +

Cell O +
wall O +
biogenesis O +
is O +
a O +
dynamic O +
process O +
relying O +
on O +
the O +
coordinated O +
activity O +
of O +
several O +
extracellular O +
enzymes O -
. O -

PHR1 O +
is O +
a O +
pH O -
- O -
regulated O +
gene O +
of O +
Candida B-Species +
albicans L-Species +
encoding O +
a O +
glycosylphosphatidylinositol O -
- O -
anchored O +
Beta O -
( O -
1,3 O -
) O -
-glucanosyltransferase O +
of O +
family O +
GH72 O +
which O +
acts O +
as O +
a O +
cell O +
wall O +
remodelling O +
enzyme O +
and O +
is O +
crucial O +
for O +
morphogenesis O +
and O +
virulence O -
. O -

In O +
order O +
to O +
explore O +
the O +
function O +
of O +
Phr1p O -
, O +
we O +
obtained O +
a O +
green O +
fluorescent O +
protein O +
( O -
GFP O -
) O +
fusion O +
to O +
determine O +
its O +
localization O -
. O -

During O +
induction O +
of O +
vegetative O +
growth O -
, O +
Phr1p O -
- O -
GFP O +
was O +
concentrated O +
in O +
the O +
plasma O +
membrane O +
of O +
the O +
growing O +
bud O -
, O +
in O +
the O +
mother O -
- O -
bud O +
neck O -
, O +
and O +
in O +
the O +
septum O -
. O -

Phr1p O -
- O -
GFP O +
was O +
recovered O +
in O +
the O +
detergent O -
- O -
resistant O +
membranes O +
indicating O +
its O +
association O +
with O +
the O +
lipid O +
rafts O +
as O +
the O +
wild O +
type O +
Phr1p O -
. O -

Upon O +
induction O +
of O +
hyphal O +
growth O -
, O +
Phr1p O -
- O -
GFP O +
highly O +
concentrated O +
at O +
the O +
apex O +
of O +
the O +
germ O +
tubes O +
and O +
progressively O +
distributed O +
along O +
the O +
lateral O +
sides O +
of O +
the O +
hyphae O -
. O -

Phr1p O -
- O -
GFP O +
also O +
labelled O +
the O +
hyphal O +
septa O -
, O +
where O +
it O +
colocalized O +
with O +
chitin O -
. O -

Localization O +
to O +
the O +
hyphal O +
septa O +
was O +
perturbed O +
in O +
nocodazole O -
- O -
treated O +
cells O -
, O +
whereas O +
inhibition O +
of O +
actin O +
polymerization O +
hindered O +
the O +
apical O +
localization O -
. O -

Electron O +
Microscopy O +
analysis O +
of O +
the O +
hyphal O +
wall O +
ultrastructure O +
of O +
a O +
PHR1 O +
null O +
mutant O +
showed O +
loss O +
of O +
compactness O +
and O +
irregular O +
organization O +
of O +
the O +
surface O +
layer O -
. O -

These O +
observations O +
indicate O +
that O +
Phr1p O +
plays O +
a O +
crucial O +
role O +
in O +
hyphal O +
wall O +
formation O -
, O +
a O +
highly O +
regulated O +
process O +
on O +
which O +
morphogenesis O +
and O +
virulence O +
rely O -
. O +

Hormone O +
receptor O -
- O -
like O +
in O +
96 O +
and O +
Broad O -
- O -
Complex O +
modulate O +
phenobarbital O +
induced O +
transcription O +
of O +
cytochrome O +
P450 O +
CYP6D1 O +
in O +
Drosophila U-Species +
S2 O +
cells O -
. O +

Phenobarbital O +
( O -
PB O -
) O +
is O +
a O +
prototypical O +
inducer O +
for O +
studies O +
of O +
xenobiotic O +
responses O +
in O +
animals O -
. O -

In O +
mammals O -
, O +
the O +
nuclear O +
receptors O +
constitutive O +
androstane O +
receptor O +
( O -
CAR O -
) O +
and O +
pregnane O +
X O +
receptor O +
( O -
PXR O -
) O +
have O +
been O +
identified O +
as O +
key O +
transcription O +
factors O +
regulating O +
PB O +
induced O +
transcription O +
of O +
xenobiotic O +
responsive O +
genes O -
. O -

In O +
insects O -
, O +
much O +
less O +
is O +
known O +
about O +
the O +
transcription O +
factors O +
involved O +
in O +
regulating O +
PB O +
induced O +
transcription O -
, O +
although O +
CAR O +
and O +
PXR O +
have O +
a O +
single O +
orthologue O +
hormone O +
receptor O -
- O -
like O +
in O +
96 O +
( O -
HR96 O -
) O +
in O +
Drosophila B-Species +
melanogaster L-Species -
. O -

Using O +
dual O +
luciferase O +
reporter O +
assays O +
in O +
Drosophila U-Species +
Schneider O +
( O -
S2 O -
) O +
cells O -
, O +
constructs O +
containing O +
variable O +
lengths O +
of O +
the O +
promoter O +
of O +
the O +
PB O +
inducible O +
cytochrome O +
P450 O +
CYP6D1 O +
were O +
evaluated O +
in O +
the O +
presence O +
and O +
absence O +
of O +
PB O -
. O -

The O +
promoter O +
region O +
between O +
-330 O +
and O +
-280 O +
( O -
relative O +
to O +
the O +
position O +
of O +
transcription O +
start O +
site O -
, O +
+ O -
1 O -
) O +
was O +
found O +
to O +
be O +
critical O +
for O +
PB O +
induction O -
. O -

Putative O +
binding O +
sites O +
for O +
Drosophila U-Species +
Broad O -
- O -
Complex O +
( O -
BR O -
- O -
C O -
) O +
and O +
deformed O +
( O -
Dfd O -
) O +
were O +
identified O +
within O +
this O +
promoter O +
region O +
using O +
TFsearch O -
. O -

RNA O +
interference O +
( O -
RNAi O -
) O +
treatment O +
of O +
S2 O +
cells O +
in O +
conjunction O +
with O +
CYP6D1 O +
promoter O +
assays O +
showed O +
that O +
suppression O +
of O +
Drosophila U-Species +
HR96 O +
and O +
BR O -
- O -
C O +
transcription O +
in O +
S2 O +
cells O +
resulted O +
in O +
a O +
significant O +
decrease O +
and O +
increase O -
, O +
respectively O -
, O +
of O +
PB O +
induction O -
. O -

Effects O +
of O +
HR96 O +
and O +
BR O -
- O -
C O +
in O +
mediating O +
PB O +
induction O +
were O +
PB O +
specific O +
and O +
PB O +
dependent O -
. O -

This O +
represents O +
new O +
functional O +
evidence O +
that O +
Drosophila U-Species +
HR96 O +
and O +
BR O -
- O -
C O +
can O +
act O +
as O +
an O +
activator O +
and O +
repressor O -
, O +
respectively O -
, O +
in O +
regulating O +
PB O +
induced O +
transcription O +
in O +
insects O -
. O +

Nucleotide O +
parasitism O +
by O +
Simkania B-Species +
negevensis L-Species +
( O -
Chlamydiae O -
) O -
. O -

Intracellular O +
bacteria O +
live O +
in O +
an O +
environment O +
rich O +
in O +
most O +
essential O +
metabolites O +
but O +
need O +
special O +
mechanisms O +
to O +
access O +
these O +
substrates O -
. O -

Nucleotide O +
transport O +
proteins O +
( O -
NTTs O -
) O +
catalyze O +
the O +
import O +
of O +
ATP O +
and O +
other O +
nucleotides O +
from O +
the O +
eukaryotic O +
host O +
into O +
the O +
bacterial O +
cell O +
and O +
render O +
de O +
novo O +
synthesis O +
of O +
these O +
compounds O +
dispensable O -
. O -

The O +
draft O +
genome O +
sequence O +
of O +
Simkania B-Species +
negevensis I-Species +
strain L-Species +
Z O -
, O +
a O +
chlamydial O +
organism O +
considered O +
a O +
newly O +
emerging O +
pathogen O -
, O +
revealed O +
four O +
genes O +
encoding O +
putative O +
nucleotide O +
transport O +
proteins O +
( O -
SnNTT1 O +
to O +
SnNTT4 O -
) O -
, O +
all O +
of O +
which O +
are O +
transcribed O +
during O +
growth O +
of O +
S. B-Species +
negevensis L-Species +
in O +
Acanthamoeba O +
host O +
cells O -
, O +
as O +
confirmed O +
by O +
reverse O +
transcription O -
- O -
PCR O -
. O -

Using O +
heterologous O +
expression O +
in O +
Escherichia B-Species +
coli L-Species -
, O +
we O +
could O +
show O +
that O +
SnNTT1 O +
functions O +
as O +
an O +
ATP O -
/ O -
ADP O +
antiporter O -
, O +
SnNTT2 O +
as O +
a O +
guanine O +
nucleotide O -
/ O -
ATP O -
/ O -
H O -
( O -
+ O -
) O +
symporter O +
driven O +
by O +
the O +
membrane O +
potential O -
, O +
and O +
SnNTT3 O +
as O +
a O +
nucleotide O +
triphosphate O +
antiporter O -
. O -

In O +
addition O -
, O +
SnNTT3 O +
is O +
able O +
to O +
transport O +
dCTP O -
, O +
which O +
has O +
not O +
been O +
shown O +
for O +
a O +
prokaryotic O +
transport O +
protein O +
before O -
. O -

No O +
substrate O +
could O +
be O +
identified O +
for O +
SnNTT4 O -
. O -

Taking O +
these O +
data O +
together O -
, O +
S. B-Species +
negevensis L-Species +
employs O +
a O +
set O +
of O +
nucleotide O +
transport O +
proteins O +
to O +
efficiently O +
tap O +
its O +
host O -
's O +
energy O +
and O +
nucleotide O +
pools O -
. O -

Although O +
similar O +
to O +
other O +
chlamydiae O -
, O +
these O +
transporters O +
show O +
distinct O +
and O +
unique O +
adaptations O +
with O +
respect O +
to O +
substrate O +
specificities O +
and O +
mode O +
of O +
transport O -
. O +

Promoter O +
discrimination O +
at O +
class O +
I O +
MarA O +
regulon O +
promoters O +
mediated O +
by O +
glutamic O +
acid O +
89 O +
of O +
the O +
MarA O +
transcriptional O +
activator O +
of O +
Escherichia B-Species +
coli L-Species -
. O +

Three O +
paralogous O +
transcriptional O +
activators O +
MarA O -
, O +
SoxS O -
, O +
and O +
Rob O -
, O +
activate O +
> O +
40 O +
Escherichia B-Species +
coli L-Species +
promoters O -
. O -

To O +
understand O +
why O +
MarA O +
does O +
not O +
activate O +
certain O +
promoters O +
as O +
strongly O +
as O +
SoxS O -
, O +
we O +
compared O +
MarA O -
, O +
MarA O +
mutants O -
, O +
and O +
SoxS O +
for O +
their O +
abilities O +
to O +
activate O +
16 O +
promoters O +
and O +
to O +
bind O +
their O +
cognate O +
marbox O +
binding O +
sites O -
. O -

Replacement O +
of O +
the O +
MarA O +
glutamic O +
acid O +
residue O +
89 O +
with O +
alanine O +
greatly O +
increased O +
the O +
marbox O +
binding O +
and O +
activation O +
of O +
many O +
class O +
I O +
promoters O -
. O -

Like O +
cells O +
constitutive O +
for O +
SoxS O -
, O +
cells O +
expressing O +
the O +
MarA O +
with O +
the O +
E89A O +
mutation O +
were O +
more O +
resistant O +
to O +
superoxides O +
than O +
those O +
harboring O +
WT O +
MarA. O +
The O +
activities O +
of O +
several O +
other O +
E89 O +
substitutions O +
ranked O +
as O +
follows O -
: O +
E89A O +
> O +
E89 O -
G O +
> O +
E89V O +
> O +
WT O +
> O +
E89D O -
. O -

Increased O +
binding O +
and O +
activation O +
occurred O +
only O +
at O +
class O +
I O +
promoters O +
when O +
the O +
12th O +
base O +
of O +
the O +
promoter O -
's O +
marbox O +
( O -
a O +
position O +
at O +
which O +
there O +
is O +
no O +
known O +
interaction O +
between O +
the O +
marbox O +
and O +
MarA O -
) O +
was O +
not O +
a O +
T O +
residue O -
. O -

Furthermore O -
, O +
WT O +
MarA O +
binding O +
to O +
a O +
synthetic O +
marbox O +
in O +
vitro O +
was O +
enhanced O +
when O +
the O +
phosphate O +
group O +
between O +
positions O +
12 O +
and O +
13 O +
was O +
eliminated O +
on O +
one O +
strand O -
. O -

The O +
results O +
demonstrate O +
that O +
relatively O +
minor O +
changes O +
in O +
a O +
single O +
amino O +
acid O +
side O +
chain O +
( O -
e.g. O -
, O +
alanine O +
to O +
valine O +
or O +
glutamic O +
acid O +
to O +
aspartic O +
acid O -
) O +
can O +
strongly O +
influence O +
activity O +
despite O +
any O +
evidence O +
that O +
the O +
side O +
chain O +
is O +
involved O +
in O +
positive O +
interactions O +
with O +
either O +
DNA O +
or O +
RNA O +
polymerase O -
. O -

We O +
present O +
a O +
model O +
which O +
attributes O +
the O +
differences O +
in O +
binding O +
and O +
activation O +
to O +
the O +
interference O +
between O +
the O +
Beta- O +
and O +
gamma O -
- O -
carbons O +
of O +
the O +
amino O +
acid O +
at O +
position O +
89 O +
and O +
the O +
phosphate O +
group O +
between O +
positions O +
12 O +
and O +
13 O -
. O +

The O +
Serengeti O +
food O +
web O -
: O +
empirical O +
quantification O +
and O +
analysis O +
of O +
topological O +
changes O +
under O +
increasing O +
human U-Species +
impact O -
. O +

1 O -
. O -

To O +
address O +
effects O +
of O +
land O +
use O +
and O +
human U-Species +
overexploitation O +
on O +
wildlife O +
populations O -
, O +
it O +
is O +
essential O +
to O +
better O +
understand O +
how O +
human U-Species +
activities O +
have O +
changed O +
species O +
composition O -
, O +
diversity O +
and O +
functioning O -
. O -

Theoretical O +
studies O +
modelled O +
how O +
network O +
properties O +
change O +
under O +
human U-Species -
- O -
induced O -
, O +
non O -
- O -
random O +
species O +
loss O -
. O -

However O -
, O +
we O +
lack O +
data O +
on O +
realistic O +
species O -
- O -
loss O +
sequences O +
in O +
threatened O -
, O +
real O -
- O -
world O +
food O +
webs O +
to O +
parameterize O +
these O +
models O -
. O -

2 O -
. O +
Here O -
, O +
we O +
present O +
a O +
first O +
size O -
- O -
structured O +
topological O +
food O +
web O +
of O +
one O +
of O +
the O +
most O +
pristine O +
terrestrial O +
ecosystems O +
in O +
the O +
world O -
, O +
the O +
Serengeti O +
ecosystem O +
( O -
Tanzania O -
) O -
. O -

The O +
food O +
web O +
consists O +
of O +
95 O +
grouped O +
nodes O +
and O +
includes O +
both O +
invertebrates O +
and O +
vertebrates O +
ranging O +
from O +
body O +
masses O +
between O +
10 O -
( O -
-7 O -
) O +
and O +
10 O -
( O -
4 O -
) O +
kg O -
. O -

3 O -
. O -

We O +
study O +
the O +
topological O +
changes O +
in O +
this O +
food O +
web O +
that O +
result O +
from O +
the O +
simulated O +
IUCN O -
- O -
based O +
species O -
- O -
loss O +
sequence O +
representing O +
current O +
species O +
vulnerability O +
to O +
human U-Species +
disturbances O +
in O +
and O +
around O +
this O +
savanna O +
ecosystem O -
. O -

We O +
then O +
compare O +
this O +
realistic O +
extinction O +
scenario O +
with O +
other O +
extinction O +
sequences O +
based O +
on O +
body O +
size O +
and O +
connectance O +
and O +
perform O +
an O +
analysis O +
of O +
robustness O +
of O +
this O +
savanna O +
food O +
web O -
. O -

4 O -
. O -

We O +
demonstrate O +
that O +
real O -
- O -
world O +
species O +
loss O +
in O +
this O +
case O +
starts O +
with O +
the O +
biggest O +
( O -
mega O -
) O +
herbivores O +
and O +
top O +
predators O -
, O +
causing O +
higher O +
predator O -
- O -
prey O +
mass O +
ratios O -
. O -

However O -
, O +
unlike O +
theoretically O +
modelled O +
linear O +
species O +
deletion O +
sequences O -
, O +
this O +
causes O +
poor O -
- O -
connected O +
species O +
to O +
be O +
lost O +
first O -
, O +
while O +
more O +
highly O +
connected O +
species O +
become O +
lost O +
as O +
human U-Species +
impact O +
progresses O -
. O -

This O +
food O +
web O +
shows O +
high O +
robustness O +
to O +
decreasing O +
body O +
size O +
and O +
increasing O +
connectance O +
deletion O +
sequences O +
compared O +
with O +
a O +
high O +
sensitivity O +
to O +
the O +
decreasing O +
connectance O +
deletion O +
scenario O -
. O -

5 O -
. O -

Furthermore O -
, O +
based O +
on O +
the O +
current O +
knowledge O +
of O +
the O +
Serengeti O +
ecosystem O -
, O +
we O +
discuss O +
how O +
the O +
focus O +
on O +
food O +
web O +
topology O +
alone O -
, O +
disregarding O +
nontrophic O +
interactions O -
, O +
may O +
lead O +
to O +
an O +
underestimation O +
of O +
human U-Species +
impacts O +
on O +
wildlife O +
communities O -
, O +
with O +
the O +
number O +
of O +
trophic O +
links O +
affected O +
by O +
a O +
factor O +
of O +
two O -
. O -

6 O -
. O -

This O +
study O +
underlines O +
the O +
importance O +
of O +
integrative O +
efforts O +
between O +
the O +
development O +
of O +
food O +
web O +
theory O +
and O +
basic O +
field O +
work O +
approaches O +
in O +
the O +
quantification O +
of O +
the O +
structure O +
of O +
interaction O +
networks O +
to O +
sustain O +
natural O +
ecosystems O +
in O +
a O +
changing O +
world O -
. O +

Activation O +
of O +
the O +
SoxR O +
regulon O +
in O +
Streptomyces B-Species +
coelicolor L-Species +
by O +
the O +
extracellular O +
form O +
of O +
the O +
pigmented O +
antibiotic O +
actinorhodin O -
. O +

The O +
redox O -
- O -
sensitive O +
transcription O +
factor O +
SoxR O +
in O +
enteric O +
bacteria O +
senses O +
and O +
regulates O +
the O +
cellular O +
response O +
to O +
superoxide O +
and O +
nitric O +
oxide O -
. O -

In O +
other O +
bacterial O +
groups O -
, O +
however O -
, O +
it O +
may O +
respond O +
to O +
redox O -
- O -
active O +
small O +
molecules O -
, O +
as O +
demonstrated O +
for O +
pyocyanin O +
sensing O +
in O +
pseudomonads O -
. O -

The O +
antibiotic O -
- O -
producing O +
soil O +
bacterium O +
Streptomyces B-Species +
coelicolor L-Species +
contains O +
a O +
gene O +
for O +
an O +
SoxR O +
homologue O +
( O -
SCO1697 O -
) O +
whose O +
DNA O +
recognition O +
helix O +
is O +
identical O +
to O +
that O +
of O +
Escherichia B-Species +
coli L-Species +
SoxR. O +
Using O +
the O +
E. B-Species +
coli L-Species +
SoxR O +
binding O +
sequence O -
, O +
we O +
predicted O +
five O +
candidate O +
genes O +
of O +
the O +
SoxR O +
regulon O +
and O +
demonstrated O +
that O +
SoxR O +
binds O +
to O +
their O +
promoter O +
regions O +
and O +
activates O +
their O +
expression O +
concurrently O +
with O +
the O +
production O +
of O +
the O +
blue O +
antibiotic O +
actinorhodin O +
( O -
a O +
benzoisochromanequinone O -
) O -
. O -

These O +
genes O +
encode O +
a O +
probable O +
NADPH O -
- O -
dependent O +
flavin O +
reductase O +
( O -
SCO2478 O -
) O -
, O +
an O +
NADPH O -
- O -
dependent O +
quinone O +
reductase O +
( O -
SCO4266 O -
) O -
, O +
an O +
ABC O +
transporter O +
( O -
SCO7008 O -
) O -
, O +
a O +
monooxygenase O +
( O -
SCO1909 O -
) O -
, O +
and O +
a O +
hypothetical O +
protein O +
( O -
SCO1178 O -
) O -
. O -

Addition O +
of O +
actinorhodin O +
to O +
exponentially O +
growing O +
cells O +
activated O +
the O +
expression O +
of O +
SoxR O +
target O +
genes O +
in O +
an O +
SoxR O -
- O -
dependent O +
manner O -
. O -

The O +
secreted O +
gamma O -
- O -
actinorhodin O +
was O +
over O +
10-fold O +
more O +
effective O +
in O +
activation O +
than O +
the O +
intracellular O +
form O +
of O +
actinorhodin O -
, O +
suggesting O +
that O +
SoxR O +
is O +
specified O +
to O +
respond O +
more O +
to O +
exogenous O +
signals O +
than O +
to O +
intracellular O +
metabolites O -
. O -

The O +
DeltasoxR O +
mutant O +
was O +
not O +
compromised O +
in O +
resistance O +
against O +
oxidants O +
but O +
was O +
slow O +
in O +
forming O +
aerial O +
mycelium O +
on O +
R2YE O +
medium O +
with O +
reduced O +
sporulation O -
, O +
and O +
its O +
production O +
of O +
actinorhodin O +
and O +
undecylprodigiosin O +
was O +
lowered O +
by O +
about O +
50 O -
% O +
and O +
30 O -
% O -
, O +
respectively O -
, O +
compared O +
to O +
that O +
of O +
the O +
wild O +
type O -
. O -

These O +
results O +
support O +
the O +
proposal O +
that O +
SoxR O +
senses O +
redox O -
- O -
active O +
molecules O -
, O +
such O +
as O +
actinorhodin O +
in O +
S. B-Species +
coelicolor L-Species -
, O +
and O +
induces O +
a O +
protective O +
function O +
against O +
them O -
. O -

It O +
also O +
functions O +
to O +
ensure O +
that O +
cells O +
undergo O +
optimal O +
differentiation O +
and O +
secondary O +
metabolite O +
production O -
. O +

Aerobic O +
degradation O +
of O +
mercaptosuccinate O +
by O +
the O +
gram O -
- O -
negative O +
bacterium O +
Variovorax B-Species +
paradoxus L-Species +
strain O +
B4 O -
. O +

The O +
Gram O -
- O -
negative O +
bacterium O +
Variovorax B-Species +
paradoxus L-Species +
strain O +
B4 O +
was O +
isolated O +
from O +
soil O +
under O +
mesophilic O +
and O +
aerobic O +
conditions O +
to O +
elucidate O +
the O +
so O +
far O +
unknown O +
catabolism O +
of O +
mercaptosuccinate O +
( O -
MS O -
) O -
. O -

During O +
growth O +
with O +
MS O +
this O +
strain O +
released O +
significant O +
amounts O +
of O +
sulfate O +
into O +
the O +
medium O -
. O -

Tn5::mob O -
- O -
induced O +
mutagenesis O +
was O +
successfully O +
employed O +
and O +
yielded O +
nine O +
independent O +
mutants O +
incapable O +
of O +
using O +
MS O +
as O +
a O +
carbon O +
source O -
. O -

In O +
six O +
of O +
these O +
mutants O -
, O +
Tn5::mob O +
insertions O +
were O +
mapped O +
in O +
a O +
putative O +
gene O +
encoding O +
a O +
molybdenum O +
( O -
Mo O -
) O +
cofactor O +
biosynthesis O +
protein O +
( O -
moeA O -
) O -
. O -

In O +
two O +
further O +
mutants O +
the O +
Tn5::mob O +
insertion O +
was O +
mapped O +
in O +
the O +
gene O +
coding O +
for O +
a O +
putative O +
molybdopterin O +
( O -
MPT O -
) O +
oxidoreductase O -
. O -

In O +
contrast O +
to O +
the O +
wild O +
type O -
, O +
these O +
eight O +
mutants O +
also O +
showed O +
no O +
growth O +
on O +
taurine O -
. O -

In O +
another O +
mutant O +
a O +
gene O +
putatively O +
encoding O +
a O +
3-hydroxyacyl O -
- O -
coenzyme O +
A O +
dehydrogenase O +
( O -
paaH2 O -
) O +
was O +
disrupted O +
by O +
transposon O +
insertion O -
. O -

Upon O +
subcellular O +
fractionation O +
of O +
wild O -
- O -
type O +
cells O +
cultivated O +
with O +
MS O +
as O +
sole O +
carbon O +
and O +
sulfur O +
source O -
, O +
MPT O +
oxidoreductase O +
activity O +
was O +
detected O +
in O +
only O +
the O +
cytoplasmic O +
fraction O -
. O -

Cells O +
grown O +
with O +
succinate O -
, O +
taurine O -
, O +
or O +
gluconate O +
as O +
a O +
sole O +
carbon O +
source O +
exhibited O +
no O +
activity O +
or O +
much O +
lower O +
activity O -
. O -

MPT O +
oxidoreductase O +
activity O +
in O +
the O +
cytoplasmic O +
fraction O +
of O +
the O +
Tn5::mob O -
- O -
induced O +
mutant O +
Icr6 O +
was O +
3-fold O +
lower O +
in O +
comparison O +
to O +
the O +
wild O +
type O -
. O -

Therefore O -
, O +
a O +
new O +
pathway O +
for O +
MS O +
catabolism O +
in O +
V. B-Species +
paradoxus L-Species +
strain O +
B4 O +
is O +
proposed O -
: O +
( O -
i O -
) O +
MPT O +
oxidoreductase O +
catalyzes O +
the O +
conversion O +
of O +
MS O +
first O +
into O +
sulfinosuccinate O +
( O -
a O +
putative O +
organo O -
- O -
sulfur O +
compound O +
composed O +
of O +
succinate O +
and O +
a O +
sulfino O +
group O -
) O +
and O +
then O +
into O +
sulfosuccinate O +
by O +
successive O +
transfer O +
of O +
oxygen O +
atoms O -
, O +
( O -
ii O -
) O +
sulfosuccinate O +
is O +
cleaved O +
into O +
oxaloacetate O +
and O +
sulfite O -
, O +
and O +
( O -
iii O -
) O +
sulfite O +
is O +
oxidized O +
to O +
sulfate O -
. O +

